AUTHENTICATED
U.S. GOVERNMENT
INFORMATION
GPO

Federal Register

8–2–01 Thursday
Vol. 66 No. 149 August 2, 2001
Pages 40107–40572

The **FEDERAL REGISTER** is published daily, Monday through Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Committee of the Federal Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition.

The **Federal Register** provides a uniform system for making available to the public regulations and legal notices issued by Federal agencies. These include Presidential proclamations and Executive Orders, Federal agency documents having general applicability and legal effect, documents required to be published by act of Congress, and other Federal agency documents of public interest.

Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, see http://www.nara.gov/fedreg.

The seal of the National Archives and Records Administration authenticates the Federal Register as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the **Federal Register** shall be judicially noticed.

The **Federal Register** is published in paper and on 24x microfiche. It is also available online at no charge as one of the databases on GPO Access, a service of the U.S. Government Printing Office.

The online edition of the **Federal Register** is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6 a.m. each day the **Federal Register** is published and it includes both text and graphics from Volume 59, Number 1 (January 2, 1994) forward.

GPO Access users can choose to retrieve online **Federal Register** documents as TEXT (ASCII text, graphics omitted), PDF (Adobe Portable Document Format, including full text and all graphics), or SUMMARY (abbreviated text) files. Users should carefully check retrieved material to ensure that documents were properly downloaded.

On the World Wide Web, connect to the **Federal Register** at http://www.access.gpo.gov/nara. Those without World Wide Web access can also connect with a local WAIS client, by Telnet to swais.access.gpo.gov, or by dialing (202) 512-1661 with a computer and modem. When using Telnet or modem, type swais, then log in as guest with no password.

For more information about GPO Access, contact the GPO Access User Support Team by E-mail at gpoaccess@gpo.gov; by fax at (202) 512–1262; or call (202) 512–1530 or 1–888–293–6498 (toll free) between 7 a.m. and 5 p.m. Eastern time, Monday–Friday, except Federal holidays.

The annual subscription price for the **Federal Register** paper edition is $638, or $697 for a combined **Federal Register,** Federal Register Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the **Federal Register** including the Federal Register Index and LSA is $253. Six month subscriptions are available for one-half the annual rate. The charge for individual copies in paper form is $9.00 for each issue, or $9.00 for each group of pages as actually bound; or $2.00 for each issue in microfiche form. All prices include regular domestic postage and handling. International customers please add 25% for foreign handling. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard or Discover. Mail to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250–7954.

There are no restrictions on the republication of material appearing in the **Federal Register.**

How To Cite This Publication: Use the volume number and the page number. Example: 66 FR 12345.

SUBSCRIPTIONS AND COPIES

PUBLIC	
Subscriptions:	
Paper or fiche	**202–512–1800**
Assistance with public subscriptions	**512–1806**
General online information	**202–512–1530; 1–888–293–6498**
Single copies/back copies:	
Paper or fiche	**512–1800**
Assistance with public single copies	**512–1803**
FEDERAL AGENCIES	
Subscriptions:	
Paper or fiche	**523–5243**
Assistance with Federal agency subscriptions	**523–5243**

Printed on recycled paper.

Contents

Federal Register

Vol. 66, No. 149

Thursday, August 2, 2001

Agricultural Marketing Service
PROPOSED RULES
Potatoes (Irish) grown in—
Colorado, 40153–40158
Tomatoes grown in—
Florida, 40158–40161

Agriculture Department
See Agricultural Marketing Service
See Food and Nutrition Service
See National Agricultural Statistics Service

Census Bureau
NOTICES
Agency information collection activities:
Proposed collection; comment request, 40190–40191

Centers for Medicare & Medicaid Services
PROPOSED RULES
Medicare:
Physician fee schedule (2002 CY); payment policies and relative value unit adjustments, 40371–40566
NOTICES
Committees; establishment, renewal, termination, etc.:
Practicing Physicians Advisory Council, 40289

Coast Guard
RULES
Drawbridge operations:
Louisiana, 40117–40118
New York, 40116–40117
North Carolina, 40118–40119
Ports and waterways safety:
St. Clair River, MI; safety zone, 40120–40121

Commerce Department
See Census Bureau
See International Trade Administration
See National Oceanic and Atmospheric Administration
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 40189–40190

Consumer Product Safety Commission
RULES
Poison-prevention packaging:
Child-resistant packaging requirements—
Over-the-counter drug products, 40111–40116

Copyright Office, Library of Congress
RULES
Copyright office and procedures:
Technical amendments
Correction, 40322

Defense Department
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 40235–40236

Education Department
NOTICES
Agency information collection activities:
Proposed collection; comment request, 40237–40238
Grants and cooperative agreements; availability, etc.:
Dropout Prevention Demonstration Program, 40567–40568

Employment and Training Administration
NOTICES
Alien temporary employment labor certification process:
Agriculture and logging; adverse effect wage rates, meal charges, and maximum travel subsistence reimbursement, 40298–40299

Energy Department
See Federal Energy Regulatory Commission

Environmental Protection Agency
RULES
Air pollutants, hazardous; national emission standards:
Pharmaceuticals production, 40121–40137
Air quality implementation plans; approval and promulgation; various States:
Florida, 40137–40139
Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:
Isoxadifen-ethyl, 40140–40141
Tepraloxydim, 40141–40151
PROPOSED RULES
Air pollutants, hazardous; national emission standards:
Pharmaceuticals production, 40166–40168
Reinforced plastic composites production, 40323–40369
Air quality implementation plans; approval and promulgation; various States:
California, 40168–40170
Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:
Rhodamine B, 40170–40174
NOTICES
Meetings:
National Drinking Water Advisory Council, 40281–40282
Water pollution control:
Total maximum daily loads—
New Jersey; addition of six waters to list, 40282–40283

Executive Office of the President
See Presidential Documents

Federal Aviation Administration
RULES
Airworthiness directives:
Eurocopter France, 40109–40110
PROPOSED RULES
Airworthiness directives:
Boeing, 40162–40166
Boeing; withdrawn, 40161–40162

Federal Communications Commission
PROPOSED RULES
Digital television stations; table of assignments:
New Mexico, 40174

Federal Deposit Insurance Corporation
NOTICES
Meetings; Sunshine Act, 40283–40284

Federal Election Commission
NOTICES
Meetings; Sunshine Act, 40284

Federal Energy Regulatory Commission
NOTICES
Electric rate and corporate regulation filings:
Xcel Energy Services, Inc., et al., 40241–40243
Environmental statements; availability, etc.:
Maritimes & Northeast Pipeline L.L.C. et al., 40243
Nantahala Power & Light, 40243–40244
Hydroelectric applications, 40244–40245
Natural Gas Policy Act et al.
Natural gas sales to California market; reporting requirements, 40245–40281
Practice and procedure:
Off-the-record communications, 40281
Applications, hearings, determinations, etc.:
ANR Pipeline Co., 40238
Columbia Gas Transmission Corp., 40238–40239
Eastern Shore Natural Gas Co., 40239
Gulf South Pipeline Co., LP, 40239
Kern River Gas Transmission Co., 40239–40240
Tennessee Gas Pipeline Co., 40240–40241

Federal Highway Administration
NOTICES
Environmental statements; notice of intent:
Riverside County, CA, 40312–40313

Federal Reserve System
NOTICES
Banks and bank holding companies:
Formations, acquisitions, and mergers, 40284

Federal Trade Commission
RULES
Appliances, consumer; energy consumption and water use information in labeling and advertising:
Comparability ranges—
Room air conditioners, heat pump water heaters, storage-type water heaters, gas-fired instantaneous water heaters, furnaces, boilers, and pool heaters, 40110–40111
NOTICES
Premerger notification waiting periods; early terminations, 40284–40287

Food and Drug Administration
NOTICES
Reports and guidance documents; availability, etc.:
Food Additive Safety Office; regulatory submissions in electronic format; general considerations and for food and color additive petitions; correction, 40322

Food and Nutrition Service
PROPOSED RULES
Child nutrition programs:
Women, infants, and children; special supplemental nutrition programs—
Vendor management systems; mandatory selection criteria, limitation of vendors, training requirements, high-risk vendors identification criteria, etc., 40152–40153

Health and Human Services Department
See Centers for Medicare & Medicaid Services
See Food and Drug Administration
See Substance Abuse and Mental Health Services Administration
NOTICES
Meetings:
Vital and Health Statistics National Committee, 40287–40288
Organization, functions, and authority delegations:
Deputy Under Secretary for Intergovernmental Affairs, 40288
Scientific misconduct findings; administrative actions:
Pandurangi, Raghoottama S., Ph.D., 40288–40289

Housing and Urban Development Department
NOTICES
Agency information collection activities:
Proposed collection; comment request, 40230
Submission for OMB review; comment request, 40291–40292

Indian Arts and Crafts Board
NOTICES
Agency information collection activities:
Proposed collection; comment request, 40292–40295

Interior Department
See Minerals Management Service

International Trade Administration
NOTICES
Antidumping:
Honey from—
China, 40191–40192
Stainless steel bar from—
France, 40201–40208
Germany, 40208–40214
Italy, 40214–40222
Korea, 40222–40228
Taiwan, 40198–40201
United Kingdom, 40192–40197
Countervailing duties:
Softwood lumber products from—
Canada, 40228–40229

Labor Department
See Employment and Training Administration
NOTICES
Agency information collection activities:
Proposed collection; comment request, 40296–40298

Library of Congress
See Copyright Office, Library of Congress

Minerals Management Service
NOTICES
Environmental statements; availability, etc.:
TotalFinaElf Exploration & Production USA, Inc., et al.; hydrocarbon reserves off Louisiana and Alabama; deepwater development plan, 40295–40296

National Agricultural Statistics Service
NOTICES
Agency information collection activities:
Proposed collection; comment request, 40189

National Archives and Records Administration
PROPOSED RULES
Records management:
Records disposition procedures; simplification
Correction, 40166

National Highway Traffic Safety Administration
PROPOSED RULES
Motor vehicle safety standards:
Motor vehicle coolant systems; radiator and coolant reservoir caps, 40176

National Oceanic and Atmospheric Administration
RULES
Fishery conservation and management:
Atlantic highly migratory species—
Atlantic bluefin tuna, 40151
PROPOSED RULES
Endangered and threatened species:
Gulf of Maine/Bay of Fundy population of harbor porpoise, 40176–40187
Fishery conservation and management:
Caribbean, Gulf, and South Atlantic fisheries—
Gulf of Mexico shrimp, 40187–40188
West Coast States and Western Pacific fisheries—
Pacific Coast groundfish, 40188
NOTICES
Agency information collection activities:
Proposed collection; comment request, 40229–40233, 40290–40291
Committees; establishment, renewal, termination, etc.:
Cordell Bank National Marine Sanctuary Advisory Council, 40233
Gulf of the Farallones National Marine Sanctuary Advisory Council, 40233–40234
Meetings:
New England Fishery Management Council, 40234–40235
Permits:
Marine mammals, 40235

National Science Foundation
NOTICES
Meetings; Sunshine Act, 40300

Nuclear Regulatory Commission
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 40300
Environmental statements; availability, etc.:
Exelon Generation Co., LLC, 40300–40301

Presidential Documents
EXECUTIVE ORDERS
Government agencies and employees:
Energy-efficient standby power devices (EO 13221), 40569–40571
ADMINISTRATIVE ORDERS
Immigration; migration and refugee assistance (Presidential Determination No. 2001-22 of July 26, 2001), 40107

Public Health Service
See Food and Drug Administration
See Substance Abuse and Mental Health Services Administration

Research and Special Programs Administration
PROPOSED RULES
Hazardous materials:
Hazardous materials transportation—
Loading, unloading, and storage, 40174–40175

Securities and Exchange Commission
NOTICES
Investment Advisers Act of 1940:
Exemption applications—
International Bank for Reconstruction and Development et al., 40301–40302
Self-regulatory organizations; proposed rule changes:
Chicago Board Options Exchange, Inc., 40302–40303
National Association of Securities Dealers, Inc., 40304–40306
New York Stock Exchange, Inc., 40306–40308

Small Business Administration
NOTICES
Disaster loan areas:
Ohio, Indiana, and Kentucky, 40308–40309

State Department
NOTICES
Art objects; importation for exhibition:
Short Century: Independence and Liberation Movements in Africa (1945-1994), 40309
Grants and cooperative agreements; availability, etc.:
Higher education partnership programs administration, 40309–40312

Statistical Reporting Service
See National Agricultural Statistics Service

Substance Abuse and Mental Health Services Administration
NOTICES
Meetings:
Mental Health Services Center National Advisory Council, 40290
Substance Abuse Prevention Center National Advisory Council, 40290

Surface Transportation Board
NOTICES
Motor carriers:
Control applications—
Tedesco Family ESB Trust, 40313–40314
Railroad services abandonment:
New York Central Lines, LLC, 40314–40315

Transportation Department
See Coast Guard
See Federal Aviation Administration
See Federal Highway Administration
See National Highway Traffic Safety Administration
See Research and Special Programs Administration
See Surface Transportation Board

Treasury Department
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 40315

Veterans Affairs Department
NOTICES
Agency information collection activities:
Proposed collection; comment request, 40315–40316

Submission for OMB review; comment request, 40316–40321

Separate Parts In This Issue

Part II
Environmental Protection Agency, 40323–40369

Part III
Department of Health and Human Services, Centers for Medicare and Medicaid Services, 40371–40566

Part IV
Department of Education, 40567–40568

Part V
The President, 40569–40571

Reader Aids

Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, reminders, and notice of recently enacted public laws.

CFR PARTS AFFECTED IN THIS ISSUE

A cumulative list of the parts affected this month can be found in the Reader Aids section at the end of this issue.

3 CFR

Administrative Orders:

Presidential Determinations:

No. 2001–22 of July 26, 2001 40107

Executive Orders:

13221 (See Notice of July 31, 2001) 40571

7 CFR

Proposed Rules:

246.....40152

948 (2 documents) 40153, 40155

966.....40158

14 CFR

39.....40109

Proposed Rules:

39 (2 documents) 40161, 40162

16 CFR

305.....40110

1700.....40111

33 CFR

117 (3 documents) 40116, 40117, 40118

165.....40120

36 CFR

Proposed Rules:

1228.....40166

37 CFR

202.....40322

40 CFR

9.....40121

52.....40137

63.....40121

180 (2 documents) 40140, 40141

Proposed Rules:

52.....40168

63 (2 documents) ....., 40166, 40324,

153.....40170

180.....40170

42 CFR

Proposed Rules:

405.....40372

410.....40372

411.....40372

414.....40372

415.....40372

47 CFR

Proposed Rules:

73.....40174

49 CFR

Proposed Rules:

171.....40174

173.....40174

174.....40174

175.....40174

176.....40174

177.....40174

178.....40174

571.....40176

50 CFR

635.....40151

Proposed Rules:

223.....40176

622.....40187

660.....40188

Federal Register
Vol. 66, No. 149
Thursday, August 2, 2001

Presidential Documents

Title 3—

The President

Presidential Determination No. 2001–22 of July 26, 2001

Determination Pursuant to Section 2(c)(1) of the Migration and Refugee Assistance Act of 1962, as Amended

Memorandum for the Secretary of State

Pursuant to section 2(c)(1) of the Migration and Refugee Assistance Act of 1962, as amended, 22 U.S.C. 2601(c)(1), I hereby determine that it is important to the national interest that up to $27 million be made available from the U.S. Emergency Refugee and Migration Assistance Fund to meet unexpected urgent refugee and migration needs, including those of refugees, displaced persons, conflict victims, and other persons at risk due to the situations in Guinea, Sierra Leone, Eritrea, and Afghanistan. These funds may be used, as appropriate, to provide contributions to international, governmental, and nongovernmental organizations, and as necessary, for administrative expenses of the Bureau of Population, Refugees, and Migration. Of the $27 million hereby determined, not more than $5 million shall be reserved on a contingency basis in order to allow for immediate United States response to unexpected urgent refugee and migration needs.

You are authorized and directed to inform the appropriate committees of the Congress of this determination and the obligation of funds under this authority, and to arrange for the publication of this memorandum in the **Federal Register**.



THE WHITE HOUSE,
Washington, July 26, 2001.

[FR Doc. 01–19498
Filed 8–1–01; 8:45 am]
Billing code 4710–10–M

Rules and Regulations

Federal Register

Vol. 66, No. 149

Thursday, August 2, 2001

This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2001–SW–03–AD; Amendment 39–12354; AD 2001–15–19]

RIN 2120–AA64

Airworthiness Directives; Eurocopter France Model AS–365N3 Helicopters

AGENCY: Federal Aviation Administration, DOT.

ACTION: Final rule.

SUMMARY: This amendment adopts a new airworthiness directive (AD) for Eurocopter France (ECF) Model AS–365N3 helicopters that requires modifying the Full Authority Digital Engine Control (FADEC) software within 90 days after the effective date of this AD. This amendment is prompted by a design problem in the FADEC ''power loss printed circuit board'' software found during laboratory testing. The actions specified by this AD are intended to prevent loss of the FADEC one-engine-inoperative power and subsequent loss of control of the helicopter.

DATES: Effective September 6, 2001.

The incorporation by reference of certain publications listed in the regulations is approved by the Director of the Federal Register as of September 6, 2001.

ADDRESSES: The service information referenced in this AD may be obtained from American Eurocopter Corporation, 2701 Forum Drive, Grand Prairie, Texas 75053–4005, telephone (972) 641–3460, fax (972) 641–3527. This information may be examined at the FAA, Office of the Regional Counsel, Southwest Region, 2601 Meacham Blvd., Room 663, Fort Worth, Texas; or at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC.

FOR FURTHER INFORMATION CONTACT: Carroll Wright, Aviation Safety Engineer, FAA, Rotorcraft Directorate, Regulations Group, Fort Worth, Texas 76193–0111, telephone (817) 222–5120, fax (817) 222–5961.

SUPPLEMENTARY INFORMATION: A proposal to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) to include an AD for ECF Model AS–365N3 helicopters was published in the **Federal Register** on May 9, 2001 (66 FR 23632). That action proposed to require modifying the FADEC software and wiring within 90 days after the effective date of the AD.

Interested persons have been afforded an opportunity to participate in the making of this amendment. No comments were received on the proposal or the FAA's determination of the cost to the public. The FAA has determined that air safety and the public interest require the adoption of the rule as proposed.

The FAA estimates that 1 helicopter of U.S. registry will be affected by this AD and that it will take approximately 17 work hours per helicopter to modify the wiring. The average labor rate is $60 per work hour. The FADEC software modification has an estimated turbomeca labor charge of $1200. The manufacturer has stated that the wiring kits will be furnished at no cost. Based on these figures, the total cost impact of the proposed AD on U.S. operators is estimated to be $2220.

The regulations adopted herein will not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this final rule does not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this action (1) is not a ''significant regulatory action'' under Executive Order 12866; (2) is not a ''significant rule'' under DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A final evaluation has been prepared for this action and it is contained in the Rules Docket. A copy of it may be obtained from the Rules Docket at the location provided under the caption **ADDRESSES.**

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.

Adoption of the Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration amends part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by adding a new airworthiness directive to read as follows:

2001–15–19 Eurocopter France: Amendment 39–12354. Docket No. 2001–SW–03–AD.

Applicability: Model AS–365N3 helicopters, certificated in any category.

Note 1: This AD applies to each helicopter identified in the preceding applicability provision, regardless of whether it has been otherwise modified, altered, or repaired in the area subject to the requirements of this AD. For helicopters that have been modified, altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (b) of this AD. The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD; and if the unsafe condition has not been eliminated, the request should include specific proposed actions to address it.

Compliance: Within 90 days after the effective date of this AD, unless previously accomplished.

To prevent loss of the Full Authority Digital Engine Control (FADEC) one-engine-inoperative power and subsequent loss of control of the helicopter, accomplish the following:

(a) Modify the FADEC software in accordance with the Accomplishment Instructions of Eurocopter France Service Bulletin No. 71.00.13, Revision 1, dated October 17, 2000 (except this AD does not

require contact with the manufacturer as specified in the caution statement in paragraph 2.B. and the Note I in paragraph 2.B.2.).

(b) An alternative method of compliance or adjustment of the compliance time that provides an acceptable level of safety may be used if approved by the Manager, Regulations Group, Rotorcraft Directorate, FAA. Operators shall submit their requests through an FAA Principal Maintenance Inspector, who may concur or comment and then send it to the Manager, Regulations Group.

Note 2: Information concerning the existence of approved alternative methods of compliance with this AD, if any, may be obtained from the Regulations Group.

(c) Special flight permits may be issued in accordance with 14 CFR 21.197 and 21.199 to operate the helicopter to a location where the requirements of this AD can be accomplished.

(d) The modification shall be done in accordance with the Accomplishment Instructions of Eurocopter France Service Bulletin No. 71.00.13, Revision 1, dated October 17, 2000. This incorporation by reference was approved by the Director of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies may be obtained from American Eurocopter Corporation, 2701 Forum Drive, Grand Prairie, Texas 75053–4005, telephone (972) 641–3460, fax (972) 641–3527. Copies may be inspected at the FAA, Office of the Regional Counsel, Southwest Region, 2601 Meacham Blvd., Room 663, Fort Worth, Texas; or at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC.

(e) This amendment becomes effective on September 6, 2001.

Note 3: The subject of this AD is addressed in Direction Generale De L'Aviation Civile (France) AD Nos. 2000–517–051(A) and 1998–517–048(A) R2, both dated December 13, 2000; 1998–517–048(A) R1, dated April 5, 2000; and 1998–517–048(A), dated January 13, 1999.

Issued in Fort Worth, Texas, on July 23, 2001.

Eric Bries,

Acting Manager, Rotorcraft Directorate, Aircraft Certification Service.

[FR Doc. 01–18972 Filed 8–1–01; 8:45 am]

BILLING CODE 4910–13–U

FEDERAL TRADE COMMISSION

16 CFR Part 305

Rule Concerning Disclosures Regarding Energy Consumption and Water Use of Certain Home Appliances and Other Products Required Under the Energy Policy and Conservation Act (''Appliance Labeling Rule'')

AGENCY: Federal Trade Commission.

ACTION: Final rule.

SUMMARY: The Federal Trade Commission (Commission) announces that the current ranges of comparability required by the Appliance Labeling Rule (Rule) for room air conditioners, heat pump water heaters, storage-type water heaters, gas-fired instantaneous water heaters, furnaces, boilers, and pool heaters will remain in effect until further notice.

EFFECTIVE DATE: October 31, 2001.

FOR FURTHER INFORMATION CONTACT: Hampton Newsome, Attorney, Division of Enforcement, Federal Trade Commission, Washington, DC 20580 (202–326–2889);hnewsome@ftc.gov.

SUPPLEMENTARY INFORMATION: The Rule was issued by the Commission in 1979, 44 FR 66466 (Nov. 19, 1979), in response to a directive in the Energy Policy and Conservation Act of 1975.[1] The Rule covers eight categories of major household appliances: refrigerators and refrigerator-freezers, freezers, dishwashers, clothes washers, water heaters (this category includes storage-type water heaters, gas-fired instantaneous water heaters, and heat pump water heaters), room air conditioners, furnaces (this category includes boilers), and central air conditioners (this category includes heat pumps). The Rule also covers pool heaters, 59 FR 49556 (Sept. 28, 1994), and contains requirements that pertain to fluorescent lamp ballasts, 54 FR 28031 (July 5, 1989), certain plumbing products, 58 FR 54955 (Oct. 25, 1993), and certain lighting products, 59 FR 25176 (May 13, 1994, eff. May 15, 1995).

The Rule requires manufacturers of all covered appliances and pool heaters to disclose specific energy consumption or efficiency (derived from the DOE test procedures) at the point of sale in the form of an ''Energy Guide'' label and in catalogs. It also requires manufacturers of furnaces, central air conditioners, and heat pumps either to provide fact sheets showing additional cost information, or to be listed in industry directory showing the cost information for their products. The Rule requires manufacturers to include, on labels and fact sheets, an energy consumption or efficiency figure and a ''range of comparability.'' This range shows the highest and lowest energy consumption or efficiencies for all comparable appliance models so consumers can compare the energy consumption or efficiency of other models (perhaps competing brands) similar to the label model. The Rule also requires manufacturers to include, on labels for some products, a secondary energy usage disclosure in the form of an estimated annual operating cost based on a specified DOE national average cost for fuel the applicance uses.

Section 305.8(b) of the Rule requires manufactures, after filing an initial report, to report certain information annually to the Commission by specified dates for each product type.[2] These reports, which are to assist the Commission in preparing the ranges of comparability, contain the estimated annual energy consumption or energy efficiency ratings for the appliances derived from tests performed pursuant to the DOE test procedures. Because manufacturers regularly add new models to their lines, improve existing models, and drop others, the data base from which the range of comparability are calculated is constantly changing. To keep the required information consistent with these changes, under Section 305.10 of the Rule, the Commission will publish new ranges if an analysis of the new information indicates that the upper or lower limits of the ranges have changed by more than 15%. Otherwise, the Commission will publish a statement that the prior ranges remain in effect for the next year.

Manufacturers have submitted data for room air conditioners, water heaters (including storage-type, gas-fired instantaneous, and heat pump water heaters), furnaces, boilers, and pool heaters. The ranges of comparability for room air conditioners, heat pump water heaters, storage-type water heaters, gas-fired instantaneous water heaters, furnaces, boilers, and pool heaters have not changed by more than 15% from the current ranges for these products. Therefore, the current ranges for these products will remain in effect until further notice.

This means that manufacturers of storage-type water heaters, furnaces, and boilers must continue to use the ranges that were published on September 23, 1994 (59 FR 48796). These manufacturers must continue to base the disclosures of estimated annual operating cost required at the bottom of EnergyGuides for these products on the 1994 Representative Average Unit Costs of Energy for electricity (8.41 cents per kilo Watt-hour), natural gas (60.4 cents per therm), propane (98 cents per gallon), and/or heating oil ($1.05 per gallon) that were published by DOE on December 29, 1993 (58 FR 68901), and

[1] 42 U.S.C. 6294. The status also requires the Department of Energy (DOE) to develop test procedures that measure how much energy the appliances use, and to determine the representative average cost a consumer pays for the different types of energy available.

[2] Reports from room air conditioners, heat pump water heaters, storage-type water heaters, gas-fired instantaneous water heaters, furnaces, boilers, and pool heaters are due May 1.

by the Commission on February 8, 1994 (59 FR 5699).

Manufacturers of heat pump water heaters must continue to use the ranges that were published on September 1, 2000 (65 FR 53163). Manufacturers of heat pump water heaters must continue to base the disclosures of estimated annual operating cost required at the bottom of EnergyGuides for these products on the 2000 Representative Average Unit Costs of Energy for electricity (8.03 cents per kiloWatt-hour) that were published by DOE on March 8, 2001 (66 FR 27856), and by the Commission on May 21, 2001 (66 FR 27856).

Manufacturers of gas-fired instantaneous water heaters must continue to use the ranges of comparability that were published on December 20, 1999 (64 FR 71019). They must continue to base the disclosures of estimated annual operating cost required at the bottom of EnergyGuides for these products on the 1999 Representative Average Unit Cost of Energy for natural gas (68.8 cents per therm) and propane (77 cents per gallon) that were published by DOE on January 5, 1999 (64 FR 487) and by the Commission on February 17, 1999 (64 FR 7783).

Manufacturers of pool heaters must continue to use the ranges that were published on August 21, 1995 (60 FR 43367). Manufacturers of room air conditioners must continue to use the corrected ranges for room air conditioners that were published on November 13, 1995 (60 FR 56945, at 56949). Manufacturers of pool heaters and room air conditioners must continue to base the disclosures of estimated annual operating cost required at the bottom of EnergyGuides for these products on the 1995 Representative Average Unit Costs of Energy for electricity (8.67 cents per kiloWatt-hour), natural gas (63 cents per therm), propane (98.5 cents per gallon), and/or heating oil ($1.008 per gallon) that were published by DOE on January 5, 1995 (60 FR 1773), and by the Commission on February 17, 1995 (60 FR 9295).

For up-to-date tables showing current range and cost information for all covered appliances, see the Commission's Appliance Labeling Rule web page at *www.ftc.gov/appliances.*

List of Subjects in 16 CFR Part 305

Advertising, Energy conservation, Household appliances, Labeling, Reporting and recordkeeping requirements.

The authority citation for Part 305 continues to read as follows:

Authority: 42 U.S.C. 6294.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 01–19339 Filed 8–1–01; 8:45 am]

BILLING CODE 6750–01–M

CONSUMER PRODUCT SAFETY COMMISSION

16 CFR Part 1700

Child-Resistant Packaging for Certain Over-The-Counter Drug Products

AGENCY: Consumer Product Safety Commission.

ACTION: Final rule.

SUMMARY: Pursuant to its 3–0 vote to do so, the Consumer Product Safety Commission (CPSC or Commission) is issuing a rule to require child-resistant (CR) packaging on drugs (OTC switched drugs) approved by the Food and Drug Administration (FDA) for over-the-counter (OTC) sale that contain active ingredients previously available only in prescription drugs. Current Commission regulations require CR packaging for most oral drug products containing prescription-only active ingredients. However, prior to issuance of this rule there was no general requirement to maintain CR packaging of such drug products in forms subsequently approved by the FDA for OTC sale.

The Commission is also revoking the current prohibition on granting a petition for an exemption from a CR packaging requirement prior to FDA approval of the drug product in question.

The Commission takes these actions under authority of the Poison Prevention Packaging Act of 1970, as amended.

DATES: The rule will become effective on January 29, 2002, and applies only to products for which the new drug application (NDA) or abbreviated new drug application (ANDA) for the OTC switch is submitted to the FDA on or after that date.

FOR FURTHER INFORMATION CONTACT: Suzanne Barone, Ph.D., Directorate for Health Sciences, Consumer Product Safety Commission, Washington, D.C. 20207; telephone (301) 504–0477 ext. 1196 or Geri Smith, Office of Compliance, Consumer Product Safety Commission, Washington, D.C. 20207; telephone (301) 504–0608 ext. 1160.

SUPPLEMENTARY INFORMATION:

A. Background

1. Prior Regulatory Approach

The Poison Prevention Packaging Act of 1970 (PPPA), 15 U.S.C. 1471–1476, was established to protect children from serious personal injury or serious illness resulting from handling, using, or ingesting hazardous substances. Under the PPPA, the CPSC can require child-resistant packaging of hazardous household chemicals, including drugs. The CPSC currently requires child-resistant packaging of oral prescription medications, unless they have been specifically exempted from the packaging requirements. 16 CFR 1700.14(a)(10). In contrast, OTC drugs, which are also called nonprescription drugs because they can be sold to consumers without prescription by a licensed medical practitioner, have not previously been regulated as a class under the PPPA.

Regulations have been issued to require child-resistant packaging of several individual OTC products including diphenhydramine, ibuprofen, loperamide, naproxen, and ketoprofen. These oral drugs were available originally only by prescription and therefore required child-resistant packaging under the oral prescription drug regulation. The FDA subsequently granted OTC status to these drugs, thus removing them from the scope of the child-resistant packaging requirements of the oral prescription drug regulation. After each of these substances was granted OTC status, the Commission promulgated a separate regulation to require the child-resistant packaging of the drug.

2. Relevant Statutory and Regulatory Provisions

The PPPA authorizes the Commission to establish standards for the ''special packaging'' of any household substance if: (1) The degree or nature of the hazard to children in the availability of such substance, by reason of its packaging, is such that special packaging is required to protect children from serious personal injury or serious illness resulting from handling, using, or ingesting such substance; and (2) the special packaging is technically feasible, practicable, and appropriate for such substance. 15 U.S.C. 1472(a).

CR or ''special'' packaging must be designed or constructed to be: (1) Significantly difficult for children under 5 years of age to open or obtain a toxic or harmful amount of the substance contained therein within a reasonable time; and (2) not difficult for ''normal

adults'' to use properly. 15 U.S.C. 1471(4). Household substances for which the Commission may require CR packaging include (among other categories) foods, drugs, or cosmetics as these terms are defined in the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 321. 15 U.S.C. 1471(2)(B). The Commission has promulgated performance requirements for special packaging. 16 CFR 1700.15 and 1700.20.

Section 4(a) of the PPPA, 15 U.S.C. 1473(a), allows the manufacturer or packer to package a nonprescription product subject to special packaging standards in one size of non-CR packaging only if the manufacturer (or packer) also supplies the product in a CR package of a popular size, and the non-CR package bears conspicuous labeling stating ''This package for households without young children.'' 15 U.S.C. 1473(a), 16 CFR 1700.5.

3. The Proposed Rule

On August 30, 2000, the Commission issued a notice of proposed rulemaking (NPR) that would require that CR packaging requirements applicable to an oral prescription drug product continue to apply when that drug product or any other drug product containing an active ingredient of that product is granted OTC status by the FDA. 65 FR 52678. The proposed rule would require that the new use or new dose be sold in CR packaging even if the new use or dose was not approved when the drug product was only available by prescription. This is consistent with the current regulatory approach for a new use for an oral OTC product that is already subject to a CR packaging requirement.

The proposed rule would not extend CR packaging requirements to OTC-switched products that are not oral formulations, even if they contain any of the same active ingredients as an oral preparation.

The proposed rule would require CR packaging for any OTC oral drug product containing an active ingredient that was available by prescription even if the OTC dosage is lower than the prescription strength. This recognizes the reality that absent CR packaging, the ''dose'' potentially available to a child is the entire package contents.

4. Exemptions

An exemption procedure exists for PPPA-regulated products that do not pose a risk of serious injury or illness to children or for which CR packaging is not technically feasible, practicable, or appropriate. 16 CFR part 1702. Under the proposed rule, this exemption procedure would remain available to manufacturers of OTC-switched products.

The proposed rule would revoke 16 CFR 1702.16(b) so that exemption petitions can be submitted and considered by the Commission earlier in the process, *i.e.,* before FDA approval. This would enable manufacturers to seek an exemption from the CR packaging requirements and have a Commission decision prior to submitting an application to the FDA for approval of an OTC or prescription drug product.

To assist consumers and industry in identifying which OTC-switched drug products require CR packaging, the preamble to the proposal indicated that the Commission intended to maintain a list of OTC-switched drug products subject to the regulation as an appendix to the regulations at 16 CFR 1700.14.

B. Response to Comments

Five comments were received in response to the NPR. Three of the five comments received supported the rule as proposed (CP01–1, 2, 5).

Comment: Several commenters questioned whether the PPPA permits imposing child-resistant packaging requirements on a category of drugs and then placing the burden on a manufacturer to seek exemption of individual drugs. (CP01–1–3, 4)

Response: The PPPA authorizes regulation of a category of substances where the required findings can be made for that category. In fact, a number of entries under the CPSC regulation imposing the PPPA child-resistant packaging requirement, 16 CFR 1700.14(a), are defined as broad categories. (See, for example: controlled drugs—''any preparation for human use that consists in whole or in part of any substance subject to control under the Comprehensive Drug Abuse Prevention and Control Act * * *,'' (16 CFR 1700.14(a)(4); prescription drugs—''any drug for human use that is in a dosage form intended for oral administration * * *,'' (16 CFR 1700.14(a)(10)).

All members of the class that would be required to be in child-resistant packaging by an OTC-switch rulemaking were previously covered by the PPPA child-resistant packaging requirement for oral prescription drugs (16 CFR 1700.14(a)(10)). The statutory findings for that class were made by the FDA in the 1972–1973 rulemaking that imposed child-resistant packaging on oral prescription drugs. 38 FR 9431 (April 16, 1973).

The ability of a drug to cause serious injury to a child does not change when it is sold OTC. Child-resistant packaging remains technically feasible, practicable, and appropriate for the OTC version, just as was the case when it was required for the prescription formulation. Furthermore, the continued need for child-resistant packaging is not a factor considered by the FDA when making its decision to approve the switch of a drug from prescription to OTC status. Under the OTC-switch rule as proposed, and as issued in final form today, the responsibility/burden on a manufacturer to justify an exemption for an OTC-switched drug via the procedures of 16 CFR 1702 is the same as it was before the drug was switched.

The courts have typically approved the validity of regulatory schemes where a rule addresses a general situation that is too complex for the rule to be appropriate in every instance, but where an exemption procedure is established to deal with special situations. *See, e.g., United States* v. *Allegheny-Ludlum Steel Corp.,* 406 U.S. 742 (1972); *see also Phillips Petroleum Co.* v. *EPA,* 803 F.2d 545, 562 (10th Cir. 1986)(upholding a regulation applying a ''generic streamlined approach or procedure'' on the grounds of ''feasibility and practicality'' where the plaintiff argued that the statute required a case-by-case review).

In a case that addressed the Commission's Flammable Fabrics Act regulatory authority, which is analogous to that under the PPPA, the First Circuit affirmed the categorical approach to regulation. *Bunny Bear* v. *Peterson,* 473 F.2d 1002 (1st Cir. 1973). The *Bunny Bear* court also addressed the ''burden'' issue by stating that when the regulatory agency ''plausibly opts for the inclusion of a particular product [in a regulatory scheme], it is not unreasonable to require affected manufacturers to point out with particularity those features which make special treatment [i.e., exemption] necessary.'' *Bunny Bear* at 1007.

Comment: One commenter requested that OTC products be available in both child-resistant packaging and non child-resistant packaging for the elderly and disabled (CP01–1).

Response: The PPPA provides for the use of both child-resistant and non child-resistant packaging. Section 4 of the Act allows manufacturers to package a product in one size that does not meet the child-resistant packaging standards. 15 U.S.C. 1473. A product so packaged must carry a labeling statement warning that it is not recommended for use in households with young children. There is no requirement that manufacturers have a non child-resistant size.

It is the manufacturer's decision whether or not to market a

noncomplying size. Manufacturers who market one size of their product in non child-resistant packaging must also supply the product in popular-sized packages that are child-resistant. If the manufacturer does not comply with this provision, the Commission can require that the product be packaged exclusively in child-resistant packaging. 15 U.S.C. 1473(c).

Child-resistant packaging has also become more ''adult-friendly.'' In 1995 the Commission issued a revised test method that tests participants aged 50 to 70, rather than 18 to 45 years of age, to ensure that most adults can use child resistant packaging properly. 16 CFR § 1700.20(a)(3)(i).

Comment: One commenter requested that manufacturers and sellers have 18-months advance notice of the effective date of these packaging changes and that they only be implemented for newly manufactured packages (CP01–2).

Response: The packaging regulation as proposed and as issued in final form applies only to a drug granted OTC status as a result of a new drug applications (NDA) or abbreviated new drug application (ANDA) submitted to the FDA on or after the effective date of the final OTC-switch rule. The rule does not affect any product that is approved for OTC sale before that date. The rule does not impact the current production or sale of previously switched products. Therefore the effective date of 180 days after issuance of a final rule should be adequate for companies currently preparing NDA or ANDA submissions requesting OTC status for oral prescriptions.

Comment: One commenter requested that a comprehensive list of affected products and ingredients be made available in advance of the effective date (CP01–2).

Response: The CPSC will publish a list of drugs that are affected by the rule as soon as the Agency becomes aware of them. CPSC will work with the FDA to obtain timely notification of approval of oral prescription drugs that are granted OTC status. No oral prescription drug approved for OTC sale (or for which the NDA or ANDA for an OTC switch was submitted) before the effective date is affected by the rule. The list will include only OTC switched drugs for which the NDA or ANDA was submitted on or after the effective date of the final rule.

Comment: One commenter questioned the efficiency of the proposed rule in saving staff resources because of the resources potentially needed to consider requests for exemptions. The commenter stated that it may be just as efficient to continue the practice of considering the need for child-resistant packaging on a case-by-case basis (CP01–3).

Response: The primary goal of this rulemaking is not to save staff resources but to continue to protect children from serious injury from ingesting oral prescription drugs that are granted OTC status and become widely available. This rule eliminates the potential for newly switched oral OTC drugs to be packaged and sold without child-resistant packaging before a decision concerning the continued need for child-resistant packaging is made by the Commission. Furthermore, these drugs were already required to be in child-resistant packaging in their prior, prescription-only form. Finally, it is worth noting that some companies already voluntarily use child-resistant packaging for their ''OTC switched'' products.

The staff cannot estimate how many petitions for exemption from the child-resistant packaging requirements the Commission will receive.

Comment: Two commenters requested revisions to the Commission's PPPA regulations that define child-resistant unit packaging (CP01–3, 4).

Response: The child-resistant unit packaging regulations are not part of this rulemaking. Therefore the comment is beyond the scope of this rulemaking. Accordingly, the Commission is not required to respond to it. *See, e.g., American Iron & Steel Institute* v. *EPA,* 886 F.2d 390, 398 (D.C. Cir. 1989), *cert. denied,* 497 U.S. 1003 (1990).

Comment: One commenter requested clarification that the Commission will accept and act on a petition for exemption early in the process, before a NDA or ANDA is submitted to the FDA.

Response: In the preamble to the proposed rule, the Commission stated that, ''* * * the Commission is proposing to revoke 16 CFR 1702.16(b) so that exemption petitions can be submitted and considered by the Commission earlier in the process, i.e., before FDA approval. This would enable manufacturers to seek an exemption from the child-resistant packaging requirements and have a Commission decision prior to submitting an application to the FDA for approval of an OTC or prescription drug product.'' 65 FR 52682. Since 16 CFR 1702.16(b) is revoked by today's rule, there is no longer any restriction on the timing of Commission consideration of a petition for exemption from an otherwise applicable child-resistant packaging requirement.

The exemption process involves rulemaking. This process can be expedited if the manufacturer meets with the CPSC staff to discuss the process before filing a petition for exemption with the Commission as outlined in 16 CFR part 1702.

Comment: One commenter expressed a concern that if a petition is submitted before the NDA is submitted, it could prematurely signal a company's business plans. They believed that a confidential exemption procedure might be necessary but stated the concern that it would not be compatible with the current rulemaking approach to exemptions. (CP01–3)

Response: The commenter is correct that the child-resistant packaging exemption procedure involves public notice and comment. A petitioner must be willing to make toxicity and safety information available for Commission and public review.

There are many factors that a company considers when deciding to pursue OTC status for an oral prescription drug. These may include safety of use and potential misuse, ability of a consumer to self-treat using the medication, or a new market for a drug at the end of its patent, etc. There is much speculation in the press about drugs that may be ''switched'' based upon these factors. The commenter (Consumer Healthcare Products Association) publishes a list of potential switches that have been named in the trade or popular press.[1] The FDA requested comments and held a public meeting last year to discuss potential OTC drugs.[2] Much of the discussion at the public hearing focused on classes of drugs that may or may not be appropriate for OTC sale.

A manufacturer of an oral prescription drug that is contemplating seeking approval for an OTC switch could request an exemption for the prescription drug. It is the active ingredient itself at a defined level that would then be exempted. Under the rule as proposed, an exempted oral prescription drug would remain exempted from child-resistant packaging when it is granted OTC status. For example, if an oral contraceptive or colestipol were made available OTC, it would not require child-resistant packaging if the OTC preparation met the same conditions as the exempted oral prescription form. (16 CFR 1700.14(a)(10)(iv) and (xv)). A manufacturer would still have the option of petitioning the Commission for exemption after the drug is approved for OTC sale.

[1] Available on the CHPA website: www.chpa-info.org

[2] 65 FR 24704

C. Statutory Considerations

1. Hazard to Children

Before issuing a rule requiring CR packaging, the Commission must find that the degree or nature of the hazard to children in the availability of OTC-switched drug products by reason of their packaging is such that special packaging is required to protect children from serious injury or illness from handling, using, or ingesting the drug products. 15 U.S.C. 1472(a)(1). These statutory findings were made when the rule requiring CR packaging for oral prescription drug products was promulgated in 1973. 38 Fed. Reg. 9431 (April 16, 1973).

OTC-switches did not begin to occur until several years after the 1973 rule requiring CR packaging for oral prescription drug products was promulgated. The first such switches were carried out in response to recommendations resulting from an FDA Advisory Panel's review of over-the-counter drug products.

The need to continue to protect children remains when oral prescription drug products are granted OTC status. As noted previously, a decision by the FDA to grant OTC status for a prescription drug product is not a determination that there is no toxicity to a child if the drug product is accidentally ingested. The active ingredient(s) contained in the drug product have the same toxicity whether in prescription or OTC form. The issue is whether drug products switched to OTC status at a lower dosage than was available by prescription are still hazardous to young children. This is the case since absent CR packaging, the ''dose'' available to a child can be the entire contents of the OTC product package. The Commission's experiences with ibuprofen and naproxen demonstrate that toxic amounts of the active ingredients are available even when lower dosages are approved for OTC product sale.

Another important consideration is that OTC drug products are more readily available to consumers and therefore more accessible to children than prescription products containing the same active ingredient(s). The Commission concludes that the available data support the finding that maintaining CR packaging is necessary to protect children from serious injury or illness from ingesting oral prescription drug products that have been granted OTC status.

2. Technical Feasibility, Practicability, and Appropriateness

As a prerequisite to a CR packaging rule, the Commission must also find that the special packaging is ''technically feasible, practicable, and appropriate.'' 15 U.S.C. 1472(a)(2). Technical feasibility may be found when technology exists or can be readily developed and implemented by the effective date to produce packaging that conforms to the standards. Practicability means that special packaging complying with the standards can utilize modern mass production and assembly line techniques. Packaging is appropriate when complying packaging will adequately protect the integrity of the active ingredient(s) in the product and not interfere with its intended storage or use. See S. Rep. No. 91–845, at 10 (1970).

In some cases the same packaging can be used for the OTC product as for the prescription product. However, companies must modify the labels since FDA labeling requirements for OTC drug products differ from the labeling requirements for prescription drugs. Also, most companies develop new packaging specifically for the OTC market. Unit dose packaging is popular for the OTC market, especially for drug products such as antihistamines that are sold in limited quantities. Other products containing active ingredients such as the anti-inflammatory compounds ibuprofen and naproxen are sold in bottles. CR designs of this sort of unit and reclosable packaging are commercially available. The change in status of the drug from prescription-only to OTC does not change the availability of the CR packaging in mass-produced quantities, or detract from its ability to maintain the shelf life of switched drug products. Therefore, the Commission concludes that CR packaging for OTC-switched drug products is technically feasible, practicable, and appropriate.

3. Other Considerations

Section 3(b) of the PPPA requires that the Commission consider the following in establishing a special packaging standard:

a. The reasonableness of the standard;

b. Available scientific, medical, and engineering data concerning special packaging and concerning childhood accidental ingestions, illness, and injury caused by household substances;

c. The manufacturing practices of industries affected by the PPPA; and

d. The nature and use of the household substance. 15 U.S.C. 1472(b).

The Commission has considered these factors with respect to the various determinations made in this rulemaking, and finds no reason to conclude that the rule is unreasonable or otherwise inappropriate.

D. Applicability

The packaging configuration for a drug product to be switched is determined before a company submits the NDA or the ANDA for the OTC-switch to the FDA. Accordingly, this rule applies prospectively to drug products for which the application for the OTC-switch is submitted to the FDA on or after the effective date of the final rule (180 days after publication).

E. Effective Date

The PPPA provides that no regulation shall take effect sooner than 180 days or later than one year after the date such final regulation is issued, except that, for good cause, the Commission may establish an earlier effective date if it determines an earlier date to be in the public interest. 15 U.S.C. 1471n. The NPR proposed an effective date of 180 days after publication of the final rule. The commenter suggesting a further delayed effective date seemed to believe that the proposed rule might apply to an oral prescription drug for which an NDA or ANDA had been submitted to the FDA prior to the effective date or for which the OTC switch had been approved by the FDA prior to the effective date. This is not the case. The rule as proposed and as issued today applies only to drugs for which the NDA or ANDA for the OTC switch is submitted on or after the effective date. Thus the final rule takes effect 180 days after publication.

F. Regulatory Flexibility Act Certification

When an agency undertakes a rulemaking proceeding, the Regulatory Flexibility Act (RFA), as amended by the Small Business Regulatory Enforcement Fairness Act of 1996, 5 U.S.C. 601 *et seq.*, generally requires the agency to prepare initial and final regulatory flexibility analyses describing the impact of the rule on small businesses and other small entities. Section 605 of the RFA provides that an agency is not required to prepare a regulatory flexibility analysis if the head of the agency certifies that the rule will not have a significant economic impact on a substantial number of small entities.

The Commission's Directorate for Economic Analysis prepared an assessment of the impact of a rule to maintain CR packaging for OTC-switched drug products. A copy of the analysis is available for inspection in

the docket for this rulemaking. The assessment reports that the incremental cost of providing basic CR packaging is usually small ($0.005–$0.02/per package). The assessment notes that the incremental cost may be somewhat higher if the marketer elects to provide more elaborate packaging in an effort to create ''shelf appeal'' to attract consumers and compete with other OTC products in the same therapeutic category.

Because these costs (if any) are likely to be passed on to consumers, it is unlikely that the rule will have a substantial effect on a significant number of small businesses.

Many previously OTC-switched drug products are already sold in CR packaging. In some instances, for example with certain oral dosage formulations of acetaminophen, ibuprofen and loperamide, this is because the Commission has affirmatively required CR packaging. In other cases, the marketer has elected voluntarily to use CR packaging.

This rule revokes the existing requirement at 16 CFR 1702.16(b) that new drug approval be obtained from the FDA prior to Commission approval of a petition seeking exemption from a CR packaging requirement. Allowing for advance consideration and approval of any legitimate CR packaging exemption petition should minimize or eliminate any unwarranted economic impact that would otherwise result from maintaining the CR packaging requirement on OTC-switched oral prescription drug products or from requiring a change to CR packaging post-marketing.

Based on the foregoing assessment, the Commission certifies that this rule to maintain CR packaging for OTC-switched drug products does not have a significant impact on a substantial number of small businesses or other small entities.

G. Environmental Considerations

Pursuant to the National Environmental Policy Act, and in accordance with Council on Environmental Quality regulations and CPSC procedures for environmental review, the Commission has assessed the possible environmental effects associated with the proposed PPPA requirements for OTC-switched drug products.

The Commission's regulations state that rules requiring special packaging for consumer products normally have little or no potential for affecting the human environment. 16 CFR 1021.5(c)(3). Nothing in this rule alters that expectation. Therefore, because the rule would have no adverse effect on the environment, neither an environmental assessment nor an environmental impact statement is required.

H. Executive Order No. 12,988

As provided for in Executive Order No. 12,988 the CPSC states the preemptive effect of this proposed regulation as follows.

The PPPA provides that, generally, when a special packaging standard issued under the PPPA is in effect, ''no State or political subdivision thereof shall have any authority either to establish or continue in effect, with respect to such household substance, any standard for special packaging (and any exemption therefrom and requirement related thereto) which is not identical to the [PPPA] standard.'' 15 U.S.C. 1476(a). A State or local standard may be excepted from this preemptive effect if (1) the State or local standard provides a higher degree of protection from the risk of injury or illness than the PPPA standard; and (2) the State or political subdivision applies to the Commission for an exemption from the PPPA's preemption clause and the Commission grants the exemption through procedures specified at 16 CFR part 1061. 15 U.S.C. 1476(c)(1). In addition, the Federal government, or a State or local government, may establish and continue in effect a non-identical special packaging requirement that provides a higher degree of protection than the PPPA requirement for a household substance for the Federal, State or local government's own use. 15 U.S.C. 1476(b).

Thus, with the exceptions noted above, this rule preempts non-identical state or local special packaging standards for such drug products.

List of Subjects in 16 CFR Part 1700

Consumer protection, Drugs, Infants and children, Packaging and containers, Poison prevention, Toxic substances, Reporting and recordkeeping requirements.

For the reasons set forth above, the Commission amends 16 CFR part 1700 as follows:

PART 1700—POISON PREVENTION PACKAGING ACT OF 1970 REGULATIONS

1. The authority citation for part 1700 continues to read as follows:

Authority: 15 U.S.C. 1471–76. Secs. 1700.1 and 1700.14 also issued under 15 U.S.C. 2079(a).

2. Section 1700.14 is amended by republishing paragraph (a) introductory text and by adding new paragraph (a)(30) to read as follows:

§ 1700.14 Substances requiring special packaging.

(a) Substances. The Commission has determined that the degree or nature of the hazard to children in the availability of the following substances, by reason of their packaging, is such that special packaging meeting the requirements of § 1700.20(a) is required to protect children from serious personal injury or serious illness resulting from handling, using, or ingesting such substances, and the special packaging herein required is technically feasible, practicable, and appropriate for these substances:

* * * * *

(30) *Over-the-Counter Drug Products.* (i) Any over-the-counter drug product in a dosage form intended for oral administration that contains an active ingredient also contained in a drug product that is or was a prescription drug product required by paragraph (a)(10) to be in special packaging shall be packaged in accordance with the provisions of § 1700.15(a),(b), and (c). This requirement applies whether or not the amount of the active ingredient in the over-the-counter drug product is different from the amount of that active ingredient in the prescription drug product. This requirement does not apply to a drug product for which an application for over-the-counter marketing has been submitted to the FDA before January 29, 2002 or which has been granted over-the-counter status by the FDA before January 29, 2002. Notwithstanding the foregoing, any special packaging requirement under this section 1700.14 otherwise applicable to an over-the-counter drug product remains in effect.

(ii) For purposes of this paragraph (30), *active ingredient* means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the body of humans; and *drug product* means a finished dosage form, for example, tablet, capsule, or solution, that contains a drug substance (active ingredient), generally, but not necessarily, in association with one or more other ingredients. (These terms are intended to have the meanings assigned to them in the regulations of the Food and Drug Administration appearing at 21 CFR 201.66 (2001) and 21 CFR 314.3 (2000), respectively.)

3. Section 1702.16 is amended by removing paragraph (b) thereof in its entirety.

Dated: July 27, 2001.

Todd A. Stevenson,

Acting Secretary, Consumer Product Safety Commission.

List of Relevant Documents

1. Briefing memorandum from Suzanne Barone, Ph.D., EH, to the Commission, ''Final Rule to Require Special Packaging for Oral Prescription Drugs that are Granted Over-the-Counter Status by the Food and Drug Administration,'' July 2, 2001.
2. Letter from Debra L. Bowen, M.D., Acting Director, Division of Over-the-Counter Drug Products, Food and Drug Administration, to Jeffrey S. Bromme, Esq., General Counsel, Consumer Product Safety Commission, October 7, 1998.
3. Memorandum from Robert L. Franklin, EC, to Suzanne Barone, Ph.D., EH, ''Economic Considerations Related to the Rule to Maintain Child-Resistant Packaging Requirements for Oral Prescription Drugs that Have Been Granted OTC Status by the FDA,'' May 31, 2001.
4. Memorandum from Suzanne Barone, Ph.D., Project manager for Poison prevention, Directorate for health Sciences, to Sadye E. Dunn, Secretary, Consumer Product Safety Commission, ''Responses to Questions from Commissioner Moore on Over-the-Counter Switches,'' June 23, 2000.

[FR Doc. 01–19225 Filed 8–1–01; 8:45 am]

BILLING CODE 6355–01–P

DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Part 117

[CGD01–01–108]

RIN 2115–AE47

Drawbridge Operation Regulations: Jamaica Bay and Connecting Waterways, NY

AGENCY: Coast Guard, DOT.

ACTION: Temporary final rule.

SUMMARY: The Coast Guard is establishing a temporary final rule governing the operation of the Belt Parkway Bridge, at mile 0.8, across Mill Basin at Brooklyn, New York. This rule allows the bridge owner to require a one-hour advance notice for bridge openings from 10 p.m. through 5 a.m., Sunday through Thursday, from July 29, 2001 through December 31, 2001. This action is necessary to facilitate structural maintenance at the bridge.

DATES: This temporary final rule is effective from July 29, 2001 through December 31, 2001.

ADDRESSES: Material received from the public, as well as documents indicated in this preamble as being available in the docket, are part of docket (CGD01–01–108) and are available for inspection or copying at the First Coast Guard District, Bridge Branch Office, 408 Atlantic Avenue, Boston, Massachusetts, 02110, 6:30 a.m. to 3 p.m., Monday through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Mr. Joseph Schmied, Project Officer, First Coast Guard District, (212) 668–7165.

SUPPLEMENTARY INFORMATION:

Regulatory Information

The Coast Guard has determined that good cause exists under the Administrative Procedure Act (5 U.S.C. 553) for not publishing a NPRM with comment and for making this regulation effective in less than 30 days after publication in the **Federal Register**. The Coast Guard believes notice and comment are unnecessary because our review of the bridge logs for the past two years shows that there have been no bridge openings requested at night during the time period this rule will be in effect. Making this rule effective less than thirty days after publication is necessary because the bridge owner advised the Coast Guard that emergency structural maintenance must be performed to insure safe operation of the bridge. In view of the historic absence of night time bridge opening requests and the demonstrated need to perform structural maintenance, any delay encountered in this regulation's effective date would be unnecessary and contrary to the public interest.

Background

The Belt Parkway Bridge, at mile 0.8, across the Mill Basin, has a vertical clearance of 34 feet at mean high water, and 39 feet at mean low water in the closed position. The existing drawbridge operating regulations are listed at 33 CFR 117.795(b).

The bridge owner, New York City Department of Transportation (NYCDOT), requested a temporary regulation to facilitate structural maintenance to replace the deteriorated roadway deck at the bridge.

Regulatory Evaluation

This rule is not a ''significant regulatory action'' under section 3(f) of Executive Order 12866 and does not require an assessment of potential costs and benefits under section 6(a)(3) of that Order. The Office of Management and Budget has not reviewed it under that Order. It is not ''significant'' under the regulatory policies and procedures of the Department of Transportation (DOT) (44 FR 11040; February 26, 1979). This conclusion is based on the fact that there have been no requests to open the bridge during the time period the bridge owner has requested an advance notice requirement.

Small Entities

Under the Regulatory Flexibility Act (5 U.S.C. 601–612) we considered whether this rule would have a significant economic impact on a substantial number of small entities. ''Small entities'' comprises small businesses, not-for profit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations less than 50,000.

The Coast Guard certifies under 5 U.S.C. 605(b) that this rule will not have a significant economic impact on a substantial number of small entities. This conclusion is based on the fact that there have been no requests to open the bridge during the time period the bridge owner has requested an advance notice requirement.

Assistance for Small Entities

Under section 213(a) of the Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104–121), we offered to assist small entities in understanding the rule so that they could better evaluate its effects on them and participate in the rulemaking process. Small businesses may send comments on the actions of Federal employees who enforce, or otherwise determine compliance with, Federal regulations to the Small Business and Agriculture Regulatory Enforcement Ombudsman and the Regional Small Business Regulatory Fairness Boards. The Ombudsman evaluates these actions annually and rates each agency's responsiveness to small business. If you wish to comment on actions by employees of the Coast Guard, call 1–888–REG–FAIR (1–888–734–3247).

Collection of Information

This rule calls for no new collection of information under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520).

Federalism

We have analyzed this rule under Executive Order 13132 and have determined that this rule does not have implications for federalism under that Order.

Unfunded Mandates Reform Act

The Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1531–1538) governs the issuance of Federal regulations that require unfunded mandates. An unfunded mandate is a regulation that requires a State, local, or tribal

government or the private sector to incur direct costs without the Federal Government's having first provided the funds to pay those unfunded mandate costs. This rule will not impose an unfunded mandate.

Taking of Private Property

This rule will not effect a taking of private property or otherwise have taking implications under Executive Order 12630, Governmental Actions and Interference with Constitutionally Protected Property Rights.

Civil Justice Reform

This rule meets applicable standards in sections 3(a) and 3(b)(2) of Executive Order 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.

Protection of Children

We have analyzed this rule under Executive Order 13045, Protection of Children from Environmental Health Risks and Safety Risks. This rule is not an economically significant rule and does not concern an environmental risk to health or risk to safety that may disproportionately affect children.

Environment

The Coast Guard considered the environmental impact of this rule and concluded that under figure 2–1, paragraph (32)(e) of Commandant Instruction M16475.1C, this rule is categorically excluded from further environmental documentation because promulgation of changes to drawbridge regulations have been found to not have a significant effect on the environment. A written ''Categorical Exclusion Determination'' is not required for the temporary final rule.

Indian Tribal Governments

This final rule does not have tribal implications under Executive Order 13175, Consultation and Coordination with Indian Tribal Governments, because it does not have substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes.

Energy Effects

We have analyzed this rule under Executive Order 13211, Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use. We have determined that it is not a ''significant energy action'' under that order because it is not a ''significant regulatory action'' under Executive Order 12866 and is not likely to have a significant adverse effect on the supply, distribution, or use of energy. It has not been designated by the Administrator of the Office of Information and Regulatory Affairs as a significant energy action. Therefore, it does not require a Statement of Energy Effects under Executive Order 13211.

List of Subjects in 33 CFR Part 117

Bridges.

Regulations

For the reasons set out in the preamble, the Coast Guard amends 33 CFR part 117 as follows:

PART 117—DRAWBRIDGE OPERATION REGULATIONS

1. The authority citation for part 117 continues to read as follows:

Authority: 33 U.S.C. 499; 49 CFR 1.46; 33 CFR 1.05–1(g); section 117.255 also issued under the authority of Pub. L. 102–587, 106 Stat. 5039.

2. From July 29, 2001 through December 31, 2001, § 117.795 is temporarily amended by suspending paragraph (b) and adding a new paragraph (d) to read as follows:

§ 117.795 Jamaica Bay and connecting waterways.

* * * * *

(d)(1) The draws of the New York City highway bridge, mile 0.8, across Mill Basin on Belt Parkway, need not be opened for the passage of vessels from noon to 9 p.m. on Sundays from July 29, 2001 to December 31, 2001 and on Labor Day. However, on these days, from two hours before to one hour after predicted high tide, the draw shall open on signal. For the purposes of this section, predicted high tide occurs 15 minutes later than that predicted for Sandy Hook, as given in the tide tables published by the National Oceanic and Atmospheric Administration.

(2) From 10 p.m. to 5 a.m., Sunday through Thursday, from July 29, 2001 through December 31, 2001, the draw shall open on signal after at least a one-hour advance notice is given by calling the number posted at the bridge.

(3) At all times, public vessels of the United States and state or local vessels used for public safety shall be passed as soon as possible.

Dated: July 20, 2001.

G.N. Naccara,

Rear Admiral, U.S. Coast Guard, Commander, First Coast Guard District.

[FR Doc. 01–18921 Filed 8–1–01; 8:45 am]

BILLING CODE 4910–15–U

DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Part 117

[CGD08–01–019]

Drawbridge Operating Regulation; Ouachita River, LA

AGENCY: Coast Guard, DOT.

ACTION: Notice of temporary deviation from regulations.

SUMMARY: The Commander, Eighth Coast Guard District has issued a temporary deviation from the regulation in 33 CFR 117.5 governing the operation of the Kansas City Southern Railroad swing span bridge across the Ouachita River, mile 167.1, at Monroe, Ouachita Parish, Louisiana. This deviation allows the bridge owner to close the bridge to navigation from noon on Sunday, August 19, 2001 until noon on Tuesday, August 21, 2001. Presently, the draw is required to open on signal for the passage of vessels. This temporary deviation was issued to allow for repairs to the turn span of the bridge.

DATES: This deviation is effective from noon on August 19, 2001 until noon on August 21, 2001.

ADDRESSES: Unless otherwise indicated, documents referred to in this notice are available for inspection or copying at the office of the Eighth Coast Guard District, Bridge Administration Branch, Commander (ob), 501 Magazine Street, New Orleans, Louisiana, 70130–3396. The Bridge Administration Branch maintains the public docket for this temporary deviation.

FOR FURTHER INFORMATION CONTACT: David Frank, Bridge Administration Branch, telephone (504) 589–2965.

SUPPLEMENTARY INFORMATION: The Kansas City Southern Railroad swing span bridge across the Ouachita River, mile 167.1, at Monroe, Ouachita Parish, Louisiana has a vertical clearance of 2 feet above high water in the closed-to-navigation position and 52 feet above high water in the open-to-navigation position. Navigation on the waterway consists primarily of tugs with tows. Modjeski and Masters, consulting engineers for the Kansas City Southern Railroad requested a temporary deviation from the normal operation of the drawbridge in order to accommodate the jacking of the swing span at the center and ends (bridge in the closed position) sufficient to raise the center circular turning track several inches to improve the opening and closing of the swing span. This maintenance is

necessary for the continued operation of the bridge.

This deviation allows the draw of Kansas City Southern Railroad swing span bridge across the Ouachita River, mile 167.1, to remain closed to navigation from noon on August 19, 2001 until noon on August 21, 2001.

Dated: July 26, 2001.

Roy J. Casto,

RADM, USCG, Commander, 8th CG District.

[FR Doc. 01–19333 Filed 8–1–01; 8:45 am]

BILLING CODE 4910–15–P

DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Part 117

[CGD05–01–001]

RIN 2115–AE47

Drawbridge Operation Regulation; Beaufort Channel, Beaufort, NC

AGENCY: Coast Guard, DOT.

ACTION: Final rule.

SUMMARY: The Coast Guard is changing the regulations that govern the operation of the Graydon Paul Drawbridge on US 70 across Beaufort Channel, also known as Gallant's Channel mile 0.1, located in Beaufort, North Carolina, at the request of the North Carolina Department of Transportation.

The final rule reduces the number of bridge openings during times of peak highway traffic. This final rule is intended to reduce motor vehicular delays and congestion related to commuter traffic going to and from work in the mornings and evenings, while still providing for the reasonable needs of navigation.

DATES: This final rule is effective on September 4, 2001.

ADDRESSES: Comments and material received from the public, as well as documents indicated in this preamble as being available in the docket are part of docket CGD05–01–001, and are available for inspection or copying at the office of the Commander (Aowb), Fifth Coast Guard District, Federal Building, 4th Floor, 431 Crawford Street, Portsmouth, Virginia 23704–5004, between 8 a.m. and 4:30 p.m., Monday through Friday, except Federal holidays. The telephone number is (757) 398–6222.

FOR FURTHER INFORMATION CONTACT: Ann Deaton, Bridge Administrator, Fifth Coast Guard District, (757) 398–6222.

SUPPLEMENTARY INFORMATION:

Regulatory History

On April 13, 2001, the Coast Guard published a Notice of Proposed Rulemaking (NPRM) entitled ''Drawbridge Operation Regulations; Beaufort Channel, Beaufort, NC'' in the **Federal Register** (66 FR 19105). The Coast Guard received 5 letters commenting on the proposed rulemaking. No public hearing was requested and none was held.

Background and Purpose

The Graydon Paul Drawbridge across Beaufort Channel, located in Beaufort, North Carolina, is owned and operated by the North Carolina Department of Transportation (NCDOT). The current regulation at 33 CFR 117.822 requires the bridge to open on signal, except that from 6 a.m. to 10 p.m., the draw opens on signal for all vessels waiting to pass every hour on the hour, twenty minutes past the hour and forty minutes past the hour; except that on weekdays the bridge need not open at 7:40 a.m., 8:40 a.m., 4:40 p.m. and 5:40 p.m.

NCDOT requested that openings of the Graydon Paul Drawbridge be further restricted by limiting drawbridge openings to on the hour and half hour seven days a week and rush hour restrictions from 6:30 a.m. to 8 a.m. and 4:30 p.m. to 6 p.m. during weekday morning and evening rush hours. This request to change the current regulation is based on heavy vehicular commuter traffic traveling to and from the Town of Beaufort during peak rush hour periods. The Graydon Paul Drawbridge is located on US Highway 70, which is the only corridor entering and exiting the town of Beaufort from Morehead City, North Carolina. Drawbridge openings create long traffic backups often extending for 6 to 7 miles. The heavy congestion often results in vehicular accidents. NCDOT contends that openings on the hour and half hour and extending rush hour restrictions will allow the bridge to clear the traffic before another opening occurred. Vehicular traffic congestion on US Highway 70 will be reduced and highway safety will be increased without placing undue hardship on vessel traffic.

NCDOT provided the Coast Guard with statistical data which shows that 12–13000 vehicles cross the drawbridge each day. When drawbridge openings occur every twenty minutes, traffic backups extend for several miles and cannot clear before the next opening. One mile South of the Graydon Paul Drawbridge on the same route is the Morehead City US 70 Bridge, which is a fixed 65 ft vertical clearance bridge on the Atlantic Intracoastal Waterway (AICWW). It is an alternate route for boaters to go around through the AICWW by Morehead City back to Beaufort. Motorist do not have an alternate route on US 70 back and forth to and from Beaufort to Morehead City. In reviewing the recent draw logs and traffic counts, the Coast Guard has determined that the current regulations do not allow traffic to clear especially during rush hour periods and there was minimal vessel traffic at these times, therefore, a reduction in the number of openings will not substantially impact navigational traffic, but will provide a positive offsetting benefit to vehicular traffic.

The Coast Guard is amending § 117.822 by changing drawbridge openings from 6 a.m. to 10 p.m. to opening on the hour and half hour and eliminating openings from 6:30 a.m. to 8 a.m. and 4:30 p.m. to 6 p.m. on weekdays only, year round. All other provisions of the existing regulation will remain the same.

Discussion of Comments and Changes

The Coast Guard received 5 letters on the NPRM in support of the proposed changes to the regulation. The comments applauded the change and went further in asking that the bridge be welded shut. Since all of the comments favorably addressed the proposed change for which comments were being solicited, and the Coast Guard has determined permanently closing the bridge to all vessel traffic would interfere with navigation, the final rule is being implemented without change.

Regulatory Evaluation

This final rule is not a significant regulatory action under section 3(f) of Executive Order 12866, Regulatory Planning and Review, and does not require an assessment of potential costs and benefits under section 6(a)(3) of that order. The Office of Management and Budget has not reviewed it, under that order. It is not significant under the regulatory policies and procedures of the Department of Transportation (DOT) (44 FR 11040; February 26, 1979).

The Coast Guard expects the economic impact of this final rule to be so minimal that a full Regulatory Evaluation under paragraph 10e of the regulatory policies and procedures of DOT is unnecessary.

The Coast Guard reached this conclusion based on the fact that the final rule will not prevent mariners from transiting the bridge, but merely require them to plan their transits in accordance with the scheduled bridge openings.

Small Entities

Under the Regulatory Flexibility Act (5 U.S.C. 601–612), the Coast Guard has considered whether this final rule will have a significant economic impact on a substantial number of small entities. The term ''Small entities'' comprises small businesses, not-for-profit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations of less than 50,000. The Coast Guard certifies under 5 U.S.C. 605(b) that this final rule will not have a significant economic impact on a substantial number of small entities. This is based on the fact that we contacted the local commercial facilities affected by this change to the regulations and received no adverse comments. The proposed regulation will still provide for the reasonable needs of navigation while improving highway conditions by restricting the vessel openings of the bridge from every twenty minutes to on the hour and half hour.

Collection of Information

This final rule would call for no new collection of information under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520).

Assistance for Small Entities

Under section 213(a) of the Small Business Regulatory Enforcement Fairness Act of 1996 (Public Law 104–121), we offered to assist small entities in understanding the rule so that they could better evaluate its effects on them and participate in the rulemaking process.

Small businesses may send comments on the actions of Federal employees who enforce, or otherwise determine compliance with, Federal regulations to the Small Business and Agriculture Regulatory Enforcement Ombudsman and the Regional Small Business Regulatory Fairness Boards. The Ombudsman evaluates these actions annually and rates each agency's responsiveness to small business. If you wish to comment on actions by employees of the Coast Guard, call 1–888–REG–FAIR (1–888–734–3247).

Federalism

A rule has implications for federalism under Executive Order 13132, Federalism, if it has a substantial direct effect on State or local governments and would either preempt State law or impose a substantial direct cost of compliance on them. We have analyzed this rule under that Order and have determined that it does not have implications for federalism.

Unfunded Mandates Reform Act

The Unfunded Mandates reform Act of 1995 (2 U.S.C. 1531–1538) requires Federal agencies to assess the effects of their discretionary regulatory actions. In particular, the Act addresses actions that may result in the expenditure by the State, local, or tribal government, in the aggregate, or by the private sector of $100,000,000 or more in any one year. Though this rule will not result in such an expenditure, we do discuss the effects of this rule elsewhere in the preamble.

Taking of Private Property

This rule will not effect the taking of private property or otherwise have taking implications under Executive Order 12630, Governmental Actions and Interference with Constitutionally Protected Property Rights.

Civil Justice Reform

This rule meets applicable standards in sections 3(a) and 3(b)(2) of Executive Order 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.

Protection of Children

We have analyzed this rule under Executive Order 13045, Protection of Children from Environmental Health Risks and Safety Risks. This rule is not an economically significant rule and does not create an environmentally significant rule and does not create an environmental risk to health or risk to safety that may disproportionately affect children.

Indian Tribal Governments

This rule does not have tribal implications under Executive Order 13175, Consultation and Coordination with Indian Tribal Governments, because it does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes.

Energy Effects

We have analyzed this rule under Executive Order 13211, Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use. We have determined that is not a ''significant energy action'' under that order because it is not a ''significant regulatory action'' under Executive Order 12866 and is not likely to have a significant adverse effect on the supply, distribution, or use of energy. It has not been designated by the Administrator of the Office of Information and Regulatory Affairs as a significant energy action. Therefore, it does not require a Statement of Energy Effects under Executive Order 13211.

Environment

The Coast Guard considered the environmental impact of this final rule and concluded that under figure 2–1, paragraph (32)(e) of COMDTINST M16475.1C, this final rule is categorically excluded from further environmental documentation based on the fact that it is a promulgation of the operating regulations for a drawbridge. A Categorical Exclusion Determination statement has been prepared and placed in the rulemaking docket.

List of Subjects in 33 CFR Part 117

Bridges.

For the reasons discussed in the preamble, the Coast Guard amends 33 CFR part 117 as follows:

PART 117—DRAWBRIDGE OPERATION REGULATIONS

1. The authority citation for part 117 continues to read as follows:

Authority: 33 U.S.C. 499; 49 CFR 1.46; 33 CFR 1.05–1(g); Section 117.255 also issued under the authority of Pub. L. 102–587, 106 Stat. 5039.

2. Section 117.822 is revised to read as follows:

§ 117.822 Beaufort Channel, NC.

The draw of the US 70 bridge, mile 0.1, at Beaufort, shall open as follows:

(a) From 6 a.m. to 10 p.m., the draw need only open every hour on the hour and on the half hour; except that Monday through Friday the bridge need not open between the hours of 6:30 a.m. to 8 a.m. and 4:30 p.m. to 6 p.m.

(b) From 10 p.m. to 6 a.m., the bridge shall open on signal.

Dated: July 24, 2001.

Thad W. Allen,

Vice Admiral, U.S. Coast Guard, Commander, Fifth Coast Guard District.

[FR Doc. 01–19334 Filed 8–1–01; 8:45 am]

BILLING CODE 4910–15–P

DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Part 165

[CGD09–01–099]

RIN 2115–AA97

Safety Zone; Blue Water Offshore Classic, St. Clair River, MI

AGENCY: Coast Guard, DOT.

ACTION: Temporary final rule.

SUMMARY: The Coast Guard is establishing a temporary moving safety zone 1000 yards ahead, 1000 yards astern, and 50 yards to each side of any deep draft vessel that can safely navigate only within the channel of St. Clair River, during the Blue Water Offshore Classic on August 3, 4 and 5, 2001. The moving safety zone is necessary to prevent damage or injury to the deep draft vessels or personnel involved in the Blue Water Offshore Power Boat Race. Only authorized vessels are permitted to enter or remain within the safety zone.

DATES: This temporary final rule is effective from 8 a.m. on August 3, 2001, through 6 p.m. on August 5, 2001.

ADDRESSES: Comments and material received from the public, as well as documents indicated in this preamble as being available in the docket, are part of docket CGD09–01–099 and are available for inspection or copying at: U.S. Coast Guard Marine Safety Office Detroit, 110 Mt. Elliott St. Detroit, MI 48207, between 8 a.m. and 4 p.m., Monday through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT: ENS Brandon Sullivan, U.S. Coast Guard Marine Safety Office Detroit, telephone number (313) 568–9558.

SUPPLEMENTARY INFORMATION:

Regulatory Information

We did not publish a notice of proposed rulemaking (NPRM) for this regulation. Under 5 U.S.C. 553(b)(B), the Coast Guard finds that good cause exists for not publishing an NPRM. Under 5 U.S.C. 553(d)(3), the Coast Guard finds that good cause exists for making this rule effective less than 30 days after publication in the **Federal Register**. The permit application was not received in time to publish an NPRM followed by a final rule before the effective date. Delaying this rule would be contrary to the public interest of ensuring the safety of spectators and vessels during this event and immediate action is necessary to prevent possible loss of life or property.

Background and Purpose

A temporary moving safety zone is necessary to ensure the safety of commercial vessels and race participants from the hazards associated with high-speed powerboat racing. The likely combination of large numbers of recreational vessels, congested waterways, high-speed watercraft, and deep draft commercial vessels could easily result in serious injuries or fatalities. Establishing a moving safety zone to control vessel movement around the commercial vessels while transiting through the racecourse will help ensure the safety of persons and property at this event and help minimize the associated risk.

The moving safety zone will encompass all waters within 1000 yards ahead, 1000 yards behind, and 50 yards on either side of any deep draft vessel that can only safely navigate within the channel of St. Clair River.

The moving safety zone will be enforced to the South, 500 yards East of the Newman and River Road Intersection at position 42°51′54″ N, 082°28′00″ W. These coordinates are based upon North American Datum 1983 (NAD 83). To the North, the moving safety zone will be enforced 300 yards East of the St. Clair Michigan State Police Docks at position 42°28′54″ N, 082°28′48″ W (NAD 83).

All persons and vessels shall comply with the instructions of the Coast Guard Captain of the Port or the designated on scene patrol representative. Entry into, transiting, or anchoring within the safety zone is prohibited unless authorized by the Captain of the Port Detroit or his designated on scene representative. The Captain of the Port or his designated on scene representative may be contacted via VHF Channel 16.

Regulatory Evaluation

This rule is not a ''significant regulatory action'' under section 3(f) of Executive Order 12866 and does not require an assessment of potential costs and benefits under section 6(a)(3) of that order. The Office of Management and Budget has not reviewed this rule under that order. It is not ''significant'' under the regulatory policies and procedures of the Department of Transportation (DOT) (44 FR 11040, February 26, 1979). We expect the economic impact of this rule to be so minimal that a full Regulatory Evaluation under paragraph 10(e) of the regulatory policies and procedures of DOT is unnecessary.

This determination is based on the minimal time that vessels will be restricted from the zone, and therefore minor if any impacts to Mariners.

Small Entities

Under the Regulatory Flexibility Act (5 U.S.C. 601–612), we considered whether this rule would have a significant impact on a substantial number of small entities. The term ''small entities'' comprises small businesses, not-for-profit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations of less than 50,000.

The Coast Guard certifies under 5 U.S.C. 605(b) that this rule would not have a significant economic impact on a substantial number of small entities.

This rule would affect the following entities, some of which might be small entities: The owners or operators of commercial vessels intending to transit or anchor in a portion of the activated safety zone.

This moving safety zone will not have a significant economic impact on a substantial number of small entities for the following reasons: The safety zone is only in effect from 6 a.m. until 8 p.m. on the days of the event; commercial vessel traffic will not be impeded in any way by this moving safety zone and traffic may be allowed to pass through the safety zone under Coast Guard escort with the permission of the Captain of the Port Detroit or his designated on-scene representative. Before the effective period, we will issue maritime advisories widely available to users of the St. Clair River by the Ninth Coast Guard District Local Notice to Mariners, and Marine Information Broadcasts. Facsimile broadcasts may also be made.

If you think that your business, organization, or governmental jurisdiction qualifies as a small entity and that this rule would have a significant economic impact on it, please submit a comment (see **ADDRESSES**) explaining why you think it qualifies and how and to what degree this rule would economically affect it.

Assistance for Small Entities

Under section 213(a) of the Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104–121), we want to assist small entities in understanding this rule so that they can better evaluate its effects and participate in the rulemaking process. If the rule would affect your small business, organization, or governmental jurisdiction and you have questions concerning its provisions or options for compliance, please contact Marine Safety Office Detroit (see **ADDRESSES**).

Small businesses may send comments on the actions of Federal employees

who enforce, or otherwise determine compliance with, Federal regulations to the Small Business and Agriculture Regulatory Enforcement Ombudsman and the Regional Small Business Regulatory Fairness Boards. The Ombudsman evaluates these actions annually and rates each agency's responsiveness to small business. If you wish to comment on actions by employees of the Coast Guard, call 1–888–REG–FAIR (1–888–734–3247).

Collection of Information

This rule would call for no new collection of information under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520).

Federalism

We have analyzed this rule under Executive Order 13132 and have determined that this rule does not have implications for federalism under that Order.

Unfunded Mandates Reform Act

The Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1531–1538) requires Federal agencies to assess the effects of their discretionary regulatory actions. In particular, the Act addresses actions that may result in the expenditure by a State, local, or tribal government, in the aggregate, or by the private sector of $100,000,000 or more in any one year. Though this rule will not result in such an expenditure, we do discuss the effects of this rule elsewhere in this preamble.

Taking of Private Property

This rule would not affect a taking of private property or otherwise have taking implications under Executive Order 12630, Governmental Actions and Interference with Constitutionally Protected Property Rights.

Civil Justice Reform

This rule meets applicable standards in sections 3(a) and 3(b)(2) of Executive Order 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.

Protection of Children

The Coast Guard has analyzed this rule under Executive Order 13045, Protection of Children from Environmental Health Risks and Safety Risks. This rule is not an economically significant rule and does not concern an environmental risk to health or risk to safety that may disproportionately affect children.

Environment

We have considered the environmental impact of this rule and concluded that, under figure 2–1, paragraph 34(g) of Commandant Instruction M16475.1C, this rule is categorically excluded from further environmental documentation. A written categorical exclusion determination is available in the docket for inspection or copying where indicated under **ADDRESSES.**

Indian Tribal Governments

This rule does not have tribal implications under Executive Order 13175, Consultation and Coordination with Indian Tribal Governments, because it does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes.

List of Subjects in 33 CFR Part 165

Harbors, Marine Safety, Navigation (water), Reporting and recordkeeping requirements, Security measures, Waterways.

For the reasons discussed in the preamble, the Coast Guard amends 33 CFR part 165 as follows:

PART 165—REGULATED NAVIGATION AREAS AND LIMITED ACCESS AREAS

1. The authority citation for part 165 continues to read as follows:

Authority: 33 U.S.C. 1231; 50 U.S.C. 191, 33 CFR 1.05–1(g), 6.04–1, 6.04–6, 160.5; 49 CFR 1.46.

2. A new temporary § 165.T09–980 is added to read as follows:

§ 165.T09–980 Safety Zone; Blue Water Offshore Classic, St. Clair River, MI.

(a) *Location.* This moving safety zone encompasses all waters within 1000 yards ahead, 1000 yards behind, and 50 yards on either side of any deep draft vessel that can only safely navigate within the channel of the St. Clair River. The moving safety zone will be enforced to the South, starting 500 yards East of the Newman and River Road Intersection at position 42°51′54″ N, 082°28′00″ W. To the North, the moving safety zone will be enforced starting 300 yards East of the St. Clair Michigan State Police Docks at position 42°28′54″ N, 082°28′48″ W. These coordinates are based upon North American Datum 1983 (NAD 83).

(b) *Enforcement times and dates.* This section will be enforced 8 a.m. until 6 p.m. on August 3, 4 and 5, 2001. The designated on-scene Patrol Commander may be contacted via VHF Channel 16.

(c) *Regulations.* In accordance with the general regulations in § 165.23 of this part, entry into the safety zone is prohibited unless authorized by the Coast Guard Captain of the Port Detroit, or his designated on-scene representative.

Dated: July 25, 2001.

S.P. Garrity,

Captain, U.S. Coast Guard, Captain of the Port Detroit.

[FR Doc. 01–19314 Filed 8–1–01; 8:45 am]

BILLING CODE 4910–15–U

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Parts 9 and 63

[FRL–7020–3]

RIN 2060–AE83

National Emission Standards for Pharmaceuticals Production

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule and direct final rule; corrections and amendments.

SUMMARY: The EPA is taking direct final action to amend the national emission standards for hazardous air pollutants (NESHAP) for pharmaceuticals production. This direct final rule provides additional compliance options for process vent and storage tank emissions, specifies additional methods that may be used to analyze wastewater, shifts one compound from the list of partially soluble hazardous air pollutants (HAP) to the list of soluble HAP, eliminates an unintended restriction on the use of enhanced biological treatment, allows a sewer line between drains and the first downstream junction box to be vented, clarifies how to assign storage tanks that are shared among pharmaceutical manufacturing process units and other types of process units, clarifies the monitoring frequency requirements for connectors, clarifies and simplifies recordkeeping and reporting requirements, eliminates inconsistencies, and corrects several referencing and typesetting errors. We view these revisions to be minor and noncontroversial, and we anticipate no adverse comment.

In compliance with the Paperwork Reduction Act (PRA), this action also amends the table that lists the Office of Management and Budget (OMB) control numbers issued under the PRA for the pharmaceuticals production rule.

DATES: The amendments to 40 CFR part 9 are effective on August 2, 2001. The direct final rule amendments to 40 CFR

part 63 are effective on October 16, 2001 without further notice, unless EPA receives adverse comments by September 4, 2001, or by September 17, 2001 if a public hearing is requested. See the proposed rule in this issue of the **Federal Register** for information on the hearing. If we receive any adverse comments, and those comments apply to an amendment, paragraph, or section of this rule, and that provision may be addressed separately from the remainder of the rule, we will withdraw only those provisions on which we received adverse comments. We will publish a timely withdrawal in the **Federal Register** indicating which provisions will not take effect.

ADDRESSES: *Comments.* By U.S. Postal Service, send comments (in duplicate, if possible) to: Air and Radiation Docket and Information Center (6102), Attention Docket Number A–96–03, U.S. EPA, 1200 Pennsylvania Avenue, NW, Washington, DC 20460. In person or by courier, deliver comments (in duplicate if possible) to: Air and Radiation Docket and Information Center (6102), Attention Docket Number A–96–03, U.S. EPA, 401 M Street, SW, Washington DC 20460. The EPA requests that a separate copy of each public comment be sent to the contact person listed below (see **FOR FURTHER INFORMATION CONTACT**). Comments may also be submitted electronically by following the instructions provided in **SUPPLEMENTARY INFORMATION**. *Docket.* Docket No. A–96–03 contains supporting information used in developing the NESHAP. The docket is located at the U.S. EPA, 401 M Street, SW, Washington, DC 20460 in Room M–1500, Waterside Mall (ground floor), and may be inspected from 8 a.m. to 5:30 p.m., Monday through Friday, excluding legal holidays.

FOR FURTHER INFORMATION CONTACT: Mr. Randy McDonald, Organic Chemicals Group, Emission Standards Division (MD–13), U.S. EPA, Research Triangle Park, North Carolina 27711, telephone number (919) 541–5402, electronic mail address: mcdonald.randy@epa.gov.

SUPPLEMENTARY INFORMATION: *Comments.* Comments and data may be submitted by electronic mail (e-mail) to: a-and-r-docket@epa.gov. Electronic comments must be submitted as an ASCII file to avoid the use of special characters and encryption problems and will also be accepted on disks in WordPerfect version 5.1, 6.1, or Corel 8 file format. All comments and data submitted in electronic form must note the docket number A–96–03. No confidential business information (CBI) should be submitted by e-mail. Electronic comments may be filed online at many Federal Depository Libraries.

Commenters wishing to submit proprietary information for consideration must clearly distinguish such information from other comments and clearly label it as CBI. Send submissions containing such proprietary information directly to the following address, and not to the public docket, to ensure that proprietary information is not inadvertently placed in the docket: Attention: Mr. Randy McDonald, c/o OAQPS Document Control Officer (Room 740B), U.S. EPA, 411 W. Chapel Hill Street, Durham, NC 27701. The EPA will disclose information identified as CBI only to the extent allowed by the procedures set forth in 40 CFR part 2. If no claim of confidentiality accompanies a submission when it is received by EPA, the information may be made available to the public without further notice to the commenter.

Docket. The docket is an organized and complete file of all the information considered by EPA in the development of this rulemaking. The docket is a dynamic file because material is added throughout the rulemaking process. The docketing system is intended to allow members of the public and industries involved to readily identify and locate documents so that they can effectively participate in the rulemaking process. Along with the proposed and promulgated standards and their preambles, the contents of the docket will serve as the record in the case of judicial review. (See section 307(d)(7)(A) of the Clean Air Act (CAA).) The regulatory text and other materials related to this rulemaking are available for review in the docket or copies may be mailed on request from the Air Docket by calling (202) 260–7548. A reasonable fee may be charged for copying docket materials.

Worldwide Web (WWW). In addition to being available in the docket, an electronic copy of this action will also be available through the WWW. Following signature, a copy of this action will be posted on the EPA's Technology Transfer Network (TTN) policy and guidance page for newly proposed or promulgated rules: http://www.epa.gov/ttn/oarpg. The TTN at EPA's web site provides information and technology exchange in various areas of air pollution control. If more information regarding the TTN is needed, call the TTN HELP line at (919) 541–5384.

Regulated Entities. The regulated category and entities affected by this action include:

Category	NAICS codes	SIC codes	Examples of regulated entities
Industry	325411 and 325412	2833 and 2834	• Producers of finished dosage forms of drugs (e.g., tablets, capsules, and solutions), active ingredients, or precursors.
	Typically 325199	Typically 2869	• Producers of material whose primary use is as an active ingredient of precursor.

This table is not intended to be exhaustive, but rather provides a guide for readers likely to be interested in the revisions to the regulation affected by this action. To determine whether your facility, company, business, organization, etc., is regulated by this action, you should carefully examine all of the applicability criteria in § 63.1250 of the rule. If you have questions regarding the applicability of these amendments to a particular entity, consult the person listed in the preceding **FOR FURTHER INFORMATION CONTACT** section.

Judicial Review. Under section 307(b)(1) of the CAA, judicial review of this direct final rule is available only by filing a petition for review in the U.S. Court of Appeals for the District of Columbia by October 1, 2001. Under section 307(d)(7)(B) of the CAA, only an objection to this direct final rule that was raised with reasonable specificity during the period for public comment can be raised during judicial review. Moreover, under section 307(b)(2) of the CAA, the requirements established by this direct final rule may not be challenged separately in any civil or criminal proceeding brought to enforce these requirements. Also under section 307(b)(1) of the CAA, judicial review of the amendment to part 9 in this action is available by filing a petition for review in the U.S. Court of Appeals for

the District of Columbia Circuit within October 1, 2001. Under section 307(b)(2) of the CAA, the requirements that are the subject of this amendment may not be challenged later in civil or criminal proceedings brought by the EPA to enforce these requirements.

Outline. The information presented in this preamble is organized as follows:

I. Why are we publishing these amendments as a direct final rule?
II. What amendments are we making to part 9 to reflect OMB approval of the information collection request for subpart GGG?
III. What amendments are we making to the process vent provisions?
IV. What amendments are we making to the wastewater provisions?
V. What amendments are we making to the storage tank provisions?
VI. What minor technical corrections are we making?
VII. What are the administrative requirements for this direct final rule?
A. Executive Order 12866, Regulatory Planning and Review
B. Executive Order 13132, Federalism
C. Executive Order 13175, Consultation and Coordination with Indian Tribal Governments
D. Executive Order 13045, Protection of Children for Environmental Health Risks and Safety Risks
E. Unfunded Mandates Reform Act of 1995
F. Regulatory Flexibility Act (RFA), as Amended by the Small Business Regulatory Enforcement Fairness Act of 1996 (SBREFA), 5 U.S.C. 601 *et seq.*
G. Paperwork Reduction Act
H. National Technology Transfer and Advancement Act
I. The Congressional Review Act
J. Executive Order 13211 (Energy Effects)

I. Why Are We Publishing These Amendments as a Direct Final Rule?

In this direct final rule, we are correcting referencing and typesetting errors, identifying additional test methods that may be used to analyze wastewater, classifying triethylamine as a soluble HAP instead of a partially soluble HAP, adding an outlet concentration limit compliance option for storage tanks, clarifying the monitoring frequency for connectors, clarifying storage tank assignment procedures, and adding planned routine maintenance provisions for centralized combustion control devices (CCCD). These changes provide clarifications and additional compliance options. In all instances, we believe that these changes have the potential to reduce the burden on both owners and operators of affected sources and on the State or local agency implementing the rule, although we are unable to quantify reductions in hours for these amendments. For these reasons, we view these amendments as noncontroversial and anticipate no adverse comments, and we are publishing these amendments in a direct final rule.

If an adverse comment applies to an amendment, paragraph, or section of this direct final rule, and that provision may be addressed separately from the remainder of the rule, we will withdraw only those provisions on which we received adverse comments. In the ''Proposed Rules'' section of this **Federal Register**, we are publishing a separate document that will serve as the proposal for any provisions in this direct final rule on which we receive adverse comments. The EPA will publish a timely withdrawal before the effective date of this rule indicating which provisions are being withdrawn. If part or all of this direct final rule is withdrawn, all public comments received will be addressed in a subsequent final rule based on the proposal. We will not institute a second comment period on the subsequent final rule. Any parties interested in commenting must do so at this time. The nature of the changes contained in this direct final rule are such that it will benefit both industry and the States for these changes to become effective sooner, rather than later, as will be described in more detail below.

II. What Amendments Are We Making to Part 9 To Reflect OMB Approval of the Information Collection Request for Subpart GGG?

This final rule amends the table of currently approved Information Collection Request (ICR) control numbers issued by OMB. As noted in section VII.G of this preamble, as well as in the preambles to earlier amendments and the promulgated rule, OMB has approved the information collection requirements contained in subpart GGG and assigned OMB control No. 2060–0358. However, when we amended § 9.1 on September 21, 1998, we entered the incorrect number 2060–0314. Because the correct number was listed in the earlier preambles and amendment of the table is technical in nature, we believe that another notice and comment period for this amendment is unnecessary and that there is good cause under the Administrative Procedure Act (5 U.S.C. 553(b)) to amend this table without prior notice and comment.

III. What Amendments Are We Making to the Process Vent Provisions?

This direct final rule specifies requirements for meeting the process vent standards during periods of planned routine maintenance of CCCD. Use of a CCCD, while not required by subpart GGG, is a common control technique at existing pharmaceutical production facilities because the facilities have found such a device to be more reliable and efficient than multiple point-of-use devices. However, under subpart GGG as currently written, when routine maintenance on a CCCD is needed, you must either shutdown all processes or have a backup control device that you have demonstrated achieves the same level of control. We understand that shutting down all processes is inefficient and costly for at least two reasons: (1) Because all processes have different cycles, the shutdown would almost certainly have to be staggered, which means some process equipment would have to be shutdown for a longer period than is needed simply to perform the maintenance on the control device; and (2) pharmaceutical production facilities often shutdown only a section of the facility for maintenance as opposed to the entire facility because it is impractical to have an in-house maintenance staff large enough to perform such maintenance in a short period of time, and outside resources may not be sufficiently skilled or available when needed. We also realize that demonstrating compliance for a backup device could be a significant burden. To address these concerns, this direct final rule provides an additional compliance option for periods of planned routine maintenance of a CCCD that is simple to implement and achieves reductions that are at least equivalent to the maximum achievable control technology (MACT) floor.

The new planned routine maintenance provisions specify separate requirements for organic HAP emissions and hydrogen chloride (HCl) emissions. You must route emissions from process vents with organic HAP emissions greater than 15 pounds per day (lb/day) through a closed vent system to a condenser that operates at: (1) Less than 50 degrees centigrade (C) when the emission stream contains HAP with a partial pressure greater than 20 kilopascals (kPa) and (2) less than −5 degrees C when the emission stream contains HAP with a partial pressure less than or equal to 20 kPa. The partial pressures must be determined at 25 C. These requirements are designed to be similar to State reasonably available control technology rules that are based on the generalized control program described on page 1–5 of the 1978 Control Techniques Guideline (CTG) Document for Control of Volatile Organic Emissions from Manufacture of

Synthesized Pharmaceutical Products (EPA 450/2–78–029). However, to achieve the MACT floor control level of 93 percent, the operating temperatures required by the planned routine maintenance provisions differ from those specified in the CTG, and all vents with organic HAP emissions greater than 15 lb/day must be controlled (not just vents from the unit operations listed in the CTG). The planned routine maintenance provisions are limited to the use of condensers as specified above to keep the compliance requirements simple and because many facilities typically already have backup condensers available onsite.

Because the CTG did not cover HCl emissions, the planned routine maintenance provisions specify that you must route emissions from process vents with HCl emissions greater than or equal to 15 lb/day through a closed vent system to a caustic scrubber. As with the condenser, we have kept compliance requirements simple. Compliance is demonstrated by daily monitoring of the scrubber effluent and maintaining the effluent at pH 9 or greater.

Although § 63.1258 of the pharmaceuticals production NESHAP specifies parameters for scrubbers, we are not requiring monitoring of the scrubber liquid flow rate or pressure drop for caustic scrubbers during periods of planned routine maintenance. The effectiveness of absorbing HCl into caustic solution is so great that monitoring effluent pH is adequate to demonstrate compliance. The relatively small amount of HCl generated during periods of planned routine maintenance does not justify the need to burden the industry with design evaluation demonstrations and continuous monitoring for each individual scrubber application during the limited period of planned routine maintenance.

Hydrogen chloride has a great affinity for water. Referencing the ''Chemical Engineering Handbook'' by Perry and Chilton, solubility of HCl is almost 70 grams per 100 grams of water at 30 degrees C. An aqueous solution at the same temperature can absorb up to 10 percent HCl before reaching an equilibrium of 20 parts per million volume (ppmv) of HCl in the gas phase. In addition, absorption increases as vapor pressure decreases, and vapor pressure of HCl can be decreased significantly by adding a chemical reactant such as sodium hydroxide (NaOH) to tie up the solute gas. The chemical reaction in a caustic scrubber frees up liquid volume for dissolving more gas. A caustic scrubber operating such that the effluent stays at or above pH 9 is considered a very effective control device.

The 15 lb/day emission rate cutoffs apply to emissions from vents on individual unit operations, not to aggregated emissions from multiple unit operations that are manifolded together into a common header (i.e., the emission rates must be determined only at the equipment where the emissions enter the closed vent system prior to being combined with emissions from other unit operations). Therefore, a manifolded stream with emissions that exceed 15 lb/day is not subject to control requirements during periods of planned routine maintenance of the CCCD if the emissions from each of the unit operation vents that are combined in that manifold have emissions less than 15 lb/day. If any individual unit operation vents with emissions less than 15 lb/day are manifolded with a unit operation vent that has emissions greater than or equal to 15 lb/day, then the entire manifolded stream must be controlled (or the emissions from the unit operation with emissions greater than 15 lb/day must be diverted from the other vents in the manifold for control).

You may use the planned routine maintenance provisions if you use the CCCD to comply with any of the requirements in § 63.1254(a) of the pharmaceuticals production NESHAP for process vents from all non-dedicated pharmaceutical manufacturing process units (PMPU) that are controlled by the CCCD. However, there are several requirements to ensure that the level of control achieved is at least equivalent to the MACT floor. First, you may only route emissions from vents that are subject to the 98 percent reduction requirement in § 63.1254(a)(3) if you demonstrate that the planned routine maintenance is needed and that there is no way to perform it during periods when a process with such a vent is not operating. To make this demonstration, you must document your plans in either your Notification of Compliance Status Report or in a periodic report that is submitted prior to the planned routine maintenance event. Second, if you use the CCCD to control emissions so as to comply with the annual mass limit, you must calculate controlled emissions during periods of planned routine maintenance assuming the control efficiency is 93 percent. Third, whenever you implement the planned routine maintenance provisions, you must monitor the condenser outlet temperature as specified in § 63.1258(i). This requirement applies even if you comply with the alternative standard or if the CCCD is a boiler, process heater, or hazardous waste incinerator that meets any of the criteria in § 63.1257(a)(4). Fourth, you may not use the process vents in emissions averaging during the period that you comply with the planned routine maintenance provisions. During this time period, the process vents are being controlled to the level of the MACT floor; thus, no debits or credits can be calculated.

There are also several other restrictions on how the planned routine maintenance provisions may be implemented. For example, the planned routine maintenance provisions may be implemented for no more than 240 hours per year (hr/yr). This time period is consistent with the time allowed in § 63.1253(e) of the pharmaceuticals production NESHAP for planned routine maintenance of a control device used to control storage tank emissions. As we have stated in previous rulemaking packages, we believe this time is sufficient to perform maintenance on combustion devices (59 FR 19441, April 22, 1994). In addition, the planned routine maintenance provisions are not available for process vents from dedicated PMPU because planning a shutdown for such a PMPU can be more easily scheduled than for non-dedicated PMPU whose operation is more unpredictable in nature. Finally, the planned routine maintenance provisions may not be used for emissions from wastewater systems or equipment leaks because the MACT floor level of control for these emissions is 95 percent. If the CCCD is used to control emissions from storage tanks, you may elect to control them with the condenser during periods of planned routine maintenance. However, this control is not required because § 63.1253(e) specifies that the emission limitations are not applicable during periods of planned routine maintenance up to 240 hr/yr.

IV. What Amendments Are We Making to the Wastewater Provisions?

This direct final rule makes four changes to the wastewater provisions. One change is that we are adding two EPA test methods to the list of acceptable test methods that may be used to analyze wastewater samples. The second change is that we are reclassifying triethylamine as a soluble HAP instead of as a partially soluble HAP. The third change is to allow wastewater streams with more than 50 parts per million weight (ppmw) of partially soluble HAP to be sent to an enhanced biological treatment unit if the partially soluble HAP has already been reduced by 99 percent or more. The fourth change is to modify the

venting requirements for individual drain systems. In addition, although we are not changing the sampling requirements, we are clarifying those requirements.

Section 63.1257(b)(10)(ii) of the amended final rule states that you may use EPA Methods 624, 625, 1624, and 1625 of 40 CFR part 136 to determine the concentration of various HAP in wastewater samples (65 FR 52610, August 29, 2000). This direct final rule adds EPA Methods 1666 and 1671 to that list so that you may use them routinely without performing the method validation procedures required in § 63.1257(b)(10)(iv). The two new methods can be used to measure certain analytes (e.g., methanol, acetonitrile, and n-hexane) that cannot be measured using the other methods in 40 CFR part 136. These two methods were added to 40 CFR part 136 when the revisions to the pharmaceutical effluent limitation guidelines and standards were promulgated in September 1998. They have the same quality assurance/quality control requirements as the earlier methods; in particular, sampling must be conducted so as to minimize loss of volatile compounds. In addition, they can detect target HAP at the outlet concentrations that may be required by the rule (e.g., as low as 13 ppmw in the outlet from a treatment unit that must reduce partially soluble HAP by 99 percent).

For the final rule, compounds were classified as either partially soluble HAP or soluble HAP based on their Henry's Law constants. Triethylamine was classified as a partially soluble HAP listed in Table 2 of subpart GGG because its Henry's Law constant is relatively high. However, in this direct final rule, we are now removing triethylamine from Table 2 of subpart GGG and reclassifying it as a soluble HAP in Table 3 of subpart GGG because it has two unique characteristics that distinguish it from the listed partially soluble HAP. First, at pH ranges of 6 to 9 (typical for pharmaceutical production wastewater), triethylamine has unique ionic disassociative properties, unlike the listed partially soluble HAP. In the liquid phase, the nitrogen in triethylamine has an unshared pair of electrons that readily react with a proton in the liquid. As a result, virtually all of the free triethylamine in solution is converted to triethylammonium ions, which are soluble, non-volatile, and stable. Second, triethylamine is unique among the HAP used in the pharmaceutical production industry in that it typically is used as an organic base in reactions (in situations where an inorganic base is not acceptable) and not as a primary solvent.

Section 63.1256(g)(10) of the pharmaceuticals production NESHAP specifies that the partially soluble HAP concentration in wastewater streams sent to an enhanced biological treatment unit must be less than 50 ppmw. An unintended effect of this restriction is that it applies even if the partially soluble HAP has been reduced by more than 99 percent by treatment upstream of the enhanced biological treatment unit. This restriction is unnecessary because a 99 percent reduction in the partially soluble HAP is otherwise sufficient; there is no reason to prevent the use of enhanced biological treatment to reduce the soluble HAP in the same stream. Therefore, we have amended § 63.1256(g)(10) to clarify that a wastewater stream may be sent to an enhanced biological treatment unit if the partially soluble HAP is reduced to a concentration less than 50 ppmw or by at least 99 percent (i.e., in accordance with § 63.1256(g)(8)) in a treatment unit upstream of the enhanced biological treatment unit.

Section 63.1256(e) of subpart GGG specifies work practice standards to suppress emissions from individual drain systems. These standards allow junction boxes to be vented, but not sewer lines. Without a vent, wastewater may backup in drains and not flow properly to the first downstream junction box if there are low points in the sewer line. To alleviate this problem, we have revised § 63.1256(e)(4)(iii) to allow venting of a sewer line between drains and the first downstream junction box, provided certain conditions are met. First, the drains must be equipped with either water seals or tightly fitting caps or plugs as specified in § 63.1256(e)(4)(i). Second, the sewer line entrance to the first downstream junction box must be water sealed. These provisions apply regardless of whether the junction box is vented to the atmosphere or to a process or control device. They also are standard operating practices, and they ensure that air will not flow through the sewer line and be emitted from the vent on the sewer line. Finally, the size of the atmospheric opening is minimized by having the sewer line vent pipe meet the same design criteria as for vents on junction boxes.

The final rule specifies that wastewater samples may be grab samples or composite samples, samples must be taken at approximately equally-spaced time intervals over a 1-hour period, each 1-hour period constitutes a run, and a performance test must consist of at least three runs (§ 63.1257(e)(2)(iii)(B), (C)(*1*), (D)(*1*), and (E)(*1*)). Similar requirements are specified for gas stream samples at the exit of a combustion treatment unit or at the inlet or exit of control devices (§ 63.1257(e)(2)(iii)(D)(*4*) and (e)(3)(i)(C)). As in the Hazardous Organic NESHAP (HON) (40 CFR part 63, subpart G), we intentionally did not specify exactly how to take samples because the procedures will vary depending on the circumstances and the selected test method. In some cases, any of the options may be acceptable, whereas in other cases, some options may not be available. For example, if you conduct wastewater sampling in accordance with a sampling plan based on the sample handling requirements in EPA Method 25D of 40 CFR part 60, appendix A, you would have to take grab samples; you would not be able to take composite samples. On the other hand, for emission stream samples where concentration measurements are to be determined using EPA Method 18 of 40 CFR part 60, appendix A, you have the option of taking either grab samples or composite samples. The rule does not specify the number of samples that you must collect because we do not want to restrict the number of samples that you take to cover different, representative operating conditions (as opposed to supplementing with modeling or engineering assessments). However, you must take at least one sample per run. The requirement to take samples at equally-spaced time intervals over the 1-hour period means that the samples must be taken at the same point in the 1-hour period for each of the three runs; this requirement applies even if you take only one sample per run.

V. What Amendments Are We Making to the Storage Tank Provisions?

This direct final rule adds an outlet concentration limit compliance option for storage tank emissions. Under this option, you must conduct an initial performance test to demonstrate that emissions are reduced to outlet concentrations less than or equal to 20 ppmv as total organic compound (TOC) and less than or equal to 20 ppmv as hydrogen halides and halogens. You also must establish applicable operating parameter levels during the performance test to use as monitoring limits for ongoing compliance demonstrations. This option is identical to options already provided for process vent emissions and wastewater emissions.

The exclusion of this option for storage tanks was an oversight that was only recently discovered. We always intended to provide this option for storage tank emissions as well as other

types of emissions, as evidenced by the fact that we included a statement specifying how to demonstrate initial compliance with such an option in § 63.1257(c)(1) of the final rule (63 FR 50355, September 21, 1998). In previous amendments, we inadvertently modified this statement to refer to compliance with the alternative standard (65 FR 52610, August 29, 2000). Therefore, in addition to providing the outlet concentration limit as an option in § 63.1253(b)(2) and (c)(2), this direct final rule also restores the original intent of the provision in § 63.1257(c)(1).

VI. What Minor Technical Corrections Are We Making?

This direct final rule corrects referencing errors, corrects drafting and typesetting errors, and clarifies the intent of several provisions. All of the minor technical corrections are described in Table 1.

TABLE 1.—MINOR TECHNICAL CORRECTIONS TO SUBPART GGG

Section of subpart GGG	Description of correction
§ 63.1250(e)	The original language in these paragraphs specified only how to determine ownership if a storage tank was shared among PMPU's. The revised language in paragraphs (e)(2) and (3) clarifies how to determine ownership of a tank that is shared among one or more PMPU's and other types of process units. The requirement to assign storage tanks to a process unit based on predominant use has not changed. We also revised the introductory text to paragraph (e) to specify that if you produce only pharmaceutical products, you do not need to assign storage tanks to a PMPU except when you comply with the pollution-prevention alternative and when you need to determine whether a dedicated PMPU is subject to new source standards. Otherwise, the assignment requirement is not needed at these facilities because all of the storage tanks are subject to storage tank requirements in the rule, and there are no other applicability requirements based on total emissions from a PMPU. We expect that this clarification will reduce the burden for some facilities.
§ 63.1250(h)(2)	Clarified the overlapping provisions by discussing the requirements in two paragraphs instead of one. One paragraph describes your options if you have a control device subject to both the pharmaceuticals production NESHAP and any of the subparts AA, BB, or CC in 40 CFR parts 264 and/or 265. The second paragraph describes your options if you have equipment subject to the equipment leak provisions in both § 63.1255 and in subpart BB of 40 CFR parts 264 and/or 265. Options for waste management units subject to both the pharmaceuticals production NESHAP and subpart CC of 40 CFR parts 264 and/or 265 are described in § 63.1250(h)(5).
§ 63.1253(f)(7)(i)	Corrected this paragraph by replacing the incorrect reference to paragraph (b)(7)(i) with the correct reference to paragraph (f)(7).
§ 63.1255(b)(4)(iii)(A)	Corrected this paragraph by replacing the incorrect reference to paragraph (b)(3)(iii)(B) with the correct reference to paragraph (b)(4)(iii)(B).
§ 63.1255(b)(4)(iii)(D)	Revised this paragraph to clarify that you must monitor leaking connectors once per year until the percent leaking connectors is less than 0.5 percent. After the percent leaking connectors falls below 0.5 percent, you may again implement the applicable less frequent monitoring schedule. Without this clarification, the paragraph could be interpreted to mean that you must always monitor leaking connectors once per year.
§ 63.1255(c)(2)(iii), (c)(3), and (5)(iv)	The original language in these paragraphs was inconsistent. Paragraph (c)(5)(iv) required EPA Method 21 monitoring to verify the presence of a leak if indications of liquids dripping were detected during a visual inspection. Paragraph (c)(2)(iii) simply stated that a leak was present if there were visual indications of liquids dripping. We revised both paragraphs to specify that if there are visual indications of liquids dripping during a weekly visual inspection, then you must either monitor using EPA Method 21 or eliminate the visual indication of liquids dripping before the next weekly inspection. These changes also make the paragraphs consistent with the Consolidated Federal Air Rule and 40 CFR part 63, subpart UU (the Generic MACT). We also revised paragraph (c)(3) to clarify that the repair provisions for all leaking pumps/agitators are the same.
§ 63.1255(c)(4)(ii)	The original language in this paragraph specified that you must monitor pumps monthly instead of quarterly if, on a 1-year rolling average, greater than 10 percent or 3 pumps have leaked in a group of processes. As written, this paragraph could be interpreted to mean that all subsequent monitoring for that group of processes must be monthly. This was not our intent. To correct this oversight, we have revised the paragraph to specify that you may revert to quarterly monitoring after the 1-year rolling average again indicates that less than 10 percent or fewer than 3 pumps have leaked.
§ 63.1255(e)(7)(iii)	Added a sentence to this paragraph to clarify that monitoring in the 3 months after repair is in addition to the monitoring required to demonstrate repair. This amendment is consistent with the language in the Consolidated Federal Air Rule and 40 CFR part 63, subpart UU. It is also consistent with the intent of the HON.
§ 63.1255(e)(9)	Corrected this paragraph by replacing the incomplete reference to paragraphs (e)(4)(iii) and (iv) with a reference to paragraphs (e)(4)(iii), (iv), and (v). The reference to paragraph (e)(4)(v) was inadvertently left out of the final rule. The change makes the paragraph consistent with the Consolidated Federal Air Rule.
§ 63.1255(h)(1)(ii)	Deleted the word ''and'' at the end of this paragraph because, as specified in paragraph (h)(1), the only reports that must be submitted are those specified in paragraphs (h)(1)(i) and (ii).
§ 63.1255(h)(3)(i)	Revised the schedule for submitting Periodic reports with information on equipment leak compliance to be consistent with the schedule specified in § 63.1260(g)(1).
§ 63.1256(c)(1)(i)(A)	Corrected this paragraph by replacing the incorrect reference to paragraph (c)(1)(iv) with the correct reference to paragraph (c)(1)(v).

TABLE 1.—MINOR TECHNICAL CORRECTIONS TO SUBPART GGG—Continued

Section of subpart GGG	Description of correction
§ 63.1256(e)(4)(i)(B)	The original language in this paragraph used the terms ''flexible cap'' and ''flexible shield,'' interchangeably. To clarify our intent, we revised the paragraph to use only the term ''flexible shield.''
§ 63.1256(g)(9)(ii)	Revised this paragraph to allow design evaluations, as well as performance tests, to demonstrate removal or destruction of soluble HAP by 90 percent in all treatment units except open biological treatment units. This change makes the requirements of this paragraph consistent with the requirements in paragraph (g)(4). It also makes this paragraph consistent with the amended requirements in paragraphs (g)(8)(ii), (11)(ii), and (12) of this section. We inadvertently neglected to amend this paragraph at the same time that the others were amended.
§ 63.1257(a)(6)	Corrected this paragraph by replacing the incorrect reference to § 63.1258(b)(1) through (5) with the correct reference to § 63.1258(b)(1) through (4). Section 63.1258(b)(5) is not applicable because it relates to the alternative standard, whereas § 63.1257(a)(6) is describing monitoring requirements to demonstrate compliance with the outlet concentration limits of 20 ppmv TOC and 20 ppmv hydrogen halides and halogens.
§ 63.1257(d)(2)(i)(D)(*9*)	Corrected Equation 31 by replacing ''N_{HAP}'' with ''n_{HAP}.''
§ 63.1257(d)(2)(i)(D)(*10*)	Corrected Equation 32 by replacing individual HAP partial pressures with partial pressures for individual condensable compounds.
§ 63.1257(d)(2)(i)(E)	Added a sentence specifying that individual HAP partial pressures in the equation to calculate emissions from vacuum systems may be calculated using Raoult's Law. This change makes the procedures for this equation consistent with the procedures that are allowed for calculating emissions from other types of emission episodes.
§ 63.1257(d)(3)(iii)(B)	Corrected this paragraph by replacing the incorrect reference to paragraphs (d)(2)(iii)(B)(*1*) and (*2*) with the correct reference to paragraphs (d)(3)(iii)(B)(*1*) and (*2*).
§ 63.1257(e)(2)(iii)(B)	Corrected this paragraph by replacing the incorrect reference to paragraph (b)(10)(iii) with the correct reference to paragraph (b)(10)(vi) and replacing the incorrect reference to paragraphs (b)(10)(i), (ii), and (iii) with the correct reference to paragraphs (b)(10)(i) through (vi).
§ 63.1257(e)(2)(iii)(C)(*1*), (D)(*1*), and (E)(*1*)	Corrected these paragraphs by replacing the incorrect reference to paragraph (b)(10)(v) with the correct reference to paragraph (b)(10)(vi).
§ 63.1258(b)(3)	Deleted the reference to process vents from the heading to this paragraph. The intent of this paragraph is to specify procedures for setting parameter levels for all control devices, not just those used to control process vent emissions.
§ 63.1258(b)(5)(i)(A)	Deleted the last sentence in this paragraph because it conflicts with the requirement in § 63.1258(b)(1)(x) that calibration of CEMS include, at a minimum, quarterly cylinder gas audits.
§ 63.1258(b)(5)(ii)(A)(*2*)	Revised this paragraph to specify that it applies if you comply with the alternative standard instead of achieving a control efficiency of ''98 percent,'' not ''98 percent or less.'' Paragraph (b)(5)(ii)(A)(*1*) specifies requirements if you comply with the alternative standard instead of achieving a control efficiency of 95 percent or less. Subpart GGG has no control efficiency requirements between 95 and 98 percent. Therefore, the phrase ''or less'' in paragraph (b)(5)(ii)(A)(*2*) is both unnecessary and conflicts with paragraph (b)(5)(ii)(A)(*1*).
§ 63.1258(b)(8)(iii)	Revised this paragraph to clarify that violations of the alternative standard apply to the 50 ppmv option for noncombustion devices, as well as the 20 ppmv option for combustion devices. We inadvertently neglected to amend this paragraph when we added the 50 ppmv option to the alternative standard (65 FR 52588, August 29, 2000).
§ 63.1258(h)(6) and (7)	Corrected these paragraphs by replacing the incorrect references to paragraphs (h)(8)(i) and (ii) with the correct reference to paragraph (h)(8).
§ 63.1258(h)(10)	Added paragraph (h)(10) to specify that closed-vent systems operated and maintained under negative pressure are not subject to the inspection requirements for closed-vent systems. For this type of closed-vent system, you must install a pressure gauge or other pressure measurement device that can be used to verify that the negative pressure is being maintained when the control device is operating. This new provision is consistent with the provision in § 63.1255(b)(4)(ii)(B) for closed-vent systems used to route equipment leak emissions to a control device.
§ 63.1259(a)(3)(iii) and (b)(13)	Deleted the reference to § 63.10(b)(2)(iii) in paragraph (a)(3)(iii) because, as noted in Table 1 to subpart GGG, this section of the General Provisions does not apply to subpart GGG. The reference also is unnecessary because the requirement to record maintenance performed on the control device is clearly specified in this paragraph. However, because this maintenance recordkeeping requirement will not always be related to a startup, shutdown, or malfunction procedure, we also moved it to a new paragraph (b)(13).
§ 63.1259(b)(5)(i)	Corrected this paragraph by removing the references to individual process vents and § 63.1254(a)(3). This paragraph requires records of emissions for certain nonstandard batches. At an existing source, these records are needed to demonstrate compliance with a process-based percent reduction requirement for process vents from nonstandard batches if you control some vents to more than 93 percent and others to less than 93 percent (or 98 percent for new sources). Assuming the monitored operating parameters are at acceptable levels, the control efficiency for each control device is unchanged, but the overall control level for the process could change if the impact of the nonstandard batch on uncontrolled emissions is not identical for each vent. This situation cannot occur for individual vents that are subject to percent reduction requirements under § 63.1254(a)(3); thus, there is no need to maintain a record of nonstandard batch emissions for these vents.

TABLE 1.—MINOR TECHNICAL CORRECTIONS TO SUBPART GGG—Continued

Section of subpart GGG	Description of correction
§ 63.1259(b)(8)	Revised this paragraph to require a log or schedule of operating scenarios that is updated daily or, at a minimum, each time a different operating scenario takes effect. The original requirements to update the schedule or log daily and prior to making a change are unnecessarily burdensome.
§ 63.1259(i)(7)	Paragraph (i)(7) requires records of information associated with inspections of closed vent systems during which a leak is detected. As currently written, paragraph (i)(7)(i) requires records identifying the leaking equipment and records of the instrument identification number and operator name. This paragraph may be confusing because the instrument identification number and operator name can be recorded only for leaks that are detected using the instrument method. To clarify the requirements, we revised the language and split it into two paragraphs. The revised paragraph (i)(7)(i) requires records identifying the leaking equipment; this record is required regardless of the technique used to identify the leak. The revised paragraph (i)(7)(ii) requires a record of the instrument identification number and operator name for each leak that is detected using the instrument method. For each leak detected by sensory observations, this paragraph also requires a record indicating that the leak was detected by sensory observations. The original paragraphs (i)(7)(ii) through (viii) are redesignated as paragraphs (i)(7)(iii) through (ix).
§ 63.1260(g)(1)	Added statement specifying that each periodic report after the first report covers the 6-month period following the preceding report. Also deleted the requirement to submit the Periodic reports 60 operating days after the end of the applicable reporting period because it could conflict with the requirements to submit the first periodic report no later than 240 days after the Notification of Compliance Status Report is due and to submit subsequent reports every 6 months thereafter. These changes also make paragraph (g)(1) consistent with § 63.1255(h)(3)(i).
§ 63.1260(g)(2)(v)	Corrected this paragraph by replacing the incorrect reference to paragraph (g)(2)(iv)(A) with the correct reference to paragraph (g)(2)(v)(A).
§ 63.1260(g)(2)(vii)	Revised this paragraph to specify that the first periodic report must include each operating scenario operated since the due date of the Notification of Compliance Status Report, not since the compliance date. This change makes the time period for this information consistent with the time period covered by the first periodic report, as specified in § 63.1260(g)(1).
§ 63.1260(h)	Revised this paragraph to require process change notifications as part of the Periodic report instead of quarterly. We determined that requiring submittal of the process change notification more frequently than the Periodic report was an unnecessary burden.
§ 63.1260(i)	We made two changes to clarify this paragraph and make it more consistent with the startup, shutdown, and malfuction (SSM) reporting requirements in § 63.10(d)(5). First, we split the requirements into two paragraphs; the first paragraph specifies reporting requirements for actions that are consistent with the SSM plan, and the second paragraph specifies immediate reporting requirements for actions that are not consistent with the SSM plan. Second, we deleted the requirement to report records required by § 63.1259(a)(3)(iii) because reporting this information is inconsistent with § 63.10(d)(5)(i) of the General Provisions, which requires only a statement that the procedures in the SSM plan were followed.
Table 1 to subpart GGG	Corrected typesetting errors in entries §§ 63.1(c)(5), 63.5(e), and 63.8(e)(5)(i). Also corrected the entry for § 63.6(i) by replacing the incorrect reference to § 63.1250(f)(4) with the correct reference to § 63.1250(f)(6), and by indicating that the approval provisions in § 63.6(i)(7) through (14) apply to requests for approval of compliance extensions that are requested according to § 63.1250(f)(6).

VII. What Are the Administrative Requirements for This Direct Final Rule?

A. Executive Order 12866, Regulatory Planning and Review

Under Executive Order 12866 (58 FR 51735, October 4, 1993), EPA must determine whether the regulatory action is ''significant'' and therefore, subject to OMB review and the requirements of the Executive Order. The Executive Order defines ''significant regulatory action'' as one that is likely to result in a rule that may:

(1) Have an annual effect on the economy of $100 million or more or adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities;

(2) Create a serious inconsistency or otherwise interfere with an action taken or planned by another agency;

(3) Materially alter the budgetary impact of entitlements, grants, user fees, or loan programs, or the rights and obligations of recipients thereof; or

(4) Raise novel legal or policy issues arising out of legal mandates, the President's priorities, or the principles set forth in the Executive Order.

Pursuant to the terms of Executive Order 12866, it has been determined that these amendments do not constitute a ''significant regulatory action'' because they do not meet any of the above criteria. Consequently, this action was not submitted to OMB for review under Executive Order 12866.

B. Executive Order 13132, Federalism

Executive Order 13132 (64 FR 43255, August 10, 1999) requires EPA to develop an accountable process to ensure ''meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications.'' ''Policies that have federalism implications'' is defined in the Executive Order to include regulations that have ''substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.''

These rule amendments do not have federalism implications. They will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132, because State and local governments do not own or operate any sources that would be subject to these amendments. Thus, the requirements of section 6 of the Executive Order do not apply to these rules.

C. Executive Order 13175, Consultation and Coordination With Indian Tribal Governments

Executive Order 13175, entitled ''Consultation and Coordination with Indian Tribal Governments'' (65 FR 67249, November 6, 2000), requires EPA to develop an accountable process to ensure ''meaningful and timely input by tribal officals in the development of regulatory policies that have tribal implications.'' ''Policies that have tribal implications'' are defined in the Executive Order to include regulations that have ''substantial direct effects on one or more Indian tribes, on the relationship between the Federal government and the Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes.''

These rule amendments do not have tribal implications. They will not have substantial direct effects on tribal governments, or on the relationship between the Federal government and Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes, as specified in Executive Order 13175. No tribal governments own or operate pharmaceutical production facilities. Thus, Executive Order 13175 does not apply to these rule amendments.

D. Executive Order 13045, Protection of Children From Environmental Health Risks and Safety Risks

Executive Order 13045 (62 FR 19885, April 23, 1997) applies to any rule that: (1) Is determined to be ''economically significant'' as defined under Executive Order 12866, and (2) concerns an environmental health or safety risk that EPA has reason to believe may have a disproportionate effect on children. If the regulatory action meets both criteria, EPA must evaluate the environmental health or safety effects of the planned rule on children, and explain why the planned regulation is preferable to other potentially effective and reasonably feasible alternatives considered by EPA.

The EPA interprets Executive Order 13045 as applying only to those regulatory actions that are based on health or safety risks, such that the analysis required under section 5–501 of the Executive Order has the potential to influence the regulation. These rule amendments are not subject to Executive Order 13045 because they are based on technology performance, not health or safety risks. Furthermore, these rule amendments have been determined not to be ''economically significant'' as defined under Executive Order 12866.

E. Unfunded Mandates Reform Act of 1995

Title II of the Unfunded Mandates Reform Act of 1995 (UMRA), Public Law 104–4, establishes requirements for Federal agencies to assess the effects of their regulatory actions on State, local, and tribal governments and the private sector. Under section 202 of the UMRA, EPA generally must prepare a written statement, including a cost-benefit analysis, for proposed and final rules with ''Federal mandates'' that may result in expenditures by State, local, and tribal governments, in aggregate, or by the private sector, of $100 million or more in any 1 year. Before promulgating an EPA rule for which a written statement is needed, section 205 of the UMRA generally requires EPA to identify and consider a reasonable number of regulatory alternatives and adopt the least-costly, most cost-effective, or least burdensome alternative that achieves the objectives of the rule. The provisions of section 205 do not apply when they are inconsistent with applicable law. Moreover, section 205 allows EPA to adopt an alternative other than the least-costly, most cost-effective, or least-burdensome alternative if the Administrator publishes with the final rule an explanation why that alternative was not adopted. Before EPA establishes any regulatory requirements that may significantly or uniquely affect small governments, including tribal governments, it must have developed under section 203 of the UMRA a small government agency plan. The plan must provide for notifying potentially affected small governments, enabling officials of affected small governments to have meaningful and timely input in the development of EPA regulatory proposals with significant Federal intergovernmental mandates, and informing, educating, and advising small governments on compliance with the regulatory requirements.

The EPA has determined that these rule amendments do not contain a Federal mandate that may result in expenditures of $100 million or more for State, local, or tribal governments, in the aggregate, or the private sector in any 1 year. The maximum total annual cost of the Pharmaceuticals Production NESHAP for any year has been estimated to be approximately $64 million (63 FR 50287, September 21, 1998), and today's amendments do not add new requirements that would increase this cost. Thus, these rule amendments are not subject to the requirements of sections 202 and 205 of the UMRA. In addition, EPA has determined that these rule amendments contain no regulatory requirements that might significantly or uniquely affect small governments because they contain no requirements that apply to such governments or impose obligations upon them. Therefore, these rule amendments are not subject to the requirements of section 203 of the UMRA.

F. Regulatory Flexibility Act (RFA), as Amended by the Small Business Regulatory Enforcement Fairness Act of 1996 (SBREFA), 5 U.S.C. 601 et seq.

The EPA has determined that it is not necessary to prepare a regulatory flexibility analysis in connection with this direct final rule. The EPA has also determined that this direct final rule will not have a significant impact on a substantial number of small entities. For purposes of assessing the impacts of this direct final rule on small entities, a small entity is defined as: (1) A small business in the North American Industrial Classification System (NAICS) code 325411 or 325412 that has as many as 750 employees; (2) a small business in NAICS code 325199 that has as many as 1,000 employees; (3) a small governmental jurisdiction that is a government of a city, county, town, school district, or special district with a population of less than 50,000; and (4) a small organization that is any not-for-profit enterprise which is independently owned and operated and is not dominant in its field.

After considering the economic impacts of today's rule amendments on small entities, EPA has concluded that this action will not have a significant economic impact on a substantial number of small entities. In determining whether a rule has a significant economic impact on a substantial number of small entities, the impact of concern is any significant adverse economic impact on small entities, since the primary purpose of the regulatory flexibility analyses is to identify and address regulatory alternatives ''which minimize any

significant economic impact on small entities'' (5 U.S.C. sections 603 and 604). Thus, an agency may conclude that a rule will not have a significant economic impact on a substantial number of small entities if the rule relieves burden, or otherwise has a positive economic effect on all of the small entities subject to the rule. Today's rule amendments impose no additional regulatory requirements on owners or operators of affected sources, many of the rule amendments provide additional compliance options, and other rule amendments clarify requirements and correct minor drafting errors. We have therefore, concluded that these rules will relieve regulatory burden for all small entities.

G. Paperwork Reduction Act

The OMB has approved the information collection requirements contained in the 1998 pharmaceuticals production NESHAP under the provisions of the Paperwork Reduction Act, 44 U.S.C. 3501 *et seq.* and has assigned OMB control No. 2060–0358. An Information Collection Request (ICR) document has been prepared by EPA (ICR No. 1781.01), and a copy may be obtained from Sandy Farmer by mail at U.S. Environmental Protection Agency, Office of Environmental Information, Collection Strategies Division (2822), 1200 Pennsylvania Avenue, NW, Washington DC 20460, by email at farmer.sandy@epa.gov, or by calling (202) 260–2740.

The amendments contained in these final rules will have no net impact on the information collection burden estimates made previously. Consequently, the ICR has not been revised.

H. National Technology Transfer and Advancement Act

Section 12(d) of the National Technology Transfer and Advancement Act (NTTAA), Public Law 104–113 (March 7, 1996), directs all Federal agencies to use voluntary consensus standards instead of government-unique standards in their regulatory activities unless to do so would be inconsistent with applicable law or otherwise impractical. Voluntary consensus standards are technical standards (e.g., material specifications, test methods, sampling and analytical procedures, and business practices) that are developed or adopted by one or more voluntary consensus bodies. Examples of organizations generally regarded as voluntary consensus standards bodies include the American Society for Testing and Materials (ASTM), the National Fire Protection Association (NFPA), and the Society of Automotive Engineers (SAE). The NTTAA requires Federal agencies like EPA to provide Congress, through OMB, with explanations when an agency does not use available and applicable voluntary consensus standards.

During the rulemaking, EPA searched for voluntary consensus standards that might be applicable. The search identified no applicable voluntary consensus standards. Accordingly, the NTTAA requirement to use applicable voluntary consensus standards does not apply to this direct final rule.

I. Congressional Review Act

The Congressional Review Act (CRA), 5 U.S.C. 801, *et seq.*, as added by the SBREFA of 1996, generally provides that before a rule may take effect, the agency adopting the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. The EPA will submit a report containing this direct final rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of this rule in the **Federal Register**. A major rule cannot take effect until 60 days after it is published in the **Federal Register**. This direct final rule is not a ''major rule'' as defined by 5 U.S.C. 804(2). This direct final rule will be effective on October 16, 2001.

Section 808 allows the issuing agency to make a rule effective sooner than otherwise provided by the CRA if the agency makes a good cause finding that notice and public procedure is impracticable, unnecessary or contrary to the public interest. This determination must be supported by a brief statement (5 U.S.C. 808(2)). As stated previously, for the amendments to the table that lists OMB control numbers, EPA has made such a good cause finding, including the reasons therefor, and established an effective date of August 2, 2001. The EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the **Federal Register**. This action is not a ''major rule'' as defined by 5 U.S.C. 804(2).

J. Executive Order 13211 (Energy Effects)

This rule is not subject to Executive Order 13211, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use'' (66 FR 28355 (May 22, 2001)) because it is not a significant regulatory action under Executive Order 12866.

List of Subjects in 40 CFR Parts 9 and 63

Environmental protection, Administrative practice and procedure, Air pollution control, Hazardous substances, Intergovernmental relations, Reporting and recordkeeping requirements.

Dated: July 24, 2001.

Christine Todd Whitman,

Administrator.

For the reasons set out in the preamble, parts 9 and 63 of title 40, chapter I of the Code of Federal Regulations are amended as follows:

PART 9—[AMENDED]

1. The authority citation for part 9 continues to read as follows:

Authority: 7 U.S.C. 135 *et seq.*, 136–136y; 15 U.S.C. 2001, 2003, 2005, 2006, 2601–2671; 21 U.S.C. 331j, 346a, 348; 31 U.S.C. 9701; 33 U.S.C. 1251 *et seq.*, 1311, 1313d, 1314, 1318, 1321, 1326, 1330, 1342, 1344, 1345(d) and (e), 1361; E.O. 11735, 38 FR 21243, 3 CFR, 1971–1975 Comp. p. 973; 42 U.S.C. 241, 242b, 243, 246, 300f, 300g, 300g–1, 300g–2, 300g–3, 300g–4, 300g–5, 300g–6, 300j–1, 300j–2, 300j–3, 300j–4, 300j–9 1857 *et seq.*, 6901–6992k, 7401–7671g, 7542, 9601–9657, 11023, 11048.

2. Section 9.1 is amended by revising the entry ''63.1259–63.1260'' in the table under the indicated heading to read as follows:

§ 9.1 OMB approvals under the Paperwork Reduction Act.

* * * * *

40 CFR Citation	OMB Control No.
* * * * *	
National Emission Standards for Hazardous Air Pollutants for Source Categories.[3]	
* * * * *	
63.1259–63.1260	2060–0358
* * * * *	

[3] The ICR's referenced in this section of the table encompass the applicable General Provisions contained in 40 CFR part 63, subpart A, which are not independent information collection requirements.

PART 63—[AMENDED]

3. The authority citation for part 63 continues to read as follows:

Authority: 42 U.S.C. 7401, *et seq.*

Subpart GGG—National Emission Standards for Pharmaceuticals Production

4. Section 63.1250 is amended by:

a. Revising paragraph (e); and

b. Revising paragraph (h)(2). The revisions read as follows:

§ 63.1250 Applicability.

* * * * *

(e) *Storage tank ownership determination.* The owner or operator shall follow the procedures specified in paragraphs (e)(1) through (5) of this section to determine to which PMPU a storage tank shall belong. If an owner or operator produces only pharmaceutical products, the procedures specified in paragraphs (e)(1) through (5) of this section are required only to determine applicability and demonstrate compliance with the pollution-prevention alternative specified in § 63.1252(e), or to determine new source applicability for a PMPU dedicated to manufacturing a single product as specified in paragraph (b) of this section.

(1) If a storage tank is dedicated to a single PMPU, the storage tank shall belong to that PMPU.

(2) If a storage tank is shared among process units (including at least one PMPU), then the storage tank shall belong to the process unit located on the same plant site as the storage tank that has the greatest annual volume input into or output from the storage tank (i.e., said PMPU or process unit has the predominant use of the storage tank).

(3) If predominant use cannot be determined for a storage tank that is shared among process units (including at least one PMPU), then the owner or operator shall assign the storage tank to any one of the PMPU's that shares it and is also subject to this subpart.

(4) If the predominant use of a storage tank varies from year to year, then predominant use shall be determined based on the utilization that occurred during the year preceding September 21, 1998 for existing affected sources. For new affected sources, predominant use will be based on the first year after initial startup. The determination of predominant use shall be reported in the Notification of Compliance Status required by § 63.1260(f). If the predominant use changes, the redetermination of predominant use shall be reported in the next Periodic report.

(5) If the storage tank begins receiving material from (or sending material to) another PMPU, or ceases to receive material from (or send material to) a PMPU, or if the applicability of this subpart to a storage tank has been determined according to the provisions of paragraphs (e)(1) through (4) of this section and there is a significant change in the use of the storage tank that could reasonably change the predominant use, the owner or operator shall reevaluate the applicability of this subpart to the storage tank and report such changes to EPA in the next Periodic report.

* * * * *

(h) * * *

(2) *Consistency with 40 CFR parts 264 and 265, subparts AA, BB, and/or CC.* (i) After the compliance dates specified in this section, if any control device subject to this subpart is also subject to monitoring, recordkeeping, and reporting requirements in 40 CFR part 264, subpart AA, BB, or CC, or is subject to monitoring and recordkeeping requirements in 40 CFR part 265, subpart AA, BB, or CC, and the owner or operator complies with the periodic reporting requirements under 40 CFR part 264, subpart AA, BB, or CC that would apply to the device if the facility had final-permitted status, the owner or operator may elect to comply either with the monitoring, recordkeeping, and reporting requirements of this subpart, or with the monitoring, recordkeeping, and reporting requirements in 40 CFR parts 264 and/or 265, as described in this paragraph, which shall constitute compliance with the monitoring, recordkeeping, and reporting requirements of this subpart. If the owner or operator elects to comply with the monitoring, recordkeeping, and reporting requirements in 40 CFR parts 264 and/or 265, the owner or operator shall report all information required by § 63.1260(g) and (i). The owner or operator shall identify in the Notification of Compliance Status, required by § 63.1260(f), the monitoring, recordkeeping, and reporting authority under which the owner or operator will comply.

(ii) After the compliance dates specified in this section, if any equipment at an affected source that is subject to § 63.1255, is also subject to 40 CFR part 264, subpart BB, or to 40 CFR part 265, subpart BB, then compliance with the recordkeeping and reporting requirements of 40 CFR parts 264 and/or 265 may be used to comply with the recordkeeping and reporting requirements of § 63.1255, to the extent that the requirements of 40 CFR parts 264 and/or 265 duplicate the requirements of § 63.1255. The owner or operator shall identify in the Notification of Compliance Status, required by § 63.1260(f), if the owner or operator will comply with the recordkeeping and reporting authority under 40 CFR parts 264 and/or 265.

* * * * *

5. Section 63.1251 is amended by adding a definition in alphabetical order for *centralized combustion control device* to read as follows:

§ 63.1251 Definitions.

* * * * *

Centralized combustion control device (CCCD) means enclosed combustion devices that are used to control process vent emissions from non-dedicated PMPU's at a facility. Centralized combustion control devices may also be used to control emissions from source types including, but not limited to, storage tanks, waste management units, and equipment leaks.

* * * * *

6. Section 63.1252 is amended by adding paragraph (h) to read as follows:

§ 63.1252 Standards: General.

* * * * *

(h) *Planned routine maintenance for centralized combustion control devices.* The owner or operator may operate non-dedicated PMPU's during periods of planned routine maintenance for CCCD in accordance with the provisions specified in paragraphs (h)(1) through (6) of this section.

(1) For equipment leaks and wastewater emissions that normally are controlled by the CCCD, if any, the owner or operator must continue to comply with the requirements in §§ 63.1255(b)(4)(ii) and 63.1256(h), respectively, using other control devices during the planned routine maintenance period for the CCCD.

(2) During the planned routine maintenance period, the owner or operator must route emissions from process vents with organic HAP emissions greater than 15 pounds per day (lb/day) through a closed-vent system to a condenser that meets the conditions specified in paragraphs (h)(2)(i) through (iii) of this section.

(i) The outlet gas temperature must be less than −50°C (−58°F) when the emission stream contains organic HAP with a partial pressure greater than 20 kPa (2.9 psia).

(ii) The outlet gas temperature must be less than −5°C (23°F) when the emission stream contains organic HAP with a partial pressure less than or equal to 20 kPa (2.9 psia).

(iii) The HAP partial pressures in paragraphs (h)(2)(i) and (ii) of this section must be determined at 25°C.

(3) The owner or operator must route HCl emissions from process vents with HCl emissions greater than 15 lb/day through a closed-vent system to a caustic scrubber, and the pH of the scrubber effluent must be maintained at or above 9.

(4) For the purposes of the emission calculations required in paragraphs (h)(2) and (3) of this section, the term ''process vent'' shall mean each vent from a unit operation. The emission calculation shall not be performed on the aggregated emission stream from multiple unit operations that are manifolded together into a common header. Once an affected process vent has been controlled in accordance with this section, it is no longer subject to the requirements of this section or § 63.1254 during the routine maintenance period.

(5) The total period of planned routine maintenance, during which non-dedicated PMPU's that are normally controlled by the CCCD continue to operate, and process vent emissions are controlled as specified in paragraphs (h)(2) and (3) of this section, must not exceed 240 hours in any 365-day period.

(6) While being controlled as specified in paragraphs (h)(2) and (3) of this section, the process vents may not be used in emissions averaging.

7. Section 63.1253 is amended by:

a. Redesignating paragraphs (b)(2) through (4) as paragraphs (b)(3) through (5) and adding paragraph (b)(2);

b. Redesignating paragraphs (c)(2) through (4) as paragraphs (c)(3) through (5) and adding paragraph (c)(2);

c. Revising the second sentence in paragraph (e); and

d. Revising ''paragraph (b)(7)(i)'' to read ''paragraph (f)(7)'' in paragraph (f)(7)(i).

The revisions and additions read as follows:

§ 63.1253 Standards: Storage tanks.

* * * * *

(b) * * *

(2) Reduces emissions to outlet concentrations less than or equal to 20 ppmv as TOC and less than or equal to 20 ppmv as hydrogen halides and halogens;

* * * * *

(c) * * *

(2) Reduces emissions to outlet concentrations less than or equal to 20 ppmv as TOC and less than or equal to 20 ppmv as hydrogen halides and halogens; STARS≤

(e) * * * Periods of planned routine maintenance of the control devices (including CCCD subject to § 63.1252(h)), during which the control device does not meet the specifications of paragraphs (b) through (d) of this section, as applicable, shall not exceed 240 hours in any 365-day period.

* * * * *

8. Section 63.1254 is amended by adding paragraph (a)(4) to read as follows:

§ 63.1254 Standards: Process vents.

(a) * * *

(4) *Planned routine maintenance.* For each PMPU that is controlled with a CCCD, the owner or operator must comply with the provisions specified in either paragraph (a)(4)(i), (ii), or (iii) of this section during periods of planned routine maintenance of the CCCD. The owner or operator is not required to comply with the same provision for all of the PMPU's controlled by the CCCD.

(i) Shutdown the affected process.

(ii) Comply with the requirements of paragraphs (a)(1) through (3) of this section by using other means.

(iii) For a non-dedicated PMPU, implement the procedures described in paragraphs (a)(4)(iii)(A) through (C) of this section for those process vents that are normally controlled by the CCCD. This option is not available for process vents from dedicated PMPU's.

(A) If the owner or operator uses a CCCD to comply with the 93 percent reduction requirement in paragraph (a)(1)(i) or (ii) of this section, the outlet concentration limit in paragraph (a)(1)(ii)(A) of this section, the alternative standard as specified in paragraphs (a)(1)(ii)(D) and (c) of this section, or the annual mass limit in paragraph (a)(2) of this section, implement the provisions in § 63.1252(h) during planned routine maintenance of the CCCD.

(B) If the owner or operator reduces HAP emissions from process vents by using a CCCD that is also a control device specified in § 63.1257(a)(4), implement the provisions in § 63.1252(h) during planned routine maintenance of the CCCD.

(C) If the owner or operator uses a CCCD to reduce emissions from a process vent subject to paragraph (a)(3) of this section, implement the planned routine maintenance provisions in § 63.1252(h) for that vent only if the reason the planned routine maintenance is needed, and the reason it cannot be performed at a time when the vent subject to paragraph (a)(3) of this section is not operating, has been described in the Notification of Compliance Status Report or a periodic report submitted before the planned routine maintenance event.

* * * * *

9. Section 63.1255 is amended by:

a. Adding paragraph (b)(4)(ii)(C);

b. Revising ''paragraphs (b)(3)(iii)(B) through (F)'' to read ''paragraphs (b)(4)(iii)(B) through (F)'' in paragraph (b)(4)(iii)(A);

c. Revising paragraph (b)(4)(iii)(D);

d. Revising paragraph (c)(2)(iii);

e. Revising paragraph (c)(3)(i);

f. Revising paragraph (c)(4)(ii);

g. Revising paragraph (c)(5)(iv);

h. Removing paragraphs (c)(5)(vi)(C) and (D) and adding paragraph (c)(5)(vii);

i. Adding a sentence at the end of paragraph (e)(7)(iii) introductory left;

j. Revising the second sentence in paragraph (e)(9);

k. Revising paragraph (h)(1)(ii); and

l. Revising paragraph (h)(3)(i).

The revisions and additions read as follows:

§ 63.1255 Standards: Equipment leaks.

* * * * *

(a) * * *

(4) * * *

(ii) * * *

(C) The requirements apply at all times, except as specified in § 63.1250(g). The owner or operator may not comply with the planned routine maintenance provisions in § 63.1252(h).

(iii) * * *

(D) Except as provided in paragraph (b)(4)(iii)(B) of this section, if leaking connectors comprise at least 0.5 percent but less than 1.0 percent of the connectors during the last monitoring period, the owner or operator shall monitor at least once every 2 years for the next monitoring period. At the end of that 2-year monitoring period, if the percent leaking connectors is greater than or equal to 0.5 percent, the owner or operator shall monitor once per year until the percent leaking connectors is less than 0.5 percent. If, at the end of a monitoring period, the percent leaking connectors is less than 0.5 percent, the owner or operator shall monitor in accordance with paragraph (b)(4)(iii)(C) or (F) of this section, as appropriate.

* * * * *

(c) * * *

(2) * * *

(iii) *Visual Inspections.* Each pump and agitator shall be checked by visual inspection each calendar week for indications of liquids dripping from the pump or agitator seal. If there are indications of liquids dripping from the pump or agitator seal at the time of the weekly inspection, the owner or operator shall follow the procedure specified in either paragraph (c)(2)(iii)(A) or (B) of this section prior to the next weekly inspection.

(A) The owner or operator shall monitor the pump or agitator by the method specified in § 63.180(b). If the instrument reading indicates a leak as specified in paragraph (c)(2)(ii) of this section, a leak is detected.

(B) The owner or operator shall eliminate the visual indications of liquids dripping.

(3) * * *

(i) When a leak is detected pursuant to paragraph (c)(2)(i), (c)(2)(iii)(A),

(c)(5)(iv)(A), or (c)(5)(vi)(B) of this section, it shall be repaired as soon as practicable, but not later than 15 calendar days after it is detected, except as provided in paragraph (b)(4)(i) of this section.

* * * * *

(4) * * *

(ii) If, calculated on a 1-year rolling average, the greater of either 10 percent or three of the pumps in a group of processes leak, the owner or operator shall monitor each pump once per month, until the calculated 1-year rolling average value drops below 10 percent or three pumps, as applicable.

* * * * *

(5) * * *

(iv) Each pump/agitator is checked by visual inspection each calendar week for indications of liquids dripping from the pump/agitator seal. If there are indications of liquids dripping from the pump or agitator seal at the time of the weekly inspection, the owner or operator shall follow the procedures specified in either paragraph (c)(5)(iv)(A) or (B) of this section prior to the next required inspection.

(A) The owner or operator shall monitor the pump or agitator using the method specified in § 63.180(b) to determine if there is a leak of organic HAP in the barrier fluid. If the instrument reading indicates a leak, as specified in paragraph (c)(2)(ii) of this section, a leak is detected.

(B) The owner or operator shall eliminate the visual indications of liquids dripping.

* * * * *

(vii) When a leak is detected pursuant to paragraph (c)(5)(iv)(A) or (B) of this section, the leak must be repaired as specified in paragraph (c)(3) of this section.

* * * * *

(e) * * *

(7) * * *

(iii) * * * The monitoring required by this paragraph is in addition to the monitoring required to satisfy the definitions of ''repaired'' and ''first attempt at repair.''

* * * * *

(9) * * * Instead, the owner or operator shall monitor each valve in organic HAP service for leaks once each quarter, or comply with paragraph (e)(4)(iii), (iv), or (v) of this section, except as provided in paragraph (f) of this section.

* * * * *

(h) * * *

(1) * * *

(ii) Periodic reports described in paragraph (h)(3) of this section.

* * * * *

(3) * * *

(i) A report containing the information in paragraphs (h)(3)(ii), (iii), and (iv) of this section shall be submitted semiannually. The first report shall be submitted no later than 240 days after the Notification of Compliance Status Report is due and shall cover the 6-month period beginning on the date the Notification of Compliance Status Report is due. Each subsequent report shall cover the 6-month period following the preceding period.

* * * * *

10. Section 63.1256 is amended by:

a. Revising ''paragraph (c)(1)(iv)'' to read ''paragraph (c)(1)(v)'' in paragraph (c)(1)(i)(A);

b. Revising ''flexible cap'' to read ''flexible shield'' in the last sentence in paragraph (e)(4)(i)(B);

c. Revising paragraph (e)(4)(iii);

d. Revising paragraph (g)(9)(ii);

e. Revising the first sentence in paragraph (g)(10);

f. Revising paragraph (h) introductory text; and

g. Adding paragraph (h)(5).

The revisions and additions read as follows:

§ 63.1256 Standards: Wastewater.

* * * * *

(e) * * *

(4) * * *

(iii) The owner or operator shall operate and maintain sewer lines as specified in paragraphs (e)(4)(iii)(A) and (B) of this section.

(A) Except as specified in paragraph (e)(4)(iii)(B) of this section, each sewer line shall not be open to the atmosphere and shall be covered or enclosed in a manner so as to have no visible gaps or cracks in joints, seals, or other emission interfaces.

Note: This provision applies to sewers located inside and outside of buildings.

(B) A sewer line connected to drains that are in compliance with paragraph (e)(4)(i) of this section may be vented to the atmosphere, provided that the sewer line entrance to the first downstream junction box is water sealed and the sewer line vent pipe is designed as specified in paragraph (e)(4)(ii)(B)(*1*) of this section.

* * * * *

(g) * * *

(9) * * *

(ii) *Percent mass removal/destruction option.* The owner or operator shall reduce the mass of total soluble HAP by 90 percent or more, either by removal or destruction. The removal/destruction efficiency shall be determined by the procedures in § 63.1257(e)(2)(ii) or (e)(2)(iii)(C) for noncombustion, nonbiological treatment processes; § 63.1257(e)(2)(ii) or (e)(2)(iii)(D) for combustion processes; § 63.1257(e)(2)(iii)(F) for open biological treatment processes; and § 63.1257(e)(2)(ii) or (e)(2)(iii)(G) for closed, biological treatment processes.

(10) *Control option: Enhanced biotreatment for wastewater containing soluble HAP.* The owner or operator may elect to treat affected wastewater streams containing soluble HAP in an enhanced biological treatment system, as defined in § 63.1251, provided the wastewater stream contains less than 50 ppmw partially soluble HAP, or the owner or operator complies with the requirements of paragraph (g)(8) of this section before treating the affected wastewater stream in the enhanced biological treatment system. * * *

* * * * *

(h) For each control device or combination of control devices used to comply with the provisions in paragraphs (b) through (f) and (g)(5) of this section, the owner or operator shall operate and maintain the control device or combination of control devices in accordance with the requirements of paragraphs (h)(1) through (5) of this section.

* * * * *

(5) The provisions in paragraphs (h)(1) through (4) of this section apply at all times, except as specified in § 63.1250(g). The owner or operator may not comply with the planned routine maintenance provisions in § 63.1252(h) for vent streams from waste management units.

* * * * *

11. Section 63.1257 is amended by:

a. Revising the last sentence in paragraph (a)(6);

b. Revising paragraph (b)(10)(ii);

c. Revising paragraph (c)(1) introductory text;

d. Adding a sentence at the end of paragraph (d)(1)(i);

e. Revising ''N_{HAP}'' to read ''n_{HAP}'' in equation 31 in paragraph (d)(2)(i)(D)(*9*);

f. Revising paragraph (d)(2)(i)(D)(*10*);

g. Adding a sentence after the first sentence in paragraph (d)(2)(i)(E);

h. Revising ''paragraphs (d)(2)(iii)(B)(*1*) and (*2*)'' to read ''paragraphs (d)(3)(iii)(B)(*1*) and (*2*)'' in paragraph (d)(3)(iii)(B) introductory text;

i. Revising ''paragraph (b)(10)(iii)'' to read ''paragraph (b)(10)(vi)'' and revising ''paragraphs (b)(10)(i), (ii), and (iii)'' to read ''paragraphs (b)(10)(i) through (vi)'' in paragraph (e)(2)(iii)(B); and

j. Revising ''paragraph (b)(10)(v)'' to read ''paragraph (b)(10)(vi)'' in

paragraphs (e)(2)(iii)(C)(*1*), (D)(*1*), and (E)(*1*).

The revisions and additions read as follows:

§ 63.1257 Test methods and compliance procedures.

(a) * * *

(6) * * * The owner or operator shall comply with the monitoring provisions in § 63.1258(b)(1) through (4) on the initial compliance date.

* * * * *

(b) * * *

(10) * * *

(ii) *EPA Method 624, 625, 1624, 1625, 1666, or 1671.* Use procedures specified in EPA Method 624, 625, 1624, 1625, 1666, or 1671 of 40 CFR part 136, appendix A, and comply with requirements in paragraph (b)(10)(vi) of this section.

* * * * *

(c) * * *

(1) *Performance test.* If this option is chosen to demonstrate initial compliance with the percent reduction requirement of § 63.1253(b)(1) or (c)(1)(i), the efficiency of the control device shall be calculated using performance test data as specified in paragraphs (c)(1)(i) through (iii) of this section. To demonstrate initial compliance with the outlet concentration requirements in § 63.1253(b)(2) and (c)(2), the owner or operator must conduct a performance test and fulfill the requirements of paragraph (a)(6) of this section.

* * * * *

(d) * * *

(1) * * *

(i) * * * Controlled emissions during periods of planned routine maintenance of a CCCD as specified in § 63.1252(h), must be calculated assuming the HAP emissions are reduced by 93 percent.

* * * * *

(2) * * *

(i) * * *

(D) * * *

(*10*) Emissions from depressurization may be calculated using equation 32 of this subpart:

$$E = \frac{V}{(R)(T)} \times 1n\left(\frac{P_1 - \sum_{j=1}^{m}(P_j)}{P_2 - \sum_{j=1}^{m}(P_j)}\right) \times \sum_{i=1}^{n}(P_i)(MW_i) \qquad \text{(Eq. 32)}$$

Where:

V = free volume in vessel being depressurized

R = ideal gas law constant

T = temperature of the vessel, absolute

P_1 = initial pressure in the vessel

P_2 = final pressure in the vessel

P_j = partial pressure of the individual condensable compounds (including HAP)

MW_i = molecular weight of the individual HAP compounds

n = number of HAP compounds in the emission stream

m = number of condensable compounds (including HAP) in the emission stream

i = identifier for a HAP compound

j = identifier for a condensable compound.

(E) * * * The individual HAP partial pressures may be calculated using Raoult's Law. * * *

* * * * *

12. Section 63.1258 is amended by:

a. Revising paragraph (b)(3) heading;

b. Revising paragraph (b)(5)(i)(A);

c. Revising paragraph (b)(5)(ii)(A)(*2*);

d. Revising paragraph (b)(8)(iii);

e. Adding a sentence between the first and second sentences in paragraph (c);

f. Revising ''paragraph (h)(9)'' to read ''paragraphs (h)(9) and (10)'' in paragraph (h)(1);

g. Revising ''paragraph (h)(8)(i)'' to read ''paragraph (h)(8)'' in paragraph (h)(6) introductory text;

h. Revising ''paragraph (h)(8)(ii)'' to read ''paragraph (h)(8)'' in paragraph (h)(7) introductory text;

i. Adding paragraph (h)(10); and

j. Adding paragraph (i).

The revisions and additions read as follows:

§ 63.1258 Monitoring requirements.

* * * * *

(b) * * *

(3) *Procedures for setting parameter levels for control devices used to control emissions.* * * *

* * * * *

(5) * * *

(i) * * *

(A) A TOC monitor meeting the requirements of EPA Performance Specification 8, 9, or 15 of appendix B of 40 CFR part 60 shall be installed, calibrated, and maintained according to § 63.8.

* * * * *

(ii) * * *

(A) * * *

(*2*) If complying with the alternative standard instead of achieving a control efficiency of 98 percent, the owner or operator must maintain a minimum residence time of 0.75 seconds and a minimum combustion chamber temperature of 816°C.

* * * * *

(8) * * *

(iii) Except as provided in paragraph (b)(8)(iv) of this section, exceedances of the 20 or 50 ppmv TOC outlet emission limit, averaged over the operating day, will result in no more than one violation per day per control device. Except as provided in paragraph (b)(8)(iv) of this section, exceedances of the 20 or 50 ppmv hydrogen halide or halogen outlet emission limit, averaged over the operating day, will result in no more than one violation per day per control device.

* * * * *

(c) * * * During periods of planned routine maintenance when emissions are controlled as specified in § 63.1252(h), the owner or operator must calculate controlled emissions assuming the HAP emissions are reduced by 93 percent. * * *

* * * * *

(h) * * *

(10) Instead of complying with the provisions of paragraphs (h)(2) through (8) of this section, an owner or operator may design a closed-vent system to operate at a pressure below atmospheric pressure. The system shall be equipped with at least one pressure gauge or other pressure measurement device that can be read from a readily accessible location to verify that negative pressure is being maintained in the closed-vent system when the associated control device is operating.

(i) *Planned routine maintenance.* During periods of planned routine maintenance when organic HAP emissions are controlled as specified in § 63.1252(h)(2), the owner or operator must monitor the condenser outlet gas temperature according to the procedures specified in paragraph (b)(1)(iii) of this section. During periods of planned routine maintenance when HCl emissions are controlled as specified in § 63.1252(h)(3), the owner or operator

must monitor the pH of the scrubber effluent once per day.

13. Section 63.1259 is amended by:

a. Revising paragraph (a)(3)(iii);

b. Revising paragraph (b)(5)(i) introductory text;

c. Redesignating paragraphs (b)(5)(ii)(D) and (E) as paragraphs (b)(5)(ii)(E) and (F);

d. Adding paragraph (b)(5)(ii)(D);

e. Revising paragraph (b)(8);

f. Revising paragraph (b)(10);

g. Adding paragraph (b)(13);

h. Revising ''paragraphs (i)(7)(i) through (viii)'' to read ''paragraphs (i)(7)(i) through (ix)'' in paragraph (i)(7) introductory text; and

i. Redesignating paragraphs (i)(7)(i) through (viii) as paragraphs (i)(7)(ii) through (ix), adding paragraph (i)(7)(i), and revising redesignated paragraph (i)(7)(ii).

The revisions and additions read as follows:

§ 63.1259 Recordkeeping requirements.

(a) * * *

(3) * * *

(iii) For each startup, shutdown, or malfunction, the owner or operator shall record all information necessary to demonstrate that the procedures specified in the affected source's startup, shutdown, and malfunction plan were followed, as specified in § 63.6(e)(3)(iii); alternatively, the owner or operator shall record any actions taken that are not consistent with the plan, as specified in § 63.6(e)(3)(iv).

* * * * *

(b) * * *

(5) * * *

(i) For processes that are in compliance with the percent reduction requirements of § 63.1254(a)(1) or (b)(1) and that contain vents controlled to less than the percent reduction requirement, the records specified in paragraphs (b)(5)(i)(A) through (C) of this section are required.

* * * * *

(ii) * * *

(D) Actual controlled emissions for each batch operated during periods of planned routine maintenance of a CCCD, calculated according to § 63.1258(c).

* * * * *

(8) A schedule or log of each operating scenario updated daily or, at a minimum, each time a different operating scenario is put into operation.

* * * * *

(10) Periods of planned routine maintenance as described in §§ 63.1252(h) and 63.1257(c)(5).

* * * * *

(13) All maintenance performed on the air pollution control equipment.

* * * * *

(i) * * *

(7) * * *

(i) Identification of the leaking equipment.

(ii) The instrument identification numbers and operator name or initials, if the leak was detected using the procedures described in § 63.1258(h)(3); or a record that the leak was detected by sensory observations.

* * * * *

14. Section 63.1260 is amended by:

a. Adding paragraph (f)(7);

b. Revising paragraph (g)(1) introductory text;

c. Revising ''paragraphs (g)(2)(iv)(A) through (D)'' to read ''paragraphs (g)(2)(v)(A) through (D)'' in paragraph (g)(2)(v) introductory text;

d. Revising paragraph (g)(2)(vi);

e. Revising the last sentence in paragraph (g)(2)(vii);

f. Revising paragraph (h)(1) introductory text; and

g. Revising paragraph (i).

The revisions and additions read as follows:

§ 63.1260 Reporting requirements.

* * * * *

(f) * * *

(7) Anticipated periods of planned routine maintenance of a CCCD subject to § 63.1252(h) during the period between the compliance date and the end of the period covered by the first Periodic report, and if applicable, the rationale for why the planned routine maintenance must be performed while a process with a vent subject to § 63.1254(a)(3) will be operating.

(g) * * *

(1) *Submittal schedule.* Except as provided in paragraphs (g)(1)(i), (ii), and (iii) of this section, an owner or operator shall submit Periodic reports semiannually. The first report shall be submitted no later than 240 days after the Notification of Compliance Status is due and shall cover the 6-month period beginning on the date the Notification of Compliance Status is due. Each subsequent Periodic report shall cover the 6-month period following the preceding period.

* * * * *

(2) * * *

(vi) The information specified in paragraphs (g)(2)(vi)(A) through (C) for periods of planned routine maintenance.

(A) For each storage tank subject to control requirements, periods of planned routine maintenance during which the control device does not meet the specifications of § 63.1253(b) through (d).

(B) For a CCCD subject to § 63.1252(h), periods of planned routine maintenance during the current reporting period and anticipated periods of planned routine maintenance during the next reporting period.

(C) Rationale for why planned routine maintenance of a CCCD subject to § 63.1252(h) must be performed while a process with a vent subject to § 63.1254(a)(3) will be operating, if applicable. This requirement applies only if the rationale is not in, or differs from that in, the Notification of Compliance Status report.

(vii) * * * For the initial Periodic report, each operating scenario for each process operated since the due date of the Notification of Compliance Status Report shall be submitted.

* * * * *

(h) * * *

(1) Except as specified in paragraph (h)(2) of this section, whenever a process change is made, or a change in any of the information submitted in the Notification of Compliance Status Report, the owner or operator shall submit the information specified in paragraphs (h)(1)(i) through (iv) of this section with the next Periodic report required under paragraph (g) of this section.

* * * * *

(i) *Reports of startup, shutdown, and malfunction.* An owner or operator shall prepare startup, shutdown, and malfunction reports as specified in paragraphs (i)(1) and (2) of this section.

(1) If actions taken by an owner or operator during a startup, shutdown, or malfunction of an affected source (including actions to correct a malfunction) are consistent with the procedures specified in the source's startup, shutdown, and malfunction plan, the owner or operator shall state this fact in a startup, shutdown, or malfunction report. The report shall also include the information specified in § 63.1259(a)(3)(i) and (ii) and shall contain the name, title, and signature of the owner or operator or other responsible official who is certifying its accuracy. For the purposes of this subpart, the startup, shutdown, and malfunction reports shall be submitted on the same schedule as the periodic reports required under paragraph (g) of this section instead of the schedule specified in § 63.10(d)(5)(i). Reports are only required if a startup, shutdown, or malfunction occurred during the reporting period.

(2) Any time an owner or operator takes an action that is not consistent

with the procedures specified in the affected source's startup, shutdown, and malfunction plan, the owner or operator shall submit immediate startup, shutdown, and malfunction reports as specified in § 63.10(d)(5)(ii).

* * * * *

15. Table 1 to subpart GGG is amended by:

a. Revising entries ''63.1(c)(5),'' ''63.5(e),'' and ''63.8(e)(5)(i)''; and

b. Removing entry ''63.6(i)'' and adding entries ''63.6(i) (1) through (7)'' and ''63.6(i) (8) through (14).''

The revisions and additions read as follows:

TABLE 1 TO SUBPART GGG.—GENERAL PROVISIONS APPLICABILITY TO SUBPART GGG

General provisions reference	Summary of requirements	Applies to subpart GGG	Comments
*	*	*	*
§ 63.1(c)(5)	Notification requirements for an area source that increases HAP emissions to major source levels.	Yes	
*	*	*	*
§ 63.5(e)	Construction/reconstruction approval	Yes	
*	*	*	*
§ 63.6(i)(1) through (7)	Requests for compliance extensions	No	§ 63.1250(f)(6) specifies provisions for compliance extensions.
§ 63.6(i)(8) through (14)	Approval of compliance extensions	Yes	Except references to § 63.6(i)(4) through (6) mean § 63.1250(f)(6).
*	*	*	*
§ 63.8(e)(5)(i)	Reporting performance evaluation results	Yes	See § 63.1260(a).
*	*	*	*

16. Table 2 to subpart GGG is revised to read as follows:

TABLE 2 TO SUBPART GGG.—PARTIALLY SOLUBLE HAP

1,1,1–Trichloroethane (methyl chloroform)	Chloroform
1,1,2,2-Tetrachloroethane	Chloromethane
1,1,2-Trichloroethane	Chloroprene
1,1-Dichloroethylene (vinylidene chloride)	Cumene
1,2-Dibromoethane	Dichloroethyl ether
1,2-Dichloroethane (ethylene dichloride)	Dinitrophenol
1,2-Dichloropropane	Epichlorohydrin
1,3-Dichloropropene	Ethyl acrylate
2,4,5-Trichlorophenol	Ethylbenzene
2-Butanone (mek)	Ethylene oxide
1,4-Dichlorobenzene	Hexachlorobenzene
2-Nitropropane	Hexachlorobutadiene
4–Methyl-2-pentanone (MIBK)	Hexachloroethane
Acetaldehyde	Methyl methacrylate
Acrolein	Methyl-t-butyl ether
Acrylonitrile	Methylene chloride
Allyl chloride	N,N-dimethylaniline
Benzene	Propionaldehyde
Benzyl chloride	Propylene oxide
Biphenyl	Styrene
Bromoform (tribromomethane)	Tetrachloroethene (perchloroethylene)
Bromomethane	Tetrachloromethane (carbon tetrachloride
Butadiene	Toluene
Carbon disulfide	Trichlorobenzene (1,2,4-)
Chlorobenzene	Trichloroethylene
Chloroethane (ethyl chloride)	Trimethylpentane
Vinyl acetate	Xylene (p)
Vinyl chloride	N-hexane
Xylene (m).	
Xylene (o).	

17. Table 3 to subpart GGG is revised to read as follows:

TABLE 3 TO SUBPART GGG.—SOLUBLE HAP

Compound
1,1-Dimethylhydrazine.
1,4-Dioxane.
Acetonitrile.
Acetophenone.
Diethyl sulfate.
Dimethyl sulfate.
Dinitrotoluene.
Ethylene glycol dimethyl ether.
Ethylene glycol monobutyl ether acetate.
Ethylene glycol monomethyl ether acetate.
Isophorone.
Methanol (methyl alcohol).
Nitrobenzene.
Toluidene.
Triethylamine.

18. Table 9 to subpart GGG. is revised to read as follows:

TABLE 9 TO SUBPART GGG—DEFAULT BIORATES FOR SOLUBLE HAP

Compound name	Biorate (K1), L/g MLVSS-hr
Acetonitrile	0.100
Acetophenone	0.538
Diethyl sulfate	0.105
Dimethyl hydrazine(1,1)	0.227
Dimethyl sulfate	0.178
Dinitrotoluene(2,4)	0.784
Dioxane(1,4)	0.393
Ethylene glycol dimethyl ether	0.364
Ethylene glycol monobutyl ether acetate	0.496
Ethylene glycol monomethyl ether acetate	0.159
Isophorone	0.598
Methanol	[a]
Nitrobenzene	2.300
Toluidine (-0)	0.859
Triethylamine	1.064

[a] For direct dischargers, the default biorate for methanol is 3.5 L/g MLVSS-hr; for indirect dischargers, the default biorate for methanol is 0.2 L/g MLVSS-hr.

[FR Doc. 01–18879 Filed 8–1–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[FL–83–1–200101; FRL–7022–3]

Approval and Promulgation of Implementation Plans: Florida; Approval of Revisions to the Florida State Implementation Plan

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

SUMMARY: EPA is approving revisions to the Florida State Implementation Plan (SIP) submitted on December 10, 1999, by the State of Florida through the Florida Department of Environmental Protection (FDEP). This submittal consists of revisions to the ozone air quality maintenance plans for the Jacksonville (Duval County) and Southeast Florida (Broward, Dade, and Palm Beach Counties) areas to remove the emission reduction credits attributable to the Motor Vehicle Inspection Program (MVIP) from the future year emission projections contained in those plans. Florida submitted technical amendments to this revision on January 18, 2000. This revision updates the control strategy by removing emissions credit for the MVIP, and as such, transportation conformity must be redetermined by the Metropolitan Planning Organizations (MPOs) within 18 months of the final approval of this notice. EPA proposed approval of this revision to the Florida SIP on March 17, 2000.

EFFECTIVE DATE: This rule will be effective September 4, 2001.

ADDRESSES: Materials relevant to this rulemaking are contained in Docket No. FL83–200101. The docket is available at the following address for inspection during normal business hours: Environmental Protection Agency, Atlanta Federal Center, Region 4 Air Planning Branch, 61 Forsyth Street S.W., Atlanta, Georgia 30303–3104.

FOR FURTHER INFORMATION CONTACT: Joey LeVasseur at 404/562–9035 (E-mail: *levasseur.joey@epa.gov*).

SUPPLEMENTARY INFORMATION: The following sections: Background, Response to Comments, and Final Action, provide additional information concerning the revisions to the ozone air quality maintenance plans for the Jacksonville and Southeast Florida areas to remove the emission reduction credits attributable to the MVIP from the future year emission projections contained in those plans.

I. Background

Today's action finalizes EPA's approval of the maintenance plan revisions submitted on December 10, 1999. A detailed description of Florida's submittal may be found in the Notice of Proposed Rulemaking for today's action, which was published in the **Federal Register** on March 17, 2000. On April 13, 2000, EPA extended the proposal's comment period and on June 20, 2000, EPA reopened the comment period and announced a public hearing. The hearing was held on July 20, 2000. EPA received numerous comments during the comment period. In addition to comments on the proposed action, EPA also received comments on the Florida Legislature's decision to shutdown the MVIP in all areas in the State. That decision and action by the Florida Legislature has no bearing on today's action and such comments will not be addressed here.

II. Response to Comments

1. *Comment:* ''Elimination of the MVIP will result in adverse consequences. The likelihood that

damaged or destroyed original equipment catalytic converters will be replaced has diminished and the likelihood that catalytic converters will be illegally removed has increased.''

2. *Comment:* ''Although cleaner engine and fuel technologies will help reduce emissions of tailpipe exhaust and evaporating gasoline, cars must be properly maintained and emission control systems must remain functional if these reductions are to be fully realized. The MVIP serves as a continuing incentive for motorists to have their vehicles serviced regularly, to replace emission control components as needed, and to avoid tampering with emission control equipment.''

Response to comments 1 and 2: The revision to the maintenance plan takes into account the fact that some automobiles will not be properly maintained. This fact is reflected in the increase in the emissions budgets.

3. *Comment:* ''EPA should disapprove Florida's request because it is fundamentally deficient on the merits.''

4. *Comment:* ''FDEP's proposed modification is deficient in several fundamental respects. Among these deficiencies are both procedural and substantive defects, including the following:

The nature and status of FDEP's proposal, and of EPA's notice of proposed rulemaking, are fundamentally ambiguous so that it is impossible to comment meaningfully on the proposal at this time. Thus, any further EPA action on FDEP's proposal would constitute a violation of the Administrative Procedure Act, 5 U.S.C. sections 551–559.

Under the terms of section 175A of the Clean Air Act (CAA), maintenance plans may be revised only once, 8 years after redesignation and, even if ''interim'' modifications were permitted, the request must address projected emissions that occur over a 10 year time frame, commencing from the year of modification of the plan. FDEP must therefore demonstrate attainment of the relevant ozone standard through 2010–11, not merely 2005.

Trends in ozone design values in Southeast Florida and Duval County indicate that the MVIP remains critical to the maintenance of attainment status in those areas. In this regard, despite reductions in volatile organic compounds (VOC) and nitrogen oxides (NO_X) (ozone precursor) emissions, ozone concentrations in the relevant counties over the past several years have remained flat or increased.

FDEP's proposal fails to meet the requirements of CAA section 175A, which require that the MVIP be included in the maintenance plans as a fully qualified, legislatively authorized, contingency measure.

Without the MVIP, Southeast Florida and Duval County will likely be unable to make the transportation conformity demonstrations required by the CAA, and FDEP has failed to address this key concern in any meaningful manner.''

Response to comments 3 and 4: Any revision to the maintenance plan must not have an adverse impact on maintenance of the national ambient air quality standard (NAAQS) for any criteria pollutant. Guidance on this issue is contained in a memorandum dated September 17, 1993, from Michael Shapiro, Acting Assistant Administrator for Air and Radiation entitled, ''State Implementation Plan Requirements for Areas Submitting Requests for Redesignation to Attainment of the Ozone and Carbon Monoxide National Ambient Air Quality Standards on or after November 15, 1992.'' This memo states:

> As a general policy, a state may not relax the adopted and implemented SIP upon the area's redesignation to attainment. States should continue to implement existing control strategies in order to maintain the standard. However, section 175A recognizes that States may be able to move SIP measures to the contingency plan upon redesignation if the state can adequately demonstrate that such action will not interfere with maintenance of the standard.

The requirement for a second 10-year plan does not prohibit revisions to the existing 10-year maintenance plan. A revision to the existing 10-year maintenance plan prior to the required extension does not require the plan to be extended for another 10 years.

Ozone trends are not at issue in this revision. There is no requirement that ozone concentrations cannot increase from one year to another, as long as there is not a violation of the one-hour ozone NAAQS.

In this revision, Florida demonstrates that the area can maintain the one-hour ozone NAAQS without the implementation of the MVIP. The EPA has reviewed the State's emissions inventory and modeling analyses and finds that they meet applicable guidance and requirements. Therefore, the State has made the necessary demonstration that the MVIP is not necessary to maintain the one-hour ozone NAAQS and that attainment of the NAAQS for any other pollutant will not be affected by removing the MVIP from the SIP. In accordance with EPA's November 15, 1992, policy, the State must include the MVIP as a contingency measure in the maintenance plan for the redesignated area, which it has done.

Florida does not in this revision to the maintenance plan need to address the transportation conformity determination issue. This revision only removes the emission reduction credits attributable to the MVIP from the maintenance plan. Florida currently has a transportation conformity plan in place, but will need to perform another transportation conformity determination within 18 months of this final action, due to the revision to the emissions budgets.

5. *Comment:* ''The MVIP is working to reduce air pollution. If the program is working, it should be continued.''

6. *Comment:* ''If the program is not that effective, the EPA should force Florida to enhance the program.''

Response to comments 5 and 6: Ground level ozone is formed by the reaction of hydrocarbons and nitrogen oxides (NO_X) in the presence of sunlight. Both hydrocarbons and NO_X are emitted by vehicles. However, air quality modeling performed by FDEP has indicated that the amount of NO_X in the atmosphere is the controlling factor in the formation of ground level ozone over Florida. Therefore, controlling NO_X becomes a more effective strategy for reducing ground level ozone concentrations. While the MVIP program in Florida has been effective at reducing hydrocarbon and carbon monoxide emissions from vehicles, is was not designed to reduce NO_X. Such an inspection/maintenance program test must be conducted with the vehicle placed under a simulated driving load, on a dynamometer, as in the IM240 test. The implementation of such a test requires new testing equipment and longer test durations. Such a test is not mandated by the CAA for either the South Florida or Duval County ozone maintenance areas, and therefore can not be required by EPA at this time. As noted above, if the State can make the necessary demonstration that the MVIP is not necessary to maintain the one-hour ozone NAAQS, then the EPA cannot require the State to keep the program or to enhance it.

III. Final Action

EPA is approving the aforementioned revisions to the Florida SIP because they are consistent with CAA and EPA requirements.

Administrative Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. This action merely approves state law as meeting federal requirements and imposes no additional requirements

beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule approves pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4). For the same reason, this rule also does not significantly or uniquely affect the communities of tribal governments, as specified by Executive Order 13084 (63 FR 27655, May 10, 1998). This rule will not have substantial direct effects on the states, on the relationship between the national government and the states, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant.

In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings'' issued under the Executive Order. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

The Congressional Review Act, 5 U.S.C. section 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the **Federal Register**. A major rule cannot take effect until 60 days after it is published in the **Federal Register**. This action is not a ''major rule'' as defined by 5 U.S.C. section 804(2).

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by October 1, 2001. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Carbon monoxide, Hydrocarbons, Intergovernmental relations, Nitrogen dioxide, Ozone, Reporting and recordkeeping requirements.

Dated: July 16, 2001.

A. Stanley Meiburg,

Acting Regional Administrator, Region 4.

Part 52 of chapter I, title 40, *Code of Federal Regulations* is amended as follows:

PART 52—[AMENDED]

1. The authority citation for part 52 continues to read as follows:

Authority: 42 U.S.C. 7401 *et seq.*

Subpart K—Florida

2. Section 52.520 is amended by adding a new paragraph (e) to read as follows:

§ 52.520 Identification of plan.

* * * * *

(e) EPA-approved Florida non-regulatory provisions.

Provision	State effective date	EPA approval date	Federal Register notice	Explanation
Revision to Maintenance Plans for the Jacksonville and Southeast Florida Areas.	December 10, 1999	August 2, 2001	[Insert cite of publication].	

[FR Doc. 01–19162 Filed 8–1–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[OPP–301156; FRL–6794–3]

RIN 2070–AB78

Isoxadifen-ethyl; Pesticide Tolerance Technical Correction

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule; technical correction.

SUMMARY: EPA issued a final rule in the **Federal Register** of June 21, 2001 establishing time-limited tolerances for isoxadifen-ethyl. This document makes a technical correction to the tolerance regulation to correctly show the application rate in the tolerance expression.

DATES: This technical correction is effective August 2, 2001.

ADDRESSES: Comments may be submitted by mail, electronically, or in person. Please follow the detailed instructions for each method as provided in Unit II. of the **SUPPLEMENTARY INFORMATION.** To ensure proper receipt by EPA, it is imperative that you identify docket control number OPP–301156 in the subject line on the first page of your response.

FOR FURTHER INFORMATION CONTACT: By mail: Vera Soltero, Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: (703) 308–9359; e-mail address: soltero.vera@epa.gov.

SUPPLEMENTARY INFORMATION:

I. Does this Action Apply to Me?

You may be affected by this action if you are an agricultural producer, food manufacturer, or pesticide manufacturer. Potentially affected categories and entities may include, but are not limited to:

Categories	NAICS	Examples of Potentially Affected Entities
Industry	111	Crop production
	112	Animal production
	311	Food manufacturing
	32532	Pesticide manufacturing

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in the table could also be affected. The North American Industrial Classification System (NAICS) codes have been provided to assist you and others in determining whether or not this action might apply to certain entities. If you have questions regarding the applicability of this action to a particular entity, consult the person listed under **FOR FURTHER INFORMATION CONTACT.**

II. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. *Electronically*. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http://www.epa.gov/. To access this document, on the Home Page select ''Laws and Regulations,''" Regulations and Proposed Rules,'' and then look up the entry for this document under the ''**Federal Register**— -Environmental Documents.'' You can also go directly to the **Federal Register** listings at http://www.epa.gov/fedrgstr/.

2. *In person*. The Agency has established an official record for this action under docket control number OPP–301156. The official record consists of the documents specifically referenced in this action, any public comments received during an applicable comment period, and other information related to this action, including any information claimed as Confidential Business Information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period, is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Hwy., Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

III. What Does this Technical Correction Do?

In the **Federal Register** of June 9, 1999 (64 FR 30997) (FRL–6082–6) EPA published a notice pursuant to section 408 of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a, as amended by the Food Quality Protection Act (FQPA) (Public Law 104–170) announcing the filing of a pesticide tolerance petition (9E5060) by AgrEvo USA, now doing business as Aventis Crop Science, P.O. Box 12014, 2 T.W. Alexander Drive, Research Triangle Park, NC 27709. This notice included a summary of the petition prepared by the petitioner, including a statement specifying isoxadifen-ethyl's application rate as amount of safener (in pounds) per acre.

Time-limited tolerances for isoxadifen-ethyl on various rice commodities were established in the **Federal Register** on June 21, 2001 (66 FR 33179) (FRL–6786–1). In that document, the tolerance expression inadvertently described the application rate of the compound isoxadifen-ethyl as 0.17 pound of safener per pound of active ingredient. The tolerance expression should have read: 0.17 pound of safener per acre.

IV. Why is this Technical Correction Issued as a Final Rule?

Section 553 of the Administrative Procedure Act (APA), 5 U.S.C. 553(b)(B), provides that, when an Agency for good cause finds that notice and public procedure are impracticable, unnecessary or contrary to the public interest, the Agency may issue a rule without providing notice and an opportunity for public comment. EPA has determine that there is good cause for making today's rule final without prior proposal and opportunity of comment, because EPA is amending the tolerance expression to include the language (pounds safener per acre) that was previously used in the notice of filing.

V. Do Any of the Regulatory Assessment Requirements Apply to this Action?

This final rule implements a technical correction to the Code of Federal Regulations, and it does not otherwise impose or amend any requirements. As such, the Office of Management and Budget (OMB) has determined that a technical correction is not a ''significant regulatory action'' subject to review by OMB under Executive Order 12866, entitled *Regulatory Planning and Review* (58 FR 51735, October 4, 1993). Nor does this final rule contain any information collection requirements that require review and approval by OMB pursuant to the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501 et seq.).

Because this action is not economically significant as defined by section 3(f) of Executive Order 12866, this action is not subject to Executive Order 13045, entitled Protection of Children from Environmental Health Risks and Safety Risks (62 FR 19885, April 23, 1997). This action will not

result in environmental justice related issues and does not, therefore, require special consideration under Executive Order 12898, entitled *Federal Actions to Address Environmental Justice in Minority Populations and Low-Income Populations* (59 FR 7629, February 16, 1994).

Since the Agency has made a ''good cause'' finding that this action is not subject to notice-and-comment requirements under the APA or any other statute (see Unit IV.), this action is not subject to provisions of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et seq.), or to sections 202 and 205 of the Unfunded Mandates Reform Act of 1995 (UMRA) (Public Law 104–4). In addition, this action does not significantly or uniquely affect small governments or impose a significant intergovernmental mandate, as described in sections 203 and 204 of UMRA.

This final rule will not have substantial direct effects on the States or on one or more Indian tribes, on the relationship between the national government and the States or one or more Indian tribes, or on the distribution of power and responsibilities among the various levels of government or between the Federal government and Indian tribes. As such, this action does not have any '' tribal implications'' as described in Executive Order 13175, entitled *Consultation and Coordination with Indian Tribal Governments* (65 FR 67249, November 6, 2000), or any ''federalism implications '' as described in Executive Order 13132, entitled Federalism (64 FR 43255, August 10, 1999).

This action does not involve any technical standards that require the Agency's consideration of voluntary consensus standards pursuant to section 12(d) of the National Technology Transfer and Advancement Act of 1995 (NTTAA), Public Law 104–113, section 12(d) (15 U.S.C. 272 note). In issuing this final rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct, as required by section 3 of Executive Order 12988, entitled *Civil Justice Reform* (61 FR 4729, February 7, 1996).

EPA has complied with Executive Order 12630, entitled *Governmental Actions and Interference with Constitutionally Protected Property Rights* (53 FR 8859, March 15, 1988), by examining the takings implications of this rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings '' issued under the Executive Order. For information about the applicability of the regulatory assessment requirements to the final rule that was issued on July 14, 2000 (64 FR 43704), please refer to the discussion in Unit VIII. of that document.

VI. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 et seq., as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the Agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the **Federal Register**. This rule is not a ''major rule '' as defined by 5 U.S.C. 804(2).

List of Subjects in 40 CFR Part 180

Environmental protection, Administrative practice and procedure, Agricultural commodities, Pesticides and pests, Reporting and record keeping requirements.

Dated: July 23, 2001.

James Jones,

Director, Registration Division, Office of Pesticide Programs.

Therefore, 40 CFR part 180 is amended as follows:

PART 180—-[AMENDED]

1. The authority citation for part 180 continues to read as follows:

Authority: 21 U.S.C. 321(q), 346a, 371.

2. Section 180.570 is amended by revising paragraph (a) to read as follows:

§ 180.570 Isoxadifen-ethyl; tolerances for residues.

(a) *General*. Tolerances that expire as indicated in the table below are established for residues of isoxadifen-ethyl (ethyl 5,5-diphenyl-2-isoxazoline-3-carboxylate, CAS No. 163520–33–0) and its metabolites: 4,5-dihydro-5,5-diphenyl-3-isoxazolecarboxylic acid and β-hydroxy-β-benezenepropanenitrile when in the commodities listed below. This safener will be used only in conjunction with the active ingredient fenoxaprop-*p*-ethyl, at a rate of 0.17 pound of safener per acre.

Commodity	Parts per million	Expiration/ Revocation date
Rice, bran	0.80	6/21/04
Rice, grain	0.10	6/21/04
Rice, hulls	0.50	6/21/04
Rice, straw	0.25	6/21/04

* * * * *

[FR Doc. 01–19326 Filed 8–1–01; 8:45 am]

BILLING CODE 6560–50–S

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[OPP–301148; FRL–6791–7]

RIN 2070–AB78

Tepraloxydim; Pesticide Tolerance

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

SUMMARY: This regulation establishes a tolerance for combined residues of tepraloxydim (2-[1-[[[(2E)-3-chloro-2-propenyl]oxy]imino]propyl]-3-hydroxy-5-(tetrahydro-2H-pyran-4-yl)-cyclohexene-1-one) and its metabolites convertible to GP (3- (tetrahydropyran-4-yl)pentane-1,5-dioic acid) and OH-GP (3-hydroxy-3-(tetrahydropyran-4-yl)pentane-1,5-dioic acid), calculated as tepraloxydim, in or on canola, seed;

cotton, undelinted seed; cotton, gin byproducts; soybean, seed; soybean, hulls; and soybean, aspirated grain fractions; and the combined residues of tepraloxydim and its metabolites convertible to GP, OH-GP, and GL (3-(2-oxotetrahydropyran-4-yl)pentane-1,5-dioic acid), calculated as tepraloxydim, in or on milk; meat of cattle, goats, hogs, horses, and sheep; meat byproduct (except kidney) of cattle, goats, hogs, horses, and sheep; kidney of cattle, goats, hogs, horses, and sheep; fat of cattle, goats, hogs, horses, and sheep; poultry, meat; poultry, meat byproducts (except liver), poultry, fat; poultry, liver, and eggs. Nippon Soda Company, Ltd requested this tolerance under the Federal Food, Drug, and Cosmetic Act, as amended by the Food Quality Protection Act of 1996.

DATES: This regulation is effective August 2, 2001. Objections and requests for hearings, identified by docket control number OPP–301148, must be received by EPA on or before October 1, 2001.

ADDRESSES: Written objections and hearing requests may be submitted by mail, in person, or by courier. Please follow the detailed instructions for each method as provided in Unit VI. of the **SUPPLEMENTARY INFORMATION**. To ensure proper receipt by EPA, your objections and hearing requests must identify docket control number OPP–301148 in the subject line on the first page of your response.

FOR FURTHER INFORMATION CONTACT: By mail: Jim Tompkins, Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW.,Washington, DC 20460; telephone number: (703) 305–5697 ; and e-mail address: tompkins.jim@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

You may be affected by this action if you are an agricultural producer, food manufacturer, or pesticide manufacturer. Potentially affected categories and entities may include, but are not limited to:

Categories	NAICS	Examples of Potentially Affected Entities
Industry	111	Crop production
	112	Animal production
	311	Food manufacturing
	32532	Pesticide manufacturing

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in the table could also be affected. The North American Industrial Classification System (NAICS) codes have been provided to assist you and others in determining whether or not this action might apply to certain entities. If you have questions regarding the applicability of this action to a particular entity, consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. *Electronically.*You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http://www.epa.gov/. To access this document, on the Home Page select ''Laws and Regulations'', ''Regulations and Proposed Rules,'' and then look up the entry for this document under the ''**Federal Register**—-Environmental Documents.'' You can also go directly to the **Federal Register** listings at http://www.epa.gov/fedrgstr/. To access the OPPTS Harmonized Guidelines referenced in this document, go directly to the guidelines at http://www.epa.gov/opptsfrs/home/guidelin.htm. A frequently updated electronic version of 40 CFR part 180 is available at http://www.access.gpo.gov/nara/cfr/cfrhtml_180/Title_40/40cfr180_00.html, a beta site currently under development.

2. *In person.* The Agency has established an official record for this action under docket control number OPP–301148. The official record consists of the documents specifically referenced in this action, and other information related to this action, including any information claimed as Confidential Business Information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Hwy., Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

II. Background and Statutory Findings

In the **Federal Register** of December 22, 1999 64 FR 71774) (FRL–6398–6), EPA issued a notice pursuant to section 408 of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a as amended by the Food Quality Protection Act of 1996 (FQPA) (Public Law 104–170) announcing the filing of a pesticide petition (PP 8F4945) for tolerance by BASF Corporation, acting as agent for Nippon Soda Company, Ltd., P.O. Box 13528, Research Triangle Park, NC 27709–3528. This notice included a summary of the petition prepared by Nippon Soda, the registrant. There were no comments received in response to the notice of filing.

The petition requested that 40 CFR part 180 be amended by establishing a tolerance for combined residues of the herbicide tepraloxydim, (2-[1-[[[(2E)-3-chloro-2-propenyl]oxy]imino]propyl]-3-hydroxy-5-(tetrahydro-2H-pyran-4-yl)-cyclohexene-1-one) and its metabolites convertible to GP (3-(tetrahydropyran-4-yl)pentane-1,5-dioic acid) and OH-GP (3-hydroxy-3-(tetrahydropyran-4-yl)pentane-1,5-dioic acid) (calculated as the herbicide) in or on the raw agricultural commodities cotton, seed at 0.2 part per million (ppm); cotton meal at 0.2 ppm, cotton gin trash at 3.0 ppm; soybean seed at 5.0 ppm; soybean hulls, poultry meat and fat at 0.5 ppm; and poultry, liver at 1.0 ppm; and eggs at 0.2 ppm.

During the course of the review, the Agency determined that the available data support the following tolerances: tepraloxydim (2-[1-[[[(2E)-3-chloro-2-propenyl]oxy]imino]propyl]-3-hydroxy-5-(tetrahydro-2H-pyran-4-yl)-cyclohexene-1-one) and its metabolites convertible to GP (3-(tetrahydropyran-4-yl)pentane-1,5-dioic acid) and OH-GP (3-hydroxy-3-(tetrahydropyran-4-yl)pentane-1,5-dioic acid), calculated as tepraloxydim, in or on cotton, undelinted seed at 0.2 ppm; cotton, gin byproducts at 3.0 ppm; soybean, seed at 6.0 ppm; soybean, hulls at 8.0 ppm; and soybean, aspirated grain fractions at 1200 ppm; and the combined residues of tepraloxydim and its metabolites convertible to GP, OH-GP, and GL (3-(2-oxotetrahydropyran-4-yl)pentane-1,5-dioic acid), calculated as tepraloxydim, in or on milk at 0.1 ppm; meat of cattle, goats, hogs, horses, and sheep at 0.2 ppm; meat byproduct (except kidney) of cattle, goats, hogs, horses, and sheep at 0.2 ppm; kidney of cattle, goats, hogs, horses, and sheep at 0.5 ppm; fat of cattle, goats, hogs, horses, and sheep at 0.15 ppm; poultry, meat at 0.2 ppm; poultry, meat byproducts (except liver)

at 0.2 ppm; poultry, fat at 0.3 ppm; poultry, liver at 1.0 ppm; and eggs at 0.20 ppm. The available data also support the establishment of a tolerance with regional registration, as defined in § 180.1(n) for the combined residues of tepraloxydim and its metabolites convertible to GP and OH-GP, calculated as tepraloxydim in or on the raw agricultural commodity canola, seed at 0.5 ppm.

Section 408(b)(2)(A)(i) of the FFDCA allows EPA to establish a tolerance (the legal limit for a pesticide chemical residue in or on a food) only if EPA determines that the tolerance is ''safe.'' Section 408(b)(2)(A)(ii) defines ''safe'' to mean that'' there is a reasonable certainty that no harm will result from aggregate exposure to the pesticide chemical residue, including all anticipated dietary exposures and all other exposures for which there is reliable information.'' This includes exposure through drinking water and in residential settings, but does not include occupational exposure. Section 408(b)(2)(C) requires EPA to give special consideration to exposure of infants and children to the pesticide chemical residue in establishing a tolerance and to ''ensure that there is a reasonable certainty that no harm will result to infants and children from aggregate exposure to the pesticide chemical residue....''

EPA performs a number of analyses to determine the risks from aggregate exposure to pesticide residues. For further discussion of the regulatory requirements of section 408 and a complete description of the risk assessment process, see the final rule on Bifenthrin Pesticide Tolerances (62 FR 62961, November 26, 1997) (FRL–5754–7).

III. Aggregate Risk Assessment and Determination of Safety

Consistent with section 408(b)(2)(D), EPA has reviewed the available scientific data and other relevant information in support of this action. EPA has sufficient data to assess the hazards of and to make a determination on aggregate exposure, consistent with section 408(b)(2), for a tolerance[s] for the combined residues of tepraloxydim (2-[1-[[[(2E)-3-chloro-2-propenyl]oxy]imino]propyl]-3-hydroxy-5-(tetrahydro-2H-pyran-4-yl)-cyclohexene-1-one) and its metabolites convertible to GP (3-(tetrahydropyran-4-yl)pentane-1,5-dioic acid) and OH-GP (3-hydroxy-3-(tetrahydropyran-4-yl)pentane-1,5-dioic acid), calculated as tepraloxydim, in or on cotton, undelinted seed at 0.2 ppm; cotton, gin byproducts at 3.0 ppm; soybean, seed at 6.0 ppm; soybean, hulls at 8.0 ppm; soybean, aspirated grain fractions at 1200 ppm; and the combined residues of tepraloxydim and its metabolites convertible to GP, OH-GP, and GL (3-(2-oxotetrahydropyran-4-yl)pentane-1,5-dioic acid), calculated as tepraloxydim, in or on milk at 0.1 ppm; meat of cattle, goats, hogs, horses, and sheep at 0.2 ppm; meat byproduct (except kidney) of cattle, goats, hogs, horses, and sheep at 0.2 ppm; kidney of cattle, goats, hogs, horses, and sheep at 0.5 ppm; fat of cattle, goats, hogs, horses, and sheep at 0.15 ppm; poultry, meat at 0.2 ppm; poultry, meat byproducts (except liver) at 0.2 ppm; poultry, fat at 0.3 ppm; poultry, liver at 1.0 ppm; and eggs at 0.20 ppm; and a tolerance with regional registration, as defined in § 180.1(n) for the combined residues of tepraloxydim and its metabolites convertible to GP and OH-GP, calculated as tepraloxydim, in or on the raw agricultural commodity canola, seed at 0.5 ppm. EPA's assessment of exposures and risks associated with establishing the tolerance follows.

A. Toxicological Profile

EPA has evaluated the available toxicity data and considered its validity, completeness, and reliability as well as the relationship of the results of the studies to human risk. EPA has also considered available information concerning the variability of the sensitivities of major identifiable subgroups of consumers, including infants and children. The nature of the toxic effects caused by tepraloxydim are discussed in the following Table 1 as well as the no observed adverse effect level (NOAEL) and the lowest observed adverse effect level (LOAEL) from the toxicity studies reviewed.

TABLE 1.— SUBCHRONIC, CHRONIC, AND OTHER TOXICITY

Guideline No.	Study Type	Results
870.3100	90–Day oral toxicity in rats	NOAEL = M=22, F=26 mg/kg/day LOAEL = M=223, F=257 mg/kg/day based on decreased body weight/body weight gain, changes in kidney proximal tubule, and changes in clinical chemistry parameters indicative of liver and kidney impairment.
870.3150	90–Day oral toxicity in dogs	NOAEL = M=12.9, F=14.3 mg/kg/day LOAEL = M=63.3, F=68.0 mg/kg/day based on increased liver and thyroid weights and histopathology of spleen.
870.3200	28–Day dermal toxicity in rats	NOAEL = 1,000 mg/kg/day (limit dose) LOAEL = Not determined.
870.3700a	Prenatal developmental in rats	Maternal NOAEL = 120 mg/kg/day LOAEL = 360 mg/kg/day based on decreased body weight and food consumption. Developmental NOAEL = 40 mg/kg/day LOAEL = 120 mg/kg/day based on decreased fetal body weight, retarded ossification, and hydroureter.
870.3700b	Prenatal developmental in rabbits	Maternal NOAEL = 60 mg/kg/day; LOAEL = 180 mg/kg/day based on decreased body weight and food consumption. Developmental NOAEL = ≥ 180 mg/kg/day (HTD) LOAEL = >180 mg/kg/day based on no developmental effects at the HTD.
870.3800	Reproduction and fertility effects in rats	Parental/Systemic NOAEL = M=50.6, F=55.0 mg/kg/day

TABLE 1.— SUBCHRONIC, CHRONIC, AND OTHER TOXICITY—Continued

Guideline No.	Study Type	Results
		LOAEL = M= 260.0, F= 276.0 mg/kg/day based on decreased body weight/ weight gain and food consumption. Reproductive NOAEL = ≥ 260 mg/kg/day LOAEL = > 260 mg/kg/day based on no reproductive effects. Offspring NOAEL = M=50.6, F=55.0 mg/kg/day LOAEL = M= 260.0, F= 276.0 mg/kg/day based on reduced pup body weight gain and lower pup body weight during lactation.
870.4100b	Chronic toxicity in dogs	NOAEL = M=11.5, F=12.5 mg/kg/day LOAEL = M=56.0, F=60.6 mg/kg/day based on reduced epididymal and prostate activities, transitional epithelial hyperplasia of the urinary bladder, and abnormal liver function and liver foci.
870.4200	Carcinogenicity in rats	NOAEL = M=5, F=38 mg/kg/day LOAEL = M=30, F=272 mg/kg/day based on hepatic lesions in both sexes, increased incidences of hepatocellular adenoma/carcinoma in females, adrenal medullary tumors in females, and uterine schwannoma in females. Some evidence of carcinogenicity in females
870.4300	Carcinogenicity in mice	NOAEL = M=37, F=52 mg/kg/day LOAEL = M=332, F=490 mg/kg/day based on decreased body weight/gain, increased relative liver weight in males, and uterine sclerosis. Female mice developed liver tumors at an excessively toxic dose.
870.5100	Gene Mutation	Ames test: Negative at all doses; cytotoxic at HTD of 5,000 μg/ml. Mammalian (CHO/HPRT): Negative; HTD = 3,000 μg/ml (limit of solubility = 1000 μg/ml).
870.5395 and 870.5375	Cytogenetics	*In vivo* (mouse bone marrow): Negative; HTD = 500 mg/kg. *In vitro* (chromosomal aberration in CHO cells): Negative; HTD = 1,000 μg/ml (limit of solubility).
870.5550	Other Effects	UDS in primary male rat hepatocytes: Negative; HTD = 500 μg/ml; cytotoxic at ≥ 100 μg/ml.
870.6200a	Acute neurotoxicity screening battery (unacceptable)	NOAEL = < 500 mg/kg LOAEL = 500 mg/kg based on decreased motor activity.
870.6200b	Subchronic neurotoxicity screening battery (unacceptable)	NOAEL = M=103, F=124 mg/kg/day LOAEL = M=428, F=513 mg/kg/day based on increased motor activity, and decreased body weight, food consumption, food efficiency.
870.7485	Metabolism and pharmacokinetics	In pharmacokinetics/metabolism studies in the rat, tepraloxydim was readily and almost completely absorbed after oral administration (single dose of 30 or 300 mg/kg), but was rapidly excreted mainly via the urine (65–80%). Excretion was nearly 2–3 fold higher in the bile than the feces, which suggests enterohepatic recirculation. The rat plasma half life of radiolabeled tepraloxydim is nearly 4.4 and 10 hours at the low and high dose, respectively. No accumulation of radioactivity was observed in any tissue at 120 hours post-dosing. A large number of metabolites were detected in the urine, feces, and bile; the main metabolic pathway being oxidation at the pyran ring to the lactone via a hydroxy metabolite, and cleavage of the oxime ether group with the imine and oxazol as products. At near plasma t_{max} (one hour post dosing), the plasma, liver, and kidney almost exclusively contained the parent compound. The results indicate that the distribution, metabolism, and excretion of tepraloxydim is independent from dose levels, sex, route of administration (oral vs. i.v.), or site of label (pyran vs. cyclohexanone).
870.7600	Dermal penetration (unacceptable)	The available rat dermal absorption study is considered unacceptable. A dermal absorption rate of 36% was derived based on the results of a 28–day dermal toxicity study in rats and developmental toxicity study in rats.

B. Toxicological Endpoints

The dose at which no adverse effects are observed (the NOAEL) from the toxicology study identified as appropriate for use in risk assessment is used to estimate the toxicological level of concern (LOC). However, the lowest dose at which adverse effects of concern are identified (the LOAEL) is sometimes used for risk assessment if no NOAEL was achieved in the toxicology study

selected. An uncertainty factor (UF) is applied to reflect uncertainties inherent in the extrapolation from laboratory animal data to humans and in the variations in sensitivity among members of the human population as well as other unknowns. An UF of 100 is routinely used, 10X to account for interspecies differences and 10X for intra species differences.

For dietary risk assessment (other than cancer) the Agency uses the UF to calculate an acute or chronic reference dose (acute RfD or chronic RfD) where the RfD is equal to the NOAEL divided by the appropriate UF (RfD = NOAEL/UF). Where an additional safety factor is retained due to concerns unique to the FQPA, this additional factor is applied to the RfD by dividing the RfD by such additional factor. The acute or chronic Population Adjusted Dose (aPAD or cPAD) is a modification of the RfD to accommodate this type of FQPA Safety Factor.

For non-dietary risk assessments (other than cancer) the UF is used to determine the LOC. For example, when 100 is the appropriate UF (10X to account for interspecies differences and 10X for intraspecies differences) the LOC is 100. To estimate risk, a ratio of the NOAEL to exposures (margin of exposure (MOE) = NOAEL/exposure) is calculated and compared to the LOC.

The linear default risk methodology (Q*) is the primary method currently used by the Agency to quantify carcinogenic risk. The Q* approach assumes that any amount of exposure will lead to some degree of cancer risk. A Q* is calculated and used to estimate risk which represents a probability of occurrence of additional cancer cases (e.g., risk is expressed as 1×10^{-6} or one in a million). Under certain specific circumstances, MOE calculations will be used for the carcinogenic risk assessment. In this non-linear approach, a ''point of departure'' is identified below which carcinogenic effects are not expected. The point of departure is typically a NOAEL based on an endpoint related to cancer effects though it may be a different value derived from the dose response curve. To estimate risk, a ratio of the point of departure to exposure (MOE_{cancer} = point of departure/exposures) is calculated. A summary of the toxicological endpoints for tepraloxydim used for human risk assessment is shown in the following Table 2:

TABLE 2.— SUMMARY OF TOXICOLOGICAL DOSE AND ENDPOINTS FOR TEPRALOXYDIM FOR USE IN HUMAN RISK ASSESSMENT

Exposure Scenario	Dose (mg/kg/day), Uncertainty Factor (UF)	Population (if applicable); Endpoint	Study and Toxicological Effects
Acute Dietary	NOAEL = 40; UF = 100; FQPA* = 3X; Females 13–50 ONLY.	Females 13–50: Reduced fetal body weight, reduced ossification indicative of delayed maturation, and the occurrence of hydroureter at 120 mg/kg/day (LOAEL). General Population: This risk assessment is not required. No appropriate single dose end-point. Acute RfD = 0.4 mg/kg Acute PAD = 0.13 mg/kg/day (Females 13–50 ONLY)	Developmental Toxicity-Rat
Chronic Dietary	NOAEL = 5 UF = 100; FQPA = 1X	NOAEL = 100 ppm (5 mg/kg/day) based on male liver microscopic lesions (eosinophilic foci) at 600 ppm (30 mg/kg/day). Chronic RfD = 0.05 mg/kg/day	Carcinogenicity-Rat
Incidental Oral, Short-Term	NOAEL = 120; FQPA = 1X	Reduced maternal body weight gain and food consumption at 360 mg/kg/day (LOAEL).	Developmental Toxicity-Rat
Incidental Oral, Intermediate-Term	NOAEL = 22; FQPA = 1X	NOAEL = 300 ppm (males 22, females 26 mg/kg/day) based on reduced body weight/body weight gain, proximal tubule kidney changes in males, and clinical chemistry changes indicative of hepatic and kidney impairment in both sexes at 3000 ppm (223 and 257 mg/kg/day.	Subchronic Oral Toxicity-Rat
Dermal, Short- and Intermediate-Term	NOAEL = 40	Reduced fetal body weight, reduced ossification indicative of delayed maturation, and the occurrence of hydroureter at 120 mg/kg/day (LOAEL). The dermal absorption factor of 36% should be used for route-to-route extrapolation.	Developmental Toxicity-Rat
Dermal, Long-Term	NOAEL= N/A	This risk assessment is not required due to the seasonal use of the chemical.	N/A
Inhalation, Short-and Intermediate-Term	NOAEL= 40	Reduced fetal body weight, reduced ossification indicative of delayed maturation, and the occurrence of hydroureter at 120 mg/kg/day (LOAEL). Use route-to-route extrapolation and a 100% absorption rate (default value).	Developmental Toxicity-Rat
Inhalation, Long-Term	NOAEL = N/A	This risk assessment is not required due to the seasonal use of the chemical.	N/A

* The reference to the FQPA Safety Factor refers to any additional safety factor retained due to concerns unique to the FQPA.

C. Exposure Assessment

1. *Dietary exposure from food and feed uses.* Tolerances have been not established (40 CFR part 180) for the combined residues of tepraloxydim and its metabolites, in or on a variety of raw agricultural commodities. Risk assessments were conducted by EPA to assess dietary exposures from tepraloxydim in food as follows:

i. *Acute exposure.* Acute dietary risk assessments are performed for a food-use pesticide if a toxicological study has indicated the possibility of an effect of concern occurring as a result of a 1 day or single exposure. The Dietary Exposure Evaluation Model (DEEM®) analysis evaluated the individual food consumption as reported by respondents in the USDA 1989–1992 nationwide Continuing Surveys of Food Intake by Individuals (CSFII) and accumulated exposure to the chemical for each commodity. The following assumptions were made for the acute exposure assessments: For acute risk assessments, a food consumption distribution is calculated for each population subgroup of interest based on 1 day consumption data. The only population subgroup of concern for this risk assessment is females (13–50 years old). The consumption distribution can be multiplied by a residue point estimate for a deterministic (Tier I/II type) exposure/risk assessment, or used with a residue distribution in a probabilistic (Monte Carlo) type risk assessment. Exposure estimates are expressed in mg/kg bw/day and as a percent of the aPAD.

In conducting this acute dietary risk assessment, the Agency has made highly conservative assumptions. Default concentration factors were used for the processed commodities. One hundred percent of the proposed crops are assumed to be treated with tepraloxydim and residues were assumed to be at tolerance levels. This is expected to result in an overestimate of dietary exposure. Therefore, this acute dietary (food only) risk assessment should be viewed as a highly conservative risk estimate. The percent aPAD that would be above EPA's level of concern would be 100%. Percent crop treated (PCT) and/or anticipated residues were not used. A DEEM acute analysis was performed using proposed and recommended tolerance levels for the combined residues of tepraloxydim and its metabolites for females (13–50 years old). Based on the results of this analysis, exposure to tepraloxydim from food will utilize 4.4% of aPAD for females (13–50 years old), the only population subgroup of concern.

ii. *Chronic exposure.* In conducting this chronic dietary risk assessment the DEEM® analysis evaluated the individual food consumption as reported by respondents in the USDA 1989–1992 nationwide CSFII and accumulated exposure to the chemical for each commodity. The following assumptions were made for the chronic exposure assessments: For chronic dietary risk assessment, residue estimates for foods (e.g. apples) or food-forms (e.g. apple juice) of interest are multiplied by the averaged consumption estimate of each food/food-form of each population subgroup. Exposure estimates are expressed in mg/kg/day and as a percent of the cPAD.

In conducting this chronic dietary risk assessment, the Agency has made highly conservative assumptions which result in an overestimate of human dietary exposure. A DEEM chronic exposure analysis was performed using the proposed tolerance level residues and 100% of the crop treated to estimate the exposure for the general population and subgroups of interest. This is expected to result in an overestimate of dietary risk. Therefore, this chronic dietary (food only) risk assessment should be viewed as a highly conservative risk estimate. Thus, in making a safety determination for these tolerances, EPA takes into account this highly conservative exposure assessment. The Agency is generally concerned with chronic exposures that exceed 100% of the cPAD or chronic RfD. Percent crop and/or anticipated residues were not used. Based on this analysis the exposure to tepraloxydim from food will utilize 6.8% cPAD for the general population, 31% cPAD for all infants (>1 year old), 15% cPAD for children (1–6 old), 10% cPAD for children (7–12 old), 7.4% cPAD for males (13–19 old), and 5.0% for females (13–50 old) and males (20+ years old).

iii. *Cancer.* Tepraloxydim has been reviewed by the Agency for carcinogenicity classification. In accordance with the EPA Draft Guidelines for Carcinogenic Risk Assessment (July, 1999), the Agency has classified tepraloxydim as data are inadequate for an assessment of human carcinogenic potential because some evidence is suggestive of carcinogenic effects, but other equally pertinent evidence does not confirm a concern. The Agency concluded that quantification of human cancer risk is not required because although there was some evidence of carcinogenicity in female rats based on an increased incidence of liver tumors at the high dose, this finding was not supported by the results of the chronic study. The Agency also concluded that female mice developed liver tumors at an excessively toxic dose, and although male mice had non-neoplastic liver changes similar to or exceeding those seen in female mice at the same dose, there was no increase in liver tumor incidence in males. Further more tepraloxydim was not mutagenic in a battery of assays. Therefore a cancer risk assessment was not performed.

2. *Dietary exposure from drinking water.* The Agency lacks sufficient monitoring exposure data to complete a comprehensive dietary exposure analysis and risk assessment for tepraloxydim in drinking water. Because the Agency does not have comprehensive monitoring data, drinking water concentration estimates are made by reliance on simulation or modeling taking into account data on the physical characteristics of tepraloxydim.

The Agency uses the Generic Estimated Environmental Concentration (GENEEC) or the Pesticide Root Zone/Exposure Analysis Modeling System (PRZM/EXAMS) to estimate pesticide concentrations in surface water and SCI-GROW, which predicts pesticide concentrations in groundwater. In general, EPA will use GENEEC (a tier 1 model) before using PRZM/EXAMS (a tier 2 model) for a screening-level assessment for surface water. The GENEEC model is a subset of the PRZM/EXAMS model that uses a specific high-end runoff scenario for pesticides. GENEEC incorporates a farm pond scenario, while PRZM/EXAMS incorporate an index reservoir environment in place of the previous pond scenario. The PRZM/EXAMS model includes a percent crop area factor as an adjustment to account for the maximum percent crop coverage within a watershed or drainage basin.

None of these models include consideration of the impact processing (mixing, dilution, or treatment) of raw water for distribution as drinking water would likely have on the removal of pesticides from the source water. The primary use of these models by the Agency at this stage is to provide a coarse screen for sorting out pesticides for which it is highly unlikely that drinking water concentrations would ever exceed human health levels of concern.

Since the models used are considered to be screening tools in the risk assessment process, the Agency does not use estimated environmental concentrations (EECs) from these models to quantify drinking water exposure and risk as a %RfD or %PAD. Instead, drinking water levels of

comparison (DWLOCs) are calculated and used as a point of comparison against the model estimates of a pesticide's concentration in water. DWLOCs are theoretical upper limits on a pesticide's concentration in drinking water in light of total aggregate exposure to a pesticide in food, and from residential uses. Since DWLOCs address total aggregate exposure to tepraloxydim they are further discussed in the aggregate risk sections below.

Based on the GENEEC and SCI-GROW models the EECs of tepraloxydim for acute exposures are estimated to be 17.6 µg/L for surface water and 0.0015 µg/L parts per billion (ppb) for groundwater. EECs for chronic exposures are estimated to be 10.3 µg/L ppb for surface water and 0.0015 µg/L ppb for ground water.

3. *From non-dietary exposure*. The term ''residential exposure'' is used in this document to refer to non-occupational, non-dietary exposure (e.g., for lawn and garden pest control, indoor pest control, termiticides, and flea and tick control on pets).

Tepraloxydim is not registered for use on any sites that would result in residential exposure.

4. *Cumulative exposure to substances with a common mechanism of toxicity*. Section 408(b)(2)(D)(v) requires that, when considering whether to establish, modify, or revoke a tolerance, the Agency consider ''available information'' concerning the cumulative effects of a particular pesticide's residues and ''other substances that have a common mechanism of toxicity.''

EPA does not have, at this time, available data to determine whether tepraloxydim has a common mechanism of toxicity with other substances or how to include this pesticide in a cumulative risk assessment. Unlike other pesticides for which EPA has followed a cumulative risk approach based on a common mechanism of toxicity, tepraloxydim does not appear to produce a toxic metabolite produced by other substances. For the purposes of this tolerance action, therefore, EPA has not assumed that tepraloxydim has a common mechanism of toxicity with other substances. For information regarding EPA's efforts to determine which chemicals have a common mechanism of toxicity and to evaluate the cumulative effects of such chemicals, see the final rule for Bifenthrin Pesticide Tolerances (62 FR 62961, November 26, 1997).

D. Safety Factor for Infants and Children

1. *Safety factor for infants and children—In general*. FFDCA section 408 provides that EPA shall apply an additional tenfold margin of safety for infants and children in the case of threshold effects to account for prenatal and postnatal toxicity and the completeness of the database on toxicity and exposure unless EPA determines that a different margin of safety will be safe for infants and children. Margins of safety are incorporated into EPA risk assessments either directly through use of a margin of exposure (MOE) analysis or through using uncertainty (safety) factors in calculating a dose level that poses no appreciable risk to humans.

2. *Prenatal and postnatal sensitivity*. Based on the available data, both quantitative and qualitative evidence of increased susceptibility was observed following *in utero* tepraloxydim exposure to rats. In the prenatal rat developmental toxicity study, the developmental toxicity NOAEL/LOAEL is below the maternal toxicity NOAEL/LOAEL. Additionally, the developmental effects observed (reduced fetal body weights, retarded ossification indicative of delayed maturation, and the occurrence of hydroureter) were considered to be more severe than those observed in maternal animals (decreased body weight gain and food consumption). No evidence of increased susceptibility was seen following pre/post natal exposure in the 2-generation reproduction study.

3. *Conclusion*. The toxicology database for tepraloxydim is complete except for a developmental neurotoxicity study which is required due to evidence of neurotoxicity (effects on motor activity and grip strength) observed in acute and subchronic neurotoxicity studies with adult animals and a 28-day inhalation toxicity study is required because there is no inhalation toxicity available for risk assessment. The exposure data are complete or are estimated based on data that reasonably accounts for potential exposures. EPA determined that the 10X safety factor to protect infants and children should be reduced to 3x for tepraloxydim. The Agency concluded that a safety factor is required for tepraloxydim since there is evidence of increased susceptibility of the young demonstrated in the prenatal developmental study in rats. The Committee recommended that the FQPA safety factor be reduced to 3x because: the toxicology database is complete; the requirement of a developmental neurotoxicity study is not based on criteria reflecting special concern for the developing fetuses or young which are generally used for requiring a DNT study - and a safety factor (e.g.: neuropathy in adult animals; CNS malformations following prenatal exposure; brain weight or sexual maturation changes in offspring; and/or functional changes in offspring) - and therefore does not warrant an FQPA safety factor[1]; the dietary (food and drinking water) exposure assessments will not underestimate the potential exposures for infants and children; and there are currently no residential uses.

The FQPA safety factor for tepraloxydim is applicable to only Females 13–50 years population subgroup for acute dietary risk assessment (there are currently no residential exposure scenarios), since there is concern for increased susceptibility of the young demonstrated in the prenatal developmental study in rats. The developmental effects are presumed to occur following a single exposure of females of child-bearing age and, therefore, are appropriate for risk assessment for females aged 13–50 years old.

E. Aggregate Risks and Determination of Safety

To estimate total aggregate exposure to a pesticide from food, drinking water, and residential uses, the Agency calculates DWLOCs which are used as a point of comparison against the model estimates of a pesticide's concentration in water (EECs). DWLOC values are not regulatory standards for drinking water. DWLOCs are theoretical upper limits on a pesticide's concentration in drinking water in light of total aggregate exposure to a pesticide in food and residential uses. In calculating a DWLOC, the Agency determines how much of the acceptable exposure (i.e., the PAD) is available for exposure through drinking water e.g., allowable chronic water exposure (mg/kg/day) = cPAD - (average food + residential exposure). This allowable exposure through drinking water is used to calculate a DWLOC.

A DWLOC will vary depending on the toxic endpoint, drinking water consumption, and body weights. Default body weights and consumption values as used by the USEPA Office of Water are used to calculate DWLOCs: 2L/70 kg (adult male), 2L/60 kg (adult female), and 1L/10 kg (child). Default body weights and drinking water consumption values vary on an individual basis. This variation will be taken into account in more refined screening-level and quantitative

[1] This is an interim step towards accordance with the proposed OPP Policy on Determination of the Appropriate FQPA Safety Factor(s) for Use in the Tolerance-Setting Process' which was presented to the FIFRA SAP meeting in May, 1999 and placed in the Docket for Public Comment (64 FR 37001, July 8, 1999; Docket No. 37001).

drinking water exposure assessments. Different populations will have different DWLOCs. Generally, a DWLOC is calculated for each type of risk assessment used: acute, short-term, intermediate-term, chronic, and cancer.

When EECs for surface water and groundwater are less than the calculated DWLOCs, the Office of Pesticide Programs concludes with reasonable certainty that exposures to the pesticide in drinking water (when considered along with other sources of exposure for which OPP has reliable data) would not result in unacceptable levels of aggregate human health risk at this time. Because OPP considers the aggregate risk resulting from multiple exposure pathways associated with a pesticide's uses, levels of comparison in drinking water may vary as those uses change. If new uses are added in the future, OPP will reassess the potential impacts of residues of the pesticide in drinking water as a part of the aggregate risk assessment process.

1. *Acute risk*. Using the exposure assumptions discussed in this unit for acute exposure, the acute dietary exposure from food to tepraloxydim will occupy 4.4% of the aPAD for females 13 years and older. In addition, there is potential for acute dietary exposure to tepraloxydim in drinking water. After calculating DWLOCs and comparing them to the EECs for surface and ground water, EPA does not expect the aggregate exposure to exceed 100% of the aPAD, as shown in the following Table 3:

TABLE 3.— AGGREGATE RISK ASSESSMENT FOR ACUTE EXPOSURE TO TEPRALOXYDIM

Population Subgroup	aPAD (mg/kg)	% aPAD (Food)	Surface Water EEC (µg/L)3	Ground Water EEC (µg/L)3	Acute DWLOC (µg/L)3
Females (13–50 years)	0.13	4.4	17.6	0.0015	3,700

2. *Chronic risk*. Using the exposure assumptions described in this unit for chronic exposure, EPA has concluded that exposure to teparloxydim from food will utilize 6.8% of the cPAD for the U.S. population, 31% of the cPAD for all infants (< 1 year old and 15% of the cPAD for children (1-6 years old) and 5.0% of the cPAD for females (13–50 years old). There are no residential uses for tepraloxydim that result in chronic residential exposure to tepraloxydim. In addition, there is potential for chronic dietary exposure to tepraloxydim in drinking water. After calculating DWLOCs and comparing them to the EECs for surface and ground water, EPA does not expect the aggregate exposure to exceed 100% of the cPAD, as shown in the following Table 4:

TABLE 4.— AGGREGATE RISK ASSESSMENT FOR CHRONIC (NON-CANCER) EXPOSURE TO TEPRALOXYDIM

Population Subgroup	cPAD mg/kg/day	% cPAD (Food)	Surface Water EEC (µg/L)	Ground Water EEC (µg/L)	Chronic DWLOC (µg/L)
U.S. Population	0.05	6.8	10.3	0.0015	1,600
Females (13–50 years old)	0.05	5.0	10.3	0.0015	1,400
All Infants (<1 year)	0.05	31.0	10.3	0.0015	350
Males (13–19 years old)	0.05	5.0	10.3	0.0015	1,600

3. *Short-term risk*. Short-term aggregate exposure takes into account residential exposure plus chronic exposure to food and water (considered to be a background exposure level).

Tepraloxydim is not registered for use on any sites that would result in residential exposure. Therefore, the aggregate risk is the sum of the risk from food and water, which do not exceed the Agency's level of concern.

4. *Intermediate-term risk*. Intermediate-term aggregate exposure takes into account residential exposure plus chronic exposure to food and water (considered to be a background exposure level).

Tepraloxydim is not registered for use on any sites that would result in residential exposure. Therefore, the aggregate risk is the sum of the risk from food and water, which do not exceed the Agency's level of concern.

5. *Aggregate cancer risk for U.S. population*. Tepraloxydim has been reviewed by the Agency for carcinogenicity classification. In accordance with the EPA Draft Guidelines for Carcinogenic Risk Assessment (July, 1999), the Agency has classified tepraloxydim as data are inadequate for an assessment of human carcinogenic potential because some evidence is suggestive of carcinogenic effects, but other equally pertinent evidence does not confirm a concern. The Agency concluded that quantification of human cancer risk is not required because although there was some evidence of carcinogenicity in female rats based on an increased incidence of liver tumors at the high dose, this finding was not supported by the results of the chronic study. The Agency also concluded that female mice developed liver tumors at an excessively toxic dose, and although male mice had non-neoplastic liver changes similar to or exceeding those seen in female mice at the same dose, there was no increase in liver tumor incidence in males. Further more, tepraloxydim was not mutagenic in a battery of assays. Therefore a cancer risk assessment was not performed.

6. *Determination of safety*. Based on these risk assessments, EPA concludes that there is a reasonable certainty that no harm will result to the general population, and to infants and children from aggregate exposure to tepraloxydim residues.

IV. Other Considerations

A. Analytical Enforcement Methodology

Analytical methods (gas chromotography (GC/MS (selected ion monitoring)) have been proposed as analytical enforcement methods by the petitioner for raw agricultural, processed, and livestock commodities. These methods have been validated by the petitioner for gathering residue data. The initial raw agricultural commodity method has a longer completion time than currently permitted by current EPA Guidelines. A shorter, improved method for agricultural commodities and the

livestock commodity methods are being evaluated by EPA's Analytical Chemistry Branch. Prior to publication in PAM II and upon request, the analytical methods will be available from the Analytical Chemistry Branch (ACB), Biological and Economic Analysis Division (BEAD), Environmental Sciences Center, 701 Mapes Road, Fort George C. Meade, MD 20755–5350, contact Frances D. Griffith Jr., telephone (410–305–2905, e-mail griffith,frances@epa.gov. The analytical standards for these methods are also available from EPA's National Pesticide Standard Repository at the same location. Successful completion of method trials for proposed analytical methods are a condition of registration

B. International Residue Limits

There are no Codex, Canadian, or Mexican maximum residue limits (MRLs) established for tepraloxydim. Harmonization is not an issue at this time.

C. Conditions

The following are conditions of registration.

1. Successful completion of method trials for the proposed analytical enforcement methods.
2. A regional registration for canola in the states of Minnesota, Montana, North Dakota, and South Dakota.
3. Submission of additional storage stability data are needed to support the ruminant feeding study (samples stored for 217–337 days) and Agency review of storage stability data currently under review.
4. Submission of a developmental neurotoxicity study.
5. Submission of a 28–day inhalation toxicity study.

V. Conclusion

Therefore, the tolerance is established for combined residues of tepraloxydim (2-[1-[[[(2E)-3-chloro-2-propenyl]oxy]imino]propyl]-3-hydroxy-5-(tetrahydro-2H-pyran-4-yl)-cyclohexene-1-one) and its metabolites convertible to GP (3-(tetrahydropyran-4-yl)pentane-1,5-dioic acid) and OH-GP (3-hydroxy-3- (tetrahydropyran-4-yl)pentane-1,5-dioic acid), calculated as tepraloxydim, in or on cotton, undelinted seed at 0.2 ppm; cotton, gin byproducts at 3.0 ppm; soybean, seed at 6.0 ppm; soybean, hulls at 8.0 ppm; soybean, aspirated grain fractions at 1,200 ppm; and the combined residues of tepraloxydim and its metabolites convertible to GP, OH-GP, and GL (3-(2-oxotetrahydropyran-4-yl)pentane-1,5-dioic acid), calculated as tepraloxydim, in or on milk at 0.1 ppm; meat of cattle, goats, hogs, horses, and sheep at 0.2 ppm; meat byproduct (except kidney) of cattle, goats, hogs, horses, and sheep at 0.2 ppm; kidney of cattle, goats, hogs, horses, and sheep at 0.5 ppm; fat of cattle, goats, hogs, horses, and sheep at 0.15 ppm; poultry, meat at 0.2 ppm; poultry, meat byproducts (except liver) at 0.2 ppm; poultry, fat at 0.3 ppm; poultry, liver at 1.0 ppm; and eggs at 0.20 ppm; and a tolerance with regional registration, as defined in § 180.1 (n) for the combined residues of tepraloxydim and its metabolites convertible to GP and OH-GP, calculated as tepraloxydim, in or on the raw agricultural commodity canola, seed at 0.5 ppm.

VI. Objections and Hearing Requests

Under section 408(g) of the FFDCA, as amended by the FQPA, any person may file an objection to any aspect of this regulation and may also request a hearing on those objections. The EPA procedural regulations which govern the submission of objections and requests for hearings appear in 40 CFR part 178. Although the procedures in those regulations require some modification to reflect the amendments made to the FFDCA by the FQPA of 1996, EPA will continue to use those procedures, with appropriate adjustments, until the necessary modifications can be made. The new section 408(g) provides essentially the same process for persons to ''object'' to a regulation for an exemption from the requirement of a tolerance issued by EPA under new section 408(d), as was provided in the old FFDCA sections 408 and 409. However, the period for filing objections is now 60 days, rather than 30 days.

A. What Do I Need to Do to File an Objection or Request a Hearing?

You must file your objection or request a hearing on this regulation in accordance with the instructions provided in this unit and in 40 CFR part 178. To ensure proper receipt by EPA, you must identify docket control number OPP–301148 in the subject line on the first page of your submission. All requests must be in writing, and must be mailed or delivered to the Hearing Clerk on or before October 1, 2001.

1. *Filing the request.* Your objection must specify the specific provisions in the regulation that you object to, and the grounds for the objections (40 CFR 178.25). If a hearing is requested, the objections must include a statement of the factual issues(s) on which a hearing is requested, the requestor's contentions on such issues, and a summary of any evidence relied upon by the objector (40 CFR 178.27). Information submitted in connection with an objection or hearing request may be claimed confidential by marking any part or all of that information as CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. A copy of the information that does not contain CBI must be submitted for inclusion in the public record. Information not marked confidential may be disclosed publicly by EPA without prior notice.

Mail your written request to: Office of the Hearing Clerk (1900), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460. You may also deliver your request to the Office of the Hearing Clerk in Rm. C400, Waterside Mall, 401 M St., SW., Washington, DC 20460. The Office of the Hearing Clerk is open from 8 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Office of the Hearing Clerk is (202) 260–4865.

2. *Tolerance fee payment.* If you file an objection or request a hearing, you must also pay the fee prescribed by 40 CFR 180.33(i) or request a waiver of that fee pursuant to 40 CFR 180.33(m). You must mail the fee to: EPA Headquarters Accounting Operations Branch, Office of Pesticide Programs, P.O. Box 360277M, Pittsburgh, PA 15251. Please identify the fee submission by labeling it ''Tolerance Petition Fees.''

EPA is authorized to waive any fee requirement ''when in the judgement of the Administrator such a waiver or refund is equitable and not contrary to the purpose of this subsection.'' For additional information regarding the waiver of these fees, you may contact James Tompkins by phone at (703) 305–5697, by e-mail at tompkins.jim@epa.gov, or by mailing a request for information to Mr. Tompkins at Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

If you would like to request a waiver of the tolerance objection fees, you must mail your request for such a waiver to: James Hollins, Information Resources and Services Division (7502C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

3. *Copies for the Docket.* In addition to filing an objection or hearing request with the Hearing Clerk as described in Unit VI.A., you should also send a copy of your request to the PIRIB for its inclusion in the official record that is described in Unit I.B.2. Mail your copies, identified by docket control number OPP–301148, to: Public Information and Records Integrity Branch, Information Resources and

Services Division (7502C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460. In person or by courier, bring a copy to the location of the PIRIB described in Unit I.B.2. You may also send an electronic copy of your request via e-mail to: opp-docket@epa.gov. Please use an ASCII file format and avoid the use of special characters and any form of encryption. Copies of electronic objections and hearing requests will also be accepted on disks in WordPerfect 6.1/8.0 or ASCII file format. Do not include any CBI in your electronic copy. You may also submit an electronic copy of your request at many Federal Depository Libraries.

B. When Will the Agency Grant a Request for a Hearing?

A request for a hearing will be granted if the Administrator determines that the material submitted shows the following: There is a genuine and substantial issue of fact; there is a reasonable possibility that available evidence identified by the requestor would, if established resolve one or more of such issues in favor of the requestor, taking into account uncontested claims or facts to the contrary; and resolution of the factual issue(s) in the manner sought by the requestor would be adequate to justify the action requested (40 CFR 178.32).

VII. Regulatory Assessment Requirements

This final rule establishes a tolerance under FFDCA section 408(d) in response to a petition submitted to the Agency. The Office of Management and Budget (OMB) has exempted these types of actions from review under Executive Order 12866, entitled *Regulatory Planning and Review* (58 FR 51735, October 4, 1993). This final rule does not contain any information collections subject to OMB approval under the Paperwork Reduction Act (PRA), 44 U.S.C. 3501 *et seq.*, or impose any enforceable duty or contain any unfunded mandate as described under Title II of the Unfunded Mandates Reform Act of 1995 (UMRA) (Public Law 104–4). Nor does it require any special considerations under Executive Order 12898, entitled *Federal Actions to Address Environmental Justice in Minority Populations and Low-Income Populations* (59 FR 7629, February 16, 1994); or OMB review or any Agency action under Executive Order 13045, entitled *Protection of Children from Environmental Health Risks and Safety Risks* (62 FR 19885, April 23, 1997). This action does not involve any technical standards that would require Agency consideration of voluntary consensus standards pursuant to section 12(d) of the National Technology Transfer and Advancement Act of 1995 (NTTAA), Public Law 104–113, section 12(d) (15 U.S.C. 272 note). Since tolerances and exemptions that are established on the basis of a petition under FFDCA section 408(d), such as the tolerance in this final rule, do not require the issuance of a proposed rule, the requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 *et seq.*) do not apply. In addition, the Agency has determined that this action will not have a substantial direct effect on States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132, entitled *Federalism*(64 FR 43255, August 10, 1999). Executive Order 13132 requires EPA to develop an accountable process to ensure ''meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications.'' ''Policies that have federalism implications'' is defined in the Executive Order to include regulations that have ''substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.'' This final rule directly regulates growers, food processors, food handlers and food retailers, not States. This action does not alter the relationships or distribution of power and responsibilities established by Congress in the preemption provisions of FFDCA section 408(n)(4). For these reasons, the Agency has determined that this rule does not have any tribal implications as described in Executive Order 13175, entitled *Consultation and Coordination with Indian Tribal Governments* (65 FR 67249, November 6, 2000). Executive Order 13175, requires EPA to develop an accountable process to ensure meaningful and timely input by tribal officials in the development of regulatory policies that have tribal implications. Policies that have tribal implications is defined in the Executive Order to include regulations that have a substantial direct effects in one or more Indian Tribes, or the distribution of power and responsibilities between the Federal Government and Indian Tribes. This rule will not have substantial direct effects on tribal governments, or on the distribution of power and responsibilities between the Federal government and Indian tribes, as specified in Executive Order 13175. Thus, Executive Order 13175 does not apply to this rule.

VIII. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of this final rule in the **Federal Register**. This final rule is not a ''major rule'' as defined by 5 U.S.C. 804(2).

List of Subjects in 40 CFR Part 180

Environmental protection, Administrative practice and procedure, Agricultural commodities, Pesticides and pests, Reporting and recordkeeping requirements.

Dated: July 26, 2001.

James Jones,

Acting Director, Office of Pesticide Programs.

Therefore, 40 CFR chapter I is amended as follows:

PART 180—[AMENDED]

1. The authority citation for part 180 continues to read as follows:

Authority: 21 U.S.C. 321(q), 346(a) and 371.

2. Section 180.573 is added to read as follows:

§ 180.573 Tepraloxydim; Tolerances for residues.

(a) *General.* (1) Tolerances are established for the residues of tepraloxydim (2-[1-[[[(2E)-3-chloro-2-propenyl]oxy]imino]propyl]-3-hydroxy-5-(tetrahydro-2H-pyran-4-yl)-cyclohexene-1-one) and its metabolites convertible to GP (3-(tetrahydropyran-4-yl)pentane-1,5-dioic acid) and OH-GP (3-hydroxy-3-(tetrahydropyran-4-yl)pentane-1,5-dioic acid), calculated as tepraloxydim in or on the following raw agricultural commodities.

Commodity	Parts per million
Cotton, undelinated seed	0.2
Cotton, gin byproducts	3.0
Soybean, seed	6.0
Soybean, hulls	8.0

Commodity	Parts per million
Soybean, aspirated grain fraction	1200.0

(2) Tolerances are established for the combined residues of tepraloxydim and its metabolites convertible to GP, OH-GP, and GL (3-(2-oxotetrahydropyran-4-yl)-1,5-dioic acid), calculated as tepraloxydim in or on the following commodities

Commodity	Parts per million
Cattle, fat	0.15
Cattle, kidney	0.50
Cattle, meat	0.20
Cattle, meat by products (except kidney)	0.20
Eggs	0.20
Goat, fat	0.15
Goat, kidney	0.50
Goat, meat	0.20
Goat, meat by products (except kidney)	0.20
Hog, fat	0.15
Hog, kidney	0.50
Hog, meat	0.20
Hog, meat by products (except kidney)	0.20
Horse, fat	0.15
Horse, kidney	0.50
Horse, meat	0.20
Horse, meat by products (except kidney)	0.20
Milk	0.10
Poultry, fat	0.30
Poultry, liver	1.00
Poultry, meat	0.20
Poultry, meat by products (except liver)	0.20
Sheep, fat	0.15
Sheep, kidney	0.50
Sheep, meat	0.20
Sheep, meat by products (except kidney)	0.20

(b) *Section 18 emergency exemptions.* [Reserved]

(c) *Tolerances with regional registrations.* A tolerance with regional registration, as defined in § 180.1(n) is established for the combined residues of tepraloxydim and its metabolites convertible to GP and OH-GP, calculated as tepraloxydim in or on the following raw agricultural commodity:

Commodity	Parts per million
Canola, seed	0.50

(d) *Indirect or inadvertent residues.* [Reserved]

[FR Doc. 01–19325 Filed 8–1–01; 8:45 a.m.]

BILLING CODE 6560–50–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 635

[I.D. 072501A]

Atlantic Highly Migratory Species Fisheries; Atlantic Bluefin Tuna

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Adjustment of General category daily retention limit.

SUMMARY: NMFS has determined that the Atlantic bluefin tuna (BFT) General category daily catch limit should be adjusted in order to allow for maximum utilization of the 2001 General category June through August subquota. Therefore, NMFS increases the daily retention limit from one to two large medium or giant BFT for the remainder of the June through August time-period.

DATES: Effective July 30, 2001 through August 31, 2001.

FOR FURTHER INFORMATION CONTACT: Pat Scida or Brad McHale, 978–281–9260.

SUPPLEMENTARY INFORMATION: Regulations implemented under the authority of the Atlantic Tunas Convention Act (16 U.S.C. 971 *et seq.*) and the Magnuson-Stevens Fishery Conservation and Management Act (16 U.S.C. 1801 *et seq.*) governing the harvest of BFT by persons and vessels subject to U.S. jurisdiction are found at 50 CFR part 635. BFT fishing category quotas and General category effort controls (including time-period subquotas and Restricted-Fishing Days (RFDs)) are specified annually under §§ 635.23(a) and 635.27(a). The 2001 BFT quotas and General category effort controls were implemented July 13, 2001 (66 FR 37421, July 18, 2001).

Adjustment of Daily Retention Limit

Under § 635.23(a)(4), NMFS may increase or decrease the daily retention limit of large medium and giant BFT over a range from zero (on RFDs) to a maximum of three per vessel to allow for maximum utilization of the quota for BFT. Based on a review of dealer reports, daily landing trends, and the availability of BFT on the fishing grounds, NMFS has determined that an increase of the daily retention limit is appropriate and necessary to allow full use of the June through August subquota while ensuring an August fishery. Therefore, NMFS adjusts the daily retention limit for the remainder of the June through August subquota time-period to two large medium or giant BFT per vessel. This adjustment does not affect the previously scheduled RFDs for August (August 11, 12, and 13), on which the daily retention in the General category will be zero, and on which General category vessels may not fish for BFT.

The intent of this adjustment is to allow for maximum utilization of the June through August subquota (specified under § 635.27(a)) by General category participants in order to help achieve optimum yield in the General category fishery, to collect a broad range of data for stock monitoring purposes, and to be consistent with the objectives of the Fishery Management Plan for Atlantic Tunas, Swordfish and Sharks.

While catch rates have been low so far this season, NMFS recognizes that they may increase. In addition, due to the temporal and geographical nature of the fishery, certain gear types and areas are more productive at various times during the fishery. In order to ensure that the June through August subquota is not filled prematurely and to ensure equitable fishing opportunities in all areas and for all gear types, NMFS has not waived the RFDs in August, which correspond to market closures in Japan, and could promote better ex-vessel prices.

Classification

This action is taken under § 635.23(a)(4) and is exempt from review under Executive Order 12866.

Authority: 16 U.S.C. 971 *et seq.* and 1801 *et seq.*

Dated: July 27, 2001.

Bruce C. Morehead,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 01–19235 Filed 7–27–01; 4:53 pm]

BILLING CODE 3510–22–S

Proposed Rules

Federal Register

Vol. 66, No. 149

Thursday, August 2, 2001

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

DEPARTMENT OF AGRICULTURE

Food and Nutrition Service

7 CFR Part 246

RIN: 0584–AA80

Special Supplemental Nutrition Program for Women, Infants and Children (WIC): Food Delivery Systems—Delay of Implementation Date; Proposed Rule

AGENCY: Food and Nutrition Service, USDA.

ACTION: Proposed rule.

SUMMARY: This proposed rule would delay the implementation date of the final rule entitled Special Supplemental Nutrition Program for Women, Infants and Children (WIC): Food Delivery Systems, published in the **Federal Register** on December 29, 2000, 65 FR 83248, which became effective on April 28, 2001 and has an implementation date of February 27, 2002. The rule strengthens vendor management in retail food delivery systems by establishing mandatory selection criteria, training requirements, criteria to be used to identify high-risk vendors, and monitoring requirements, including compliance investigations. The proposed delay of the implementation date until October 1, 2002 is necessary to provide State agencies additional time to implement the rule, to promote more effective and efficient implementation of the new requirements, and because the new implementation date corresponds with the beginning of the Federal fiscal year.

DATES: To be assured of consideration, written comments must be postmarked on or before September 4, 2001. Since comments are being accepted simultaneously on several separate rulemakings, commenters on this proposed rule are asked to label their comments: ''Delay of Implementation Date.'' Electronic transmissions of comments, including data faxes and electronic mail, will not be accepted. Any comments received on requirements or provisions contained in the final rule published on December 29, 2000, will not be considered.

ADDRESSES: Comments should be sent to Patricia N. Daniels, Director, Supplemental Food Programs Division, Food and Nutrition Service, U.S. Department of Agriculture, 3101 Park Center Drive, Room 1414, Alexandria, VA 22302. All written submissions will be available for public inspection at this address during normal business hours (8:30 a.m. to 5:00 p.m.), Mondays through Fridays.

FOR FURTHER INFORMATION CONTACT: Debra R. Whitford, Chief, Policy and Program Development Branch, at the above address or by telephone to (703) 305–2746.

SUPPLEMENTARY INFORMATION:

Background

Why Are We Proposing To Delay the Implementation Date?

A final rule entitled Special Supplemental Nutrition Program for Women, Infants and Children (WIC): Food Delivery Systems, was published in the **Federal Register** on December 29, 2000, 65 FR 83248, with an implementation date of February 27, 2002. The rule strengthens vendor management in retail food delivery systems by establishing mandatory selection criteria, training requirements, criteria to be used to identify high-risk vendors, and monitoring requirements, including compliance investigations. Some of the requirements in the final rule, such as the annual identification of high-risk vendors and related monitoring requirements, are based on the Federal fiscal year. Further, the rule establishes many new State Plan requirements. Approval of State Plans for each fiscal year is a prerequisite to the receipt of Federal funds for that fiscal year. Moving the implementation date to the beginning of the fiscal year, October 1, 2002, is intended to result in more efficient and effective implementation of the rule by State agencies. For these reasons, we believe the October 1, 2002 date is a more appropriate alternative implementation date.

Why Is the Comment Period Limited to 30 Days?

In light of the noncontroversial nature and limited scope of this change, the Department limited the comment period to 30 days to provide State agencies with notification of this change as quickly as possible.

Executive Order 12866

This proposed rule has been determined to be not significant for purposes of Executive Order 12866, and, therefore, has not been reviewed by the Office of Management and Budget (OMB).

Regulatory Flexibility Act

This rule has been reviewed with regard to the requirements of the Regulatory Flexibility Act (5 U.S.C. 601–612). The Acting Administrator of the Food and Nutrition Service (FNS) has certified that this rule will not have a significant economic impact on a substantial number of small entities. While procedures in this rulemaking will affect State and local agencies that administer the WIC Program, any economic effect will not be significant.

Unfunded Mandate Reform Act of 1995

Title II of the Unfunded Mandate Reform Act of 1995 (UMRA), Public Law 104–4, establishes requirements for Federal agencies to assess the effects of their regulatory actions on State, local, and tribal governments and the private sector. Under section 202 of the UMRA, FNS generally must prepare a written statement, including a cost-benefit analysis, for proposed and final rules with ''Federal mandates'' that may result in expenditures to State, local, or tribal governments, in the aggregate, or to the private sector, of $100 million or more in any one year. When such a statement is needed for a rule, section 205 of the UMRA generally requires FNS to identify and consider a reasonable number of regulatory alternatives and adopt the least costly, more cost-effective or least burdensome alternative that achieves the objectives of the rule. This rule contains no Federal mandates (under the regulatory provisions of Title II of the UMRA) for State, local, and tribal governments or the private sector of $100 million or more in any one year. Thus, this rule is not subject to the requirements of sections 202 and 205 of the UMRA.

Executive Order 12372

The WIC Program is listed in the Catalog of Federal Domestic Assistance under 10.557. For the reasons set forth

in the final rule in 7 CFR Part 3015, Subpart V, and related Notice (48 FR 29115), this program is included in the scope of Executive Order 12372 which requires intergovernmental consultation with State and local officials.

Paperwork Reduction Act of 1995

This proposed rule contains no new information collection requirements under the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The existing recordkeeping and reporting requirements, which were approved by OMB under control number 0584–0045, will not change as a result of this rule.

Executive Order 12988

This proposed rule has been reviewed under Executive Order 12988, Civil Justice Reform. This proposed rule is intended to have preemptive effect with respect to any State or local laws, regulations, or policies which conflict with its provisions or which would otherwise impede its full implementation. This rule is not intended to have retroactive effect unless so specified in the **DATES** section of the preamble. Prior to any judicial challenge to the application of the provisions of this proposed rule, all applicable administrative procedures must be exhausted.

List of Subjects in 7 CFR Part 246

Administrative practice and procedure, Civil rights, Food assistance programs, Food and Nutrition Service, Food donations, Grant programs—health, Grant programs—social programs, Indians, Infants and children, Maternal and child health, Nutrition, Nutrition education, Penalties, Reporting and recordkeeping requirements, Public assistance programs, WIC, Women.

George A. Braley,

Acting Administrator, Food and Nutrition Service.

[FR Doc. 01–19331 Filed 8–1–01; 8:45 am]

BILLING CODE 3410–30–P

DEPARTMENT OF AGRICULTURE

Agricultural Marketing Service

7 CFR Part 948

[Docket No. FV01–948–3 PR]

Irish Potatoes Grown in Colorado; Increased Assessment Rate

AGENCY: Agricultural Marketing Service, USDA.

ACTION: Proposed rule.

SUMMARY: This rule would increase the assessment rate established for the Colorado Potato Administrative Committee, Area II (Committee) for the 2001–02 and subsequent fiscal periods from $0.0015 to $0.0035 per hundredweight of potatoes handled. The Committee locally administers the marketing order, which regulates the handling of potatoes grown in Colorado. Authorization to assess potato handlers enables the Committee to incur expenses that are reasonable and necessary to administer the program. The fiscal period begins September 1 and ends August 31. The assessment rate would remain in effect indefinitely unless modified, suspended, or terminated.

DATES: Comments must be received by September 4, 2001.

ADDRESSES: Interested persons are invited to submit written comments concerning this rule. Comments must be sent to the Docket Clerk, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, room 2525–S, P.O. Box 96456, Washington, DC 20090–6456; Fax: (202) 720–8938, or E-mail: moab.docketclerk@usda.gov. Comments should reference the docket number and the date and page number of this issue of the **Federal Register** and will be available for public inspection in the Office of the Docket Clerk during regular business hours, or can be viewed at: http://www.ams.usda.gov/fv/moab.html.

FOR FURTHER INFORMATION CONTACT: Dennis L. West, Northwest Marketing Field Office, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, 1220 SW Third Avenue, suite 385, Portland, Oregon 97204–2807; telephone: (503) 326–2724, Fax: (503) 326–7440; or George Kelhart, Technical Advisor, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, room 2525–S, P.O. Box 96456, Washington, DC 20090–6456; telephone: (202) 720–2491, Fax: (202) 720–8938.

Small businesses may request information on complying with this regulation by contacting Jay Guerber, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, room 2525–S, P.O. Box 96456, Washington, DC 20090–6456; telephone: (202) 720–2491, Fax: (202) 720–8938, or E-mail: Jay.Guerber@usda.gov.

SUPPLEMENTARY INFORMATION: This rule is issued under Marketing Agreement No. 97 and Order No. 948, both as amended (7 CFR part 948), regulating the handling of Irish potatoes grown in Colorado, hereinafter referred to as the ''order.'' The order is effective under the Agricultural Marketing Agreement Act of 1937, as amended (7 U.S.C. 601–674), hereinafter referred to as the ''Act.''

The Department of Agriculture (Department) is issuing this rule in conformance with Executive Order 12866.

This rule has been reviewed under Executive Order 12988, Civil Justice Reform. Under the order now in effect, Colorado potato handlers are subject to assessments. Funds to administer the order are derived from such assessments. It is intended that the assessment rate as proposed herein would be applicable to all assessable potatoes beginning on September 1, 2001, and continue until amended, suspended, or terminated. This rule will not preempt any State or local laws, regulations, or policies, unless they present an irreconcilable conflict with this rule. The Act provides that administrative proceedings must be exhausted before parties may file suit in court. Under section 608c(15)(A) of the Act, any handler subject to an order may file with the Secretary a petition stating that the order, any provision of the order, or any obligation imposed in connection with the order is not in accordance with law and request a modification of the order or to be exempted therefrom. Such handler is afforded the opportunity for a hearing on the petition. After the hearing the Secretary would rule on the petition. The Act provides that the district court of the United States in any district in which the handler is an inhabitant, or has his or her principal place of business, has jurisdiction to review the Secretary's ruling on the petition, provided an action is filed not later than 20 days after the date of the entry of the ruling.

This rule would increase the assessment rate established for the Committee for the 2001–02 and subsequent fiscal periods from $0.0015 to $0.0035 per hundredweight of potatoes handled.

The Colorado potato order provides authority for the Committee, with the approval of the Department, to formulate an annual budget of expenses and collect assessments from handlers to administer the program. The members of the Committee are producers and handlers of Colorado Area II potatoes. They are familiar with the Committee's needs and with the costs for goods and services in their local area and are thus in a position to formulate an appropriate budget and assessment rate. The assessment rate is

formulated and discussed in a public meeting. Thus, all directly affected persons have an opportunity to participate and provide input.

For the 1998–99 and subsequent fiscal periods, the Committee recommended, and the Department approved, an assessment rate that would continue in effect from fiscal period to fiscal period unless modified, suspended, or terminated by the Secretary upon recommendation and information submitted by the Committee or other information available to the Secretary.

The Committee met on May 17, 2001, and unanimously recommended 2001–02 expenditures of $73,618 and an assessment rate of $0.0035 per hundredweight of potatoes handled. In comparison, last year's budgeted expenditures were $71,132. The assessment rate of $0.0035 is $0.002 higher than the rate currently in effect. For budget purposes, the committee projected the quantity of assessable potatoes for 2001–02 at 16,500,000 hundredweight and assessment revenue of $57,750 ($0.0035 x 16,500,000 hundredweight). The Committee recommended the increased assessment rate because the current rate of $0.0015 would not generate enough income to adequately administer the program through the 2001–02 fiscal period. The major expenditures recommended by the Committee for the 2001–02 year include $40,793 for salaries, $9,950 for office expenses, which include telephone service, supplies and postage, and $7,650 for building maintenance. Budgeted expenses for these items in 2000–01 were $39,793, $10,700, and $6,250, respectively.

The Committee developed the $0.0035 assessment rate recommendation by taking into consideration the 2001–02 budget, the estimated 2001–02 potato crop, the relatively small size of the current monetary reserve ($32,000), and other factors such as the recent attrition in farms and handlers. Although the recommended increase would more than double the current assessment rate, the Committee may need to draw up to an additional $15,868 from its reserves to meet budgeted expenses. The current reserve of approximately $32,000 is below the maximum amount authorized by the order of approximately two fiscal periods' expenses (§ 948.78). At the current rate, funds to cover anticipated expenses would not be adequate.

As mentioned earlier, based on projected shipments of 16,500,000 hundredweight, the recommended assessment rate of $0.0035 should provide $57,750 in assessment income. Income from such hander assessments, combined with interest income and funds from the Committee's authorized reserve, would be adequate to meet budgeted expenses for the 2001–02 fiscal period.

The proposed assessment rate would continue in effect indefinitely unless modified, suspended, or terminated by the Secretary upon recommendation and information submitted by the Committee or other available information.

Although this assessment rate would be in effect for an indefinite period, the Committee would continue to meet prior to or during each fiscal period to recommend a budget of expenses and consider recommendations for modification of the assessment rate. The dates and times of Committee meetings are available from the Committee or the Department. Committee meetings are open to the public and interested persons may express their views at these meetings. The Department would evaluate Committee recommendations and other available information to determine whether modification of the assessment rate is needed. Further rulemaking would be undertaken as necessary. The Committee's 2001–02 budget and those for subsequent fiscal periods would be reviewed and, as appropriate, approved by the Department.

Initial Regulatory Flexibility Analysis

Pursuant to requirements set forth in the Regulatory Flexibility Act (RFA), the Agricultural Marketing Service (AMS) has considered the economic impact of this rule on small entities. Accordingly, AMS has prepared this initial regulatory flexibility analysis.

The purpose of the RFA is to fit regulatory actions to the scale of business subject to such actions in order that small businesses will not be unduly or disproportionately burdened. Marketing orders issued pursuant to the Act, and the rules issued thereunder, are unique in that they are brought about through group action of essentially small entities acting on their own behalf. Thus, both statutes have small entity orientation and compatibility.

There are approximately 250 producers of Colorado Area II potatoes and approximately 93 handlers subject to regulation under the marketing order. Small agricultural producers are defined by the Small Business Administration (13 CFR 121.201) as those having annual receipts of less than $500,000, and small agricultural service firms are defined as those whose annual receipts are less than $5,000,000.

Based upon information provided by the Committee, 96 percent of the handlers of Area II potatoes have shipped under $5,000,000 worth of potatoes during the most recent season for which statistics are available. In addition, information provided by the National Agricultural Statistics Service was considered in determining the number of large and small producers by acreage, production, and producer prices. According to the information provided, the recent average yield per acre was 335 hundredweight of potatoes, and the recent season average producer price was $4.20 per hundredweight. This equates to average gross annual producer receipts of approximately $430,542 each. Based on the foregoing, it can be concluded that a majority of producers and handlers of Area II potatoes may be classified as small entities, excluding receipts from other sources.

This rule would increase the assessment rate established for the Committee and collected from handlers for the 2001–02 and subsequent fiscal periods from $0.0015 to $0.0035 per hundredweight of potatoes handled. The Committee unanimously recommended 2001–02 expenditures of $73,618 and an assessment rate of $0.0035 per hundredweight. The proposed assessment rate of $0.0035 is $0.002 more than the rate currently in effect and would increase the financial burden on handlers by approximately $33,000. The quantity of assessable fresh potatoes for the 2001–02 season is estimated at 16,500,000 hundredweight. The $0.0035 rate should provide $57,750 in assessment income which, when combined with interest income and income from the Committee's monetary reserve, would be adequate to cover budgeted expenses. The current rate would not provide enough funds to cover anticipated expenses.

The major expenditures recommended by the Committee for the 2001–02 year include $40,793 for salaries, $9,950 for office expenses, which include telephone service, supplies and postage, and $7,650 for building maintenance. Budgeted expenses for these items in 2000–01 were $39,793, $10,700, and $6,250, respectively.

The Committee recommended the increased assessment rate to help offset higher administration costs and to decrease the rate in which the monetary reserve has been relied upon in recent fiscal periods. Based on the Committee's 2001–02 crop estimate, the current reserve of $32,000 could be reduced by as much as $15,868 with the recommended assessment rate.

The Committee reviewed and unanimously recommended 2001–02

expenditures of $73,618. This compares to last year's approved budget of $71,132. Prior to arriving at a budget, alternative expenditures and assessment levels were discussed by the Committee, including higher and lower rates of assessment. When considering the relatively poor economic returns the industry has faced during the past six seasons and the resultant instability within the potato industry, as well as the 2001–02 budget and the current size of the monetary reserve ($32,000), the Committee concluded that an increase in the rate of assessment to $0.0035 per hundredweight of potatoes would allow it to properly administer the program.

A review of historical information, as well as preliminary information pertaining to the upcoming fiscal period, indicates that the producer price for the 2001–02 season could range between $2.06 and $7.35 per hundredweight of potatoes. Therefore, the estimated assessment revenue for the 2001–02 fiscal period as a percentage of total producer revenue could range between 0.170 and 0.048 percent.

This action would increase the assessment obligation imposed on handlers. While assessments impose some additional costs on handlers, the costs are minimal and uniform on all handlers. Some of the additional costs may be passed on to producers. However, these costs would be offset by the benefits derived by the operation of the order. In addition, the Committee's meeting was widely publicized throughout the Colorado Area II potato industry and all interested persons were invited to attend the meeting and participate in Committee deliberations on all issues. Like all Committee meetings, the May 17, 2001, meeting was a public meeting and all entities, both large and small, were able to express views on this issue. Finally, interested persons are invited to submit information on the regulatory and informational impacts of this action on small businesses.

This proposed rule would impose no additional reporting or recordkeeping requirements on either small or large potato handlers. As with all Federal marketing order programs, reports and forms are periodically reviewed to reduce information requirements and duplication by industry and public sector agencies.

The Department has not identified any relevant Federal rules that duplicate, overlap, or conflict with this rule.

A small business guide on complying with fruit, vegetable, and specialty crop marketing agreements and orders may be viewed at: http://www.ams.usda.gov/fv/moab.html. Any questions about the compliance guide should be sent to Jay Guerber at the previously mentioned address in the **FOR FURTHER INFORMATION CONTACT** section.

A 30-day comment period is provided to allow interested persons to respond to this proposed rule. Thirty days is deemed appropriate because: (1) The 2001–02 fiscal period begins on September 1, 2001, and the order requires that the rate of assessment for each fiscal period apply to all assessable potatoes handled during such fiscal period; (2) the Committee needs to have sufficient funds to pay its expenses which are incurred on a continuous basis; and (3) handlers are aware of this action which was unanimously recommended by the Committee at a public meeting and is similar to other assessment rate actions issued in past years.

List of Subjects in 7 CFR Part 948

Marketing Agreements, Potatoes, Reporting and recordkeeping requirements.

For the reasons set forth in the preamble, 7 CFR part 948 is proposed to be amended as follows:

PART 948—IRISH POTATOES GROWN IN COLORADO

1. The authority citation for 7 CFR part 948 continues to read as follows:

Authority: 7 U.S.C. 601–674.

2. Section 948.216 is revised to read as follows:

§ 948.216 Assessment rate.

On and after September 1, 2001, an assessment rate of $0.0035 per hundredweight is established for Colorado Area II potatoes.

Dated: July 27, 2001.

Kenneth C. Clayton,

Acting Administrator, Agricultural Marketing Service.

[FR Doc. 01–19265 Filed 8–1–01; 8:45 am]

BILLING CODE 3410–02–P

DEPARTMENT OF AGRICULTURE

Agricultural Marketing Service

7 CFR Part 948

[Docket No. FV01–948–1 PR]

Irish Potatoes Grown in Colorado; Modification of Area No. 3 Handling Regulation

AGENCY: Agricultural Marketing Service, USDA.

ACTION: Proposed rule.

SUMMARY: This rule invites comments on proposed exemptions to the handling regulation prescribed under the marketing order (order) for Colorado Area No. 3 potatoes. These relaxations were unanimously recommended by the Colorado Potato Administrative Committee for Area No. 3 (Committee), the agency responsible for local administration of the order. This rule would exempt potatoes shipped for the purpose of experimentation and the manufacture or conversion into specified products from the grade, size, maturity, inspection and assessment requirements of the order. Relaxing handling requirements is expected to provide handlers with greater marketing flexibility, producers with increased returns, and consumers with more choices in buying fresh potatoes. This rule also clarifies the regulatory text by specifying that potatoes shipped for livestock feed, charity, and certified seed are exempt from assessment requirements.

DATES: Comments must be received by August 22, 2001.

ADDRESSES: Interested persons are invited to submit written comments concerning this proposal. Comments must be sent to the Docket Clerk, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, room 2525–S, P.O. Box 96456, Washington, DC 20090–6456; Fax: (202) 720–8938, or E-mail: *moab.docketclerk@usda.gov*. All comments should reference the docket number and the date and page number of this issue of the **Federal Register** and will be made available for public inspection in the Office of the Docket Clerk during regular business hours, or can be viewed at: *http://www.ams.usda.gov/fv/moab.html*.

FOR FURTHER INFORMATION CONTACT: Dennis L. West, Northwest Marketing Field Office, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, 1220 SW Third Avenue, room 385, Portland, Oregon 97204; telephone: (503) 326–2724, Fax: (503) 326–7440; or George J. Kelhart, Technical Advisor, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, Room 2525–S, P.O. Box 96456, Washington, DC 20090–6456; telephone: (202) 720–2491, Fax: (202) 720–8938.

Small businesses may request information on complying with this regulation by contacting Jay Guerber, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, room 2525–S, P.O. Box 96456, Washington, DC 20090–6456; telephone: (202) 720–2491, Fax: (202)

720–8938, or E-mail: *Jay.Guerber@usda.gov*.

SUPPLEMENTARY INFORMATION: This proposal is issued under Marketing Agreement No. 97 and Marketing Order No. 948 (7 CFR part 948), both as amended, regulating the handling of Irish potatoes grown in Colorado, hereinafter referred to as the ''order.'' The order is authorized by the Agricultural Marketing Agreement Act of 1937, as amended, (7 U.S.C. 601–674), hereinafter referred to as the ''Act.''

The Department of Agriculture (Department) is issuing this rule in conformance with Executive Order 12866.

This proposal has been reviewed under Executive Order 12988, Civil Justice Reform. This rule is not intended to have retroactive effect. This proposal will not preempt any State or local laws, regulations, or policies, unless they present an irreconcilable conflict with this rule.

The Act provides that administrative proceedings must be exhausted before parties may file suit in court. Under section 608c(15)(A) of the Act, any handler subject to an order may file with the Secretary a petition stating that the order, any provision of the order, or any obligation imposed in connection with the order is not in accordance with law and request a modification of the order or to be exempted therefrom. A handler is afforded the opportunity for a hearing on the petition. After the hearing the Secretary would rule on the petition. The Act provides that the district court of the United States in any district in which the handler is an inhabitant, or has his or her principal place of business, has jurisdiction to review the Secretary's ruling on the petition, provided an action is filed not later than 20 days after the date of the entry of the ruling.

This rule invites comments on proposed exemptions to the handling regulation prescribed under the order. This rule would exempt potatoes shipped for the purpose of experimentation and the manufacture or conversion into specified products from the grade, size, maturity, inspection and assessment requirements of the order. These proposed exemptions were unanimously recommended by the Committee. This rule also clarifies the regulatory text by specifying that potatoes shipped for livestock feed, charity, and certified seed are exempt from assessment requirements.

Section 948.22 authorizes the issuance of regulations for grade, size, quality, maturity, and pack for any variety or varieties of potatoes grown in different portions of the production area during any period. Section 948.23 authorizes the issuance of regulations that modify, suspend, or terminate requirements issued under § 948.22 or to facilitate the handling of potatoes for special purposes. Section 948.24 requires adequate safeguards be prescribed to ensure that potatoes handled pursuant to § 948.23 enter authorized trade channels. Safeguard procedures for special purpose shipments are specified in §§ 948.120 through 948.125. Section 948.387 of the order's handling regulations establishes the grade, size, maturity, and inspection requirements. The Committee's assessment rate is established under § 948.215.

At its meeting on December 14, 2000, the Committee unanimously recommended that potatoes shipped for the purpose of experimentation and the manufacture or conversion into specified products be exempt from the grade, size, maturity, and inspection requirements provided under the order's regulations for Area No. 3. The Committee recommended that experimentation and the manufacture or conversion into specified products be added under § 948.387(d) as special purpose shipments.

As is currently required for all special purpose shipments, handlers would apply for and obtain a Certificate of Privilege for handling such potatoes and furnish the Committee such information as it may require to track shipments, determine whether applicable requirements have been met, and verify whether proper disposition has occurred.

At a subsequent meeting on March 8, 2001, the Committee reconfirmed its earlier action and, in addition, unanimously recommended that shipments for livestock feed, charity, certified seed, and for the purpose of experimentation and the manufacture or conversion into specified products be exempt from assessment requirements. Shipments of potatoes for livestock feed, charity, and certified seed are specified as special purpose shipments are currently exempt from grade, size, maturity, and inspection requirements.

Some producers and handlers within the production area are interested in developing new uses for fresh potatoes using experimental varieties and packs. The Committee also anticipates that some handlers may want to ship traditional varieties, or experimental varieties, for use in the manufacture or conversion into special products, or perform the manufacture or conversion themselves prior to shipment. Handlers are, for example, attempting to develop new special products such as fresh cut potatoes shipped in vacuum-sealed bags. Handlers have also expressed a desire to experiment with the shipment of potatoes of different varieties in the same container. This is not currently possible because the potatoes do not meet the minimum grade requirement that a particular lot of potatoes has ''similar'' varietal characteristics.

The Committee strongly encourages innovation that could result in the development of new varieties, markets, or opportunities for the expanded use of fresh forms of potato products, such as fresh cut potatoes in vacuum-sealed bags, that would benefit the Colorado potato industry. Some of the new varieties have irregular shapes or are small in size, and will not meet minimum order requirements. This prevents them from being shipped except under the minimum quantity exemption of 1,000 pounds specified in paragraph (f) of § 948.387. Thus, handlers are prevented from shipping larger quantities.

For the purpose of this rule, the term ''manufacture or conversion into specified products'' means the preparation of potatoes for market into products by peeling, slicing, dicing, applying material to prevent oxidation, or other means approved by the Committee, but not including other processing. Under the current regulation, potatoes for manufacture or conversion into specified products are required to be inspected and certified as meeting the specified quality requirements prior to preparation for market.

The current regulation requires that all potatoes shipped to fresh market, with the exception of those meeting minimum quantity and special purpose exemptions, be inspected and assessed. These regulations do not provide adequate relief for commercially viable shipments of non-traditional varieties, potatoes for experimentation, or the shipment of potatoes for the manufacture or conversion into products. This rule would exempt such shipments and relieve handlers of this regulatory burden.

This proposed relaxation of the Area No. 3 handling regulation is expected to encourage new product development that could lead to market expansion, which would benefit producers, handlers, buyers, and consumers. By relaxing the handling requirements on traditional and experimental varieties and on new and innovative fresh potato products, additional opportunities should be available to increase the fresh utilization of Colorado potatoes.

The Committee also unanimously recommended that shipments of potatoes for livestock feed, charity, and certified seed potatoes be exempt from assessment requirements. This Committee recommendation was made with the intent of treating all special purpose shipments in the same manner. As explained previously, shipments to these fresh outlets are currently exempt from the grade, size, maturity, and inspection requirements. The order only regulates, however, the shipment of potatoes outside the State of Colorado. It is very uncommon for Area No. 3 potatoes to be shipped for livestock feed, charity, or certified seed outside of the State of Colorado. It is not expected that exempting such shipments from assessments would have any effect of increasing shipments. Thus, this recommendation is expected to have little impact on handlers or the Committee's assessment income. And finally, this rule would clarify the current handling regulation to indicate that special purpose shipments for canning, freezing, and ''other processing'' are exempt from assessments. Such shipments are exempt from regulation under federal marketing orders in conformity with an amendment to the Act (Public Law No. 92–233, Feb. 15, 1972).

Initial Regulatory Flexibility Analysis

Pursuant to requirements set forth in the Regulatory Flexibility Act (RFA), the Agricultural Marketing Service (AMS) has considered the economic impact of this action on small entities. Accordingly, the AMS has prepared this initial regulatory flexibility analysis.

The purpose of the RFA is to fit regulatory actions to the scale of business subject to such actions in order that small businesses will not be unduly or disproportionately burdened. Marketing orders issued pursuant to the Act, and rules issued thereunder, are unique in that they are brought about through group action of essentially small entities acting on their own behalf. Thus, both statutes have small entity orientation and compatibility.

There are approximately 13 handlers of Colorado Area No. 3 potatoes who are subject to regulation under the marketing order and approximately 31 producers of Colorado potatoes in the regulated area. Small agricultural service firms are defined by the Small Business Administration (13 CFR 121.201) as those having annual receipts of less than $5,000,000, and small agricultural producers are defined as those whose annual receipts are less than $500,000.

Based upon information provided by the Committee, all handlers of Area No. 3 potatoes have shipped under $5,000,000 worth of potatoes during the most recent season for which numbers are available. In addition, information reported by the National Agricultural Statistics Service was considered in determining the number of large and small producers by acreage, production, and producer prices. According to the information provided, the average yield per acre was 340 hundredweight, and the season average producer price was $5.95 per hundredweight for 1999 crop. This equates to average gross receipts to producers of approximately $107,200. Based on the foregoing, it can be concluded that all handlers and the majority of producers of Area 3 potatoes may be classified as small entities, excluding receipts from other sources.

This proposed rule would exempt special purpose shipments of potatoes from the grade, size, maturity, inspection and assessment requirements prescribed under the order's handling regulations for Colorado Area No. 3 potatoes. Based on authority in §§ 948.22, 948.23, and 948.24 of the order, the Committee at its meeting on December 14, 2000, unanimously recommended that potatoes shipped for the purpose of experimentation and the manufacture or conversion into specified products be exempt from the grade, size, maturity, and inspection requirements of the order. The Committee at its meeting on March 8, 2001, recommended that potatoes for experimentation and the manufacture or conversion into specified products be exempt from assessment requirements. It also recommended that the regulatory text of the applicable provisions be clarified by specifying that potatoes shipped for livestock feed, charity, and certified seed are exempt from assessment requirements.

Producers and handlers within the production area are interested in developing innovative uses for fresh potatoes. The Committee anticipates that some handlers may want to ship traditional or experimental varieties for the manufacture or conversion of potatoes into fresh forms such as fresh cut french fries using experimental packaging and preservation methods. The Committee strongly encourages innovation that could result in the development of new varieties and market opportunities for the expanded use of fresh forms of potato products, such as those packaged in vacuum-sealed bags. The relaxation of Area No. 3 handling and assessment requirements is expected to encourage new product development which would benefit producers, handlers, buyers, and consumers and increase the fresh utilization of Colorado potatoes. The proposed changes are expected to have a positive economic impact on the Colorado potato industry.

As with all special purpose shipments, handlers are currently required to apply and obtain a Certificate of Privilege for handling such potatoes and furnish the Committee such information as they may require to track shipments, determine whether applicable requirements have been met, and verify whether proper disposition has occurred. It is the intent of the Committee to keep reporting requirements to a minimum level necessary to monitor compliance while determining the viability and extent of any changes in the marketing of the area potatoes. There is no available information detailing how many potatoes this relaxation will allow to be marketed. During the previous growing season, one producer planted less than 20 acres of the non-traditional, experimental type varieties on a trial basis. No viable alternatives to this action were identified that would ensure innovations in marketing and product development. Furthermore, the goals expressed by the committee could not be solved absent this action.

The Committee estimates that two or three handlers may apply for and obtain a Certificate of Privilege for the handling of potatoes for experimentation or for the manufacture or conversion into specified products. It is estimated that the time taken by the handlers who apply will total less than ten hours and this time is currently approved under OMB No. 0581–0178 by the Office of Management and Budget (OMB) in accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35).

As with all Federal marketing order programs, reports and forms are periodically reviewed to reduce information requirements and duplication by industry and public sector agencies. The Department has not identified any relevant Federal rules that duplicate, overlap or conflict with this rule.

In addition, the Committee's meetings were widely publicized throughout the Colorado potato industry and all interested persons were invited to attend the meetings and participate in Committee deliberations on all issues. Like all Committee meetings, those held on December 14, 2000, and March 8, 2001, were open to the public and all entities, both large and small, were able to express their views on this issue. Finally, interested persons are invited to

submit information on the regulatory and informational impacts of this action on small businesses.

A small business guide on complying with fruit, vegetable, and specialty crop marketing agreements and orders may be viewed at: *http://www.ams.usda.gov/fv/moab.html.* Any questions about the compliance guide should be sent to Jay Guerber at the previously mentioned address in the **FOR FURTHER INFORMATION CONTACT** section.

A 20-day comment period is provided to allow interested persons to respond to this proposal. Twenty days is deemed appropriate because handlers should be able to take advantage of the relaxed requirements as soon as possible. The shipping season began on July 1, 2001. All written comments timely received will be considered before a final determination is made on this matter.

List of Subjects in 7 CFR Part 948

Marketing agreements, Potatoes, Reporting and recordkeeping requirements.

For the reasons set forth in the preamble, 7 CFR part 948 is proposed to be amended as follows:

PART 948—IRISH POTATOES GROWN IN COLORADO

1. The authority citation for 7 CFR part 948 continues to read as follows:

Authority: 7 U.S.C. 601–674.

2. In § 948.387, paragraph (d)(1) is revised, a new paragraph (d)(1)(v) is added, and in paragraph (g) a new sentence is added before the last sentence to read as follows:

§ 948.387 Handling regulation.

* * * * *

(d) * * *

(1) The grade, size, maturity and inspection requirements of paragraphs (a), (b), and (c) of this section and the assessment requirements of this part shall not be applicable to shipments of potatoes for:

(i) * * *

(v) Experimentation and the manufacture or conversion into specified products.

* * * * *

(g) *Definitions.* * * * The term *manufacture or conversion into specified products* means the preparation of potatoes for market into products by peeling, slicing, dicing, applying material to prevent oxidation, or other means approved by the committee, but not including other processing. * * *

* * * * *

Dated: July 27, 2001.

Kenneth C. Clayton,

Acting Administrator, Agricultural Marketing Service.

[FR Doc. 01–19264 Filed 8–1–01; 8:45 am]

BILLING CODE 3410–02–P

DEPARTMENT OF AGRICULTURE

Agricultural Marketing Service

7 CFR Part 966

[Docket No. FV01–966–1 PR]

Tomatoes Grown in Florida; Changes to the Handling Regulation for Producer Field-Packed Tomatoes

AGENCY: Agricultural Marketing Service, USDA.

ACTION: Proposed rule.

SUMMARY: This rule invites comments on changes to the requirements currently prescribed for producer field-packed tomatoes under the Florida tomato marketing order (order). The order regulates the handling of tomatoes grown in Florida, and is administered locally by the Florida Tomato Committee (Committee). This rule would remove the net weight and weight labeling exemptions for producer field-packed tomatoes. Producer field-packed tomatoes compete directly with packinghouse tomatoes that must meet the net weight requirement. This change would require all tomatoes, regardless of where they are packed, to meet the same net weight requirements so that these requirements are the same for producer field-packed tomatoes and packinghouse tomatoes.

DATES: Comments must be received by August 22, 2001.

ADDRESSES: Interested persons are invited to submit written comments concerning this proposal. Comments must be sent to the Docket Clerk, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, room 2525–S, P.O. Box 96456, Washington, DC 20090–6456; Fax: (202) 720–8938, or E-mail: moab.docketclerk@usda.gov. All comments should reference the docket number and the date and page number of this issue of the **Federal Register** and will be made available for public inspection in the Office of the Docket Clerk during regular business hours, or can be viewed at: http://www.ams.usda.gov/fv/moab.html.

FOR FURTHER INFORMATION CONTACT: Doris Jamieson, Southeast Marketing Field Office, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, P.O. Box 2276, Winter Haven, Florida 33883; telephone: (863) 299–4770, Fax: (863) 299–5169; or George Kelhart, Technical Advisor, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, room 2525–S, P.O. Box 96456, Washington, DC 20090–6456; telephone: (202) 720–2491, Fax: (202) 720–8938.

Small businesses may request information on complying with this regulation by contacting Jay Guerber, Marketing Order Administration Branch, Fruit and Vegetable Programs, AMS, USDA, P.O. Box 96456, room 2525–S, Washington, DC 20090–6456; telephone: (202) 720–2491, Fax: (202) 720–8938, or E-mail: Jay.Guerber@usda.gov.

SUPPLEMENTARY INFORMATION: This proposal is issued under Marketing Agreement No. 125 and Order No. 966, both as amended (7 CFR part 966), regulating the handling of tomatoes grown in Florida, hereinafter referred to as the ''order.'' The marketing agreement and order are effective under the Agricultural Marketing Agreement Act of 1937, as amended (7 U.S.C. 601–674), hereinafter referred to as the ''Act.''

The Department of Agriculture (Department) is issuing this rule in conformance with Executive Order 12866.

This proposal has been reviewed under Executive Order 12988, Civil Justice Reform. This rule is not intended to have retroactive effect. This proposal will not preempt any State or local laws, regulations, or policies, unless they present an irreconcilable conflict with this rule.

The Act provides that administrative proceedings must be exhausted before parties may file suit in court. Under section 608c(15)(A) of the Act, any handler subject to an order may file with the Secretary a petition stating that the order, any provision of the order, or any obligation imposed in connection with the order is not in accordance with law and request a modification of the order or to be exempted therefrom. A handler is afforded the opportunity for a hearing on the petition. After the hearing the Secretary would rule on the petition. The Act provides that the district court of the United States in any district in which the handler is an inhabitant, or has his or her principal place of business, has jurisdiction to review the Secretary's ruling on the petition, provided an action is filed not later than 20 days after the date of the entry of the ruling.

This proposal invites comments on removing the net weight exemption currently prescribed for producer field-packed tomatoes under the Florida tomato marketing order. The Committee recommended this change at its meeting on February 27, 2001, with a vote of eight in favor and two opposed.

Under the order, tomatoes produced in the production area and shipped to fresh market channels outside the regulated area are required to meet grade, size, inspection, and container requirements. These requirements apply during the period October 10 through June 15 each year. Current requirements include a minimum grade of U.S. No. 2 and a minimum size of 2 9/32 inches in diameter. Current pack and container requirements outline the types of information that need to appear on a container, weight restrictions, and where the containers must be packed.

Section 966.52 of the Florida tomato marketing order provides authority for the modification, suspension, and termination of regulations. It includes authority to establish and modify pack and container requirements for tomatoes grown in the defined production area and handled under the order.

Section 966.323 specifies the handling regulations issued under the order. Section 966.323(a)(3)(i) requires that certain types of tomatoes packed by registered handlers be packed in containers of 10, 20, and 25 pounds designated net weights. The net weight of a container's contents cannot be less than the designated net weight or exceed the designated net weight by more than two pounds. Section 966.323(a)(3)(ii) requires that certain types of tomatoes be packed by registered handlers in containers that are marked with the designated net weight and with the name and address of the registered handler, and that such containers must be packed at the registered handler's facilities.

Section 966.323(d)(1) currently exempts producer field-packed tomatoes from the container net weight requirements and the requirement that each container or lid be marked to indicate the designated net weight. It also exempts producer field-packed tomatoes from the requirement that all containers must be packed at a registered handler's facilities. However, field-packed tomatoes still must meet the other requirements of the marketing order, including established grade, size, container, pack, and inspection requirements.

This rule would remove the net weight and weight labeling exemptions for producer field-packed tomatoes. This change would require all tomatoes, unless specifically granted an exemption, to meet the same net weight requirements regardless of where they are packed.

Producer field-packed tomatoes are tomatoes which at the time of inspection are No. 3 color or higher (according to color classification requirements in the U.S. tomato standards), that are picked and place packed in new containers in the field by a producer as defined in § 966.150 of the rules and regulations. The tomatoes are then transported to a registered handler's facilities for final preparation for market and for inspection.

Producer field-packed tomatoes are picked by hand and place packed in containers in layers. When place packing a container of tomatoes, the fill is determined by the size of the tomato, dimensions of the container, and the way the tomatoes are positioned in the box. Each layer is tightly packed by rotating the tomatoes and by the size selection of the tomatoes. Each 25-pound container usually has three to four layers of tomatoes.

Most tomatoes from Florida are packed and shipped at the mature green stage. Shipments of mature green tomatoes represented approximately 83.7 percent of total fresh shipments during the 1999–2000 season. Tomatoes are picked and packed at the mature green stage to facilitate handling. The vast majority of mature green tomatoes are packed using a mechanized process. The tomatoes are brought to the packinghouse where they are run across sizing equipment, and then are packed in volume fill containers by size and weight. At the mature green stage, the tomatoes are firm and are able to withstand the packing process. This is an efficient process that facilitates packing in volume.

However, when packing a producer field-packed tomato that is more ripe and mature, the process used to pack mature greens is not as effective. This is because as the tomato begins to ripen it begins to soften. Tomatoes of No. 3 color and above cannot tolerate the rigors of the mechanized handling process. This packing process bruises and damages more mature tomatoes, increasing the volume of culls and tomatoes that fail inspection.

When the net weight exemption for producer field-packed tomatoes was established October 10, 1998 (63 FR 54556), the Committee thought that meeting the net weight requirement would be difficult without the precision of the mechanical process available at the packinghouse. Therefore, the Committee recommended establishing the net weight exemption to facilitate the packing of field-packed tomatoes. However, after several years of experience, those packing producer field-packed tomatoes have enhanced their skill for packing tomatoes in the field. Many now pack to meet the net weight requirement even though the exemption is available.

Field-packed tomatoes are sized as either 5X6 or 6X6 and larger with no upper limit on either size. This differs from the size requirements for tomatoes packed at a packinghouse. Packinghouse tomatoes must meet a minimum and a maximum size requirement on tomatoes designated as 6X6. Because there is no upper limit on the either 5X6 or 6X6 sized field-packed tomatoes, handlers have more flexibility to add and remove tomatoes of different sizes in order to meet a specified weight requirement without compromising their ability to meet the size requirement. Handlers can replace larger tomatoes with smaller ones and vice versa in order to adjust box weight to meet the net weight requirements. In its discussion, the Committee stated that most handlers of producer field-packed tomatoes are voluntarily meeting the 25-pound net weight requirements.

It also found that some handlers have started using the net weight exemption as a marketing tool. The Committee stated that producer field-packed tomatoes packed in containers designed to hold a 25-pound designated net weight were being presented for sale with weights of 28 to 32 pounds. The net weight requirement only allows packinghouses to put between 25 and 27 pounds of tomatoes to a box. Some handlers of producer field-packed tomatoes are adding additional tomatoes to the containers to create a marketing advantage over those handlers required to meet the net weight requirements. Buyers prefer the additional weight in containers of field-packed tomatoes to packinghouse tomatoes because they are getting more tomatoes for their money.

In its discussions, Committee members stated that over packing containers is a poor marketing practice. Selling a container of tomatoes that weighs more than 25 pounds at the price for a 25-pound container has a price depressing effect on the market, and reduces returns to growers. It was also noted that the marketing order was put in place to create an orderly market for all tomatoes grown in Florida because the market at that time was in such disarray. The net weight was established to provide an industry standard and give buyers and sellers a uniform point of comparison. With the volume of producer field-packed tomatoes increasing, several Committee

members stated that continuing with the net weight exemption for field-packed tomatoes was taking a step backwards in terms of orderly marketing.

In addition, there was also concern regarding the possibility that damaged tomatoes could reach the market. Committee members stated that when a 25-pound box of tomatoes is filled to exceed a 27-pound net weight, there is an increased chance that tomatoes will be crushed when placing the lid on the container. Overfilling could also result in fruit being damaged during shipment.

The market for red, vine-ripe tomatoes has grown over the past few years. The Committee now estimates that between five and fifteen percent of the total daily fresh tomato shipments from Florida are producer field-packed tomatoes. This is a one to two percent increase from last season. Retailers consider the fast growing market for red, vine-ripe tomatoes to be the way of the future and the Committee estimates that the volume of producer field-packed tomatoes will continue to grow in order to supply this market. Therefore, the Committee wants to continue to develop this market by providing a uniform, quality product.

Therefore, this rule would remove the exemption from the net weight requirement for producer field-packed tomatoes, and would require producer field-packed tomatoes to meet the same net weight and weight labeling requirements as those packed in a packinghouse.

The two Committee members who opposed the recommendation agreed that a problem exists with the net weight exemption for producer field-packed tomatoes. However, they were not sure that the action recommended was the best solution to the problem and wanted more time to consider the issue. Therefore, they voted against the proposal.

Section 8e of the Act requires that whenever grade, size, quality, or maturity requirements are in effect for certain commodities under a domestic marketing order, including tomatoes, imports of that commodity must meet the same or comparable requirements. However, the Act does not authorize the imposition of pack and container requirements on imports, when such requirements are in effect under a domestic marketing order. Therefore, no change is necessary in the tomato import regulation as a result of this action.

This change would not affect the exemption for single layer and two-layer place packed tomatoes. They would continue to be exempt from the net weight requirements under the order. Therefore, producer field-packed tomatoes place packed in single or two layer packs would continue to be exempt from the net weight requirements.

Pursuant to requirements set forth in the Regulatory Flexibility Act (RFA), the Agricultural Marketing Service (AMS) has considered the economic impact of this action on small entities. Accordingly, AMS has prepared this initial regulatory flexibility analysis.

The purpose of the RFA is to fit regulatory actions to the scale of business subject to such actions in order that small businesses will not be unduly or disproportionately burdened. Marketing orders issued pursuant to the Act, and rules issued thereunder, are unique in that they are brought about through group action of essentially small entities acting on their own behalf. Thus, both statutes have small entity orientation and compatibility.

There are approximately 82 handlers of Florida tomatoes who are subject to regulation under the marketing order and approximately 100 tomato producers in the regulated area. Small agricultural service firms are defined by the Small Business Administration (13 CFR 121.201) as those having annual receipts of less than $5,000,000, and small agricultural producers are defined as those having annual receipts of less than $500,000.

Based on the industry and Committee data, the average annual price for fresh Florida tomatoes during the 1999–2000 season was $6.89 per 25-pound carton or equivalent, and total fresh shipments for the 1999–2000 season were 58,006,721 25-pound equivalent cartons of tomatoes. Based on this information, the majority of handlers would be classified as small entities as defined by the SBA. The majority of producers of Florida tomatoes may also be classified as small entities.

This proposal would revise the handling requirements currently prescribed for producer field-packed tomatoes under § 966.323 of the order. Currently, producer field-packed tomatoes are exempt from the net weight requirements under the order. The net weight requirement only allows packinghouses to put between 25 and 27 pounds of tomatoes into a box designed to hold 25 pounds. Some handlers of producer field-packed tomatoes are adding additional tomatoes to their containers to the detriment of handlers required to meet the net weight requirements. This rule would remove the exemption from the net weight requirement for producer field-packed tomatoes and require all tomatoes, regardless of where they are packed, to meet the same net weight requirements. Authority for this action is provided in § 966.52 of the order.

There could be some additional costs associated with this rule. Removing the net weight exemption would require those packing producer field-packed tomatoes to take the steps necessary to ensure that the tomatoes meet the net weight requirement. This could result in additional costs from the purchase of equipment to weigh the boxes and additional labor needed. However, many of those packing producer field-packed tomatoes have already incurred these costs and are meeting the net weight requirements voluntarily.

Currently, boxes containing between 28 and 32 pounds of field-packed tomatoes may be sold for the same price as a box containing 25 to 27 pounds of tomatoes. This reduces total pack out, depresses price, and reduces returns to the grower. In addition, these tomatoes are being sold into what retailers consider to be the fastest growing segment of the tomato market. Over packing boxes increases the probability that some tomatoes will be damaged. Shipping damaged tomatoes could have a negative impact on the market and the ability of Florida tomato handlers in meeting that market's needs. This rule would help counter that possibility.

This rule was recommended to benefit the Florida tomato industry. The costs or benefits of this rule would not be disproportionately greater or less for small handlers or producers than for larger entities.

The Committee discussed alternatives to this change, including making no change to the regulation. However, Committee members agreed that action needed to be taken, so this alternative was rejected. Another alternative considered was to change the size of the box for field-packed tomatoes. Some members of the Committee stated that this would not solve the problem, only add another box size, noting that handlers are already selling a 25-pound container of producer field-packed tomatoes that weighs more than 25 pounds. Changing only the size of the container would not prevent handlers from continuing to overfill the cartons. Therefore, this alternative was also rejected.

This proposed rule would remove the exemption from the net weight requirement for producer field-packed tomatoes under the Florida tomato marketing order.

This action would not impose any additional reporting or recordkeeping requirements on either small or large tomato handlers. As with all Federal marketing order programs, reports and

forms are periodically reviewed to reduce information requirements and duplication by industry and public sector agencies. In addition, the Department has not identified any relevant Federal rules that duplicate, overlap or conflict with this proposed rule.

Further, the Committee's meeting was widely publicized throughout the tomato industry and all interested persons were invited to attend the meeting and participate in Committee deliberations on all issues. Like all Committee meetings, the February 27, 2001, meeting was a public meeting and all entities, both large and small, were able to express views on this issue. Finally, interested persons are invited to submit information on the regulatory and informational impacts of this action on small businesses.

A small business guide on complying with fruit, vegetable, and specialty crop marketing agreements and orders may be viewed at: http://www.ams.usda.gov/fv/moab.html. Any questions about the compliance guide should be sent to Jay Guerber at the previously mentioned address in the **FOR FURTHER INFORMATION CONTACT** section.

This rule invites comments on a change to the handling requirements currently prescribed under the Florida tomato marketing order. A 20-day comment period is provided to allow interested persons to respond to this proposal. Twenty days is deemed appropriate because any changes resulting from this proposed rule should be effective by the start of the 2001/2002 season, which begins October 10, 2001. All written comments timely received will be considered before a final determination is made on this matter.

List of Subjects in 7 CFR Part 966

Marketing agreements, Reporting and recordkeeping requirements,Tomatoes.

For the reasons set forth in the preamble, 7 CFR part 966 is proposed to be amended as follows:

PART 966—TOMATOES GROWN IN FLORIDA

1. The authority citation for 7 CFR part 966 continues to read as follows:

Authority: 7 U.S.C. 601–674.

2. Section 966.323 is amended by revising the last sentence of paragraph (d)(1) to read as follows:

§ 966.323 Handling regulation.

* * * * *

(d) *Exemption.* (1) * * * Producer field-packed tomatoes must meet all of the requirements of this section except for the requirement that all containers must be packed at registered handler facilities as specified in paragraph (a)(3)(ii) of this section, and the requirement that such tomatoes designated as size 6 x 6 must meet the maximum diameter requirement specified in paragraph (a)(2)(i) of this section: *Provided*, That 6 x 6 and larger is used to indicate the listed size designation on containers.

* * * * *

Dated: July 27, 2001.

Kenneth C. Clayton,

Acting Administrator, Agricultural Marketing Service.

[FR Doc. 01–19266 Filed 8–1–01; 8:45 am]

BILLING CODE 3410–02–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 99–NM–132–AD]

RIN 2120–AA64

Airworthiness Directives; Boeing Model 767 Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Proposed rule; withdrawal.

SUMMARY: This action withdraws a notice of proposed rulemaking (NPRM) that proposed a new airworthiness directive (AD), applicable to certain Boeing Model 767 series airplanes. That action would have required repetitive inspections of the side load underwing fitting bushings for broken sealant or bushing migration, and corrective action, if necessary. That action also would have provided for optional terminating action in lieu of repetitive inspections. Since the issuance of the NPRM, the Federal Aviation Administration (FAA) has received new data and has issued alternative rulemaking action. Accordingly, the proposed rule is withdrawn.

FOR FURTHER INFORMATION CONTACT: John D. Craycraft, Aerospace Engineer, Airframe Branch, ANM–120S, FAA, Seattle Aircraft Certification Office, 1601 Lind Avenue, SW., Renton, Washington 98055–4056; telephone (425) 227–2782; fax (425) 227–1181.

SUPPLEMENTARY INFORMATION: A proposal to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) to add a new airworthiness directive (AD), applicable to certain Boeing Model 767 series airplanes, was published in the **Federal Register** as a Notice of Proposed Rulemaking (NPRM) on November 24, 1999 (64 FR 66119). The proposed rule would have required repetitive inspections of the side load underwing fitting bushings for broken sealant or bushing migration, and corrective action, if necessary. The proposed rule also would have provided for optional terminating action in lieu of repetitive inspections. The proposed rule was prompted by reports of migrated bushings and corrosion on the side load fittings. The proposed actions were intended to prevent corrosion in the side load underwing fitting, which could result in cracking and consequent reduced structural integrity of the wing strut.

Actions Since Issuance of the NPRM

Since the issuance of that NPRM on November 18, 1999, the FAA has issued alternative rulemaking action, which, in addition to comments we have received in response to the NPRM, has caused us to reconsider our previous position on this rulemaking action.

We have considered the comments and recommendations we received. Although one commenter supports the NPRM as proposed, eight other commenters object to it for various reasons. Some of those reasons follow:

- Bushing migration does not present an immediate safety concern, and no significant corrosion has been found in the side load underwing fitting. For these reasons, the commenters believe that the inspections specified in the NPRM are unnecessary.
- The cost estimates in the NPRM are too low because of the extensive work required, special tooling, and the resultant impact on scheduled service. Operators recommend increasing the cost estimates to include additional costs for labor, access and closeup, and special tooling and equipment.
- The compliance times for the inspections, as specified in the NPRM, would put affected airplanes out of service for an extended period. One commenter states that the manufacturer would not be able to provide an adequate number of kits within the specified compliance time. Operators recommend that the compliance times coincide with other existing maintenance programs such as the Strut Improvement Program (SIP) and the Corrosion Prevention and Control Program (CPCP).
- Removing and reinstalling the wing struts is not a routine task performed at regular maintenance intervals. In addition, the frequency of strut removal specified in the NPRM would severely impact airline schedules. The manufacturer recommends removing the strut only during a CPCP inspection,

which is accomplished at or before 18 years in service. Limiting strut removal will reduce the element of human error, structural damage to the lug areas, and improper sealing of the bushings.

- The repetitive inspections specified by paragraph (b) of the NPRM should be allowed to continue until incorporation of the SIP.

FAA's Determination

Since the issuance of the NPRM, the FAA has issued three ADs to require accomplishment of the 767 SIP. Although the NPRM requires repetitive inspections and corrective action if a broken sealant or bushing migration is detected, the new ADs require modification of the nacelle strut and wing structure on both the left and right sides of the airplane. The FAA adds that the discrepancy (broken sealant or bushing migration) specified in the NPRM also is addressed by the actions included in the 767 SIP. In addition, since issuance of Boeing Service Bulletin 767–57–0063, dated May 7, 1998, Boeing has provided to the FAA additional data indicating that the recommended compliance times listed in that service bulletin were overly conservative. For these reasons, the FAA has determined that issuance of the NPRM is no longer necessary since the intent of that AD will be accomplished by the following previously issued ADs:

- AD 2001–02–07, amendment 39–12091 (66 FR 8085, January 29, 2001).
- AD 2001–06–12, amendment 39–12159 (65 FR 17492, April 2, 2001).
- AD 2000–19–09, amendment 39–11910 (65 FR 58641, October 2, 2000).

FAA's Conclusions

Upon further consideration, the FAA has determined that, in light of the above information, the identified unsafe condition has been addressed. Accordingly, the NPRM is hereby withdrawn.

Withdrawal of this NPRM constitutes only such action, and does not preclude the agency from issuing another action in the future, nor does it commit the agency to any course of action in the future.

Regulatory Impact

Since this action only withdraws a notice of proposed rulemaking, it is neither a proposed nor a final rule and therefore is not covered under Executive Order 12866, the Regulatory Flexibility Act, or DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979).

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Withdrawal

Accordingly, the notice of proposed rulemaking, Docket 99–NM–132–AD, published in the **Federal Register** on November 24, 1999 (64 FR 66119), is withdrawn.

Issued in Renton, Washington, on July 26, 2001.

Donald L. Riggin,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 01–19262 Filed 8–1–01; 8:45 am]

BILLING CODE 4910–13–U

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 99–NM–21–AD]

RIN 2120–AA64

Airworthiness Directives; Boeing Model 737–100, –200, –200C, –300, –400, and –500 Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Supplemental notice of proposed rulemaking; reopening of comment period.

SUMMARY: This document revises an earlier proposed airworthiness directive (AD); applicable to certain Boeing Model 737–100, –200, and –200C series airplanes; which would have required inspections for corrosion and cracking of the inboard track of each outboard flap, and repair, if necessary, and would have provided an optional terminating action. This new action expands the applicability and removes the optional terminating action of the proposed AD. For certain airplanes, this action would require new repetitive inspections for discrepancies of the rear spar attachments and cracks in the upper flange of the inboard track at the rear spar attachment of each outboard flap, and eventual rework of the flap track assembly and rear spar attachments, including replacement of the flap track with a new track, if necessary. For all airplanes, this action would require repetitive inspections for cracks in the upper flange of the inboard flap tracks at the rear spar attachments, and corrective action, if necessary. These actions are necessary to find and fix discrepancies of the inboard tracks of the outboard flaps, which could result in loss of the outboard trailing edge flaps and consequent reduced controllability of the airplane. These actions are intended to address the identified unsafe condition.

DATES: Comments must be received by September 6, 2001.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM–114, Attention: Rules Docket No. 99–NM–21–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227–1232. Comments may also be sent via the Internet using the following address: 9–anm–nprmcomment@faa.gov. Comments sent via fax or the Internet must contain ''Docket No. 99–NM–21–AD'' in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 for Windows or ASCII text.

The service information referenced in the proposed rule may be obtained from Boeing Commercial Airplane Group, P.O. Box 3707, Seattle, Washington 98124–2207. This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington.

FOR FURTHER INFORMATION CONTACT: James Blilie, Aerospace Engineer, Airframe Branch, ANM–120S, FAA, Seattle Aircraft Certification Office, 1601 Lind Avenue, SW., Renton, Washington 98055–4056; telephone (425) 227–2131; fax (425) 227–1181.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this document may be changed in light of the comments received.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report

summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this proposal must submit a self-addressed, stamped postcard on which the following statement is made: ''Comments to Docket Number 99–NM–21–AD.'' The postcard will be date-stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM–114, Attention: Rules Docket No. 99–NM–21–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056.

Discussion

A proposal to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) to add an airworthiness directive (AD), applicable to certain Boeing Model 737–100, –200, and –200C series airplanes, was published as a notice of proposed rulemaking (NPRM) in the **Federal Register** on April 26, 1999 (64 FR 20224). That NPRM would have required inspections to detect corrosion and cracking of the inboard track of each outboard flap where the track attaches to the rear spar, and repair, if necessary. For certain airplanes, that proposal also would have provided optional terminating action for the proposed repetitive inspections for those airplanes. That NPRM was prompted by several reports of cracking of the inboard track of the outboard flap. That condition, if not corrected, could result in loss of the outboard trailing edge flap and consequent reduced controllability of the airplane.

Explanation of New Service Information

Since the issuance of that NPRM, the FAA has reviewed and approved Boeing Service Bulletin 737–57A1249, Revision 1, including Appendix A, dated June 1, 2000. That service bulletin describes procedures for repetitive detailed visual inspections to find discrepancies (including corrosion, or missing, damaged, or migrated anti-fret strips and tapered shims) of the rear spar attachments of the flap tracks. That service bulletin also describes procedures for repetitive detailed visual, high frequency eddy current (HFEC), and ultrasonic inspections to find cracking in the upper flange of the inboard track of each outboard flap at the rear spar attachment. The service bulletin also describes procedures for rework of the flap track assembly and rear spar attachments. The rework procedures include the following:

- Removal of the flap track.
- A detailed visual inspection for a missing, damaged, or migrated anti-fret strip and tapered shim of the rear spar attachments of the flap tracks; replacement of the anti-fret strip with a new aluminum anti-fret strip (or installation of an aluminum strip if no strip is installed), if necessary; and replacement of the tapered shim with a new shim (or installation of a shim if no shim is installed).
- Eddy current and ultrasonic inspections for fatigue cracking of the flap tracks.
- A detailed visual inspection for corrosion of the flap tracks.
- Rework of attachment holes.
- Replacement of the flap track with a new track, if necessary.

The procedures described in Boeing Service Bulletin 737–57A1249, Revision 1, are similar to the procedures described in Boeing Service Bulletin 737–57–1065, Revision 3, dated December 17, 1982, which was referenced in the original NPRM as the appropriate source of service information for certain proposed actions. Among other things, however, Boeing Service Bulletin 737–57A1249, Revision 1, describes more rework instructions than does Boeing Service Bulletin 737–57–1065. Airplanes reworked according to Boeing Service Bulletin 737–57–1065 would require additional rework according to this proposed AD and Boeing Service Bulletin 737–57A1249, Revision 1.

Actions Since Issuance of NPRM

The NPRM listed certain Boeing Model 737–100, –200, and –200C series airplanes in its applicability statement. Since the issuance of the NPRM, the FAA has received a report of similar cracking in the area addressed by the NPRM on a Boeing Model 737–300 series airplane. The interface between the inboard track of each outboard flap and the rear spar on the subject Model 737–300 series airplane had been modified according to procedures similar to those identified as optional terminating action in the NPRM. Other Model 737–300, –400, and –500 series airplanes also have been similarly modified. Because of this report, the FAA finds that certain Model 737–300, –400, and –500 series airplanes—in addition to the Model 737–100, –200, and –200C series airplanes identified in the NPRM—may be subject to the unsafe condition addressed by this proposed AD. Therefore, the applicability statement of this supplemental NPRM lists all of these airplanes.

In addition, Boeing Service Bulletin 737–57A1249, Revision 1, states that no more work is necessary following the rework of the flap track described in that service bulletin. Because of the report of cracking on the Model 737–300 series airplane described above, the FAA finds that rework according to Boeing Service Bulletin 737–57A1249, Revision 1, may not ensure an adequate level of safety for the service life of the airplane. Therefore, this supplemental NPRM proposes to require additional repetitive inspections following the rework or the modification equivalent to the rework that was done during production on certain airplanes.

Comments

Due consideration has been given to the comments received in response to the NPRM. Certain comments have resulted in changes to the proposal, and those comments are addressed below.

Request To Clarify Airplanes Not Affected By Proposed Rule

One commenter requests that the FAA revise the proposed rule to clarify that certain airplanes are not subject to the proposed actions. The commenter states that airplanes having line numbers (L/N) 1032 through 1585 on which new flap tracks were installed according to Boeing Service Bulletin 737–57–1203, dated November 15, 1990, do not need to have flap tracks replaced as specified in the proposed rule. The commenter states that new flap tracks installed according to that service bulletin have the new aluminum anti-fret strip that this proposed AD would require and meet all requirements of the proposed rule.

The FAA concurs with the commenter's request. The applicability of this supplemental NPRM has been revised to exclude airplanes on which new flap tracks were installed according to Boeing Service Bulletin 737–57–1203.

Request To Require Repetitive Inspections for All Airplanes

One commenter requests that repetitive inspections for cracking be required for all airplanes. For airplanes having L/Ns 870 through 1585 inclusive on which replacement flap tracks are installed, paragraph (c) of the NPRM states that no further action is required if no corrosion or cracking is found during the initial inspection. The commenter states that one-time visual and HFEC inspections may not be sufficient to ensure that any crack is found in a timely manner.

The FAA concurs with the commenter's request, and paragraph (c) of the NPRM has not been included in this supplemental NPRM. This supplemental NPRM proposes to require inspections and eventual rework or replacement of flap tracks for all airplanes with L/Ns 1 through 869 inclusive and airplanes with L/Ns 870 through 1585 inclusive on which the original flap tracks have been replaced with certain flap tracks. As stated above, this supplemental NPRM also proposes to require post-rework repetitive inspections for all airplanes identified in the applicability statement of this document.

Request To Clarify Need for Additional Work on Certain Airplanes

One commenter, the manufacturer, requests that the proposed AD be revised to make it clear that airplanes modified according to Boeing Service Bulletin 737–57–1065, Revision 3, require additional work according to Boeing Service Bulletin 737–57A1249. The commenter states that this change is necessary because Boeing Service Bulletin 737–57–1065, Revision 3, was not intended to address the specific unsafe condition identified in the proposed AD.

The FAA concurs with the commenter's request and has included appropriate statements in the ''Explanation of New Service Information'' section of the preamble of this supplemental NPRM. Also, a new ''Note 2'' has been added to the body of this proposed AD to state that airplanes modified according to Boeing Service Bulletin 737–57–1065 are subject to additional work as described in this AD and in Boeing Service Bulletin 737–57A1249, Revision 1.

Request To Clarify Terminology

One commenter requests various changes to language used in the NPRM. The changes recommended by the commenter include:

- Refer to ''anti-fret strip'' instead of ''rub strip'' in the ''Discussion'' and ''Explanation of Relevant Service Information'' sections of the proposed AD.
- Clarify the procedures involved in the rework as described in the ''Explanation of Relevant Service Information'' section of the proposed AD.
- Clarify the cause of the unsafe condition by revising the sentence in the ''Discussion'' section of the proposed AD that reads, ''inadequate clamp-up of the attachment bolts can make the area where the flap track attaches to the rear spar more vulnerable to moisture absorption and, consequently, to corrosion'' to read, ''insufficient clamp-up of the attachment bolts can cause damage to the attachment seals, tapered shim, anti-fret strip, and protective finishes, and make the area where the flap track attaches to the rear spar more vulnerable to moisture absorption and, consequently, to corrosion.''
- Identify the area affected by cracking as ''the upper flange of the inboard track of each/the outboard flap at the rear spar attachment'' in the ''Discussion'' and ''Explanation of Requirements of Proposed Rule'' sections of the preamble, and in the statement of unsafe condition in the body of the proposed AD.

The FAA concurs with the intent of the commenter's request. Though some of the specific sections of the preamble referenced by the commenter are not repeated in this supplemental NPRM, the changes suggested by the commenter have been made in this supplemental NPRM wherever appropriate.

Explanation of New Requirements of Proposal

Since an unsafe condition has been identified that is likely to exist or develop on other products of this same type design, the proposed AD would require, for certain airplanes, new repetitive inspections for discrepancies (including corrosion, or missing, damaged, or migrated anti-fret strips and tapered shims) of the rear spar attachments and cracks in the upper flange of the inboard track at the rear spar attachment of each outboard flap. For certain airplanes, the proposed AD also would require eventual rework of the flap track assembly and rear spar attachments, including replacement of the flap track with a new track, if necessary. For all airplanes, this action would require post-rework repetitive inspections for cracks in the upper flange of the inboard flap tracks at the rear spar attachments, and corrective action, if necessary. The actions would be required to be accomplished according to Boeing Service Bulletin 737–57A1249, Revision 1, except as discussed below.

Differences Between Supplemental NPRM and Service Bulletin

This supplemental NPRM differs from Boeing Service Bulletin 737–57A1249, Revision 1, in the following ways:

- Though the service bulletin states compliance times in terms of flight cycles and calendar time, this proposed AD states compliance times only in calendar time. The FAA finds it appropriate to state compliance times for the requirements of this proposed AD only in calendar time because corrosion cracking is a function of time, not flight cycles.
- The airplane manufacturer recommends that the actions in the service bulletin be accomplished on airplanes with 20,000 flight cycles or more, or 10 years of service. The FAA finds that, as of the effective date of this AD, all airplanes identified in paragraph (a) of this proposed AD will have been in service for more than 10 years since their date of manufacture. Therefore, this supplemental NPRM does not refer to this threshold in the compliance times for paragraphs (a), (b), and (c) of this AD.
- Operators also should note that, though the service bulletin specifies that the manufacturer may be contacted for disposition of certain repair conditions, this proposed AD would require the repair of those conditions to be accomplished according to a method approved by the FAA, or according to data meeting the type certification basis of the airplane approved by a Boeing Company Designated Engineering Representative who has been authorized by the FAA to make such findings.

Conclusion

Since this change expands the scope of the originally proposed rule, the FAA has determined that it is necessary to reopen the comment period to provide additional opportunity for public comment.

Cost Impact

There are approximately 2,890 airplanes of the affected design in the worldwide fleet. The FAA estimates that 1,100 airplanes of U.S. registry would be affected by this proposed AD.

It would take approximately 4 work hours per airplane to accomplish the proposed inspections, at an average labor rate of $60 per work hour. Based on these figures, the cost impact of the proposed inspections on U.S. operators is estimated to be $264,000, or $240 per airplane, per inspection cycle.

It would take approximately 12 work hours per airplane to accomplish the proposed rework, at an average labor rate of $60 per work hour. Required parts would cost approximately $532. Based on these figures, the cost impact of the rework proposed by this AD on U.S. operators is estimated to be $1,377,200, or $1,252 per airplane.

The cost impact figures discussed above are based on assumptions that no operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if

this AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a ''significant regulatory action'' under Executive Order 12866; (2) is not a ''significant rule'' under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption **ADDRESSES**.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by adding the following new airworthiness directive:

Boeing: Docket 99–NM–21–AD.

Applicability: Model 737–100, –200, –200C, –300, –400, and –500 series airplanes; certificated in any category; EXCEPT airplanes on which any replacement flap tracks were installed according to Boeing Service Bulletin 737–57–1203, dated November 15, 1990, or production equivalent.

Note 1: This AD applies to each airplane identified in the preceding applicability provision, regardless of whether it has been otherwise modified, altered, or repaired in the area subject to the requirements of this AD. For airplanes that have been modified, altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (f) of this AD. The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD; and, if the unsafe condition has not been eliminated, the request should include specific proposed actions to address it.

Compliance: Required as indicated, unless accomplished previously.

Note 2: Airplanes modified according to Boeing Service Bulletin 737–57–1065 are subject to additional work as described in this AD and in Boeing Service Bulletin 737–57A1249, Revision 1, dated June 1, 2000.

To find and fix discrepancies of the inboard tracks of the outboard flaps, which could result in loss of the outboard trailing edge flaps and consequent reduced controllability of the airplane, accomplish the following:

Initial Inspections

(a) For airplanes with line numbers (L/N) 1 through 869 inclusive, and airplanes with L/Ns 870 through 1585 on which the original flap tracks have been replaced with certain tracks as specified in Boeing Service Bulletin 737–57A1249, Revision 1, including Appendix A, dated June 1, 2000: Within 6 months after the effective date of this AD, whichever occurs later, accomplish the requirements of paragraphs (a)(1) and (a)(2) of this AD, according to Boeing Service Bulletin 737–57A1249, Revision 1, including Appendix A, dated June 1, 2000.

(1) Perform a detailed visual inspection for discrepancies (e.g., corrosion, or missing, damaged, or migrated anti-fret strips and tapered shims) of the rear spar attachments of the flap tracks.

(2) Perform detailed visual, high frequency eddy current (HFEC), and ultrasonic inspections for cracking in the upper flange of the inboard track of each outboard flap at the rear spar attachments.

Note 3: Inspections and rework accomplished according to Boeing Alert Service Bulletin 737–57A1249, including Appendix A, dated December 16, 1999, is considered acceptable for compliance with the applicable action specified in this AD.

Note 4: For the purposes of this AD, a detailed visual inspection is defined as: ''An intensive visual examination of a specific structural area, system, installation, or assembly to detect damage, failure, or irregularity. Available lighting is normally supplemented with a direct source of good lighting at intensity deemed appropriate by the inspector. Inspection aids such as mirror, magnifying lenses, etc., may be used. Surface cleaning and elaborate access procedures may be required.''

Repetitive Inspections

(b) For airplanes subject to paragraph (a) of this AD: If no discrepancy is found during any inspection required by paragraph (a) of this AD, thereafter, repeat the inspections specified in paragraph (a) of this AD at intervals not to exceed 9 months, until the actions required by paragraph (c) of this AD have been accomplished.

Rework

(c) For airplanes subject to paragraph (a) of this AD: At the applicable time specified in paragraph (c)(1) or (c)(2) of this AD, accomplish rework of the flap track assembly and aft flap track attachments (including removal of the flap track; a detailed visual inspection for a missing, damaged, or migrated anti-fret strip and tapered shim of the rear spar attachments of the flap track; replacement of the anti-fret strip with a new aluminum anti-fret strip (or installation of an aluminum strip if no strip is installed), as applicable; replacement of the tapered shim with a new shim (or installation of a shim if no shim is installed); eddy current and ultrasonic inspections for fatigue cracking of the flap tracks; a detailed visual inspection for corrosion of the flap tracks; and rework of attachment holes), including replacement of the flap tracks, as applicable, by accomplishing all actions specified in part II of the Accomplishment Instructions of Boeing Service Bulletin 737–57A1249, Revision 1, including Appendix A, dated June 1, 2000. Do these actions according to that service bulletin, except as provided by paragraph (e) of this AD. Accomplishment of the actions required by this paragraph constitutes terminating action for the repetitive inspections required by paragraph (b) of this AD.

(1) If no discrepancy is found during any inspection required by paragraph (a) or (b) of this AD: Do the rework within 24 months after the effective date of this AD, whichever occurs later.

(2) If any discrepancy is found during any inspection required by paragraph (a) or (b) of this AD: Do the rework prior to further flight.

Repetitive Inspections

(d) For all airplanes: At the applicable time specified in paragraph (d)(1) or (d)(2) of this AD, and thereafter at least every 24 months, perform detailed visual, HFEC, and ultrasonic inspections for cracking in the upper flange of the inboard track of each outboard flap at the rear spar attachments according to Part II of the Accomplishment Instructions of Boeing Service Bulletin 737–57A1249, Revision 1, including Appendix A, dated June 1, 2000.

(1) For airplanes subject to paragraph (c) of this AD, do the inspections within 10 years after accomplishment of the rework according to paragraph (c) of this AD.

(2) For airplanes other than those identified in paragraph (d)(1) of this AD, do the inspections within 10 years since the airplane's date of manufacture, or within 6 months after the effective date of this AD, whichever occurs later.

Repair Instructions and Exception to Procedures in Service Information

(e) If any discrepancy is found during any action required by paragraphs (a), (b), or (c) of this AD, and the service bulletin specifies to contact Boeing for appropriate action; OR if any discrepancy is found during inspections according to paragraph (d) of this AD: Prior to further flight, repair according to a method approved by the Manager, Seattle Aircraft Certification Office (ACO), FAA; or according to data meeting the type certification basis of the airplane approved by a Boeing Company Designated Engineering Representative (DER) who has been authorized by the Manager, Seattle ACO, to make such findings. For a repair method to be approved by the Manager, Seattle ACO, as required by this paragraph, the approval letter must specifically reference this AD.

Alternative Methods of Compliance

(f) An alternative method of compliance or adjustment of the compliance time that provides an acceptable level of safety may be used if approved by the Manager, Seattle ACO. Operators shall submit their requests through an appropriate FAA Principal Maintenance Inspector, who may add comments and then send it to the Manager, Seattle ACO.

Note 5: Information concerning the existence of approved alternative methods of compliance with this AD, if any, may be obtained from the Seattle ACO.

Special Flight Permits

(g) Special flight permits may be issued in accordance with sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate the airplane to a location where the requirements of this AD can be accomplished.

Issued in Renton, Washington, on July 26, 2001.

Vi L. Lipski,

Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 01–19261 Filed 8–1–01; 8:45 am]

BILLING CODE 4910–39–P

NATIONAL ARCHIVES AND RECORDS ADMINISTRATION

36 CFR Part 1228

RIN 3095–AB02

Records Disposition

AGENCY: National Archives and Records Administration (NARA).

ACTION: Proposed rule; correction.

SUMMARY: This document corrects the preamble of a proposed rule published in the **Federal Register** on July 17, 2001, at 66 FR 37202. The proposed rule would change the records management regulations in Subchapter B to simplify certain records disposition procedures. Inadvertently, a paragraph was omitted from the **SUPPLEMENTARY INFORMATION** section of the preamble that identifies specific issues for which NARA seeks Federal agency comment.

FOR FURTHER INFORMATION CONTACT: Nancy Allard at telephone number 301–713–7360 or fax number 301–713–7270.

Correction

In proposed rule FR Doc. 01–17791, beginning on page 37202 in the issue of July 17, 2001, make the following correction, in the **SUPPLEMENTARY INFORMATION** section. On page 37203 in the 1st column, add at the end of the first full paragraph the following new paragraph:

''The changes proposed in this rulemaking are intended to reduce Federal agency burden in the areas of submitting records disposition manuals to NARA and implementing disposition authorities for records covered by General Records Schedules. We specifically seek agency comment on the clarity of these proposed changes and whether they will indeed provide a benefit to the agencies.''

Dated: July 30, 2001.

Nancy Y. Allard,

NARA Federal Register Liaison.

[FR Doc. 01–19310 Filed 8–1–01; 8:45 am]

BILLING CODE 7515–01–U

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 63

[FRL–7020–2]

RIN 2060–AE83

National Emission Standards for Hazardous Air Pollutants for Pharmaceuticals Production

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: The EPA is proposing to amend the national emission standards for hazardous air pollutants (NESHAP) for pharmaceuticals production. This action proposes to correct referencing errors, add test methods for analyzing wastewater, define triethylamine as a soluble hazardous air pollutant (HAP) instead of a partially soluble HAP, add an outlet concentration limit for storage tank emissions, clarify the monitoring frequency requirements for connectors, and add planned routine maintenance provisions for centralized combustion control devices.

In the ''Rules and Regulations'' section of this **Federal Register**, we are making these corrections in a direct final rule, without prior proposal, because we view these revisions as noncontroversial, and we anticipate no adverse comments. We have explained our reasons for these corrections in the preamble to the direct final rule.

If we receive no adverse comments, we will take no further action on this proposed rule. If an adverse comment applies to an amendment, paragraph, or section, and that provision may be addressed separately from the remainder of the rule, we will withdraw only those provisions on which we received adverse comments. We will publish a timely withdrawal in the **Federal Register** indicating which provisions are being withdrawn. If part or all of the direct final rule in the ''Rules and Regulations'' section of this **Federal Register** is withdrawn, all public comments pertaining to those provisions will be addressed in a subsequent final rule based on this proposed rule. We will not institute a second comment period on that subsequent final rule. Any parties interested in commenting must do so at this time.

DATES: Comments. Written comments must be received by September 4, 2001, unless a hearing is requested by August 13, 2001. If a hearing is requested, written comments must be received by September 17, 2001.

Public Hearing. If anyone contacts the EPA requesting to speak at a public hearing by August 13, 2001, a public hearing will be held on August 16, 2001.

ADDRESSES: *Comments.* By U.S. Postal Service, send comments (in duplicate, if possible) to: Air and Radiation Docket and Information Center (6102), Attention Docket Number A–96–03, U.S. EPA, 1200 Pennsylvania Avenue, NW., Washington, DC 20460. In person or by courier, deliver comments (in duplicate if possible) to: Air and Radiation Docket and Information Center (6102), Attention Docket Number A–96–03, U.S. EPA, 401 M Street, SW., Washington DC 20460. The EPA requests that a separate copy of each public comment be sent to the contact person listed below (see **FOR FURTHER INFORMATION CONTACT**). Comments may also be submitted electronically by following the instructions provided in **SUPPLEMENTARY INFORMATION**.

Public Hearing. If a public hearing is held, it will be held at the EPA's Office of Administration Auditorium, Research Triangle Park, North Carolina at 10:30 a.m.

Docket. Docket No. A–96–03 contains supporting information used in developing the NESHAP. The docket is

located at the U.S. EPA, 401 M Street, SW., Washington, DC 20460 in Room M–1500, Waterside Mall (ground floor), and may be inspected from 8 a.m. to 5:30 p.m., Monday through Friday, excluding legal holidays.

FOR FURTHER INFORMATION CONTACT: Mr. Randy McDonald, Organic Chemicals Group, Emission Standards Division (MD–13), U.S. EPA, Research Triangle Park, North Carolina 27711, telephone number (919) 541–5402, electronic mail address: mcdonald.randy@epa.gov.

SUPPLEMENTARY INFORMATION:

Comments. Comments and data may be submitted by electronic mail (e-mail) to: a-and-r-docket@epa.gov. Electronic comments must be submitted as an ASCII file to avoid the use of special characters and encryption problems and will also be accepted on disks in WordPerfect version 5.1, 6.1, or Corel 8 file format. All comments and data submitted in electronic form must note the docket number A–96–03. No confidential business information (CBI) should be submitted by e-mail. Electronic comments may be filed online at many Federal Depository Libraries.

Commenters wishing to submit proprietary information for consideration must clearly distinguish such information from other comments and clearly label it as CBI. Send submissions containing such proprietary information directly to the following address, and not to the public docket, to ensure that proprietary information is not inadvertently placed in the docket: Attention: Mr. Randy McDonald, c/o OAQPS Document Control Officer (Room 740B), U.S. EPA, 411 W. Chapel Hill Street, Durham, NC 27701. The EPA will disclose information identified as CBI only to the extent allowed by the procedures set forth in 40 CFR part 2. If no claim of confidentiality accompanies a submission when it is received by EPA, the information may be made available to the public without further notice to the commenter.

Public Hearing. Persons interested in presenting oral testimony or inquiring as to whether a hearing is to be held should contact Ms. Maria Noell, U.S. EPA, MD–13, Research Triangle Park, NC 27711, telephone (919) 541–5607, at least 2 days in advance of the public hearing. Persons interested in attending the public hearing must also call Ms. Maria Noell to verify the time, date, and location of the hearing. The public hearing will provide interested parties the opportunity to present data, views, or arguments concerning these proposed amendments.

Docket. The docket is an organized and complete file of all the information considered by the EPA in the development of this rulemaking. The docket is a dynamic file because material is added throughout the rulemaking process. The docketing system is intended to allow members of the public and industries involved to readily identify and locate documents so that they can effectively participate in the rulemaking process. Along with the proposed and promulgated standards and their preambles, the contents of the docket will serve as the record in the case of judicial review. (See section 307(d)(7)(A) of the Clean Air Act (CAA).) The regulatory text and other materials related to this rulemaking are available for review in the docket or copies may be mailed on request from the Air Docket by calling (202) 260–7548. A reasonable fee may be charged for copying docket materials.

Worldwide Web (WWW). In addition to being available in the docket, an electronic copy of this proposed rule will also be available through the WWW. Following signature, a copy of this action will be posted on the EPA's Technology Transfer Network (TTN) policy and guidance page for newly proposed or promulgated rules http://www.epa.gov/ttn/oarpg. The TTN at EPA's web site provides information and technology exchange in various areas of air pollution control. If more information regarding the TTN is needed, call the TTN HELP line at (919) 541–5384.

Regulated Entities. The regulated category and entities affected by this action include:

Category	NAICS codes	SIC codes	Examples of regulated entities
Industry	325411 and 325412	2833 and 2834	• Producers of finished dosage forms of drugs (e.g., tablets, capsules, and solutions), active ingredients, or precursors.

This table is not intended to be exhaustive, but rather provides a guide for readers likely to be interested in the revisions to the rule affected by this action. To determine whether your facility, company, business, organization, etc., is regulated by this action, you should carefully examine all of the applicability criteria in § 63.1250 of the rule. If you have questions regarding the applicability of these proposed amendments to a particular entity, consult the person listed in the preceding **FOR FURTHER INFORMATION CONTACT** section.

What Are the Administrative Requirements for This Action?

Regulatory Flexibility Act (RFA), as Amended by the Small Business Regulatory Enforcement Fairness Act of 1996 (SBREFA), 5 U.S.C. 601 et seq.

The RFA generally requires an agency to prepare a regulatory flexibility analysis of any rule subject to notice and comment rulemaking requirements under the Administrative Procedure Act or any other statute unless the agency certifies that the rule will not have a significant economic impact on a substantial number of small entities. Small entities include small businesses, small organizations, and small governmental jurisdictions.

For purposes of assessing the impacts of this proposed rule on small entities, a small entity is defined as: (1) A small business in the North American Industrial Classification System (NAICS) code 325411 or 325412 that has as many as 750 employees; (2) a small business in NAICS code 325199 that has as many as 1,000 employees; (3) a small governmental jurisdiction that is a government of a city, county, town, school district or special district with a population of less than 50,000; and (4) a small organization that is any not-for-profit enterprise which is independently owned and operated and is not dominant in its field.

After considering the economic impacts of this proposed rule on small entities, I certify that this action will not have a significant economic impact on a substantial number of small entities. The EPA has determined that none of the small entities will experience a significant impact because the amendments impose no additional regulatory requirements on owners or

operators of affected sources. Many of the amendments provide additional compliance options, and other amendments clarify requirements and correct minor drafting errors.

For information regarding other administrative requirements for this action, please see the direct final rule action that is located in the ''Rules and Regulations'' section of this **Federal Register** publication.

List of Subjects in 40 CFR Parts 9 and 63

Environmental protection, Administrative practice and procedure, Air pollution control, Hazardous substances, Intergovernmental relations, Reporting and recordkeeping requirements.

Dated: July 24, 2001.

Christine Todd Whitman,

Administrator.

[FR Doc. 01–18880 Filed 8–1–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[CA 241–0255; FRL–7022–9]

Revisions to the California State Implementation Plan, Bay Area Air Quality Management District

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA is proposing a limited approval and limited disapproval of revisions to the Bay Area Air Quality Management District (BAAQMD) portion of the California State Implementation Plan (SIP). These revisions concern volatile organic compound (VOC) emissions from storage of organic liquids and leaking equipment at petroleum refineries, chemical plants, bulk plants and bulk terminals. We are proposing action on local rules that regulate these emission sources under the Clean Air Act as amended in 1990 (CAA or the Act). We are taking comments on this proposal and plan to follow with a final action.

DATES: Any comments must arrive by September 4, 2001.

ADDRESSES: Mail comments to Andy Steckel, Rulemaking Office Chief (AIR–4), U.S. Environmental Protection Agency, Region IX, 75 Hawthorne Street, San Francisco, CA 94105–3901.

You can inspect copies of the submitted SIP revisions and EPA's technical support documents (TSDs) at our Region IX office during normal business hours. You may also see copies of the submitted SIP revisions at the following locations:

California Air Resources Board, Stationary Source Division, Rule Evaluation Section, 1001 ''I'' Street, Sacramento, CA 95814

Bay Area Air Quality Management District, 939 Ellis Street, San Francisco, CA 94109

FOR FURTHER INFORMATION CONTACT: Christine Vineyard, Rulemaking Office (AIR–4), U.S. Environmental Protection Agency, Region IX, (415) 744–1197.

SUPPLEMENTARY INFORMATION: Throughout this document, ''we,'' ''us'' and ''our'' refer to EPA.

Table of Contents

I. The State's Submittal
A. What rules did the State submit?
B. What is the purpose of the submitted rule revisions?
II. EPA's Evaluation and Action
A. How is EPA evaluating the rules?
B. Do the rules meet the evaluation criteria?
C. What are the rule deficiencies?
D. Proposed action and public comment.
III. Background Information
Why were these rules submitted?
IV. Administrative Requirements

I. The State's Submittal

A. What rules did the State submit?

Table 1 lists the rules addressed by this proposal with the dates that they were adopted by local air agencies and submitted by the California Air Resources Board (CARB).

TABLE 1.—SUBMITTED RULES

Local agency	Rule No.	Rule title	Adopted	Submitted
BAAQMD	8–5	Storage of Organic Liquids	12/15/99	03/28/00
BAAQMD	8–18	Equipment Leaks	01/07/98	03/28/00

On May 19, 2000, this rule submittal was found to meet the completeness criteria in 40 CFR part 51, appendix V, which must be met before formal EPA review.

B. What Is the Purpose of the Submitted Rule Revisions?

Revisions to Rule 8–5, Storage of Organic Liquids, are intended to:

- Implement a control measure for slotted guide poles.
- Modify requirements for primary metallic-shoe type seals used in internal floating roof tanks containing organic liquids that produce ozone forming air pollutants.

Revisions to Rule 8–18, Equipment Leaks, are intended to:

- Consolidate the regulation of fugitives in a single rule, transferring provisions contained in District Rule 8–25, Pumps and Compressor Seals at Petroleum Refineries, Chemical Plants, Bulk Plants and Bulk Terminals, to Rule 8–18. District Rule 8–25 is being deleted.
- Provide a more stringent leak standard for pressure relief devices.
- Add compliance options to allow the use of new leak and detection and repair technology.

The TSDs have more information about these rules.

II. EPA's Evaluation and Action

A. How Is EPA Evaluating the Rules?

Generally, SIP rules must be enforceable (see section 110(a) of the Act), must require Reasonably Available Control Technology (RACT) for major sources in nonattainment areas (see section 182(a)(2)(A)), and must not relax existing requirements (see sections 110(l) and 193). The BAAQMD regulates an ozone nonattainment area (see 40 CFR part 81), so Rules 8–5 and 8–18 must fulfill RACT.

Guidance and policy documents that we used to define specific enforceability and RACT requirements include the following:

1. Portions of the proposed post-1987 ozone and carbon monoxide policy that concern RACT, 52 FR 45044, November 24, 1987.

2. ''Issues Relating to VOC Regulation Cutpoints, Deficiencies, and Deviations; Clarification to Appendix D of November 24, 1987 **Federal Register** Document,'' (Blue Book), notice of availability published in the May 25, 1988 **Federal Register**.

3. ''Control of Volatile Organic Emissions from Petroleum Liquid Storage in External Floating Roof Tanks,'' EPA–450/2–78–047.

4. ''Control of Volatile Organic Emissions from Petroleum Liquid Storage in Fixed Roof Tanks,'' EPA–450/2–77–036.

5. ''Control of Volatile Organic Compound Leaks from Synthetic Organic Chemical and Polymer Manufacturing Equipment,'' EPA–450/3–83–006.

6. ''Model Volatile Organic Compounds Rules for Reasonably Available Control Technology,'' Office of Air Quality Planning and Standards, June 1992.

B. Do the rules meet the evaluation criteria?

These rules improve the SIP by establishing more stringent emission limits and by implementing new control measures for slotted guide poles. These rules are largely consistent with the relevant policy and guidance regarding enforceability, RACT and SIP relaxations. Rule provisions which do not meet the evaluation criteria are summarized below and discussed further in the TSD.

C. What Are the Rule Deficiencies?

These provisions conflict with section 110 and part D of the Act and prevent full approval of the SIP revision.

1. Rule 8–5 exempts sources from control requirements during certain startup, shutdown, and maintenance conditions in violation of EPA's 1999 guidance on excess emission during malfunctions, startup, and shutdown.

2. Rule 8–18 contains director's discretion in the allowance of compliance options and the use of new leak detection and repair technology without EPA approval.

D. Proposed Action and Public Comment

As authorized in sections 110(k)(3) and 301(a) of the Act, EPA is proposing a limited approval of the submitted rules to improve the SIP. If finalized, this action would incorporate the submitted rules into the SIP, including those provisions identified as deficient. This approval is limited because EPA is simultaneously proposing a limited disapproval of the rules under section 110(k)(3). If this disapproval is finalized, sanctions will be imposed under section 179 of the Act unless EPA approves subsequent SIP revisions that correct the rule deficiencies within 18 months. These sanctions would be imposed according to 40 CFR 52.31. A final disapproval would also trigger the federal implementation plan (FIP) requirement under section 110(c). Note that the submitted rules have been adopted by the BAAQMD, and EPA's final limited disapproval would not prevent the local agency from enforcing them.

We will accept comments from the public on the proposed limited approval and limited disapproval for the next 30 days.

III. Background Information

Why Were These Rules Submitted?

VOCs help produce ground-level ozone and smog, which harm human health and the environment. Section 110(a) of the CAA requires states to submit regulations that control VOC emissions. Table 2 lists some of the national milestones leading to the submittal of these local agency VOC rules.

TABLE 2.—OZONE NONATTAINMENT MILESTONES

Date	Event
March 3, 1978	EPA promulgated a list of ozone nonattainment areas under the Clean Air Act as amended in 1977. 43 FR 8964; 40 CFR 81.305.
May 26, 1988	EPA notified Governors that parts of their SIPs were inadequate to attain and maintain the ozone standard and requested that they correct the deficiencies (EPA's SIP-Call). See section 110(a)(2)(H) of the pre-amended Act.
November 15, 1990	Clean Air Act Amendments of 1990 were enacted. Pub. L. 101–549,104 Stat. 2399, codified at 42 U.S.C. 7401–7671q.
May 15, 1991	Section 182(a)(2)(A) requires that ozone nonattainment areas correct deficient RACT rules by this date.

IV. Administrative Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this proposed action is not a ''significant regulatory action'' and therefore is not subject to review by the Office of Management and Budget. For this reason, this proposed action is also not subject to Executive Order 32111, ''Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use'' (66 FR 28355, May 22, 2001). This proposed action merely approves state law as meeting federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this proposed rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 et seq.). Because this rule proposes to approve pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104–4). This rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This proposed rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant.

In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission

that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this proposed rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings' issued under the executive order. This proposed rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.).

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Hydrocarbons, Intergovernmental relations, Ozone, Reporting and recordkeeping requirements, Volatile organic compound.

Authority: 42 U.S.C. 7401 et seq.

Dated: July 24, 2001.

Jane Diamond,

Acting Regional Administrator, Region IX.

[FR Doc. 01–19323 Filed 8–1–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Parts 153 and 180

[OPP–301026; FRL–6598–4]

RIN 2070–AB18

Pesticide Chemicals Not Requiring a Tolerance or an Exemption from a Tolerance; Rhodamine B; Revocation of Unlimited Tolerance Exemptions

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA is proposing to create a new subpart E in 40 CFR part 180. This subpart will be titled Pesticide Chemicals Not Requiring a Tolerance or an Exemption from a Tolerance. It will contain a list of the pesticide chemicals (including, as appropriate, their limitations and use patterns) for which the Agency has determined that neither a tolerance nor an exemption from the requirement of a tolerance is needed under the Federal Food Drug and Cosmetic Act (FFDCA). This document also proposes to revoke two unlimited tolerance exemptions for the inert ingredient Rhodamine B. These tolerance exemptions were established under Section 408 of the FFDCA, 21 U.S.C. 346a. EPA is proposing to revoke these tolerances because all food-use products containing Rhodamine B have been voluntarily cancelled. Concurrent with the revocation of the two unlimited tolerances for Rhodamine B, the Agency is also proposing to designate the use of the inert (other) ingredient Rhodamine B as a dye for seed treatment only, a use for which neither a tolerance nor an exemption from the requirement of a tolerance is needed. This determination is based on the Agency's review and evaluation of submitted data, which indicated that there was no uptake of Rhodamine B when used as a dye for seed treatment. The Agency is acting on its own initiative. These regulatory actions are part of the tolerance reassessment requirements of the Federal Food, Drug, and Cosmetic Act (FFDCA) section 408(q), as amended by the Food Quality Protection Act (FQPA) of 1996. By law, EPA is required to reassess 66% of the tolerances in existence on August 2, 1996, by August 2002, or about 6,400 tolerances. The regulatory actions proposed in this document, the proposed revocation of two tolerance exemptions, would be counted toward the August 2002 deadline.

DATES: Comments, identified by docket control number OPP–301026, must be received on or before October 1, 2001.

ADDRESSES: Comments may be submitted by mail, electronically, or in person. Please follow the detailed instructions for each method as provided in Unit I. of the **SUPPLEMENTARY INFORMATION**. To ensure proper receipt by EPA, it is imperative that you identify docket control number OPP–301026 in the subject line on the first page of your response.

FOR FURTHER INFORMATION CONTACT: Kathryn Boyle, Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: 703–305–6304; fax number: 703–305–0599; e-mail address: boyle.kathryn@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

You may be potentially affected by this action if you are an agricultural producer, food manufacturer, or pesticide manufacturer. Potentially affected categories and entities may include, but are not limited to:

Categories	NAICS	Examples of Potentially Affected Entities
Industry	111	Crop production
	112	Animal production
	311	Food manufacturing
	32532	Pesticide manufacturing

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in this table could also be affected. The North American Industrial Classification System (NAICS) codes are provided to assist you and others in determining whether or not this action might apply to certain entities. If you have questions regarding the applicability of this action to a particular entity, consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. *Electronically*. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http://www.epa.gov/. To access this document, on the Home Page select ''Laws and Regulations,'' ''Regulations and Proposed Rules,'' and then look up the entry for this document under the ''**Federal Register**—Environmental Documents.'' You can also go directly to the **Federal Register** listings at http://www.epa.gov/fedrgstr/. A frequently updated electronic version of 40 CFR parts 153 and 180 are available at: http://www.access.gpo.gov/nara/cfr/cfrhtml_00/Title_40/40cfr153_00.html and http://www.access.gpo.gov/nara/cfr/cfrhtml_00/Title_40/40cfr180_00.html, respectively, a beta site currently under development.

2. *In person*. The Agency has established an official record for this action under docket control number OPP–301026. The official record consists of the documents specifically referenced in this action, any public comments received during an applicable comment period, and other information related to this action, including any information claimed as Confidential Business Information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in

those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period, is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Hwy., Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

C. How and to Whom Do I Submit Comments?

You may submit comments through the mail, in person, or electronically. To ensure proper receipt by EPA, it is imperative that you identify docket control number OPP–301026 in the subject line on the first page of your response.

1. *By mail*. Submit your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.

2. *In person or by courier*. Deliver your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall #2, 1921 Jefferson Davis Hwy., Arlington, VA. The PIRIB is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305–5805.

3. *Electronically*. You may submit your comments electronically by e-mail to: opp-docket@epa.gov, or you can submit a computer disk as described above. Do not submit any information electronically that you consider to be CBI. Avoid the use of special characters and any form of encryption. Electronic submissions will be accepted in WordPerfect 6.1/8.0 or ASCII file format. All comments in electronic form must be identified by docket control number OPP–301026. Electronic comments may also be filed online at many Federal Depository Libraries.

D. How Should I Handle CBI that I Want to Submit to the Agency?

Do not submit any information electronically that you consider to be CBI. You may claim information that you submit to EPA in response to this document as CBI by marking any part or all of that information as CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. In addition to one complete version of the comment that includes any information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public version of the official record. Information not marked confidential will be included in the public version of the official record without prior notice. If you have any questions about CBI or the procedures for claiming CBI, please consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

E. What Should I Consider as I Prepare My Comments for EPA?

You may find the following suggestions helpful for preparing your comments:

1. Explain your views as clearly as possible.
2. Describe any assumptions that you used.
3. Provide copies of any technical information and/or data you used that support your views.
4. If you estimate potential burden or costs, explain how you arrived at the estimate that you provide.
5. Provide specific examples to illustrate your concerns.
6. Offer alternative ways to improve the proposed rule or collection activity.
7. Make sure to submit your comments by the deadline in this document.
8. To ensure proper receipt by EPA, be sure to identify the docket control number assigned to this action in the subject line on the first page of your response. You may also provide the name, date, and **Federal Register** citation.

II. Background

A. What Action is the Agency Taking?

1. The Agency is creating in 40 CFR part 180 a new subpart E to be entitled Pesticide Chemicals Not Requiring a Tolerance or an Exemption from a Tolerance

Under the Federal Food, Drug, and Cosmetic Act (FFDCA), the Agency regulates pesticide chemicals in food by establishing tolerances or exemptions from the requirement of a tolerance. A pesticide chemical needs a tolerance or an exemption from the requirement of a tolerance if the pesticide is used in a manner which has a reasonable likelihood of producing residues in food. In practice, EPA presumes that a pesticide used on, in, or near growing crops, livestock or food has a reasonable likelihood of resulting in residues in or on food. However, there are instances when a pesticide chemical requires neither a tolerance nor an exemption from the requirement of a tolerance. These chemicals and uses have not been listed in 40 CFR part 180. However, to insure consistent treatment of such chemicals, EPA has decided to create this new subpart to contain these chemicals.

One of the uses of this new subpart will be to list pesticide chemicals that qualify under EPA's ''Threshold of Regulation Policy - Deciding Whether a Pesticide with a Food-Use Pattern Needs a Tolerance'' as announced in the **Federal Register** of October 27, 1999, (64 FR 57881) (FRL–6388–2). Under this policy, a tolerance or tolerance exemption is generally not needed if: (a) using a reliable and appropriately sensitive analytical method to measure residues in the commodity, no residues are detected in the commodity under expected conditions of use; and (b) using reasonably protective criteria, the estimated potential risk of any theoretically possible residues in food is not of concern.

Another of the uses of this subpart will be to list pesticide chemicals that are actually used in or on food crops, but that have been determined to not have a reasonable likelihood of producing residues in food (generally referred to as a ''non-food use''). An example of such a use would be inert ingredients such as dyes that are used in seed treatments. The determination that a seed treatment use is non-food is generally made after reviewing the results of a radio-labeled magnitude of the residue (uptake) study that can confirm that residues of the pesticide chemical will not be present at levels greater than 5 parts per billion (ppb).

Since seed treatment dyes can be included in this new subpart, minor revisions to 40 CFR 153.155(c) are also proposed. This section currently specifies that dyes used in seed treatment are contained in 40 CFR 180.1001 (c) and (d), and thus requires modifications to include the seed treatment uses that could be included in the proposed subpart E.

2. With the establishment of the new subpart E, EPA is proposing two amendments to its tolerance regulations. First, on its own initiative, the Agency is proposing that 40 CFR 180.1001 be amended by deleting in paragraphs (c) and (e) the current exemption from the requirement of a tolerance without limitation for residues of Rhodamine B (CAS No. 81–88–9). Second, again on its own initiative, EPA is proposing to

establish in the newly created subpart E the use of Rhodamine B as a dye for seed treatment only.

B. What is the Agency's Authority for Taking this Action?

This proposed rule is issued pursuant to section 408(e) of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a(e), as amended by the Food Quality Protection Act of 1996 (FQPA) (Public Law 104–170). Section 408(e) of FFDCA authorizes EPA to establish, modify, or revoke tolerances, and exemptions from the requirement of a tolerance for residues of pesticide chemicals in or on raw agricultural commodities and processed foods. Without a tolerance or tolerance exemption, food containing pesticide residues is considered to be unsafe and therefore ''adulterated'' under section 402(a) of the FFDCA. If food containing pesticide residues is found to be adulterated, the food may not be distributed in interstate commerce (21 U.S.C. 331(a) and 342(a).

For a pesticide to be sold and distributed, the pesticide must not only have the appropriate tolerances or tolerance exemptions under FFDCA, but also must be registered with EPA under section 3 or section 24 or approved by EPA under section 5 or section 18 (for a specific use pattern) of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), as amended by FQPA (7 U.S.C. 136 et. seq.) Registration is a licensing process in which EPA evaluates each proposed product, its uses, and its labeling to determine whether it meets the standard for registration in FIFRA. That standard states that, for a registration to be approved, EPA must determine that the pesticide product, when used in accordance with its intended uses and with widespread and commonly recognized practice, will not cause unreasonable adverse effects on the environment.

C. When do These Actions Become Effective?

EPA proposes that these actions become effective immediately following publication of the final rule in the **Federal Register**. The information available to the Agency indicates that all non-seed treatment food-use products containing Rhodamine B have been voluntarily canceled or reformulated using inert ingredients other than Rhodamine B. EPA believes that at the time of publication of the final rule in the **Federal Register** all existing stocks of non-seed treatment Rhodamine B products will have been exhausted for some time. Therefore, EPA believes the effective date proposed in this document should be reasonable. However, if EPA is presented with information that existing stocks would still be available for use after the expiration date and that information is verified, EPA will consider extending the expiration date of the tolerance exemption. If you have comments regarding existing stocks and whether the effective date accounts for these stocks, please submit comments as described under **SUPPLEMENTARY INFORMATION.**

D. What Is the Contribution to Tolerance Reassessment?

By law, EPA is required to reassess 66% or about 6,400 of the tolerances in existence on August 2, 1996, by August 2002. This proposed rule proposes to revoke two tolerance exemptions. Therefore, upon publication of the final rule, two tolerance reassessments will be counted toward the August 2002 review deadline of FFDCA section 408(q), as amended by FQPA in 1996.

III. Background of Use of Rhodamine B as a Dye for Seed-Treatment

Rhodamine B (xanthylium, 9-(2-carboxyphenyl)-3,6-bis(diethylamino)-,chloride, or Violet 10, or D&C Red No. 19) is a List 1 inert ingredient. The criteria used to place chemicals on List 1 were carcinogenicity; adverse reproductive effects, neurotoxicity or other chronic effects, or developmental toxicity. These effects should have been demonstrated in laboratory or human studies and the data subject to peer review. Rhodamine B is a carcinogen, and therefore met one of the criteria for classification as a List 1 inert ingredient.

A Data Call-In (DCI) Notice was issued in February 1993 requiring that registrants whose products contained Rhodamine B generate additional data to support continued registration of their products. In response to the 1993 DCI the Rhodamine B Seed Treatment Coalition was formed by member companies Gustafson LLC; Pioneer Hi-Bred International; Platte Chemical Co. Inc.; Trace Chemical Co. Inc.; Uniroyal Chemical Co., Inc; and Wilbur-Ellis Co. The Coalition's objective was to support the use of Rhodamine B for use as a dye for seed treatment only. Seed treatment dyes are used to distinguish pesticide-treated seeds that are sold/distributed in commerce from seeds used as food for humans or feed for animals. Generally the Agency assumes that a seed treatment use is a food-use, that is, the use is likely to result in residues in or on food.

The members of the Rhodamine B Seed Treatment Coalition submitted to the Agency a radiolabeled magnitude of the residue study in which Rhodamine B was used to dye seeds that were then planted and grown to harvest. The radiolabeled Rhodamine B was applied to the treated seed at both the proposed use rate and twice the proposed use rate. The Agency's review and evaluation of the study indicated that any residues of Rhodamine B present in the harvested edible portions of the food/feed would be at levels less than 1 ppb. This is less than the 5 ppb level that is generally used to define ''no uptake of residues''or a non-food use. Since there was no uptake of Rhodamine B in a radiolabeled residue study, there is no reasonable expectation of finite residues of Rhodamine B in food or feed crops resulting from the use of Rhodamine B as a dye in seed treatment. The Agency concludes that Rhodamine B when used as a dye in seed treatment is a non-food use, that is, the use is not likely to result in residues in food or feed. Therefore, neither a tolerance nor a tolerance exemption is needed.

Previously all dyes used in seed treatments were listed in 40 CFR 180.1001(c) and (d), which are listings of food-use inert ingredients that are exempted from the requirement of a tolerance. However, the determination that Rhodamine B when used as a seed treatment is unlikely to result in residues in food/feed, means that neither a tolerance nor a tolerance exemption is required. Previously, these chemicals and uses would not have been listed in 40 CFR part 180. However, to insure consistent treatment of such chemicals, EPA has decided to create subpart E to contain these chemicals and immediately populate the subpart with Rhodamine B with a limitation for use as a dye for seed treatment only.

IV. Regulatory Assessment Requirements

The Office of Management and Budget (OMB) has exempted these types of actions from review Under Executive Order 12866, entitled Regulatory Planning and Review (58 FR 51735, October 4, 1993), this action is not a ''significant regulatory action'' subject to review by the Office of Management and Budget (OMB).

This proposed rule does not contain any information collections subject to OMB approval under the Paperwork Reduction Act (PRA), 44 U.S.C. 3501 et seq., or impose any enforceable duty or contain any unfunded mandate as described under Title II of the Unfunded Mandates Reform Act of 1995 (UMRA) (Public Law 104–4). Nor does it require

any special considerations under Executive Order 12898, entitled *Federal Actions to Address Environmental Justice in Minority Populations and Low-Income Populations* (59 FR 7629, February 16, 1994); or OMB review or any Agency action under Executive Order 13045, entitled *Protection of Children from Environmental Health Risks and Safety Risks* (62 FR 19885, April 23, 1997). This action does not involve any technical standards that would require Agency consideration of voluntary consensus standards pursuant to section 12(d) of the National Technology Transfer and Advancement Act of 1995 (NTTAA), Public Law 104–113, section 12(d) (15 U.S.C. 272 note).

This proposed rule establishes a new subpart in the Code of Federal Regulations. Under section 605(b) of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et seq.), the Agency hereby certifies that the proposed action to reorganize 40 CFR part 180 will not have significant negative economic impact on a substantial number of small entities. Creating a new subpart does not have a substantive effect and hence causes no impact.

This proposed rule also revokes two tolerance exemptions, and establishes the use of Rhodamine B as a dye for seed treatment only. The revoked tolerance exemptions apply to pesticide products that have been voluntarily canceled or reformulated using inert ingredients other than Rhodamine B. EPA expects that any existing stocks of these products have been exhausted for some time. Pursuant to the Regulatory Flexibility Act, the Agency previously assessed whether revocations of tolerances or tolerance exemptions might significantly impact a substantial number of small entities and concluded that, as a general matter, these actions do not impose a significant economic impact on a substantial number of small entities. This analysis was published on December 17, 1997 (62 FR 66020), and was provided to the Chief Counsel for Advocacy of the Small Business Administration. Taking into account this analysis, and available information concerning the pesticide chemical (inert ingredient) listed in this rule, I certify that this action will not have a significant economic impact on a substantial number of small entities. Furthermore, the Agency knows of no extraordinary circumstances that exist as to the present revocation that would change EPA's previous analysis. Generally, when considering an active ingredient, as per the 1997 notice, EPA would review its available data on imports and foreign pesticide usage. These data bases (which focus on active ingredients) would then be used, as appropriate, to conclude that there is a reasonable international supply of food not treated with the canceled pesticide. Because these data are less readily available for inert ingredients, the finding for Rhodamine B is based primarily on the fact that the chemical has been replaced in U.S. registered pesticide products that previously contained Rhodamine B (except for seed treatments). Most likely, Rhodamine B has also been replaced in pesticides sold and used in foreign countries exporting food products to the United States. Given that Rhodamine B is a dye, and that substitution of one dye for another in pesticide products does not usually require a significant amount of reformulation effort, it remains appropriate to conclude that there is a reasonable international supply of food not treated with Rhodamine B.

In addition, the Agency has determined that this action will not have a substantial direct effect on States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132, entitled *Federalism* (64 FR 43255, August 10, 1999). Executive Order 13132 requires EPA to develop an accountable process to ensure ''meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications.'' ''Policies that have federalism implications'' is defined in the Executive Order to include regulations that have ''substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.'' This final rule directly regulates growers, food processors, food handlers and food retailers, not States. This proposed rule does not affect States directly. This action does not alter the relationships or distribution of power and responsibilities established by Congress in the preemption provisions of FFDCA section 408(n)(4).

For these same reasons, the Agency has determined that this rule does not have any ''tribal implications'' as described in Executive Order 13175, entitled *Consultation and Coordination with Indian Tribal Governments* (65 FR 67249, November 6, 2000). Executive Order 13175, requires EPA to develop an accountable process to ensure ''meaningful and timely input by tribal officials in the development of regulatory policies that have tribal implications.'' ''Policies that have tribal implications'' is defined in the Executive Order to include regulations that have ''substantial direct effects on one or more Indian tribes, on the relationship between the Federal government and the Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes.'' This rule will not have substantial direct effects on tribal governments, on the relationship between the Federal government and Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes, as specified in Executive Order 13175. Thus, Executive Order 13175 does not apply to this rule.

List of Subjects in 40 CFR Parts 153 and 180

Environmental protection, Administrative practice and procedure, Agricultural commodities, Pesticides and pests, Reporting and recordkeeping requirements.

Dated: June 19, 2001.

Marcia E. Mulkey,

Director, Office of Pesticide Programs.

Therefore, it is proposed that 40 CFR chapter I be amended as follows:

PART 153—[AMENDED]

1. The authority citation for part 153 would continue to read as follows:

Authority: 7 U.S.C. 136 et. seq.

2. Section 153.155(c) is revised to read as follows.

§ 153.155 Seed treatment products.

* * * * *

(c) EPA-approved dyes for seed treatment are listed in:

(1) Section 180.1001(c) and (d) if an exemption from the requirement of a tolerance has been established.

(2) Section 180.2010 if EPA has determined that residues of the dye will be present, if at all, at levels that are below the threshold of regulation.

(3) Section 180.2020 if EPA has determined that no tolerance or exemption from the requirement of a tolerance is needed as a result of a determination by EPA that the use is unlikely to result in residues in food/feed.

PART 180—[AMENDED]

1. The authority citation for part 180 would continue to read as follows:

Authority: 21 U.S.C. 321(q), 346(a) and 371.

§ 180.1001 [Amended]

2. In §180.1001 the tables in paragraphs (c) and (e) are amended by removing the entry for ''Rhodamine B''.

3. Part 180 is amended by adding new subpart E, entitled '' Pesticide Chemicals Not Requiring a Tolerance or an Exemption from a Tolerance'' to read as follows:

Subpart E—Pesticide Chemicals Not Requiring a Tolerance or an Exemption from a Tolerance

Sec.
180.2000 Scope.
180.2003 Definitions.
180.2010 Threshold of regulation determinations. [Reserved]
180.2020 Non-food determinations.

§ 180.2000 Scope.

This subpart sets forth the pesticide chemicals for use in agricultural or other food-related settings for which neither a tolerance nor an exemption is deemed to be needed by EPA.

§ 180.2003 Definitions.

(a) ''Food uses'' are the uses of a pesticide chemical that are likely to yield residues in food or feed crops, meat, milk, poultry or eggs.

(b) ''Non-food uses'' are those uses that are not likely to yield residues in food or feed crops, meat, milk, poultry or eggs.

§ 180.2010 Threshold of regulation determinations. [Reserved]

§ 180.2020 Non-food determinations.

The following pesticide chemical uses do not need a tolerance or exemption from the requirement of a tolerance based on EPA's determination that they do not result in residues in or on food.

Pesticide Chemical	CAS Reg. No.	Limits	Uses
Rhodamine B	81–88–9	Not to exceed 2% by weight of the formulated product and 60 ppm on the treated seed..	dye for seed treatment

[FR Doc. 01–19327 Filed 8–1–01; 8:45 a.m.]
BILLING CODE 6560–50–S

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA 01–1770, MM Docket No. 01–160, RM–10159]

Digital Television Broadcast Service; Albuquerque, NM

AGENCY: Federal Communications Commission.

ACTION: Proposed rule.

SUMMARY: The Commission requests comments on a petition filed by ACME Television Licenses of New Mexico, LLC, licensee of station KASY–TV, NTSC channel 50, Albuquerque, New Mexico, requesting the substitution of DTV channel 45 for station KASY–TV's assigned DTV channel 51c. DTV Channel 45 can be allotted to Albuquerque, New Mexico, in compliance with the principle community coverage requirements of Section 73.625(a) at reference coordinates (35–12–48 N. and 106–27–00 W.). As requested, we propose to allot DTV Channel 45 to Albuquerque with a power of 245 and a height above average terrain (HAAT) of 1287 meters.

DATES: Comments must be filed on or before September 17, 2001, and reply comments on or before October 2, 2001.

ADDRESSES: Federal Communications Commission, 445 12th Street, SW., Room TW–A325, Washington, DC 20554. In addition to filing comments with the FCC, interested parties should serve the petitioner, or its counsel or consultant, as follows: Harold K. McCombs, Dickstein, Shapiro, Morin & Oshinsky, LLP, 2101 L Street NW., Washington, DC 20037 (Counsel for ACME Television Licenses of New Mexico, LLC).

FOR FURTHER INFORMATION CONTACT: Pam Blumenthal, Mass Media Bureau, (202) 418–1600.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's Notice of Proposed Rule Making, MM Docket No. 01–160, adopted July 24, 2001, and released July 27, 2001. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC Reference Center 445 12th Street, SW., Washington, DC. The complete text of this decision may also be purchased from the Commission's copy contractor, International Transcription Services, Inc., (202) 857–3800, 1231 20th Street, NW., Washington, DC 20036.

Provisions of the Regulatory Flexibility Act of 1980 do not apply to this proceeding.

Members of the public should note that from the time a Notice of Proposed Rule Making is issued until the matter is no longer subject to Commission consideration or court review, all *ex parte* contacts are prohibited in Commission proceedings, such as this one, which involve channel allotments. See 47 CFR 1.1204(b) for rules governing permissible *ex parte* contacts.

For information regarding proper filing procedures for comments, see 47 CFR 1.415 and 1.420.

List of Subjects in 47 CFR Part 73

Television, Digital television broadcasting.

For the reasons discussed in the preamble, the Federal Communications Commission proposes to amend 47 CFR part 73 as follows:

PART 73—TELEVISION BROADCAST SERVICES

1. The authority citation for part 73 continues to read as follows:

Authority: 47 U.S.C. 154, 303, 334, and 336.

§ 73.622 [Amended]

2. Section 73.622(b), the Table of Digital Television Allotments under New Mexico is amended by removing DTV Channel 51c and adding DTV Channel 45 at Albuquerque.

Federal Communications Commission.

Barbara A. Kreisman,

Chief, Video Services Division, Mass Media Bureau.

[FR Doc. 01–19243 Filed 8–1–01; 8:45 am]
BILLING CODE 6712–01–P

DEPARTMENT OF TRANSPORTATION

Research and Special Programs Administration

49 CFR Parts 171, 173, 174, 175, 176, 177, and 178

[Docket No. RSPA–98–4952 (HM–223)]

RIN 2137–AC68

Applicability of the Hazardous Materials Regulations to Loading, Unloading, and Storage; Extension of Comment Period and Announcement of Public Meetings

AGENCY: Research and Special Programs Administration (RSPA), DOT.

ACTION: Proposed rule; extension of time to file comments and public meeting announcement.

SUMMARY: On June 14, 2001, RSPA published a notice of proposed rulemaking to clarify the applicability of the Hazardous Materials Regulations to specific functions and activities, including hazardous materials loading, unloading, and storage operations. We are extending until November 30, 2001, the period for filing comments to the proposed rule. In addition, we are conducting two public meetings to facilitate public comment on the proposed rule. One public meeting is scheduled for September 14, 2001, in Washington, DC; a second public meeting is scheduled for October 30, 2001, in Diamond Bar, California.

DATES: *Comments.* Submit comments by November 30, 2001. To the extent possible, we will consider comments received after this date in making our decision on a final rule.

Public Meeting Dates. Two public meetings will be held—one on September 14, 2001, from 8:30 a.m. to 5:30 p.m. and another on October 30, 2001, from 9 a.m. to 5 p.m.

ADDRESSES: *Written comments.* Submit comments to the Dockets Management System, U.S. Department of Transportation, Room PL 401, 400 Seventh Street, SW., Washington, DC 20590–0001. Comments should identify Docket Number RSPA–98–4952 (HM–223) and be submitted in two copies. If you wish to receive confirmation of receipt of your written comments, include a self-addressed, stamped postcard. You may also e-mail comments by accessing the Dockets Management System web site at ''http://dms.dot.gov/'' and following the instructions for submitting a document electronically.

The Dockets Management System is located on the Plaza level of the Nassif Building at the Department of Transportation at the above address. You can review public dockets there between the hours of 9:00 a.m. and 5:00 p.m., Monday through Friday, except federal holidays. You can also review comments on-line at the DOT Dockets Management System web site at ''http://dms.dot.gov/.''

Public Meetings. The September 14, 2001 public meeting will be held in Washington, DC in the Auditorium, Federal Aviation Administration National Headquarters, 800 Independence Avenue, SW., Washington, DC 20591. The October 30, 2001 public meeting will be held at the Headquarters Building, South Coast Air Quality Management, 21865 East Copley Drive, Diamond Bar, California 91765. For information on facilities or services for persons with disabilities or to request special assistance at the meetings, contact Mr. Michael Johnsen at 202–366–8553 as soon as possible.

FOR FURTHER INFORMATION CONTACT: Michael Johnsen (202) 366–8553, Office of Hazardous Materials Standards, Research and Special Programs Administration; or Susan Gorsky (202) 366–8553, Office of Hazardous Materials Standards, Research and Special Programs Administration. If you wish to speak at one of the public meetings, you should contact Mr. Johnsen.

SUPPLEMENTARY INFORMATION:

Background

On June 14, 2001, the Research and Special Programs Administration (RSPA, we) published a notice of proposed rulemaking (NPRM) (66 FR 32420) under Docket RSPA–98–4952 (HM–223) to clarify the applicability of the Hazardous Materials Regulations (HMR; 49 CFR Parts 171–180) to specific functions and activities, including hazardous materials loading and unloading operations and storage of hazardous materials during transportation. The HM–223 rulemaking has four overall goals. First, we want to maintain nationally uniform standards applicable to functions performed in advance of transportation to prepare hazardous materials for transportation. Second, we want to maintain nationally uniform standards applicable to transportation functions. Third, we want to distinguish functions that are subject to the HMR from functions that are not subject to the HMR. Finally, we want to clarify that facilities within which HMR-regulated functions are performed may also be subject to federal, state, or local regulations governing occupational safety and health or environmental protection.

To achieve these goals, the NPRM proposes to list in the HMR pre-transportation and transportation functions to which the HMR apply. Pre-transportation functions are functions performed to prepare hazardous materials for movement in commerce by persons who offer a hazardous material for transportation or cause a hazardous material to be transported. Transportation functions are functions performed as part of the actual movement of hazardous materials in commerce, including loading, unloading, and storage of hazardous materials that is incidental to their movement. The NPRM also proposes to clarify that ''transportation in commerce,'' for purposes of applicability of the HMR, begins when a carrier takes possession of a hazardous material and continues until the carrier delivers the package containing the hazardous material to its destination as indicated on shipping papers. In addition, the NPRM proposes to include in the HMR an indication that facilities at which functions regulated by the HMR occur may also be subject to applicable standards and regulations of other federal agencies and state, local, and tribal governments. Finally, the NPRM proposes to include in the HMR the statutory criteria under which non-federal governments may be precluded from regulating in certain areas under the preemption provisions of the federal hazardous materials transportation law (49 U.S.C. 5101 *et seq.*)

Public Meetings

To facilitate public comment on the NPRM, we are hosting two public meetings to discuss the proposed changes. The first public meeting is scheduled for September 14, 2001, in Washington, DC. The second public meeting will be in Diamond Bar, California, on October 30, 2001. To allow sufficient time to conduct the meetings and for interested parties to submit comments on the NRPM after the public meetings, we are extending the comment period until November 30, 2001.

The public meetings will provide an informal forum for interested persons to offer comments on the HM–223 NPRM. A transcript for each meeting will be prepared and submitted to the HM–223 docket. We anticipate significant public interest in this rulemaking; therefore, we ask that you limit your remarks to 10 minutes to assure that all participants have an opportunity to speak. The meetings may conclude earlier than scheduled if all persons wishing to offer comments have been heard.

If you plan to submit a written statement, you should submit 5 copies of the statement at the meeting. If you wish to speak at one of the public meetings, please contact Michael Johnsen at 202–366–8553 as soon as possible.

Issued in Washington, DC on July 30, 2001.

Robert A. McGuire,

Associate Administrator for Hazardous Materials Safety, Research and Special Programs Administration.

[FR Doc. 01–19335 Filed 8–1–01; 8:45 am]

BILLING CODE 4910–60–P

DEPARTMENT OF TRANSPORTATION

National Highway Traffic Safety Administration

49 CFR Part 571

[DOT Docket No. NHTSA–01–9765]

RIN 2127–AE59

Federal Motor Vehicle Safety Standards; Radiator and Coolant Reservoir Caps, Venting of Motor Vehicle Coolant Systems

AGENCY: National Highway Traffic Safety Administration (NHTSA), DOT.

ACTION: Extension of comment period for a notice of proposed rulemaking (NPRM).

SUMMARY: This document extends the comment period on an NPRM that proposed a new Federal motor vehicle safety standard regulating new radiator caps and coolant reservoir caps, and new passenger cars, multipurpose passenger vehicles and light trucks with such caps. We are taking this action in response to a petition from the Alliance of Automobile Manufacturers.

DATES: Comments on DOT Docket No. NHTSA–01–9765 must be received by September 28, 2001.

ADDRESSES: Comments should refer to DOT Docket No. NHTSA–01–9765 and be submitted to: Docket Management, Room PL–401, 400 Seventh Street, SW., Washington, DC, 20590.

You may call the Docket at 202–366–9324. You may visit the Docket from 10 a.m. to 5 p.m., Monday through Friday, except on Federal holidays.

FOR FURTHER INFORMATION CONTACT: For non-legal issues, you may call Mr. Kenneth O. Hardie, Office of Crash Avoidance Standards at (202) 366–6987. His FAX number is (202) 493–2739.

For legal issues, you may call Ms. Dorothy Nakama, Office of the Chief Counsel at (202) 366–2992. Her FAX number is (202) 366–3820.

You may send mail to both of these officials at National Highway Traffic Safety Administration, 400 Seventh St., SW., Washington, DC, 20590.

SUPPLEMENTARY INFORMATION: On June 1, 2001, we (NHTSA) published in the **Federal Register** (66 FR 29747) a notice of proposed rulemaking proposing a new Federal motor vehicle safety standard regulating new radiator caps and coolant reservoir caps, and new passenger cars, multipurpose passenger vehicles and light trucks with such caps. We stated our belief that the new standard, if implemented, would result in fewer scald injuries that occur when people attempt to remove caps from motor vehicle radiators or coolant reservoirs that are under high pressure and contain hot fluids. However, the rulemaking would not require that radiator caps or coolant reservoir caps be provided on any motor vehicle. The NPRM had a comment due date of July 31, 2001.

In a letter dated July 2, 2001, the Alliance of Automobile Manufacturers (the Alliance) petitioned us for an extension of the comment period. Members of the Alliance include BMW Group, DaimlerChrysler, Fiat, Ford Motor Company, General Motors, Isuzu, Mazda, Mitsubishi Motors, Nissan, Porsche, Toyota, Volkswagen, and Volvo. The letter stated that the Alliance ''has conducted a preliminary review of the Radiator and Coolant Reservoir Caps, Venting of Motor Vehicle Coolant Systems—Notice of Proposed Rulemaking'' and asked for an additional 30 days to comment on the NPRM.

The Alliance gave two reasons for why it needed the extra time. First, during the ''critical time'' before which the comments are due, some Alliance members will be ''on extended shutdown'' and would therefore not be able to sufficiently participate in the formulation of the Alliance's comments. Second, the Alliance noted that the NPRM and Preliminary Regulatory Evaluation both reference testing that we had conducted at NHTSA's Vehicle Research and Test Center (VRTC) in East Liberty, Ohio. Although the NPRM said that the test data would be docketed, as of July 2, 2001, the test data were not yet available for public inspection.

Because we agree with the Alliance that test results should be available to persons wishing to comment on the NPRM, we have decided that it is in the public interest to grant the petitioner's request. The test results are on videotape and will be available for review at: NHTSA/FHWA National Crash Analysis Center, George Washington University (GWU), VIRGINIA CAMPUS 20101 Academic Way, NCAC Library, Ashburn, VA 20147.

Because it cannot be scanned, this videotape is not available for review through the on-line DOT Docket Management System web site. We are in the process of making arrangements with GWU to ensure public accessibility to the videotape. When public access is assured, we will post a notice of ''Availability of Non-Scannable Items'' in DOT Docket No. NHTSA–01–9765. GWU contact persons for the videotape are Ms. K.D. Agrali or Ms. Jenni Behrs, GWU Film Technicians. Their telephone number is: (703) 726–8236.

We realize that it may take some interested parties additional time to go to GWU's Ashburn campus to review the videotape, and have therefore decided to allow more time for public comment than that requested by the Alliance. Accordingly, the public comment closing date for DOT Docket NHTSA–01–9765 is extended from July 31, 2001 to Friday, September 28, 2001.

Authority: 49 U.S.C. 322, 30111, 30115, 30117, and 30166; delegation of authority at 49 CFR 1.50.

Issued on: July 27, 2001.

Stephen R. Kratzke,

Associate Administrator for Safety Performance Standards.

[FR Doc. 01–19236 Filed 7–30–01; 10:06 am]

BILLING CODE 4910–59–P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 223

[Docket No. 010723187–1187–01, I.D. 061101I]

RIN 0648–AP33

Threatened Fish and Wildlife; Status Review of the Gulf of Maine/Bay of Fundy Population of Harbor Porpoise under the Endangered Species Act (ESA)

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of preliminary determination; draft status review; request for comments.

SUMMARY: The National Marine Fisheries Service (NMFS) conducted a status review of the Gulf of Maine/Bay of Fundy (GOM/BOF) stock of harbor porpoise (*Phocoena phocoena*). Based on analysis of the best scientific and commercial data available, as required by the Endangered Species Act (ESA), NMFS has made a preliminary determination that listing is not warranted at this time and intends to remove this stock from the ESA candidate species list. This document requests comments on the draft status review.

DATES: Comments must be received on or before 5 pm EST September 4, 2001.

ADDRESSES: Comments on this action should be sent to: Chief, Marine Mammal Division, National Marine

Fisheries Service, 1315 East-West Highway, Silver Spring, MD 20910.

FOR FURTHER INFORMATION CONTACT: Emily Hanson, Office of Protected Resources, 301–713–2322 ext. 101; Kim Thounhurst, Northeast Region, 978–281–9138; or Diane Borggaard, Southeast Region, 727–570–5312. Individuals who use a telecommunications device for the deaf may call the Federal Information Relay Service at 1–800–877–8339 between 8 a.m. and 4 p.m. Eastern time, Monday through Friday, excluding Federal holidays.

SUPPLEMENTARY INFORMATION:

Background of ESA Actions

On September 18, 1991, the Sierra Club Legal Defense Fund, on behalf of the International Wildlife Coalition and 12 other organizations, submitted a petition to list the harbor porpoise as threatened under the Endangered Species Act (ESA). NMFS published a notice of receipt of petition to list the GOM/BOF stock as threatened on December 13, 1991 (56 FR 65044). On January 7, 1993, NMFS published a proposed rule to list the GOM/BOF stock of harbor porpoise as threatened under the ESA (58 FR 3108). The proposed listing was based on information demonstrating that: (a) the rate of bycatch of harbor porpoise in commercial gillnet fisheries (extending from the Bay of Fundy, Canada, south throughout the Gulf of Maine) might reduce this population to the point where it would become threatened throughout all or a portion of its range; and, (b) there were no regulatory measures in place to reduce this bycatch. NMFS extended the comment period on the proposed rule until August 7, 1993 (58 FR 17569, April 5, 1993) to hold public hearings. On November 8, 1993 (58 FR 59230), the date for the final determination on the proposal to list was extended for six months to allow for further data collection and analyses about harbor porpoise stock structure. On July 15, 1994, NMFS reopened the comment period for 30 days to allow for public comment on the new analyses (59 FR 36158).

The New England Harbor Porpoise Working Group (HPWG), an informal stakeholder group, met on July 21, 1994, to discuss harbor porpoise bycatch and the ESA listing proposal. As a result of the concerns expressed at that meeting, NMFS again extended the comment period on the proposed rule until September 11, 1994 (59 FR 41270). At that time, NMFS also decided to wait for the 1995 bycatch data prior to proceeding with a listing determination.

NMFS had not yet made a final determination when, in 1996, Congress imposed a 1–year moratorium on listing species under the ESA. During 1997 and 1998, NMFS kept the listing issue under review in light of new population abundance and bycatch data, ongoing New England Fishery Management Council (NEFMC) and NMFS fishery management efforts to reduce harbor porpoise bycatch, and the Marine Mammal Protection Act (MMPA) Section 118 Take Reduction Team (TRT) process established pursuant to the 1994 amendments to the MMPA.

On October 22, 1998, NMFS reopened the comment period on the proposed rule to list the GOM/BOF harbor porpoise as a threatened species under the ESA (63 FR 56596). This action was taken because of the amount of time that had passed since the close of the previous comment period and to allow for the review of the best scientific information available.

The listing determination was also the subject of litigation with the Center for Marine Conservation, the Humane Society of the United States, and the International Wildlife Coalition (*Center for Marine Conservation et al.*v. *Daley et al.*, Civ. No. 1:98CV02029 EGS). In the settlement agreement arising from this litigation, NMFS agreed to make a final listing determination by January 4, 1999. Upon consideration of comments received on the proposed rule published in October 1998, review of the best available data, and implementation of the Harbor Porpoise Take Reduction Plan (HPTRP), NMFS determined that listing of the GOM/BOF population of harbor porpoise as threatened under the ESA was not warranted. On January 5, 1999, NMFS withdrew the proposal to list the GOM/BOF population of harbor porpoise as threatened under the ESA (64 FR 465). On January 5, 1999, NMFS also published a notice retaining the GOM/BOF population of harbor porpoise on the ESA list of candidate species (64 FR 480).

Pursuant to the settlement agreement in *Center for Marine Conservation et al.* v. *Daley et al.*, in the event that NMFS determined not to list harbor porpoise under the ESA, NMFS agreed to commence a review of the biological status of the GOM/BOF harbor porpoise population on or before March 31, 2001, and to consider the need to publish a proposal to list the population based on the review at that time. On March 29, 2001, NMFS published a **Federal Register** notification announcing the commencement of the status review and requesting information (66 FR 17150).

The settlement agreement also requires that NMFS make the draft status review available for a 30–day public comment period on or before July 31, 2001. This document complies with that requirement.

This status review focuses on new information and analyses available since publication of the January 5, 1999, withdrawal of the proposed rule. For detailed information on the data and analyses prior to January 5, 1999, refer to the Federal Register publications cited above. Additionally, detailed information about the GOM/BOF stock of harbor porpoise is available in NMFS U.S. Atlantic and Gulf of Mexico Marine Mammal Stock Assessment Reports.

Species Status and Factors Affecting the Species

For this status review and the preliminary determination not to list the GOM/BOF harbor porpoise under the ESA, NMFS considered stock definition information, population abundance, bycatch data, NEFMC/NMFS ongoing fishery management efforts to reduce harbor porpoise bycatch, and progress in bycatch reduction under the Harbor Porpoise Take Reduction Plan (HPTRP) since the January 5, 1999, withdrawal of the proposed rule to list the GOM/BOF population as threatened under the ESA.

Stock Definition

Gaskin (1984, 1992) proposed that there were four separate populations of harbor porpoise in the western North Atlantic: the Gulf of Maine/Bay of Fundy population; the Gulf of St. Lawrence population; the Newfoundland population; and the Greenland population. Analyses involving mitochondrial DNA (Wang, *et al.* 1996; Rosel, *et al.* 1999a; Rosel, *et al.* 1999b), organochlorine contaminants (Westgate, *et al.* 1997; Westgate and Tolley, 1999), heavy metals (Johnston, 1995), and life history parameters (Read and Hohn, 1995) support Gaskin's proposal. Genetic studies using mitochondrial DNA (Rosel, *et al.* 1999a) and contaminant studies using total PCBs (Westgate and Tolley, 1999) suggest that female Gulf of Maine/Bay of Fundy harbor porpoises are distinct from females from the other populations in the Northwest Atlantic. Studies comparing mitochondrial DNA (Rosel, *et al.* 1999a; Palka, *et al.* 1996) and CHLORs, DDTs, PCBs and CHBs (Westgate and Tolley, 1999) indicate that male Gulf of Maine/Bay of Fundy harbor porpoises are distinct from Newfoundland and Greenland males, but not from Gulf of St. Lawrence males. Analyses of stranded animals from the

Mid-Atlantic states suggest that the Mid-Atlantic aggregation of harbor porpoises includes the Gulf of Maine/Bay of Fundy stock and other stocks (Rosel, *et al.* 1999a). However, the majority of the samples used in the Rosel, et al. (1999a) study were from stranded juvenile animals. Further work is underway to examine adult animals from the Mid-Atlantic region.

Nuclear microsatellite markers have also been applied to samples from the four populations, but failed to detect significant population sub-division in either males or females (Rosel, *et al.* 1999a). This pattern may be indicative of female philopatry coupled with dispersal of male harbor porpoises.

Analyses since the 1998 status review continue to support the hypothesis of four separate populations of harbor porpoise in the western North Atlantic.

Abundance

To estimate the population size of harbor porpoises in the Gulf of Maine/Bay of Fundy region, four line-transect sighting surveys were conducted during the summers of 1991, 1992, 1995, and 1999. The abundance estimates were 37,500 harbor porpoises in 1991 [CV=0.29 and 95-percent confidence interval (CI)=26,700–86,400] (Palka, 1995a); 67,500 harbor porpoises in 1992 (CV=0.23 and 95–percent CI=32,900–104,600) (Palka, 1996); 74,000 harbor porpoises in 1995 (CV=0.20 and 95–percent CI=40,900–109,100) (Palka, 1996); and 89,700 harbor porpoises in 1999 (CV=0.22 and 95–percent CI=53,400–150,900) (Palka, 2000). The inverse variance weighted-average abundance estimate (Smith, *et al.* 1993) of the 1991 to 1995 estimates was 54,300 harbor porpoises (CV=0.14 and 95–percent CI=41,300-71,400). Possible reasons for inter-annual differences in abundance and distribution include experimental error, inter-annual changes in water temperature and availability of primary prey species (Palka, 1995b), and movement among population units (e.g., between the Gulf of Maine and Gulf of St. Lawrence). The upper Bay of Fundy and northern Georges Bank were surveyed in 1999, but not in earlier surveys. Harbor porpoises were observed in the upper Bay of Fundy and northern George's Bank areas, and therefore the expansion of the survey into these two areas may account for some or all of the increase in the 1999 abundance estimate (Palka, 2000).

The best abundance estimate of the Gulf of Maine/Bay of Fundy harbor porpoise stock is 89,700 (CV=0.22) animals. The 1999 estimate is considered to be the best available because it is the most current and because the 1999 survey discovered portions of the harbor porpoise range not covered in previous surveys.

Analyses are underway to determine whether information necessary to detect a trend in abundance can be obtained from the four NMFS surveys. Until such a trend can be identified, it is not possible to state conclusively that the abundance of this stock has increased during any time in the survey period.

Potential Biological Removal (PBR) Level

The PBR level is the product of minimum population size, one-half the maximum net productivity rate, and a ''recovery'' factor (MMPA Sec. 3. 16 U.S.C. 1362, Wade and Angliss, 1997). Based on the 1999 survey, NMFS has increased the value for the minimum population size to 74,695 (CV=0.22) in the draft 2001 Stock Assessment Report (SAR), currently undergoing public review (66 FR 30706, June 7, 2001). The maximum net productivity rate is 0.04, the default value for cetaceans. The ''recovery'' factor, which accounts for endangered, depleted, threatened stocks, or stocks of unknown status relative to optimum sustainable population (OSP) is assumed to be 0.5 because this stock is of unknown status. Due to the increased minimum population estimate, NMFS has also increased the PBR for the GOM/BOF harbor porpoise stock from 483 to 747 in the draft 2001 SAR. NMFS is using a PBR of 747 for the purposes of this status review.

Human-Caused Mortality

The U.S. average annual mortality estimate prior to implementation of the HPTRP (1994-1998) was 1,521 (CV=0.10) harbor porpoises from U.S. fisheries and 57 harbor porpoises from Canadian fisheries. GOM/BOF harbor porpoise takes have been documented in the U.S. Northeast sink gillnet and Mid-Atlantic coastal gillnet fisheries and in the Canadian Bay of Fundy sink gillnet and herring weir fisheries. Data to estimate the mortality and serious injury of harbor porpoise comes from U.S. and Canadian Sea Sampling Programs and from records of strandings in U.S. waters. Implementation of the HPTRP and related Fishery Management Plan (FMP) restrictions changed the U.S. gillnet fisheries substantially, and therefore only mortality estimates for 1999 and 2000, which represents the time since implementation of the HPTRP and FMP restrictions, are included in this analysis. The total annual estimated average human-caused mortality for 1999 is 366 harbor porpoises, derived from the following four components: 323 harbor porpoises (CV=0.25) from U.S. fisheries using observer data; approximately 20 harbor porpoises (preliminary estimate with unknown CV) from Canadian fisheries using observer data; 19 harbor porpoises from unknown U.S. fisheries using strandings data; 1 harbor porpoise from unknown human-caused mortality in the U.S. (a mutilated stranded harbor porpoise); and 3 documented mortalities from Canadian herring weirs.

A preliminary estimate of harbor porpoise bycatch in U.S. fisheries for 2000 indicates that 529 harbor porpoises were taken in the U.S. fisheries in 2000, including 507 (CV=0.37) estimated takes from the Northeast sink gillnet fishery, 21 (CV=0.76) estimated takes from the Mid-Atlantic coastal gillnet fishery, and 1 take from an unknown fishery as indicated by stranding data.

The 2000 harbor porpoise bycatch estimate for Canadian fisheries is not available at this time. However, preliminary raw data indicate that in 549 gillnets observed, 8 harbor porpoises were observed taken.

Population Viability Analysis

The analysis performed by Wade (1998) and presented in the October 22, 1998, proposed rule was updated using new estimates of abundance and mortality for the GOM/BOF harbor porpoise stock. Using the 1999 survey abundance estimate (89,700 animals) and the 1999 mortality estimate (366 animals), there was no chance of extinction (0.0) in 100 years. A summary of parameter values and distributions used in the simulations and results of the analysis can be found in Wade (2001).

Summary of ESA Factors Affecting the Species

Endangered Species Act Listing Criteria

As defined in 50 CFR 424.02 of the regulations implementing the ESA, an ''endangered species'' is a species that is in danger of extinction throughout all or a significant portion of its range. Similarly, a ''threatened species'' is a species that is likely to become an endangered species within the foreseeable future throughout all or a significant portion of its range. As described in section 4(a)(1) of the ESA, the Secretaries of Commerce or Interior determine whether any species is an endangered species or threatened species because of any of the following factors: (A) The present or threatened destruction, modification, or curtailment of its habitat or range; (B) overutilization for commercial,

recreational, scientific, or educational purposes; (C) disease or predation; (D) the inadequacy of existing regulatory mechanisms; or (E) other natural or manmade factors affecting its continued existence. These factors are discussed here, as they apply to the GOM/BOF population of harbor porpoise, in light of information that has become available since the January 5, 1999, withdrawal of the proposal to list the species as threatened.

A. The Present or Threatened Destruction, Modification, or Curtailment of Habitat or Range

The GOM/BOF stock of harbor porpoise is found in U.S. and Canadian Atlantic waters. During the summer (July to September), harbor porpoise are concentrated in the northern Gulf of Maine and southern Bay of Fundy region, generally in waters less than 150 meters deep (Gaskin 1977; Kraus *et al.* 1983; Palka 1995 a,b). During fall (October to December) and spring (April to June), harbor porpoise are widely dispersed from New Jersey to Maine, with lower densities farther north and south. They are seen from the coastline to deep waters (≤1800 meters; Westgate et al. 1998), although the majority of the population is found over the continental shelf. During the winter (January to March), intermediate densities of harbor porpoise can be found in waters off New Jersey to North Carolina, and lower densities are found in waters off New York to New Brunswick, Canada.

Although the shoreline bordering the nearshore habitat of harbor porpoise along the eastern U.S. coastline is developed in many areas and may have affected coastal habitat, there is no new or additional evidence to indicate that shoreline development has affected the habitat of harbor porpoise in a manner that has contributed to a decline of the GOM/BOF population or that the range of this species has changed significantly as a result of shoreline development or change in coastal habitat.

B. Overutilization for Commercial, Recreational, Scientific, or Educational Purposes

This section discusses serious injury/mortality of harbor porpoise incidental to the operation of the Northeast sink gillnet and Mid-Atlantic coastal gillnet fisheries, unknown U.S. fisheries as suggested by stranding data, the Canadian Bay of Fundy groundfish gillnet and herring weir fisheries, and takes that may have occurred incidental to scientific research activities. It is unknown whether lethal takes of harbor porpoises are occurring incidental to recreational fishing activities. Detailed information about human-caused mortality to harbor porpoise is available in the GOM/BOF Harbor Porpoise chapter of the U.S. Atlantic and Gulf of Mexico Marine Mammal Stock Assessment Reports for 2000 and draft report for 2001.

Northeast Sink Gillnet Fishery

Before 1998, most of the documented harbor porpoise takes from U.S. fisheries were from the Northeast sink gillnet fishery. Prior to the present Sea Sampling Program and fishing effort reporting, Gilbert and Wynne (1985, 1987), using rough estimates of fishing effort, calculated that a maximum of 600 harbor porpoises were killed annually in this fishery in the Gulf of Maine. NMFS started an observer program in 1990 to investigate marine mammal takes in the Northeast sink gillnet fishery. Summing all years, there were 452 harbor porpoise mortalities observed in this fishery between 1990 and 2000 and one animal released alive and uninjured. Estimated annual bycatch (CV in parentheses) from those observed takes in this fishery during 1990-1998 was 2,900 in 1990 (0.32); 2,000 in 1991 (0.35); 1,200 in 1992 (0.21); 1,400 in 1993 (0.18) (Bravington and Bisack, 1996; CUD 1994); 2,100 in 1994 (0.18); 1,400 in 1995 (0.27) (Bisack, 1997a); 1,200 (0.25) in 1996; 782 (0.22) in 1997; and 332 (0.46) in 1998. (The increase in the 1998 CV is assumed to result from the small number of observed takes.)

Average estimated harbor porpoise mortality and serious injury in the Northeast sink gillnet fishery before implementation of the Take Reduction Plan was 1,163 (0.11) animals per year. In 1999 and 2000, estimates of harbor porpoise serious injury and mortality were 270 animals (CV=0.28) and 507 animals (CV=0.37), respectively. The 2-year average estimate of serious injury/mortality for this fishery is 389 animals (CV=0.26) per year.

Mid-Atlantic Coastal Gillnet Fishery

NMFS started an observer program in the Mid-Atlantic coastal gillnet fishery in July of 1993. This fishery, which extends from North Carolina to New York, is a combination of small vessel fisheries that target a variety of fish species. No harbor porpoises were observed taken in the Mid-Atlantic coastal gillnet fishery during 1993 and 1994. From 1995 through 2000, 114 harbor porpoises were observed taken in this fishery. Annual average estimated harbor porpoise mortality and serious injury from the Mid-Atlantic coastal gillnet fishery before implementation of the HPTRP (1995-1998) was 358 animals (CV=0.20). In 1999 and 2000, the estimated harbor porpoise serious injury and mortality attributable to this fishery was 53 animals (CV=0.49) and 21 animals (CV=0.76), respectively. The 2-year average estimate of serious injury/mortality for this fishery is 37 animals (CV=0.41) per year. New genetic data indicate that more than one population of harbor porpoise occurs in the mid-Atlantic in the winter; therefore, it is possible that some of the takes are not from the GOM/BOF stock of harbor porpoise.

Unknown Fishery

The NMFS strandings and entanglement database contains 228 reports of stranded harbor porpoises during 1999. The stranded carcasses were examined for signs of fishery interaction and other human impacts. Of the animals for which a determination could be made, evidence of fishery interaction involving gillnet gear was found on 38. Of the 38 fishery-interaction strandings, it was determined that 19 were in areas and times that were not included in mortality estimates derived from observer data. Twenty-six harbor porpoise mortalities were reported from the database in 2000. Of these 26, it was determined that the cause of death of one animal was from fishery interactions and that this event was not duplicative of the observed take estimate for the stratum in which the stranding occurred.

Canadian Bay of Fundy Sink Gillnet

An observer program was implemented in the summer of 1993 in the Canadian Bay of Fundy Sink Gillnet Fishery. Average estimated harbor porpoise mortality from 1995 to 1999 was 36 animals per year; the mortality from 2000 has not yet been estimated. An estimate of variance is not possible.

Bay of Fundy Herring Weirs

Harbor porpoises are taken frequently in Canadian herring weirs, although a program has been implemented to reduce the mortality occurring from these takes. There have been no efforts to observe the U.S. component of this fishery and no takes reported from opportunistic platforms. Average estimated harbor porpoise mortality in the Canadian BOF herring weir fishery from 1995 to 1999 was 2.8 animals per year. The mortality from 2000 has not yet been estimated. An estimate of variance is not possible.

C. Disease or Predation

Evidence of disease and predation on individuals of the GOM/BOF harbor

porpoise population has been recorded by the Northeast and Southeast Marine Mammal Stranding Networks and during various necropsy workshops hosted by NMFS. There is no indication that disease has had a measurable impact on the GOM/BOF harbor porpoise population. Likewise, although it is assumed that predation on harbor porpoise is occurring, there is no evidence to suggest that the rate of predation has increased such that it would adversely affect the net rate of increase of the GOM/BOF population.

D. The Inadequacy of Existing Regulatory Mechanisms

This portion of the status review evaluates whether current regulatory mechanisms are adequate to prevent impacts that could result in a determination that the Gulf of Maine/Bay of Fundy (GOM/BOF) harbor porpoise population is threatened or endangered. NMFS' proposed listing (58 FR 3108, January 7, 1993), revised proposed listing (63 FR 56596, October 22, 1998), and final determination (64 FR 465, January 5, 1999) included analyses of regulatory mechanisms in place prior to implementation of the Harbor Porpoise Take Reduction Plan (HPTRP). This document focuses only on the effect of the HPTRP and other regulatory actions taken since the January 5, 1999, final determination.

The January 7, 1993, proposal to list harbor porpoise as threatened was based on high levels of mortality of harbor porpoise incidental to commercial fishing and the inadequacy of regulatory mechanisms to address that mortality. The final 1999 determination not to list harbor porpoise was based on a finding that the bycatch reduction mechanisms built into the HPTRP, the Northeast Multispecies FMP, and the Canadian Harbor Porpoise Conservation Strategy provided adequate regulatory mechanisms to deal with high levels of mortality. The bycatch reduction levels built into these measures were analyzed in the January 5, 1999, **Federal Register** document. The following discussion updates that analysis with the actual bycatch levels that occurred during 1999 and 2000, FMP restrictions that have been implemented since the implementation of the HPTRP, and Canadian bycatch levels in those same years.

Regulatory Mechanisms in Effect During 1999 and 2000

The key regulatory mechanism specifically addressing harbor porpoise bycatch in U.S. commercial fisheries is the HPTRP, which was published pursuant to Section 118 of the MMPA on December 2, 1998 (63 FR 66464). In addition to measures implemented through the HPTRP, NMFS also implemented time/area closures for rebuilding groundfish stocks under the Multispecies FMP that would also benefit harbor porpoise. To avoid duplication, the measures put in place through the Multispecies FMP were not incorporated into the HPTRP, but the effects were included in the calculation of expected harbor porpoise bycatch reduction. This strategy and the predicted bycatch reduction are discussed and analyzed in the Environmental Assessment (EA) prepared for the HPTRP and in the preamble of the December 2, 1998, HPTRP final rule and are incorporated by reference.

Harbor Porpoise Take Reduction Plan (HPTRP)

NMFS established two take reduction teams to address bycatch of the GOM/BOF population of harbor porpoise in commercial fisheries. The Gulf of Maine Harbor Porpoise Take Reduction Team (HPTRT) was established on February 12, 1996, to address incidental takes of the GOM/BOF stock of harbor porpoise in the Northeast sink gillnet fishery. The Mid-Atlantic Take Reduction Team (MATRT) was established on February 25, 1997, to address interactions between the GOM/BOF population of harbor porpoise and the Mid-Atlantic coastal gillnet fishery. Each team submitted take reduction plans to NMFS, and NMFS combined the measures recommended by each team for harbor porpoise bycatch reduction into one Harbor Porpoise Take Reduction Plan (HPTRP). Therefore, the HPTRP addresses bycatch in both the Northeast sink gillnet fishery and the Mid-Atlantic coastal gillnet fishery. The proposed rule was published on September 11, 1998 (63 FR 48670), and finalized on December 2, 1998 (63 FR 66464). NMFS published a notice on December 23, 1998 (63 FR 71041) that corrected errors to New England closure boundaries.

The primary measures to reduce bycatch implemented in the HPTRP included time/area closures and time/area periods where use pingers is required for the Northeast sink gillnet fishery and time/area closures and gear modifications and restrictions for the Mid-Atlantic coastal gillnet fishery. The specific measures implemented in the HPTRP are incorporated by reference. The analysis presented in the EA prepared for the HPTRP estimated that the measures implemented in the HPTRP would reduce the incidental mortality and serious injury of harbor porpoise from approximately 2,040 animals per year to less than the PBR level of 483 animals per year. The measures implemented to address harbor porpoise mortality and serious injury in the Northeast sink gillnet fishery were expected to reduce the incidental mortality and serious injury of harbor porpoise from an average of 1,833 animals per year to 309 animals per year. The measures implemented to address harbor porpoise mortality and serious injury in the Mid-Atlantic coastal gillnet fishery were expected to decrease harbor porpoise mortality and serious injury from an average fo 207 animals per year to less than 50 animals per year.

The HPTRT and MATRT have both met twice since implementation of the HPTRP to review elements of the Plan, discuss how it is working, identify areas for improvement, and discuss approaches to meet further bycatch reduction goals mandated by section 118 of the MMPA. At a meeting in December of 1999, the HPTRP submitted consensus recommendations to NMFS addressing pinger operation and testing, data use and reliability, effort measurement, clarification of the impact of discards on the bycatch estimates, enforcement, analysis of pinger data, gear studies, analysis of and involvement in fishery management plans, authorization of the use of higher-frequency pingers, and investigation of enhanced acoustically reflective gillnet gear as a bycatch reduction tool.

At a meeting in January of 2000, the MATRT submitted consensus recommendations to NMFS regarding observer coverage, non-compliance with the requirement to carry an observer, the role of the MATRT in reviewing proposed rules, adjustment of the Delaware Bay exemption line, the lower bound in the definition of the small mesh fishery, fishing industry investigation of mitigation strategies for harbor porpoise and bottlenose dolphin including pingers and reflective gillnetting, NMFS mitigation strategies, and investigation of interactions between recreational gear and harbor porpoise and bottlenose dolphins.

On October 27, 2000, NMFS issued a proposed rule redefining Delaware Bay in the list of exempted waters to include waters landward of the 72 COLREGS line (65 FR 64415). The MATRT recommended by consensus that NMFS redefine the list of exempted waters because, in its opinion, harbor porpoise stranding and observer data indicated that harbor porpoise were not taken within Delaware Bay. The final rule exempting Delaware Bay was published on January 11, 2001 (66 FR 2336).

NMFS reconvened the MATRT in November 2000. The team recommended that NMFS solicit team input on regulatory changes, streamline coordination between fishery management plan measures and take reduction plan measures, modify and standardize gear definitions, improve the observer program, develop gear research and education measures that may result in additional bycatch reduction, and evaluate incidental take of harbor porpoise and bottlenose dolphin in recreational fisheries.

NMFS reconvened the HPTRT in December 2000. The team recommended that NMFS establish a program in cooperation with the states to certify that pingers are operational, develop a schedule for penalties for non-compliance with the plan, notify permit holders about problems with non-compliance, consider moving the southern boundaries of the Cape Cod South closure to include takes observed in 2000, and develop a proposal for a stand-alone MMPA plan (i.e., one that contains all measures necessary for porpoise protection rather than incorporating FMP measures designed for fish conservation).

Multispecies Fishery Management Plan (Multispecies FMP)

The Multispecies FMP measures incorporated into the HPTRP strategy at the time of the December 1998 final rule included time/area, seasonal, and year-round closures for groundfish protection implemented under Framework 25 (63 FR 15326, March 31, 1998), which built on Amendments 5 (59 FR 9884, March 1, 1994) and 7 (61 FR 27710, May 31, 1996) and Framework 9 (60 FR 19364, April 18, 1995) of the Multispecies FMP.

NMFS expanded the time/area closure system in the Multispecies FMP in 1999. Framework 26 (64 FR 2601, January 15, 1999), implemented shortly after implementation of the HPTRP, expanded one closure and added two others. Framework 27 (64 FR 24066, May 5, 1999) expanded the GOM inshore seasonal closure areas for March through June, the Cashes Ledge closure area and time of closures (as defined under the FMP), created an additional closure in Massachusetts Bay, and eliminated the Northeast closure as a groundfish closure, although it was retained as a harbor porpoise closure area. Framework 28 (64 FR 15704, April 1, 1999) made several changes for consistency with the HPTRP, including opening an area previously closed to gillnet fishing under the Multispecies FMP for porpoise protection, as long as pingered nets were used.

Multispecies FMP groundfish time/area closures in effect for Calendar Year 2000 included some from the 1999 fishing year as well as those implemented in Frameworks 31 and 33. Framework 31 (65 FR 377, January 5, 2000) included an additional inshore area closure. Framework 33 (65 FR 21658, April 24, 2000) expanded the time/area closure system for groundfish protection, including a one-year extension of the year-round Western GOM closure, addition of a closure of a portion of Georges Bank east and southeast of Cape Cod during May, and conditional closures of a portion of Massachusetts Bay/Stellwagen Bank in January and Cashes Ledge (as defined by the FMP) in November that would be triggered if cod landings reached certain levels. Both the November 2000 and the January 2001 conditional closures were triggered, but the latter is outside the time period of this analysis.

NMFS also implemented Framework Adjustments 29, 30, 32, 34, and 35 to the Multispecies FMP for Fishing Years 1999 and 2000. However, these frameworks did not affect time/area closures applicable to gillnet gear, and are therefore not discussed here.

Estimated Harbor Porpoise Bycatch During 1999 and 2000 Relative to Historical Levels

The estimates of GOM/BOF harbor porpoise bycatch for 1999 and 2000 are derived from the following components: (a) bycatch attributable to the Northeast sink gillnet fishery, (b) bycatch attributable to the Mid-Atlantic coastal gillnet fishery, (c) bycatch attributable to the BOF Canadian sink gillnet fishery, (d) bycatch attributable to the BOF Canadian herring weir fishery, and (e) records of fishery interactions reported in the stranding data, as appropriate.

NMFS analyzes harbor porpoise bycatch derived from observer coverage in the Northeast sink gillnet fishery and Mid-Atlantic coastal gillnet fishery in three seasonal components: Winter (January-May), Summer (June-August), and Fall (September-December). Other sources of bycatch are then added to these estimates to derive the total annual estimate.

Northeast Sink Gillnet Fishery

The estimated bycatch attributable to the Northeast sink gillnet fishery (as defined in the MMPA List of Fisheries) during the winter, summer, and fall seasons for 1999 and 2000 is presented in Tables 1, 2, and 3, respectively.

During the winter season of 1999, time-area closures and pinger restrictions affected this fishery under both the HPTRP and the Multispecies FMP. During the winter, the majority of FMP closures occurred in the GOM. In 2000, the same HPTRP restrictions were in place, but the FMP measures changed. Estimated winter bycatch for this fishery was 149 (CV=0.43) in 1999 and 159 (CV=0.64) in 2000 (Table 1). Winter fishing effort, measured in tons landed, decreased from 5,380 metric tons in 1999 to 3,982 metric tons in 2000 (NMFS unpublished data). Thus, the bycatch remained approximately the same in 2000 although fishing catch was reduced relative to 1999.

The HPTRP incorporates some restrictions that have been in effect under the Multispecies FMP since 1994. Therefore, the best baseline estimate of harbor porpoise bycatch in New England prior to the implementation of porpoise protection measures is the average annual bycatch for the earliest years of the NMFS Sea Sampling Program, 1990-1993. Based on data presented in Bravington and Bisack (1996), the average historical (1990-1993) winter bycatch in this fishery was 988 animals. The winter bycatch in 1999 and 2000 was substantially less than historical levels for this season. Winter 1999 and 2000 harbor porpoise serious injury and mortality in the Northeast Sink Gillnet Fishery is presented in Table 1.

TABLE 1. HARBOR PORPOISE SERIOUS INJURY/MORTALITY ATTRIBUTED TO THE NORTHEAST SINK GILLNET FISHERY — WINTER SEASON 1999 AND 2000

Winter Season (January – May)

Area	Bycatch Based on Observed Takes	
	1999	2000
Port Group Strata		
Northern Maine	CBD[a]	CBD
Southern Maine	CBD	0
New Hampshire	CBD	CBD
North of Boston	0	0
South of Boston	0	12
South Cape	CBD	132
East Cape	0	0
Offshore	108	0
Closure Strata		
Northeast	CBD	CBD
Mid-coast	0	15
Massachusetts Bay	0	0
Cape Cod Bay	CBD	CBD
South Cape	41	0
Great South Channel	CBD	0
Offshore	0	0
Cashes Ledge	0	CBD

TABLE 1. HARBOR PORPOISE SERIOUS INJURY/MORTALITY ATTRIBUTED TO THE NORTHEAST SINK GILLNET FISHERY — WINTER SEASON 1999 AND 2000—Continued

Winter Season (January – May)

Area	Bycatch Based on Observed Takes	
	1999	2000
Estimated Total Winter Bycatch in New England	149	159

CBD[a]=cannot be determined and represents strata where the bycatch is unknown because there was no observer coverage.

During the summer season, relatively few time-area closures and no pinger restrictions affected this fishery in 1999 or 2000. Estimated summer bycatch for this fishery was 29 (CV=0.94) in 1999 and 0 in 2000. Fishing effort in the summer season consisted of 7,509 metric tons landed in 1999 and 5,656 metric tons in 2000 (NMFS unpublished data). Based on data presented in Bravington and Bisack (1996), the average historical (1990–1993) summer bycatch in this fishery was 107 animals. Thus, the summer bycatch for both 1999 and 2000 was below the historical average. This is not unusual because most of the GOM/BOF harbor porpoise population moves north into the Bay of Fundy during the summer. Summer 1999 and 2000 harbor porpoise serious injury and mortality in the Northeast Sink Gillnet Fishery is presented in Table 2.

TABLE 2. HARBOR PORPOISE SERIOUS INJURY/MORTALITY ATTRIBUTED TO THE NORTHEAST SINK GILLNET FISHERY — SUMMER SEASON 1999 AND 2000

Summer Season (June – August)

Area	Bycatch Based on Observed Takes	
	1999	2000
Port Group Strata		
Northern Maine	CBD[a]	CBD
Southern Maine	0	0
New Hampshire	29	0
North of Boston	0	0
South of Boston	0	0
South Cape	0	0
East Cape	0	0
Offshore	0	0
Closure Strata		
Northeast	CBD	CBD
Mid-coast	CBD	CBD
Massachusetts Bay	CBD	CBD
Cape Cod Bay	CBD	CBD

TABLE 2. HARBOR PORPOISE SERIOUS INJURY/MORTALITY ATTRIBUTED TO THE NORTHEAST SINK GILLNET FISHERY — SUMMER SEASON 1999 AND 2000—Continued

Summer Season (June – August)

Area	Bycatch Based on Observed Takes	
	1999	2000
South Cape	CBD	CBD
Great South Channel	CBD	0
Offshore	CBD	CBD
Cashes Ledge	CBD	CBD
Estimated Total Summer Bycatch in New England	29	0

CBD[a]=cannot be determined and represents strata where the bycatch is unknown because there was no observer coverage.

During the fall, HPTRP restrictions for this fishery are primarily pinger restrictions, with the exception of the Northeast closure. FMP time-area closures were also in place during the fall of 1999 and 2000. Estimated fall bycatch for this fishery was 92 (CV=0.43) in 1999 and 348 (CV=0.45) in 2000. Fall fishing effort was measured at 5,793 metric tons in 1999 and 4,849 metric tons in 2000. Based on data presented in Bravington and Bisack (1996), the average historical (1990-1993) fall bycatch in this fishery was 770 animals. Thus, the fall bycatch for both 1999 and 2000 was below the historical average. Fall 1999 and 2000 harbor porpoise serious injury and mortality in the Northeast Sink Gillnet Fishery is presented in Table 3.

TABLE 3. HARBOR PORPOISE SERIOUS INJURY/MORTALITY ATTRIBUTED TO THE NORTHEAST SINK GILLNET FISHERY—FALL SEASON 1999 AND 2000

Fall Season (June – August)

Area	Bycatch Based on Observed Takes	
	1999	2000
Port Group Strata		
Northern Maine	CBD[a]	CBD
Southern Maine	CBD	0
New Hampshire	CBD	0
North of Boston	0	0
South of Boston	0	0
South Cape	0	0
East Cape	0	0
Offshore	0	0
Closure Strata		
Northeast	CBD	CBD
Mid-coast	92	348
Massachusetts Bay	0	0
Cape Cod Bay	CBD	CBD

TABLE 3. HARBOR PORPOISE SERIOUS INJURY/MORTALITY ATTRIBUTED TO THE NORTHEAST SINK GILLNET FISHERY—FALL SEASON 1999 AND 2000—Continued

Fall Season (June – August)

Area	Bycatch Based on Observed Takes	
	1999	2000
South Cape	0	0
Great South Channel	CBD	CBD
Offshore	0	CBD
Cashes Ledge	CBD	CBD
Estimated Total Fall Bycatch in New England	92	348

CBD[a]=cannot be determined and represents strata where the bycatch is unknown because there was no observer coverage.

Adding the bycatch from the three seasons results in a total bycatch of 270 (CV=0.28) for the New England sink gillnet fishery in 1999 and 507 (CV=0.37) in 2000. Inter-annual variability in harbor porpoise and groundfish distribution is expected, and this variability will likely be reflected in observed bycatch patterns. Therefore, NMFS typically takes an average of several years to derive the best representation of the bycatch scenario. The average annual estimated bycatch for this fishery during 1999-2000 was 389 (CV=0.26) animals.

The historical (1990-1993) average harbor porpoise serious injury/mortality for this fishery was estimated at 1,875 (CV=0.32) animals (Blaylock, *et al.* 1995). The goal of the HPTRP was to reduce the bycatch by 79 percent, resulting in an expected reduction to 385 takes per year. This value represents a level below the PBR, which was 483 in 1998, and considered the potential for mortality from sources other than the Northeast sink gillnet and Mid-Atlantic coastal gillnet fisheries. As discussed in the EA for the HPTRP final rule, the estimated bycatch for this fishery, taking into account measures implemented through Framework 25, was expected to be 157. This bycatch reduction was not realized in either 1999 or 2000 despite expansion of Multispecies FMP closures since Framework 25. The reasons for the observed take levels in 1999 and 2000 are currently not known. In addition, it is likely that non-compliance with HPTRP and FMP regulations in the fall of 2000 contributed to the increase in bycatch for that year. However, both the 1999 and 2000 bycatch levels represent a substantial decrease over the historical level of 1,875 estimated porpoise takes in this fishery. In addition, the take in

this fishery combined with that from other sources was below the current PBR in both 1999 and 2000.

Mid-Atlantic Coastal Gillnet Fishery

The estimated bycatch attributable to the Mid-Atlantic coastal gillnet fishery in 1999 and 2000 is presented in Table 4. In 1999 and 2000, bycatch was observed in the Mid-Atlantic only during the winter season. NMFS did not incorporate any FMP restrictions into the HPTRP strategy for the Mid-Atlantic coastal gillnet fishery. HPTRP restrictions for the Mid-Atlantic include time-area closures and gear restrictions, which were developed to target the monkfish and dogfish subfisheries and based on gear characteristics most closely associated with harbor porpoise bycatch in these fisheries.

Most of the Mid-Atlantic measures in the HPTRP are divided into two categories, which correspond to ''large mesh'' and ''small mesh'' gear as defined in the HPTRP. Only one time-area closure, the ''Mudhole'' closure off New Jersey, applies to both mesh categories. The lower bound of ''small mesh'' is defined in the HPTRP as mesh of sizes greater than 5.0 inches (12.7 cm), so mesh sizes of 5.0 inches (12.7 cm) and smaller are not regulated by the HPTRP in the Mid-Atlantic. Although takes have been observed in gear with mesh sizes 5.0 inches (12.7 cm) and smaller, there is no basis at this time to apply the current gear restrictions to those mesh sizes. Further information obtained from observer coverage and gear research may yield information which can be used to develop additional gear modifications.

The monkfish and dogfish fisheries have changed significantly as a result of FMP measures. The stock rebuilding programs in the FMPs for monkfish and dogfish have substantially reduced fishing effort in these two subfisheries of the Mid-Atlantic coastal gillnet fishery.

As presented in Table 4, the estimated annual harbor porpoise mortality attributable to the Mid-Atlantic coastal gillnet fishery was 53 (CV=0.49) in 1999 and 21 (CV=0.76) in 2000. The goal for the Mid-Atlantic component of the HPTRP was to reduce takes in this fishery from 207 per year to 43 per year. According to the bycatch estimates based on observed takes for 1999 and 2000, this goal was not reached in 1999 but was reached in 2000. However, the HPTRP measures for the Mid-Atlantic were intended to address bycatch in the monkfish and dogfish subfisheries. The takes documented in 1999 and 2000 did not occur in either the monkfish or dogfish subfisheries; rather, they occurred in the shad subfishery. The bycatch estimates for both 1999 and 2000 represent a substantial reduction from the goal of 207. The average estimated bycatch for this fishery during 1999-2000 was 37 (CV=0.41) animals per year.

TABLE 4. HARBOR PORPOISE SERIOUS INJURY/MORTALITY ATTRIBUTED TO THE MID-ATLANTIC SINK GILLNET FISHERY – WINTER SEASON 1999 AND 2000

Winter Season (January – May)

State	Bycatch Based on Observed Takes	
	1999	2000
New York	0	0
New Jersey	0	0
Delaware	0	21
Maryland	53	0
Virginia	0	0
North Carolina	0	0
Estimated Total Winter By-catch in the Mid-Atlantic	53	21

Unknown Mid-Atlantic Fishery

In 1999, 228 harbor porpoise stranded along the U.S. East Coast. With regard to the strandings for which a fishery interaction determination could be made, 38 exhibited signs of fishery interaction involving monofilament line or mesh. Of those 38, one was in New England and the remainder in the Mid-Atlantic. NMFS estimates that 19 of the 37 in the Mid-Atlantic resulted from events occurring in times/areas where they would not have been detected by the Sea Sampling Program. An extrapolated estimate cannot be derived from the stranding numbers because the extrapolation factor is unknown. However, these 19 strandings are added to the extrapolated estimates of mortality and serious injury for 1999.

The Mid-Atlantic coastal gillnet fishery is the only fishery with documented takes of harbor porpoise in the Mid-Atlantic. However, there are other commercial and recreational fisheries in the Mid-Atlantic which may use gear that would make net marks similar to the gear used in the Mid-Atlantic coastal gillnet fishery. Therefore, NMFS is currently attributing the 19 takes to an unknown fishery. Should any Mid-Atlantic fisheries not currently regulated by the HPTRP be identified as sources of harbor porpoise serious injury/mortality, section 118 of the MMPA gives NMFS the authority to add representatives of these fisheries to the MATRT. However, restrictions can only be implemented through the HPTRP for commercial fisheries at this time, i.e., not recreational fisheries.

Summary and Discussion of U.S. Fishery Takes

The bycatch in both the Northeast sink gillnet fishery and the Mid-Atlantic coastal gillnet fishery in 1999 and 2000 reflects a substantial reduction from historical levels of harbor porpoise mortality and serious injury. NMFS assumes that this reduction has been achieved through measures implemented through the HPTRP and FMP actions.

The combination of HPTRP and FMP measures was sufficient to reduce the bycatch to below PBR in both 1999 and 2000. However, because FMP closures are subject to change in a different management process than the HPTRP, the degree of harbor porpoise protection realized from the combined strategy will always be vulnerable to changes in the FMP closure system when the goal of maintaining the bycatch below PBR is dependent upon the FMP closures. As long as this strategy is maintained, active monitoring and response to changes in FMP restrictions will be required. Furthermore, if the goals of the FMPs are met, the closures could be lifted, resulting in an unknown effect on harbor porpoise bycatch. NMFS will monitor actions taken under the FMPs to ensure that any changes to fishery management measures that may or do result in unanticipated increases in harbor porpoise bycatch rates are mitigated through one of the available regulatory mechanisms. NMFS may also revise the HPTRP to incorporate all measures necessary to ensure reduced harbor porpoise bycatch rather than relying on FMP time/area closures.

In the Multispecies FMP, NMFS has maintained porpoise protection measures up through Framework 28. Because porpoise bycatch reduction is also an objective of the Multispecies FMP, the FMP authority represents a supplementary regulatory mechanism for addressing harbor porpoise bycatch.

In addition, the Atlantic States Marine Fisheries Commission (ASMFC) has adopted protected species items in their charter for development of inter-state FMPs. This provides another potential regulatory mechanism for implementing porpoise bycatch reduction measures.

Mechanisms for Addressing Take Incidental to Canadian Commercial Fisheries

Canadian regulatory mechanisms were described in the October 22, 1998, **Federal Register** notice. The two commercial fisheries in the Bay of

Fundy known to take harbor porpoise are the groundfish sink gillnet fishery and the herring weir fishery.

Bay of Fundy (Canadian) Sink Gillnet Fishery

The Canada Department of Fisheries and Oceans (DFO) finalized the Harbor Porpoise Conservation Plan in 1994. This plan was intended to reduce the mortality of harbor porpoise in the BOF sink gillnet fishery to sustainable levels. In 1995, DFO developed an expanded program called Harbor Porpoise Conservation Strategy for the Bay of Fundy (HPCS). This plan incorporated gillnet fishing effort reduction, required pinger use, expanded observer coverage, and included a fisher education program. In 1999 and 2000, no porpoise-specific changes have been made to the HPCS.

The goal of the HPCS was to reduce the bycatch to a level below two percent of the GOM/BOF porpoise population abundance estimate, a target of 110 animals per year in the Bay of Fundy. This goal was reached in 1999 and is expected to have been met in 2000. The bycatch for 1999 is estimated at 20 animals, and the 2000 estimate is not expected to exceed 20. By comparison, bycatch was estimated to be 424 animals in 1993 and 101 animals in 1994 (Trippel, *et al.* 1996). Thus, the bycatch in recent years is well below the level prior to implementation of the HPCS.

Since 1998, DFO has been assisting the Bay of Fundy sink gillnet fishery in testing alternative gillnet gear developed in the U.S. by individuals involved in porpoise bycatch reduction efforts throughout the GOM/BOF. This gear shows promise as a bycatch reduction tool for harbor porpoise (and possibly marine birds) and may be tested in U.S. waters in the near future.

Mechanisms for Addressing Take Incidental to Recreational Fisheries and Other Sources of Incidental Take

Although no takes of harbor porpoise in recreational gear have been documented, it is possible that such takes are occurring. Any takes that occur by recreational fisheries would be in violation of the take provisions of the MMPA unless authorized under section 101(a)(5) of the MMPA.

Other human activities could result in lethal takes of harbor porpoise, and such takes would also be addressed in section 101 (a)(5) of the MMPA. No lethal takes of harbor porpoise have been documented incidental to human activities other than commercial fisheries, except for scientific research activities, as discussed in the following section.

Mechanisms for Addressing Take Resulting from Scientific Research Activities

In the U.S., scientists wishing to undertake research activities specifically targeting harbor porpoise are required to obtain permits under the scientific research provision of the MMPA. NMFS is not aware of any reports of mortality or serious injury from scientific research activities other than a mortality of a harbor porpoise recorded during a gillnet survey conducted by the Maryland Department of Marine Resources in upper Chesapeake Bay in the mid-1990s. However, there have been research projects specifically directed at studying harbor porpoise, and non-lethal takes were authorized under the MMPA scientific research permit provisions for those activities.

Mechanisms for Addressing Intentional Take

Intentional lethal take of marine mammals is prohibited by the MMPA with the exception of cases where human safety is threatened. Since it is unlikely that human safety would be threatened during an encounter with a harbor porpoise, this type of take is unlikely to occur.

Other Available Regulatory Mechanisms

Acute impacts to the GOM/BOF harbor porpoise population could occur as a result of unusually high mortality events caused by natural or human-caused factors (e.g., disease, biotoxins, oil spill). Section 404 of Title IV of the MMPA requires the Secretary of Commerce to establish a marine mammal unusual mortality event working group that is responsible for identifying when an unusual mortality event is occurring and to develop a contingency plan to assist the Secretary in responding to the event. NMFS has established the working group, a policy for identifying unusual mortality events, and a generic contingency plan (Wilkinson 1996). This mechanism is available should it become necessary to respond to a suspected mortality event.

E. Other Natural or Anthropogenic Factors Affecting the Continued Existence of the Species or Distinct Population Segment(s)

NMFS has identified several anthropogenic factors that could contribute to the threat or endangerment of the GOM/BOF harbor porpoise population. These include pathology due to contaminants, intentional takes for subsistence, and competition with commercial fisheries.

Contaminants

The presence of contaminants in the tissues of harbor porpoise could affect the survival and/or reproductive capacity of individuals. There is no new evidence since the 1998 status review to indicate that contaminants in harbor porpoise tissues pose a serious threat to this population at the present time.

Subsistence Harvest

Harbor porpoises were harvested by indigenous hunters in Maine and Canada before the 1960s (NEFSC 1992). The extent of these past harvests is unknown, though it is believed to have been small. Up until the early 1980s, small subsistence kills of harbor porpoise in the GOM/BOF by indigenous hunters of the Passamaquoddy Nation in both U.S. and Canadian waters were reported. The hunt was believed to have nearly stopped (Polacheck 1989), however, public media reports in September 1997 depicted a Passamaquoddy hunter dressing out a harbor porpoise that had been taken in Canadian waters. Any subsistence harvest that may be occurring at the present time is assumed to be at such a low level that it would not contribute to the threat or endangerment of the GOM/BOF harbor porpoise population.

Competition with Commercial Fisheries

Harbor porpoise could be competing with commercial fisheries where there is overlap between commercial target species and porpoise prey species. Porpoise food habits are not conclusively known in the Western North Atlantic; however, some information on prey preferences is available from analysis of the stomach contents of porpoise incidentally taken in commercial fisheries. Stomachs from 95 harbor porpoises caught in groundfish gillnets in the Gulf of Maine between September and December 1989–94 were analyzed by Gannon, *et al.* (1998). Results of this work suggest that Atlantic herring (*Clupea harengus*) is the most important harbor porpoise prey in the GOM/BOF during late summer and autumn based on frequency of occurrence. Pearlsides (*Maurolicus weitzmani*), silver hake (*Merluccius bilinearis*), and red and white hake (*Urophycis* spp.) were the next most common prey species (Gannon, *et al.* 1998). Commercial fisheries exist for several of these species, including herring in the GOM, BOF, and Mid-Atlantic and the hake species in the GOM and BOF.

Competition effects would be enhanced if the commercial fishery is

targeting the same age class of the harbor porpoise prey species in question and in the same time/area. If competition is occurring, adverse impacts to the porpoise population would be measured in effects on reproductive performance. No such effects have been identified to date. FMPs are now in place for the herring and hakes, including requirements for reporting of catch. Therefore, the harvest is controlled, and it will be possible to closely monitor the level of effort in these fisheries. With further work in identifying harbor porpoise population trends, it will be possible in the future to compare the trajectory of the porpoise population with that of the fishing effort.

Proposed Determination

Section 4 (b)(1) of the ESA requires the Secretary of Commerce to make a listing determination solely on the basis of the best scientific and commercial data available and after taking into account efforts being made to protect the species. Therefore, in reviewing the status of the GOM/BOF population of harbor porpoise, NMFS has assessed the status of the species, identified factors that could result in a threat or endangerment to the species, and evaluated available conservation measures to determine whether such measures adequately mitigate risks to the species.

The 1998 status review and proposal to list the GOM/BOF stock of harbor porpoise as threatened under the ESA identified mortality and serious injury incidental to commercial fishing as the primary threat to this stock of harbor porpoise. However, in 1999 the proposal to list the GOM/BOF stock of harbor porpoise as threatened under the ESA was withdrawn because bycatch reduction measures implemented in the United States and Canada were sufficient to reduce harbor porpoise mortality and serious injury incidental to commercial fishing. Despite the withdrawal of the proposal to list the GOM/BOF stock of harbor porpoise as threatened under the ESA, NMFS maintained harbor porpoise on the ESA candidate species list to notify the public of NMFS' concern regarding the population and to ensure continued monitoring of the species' status.

Since 1999, NMFS has obtained no information to suggest that: (1) other factors could cause the stock to be threatened under the ESA, or (2) that the bycatch reduction measures in place are inadequate regulatory mechanisms to reduce harbor porpoise mortality and serious injury. An analysis of the five listing factors indicates at this time that none of these factors, alone or in combination with one another, is likely to threaten or endanger the GOM/BOF harbor porpoise population. Therefore, listing the GOM/BOF population of harbor porpoise as threatened or endangered is not warranted at this time. In addition, because of the reduction in harbor porpoise mortality since 1999, it is appropriate to remove the GOM/BOF harbor porpoise population from the candidate species list.

The most significant factors that NMFS considered are the results of implementation of measures promulgated under the MMPA and Magnuson-Stevens Fishery Conservation and Management Act to reduce the level of harbor porpoise mortality incidental to commercial fishing in U.S. waters and the Harbor Porpoise Conservation Strategy implemented by the Canada Department of Fisheries and Oceans. Although it is likely that porpoise mortality will continue to occur incidental to fishery operation, existing regulatory mechanisms for addressing the threat of bycatch in commercial fisheries are adequate to remove the potential that lethal take in these fisheries does or will pose a threat or endangerment to this population. Regulatory agencies have the authority to adapt management measures if unanticipated changes in porpoise bycatch patterns occur.

NMFS' conclusion that these conservation efforts promote the sustainability of the GOM/BOF population of harbor porpoise is based on the following factors: (1) These plans, which include specific porpoise bycatch reduction measures, have been in place for the past 2 years, and the mortality of harbor porpoise has dropped to below the PBR level; (2) a population viability analysis did not result in any extinction projections (Wade 2001); (3) the abundance and distribution of harbor porpoise are greater than previously believed, resulting in an increase in PBR; and (4) bycatch reduction objectives and time frames for achieving these objectives relative to MMPA take reduction goals have been established and include adaptive management principles.

Although the HPTRP and other bycatch reduction efforts have reduced the incidental take of harbor porpoise in the gillnet fisheries to below PBR in both 1999 and 2000, it is clear from the observation efforts during the first 2 years of HPTRP implementation that the plan's effectiveness must continue to be monitored. NMFS is aware of non-compliance with HPTRP regulations that may have reduced the plan's effectiveness, requiring additional outreach and enforcement to maximize the effectiveness of the HPTRP. Furthermore, fishery management measures have changed since the implementation of the HPTRP and are likely to continue to change on an annual basis. It is possible that closures implemented for fish conservation will be removed when fish stocks reach their rebuilding targets, which could result in an increased risk to harbor porpoise and may require adjustment of the HPTRP. NMFS will continue to monitor the bycatch levels and adjust the HPTRP as necessary to reach a zero mortality and serious injury rate as established in Section 118 of the MMPA. NMFS will monitor any new regulations or changes to existing regulations that may affect harbor porpoise bycatch and evaluate whether management measures need to be changed. NMFS intends to reconvene the TRTs as appropriate to monitor the implementation of the HPTRP relative to MMPA goals.

Biological Information Solicited

To ensure that this review of the status of the GOM/BOF harbor porpoise population is comprehensive and based on the best available information, NMFS is soliciting information and comments from any interested person concerning the status of the Gulf of Maine/Bay of Fundy stock of harbor porpoise and any of the issues discussed above in our preliminary determination of the status of this population. NMFS is primarily interested in new information that has become available since NMFS last determined that listing of this stock was not warranted (64 FR 465, January 5, 1999). It is requested that data, information, and comments be accompanied by (1) supporting documentation such as maps, logbooks, bibliographic reference, personal notes, or reprints of pertinent publications; and (2) the name of the person submitting the data, his/her address, and any association, institution, or business that the person represents. NMFS will consider all comments prior to making its final determination on the status of the GOM/BOF harbor porpoise stock, whether to list it under the ESA, and whether to remove it from the Candidate Species List.

References (available upon request)

Bisack, K. D. 1997a. Harbor porpoise bycatch estimates in the New England multispecies sink gillnet fishery: 1994 and 1995. *Rep. int Whal. Commn.* 47: 705–14.

Blaylock, R.A., J.W. Hain, L.J. Hansen, D.L. Palka, and G.T. Waring. 1995. U.S. Atlantic and Gulf of Mexico marine

mammal stock assessments. NOAA Tech. Mem. NMFS-SEFSC–363, 211 pp.

Bravington, M. V. and K. D. Bisack. 1996. Estimates of harbor porpoise bycatch in the Gulf of Maine sink gillnet fishery, 1990–1993. *Rep. Int Whal. Commn*.46:567–74.

Caswell, H., S. Brault, A. Read and T. Smith. 1998. Harbor porpoise and fisheries: an uncertainty analysis of incidental mortality. *Ecological Applications* 84(4):1226–1238.

Cox, T. M., A. J. Read, S. Barco, J. Evans, D. P. Gannon, H. N. Koopman, W.A . McLellan, K. Murray, J. Nicolas, D. A. Pabst, C. W. Potter, W. M. Swingle, V. G. Thayer, K. M. Touhey and A. J. Westgate. 1998. Documenting the bycatch of harbor porpoises, *Phocoena phocoena*, in coastal gill net fisheries from stranded carcasses. *Fish. Bull*. U.S. 96 (4):727–734.

CUD (Conservation and Utilization Division). 1994. Estimating harbor porpoise bycatch in the Gulf of Maine sink gillnet fishery, NOAA, NMFS, NEFSC Ref. Doc. 94–24, Woods Hole, MA.

DFO (Department of Fisheries and Oceans). 1998. Harbour porpoise bycatch in the lower Bay of Fundy gillnet fishery. DFO Maritimes Regional Fisheries Status Report 98/7E. (Available from Department of Fisheries and Oceans, Resource management Branch, P.O. Box 550, Halifax, NS B3J 2S7, Canada..)

Gannon, D. P., J. E. Craddock and A. J. Read. 1998. Autumn food habits of harbor porpoises, *Phocoena phocoena*, in the Gulf of Maine. *Fish. Bull. U.S.* 96(3):428-437.

Gaskin, D. E. 1977. Harbour porpoise, *Phocoena phocoena* (L.), in the western approaches to the Bay of Fundy 1969–75. Rep. Int. Whal. Comm 27:487-492.

Gaskin, D. E. 1984. The harbor porpoise Phocoena phocoena (L.): Regional populations, status, and information on direct and indirect catches. Rep. Int Whal. Commn 34:569–586.

Gaskin, D. E. 1992. The status of the harbour porpoise. *Can. Fld. Nat*. 106:36-54.

Gilbert, J. R. and K. M. Wynne. 1985. Harbor seal populations and fisheries interactions with marine mammals in New England, 1984. Fourth Annual Report, Contract NA–80–FA-C-00029, Northeast Fisheries Center, Woods Hole, MA, 15 pp.

Gilbert, J. R. and K. M. Wynne. 1987. Harbor seal populations and fisheries interactions with marine mammals in New England. Final Report Contract NA-EA-C-0070, Northeast Fisheries Center, Woods Hole, Massachusetts. 15 pp.

Haley, N. J. and A. J. Read. 1993. Summary of the workshop on harbor porpoise mortalities and human interaction. NOAA Tech. Mem. NMFS-F/NER 5.

Hooker, S. K., R. W. Baird and M. A. Showell. 1997. Cetacean strandings and bycatches in Nova Scotia, Eastern Canada, 1991-1996. Meeting document SC/49/O5 submitted to the 1997 International Whaling Commission Scientific Committee meeting in Bournemouth, UK.

Johnston, D. W. 1995. Spatial and temporal differences in heavy metal concentrations in the tissues of harbour porpoises (*Phocoena phocoena* L.) from the western North Atlantic. M.S. Thesis, University of Guelph, Guelph, Ontario, Canada. 152 pp.

Kingsley, M. C. S. and R. R. Reeves. 1998. Aerial surveys of cetaceans in the Gulf of St. Lawrence in 1995 and 1996. *Can. J. Zool*. 76:1529-1550.

Koopman, H. N., A. J. Westgate and A. J. Read. 1999. Hematology values of wild harbor porpoise (*Phocoena phocoena*) from the Bay of Fundy Canada. *Mar. Mammal Sci*. 15 (1):52-64.

Kraus, S. D. and S. Brault. (in press). A springtime field test of the use of pingers to reduce incidental mortality of harbor porpoises in gillnets. *Rep. Int. Whal. Commn*.

Kraus, S. D., A. Read, E. Anderson, K. Baldwin, A. Solow, T. Sprawling and J. Williamson. 1997. Acoustic alarms reduce porpoise mortality. *Nature* 388:525.

Kraus, S. D., J. H. Prescott and G. S. Stone. 1983. Harbour porpoise, *Phocoena phocoena*, in the U.S. coastal waters of the Gulf of Maine: A survey to determine seasonal distribution and abundance. Report to the Director, National Marine Fisheries Service, Northeast Region, Woods Hole, MA, 15 pp.

Lamb, A. 2000. Patterns of harbor porpoise mortality in two US Atlantic sink gillnet fisheries and changes in life history parameters. Masters Thesis from Boston University.

Lucas, Z. N. and S. K. Hooker. 2000. Cetacean strandings on Sable Island, Nova Scotia, 1970–1998. *Canadian Field-Naturalist* 114 (1): 46-61.

Molyneaux, P. 2000. Tradition at stake. *National Fisherman* 80 (11):26–29.

Neimanis, A. S., A. J. Read, A. J. Westgate, H. N. Koopm an, J. Y. Wang, L. D. Murison and D. E. Gaskin. 1995. Entrapment of har our porpoises (*Phocoena phocoena*) in herring weirs in the Bay of Fundy, Canada. Working paper SC/47/Sm18 for the International Whaling Commission, Dublin, Ireland.

NEFSC (NMFS Northeast Fisheries Science Center). 1992. Harbor porpoise in eastern North America: Status and research needs. Results of a scientific workshop held May 5-8, 1992 at the Northeast Fisheries Science Center, Woods Hole, MA. NOAA, NMFS, NEFSC Ref. Doc. 92-06, Woods Hole, MA.

Palka, D. 2000. Abundance of the Gulf of Maine/Bay of Fundy harbor porpoise based on shipboard and aerial surveys during 1999. NOAA/NMFS/NEFSC Ref. Doc. 00–07; 29 pp. Available from: National Marine Fisheries Service, 166 Water Street, Woods Hole, MA 02543–1026.

Palka, D. 1996. Update on abundance of Gulf of Maine/Bay of Fundy harbor porpoises. NOAA/NMFS/NEFSC Ref. Doc. 96-04; 37 pp. Available from: National Marine Fisheries Service, 166 Water Street, Woods Hole, MA 02543–1026.

Palka, D. 1995a. Abundance estimate of the Gulf of Maine harbor porpoise. pp. 27-50 In: A. Bj<rge and G.P. Donovan (eds.) Biology of the Phocoenids. *Rep. Int Whal. Commn*. Special Issue 16.

Palka, D. 1995b. Influences on spatial patterns of Gulf of Maine harbor porpoises. pp. 69–75 In: A.S. Blix, L. Wall<e and. Ulltang (eds.) Whales, seals, fish and man. Elsevier Science B.V. The Netherlands.

Palka, D. (ed). 1994. Results of a scientific workshop to evaluate the status of harbor porpoises (*Phocoena phocoena*) in the western North Atlantic. NOAA, NMFS, NEFSC [Northeast Fisheries Science Center] Ref. Doc. 94-09, Woods Hole, MA.

Palka, D. L., A. J. Read, A. J. Westgate and D. W. Johnston. 1996. Summary of current knowledge of harbour porpoises in U.S. and Canadian Atlantic waters. Rep. Int Whal. Commn. 46:559–565.

Polacheck, T. 1989. Harbor porpoises and the gillnet fishery. *Oceanus*32 (1):63-70.

Polacheck, T., F. W. Wenzel, and G. Early. 1995. What do stranding data say about harbor porpoises (*Phocoena phocoena*). Pp 169–180 in: A. Bj<rge and G.P. Donovan (eds.) Biology of the Phocoenids. *Rep. Int Whal. Commn*. Special Issue 16.

Read, A. J. 1994. Interactions between cetaceans and gillnet and trap fisheries in the northwest Atlantic. *Rep. Int Whal. Commn*. Special Issue 15: 133–147.

Read, A. J. and A. A. Hohn. 1995. Life in the fast lane: The life history of harbour porpoises from the Gulf of Maine. *Mar. Mammal Sci*. 11(4)423-440.

Read, A. J. and A. J. Westgate. 1997. Monitoring the movements of harbour porpoises (*Phocoena phocoena*) with

satellite telemetry. *Marine Biology* 130:315–22.

Rosel, P. E., S. C. France, J. Y. Wang and T. D. Kocher. 1999a. Genetic structure of harbour porpoise *Phocoena phocoena* populations in the northwest Atlantic based on mitochondrial and nuclear markers.

Rosel, P. E., S. C. France, J. Y. Wang and T. D. Kocher. 1999a. Genetic structure of harbour porpoise Phocoena phocoena populations in the northwest Atlantic based on mitochondrial and nuclear markers. Molecular Ecology 8: S41-S54. *Molecular Ecology*8: S41-S54.

Rosel, P. E., R. Tiedemann and M. Walton. 1999b. Genetic evidence for limited trans-Atlantic movements of the harbor porpoise *Phocoena phocoena. Marine Biology*133: 583-591.

Smith, G. J. D., A. J. Read and D. E. Gaskin. 1983. Incidental catch of harbor porpoises, *Phocoena phocoena* (L.), in herring weirs in Charlotte County, New Brunswick, Canada. *Fish. Bull., U.S.* 81(3):660–2.

Smith, T., D. Palka and K. Bisack. 1993. Biological significance of bycatch of harbor porpoise in the Gulf of Maine demersal gillnet fishery. NOAA, NMFS, NEFSC [Northeast Fisheries Science Center] Ref. Doc. 93–23, Woods Hole, MA.

Trippel, E. A., J. Y. Wang, M. B. Strong, L. S. Carter and J. D. Conway. 1996. Incidental mortality of harbour porpoise (*Phocoena phocoena*) by the gillnet fishery in the lower Bay of Fundy. *Can. J. Fish. Aquat. Sci.* 53:1294-1300.

Trippel, E. A., M. B. Strong, J. M. Terhune and J. D. Conway. 1999. Mitigation of harbour porpoise (*Phocoena phocoena*) bycatch in the gillnet fishery in the lower Bay of Fundy. *Can. J. Fish. Aquat. Sci.* 56:113–123.

Wade, P. R. and R. P. Angliss. 1997. Guidelines for assessing marine mammal stocks: Report of the GAMMS workshop April 3–5, 1996, Seattle, Washington. U.S. Dep. Commer., NOAA Tech. Memo. NMFS–OPR–12, 93 pp.

Wade, P. R. 1998. Population viability analysis of the Gulf of Maine/Bay of Fundy harbor porpoise. Office of Protected Resources Report, National Marine Fisheries Service.

Wade, P. R. 2001. Revised population viability analysis of the Gulf of Maine/ Bay of Fundy harbor porpoise using abundance and mortality estimates through 1999. National Marine Mammal Laboratory, Alaska Fisheries Science Center, National Marine Fisheries Service.

Wang, J. Y., D. E. Gaskin and B. N. White. 1996. Mitochondrial DNA analysis of harbour porpoise, Phocoena phocoena, subpopulations in North American waters. *Can J Fish Aquat Sciences* 53:1632–45.

Walden, J. 1996. The New England gillnet effort study. NOAA, NMFS, NEFSC Ref. Doc. No. 96-10, 38 pp. Northeast Fisheries Science Center, Woods Hole, MA.

Westgate, A. J. and K. A. Tolley. 1999. Geographical differences in organochlorine contaminants in harbour porpoises *Phocoena phocoena* from the western North Atlantic. Marine Ecology-Progress Series 177:255–268.

Westgate, A. J., A. J. Read, T. M. Cox, T. D. Schofield, B. R. Whitaker and K. E. Anderson. 1998. Monitoring a rehabilitated harbor porpoise using satellite telemetry. *Mar. Mammal Sci.* 14 (3):599–604.

Westgate, A. J., D. C. G. Muir, D. E. Gaskin and M. C. S. Kingsley. 1997. Concentrations and accumulation patterns of organochlorine contaminants in the blubber of harbour porpoises, Phocoena phocoena, from the coast of Newfoundland, the Gulf of St. Lawrence and the Bay of Fundy/Gulf of Maine. *Envir. Pollut.* 95: 105–119.

Wilkinson, D. 1996. National contingency plan for response to unusual marine mammal mortality events. U.S. Dep. Commer. NOAA Tech. Memo. NMFS–OPR–9, 118 p.

Authority: 16 U.S.C. 1531 *et seq.*

Dated: July 27, 2001.

William T. Hogarth,

Acting Assistant Administrator, National Marine Fisheries Service.

[FR Doc. 01–19354 Filed 7–30–01; 2:45 pm]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 622

[I.D. 072301B]

Fisheries of the Caribbean, Gulf of Mexico, and South Atlantic; Shrimp Fishery of the Gulf of Mexico; Public Hearings

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of public hearings; request for comments.

SUMMARY: The Gulf of Mexico Fishery Management Council (Council) will convene public hearings to receive comments on its proposed Draft Amendment 10 to the Fishery Management Plan for the Shrimp Fishery of the Gulf of Mexico, U.S. Waters (Draft Amendment 10).

DATES: The public hearings will be held in August, 2001. See **SUPPLEMENTARY INFORMATION** for specific dates and times of the public hearings. Written comments on Draft Amendment 10 will be accepted until September 7, 2001.

ADDRESSES: Written comments should be sent to and copies of Draft Amendment 10 are available from the Gulf of Mexico Fishery Management Council, 3018 U.S. Highway 301, North, Suite 1000, Tampa, FL 33619; telephone 813–228–2815. Public hearings will be held in Texas and Florida. See **SUPPLEMENTARY INFORMATION** for specific hearing locations.

FOR FURTHER INFORMATION CONTACT: Dr. Richard Leard, Senior Fishery Biologist, Gulf of Mexico Fishery Management Council; telephone: 813–228–2815.

SUPPLEMENTARY INFORMATION: The public hearings will be convened to take public comment on Draft Amendment 10. The amendment contains alternative measures for reducing bycatch in the Gulf of Mexico shrimp fishery off the west coast of Florida, south and east of Cape San Blas, FL (85°30′ W long.). The Council is considering alternative measures including area and/or seasonal shrimp fishery closures as well as requiring bycatch reduction devices (BRDs) in shrimp trawls used in the subject area.

Time and Location for Public Hearings

Public hearings for Draft Amendment 10 will be held at the following locations and dates from 7 p.m. – 10 p.m.

1. Tuesday, August 14, 2001, Laguna Madre Learning Center, Port Isabel High School, Highway 100, Port Isabel, TX 78578, telephone: 956–943–0052;

2. Wednesday, August 15, 2001, Palacios Recreation Center, 2401 Perryman, Palacios, TX 77465, telephone: 361–972–2387;

3. Monday, August 20, 2001, Holiday Inn Beachside, 3841 North Roosevelt Boulevard, Key West, FL 33040, telephone: 305–294–2571;

4. Tuesday, August 21, 2001, Edison Comm. College, Room H101, Ft. Myers, FL (use Shoreline Blvd entrance Park in 1st lot on right [Lot 8]. For Map directions see: http://www.edison.edu/ aboutecc/lee—campus.htm;

5. Thursday, August 23, 2001, Tampa Airport Hilton, 2225 Lois Avenue, Tampa, FL 33607, telephone: 813–877–6688; and

6. Tuesday, August 28, 2001, Franklin County Courthouse, 33 Market Street,

Apalachicola, FL 32320, telephone: 850–653–8861.

The Council will also hear public testimony before taking final action on the amendment on September 12, 2001, at its meeting in New Orleans, LA. A notification of the date, time, and location of that meeting will be published in the **Federal Register**. The Council will accept written comments received by September 7, 2001.

Special Accommodations

These meetings are physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Anne Alford at the Council (see **ADDRESSES**) by July 31, 2001.

Dated: July 27, 2001.

Dean Swanson,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 01–19359 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 660

[ID 071301D]

Fisheries Off West Coast States and in the Western Pacific; Pacific Coast Groundfish Fishery; Application for an Exempted Fishing Permit

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of receipt of an application for an exempted fishing permit (EFP); request for comments.

SUMMARY: NMFS announces receipt of an application for an EFP from the Pacific Marine Conservation Council (PMCC), State of California Department of Fish and Game (CDF&G), and Kenyon Hensel. The primary purpose of the EFP is to collect quantitative information to assess the selectivity of open access vertical hook-and-line and rod-and-reel gear used in the open access fishery off California. If awarded, the EFP would allow a small number of vessels to land groundfish species in excess of cumulative trip limits and to sell a portion of the yellowtail rockfish for profit, providing the vessel carries a State sponsored observer. This EFP proposal is intended to promote the objectives of the Pacific Coast Groundfish Fishery Management Plan (FMP) by providing data on gear selectivity and supporting a cooperative partnership to collect data to enhance management of the groundfish fishery.

DATES: Comments must be received by September 4, 2001.

ADDRESSES: ADDRESSES: Copies of the EFP application are available from Becky Renko, Northwest Region, NMFS, 7600 Sand Point Way N.E., Bldg. 1, Seattle, WA 98115–0070.

FOR FURTHER INFORMATION CONTACT: Becky Renko, 206–526–6140.

SUPPLEMENTARY INFORMATION: This action is authorized by the FMP and implementing regulations at 50 CFR 600.745 and 50 CFR 660.350.

On June 13, 2001, NMFS received a joint EFP application from PMCC, CDF&G, and Kenyon Hensel, a commercial fisher. The primary purpose of the exempted fishing activity is to provide quantitative information that can be used to assess the selectivity of open access vertical hook-and-line and rod-and-reel gear used in the open access fishery off California. In addition, fishing under the EFP is expected to provide valuable information on at-sea catch monitoring aboard small groundfish vessels.

Fishing for yellowtail rockfish, an abundant and commercially important groundfish species, is constrained by efforts to rebuild canary rockfish, an overfished species. This is because the two species are typically caught together. Open access fishers who target yellowtail rockfish believe that the fishery can be prosecuted with a much lower rockfish bycatch rate than is currently assumed.

Under the current open access trip limits for canary rockfish, fishers are allowed to land up to 50 lb (23 kg) per month of canary rockfish and up to 100 lb (45 kg) per month of yellowtail rockfish. Because the applicants believe that the current limits are too restraining to conduct an assessment of gear selectivity, they are requesting that participating vessels be allowed to land up to 1,000 lb (454 kg) yellowtail rockfish per month. Up to 500 lb (227 kg) of the yellowtail rockfish landed per month could be sold for profit by the vessel. Any monthly yellowtail landings greater than 500 lb,(227 kg) would be forfeited to the state of California. In addition, vessels would be required to retain all harvested rockfish species. Landings in excess of the applicable trip limits would be forfeited to the State of California.

If issued, this EFP would allow designated vessels to retain rockfish in excess of cumulative trip limits and would allow them to sell a portion of the yellowtail rockfish for profit. In addition to the 50–lb (23-kg) per month cumulative limit for canary rockfish, a canary sub-limit of 30 lb (14 kg) per trip would apply. The EFP would also provide for a state-run observer program in which observers collect: species composition and length/weight data, and information on fishing effort, gear configurations and fishing schedules. Without an EFP, groundfish regulations at 50 CFR 660.306 (f) restrict vessels from landing groundfish species or species groups in excess of trip limits.

Data collected during this project is expected to have a broader significance to the management of the groundfish fishery by providing: (1) Quantitative information necessary to evaluate the selectivity of vertical hook-and-line and rod-and reel gear used by open access fishers; (2) catch composition data; (3) length and weight data from harvested catch that is otherwise not available, (4) information on the full retention of rockfish catch; and (5) valuable information on at-sea catch monitoring aboard small groundfish vessels.

If the EFP is issued, approximately 1-5 vessels are expected to fish under the EFP using vertical hook-and-line and rod-and-reel gear, from August to October 2001 and again from June to October 2002. The proposed fishing would initially occur in nearshore waters, 19-55 fathoms, off Crescent City, CA, but may be expanded into other areas depending on the number of participating vessels and the final sampling plan. With the exception of rockfish, landings of all other groundfish will be within the applicable trip limit limits for those species.

In accordance with regulations, NMFS has determined that the proposal warrants further consideration and has consulted with the Council. The Council considered the EFP application during its June 11-5, 2001, meeting in Burlingame, CA and supported approval of the application. A copy of the application is available for review from NMFS (see **ADDRESSES**). Based on the results of this EFP, this action may lead to future rulemaking.

Authority: 16 U.S.C. 1801 *et seq.*

Dated: July 26, 2001.

Dean Swanson,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 01–19217 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–22–S

Notices

Federal Register

Vol. 66, No. 149

Thursday, August 2, 2001

This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

DEPARTMENT OF AGRICULTURE

National Agricultural Statistics Service

Notice of Intent To Extend and Revise a Currently Approved Information Collection

AGENCY: National Agricultural Statistics Service, USDA.

ACTION: Notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995 (Pub. L. No. 104–13) and Office of Management and Budget regulations at 5 CFR part 1320 (60 FR 44978, August 29, 1995), this notice announces the National Agricultural Statistics Service (NASS) intention to request extension and revision of a currently approved information collection, the Respondent Information Evaluation.

DATES: Comments on this notice must be received by October 9, 2001 to be assured of consideration.

FOR FURTHER INFORMATION CONTACT: Contact Rich Allen, Associate Administrator, National Agricultural Statistics Service, U.S. Department of Agriculture, Room 4117 South Building, 1400 Independence Avenue SW., Washington, DC 20250–2001, (202) 720–4333.

SUPPLEMENTARY INFORMATION:

Title: Respondent Information Evaluation.

OMB Control Number: 0535–0231.

Expiration Date of Approval: 09/30/01.

Type of Request: To Extend and Revise a Currently Approved Information Collection.

Abstract: The National Agricultural Statistics Service is continuing a coordinated effort to increase the cooperation of survey respondents in our information collections. This effort will include the ongoing development of a program to educate agricultural producers about the functions of NASS and the uses of survey data. As a major part of this education program, we will emphasize to data providers the importance of unbiased NASS estimates and the potential consequences if these estimates were unavailable. Ways to disseminate this message will also be investigated and tested. Data users will be surveyed to gain insight into uses of NASS data. Data providers will be surveyed to obtain their opinions of how NASS survey data are used.

These data will be collected under the authority of 7 U.S.C. 2204(a). Individually identifiable data collected under this authority are governed by Section 1770 of the Food Security Act of 1985, 7 U.S.C. 2276, which requires USDA to afford strict confidentiality to non-aggregated data provided by respondents.

Estimate of Burden: Public reporting burden for the collection of information from data users is estimated to average 10 minutes per response; burden for data providers is estimated to average 2 minutes per response.

Respondents: Subscribers to NASS commodity reports (data users) and agricultural producers (data providers).

Estimated Number of Respondents: 700 report subscribers and 9,000 producers.

Estimated Total Annual Burden on Respondents: 455 hours.

Copies of this information collection and related instructions can be obtained without charge from Ginny McBride, the Agency OMB Clearance Officer, at (202) 720–5778.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Comments may be sent to: Ginny McBride, Agency OMB Clearance Officer, U.S. Department of Agriculture, Room 5330B South Building, 1400 Independence Avenue SW., Washington, DC 20250–2024 or *gmcbride@nass.usda.gov.* All responses to this notice will become a matter of public record and be included in the request for OMB approval.

Signed at Washington, DC, May 22, 2001.

Rich Allen,

Associate Administrator.

[FR Doc. 01–19297 Filed 8–1–01; 8:45 am]

BILLING CODE 3410–20–P

DEPARTMENT OF COMMERCE

[I.D. 072601B]

Submission for OMB Review; Comment Request

The Department of Commerce has submitted to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

Agency: National Oceanic and Atmospheric Administration (NOAA).

Title: Sea Grant Program Application Requirements for Grants, for John A. Knauss Marine Policy Fellowships, and for Designation as a Sea Grant College or Regional Consortia.

Form Number(s): NOAA Forms 90–1, 90-2, and 90–4.

OMB Approval Number: 0648–0362.

Type of Request: Regular submission.

Burden Hours: 580.

Number of Respondents: 91.

Average Hours Per Response: 30 minutes for a NOAA Form 90–1, 20 minutes for a NOAA Form 90-2, 15 minutes for a NOAA Form 90–4, 20 hours for an application for designation as a Sea Grant College or Regional Consortia, and 2 hours for an application for a Dean John A. Knauss Marine Policy Fellowship.

Needs and Uses: Applications are required for designation of an institution of higher education as a Sea Grant College, and for the designation of regional consortia, institutes, laboratories, or state and local agencies as Sea Grant Programs. Applications are also required in order to be awarded a Dean John. A. Knauss Fellowship for Marine Policy. Grant monies are available for funding activities that help to attain the objectives of the Sea Grant Program. In addition to the SF–424 and

other standard grant application requirements, three additional forms are required with a grant application. These are the Sea Grant Control Form, the Project Record Form, and the Sea Grant Budget Form (used in place of the SF–424a or 424c).

Affected Public: State, local, or tribal government; not-for-profit institutions.

Frequency: On occasion, annual.

Respondent's Obligation: Required to obtain or retain a benefit.

OMB Desk Officer: David Rostker, (202) 395–3897.

Copies of the above information collection proposal can be obtained by calling or writing Madeleine Clayton, Departmental Paperwork Clearance Officer, (202) 482–3129, Department of Commerce, Room 6086, 14th and Constitution Avenue, NW, Washington, DC 20230 (or via the Internet at MClayton@doc.gov).

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to David Rostker, OMB Desk Officer, Room 10202, New Executive Office Building, Washington, DC 20503.

Dated: July 25, 2001.

Madeleine Clayton,

Departmental Paperwork Clearance Officer, Office of the Chief Information Officer.

[FR Doc. 01–19218 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–KA–S

DEPARTMENT OF COMMERCE

Census Bureau

2002 Economic Census—Vehicle Inventory and Use Survey (VIUS)

ACTION: Proposed collection; comment request.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)).

DATES: Written comments must be submitted on or before October 1, 2001.

ADDRESSES: Direct all written comments to Madeleine Clayton, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6086, 14th and Constitution Avenue, NW, Washington, DC 20230 (or via the Internet at mclayton@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument(s) should be directed to Kimberly Moore, Census Bureau, Room 2744, Building 3, Washington, DC 20233, (301) 457–2797 (or via the Internet at Kimberly.P.Moore@census.gov).

SUPPLEMENTARY INFORMATION

I. Abstract

The Census Bureau is the preeminent collector and provider of timely, relevant, and quality data about the people and economy of the United States. Economic data are the Census Bureau's primary program commitment during nondecennial census years. The Economic Census, conducted under authority of Title 13 U.S.C., is the primary source of facts about the structure and functioning of the Nation's economy and features unique industry and geographic detail. Economic Census statistics serve as part of the framework for the national accounts and provide essential information for government, business and the general public. The 2002 Economic Census will cover virtually every sector of the U.S. economy.

The 2002 Vehicle Inventory and Use Survey, a component of the Economic Census, will produce basic statistics (number of trucks, annual miles, and average miles per truck) on the physical and operational characteristics of the nation's private and commercial truck population. It also will yield a variety of subject statistics including trucks by major use, fuel type, miles per gallon, and products carried. The Census Bureau will publish truck results at the state and national level.

Primary strategies for reducing burden in the Vehicle Inventory and Use Survey data collection include employing a stratified random sample to use the least number of sampling units required to produce reliable statistics, providing check boxes with ranges in lieu of requiring specific responses, and utilizing a short form for light trucks with homogeneous characteristics.

II. Method of Collection

The Vehicle Inventory and Use Survey will survey a sample of private and commercial trucks registered in the 50 States and the District of Columbia. Government-owned trucks will not be sampled. Trucks will be divided into 5 different groups: ''pick-up,'' ''van,'' ''single-unit light,'' ''single-unit heavy,'' and ''truck tractors.'' All trucks will be selected at random with probabilities of selection varying by group and state. For each selected truck, a questionnaire will be mailed to the owner identified in the truck registration record. The owner will be asked to respond only for the truck identified by the registration information imprinted on the questionnaire, regardless of whether or not it is still in their possession.

Mail selection procedures will distinguish the following groups of trucks:

A. Light Trucks

A sample of ''pickups'' and ''vans'' (including panel trucks, minivans, and sport utility vehicles) will be selected. We estimate that the census mail canvass for 2002 will include approximately 32,000 light trucks out of an overall estimated universe of over 70 million privately and commercially registered light trucks.

B. Medium and Heavy Trucks

Selection procedures will assign all single-unit trucks (excluding those in the pickup and van strata) with a gross vehicle weight (GVW) of 26,000 pounds or less to the ''single-unit light'' group, the remaining single unit trucks to the ''single-unit heavy'' group, and truck tractors to the ''truck tractor'' group. We estimate that the census mail canvass for 2002 will include approximately 103,500 medium and heavy trucks out of an overall estimated universe of over 6 million privately and commercially registered medium and heavy trucks.

III. Data

OMB Number: Not available.

Form Number:

TC–9501 Light Trucks.

TC–9502 Medium and Heavy Trucks.

Type of Review: Regular review.

Affected Public: Individuals, Farms, Businesses and other for-profit institutions, Non-profit institutions, Small businesses or organizations.

Estimated Number of Respondents:

TC–9501 (Light Trucks): 31,851.

TC–9502 (Medium and Heavy Trucks): 103,503.

Total Number of Respondents: 135,354.

Estimated Time Per Response:.

TC–9501 (Light Trucks): .4 hours.

TC–9502 (Medium and Heavy Trucks): .7 hours.

Estimated Total Annual Burden Hours:

TC–9501 (Light Trucks): 12,740.

TC–9502 (Medium and Heavy Trucks): 72,452.

Total Annual Burden Hours: 85,192.

Estimated Total Annual Cost:

TC–9501 (Light Trucks): $231,868.

TC–9502 (Medium and Heavy Trucks): $1,318,626.

Total Annual Cost: $1,550,494.

Respondent's Obligation. Mandatory.

Legal Authority: Title 13, Section 131 of the United States Code.

IV. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary or the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: July 27, 2001.

Madeleine Clayton,

Departmental Paperwork Clearance Officer, Office of the Chief Information Officer.

[FR Doc. 01–19242 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–07–P

DEPARTMENT OF COMMERCE

International Trade Administration

[A–570–863]

Notice of Amended Preliminary Antidumping Duty Determination of Sales at Less Than Fair Value: Honey From the People's Republic of China

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

ACTION: Notice of amended preliminary antidumping duty determination of sales at less than fair value: Honey from the People's Republic of China.

EFFECTIVE DATE: August 2, 2001.

FOR FURTHER INFORMATION CONTACT: Angelica Mendoza (Inner Mongolia and Zhejiang) at (202) 482–3019, Fred Baker (Kunshan) at (202) 482–2924, Charles Rast at (202) 482–1324 or Donna Kinsella at (202) 482–0194; Antidumping and Countervailing Duty Enforcement Group III, Office Eight, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue NW., Washington, DC 20230.

Amendment of Preliminary Determination

The Department of Commerce (the Department) is amending the preliminary determination in the antidumping investigation of honey from the People's Republic of China (PRC). This amended preliminary determination results in a revised antidumping rate for one respondent.

Background

On May 4, 2001, the Department issued its affirmative preliminary determination in this proceeding. *See Notice of Preliminary Determination of Sales at Less than Fair Value: Honey from the People's Republic of China,* 66 FR 24101 (May 11, 2001) (*Preliminary Determination*). That preliminary determination covered the following manufacturers/exporters: Inner Mongolia Autonomous Region Native Produce and Animal By-Products Import and Export Corporation (Inner Mongolia), Kunshan Foreign Trading Company (Kunshan), Zhejiang Native Produce and Animal By-Products Import and Export Corporation (Zhejiang), High Hope International Group Jiangsu Foodstuffs Import and Export Corporation (High Hope), Shanghai Eswell Enterprise Company Ltd. (Shanghai Eswell), Anhui Native Produce Import and Export Corporation (Anhui), and Henan Native Produce Import and Export Corporation (Henan).

On May 21, 2001, the Department received from the petitioners a timely allegation of ministerial errors in the preliminary determination. The petitioners alleged that the Department:

- Incorrectly calculated the value of iron drums for three respondents;
- Applied an incorrect inflation factor for two respondents;
- Used an incorrect byproduct production figure in calculating the volume of beeswax for one respondent;
- Failed to value water in its calculation of energy costs for one respondent.

See letter from Collier Shannon Scott alleging ministerial errors in the preliminary determination (May 21, 2001).

Significant Ministerial Error

A significant ministerial error is defined as an error, the correction of which, singly or in combination with other errors, would result in (1) a change of at least five absolute percentage points in, but not less than 25 percent of, the weighted-average dumping margin calculated in the original (erroneous) preliminary determination; or (2) a difference between a weighted-average dumping margin of zero or *de minimis* and a weighted-average dumping margin of greater than *de minimis* or vice versa. See 19 CFR 351.224(g).

Amended Determination

The Department has reviewed its preliminary calculations and agrees that what the petitioners identified as ministerial errors do constitute ministerial errors within the meaning of 19 CFR 351.224(f). Moreover, from our review of the calculations we have determined that the Department also erred by:

- Using incorrect freight forwarding rates in valuing the freight charges for one respondent;
- Applying the by-product offset for of beeswax on a kilogram, rather than metric ton basis for one respondent;
- Failing to convert the value of beeswax into the correct currency for one respondent;
- Failing to calculate a single weighted-average normal value for one respondent who had two suppliers;
- Applying an inflator to labor rates taken from the Department's website.

For a detailed analysis and the Department's determinations, see the July 25, 2001 Memorandum to Richard O. Weible from Angelica Mendoza regarding Ministerial Error Allegations on file in room B–099 of the main Commerce building. As a result of our analysis of petitioners' allegations and the other ministerial errors we have identified, we are amending our preliminary determination to revise the antidumping rates in accordance with 19 CFR 351.224(e). However, we have determined that only for Zheijing were the ministerial errors significant within the meaning of 19 CFR 351.224(g). Therefore, this amended preliminary determination reflects a revised margin only for Zheijing. Suspension of liquidation will be revised accordingly and parties will be notified of this determination, in accordance with section 733(d) and (f) of the Tariff act of 1930, as amended (the Tariff Act).

The following weighted-average dumping margins apply:

Manufacturer/exporter	Margin (percent)
Inner Mongolia	44.00
Kunshan	37.51
Zhejiang	22.05
High Hope	39.76
Shanghai Eswell	39.76
Anhui	39.76
Henan	39.76
PRC-wide Entity	183.80

The PRC-wide rate has not been amended, and applies to all entries of the subject merchandise except for entries from exporters/producers that are identified individually above.

Critical Circumstances

In our preliminary determination we found critical circumstances with respect to Zhejiang. In order to find critical circumstances in situations in which there is no previous history of dumping of the product, the Department must find that there is a reasonable basis to believe or suspect that an importer knew or should have known that the exporter was selling the subject merchandise at less than fair value. *See* section 733(e)(1)(A) of the Tariff Act. In doing so, the Department normally considers margins of 25 percent or more for EP sales sufficient to impute such knowledge of dumping. *See, e.g., Preliminary Determination,* 66 FR at 24106. In this case we imputed to Zhejiang's importers knowledge that Zhejiang was selling honey to the United States at dumped prices based on the 38.96 percent margin originally calculated for Zhejiang. *Id.* Given that, as a result of this correction of ministerial errors, the margin for Zhejiang is now less than 25 percent, we are no longer imputing knowledge of dumping with respect to imports from Zhejiang. Therefore, we now find that critical circumstances do not exist as to imports from Zhejiang. As a result, we will instruct the U.S. Customs Service to liquidate all entries of subject merchandise exported by Zhejiang that are entered, or withdrawn from warehouse, for consumption before May 11, 2001, which was the date of publication of the original preliminary determination in the **Federal Register**.

This determination is issued and published pursuant to section 733(f) and 777(i)(1) of the Tariff Act.

Faryar Shirzad,

Assistant Secretary for Import Administration.

[FR Doc. 01–19348 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

[A–412–822]

Notice of Preliminary Determination of Sales at Less Than Fair Value and Postponement of Final Determination: Stainless Steel Bar From the United Kingdom

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

ACTION: Notice of preliminary determination of sales at less than fair value.

SUMMARY: We preliminarily determine that stainless steel bar from the United Kingdom is being, or is likely to be, sold in the United States at less than fair value, as provided in section 733(b) of the Tariff Act of 1930, as amended.

Interested parties are invited to comment on this preliminary determination. Since we are postponing the final determination, we will make our final determination not later than 135 days after the date of publication of this preliminary determination in the **Federal Register**.

EFFECTIVE DATE: August 2, 2001.

FOR FURTHER INFORMATION CONTACT: Kate Johnson or Rebecca Trainor, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–4929 or (202) 482–4007, respectively.

SUPPLEMENTARY INFORMATION:

The Applicable Statute

Unless otherwise indicated, all citations to the Tariff Act of 1930, as amended (''the Act''), are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act (''URAA''). In addition, unless otherwise indicated, all citations to the Department of Commerce (''Department's'') regulations are to the regulations at 19 CFR Part 351 (April 2000).

Background

Since the initiation of this investigation (*Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom*, 66 FR 7620 (January 24, 2001) (*Initiation Notice*), as amended by *Corrections, Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom,* 66 FR 14986 (March 14, 2001), the following events have occurred:

On January 26, 2001, we solicited comments from interested parties regarding the criteria to be used for model-matching purposes and we received comments on our proposed matching criteria on February 8, 2001.

On February 12, 2001, the United States International Trade Commission (''ITC'') preliminarily determined that there is a reasonable indication that imports of stainless steel bar (''SSB'') from the United Kingdom are materially injuring the United States industry (*see* ITC Investigation No. 701–TA–913–918 (Publication No. 3395)).

Also on February 12, 2001, we selected the three largest producers/exporters of SSB from the United Kingdom as the mandatory respondents in this proceeding. For further discussion, *see* Memorandum from The Team to Richard W. Moreland, Deputy Assistant Secretary for Import Administration, entitled ''Respondent Selection,'' dated February 12, 2001. We subsequently issued the antidumping questionnaires to Corus Engineering Steels Ltd. (''Corus''), Crownridge Stainless Steel Limited (''Crownridge''), and Firth Rixson Special Steels, Ltd. (''FRSS'') on February 20, 2001.

On February 13, 2001, Corus requested that certain special-quality oil field equipment steel grades be excluded from the scope of this investigation. *See* ''Scope of Investigation'' section of this notice for further discussion.

In February and March 2001, the petitioners [1] made submissions requesting that the Department require the respondents to report the actual content of the primary chemical components of SSB for each sale of SSB made during the period of investigation (''POI''). Also, in February and March 2001, the respondents in this and other concurrent SSB investigations requested that the Department deny the petitioners' request. The Department, upon consideration of the comments from all parties on this matter, issued a memorandum on April 3, 2001, indicating its decision not to require the respondents to report such information on a transaction-specific basis. However, the Department did require that respondents report certain additional information concerning SSB grades sold to the U.S. and home markets during the POI. (For details, *see*

[1] Carpenter Technology Corp., Crucible Specialty Metals, Electralloy Corp., Empire Specialty Steel Inc., Slater Steels Corp., and the United Steelworkers of America.

Memorandum from The Stainless Steel Bar Teams to Louis Apple and Susan Kuhbach, Office Directors, dated April 3, 2001).

During the period March through June 2001, the Department received responses to Sections A, B, C and D of its original and supplemental questionnaires from Corus and FRSS.

On April 27, 2001, pursuant to 19 CFR 351.205(e), the petitioners made a timely request to postpone the preliminary determination. We granted this request on May 7, 2001, and postponed the preliminary determination until no later than July 26, 2001. (*See Notice of Postponement of Preliminary Determinations of Sales at Less Than Fair Value: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom,* 66 FR 24114 (May 11, 2001).

On July 10 and 11, 2001, the petitioners provided comments on the questionnaire responses of FRSS and Corus, respectively, for the Department's consideration in the preliminary determination. Corus and FRSS responded to these comments on July 16 and 17, 2001, respectively.

Postponement of Final Determination and Extension of Provisional Measures

Pursuant to section 735(a)(2) of the Act, on June 8, 2001, and July 16, 2001, Corus and FRSS, respectively, requested that, in the event of an affirmative preliminary determination in this investigation, the Department postpone its final determination until not later than 135 days after the date of the publication of the preliminary determination in the **Federal Register**, and extend the provisional measures to not more than six months. In accordance with 19 CFR 351.210(b), because (1) our preliminary determination is affirmative, (2) Corus and FRSS account for a significant proportion of exports of the subject merchandise, and (3) no compelling reasons for denial exist, we are granting the respondent's request and are postponing the final determination until no later than 135 days after the publication of this notice in the **Federal Register**. Suspension of liquidation will be extended accordingly.

Scope of Investigation

For purposes of this investigation, the term ''stainless steel bar'' includes articles of stainless steel in straight lengths that have been either hot-rolled, forged, turned, cold-drawn, cold-rolled or otherwise cold-finished, or ground, having a uniform solid cross section along their whole length in the shape of circles, segments of circles, ovals, rectangles (including squares), triangles, hexagons, octagons, or other convex polygons. Stainless steel bar includes cold-finished stainless steel bars that are turned or ground in straight lengths, whether produced from hot-rolled bar or from straightened and cut rod or wire, and reinforcing bars that have indentations, ribs, grooves, or other deformations produced during the rolling process.

Except as specified above, the term does not include stainless steel semi-finished products, cut length flat-rolled products (*i.e.,* cut length rolled products which if less than 4.75 mm in thickness have a width measuring at least 10 times the thickness, or if 4.75 mm or more in thickness having a width which exceeds 150 mm and measures at least twice the thickness), products that have been cut from stainless steel sheet, strip or plate, wire (*i.e.,* cold-formed products in coils, of any uniform solid cross section along their whole length, which do not conform to the definition of flat-rolled products), and angles, shapes and sections.

The stainless steel bar subject to this investigation is currently classifiable under subheadings 7222.11.00.05, 7222.11.00.50, 7222.19.00.05, 7222.19.00.50, 7222.20.00.05, 7222.20.00.45, 7222.20.00.75, and 7222.30.00.00 of the *Harmonized Tariff Schedule of the United States* (''HTSUS''). Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the scope of this investigation is dispositive.

In accordance with our regulations, we set aside a period of time for parties to raise issues regarding product coverage and encouraged all parties to submit comments within 20 calendar days of publication of the *Initiation Notice* (*see* 66 FR 7620–7621). The respondents in this and the companion SSB investigations filed comments seeking to exclude certain products from the scope of these investigations. The specific products identified in their exclusion requests are:

- Stainless steel tool steel
- Welding wire
- Special-quality oil field equipment steel (SQOFES)
- Special profile wire

We have addressed these requests in a Memorandum to Susan Kuhbach and Louis Apple from The Stainless Steel Bar Team, dated July 26, 2001, entitled ''Scope Exclusion Requests,'' and a Memorandum to Louis Apple from The Stainless Steel Bar Team, dated July 26, 2001, entitled ''Whether Special Profile Wire Product is Included in the Scope of the Investigation.'' Our conclusions are summarized below.

Regarding stainless steel tool steel, welding wire, and SQOFES, after considering the respondents' comments and the petitioners' objections to the exclusion requests, we preliminarily determine that the scope is not overly broad. Therefore, stainless steel tool steel, welding wire, and SQOFES are within the scope of these SSB investigations. In addition, we preliminarily determine that SQOFES does not constitute a class or kind of merchandise separate from SSB.

Regarding special profile wire, we have preliminarily determined that this product does not fall within the scope as it is written because its cross section is in the shape of a concave polygon. Therefore, we have not included special profile wire in these investigations.

Finally, we note that in the concurrent countervailing duty investigation of stainless steel bar from Italy, the Department preliminarily determined that hot-rolled stainless steel bar is within the scope of these investigations. (*See, Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Countervailing Duty Determination with Final Antidumping Duty Determination: Stainless Steel Bar from Italy,* 66 FR 30414 (June 6, 2001)).

Period of Investigation

The POI is October 1, 1999, through September 30, 2000.

Use of Facts Available

Crownridge

On February 20, 2001, we sent an antidumping questionnaire to Crownridge, however, Crownridge did not respond. Prior to this date, on February 8, 2001, the U.S. Embassy in London informed us that Crownridge was no longer in business, and had been liquidated on February 6, 2001. That Crownridge was no longer in business was subsequently confirmed by counsel to Crownridge, as well as by representatives of the U.S. Embassy in London and our own research. Nevertheless, on June 15, 2001, we made a final attempt to contact the company, but were unsuccessful.

FRSS

FRSS responded to the Department's questionnaires, but failed to provide sufficient sales and cost information on which to base a preliminary antidumping duty margin, despite numerous opportunities to do so. FRSS's initial sections A–C questionnaire responses of March 23,

2001, and April 13, 2001, were deficient and/or unresponsive to many of the questions asked in the questionnaire. On May 21, 2001, we sent the respondent an extensive supplemental questionnaire on sections A–C, to which we received an inadequate response on June 11, 2001. At our request, on June 14, 2001, we met with counsel to FRSS to discuss the significant omissions and deficiencies of the questionnaire responses, and to alert counsel to the fact that the initial section D (cost of production) response was also largely inadequate, and lacked the elementary detail and narrative explanations necessary for cost calculation purposes. We allowed the company an additional opportunity to provide the missing sales and cost information discussed at the meeting. (For further details of this meeting, *see* Memorandum to the File from Brian Ledgerwood, dated June 18, 2001). On June 15, 2001, we issued a supplemental questionnaire for section D. Although FRSS's responses on June 22 and 29, 2001, to these last information requests were partially responsive, they still lacked the basic product, sales expense, and cost of production information necessary to perform the antidumping margin analysis.

Analysis

For the forgoing reasons, we determine that it is appropriate to apply antidumping margins based on the facts otherwise available to Crownridge and FRSS in accordance with section 776(a)(2)(A) and (B) of the Act, respectively. For further details regarding this determination, *see* the Memorandum to Richard W. Moreland from Louis Apple entitled ''Preliminary Determination of Stainless Steel Bar (SSB) from the United Kingdom: Use of Facts Available,'' dated July 26, 2001 (*Facts Available Memorandum*).

Section 776(a)(2) of the Act provides that, if an interested party (1) withholds information that has been requested by the Department, (2) fails to provide such information in a timely manner or in the form or manner requested, (3) significantly impedes a determination under the antidumping statute, or (4) provides such information but the information cannot be verified, the Department shall, subject to subsections 782(c)(1) and (e) of the Act, use facts otherwise available in reaching the applicable determination.

Section 776(b) of the Act provides that adverse inferences may be used when a party has failed to cooperate by not acting to the best of its ability to comply with requests for information. See also Statement of Administrative Action accompanying the URAA, H.R. Rep. No. 103–316, vol. 1, at 870 (1994) (SAA). While Crownridge failed to respond to the Department's questionnaire, we are satisfied that because of the special circumstances surrounding Crownridge, it was unable to provide a response. Therefore, the Department has determined that no adverse inference is warranted. Consequently, as non-adverse facts available, we have assigned Crownridge the all-others rate in this preliminary determination.

As explained above, FRSS was provided several opportunities to respond fully to the Department's questionnaires. In spite of our efforts, that included meeting with counsel for FRSS specifically to delineate deficiencies in its questionnaire responses, FRSS's responses continue to contain major deficiencies and omissions of data which render them unusable for purposes of the preliminary determination. In particular, FRSS failed to identify an affiliated producer of SSB which produced and sold SSB during the POI until late in the investigation, and then failed to provide basic sales and cost data for its affiliate. For further discussion, see the Facts Available Memorandum. Therefore, we preliminarily find that FRSS failed to act to the best of its ability to provide the information requested. Accordingly, we believe it is appropriate to use an adverse inference in selecting the facts otherwise available on which to base the antidumping rate for FRSS.

In accordance with our standard practice, we determine the margin used as adverse facts available by selecting the higher of (1) the highest margin stated in the notice of initiation, or (2) the highest margin calculated for any respondent. As adverse facts available (''AFA''), we have assigned to FRSS the highest margin in the petition. *See, e.g., Notice of Preliminary Determinations of Sales at Less Than Fair Value: Certain Large Diameter Carbon and Alloy Seamless Standard, Line and Pressure Pipe From Japan and Certain Small Diameter Carbon and Alloy Seamless Standard, Line and Pressure Pipe From Japan and the Republic of South Africa,* 64 FR 69718, 69722 (December 14, 1999); followed in *Notice of Final Determinations of Sales at Less Than Fair Value: Certain Large Diameter Carbon and Alloy Seamless Standard, Line and Pressure Pipe From Japan and Certain Small Diameter Carbon and Alloy Seamless Standard, Line and Pressure Pipe From Japan and the Republic of South Africa,* 65 FR 25907 (May 4, 2000); and *Notice of Preliminary Determination of Sales at Less Than Fair Value: Stainless Steel Wire Rod from Korea and Germany,* 63 FR 10826, 10847 (March 5, 1998); followed in *Notice of Final Determination of Sales at Less Than Fair Value: Stainless Steel Wire Rod from Korea and Germany,* 63 FR 40433 (July 29, 1998).

Section 776(c) of the Act provides that, when the Department relies on secondary information (such as the petition) in using the facts otherwise available, it must, to the extent practicable, corroborate that information from independent sources that are reasonably at its disposal. In this case, when analyzing the petition for purposes of the initiation, we reviewed all of the data upon which the petitioners relied in calculating the estimated dumping margins, and determined that the margins in the petition were appropriately calculated and supported by adequate evidence in accordance with the statutory requirements for initiation. In order to corroborate the petition margins for purposes of using them as AFA, we re-examined the price and cost information provided in the petition in light of information developed during this investigation. (*See* the *Facts Available Memorandum* for further details of our corroboration methodology.)

In accordance with section 776(c) of the Act, we were able to corroborate the information in the petition using information from independent sources that were reasonably at our disposal. As a result, we have preliminarily assigned FRSS the highest rate contained in the petition, 125.77 percent. Also, for the reasons stated above, we have preliminarily assigned to Crownridge, the ''all others'' rate as facts available in accordance with section 776(a) of the Act.

Fair Value Comparisons

To determine whether Corus's sales of SSB from the United Kingdom to the United States were made at less than fair value (''LTFV''), we compared the constructed export price (''CEP'') to the Normal Value (''NV''), as described in the ''Constructed Export Price'' and ''Normal Value'' sections of this notice, below. In accordance with section 777A(d)(1)(A)(i) of the Act, we compared POI weighted-average CEPs to NVs.

Product Comparisons

In accordance with section 771(16) of the Act, we considered all products produced and sold by the respondent (*i.e.*, Corus) in the home market during the POI that fit the description in the ''Scope of Investigation'' section of this

notice to be foreign like products for purposes of determining appropriate product comparisons to U.S. sales. We compared U.S. sales to sales made in the home market, where appropriate. Where there were no sales of identical merchandise in the home market made in the ordinary course of trade to compare to U.S. sales, we compared U.S. sales to sales of the most similar foreign like product made in the ordinary course of trade. In making the product comparisons, we matched foreign like products based on the physical characteristics reported by the respondent in the following order of importance: general type of finish; grade; remelting process; type of final finishing operation; shape; and size.

With respect to grade, we matched products sold in the U.S. and home markets on the basis of the three most similar matches proposed by the respondent, where possible.

On July 10 and 13, 2001, the petitioners submitted general comments on product-matching issues for the Department's consideration in the preliminary determination. These comments were not received in time to be fully analyzed for the preliminary determination, but will be considered for the final determination.

With respect to home market sales of non-prime merchandise made by Corus during the POI, in accordance with our past practice, we excluded these sales from our preliminary analysis based on the limited quantity of such sales in the home market and the fact that no such sales were made to the United States during the POI. (*See, e.g., Final Determinations of Sales at Less Than Fair Value: Certain Hot-Rolled Carbon Steel Flat Products, Certain Cold-Rolled Carbon Steel Flat Products, Certain Corrosion-Resistant Carbon Steel Flat Products, and Certain Cut-to-Length Carbon Steel Plate from Korea*, 58 FR 37176, 37180 (July 9, 1993)).

Constructed Export Price

Corus reported all of its U.S. sales as CEP sales made to unaffiliated customers in the United States through its U.S. affiliates. We calculated CEP, in accordance with subsection 772(b) of the Act, for sales made to the first unaffiliated purchaser that took place after importation into the United States by a seller affiliated with the producer or exporter.

We based CEP on the packed ''delivered,'' ''customer pick-up at U.S. port,'' or ''customer pick-up at warehouse'' prices to unaffiliated purchasers in the United States. We made adjustments to the starting price (*i.e.*, gross unit price inclusive of alloy surcharges, as applicable), where appropriate, for price-billing errors (i.e., invoice adjustments) and freight revenue. We made deductions for early payment discounts and rebates, where applicable. We also made deductions for movement expenses in accordance with section 772(c)(2)(A) of the Act; these included, where appropriate, foreign inland freight, foreign brokerage and handling, ocean freight, marine insurance, U.S. brokerage and handling, U.S. customs duties (including harbor maintenance fees and merchandise processing fees), U.S. inland insurance, U.S. inland freight expenses (freight from port to warehouse and freight from warehouse to the customer), and U.S. handling charges. In accordance with section 772(d)(1) of the Act, we deducted those selling expenses associated with economic activities occurring in the United States, including direct selling expenses (credit costs and warranty expenses), inventory carrying costs, and indirect selling expenses. We made an adjustment for profit in accordance with section 772(d)(3) of the Act.

Normal Value

A. Home Market Viability

In order to determine whether there is a sufficient volume of sales in the home market to serve as a viable basis for calculating NV (*i.e.,* whether the aggregate volume of home market sales of the foreign like product is equal to or greater than five percent of the aggregate volume of U.S. sales), we compared the respondent's volume of home market sales of the foreign like product to the volume of U.S. sales of the subject merchandise, in accordance with section 773(a)(1)(B) of the Act. Because the respondent's aggregate volume of home market sales of the foreign like product was greater than five percent of its aggregate volume of U.S. sales for the subject merchandise, we determined that the respondent's home market was viable.

B. Affiliated-Party Transactions and Arm's-Length Test

The Department's standard practice with respect to the use of home market sales to affiliated parties for NV is to determine whether such sales are at arm's-length prices. Therefore, in accordance with that practice, we performed an arm's-length test on Corus's sales to affiliates as follows.

Sales to affiliated customers in the home market not made at arm's-length prices were excluded from our analysis because we considered them to be outside the ordinary course of trade. *See* 19 CFR 351.102(b). To test whether these sales were made at arm's-length prices, we compared on a model-specific basis the starting prices of sales to affiliated and unaffiliated customers net of all movement charges, direct selling expenses, and packing.

Where, for the tested models of subject merchandise, prices to the affiliated party were on average 99.5 percent or more of the price to the unaffiliated parties, we determined that sales made to the affiliated party were at arm's length. See 19 CFR 351.403(c). In instances where no price ratio could be constructed for an affiliated customer because identical merchandise was not sold to unaffiliated customers, we were unable to determine that these sales were made at arm's-length prices and, therefore, excluded them from our LTFV analysis. *See Final Determination of Sales at Less Than Fair Value: Certain Cold-Rolled Carbon Steel Flat Products from Argentina*, 58 FR 37062, 37077 (July 9, 1993). Where the exclusion of such sales eliminated all sales of the most appropriate comparison product, we made a comparison to the next most similar model.

C. Cost of Production Analysis

Based on our analysis of an allegation contained in the petition, we found that there were reasonable grounds to believe or suspect that sales of SSB in the home market were made at prices below their cost of production (''COP''). Accordingly, pursuant to section 773(b) of the Act, we initiated a country-wide sales-below-cost investigation to determine whether sales were made at prices below their respective COP (*see Initiation Notice,* 66 FR at 7625).

1. Calculation of COP

In accordance with section 773(b)(3) of the Act, we calculated COP based on the sum of the cost of materials and fabrication for the foreign like product, plus an amount for general and administrative expenses (''G&A''), interest expenses, and home market packing costs (*see* ''Test of Home Market Sales Prices'' section below for treatment of home market selling expenses). We relied on the COP data submitted by Corus.

2. Test of Home Market Sales Prices

On a product-specific basis, we compared the weighted-average COP to the home market sales of the foreign like product, as required under section 773(b) of the Act, in order to determine whether the sale prices were below the COP. The prices were exclusive of any applicable movement charges, rebates, discounts, and direct and indirect

selling expenses. In determining whether to disregard home market sales made at prices less than their COP, we examined, in accordance with sections 773(b)(1)(A) and (B) of the Act, whether such sales were made (1) within an extended period of time, (2) in substantial quantities, and (3) at prices which did not permit the recovery of all costs within a reasonable period of time.

3. Results of the COP Test

Pursuant to section 773(b)(1), where less than 20 percent of the respondent's sales of a given product are at prices less than the COP, we do not disregard any below-cost sales of that product, because we determine that in such instances the below-cost sales were not made in ''substantial quantities.'' Where 20 percent or more of a respondent's sales of a given product are at prices less than the COP, we disregard those sales of that product, because we determine that in such instances the below-cost sales represent ''substantial quantities'' within an extended period of time, in accordance with section 773(b)(1)(A) of the Act. In such cases, we also determine whether such sales were made at prices which would not permit recovery of all costs within a reasonable period of time, in accordance with section 773(b)(1)(B) of the Act.

We found that, for certain specific products, more than 20 percent of Corus's home market sales were at prices less than the COP and, in addition, such sales were made within a reasonable period of time and did not provide for the recovery of costs. We therefore excluded these sales and used the remaining above-cost sales, if any, as the basis for determining NV, in accordance with section 773(b)(1).

D. Level of Trade

Section 773(a)(1)(B)(i) of the Act states that, to the extent practicable, the Department will calculate NV based on sales at the same level of trade (''LOT'') as the EP or CEP. Sales are made at different LOTs if they are made at different marketing stages (or their equivalent). 19 CFR 351.412(c)(2). Substantial differences in selling activities are a necessary, but not sufficient, condition for determining that there is a difference in the stages of marketing. *Id.*; *see also Notice of Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate From South Africa*, 62 FR 61731, 61732 (November 19, 1997). In order to determine whether the comparison sales were at different stages in the marketing process than the U.S. sales, we reviewed the distribution system in each market (*i.e.*, the ''chain of distribution''),[2] including selling functions,[3] class of customer (''customer category''), and the level of selling expenses for each type of sale.

Pursuant to section 773(a)(1)(B)(i) of the Act, in identifying levels of trade for EP and comparison market sales (*i.e.*, NV based on either home market or third country prices[4]), we consider the starting prices before any adjustments. For CEP sales, we consider only the selling activities reflected in the price after the deduction of expenses and profit under section 772(d) of the Act. *See Micron Technology, Inc.* v. *United States*, 243 F. 3d 1301, 1314–1315 (Fed. Cir. 2001).

When the Department is unable to match U.S. sales to sales of the foreign like product in the comparison market at the same LOT as the EP or CEP, the Department may compare the U.S. sale to sales at a different LOT in the comparison market. In comparing EP or CEP sales at a different LOT in the comparison market, where available data make it practicable, we make a LOT adjustment under section 773(a)(7)(A) of the Act. Finally, for CEP sales only, if a NV LOT is more remote from the factory than the CEP LOT and we are unable to make a LOT adjustment, the Department shall grant a CEP offset, as provided in section 773(a)(7)(B) of the Act. *See Notice of Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate from South Africa*, 62 FR 61731 (November 19, 1997).

In this case, Corus had only CEP sales. It reported that comparison-market and CEP sales were made at different LOTs, and that comparison-market sales were made at a more advanced LOT than were sales to its U.S. affiliates, Corus America Inc. (''CAI'') and Avesta Sheffield Bar Company (''ASB''). Corus requested that the Department make a CEP offset in lieu of a LOT adjustment, as it was unable to quantify the price differences related to sales made at the different LOTs.

Corus reported home market sales through one channel of distribution: sales of subject merchandise from the mill directly to affiliated and unaffiliated customers. Corus offers the same support and assistance to all its home market customers, including assistance in order specification, delivery, and after-sale technical support. Accordingly, all of Corus's home market sales are made in the same channel of distribution and constitute one LOT.

In the U.S. market, Corus reported two channels of distribution (*i.e.*, through its U.S. affiliate CAI, who sells ''back-to-back'' to unaffiliated U.S. customers and maintains no inventory; and through another affiliated company, ASB, which imports and inventories subject merchandise and makes its sales from its warehouse facilities). Corus offers the same support for its sales to CAI and ASB, accepting purchase orders and sending order confirmations as well arranging for production and reviewing and approving quality claims. Based on our overall analysis, we found that the channels of distribution did not differ from each other with respect to selling activities and, therefore, constituted one LOT.

We compared the CEP LOT to the home market LOT and concluded that the selling functions performed for the home market customers are sufficiently similar to those performed for the U.S. customers to warrant considering them the same LOT. For both LOTs there is a high degree of selling activity related to quality assurance and warranty services, while there is a low (or non-existent) level of selling activity associated with maintaining a warehouse and inventory. Both LOTs also have similar levels of selling activity with regard to most freight and delivery services.

More specifically, the table submitted as Exhibit B–16 of the June 22, 2001, response (*selling functions table*) indicates that the degree of sales activity that Corus claimed it provided for its sales in the home market and for its U.S. sales is the same for the vast majority of selling functions identified.

However, for the remaining selling functions for which Corus claimed a different degree of sales activity for its U.S. sales and its home market sales, the levels of activity reported by Corus in the selling functions table are inconsistent with the sales process descriptions in the questionnaire response. For example, the March 27, 2001, response at pages A–16 and A–18

[2] The marketing process in the United Sates and comparison markets begins with the producer and extends to the sale to the final user or consumer. The chain of distribution between the two may have many or few links, and the respondents' sales occur somewhere along this chain. In performing this evaluation, we considered the narrative responses of each respondent to properly determine where in the chain of distribution the sale occurs.

[3] Selling functions associated with a particular chain of distribution help us to evaluate the level(s) of trade in a particular market. For purposes of this preliminary determination, we have organized the common SSB selling functions into four major categories: sales process and marketing support, freight and delivery, inventory and warehousing, and quality assurance/warranty services. Other selling functions unique to specific companies were considered, as appropriate.

[4] Where NV is based on constructed value (''CV''), we determine the NV LOT based on the LOT of the sales from which we derive selling expenses, G&A and profit for CV, where possible.

states that Corus sells to longstanding and ongoing customers in both markets. However, in the selling functions table, Corus reports a different degree of market research in each market. Furthermore, the selling functions table indicates a high degree of sales activity for identifying customers and making sales calls in the United Kingdom and a low degree of such activity for U.S. sales. Yet, in the sales process description in the response Corus states that its home market customers typically call or fax the Corus sales office with inquiries and then place orders by phone, fax, or mail. We are not persuaded by Corus's claim that it provides a high degree of sales activity with regard to identifying customers and making sales calls when the customers contact Corus by phone, fax, or mail. Moreover, for longstanding and ongoing customers a high degree of sales activity for identifying customers and making sales calls seems misplaced. In addition, in the selling functions table Corus attempts to distinguish the sales activity for its U.S. and home market sales with regard to the degree of service provided for performance of a customer credit check, indicating a high degree of activity for home market sales and a low degree for U.S. sales. This type of activity should be necessary when Corus sells to new and unfamiliar customers in the home market—not longstanding and ongoing customers.

Inasmuch as we consider Corus's CEP sales to be at the same LOT as that of the home market sales, Corus does not qualify for a LOT adjustment or CEP offset pursuant to sections 773(a)(7)(A) or (B) of the Act, respectively.

E. Calculation of Normal Value Based on Comparison Market Prices

We calculated NV based on delivered prices to unaffiliated customers or prices to affiliated customers that we determined to be at arm's-length (*i.e.,* gross unit price inclusive of alloy surcharges, as applicable). We made adjustments, where appropriate, to the starting price for billing/invoice corrections. We made deductions, where applicable, for discounts, rebates, and inland freight. We made adjustments for differences in costs attributable to differences in the physical characteristics of the merchandise in accordance with section 773(a)(6)(C)(ii) of the Act and 19 CFR 351.411. In addition, we made adjustments under section 773(a)(6)(C)(iii) of the Act and 19 CFR 351.410 for differences in circumstances of sale for imputed credit expenses and warranties. We also added U.S. packing costs and deducted home market packing costs in accordance with sections 773(a)(6)(A) and (B) of the Act, respectively.

Currency Conversion

We made currency conversions into U.S. dollars in accordance with section 773A(a) of the Act based on the exchange rates in effect on the dates of the U.S. sales as certified by the Federal Reserve Bank.

Verification

As provided in section 782(i) of the Act, we will verify all information relied upon in making our final determination.

Suspension of Liquidation

In accordance with section 733(d)(2) of the Act, we are directing the Customs Service to suspend liquidation of all imports of subject merchandise that are entered, or withdrawn from warehouse, for consumption on or after the date of publication of this notice in the **Federal Register**. We will instruct the Customs Service to require a cash deposit or the posting of a bond equal to the weighted-average amount by which the NV exceeds the export price or constructed export price, as indicated in the chart below. These suspension-of-liquidation instructions will remain in effect until further notice. The weighted-average dumping margins are as follows:

Exporter/manufacturer	Weighted-average margin percentage
Corus Engineering Steels Ltd	6.85
Crownridge Stainless Steel Limited	6.85
Firth Rixson Special Steels, Ltd	125.77
All Others *	6.85

*Pursuant to section 735(c)(5)(A), we have excluded from the calculation of the all-others rate margins which are zero or *de minimis*, or determined entirely on facts available.

ITC Notification

In accordance with section 733(f) of the Act, we have notified the ITC of our determination. If our final determination is affirmative, the ITC will determine before the later of 120 days after the date of this preliminary determination or 45 days after our final determination whether these imports are materially injuring, or threaten material injury to, the U.S. industry.

Disclosure

We will disclose the calculations used in our analysis to parties in this proceeding in accordance with 19 CFR 351.224(b).

Public Comment

Case briefs for this investigation must be submitted to the Department no later than November 5, 2001. Rebuttal briefs must be filed by November 13, 2001. A list of authorities used, a table of contents, and an executive summary of issues should accompany any briefs submitted to the Department. Executive summaries should be limited to five pages total, including footnotes. Section 774 of the Act provides that the Department will hold a public hearing to afford interested parties an opportunity to comment on arguments raised in case or rebuttal briefs, provided that such a hearing is requested by an interested party. If a request for a hearing is made in this investigation, the hearing will tentatively be held on November 16, 2001, at the U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230. Parties should confirm by telephone the time, date, and place of the hearing 48 hours before the scheduled time.

Interested parties who wish to request a hearing, or to participate if one is requested, must submit a written request to the Assistant Secretary for Import Administration, U.S. Department of Commerce, Room 1870, within 30 days of the publication of this notice. Requests should contain: (1) The party's name, address, and telephone number; (2) the number of participants; and (3) a list of the issues to be discussed. Oral presentations will be limited to issues raised in the briefs.

If this investigation proceeds normally, we will make our final determination by no later than 135 days after the publication of this notice in the **Federal Register**.

This determination is published pursuant to sections 733(f) and 777(i) of the Act.

Dated: July 26, 2001.

Faryar Shirzad,

Assistant Secretary for Import Administration.

[FR Doc. 01–19346 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

[A–583–836]

Notice of Preliminary Determination of Sales at Not Less Than Fair Value and Postponement of Final Determination: Stainless Steel Bar From Taiwan

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

ACTION: Notice of preliminary determination of sales at not less than fair value.

SUMMARY: We preliminarily determine that stainless steel bar from Taiwan is not being, nor is likely to be, sold in the United States at less than fair value, as provided in section 733(b) of the Tariff Act of 1930, as amended.

Interested parties are invited to comment on this preliminary determination. Since we are postponing the final determination, we will make our final determination not later than 135 days after the date of publication of this preliminary determination in the **Federal Register**.

EFFECTIVE DATE: August 2, 2001.

FOR FURTHER INFORMATION CONTACT: Blanche Ziv or Annika O'Hara, Office 1, AD/CVD Enforcement, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–4207 and (202) 482–3798, respectively.

SUPPLEMENTARY INFORMATION:

The Applicable Statute

Unless otherwise indicated, all citations to the Tariff Act of 1930, as amended (''the Act''), are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act (''URAA''). In addition, unless otherwise indicated, all citations to the Department of Commerce (''Department's'') regulations are to 19 CFR Part 351 (April 2000).

Background

Since the initiation of this investigation (*Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom*, 66 FR 7620 (January 24, 2001) (''*Initiation Notice*''), as amended by *Corrections, Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom*, 66 FR 14986 (March 14, 2001)), the following events have occurred:

On January 26, 2001, we solicited comments from interested parties regarding the criteria to be used for model-matching purposes. We received comments on our proposed matching criteria on February 8, 2001.

On February 12, 2001, the United States International Trade Commission (''ITC'') preliminarily determined that there is a reasonable indication that imports of stainless steel bar (''SSB'') from Taiwan are materially injuring the United States industry (see ITC Investigation No. 701–TA–913–918 (Publication No. 3395)).

On February 21, 2001, we selected the largest producer/exporter of SSB from Taiwan as the mandatory respondent in this proceeding. For further discussion, *see Memorandum from The Team to Richard W. Moreland*, dated February 21, 2001. We issued an antidumping questionnaire to the selected respondent, Gloria Metals Technology Corporation, (''Gloria''), on February 21, 2001.

In February and March, 2001, the petitioners in this case (*i.e.*, Carpenter Technology Corp., Crucible Specialty Metals, Electralloy Corp., Empire Specialty Steel Inc., Slater Steels Corp., and the United Steelworkers of America) made submissions requesting that the Department require the respondents to report the actual content of the primary chemical components of SSB for each sale of SSB made during the period of investigation (''POI''). Also, in February and March 2001, the respondents in the other concurrent SSB investigations requested that the Department deny the petitioners' request. The Department, upon consideration of the comments from all parties on this matter, issued a memorandum on April 3, 2001, indicating its decision not to require the respondents to report such information on a transaction-specific basis. However, the Department did require that respondents report certain additional information concerning SSB grades sold to the U.S. and home markets during the POI. (For details, *see Memorandum from The Stainless Steel Bar Teams to Louis Apple and Susan Kuhbach, Directors, Office of AD/CVD Enforcement 1/2*, dated April 3, 2001).

During the period March through June 2001, the Department received responses to Sections A, B, C and D of the Department's original and supplemental questionnaires from Gloria and its affiliate, Golden Win Steel Corporation (''Golden Win'') (collectively, ''Gloria'').

On April 27, 2001, pursuant to 19 CFR 351.205(e), the petitioners made a timely request to postpone the preliminary determination. We granted this request on May 7, 2001, and postponed the preliminary determination until no later than July 26, 2001. (*See Notice of Postponement of Preliminary Determinations of Sales at Less Than Fair Value: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom*, 66 FR 24114 (May 11, 2001)).

Postponement of Final Determination

Pursuant to section 735(a)(2)(B) of the Act, on July 17, 2001, the petitioners requested that, in the event of a negative preliminary determination, the Department postpone its final determination in this investigation. In accordance with 19 CFR 351.210(b)(i), because our preliminary determination is negative and no compelling reasons for denial exist, we are granting the petitioners' request and are postponing the final determination until no later than 135 days after the publication of this notice in the **Federal Register**.

Scope of Investigation

For purposes of this investigation, the term ''stainless steel bar'' includes articles of stainless steel in straight lengths that have been either hot-rolled, forged, turned, cold-drawn, cold-rolled or otherwise cold-finished, or ground, having a uniform solid cross section along their whole length in the shape of circles, segments of circles, ovals, rectangles (including squares), triangles, hexagons, octagons, or other convex polygons. Stainless steel bar includes cold-finished stainless steel bars that are turned or ground in straight lengths, whether produced from hot-rolled bar or from straightened and cut rod or wire, and reinforcing bars that have indentations, ribs, grooves, or other deformations produced during the rolling process.

Except as specified above, the term does not include stainless steel semi-finished products, cut length flat-rolled products (*i.e.*, cut length rolled products which if less than 4.75 mm in thickness have a width measuring at least 10 times the thickness, or if 4.75 mm or more in thickness having a width which exceeds 150 mm and measures at least twice the thickness), products that have been cut from stainless steel sheet, strip or plate, wire (*i.e.*, cold-formed products in coils, of any uniform solid cross section along their whole length, which do not conform to the definition of flat-rolled products), and angles, shapes and sections.

The stainless steel bar subject to this investigation is currently classifiable under subheadings 7222.11.00.05, 7222.11.00.50, 7222.19.00.05, 7222.19.00.50, 7222.20.00.05, 7222.20.00.45, 7222.20.00.75, and 7222.30.00.00 of the *Harmonized Tariff Schedule of the United States* (''HTSUS''). Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the scope of this investigation is dispositive.

In accordance with our regulations, we set aside a period of time for parties to raise issues regarding product coverage and encouraged all parties to submit comments within 20 calendar days of publication of the *Initiation Notice* (66 FR at 7620–7621). The respondents in the companion SSB investigations filed comments seeking to exclude certain products from the scope of these investigations. The specific products identified in their exclusion requests are:

- Stainless steel tool steel
- Welding wire
- Special-quality oil field equipment steel (SQOFES)
- Special profile wire

We have addressed these requests in a *Memorandum to Susan Kuhbach and Louis Apple from The Stainless Steel Bar Team*, dated July 26, 2001, entitled ''Scope Exclusion Requests,'' and a *Memorandum to Louis Apple from The Stainless Steel Bar Team*, dated July 26, 2001, entitled ''Whether Special Profile Wire Product is Included in the Scope of the Investigation.'' Our conclusions are summarized below.

Regarding stainless steel tool steel, welding wire, and SQOFES, after considering the respondents' comments and the petitioners' objections to the exclusion requests, we preliminarily determine that the scope is not overly broad. Therefore, stainless steel tool steel, welding wire, and SQOFES are within the scope of these SSB investigations. In addition, we preliminarily determine that SQOFES does not constitute a separate class or kind of merchandise from SSB.

Regarding special profile wire, we have preliminarily determined that this product does not fall within the scope as it is written because its cross section is in the shape of a concave polygon and the scope does not cover stainless steel with such cross sections in the shape of concave polygons. Therefore, we have not included special profile wire in these investigations.

Finally, we note that in the concurrent countervailing duty investigation of stainless steel bar from Italy, the Department preliminarily determined that hot-rolled stainless steel bar is within the scope of these investigations. Because the petitioners intended for this product to be included in the scope, we have determined that the scope language is not overly-inclusive with regard to this product. As a result, we have not modified the scope of this investigation because the current scope language includes hot-rolled bar, as intended by the petitioners. (*See, Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Countervailing Duty Determination with Final Antidumping Duty Determination: Stainless Steel Bar from Italy*, 66 FR 30414 (June 6, 2001).

Period of Investigation

The POI is October 1, 1999, through September 30, 2000.

Fair Value Comparisons

To determine whether sales of SSB from Taiwan to the United States were made at less than fair value (''LTFV''), we compared the export price (''EP'') to the Normal Value (''NV''), as described in the ''Export Price'' and ''Normal Value'' sections of this notice below. In accordance with section 777A(d)(1)(A)(i) of the Act, we compared POI weighted-average EP to NV.

Product Comparisons

In accordance with section 771(16) of the Act, we considered all products produced and sold by the Gloria in the home market during the POI that fit the description in the ''Scope of Investigation'' section of this notice to be foreign like products for purposes of determining appropriate product comparisons to U.S. sales. We compared U.S. sales to sales made in the home market, where appropriate. Where there were no sales of identical merchandise in the home market made in the ordinary course of trade to compare to U.S. sales, we compared U.S. sales to sales of the most similar foreign like product made in the ordinary course of trade. In making the product comparisons, we matched foreign like products based on the physical characteristics reported by the respondents in the following order of importance: general type of finish; grade; remelting process; type of final finishing operation; shape; and size.

On July 11 and 13, 2001, the petitioners submitted general comments on product-matching issues for the Department's consideration in the preliminary determination. These comments were not received in time to be fully analyzed for the preliminary determination, but will be considered for the final determination.

Export Price

We calculated EP, in accordance with section 772(a) of the Act, because the merchandise was sold to the first unaffiliated purchaser in the United States prior to importation by the exporter or producer outside the United States, based on the facts of record. We based EP on the packed delivered price to unaffiliated purchasers in the United States. We made adjustments for returns. We made deductions for movement expenses in accordance with section 772(c)(2)(A) of the Act; these included, where appropriate, foreign inland freight, foreign brokerage and handling, international freight, marine insurance, and U.S. customs duties (including harbor maintenance fees and merchandise processing fees). (*See Calculation Memorandum* dated July 26, 2001.)

Normal Value

A. Home Market Viability

In order to determine whether there is a sufficient volume of sales in the home market to serve as a viable basis for calculating NV (*i.e.*, whether the aggregate volume of home market sales of the foreign like product is equal to or greater than five percent of the aggregate volume of U.S. sales), we compared the respondent's volume of home market sales of the foreign like product to the volume of U.S. sales of the subject merchandise, in accordance with section 773(a)(1)(C) of the Act. Because the respondent's aggregate volume of home market sales of the foreign like product was greater than five percent of its aggregate volume of U.S. sales for the subject merchandise, we determined that the home market was viable for the respondent.

B. Affiliated-Party Transactions and Arm's-Length Test

The Department's standard practice with respect to the use of home market sales to affiliated parties for NV is to determine whether such sales are at arm's-length prices. Therefore, in accordance with that practice, we performed an arm's-length test on Gloria's sales to affiliates as follows.

Sales to affiliated customers in the home market not made at arm's-length prices (if any) were excluded from our analysis because we considered them to be outside the ordinary course of trade. *See* 19 CFR 351.102. To test whether these sales were made at arm's-length prices, we compared on a model-specific basis the starting prices of sales

to affiliated and unaffiliated customers net of all movement charges, direct selling expenses, and packing. Where, for the tested models of subject merchandise, prices to the affiliated party were on average 99.5 percent or more of the price to the unaffiliated parties, we determined that sales made to the affiliated party were at arm's length. *See* 19 CFR 351.403(c). In instances where no price ratio could be constructed for an affiliated customer because identical merchandise was not sold to unaffiliated customers, we were unable to determine that these sales were made at arm's-length prices and, therefore, excluded them from our LTFV analysis. *See Final Determination of Sales at Less Than Fair Value: Certain Cold-Rolled Carbon Steel Flat Products from Argentina* (58 FR 37062, 37077 (July 9, 1993)). Where the exclusion of such sales eliminated all sales of the most appropriate comparison product, we made a comparison to the next most similar model.

C. Cost of Production Analysis

Based on our analysis of the allegation contained in the petition, we found that there were reasonable grounds to believe or suspect that sales of SSB in the home market were made at prices below their cost of production (COP). Accordingly, pursuant to section 773(b) of the Act, we initiated a country-wide sales-below-cost investigation to determine whether sales were made at prices below their respective COP (*See Initiation Notice*, 66 FR at 7624).

1. Calculation of COP

In accordance with section 773(b)(3) of the Act, we calculated COP based on the sum of the cost of materials and fabrication for the foreign like product, plus an amount for general and administrative expenses (G&A), interest expenses, and home market packing costs (*See* ''Test of Home Market Sales Prices'' section below for treatment of home market selling expenses). We relied on the COP data submitted by Gloria, except in the following instances: We made adjustments to the reported direct material costs to account for costs differences between grades; we have increased the reported costs for direct materials, direct labor, and fixed and variable overhead, based on information in Gloria's financial statements; and we have recalculated the G&A expense ratio to exclude an item that was inappropriately included as an offset to the respondent's G&A calculation. (*See Calculation Memorandum* dated July 26, 2001.)

2. Test of Home Market Sales Prices

On a product-specific basis, we compared the adjusted weighted-average COP to the home market sales of the foreign like product, as required under section 773(b) of the Act, in order to determine whether the sale prices were below the COP. The prices were exclusive of any applicable movement charges, and direct and indirect selling expenses. In determining whether to disregard home market sales made at prices less than their COP, we examined whether such sales were made (1) within an extended period of time, (2) in substantial quantities, and (3) at prices which did not permit the recovery of all costs within a reasonable period of time.

3. Results of the COP Test

Pursuant to section 773(b)(1), where less than 20 percent of the respondent's sales of a given product are at prices less than the COP, we do not disregard any below-cost sales of that product, because we determine that in such instances the below-cost sales were not made in ''substantial quantities.'' Pursuant to 773(b)(2)(C), ''substantial quantities'' exist when the volume of sales made at below the COP represents 20 percent or more of the volume of sales under consideration for the determination of normal value. Where 20 percent or more of a respondent's sales of a given product are at prices less than the COP, we disregard those sales of that product, because we determine that in such instances the below-cost sales represent ''substantial quantities'' within an extended period of time, in accordance with section 773(b)(1)(A) of the Act. In such cases, we also determine whether such sales were made at prices which would not permit recovery of all costs within a reasonable period of time, in accordance with section 773(b)(1)(B) of the Act.

We found that, for certain specific products, more than 20 percent of Gloria's home market sales were at prices less than the COP and, in addition, such sales were made within an extended period of time and did not provide for the recovery of costs. We therefore excluded these sales and used the remaining above-cost sales, if any, as the basis for determining NV, in accordance with section 773(b)(1).

For those U.S. sales of SSB for which there were no comparable home market sales in the ordinary course of trade (*e.g.*, above-cost), we compared EP sales to constructed value (''CV''), in accordance with section 773(a)(4) of the Act.

D. Level of Trade

Section 773(a)(1)(B)(i) of the Act states that, to the extent practicable, the Department will calculate NV based on sales at the same level of trade (''LOT'') as the EP. Sales are made at different LOTs if they are made at different marketing stages (or their equivalent). 19 CFR 351.412(c)(2). Substantial differences in selling activities are a necessary, but not sufficient, condition for determining that there is a difference in the stages of marketing. *Id.*; *See also Notice of Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate From South Africa*, 62 FR 61731, 61732 (November 19, 1997). In order to determine whether the comparison sales were at different stages in the marketing process than the U.S. sales, we reviewed the distribution system in each market (*i.e.,* the ''chain of distribution''),[1] including selling functions,[2] class of customer (''customer category''), and the level of selling expenses for each type of sale.

Pursuant to section 773(a)(1)(B)(i) of the Act, in identifying levels of trade for EP and comparison market sales (*i.e.*, NV based on either home market or third country prices [3]), we consider the starting prices before any adjustments. *See Micron Technology, Inc.* v. *United States*, 243 F. 3d 1301, 1314–1315 (Fed. Cir. 2001) (affirming this methodology).

When the Department is unable to match U.S. sales to sales of the foreign like product in the comparison market at the same LOT as the EP, the Department may compare the U.S. sale to sales at a different LOT in the comparison market. In comparing EP sales at a different LOT in the comparison market, where available data make it practicable, we make a LOT adjustment under section 773(a)(7)(A) of the Act.

Gloria has reported that it sells to distributors and end users in the home

[1] The marketing process in the United States and comparison markets begins with the producer and extends to the sale to the final user or consumer. The chain of distribution between the two may have many or few links, and the respondents' sales occur somewhere along this chain. In performing this evaluation, we considered the narrative responses of each respondent to properly determine where in the chain of distribution the sale occurs.

[2] Selling functions associated with a particular chain of distribution help us to evaluate the level(s) of trade in a particular market. For purposes of this preliminary determination, we have organized the common SSB selling functions into four major categories: sales process and marketing support, freight and delivery, inventory and warehousing, and quality assurance/warranty services. Other selling functions unique to specific companies were considered, as appropriate.

[3] Where NV is based on CV, we determine the NV LOT based on the LOT of the sales from which we derive selling expenses, G&A and profit for CV, where possible.

market and to trading companies and end users in the United States. Gloria has reported a single channel of distribution and a single level of trade in each market, and has not requested a level of trade adjustment. We examined the information reported by Gloria regarding its marketing process for making the reported home market and U.S. sales, including the type and level of selling activities performed and customer categories. As Gloria has reported, we found a single level of trade in the United States, and a single, identical level of trade in the home market. Thus, it was unnecessary to make any level-of-trade adjustment for comparison of EP and home market prices.

E. Calculation of Normal Value Based on Comparison Market Prices

We calculated NV based on delivered prices to unaffiliated customers. We adjusted the reported quantity to account for returns. We made deductions, where appropriate, from the starting price for inland freight and warehousing. We made adjustments for differences in costs attributable to differences in the physical characteristics of the merchandise in accordance with section 773(a)(6)(C)(ii) of the Act and 19 CFR 351.411 of the Department's regulations. In addition, we made adjustments under section 773(a)(6)(C)(iii) of the Act for differences in circumstances of sale for direct selling expenses, imputed credit expenses and warranties.

We also made adjustments, in accordance with 19 CFR 351.410(e), for indirect selling expenses incurred in the comparison market or the United States, where commissions were granted on sales in one market but not in the other (the ''commission offset''). Gloria paid commissions on some U.S. sales of subject merchandise but did not pay commissions on its home market sales. Therefore, in accordance with 19 CFR 351.410(e), we offset the commission incurred in the U.S. market, with indirect selling expenses incurred in the home market (*i.e.,* indirect selling expenses and inventory carrying costs) by the lesser of the commission or the indirect selling expenses. We adjusted Golden Win's reported indirect selling expense ratio to account for Gloria's overstatement of deductions to the total indirect selling expense amount. We also deducted home market packing costs and added U.S. packing costs in accordance with section 773(a)(6)(A) and (B) of the Act.

Currency Conversion

We made currency conversions into U.S. dollars in accordance with section 773A(a) of the Act based on the exchange rates in effect on the dates of the U.S. sales as certified by the Federal Reserve Bank.

Verification

As provided in section 782(i) of the Act, we will verify all information relied upon in making our final determination.

Suspension of Liquidation

The weighted-average dumping margins are as follows:

Exporter/manufacturer	Weighted-average margin percentage
Gloria Metals Technology.	0.98 (*de minimis.*)
All Others	0.98 (*de minimis.*)

Because the estimated weighted-average dumping margin for Gloria, the only examined company, is *de minimis*, we are not directing the Customs Service to suspend liquidation of entries of SSB from Taiwan.

ITC Notification

In accordance with section 733(f) of the Act, we have notified the ITC of our determination. If our final determination is affirmative, pursuant to section 735(b)(3) of the Act, the ITC will determine within 75 days after our final determination whether these imports are materially injuring, or threaten material injury to, the U.S. industry.

Disclosure

We will disclose the calculations used in our analysis to parties in this proceeding in accordance with 19 CFR 351.224(b).

Public Comment

Case briefs for this investigation must be submitted to the Department no later than November 2, 2001. Rebuttal briefs must be filed by November 9, 2001. A list of authorities used, a table of contents, and an executive summary of issues should accompany any briefs submitted to the Department. Executive summaries should be limited to five pages total, including footnotes. Section 774 of the Act provides that the Department will hold a public hearing to afford interested parties an opportunity to comment on arguments raised in case or rebuttal briefs, provided that such a hearing is requested by an interested party. If a request for a hearing is made in this investigation, the hearing will tentatively be held on November 14, 2001, at the U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230. Parties should confirm by telephone the time, date, and place of the hearing 48 hours before the scheduled time.

Interested parties who wish to request a hearing, or to participate if one is requested, must submit a written request to the Assistant Secretary for Import Administration, U.S. Department of Commerce, Room 1870, within 30 days of the publication of this notice. Requests should contain: (1) The party's name, address, and telephone number; (2) the number of participants; and (3) a list of the issues to be discussed. Oral presentations will be limited to issues raised in the briefs.

If this investigation proceeds normally, we will make our final determination by no later than 135 days after the publication of this notice in the **Federal Register**.

This determination is published pursuant to sections 733(f) and 777(i) of the Act.

Dated: July 26, 2001.

Faryar Shirzad,

Assistant Secretary for Import Administration.

[FR Doc. 01–19347 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

[A–427–820]

Notice of Preliminary Determination of Sales at Less Than Fair Value and Postponement of Final Determination: Stainless Steel Bar From France

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

ACTION: Notice of preliminary determination of sales at less than fair value.

SUMMARY: We preliminarily determine that stainless steel bar from France is being, or is likely to be, sold in the United States at less than fair value, as provided in section 733(b) of the Tariff Act of 1930, as amended.

Interested parties are invited to comment on this preliminary determination. Since we are postponing the final determination, we will make our final determination not later than 135 days after the date of publication of this preliminary determination in the **Federal Register**.

EFFECTIVE DATE: August 2, 2001.

FOR FURTHER INFORMATION CONTACT: Brian Smith or Terre Keaton, Import

Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–1766 or (202) 482–1280, respectively.

SUPPLEMENTARY INFORMATION:

The Applicable Statute

Unless otherwise indicated, all citations to the Tariff Act of 1930, as amended (''the Act''), are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act (''URAA''). In addition, unless otherwise indicated, all citations to the Department of Commerce (''Department's'') regulations are to 19 CFR part 351 (April 2000).

Background

Since the initiation of this investigation (*Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom,* 66 FR 7620 (January 24, 2001) (*Initiation Notice*), as amended by *Corrections, Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom,* 66 FR 14986 (March 14, 2001), the following events have occurred:

On January 26, 2001, we solicited comments from interested parties regarding the criteria to be used for model-matching purposes, and we received comments on our proposed matching criteria on February 8, 2001.

On February 12, 2001, the United States International Trade Commission (''ITC'') preliminarily determined that there is a reasonable indication that imports of stainless steel bar (''SSB'') from France are materially injuring the United States industry (*see* ITC Investigation No. 701–TA–913–918 (Publication No. 3395)).

On February 12, 2001, we selected the two largest producers/exporters of SSB from France as the mandatory respondents in this proceeding. For further discussion, *see* Memorandum from the Team to Richard W. Moreland, Deputy Assistant Secretary for Import Administration entitled, ''Respondent Selection,'' dated February 12, 2001. We subsequently issued the antidumping questionnaires to Aubert & Duval, S.A. (''A&D'') and Ugine-Savoie Imphy S.A. (''U–SI'') (collectively referred to as the respondents) on February 20, 2001.

On February 13, 2001, U–SI requested that certain special profile wire product produced by its affiliate Sprint Metal, S.A. (''Sprint'') be excluded from the scope of this investigation. *See* ''Scope of Investigation'' section of this notice for further discussion. Also, on February 13, 2001, U–SI requested that it be relieved from the requirement to report affiliated party resales because sales of the foreign like product to affiliated parties during the POI constituted less than five percent of total sales of the foreign like product. On April 3, 2001, we granted U–SI's request to exclude these sales from reporting in accordance with 19 CFR 351.403(d). *See* Memorandum from the Team to Louis Apple, Office Director, dated April 3, 2001, for further details.

In February and March 2001, the petitioner [1] made submissions requesting that the Department require the respondents to report the actual content of the primary chemical components of SSB for each sale of SSB made during the period of investigation (''POI''). Also, in February and March 2001, the respondents in this and other concurrent SSB investigations requested that the Department deny the petitioners' request. The Department, upon consideration of the comments from all parties on this matter, issued a memorandum on April 3, 2001, indicating its decision not to require the respondents to report such information on a transaction-specific basis. However, the Department did require that the respondents report certain additional information concerning SSB grades sold to the U.S. and home markets during the POI. (For details, *see* Memorandum from the Stainless Steel Bar Teams to Louis Apple and Susan Kuhbach, Office Directors, dated April 3, 2001).

On April 10, 2001, A&D requested that it be permitted to report its costs on a fiscal-year rather than POI basis. For the reasons outlined in a letter dated May 16, 2001, the Department denied this request.

On April 27, 2001, pursuant to 19 CFR 351.205(e), the petitioners made a timely request to postpone the preliminary determination. We granted this request on May 7, 2001, and postponed the preliminary determination until no later than July 26, 2001. (*See Notice of Postponement of Preliminary Determinations of Sales at Less Than Fair Value: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom,* 66 FR 24114 (May 11, 2001)).

During the period March through July 16, 2001, the Department received responses to Sections A, B, C, D and E of its original and supplemental questionnaires from A&D and U–SI. On July 13, U–SI submitted revised sales and cost databases on its own initiative. For purposes of the preliminary determination, the Department did not use these revised databases in its analysis because U–SI did not provide the Department with sufficient time to examine them prior to the preliminary determination. However, the Department will examine these databases prior to verification for the final determination.

On July 9, 2001, the petitioners submitted comments on U–SI's questionnaire response for consideration in the preliminary determination. On July 18, 2000, U–SI submitted rebuttal comments in response to the petitioners' July 9, 2001, submission.

Postponement of Final Determination and Extension of Provisional Measures

Pursuant to section 735(a)(2) of the Act, on June 4, 2001, U–SI requested that, in the event of an affirmative preliminary determination in this investigation, the Department postpone its final determination until not later than 135 days after the date of the publication of the preliminary determination in the **Federal Register**, and extend the provisional measures to not more than six months. In accordance with 19 CFR 351.210(b)(2)(ii), because (1) our preliminary determination is affirmative, (2) U–SI accounts for a significant proportion of exports of the subject merchandise, and (3) no compelling reasons for denial exist, we are granting the respondent's request and are postponing the final determination until no later than 135 days after the publication of this notice in the **Federal Register**. Suspension of liquidation will be extended accordingly.

Scope of Investigation

For purposes of this investigation, the term ''stainless steel bar'' includes articles of stainless steel in straight lengths that have been either hot-rolled, forged, turned, cold-drawn, cold-rolled or otherwise cold-finished, or ground, having a uniform solid cross section along their whole length in the shape of circles, segments of circles, ovals, rectangles (including squares), triangles, hexagons, octagons, or other convex polygons. Stainless steel bar includes cold-finished stainless steel bars that are turned or ground in straight lengths, whether produced from hot-rolled bar or from straightened and cut rod or wire, and reinforcing bars that have

[1] The petitioners in this case are Carpenter Technology Corp., Crucible Specialty Metals, Electralloy Corp., Empire Specialty Steel Inc., Slater Steels Corp., and the United Steelworkers of America.

indentations, ribs, grooves, or other deformations produced during the rolling process.

Except as specified above, the term does not include stainless steel semi-finished products, cut length flat-rolled products (*i.e.,* cut length rolled products which if less than 4.75 mm in thickness have a width measuring at least 10 times the thickness, or if 4.75 mm or more in thickness having a width which exceeds 150 mm and measures at least twice the thickness), products that have been cut from stainless steel sheet, strip or plate, wire (*i.e.,* cold-formed products in coils, of any uniform solid cross section along their whole length, which do not conform to the definition of flat-rolled products), and angles, shapes and sections.

The stainless steel bar subject to this investigation is currently classifiable under subheadings 7222.11.00.05, 7222.11.00.50, 7222.19.00.05, 7222.19.00.50, 7222.20.00.05, 7222.20.00.45, 7222.20.00.75, and 7222.30.00.00 of the *Harmonized Tariff Schedule of the United States* (''HTSUS''). Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the scope of this investigation is dispositive.

In accordance with our regulations, we set aside a period of time for parties to raise issues regarding product coverage and encouraged all parties to submit comments within 20 calendar days of publication of the *Initiation Notice* (*see* 66 FR 7620–7621). The respondents in this and the companion SSB investigations filed comments seeking to exclude certain products from the scope of these investigations. The specific products identified in their exclusion requests are:

- stainless steel tool steel
- welding wire
- special-quality oil field equipment steel (SQOFES)
- special profile wire

We have addressed these requests in a Memorandum to Susan Kuhbach and Louis Apple from the Stainless Steel Bar Team, dated July 26, 2001, entitled ''Scope Exclusion Requests,'' and a Memorandum to Louis Apple from the Stainless Steel Bar Team, dated July 26, 2001, entitled ''Whether Special Profile Wire Product is Included in the Scope of the Investigation.'' Our conclusions are summarized below.

Regarding stainless steel tool steel, welding wire, and SQOFES, after considering the respondents' comments and the petitioners' objections to the exclusion requests, we preliminarily determine that the scope is not overly broad. Therefore, stainless steel tool steel, welding wire, and SQOFES are within the scope of these SSB investigations. In addition, we preliminarily determine that SQOFES does not constitute a separate class or kind of merchandise from SSB.

Regarding special profile wire, we have preliminarily determined that this product does not fall within the scope as it is written because its cross section is in the shape of a concave polygon. Therefore, we have not included special profile wire in these investigations.

Finally, we note that in the concurrent countervailing duty investigation of stainless steel bar from Italy, the Department preliminarily determined that hot-rolled stainless steel bar is within the scope of these investigations. (*See Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Countervailing Duty Determination with Final Antidumping Duty Determination: Stainless Steel Bar from Italy*, 66 FR 30414 (June 6, 2001).)

Period of Investigation

The POI is October 1, 1999, through September 30, 2000.

Use of Facts Available

While A&D attempted to respond to the Department's questionnaires, it did not provide usable data for purposes of our preliminary margin analysis. Specifically, the databases provided in its latest submissions to the Department cannot serve as an appropriate basis for a margin calculation. Given the time limitations between the receipt of A&D's last submissions to the Department and the Department's preliminary determination, we were unable to issue A&D a supplemental questionnaire requesting revised data and receive it in time for use in the preliminary determination.

Given that the necessary information to calculate A&D's margin is not available for the preliminary determination, the Department has determined that facts available is warranted in accordance with section 776(a) of the Act. Because A&D has attempted to cooperate in this investigation, as facts available, we have assigned A&D the simple average of the margins in the petition. Prior to verification, we will give A&D an opportunity to provide revised data for use in the final determination.

Section 776(c) of the Act provides that, when the Department relies on secondary information (such as the petition) in using the facts otherwise available, it must, to the extent practicable, corroborate that information from independent sources that are reasonably at its disposal. In this case, when analyzing the petition for purposes of the initiation, we reviewed all of the data upon which the petitioners relied in calculating the estimated dumping margins, and determined that the margins in the petition were appropriately calculated and supported by adequate evidence in accordance with the statutory requirements for initiation. In order to corroborate the petition margins for purposes of using them as fact available, we re-examined the price and cost information provided in the petition in light of information developed during this investigation. (*See* the Memorandum to Louis Apple from The Team entitled ''Preliminary Determination of Stainless Steel Bar from France: Use of Facts Available and Corroboration of Petition Margins,'' dated July 26, 2001, for further details of our corroboration methodology.)

In accordance with section 776(c) of the Act, we were able to corroborate the information in the petition using information from independent sources that were reasonably at our disposal. As a result, we have preliminarily assigned A&D the simple average of the margins contained in the petition, 28.07 percent.

Fair Value Comparisons

For U–SI, to determine whether sales of SSB from France to the United States were made at less than fair value (''LTFV''), we compared the export price (''EP'') or constructed export price (''CEP'') to the Normal Value (''NV''), as described in the ''Export Price'' and ''Constructed Export Price'' and ''Normal Value'' sections of this notice, below. In accordance with section 777A(d)(1)(A)(i) of the Act, we compared POI weighted-average EPs and CEPs to weighted-average NVs.

Product Comparisons

In accordance with section 771(16) of the Act, we considered all products produced and sold by U–SI in the home market during the POI that fit the description in the ''Scope of Investigation'' section of this notice to be foreign like products for purposes of determining appropriate product comparisons to U.S. sales. We compared U.S. sales to sales made in the home market, where appropriate. Where there were no sales of identical merchandise in the home market made in the ordinary course of trade to compare to U.S. sales, we compared U.S. sales to sales of the most similar foreign like product made in the ordinary course of trade. In making the product comparisons, we matched foreign like products based on the physical

characteristics reported by the respondent in the following order of importance: general type of finish; grade; remelting process; type of final finishing operation; shape; and size.

With respect to grade, we matched products sold in the U.S. and home markets on the basis of the three most similar matches proposed by the respondent, where possible.

On July 10 and 13, 2001, the petitioners submitted general comments on product matching issues for the Department's consideration in the preliminary determination. These comments were not received in time to be fully analyzed for the preliminary determination, but will be considered for the final determination.

Sub-Contracted Sales By U–SI

In its June 11, 2001, submission, U–SI indicated that it had contracted the services of its Italian affiliate (*i.e.,* Trifilerie Bedini, S.r.l. (''Bedini'')) to process non-subject merchandise (*i.e.,* stainless steel wire rod (''SSWR'') of French origin) into subject merchandise which U–SI then sold either through its affiliate (*i.e.,* Ugine France Service/ Ugine-Savoie France (''UFS/U–SF'')) in the French market or through its affiliate (*i.e.,* Ugine Stainless & Alloys, Inc. (''US&A'')) in the U.S. market. U–SI further stated that in accordance with the Department's country of origin rules, it did not report these sales as home market and/or U.S. sales in the sales listings submitted in this investigation, but rather reported them in the sales listings submitted in the concurrent investigation of SSB from Italy. After further examining U–SI's claim in the context of the Department's tolling regulation (19 CFR 351.401(h)), and based on the limited data furnished in its response, it appears that although U–SI may be the manufacturer of these sales, the product was produced by U–SI in Italy and therefore, the product is subject to the LTFV proceeding involving SSB from Italy. Therefore, for purposes of this preliminary determination, the Department has not included them in its margin analysis.

U.S. Resales by U–SI's Affiliate

In its June 11, 2001, supplemental questionnaire response, U–SI requested that it be excluded from reporting downstream sales in the United States made by its affiliate Techalloy (*i.e.,* a wire products manufacturer). U–SI stated that the total quantity of these sales was insignificant in terms of the total quantity reported for U–SI's U.S. sales through its principal U.S. affiliate, Ugine Stainless and Alloys, Inc.(''US&A''), during the POI. In addition, U–SI stated that Techalloy only made these sales as a special accommodation for one of Techalloy's U.S. wire product customers. In accordance with the Department's practice, given the allegedly insignificant amount of these resales in terms of the reported total U.S. sales quantity, subject to verification, and given that the method by which these sales were made is unrepresentative of U–SI's normal U.S. sales, we did not require that U–SI report these sales for purposes of the preliminary determination (*see Preliminary Determination of Sales at Less Than Fair Value and Postponement of Final Determination: Stainless Wire Rod from Canada,* 62 FR 51572 (October 1, 1997)).

Constructed Export Price

We calculated CEP in accordance with section 772(b) of the Act. We found that U–SI made CEP sales during the POI because the sales were made for the account of U–SI by the respondent's subsidiary in the United States to unaffiliated purchasers. In addition, U–SI reported sales of SSB which were further processed by its affiliate US&A in the United States. For the subject merchandise further processed in the United States, we used the starting price of the subject merchandise and deducted the costs of the further processing to determine CEP for such merchandise, in accordance with section 772(d)(2) of the Act.

We based CEP on the packed CIF delivered or undelivered prices to unaffiliated purchasers in the United States. We identified the correct starting price, by adjusting for billing corrections, freight revenue and other revenue associated with the sale, and by making deductions for early payment discounts, where applicable. We also made deductions for movement expenses in accordance with section 772(c)(2)(A) of the Act; these included, where appropriate, foreign inland freight (including freight from the plant/ warehouse to the port of exportation), ocean freight, marine insurance, U.S. customs duties and fees (including harbor maintenance fees, merchandise processing fees, and brokerage and handling), U.S. inland freight expenses (including freight from the U.S. port to the warehouse, freight between warehouses, and freight from the warehouse to the unaffiliated customer), and other U.S. transportation expenses (including brokerage and handling fees). In accordance with section 772(d)(1) of the Act, we deducted those selling expenses associated with economic activities occurring in the United States, including direct selling expenses (commissions, credit costs, warranty expenses, technical service expenses, and repacking expenses), and indirect selling expenses (including inventory carrying costs) incurred in the country of exportation and the United States. We recalculated US&A's reported warranty expenses on a customer-specific basis (rather than overall sales) based on the information in the record, because this recalculation is more specific to the sales in question. *See* Calculation Memorandum dated July 26, 2001. We also deducted an amount for further-manufacturing costs, where applicable, in accordance with section 772(d)(2) of the Act, and made an adjustment for profit in accordance with section 772(d)(3) of the Act.

Normal Value

A. Home Market Viability

In order to determine whether there is a sufficient volume of sales in the home market to serve as a viable basis for calculating NV (*i.e.,* whether the aggregate volume of home market sales of the foreign like product is equal to or greater than five percent of the aggregate volume of U.S. sales), we compared U–SI's volume of home market sales of the foreign like product to the volume of U.S. sales of the subject merchandise, in accordance with section 773(a)(1)(B) of the Act. Because the respondent's aggregate volume of home market sales of the foreign like product was greater than five percent of its aggregate volume of U.S. sales for the subject merchandise, we determined that its home market was viable.

B. Affiliated-Party Transactions and Arm's-Length Test

The Department's standard practice with respect to the use of home market sales to affiliated parties for NV is to determine whether such sales are at arm's-length prices. Therefore, in accordance with that practice, we performed an arm's-length test on U–SI's sales to affiliates as follows.

Sales to affiliated customers in the home market not made at arm's-length prices were excluded from our analysis because we considered them to be outside the ordinary course of trade. *See* 19 CFR 351.102(b). To test whether these sales were made at arm's-length prices, we compared on a model-specific basis the starting prices of sales to affiliated and unaffiliated customers net of all movement charges, direct selling expenses, and packing.

Where, for the tested models of subject merchandise, prices to the affiliated party were on average 99.5 percent or more of the price to the

unaffiliated parties, we determined that sales made to the affiliated party were at arm's length. *See* 19 CFR 351.403(c). In instances where no price ratio could be constructed for an affiliated customer because identical merchandise was not sold to unaffiliated customers, we were unable to determine that these sales were made at arm's-length prices and, therefore, excluded them from our LTFV analysis. *See Final Determination of Sales at Less Than Fair Value: Certain Cold-Rolled Carbon Steel Flat Products from Argentina*, 58 FR 37062, 37077 (July 9, 1993); and *Final Determination of Sales at Less Than Fair Value: Stainless Steel Wire Rod from Sweden*, 63 FR 40449, 40454 (July 29, 1998). Where the exclusion of such sales eliminated all sales of the most appropriate comparison product, we made a comparison to the next most similar model.

For the preliminary determination, we disallowed U–SI's claim that the movement expenses (*i.e.*, INLFTWH, WAREHSH, and INSUREH) associated with transferring semi-finished SSB from U–SI to UFS/US–F for further processing prior to the sale and/or shipment by UFS/US–F to the first unaffiliated customer in the home market should be deducted from gross unit price because we consider those expenses to be associated with the cost of manufacture of the finished product. Rather, we added the weighted-average amounts for these movement expenses to the reported variable overhead amounts on a control-number-specific basis in our calculation of COP (*see* ''Cost of Production Analysis'' below). With respect to the reported amount for U–SI's indirect selling expenses, inventory carrying costs, and packing expenses (*i.e.*, INDIRS1H, INVCARH, and PACKH), we treated only a portion of these expenses reported for two distribution channels associated with sales made through UFS/US–F as related to the sale of the finished product (*see* further discussion below). For the portion of indirect selling and packing expenses we considered related to the production of the semi-finished product, we recategorized those expenses as general and administrative (''G&A'') expenses and added them to the reported G&A expense. As for the inventory carrying expenses at issue, we do not consider this expense to be a production or G&A cost and therefore have not included it in the reported COP.

C. Cost of Production Analysis

Based on our analysis of an allegation contained in the petition, we found that there were reasonable grounds to believe or suspect that sales of SSB in the home market were made at prices below their COP. Accordingly, pursuant to section 773(b) of the Act, we initiated a country-wide sales-below-cost investigation to determine whether sales were made at prices below their respective COP. *See Initiation Notice*, 66 FR at 7622 (March 14, 2001)).

1. Calculation of COP

In accordance with section 773(b)(3) of the Act, we calculated COP based on the sum of the cost of materials and fabrication for the foreign like product, plus an amount for G&A expenses, interest expenses, and home market packing costs (*see* ''Test of Home Market Sales Prices'' section below for treatment of home market selling expenses). We relied on the COP data submitted by U–SI—except where noted below:

We disallowed U–SI's claim that the movement expenses (*i.e.*, INLFTWH, WAREHSH, and INSUREH) associated with transferring semi-finished SSB from U–SI to UFS/US–F for further processing prior to the sale and/or shipment by UFS/US–F to the first unaffiliated customer in the home market should be deducted from gross unit price because we consider those expenses to be associated with the cost of manufacture of the finished product. Rather, we added the weighted-average amounts for these movement expenses to the reported variable overhead amounts on a control-number-specific basis.

As explained above, we recategorized a portion of U–SI's indirect selling and packing expenses associated with transferring semi-finished SSB from U–SI to UFS/US–F for further processing as G&A expenses. *See* Calculation Memorandum dated July 26, 2001.

We also adjusted U–SI's G&A costs to include the provision for material price fluctuations which U–SI excluded from its G&A expense calculation. Additionally, we increased the G&A expenses by the amount for ''exceptional items.'' While U–SI identified the ''exceptional items'' as income and reduced the G&A expenses by this amount, these items are shown as expenses on U–SI's income statement.

We adjusted U–SI's U.S. further manufacturing costs to include the material yield loss for all products based on output quantity. *See* Memorandum from Michael Harrison to Neal Halper, Director Office of Accounting, dated July 26, 2001, Re: Cost Adjustments.

2. Test of Home Market Sales Prices

On a product-specific basis, we compared the adjusted weighted-average COP to the home market sales of the foreign like product, as required under section 773(b) of the Act, in order to determine whether the sale prices were below the COP. The prices were exclusive of any applicable movement charges, rebates, discounts, and direct and indirect selling expenses. In determining whether to disregard home market sales made at prices less than their COP, we examined, in accordance with sections 773(b)(1)(A) and (B) of the Act, whether such sales were made (1) within an extended period of time, (2) in substantial quantities, and (3) at prices which not permit the recovery of all costs within a reasonable period of time.

3. Results of the COP Test

Pursuant to section 773(b)(1), where less than 20 percent of the respondent's sales of a given product are at prices less than the COP, we do not disregard any below-cost sales of that product, because we determine that in such instances the below-cost sales were not made in ''substantial quantities.'' Where 20 percent or more of a respondent's sales of a given product are at prices less than the COP, we disregard those sales of that product, because we determine that in such instances the below-cost sales represent ''substantial quantities'' within an extended period of time, in accordance with section 773(b)(1)(A) of the Act. In such cases, we also determine whether such sales were made at prices which would not permit recovery of all costs within a reasonable period of time, in accordance with section 773(b)(1)(B) of the Act.

We found that, for certain specific products, more than 20 percent of U–SI's home market sales were at prices less than the COP, and in addition, such sales were made within an extended period of time and did not provide for the recovery of costs within a reasonable period of time. We therefore excluded these sales and used the remaining above-cost sales as the basis for determining NV in accordance with section 773(b)(1) of the Act.

D. Level of Trade

Section 773(a)(1)(B)(i) of the Act states that, to the extent practicable, the Department will calculate NV based on sales at the same level of trade (''LOT'') as the EP or CEP. Sales are made at different LOTs if they are made at different marketing stages (or their equivalent). 19 CFR 351.412(c)(2). Substantial differences in selling

activities are a necessary, but not sufficient, condition for determining that there is a difference in the stages of marketing. *Id.; see also Notice of Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate From South Africa*, 62 FR 61731, 61732 (November 19, 1997). In order to determine whether the comparison sales were at different stages in the marketing process than the U.S. sales we reviewed the distribution system in each market (*i.e.*, the ''chain of distribution''),[2] including selling functions,[3] class of customer (''customer category''), and the level of selling expenses for each type of sale.

Pursuant to section 773(a)(1)(B)(i) of the Act, in identifying levels of trade for EP and comparison market sales (*i.e.*, NV based on either home market or third country prices),[4] we consider the starting prices before any adjustments. For CEP sales, we consider only the selling activities reflected in the price after the deduction of expenses and profit under section 772(d) of the Act. *See Micron Technology, Inc.* v. *United States*, 243 f. 3d 1301, 1314–1315 (Fed. Cir. 2001).

When the Department is unable to match U.S. sales of the foreign like product in the comparison market at the same LOT as the EP or CEP, the Department may compare the U.S. sale to sales at a different LOT in the comparison market. In comparing EP or CEP sales at a different LOT in the comparison market, where available data make it practicable, we make a LOT adjustment under section 773(a)(7)(A) of the Act. Finally, for CEP sales only, if a NV LOT is more remote from the factory than the CEP LOT and we are unable to make a LOT adjustment, the Department shall grant a CEP offset, as provided in section 773(a)(7)(B) of the Act. *See Notice of Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate from South Africa*, 62 FR 61731 (November 19, 1997); *see also Notice of Preliminary Results and Partial Rescission of Antidumping Duty Administrative Review and Intent To Revoke Antidumping Duty Order in Part: Certain Pasta from Italy*, 66 FR 34414 (June 28, 2001).

We obtained information from U–SI regarding the marketing stages involved in making the reported home market and U.S. sales, including a description of the selling activities performed by the respondents for each channel of distribution. Upon review of this information, the Department found two LOTs in the home market and one LOT in the U.S. market. Where we matched U.S. sales to home market sales at a different LOT, we made a LOT adjustment in accordance with section 773(a)(7)(A) of the Act because we found that there was a pattern of consistent price differences between the two home market LOTs. Our LOT findings are summarized below:

U–SI reported two customer categories (*i.e.*, end-users and distributors) and three channels of distribution for its home market sales (*i.e.*, direct ex-works sales, ex-inventory sales of standard SSB through its affiliate UFS/U–SF, and ex-inventory sales of SSB through its affiliate UFS/U–SF which are purchased for special applications). In its response, U–SI claims that the major difference between its ex-inventory sales of standard SSB products versus its ex-inventory sales of SSB products used for special applications (''specialized SSB'') is the further manufacturing that is performed by its affiliate on the specialized SSB. Specifically, U–SI maintains that its affiliate provides the following additional services for U–SI's ex-inventory sales of specialized SSB: (1) Testing and certifications; (2) upgrading services (*i.e.*, heat treatment, machining, drilling, grinding); and (3) ''other special'' services (*i.e.*, special conditioning, cutting, marking, and chamfering finished SSB). U–SI further maintains that these distinctions constitute a different LOT.

U–SI also claims that, because its affiliate offers significantly different services and the orders are not limited by quantity for ex-inventory sales of specialized SSB when compared to ex-inventory sales of standard SSB products, UFS/U–SF charges higher prices for its sales of specialized SSB products. Therefore, U–SI requests a LOT adjustment on this basis.

In determining whether separate levels of trade actually existed in the home market, we examined whether the sales made by U–SI involved different marketing stages (or their equivalent) based on the channel of distribution, customer categories and selling functions. As noted above, U–SI's ex-inventory sales are made through the same affiliated party, the same channel of distribution, and to the same categories of customers (*i.e.*, end users and distributors).

With respect to selling activities, we note that, in some instances, the activities U–SI characterized as selling functions (*e.g.,* upgrading and other special services) are not distinct selling functions which we consider to be relevant to our LOT analysis. Furthermore, based on our analysis, we note that while there are differences in selling activities between U–SI's ex-inventory sales of standard SSB products and ex-inventory sales of specialized SSB products (*i.e.,* degree of intensity reported for sales process and marketing support, and quality assurance/warranty services), we do not find that such differences are sufficient to establish a difference in marketing stage (or its equivalent). As discussed in the Department's regulations, substantial differences in selling activities are a necessary, but not sufficient, condition for determining that there is a difference in the stage of marketing. *See* 19 CFR 351.412; *see also Notice of Final Results: Antidumping Duty Administrative Review of Antifriction Bearings from France et al.,* 62 FR 2081, 2105 (January 15, 1997). In this case, the differences in selling activities are minor in nature and therefore, we find that U–SI's ex-inventory sales of both standard and specialized SSB in the home market comprise a single LOT.

In addition, we also examined whether U–SI's direct ex-works sales and ex-inventory sales of both standard and specialized SSB involved different marketing stages (or their equivalent) based on the channel of distribution, customer categories and selling functions reported for each claimed LOT. We note that the selling functions (*i.e.,* sales process/market research, sales calls, interactions with customers, inventory maintenance, freight, technical advice and warranty servicing) that U–SI's affiliate provided for U–SI's ex-inventory sales were either at a higher level of intensity or greater in number than the selling functions (*i.e.,* sales process/market research, interaction with customers, freight, technical advice, and warranty servicing) U–SI provided for its ex-works sales. Based on this analysis, we find that U–SI's ex-works and ex-inventory sales in the home market

[2] The marketing process in the United States and comparison markets begins with the producer and extends to the sle to the final user or consumer. The chain of distribution between the two may have many or few links, and the respondents' sales occur somewhere along this chain. In performing this evaluation, we considered the narrative responses of each respondent to properly determine where in the chain of distribution the sale occurs.

[3] Selling functions associated with a particular chain of distribution help us to evaluate the level(s) of trade in a particular market. For purposes of this preliminary determinatiotn, we have organized the common SSB selling functions into four major categories: (1) Sales process and marketing support; (2) freight and delivery; (3) inventory and warehousing; and (4) quality assurance/warranty services. Other selling functions unique to specific companies were considered, as appropriate.

[4] Where NV is based on CV, we determined the NV LOT based on the LOT of the sales from which we derive selling expenses, G&A expenses, and profit for CV, where possible.

constitute two distinct LOTs and that U–SI's ex-inventory sales are at a more advanced LOT level than U–SI's ex-works sales.

U–SI reported only CEP sales in the U.S. market. For its U.S. sales, U–SI reported two channels of distribution (*i.e.,* U–SI produced SSB shipped direct from France to its U.S. affiliate (*i.e.,* US&A) and subject SSB that U–SI subcontracted out to its Italian affiliate (*i.e.,* Bedini) for further processing which is then sold by U–SI to US&A [5].

Based on our examination of U–SI's data, the evidence on the record suggests that U–SI performs the same selling functions (*i.e.,* sales process/market research, customer contact, freight, technical advice and warranty servicing) for sales made through the two channels of distribution to US&A, which are associated with expenses which we did not deduct from the starting price. Thus, all CEP sales constitute one LOT.

We then examined U–SI's submitted data to determine whether U–SI's U.S. sales to US&A were made at the same LOT as U–SI's direct ex-works sales were made in the home market. Based on our examination, the evidence on the record suggests, contrary to U–SI's assertion, that U–SI performs the same selling functions (*i.e.,* sales process/market research, customer contact, freight, technical advice and warranty servicing), at the same relative level of intensity for its sales of SSB to US&A and its ex-works sales in the home market. Therefore, we have determined that the LOT for all CEP sales is the same as the LOT for U–SI's ex-works sales in the home market. Accordingly, where possible, we matched CEP sales to home market ex-works sales and made no LOT adjustment because the sales were made at the same LOT. Where we matched CEP sales to home market ex-inventory sales, we made a LOT adjustment in accordance with section 773(a)(7)(A) of the Act because we found that there was a pattern of consistent price differences between the two home market LOTs.

E. Calculation of Normal Value Based on Comparison Market Prices

We calculated NV based on delivered prices to unaffiliated customers or prices to affiliated customers that we determined to be at arm's length. We made adjustments, where appropriate, to the starting price for billing corrections and early payment discounts. We made deductions, where appropriate, from the starting price for inland freight (from the plant to the warehouse or plant to the customer), warehousing expenses, and inland insurance (see discussion above regarding the Department's treatment of certain movement and selling expenses reported for two channels of distribution associated with sales made through UFS/US–F).

We made adjustments for differences in costs attributable to differences in the physical characteristics of the merchandise in accordance with section 773(a)(6)(C)(ii) of the Act and 19 CFR 351.411. In addition, we made adjustments under section 773(a)(6)(C)(iii) of the Act and 19 CFR 351.410 for differences in circumstances of sale for imputed credit expenses and warranty expenses (*i.e.,* WARR1H).

We recategorized certain expenses (*i.e.,* technical services (TECHSERH) and salary expenses reported as warranty expenses (WARR2H)) as indirect rather than direct selling expenses because it appears that these expenses were not directly related to the sale based on both the explanation given and allocation methodology used in U–SI's response.

U–SI (through its U.S. affiliate) paid commissions to unaffiliated sales intermediaries on some U.S. sales of subject merchandise but did not pay commissions on its home market sales which were at arms-length. Therefore, in accordance with 19 CFR 351.410(e), we offset the commission incurred in the U.S. market, with indirect selling expenses incurred in the home market to the extent of the lesser of the commission or the indirect selling expenses. As indirect selling expenses, we used both U–SI's reported home market inventory carrying costs and indirect selling expenses.

We also deducted home market packing costs and added U.S. packing costs in accordance with section 773(a)(6)(A) and (B) of the Act. Finally, we made an adjustment for differences in LOT under section 773(a)(7)(A) of the Act and 19 CFR 351.412(b)–(e) (*see* ''Level of Trade'' section above for a complete discussion).

Currency Conversion

We made currency conversions into U.S. dollars in accordance with section 773A(a) of the Act based on the exchange rates in effect on the dates of the U.S. sales as certified by the Federal Reserve Bank or reported by the Dow Jones, as appropriate.[6]

Verification

As provided in section 782(i) of the Act, we will verify all information relied upon in making our final determination.

Suspension of Liquidation

In accordance with section 733(d)(2) of the Act, we are directing the Customs Service to suspend liquidation of all imports of subject merchandise that are entered, or withdrawn from warehouse, for consumption on or after the date of publication of this notice in the **Federal Register**. We will instruct the Customs Service to require a cash deposit or the posting of a bond equal to the weighted-average amount by which the NV exceeds the EP or CEP, as indicated in the chart below. These suspension-of-liquidation instructions will remain in effect until further notice. The weighted-average dumping margins are as follows:

Exporter/manufacturer	Weighted-average margin percentage
Aubert & Duval, S.A.	28.07
Ugine-Savoie Imphy, S.A.	4.30
All Others*	4.30

*Pursuant to section 735(c)(5)(A), we have excluded from the calculation of the all-others rate margins which are zero or *de minimis,* or determined entirely on facts available.

ITC Notification

In accordance with section 733(f) of the Act, we have notified the ITC of our determination. If our final determination is affirmative, the ITC will determine before the later of 120 days after the date of this preliminary determination or 45 days after our final determination whether these imports are materially injuring, or threaten material injury to, the U.S. industry.

Disclosure

We will disclose the calculations used in our analysis to parties in this proceeding in accordance with 19 CFR 351.224(b).

Public Comment

Case briefs for this investigation must be submitted to the Department no later than November 2, 2001. Rebuttal briefs must be filed by November 9, 2001. A

[5] This merchandise is subject to this investigation unlike U–SI's tolled merchandise discussed above which is included in the Italian SSB LTFV proceeding.

[6] We normally make currency conversions into U.S. dollars in accordance with section 773A(a) of the Act based on the exchange rates in effect on the dates of the U.S. sales as certified by the Federal Reserve Bank. In this case, where home market prices, costs and expenses were reported in French francs, we made currency conversions based on the exchange rates in effect on the dates of the U.S. sales as reported by the Dow Jones because the Federal Reserve Bank does not track the franc-to-dollar exchange rate.

list of authorities used, a table of contents, and an executive summary of issues should accompany any briefs submitted to the Department. Executive summaries should be limited to five pages total, including footnotes. Section 774 of the Act provides that the Department will hold a public hearing to afford interested parties an opportunity to comment on arguments raised in case or rebuttal briefs, provided that such a hearing is requested by an interested party. If a request for a hearing is made in this investigation, the hearing will tentatively be held on November 14, 2001, at the U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230. Parties should confirm by telephone the time, date, and place of the hearing 48 hours before the scheduled time.

Interested parties who wish to request a hearing, or to participate if one is requested, must submit a written request to the Assistant Secretary for Import Administration, U.S. Department of Commerce, Room 1870, within 30 days of the publication of this notice. Requests should contain: (1) The party's name, address, and telephone number; (2) the number of participants; and (3) a list of the issues to be discussed. Oral presentations will be limited to issues raised in the briefs.

If this investigation proceeds normally, we will make our final determination by no later than 135 days after the publication of this notice in the **Federal Register**.

This determination is published pursuant to sections 733(f) and 777(i) of the Act.

Dated: July 26, 2001.

Faryar Shirzad,

Assistant Secretary for Import Administration.

[FR Doc. 01–19349 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

[A–428–830]

Notice of Preliminary Determination of Sales at Less Than Fair Value and Postponement of Final Determination: Stainless Steel Bar From Germany

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

ACTION: Notice of preliminary determination of sales at less than fair value.

SUMMARY: We preliminarily determine that stainless steel bar from Germany is being, or is likely to be, sold in the United States at less than fair value, as provided in section 733(b) of the Tariff Act of 1930, as amended.

Interested parties are invited to comment on this preliminary determination. Since we are postponing the final determination, we will make our final determination not later than 135 days after the date of publication of this preliminary determination in the **Federal Register**.

EFFECTIVE DATE: August 2, 2001.

FOR FURTHER INFORMATION CONTACT: Craig Matney, Meg Weems or Andrew Covington, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone: (202) 482–1778, (202) 482–2613, or (202) 482–3534, respectively.

SUPPLEMENTARY INFORMATION:

The Applicable Statute

Unless otherwise indicated, all citations to the Tariff Act of 1930, as amended (''the Act''), are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act (''URAA''). In addition, unless otherwise indicated, all citations to the Department of Commerce (''Department's'') regulations are to 19 CFR part 351 (April 2000).

Background

Since the initiation of this investigation (*Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom* (66 FR 7620, January 24, 2001) (''*Initiation Notice*''), as amended by *Corrections, Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom* (66 FR 14986, March 14, 2001)), the following events have occurred:

On January 26, 2001, we solicited comments from interested parties regarding the criteria to be used for model-matching purposes. We received comments on our proposed matching criteria on February 8 and 9, 2001.

On February 12, 2001, the United States International Trade Commission (''ITC'') preliminarily determined that there is a reasonable indication that imports of stainless steel bar (''SSB'') from Germany are materially injuring the United States industry (*see* ITC Investigation No. 701-TA–913–918 (Publication No. 3395)).

On February 21, 2001 , we selected the four largest producers/exporters of SSB from Germany as the mandatory respondents in this proceeding. For further discussion, *see* Memorandum from The Team to Richard W. Moreland Re: Respondent Selection dated February 21, 2001. We subsequently issued the antidumping questionnaires to Walzwerke Einsal GmbH (''Einsal''), Edelstahl Witten-Krefeld GmbH (''EWK''), BGH Edelstahl Seigen GmbH and BGH Edelstahl Freital GmbH (''BGH''), and Krupp Edelstahlprofile GmbH (''KEP'') on February 21, 2001.

On February 13, 2001, EWK requested that ''tool steel'' be excluded from the scope of this investigation. On February 13, 2001, BGH requested that ''special quality oil field equipment steel'' be excluded from the scope of this investigation. *See* ''Scope of Investigation'' section of this notice for further discussion.

In February and March 2001, the petitioners in this case (*i.e.,* Carpenter Technology Corp., Crucible Specialty Metals, Electralloy Corp., Empire Specialty Steel Inc., Slater Steels Corp., and the United Steelworkers of America) made submissions requesting that the Department require the respondents to report the actual content of the primary chemical components of SSB for each sale of SSB made during the period of investigation (''POI''). Also, in February and March 2001, the respondents in this and other concurrent SSB investigations requested that the Department deny the petitioners' request. The Department, upon consideration of the comments from all parties on this matter, issued a memorandum on April 3, 2001, indicating its decision not to require the respondents to report such information on a transaction-specific basis. However, the Department did require that respondents report certain additional information concerning SSB grades sold to the U.S. and home markets during the POI. (For details, *see* Memorandum from The Stainless Steel Bar Teams to Louis Apple and Susan Kuhbach, Directors, Office of AD/CVD Enforcement 1/2, dated April 3, 2001).

On March 6, 2001, Einsal requested that it be relieved from the requirement to report affiliated party resales because sales of the foreign like product to affiliated parties during the POI constituted less than five percent of total sales of the foreign like product. On April 3, 2001, we granted Einsal's request in accordance with 19 CFR 351.403(d). (*See* Memorandum to Richard W. Moreland, dated April 3, 2001.)

On March 21, 2001, BGH requested that it be relieved from the requirement to report affiliated party resales because sales of the foreign like product to affiliated parties during the POI constituted less than five percent of total sales of the foreign like product. On April 6, 2001, we granted BGH's request in accordance with 19 CFR 351.403(d). (*See* Memorandum to Richard W. Moreland, dated April 6, 2001.)

On March 21, 2001, EWK requested that it be relieved from the requirement to report affiliated party resales even though sales of the foreign like product to affiliated parties during the POI constituted more than five percent of total sales of the foreign like product. For the reasons stated in a Memorandum to Richard W. Moreland, dated May 11, 2001, we granted EWK's request.

On March 22, 2001, KEP requested that it be relieved from the requirement to report affiliated party resales even though sales of the foreign like product to affiliated parties during the POI constituted more than five percent of total sales of the foreign like product. For the reasons stated in a Memorandum to Richard W. Moreland, dated June 21, 2001, we granted KEP's request.

On April 17, 2001, BGH requested that it be allowed to report its cost data on a fiscal-year basis rather than a POI basis. For the reasons outlined in the letter dated May 2, 2001, we denied this request.

During the period March through June 2001, the Department received responses to Sections A, B, C and D of the Department's original and supplemental questionnaires from BGH, Einsal, EWK, and KEP.

On April 27, 2001, pursuant to 19 CFR 351.205(e), the petitioners made a timely request to postpone the preliminary determination. We granted this request on May 7, 2001, and postponed the preliminary determination until no later than July 26, 2001. (*See Notice of Postponement of Preliminary Determinations of Sales at Less Than Fair Value: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom;* 66 FR 24114, May 11, 2001).

Postponement of Final Determination and Extension of Provisional Measures

Pursuant to section 735(a)(2)(A) of the Act, on July 17 and 20, 2001, BGH and Einsal, and EWK and KEP, respectively, requested that, in the event of an affirmative preliminary determination in this investigation, the Department postpone its final determination until not later than 135 days after the date of the publication of the preliminary determination in the **Federal Register**, and extend the provisional measures to not more than six months. In accordance with 19 CFR 351.210(b)(2)(ii), because (1) our preliminary determination is affirmative, (2) BGH, Einsal, EWK, and KEP account for a significant proportion of exports of the subject merchandise, and (3) no compelling reasons for denial exist, we are granting the respondents' request and are postponing the final determination until no later than 135 days after the publication of this notice in the **Federal Register**. Suspension of liquidation will be extended accordingly.

Scope of Investigation

For purposes of this investigation, the term ''stainless steel bar'' includes articles of stainless steel in straight lengths that have been either hot-rolled, forged, turned, cold-drawn, cold-rolled or otherwise cold-finished, or ground, having a uniform solid cross section along their whole length in the shape of circles, segments of circles, ovals, rectangles (including squares), triangles, hexagons, octagons, or other convex polygons. Stainless steel bar includes cold-finished stainless steel bars that are turned or ground in straight lengths, whether produced from hot-rolled bar or from straightened and cut rod or wire, and reinforcing bars that have indentations, ribs, grooves, or other deformations produced during the rolling process.

Except as specified above, the term does not include stainless steel semi-finished products, cut length flat-rolled products (*i.e.,* cut length rolled products which if less than 4.75 mm in thickness have a width measuring at least 10 times the thickness, or if 4.75 mm or more in thickness having a width which exceeds 150 mm and measures at least twice the thickness), products that have been cut from stainless steel sheet, strip or plate, wire (*i.e.,* cold-formed products in coils, of any uniform solid cross section along their whole length, which do not conform to the definition of flat-rolled products), and angles, shapes and sections.

The stainless steel bar subject to this investigation is currently classifiable under subheadings 7222.11.00.05, 7222.11.00.50, 7222.19.00.05, 7222.19.00.50, 7222.20.00.05, 7222.20.00.45, 7222.20.00.75, and 7222.30.00.00 of the *Harmonized Tariff Schedule of the United States* (''HTSUS''). Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the scope of this investigation is dispositive.

In accordance with our regulations, we set aside a period of time for parties to raise issues regarding product coverage and encouraged all parties to submit comments within 20 calendar days of publication of the *Initiation Notice* (*see* 66 FR 7620–7621). The respondents in this and the companion SSB investigations filed comments seeking to exclude certain products from the scope of these investigations. The specific products identified in their exclusion requests are:

- Stainless Steel Tool Steel
- Welding Wire
- Special-Quality Oil Field Equipment Steel (''SQOFES'')
- Special Profile Wire

We have addressed these requests in the Memorandum to Susan Kuhbach and Louis Apple from The Stainless Steel Bar Team, dated July 26, 2001, entitled ''Scope Exclusion Requests,'' and the Memorandum to Louis Apple from The Stainless Steel Bar Team, dated July 26, 2001, entitled ''Whether Special Profile Wire Product is Included in the Scope of the Investigation.'' Our conclusions are summarized below.

Regarding stainless steel tool steel, welding wire, and SQOFES, after considering the respondents' comments and the petitioners' objections to the exclusion requests, we preliminarily determine that the scope is not overly broad. Therefore, stainless steel tool steel, welding wire, and SQOFES are within the scope of these SSB investigations. In addition, we preliminarily determine that SQOFES does not constitute a separate class or kind of merchandise from SSB.

Regarding special profile wire, we have preliminarily determined that this product does not fall within the scope as it is written because its cross section is in the shape of a concave polygon. Therefore, we have not included special profile wire in these investigations.

Finally, we note that in the concurrent countervailing duty investigation of stainless steel bar from Italy, the Department preliminarily determined that hot-rolled stainless steel bar is within the scope of these investigations. (*See, Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Countervailing Duty Determination with Final Antidumping Duty Determination: Stainless Steel Bar from Italy,* 66 FR 30414, June 6, 2001).

Period of Investigation

The POI is October 1, 1999, through September 30, 2000.

Collapsing of Affiliated Parties

KEP and EWK are affiliated parties within the meaning of section 771(33)(F) by virtue of their ultimate ownership by a common parent company, ThyssenKrupp AG. Section 351.401(f)(1) of the Department's regulations explains that the Department will treat affiliated producers as a single entity where those producers have production facilities for similar or identical products that would not require substantial retooling of either facility in order to restructure manufacturing priorities and the Department concludes that there is a significant potential for the manipulation of price or production.

KEP and EWK have argued that the two entities should not be collapsed because the current overlap in their production capability is minimal, there is little overlap in the current boards of directors, and the transactions between the two companies are similar to transactions with other, non-affiliated bar producers. Furthermore, they have argued that the cost to retool either or both of the plants to substantially increase one or both of their production ranges would be extremely high. Petitioners have argued that the current overlap is significant and that the cost of retooling KEP's and/or EWK's production facilities to produce a substantially expanded product range is not significant in relation to the resources available to ThyssenKrupp AG. Additionally, petitioners contend that the overlap in the boards of directors, the transactions between the two companies, and the potential for increased interactions between the two companies at the behest of ThyssenKrupp AG provide a significant potential for manipulation of production.

In conducting this analysis of whether KEP and EWK should be treated as a single entity under section 351.401(f) of the regulations, we first observe that KEP and EWK are affiliated with each other due to the fact that they are both wholly-owned by ThyssenKrupp AG. We also observe, as a preliminary matter, that KEP and EWK are producers with production facilities for similar products. In this regard, we acknowledge that there is limited overlap between the products produced by KEP and EWK. However, the level of existing overlap means that, even with no retooling, manufacturing priorities could be restructured.

Given these preliminary findings under section 351.401(f)(1), we turn to an analysis of the significant potential for the manipulation of price or production under section 351.401(f)(2). In conducting such an analysis, the factors the Department may consider include the level of common ownership, common managerial employees or board members on the respective boards of directors, and whether the operations of the companies are intertwined. The companies are wholly-owned by a single ultimate parent company and share two members of their respective managerial boards of directors, though KEP and EWK claim that the managerial board is not involved in the day to day operations of either firm. With regard to intertwined operations, KEP and EWK have an established relationship in which they sell each other's merchandise and purchase certain raw materials from each other and from common affiliated suppliers. In addition, by virtue of its complete ownership of the two firms, ThyssenKrupp AG potentially could dictate future production and pricing decisions and the sharing of sales information, facilities or employees.

Based on this information, we preliminarily determine that within the current production overlap there is a potential for manipulation, and that the extent of the current overlap is large enough that any manipulation could be significant. Therefore, for the preliminary determination, we have calculated a single dumping margin for KEP and EWK by weight-averaging the two firms' individually-calculated dumping margins. For the final determination, we intend to request that KEP and EWK report combined sales and cost data.

We invite comments from parties on this issue for the final determination, in particular as to whether the current production overlap provides a significant potential for price or production manipulation.

Fair Value Comparisons

To determine whether sales of SSB from Germany to the United States were made at less than fair value (''LTFV''), we compared the export price (''EP'') or constructed export price (''CEP'') to the Normal Value (''NV''), as described in the ''Export Price'' and ''Constructed Export Price'' and ''Normal Value'' sections of this notice, below. In accordance with section 777A(d)(1)(A)(i) of the Act, we compared POI weighted-average EPs and CEPs to NVs.

Product Comparisons

In accordance with section 771(16) of the Act, we considered all products produced and sold by the respondents in the home market during the POI that fit the description in the ''Scope of Investigation'' section of this notice to be foreign like products for purposes of determining appropriate product comparisons to U.S. sales. We compared U.S. sales to sales made in the home market, where appropriate. Where there were no sales of identical merchandise in the home market made in the ordinary course of trade to compare to U.S. sales, we compared U.S. sales to sales of the most similar foreign like product made in the ordinary course of trade. In making the product comparisons, we matched foreign like products based on the physical characteristics reported by the respondents in the following order of importance: general type of finish; grade; remelting process; type of final finishing operation; shape; and size. With respect to grade, we matched products sold in the U.S. and home markets on the basis of the three most similar matches proposed by the respondent, where possible.

On July 11 and 13, 2001, the petitioners submitted general comments on product-matching issues for the Department's consideration in the preliminary determination. These comments were not received in time to be fully analyzed for the preliminary determination, but will be considered for the final determination.

Export Price

For all respondents, we calculated EP, in accordance with section 772(a) of the Act, for those sales where the merchandise was sold to the first unaffiliated purchaser in the United States prior to importation by the exporter or producer outside the United States, or to an unaffiliated purchaser for exportation to the United States, based on the facts of record. We based EP on the packed delivered price to unaffiliated purchasers in the United States. We identified the correct starting price by adding any surcharges, making adjustments for any price-billing errors and freight revenue, and making deductions for early payment discounts and rebates, where applicable. We also made deductions from the starting price for movement expenses in accordance with section 772(c)(2)(A) of the Act; these included, where appropriate, domestic inland freight, ocean freight, marine insurance, U.S. brokerage and handling, U.S. customs duties (including harbor maintenance fees and merchandise processing fees), and U.S. inland freight.

Constructed Export Price

For KEP and EWK, we calculated CEP, in accordance with subsection

772(b) of the Act, for those sales to the first unaffiliated purchaser that took place after importation into the United States.

We based CEP on the packed FOB or delivered prices to unaffiliated purchasers in the United States. Where appropriate, we made adjustments for price-billing errors and freight revenue, and made deductions for early payment discounts and rebates in order to identify the correct starting price. We also made deductions for movement expenses in accordance with section 772(c)(2)(A) of the Act; these included, where appropriate, ocean freight, marine insurance, U.S. brokerage and handling, U.S. customs duties (including harbor maintenance fees and merchandise processing fees), U.S. inland insurance, U.S. inland freight expenses, and warehousing expenses. In accordance with section 772(d)(1) of the Act, we deducted those selling expenses associated with economic activities occurring in the United States, including direct selling expenses (credit costs and warranty expenses), inventory carrying costs, and indirect selling expenses. Where payment dates were unreported, we recalculated the credit expenses using the date of the preliminary determination in place of actual date of payment. Lastly, we made an adjustment for profit in accordance with section 772(d)(3) of the Act.

Normal Value

A. Home Market Viability

In order to determine whether there is a sufficient volume of sales in the home market to serve as a viable basis for calculating NV (*i.e.*, whether the aggregate volume of home market sales of the foreign like product is equal to or greater than five percent of the aggregate volume of U.S. sales), we compared each respondent's volume of home market sales of the foreign like product to the volume of U.S. sales of the subject merchandise, in accordance with section 773(a)(1)(C) of the Act. Because each respondent's aggregate volume of home market sales of the foreign like product was greater than five percent of its aggregate volume of U.S. sales for the subject merchandise, we determined that the home market was viable for all respondents.

B. Affiliated-Party Transactions and Arm's-Length Test

The Department's standard practice with respect to the use of home market sales to affiliated parties for NV is to determine whether such sales are at arm's-length prices. Therefore, in accordance with that practice, we performed an arm's-length test on each respondent's sales to affiliates as follows.

Sales to affiliated customers in the home market not made at arm's-length prices (if any) were excluded from our analysis because we considered them to be outside the ordinary course of trade. *See* 19 CFR 351.102. To test whether these sales were made at arm's-length prices, we compared on a model-specific basis the starting prices of sales to affiliated and unaffiliated customers net of all movement charges, direct selling expenses, and packing. Where, for the tested models of subject merchandise, prices to the affiliated party were on average 99.5 percent or more of the price to the unaffiliated parties, we determined that sales made to the affiliated party were at arm's length. *See* 19 CFR 351.403(c). In instances where no price ratio could be constructed for an affiliated customer because identical merchandise was not sold to unaffiliated customers, we were unable to determine that these sales were made at arm's-length prices and, therefore, excluded them from our LTFV analysis. *See Final Determination of Sales at Less Than Fair Value: Certain Cold-Rolled Carbon Steel Flat Products from Argentina* (58 FR 37062, 37077 (July 9, 1993)). Where the exclusion of such sales eliminated all sales of the most appropriate comparison product, we made a comparison to the next most similar model.

C. Cost of Production Analysis

Based on our analysis of an allegation contained in the petition, we found that there were reasonable grounds to believe or suspect that sales of SSB in the home market were made at prices below their cost of production (COP). Accordingly, pursuant to section 773(b) of the Act, we initiated a country-wide sales-below-cost investigation to determine whether sales were made at prices below their respective COP (*see* Initiation Notice at 66 FR 7623).

1. Calculation of COP

In accordance with section 773(b)(3) of the Act, we calculated COP based on the sum of the cost of materials and fabrication for the foreign like product, plus an amount for general and administrative expenses (G&A), interest expenses, and home market packing costs (see ''Test of Home Market Sales Prices'' section below for treatment of home market selling expenses). We relied on the COP data submitted by the respondents, except where noted below:

EWK. We adjusted EWK's reported cost of manufacture (''COM'') to reflect the market price of EWK's steel scrap purchased from an affiliate. We also adjusted EWK's reported G&A expense based on its financial statements. *See* July 26, 2001, Cost Adjustment Memorandum for EWK, for further information.

KEP. We adjusted KEP's reported COM to reflect the market price of KEP's nickel purchased from an affiliate. *See* July 26, 2001, Cost Adjustment Memorandum for KEP, for further information.

2. Test of Home Market Sales Prices

On a product-specific basis, we compared the adjusted weighted-average COP to the home market sales of the foreign like product, as required under section 773(b) of the Act, in order to determine whether the sale prices were below the COP. The prices were exclusive of any applicable movement charges, billing adjustments, discounts, rebates, commissions, interest revenue, warranty expenses, other direct and indirect selling expenses. In determining whether to disregard home market sales made at prices less than their COP, we examined whether such sales were made (1) within an extended period of time, (2) in substantial quantities, and (3) at prices which did not permit the recovery of all costs within a reasonable period of time.

3. Results of the COP Test

Pursuant to section 773(b)(1), where less than 20 percent of the respondent's sales of a given product are at prices less than the COP, we do not disregard any below-cost sales of that product, because we determine that in such instances the below-cost sales were not made in ''substantial quantities.'' Where 20 percent or more of a respondent's sales of a given product are at prices less than the COP, we disregard those sales of that product, because we determine that in such instances the below-cost sales represent ''substantial quantities'' within an extended period of time, in accordance with section 773(b)(1)(A) of the Act. In such cases, we also determine whether such sales were made at prices which would not permit recovery of all costs within a reasonable period of time, in accordance with section 773(b)(1)(B) of the Act.

We found that, for certain specific products, more than 20 percent of each of the respondent's home market sales were at prices less than the COP and, in addition, such sales were made within a reasonable period of time and did not provide for the recovery of costs. We therefore excluded these sales and used the remaining above-cost sales, if any, as the basis for determining NV, in accordance with section 773(b)(1).

D. Level of Trade

Section 773(a)(1)(B)(i) of the Act states that, to the extent practicable, the Department will calculate NV based on sales at the same level of trade (''LOT'') as the EP or CEP. Sales are made at different LOTs if they are made at different marketing stages (or their equivalent). 19 CFR 351.412(c)(2). Substantial differences in selling activities are a necessary, but not sufficient, condition for determining that there is a difference in the stages of marketing. *Id.*; *see also Notice of Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate From South Africa*, 62 FR 61731, 61732 (November 19, 1997). In order to determine whether the comparison sales were at different stages in the marketing process than the U.S. sales, we reviewed the distribution system in each market (*i.e.*, the ''chain of distribution''),[1] including selling functions,[2] class of customer (''customer category''), and the level of selling expenses for each type of sale.

Pursuant to section 773(a)(1)(B)(i) of the Act, in identifying levels of trade for EP and comparison market sales (*i.e.*, NV based on either home market or third country prices[3]), we consider the starting prices before any adjustments. For CEP sales, we consider only the selling activities reflected in the price after the deduction of expenses and profit under section 772(d) of the Act. *See Micron Technology, Inc.* v. *United States*, 243 F. 3d 1301, 1314–1315 (Fed. Cir. 2001).

When the Department is unable to match U.S. sales to sales of the foreign like product in the comparison market at the same LOT as the EP or CEP, the Department may compare the U.S. sale to sales at a different LOT in the comparison market. In comparing EP or CEP sales at a different LOT in the comparison market, where available data make it practicable, we make a LOT adjustment under section 773(a)(7)(A) of the Act. Finally, for CEP sales only, if a NV LOT is more remote from the factory than the CEP LOT and we are unable to make a level of trade adjustment, the Department shall grant a CEP offset, as provided in section 773(a)(7)(B) of the Act. *See Notice of Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate from South Africa*, 62 FR 61731 (November 19, 1997).

We obtained information from each respondent regarding the marketing stages involved in making the reported home market and U.S. sales, including a description of the selling activities performed by the respondents for each channel of distribution. Company-specific LOT findings are summarized below:

1. BGH

We examined the chain of distribution and the selling activities associated with sales reported by BGH to its four channels of distribution in the home market, and where appropriate, to distinct customer categories within these channels. We found that distribution channels 1 and 2, which related to produce-to-order sales to distributors and end-users, were similar with respect to sales process, freight services, warehouse/inventory maintenance and warranty service and, therefore, constituted a distinct level of trade (LOTH 1). We found that distribution channels 3 and 4, which related to warehouse inventory sales to distributors and end-users, were similar with respect to sales process, freight services, warehouse/inventory maintenance and warranty service to constitute a distinct level of trade (LOTH 2). However, we found that LOTH 2 differed significantly from LOTH 1 with respect to freight service and warehouse/inventory maintenance. Based upon our overall analysis in the home market, we found that LOTH 1 and LOTH 2 constituted two different levels of trade.

BGH reported EP sales through two channels of distribution, produce-to-order sales to distributors (channel 1) and produce-to-order sales to end-users (channel 2). We examined the chain of distribution and the selling activities associated with sales through these channels and found them to be similar with respect to sales process, freight services, warehouse/inventory maintenance and warranty service. Therefore, we preliminarily determine that the two channels constitute a single level of trade (LOTU 1).

This EP level of trade differed considerably from LOTH 2 with respect to freight services and warehousing/inventory maintenance. However, the EP level of trade was similar to LOTH 1 with respect to sales process, freight services, warehouse/inventory maintenance and warranty service. Consequently, we matched the EP sales to sales at the same level of trade in the home market (LOTH 1). Where no matches at the same level of trade were possible, and there was a pattern of consistent price differences between different levels of trade, we matched to sales in LOTH 2 and, where appropriate, we made a level of trade adjustment. *See* section 773(a)(7)(A).

2. Einsal

Einsal has reported two home market channels of distribution: Direct sales and consignment sales. In the home market, Einsal sells to master distributors, regional service centers, and end users. Sales to all customer categories in both these channels of distribution were similar with respect to sales process, freight services, warehouse/inventory maintenance and warranty service. Accordingly, we preliminarily determine that home market sales in these two channels of distribution to these three customer categories constitute a single level of trade.

In the U.S. market, Einsal had only EP sales. Einsal reported EP sales to master distributors and end users through only one channel of distribution, direct sales. Sales to these customer categories through this channel of distribution were similar with respect to sales process, freight services, warehouse/inventory maintenance and warranty service. Accordingly, we preliminarily find that Einsal had only one level of trade for its EP sales.

This EP level of trade was similar to that of the home market with respect to sales process, warehouse/inventory maintenance and warranty service, and differed only slightly with respect to freight and delivery. Consequently, we matched Einsal's U.S. sales to the single home market LOT. Thus, it was unnecessary to make any level-of-trade adjustment. *See* Section 773(a)(7)(A) of the Act.

3. EWK

EWK reported two channels of distribution in the home market: (1) Mill direct sales to order (channel 1); and (2) mill sales from stock (channel 2). Both of these channels serviced all customer types (*i.e.,* affiliated and unaffiliated service centers and end users). We examined these channels and found that

[1] The marketing process in the United States and comparison markets begins with the producer and extends to the sale to the final user or consumer. The chain of distribution between the two may have many or few links, and the respondents' sales occur somewhere along this chain. In performing this evaluation, we considered the narrative responses of each respondent to properly determine where in the chain of distribution the sale occurs.

[2] Selling functions associated with a particular chain of distribution help us to evaluate the level(s) of trade in a particular market. For purposes of this preliminary determination, we have organized the common SSB selling functions into four major categories: sales process and marketing support, freight and delivery, inventory and warehousing, and quality assurance/warranty services. Other selling functions unique to specific companies were considered, as appropriate.

[3] Where NV is based on CV, we determine the NV LOT based on the LOT of the sales from which we derive selling expenses, G&A and profit for CV, where possible.

they varied with respect to sales process, freight services, and warehousing/inventory maintenance. Based on our overall analysis of the home market, we preliminarily find that channel 1 and channel 2 constitute distinct levels of trade, LOTH 1 and LOTH 2, respectively.

In the U.S. market, EWK had both EP and CEP sales. EWK reported EP sales through only one channel of distribution and to one customer category, and therefore had only one level of trade for its EP sales. This EP level of trade differed considerably from the home market level of trade LOTH 2 with respect to freight services and warehouse/inventory maintenance. We found that LOTH 1 was similar to the EP level of trade with respect to sales process, freight services, warehouse/inventory maintenance, and warranty service. Consequently, we matched EWK's EP sales to sales at the same level of trade in the home market (LOTH 1). Where no matches at the same level of trade were possible, and there was a pattern of consistent price differences between different levels of trade, we matched to sales in LOTH 2 and, where appropriate, we made a level of trade adjustment. *See* section 773(a)(7)(A).

EWK's constructed CEP level of trade was its sales to its affiliated reseller and since it performed the same selling functions for all of these sales, we found that these CEP sales constitute one level of trade. This CEP level of trade differed considerably from the home market level of trade LOTH 2 with respect to sales process and inventory maintenance. We found that LOTH 1 was similar to the CEP LOT with respect to sales process, warehouse/inventory maintenance, and warranty service and differed only slightly with respect to delivery services.

Because we found the CEP LOT to be similar to home market level of trade LOTH 1, where possible, we matched CEP sales to normal value based on home market sales in LOTH 1 and made no CEP offset adjustment. Where we did not match products at the same level of trade, and there was a pattern of consistent prices differences between different levels of trade, we made a level of trade adjustment. See section 773(a)(7)(A). Where we did not match products at the same level of trade, and we were unable to make a level of trade adjustment because the home market level of trade was at a more advanced stage of distribution than the CEP level of trade, we made a CEP offset in accordance with section 773(a)(7)(B) of the Act.

4. KEP

KEP reported two channels of distribution in the home market: (1) Mill direct sales to order (channel 1); and (2) mill sales from stock (channel 2). KEP sold to service centers and end users through both of these distribution channels. We found that channel 1 produce-to-order sales to both customer categories were similar with respect to sales process, freight services, and warehouse/inventory maintenance, and, therefore, constituted a distinct level of trade (LOTH 1). We found that distribution channel 2 sales from stock to service centers and end users were similar with respect to sales process, freight services, and warehouse/inventory maintenance, and varied only slightly with respect to warranty service, to constitute a distinct level of trade (LOTH 2). However, we found that LOTH 2 differed significantly from LOTH 1 with respect to freight services and warehouse/inventory maintenance. Based on our overall analysis of the home market, we found that LOTH 1 and LOTH 2 constituted two different levels of trade.

In the U.S. market, KEP had both EP and CEP sales. KEP reported EP sales through only one channel of distribution and to one customer category, and therefore had only one level of trade for its EP sales. This EP level of trade differed considerably from the home market level of trade LOTH 2 with respect to freight services, warehouse/inventory maintenance, and warranty service. We found that LOTH 1 was similar to the EP level of trade with respect to sales process, freight services, and warehouse/inventory maintenance, and differed only slightly with respect to warranty service. Consequently, we matched KEP's EP sales to sales at the same level of trade in the home market (LOTH 1). Where no matches at the same level of trade were possible, and there was a pattern of consistent price differences between different levels of trade, we matched to sales in LOTH 2 and, where appropriate, we made a level of trade adjustment. *See* section 773(a)(7)(A).

KEP's constructed CEP level of trade was its sales to its affiliated reseller and since it performed the same selling functions for all of these sales, we found that these CEP sales constitute one level of trade. This CEP level of trade differed from the home market level of trade LOTH 2 principally with respect to warehouse/inventory maintenance and warranty service. We found that LOTH 1 was similar to the CEP LOT with respect to delivery services and warehouse/inventory maintenance and differed only slightly with respect to sales process.

Because we found the CEP LOT to be similar to home market level of trade LOTH 1, where possible, we matched CEP sales to normal value based on home market sales in LOTH 1 and made no CEP offset adjustment. Where we did not match products at the same level of trade, and there was a pattern of consistent prices differences between different levels of trade, we made a level of trade adjustment. *See* section 773(a)(7)(A). Where we did not match products at the same level of trade, and we were unable to make a level of trade adjustment because the home market level of trade was at a more advanced stage of distribution than the CEP level of trade, we made a CEP offset in accordance with section 773(a)(7)(B) of the Act.

E. Calculation of Normal Value Based on Comparison Market Prices

We calculated NV based on delivered prices to unaffiliated customers or prices to affiliated customers that we determined to be at arm's length. We identified the correct starting price by making adjustments for surcharges and billing errors, and making deductions for discounts and rebates. We also made adjustments for movement expenses, including inland freight, inland insurance and warehousing, where appropriate, under section 773(a)(6)(B)(ii). We adjusted KEP's method of allocating its reported warehousing expenses (*see* July 26, 2001 KEP Calculation Memorandum). We made adjustments for differences in costs attributable to differences in the physical characteristics of the merchandise in accordance with section 773(a)(6)(C)(ii) of the Act and 19 CFR 351.411. In addition, we made adjustments under section 773(a)(6)(C)(iii) of the Act for differences in circumstances of sale for imputed credit expenses, interest revenue, warranties, and other direct selling expenses, as appropriate. Where payment dates were unreported, we recalculated the credit expenses using the date of the preliminary determination in place of actual date of payment. We recalculated Einsal's credit expenses based on the adjusted starting prices (*see* Einsal Calculation Memorandum dated July 26, 2001 (Einsal Calculation Memorandum)). We also made adjustments, in accordance with 19 CFR 351.410(e), for indirect selling expenses incurred in the comparison market or U.S. sales where commissions were granted on sales in one market but not in the other (the commission offset). We recalculated

Einsal's indirect selling expenses based on the adjusted starting prices (*see* Einsal Calculation Memorandum). We deducted home market packing costs and added U.S. packing costs in accordance with section 773(a)(6)(A) and (B) of the Act.

Finally, where appropriate, we made an adjustment for differences in LOT under section 773(a)(7)(A) of the Act and 19 CFR 351.412(b)–(e). Additionally, for comparisons to CEP sales, where appropriate, we deducted from normal value the lesser of comparison-market indirect selling expenses and indirect selling expenses deducted from CEP (the CEP offset), pursuant to section 773(a)(7)(B) of the Act and 19 CFR 351.412(f).

Currency Conversion

We made currency conversions into U.S. dollars in accordance with section 773A(a) of the Act based on the exchange rates in effect on the dates of the U.S. sales as reported by the Dow Jones.[4] Einsal has demonstrated that its currency transactions on forward markets are linked to its U.S. dollar-denominated U.S. sales. Therefore, we have used the exchange rates specified in the forward sales agreements to make currency conversions for these sales, in accordance with section 773A(a).

Verification

As provided in section 782(i) of the Act, we will verify all information relied upon in making our preliminary determination.

Suspension of Liquidation

In accordance with section 733(d)(2) of the Act, we are directing the Customs Service to suspend liquidation of all imports of subject merchandise that are entered, or withdrawn from warehouse, for consumption on or after the date of publication of this notice in the **Federal Register**. We will instruct the Customs Service to require a cash deposit or the posting of a bond equal to the weighted-average amount by which the NV exceeds the export price or constructed export price, as indicated in the chart below. These suspension-of-liquidation instructions will remain in effect until further notice. The weighted-average dumping margins are as follows:

Exporter/manufacturer	Weighted-average margin percentage
BGH	18.72
Einsal	6.48
EWK/KEP	21.03
All Others	17.07

ITC Notification

In accordance with section 733(f) of the Act, we have notified the ITC of our determination. If our final determination is affirmative, the ITC will determine before the later of 120 days after the date of this preliminary determination or 45 days after our final determination whether these imports are materially injuring, or threaten material injury to, the U.S. industry.

Disclosure

We will disclose the calculations used in our analysis to parties in this proceeding in accordance with 19 CFR 351.224(b).

Public Comment

Case briefs for this investigation must be submitted to the Department no later than November 7, 2001. Rebuttal briefs must be filed by November 15, 2001. A list of authorities used, a table of contents, and an executive summary of issues should accompany any briefs submitted to the Department. Executive summaries should be limited to five pages total, including footnotes. Section 774 of the Act provides that the Department will hold a public hearing to afford interested parties an opportunity to comment on arguments raised in case or rebuttal briefs, provided that such a hearing is requested by an interested party. If a request for a hearing is made in this investigation, the hearing will tentatively be held on November 19, 2001 at the U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230. Parties should confirm by telephone the time, date, and place of the hearing 48 hours before the scheduled time.

Interested parties who wish to request a hearing, or to participate if one is requested, must submit a written request to the Assistant Secretary for Import Administration, U.S. Department of Commerce, Room 1870, within 30 days of the publication of this notice. Requests should contain: (1) The party's name, address, and telephone number; (2) the number of participants; and (3) a list of the issues to be discussed. Oral presentations will be limited to issues raised in the briefs.

If this investigation proceeds normally, we will make our final determination by no later than 135 days after the publication of this notice in the **Federal Register**.

This determination is published pursuant to sections 733(f) and 777(i) of the Act.

Dated: July 26, 2001.

Faryar Shirzad,

Assistant Secretary for Import Administration.

[FR Doc. 01–19350 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–DS–P

[4] We normally make currency conversions into U.S. dollars in accordance with section 773A(a) of the Act based on the exchange rates in effect on the dates of the U.S. sales as certified by the Federal Reserve Bank. In this case, where home market prices, costs and expenses were reported in German marks, we made currency conversions based on the exchange rates in effect on the dates of the U.S. sales as reported by the Dow Jones because the Federal Reserve Bank does not track the mark-to-dollar exchange rate.

DEPARTMENT OF COMMERCE

International Trade Administration

[A–475–829]

Notice of Preliminary Determination of Sales at Less Than Fair Value and Postponement of Final Determination: Stainless Steel Bar From Italy

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

ACTION: Notice of preliminary determination of sales at less than fair value.

SUMMARY: We preliminarily determine that stainless steel bar from Italy is being, or is likely to be, sold in the United States at less than fair value, as provided in section 733(b) of the Tariff Act of 1930, as amended.

Interested parties are invited to comment on this preliminary determination. Since we are postponing the final determination, we will make our final determination not later than 135 days after the date of publication of this preliminary determination in the **Federal Register**.

EFFECTIVE DATE: August 2, 2001.

FOR FURTHER INFORMATION CONTACT: Jarrod Goldfeder, Melani Miller, or Anthony Grasso, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–0189, (202) 482–0116, or (202) 482–3853, respectively.

SUPPLEMENTARY INFORMATION:

The Applicable Statute

Unless otherwise indicated, all citations to the Tariff Act of 1930, as amended (''the Act''), are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act (''URAA''). In addition, unless otherwise indicated, all citations

to the Department of Commerce (''Department'') regulations are to 19 CFR Part 351 (April 2000).

Background

Since the initiation of this investigation (*Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom*, 66 FR 7620 (January 24, 2001) (''*Initiation Notice*''), as amended by *Corrections, Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom*, 66 FR 14986 (March 14, 2001)), the following events have occurred:

On January 26, 2001, we solicited comments from interested parties regarding the criteria to be used for model-matching purposes, and we received comments on our proposed matching criteria on February 8, February 14, and February 15, 2001.

On February 1, 2001, Acciaierie Valbruna Srl/Acciaierie Bolzano Srl (''Valbruna''), an Italian producer of the merchandise under investigation, submitted a request to the Department that the period of investigation (''POI'') be altered. On February 9, 2001, the petitioners in this case (*i.e.*, Carpenter Technology Corp., Crucible Specialty Metals, Electralloy Corp., Empire Specialty Steel Inc., Slater Steels Corp., and the United Steelworkers of America) objected to this request. On March 1, 2001, the Department denied Valbruna's request to alter the POI. See letter from Susan Kuhbach to Valbruna dated March 1, 2001.

On February 12, 2001, the United States International Trade Commission (''ITC'') preliminarily determined that there is a reasonable indication that imports of stainless steel bar (''SSB'') from Italy are materially injuring the United States industry (*see* ITC Investigation No. 701–TA–913–918 (Publication No. 3395)).

On February 21, 2001, we selected the three largest producers/exporters of SSB from Italy (Acciaiera Foroni S.p.A. (''Foroni''), Valbruna, and Cogne Acciai Speciali Srl (''Cogne'')) as the mandatory respondents in this proceeding. For further discussion, *see* Memorandum from The Team to Richard W. Moreland, ''Respondent Selection'' dated February 21, 2001 (''*Respondent Selection Memorandum*''). We subsequently issued the antidumping questionnaires to Foroni, Valbruna, and Cogne on February 22, 2001.

On March 1, 2001, Valbruna requested that it be allowed to report its costs on a fiscal-year rather than a POI basis. Valbruna submitted further information with respect to its cost reporting on March 9 and March 19, 2001. The petitioners submitted comments on this request on March 14, 2001. On March 20, 2001, the Department notified Valbruna that it would be allowed to alter its cost reporting period as requested. (*See* March 20, 2001 letter to Valbruna for further discussion.)

On March 6, 2001, Trafilerie Bedini, Srl (''Bedini'') and Rodacciai S.p.A. (''Rodacciai'') formally requested to be treated as voluntary respondents in this investigation in response to the Department's invitation to do so in the *Respondent Selection Memorandum.* As discussed in detail below in the ''Facts Available'' section, on March 14, 2001, Cogne, one of the mandatory respondents selected by the Department, notified the Department that it would not be participating in the investigation. Based on Cogne's failure to respond to the Department's questionnaire, and in accordance with the Department's *Respondent Selection Memorandum*, on March 15, 2001, both Bedini and Rodacciai were advised that the Department would investigate them. (*See* letters to Bedini and Rodacciai dated March 15, 2001 for further discussion.)

On March 9, 2001, Acciaierie Bertoli Safau S.p.A. (''ABS'') submitted a request to exclude hot-rolled SSB greater than six inches in diameter from the scope of this investigation. On March 26, 2001, the petitioners submitted an objection to this request. Additionally, on April 6, 2001, Rodacciai submitted a request to exclude welding wire from the scope of this investigation. The petitioners submitted a response to this request on April 24, 2001. *See* ''Scope of Investigation'' section of this notice, below, for further discussion of these requests.

In February and March, 2001, the petitioners made submissions requesting that the Department require the respondents to report the actual content of the primary chemical components of SSB for each sale of SSB made during the POI. Also, in February and March 2001, the respondents in this and other concurrent SSB investigations requested that the Department deny the petitioners' request. The Department, upon consideration of the comments from all parties on this matter, issued a memorandum on April 3, 2001, indicating its decision not to require the respondents to report such information on a transaction-specific basis. However, the Department did require that respondents report certain additional information concerning SSB grades sold to the U.S. and home markets during the POI. (For details, *see* Memorandum from The Stainless Steel Bar Teams to Louis Apple and Susan Kuhbach, Directors, Office of AD/CVD Enforcement 1/2, dated April 3, 2001.)

On March 28, 2001, Rodacciai requested that it be exempted from the requirement to report affiliated party resales even though sales of the foreign like product to affiliated parties during the POI constituted more than five percent of total sales of the foreign like product. For the reasons stated in a Memorandum from John Brinkmann to Susan Kuhbach, dated April 12, 2001, we denied Rodacciai's request. On June 15, 2001, Bedini requested that it be exempted from the requirement to report affiliated party resales because sales of the foreign like product to affiliated parties during the POI constituted less than five percent of total sales of the foreign like product. On July 6, 2001, we granted Bedini's request in accordance with 19 CFR 351.403(d). (*See* Memorandum from the Team to Susan Kuhbach, dated July 6, 2001 for further details.)

During the period March through July 2001, the Department received responses to Sections A, B, C, and D of the Department's original and supplemental questionnaires from Valbruna, Rodacciai, Bedini, and Foroni. The Department also received a response to Section E from Bedini.

On April 2, 2001, Rodacciai requested that it be allowed to report its costs on a fiscal-year rather than a POI basis. The petitioners submitted comments on this request on April 5, 2001. Rodacciai responded to these comments and submitted further information on April 6, 2001. On April 21, 2001, the Department notified Rodacciai that it would not be allowed to alter its cost reporting period. (*See* April 21, 2001 letter to Rodacciai for further discussion.)

On April 27, 2001, pursuant to 19 CFR 351.205(e), the petitioners made a timely request to postpone the preliminary determination. We granted this request on May 7, 2001, and postponed the preliminary determination until no later than July 26, 2001. (*See Notice of Postponement of Preliminary Determinations of Sales at Less Than Fair Value: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom*, 66 FR 24114 (May 11, 2001).)

On July 6, July 9, July 10, and July 13, the petitioner submitted company-specific comments with respect to the upcoming preliminary determination.

Finally, on July 10, July 11, and July 13, 2001, the petitioners submitted

general and company-specific comments on product matching issues for the Department's consideration in the preliminary determination. Valbruna, Rodacciai, Bedini, Foroni, and the petitioners also submitted further company-specific comments on July 18, July 20, July 23, and July 25, 2001. These comments were not received in time to be analyzed fully for the preliminary determination, but will be considered for the final determination.

Postponement of Final Determination and Extension of Provisional Measures

Pursuant to section 735(a)(2) of the Act, on June 4, June 5, June 12, and July 17, 2001, respectively, Foroni, Bedini, Rodacciai, and Valbruna requested that, in the event of an affirmative preliminary determination in this investigation, the Department postpone its final determination until not later than 135 days after the date of the publication of the preliminary determination in the **Federal Register**, and extend the provisional measures to not more than six months. In accordance with 19 CFR 351.210(b), because (1) our preliminary determination is affirmative, (2) Bedini, Rodacciai, Foroni, and Valbruna account for a significant proportion of exports of the subject merchandise, and (3) no compelling reasons for denial exist, we are granting the respondents' request and are postponing the final determination until no later than 135 days after the publication of this notice in the **Federal Register**. Suspension of liquidation will be extended accordingly.

Scope of Investigation

For purposes of this investigation, the term ''stainless steel bar'' includes articles of stainless steel in straight lengths that have been either hot-rolled, forged, turned, cold-drawn, cold-rolled or otherwise cold-finished, or ground, having a uniform solid cross section along their whole length in the shape of circles, segments of circles, ovals, rectangles (including squares), triangles, hexagons, octagons, or other convex polygons. Stainless steel bar includes cold-finished stainless steel bars that are turned or ground in straight lengths, whether produced from hot-rolled bar or from straightened and cut rod or wire, and reinforcing bars that have indentations, ribs, grooves, or other deformations produced during the rolling process.

Except as specified above, the term does not include stainless steel semi-finished products, cut length flat-rolled products (*i.e.,* cut length rolled products which if less than 4.75 mm in thickness have a width measuring at least 10 times the thickness, or if 4.75 mm or more in thickness having a width which exceeds 150 mm and measures at least twice the thickness), products that have been cut from stainless steel sheet, strip or plate, wire (*i.e.,* cold-formed products in coils, of any uniform solid cross section along their whole length, which do not conform to the definition of flat-rolled products), and angles, shapes and sections.

The stainless steel bar subject to this investigation is currently classifiable under subheadings 7222.11.00.05, 7222.11.00.50, 7222.19.00.05, 7222.19.00.50, 7222.20.00.05, 7222.20.00.45, 7222.20.00.75, and 7222.30.00.00 of the *Harmonized Tariff Schedule of the United States* (''HTSUS''). Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the scope of this investigation is dispositive.

In accordance with our regulations, we set aside a period of time for parties to raise issues regarding product coverage and encouraged all parties to submit comments within 20 calendar days of publication of the *Initiation Notice* (*see* 66 FR 7620–7621). The respondents in this and the companion SSB investigations filed comments seeking to exclude certain products from the scope of these investigations. The specific products identified in their exclusion requests are:

A. Stainless steel tool steel

B. Welding wire

C. Special-quality oil field equipment steel (''SQOFES'')

D. Special profile wire

We have addressed these requests in Memorandum to Susan Kuhbach and Louis Apple from The Stainless Steel Bar Team, dated July 26, 2001, entitled ''Scope Exclusion Requests,'' and Memorandum to Louis Apple from The Stainless Steel Bar Team, dated July 26, 2001, entitled ''Whether Special Profile Wire Product is Included in the Scope of the Investigation.'' Our conclusions are summarized below.

Regarding stainless steel tool steel, welding wire, and SQOFES, after considering the respondents' comments and the petitioners' objections to the exclusion requests, we preliminarily determined that the scope is not overly broad. Therefore, stainless steel tool steel, welding wire, and SQOFES are within the scope of these SSB investigations. In addition, we preliminarily determine that SQOFES does not constitute a separate class or kind of merchandise from SSB.

Regarding special profile wire, we have preliminarily determined that this product does not fall within the scope as it is written because its cross section is in the shape of a concave polygon. Therefore, we have not included special profile wire in these investigations.

Finally, we note that in the concurrent countervailing duty investigation of stainless steel bar from Italy, the Department preliminarily determined that hot-rolled stainless steel bar is within the scope of these investigations. (*See Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Countervailing Duty Determination with Final Antidumping Duty Determination: Stainless Steel Bar from Italy,* 66 FR 30414 (June 6, 2001).)

Period of Investigation

The POI is October 1, 1999, through September 30, 2000.

Facts Available

On February 20, 2001, we sent an antidumping questionnaire to Cogne. On March 14, 2001, Cogne notified the Department that it would not be participating in this investigation. *See* letter from Cogne to the Secretary of Commerce dated March 14, 2001.

Section 776(a)(2) of the Act provides that, if an interested party (1) withholds information that has been requested by the Department, (2) fails to provide such information in a timely manner or in the form or manner requested, (3) significantly impedes a determination under the antidumping statute, or (4) provides such information but the information cannot be verified, the Department shall, subject to subsections 782(c)(1) and (e) of the Act, use facts otherwise available in reaching the applicable determination. Because Cogne failed to respond to our questionnaire, we must use facts otherwise available to calculate Cogne's dumping margin.

Section 776(b) of the Act provides that adverse inferences may be used when a party has failed to cooperate by not acting to the best of its ability to comply with requests for information. *See,* also, Statement of Administrative Action accompanying the URAA, H.R. Rep. No. 103–316, vol. 1, at 870 (1994). Cogne's willful failure to reply to the Department's questionnaire demonstrates it has failed to act to the best of its ability in this investigation. *See Nippon Steel Corp.* v. *United States*, 118 F. Supp. 2d 1366, 1379 (CIT 2000). Thus, the Department has determined that, in selecting among the facts otherwise available for Cogne, an adverse inference is warranted.

In accordance with our standard practice, we determine the margin used as adverse facts available by selecting the higher of (1) the highest margin stated in the notice of initiation, or (2) the highest margin calculated for any respondent. *See, e.g., Notice of Preliminary Determinations of Sales at Less Than Fair Value: Certain Large Diameter Carbon and Alloy Seamless Standard, Line and Pressure Pipe From Japan and Certain Small Diameter Carbon and Alloy Seamless Standard, Line and Pressure Pipe From Japan and the Republic of South Africa*, 64 FR 69718, 69722 (December 14, 1999), followed in *Notice of Final Determinations of Sales at Less Than Fair Value: Certain Large Diameter Carbon and Alloy Seamless Standard, Line and Pressure Pipe From Japan and Certain Small Diameter Carbon and Alloy Seamless Standard, Line and Pressure Pipe From Japan and the Republic of South Africa*, 65 FR 25907 (May 4, 2000); and *Notice of Preliminary Determination of Sales at Less Than Fair Value: Stainless Steel Wire Rod from Korea and Germany*, 63 FR 10826, 10847 (March 5, 1998), followed in *Notice of Final Determination of Sales at Less Than Fair Value: Stainless Steel Wire Rod from Korea and Germany*, 63 FR 40433 (July 29, 1998).

Section 776(c) of the Act provides that, when the Department relies on secondary information (such as the petition) in using the facts otherwise available, it must, to the extent practicable, corroborate that information from independent sources that are reasonably at its disposal. In this case, when analyzing the petition for purposes of the initiation, the Department reviewed all of the data upon which the petitioners relied in calculating the estimated dumping margins and determined that the margins in the petition were appropriately calculated and supported by adequate evidence in accordance with the statutory requirements for initiation. In order to corroborate the petition margins for purposes of using them as AFA, we re-examined the price and cost information provided in the petition in light of information developed during the investigation. For further details, *see* the Memorandum to Richard W. Moreland, ''Preliminary Determination of Stainless Steel Bar from Italy: *Corroboration Memorandum*,'' dated July 26, 2001.

In accordance with Section 776(c) of the Act, we were able to partially corroborate the information in the petition using information from independent sources that were reasonably at our disposal. Using this information, we were able to corroborate the price-to-price margin calculations in the petition, but were unable to fully corroborate the constructed value margin calculations in the petition. As a result, we have preliminarily assigned Cogne the highest price-to-price margin rate contained in the petition, 33.00 percent, for purposes of the preliminary determination.

Fair Value Comparisons

To determine whether sales of SSB from Italy to the United States were made at less than fair value (''LTFV''), we compared the export price (''EP'') or constructed export price (''CEP'') to the normal value (''NV''), as described in the ''Export Price'' and ''Constructed Export Price'' and ''Normal Value'' sections of this notice, below. In accordance with section 777A(d)(1)(A)(i) of the Act, we compared POI weighted-average EPs and CEPs to NVs. Any company-specific changes to the EP, CEP, and NV calculations are discussed in each company's individual calculation memorandum.

Product Comparisons

In accordance with section 771(16) of the Act, we considered all products produced and sold by the respondents in the home market during the POI that fit the description in the ''Scope of Investigation'' section of this notice to be foreign like products for purposes of determining appropriate product comparisons to U.S. sales. We compared U.S. sales to sales made in the home market, where appropriate. Where there were no sales of identical merchandise in the home market made in the ordinary course of trade to compare to U.S. sales, we compared U.S. sales to sales of the most similar foreign like product made in the ordinary course of trade. In making the product comparisons, we matched foreign like products based on the physical characteristics reported by the respondents in the following order of importance: General type of finish; grade; remelting process; type of final finishing operation; shape; and size. With respect to grade, we matched products sold in the U.S. and home markets on the basis of the three most similar matches proposed by the respondent, where possible.

On July 11 and 13, 2001, the petitioners submitted general comments on product-matching issues for the Department's consideration in the preliminary determination. These comments were not received in time to be analyzed fully for the preliminary determination, but will be considered for the final determination.

Export Price

We calculated EP, in accordance with section 772(a) of the Act, for those sales where the merchandise was sold to the first unaffiliated purchaser in the United States prior to importation by the exporter or producer outside the United States, or to an unaffiliated purchaser for exportation to the United States, based on the facts of record. We based EP on the packed duty-not-paid, or delivered price to unaffiliated purchasers in the United States. We identified the correct starting price, where appropriate, by accounting for billing adjustments, freight revenue, and other revenue, as well as by making deductions for early payment discounts and rebates, where applicable. We also made deductions for movement expenses in accordance with section 772(c)(2)(A) of the Act. These included, where appropriate, foreign inland freight (plant to port), foreign brokerage and handling, ocean freight, marine insurance, U.S. inland freight expenses, U.S. inland insurance, other U.S. transportation expenses (including U.S. brokerage and handling), and U.S. customs duties.

Constructed Export Price

We calculated CEP, in accordance with subsection 772(b) of the Act, for those sales to the first unaffiliated purchaser that took place after importation into the United States. We based CEP on the packed FOB, CIF, direct duty paid, or delivered prices to unaffiliated purchasers in the United States. We identified the correct starting price, where appropriate, by accounting for billing adjustments, freight revenue, and other revenue, as well as by making deductions for early payment discounts and rebates, where applicable. We also made deductions for movement expenses in accordance with section 772(c)(2)(A) of the Act. These included, where appropriate, foreign inland freight (plant to port), foreign brokerage and handling, ocean freight, marine insurance, U.S. inland freight expenses (freight from port to warehouse, freight from warehouse to the customer, and freight from warehouse to warehouse), U.S. post-sale warehousing expenses, U.S. inland insurance, other U.S. transportation expenses (including U.S. brokerage and handling), and U.S. customs duties. In accordance with section 772(d)(1) of the Act, we deducted those selling expenses associated with economic activities occurring in the United States, including direct selling expenses

(commissions, interest revenue, credit expenses, technical service expenses, and warranty expenses), inventory carrying costs, U.S. repacking expenses, and indirect selling expenses. For Bedini, we also deducted an amount for further-manufacturing costs in accordance with section 772(d)(2) of the Act. We adjusted Bedini's U.S. further-manufacturing costs to include the material yield loss for all products based on output quantity. Where applicable, we made an adjustment for profit in accordance with section 772(d)(3) of the Act.

Ugine-Savoie Imphy Sub-Contracted Sales

In its June 11, 2001, submission, Bedini indicated that, during the POI, it processed as part of a tolling operation non-subject merchandise (*i.e.,* stainless steel wire rod of French origin) that was owned by its French affiliate, Ugine-Savoie Imphy (''U–SI''), into subject merchandise. U–SI then sold this merchandise to the U.S. and other markets. Bedini further stated that, in accordance with the Department's country of origin rules, these sales were not reported as home market and/or U.S. sales in the sales listings submitted in the concurrent investigation of SSB from France, but rather were reported in the sales listings submitted in this investigation.

After further examining Bedini's claim in the context of the Department's substantial transformation practice and tolling regulation (19 CFR 351.401(h)), we concluded that this merchandise must be considered as a product of Italy, but that Bedini, as a tolling operation, cannot be considered the manufacturer or producer. Therefore, we have removed these sales from Bedini's U.S. database. At this time, we are unable to determine whether any of these sales are included in Bedini's home market database, and will examine this issue further after the preliminary determination.

Normal Value

A. Home Market Viability

In order to determine whether there is a sufficient volume of sales in the home market to serve as a viable basis for calculating NV (*i.e.,* whether the aggregate volume of home market sales of the foreign like product is equal to or greater than five percent of the aggregate volume of U.S. sales), we compared the respondents' volume of home market sales of the foreign like product to the volume of U.S. sales of the subject merchandise, in accordance with section 773(a)(1)(C) of the Act. Because each respondent's aggregate volume of home market sales of the foreign like product was greater than five percent of its aggregate volume of U.S. sales for the subject merchandise, we determined that the home market was viable for all respondents.

B. Affiliated-Party Transactions and Arm's-Length Test

The Department's standard practice with respect to the use of home market sales to affiliated parties for NV is to determine whether such sales are at arm's-length prices. Therefore, in accordance with that practice, we performed an arm's-length test on Bedini, Valbruna, and Rodacciai's sales to affiliates as follows.

Sales to affiliated customers in the home market not made at arm's-length prices (if any) were excluded from our analysis because we considered them to be outside the ordinary course of trade. *See* 19 CFR 351.102. To test whether these sales were made at arm's-length prices, we compared on a model-specific basis the starting prices of sales to affiliated and unaffiliated customers net of all movement charges, direct selling expenses, and packing. Where, for the tested models of subject merchandise, prices to the affiliated party were on average 99.5 percent or more of the price to the unaffiliated parties, we determined that sales made to the affiliated party were at arm's length. *See* 19 CFR 351.403(c) and *Antidumping Duties; Countervailing Duties; Final Rule*, 62 FR 27296, 27355 (May 19, 1997). In instances where no price ratio could be constructed for an affiliated customer because identical merchandise was not sold to unaffiliated customers, we were unable to determine that these sales were made at arm's-length prices and, therefore, excluded them from our LTFV analysis. *See Final Determination of Sales at Less Than Fair Value: Certain Cold-Rolled Carbon Steel Flat Products from Argentina*, 58 FR 37062, 37077 (July 9, 1993). Where the exclusion of such sales eliminated all sales of the most appropriate comparison product, we made a comparison to the next most similar model.

C. Cost of Production Analysis

Based on our analysis of an allegation contained in the petition, we found that there were reasonable grounds to believe or suspect that sales of SSB in the home market were made at prices below their cost of production (''COP''). Accordingly, pursuant to section 773(b) of the Act, we initiated a country-wide sales-below-cost investigation to determine whether sales were made at prices below their respective COP (*see Initiation Notice* at 66 FR 7620, 7623).

1. Calculation of COP

In accordance with section 773(b)(3) of the Act, we calculated COP based on the sum of the cost of materials and fabrication for the foreign like product, plus an amount for general and administrative expenses (''G&A''), interest expenses, and home market packing costs (*see* ''Test of Home Market Sales Prices'' section below for treatment of home market selling expenses). We relied on the COP data submitted by Foroni, Valbruna, Bedini, and Rodacciai, except where noted below.

Valbruna. We increased Valbruna's reported total cost of manufacturing to reflect an unreconciled difference between the company's cost accounting system and its reported costs. *See* Memorandum from Robert Greger to Neal Halper, Director, Office of Accounting, dated July 26, 2001, Re: Cost Adjustments.

Foroni. We adjusted Foroni's general and administrative expenses to include director's fees and exclude indirect selling expenses. We also adjusted Foroni's net financial expenses to exclude foreign exchange gains and losses on accounts receivable, bond interest income and interest income from receivables. *See* Memorandum from Robert Greger to Neal Halper, Director, Office of Accounting, dated July 26, 2001, Re: Cost Adjustments.

Rodacciai. We adjusted Rodacciai's net financial expenses to exclude foreign exchange gains and losses on accounts receivable and interest income from receivables. *See* Memorandum from team to the file, ''Preliminary Determination Calculation Memorandum for Rodacciai S.p.A.'' dated July 26, 2001.

2. Test of Home Market Sales Prices

On a product-specific basis, we compared the adjusted weighted-average COP to the home market sales of the foreign like product, as required under section 773(b) of the Act, in order to determine whether the sale prices were below the COP. The prices were inclusive of any applicable freight revenue and exclusive of any applicable movement charges, billing adjustments, discounts, rebates, commissions, interest revenue, warranty expenses, technical service expenses, and direct and indirect selling expenses. In determining whether to disregard home market sales made at prices less than their COP, we examined whether such sales were made (1) within an extended period of time, (2) in substantial

quantities, and (3) at prices which did not permit the recovery of all costs within a reasonable period of time.

3. Results of the COP Test

Pursuant to section 773(b)(1), where less than 20 percent of the respondent's sales of a given product are at prices less than the COP, we do not disregard any below-cost sales of that product, because we determine that in such instances the below-cost sales were not made in ''substantial quantities.'' Where 20 percent or more of a respondent's sales of a given product are at prices less than the COP, we disregard those sales of that product, because we determine that in such instances the below-cost sales represent ''substantial quantities'' within an extended period of time, in accordance with section 773(b)(1)(A) of the Act. In such cases, we also determine whether such sales were made at prices which would not permit recovery of all costs within a reasonable period of time, in accordance with section 773(b)(1)(B) of the Act.

We found that, for certain specific products, more than 20 percent of Bedini's, Valbruna's, Rodacciai's, and Foroni's home market sales were at prices less than the COP and, in addition, such sales were made within an extended period of time and did not provide for the recovery of costs. We therefore excluded these sales and used the remaining above-cost sales, if any, as the basis for determining NV, in accordance with section 773(b)(1) of the Act.

D. Calculation of Constructed Value

Section 773(a)(4) of the Act provides that where normal value cannot be based on comparison-market sales, normal value may be based on CV. Accordingly, for Bedini (the only company that had any sales for which NV was based on CV), when sales of comparison products could not be found, either because there were no sales of a comparable product or all sales of the comparable products failed the COP test, we based NV on CV.

In accordance with sections 773(e)(1) and (e)(2)(A) of the Act, we calculated CV based on the sum of the cost of materials and fabrication for the foreign like product, plus amounts for selling expenses, G&A, interest, profit and U.S. packing costs. We calculated the cost of materials and fabrication based on the methodology described in the ''Calculation of COP'' section of this notice. In accordance with section 773(e)(2)(A) of the Act, we based selling expenses, G&A, and profit on the amounts incurred and realized by Bedini in connection with the production and sale of the foreign like product in the ordinary course of trade for consumption in the foreign country.

E. Level of Trade

Section 773(a)(1)(B)(i) of the Act states that, to the extent practicable, the Department will calculate NV based on sales at the same level of trade (''LOT'') as the EP or CEP. Sales are made at different LOTs if they are made at different marketing stages (or their equivalent) according to 19 CFR 351.412(c)(2). Substantial differences in selling activities are a necessary, but not sufficient, condition for determining that there is a difference in the stages of marketing. *Id; see also Notice of Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate From South Africa,* 62 FR 61731, 61732 (November 19, 1997). In order to determine whether the comparison sales were at different stages in the marketing process than the U.S. sales, we reviewed the distribution system in each market (*i.e.*, the ''chain of distribution''),[1] including selling functions,[2] class of customer (''customer category''), and the level of selling expenses for each type of sale.

Pursuant to section 773(a)(1)(B)(i) of the Act, in identifying levels of trade for EP and comparison market sales (*i.e.*, NV based on either home market or third country prices [3]), we consider the starting prices before any adjustments. For CEP sales, we consider only the selling activities reflected in the price after the deduction of expenses and profit under section 772(d) of the Act. *See Micron Technology, Inc.* v. *United States*, 243 F. 3d 1301, 1314–1315 (Fed. Cir. 2001).

When the Department is unable to match U.S. sales to sales of the foreign like product in the comparison market at the same LOT as the EP or CEP, the Department may compare the U.S. sale to sales at a different LOT in the comparison market. If the comparison market sales are at a different LOT, and the difference affects price comparability, as manifested in a pattern of consistent price differences between sales at different LOTs in the country in which NV is determined, we make a level of trade adjustment under section 773(a)(7)(A) of the Act. Finally, for CEP sales only, if a NV LOT is more remote from the factory than the CEP LOT and we are unable to make a level of trade adjustment, the Department shall grant a CEP offset, as provided in section 773(a)(7)(B) of the Act. *See Notice of Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate from South Africa,* 62 FR 61731 (November 19, 1997).

We obtained information from each respondent regarding the marketing stages involved in making the reported home market and U.S. sales, including a description of the selling activities performed by the respondents for each channel of distribution. Company-specific level of trade findings are summarized below. The complete level of trade analysis for each company is incorporated into the ''Preliminary Determination Calculation Memorandum'' for each company.

Bedini. Bedini reported three channels of distribution in the home market, with two customer categories. With respect to the first channel of distribution, coded in its submissions as channel 2, we found that the sales were primarily produced-to-order sales which were shipped to distributors and end-users direct from the factory. Sales to both customer categories were similar with respect to sales process, freight services, warehouse/inventory maintenance and warranty service. We preliminarily determine that this channel of distribution constitutes a distinct LOT (''LOTH1'').

For the remaining two channels in the home market, coded as channels 3 and 4, we found that they were inventory sales by an affiliated reseller, which only differed with respect to the source of the SSB. We have therefore analyzed these reported channels as a single channel of distribution. Within this channel, sales to distributors and end-users were similar with respect to sales process, freight services, warehouse/inventory maintenance and warranty service. We preliminarily determine that this channel constitutes a distinct LOT (''LOTH2'').

We further found that LOTH1 differed significantly from LOTH2 with respect to sales process, freight service and warehouse/inventory maintenance.

[1] The marketing process in the United States and comparison markets begins with the producer and extends to the sale to the final user or consumer. The chain of distribution between the two may have many or few links, and the respondents' sales occur somewhere along this chain. In performing this evaluation, we considered the narrative responses of each respondent to properly determine where in the chain of distribution the sale occurs.

[2] Selling functions associated with a particular chain of distribution help us to evaluate the level(s) of trade in a particular market. For purposes of this preliminary determination, we have organized the common SSB selling functions into four major categories: sales process and marketing support, freight and delivery, inventory and warehousing, and quality assurance/warranty services. Other selling functions unique to specific companies were considered, as appropriate.

[3] Where NV is based on CV, we determine the NV LOT based on the LOT of the sales from which we derive selling expenses, G&A, and profit for CV, where possible.

Based upon our overall analysis in the home market, we found that LOTH1 and LOTH2 constitute two different levels of trade.

In the U.S. market, Bedini only reported CEP sales. Bedini's constructed CEP level of trade was its sales to its affiliated reseller, and since it performed the same selling functions for all of these sales, we found that these CEP sales constitute one level of trade. This CEP level of trade differed considerably from the home market level of trade LOTH2 with respect to sales process, freight services, warehouse/inventory maintenance, and warranty service. We found that LOTH1 was similar to the CEP LOT with respect to sales process, freight services and warehouse/inventory maintenance and differed only slightly with respect to warranty service.

Although Bedini claimed a CEP offset adjustment to normal value, because we found the CEP LOT to be similar to home market level of trade LOTH1, where possible, we matched CEP sales to normal value based on home market sales in LOTH1 and made no CEP offset adjustment. Where we did not match products at the same level of trade, and there was a pattern of consistent price differences between different levels of trade, we made a level of trade adjustment. *See* section 773(a)(7)(A) of the Act. Where we did not match products at the same level of trade, and we were unable to make a level of trade adjustment, because the home market level of trade was at a more advanced stage of distribution than the CEP level of trade, we made a CEP offset in accordance with section 773(a)(7)(B) of the Act.

Foroni. We examined the chain of distribution and the selling activities associated with sales reported by Foroni in the home market which were primarily produced-to-order sales shipped to distributors and end-users direct from the factory. We found the sales to both customer categories were similar with respect to sales process, freight services, warehouse/inventory maintenance and warranty service. We therefore preliminarily determine that these home market sales constitute a single level of trade.

In the U.S. market, Foroni only reported CEP sales. Foroni's constructed CEP level of trade was its sales to its affiliated reseller, and since it performed the same selling functions for these sales, we found that these CEP sales constitute one level of trade. This CEP level of trade was similar to that of the home market with respect to sales process, warehouse/inventory maintenance and warranty service, and differed only slightly with respect to freight and delivery. Since we found the CEP LOT to be similar to the home market level of trade, we matched CEP sales to normal value based on home market sales and made no CEP offset adjustment.

Rodacciai. We examined the chain of distribution and the selling activities associated with home market sales reported by Rodacciai from warehouse inventory to end-users and to distributors. We found that sales to each customer category were similar with respect to sales process, freight services, warehouse/inventory maintenance and warranty service and therefore Rodacciai's home market sales constituted a single level of trade.

In the U.S. market, Rodacciai had both EP and CEP sales. Rodacciai reported EP sales to distributors through only one channel of distribution and one customer category, and therefore had only one level of trade for its EP sales. This EP level of trade differed considerably from the home market level of trade with respect to sales process, freight services and warehousing/inventory maintenance. Consequently, we could not match the EP level of trade to sales at the same level of trade in the home market. Since there was only one level of trade in the home market, there was no pattern of consistent price differences between different levels of trade in the home market, nor do we have any other information that provides an appropriate basis for determining a level of trade adjustment. Accordingly, we have not made a level of trade adjustment. *See* section 773(a)(7)(A) of the Act.

With respect to CEP sales, Rodacciai's constructed CEP level of trade was sales to its affiliated reseller, and since it performed the same selling functions for these sales, we found that these CEP sales constitute one level of trade. This CEP level of trade differed considerably from the single home market level of trade with respect to sales process, freight services and warehouse/inventory maintenance. Consequently, we could not match to sales at the same level of trade in the home market. Since there was only one level of trade in the home market, there was no pattern of consistent price differences between different levels of trade in the home market, nor do we have any other information that provides an appropriate basis for determining a level of trade adjustment. Accordingly, we have not made a level of trade adjustment. *See* section 773(a)(7)(A) of the Act. We therefore determined NV based on the single level of trade in the home market, and because this home market level of trade was at a more advanced stage of distribution than the CEP level of trade, we made a CEP offset in accordance with section 773(a)(7)(B) of the Act.

Valbruna. Valbruna reported two channels of distribution in the home market, with two customer categories. The first channel of distribution, coded in its submissions as channel 1, included sales made to end-users and distributors by factory headquarters. Sales to both customer categories in this channel were similar with respect to sales process, freight services, warehouse/inventory maintenance and warranty service. The second channel of distribution, coded in its submissions as channel 2, were sales made to end-users and distributors by service centers. We compared these two channels of distribution and found that, while they differed slightly with respect to warehouse/inventory maintenance, they were similar with respect to sales process, freight services and warranty service. Accordingly, we preliminarily determine that home market sales in these two channels of distribution constitute a single level of trade.

In the U.S. market, Valbruna had both EP and CEP sales. Valbruna reported EP sales to a master distributor through only one channel of distribution and one customer category, and therefore had only one level of trade for its EP sales. This EP level of trade differed considerably from the home market level of trade with respect to sales process and warehousing/inventory maintenance. Consequently, we could not match the EP level of trade to sales at the same level of trade in the home market. Since there was only one level of trade in the home market, there was no pattern of consistent price differences between different levels of trade in the home market, nor do we have any other information that provides an appropriate basis for determining a level of trade adjustment. Accordingly, we have not made a level of trade adjustment. *See* section 773(a)(7)(A) of the Act.

With respect to CEP sales, Valbruna's constructed CEP level of trade was sales to its affiliated reseller, and since it performed the same selling functions for these sales, we found that these CEP sales constitute one level of trade. This CEP level of trade differed considerably from the single home market level of trade with respect to sales process and warehouse/inventory maintenance. Consequently, we could not match to sales at the same level of trade in the home market. Since there was only one level of trade in the home market, there

was no pattern of consistent price differences between different levels of trade in the home market, nor do we have any other information that provides an appropriate basis for determining a level of trade adjustment. Accordingly, we have not made a level of trade adjustment. *See* section 773(a)(7)(A) of the Act. We therefore determined NV based on the single level of trade in the home market, and because this home market level of trade was at a more advanced stage of distribution than the CEP level of trade, we made a CEP offset in accordance with section 773(a)(7)(B) of the Act.

F. Calculation of Normal Value Based on Comparison Market Prices

We calculated NV based on delivered, FOB, or ex-works/ex-warehouse prices to unaffiliated customers or prices to affiliated customers that we determined to be at arm's-length. To identify the correct starting price, we accounted for freight revenue, where appropriate, and also made deductions, where appropriate, for billing adjustments, early payment discounts, and other discounts and rebates. We also made adjustments for inland freight (plant to warehouse and plant/warehouse to customer), and warehousing expense, where appropriate, in accordance with section 773(a)(6)(B)(iii) of the Act. We made adjustments for differences in costs attributable to differences in the physical characteristics of the merchandise in accordance with section 773(a)(6)(C)(ii) of the Act and 19 CFR 351.411. In addition, where appropriate, we made adjustments under section 773(a)(6)(C)(iii) of the Act for differences in circumstances of sale for commissions, imputed credit expenses, interest revenue, warranty expenses, technical service expenses, and other direct selling expenses. We also made adjustments, in accordance with 19 CFR 351.410(e), for indirect selling expenses incurred in the comparison market or U.S. sales where commissions were granted on sales in one market but not in the other (the commission offset). We deducted home market packing costs and added U.S. packing costs in accordance with section 773(a)(6)(A) and (B) of the Act.

Finally, where appropriate, we made an adjustment for differences in LOT under section 773(a)(7)(A) of the Act and 19 CFR 351.412(b)–(e). Additionally, for certain comparisons to CEP sales, where appropriate, we deducted from normal value the lesser of comparison-market indirect selling expenses and indirect selling expenses deducted from CEP (the CEP offset), pursuant to section 773(a)(7)(B) of the Act and 19 CFR 351.412(f).

G. Calculation of Normal Value Based on Constructed Value

For price-to-CV comparisons, we made adjustments to CV in accordance with section 773(a)(8) of the Act. Where we compared CV to CEP, we deducted from CV the weighted-average home market direct selling expenses. We also made circumstances of sale adjustments. Finally, we made an adjustment for differences in LOT under section 773(a)(7)(A) of the Act and 19 CFR 351.412(b)–(e).

Currency Conversion

We made currency conversions into U.S. dollars in accordance with section 773A(a) of the Act based on the exchange rates in effect on the dates of the U.S. sales as reported by the Dow Jones.[4]

Verification

As provided in section 782(i) of the Act, we will verify all information relied upon in making our final determination.

Suspension of Liquidation

In accordance with section 733(d)(2) of the Act, with the exception of Valbruna, noted below, we are directing the Customs Service to suspend liquidation of all imports of subject merchandise that are entered, or withdrawn from warehouse, for consumption on or after the date of publication of this notice in the **Federal Register**. We will instruct the Customs Service to require a cash deposit or the posting of a bond equal to the weighted-average amount by which the NV exceeds the export price or constructed export price, as indicated in the chart below. These suspension-of-liquidation instructions will remain in effect until further notice. The weighted-average dumping margins are as follows:

Exporter/manufacturer	Weighted-average margin percentage
Acciaierie Valbruna Srl/Acciaierie Bolzano Srl	1.75
Acciaiera Foroni SpA	7.72
Trafilerie Bedini, Srl	2.63
Rodacciai S.p.A.	4.86
Cogne Acciai Speciali Srl	33.00
All Others	7.72

* Pursuant to 19 CFR 351.204(d)(3), we have excluded rates calculated for voluntary respondents from the calculation of the all-others rate under section 735(c)(5) of the Act.

** Pursuant to section 735(c)(5)(A), we have excluded from the calculation of the all-others rate margins which are zero or *de minimis*, or determined entirely on facts available.

For Valbruna, because its estimated weighted-average preliminary dumping margin is *de minimis*, we are not directing the Customs Service to suspend liquidation of Valbruna's entries.

ITC Notification

In accordance with section 733(f) of the Act, we have notified the ITC of our determination. If our final determination is affirmative, the ITC will determine before the later of 120 days after the date of this preliminary determination or 45 days after our final determination whether these imports are materially injuring, or threaten material injury to, the U.S. industry.

Disclosure

We will disclose the calculations used in our analysis to parties in this proceeding in accordance with 19 CFR 351.224(b).

Public Comment

Case briefs for this investigation must be submitted to the Department no later than November 5, 2001. Rebuttal briefs must be filed by November 13, 2001. A list of authorities used, a table of contents, and an executive summary of issues should accompany any briefs submitted to the Department. Executive summaries should be limited to five pages total, including footnotes. Section 774 of the Act provides that the Department will hold a public hearing to afford interested parties an opportunity to comment on arguments raised in case or rebuttal briefs, provided that such a hearing is requested by an interested party. If a request for a hearing is made in this investigation, the hearing will tentatively be held on November 16, 2001 at the U.S. Department of Commerce, 14th Street and Constitution Avenue, N.W., Washington, D.C. 20230. Parties should confirm by telephone the time, date, and place of the hearing 48 hours before the scheduled time.

[4] We normally make currency conversions into U.S. dollars in accordance with section 773A(a) of the Act based on the exchange rates in effect on the dates of the U.S. sales as certified by the Federal Reserve Bank. In this case, where home market prices, costs and expenses were reported in Italian lira, we made currency conversions based on the exchange rates in effect on the dates of the U.S. sales as reported by the Dow Jones because the Federal Reserve Bank does not track the lira-to-dollar exchange rate.

Interested parties who wish to request a hearing, or to participate if one is requested, must submit a written request to the Assistant Secretary for Import Administration, U.S. Department of Commerce, Room 1870, within 30 days of the publication of this notice. Requests should contain: (1) The party's name, address, and telephone number; (2) the number of participants; and (3) a list of the issues to be discussed. Oral presentations will be limited to issues raised in the briefs.

If this investigation proceeds normally, we will make our final determination by no later than 135 days after the publication of this notice in the **Federal Register**.

This determination is published pursuant to sections 733(f) and 777(i) of the Act.

Dated: July 26, 2001.

Faryar Shirzad,

Assistant Secretary for Import Administration.

[FR Doc. 01–19351 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

[A–580–847]

Notice of Preliminary Determination of Sales at Less Than Fair Value and Postponement of Final Determination: Stainless Steel Bar From Korea

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

ACTION: Notice of preliminary determination of sales at less than fair value.

SUMMARY: We preliminarily determine that stainless steel bar from Korea is being, or is likely to be, sold in the United States at less than fair value, as provided in section 733(b) of the Tariff Act of 1930, as amended.

Interested parties are invited to comment on this preliminary determination. Since we are postponing the final determination, we will make our final determination not later than 135 days after the date of publication of this preliminary determination in the **Federal Register**.

EFFECTIVE DATE: August 2, 2001.

FOR FURTHER INFORMATION CONTACT: Barbara Wojcik-Betancourt or Sophie Castro, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone: (202) 482–0629 or (202) 482–0588, respectively.

SUPPLEMENTARY INFORMATION:

The Applicable Statute

Unless otherwise indicated, all citations to the Tariff Act of 1930, as amended (''the Act''), are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act (''URAA''). In addition, unless otherwise indicated, all citations to the Department of Commerce (''Department's'') regulations are to the regulations at 19 CFR part 351 (April 2000).

Background

Since the initiation of this investigation (*Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom*, 66 FR 7620 (January 24, 2001) (*Initiation Notice*), as amended by *Corrections, Notice of Initiation of Antidumping Investigations: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom*, 66 FR 14986 (March 14, 2001), the following events have occurred:

On January 26, 2001, we solicited comments from interested parties regarding the criteria to be used for model-matching purposes, and we received comments on our proposed matching criteria on February 8, 2001.

On February 12, 2001, the United States International Trade Commission (''ITC'') preliminarily determined that there is a reasonable indication that imports of stainless steel bar (''SSB'') from Korea are materially injuring the United States industry (*see* ITC Investigation No. 701–TA–913–918 (Publication No. 3395)).

On February 12, 2001, we selected the four largest producers/exporters of SSB from Korea as the mandatory respondents in this proceeding. For further discussion, *see* Memorandum from The Team to Richard W. Moreland, Deputy Assistant Secretary for Import Administration, entitled ''Respondent Selection'', dated February 12, 2001. We subsequently issued the antidumping questionnaires to Dongbang Industrial Co., Ltd. (''Dongbang''), Changwon Specialty Steel (''Changwon''), Duferco Steel SA (''Duferco''), and Posco Steel Service and Sales (''POSTEEL'') on February 20, 2001.

On February 15, 2001, SeAH Steel Corp. (''SeAH'') appeared on the record of this investigation as a voluntary respondent. On April 23, 2001, SeAH was advised that the Department could not change its status from a voluntary to a mandatory respondent. (See Memoranda to the File dated February 27, 2001, and April 30, 2001, for further discussion.)

In February and March, 2001, the petitioners [1] in this case made submissions requesting that the Department require the respondents to report the actual content of the primary chemical components of SSB for each sale of SSB made during the period of investigation (''POI''). The respondents in this and other concurrent SSB investigations requested that the Department deny the petitioners' request. The Department, upon consideration of the comments from all parties on this matter, issued a memorandum on April 3, 2001, indicating its decision not to require the respondents to report such information on a transaction-specific basis. However, the Department did require that respondents report certain additional information concerning SSB grades sold to the U.S. and home markets during the POI. (For details, see Memorandum from The Stainless Steel Bar Teams to Louis Apple and Susan Kuhbach, Office Directors, dated April 3, 2001).

On March 13, 2001, Duferco, a trading company in Switzerland, requested that it be relieved from its requirement to respond to Sections B, C, and D of the antidumping questionnaire because the producer of the subject merchandise that Duferco sold to the United States during the POI, indicated that it intended to report all the relevant sales and cost data in its response to the antidumping questionnaire because it knew at the time of sale to Duferco that the subject merchandise would be exported to the United States. On April 12, 2001, the Department informed Duferco that it was not required to respond to Sections B, C, and D of the antidumping questionnaire. The Department also advised Duferco that pursuant to section 776(a) of the Tariff Act of 1930, as amended, if the information provided by Duferco or Duferco's supplier is not complete or cannot be verified as provided in section 782(i) of the Act, the Department may have to resort to the use of facts available. (*See* Memorandum from Barbara Wojcik-Betancourt to The File, dated April 12, 2001, for further details.)

During the period March through June 2001, the Department received responses to Sections A, B, C, and D of

[1] The petitioners in this case (*i.e.*, Carpenter Technology Corp., Crucible Speciality Metals, Electralloy Corp., Empire Specialty Steel Inc., Slater Steels Corp., and the United Steelworkers of America)

it's original and supplemental questionnaires from Changwon [2] and Dongbang. Within the same time period Duferco submitted its responses to Section A of the Department's original and supplemental questionnaires.

On April 27, 2001, pursuant to 19 CFR 351.205(e), the petitioners made a timely request to postpone the preliminary determination. We granted this request on May 7, 2001, and postponed the preliminary determination until no later than July 26, 2001. (*See Notice of Postponement of Preliminary Determinations of Sales at Less Than Fair Value: Stainless Steel Bar from France, Germany, Italy, Korea, Taiwan and the United Kingdom,* 66 FR 24114 (May 11, 2001)).

On July 10 and 11, 2001, the petitioners submitted comments with respect to Dongbang's and Changwon's Sections A–D original and supplemental questionnaire responses.

Postponement of Final Determination and Extension of Provisional Measures

Pursuant to section 735(a)(2) of the Act, on May 23, 2001, Changwon and Dongbang requested that, in the event of an affirmative preliminary determination in this investigation, the Department postpone its final determination until not later than 135 days after the date of the publication of the preliminary determination in the **Federal Register**, and extend the provisional measures to not more than six months. In accordance with 19 CFR 351.210(b), because (1) our preliminary determination is affirmative, (2) Changwon and Dongbang account for a significant proportion of exports of the subject merchandise, and (3) no compelling reasons for denial exist, we are granting the respondents' request and are postponing the final determination until no later than 135 days after the publication of this notice in the **Federal Register**. Suspension of liquidation will be extended accordingly.

Scope of Investigation

For purposes of this investigation, the term ''stainless steel bar'' includes articles of stainless steel in straight lengths that have been either hot-rolled, forged, turned, cold-drawn, cold-rolled or otherwise cold-finished, or ground, having a uniform solid cross section along their whole length in the shape of circles, segments of circles, ovals, rectangles (including squares), triangles, hexagons, octagons, or other convex polygons. Stainless steel bar includes cold-finished stainless steel bars that are turned or ground in straight lengths, whether produced from hot-rolled bar or from straightened and cut rod or wire, and reinforcing bars that have indentations, ribs, grooves, or other deformations produced during the rolling process.

Except as specified above, the term does not include stainless steel semi-finished products, cut length flat-rolled products (*i.e.,* cut length rolled products which if less than 4.75 mm in thickness have a width measuring at least 10 times the thickness, or if 4.75 mm or more in thickness having a width which exceeds 150 mm and measures at least twice the thickness), products that have been cut from stainless steel sheet, strip or plate, wire (*i.e.,* cold-formed products in coils, of any uniform solid cross section along their whole length, which do not conform to the definition of flat-rolled products), and angles, shapes and sections.

The stainless steel bar subject to this investigation is currently classifiable under subheadings 7222.11.00.05, 7222.11.00.50, 7222.19.00.05, 7222.19.00.50, 7222.20.00.05, 7222.20.00.45, 7222.20.00.75, and 7222.30.00.00 of the *Harmonized Tariff Schedule of the United States* (''HTSUS''). Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the scope of this investigation is dispositive.

In accordance with our regulations, we set aside a period of time for parties to raise issues regarding product coverage and encouraged all parties to submit comments within 20 calendar days of publication of the *Initiation Notice* (*see* 66 FR 7620–7621). The respondents in the companion SSB investigations filed comments seeking to exclude certain products from the scope of these investigations. The specific products identified in their exclusion requests are:

- Stainless steel tool steel
- Welding wire
- Special-quality oil field equipment steel (SQOFES)
- Special profile wire

We have addressed these requests in a Memorandum to Susan Kuhbach and Louis Apple from The Stainless Steel Bar Team, dated July 26, 2001, entitled ''Scope Exclusion Requests,'' and a Memorandum to Louis Apple from The Stainless Steel Bar Team, dated July 26, 2001, entitled ''Whether Special Profile Wire Product is Included in the Scope of the Investigation.'' Our conclusions are summarized below.

Regarding stainless steel tool steel, welding wire, and SQOFES, after considering the respondents' comments and the petitioners' objections to the exclusion requests, we preliminarily determine that the scope is not overly broad. Therefore, stainless steel tool steel, welding wire, and SQOFES are within the scope of these SSB investigations. In addition, we preliminarily determine that SQOFES does not constitute a separate class or kind of merchandise from SSB.

Regarding special profile wire, we have preliminarily determined that this product does not fall within the scope as it is written because its cross section is in the shape of a concave polygon. Therefore, we have not included special profile wire in these investigations.

Finally, we note that in the concurrent countervailing duty investigation of stainless steel bar from Italy, the Department preliminarily determined that hot-rolled stainless steel bar is within the scope of these investigations. (*See Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Countervailing Duty Determination with Final Antidumping Duty Determination: Stainless Steel Bar from Italy,* 66 FR 30414 (June 6, 2001)).

Period of Investigation

The POI is October 1, 1999, through September 30, 2000.

Fair Value Comparisons

To determine whether sales of SSB from Korea to the United States were made at less than fair value (''LTFV''), we compared the export price (''EP'') or constructed export price (''CEP'') to the Normal Value (''NV''), as described in the ''Export Price'' and ''Constructed Export Price'' and ''Normal Value'' sections of this notice, below. In accordance with section 777A(d)(1)(A)(i) of the Act, we compared POI weighted-average EPs and CEPs to NVs.

Product Comparisons

In accordance with section 771(16) of the Act, we considered all products produced and sold by the respondents in the home market during the POI that fit the description in the ''Scope of Investigation'' section of this notice to be foreign like products for purposes of determining appropriate product comparisons to U.S. sales. We compared U.S. sales to sales made in the home market, where appropriate. Where there were no sales of identical merchandise in the home market made in the ordinary course of trade to compare to U.S. sales, we compared U.S. sales to

[2] Due to Changwon's affiliation with POSTEEL, a trading company in Korea, Changwon provided consolidated responses, including the sales of subject merchandise made by POSTEEL during the POI.

sales of the most similar foreign like product made in the ordinary course of trade. In making the product comparisons, we matched foreign like products based on the physical characteristics reported by the respondents in the following order of importance: general type of finish; grade; remelting process; type of final finishing operation; shape; and size.

With respect to general type of finish, the Department's questionnaire recognizes two types: hot-finished and cold-finished. Changwon reported a third type of finishing category (*i.e.,* forged) that was not listed in the Department's questionnaire. According to the respondent, because one of the inputs used for the production of SSB (*i.e.,* ingots), undergoes an extra processing procedure, specifically, the ingots are re-heated and then forged to a target size using forging-press machines, the general finish classification of the SSB products that are produced using the forged processing should be separated from the hot and cold categories specified in the questionnaire. We reviewed the information on the record and have preliminarily decided not to distinguish between hot-rolling and hot-forging because there is no evidence that these processes yield different properties that result in different physical characteristics of the subject merchandise.

With respect to grade, we matched products sold in the U.S. and home markets on the basis of the three most similar matches proposed by the respondents, where possible.

With respect to ''Round-Class II'' products sold by Dongbang during the POI, in its original questionnaire response, Dongbang classified these products separately from round products in its reported shape code. In its June 11, 2001 supplemental questionnaire response, Dongbang reported Round-Class II products as a different grade rather than a separate shape, without providing the Department with a sufficient explanation as to why Class II products should be recognized as a different grade. Although Dongbang explained that Class II products undergo a more lengthy and more costly production process than non-Class II products, and provided the mechanical requirements of a Class II product as detailed in the ASTM specifications, the respondent did not show how a Class II product would constitute a separate grade with respect to chemical composition. Therefore, we have not taken into account the additional coding for Class II products in our preliminary determination and will review this issue further for the final determination.

On July 10 and 13, 2001, the petitioners submitted general comments on product matching issues for the Department's consideration in the preliminary determination. These comments were not received in time to be fully analyzed for the preliminary determination but will be considered for the final determination.

With respect to home market sales of non-prime SSB made by Changwon and Dongbang during the POI, in accordance with our past practice, we excluded these sales from our preliminary analysis based on the limited quantity of such sales in the home market and the fact that no such sales were made to the United States during the POI. (*See, e.g., Final Determinations of Sales at Less Than Fair Value: Certain Hot-Rolled Carbon Steel Flat Products, Certain Cold-Rolled Carbon Steel Flat Products, Certain Corrosion-Resistant Carbon Steel Flat Products, and Certain Cut-to-Length Carbon Steel Plate from Korea,* 58 FR 37176, 37180 (July 9, 1993)).

Export Price and Constructed Export Price

Changwon

Changwon reported all U.S. sales as EP sales. During the POI, Changwon sold subject merchandise to unaffiliated U.S. customers prior to importation through affiliated (*i.e.,* POSTEEL) and unaffiliated trading companies in Korea.

With respect to sales made through Changwon's affiliated Korean trading company POSTEEL and through POSTEEL's affiliated U.S. trading company, POSAM, prior to importation, Changwon claims that these sales are properly classified as EP sales because Changwon is not directly affiliated with the U.S. trading company, POSAM. Furthermore, Changwon claims that the U.S. trading company acts only as a sales-document processor and communication link to facilitate Changwon's U.S. sales to unaffiliated customers.

We preliminarily determine that sales made through POSTEEL's U.S. affiliate and reported by Changown as EP sales are properly classified as CEP sales. Having reviewed the evidence on the record of this investigation regarding respondent's reported EP sales, we conclude that sales between the foreign producer (*i.e.,* Changwon) and the U.S. customer were made ''in the United States'' by POSTEEL's U.S. affiliate on behalf of Changwon within the meaning of section 772(b) of the Act, and, thus, should be treated as CEP transactions (*see AK Steel Corp., et al.* v. *United States,* 226 F.3d 1361, 1374 (Fed. Cir 2000) (''*AK Steel*'')). Specifically, although Changwon initially reaches the agreement with the U.S. customer on the estimated overall volume and pricing of merchandise through POSTEEL and its U.S. affiliate, the final documents are executed by POSTEEL's U.S. affiliate. *See* respondent's March 20, 2001 section A response at A14–18. The description provided by Changwon regarding the sales process for its alleged EP sales indicates that, for these sales, the merchandise was sold (or agreed to be sold) in the United States. Therefore, we have preliminary decided to treat Changwon's reported EP sales through POSTEEL and POSAM as CEP sales. *See Polyvinyl Alcohol from Japan: Preliminary Results of Antidumping Duty Administrative Review,* 66 FR 11140 (February 22, 2001), (where the Department preliminarily determined that, pursuant to *AK Steel,* sales through a U.S. affiliate were made ''in the United States'' and were therefore classifiable as CEP transactions).

We calculated CEP, in accordance with subsection 772(b) of the Act, for those sales to the first unaffiliated purchaser that took place in the United States prior to importation by a seller affiliated with the producer or exporter as discussed above. We based CEP on the packed FOB or delivered prices to unaffiliated purchasers in the United States. We added duty drawback in accordance with section 772(c)(1)(B) of the Act. We made deductions for movement expenses in accordance with section 772(c)(2)(A) of the Act; these included, where appropriate, ocean freight, marine insurance, U.S. brokerage and handling, U.S. customs duties (including harbor maintenance fees and merchandise processing fees), U.S. inland insurance, and U.S. inland freight expenses (freight from port to warehouse and freight from warehouse to the customer). In accordance with section 772(d)(1) of the Act, we deducted those selling expenses associated with economic activities occurring in the United States, including direct selling expenses (credit costs and warranty expenses), inventory carrying costs, and indirect selling expenses. We also made an adjustment for profit in accordance with section 772(d)(3) of the Act. (*See* Calculation Memorandum dated July 26, 2001.)

We calculated EP, in accordance with section 772(a) of the Act, for those sales where the merchandise was sold to the first unaffiliated purchaser in the United States prior to importation by the exporter or producer outside the United States, or to an unaffiliated purchasers in the home market for exportation to

the United States market. We based EP on the packed delivered price to unaffiliated purchasers in the home market for exportation to the United States. We made deductions for movement expenses in accordance with section 772(c)(2)(A) of the Act; these included, where appropriate, ocean freight, marine insurance, U.S. brokerage and handling, U.S. customs duties (including harbor maintenance fees and merchandise processing fees), U.S. inland insurance, and U.S. inland freight expenses (freight from port to warehouse and freight from warehouse to the customer). We added duty drawback in accordance with section 772(c)(1)(B) of the Act. (*See* Calculation Memorandum dated July 26, 2001.)

Dongbang

For all of Dongbang's reported sales, we calculated EP, in accordance with section 772(a) of the Act, for those sales where the merchandise was sold to the first unaffiliated purchaser in the United States prior to importation by the exporter or producer outside the United States, or to an unaffiliated purchaser in the home market for exportation to the United States market, based on the facts of record. We based EP on the packed delivered price to unaffiliated purchasers in the United States and home market. We added duty drawback in accordance with section 772(c)(1)(B) of the Act. We made deductions for movement expenses in accordance with section 772(c)(2)(A) of the Act; these included, where appropriate, domestic inland freight, Korean brokerage and handling charges (including wharfage charges, terminal handling charges, inspection fees, document fees, CFS charges, container taxes and customs clearance fees), ocean freight and marine insurance. (*See* Calculation Memorandum dated July 26, 2001.)

Normal Value

A. Home Market Viability

In order to determine whether there is a sufficient volume of sales in the home market to serve as a viable basis for calculating NV (*i.e.,* whether the aggregate volume of home market sales of the foreign like product is equal to or greater than five percent of the aggregate volume of U.S. sales), we compared each respondent's volume of home market sales of the foreign like product to the volume of U.S. sales of the subject merchandise, in accordance with section 773(a)(1)(B) of the Act. Because each respondent's aggregate volume of home market sales of the foreign like product was greater than five percent of its aggregate volume of U.S. sales for the subject merchandise, we determined that the home market was viable for each respondent.

B. Cost of Production Analysis

Based on our analysis of an allegation contained in the petition, we found that there were reasonable grounds to believe or suspect that sales of SSB in the home market were made at prices below their cost of production (''COP''). Accordingly, pursuant to section 773(b) of the Act, we initiated a country-wide sales-below-cost investigation to determine whether sales were made at prices below their respective COP (*see Initiation Notice,* 66 FR at 7620–7621).

1. Calculation of COP

In accordance with section 773(b)(3) of the Act, we calculated COP based on the sum of the cost of materials and fabrication for the foreign like product, plus an amount for general and administrative expenses (''G&A''), interest expenses, and home market packing costs (see ''Test of Home Market Sales Prices'' section below for treatment of home market selling expenses). We relied on the COP data submitted by Changwon and Dongbang, except where noted below:

Changwon. Changwon submitted a cost database reflecting its production costs based on six size ranges. The Department's questionnaire recognizes three size categories (*see* antidumping questionnaire on page B–9). However, Changwon reported additional size categories (*i.e.,* six in total) that take into account general finish (*i.e.,* hot-working by either rolling or forging) and final finish (*i.e.,* smooth-turning, rough-turning or lathing). In its questionnaire response, Changwon stated that the reason it submitted six categories is because it differentiates costs in its normal books based on size at a level of detail greater than the three size categories as identified by the Department's antidumping questionnaire. Based on the respondent's representation, we have accepted the reported production costs based on the size ranges identified by the respondent.

We revised Changwon's fiscal year 2000 G&A expense rate calculation to exclude foreign exchange gains which were already reflected in the interest expense rate calculation. We used the revised interest expense rate which was submitted based on Changwon's consolidated parent company's 2000 financial statements. The COP file reflected the rate based on the 1999 financial statements. *See* Memorandum from Heidi Norris to Neal Halper, Director Office of Accounting, dated July 26, 2001, Re: Cost Adjustments.

Dongbang. Dongbang submitted two different cost databases reflecting its production costs based on five or three size ranges. Given that Dongbang does not recognize size groupings in its books and records, we have used the COP database that reports costs based on the three size groups defined in the Department's questionnaire.

We revised Dongbang's reported direct materials costs to reflect market prices in accordance with section 773(f)(3) of the Act. The record evidence shows that market price exceeds both the transfer price of the direct materials purchased from the affiliated supplier and the affiliated supplier's COP. Accordingly, we have increased Dongbang's reported direct material costs to reflect the difference between the market price and the transfer price or COP. *See* Memorandum from LaVonne Jackson to Neal Halper, Director Office of Accounting, dated July 26, 2001, Re: Cost Adjustments.

2. Test of Home Market Sales Prices

On a product-specific basis, we compared the adjusted weighted-average COP to the home market sales of the foreign like product, as required under section 773(b) of the Act, in order to determine whether the sale prices were below the COP. The prices were exclusive of any applicable movement charges and direct and indirect selling expenses. In determining whether to disregard home market sales made at prices less than their COP, we examined, in accordance with sections 773(b)(1)(A) and (B) of the Act, whether such sales were made (1) within an extended period of time, (2) in substantial quantities, and (3) at prices which did not permit the recovery of all costs within a reasonable period of time.

3. Results of the COP Test

Pursuant to section 773(b)(1) of the Act, where less than 20 percent of the respondent's sales of a given product are at prices less than the COP, we do not disregard any below-cost sales of that product, because we determine that in such instances the below-cost sales were not made in ''substantial quantities.'' Where 20 percent or more of a respondent's sales of a given product are at prices less than the COP, we disregard those sales of that product, because we determine that in such instances the below-cost sales represent ''substantial quantities'' within an extended period of time, in accordance with section 773(b)(1)(A) of the Act. In such cases, we also determine whether such sales were made at prices which

would not permit recovery of all costs within a reasonable period of time, in accordance with section 773(b)(1)(B) of the Act.

Changwon. We found that, for certain specific products, more than 20 percent of Changwon's home market sales were at prices less than the COP and, in addition, such sales were made within a reasonable period of time and did not provide for the recovery of costs. We therefore excluded these sales and used the remaining above-cost sales, if any, as the basis for determining NV, in accordance with section 773(b)(1) of the Act.

Dongbang. We found that, for certain specific products, more than 20 percent of Dongbang's home market sales were at prices less than the COP and, in addition, such sales were made within a reasonable period of time and did not provide for the recovery of costs. We therefore excluded these sales and used the remaining above-cost sales, if any, as the basis for determining NV, in accordance with section 773(b)(1) of the Act.

E. Level of Trade

Section 773(a)(1)(B)(i) of the Act states that, to the extent practicable, the Department will calculate NV based on sales in the comparison market at the same level of trade (''LOT'') as the EP or CEP transaction. Sales are made at different LOTs if they are made at different marketing stages (or their equivalent). 19 CFR 351.412(c)(2). Substantial differences in selling activities are a necessary, but not sufficient, condition for determining that there is a difference in the stages of marketing. *Id.; see also Notice of Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate From South Africa,* 62 FR 61731, 61732 (November 19, 1997). In order to determine whether the comparison sales were at different stages in the marketing process than the U.S. sales, we reviewed the distribution system in each market (*i.e.,* the ''chain of distribution''),[3] including selling functions,[4] class of customer (''customer category''), and the level of selling expenses for each type of sale.

Pursuant to section 773(a)(1)(B)(i) of the Act, in identifying levels of trade for EP and comparison market sales (*i.e.,* NV based on either home market or third country prices[5]), we consider the starting prices before any adjustments. For CEP sales, we consider only the selling activities reflected in the price after the deduction of expenses and profit under section 772(d) of the Act. *See Micron Technology, Inc.* v. *United States*, 243 F. 3d 1301, 1314–1315 (Fed. Cir. 2001).

When the Department is unable to match U.S. sales to sales of the foreign like product in the comparison market at the same LOT as the EP or CEP, the Department may compare the U.S. sale to sales at a different LOT in the comparison market. In comparing EP or CEP sales at a different LOT in the comparison market, where available data make it practicable, we make a LOT adjustment under section 773(a)(7)(A) of the Act. Finally, for CEP sales only, if a NV LOT is more remote from the factory than the CEP LOT and we are unable to make a LOT adjustment, the Department shall grant a CEP offset, as provided in section 773(a)(7)(B) of the Act. *See Notice of Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate from South Africa,* 62 FR 61731 (November 19, 1997).

We obtained information from each respondent regarding the marketing stages involved in making the reported home market and U.S. sales, including a description of the selling activities performed by the respondents for each channel of distribution. Company-specific LOT findings are summarized below.

Changwon. Changwon made home market sales to two types of customer categories: direct sales to unaffiliated distributors and end-users (*see* Changwon's March 20, 2001 section A questionnaire response at 12). We examined the chain of distribution and the selling activities associated with home market sales to each customer category, and determined that there was little difference in the relevant selling functions provided by Changwon. Specifically, Changwon does not provide technical advice, after-sale warehousing, advertising, or quality assurance for any of its home market customers. Furthermore, Changwon's home market sales of SSB were made through direct shipments from its factory to its customers. Changwon typically sells on a freight paid basis to its home market customers so Changwon does incur a high degree of sales activity related to arranging for transportation directly to the customer. Changwon did not indicate that there are any differences with respect to freight and delivery or inventory maintenance between these customer categories (*see* Changwon's May 4, 2001 Section A Supplemental Questionnaire Response at 21). Similarly, the sales support activity and marketing support provided by Changwon are limited to activities associated with the basic sales process and do not seem to vary by customer category. Based on our overall analysis, we found that the two home market categories constituted one LOT.

In the U.S. market, Changwon made both EP and CEP sales. *See* ''Export Price and Constructed Export Price'' section above regarding the Department's re-classification of Changwon's sales made through U.S. affiliate. Changwon's EP sales were made through one channel of distribution and to one category of customer, *i.e.,* they were made directly from Changwon to unaffiliated Korean trading companies, which, in turn, re-sold the merchandise to end-users in the United States (*see* Changwon's March 20, 2001 section A questionnaire response at 12). Therefore, we found that Changwon's EP sales constitute one LOT.

Changwon's CEP sales were also made through one channel of distribution and to one category of customer, *i.e.,* they were made from Changwon's U.S. affiliated trading company POSTEEL, and its affiliated U.S. importer POSAM. Therefore, we found that Changwon's CEP sales constitute one LOT. We compared the chain of distribution and selling activities associated with the CEP and EP sales and found that they were the same. Specifically, Changwon provides primarily freight services. It does not provide technical advice, after-sale warehousing, advertising, or quality assurance for any of its U.S. sales. Further, all Changwon's U.S. sales of SSB were made through direct shipments from its factory to its customers. Thus, Changwon's CEP LOT is the same as the EP LOT.

We then compared the chain of distribution and selling activities associated with the home market LOT with that of the EP/CEP LOT and found that the chain of distribution and selling activities associated with EP/CEP LOT were the same as those associated with

[3] The marketing process in the United States and comparison markets begins with the producer and extends to the sale to the final user or consumer. The chain of distribution between the two may have many or few links, and the respondents' sales occur somewhere along this chain. In performing this evaluation, we considered the narrative responses of each respondent to properly determine where in the chain of distribution the sale occurs.

[4] Selling functions associated with a particular chain of distribution help us to evaluate the level(s) of trade in a particular market. For purposes of this preliminary determination, we have organized the common SSB selling functions into four major categories: sales process and marketing support, freight and delivery, inventory and warehousing, and quality assurance/warranty services. Other selling functions unique to specific companies were considered, as appropriate.

[5] Where NV is based on constructed value (''CV''), we determined the NV LOT based on the LOT of the sales from which we derive selling expenses, G&A and profit for CV, where possible.

the home market LOT. Specifically, we observed that Changwon, does not provide technical advice, after-sale warehousing, advertising, or quality assurance in selling to its U.S. or home market customers. Furthemore, for both levels of trade there is a high degree of selling activity related to freight and delivery and inventory maintenance, while there is a low (or non-existent) level of selling activity associated with sales support, advertising, technical services, post-sale warehousing, and quality assurance. Consequently, we are matching EP and CEP sales to sales at the same LOT in the home market. In as much as we consider Changwon's EP and CEP sales to be at the same LOT as that of the home market, Changwon does not qualify for a LOT adjustment or CEP offset adjustment pursuant to section 773(a)(7)(A) or (B) of the Act, respectively.

Dongbang. In its questionnaire responses, Dongbang reported that it performs similar selling activities and provides identical selling services for both home market and U.S. sales, regardless of whether the sale is to an end-user, distributor or unaffiliated trading company (*see* Dongbang's May 4, 2001 section A supplemental questionnaire response at 22).

In the home market, Dongbang reported two customer categories (*i.e.,* end-users and distributors) and one channel of distribution (*i.e.,* direct shipment from its factory to unaffiliated customers). In determining whether separate levels of trade actually exist in the home market, we examined whether the sales made by Dongbang involved different marketing stages based on the channel of distribution, customer categories and selling functions. Based on Dongbang's submitted data, the selling activities and services associated with home market sales reported by Dongbang to its two types of customer categories are identical (*see* March 20, 2000 section A questionnaire response at 12 and Exhibit A–4). Therefore, we found that Dongbang's home market sales constitute one LOT.

In the U.S. market, Dongbang reported it sold to one category of customer (*i.e.,* trading companies) through two channels of distribution (*i.e.,* Dongbang's sales were made directly from Dongbang to unaffiliated Korean and U.S. trading companies, which, in turn, re-sold the merchandise to end-users in the United States) (*see* Dongbang's March 20, 2001 section A questionnaire response at 11). Based on Dongbang's submitted data, the selling activities and services associated with U.S. market sales reported by Dongbang through its two channels of distribution are identical. Therefore, we found that Dongbang's U.S. market sales constitute one LOT.

We also examined Dongbang's submitted data to determine whether the U.S. sales were made at the same LOT as that found in the home market. Specifically, Dongbang primarily provides freight services. It does not provide technical advice, after-sale warehousing, advertising, or quality assurance for any of its U.S. or home market sales. Further, all Dongbang's U.S. and home market sales of SSB were made through direct shipments from its factory to its customers. Therefore, no LOT adjustment is warranted.

F. Calculation of Normal Value Based on Comparison Market Prices

Changwon. We calculated NV based on delivered prices, where applicable, to unaffiliated customers in the home market. We made deductions for inland freight under section 773(a)(6)(B)(ii) of the Act. We made adjustments to normal value, for differences in costs attributable to differences in the physical characteristics of the merchandise in accordance with section 773(a)(6)(C)(ii) of the Act and 19 CFR 351.411. In addition, we made adjustments under section 773(a)(6)(C)(iii) of the Act and 19 CFR 351.410 for differences in circumstances of sale for imputed credit expenses and warranty expenses. We also deducted home market packing costs and added U.S. packing costs in accordance with sections 773(a)(6)(A) and (B) of the Act.

Dongbang. We calculated NV based on delivered prices, where applicable, to unaffiliated customers in the home market. We made deductions for inland freight under section 773(a)(6)(B)(ii) of the Act. We made adjustments, for differences in costs attributable to differences in the physical characteristics of the merchandise in accordance with section 773(a)(6)(C)(ii) of the Act and 19 CFR 351.411. In addition, we made adjustments under section 773(a)(6)(C)(iii) of the Act and 19 CFR 351.410 for differences in circumstances of sale for imputed credit expenses.

Dongbang paid commissions to unaffiliated sales intermediaries on some U.S. sales of subject merchandise but did not pay commissions on its home market sales. Therefore, in accordance with 19 CFR 351.410(e), we offset the commission incurred in the U.S. market, with indirect selling expenses incurred in the home market to the extent of the lesser of the commission or the indirect selling expenses. As indirect selling expenses, we used both Dongbang's reported home market inventory carrying costs and indirect selling expenses. We also deducted home market packing costs and added U.S. packing costs in accordance with sections 773(a)(6)(A) and (B) of the Act.

Currency Conversion

We made currency conversions into U.S. dollars in accordance with section 773A(a) of the Act based on the exchange rates in effect on the dates of the U.S. sales as certified by the Federal Reserve Bank.

Verification

As provided in section 782(i) of the Act, we will verify all information relied upon in making our final determination.

Suspension of Liquidation

In accordance with section 733(d)(2) of the Act, we are directing the Customs Service to suspend liquidation of all imports of subject merchandise that are entered, or withdrawn from warehouse, for consumption on or after the date of publication of this notice in the **Federal Register**. We will instruct the Customs Service to require a cash deposit or the posting of a bond equal to the weighted-average amount by which the NV exceeds the EP or CEP, as indicated in the chart below. These suspension-of-liquidation instructions will remain in effect until further notice. The weighted-average dumping margins are as follows:

Exporter/manufacturer	Weighted-average margin percentage
Dongbang Industrial Co., Ltd ...	7.30
Changwon Specialty Steel Co ..	10.05
All Others	9.40

ITC Notification

In accordance with section 733(f) of the Act, we have notified the ITC of our determination. If our final determination is affirmative, the ITC will determine before the later of 120 days after the date of this preliminary determination or 45 days after our final determination whether these imports are materially injuring, or threaten material injury to, the U.S. industry.

Disclosure

We will disclose the calculations used in our analysis to parties in this proceeding in accordance with 19 CFR 351.224(b).

Public Comment

Case briefs for this investigation must be submitted to the Department no later

than November 7, 2001. Rebuttal briefs must be filed by November 15, 2001. A list of authorities used, a table of contents, and an executive summary of issues should accompany any briefs submitted to the Department. Executive summaries should be limited to five pages total, including footnotes. Section 774 of the Act provides that the Department will hold a public hearing to afford interested parties an opportunity to comment on arguments raised in case or rebuttal briefs, provided that such a hearing is requested by an interested party. If a request for a hearing is made in this investigation, the hearing will tentatively be held on November 19, 2001, at the U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230. Parties should confirm by telephone the time, date, and place of the hearing 48 hours before the scheduled time.

Interested parties who wish to request a hearing, or to participate if one is requested, must submit a written request to the Assistant Secretary for Import Administration, U.S. Department of Commerce, Room 1870, within 30 days of the publication of this notice. Requests should contain: (1) The party's name, address, and telephone number; (2) the number of participants; and (3) a list of the issues to be discussed. Oral presentations will be limited to issues raised in the briefs.

If this investigation proceeds normally, we will make our final determination by no later than 135 days after the publication of this notice in the **Federal Register**.

This determination is published pursuant to sections 733(f) and 777(i) of the Act.

Dated: July 26, 2001.

Faryar Shirzad,

Assistant Secretary for Import Administration.

[FR Doc. 01–19352 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

[C–122–839]

Amendment to the Notice of Initiation of Countervailing Duty Investigation: Certain Softwood Lumber Products From Canada

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

ACTION: Notice of amendment to initiation of countervailing duty investigation.

SUMMARY: The Department of Commerce (the Department) is amending its notice of initiation of a countervailing duty investigation of certain softwood lumber products from Canada to exempt the Provinces of New Brunswick, Nova Scotia, Prince Edward Island, and Newfoundland (the Maritime Provinces) from the investigation. This exemption does not apply to certain softwood lumber products produced in the Maritime Provinces from Crown timber harvested in any other Province.

EFFECTIVE DATE: August 2, 2001.

FOR FURTHER INFORMATION CONTACT: Eric B. Greynolds at (202) 482–6071 or Maria MacKay at (202) 482–1775, Office of AD/CVD Enforcement VI, Group II, Import Administration, International Trade Administration, U.S. Department of Commerce, Room 1870, 14th Street and Constitution Avenue, N.W., Washington, D.C. 20230.

Background

The Applicable Statute and Regulations

Unless otherwise indicated, all citations to the statute are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Tariff Act of 1930 (the Act) by the Uruguay Round Agreements Act (URAA). In addition, unless otherwise indicated, all citations to the Department's regulations are references to the provisions codified at 19 CFR Part 351 (2001).

ACTIONS SINCE INITIATION: On April 30, 2001, the Department published in the **Federal Register** the ''Notice of Initiation of Countervailing Duty Investigation: Certain Softwood Lumber Products from Canada'' (66 FR 21332) (Notice of Initiation). In the Notice of Initiation, the Department did not exempt the Maritime Provinces from this investigation. However, the Department noted the possibility of addressing the unique circumstances associated with the Maritime Provinces through an exclusion process. The Department invited comments from interested parties concerning exclusions and how to address the unique circumstances of the Maritime Provinces. Initial comments were due by May 15, 2001, and several rounds of rebuttal comments were submitted in subsequent weeks.

In the comments submitted to the Department, parties argued that, consistent with the petition, the Department should have exempted certain lumber produced in the Maritime Provinces from the scope of the investigation. Specifically, petitioners asserted that the Department should have exempted the Maritime Provinces from the investigation. In a subsequent submission, petitioners requested that the Department amend the Notice of Initiation to exempt the Maritime Provinces from the investigation. The Maritime Provinces, the Maritime Lumber Bureau of Canada, and at least one company located in the Maritime Provinces also requested that the Department reconsider its decision to include the Maritime Provinces in the investigation. Additionally, the Government of Canada, in pre-initiation consultations with the Department, supported exempting the Maritime Provinces from the investigation.

ANALYSIS: We have reconsidered the status of the Maritime Provinces in this investigation. Based on all of the comments submitted, we agree with the views expressed by the interested parties that, given the unique circumstances associated with the investigation of softwood lumber from Canada, as described below, the Department should exempt certain lumber produced in the Maritime Provinces from the scope of the investigation. In reaching this decision, we were guided by the long history of trade cases and trade agreements regarding softwood lumber.

The courts have long recognized that, generally, the statute accords the Department broad discretion in the enforcement of the antidumping and countervailing duty laws. *Daewoo Elecs. Co.* v. *International Union,* 6 F.3d 1511, 1516 (Fed. Cir. 1993), *cert denied*, 512 U.S. 1204 (1994). More specifically, the courts have acknowledged that the Department has the inherent authority to define the parameters of an investigation. *Duferco Steel, Inc.* v. *U.S.,* 2110 CIT LEXIS 64 (May 29, 2001); *Mitsubishi Heavy Industries, Ltd.* v. *U.S.,* 986 F. Supp. 1428, 1432 (CIT 1997). Nevertheless, the purpose of the antidumping and countervailing duty laws is to provide the relief sought in the petition, if the allegations in the petition are borne out through investigation. Thus, while the Department has broad discretion to define an investigation, that discretion must be exercised reasonably and with ample deference to the intent of the petition.

Upon reconsideration, we have concluded that, even though the exact circumstances surrounding the exemption of the Maritimes from the 1991 investigation are not present in this case, there are still unique

circumstances, discussed in the amendment below, that warrant exempting the Maritime Provinces from this investigation. In fact, the circumstances behind the original exemption of the Maritimes from the 1986 Memorandum of Understanding (1986 MOU) have not changed for the last 15 years. Even though the exemption of the Maritimes from the 1991 countervailing duty investigation was based on a separate legal requirement (see, *Self-Initiation of Countervailing Duty Investigation: Certain Softwood Lumber Products from Canada,* 56 FR 56055, 56058 (October 31, 1991) and *Amendment to the Notice of Self-Initiation of Countervailing Duty Investigation: Certain Softwood Lumber Products from Canada,* 56 FR 56058 (October 31, 1991)), the circumstances associated with the Maritime Provinces are substantially the same as they were at the time of the 1986 MOU. Those circumstances remained the same at the time of the 1991 countervailing duty investigation, the 1996 Softwood Lumber Agreement, and at present with respect to the current investigation. Accordingly, the Department is amending the Notice of Initiation to exempt the Maritime Provinces.

Amendment

The Notice of Initiation is amended to add the following paragraph entitled ''Exemption of Maritime Provinces'':

Exemption of Maritime Provinces

The lumber dispute between Canada and the United States has a long history. Throughout much of the history of this dispute, the Maritime Provinces have been exempt from the various actions taken, including the 1986 Memorandum of Understanding on Softwood Lumber, the interim measures taken pursuant to Section 301 of the Trade Act of 1974, the 1991 countervailing duty investigation, and the recently expired Softwood Lumber Agreement. All parties have generally recognized that there are unique circumstances associated with the Maritime Provinces and have supported those exemptions. That is equally true in the case now before us. In the petition, petitioners requested that softwood lumber production in the Maritime Provinces be exempt as it was in the 1991 countervailing duty investigation. Further, petitioners did not allege that any subsidies are received by producers in the Maritime Provinces. While the absence of allegations regarding specific regions of a country would not be sufficient by itself to warrant the exemption of those regions from an investigation, this factor, when combined with all the other unique circumstances of the Maritimes, does contribute to our determination to exempt the Maritimes. The Government of Canada also supported exemption of the Maritime Provinces from the investigation given the absence of subsidy allegations.

In light of all of the unique circumstances in this case, we have determined that it is appropriate to exempt exports of certain softwood lumber products produced in the Maritime Provinces from this investigation. As in the earlier proceedings and agreements concerning softwood lumber, this exemption does not apply to certain softwood lumber products produced in the Maritime Provinces from Crown timber harvested in any other Province.

Dated: July 27, 2001.

Faryar Shirzad,

Assistant Secretary, Import Administration.

[FR Doc. 01–19345 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 072601A]

Proposed Information Collection; Comment Request; Marine Fisheries Initiative (MARFIN)

AGENCY: National Oceanic and Atmospheric Administration (NOAA).

ACTION: Proposed information collection; comment request.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Pub. L. 104–13 (44 U.S.C. 3506 (c)(2)(A)).

DATES: Written comments must be submitted on or before October 1, 2001.

ADDRESSES: Direct all written comments to Madeleine Clayton, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6086, 14th and Constitution Avenue NW, Washington DC 20230 (or via Internet at MClayton@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument(s) and instructions should be directed to Ellie Francisco Roche, F/SERX2, Room 201, 9721 Executive Center Drive North, St. Petersburg, FL 33702–2439 (phone 727–570–5324).

SUPPLEMENTARY INFORMATION:

I. Abstract

MARFIN is a competitive Federal assistance program that makes funds available to assist persons in carrying out research and development projects that will help to optimize the use of a U.S. Gulf of Mexico fishery involving the U.S. commercial or recreational fishermen. Examples of topics are harvesting methods, economic analyses, processing methods, fish stock assessment, and fish stock enhancement. A person seeking assistance must submit an application. Successful applicants must submit semi-annual and final reports.

II. Method of Collection

A MARFIN-specific project summary and budget form is used. All other requirements follow standard Federal grant application procedures and forms. Paper documentation is used.

III. Data

OMB Number: OMB Number: 0648–0175.

Form Number: None.

Type of Review: Regular submission.

Affected Public: Not-for-profit institutions, business or other for-profit organizations, individuals, and state, local, or tribal government.

Estimated Number of Respondents: 60.

Estimated Time Per Response: 4 hours for agency-unique application requirements, and 1 hour for a semi-annual performance report or a final report.

Estimated Total Annual Burden Hours: 285.

Estimated Total Annual Cost to Public: $300.

IV. Request for Comments

Comments are invited on: (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or

included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: July 25, 2001.

Madeleine Clayton,

Departmental Paperwork Clearance Officer, Office of the Chief Information Officer.

[FR Doc. 01–19220 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 072701A]

Proposed Information Collection; Comment Request; List of Gear by Fisheries and Fishery Management Councils

AGENCY: National Oceanic and Atmospheric Administration (NOAA).

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)).

DATES: Written comments must be submitted on or before October 1, 2001.

ADDRESSES: Direct all written comments to Madeleine Clayton, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6086, 14th and Constitution Avenue NW, Washington DC 20230 (or via the Internet at MClayton@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument(s) and instructions should be directed to Mark R. Millikin, F/SF3, Room 13357, 1315 East-West Highway, Silver Spring, MD 20910–3282 (phone 301–713-2341, ext. 53).

SUPPLEMENTARY INFORMATION:

I. Abstract

Under provisions of the Magnuson-Stevens Fishery Conservation and Management Act (16 U.S.C. et seq) as amended by the Sustainable Fisheries Act (P.L. 104–297), the Secretary of Commerce is required to publish a list of all fisheries under the authority of each Fishery Management Council and of all fishing gear to be used in such fisheries. Such a list has been published. Any person wishing to use gear not on the list, or engage in a fishery not on the list, must provide the appropriate Fishery Management Council (or in some cases the Secretary) with 90 days advance written notice. If the Secretary takes no action to prohibit such a fishery or use of such gear, the person may proceed.

II. Method of Collection

The respondent provides written notice. No form is used.

III. Data

OMB Number: 0648-0346.

Form Number: None.

Type of Review: Regular submission.

Affected Public: Business or other for-profit organizations.

Estimated Number of Respondents: 18.

Estimated Time Per Response: 90 minutes.

Estimated Total Annual Burden Hours: 27.

Estimated Total Annual Cost to Public: $18.

IV. Request for Comments

Comments are invited on: (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: July 25, 2001.

Madeleine Clayton,

Departmental Paperwork Clearance Officer, Office of the Chief Information Officer.

[FR Doc. 01–19222 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 072701C]

Proposed Information Collection; Comment Request; Application to Shuck Clams/Ocean Quahogs at Sea

AGENCY: National Oceanic and Atmospheric Administration (NOAA).

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506 (c)(2)(A)).

DATES: Written comments must be submitted on or before October 1, 2001.

ADDRESSES: Direct all written comments to Madeleine Clayton, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6086, 14th and Constitution Avenue NW, Washington DC 20230 (or via Internet at MClayton@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument(s) and instructions should be directed to Myles Raizin, National Marine Fisheries Service, 1 Blackburn Drive, Gloucester, MA 01930 (phone 978–281–9104).

SUPPLEMENTARY INFORMATION:

I. Abstract

The surf clam/ocean quahog fishery is managed under an individual transferable quota system that sets both individual and overall harvest goals. In order to aid in the enforcement of these quotas, fishermen are generally required to land unshucked surf clams and ocean quahogs in 32–bushel cages. Because of potential pollution problems with this practice, fishermen can shuck at sea if they obtain an authorization to do so from NOAA. NOAA will only authorize the action if a NOAA-approved observer is carried on the vessel to certify the amount of unshucked shellfish harvested. This is required because of the difficulty in converted shucked weights into bushels.

II. Method of Collection

A paper form is submitted.

III. Data

OMB Number: 0648–0240.

Form Number: None.

Type of Review: Regular submission.

Affected Public: Business or other for-profit organizations, individuals or households.

Estimated Number of Respondents: 2.

Estimated Time Per Response: 5 minutes.

Estimated Total Annual Burden Hours: 2.

Estimated Total Annual Cost to Public: $12.

IV. Request for Comments

Comments are invited on: (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: July 27, 2001.

Madeleine Clayton,

Departmental Paperwork Clearance Officer, Office of the Chief Information Officer.

[FR Doc. 01–19355 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 072701D]

Proposed Information Collection; Comment Request; Statement of Financial Interests, Regional Fishery Management Councils

AGENCY: National Oceanic and Atmospheric Administration (NOAA).

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law. 104–13 (44 U.S.C. 3506 (c)(2)(A)).

DATES: Written comments must be submitted on or before October 1, 2001.

ADDRESSES: Direct all written comments to Madeleine Clayton, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6086, 14th and Constitution Avenue NW, Washington DC 20230 (or via Internet at MClayton@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument(s) and instructions should be directed to Richard Surdi, F/SF5, RM: 13142, 1315 East-West Highway, Silver Spring MD 20910–3282 (phone 301–713–2337, ext. 169).

SUPPLEMENTARY INFORMATION:

I. Abstract

The Magnuson-Stevens Fishery Conservation and Management Act authorizes the establishment of Regional Fishery Management Councils to exercise sound judgment in the stewardship of fishery resources through the preparation, monitoring, and revision of such plans under circumstances (a) which will enable the States, the fishing industry, consumer and environmental organizations, and other interested persons to participate in, and advise on, the establishment and administration of such plans, and (b) which take into account the social and economic needs of the States. Section 302(j) of the Act requires that Council members appointed in accordance with Section 302 (b)(2) and Section 302 (b)(5) who are not subject to disclosure and recusal laws of an Indian Tribal Government disclose their financial interests in any Council fishery. These interests include harvesting, processing, or marketing activity that is being, or will be, undertaken within any fishery over which the Council concerned has jurisdiction.

A member required to disclose a financial interest shall not vote on a Council decision which would have a significant and predictable effect on such financial interest. A Council decision shall be considered to have a significant and predictable effect on a financial interest if there is a close causal link between the Council decision and an expected and substantially disproportionate benefit to the financial interest of the affected individual relative to the financial interest of other participants in the same gear type or sector of the fishery. An affected individual who may not vote may participate in Council deliberations relating to the decision after notifying the Council of the voting recusal and identifying the financial interest that would be affected.

II. Method of Collection

Respondents submit paper forms. With the exception of the Tribal Government nominees, Council nominees for appointment must provide and file a financial interest form as prescribed by the Secretary prior to the date of appointment. Seated Council members appointed by the Secretary, including the Tribal Government appointees, must file a financial interest form within 45 days of taking office and must file an update of their statements within 30 days of the time any such financial interest is acquired or substantially changed.

III. Data

OMB Number: 0648–0192.

Form Number: NOAA Form 88–195.

Type of Review: Regular submission.

Affected Public: Individuals or households.

Estimated Number of Respondents: 188.

Estimated Time Per Response: 35 minutes.

Estimated Total Annual Burden Hours: 110.

Estimated Total Annual Cost to Public: $565.

IV. Request for Comments

Comments are invited on: (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: July 27, 2001.

Madeleine Clayton,

Departmental Paperwork Clearance Officer, Office of the Chief Information Officer.

[FR Doc. 01–19356 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 072701E]

Proposed Information Collection; Comment Request; Permits for Incidental Taking of Endangered or Threatened Species

AGENCY: National Oceanic and Atmospheric Administration (NOAA).

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506 (c)(2)(A)).

DATES: Written comments must be submitted on or before October 1, 2001.

ADDRESSES: Direct all written comments to Madeleine Clayton, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6086, 14th and Constitution Avenue NW, Washington DC 20230 (or via Internet at MClayton@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument(s) and instructions should be directed to Lamont Jackson, F/PR3 Room 13632, 1315 East-West Highway, Silver Spring MD 20910–3282 (phone 301–713–1401, ext. 150).

SUPPLEMENTARY INFORMATION:

I. Abstract

The Endangered Species Act of 1973 (ESA; 16 U.S.C. 1531 *et. seq.*) imposed prohibitions against the taking of endangered species. In 1982, Congress revised the ESA to allow permits authorizing the taking of endangered species incidental to otherwise lawful activities. The corresponding regulations (50 CFR 222.222) established procedures for persons to apply for such a permit. In addition, the regulations set forth specific reporting requirements for such permit holders.

The regulations contain three sets of information collections: (l) applications for incidental take permits, (2) applications for certificates of inclusion, and (3) reporting requirements for permits issued. Certificates of inclusion are only required if a general permit is issued to a representative of a group of potential permit applicants, rather than requiring each entity to apply for and receive a permit. There are currently no general incidental take permits, and no certificates of inclusion, and none are expected in the next 3 years.

The required information is used to evaluate the impacts of the proposed activity on endangered species, to make the determinations required by the ESA prior to issuing a permit, and to establish appropriate permit conditions.

When a species is listed as threatened, section 4(d) of the ESA requires the Secretary to issue whatever regulations are deemed necessary or advisable to provide for conservation of the species. In many cases those regulations reflect blanket application of the section 9 take prohibition. However, in an interim rule for protection of listed coho salmon, NMFS recognized certain exceptions to that prohibition, including one for restoration actions taken in accord with approved watershed action plans in Oregon or California. While watershed plans are prepared for other purposes in coordination with or fulfillment of various state programs, a watershed group wishing to take advantage of the exception for restoration activities (rather than obtaining a section 10 permit) would have to submit the plan for NMFS review.

II. Method of Collection

Permit or certificate applicants must submit an application to NMFS, including all appropriate information listed on the instructions. These instructions are a user-friendly version of the requirements at 50 CFR 222.22 (b) for applications for incidental take permits.

Once issued, the permit requires that permit holders submit an annual report on activities. These reports must include information on: the activity causing incidental take, any endangered species taken (species, dates, location, and condition of animal), and the status of implementing a conservation plan to offset the impact to the species.

For watershed plans, a watershed council or other local group would submit its watershed plan to NMFS (and the state) for review against state guidance which meets the standards of 50 CFR 222.22 (c). If the plan is found consistent with the state guidance, the group would not need to apply for a section 10 permit for any incidental take that might be associated with a restoration action called for in the plan. No annual or other reporting is associated with the restoration activity exception.

III. Data

OMB Number: 0648–0230.

Form Number: None.

Type of Review: Regular submission.

Affected Public: Individuals or households, business or other for-profit organizations, not-for-profit institutions, and state, local, or tribal government.

Estimated Number of Respondents: 11.

Estimated Time Per Response: 80 hours for a permit application (including Habitat Conservation Plans), 30 minutes for an application for a Certificate of Inclusion; 8 hours for a permit report, and 10 hours for a watershed plan.

Estimated Total Annual Burden Hours: 880.

Estimated Total Annual Cost to Public: $15,840.

IV. Request for Comments

Comments are invited on: (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: July 27, 2001.

Madeleine Clayton,

Departmental Paperwork Clearance Officer, Office of the Chief Information Officer.

[FR Doc. 01–19357 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 072701F]

Proposed Information Collection; Comment Request; U.S. Fishermen Fishing in Russian Waters

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506 (c)(2)(A)).

DATES: Written comments must be submitted on or before October 1, 2001.

ADDRESSES: Direct all written comments to Madeleine Clayton, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6086, 14th and Constitution Avenue NW, Washington DC 20230 (or via the Internet at MClayton@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument(s) and instructions should be directed to Bob Dickinson, F/SF4, Room 13304, 1315 East-West Highway, Silver Spring MD 20910–3282 (phone 301–713–2276, ext. 154).

SUPPLEMENTARY INFORMATION:

I. Abstract

Regulations at 50 CFR Part 300, Subpart J, govern U.S. fishing in the economic zone of the Russian Federation. Russian authorities may permit U.S. fishermen to fish for allocations of surplus stocks in the Russian Economic Zone. Permit application information is sent to the National Oceanic and Atmospheric Administration (NOAA) for transmission to Russia. If Russia issues a permit, the vessel owner or operator must submit a permit abstract report to NOAA, and also report 24 hours before leaving the U.S. Exclusive Economic Zone (EEZ) for the Russian Economic Zone and 24 hours before re-entering the EEZ after being in the Russian Economic Zone.

The permit application information is necessary to obtain a permit. NOAA uses the other information to help ensure compliance with Russian and U.S. fishery management regulations.

II. Method of Collection

Forms are used for applications. Submission of copies of permits, vessel abstract reports, and depart and return messages are provided by fax.

III. Data

OMB Number: 0648–0228.

Form Number: None.

Type of Review: Regular submission.

Affected Public: Business and other for-profit organizations.

Estimated Number of Respondents: 10.

Estimated Time Per Response: 30 minutes.

Estimated Total Annual Burden Hours: 75.

Estimated Total Annual Cost to Public: $150.

IV. Request for Comments

Comments are invited on: (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: July 27, 2001.

Madeleine Clayton,

Departmental Paperwork Clearance Officer, Office of the Chief Information Officer.

[FR Doc. 01–19358 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

Availability of Seats for the Cordell Bank National Marine Sanctuary Advisory Council

AGENCY: National Marine Sanctuary Program (NMSP), National Ocean Service (NOS), National Oceanic and Atmospheric Administration, Department of Commerce (DOC).

ACTION: Notice and request for applications.

SUMMARY: The Cordell Bank National Marine Sanctuary (CBNMS or Sanctuary) is seeking applicants for the following five vacant seats on its Sanctuary Advisory Council (Council): Research, Education, Maritime Activities, and Community-At-Large (2 seats). Applicants are chosen based upon their particular expertise and experience in relation to the seat for which they are applying; community and professional affiliations; philosophy regarding the conversation and management of marine resources; and the length of residence in the area affected by the Sanctuary. Applicants who are chosen as members should expect to serve three-year terms, pursuant to the Council's Charter.

DATES: Applications are due by August 31, 2001.

ADDRESSES: Application kits may be obtained from Maria Brown, Cordell Bank National Marine Sanctuary, The Presidio of San Francisco, Building 991, P.O. Box 29386, San Francisco, California, 94129. Completed applications should be sent to the same address.

FOR FURTHER INFORMATION CONTACT: Maria Brown at (415) 561–6625 or mbrown@farallones.org.

SUPPLEMENTARY INFORMATION: The Council functions in an advisory capacity to the Sanctuary Manager and will be instrumental in helping to develop policies and program goals, and to identify education, outreach, research, long-term monitoring, resource protection and revenue enhancement priorities. The Council will work in concert with the Sanctuary Manager by keeping him or her informed about issue of concern throughout the Sanctuary, offering recommendations on specific issues, and aiding the Manager in achieving the goals of the Sanctuary program within the context of California's marine programs and policies.

Authority: 16 U.S.C. Section 1431 *et seq.*

(Federal Domestic Assistance Catalog Number 11.429 Marine Sanctuary Program)

Dated: July 24, 2001.

Jamison S. Hawkins,

Deputy Assistant Administrator for Oceans and Coastal Zone Management.

[FR Doc. 01–19304 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–08–M

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

Availability of Seats for the Gulf of the Farallones National Marine Sanctuary Advisory Council

AGENCY: National Marine Sanctuary Program (NMSP), National Ocean Service (NOS), National Oceanic and Atmospheric Administration, Department of Commerce (DOC).

ACTION: Notice and request for applications.

SUMMARY: The Gulf of the Farallones National Marine Sanctuary (GFNMS or Sanctuary) is seeking applicants for the following six vacant seats on its Sanctuary Advisory Council (Council): Research, Education, Maritime Activities, and Community-At-Large (3 seats). Applicants are chosen based upon their particular expertise and experience in relation to the seat for which they are applying; community and professional affiliations; philosophy regarding the conservation and management of marine resources; and the length of residence in the area affected by the Sanctuary. Applicants who are chosen as members should expect to serve three-year terms, pursuant to the Council's Charter.

DATES: Applications are due by August 31, 2001.

ADDRESSES: Application kits may be obtained from Maria Brown, Gulf of the Farallones National Marine Sanctuary, The Presidio of San Francisco, Building 991, P.O. Box 29386, San Francisco, California, 94129. Completed applications should be sent to the same address.

FOR FURTHER INFORMATION CONTACT: Maria Brown at (415) 561–6625 or mbrown@farallones.org.

SUPPLEMENTARY INFORMATION: The Council functions in an advisory capacity to the Sanctuary Manager and will be instrumental in helping to develop policies and program goals, and to identify education, outreach, research, long-term monitoring, resource protection and revenue enhancement priorities. The Council will work in concert with the Sanctuary Manager by keeping him or her informed about issues of concern throughout the Sanctuary, offering recommendations on specific issues, and aiding the Manager in achieving the goals of the Sanctuary program within the context of California's marine programs and policies.

Authority: 16 U.S.C. Section 1431 *et seq.*

(Federal Domestic Assistance Catalog Number 11.429 Marine Sanctuary Program)

Dated: July 24, 2001.

Jamison S. Hawkins,

Deputy Assistant Administrator for Oceans and Coastal Zone Management.

[FR Doc. 01–19303 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–08–M

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 071801A]

New England Fishery Management Council; Public Meetings

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of public meeting.

SUMMARY: The New England Fishery Management Council (Council) is scheduling a public meeting of its Groundfish Advisory Panel in August, 2001. Recommendations from the committee will be brought to the full Council for formal consideration and action, if appropriate.

DATES: The meeting will held on Thursday, August 16, 2001, at 9:30 a.m.

ADDRESSES: The meeting will be held at the Sheraton Colonial Hotel, One Audubon Road, Wakefield, MA 01880; telephone: (781) 245–9300.

Council address: New England Fishery Management Council, 50 Water Street, Newburyport, MA 01950; telephone: (978) 465–0492.

FOR FURTHER INFORMATION CONTACT: Paul J. Howard, Executive Director, New England Fishery Management Council; (978) 465–0492.

SUPPLEMENTARY INFORMATION: The Groundfish Advisory Panel will provide guidance to the Council and its committees as directed by the Capacity Committee on the subject of reducing latent effort (excess capacity) and possible modification to permit transfer restrictions. The Council may consider measures to address these issues, such as restrictions on unused days-at-sea (DAS), for inclusion for Amendment 13 to the Northeast Multispecies Fishery Management Plan as part of Amendment 13 or for a later amendment.

Although non-emergency issues not contained in this agenda may come before this group for discussion, those issues may not be the subject of formal action during this meeting. Action will be restricted to those issues specifically listed in this notice and any issues arising after publication of this notice that require emergency action under section 305 (c) of the Magnuson-Stevens Act, provided the public has been notified of the Council's intent to take final action to address the emergency.

Special Accommodations

This meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Paul J. Howard (see **ADDRESSES**) at least 5 days prior to the meeting dates.

Dated: , 2001.

Dean Swanson,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 01–19216 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 072301H]

New England Fishery Management Council; Public Meetings

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of public meetings.

SUMMARY: The New England Fishery Management Council (Council) is scheduling public meetings of its Herring Advisory Panel with the Mid Atlantic Fishery Council's Mackerel Advisory Panel and its Herring Oversight Committee in August, 2001 to consider actions affecting New England fisheries in the exclusive economic zone (EEZ). Recommendations from these groups will be brought to the full Council for formal consideration and action, if appropriate.

DATES: The meetings will be held on August 15 and August 22, 2001. See **SUPPLEMENTARY INFORMATION** for specific dates and times.

ADDRESSES: The meetings will be held in Wakefield and Danvers, MA. See **SUPPLEMENTARY INFORMATION** for specific locations.

Council address: New England Fishery Management Council, 50 Water Street, Mill 2, Newburyport, MA 01950; telephone: (978) 465–0492.

FOR FURTHER INFORMATION CONTACT: Paul J. Howard, Executive Director, New England Fishery Management Council; (978) 465–0492.

SUPPLEMENTARY INFORMATION:

Meeting Dates and Agendas

Wednesday, August 15, 2001 at 9:30 a.m. – Joint Herring Advisory Panel and Mid Atlantic Fishery Council Mackerel Advisory Panel Meeting.

Location: Sheraton Colonial, One Audubon Road, Wakefield, MA 01880; telephone: (781) 245–9300.

This group will discuss issues and options for limited entry/controlled

access both for the Area 1A herring fishery and for the herring and mackerel fisheries generally. They will finalize recommendations to the Herring Committee on whether to continue development of a limited entry/controlled access program in 2002. The Committee will consider the advisors' recommendations on August 22, and make a recommendation to the Council in September during the Council discussion on 2002 work-load priorities.

Wednesday, August 22, 2001 at 9:30 a.m. – Herring Oversight Committee Meeting

Location: Sheraton Ferncroft, 50 Ferncroft Drive, Danvers, MA 01923; telephone: (781) 777–2500.

The committee will review advisory panel recommendations and finalize recommendations to the Council, in its scheduling of work-load priorities, on what management actions should be undertaken in 2002 regarding the development of a limited entry/controlled access program. The committee will also discuss issues and options for Framework 1 to the Herring Fishery Management Plan. Framework 1 would implement a split season quota for Area 1A. They will also discuss a request for an increase in the joint venture (JV) allocation through a mid-season adjustment.

Although non-emergency issues not contained in this agenda may come before this group for discussion, those issues may not be the subject of formal action during this meeting. Action will be restricted to those issues specifically listed in this notice and any issues arising after publication of this notice that require emergency action under section 305 (c) of the Magnuson-Stevens Act, provided the public has been notified of the Council's intent to take final action to address the emergency.

Special Accommodations

These meetings are physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Paul J. Howard (see **ADDRESSES**) at least 5 days prior to the meeting dates.

Dated: July 25, 2001.

Dean swanson,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 01–19219 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 071601C]

Marine Mammals; File No. 981–1578–01

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Issuance of permit amendment.

SUMMARY: Notice is hereby given that Dr. Peter L. Tyack, Ph.D., Woods Hole Oceanographic Institution, Biology Department, 46 Water Street, Woods Hole, MA 02543 has been issued an amendment to scientific research Permit No.981–1578–00.

ADDRESSES: The amendment and related documents are available for review upon written request or by appointment in the following office(s):

Permits and Documentation Division, Office of Protected Resources, NMFS, 1315 East-West Highway, Room 13705, Silver Spring, MD 20910; phone (301) 713–2289; fax (301) 713–0376;

Northeast Region, NMFS, One Blackburn Drive, Gloucester, MA S. longirostris 01930-2298; phone (978) 281–9200; fax (978) 281–9371;

Southeast Region, NMFS, 9721 Executive Center Drive North, St. Petersburg, FL 33702–2432; phone (727) 570–5301; fax (727) 570–5320.

FOR FURTHER INFORMATION CONTACT: Tammy Adams or Gene Nitta, (301) 713–2289.

SUPPLEMENTARY INFORMATION: On June 8, 2001, notice was published in the **Federal Register** (66 FR 30885) that an amendment of Permit No. 981–1578–00, issued August 31, 2000 (65 FR 57319), had been requested by the above-named individual. The requested amendment has been granted under the authority of the Marine Mammal Protection Act of 1972, as amended (16 U.S.C. 1361 *et seq.*), the Regulations Governing the Taking and Importing of Marine Mammals (50 CFR part 216), the Endangered Species Act of 1973, as amended (ESA; 16 U.S.C. 1531 *et seq.*), and the regulations governing the taking, importing, and exporting of endangered and threatened species (50 CFR 222–226).

This permit, as amended, authorizes tagging of and playbacks to one additional species of baleen whale (Bryde's whale, *Balaenoptera edeni*) and three additional odontocete whale species(*Stenella attenuata*, *S. longirostris* and *S. clymene*; expands the study area to include the Bahamas and Gulf of Mexico in the North Atlantic; and adds playbacks of an additional acoustic signal, at the same maximum received level.

Issuance of this amendment, as required by the ESA was based on a finding that such permit (1) was applied for in good faith, (2) will not operate to the disadvantage of the endangered species which is the subject of this permit, and (3) is consistent with the purposes and policies set forth in section 2 of the ESA.

Dated: July 26, 2001.

Ann D. Terbush,

Chief, Permits and Documentation Division, Office of Protected Resources, National Marine Fisheries Service.

[FR Doc. 01–19360 Filed 8–1–01; 8:45 am]

BILLING CODE 3510–22–S

DEPARTMENT OF DEFENSE

Office of the Secretary

Submission for OMB Review; Comment Request

ACTION: Notice.

The Department of Defense has submitted to OMB for clearance, the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

Title and OMB Number: Defense Federal Acquisition Regulation Supplement (DFARS) Part 251, Use of Government Sources by Contractors, and Related Clauses in DFARS 252.251; OMB Number 0704–0252.

Type of Request: Extension.

Number of Respondents: 3,500.

Responses Per Respondent: 3.

Annual Responses: 10,500.

Average Burden Per Response: 0.5 hours.

Annual Burden Hours: 5,250.

Needs and Uses: This information collection requirement facilitates contractor use of Government supply sources. Contractors must provide certain information to the Government to verify their authorization to purchase from Government supply sources or to use Interagency Fleet Management System vehicles and related services. The clause at DFARS 252.251–7000, Ordering from Government Supply Sources, requires a contractor to provide an order under a Federal Supply Schedule or a Personal Property Rehabilitation Price Schedule. The clause at 252.251–7001, Use of Interagency Fleet Management System Vehicles and Related Services, requires a contractor to submit a request for use

of Government vehicles when the contractor is authorized to use such vehicles, and specifies the information to be included in the contractor's request.

Affected Public: Business or Other For-Profit; Not-For-Profit Institutions.

Frequency: On Occasion.

Respondent's Obligation: Required to Obtain or Retain Benefits

OMB Desk Officer: Mr. Lewis W. Oleinick.

Written comments and recommendations on the proposed information collection should be sent to Mr. Oleinick at the Office of Management and Budget, Desk Officer for DoD (Acquisition), Room 10236, New Executive Office Building, Washington, DC 20503.

DOD Clearance Officer: Mr. Robert Cushing.

Written requests for copies of the information collection proposal should be sent to Mr. Cushing, WHS/DIOR, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202–4302.

Dated: July 27, 2001.

Patricia L. Toppings,

Alternate OSD Federal Register Liaison Officer, Department of Defense.

[FR Doc. 01–19239 Filed 8–1–01; 8:45 am]

BILLING CODE 5001–08–M

DEPARTMENT OF DEFENSE

Office of the Secretary

Submission for OMB Review; Comment Request

ACTION: Notice.

The Department of Defense has submitted to OMB for clearance, the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

Title, Form, and OMB Number: Automated Repatriation Reporting System; DD Form 2585; OMB Number 0704–0334.

Type of Request: Extension.

Number of Respondents: 5,000.

Responses Per Respondent: 1.

Annual Responses: 5,000.

Average Burden Per Response: 20 minutes.

Annual Burden Hours: 1,667.

Needs and Uses: Executive Order 12656 establishes the responsibilities for the Department of Health and Human Services (DHHS) and the Department of Defense (DoD) to take care of any American citizen and family member that is evacuated from any country and ensure their personal needs are met. This information collection provides evacuation information necessary to account for any military and civilian, regardless of nationality. The DD Form 2585, Repatriation Processing Center Processing Sheet, is used to collect the necessary data which is entered into the Repatriation Automated Tracking System to produce a series of reports generated for and made available to the Department of Defense, federal, and state agencies.

Affected Public: Individuals or Households; Federal Government; State, Local or Tribal Government.

Frequency: On Occasion.

Respondent's Obligation: Required to Obtain or Retain Benefits.

OMB Desk Officer: Mr. Edward C. Springer.

Written comments and recommendations on the proposed information collection should be sent to Mr. Springer at the Office of Management and Budget, Desk Officer for DoD, Room 10236, New Executive Office Building, Washington, DC 20503.

DOD Clearance Officer: Mr. Robert Cushing.

Written requests for copies of the information collection proposal should be sent to Mr. Cushing, WHS/DIOR, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202–4302.

Dated: July 26, 2001.

Patricia L. Toppings,

Alternate OSD Federal Register, Liaison Officer, Department of Defense.

[FR Doc. 01–19240 Filed 8–1–01; 8:45 am]

BILLING CODE 5001–08–M

DEPARTMENT OF DEFENSE

Office of the Secretary

Submission for OMB Review; Comment Request

ACTION: Notice.

The Department of Defense has submitted to OMB for clearance, the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35).

Title and OMB Number: Post-election Voting Survey of overseas Citizens and Post-election Survey of Local Election Officials; OMB Number 0704–0125.

Type of Request: Extension.

Number of Respondents: 2,403.

Responses Per Respondent: 1.

Annual Responses: 2,403.

Average Burden Per Response: 10 minutes.

Needs and Uses: The information collection requirement is necessary to meet a requirement of the Uniformed and Overseas Citizens Absentee Voting Act (UOCAVA) of 1986 (42 U.S.C. 1973ff). UOCAVA requires a report to the President and Congress on the effectiveness of assistance under the Act, a statistical analysis of voter participation, and a description of State-Federal cooperation. UOCAVA requires the states to allow Uniformed Services personnel, their family members, and overseas citizens to use absentee registration procedures, and to vote by absentee ballot in general, special, primary, and runoff elections for Federal offices. The Act covers members of the Uniformed Services and the merchant marine to include the commissioned corps of the National Oceanic and Atmospheric Administration and Public Health Service, and their eligible dependents, Federal civilian employees overseas, and overseas U.S. citizens not affiliated with the Federal Government. The Federal Voting Assistance Program conducts the post-election survey on a statistically random basis to determine participation rates that are representative of all citizens covered by the Act, measure State-Federal cooperation, and evaluate the effectiveness of the overall absentee voting program. The information collected is used for overall program evaluation, management and improvement, and to compile the congressionally mandated report to the President and Congress.

Affected Public: Individuals or Households; State, Local or Tribal Government.

Frequency: Quadrennially.

Respondent's Obligation: Voluntary.

OMB Desk Officer: Mr. Edward C. Springer.

Written comments and recommendations on the proposed information collection should be sent to Mr. Springer at the Office of Management and Budget, Desk Officer for DoD, Room 10236, New Executive Office Building, Washington, DC 20503.

DOD Clearance Officer: Mr. Robert Cushing.

Written requests for copies of the information collection proposal should be sent to Mr. Cushing, WHS/DIOR, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202–4302.

Dated: July 26, 2001.

Patricia L. Toppings,

Alternate OSD Federal Register, Liaison Officer, Department of Defense.

[FR Doc. 01–19241 Filed 8–1–01; 8:45 am]

BILLING CODE 5001–08–M

DEPARTMENT OF EDUCATION

Notice of Proposed Information Collection Requests

AGENCY: Department of Education.

SUMMARY: The Leader, Regulatory Information Management Group, Office of the Chief Information Officer, invites comments on the proposed information collection requests as required by the Paperwork Reduction Act of 1995.

DATES: Interested persons are invited to submit comments on or before October 1, 2001.

SUPPLEMENTARY INFORMATION: Section 3506 of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) requires that the Office of Management and Budget (OMB) provide interested Federal agencies and the public an early opportunity to comment on information collection requests. OMB may amend or waive the requirement for public consultation to the extent that public participation in the approval process would defeat the purpose of the information collection, violate State or Federal law, or substantially interfere with any agency's ability to perform its statutory obligations. The Leader, Regulatory Information Management Group, Office of the Chief Information Officer, publishes that notice containing proposed information collection requests prior to submission of these requests to OMB. Each proposed information collection, grouped by office, contains the following: (1) Type of review requested, e.g. new, revision, extension, existing or reinstatement; (2) Title; (3) Summary of the collection; (4) Description of the need for, and proposed use of, the information; (5) Respondents and frequency of collection; and (6) Reporting and/or Recordkeeping burden. OMB invites public comment. The Department of Education is especially interested in public comment addressing the following issues: (1) Is this collection necessary to the proper functions of the Department; (2) will this information be processed and used in a timely manner; (3) is the estimate of burden accurate; (4) how might the Department enhance the quality, utility, and clarity of the information to be collected; and (5) how might the Department minimize the burden of this collection on the respondents, including through the use of information technology.

Dated: July 27, 2001.

John Tressler,

Leader, Regulatory Information Management, Office of the Chief Information Officer.

Office of Postsecondary Eductation

Type of Review: Revision.

Title: National Household Education Surveys Program of 2003 (NHES:2003).

Frequency: One time.

Affected Public: Individuals or households.

Reporting and Recordkeeping Hour Burden:

Responses: 2,400.

Burden Hours: 359.

Abstract: The NHES:2003 will be a survey of households using random-digit-dialing and computer-assisted telephone interviewing. Two topical surveys are to be conducted in the NHES:2003: Parent and Family Involvement in Education (PFI–NHES:2003), and Adult Education for Work-related Reasons (AEWR–NHES:2003). Respondents to the PFI–NHES:2003) will be parents of children in kindergarten through 12th grade. Respondents to the AEWR–NHES:2003 will be persons age 16 and older who are not enrolled in elementary or secondary school. The PFI survey will provide NCES with current measures of children's educational experiences and family involvement in the education of their children and allow for the analysis of change over time. The AEWR survey will provide in-depth information on the participation of adults in training and education that prepares adults for work or careers and maintains or improves their skills.

Requests for copies of the proposed information collection request may be accessed from *http://edicsweb.ed.gov,* or should be addressed to Vivian Reese, Department of Education, 400 Maryland Avenue, SW., Room 4050, Regional Office Building 3, Washington, DC 20202–4651. Requests may also be electronically mailed to the internet address OCIO_IMG_Issues@ed.gov or faxed to 202–708–9346. Please specify the complete title of the information collection when making your request.

Comments regarding burden and/or the collection activity requirements should be directed to Kathy Axt at (540) 776–7742 or via her internet address Kathy.Axt@ed.gov. Individuals who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1–800–877–8339.

[FR Doc. 01–19299 Filed 8–1–01; 8:45 am]

BILLING CODE 4000–01–P

DEPARTMENT OF EDUCATION

Notice of Proposed Information Collection Requests

AGENCY: Department of Education.

ACTION: Notice of proposed information collection requests.

SUMMARY: The Leader, Regulatory Information Management, Office of the Chief Information Officer, invites comments on the proposed information collection requests as required by the Paperwork Reduction Act of 1995.

DATES: An emergency review has been requested in accordance with the Act (44 U.S.C. Chapter 3507 (j)), since public harm is reasonably likely to result if normal clearance procedures are followed. Approval by the Office of Management and Budget (OMB) has been requested by October 1, 2001. A regular clearance process is also beginning. Interested persons are invited to submit comments on or before October 1, 2001.

ADDRESSES: Written comments regarding the emergency review should be addressed to the Office of Information and Regulatory Affairs, Attention: Lauren Wittenberg, Desk Officer: Department of Education, Office of Management and Budget; 725 17th Street, NW., Room 10235, New Executive Office Building, Washington, DC 20503 or should be electronically mailed to the internet address Lauren_Wittenberg@omb.eop.gov.

SUPPLEMENTARY INFORMATION: Section 3506 of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) requires that the Director of OMB provide interested Federal agencies and the public an early opportunity to comment on information collection requests. The Office of Management and Budget (OMB) may amend or waive the requirement for public consultation to the extent that public participation in the approval process would defeat the purpose of the information collection, violate State or Federal law, or substantially interfere with any agency's ability to perform its statutory obligations. The Leader, Information Management Group, Office of the Chief Information Officer, publishes this notice containing proposed information collection requests at the beginning of the Departmental review of the information collection. Each proposed information collection, grouped by office, contains the following: (1) Type of review requested, e.g., new, revision, extension, existing or reinstatement; (2) Title; (3) Summary of the collection; (4) Description of the need for, and

proposed use of, the information; (5) Respondents and frequency of collection; and (6) Reporting and/or Recordkeeping burden. ED invites public comment. The Department of Education is especially interested in public comment addressing the following issues: (1) Is this collection necessary to the proper functions of the Department; (2) will this information be processed and used in a timely manner; (3) is the estimate of burden accurate; (4) how might the Department enhance the quality, utility, and clarity of the information to be collected; and (5) how might the Department minimize the burden of this collection on respondents, including through the use of information technology.

Dated: July 27, 2001.

John Tressler,

Leader, Regulatory Information Management, Office of the Chief Information Officer.

Office of Educational Research and Improvement

Type of Review: New.

Title: International Survey of Upper Secondary Schools (ISUSS).

Abstract: The purpose of the International Survey of Schools at the Upper Secondary Level is to gather information on student transitions, education quality, professional development, and computer technology in 600 high schools to be compared to similar schools in other countries.

Additional Information: Last month, the National Center for Education Statistics (NCES) was overruled by the international committee sponsoring these surveys, when it was decided to conduct these surveys in the Fall of 2002. As most other countries do not have a survey clearance process similar to that in place in the United States, the effect on them of this timing decision did not create an emergency situation for them. In fact, all countries were quite eager to conduct the survey as soon as possible. In our case the public has until August 30th to send their concerns to OMB.

Frequency: One time.

Affected Public: State, Local, or Tribal Gov't, SEAs or LEAs; Federal Government.

Reporting and Recordkeeping Hour Burden:

Responses: 600.

Burden Hours: 450.

Requests for copies of the proposed information collection request should be addressed to Vivian Reese, Department of Education, 400 Maryland Avenue, SW., Room 4050, Regional Office Building 3, Washington, DC 20202–4651, or should be electronically mailed to the internet address OCIO_IMG_Issues@ed.gov, or should be faxed to 202–708–9346.

Comments regarding burden and/or the collection activity requirements, contact Kathy Axt at (540) 776–7742 or via her internet address Kathy.Axt@ed.gov. Individuals who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1–800–877–8339.

[FR Doc. 01–19300 Filed 8–1–01; 8:45 am]

BILLING CODE 4000–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP01–493–000]

ANR Pipeline Company; Notice of Proposed Changes in FERC Gas Tariff

July 27, 2001.

Take notice that on July 23, 2001, ANR Pipeline Company (ANR) tendered for filing as part of its FERC Gas Tariff, Second Revised Volume No. 1, the following tariff sheets with an effective date of August 22, 2001:

Twelfth Revised Sheet No. 1
Seventh Revised Sheet No. 191

ANR states that these tariff sheets modify ANR's tariff to provide for a general waiver of the ''shipper must have title rule'' in the event that ANR is transporting gas for others on acquired off-system capacity and to include a general statement that ANR will only transport for others using off-system capacity pursuant to its existing tariff and rates.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Sections 385.214 or 385.211 of the Commission's Rules and Regulations. All such motions or protests must be filed in accordance with Section 154.210 of the Commission's Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary,

[FR Doc. 01–19278 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP01–423–001]

Columbia Gas Transmission Corporation; Notice of Compliance Filing

July 27, 2001.

Take notice that on June 28, 2001, Columbia Gas Transmission Corporation (Columbia) tendered for filing supported information on the NTS Service Agreement No. 2001–5–10–002 filed on May 18, 2001, an agreement for firm transportation service to be provided by Columbia to DPL Energy (DPL Agreement).

Columbia states that it is filing the supported information in compliance with the Commission's June 13th order.

Columbia states that copies of the filing is being served to each party on the official service list in Docket No. RP01–423–000.

Any person desiring to protest said filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Section 385.211 of the Commission's Rules and Regulations. All such protests must be filed on or before August 3, 2001. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the

instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–19275 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP01–439–001]

Eastern Shore Natural Gas Company; Notice of Compliance Filing

July 27, 2001.

Take notice that on July 13, 2001, Eastern Shore Natural Gas Company (Eastern Shore) tendered for filing its response to the Commission's June 27, 2001 order[1] seeking additional information to support Eastern Shore's fuel retention percentages filed in Docket No. RP01–439–000.

Any person desiring to protest said filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Section 385.211 of the Commission's Rules and Regulations. All such protests must be filed on or before August 2, 2001. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection. This filing may be viewed on the Commission's web site at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket #'' and follow the instructions (please call (202) 208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–19276 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

[1] 95 FERC ¶61,446 (2001).

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP01–492–000]

Gulf South Pipeline Company, LP, Notice of Proposed Changes to FERC Gas Tariff

July 27, 2001.

Take notice that on July 20, 2001, Gulf South Pipeline Company, LP (Gulf South) tendered for filing as part of its FERC Gas Tariff, Sixth Revised Volume No. 1, the following tariff sheets, to become effective August 20, 2001:

First Revised Sheet No. 1
Sheet Nos. 3801–3899 Reserved
Original Sheet No. 3900
Sheet Nos. 3901–3999 Reserved

Gulf South states the purpose of this filing is to modify Gulf South's tariff to provide for a general waiver of the ''shipper must have title'' rule for off-system transportation or storage capacity that Gulf South has acquired and to include a statement that Gulf South will only transport gas for others using off-system capacity pursuant to its existing tariff and rates.

Gulf South copies of this filing have been served upon Gulf South's customers, state commissions and other interested parties.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Sections 385.214 or 385.211 of the Commission's Rules and Regulations. All such motions or protests must be filed in accordance with Section 154.210 of the Commission's Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–19277 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP01–405–000]

Kern River Gas Transmission Company; Notice of Application

July 27, 2001.

Take notice that on July 18, 2001, Kern River Gas Transmission Company (Kern River), 295 Chipeta Way, Salt Lake City, Utah 84158, filed in Docket No. CP01–405–000 an abbreviated application pursuant to Section 7(c) of the Natural Gas Act (NGA) and Part 157 of the Federal Energy Regulatory Commission's Regulations, for a certificate of public convenience and necessity authorizing Kern River to construct and operate: (1) Approximately 31.6 miles of 24-inch diameter delivery lateral pipeline in San Bernardino County, California (High Desert Lateral), extending from interconnects with the Kern/Mojave Common Facilities and the Pacific Gas & Electric Company (PG&E) system to the gas-fired electricity generating plant (HDPP) being built by High Desert Power Project, LLC (High Desert Power) near Victorville, California; (2) a 20-inch mainline tap on the Kern River/Mojave Pipeline Common Facilities near Kramer Junction and a receipt meter station at the start of the High Desert Lateral (Kern/Mojave Interconnect); (3) a bi-directional meter station and piping to interconnect with PG&E at the start of the High Desert Lateral, along with piping/valves to accommodate potential future installation of interconnect compression facilities (PG&E Interconnect); and (4) a delivery meter station at the terminus of the High Desert Lateral (High Desert Meter Station), all as more fully set forth in the application which is on file with the Commission and open to public inspection. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket #'' and follow the instructions (call 202–208–2222 for assistance).

Kern River states that Victorville-Gas, LLC (Victorville-Gas), the fuel supplier

for the HDPP, has executed a binding Precedent Agreement with Kern River obligating it to enter into a firm transportation service agreement for the full 282,000 Dth per day design capacity of the High Desert Lateral for a primary term of 21 years, with an evergreen provision, and subject to a negotiated rate.

Kern River states that it also is requesting approval of: (1) pro forma Rate Schedules KRF–L1 and KRI–L1 for firm and interruptible transportation service on the High Desert Lateral and other pro forma tariff provisions related to such service; (2) initial recourse rates for service under the new rate schedules; (3) the negotiated rate transportation service agreement with its initial firm shipper, Victorville-Gas; and (4) its related proposed accounting treatment; all as described more fully in the application.

Kern River states that High Desert Power and Victorville-Gas are both subsidiaries of Constellation Energy Group and that High Desert Power is constructing the HDPP, a 720 megawatt natural gas-fired, combined-cycle electric generating facility. Construction commenced in April, 2001; test operations currently are scheduled to begin in September, 2002; and commercial operation is scheduled to occur by July 1, 2003. Kern River states that the electricity generated at the HDPP will be sold to the California Department of Water Resources as a base-load resource to help serve growing power needs in Southern California. According to Kern River, High Desert Power initially will require up to approximately 141,000 Dth per day of natural gas to operate the HDPP.

Kern River states that the estimated cost of the proposed facilities is approximately $28.9 million and that the resulting recourse rate under the proposed KRF–L1 rate schedule will be $0.0583 per Dth of Maximum Daily Quantity.

Any questions regarding this application should be directed to Gary Kotter, Manager, Certificates, Kern River Gas Transmission Company, P.O. Box 58900, Salt Lake City, Utah 84158, at (801) 584–7117.

There are two ways to become involved in the Commission's review of this project. First, any person wishing to obtain legal status by becoming a party to the proceedings for this project should, on or before August 17, 2001, file with the Federal Energy Regulatory Commission, 888 First Street, NE, Washington, DC 20426, a motion to intervene in accordance with the requirements of the Commission's Rules of Practice and Procedure (18 CFR 385.214 or 385.211) and the Regulations under the NGA (18 CFR 157.10). A person obtaining party status will be placed on the service list maintained by the Secretary of the Commission and will receive copies of all documents filed by the applicant and by all other parties. A party must submit 14 copies of filings made with the Commission and must mail a copy to the applicant and to every other party in the proceeding. Only parties to the proceeding can ask for court review of Commission orders in the proceeding.

However, a person does not have to intervene in order to have comments considered. The second way to participate is by filing with the Secretary of the Commission, as soon as possible, an original and two copies of comments in support of or in opposition to this project. The Commission will consider these comments in determining the appropriate action to be taken, but the filing of a comment alone will not serve to make the filer a party to the proceeding. The Commission's rules require that persons filing comments in opposition to the project provide copies of their protests only to the party or parties directly involved in the protest.

Persons who wish to comment only on the environmental review of this project should submit an original and two copies of their comments to the Secretary of the Commission. Environmental commenters will be placed on the Commission's environmental mailing list, will receive copies of the environmental documents, and will be notified of meetings associated with the Commission's environmental review process. Environmental commenters will not be required to serve copies of filed documents on all other parties. However, the non-party commenters will not receive copies of all documents filed by other parties or issued by the Commission (except for the mailing of environmental documents issued by the Commission) and will not have the right to seek court review of the Commission's final order.

The Commission may issue a preliminary determination on non-environmental issues prior to the completion of its review of the environmental aspects of the project. This preliminary determination typically considers such issues as the need for the project and its economic effect on existing customers of the applicant, on other pipelines in the area, and on landowners and communities. For example, the Commission considers the extent to which the applicant may need to exercise eminent domain to obtain rights-of-way for the proposed project and balances that against the non-environmental benefits to be provided by the project. Therefore, if a person has comments on community and landowner impacts from this proposal, it is important either to file comments or to intervene as early in the process as possible.

Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

If the Commission decides to set the application for a formal hearing before an Administrative Law Judge, the Commission will issue another notice describing that process. At the end of the Commission's review process, a final Commission order approving or denying a certificate will be issued.

David P. Boergers,

Secretary.

[FR Doc. 01–19271 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP01–404–000]

Tennessee Gas Pipeline Company; Notice of Request Under Blanket Authorization

July 27, 2001.

Take notice that on July 16, 2001, Tennessee Gas Pipeline Company (Tennessee), P. O. Box 2511, Houston, Texas, filed a request pursuant to sections 157.205, 157.208(b)(2) and 157.211(a)(2) of the Federal Energy Regulatory Commission's (the Commission) Regulations under the Natural Gas Act (NGA), as amended, and blanket certificate authority granted September 1, 1982, in Docket No. CP82–413–000, 20 FERC ¶ 62,409 for authorization to construct, own and operate a lateral line compressor station and a meter station in order to implement firm transportation services for the Rhode Island State Energy Partners L.P. (RISEP) electric generating plant located in Providence County, Rhode Island, and the Providence Gas Company (Providence Gas), all as more fully set forth in the request, which is on file with the Commission, and open for public inspection. This filing may be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket #'' from the RIMS Menu

and follow the instructions (please call 202–208–2222 for assistance).

Tennessee states that the compressor station will consist of a single 7,150 horsepower natural gas driven compressor unit located adjacent to Tennessee's Rhode Island Lateral, Line No. 265E–100, in Providence County, Rhode Island. Addition of the compressor station will increase the capacity of the line by approximately 100 MMcf/day. Tennessee estimates the cost of construction for the compressor station is $14,100,000.

The proposed meter station will serve the RISEP power generation plant and will be located on the power plant site. The facilities will consist of a tie-in assembly, a Tee connection to the lateral line and a 12-inch ball and check valve. Tennessee estimates that approximately 250 feet of 12-inch pipe will be required to connect the tie-in assembly to the meter station that will include a 2-inch turbine meter, a 6-inch ultrasonic meter and an 8-inch ultrasonic meter as well as electronic gas measurement equipment, and other appurtenances. The estimated cost of the tap and meter station is approximately $976,800. RISEP will reimburse Tennessee approximately $210,000 to cover the cost of ''tap facilities'' as defined in the general terms and conditions of Tennessee's FERC Gas Tariff.

Any questions regarding this filing should be directed to Jay V. Allen, Counsel, call 832–676–5589 or Thomas G. Joyce, Certificates Manager, call 832–676–3299, Tennessee Gas Pipeline Company, 9 E Greenway Plaza, Houston, Texas 77046–0905.

Any person or the Commission's staff may, within 45 day after issuance of the instant notice by the Commission, file pursuant to Rule 214 of the Commission's Procedural Rules (18 CFR 385.214) a motion to intervene or notice of intervention and pursuant to Section 157.205 of the Regulations under the NGA (18 CFR 157.205), a protest to the request. If no protest is filed within the time allowed therefor, the proposed activity shall be deemed to be authorized effective the day after the time allowed for protest. If a protest is filed and not withdrawn within 30 days after the time allowed for filing a protest, the instant request shall be treated as an application for authorization pursuant to Section 7 of the NGA. Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site at *http://www.ferc.gov* under the link to the User's Guide. If you have not yet established an account, you will need to create a new account by clicking on ''Login to File'' and then ''New User Account''.

David P. Boergers,

Secretary.

[FR Doc. 01–19270 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EC01–51–000, et al.]

Xcel Energy Services, Inc., et al.; Electric Rate and Corporate Regulation Filings

July 26, 2001.

Take notice that the following filings have been made with the Commission:

1. Xcel Energy Services, Inc.

[Docket No. EC01–51–000]

Take notice that on June 21, 2001, Excel Energy Services, Inc. tendered for filing a notice of withdrawal the application it filed December 29, 2000 in Docket No. EC01–51–000.

Comment date: August 10, 2001, in accordance with Standard Paragraph E at the end of this notice.

2. Allegheny Energy Supply, Lincoln Generating Facility, LLC

[Docket No. ER01–2066–001]

Take notice that on July 24, 2001, Allegheny Energy Service Corporation on behalf of Allegheny Energy Supply Lincoln Generating Facility, LLC (Lincoln) filed revisions to its Market Rate Tariff in compliance with the Commission's Order of July 13, 2001 at Docket No. ER00–2066–000. Copies of the filing have been provided to the Public Utilities Commission of Ohio, the Pennsylvania Public Utility Commission, the Maryland Public Service Commission, the Virginia State Corporation Commission and the West Virginia Public Service Commission.

Comment date: August 14, 2001, in accordance with Standard Paragraph E at the end of this notice.

3. Allegheny Energy Supply, Gleason Generating Facility, LLC

[Docket No. ER01–2067–001]

Take notice that on July 24, 2001, Allegheny Energy Service Corporation on behalf of Allegheny Energy Supply Gleason Generating Facility, LLC (Gleason) filed revisions to its Market Rate Tariff in compliance with the Commission's Order of July 13, 2001, at Docket No. ER00–2066–000.

Copies of the filing have been provided to the Public Utilities Commission of Ohio, the Pennsylvania Public Utility Commission, the Maryland Public Service Commission, the Virginia State Corporation Commission and the West Virginia Public Service Commission.

Comment date: August 14, 2001, in accordance with Standard Paragraph E at the end of this notice.

4. Allegheny Energy Supply, Wheatland Generating Facility, LLC

[Docket No. ER01–2068–001]

Take notice that on July 24, 2001, Allegheny Energy Service Corporation on behalf of Allegheny Energy Supply Wheatland Generating Facility, LLC (Wheatland) filed revisions to its Market Rate Tariff in compliance with the Commission's Order of July 13, 2001 at Docket No. ER00–2066–000.

Copies of the filing have been provided to the Public Utilities Commission of Ohio, the Pennsylvania Public Utility Commission, the Maryland Public Service Commission, the Virginia State Corporation Commission and the West Virginia Public Service Commission.

Comment date: August 14, 2001, in accordance with Standard Paragraph E at the end of this notice.

5. Arizona Public Service Company

[Docket No. ER01–2555–000]

Take notice that on July 10, 2001, Arizona Public Service Company (APS) tendered for filing a revised Contract Demand Exhibit 1 applicable under the APS–FERC Rate Schedule No. 192 between APS and the City of Williams (Williams) for the operating year 2002.

Copies of this filing have been served on the City of Williams, and the Arizona Corporation Commission.

Comment date: August 13, 2001, in accordance with Standard Paragraph E at the end of this notice.

6. Combined Locks Energy Center, LLC

[Docket No. ER01–2659–000]

Take notice that on July 23, 2001, Combined Locks Energy Center, LLC (CLEC) filed an application for market-based rate authority pursuant to Section 205 of the Federal Power Act. The application includes a market-based rate tariff, a form of umbrella service agreement and a code of conduct (the Tariff). CLEC requests that its Tariff become effective on September 22, 2001, sixty days after the date of this filing.

CLEC has served this filing on the Public Service Commission of Wisconsin.

Comment date: August 13, 2001, in accordance with Standard Paragraph E at the end of this notice.

7. Cinergy Services, Inc.

[Docket No. ER01–2660–000]

Take notice that on July 23, 2001, Cinergy Services, Inc. (Provider) tendered for filing a Non-Firm Point-To-Point Service Agreement under Cinergy's Open Access Transmission Service Tariff (OATT) entered into between Cinergy and Capline Energy Services, L.P. (Customer).

Provider and Customer are requesting an effective date of June 25, 2001.

Comment date: August 13, 2001, in accordance with Standard Paragraph E at the end of this notice.

8. Cinergy Services, Inc.

[Docket No. ER01–2661–000]

Take notice that Cinergy Services, Inc. (Cinergy) and Exelon Generation Company, LLC (ExGen), on July 23, 2001, are requesting via a Notice of Assignment that ExGen will replace PECO Energy Corporation of Cinergy's Market-Based Power Sales Tariff Original Volume No. 7–MB, Service Agreement No. 88, dated October 29, 1997.

Cinergy and ExGen are requesting an effective date of one day after filing.

Comment date: August 13, 2001, in accordance with Standard Paragraph E at the end of this notice.

9. Cinergy Services, Inc.

[Docket No. ER01–2662–000]

Take notice that on July 23, 2001, Cinergy Services, Inc. (Cinergy) tendered for filing a Market-Based Service Agreement under Cinergy's Market-Based Power Sales Standard Tariff-MB (the Tariff) entered into between Cinergy and Energy USA—TPC Corp. (Energy USA).

Cinergy and Energy USA are requesting an effective date of June 22, 2001.

Comment date: August 13, 2001, in accordance with Standard Paragraph E at the end of this notice.

10. Cinergy Services, Inc.

[Docket No. ER01–2663–000]

Take notice that on July 23, 2001, Cinergy Services, Inc. (Provider) tendered for filing a Firm Point-To-Point Service Agreement under Cinergy's Open Access Transmission Service Tariff (OATT) entered into between Provider and Capline Energy Services, L.P. (Customer).

Provider and Customer are requesting an effective date of June 25, 2001.

Comment date: August 13, 2001, in accordance with Standard Paragraph E at the end of this notice.

11. Tampa Electric Company

[Docket No. ER01–2664–000]

Take notice that on July 24, 2001, Tampa Electric Company (Tampa Electric) tendered for filing a service agreement with Duke Energy Trading and Marketing, L.L.C. (Duke Energy) for non-firm point-to-point transmission service under Tampa Electric's open access transmission tariff. Copies of the filing have been served on Duke Energy and the Florida Public Service Commission.

Tampa Electric proposes an effective date of July 20, 2001, for the tendered service agreement, and therefore requests waiver of the Commission's notice requirement.

Comment date: August 14, 2001, in accordance with Standard Paragraph E at the end of this notice.

12. New England Power Pool

[Docket No. ER01–2665–000]

Take notice that on July 24, 2001, the New England Power Pool (NEPOOL) Participants Committee filed for acceptance materials to permit NEPOOL to expand its membership to include EmPower Energy, LLC (EmPower). The Participants Committee requests an effective date of August 1, 2001 for commencement of participation in NEPOOL by EmPower.

The Participants Committee states that copies of these materials were sent to the New England state governors and regulatory commissions and the Participants in NEPOOL.

Comment date: August 14, 2001, in accordance with Standard Paragraph E at the end of this notice.

13. Wisconsin Electric Power Company

[Docket No. ER01–2666–000]

Notice is hereby given that effective April 1, 2001, Service Agreement No. 17, effective July 26, 1997 under Wisconsin Electric Power Company's Coordination Sales Tariff, FERC Electric Tariff Second Revised Volume No. 2 has been canceled as requested by the customer Michigan Electric Coordinated Systems (MECS).

Copies of the filing have been served on MECS, Michigan Public Service Commission, and the Public Service Commission of Wisconsin.

Comment date: August 14, 2001, in accordance with Standard Paragraph E at the end of this notice.

14. WPS Resources Operating Companies

[Docket No. ER01–2667–000]

Take notice that on July 24, 2001, WPS Resources Operating Companies (WPSR) filed a Notice of Cancellation for a firm point-to-point transmission service agreement with WE Power Marketing (WE Power) under its open access transmission tariff. WPSR seeks to cancel this service agreement because under Wisconsin's electricity restructuring, the American Transmission Company, LLC (ATCLLC) will provide transmission service to this customer. WPSR requests that this cancellation take effect June 29, 2001 or on a later date approved by the Commission. To the extent necessary, the WPSR requests waiver of the Commission's notice of filing requirements.

Copies of the filing were served upon WE Power, ATCLLC, the Michigan Public Service Commission and the Public Service Commission of Wisconsin.

Comment date: August 14, 2001, in accordance with Standard Paragraph E at the end of this notice.

15. American Electric Power Company, Inc.

[Docket No. ER01–2668–000]

Take notice that on July 24, 2001, American Electric Power Company, Inc. (AEP), on behalf of itself, the AEP Operating Companies, American Electric Power Service Corporation, AEP Generating Company, and certain new subsidiaries of AEP, tendered for approval, pursuant to Section 205 of the Federal Power Act, initial and amended rate schedules in connection with its corporate restructuring plan in compliance with the restructuring programs in Ohio and Texas to facilitate the introduction of retail competition in those two states on January 1, 2002.

Copies of this filing have been provided to the retail regulators of the AEP Operating Companies and various individuals and organizations, including AEP's wholesale customers.

Comment date: August 14, 2001, in accordance with Standard Paragraph E at the end of this notice.

16. MDU Resources Group, Inc.

[Docket No. ES01–39–000]

Take notice that on July, 19, 2001, MDU Resources Group, Inc. (MDU Resources) submitted an application pursuant to section 204 of the Federal Power Act seeking authorization to issue no more than 2,600,000 shares of common stock in connection with MDU Resources' 401(k) Retirement Plan.

MDU resources also requests a waiver of the Commission's competitive bidding requirements and negotiated placement requirements at 18 CFR 34.2.

Comment date: August 16, 2001, in accordance with Standard Paragraph E at the end of this notice.

17. Golden Spread Electric Cooperative, Inc.

[Docket No. ES01–40–000]

Take notice that on July 23, 2001, Golden Spread Electric Cooperative (Golden Spread) submitted an application, pursuant to Section 204 of the Federal Power Act and Part 34 of the Federal Energy Regulatory Commission's Regulations, for blanket approval for future issuances of securities and assumptions of liabilities. Golden Spread has requested an effective date of August 20, 2001.

Comment date: August 16, 2001, in accordance with Standard Paragraph E at the end of this notice.

Standard Paragraph

E. Any person desiring to be heard or to protest such filing should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). All such motions or protests should be filed on or before the comment date. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the web at *http://www.ferc.gov* using the ''RIMS'' link, select ''Docket #'' and follow the instructions (call 202–208–2222 for assistance). Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

David P. Boergers,

Secretary.

[FR Doc. 01–19268 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP01–4–000, Docket No. CP01–5–000, Docket No. CP01–8–000]

Maritimes & Northeast Pipeline L.L.C., Algonquin Gas Transmission Company, Texas Eastern Transmission Corporation; Notice of Public Comment Meetings on the Draft Environmental Impact Statement for the Proposed Maritimes Phase III/Hubline Project

July 27, 2001.

The staff of the Federal Energy Regulatory Commission (FERC or Commission) has prepared a draft environmental impact statement (DEIS) that discusses the environmental impacts of the Maritimes Phase III/HubLine Project involving construction and operation of facilities by Maritimes & Northeast Pipeline, L.L.C. (Maritimes) in Essex and Middlesex Counties, Massachusetts and Algonquin Gas Transmission Company (Algonquin) in primarily offshore Essex, Suffolk, Plymouth, and Norfolk Counties, Massachusetts. There would be minor onshore facilities in Suffolk and Norfolk Counties. The project facilities would consist of about 25 miles of 30- and 24-inch-diameter onshore pipeline and about 35 miles of 24- and 16-inch-diameter offshore pipeline.

This notice is being sent to all persons to whom we [1] mailed the DEIS.

Public Meetings

In addition to or in lieu of sending written comments, we invite you to attend the public comment meetings the FERC will conduct in the project area. The locations and time for the meetings are listed below:

Date and Time	Location
August 14, 2001 7:00 PM.	Danvers Senior Center, 25 Stone Street, Danvers, Massachusetts
August 15, 2001 7:00 PM.	Fuller Meadows School, 143 South Main Street, Middleton, Massachusetts

The public meetings are designed to provide you with an opportunity to offer your comments on the DEIS in person. A transcript of the meetings will be made so that your comments will be accurately recorded.

[1] ''We'', ''us'', and ''our'' refer to the environmental staff of the Office of Energy Projects (OEP).

You may also provide written comments. Instructions on how to provide written or electronic comments were included in the DEIS. Please send your comments so that they will be received in Washington, DC on or before August 27, 2001.

David P. Boergers,

Secretary.

[FR Doc. 01–19269 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 2694–002]

Nantahala Power and Light, a Division of Duke Engineering Company; Notice of Availability of Environmental Assessment

July 27, 2001.

In accordance with the National Environmental Policy Act of 1969 and the Federal Energy Regulatory Commission's (Commission) regulations, 18 CFR Part 380 (Order No. 486, 52 FR 47897), the Office of Energy Projects has reviewed the application for a new license for the existing and operating Queens Creek Hydroelectric Project FERC No. 2694–002, located on Queens Creek, in Macon County, North Carolina and has prepared an Environmental Assessment (EA) for the project.

Copies of the EA are available for review in the Public Reference Branch, Room 2–A, of the Commission's offices at 888 First Street, NE., Washington, DC 20426. The EA may also be viewed on the web at http://www.ferc.gov using the ''RIMS'' link, select ''Docket#'' and follow the instructions (call 202–208–2222 for assistance).

Any comments should be filed within 30 days from the date of this notice and should be addressed to David P. Boergers, Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Room 1–A, Washington, DC 20426. Please affix ''Queens Creek Hydroelectric Project No. 2694–002'' to the top page of all comments. Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link. For further information,

contact Kevin Whalen at (202) 219–2790.

David P. Boergers,

Secretary.

[FR Doc. 01–19273 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Temporary Variance Request and Soliciting Comments, Motions To Intervene, and Protests

July 27, 2001.

Take notice that the following hydroelectric application has been filed with the Commission and is available for public inspection:

a. *Type of Application:* Request for Temporary Variance of Minimum Flow Requirement.

b. *Project No.:* 405–053.

c. *Date Filed:* July 25, 2001.

d. *Applicant:* Susquehanna Electric Company.

e. *Name of Project:* Conowingo Project.

f. *Location:* On the Susquehanna River, in Harford and Cecil Counties, Maryland and York and Lancaster Counties, Pennsylvania. The project does not utilize federal or tribal lands.

g. *Filed Pursuant to:* 18 CFR 4.200.

h. *Applicant Contact:* John J. McCormick, Jr., Plant Manager, Susquehanna Electric Company, 2569 Shures Landing Road, Darlington, MD 21034, (410) 457–2401.

i. *FERC Contact:* John K. Novak, *john.novak@ferc.fed.us,* (202) 219–2828.

j. *Deadline for filing comments, motions to intervene and protest:* August 17, 2001.

Please include the project number(P–405–053) on any comments or motions filed.

All documents (original and seven copies) should be filed with: David P. Boergers, Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426.

k. *Description of Application:* Susquehanna Electric Company (SEC) has requested Commission approval of a variance of the minimum flow requirement of the project license. Due to the rapidly decreasing flows in the Susquehanna River, SEC requests that it be allowed to include plant leakage of about 800 cubic feet per second (cfs) in the required minimum flow discharge until September 14, 2001, or until flow conditions improve where the Conowingo Project no longer requires leakage be included as part of the minimum flow requirement. According to the license, for the period June 1 to September 14, annually, SEC must provide a minimum flow release (not including leakage) below the dam of 5,000 cfs, or inflow (as measured at the USGS gage at Marietta, PA), whichever is less.

The SEC is concerned about the ability of the Conowingo Project to maintain an adequate pond level and storage capacity during the current low flow period. Maintaining storage is necessary for generation and to ensure an adequate water supply for recreational and consumptive uses of the Conowingo Reservoir to include operation of Peach Bottom Atomic Power Station and Muddy Run Pumped Storage Project. Including plant leakage in the minimum flow discharge will contribute to the maintenance of these project water uses during this low flow period. During the period of the minimum flow variance the SEC will conduct daily monitoring of the Susquehanna River below the project for potential environmental effects. If any abnormal or adverse conditions are observed the SEC will promptly notify the Maryland Department of Natural Resources.

l. *Locations of the Application:* Copies of this filing are on file with the Commission and are available for public inspection. This filing may be viewed on the Commission's web site at *http:www.ferc.gov* using the ''RIMS'' link, select ''Docket #'' and follow the instructions ((202)208–2222 for assistance). Comments, protest and interventions may be filed electronically via the Internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site under the ''e-Filing'' link.

m. Individuals desiring to be included on the Commission's mailing list should so indicate by writing to the Secretary of the Commission.

n. Protests or Motions to Intervene—Anyone may submit a protest or a motion to intervene in accordance with the requirements of Rules of Practice and Procedure, 18 CFR 385.210. 385.211, and 385.2114. In determining the appropriate action to take, the Commission will consider all protests filed, but only those who file a motion to intervene in accordance with the Commission's Rules may become a party to the proceeding. Any protests or motions to intervene must be received on or before the specified deadline date for the particular application.

o. Filing and Service of Responsive Documents—Any filings must bear in all capital letters the title ''COMMENTS'', ''RECOMMENDATION FOR TERMS AND CONDITIONS'', ''PROTESTS, OR MOTION TO INTERVENE'', as applicable, and the Project Number of the particular application to which the filing refers. Any of the above-named documents must be filed by providing the original and the number of copies provided by the Commission's regulations to: The Secretary, Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, DC 20426. A copy of any motion to intervene must also be served upon each representative of the Applicant specified in the particular application.

p. Agency Comments—Federal, state, and local agencies are invited to file comments on the described application. A copy of the application may be obtained by agencies directly from the Applicant. If an agency does not file comments within the time specified for filing comments, it will be presumed to have no comments. One copy of an agency's comments must also be sent to the Applicant's representatives.

David P. Boergers,

Secretary.

[FR Doc. 01–19272 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Application Accepted for Filing and Soliciting Comments, Protests, and Motions To Intervene

July 27, 2001.

Take notice that the following hydroelectric application has been filed with the Commission and is available for public inspection:

a. *Type of Application:* Preliminary Permit.

b. *Project No.:* 12064–000.

c. *Date filed:* July 2, 2001.

d. *Applicant:* Ochoco Irrigation District.

e. *Name and Location of Project:* The Prineville Project would be located on Crooked River in Crook County, Oregon. The proposed project would be located on a federally-owned dam administered by the U.S. Bureau of Reclamation.

f. *Filed Pursuant to:* Federal Power Act, 16 U.S.C. 791(a)–825(r).

g. *Applicant contact:* Mr. Russell Rhoden, Secretary-Manager, Ochoco Irrigation District, 1001 NW Deer Street, Prineville, OR 97754, (503) 447–6449.

h. *FERC Contact:* Tom Papsidero, (202) 219–2715.

i. *Deadline for filing comments, protests, and motions to intervene:* 60

days from the issuance date of this notice.

All documents (original and eight copies) should be filed with: David P. Boergers, Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426. Motions to intervene, protests, and comments may be filed electronically via the internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's web site at *http://www.ferc.fed.us/efi/doorbell.htm*.

Please include the project number (P–12064–000) on any comments or motions filed. The Commission's Rules of Practice and Procedure require all interveners filing documents with the Commission to serve a copy of that document on each person in the official service list for the project. Further, if an intervener files comments or documents with the Commission relating to the merits of an issue that may affect the responsibilities of a particular resource agency, they must also serve a copy of the document on that resource agency.

j. *Description of Project:* The proposed project would use the existing Bowman Dam and Prineville Reservoir which has a surface area of 4000 acres and a storage capacity of 154,700 acre-feet at 3,234 feet msl and include: (1) A proposed powerhouse with a total installed capacity of 2.9 MW, (2) one proposed 130-foot-long, 6-foot-diameter penstock within a new 10-foot-diameter concrete lined tunnel, (3) an existing 6.1-mile-long, 24.9 kv transmission line which would be upgraded to three-phase, 24.9 kv, and (4) appurtenant facilities. The project would have an average annual generation of 17.01 GWh.

k. A copy of the application is available for inspection and reproduction at the Commission's Public Reference Room, located at 888 First Street, NE., Room 2A, Washington, DC 20426, or by calling (202) 208–1371. The application may be viewed on http://www.ferc.fed.us/online/rims.htm (call (202) 208–2222 for assistance). A copy is also available for inspection and reproduction at the address in item g above.

l. Preliminary Permit—Anyone desiring to file a competing application for preliminary permit for a proposed project must submit the competing application itself, or a notice of intent to file such an application, to the Commission on or before the specified comment date for the particular application (see 18 CFR 4.36). Submission of a timely notice of intent allows an interested person to file the competing preliminary permit application no later than 30 days after the specified comment date for the particular application. A competing preliminary permit application must conform with 18 CFR 4.30(b) and 4.36.

m. Preliminary Permit—Any qualified development applicant desiring to file a competing development application must submit to the Commission, on or before a specified comment date for the particular application, either a competing development application or a notice of intent to file such an application. Submission of a timely notice of intent to file a development application allows an interested person to file the competing application no later than 120 days after the specified comment date for the particular application. A competing license application must conform with 18 CFR 4.30(b) and 4.36.

n. Notice of Intent—A notice of intent must specify the exact name, business address, and telephone number of the prospective applicant, and must include an unequivocal statement of intent to submit, if such an application may be filed, either a preliminary permit application or a development application (specify which type of application). A notice of intent must be served on the applicant(s) named in this public notice.

o. Proposed Scope of Studies under Permit—A preliminary permit, if issued, does not authorize construction. The term of the proposed preliminary permit would be 36 months. The work proposed under the preliminary permit would include economic analysis, preparation of preliminary engineering plans, and a study of environmental impacts. Based on the results of these studies, the Applicant would decide whether to proceed with the preparation of a development application to construct and operate the project.

p. Comments, Protests, or Motions to Intervene—Anyone may submit comments, a protest, or a motion to intervene in accordance with the requirements of Rules of Practice and Procedure, 18 CFR 385.210, .211, .214. In determining the appropriate action to take, the Commission will consider all protests or other comments filed, but only those who file a motion to intervene in accordance with the Commission's Rules may become a party to the proceeding. Any comments, protests, or motions to intervene must be received on or before the specified comment date for the particular application.

q. Filing and Service of Responsive Documents—Any filings must bear in all capital letters the title ''COMMENTS'', ''NOTICE OF INTENT TO FILE COMPETING APPLICATION'', ''COMPETING APPLICATION'', ''PROTEST'', or ''MOTION TO INTERVENE'', as applicable, and the Project Number of the particular application to which the filing refers. Any of the above-named documents must be filed by providing the original and the number of copies provided by the Commission's regulations to: The Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426. An additional copy must be sent to Director, Division of Hydropower Administration and Compliance, Federal Energy Regulatory Commission, at the above-mentioned address. A copy of any notice of intent, competing application or motion to intervene must also be served upon each representative of the Applicant specified in the particular application.

r. Agency Comments—Federal, state, and local agencies are invited to file comments on the described application. A copy of the application may be obtained by agencies directly from the Applicant. If an agency does not file comments within the time specified for filing comments, it will be presumed to have no comments. One copy of an agency's comments must also be sent to the Applicant's representatives.

David P. Boergers,

Secretary.

[FR Doc. 01–19274 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RM01–9–000]

Notice of Order Imposing Reporting Requirements on Natural Gas Sales to California Market

Issued July 25, 2001.

AGENCY: Federal Energy Regulatory Commission, Energy.

ACTION: Notice.

SUMMARY: The Commission is issuing an order imposing certain reporting requirement on natural gas sellers and transporters serving the California market. This reporting requirement is for a limited time, and is intended to provide the Commission with the necessary information to determine what action, if any, it should take within its jurisdiction.

DATES: The reporting requirement covers the six months from August 1, 2001 to January 31, 2002, and the first report is due October 1, 2001.

FOR FURTHER INFORMATION CONTACT: Jacob Silverman, Office of the General Counsel, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, (202) 208–2078

SUPPLEMENTARY INFORMATION:

Federal Energy Regulatory Commission

Before Commissioners: Curt Herbert, Jr., Chairman; William L. Massey, Linda Breathitt, Pat Wood, III and Nora Mead Brownell; Reporting of Natural Gas Sales To the California Market

[Docket No. RM01–9–000]

Federal Energy Regulatory Commission

Order Imposing Reporting Requirement on Natural Gas Sales to California Market

Issued July 25, 2001.

On May 18, 2001, the Commission issued an order (May 18 order) proposing to impose a reporting requirement on natural gas sellers and transporters serving the California market.[1] The specific information that the Commission proposed to collect was set forth in a series of questions included as an appendix to the order. The May 18 order requested comments on the proposal. Twenty-nine responses were filed. The parties filing comments are set forth in Attachment 1. Some commenters who support the proposal also seek to broaden the scope of information gathered. Other commenters raise a number of issues, such as the extent of the Commission's authority to collect the information, the period the information is to be collected, and a greater assurance that certain information, particularly the data on individual transactions, will not be disclosed to the public. In addition, some commenters urge clarification of a number of the questions.

In this order, the Commission concludes that it has the authority to request the information set forth in the May 18 order, and that the filing of such information by the entities identified in this order is necessary for the Commission to understand why the disparity in the price of natural gas arose in California relative to the remainder of the country and in doing so discharge our statutory responsibilities. Consequently, the order requires sellers and transporters of natural gas serving the California market to submit the information specified in this order. The information is to be submitted monthly for the six-month period covering August 1, 2001, through January 31, 2002, with the intention to extend the reporting requirement, upon approval by the Office of Management and Budget, through September 30, 2002, to coincide with the end date of the Commission's mitigation plan regarding wholesale electricity prices in California and the West.[2] In addition, as discussed in this order, the Commission concludes that the specific information gas sellers and local distribution companies (LDCs) are required to report concerning their purchase and sales transactions is exempt from disclosure under the Freedom of Information Act (FOIA). Furthermore, the Commission will permit respondents to request privileged treatment of other portions of their responses subject to the procedures in section 388.112 of the Commission's regulations regarding disclosure of information covered by any such request for privileged treatment. In addition, in response to the comments received, we have modified certain of the proposed questions. The revised questions together with the format for reporting are set forth in the appendix to this order.

Background

The May 18 order discussed our concern about a sharp increase in the price of natural gas sold in the California market, which has exceeded the increase in other markets. The Commission pointed out that the price for gas at various points on the southern California border remained higher than those in any other market in the United States, including those markets that are supplied by the same producing areas. The Commission stated that it did not currently have reliable information concerning the percentage of gas moving into the California market that is actually priced at the high spot market prices reported at the California borders.

The May 18 order noted that the increase in the price of natural gas in California was the focus of a number of complaints. Among the actions the complainants sought were (1) reimposing price-caps for short-term releases of capacity for service to the California border and to points of interconnection between interstate pipelines and California local distribution companies (LDCs),[3] (2) requiring sellers to state separately the transportation and commodity components of bundled rates for sales at these points[4] and (3) setting a benchmark price for natural gas throughout the United States.[5] Moreover, the complaints generally asserted that the high price for natural gas in the California market is a factor contributing to the current high cost of electric power in California.

The May 18 order stated that while the relatively high prices for natural gas in California were a matter of serious concern, the Commission's legal authority to take actions that would affect those prices is limited by the existing statutory framework. The Commission does have jurisdiction under the Natural Gas Act (NGA) to regulate the transportation of natural gas by interstate pipelines, and to issue certificates for the construction of new interstate pipelines. However, the Commission's jurisdiction to regulate the prices charged by sellers of natural gas is limited by the Natural Gas Policy Act of 1978 (NGPA), and Congress' subsequent enactment of the Natural Gas Wellhead Decontrol Act of 1989. The May 18 order found that the end result of these statutory provisions is that the only sales of natural gas that the Commission currently has jurisdiction to regulate are sales for resale of domestic gas by pipelines, LDCs, or their affiliates.[6]

Within this framework, and in order to help the Commission understand why the disparity in the price of natural gas had occurred in California and continues to exist, the Commission proposed to collect information from sellers of natural gas to the California market, and from interstate pipelines and LDCs serving the California market. The information proposed to be reported included data relating to the volumes and prices of sales to the California market including transportation rates, the daily operational capacity of pipelines to and in the California market, and the actual volumes flowing to and in California, and the gas sales and the transportation requirements of California LDCs.

The May 18 order stated that this information should assist the Commission in carrying out its regulatory responsibilities. First, it would help the Commission determine what part of the problem, if any, is within the scope of its jurisdiction. For example, the information to be collected concerning sales should enable the Commission to determine what percentage of the volumes sold into the

[1] 95 FERC ¶61,262 (2001).

[2] See San Diego Gas & Electric Company, *et al.*, 95 FERC ¶61,418 (2001).

[3] Docket No. RP01–180–000, filed by San Diego Gas and Electric Company (SDG&E), and Docket No. RP01–222–000, filed by The Los Angeles Department of Water and Power.

[4] Docket No. RP01–180–000.

[5] Docket No. RP01–223–000, filed by the National Association of Gas Consumers.

[6] Also, under NGPA section 2 (21) (B), sales by those entities of their own production are excluded from the Commission's jurisdiction.

California market is domestically produced gas sold by marketers affiliated with pipelines and LDCs in sales for resales, which are the only sales of natural gas now being made that the Commission has jurisdiction to regulate.[7] The information proposed to be collected would also give the Commission an accurate picture of the overall average gas costs being incurred by all purchasers of natural gas moving into the California market.

The Commission also stated that the information to be collected would enable it to determine the extent to which the cost of interstate transportation, which is subject to the Commission's jurisdiction, affects the price of the gas commodity at the California border. Currently, the Commission establishes maximum rates for interstate transportation, with the exception of negotiated rates and short-term capacity releases for which maximum rates have been waived until September 30, 2002.

The order proposed that respondents submit the information to the Commission on a quarterly basis, within thirty days after the end of the quarter. The Commission indicated that it would aggregate the data submitted and analyze it promptly. The Commission would then determine, what action, if any, is warranted.[8]

The order provided for comments on the proposed reporting requirement within thirty days of the date of issuance of the order, and stated that after receipt of the comments, the Commission would determine whether to proceed with the proposed reporting requirement.

Discussion

As indicated in the May 18 order and as discussed below, we find that it is necessary to collect the information set forth in the Appendix in order for the Commission to acquire a better understanding of how the California natural gas market functions in light of the fact that the price of natural gas in the California market has, for substantial periods, been higher than the price in other markets and trading hubs throughout the country. The Commission is also concerned about the operation of the California natural gas market since gas-fired electric generators in California help to establish the market clearing price for electric generation pursuant to the bidding system used by the California Independent System Operator.[9]

In determining the appropriate amount of information and the period over which to gather such information, the Commission has reviewed the comments filed in this proceeding. The issues raised by commenters are addressed below. Upon consideration of the comments, the Commission will modify certain questions from those proposed in the May 18 order and will collect the information for a limited period. As discussed more fully below, the Commission finds that it has the authority to request the information it seeks from all entities, including non-jurisdictional parties.

1. Commission Authority to Request Information

The May 18 order stated that ''the Commission recognizes that certain entities that will be required to respond to the data requests may not be natural gas companies subject to the Commission's NGA section 1 jurisdiction.'' [10] Nevertheless, the order stated that the Commission has the authority to seek the information from those entities under NGA sections 14 and 16.[11] The Commission held that section 14 authorizes the Commission to collect information from participants in the natural gas market without limiting the persons from whom information may be sought to ''natural gas companies'' subject to the Commission's jurisdiction. The Commission also relied on the fact that section 14 authorizes the Commission to obtain information in connection with recommending legislation, stating such information could include matters currently outside the Commission's jurisdiction. In addition the order referred to NGA section 16, which grants the Commission ''power to perform any and all acts . . . as it may find necessary or appropriate to carry out the provisions of this act.'' The order stated that the Commission must have an overall picture of what is occurring in the California market in order to determine the potential effectiveness of actions it may take within the scope of its jurisdiction. Only by collecting information concerning all California sales could the Commission obtain the overall picture and feel confident that any actions it might take within its limited jurisdiction would have the intended consequences.

A number of commenters question the Commission's conclusion that together, NGA sections 14 and 16 empower the Commission with the authority to require a non-jurisdictional entity to furnish the Commission with information that the Commission needs to carry out its functions. Commenters raising the jurisdictional issue point out that section 311 of the Federal Power Act (FPA) [12] specifically authorizes the Commission to investigate non-jurisdictional transactions, while the NGA does not include such specific language. Nevertheless, some of the commenters state that they are agreeable to the reporting requirement in this case subject to conditions, including a guarantee of confidential treatment and a sunset date, but the commenters assert that they are not waiving their right to object to the Commission's action over non-jurisdictional first sales.[13]

The Commission finds that it has the authority to obtain the information requested from all entities. As discussed below the Commission is establishing the reporting requirement for a limited time period, and for the purpose of investigating a specific problem that is a matter of urgent concern both to it and the Congress.

Among other things, NGA section 14 allows the Commission to seek information ''to aid in prescribing rules and regulations'' necessary to carry out its responsibilities under the NGA. The May 18 order stated that a number of complaints have been filed seeking relief from the high cost of natural gas in the California market, and in those complaints it was also alleged that the high price of natural gas in California is a factor contributing to the high cost of electric power in California. The Commission needs the information it is seeking through this reporting requirement to determine what actions it can and should take with respect to the current problem involving the high price of natural gas in California, which

[7] For the most part, interstate pipelines no longer sell natural gas.

[8] Because the Commission would want to receive the information as soon as possible, the order stated that the Commission, pursuant to 5 CFR 1320.13 (2000), would request the Office of Management and Budget for emergency processing of the proposed collection of information.

[9] *See* San Diego Gas & Electric Co. *et al.,* 95 FERC ¶ 61,418 (2001), establishing a price mitigation plan for Western Systems Coordinating Council (WSSC) area, including California.

[10] 95 FERC at 61,930.

[11] Section 14(a) provides:

The Commission may investigate any facts, conditions, practices, or matters which it may find necessary or proper in order to determine whether any person has violated or is about to violate any provision of [the NGA] or any rule, regulation, or order hereunder, or to aid in the enforcement of the provisions of this act or in prescribing rules or regulations thereunder, or in obtaining information to serve as a basis for recommending further legislation to the Congress.

[12] 16 U.S.C. § 825j. That section provides, in part, that ''the Commission is authorized and directed to conduct investigations regarding * * * electric energy, however produced, throughout the United States, * * * whether or not subject to the jurisdiction of the Commission. * * *''

[13] *See, e.g.,* Comment of Indicated Shippers, Pan Alberta Gas Ltd., *et al.*

would include changes in the Commission's existing rules and regulations. The Commission explained in the May 18 order that:

> In this case, the Commission must have an overall picture of what is occurring in the California market in order to determine the potential effectiveness of actions within the Commission's jurisdiction. Only by collecting information concerning all California sales can the Commission obtain the overall picture and feel confident that any actions it might take would have the intended consequences.

The information obtained would permit the Commission to determine the extent to which the high price of natural gas in the California market involves a matter over which the Commission has jurisdiction.[14] For example, if any revised rules the Commission adopted would apply only to a small amount of the natural gas sales in the California market, the efficacy of those orders would be of limited value.

NGA section 14 also authorizes the Commission to seek information ''to serve as a basis for recommending further legislation to the Congress * * * .'' The information being sought would be relevant in determining the effect of legislative proposals addressing the current situation. In the current session of Congress, a number of bills have been proposed to deal with the situation in California.[15] The information would also help the Commission respond to questions from Congress concerning the natural gas price issue in California. For example, the Commission has received requests from legislators to investigate the ''exorbitant rise in natural gas prices in California,'' [16] and for the Commission to end the suspension of the price cap on short term release transactions for sales to the California market.[17]

In this case there is a clear need for the information being sought and which is not otherwise available from other sources or other means. Furthermore, the information request is to address a specific problem—a problem which requires immediate attention. Accordingly, under the urgent and unique circumstances presented, the Commission finds that it has the authority to require non-jurisdictional entities to furnish the requested information. However, to minimize the burden on respondents and as discussed more fully below, the information will be collected for the minimum period necessary to inform the Commission regarding transactions affecting the price of natural gas in the California market.

Section 311 of the Federal Power Act (FPA) is an additional source of authority for adopting these reporting requirements. On June 19, 2001, the Commission issued an order involving price mitigation for the California power markets.[18] Under that mitigation plan, generators' price bids during reserve emergencies must reflect the marginal cost of obtaining natural gas used for generation. That number is derived using an average of the mid-point of the monthly bid-week prices at certain reported California natural gas market price points. Thus, the price for electric power would be dependent, to some extent, on the price of natural gas at certain California market points.

Under these circumstances, not only is the Commission's NGA section 14 and 16 authority applicable, but FPA section 311 also applies. That section authorizes the Commission, ''as a basis for recommending legislation,'' to request information ''regarding the generation * * * of electric energy, however produced * * * whether or not subject to the jurisdiction of the Commission * * *'' As a result the Commission has the authority to ''investigate nonjurisdictional sales of nonjurisdictional companies.'' [19] The FPA section 311 authority includes authorization to secure information concerning ''the cost of generation.'' Since natural gas is used in many generating plants to produce the electricity, the cost of natural gas is obviously a crucial element in any investigation of the cost of generating electricity. Thus, in the current situation, FPA section 311 is another basis for the Commission's authority to issue the reporting requirement.

The Commission recognizes that in one decision by the Ninth Circuit Court of Appeals describing the more extensive language of FPA section 311, there is language that commenters contend is inconsistent with the Commission's action here. In *Union Oil Company of California* v. *FPC*,[20] the court addressed a challenge to a Commission order seeking detailed information from large natural gas producers making interstate sales of natural gas, and thus at that time subject to the Commission's NGA jurisdiction. The questions asked about all their natural gas reserves, including reserves solely for intrastate, non-jurisdictional sales. Producers argued that the NGA does not provide authority for the collection of intrastate reserve data. The court agreed with the Commission's argument that obtaining intrastate data from producers subject to the Commission's jurisdiction was necessary for its determination of proper policies and rates with respect to interstate commerce in natural gas. In discussing FPA section 311, the court stated that the NGA ''limits the gathering of intrastate data to gathering it from companies falling under the Commission's jurisdiction.'' *Id.* at 1039. The court noted that the Commission had not proposed to seek information from non-jurisdictional producers. The court's statement about the Commission's information gathering authority was only dicta since the Commission had not sought to collect information from non-jurisdictional producers and thus the issue of the Commission's authority to do so was not presented to the court.

In any event, this case is distinguishable. *Union Oil* involved an ongoing reporting requirement which was to be in effect for an indefinite period, and the reporting requirement was not tied to investigating any particular problem. Here, the reporting requirement is to be in effect for only a limited period of time and, as discussed above, is intended to gather information to assist the Commission in determining what action it should take or propose to Congress about a specific problem. Moreover, in this case, the Commission invokes the authority of FPA section 311, which the *Union Oil* court held does authorize data collection from entities outside the Commission's jurisdiction. Accordingly, the Commission finds that it is authorized to request the information from all entities.

2. Reporting Period

The May 18 order proposed to require submission of the information on a quarterly basis, within thirty days after the end of the quarter. The order did not indicate any termination date for the reporting period. Many of the comments urge the Commission to limit the reporting to a defined period of time.

As explained above, the purpose of the reporting requirement is to enable

[14] No commenter has questioned the Commission's holding that the only sales it now has jurisdiction to regulate are sales for resale of domestic gas by pipelines, LDCs, and their affiliates.

[15] See *e.g.* S. 764, and H.R. 1974 which would instruct the Commission to require natural gas sellers of bundled sales to the California market to disclose the commodity portion and the transportation portion of the sale price.

[16] See letter of December 20, 2000, from Senator Dianne Feinstein of California.

[17] See letter of February 28, 2001, from Senator Dianne Feinstein of California.

[18] San Diego Gas & Electric Co. *et al.,* 95 FERC ¶ 61,418 (2001).

[19] Continental Oil Co. v. FPC, 519 F.2d 31 at 34 (5th Cir. 1975).

[20] 542 F.2d 1036 (9th Cir. 1976).

the Commission to determine what action, if any, it should take with respect to the California natural gas price disparity. The Commission requires the information to address the current problem, and it is not intended to be an ongoing reporting requirement. Given the emergency nature of this issue, and as explained above, its relation to wholesale electric price mitigation in California, the Commission is seeking emergency processing by the Office of Management and Budget (OMB) for the collection of information under 5 CFR 1320.13 (2000). Under that procedure, the authority to collect information is initially limited to 180 days. Accordingly, because the Commission requires the information as soon as possible, the Commission will require submission of the information on a monthly basis, to be submitted 30 days after the end of each month, for the six months commencing August 1, 2001 and ending January 31, 2002. This means the first report will be due October 1, 2001 and the last report on March 1, 2002.

Monthly reporting is a change from the quarterly reporting proposed in the May 18 order. Under a quarterly reporting requirement, the first data would not arrive until December 1, 2001. That would not be timely in the emergency circumstances that exist in California.

The Commission also believes the reporting period should cover the same period as the Commission's California electric power mitigation order. Accordingly, the Commission intends to seek approval from OMB to extend the reporting period to September 30, 2002, to coincide with the termination of that order. The Commission does not anticipate that it will require data after September 30, 2002, and thus would end the reporting period on that date. If the Commission should find that an extension beyond that time is necessary, the Commission would give notice of its intention and provide for an appropriate comment period.

3. Confidentiality of Submission

A number of commenters urge that the submission of the requested information that gas sellers are required to report concerning their sales transactions must be accorded confidential treatment and should not be disclosed to the public. They argue that the requested information includes sensitive commercial data such as sales contract terms, identification of buyer, and specific transactions conducted at the California border or within the state. One commenter makes a similar argument about the information that LDCs are required to provide about their gas purchase contracts.

In the May 18 order, the Commission recognized the commercially sensitive nature of much of the information to be submitted by gas sellers concerning their sales transactions. The May 18 order stated that parties furnishing information can request confidential treatment for the information pursuant to Section 388.112 of the Commission's regulations.[21] The order did not provide for public disclosure of the information. The order stated that the Commission would aggregate the data submitted and then determine what action, if any, the Commission would take.

Under section 388.112, if a party requests privileged treatment of any material submitted, that material will be placed in a nonpublic file. If public release of that document is sought under the Freedom of Information Act (FOIA), the party submitting the document will be notified of the request and given an opportunity to comment on the request. If the Commission determines to deny the claim of privilege, the submitter will be notified at least five days before public disclosure of the material, together with an explanation why the claim of privilege was denied. If the privilege claim is upheld, and the FOIA requester brings suit to compel disclosure, the Commission will notify the submitter of the suit.

FOIA contains nine exemptions from its general policy of mandating disclosure of government documents. The fourth exemption is for: trade secrets and commercial or financial information obtained from a person and privileged and confidential.[22]

Information qualifies as ''confidential'' under FOIA Exemption 4, if one or more of several conditions is met, one of which is that disclosure is likely ''to cause substantial harm to the competitive position of the person from whom the information was obtained.'' [23] FOIA Exemption 4 is incorporated in the Commission's regulations in section 388.107(d). However, even though certain information may qualify as exempt from mandatory disclosure under FOIA, the Commission can require its disclosure, where the public interest in disclosure outweighs any harm from disclosure, for example because disclosure would significantly aid the Commission in carrying out its statutory responsibilities.[24]

Certain questions adopted by this order require information about individual sales or purchase transactions. These include Questions 2, 3, and 4 directed to natural gas sellers, and Questions 4 and 8 and that part of Question 7 relating to prices directed to LDCs. For the reasons discussed below, the Commission finds that information about individual transactions provided in response to these questions falls under FOIA Exemption 4 as ''trade secrets and commercial or financial information obtained from a person and privileged or confidential.'' The Commission also finds that, in the context of the instant inquiry into the operation of the California natural gas market, the potential competitive harm from public disclosure outweighs any public interest in disclosure of data concerning individual sales transactions. Therefore, the Commission will not disclose information concerning individual transactions obtained in response to the above listed questions. This holding, as discussed below, does not apply to transportation information obtained from pipelines and LDCs.[25]

The commercial sensitivity of information about individual sales transactions has been addressed in court and Commission rulings. In *Continental Oil,* the United States Court of Appeals for the Fifth Circuit reviewed a Commission collection of sales data from interstate natural gas companies, including the names of purchasers, dates and locations of sales, pressure bases, annual sales volumes and price terms. The court upheld the Commission's right to that data but vacated the Commission's refusal to keep the data confidential. The court stated:

> The likelihood that delivery of these intimate facts would be harmful is apparent. * * * The compilation and disclosure to petitioners' competitors, purchasers and suppliers of information as to extent of supply and competitive prices in each market area would alter industry custom and existing relationships to the disadvantage of petitioners' competitive positions.[26]

The same is true here. In Order No. 636, the Commission held that, with the

[21] 18 CFR § 388.112 (2000).

[22] 5 U.S.C. § 552(a)(b)(4). This is the fourth of the nine exemptions from mandatory disclosure permitted by FOIA.

[23] National Parks and Conservation Association v. Morton, 498 F.2d 765, 770 (D.C. Cir. 1974).

[24] Pennzoil Co. v. FPC, 534 F.2d 627 (D.C. Cir. 1976).

[25] To the extent a respondent believes information sought by the other questions should be exempt from disclosure, it may request that the Commission treat that information as privileged pursuant to the procedures in section 388.112 of the Commission's regulations.

[26] Continental Oil Co. v. FPC, 519 F.2d 31 at 35 (5th Cir. 1975).

regulatory changes there ordered, the market for the sale of the gas commodity would be competitive.[27] The gas purchase and supply data the Commission is requesting, if disclosed to the public, would significantly disadvantage the competitive position of the gas sellers supplying that information. Gas sellers compete not only with each other, but also with other marketers. Competitive injury would thus occur with regard to the gas seller's relationships with its customers. In addition, disclosure could make apparent various proprietary marketing strategies and trade secrets, including how sales transactions are structured. In the highly competitive gas supply environment, such disclosure could cause competitive injury. The information furnished is entitled to protection from public disclosure if there is a ''likelihood'' of competitive injury-there need not be a showing of actual competitive ''harm.'' The individual sales transaction data are proprietary, not only from the perspective of the seller, but also from the buying entity's perspective.[28] For example, the data could show the prices a particular gas purchaser is willing to pay.

The Commission also finds that, in this case, there is no overriding public interest in disclosure of information about individual sales transactions. The Commission is seeking information here to understand the operation of the market for gas sales into California, not to investigate the conduct of particular participants in that market. Indeed, many of the sales in question are not subject to the Commission's NGA jurisdiction, and the Commission does not wish to impose more burdensome disclosure requirements on jurisdictional sellers, than on the non-jurisdictional sellers with whom they compete. In these circumstances, the Commission concludes that publication of aggregated information is sufficient to accomplish the purposes for which the Commission is seeking the information.

Accordingly, consistent with the ruling in *Continental Oil,* the Commission finds exempt from public disclosure the individual sales or purchase transaction data furnished pursuant to Sellers of Natural Gas Questions 2–4, and California LDCs Questions 4 and 8 and that part of Question 7 to relating to prices, adopted by this order. In regard to the LDC questions mentioned above, Sempra Energy Utilities states that the CPUC has found similar information to be exempt from public disclosure, due to its commercially sensitive nature.

On the other hand, the information the Commission is requesting concerning transportation contracts with pipelines, such as capacity release transactions, would not be entitled to privileged treatment because pipelines are required to post that type of information on their web sites. Nevertheless, if privileged treatment is sought with respect to any information submitted, the Commission will follow the procedures of § 388.112, and apply the appropriate principles governing the particular information.

4. General Issues as to Proposed Questions

A number of commenters assert that compilation of the data will be burdensome, and others assert that the data requested is not likely to ''tell the whole story.'' [29] Thus, while some commenters would limit the requested data to the Southern California market,[30] others urged the Commission to expand it to cover all 48 states, and require reports for each state identical to that specified for the California market in the May 18 order.[31] Some commenters contend that to some extent the data to be submitted is duplicative of data being supplied to the Commission in other Commission proceedings,[32] and thus is not necessary. Finally, many commenters assert that some questions are ambiguous or not readily answered in the form proposed, and should be clarified.[33]

As explained above, the Commission is imposing the reporting requirement to help determine what actions it should take with respect to the substantial disparity that has arisen in the past year between natural gas prices at the California border and in the rest of the country. The relatively high natural gas prices also may be a factor in the extraordinary increases in the cost of electric power in California, since many generators consume natural gas. The Commission recognizes that the reporting requirement will require responders to expend time and manpower. Nevertheless, the data are necessary for the Commission to carry out its regulatory responsibilities with respect to the natural gas market, since the information will help the Commission determine what actions it can and should take to address a problem with serious adverse effect in California. Because of the immediacy of the problem, the Commission has decided to require reporting on a monthly basis, with the first submission due by October 1, 2001.

While some commenters point out that currently prices at the northern California border have decreased to levels approximating those in other areas of the country, the Commission will not narrow the reporting requirement to cover only the southern California market. During much of the last year, prices at the northern California border have been significantly higher than in other areas of the country, and it is not clear whether the current decrease in those prices is temporary. The Commission therefore continues to believe that information must be gathered with respect to the entire California gas market.

However, the Commission will not expand the reporting requirement to cover other areas of the country. While there have been natural gas price increases in the rest of the country, it is only in California that prices have been significantly different from prices elsewhere. As the May 18 order stated, ordinarily in a competitive, seamless national market for natural gas, where gas can flow to wherever it can command the highest price, price disparities between different regions would not be expected to continue for sustained periods of time. Higher prices in one region would cause more sellers to direct gas towards that region, thereby increasing the supply in that region, which would in turn lower the price in that region and bring it in line with the national average. It is only in California where, contrary to what should occur in a competitive market, significant price disparities as compared to the rest of the country have occurred for sustained periods of time. Therefore,

[27] Pipeline Service Obligations and Revisions to Regulations Governing Self-Implementing Transportation under Part 284 of the Commission's Regulations, III FERC Stats & Regs. ¶ 30,939 at 30,437–43 (Order No. 636); III FERC Stats & Regs. ¶ 30,950 at 62,024–25 (Order No. 636–A); 61 FERC ¶ 61,272 at 62,024–5 (Order No. 636–B) (1992); *aff'd in relevant part,* United States Distribution Companies v. FERC, 88 F.3d 1105 (D.C. Cir. 1996).

[28] *See* Regulation of Natural Gas Pipelines after Partial Wellhead Decontrol, 50 FERC ¶ 61,391 (1990), in which the Commission held that information provided by interstate pipelines about individual settlements resolving their take-or-pay liability under gas purchase contracts was exempt from public disclosure because commercially sensitive.

[29] *See, e.g.,* Comments of AEC Storage and Hub Service, Inc., and Electric Power Supply Association.

[30] *See,* Canadian Association of Petroleum Producers, Alberta Department of Energy and Pacific Gas and Electric Company.

[31] *See,* National Association of Gas Consumers.

[32] *See, e.g.,* Comments of Dynegy Marketing and Trade, Occidental Energy Marketing, Inc.

[33] *See e.g.,* Comments of Indicated Shippers, and of Undersigned Producers.

the Commission will limit the reporting requirement to the California market.

Some commenters have suggested that the reporting burden could be reduced (and greater assurance of confidentiality be provided) if respondents were permitted to provide only aggregated data concerning all their sales during a month or a quarter. Also, some commenters suggest that they be permitted to report data in the format in which they currently keep such data, rather than be required to provide data in a standardized format. The Commission does not adopt these suggestions. While the Commission intends to aggregate the data itself, transaction by transaction data is necessary to ensure that the Commission obtains a full picture of how the California market is working and to enable the Commission to verify the accuracy of any aggregated data. The Commission also must have the data filed in a consistent format to enable it to aggregate the data in a meaningful fashion. The Commission, as discussed above, will protect the sensitive nature of the data concerning individual sales transactions.

The Commission recognizes, as argued by some commenters, that some of the information may be in the Commission's possession through other filings, for example the reports pipelines are required to make to the Commission. However, requiring all the information to be filed here in a consistent format is necessary to speed the Commission's analysis of the data, so that it can take any actions indicated by the data promptly.

We shall now address concerns raised with respect to the specific information questions posed to the three different groups (interstate pipelines, sellers of natural gas, and local distribution companies) that serve California natural gas markets. As discussed below, the Commission is revising some of the questions, to address the concerns raised in the comments. In this connection, the May 18 order did not include the specific period for which the questions request data but merely stated ''period —to—''. Consistent with the discussion above limiting the reporting period to six months at least initially, that phrase has been changed to read ''August 1, 2001, to January 31, 2002'' in each of the questions.

1. Questions to Interstate Natural Gas Pipelines

Proposed Question 1 addressed to interstate pipelines asked that the pipelines provide, on a daily basis starting on August 1, 2001, certain information for each contract for transportation to the California border. The Public Utilities Commission of the State of California (CPUC) urged that this daily information should be provided for the period starting January 1, 1999 through the effective date of the order, with subsequent quarterly reports for future days. The Commission will not require pipelines to supply the information requested in Question 1 for periods before August 1, 2001. The Commission is seeking to minimize the burden of these reporting requirements, consistent with achieving the purpose of the reporting requirement of monitoring what is currently occurring in California to determine what actions can or should be taken on a prospective basis. For this purpose, detailed information concerning transportation contracts in effect during past periods is unnecessary.

Question 1, as proposed, also requests pipelines to identify the daily volumes scheduled by, and delivered to each shipper for the period August 1, 2001 to January 31, 2002. CPUC asserts that pipelines should also be required to report daily nominated volumes by shipper to provide corroboration on reported information between pipelines and sellers. It also urges that prices should be reported on an $$/MMBtu basis, and the term and effective date of each contract should be provided as well.

The Commission agrees with CPUC that daily nominated volumes should be reported to ensure that the Commission can cross-check the information supplied. The Commission will also require that prices be reported on an $$/MMBtu basis to ensure consistency of answers, and require the pipeline to report the term and effective date of each contract.

Independent Petroleum Association of America (IPAA) requests that pipelines be required to report what gas actually flowed the previous day. IPAA contends that this information is important because nominated capacity which has not been scheduled or confirmed appears as capacity already used and, as such, effectively takes that capacity off the market. Question 1, as revised by the Commission in response to the CPUC, will provide this information on a contract-by-contract basis for the August 2001 through January 2002 period, since pipelines must report daily nominated, scheduled, and *delivered* volumes. In addition, in response to IPAA's comment, the Commission is modifying proposed Questions 3(c) and 4(c), which requested each pipeline's ''daily scheduled system volume'' for the periods August 2001 through January 2002 and May 1999 through May 2000, respectively. As adopted, Questions 3(c) and 4(c) will require each pipeline to report its ''daily scheduled and delivered system volume.''

2. Questions to Sellers of Natural Gas

Commenters requested a number of clarifications concerning the proposed questions addressed to ''Sellers of Natural Gas to the California Market'', including what sales are intended to be covered by the proposed questions. The Commission clarifies the questions as discussed below.

Question 1

Proposed Question 1 requires gas sellers to identify any affiliation they have with interstate and intrastate pipelines or LDCs. One commenter [34] suggests that sellers should only be required to report affiliations with pipelines and LDCs the seller uses to ship gas to and within California. It asserts sellers into the California market may have affiliations with pipelines and LDCs in other areas of the country who perform no business in California and such affiliations are not relevant to Commission's inquiry concerning California gas prices.

The Commission adopts Question 1 as proposed and will require sellers to identify their affiliations with all pipelines and LDCs wherever located. A primary purpose of the reporting requirement is to determine what proportion of sales in California are subject to the Commission's jurisdiction. The Commission has jurisdiction over all sales for resale of domestic gas by gas sellers affiliated with pipelines or LDCs, regardless of where they are located. Therefore, all such affiliations are relevant to the Commission's inquiry.

Scope of Proposed Questions 2 and 5

Proposed Question 2 required sellers to provide certain information concerning ''each sales contract under which the gas is physically delivered at or into the California market.'' Proposed Question 5 required sellers to provide certain information concerning each ''gas purchase contract under which the gas is physically delivered at or into the California market.''

A number of commenters question the type of sales and purchase contracts that are covered by these questions, namely, whether the Commission is seeking information only regarding sales and purchases when the gas is delivered at the California border or inside California, or whether the questions also cover sales and purchases when

[34] Comments of PPL.

deliveries are made at locations outside California, but the gas may ultimately be destined to be delivered to and consumed in California.[35]

The Commission clarifies that in Question 2 it is only requiring sellers to report information with respect to sales they make when the gas is delivered at points on the California border or within California. When a sales contract requires deliveries at some point outside California, the seller cannot be expected to know in all cases whether the gas is ultimately destined for California. Therefore, the Commission recognizes that sellers making sales in which the deliveries takes place outside California should not be required to report those sales.

Proposed Question 5 [36] is also addressed only to natural gas sellers who make sales with deliveries at points on the California border or within California. However, proposed Question 5 requires those sellers to report certain information concerning their gas *purchase* contracts. Since the gas sellers may have purchased the gas sold in sales subject to Question 2 at delivery points outside California, Question 5 is not limited solely to gas purchase contracts with delivery points at the California border or within California. However, it is limited to the gas purchase contracts in which gas sellers obtained the gas they sold at points on the California border or within California. The Commission is satisfied that, together, the proposed questions as constituted will yield data that will enable the Commission to obtain a full picture of how sales are currently being made in California, and to determine what action, if any, is required.

Commenters also seek clarification on whether the Commission intends sellers not only to report information regarding the sale, but also to report the details of the transactions in which they acquired the gas being sold.[37] Consistent with the above discussion, the Commission will grant the requested clarification. Question 5 is intended to obtain that information.

Question 2

The Commission's proposed Question 2, among other things, requests sellers of natural gas to include in their responses the names of the buyers and whether such entities are energy marketers, local distribution companies, or end users. Several commenters raised a concern about identifying the buyer by name with a suggestion to permit respondents to code buyer identities.[38] They claim that this is the most sensitive information sought by the proposed reporting requirements.

The name of the buyer is necessary because without it the Commission will not be in a position to analyze the data, especially where the same gas may be sold a number of times at the California border. The Commission does recognize the commercial sensitivity of a seller's identification of its purchasers. For this reason, as discussed above, the Commission has found that such information is exempt from public disclosure. Thus the concern of the commenters about confidentiality has been addressed because the information is entitled to protection in accordance with the rule in *Continental Oil.*

The Commission's proposed Question 2, among other things, also requests that sellers of natural gas identify whether the buyer is affiliated with a pipeline. Several commenters assert that sellers do not have access to the buyer's affiliate information and therefore should not be placed in the position of having to research and report the pipeline affiliation or industry ''category''.[39] The Commission agrees, and will grant the requested clarification. Part (e) of proposed Question 2 will be eliminated from the reporting requirements for sellers of natural gas.

El Paso Merchant Energy, LP (Merchant) suggests that the Commission should include collection of data on the financial market as well as the physical market. The Commission believes that, for the purpose that it is instituting the reporting requirement, data is only necessary concerning sales in which actual physical deliveries are made at the California border or within California. Therefore, the Commission will not require information about sales where there are no physical deliveries. However, if Merchant wishes to furnish such information covering its own transactions, the Commission would accept such information.

The Commission is also modifying proposed Questions 2(e) and 5(e) with respect to the price paid so respondents shall answer ''whether the price is fixed or indexed (identify the index).'' This makes these questions similar to Question 4 (e) to LDCs which also asks for price information.

Question 3

Proposed Question 3 requires the seller of natural gas to state the transportation component and the gas component of the sales price, and if these are not specifically indicated in the contract, the seller is to provide a valuation of each component, together with an explanation of how that was determined. Some commenters point out that sales contracts typically provide only for a single, overall delivered price. The seller and purchaser never agree on separate prices for the transportation and commodity components. Commenters therefore argued that this question is flawed, since it would require each seller to make an after-the-fact ''artificial'' and ''subjective'' valuation of each component since there is no established standard for dividing the delivered price into separate components [40] and that parties should not be required to ''force fit'' a delivered price into a transportation and commodity component.[41] Several commenters state that there is the potential for differing responses upon which no meaningful conclusions can be made and that the Commission should clarify how it anticipates the parties to value each component.[42]

If the seller's sales contract does specify the transportation component of the price, then the seller should report the amount so specified. If the sales contract does not specify the transportation component but only includes an overall price, then the seller should report the transportation cost it incurred in moving the gas from the point where it purchased the gas to the point where it delivered the gas to its buyer and how it determined that amount. If the seller delivered the gas at the same point where it purchased the gas, then there is no transportation element in the sale and the seller should respond ''n.a.''

Question 4

The Commission's proposed Question 4 requires that sellers of natural gas provide information concerning their contracts for transportation to the California border, including volumes nominated and volumes scheduled by the pipeline. Several commenters state that they do not maintain nomination

[35] Comments of Pan Alberta Gas, Ltd., et al., and Indicated Shippers.

[36] Proposed seller's Question 5 will be Question 4 in the reporting requirement as adopted because, as discussed below, the Commission is eliminating Proposed Question 4.

[37] See e.g., Comments of Pan-Alberta Gas, Ltd. *et al.*

[38] See e.g., Comments of Sempra Energy Trading Corp.

[39] See e.g., Comments of Indicated Shippers and Natural Gas Supply Association.

[40] *See,* Comments of Dynegy Marketing and Trade.

[41] *See,* Comments of Natural Gas Supply Association.

[42] See e.g., Comments of Indicated Shippers, Reliant Energy Services, Inc. and Sempra Energy Trading Corp.

and scheduled volume information in their records. They believe that this information is more easily obtained from the pipeline.[43]

The Commission has determined to eliminate Question 4 in its entirety from the reporting requirements for sellers of natural gas. The questions to interstate pipelines provide the Commission with the same information, and therefore there is no need for a duplicative question to gas sellers.

Question 5

The Commission's proposed Question 5, among other things, requests that sellers of natural gas identify the pipeline associated with a particular gas purchase contract. Sempra Energy Trading Corp. seeks clarification that the Commission intends respondents to identify the interstate pipeline on which gas is shipped either to the California border or to a delivery point within California. Sempra Energy Trading Corp. states that some purchase contracts may specify a single pipeline on which the sales transaction takes place while other gas purchase contracts may indicate more than one pipeline, i.e., the pipeline upstream of the point of delivery and the pipeline downstream of the point of delivery.

The Commission will grant the requested clarification and will require respondents to identify the pipeline upstream of the point where the gas is delivered to them and the pipeline the respondents use to the take the gas away from the delivery point responding to Question 5(b).

Natural Gas Supply Association requests that the Commission clarify Question 5 to determine whether volumes will be reported on a daily or other basis. The Commission will grant the requested clarification and require respondents to report volumes on a daily basis.

The Commission is also adding to proposed Question 5 a requirement that gas sellers identify the entity from whom they purchase the gas under each gas purchase contract.

3. Questions to California LDCs

In order to ensure that there is no misunderstanding, the Commission intends that intrastate pipelines and Hinshaw pipelines should respond to the reporting requirement either as sellers of natural gas, or as LDCs, depending upon which group they fall under.

Questions 1 and 2

The Commission's proposed LDC Question 1, among other things, requests that LDCs provide information concerning system gas sales and transportation requirements (i.e., contract demand and daily demands) delineated by core, non-core, electric generation and non-utility loads. Question 1 also requests a breakdown of these loads by type of service (*e.g.,* sales or transportation) and quality of service (firm or interruptible). Proposed Question 2 requests LDCs to provide information concerning each contract they have with transportation customers, including contract demand by shipper, daily scheduled and delivered volumes, whether the service is firm or interruptible, the rate charged, and the receipt and delivery points associated with the contract.

Southern California Gas Company and San Diego Gas & Electric Company (Sempra Utilities) states that daily estimated demand can be provided. However, Sempra Utilities contends that concepts such as ''firm'' and ''interruptible'' and ''contract demands'' for sales and transport are inapplicable to the services currently provided by them and therefore that information is not available. If Sempra Utilities use different terms for the types of services identified in the question such as firm and interruptible, then they should report the required information in the terms they use. To the extent customers do not have contract demands, then Sempra Utilities may respond to questions about contract demands by setting forth any contractual terms that limit a customer's usage.[44]

Question 3

The Commission's proposed Question 3 seeks information on a daily basis concerning each contract the LDC has with a sales customer. The requested information includes contract demand, term, volume and price for each sales contract. The Sempra Utilities state that they do not have individual contracts with their approximately 6 million core customers and that they only meter those core customers on a monthly, rather than a daily, basis. Sempra Utilities suggest that even on a monthly basis, information concerning each individual core customer's consumption would not be useful to the Commission. Sempra Utilities assert that the information to be provided in response to Question 1 should be sufficient for the Commission.

Question 1 requests only that the LDC provide its system's gas sales and transportation requirements solely by customer class and does not ask for information concerning volumes sold or prices charged. Question 3, by contrast, requests information relative to sales contracts with individual customers, including volumes sold and prices charged. The Commission recognizes that the Sempra Utilities do not have contracts with, or daily information concerning consumption by their individual core customers. Therefore, Sempra Utilities may provide the information requested by Question 3 for the core customer class as a whole, without breaking the information down by individual core customer. The Sempra Utilities may also respond to the question concerning contract demands as it relates to core customers by stating ''N/A.''

Sempra Utilities have not stated that they do not have contracts with the individual customers in their other customer classes, including non-core, electric generation, and non-utility loads. Nor have they stated they do not meter such customers on a daily basis. Therefore, there appears no reason why Sempra Utilities cannot provide all the information requested by Question 3 with respect to all individual customers other than the core customers.

Question 4

Proposed Question 4 asks LDCs for information concerning each of their gas purchase contracts. Included in the information requested is whether the price in each gas purchase contract is fixed or indexed. Sempra Utilities state that the Commission has not requested other gas sellers to provide such information about their gas purchase contracts, and they assert that LDCs should not be required to provide more information than other gas sellers.

The Commission will adopt this question as proposed. In this order the Commission is modifying the questions to gas sellers to require them to state whether the price in their contracts is indexed. Therefore LDCs are not being treated differently with respect to this question.

Question 5

The Commission's proposed Question 5 seeks daily information identifying, by interstate pipeline, the type and quantity of transportation service each LDC system has under contract. Additionally, Question 5 requests that each LDC provide, at each receipt point, maximum peak day design capacity, the

[43] See e.g., Comments of Indicated Shippers, and Sempra Energy Trading Corp.

[44] The problems incident to the lack of firm service for customers of Sempra Utilities has been evident in a number of Commission proceedings. *See,* e.g., Kern River Gas Transmission Company, 95 FERC ¶ 61,022 at 61,060–61 (2001).

daily maximum flowing capacity, and the daily scheduled volumes of the local distribution system.

The Commission is modifying this question to also require respondents to provide daily nominated capacity at each point.

Question 6

The Commission's proposed Question 6 seeks daily storage information including capacity and deliverability rights, daily storage balances, and injections and withdrawals. Question 6 also seeks this information by each storage facility. The Sempra Utilities state that information is not available by storage field but that it can provide system-wide daily storage balances, injections and withdrawals.

The Commission will grant the requested clarification. Responders can provide the daily storage information on an aggregated basis, without separating the data by storage facility.

Question 7

The Commission's proposed Question 7 requires the California LDCs to provide information on how much of their system's supply was gas supply from intrastate production sources. The question further requires LDCs to identify the source, volume, receipt point and price. The Sempra Utilities state that they can provide the information requested except that they do not have pricing information and therefore cannot provide it.

The question requires information with regard to all gas flowing on the LDCs' system, not only the gas they purchase. The Commission recognizes that the LDCs will not have pricing information for gas that they may transport on behalf of others. However, for gas that the LDCs purchase, they should have pricing information, and that information should be reported. As discussed above, the Commission will treat such pricing information as confidential.

5. Information Collection Statement

The following collection of information has been submitted to the Office of Management and Budget (OMB) for review under § 3507(d) of the Paperwork Reduction Act of 1995, 44 U.S.C. 3507(d) and OMB's emergency processing procedures at 5 CFR 1320.13 (2000). The Commission has requested emergency processing because of the unanticipated events that have occurred in California with respect to natural gas prices that have raised serious concerns.

Estimated Annual Burden:

Data collection	Number of respondents	Number of responses	Hours per response	Total annual hours
FERC–721	89	534	208	19,847

Total Annual Hours for Collection:
(Reporting + Recordkeeping, (if appropriate))= 19,847
Initial Reports: 178 hours Per respondent for data collection = 15,842 hours
30 hours Per respondent for utilizing Information technology = 2,670 hours
Subtotal = 18,512 hours
Subsequent reports: 3 hrs. Per respondent = 1,335 hours
Total = 19,847 hours

Information Collection Costs:

Annualized Capital/Start-up Costs	$300,480.00
Annualized Costs (Operations & Maintenance)	1,933,090.00
Total Annualized Costs	2,233,570.00

Average cost per respondent = $25,096.00.

OMB's regulations [45] require it to approve certain information collection requirements, other than those contained in either proposed rules published for public comment in the **Federal Register**, or in current rules that were published as final rules in the **Federal Register**. The Commission has submitted as noted above, this information collection to OMB under their emergency processing procedures.

Title: FERC–721, Reporting of Natural Gas Sales to California.

Action: Proposed Collection.

OMB Control No: 1902–(to be determined).

Respondents: Business or other for profit.

Frequency of Responses: Monthly.

Necessity of Information: The information is needed in order for the Commission to acquire a better understanding of how the California natural gas market functions in light of the fact that the price of natural gas in the California market has, for substantial periods, been higher than the price in other markets and trading hubs throughout the country, and because gas-fired electric generators in California are used to establish the market clearing price for electric generation pursuant to the bidding system used by the California Independent System Operator. The information provided so far to the Commission has not been adequate to permit that understanding.

Internal Review: The Commission has reviewed the requirements pertaining to FERC–721 and determined the proposed information is necessary because the Commission needs to understand the fluctuations that have occurred in the price of natural gas in California, and its variance from the price markets in the rest of the country. The information to be collected will assist the Commission to determine what percentage of the volumes sold into the California market is domestically produced gas sold by marketers affiliated with pipelines and LDC in sales for resales, which are currently the only sales in California that is the subject of the Commission's jurisdiction. The information proposed to be collected will also give the Commission an accurate picture of the overall gas costs being incurred by all purchasers of natural gas moving into the California market.

The requirements conform to the Commission's plan for efficient information collection, communication, and management within the natural gas industry. The Commission has assured itself, by means of internal review, that there is specific, objective support for the burden estimates associated with the information requirements.

For submitting comments concerning the collection of information, please refer to the Commission's **Federal Register** notice requesting OMB approval under emergency processing procedures. That notice elaborates on where the public should direct comments on the need and practical utility of this information collection, accuracy of the burden estimates, ways to enhance the quality, clarity of the information to be collected, and suggested methods to minimize the respondent's burden.

The Commission Orders

All interstate natural gas pipelines that deliver gas at points on the California border or within California, and sellers of natural gas at points on the California border or within California, and Local Distribution

[45] 5 CFR 1320.10 and 5 CFR 1320.13 (2000).

Companies within California are directed to file under oath the information identified in the appendix to this order for the period August 1, 2001, to January 31, 2002, 30 days after the end of each such month in that period.

By the Commission.

David P. Boergers,

Secretary.

Appendix

Answers to all questions below that require a statement of volumes should set forth the requested volumes on an MMBtu basis.

For Interstate Natural Gas Pipelines:

1. On a daily basis for the period August 1, 2001 to January 31, 2002, please provide the following information for each contract for transportation to the California border:

a. the transaction or contract identification number;
b. the terms and effective date of the contract;
c. contract demand by shipper;
d. the daily scheduled volume by shipper;
e. the daily nominated volume by shipper;
f. the daily delivered volume by shipper;
g. whether the service is firm or interruptible;
h. the rate charged in $$/MMbtu;
i. primary receipt and delivery points associated with the contract; and,
j. whether the shipper is affiliated with the pipeline.

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

2. For the period August 1, 2001 to January 31, 2002, please provide the following information for each capacity release transaction for transportation to the California border:

a. the transaction or contract identification number, or offer number; (This number should tie to contract number reported in Question 1,a., above)
b. the name of the releasing shipper;
c. the name of the acquiring shipper;
d. the contract quantity;
e. the acquiring shipper's contract rate; and,
f. the releasing shipper's contract rate.

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

3. On a daily basis for the period August 1, 2001 to January 31, 2002, please provide the following system information:

a. the maximum peak day design capacity;
b. the daily maximum flowing capacity;
c. the daily scheduled system volume;
d. the daily delivered system volume;
e. the daily scheduled volume at each California delivery point;
f. an explanation of each instance that the daily maximum flowing capacity is below the maximum peak day design capacity; and,
g. an explanation of any daily variance in the maximum flowing capacity.

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

4. On a daily basis for May 1999 and May 2000, please provide the following system information:

a. the maximum peak day design capacity;
b. the daily maximum flowing capacity;
c. the daily scheduled system volume;
d. the daily delivered system volume, and,
e. the daily scheduled volume at each California delivery point.

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

For Sellers of Natural Gas to the California Market:

1. State whether the seller is affiliated with an interstate or intrastate natural gas pipeline company or local distribution company, and, if so, give the name and address the affiliated company.

2. On a daily basis for the period August 1, 2001 to January 31, 2002, please provide the following information for each contract in which you sold natural gas and the gas is physically delivered at points on the California border or in California:

a. the sales contract's identification number;
b. the term of the sales contract (beginning and ending dates);
c. the name of the buyer identifying whether the buyer is an energy marketer, local distribution company, or end user;
d. the volumes sold (on a MMBtu basis);
e. the price paid by buyer, and
f. whether the price is fixed or indexed (identify the index).

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

3. For each sales contract, identify separately the transportation component and the gas commodity component of the price. If the sales contract specifies the transportation component of the price, the seller shall report that amount. If the sales contract only includes an overall price, then the seller shall report the transportation cost it incurred in moving the gas from the point where it purchased the gas to the point where it sold the gas and how it determined that amount. If the sale was made at the same point where the gas was purchased, and there is no transportation element in the sale, the seller shall respond ''n.a.''

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

4. For the period August 1, 2001 to January 31, 2002, please provide the following information on a daily basis for each of your gas purchase contracts associated with the sales contracts you identified in response to Question 2:

a. the purchase contract's identification number;
b. the pipeline upstream of the point of delivery; and the pipeline downstream of the point of delivery;
c. the term of the purchase contract (beginning and ending dates);
d. the daily volumes (on a MMBtu basis) purchased;
e. the price paid;
f. whether the price is fixed or indexed (identify the index),
g. identify the entity from whom the responder purchased the gas; and,
h. identify the point where responder took title to the gas.

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

For Local Distribution Companies In California

1. Provide your system's gas sales and transportation requirements, (i.e, contract demands and daily demands) by core, non-core, electric generation, and non-utility loads. Provide a break down of these demands by type of service (e.g., sales and transportation) and quality of service(firm/interruptible).

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

2. On a daily basis for the period August 1, 2001 to January 31, 2002, please provide the following information for each contract the local distribution company has with a transportation customer:

a. contract demand by shipper;
b. the daily scheduled volume by shipper;
c. the daily delivered volume by shipper;
d. whether the service is firm or interruptible;
e. the rate charged; and,
f. receipt and delivery points associated with the contract.

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

3. On a daily basis for the period August 1, 2001 to January 31, 2002, please provide the following information for each contract the local distribution company has with a sales customer:

a. the contract demand by purchaser;
b. the term of the sales contract (beginning and ending dates);
c. the volumes (on a MMBtu basis) sold; and,
d. the price paid by purchaser.

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

4. On a daily basis for the period August 1, 2001 to January 31, 2002, please provide the following information for each gas purchase contract:

a. the purchase contract's identification number;
b. the term of the purchase contract (beginning and ending dates);

c. the volumes (on a MMBtu basis) bought;
d. the price paid;
e. whether the price is fixed or indexed (identify the index); and,
f. identify the point where (name of local distribution company) took title to the gas.

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

5. On a daily basis for the period August 1, 2001 to January 31, 2002, please provide by interstate pipeline the type and quantity of transportation service your system has under contract. At each receipt point, provide maximum peak day design capacity, the daily maximum flowing capacity, the daily nominated capacity and the daily scheduled volumes of the local distribution system.

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

6. On a daily basis for the period August 1, 2001 to January 31, 2002, please provide on a system-wide basis your storage service rights i.e., capacity and deliverability rights. Additionally, provide daily storage balances, injections and withdrawls.

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

7. On a daily basis for the period August 1, 2001 to January 31, 2002, please provide how much of your system's gas supply was from intrastate production sources. Separately identify the sources, volumes, receipt points, and prices. Include the total system supply in your response.

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

8. Provide a summary of your system's gas purchases in the following categories:

a. daily spot purchases;
b. monthly;
c. short-term (more than 1 month and less than 1 year);
d. medium-term (1–3 years); and,
e. long-term (more than 3 years).

by month for each of the last three years in the following format:

a. price;
b. volume; and,
c. identify, by name, where these purchases were made (producing basin or at the California border).

Along with the hard copy response, please provide a CD–ROM containing the response to this question. Please provide this information in Excel version 97 or 2000 or comma separated value (CSV) format.

BILLING CODE 6717–01–P

DATA TEMPLATE FOR INTERSTATE PIPELINES

QUESTIONS 1 THROUGH 4

Question #1: Interstate Pipelines : Contracts for Transportation to the California Border

General Instructions

- You will need to report four (4) types of records in a single file to answer Question #1. (Each of the 4 questions [not record types] should be answered in a separate file.)
- Provide your response to this question in a file with the following name: "PQ1nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each of the 4 types of records refers to a "category" of data. Each category, except the header information, will have a variable number of records in each filing. Specifically, the categories are: I.) general ("header") information about the transportation contracts filing; II.) information on each transportation contract; III.) information on primary delivery and receipt points used in each contract; and, IV.) daily operational (volume) data.

The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
I. PHT	Header Information	One record for each filing.
II. PCT	Transportation Contracts Information	One record for each transportation contract in this filing.
III. PPT	Contract Point Information	One record per day for each primary delivery or receipt point for each contract.
IV. PDT	Daily Transportation Contract Volumes	One record for each day of the reporting period for each contract.

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier for transportation ("PHT", "PCT", "PPT" or "PDT") in Column [B]
- provide the DUNS number for your pipeline and each shipper on a contract
- provide the point name and GISB Point ID Code (Data Reference Number) for every primary delivery and receipt point (see www.gisb.org) (if the GISB Data Reference Number is not available then report your internal code for the point)
- do not report non-permanent capacity releases in your response to this question. Report capacity releases in Question # 2.

Column Headings for Prescribed Record Formats

I. Header Record for Transportation "PHT" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq #	Record Type PHT	Pipeline DUNS #	Pipeline Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

II. Contract Record "PCT" [one record per contract]

[A] Seq #	[B] Record Type PCT	[C] Pipeline DUNS #	[D] Contract or Transaction ID #	[E] Shipper Name	[F] Shipper DUNS #	[G] Contract Demand (MMBtu/day)	[H] Firm or Interruptible (F or I)	[I] Term Begin Date (mm/dd/yyyy)	[J] Term End Date (mm/dd/yyyy)	[K] Contract Effective Date (mm/dd/yyyy)	[L] Shipper Affiliated w Pipeline (Y/N)

III. Delivery and Receipt Point Record "PPT" [one record per day for each primary delivery or receipt point per contract]

[A] Seq #	[B] Record Type PPT	[C] Pipeline DUNS #	[D] Contract or Transaction ID #	[E] Date (mm/dd/yyyy)	[F] Point Type R - Receipt D - Delivery	[G] Name of Primary Point	[H] Point ID Code (per GISB)

IV. Daily Volume Record "PDT" [one record for each day per contract]

[A] Seq #	[B] Record Type PDT	[C] Pipeline DUNS #	[D] Contract or Transaction ID #	[E] Date (mm/dd/yyyy)	[F] Daily Scheduled Volume (MMBtu)	[G] Daily Delivered Volume (MMBtu)	[H] Daily Nominated Volume (MMBtu)	[I] Rate ($/MMBtu/day)

Example Data:

1	PHT	123456789	XYZ Pipeline	09/15/2001	08/01/2001	John Doe	202-123-4567	O				
2	PCT	123456789	Contract 1	ABC Shipper	987654321	10000	F		07/01/1999	07/01/2010	06/01/1999	N
3	PPT	123456789	Contract 1	08/01/2001	R	Rec Point A	2345					
4	PPT	123456789	Contract 1	08/01/2001	R	Rec Point B	5678					
5	PPT	123456789	Contract 1	08/01/2001	D	Del Pt A	1234					
6	PPT	123456789	Contract 1	08/01/2001	D	Del Pt B	87655					
7	PPT	123456789	Contract 1	08/01/2001	D	Del Pt C	5432					
8	PDT	123456789	Contract 1	08/01/2001	10000	9000	9500	0.25				
9	PPT	123456789	Contract 1	08/02/2001	R	Rec Point D	3261					
10	PPT	123456789	Contract 1	08/02/2001	R	Rec Point B	5678					
11	PPT	123456789	Contract 1	08/02/2001	D	Del Pt A	1234					
12	PPT	123456789	Contract 1	08/02/2001	D	Del Pt Q	5435					
13	PPT	123456789	Contract 1	08/02/2001	D	Del Pt C	5432					
14	PDT	123456789	Contract 1	08/02/2001	10010	9005	9450	0.35				

etc.

Question #2: Interstate Pipelines - Capacity Release Transactions for Transportation to the California Border

General Instructions

- You will need to report two (2) types of records in a single file to answer Question #2. (Each of the 4 questions [not record types] should be answered in a separate file.)
- Provide your response to this question in a file with the following name: "PQ2nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated

- The 2 record types you should use to respond to this question are:

Record Type	Record Description	Frequency of responses
V. PHC	Header Information	One record for each filing.
VI. PDC	Capacity Release Contract Information	One record for each capacity release contract in effect during the reporting period

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier for capacity release information, either "PHC" or "PDC", in Column [B]
- provide the DUNS number for your pipeline and each releasing and acquiring shipper on a contract
- provide the beginning and end dates for each release as well as the award date of the release and the requested rate information

Column Headings for Prescribed Record Formats

V. Header Record for Capacity Release "PHC" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type PHC	Pipeline DUNS #	Pipeline Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

VI. Detail Capacity Release Record "PDC" [one record per release]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]	[J]	[K]	[L]	[M]	[N]	[O]
Seq. #	Record Type PDC	Pipeline DUNS #	Contract or Transaction ID #	Offer #	Releasing Shipper Name	Releasing Shipper DUNS #	Acquiring Shipper Name	Acquiring Shipper DUNS #	Contract Quantity (MMBtu/ day)	Releasing Shipper's Contract Rate ($/ MMBtu/ day)	Acquiring Shipper's Contract Rate ($/ MMBtu/ day)	Term Begin Date (mm/ dd/ yyyy)	Term End Date (mm/ dd/ yyyy)	Award Date (mm/ dd/ yyyy)

Example Data:

1	PHC	123456789	XYZ Pipeline	09/15/2001	08/01/2001	John Smith	202-123-4567	O						
2	PDC	123456789	Contract 1	12345	Releasor 1	987654321	Shipper 1		345678912	10000	0.33	0.25	09/01/2001	09/30/2001	08/29/2001
3	PDC	123456789	Contract 2	5678	Releasor B	234567891	Shipper C		789123456	8000	0.35	0.27	09/01/2001	09/30/2001	08/28/2001
4	PDC	123456789	Contract D	3345	Releasor Z	345678912	Shipper Q		543216789	6000	0.38	0.37	09/01/2001	09/30/2001	08/29/2001

etc.

Question #3: Interstate Pipelines - System Information

General Instructions

- You will need to report four (4) types of records in a single file to answer Question #3. (Each of the 4 questions [not record types] should be answered in a separate file.)
- Provide your response to this question in a file with the following name: "PQ3nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each of the 4 types of records refers to a "category" of data. Each category, except header information, will have a variable number of records for the filing.
  The categories are: VII.) general system information ("header") for the filing; VIII.) daily system information; IX.) daily system information for California delivery points; and, X.) footnote information

The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
VII. PHS	Header Information	One record for each filing.
VIII. PDS	Daily System Information	One record for each day of the reporting period
IX. PPS	Daily Information for CA Delivery Points	One record per day for each CA delivery point
X. PFS	Footnotes	One or more records per footnote.

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier for system information ("PHS", "PDS", "PPS" or "PFS" in Column [B]
- provide the point name and GISB Point ID Code (Data Reference Number) for every delivery point (see www.gisb.org) (if the GISB Data Reference Number is not available then report your internal code for the point)
- Note: Complete the Footnote ID field in Record Type PDS, column [I] when (1) the Daily Maximum Flowing Capacity is below the Maximum Peak Day Design Capacity, or 2) to explain any daily variance in Maximum Flowing Capacity. Use the same Footnote ID code in record type PFS Column [D] and provide a brief explanation in the PFS record, Column [E].

Column Headings for Prescribed Record Formats

VII. Header Record for System Information "PHS" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **PHS**	Pipeline DUNS #	Pipeline Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

VIII. Daily Record for System Information "PDS" [one record per day]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **PDS**	Pipeline DUNS #	Date (mm/dd/yyyy)	Maximum Peak Day Design Capacity (MMBtu)	Daily Maximum Flowing Capacity (MMBtu)	Daily Scheduled System Volume (MMBtu)	Daily Delivered System Volume (MMBtu)	Footnote ID (integer)

IX. Point Record for System Information "PPS" [one record per day per CA delivery pt]

[A]	[B]	[C]	[D]	[E]	[F]	[G]
Seq. #	Record Type **PPS**	Pipeline DUNS #	Date (mm/dd/yyyy)	CA Delivery Point Name	Point ID Code (per GISB)	Daily Scheduled Volume at Point (MMBtu)

X. Footnote Record for System Information "PFS" [allow multiple records per footnote]

[A] Seq. #	[B] Record Type **PFS**	[C] Pipeline DUNS #	[D] Footnote ID Refers to PDS record Column [I] (integer)	[E] Footnote Text (ASCII Text)

Example Data:

1	PHS	123456789	XYZ Pipeline	09/15/2001	08/01/2001	John James	202-123-6789	O	
2	PDS	123456789	08/01/2001	50000	48000	45000	45000		10
3	PDS	123456789	08/02/2001	50000	50000	48000	48000		
4	PDS	123456789	08/03/2001	50000	50000	46000	45000		
etc.									
20	PPS	123456789	08/01/2001	Point A	3456	2000			
21	PPS	123456789	08/02/2001	Point A	3456	1980			
etc.									
30	PPS	123456789	08/01/2001	Point B	7654	3000			
31	PPS	123456789	08/02/2001	Point B	7654	2880			
etc.									
60	PFS	123456789		10	Text for reason why daily max flowing capacity is below max peak day design capacity.				

Question #4: Interstate Pipelines - System Information for May 1999 and May 2000

General Instructions

- Question #4 asks for information similar to Question #3, but only for May 1999 and May 2000.
- You will only need to submit answers to Question #4 once, in your initial filing, and you do not have to continue to send this information in subsequent filings..
- You will need to report three (3) types of records in a single file to answer Question #4. (Each of the 4 questions [not record types] should be answered in a separate file.)
- Provide your response to this question in a file with the following name: "PQ4nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each of the 3 types of records refers to a "category" of data. Each category, except header information, will have a variable number of records for the filing.
  The categories are: XI.) general system information ("header") for the filing for May 1999 and May 2000;
  XII.) daily system information for May 1999 and May 2000; and
  XIII.) daily volume information for CA delivery points in May 1999 and 2000.

The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
XI. PHSM	Header Information	One record for each filing.
XII. PDSM	Daily System Information	One record for each day in May 1999 and May 2000
XIII. PPSM	Daily Information for CA Delivery Points	One record for each day in May 1999 and May 2000 for each California delivery point

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier for system information for May 1999 and May 2000 ("PHSM", "PDSM" or "PPSM") in Column [B] (please note that this format has record type identifiers that are 4 characters long)
- provide the point name and GISB Point ID Code (Data Reference Number) for each CA delivery point (see www.gisb.org) (if the GISB Data Reference Number is not available then report your internal code for the point)

Column Headings for Prescribed Record Formats

XI. Header Record for May 1999 and May 2000 System Information "PHSM" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **PHSM**	Pipeline DUNS #	Pipeline Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

XII. Daily Record for May 1999 and May 2000 System Information "PDSM" [one record per day]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]
Seq. #	Record Type **PDSM**	Pipeline DUNS #	Date (mm/dd/yyyy) where: mm = 05 yyyy = 1999 or 2000	Maximum Peak Day Design Capacity (MMBtu)	Daily Maximum Flowing Capacity (MMBtu)	Daily Scheduled System Volume (MMBtu)	Daily Delivered System Volume (MMBtu)

XIII. Point Record for May 1999 and May 2000 System Information "PPSM" [one record per day and CA delivery point]

[A] Seq. #	[B] Record Type **PPSM**	[C] Pipeline DUNS #	[D] Date (mm/dd/yyyy) where: mm = 05 yyyy = 1999 or 2000	[E] CA Delivery Point Name	[F] Point ID Code (per GISB)	[G] Daily Scheduled Volume at CA Point (MMBtu)	
Example Data:							
1	PHSM	123456789	XYZ Pipeline	09/15/2001	John James	202-123-6789	O
2	PDSM	123456789	05/01/1999	50000	48000	45000	45000
3	PDSM	123456789	05/02/1999	50000	50000	48000	48000
4	PDSM	123456789	05/03/1999	50000	50000	46000	46000
etc.							
22	PDSM	123456789	05/01/2000	50000	48000	45000	44000
23	PDSM	123456789	05/02/2000	50000	50000	48000	48000
24	PDSM	123456789	05/03/2000	50000	50000	46000	45000
etc.							
50	PPSM	123456789	05/01/1999	Point A	3456	2000	
51	PPSM	123456789	05/02/1999	Point A	3456	1980	
etc.							
80	PPSM	123456789	05/01/2000	Point B	7654	3000	
81	PPSM	123456789	05/02/2000	Point B	7654	2880	
etc.							

DATA TEMPLATE FOR SELLERS OF NATURAL GAS

QUESTIONS 1 THROUGH 4

Question #1: Sellers of Natural Gas to the California Market - Affiliation

General Instructions

- You will need to report one (1) record type in a single file to answer Question #1. (Questions #1 and #4 should each be answered in separate files. Questions #2 and #3 should be answered in the same file).
- Provide your response to this question in a file with the following name: "SQ1nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated

- The record type for this question is:

Record Type		Record Description	Frequency of responses
I.	SHA	Header (General Information)	One record for each interstate or intrastate natural gas pipeline or local distribution company with which seller is affiliated. Note: If you are not affiliated with any gas pipeline or local distribution company, then submit a single record and complete columns [A] through [F] (see below), with column [F] = "N"

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide the valid record type identifier "SHA" in Column [B]

Column Headings for Prescribed Record Format

I. Header Record for Affiliation Information "SHA" [one record for each affiliate]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]	[J]
Seq #	Record Type **SHA**	Respondent DUNS #	Respondent Name	Report Date (mm/dd/yyyy)	Affiliated (Y/N)	Affiliates Name	Affiliates Address	Affiliate Type (R - Interstate Pipeline) (A - Intrastate Pipeline) (D - LDC)	Original/Revised Filing Indicator (O, if original R, if revised)
Example Data:									
1	SHA	12345	ABC Corp	09/15/2001	Y	XYZ Pipelin	Mailing Address	R	O
2	SHA	12345	ABC Corp	09/15/2001	Y	ABC Corp	Mailing Address	D	O
etc.									

Questions #2 & #3: Sellers of Natural Gas to the California Market - Sales Contracts

General Instructions

- You will need to report four (4) types of records in a single file to answer Questions #2 and #3. (Answer these two questions together in a single file. Answer the other questions each in a separate file).
- Provide your response to this question in a file with the following name: "SQ23nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to these questions (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each type of record refers to a "category" of data. Each category, except the header information, will have a variable number of records in each filing.
  Specifically, the categories are: II.) general ("header") information about the respondent and the reporting date; III.) information on each contract; IV.) daily volume and price data for each contract; and. V.) explanation of how transportation cost is determined.

- The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
II. SHS	Header Information	One record for each filing.
III. SCS	Sales Contract Information	One record for each contract
IV. SDS	Daily Volume and Price Information on Sales Contract	One record for each day for each contract
V. SFS	Footnote (Explanation)	One record per explanation or footnote

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier ("SHS", "SCS", "SDS" or "SFS") in Column [B]
- provide the DUNS number for your Company and the DUNS number for all buyers, if known
- provide the beginning and end dates for each contract as well as buyer type.
- provide, in the footnote record, an explanation of how you determined the transportation cost incurred, in cases where the sales contract only includes an overall price

Column Headings for Prescribed Record Formats

II. Header Record for Sales Contracts "SHS" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **SHS**	Respondent DUNS #	Respondent Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

III. Sales Contract Record "SCS" [one record per Contract]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **SCS**	Respondent DUNS #	Sales Contract ID #	Contract Begin Date (mm/dd/yyyy)	Contract End Date (mm/dd/yyyy)	Buyer Name	Buyer DUNS #	Buyer Type (M - Marketer) (D - LDC) (E - End user)

IV. Daily Volumes Record for each Sales Contract "SDS" [one record for each Day of a Contract]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]	[J]	[K]	[L]
Seq. #	Record Type **SDS**	Respondent DUNS #	Sales Contract ID #	Date (mm/dd/yyyy)	Volume Sold (MMBtu/ day)	Price Paid by Buyer ($/MMBtu/day)	Transportation Component of Price ($/MMBtu/day)	Gas Commodity Component of Price ($/MMBtu/day)	Fixed or Indexed Price (F - Fixed I - Indexed)	Index Name (if Col [J] = I)	Footnote Id (integer)

V. Footnote Record for Explanation of How Transportation Cost Determined "SFS"
[report multiple records per footnote, as needed]

[A] Seq. #	[B] Record Type **SFS**	[C] Respondent DUNS #	[D] Footnote ID (refers to SDS record, Column [L]) (integer)	[E] Footnote Text

Example Data:

1	SHS	987654321	ABS Seller	09/15/2001	08/01/2001	John Smith	202-123-4567	O				
2	SCS	987654321	12345	05/01/2001	06/30/2005	XYZ Company	878787	M				
3	SDS	987654321	12345	08/01/2001	5000	0.25	0.05		0.20	F		
4	SDS	987654321	12345	08/02/2001	5000	0.25	0.05		0.20	F		
5	SDS	987654321	12345	08/03/2001	5000	0.25	0.05		0.20	F		
etc.												
43	SCS	987654321	55555	05/01/2001	12/29/2004	ABC Company	45555	D				
44	SDS	987654321	55555	08/01/2001	3000	0.41	0.06		0.35	I	Inside FERC monthly Henry Hub	10
45	SDS	987654321	55555	08/02/2001	3000	0.41	0.06		0.35	I	Inside FERC monthly Henry Hub	10
46	SDS	987654321	55555	08/03/2001	3000	0.41	0.06		0.35	I	Inside FERC monthly Henry Hub	10
etc.												
100	SFS	987654321	10	Explanation of how transportation portion of price determined.								
etc.												

Question #4: Sellers of Natural Gas Into the California Market - Gas Purchase Contracts

General Instructions

- You will need to report two (2) record types in a single, separate file to answer Question #4.
- Provide your response to this question in a file with the following name: "SQ4nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each type of record refers to a "category" of data.
  The categories are: VI.) general information "header" for the filing; VII.) gas purchase contract information;
  The gas purchase contract information will have a variable number of records for the filing.

- The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
VI. SHP	Header Information	One record for each filing.
VII. SGP	Gas Purchase Contract Information	One record per day for each gas purchase contract associated with sales contracts identified in your response to Questions #2 and #3

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier ("SHP" or "SGP") in Column [B]
- provide the point id you use to uniquely identify the point where title to the gas was taken
  Note: use the same point id codes in all future filings

Column Headings for Prescribed Record Formats

VI. Header Record for Gas Purchase Contracts "SHP" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type SHP	Respondent DUNS #	Respondent Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

VII. Gas Purchase Contract Information "SGP" [one record per contract per day]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]	[J]	[K]	[L]	[M]	[N]	[O]	[P]
Seq. #	Record Type SGP	Respondent DUNS #	Date (mm/dd/yyyy)	Gas Purchase Contract ID #	Pipeline That Transports Upstream of the Point of Delivery	Pipeline That Transports Downstream of the Point of Delivery	Contract Begin Date (mm/dd/yyyy)	Contract End Date (mm/dd/yyyy)	Daily Volume Purchased (MMBtu/day)	Price Paid ($/MMBtu/day)	Fixed or Indexed Price (F - Fixed I - Indexed)	Index Name (if Col [L] = I)	Name of Entity from Whom Gas Purchased	Name of Point Where Title to Gas Taken	Point Id
Example Data:															
1	SHP	987654321	ABS Seller	09/15/2001	08/01/2001	John Smith	202-123-4567	O							
2	SGP	987654321	08/01/2001	Contract # 1	XYZ Pipeline	QRZ Pipeline	06/01/1999	06/01/2015	10000	0.25	I	Inside FERC monthly Henry Hub	Company A	Point A	4534
3	SGP	987654321	08/02/2001	Contract # 1	XYZ Pipeline	QRZ Pipeline	06/01/1999	06/01/2015	10000	0.25	I	Inside FERC monthly Henry Hub	Company A	Point A	4534
4	SGP	987654321	08/03/2001	Contract # 1	XYZ Pipeline	QRZ Pipeline	06/01/1999	06/01/2015	8900	0.22	I	Inside FERC monthly Henry Hub	Company A	Point C	3323
etc.															
40	SGP	987654321	08/01/2001	Contract # 2	LMN Pipeline	ZZZ Pipeline	04/01/1999	04/01/2010	5000	0.35	F		Company B	Point Z	1123
etc.															

DATA TEMPLATE FOR LDCS

QUESTIONS 1 THROUGH 8

Question #1: Local Distribution Companies (LDC) - System Gas Sales and Transportation Requirements

General Instructions

- You will need to report two (2) types of records in a single file to answer Question #1. (Each of the 8 Questions [not record types] should be answered in a separate file.)
- Provide your response to this question in a file with the following name: "LQ1nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each type of record refers to a "category" of data. Specifically, the categories are: I.) general ("header") information about this filing; and and II.) daily load type, service type and quality of service information

- The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
I. LHS	Header Information	One record for each filing.
II. LDS	Daily Requirements by Load Type, Service Type and Quality of Service	One record for each day/type of service/ type of load/quality of service

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier ("LHS" or "LDS") in Column [B]
- provide your DUNS number

Column Headings for Prescribed Record Formats

I. Header Record for LDC System Gas Sales and Transpo "LHS" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq #	Record Type **LHS**	Respondent DUNS #	Respondent Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

II. Daily Record for LDC System Gas Sales and Transportation Requirements "LDS"
[one record per day/type of service/type of load/quality of service]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq #	Record Type **LDS**	Respondent DUNS #	Date (mm/dd/yyyy)	Type of Service (S - Sales T - Transportation)	Type of Load (CO - Core NC - Non-Core EL - Electric Gen NU - Non-Utility)	Quality of Service (F - Firm I - Interruptible)	Contract Demand (MMBtu /day)	Daily Demand (MMBtu /day)

Example Data:

1	LHS	123456789	ABC LDC		09/15/2001	08/01/2001	John Smith	202-123-4567	O
2	LDS	123456789	08/01/2001	S		CO	F	5000	4500
3	LDS	123456789	08/01/2001	S		NC	I	5500	5000
4	LDS	123456789	08/01/2001	T		EL	F	4000	4000
5	LDS	123456789	08/01/2001	T		NU	F	2000	1800
6	LDS	123456789	08/02/2001	S		CO	F	5000	4800

etc.

Question #2: Local Distribution Companies (LDC) - Transportation Contracts

General Instructions

- You will need to report four (4) types of records in a single file to answer Question #2. (Each of the 8 questions [not record types] should be answered in a separate file.)
- Provide your response to this question in a file with the following name: "LQ2nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each type of record refers to a "category" of data. Each category, except header information, may have a variable number of records for the filing.
  The categories are: III.) general "header" information, IV.) information on each transportation contract; V.) information on receipt and delivery points for a contract; and, VI.) daily volume information for each contract.

- The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
III. LHT	Header Information	One record for each filing.
IV. LCT	Transportation Contract Information	One record for each contract
V. LPT	Delivery and Receipt Point Information	One record per day for each point within a contract
VI. LDT	Daily Records on Volume	One record per day for each contract

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier ("LHT", "LCT", "LPT" or "LDT") in Column [B]
- provide your DUNS number and the DUNS number for each transportation customer
- provide the Point ID Code you use to uniquely identify each primary delivery and receipt point
  Note: be sure to report using the same Point ID codes in all future filings.

Column Headings for Prescribed Record Formats

III. Header Record for Transportation Contracts "LHT" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **LHT**	Respondent DUNS #	Respondent Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

IV. Transportation Contract Information Record "LCT" [one record per contract]

[A]	[B]	[C]	[D]	[E]	[F]
Seq. #	Record Type **LCT**	Respondent DUNS #	Transpo. Contract #	Transpo. Customer Name	Transpo. Customer DUNS #

V. Delivery Point and Receipt Point Information Record "LPT"
[one record per day for each primary point within a contract]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]
Seq. #	Record Type **LPT**	Respondent DUNS #	Transpo. Contract #	Date (mm/dd/yyyy)	Point Type R - Receipt D - Delivery	Point Name	Point ID Code

VI. Daily Volume Information Record "LDT" [one record for each day for each contract]

[A] Seq. #	[B] Record Type **LDT**	[C] Respondent DUNS #	[D] Transpo. Contract #	[E] Date (mm/dd/yyyy)	[F] Daily Scheduled Volume (MMBtu)	[G] Daily Delivered Volume (MMBtu)	[H] Contract Demand (MMBtu/day)	[I] Firm or Interruptible (F or I)	[J] Rate Charged ($/MMBtu/day)
Example Data:									
1	LHT	123456789	ABC LDC	09/15/2001	08/01/2001	John Smith	202-123-4567	O	
2	LCT	123456789	Contract 1	Transpo Customer 1	987654321				
3	LPT	123456789	Contract 1	08/01/2001	R	Point A	2349		
4	LPT	123456789	Contract 1	08/01/2001	D	Point B	1234		
5	LDT	123456789	Contract 1	08/01/2001	10000	10000	11000	F	0.05
6	LPT	123456789	Contract 1	08/02/2001	R	Point A	2349		
7	LPT	123456789	Contract 1	08/02/2001	D	Point B	1234		
8	LDT	123456789	Contract 1	08/02/2001	9998	9995	11000	F	0.05
etc.									
40	LCT	123456789	Contract 2	Transpo Customer 2	567891234				
41	LPT	123456789	Contract 2	08/01/2001	R	Point Z	3322		
42	LPT	123456789	Contract 2	08/01/2001	D	Point Q	4356		
43	LDT	123456789	Contract 2	08/01/2001	5000	5000	5000	F	0.06
etc.									

Question #3: Local Distribution Companies (LDC) - Sales Contracts

General Instructions

- You will need to report three (3) types of records in a single file to answer Question #3. (Each of the 8 Questions [not record types] should be answered in a separate file.)
- Provide your response to this question in a file with the following name: "LQ3nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each type of record refers to a "category" of data. Each category, except header information, may have a variable number of records for the filing.
  The categories are: VII.) general "header" information; VIII.) contract information; IX.) daily volume and price information for each contract.

- The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
VII. LHL	Header Information	One record for each filing
VIII. LCL	Sales Contract Information	One record for each contract
IX. LDL	Daily Volume, Price Information	One record per day for each contract

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier ("LHL", "LCL", or "LDL") in Column [B]
- provide your DUNS number and the DUNS number for each entity who you sold gas to ("the purchaser")
- provide the beginning and end date of each contract

Column Headings for Prescribed Record Formats

VII. Header Record for Sales Contracts "LHL" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **LHL**	Respondent DUNS #	Respondent Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

VIII. Sales Contract Information Record "LCL" [one record for each contract]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]
Seq. #	Record Type **LCL**	Respondent DUNS #	Sales Contract #	Contract Begin Date (mm/dd/yyyy)	Contract End Date (mm/dd/yyyy)	Purchaser Name	Purchaser DUNS #

IX. Daily Volume and Price Record for Sales Contracts "LDL" [one record per day for each contract]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]
Seq. #	Record Type **LDL**	Respondent DUNS #	Sales Contract #	Date (mm/dd/yyyy)	Contract Demand (MMBtu/day)	Volume Sold (MMBtu/day)	Price Paid by Purchaser ($/MMBtu/day)

Example Data:

1	LHL	123456789	ABC LDC	09/15/2001	08/01/2001	Joe James	202-123-5555	O
2	LCL	123456789	Contract A	01/01/1999	01/01/2010	Purchaser A	543219876	
3	LDL	123456789	Contract A	08/01/2001	5000	4990	0.32	
4	LDL	123456789	Contract A	08/02/2001	5000	4850	0.32	

etc.

Question #4: Local Distribution Companies (LDC) - Gas Purchase Contracts

General Instructions

- You will need to report three (3) types of records in a single file to answer Question #4. (Each of the 8 Questions [not record types] should be answered in a separate file.)
- Provide your response to this question in a file with the following name: "LQ4nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each type of record refers to a "category" of data. Each category, except header information, may have a variable number of records for the filing.
  The categories are: X.) general "header" information; XI.) contract information; XII.) daily volume and price information for each contract

- The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
X. LHP	Header Information	One record for each filing
XI. LCP	Gas Purchase Contract Information	One record for each contract
XII. LDP	Daily Records on Volume, Price	One record per day for each contract

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier ("LHP", "LCP", or "LDP") in Column [B]
- provide your DUNS number and the DUNS number for each entity you purchased gas from ("the seller")
- provide the beginning and end date of each contract and the type of pricing (fixed or indexed) used in that contract
- provide the point ID code you use to uniquely identify the point where you took title to the gas
  Note: be sure to report using the same point ID codes in all future filings.

Column Headings for Prescribed Record Formats

X. Header Record for LDC Gas Purchase Contracts "LHP" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **LHP**	Respondent DUNS #	Respondent Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

XI. Gas Purchase Contract Information Record "LCP" [one record for each contract]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]
Seq. #	Record Type **LCP**	Respondent DUNS #	Gas Purchase Contract ID #	Contract Begin Date (mm/dd/yyyy)	Contract End Date (mm/dd/yyyy)	Seller Name	Seller DUNS #

XII. Daily Volume and Price Record for Gas Purchase Contracts "LDP" [one record per day for each contract]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]	[J]	[K]
Seq. #	Record Type **LDP**	Respondent DUNS #	Gas Purchase Contract ID #	Date (mm/dd/yyyy)	Volume Bought (MMBtu/day)	Price Paid ($/MMBtu/day)	Fixed or Indexed Price (F - Fixed I - Indexed)	Index Name (if Col [H] = I)	Point Name Where Title to Gas Taken	Point Id

Example Data:

1	LHP	123456789	ABC LDC	09/15/2001	08/01/2001	Joe James	202-123-5555	O		
2	LCP	123456789	Contract A	01/01/1998	01/01/2015	Seller A	345678912			
3	LDP	123456789	Contract A	08/01/2001	10000	0.12	I	Inside FERC monthly Henry Hub	Point A	12345
4	LDP	123456789	Contract A	08/02/2001	9950	0.12	I	Inside FERC monthly Henry Hub	Point B	3456
etc.										
30	LCP	123456789	Contract B	01/01/1995	01/01/2010	Seller B	112233455			
31	LDP	123456789	Contract B	08/01/2001	5000	0.11	F		Point Q	1123
etc.										

Question #5: Local Distribution Companies (LDC) - Gas Transportation Contracts with Interstate Pipelines

General Instructions

- You will need to report three (3) types of records in a single file to answer Question #5. (Each of the 8 Questions [not record types] should be answered in a separate file.)
- Provide your response to this question in a file with the following name: "LQ5nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each type of record refers to a "category" of data. Each category, except header information, may have a variable number of records for the filing.
  The categories are: XIII.) general "header" information;
  XIV.) contract information; and, XV.) daily volume and receipt point information for each contract.

- The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
XIII. LHI	Header Information	One record for each filing.
XIV. LCI	Gas Transportation Contract Information	One record for each contract
XV. LPI	Daily Records on Contract Volumes, Points	One record for each day and receipt point within a contract

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier ("LHI", "LCI", or "LPI") in Column [B]
- provide your DUNS number and the DUNS number for each pipeline which transported gas for you
- provide the point ID Code you use to uniquely identify each receipt point
  Note: be sure to report using the same point ID codes in all future filings.

Column Headings for Prescribed Record Formats

XIII. Header Record for Gas Transportation Contracts "LHI" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **LHI**	Respondent DUNS #	Respondent Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

XIV. Gas Transportation Contract Information Record "LCI" [one record for each contract]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]	[J]
Seq. #	Record Type **LCI**	Respondent DUNS #	Transportation Contract #	Contract Begin Date (mm/dd/yyyy)	Contract End Date (mm/dd/yyyy)	Interstate Pipeline Name	Interstate Pipeline DUNS #	Contract Demand (MMBtu /day)	Firm or Interruptible (F or I)

XV. Daily Volume and Point Record for Gas Transportation Contracts "LPI" [one record for each day and receipt point within a contract]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]	[J]	[K]
Seq. #	Record Type **LPI**	Respondent DUNS #	Transportation Contract #	Date (mm/dd/yyyy)	Receipt Point Name	Receipt Point ID Code	Max Peak Day Design Capacity (MMBtu)	Daily Max Flowing Capacity (MMBtu/ day)	Daily Scheduled Volume (MMBtu/ day)	Daily Nominated Capacity (MMBtu/ day)

Example Data:

1	LHI	123456789	ABC LDC	09/15/2001	08/01/2001	Bill Smith	202-123-5432	O		
2	LCI	123456789	Contract XYZ	01/01/1995	01/01/2005	ABC Pipeline	456789123	2800	F	
3	LPI	123456789	Contract XYZ	08/01/2001	Receipt Pt A	33456	3000	2580	2600	2600
4	LPI	123456789	Contract XYZ	08/01/2001	Receipt Pt B	23234	2500	2400	2400	2400
5	LPI	123456789	Contract XYZ	08/02/2001	Receipt Pt A	33456	3000	2590	2600	2600
6	LPI	123456789	Contract XYZ	08/02/2001	Receipt Pt B	23234	2500	2400	2400	2400
etc.										
50	LCI	123456789	Contract QRS	01/01/1996	01/01/2005	123 Pipeline	234567891	2000	F	
51	LPI	123456789	Contract QRS	08/01/2001	Receipt Pt R	11221	2000	1950	1940	1940
etc.										

Question #6: Local Distribution Companies (LDC) - Storage Service Rights

General Instructions

You will need to report two (2) types of records in a single file to answer Question #6. (Each of the 8 Questions [not record types] should be answered in a separate file.)

Provide your response to this question in a file with the following name: "LQ6nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date

Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.

- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format

If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated

- Each type of record refers to a "category" of data.

The categories are: XVI.) general "header" information; and
XVII.) daily information on system-wide gas storage service rights and injections, withdrawals, and storage balances

- The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
XVI. LHG	Header Information	One record for each filing.
XVII. LDG	System-Wide Gas Storage Service Rights, and Daily Injections, Withdrawals and Storage Balances	One record for each day

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier ("LHG" or "LDG") in Column [B]
- provide your DUNS number

Column Headings for Prescribed Record Formats

XVI. Header Record for Gas Transportation Contracts "LHG" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type LHG	Respondent DUNS #	Respondent Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

XVII. System-Wide Gas Storage Service Rights and Daily Injections, Withdrawals and Storage Balances "LDG" [one record for each day]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type LDG	Respondent DUNS #	Date (mm/dd/yyyy)	System-Wide Storage Capacity Rights (MMBtu)	System-Wide Storage Deliverability Rights (MMBtu)	Daily Storage Injections (MMBtu)	Daily Storage Withdrawals (MMBtu)	Daily Storage Balance (MMBtu)

Example Data:

1	LHG	123456789	ABC LDC	09/15/2001	08/01/2001	John Ames	202-123-1123	O
2	LDG	123456789	08/01/2001	300000	100000	100		200000
3	LDG	123456789	08/02/2001	300000	100000	105		200105

Question #7: Local Distribution Companies (LDC) - System Gas Supply from Intrastate Production Sources

General Instructions

- You will need to report three (3) types of records in a single file to answer Question #7. (Each of the 8 questions [not record types] should be answered in a separate file.)
- Provide your response to this question in a file with the following name: "LQ7nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each type of record refers to a "category" of data. Each category, except header information, may have a variable number of records for the filing.
  The categories are: XVIII.) general "header" information,
  XIX.) daily information on volumes and prices by contract and intrastate supply source, and
  XX.) information on receipt points for a contract

- The corresponding record types for these categories are:

Record Type		Record Description	Frequency of responses
XVIII.	LHA	Header Information	One record for each filing
XIX.	LDA	Daily Intrastate Gas Supply Contract Information by Source	One record for each Day/Contract/Source
XX.	LPA	Receipt Point Information for Intrastate Supply Contracts	One record per day for each receipt point within a contract

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier ("LHA", "LDA", or "LPA") in Column [B]
- provide your DUNS number
- provide the point ID code you use to uniquely identify each receipt point
  Note: be sure to report using the same point ID codes in all future filings.

Column Headings for Prescribed Record Formats

XVIII. Header Record for Intrastate Gas Supply "LHA" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **LHA**	Respondent DUNS #	Respondent Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

XIX. Daily Intrastate Gas Supply Contract Information by Source "LDA" [one record per day/contract/source]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **LDA**	Respondent DUNS #	Gas Supply Contract #	Date (mm/dd/yyyy)	Intrastate Supply Source	Daily Supply Volume from Intrastate Source (MMBtu)	Price for Supply from Intrastate Source ($/MMBtu/day)	Daily Total System Supply (MMBtu)

XX. Receipt Point Information for Intrastate Supply Contracts "LPA"
[one record per day for each receipt point for a contract]

[A]	[B]	[C]	[D]	[E]	[F]	[G]
Seq. #	Record Type **LPA**	Respondent DUNS #	Gas Supply Contract #	Date (mm/dd/yyyy)	Receipt Point Name	Receipt Point ID

Example Data:

1	LHA	123456789	ABC LDC	09/15/2001	08/01/2001	John Smith	202-123-4567	O
2	LDA	123456789	Contract 1	08/01/2001	Supply Source 1	3000	0.21	100000
3	LPA	123456789	Contract 1	08/01/2001	Receipt Pt A	12321		
3	LDA	123456789	Contract 1	08/02/2001	Supply Source 1	3290	0.21	100000
4	LPA	123456789	Contract 1	08/02/2001	Receipt Pt B	33321		
4	LDA	123456789	Contract 1	08/03/2001	Supply Source 1	3295	0.25	105000

etc.

Question #8: Local Distribution Companies (LDC) - System Gas Purchases Summary

General Instructions

- You will need to report two (2) types of records in a single file to answer Question #8. (Each of the 8 Questions [not record types] should be answered in a separate file.)
- Provide your response to this question in a file with the following name: "LQ8nnnnnnmmddyy.xls", where nnnnnn is the first 6 characters of the name of the responding company, and mmddyy is the reporting date
- Submit the files containing responses to all the questions on a compact disc (CD) according to the electronic filing formats prescribed herein. Enclose the CD in a disc protector with a label affixed to the protector stating the respondent's name and the names of the files on the CD.
- File your response to this question (see Example Data below) in either Excel (version 97 or 2000) format or comma-separated-value (CSV) format
- If you need to submit a revised filing, you must restate the original file with all additions, deletions, revisions, and corrections incorporated
- Each type of record refers to a "category" of data.
  The categories are: XXI.) general "header" information;
  XXII.) summary of system gas purchases by category and location.

- The corresponding record types for these categories are:

Record Type	Record Description	Frequency of responses
XXI. LHU	Header Information	One record for each filing.
XXII. LMU	Purchases by Category and Location	One record for each purchase category / location for the reporting month

Specific Instructions

- provide a unique and sequential number for each record in Column [A] in your response to this question.
- provide a valid record type identifier ("LHU" or "LMU") in Column [B]
- provide your DUNS number
- use these abbreviations for the "Purchase Categories" requested below:
  - SP Daily Spot Purchases
  - MO Monthly
  - ST Short-Term (more than 1 month and less than 1 year)
  - MT Medium-Term (1-3 years)
  - LT Long-Term (more than 3 years)
- **in your first filing, report information for each month for the last 3 years, including the current month**
- **in subsequent filings, report information only for the current month**

Column Headings for Prescribed Record Formats

XXI. Header Record for System gas Purchases Summary "LHU" [one record per filing]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]
Seq. #	Record Type **LHU**	Respondent DUNS #	Respondent Name	Filing Date (mm/dd/yyyy)	First Day of Reporting Period (mm/dd/yyyy)	Name of Contact Person	Phone Number of Contact Person	Original/Revised Filing Indicator (O, if original R, if revised)

XXII. System Gas Purchases by Category and Location for the Month "LMU"
[one record per month for each Category/Location]

[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]
Seq. #	Record Type **LMU**	Respondent DUNS #	Month/ Year (mm/yyyy)	Purchase Category (SP - daily spot MO - monthly ST - short term MT - med. term LT - long term)	Volume-Weighted Price Paid ($/MMBtu /day)	Volume Purchased (MMBtu)	Location where purchases were made (Producing Basin Name, or at CA Border)

Example Data:

1 LHU	123456789	ABC LDC		09/15/2001	08/01/2001	Joe Adams	202-123-7654	O
2 LMU	123456789	09/1998	SP		0.11	10000	CA Border	
3 LMU	123456789	09/1998	MO		0.09	5000	San Juan	
4 LMU	123456789	09/1998	MO		0.12	4000	CA Border	
5 LMU	123456789	10/1998	SP		0.12	8000	San Juan	
6 LMU	123456789	10/1998	MO		0.14	6000	CA Border	
etc.								
105 LMU	123456789	08/2001	SP		0.21	10000	CA Border	
106 LMU	123456789	08/2001	MO		0.14	5000	San Juan	
etc.								

BILLING CODE 6717–01–C

Attachment

Commenters

AEC Storage and HUB Services
American Public Gas Association
California Electricity Oversight Board
The Canadian Association of Petroleum Producers and the Alberta Department of Energy
Duke Energy
Dynergy Marketing and Trade
Electric Power Supply Association
El Paso Merchant Energy, L.P.
Enron North America Corp. and Enron Energy Services, Inc.
Independent Petroleum Association of America
Indicated Shippers-Aera Energy, LLC, Amoco Production Company, Burlinton Resources Oil & Gas Company LP, Conoco Inc., Coral Energy Resources LLC, Marathon Oil, Texaco Natural Gas Inc.
National Association of Gas Consumers
The Natural Gas Supply Association
Nevada Attorney General's Bureau of Consumer Protection
Occidental Energy Marketing
Pacific Gas and Electric Company
Pan-Alberta Gas LTD., Pan-Alberta Gas (U.S.) Inc., Mirant Americas Energy Marketing Canada, LTD., and Mirant Americas Energy Marketing, LP.
PG&E Nation Al Energy Group Companies
PPL Energyplus, LLC
Process Gas Consumers Group, the American Iron and Steel Institute, the Georgia Industrial Group, American Forest and Paper Association and United States Gypsum Company
The Public Utilities Commission of the State of California
Northwest Industrial Gas Users
Reliant Energy Services, Inc.
Sempra Energy Trading Corp.
Southern California Gas Company and San Diego Gas & Electric Company
Tractabel Power, Inc. and Tractabel Energy Marketing, Inc.
TXU Energy Trading Company
Undersigned Producers-Exxon Mobil Corporation, Conoco Inc., and Chevron U.S.A. Inc
The Williams Companies, Inc.

[FR Doc. 01–19267 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RM98–1–000]

Regulations Governing Off-the-Record Communications; Public Notice

July 27, 2001.

This constitutes notice, in accordance with 18 CFR 385.2201(h), of the receipt of exempt and prohibited off-the-record communications.

Order No. 607 (64 FR 51222, September 22, 1999) requires Commission decisional employees, who make or receive an exempt or a prohibited off-the-record communication relevant to the merits of a contested on-the-record proceeding, to deliver a copy of the communication, if written, or a summary of the substance of any oral communication, to the Secretary.

Prohibited communications will be included in a public, non-decisional file associated with, but not part of, the decisional record of the proceeding. Unless the Commission determines that the prohibited communication and any responses thereto should become part of the decisional record, the prohibited off-the-record communication will not be considered by the Commission in reaching its decision. Parties to a proceeding may seek the opportunity to respond to any facts or contentions made in a prohibited off-the-record communication, and may request that the Commission place the prohibited communication and responses thereto in the decisional record. The Commission will grant such requests only when it determines that fairness so requires. Any person identified below as having made a prohibited off-the-record communication should serve the document on all parties listed on the official service list for the applicable proceeding in accordance with Rule 2010, 18 CFR 385.2010.

Exempt off-the-record communications will be included in the decisional record of the proceeding, unless the communication was with a cooperating agency as described by 40 CFR 1501.6, made under 18 CFR 385.2201(e)(1)(v).

The following is a list of exempt and prohibited off-the-record communications received in the Office of the Secretary within the preceding 14 days. The documents may be viewed on the Internet at http://www.ferc.fed.us/online/rims.htm (call 202–208–2222 for assistance).

Exempt

1. Project No. 2415–041—07–26–01—Allyson Brooks
2. Project No. 2042–013—07–26–01—Tim Welch
3. Project No. 1962–000—07–24–01—Charles Hall

David P. Boergers,

Secretary.

[FR Doc. 01–19279 Filed 8–1–01; 8:45 am]

BILLING CODE 6717–01–P

ENVIRONMENTAL PROTECTION AGENCY

[FRL–7021–8]

Meeting of the National Drinking Water Advisory Council; Notice of Public Meeting

AGENCY: Environmental Protection Agency.

ACTION: Notice.

SUMMARY: Under section 10(a)(2) of Public Law 92–423, ''The Federal Advisory Committee Act,'' notice is hereby given that a meeting of the National Drinking Water Advisory Council established under the Safe Drinking Water Act, as amended (42 U.S.C.S300f *et seq.*), will be held on August 22, 2001 from 1:00 p.m. until 5:00 p.m. and August 30, 2001 from 1:00 p.m. until 5:00 p.m. (Eastern Standard Time), at Resolve 1255 23rd St. NW.,

(Suite 275), Washington, DC. Some members of the Council will be participating by conference call. The meeting is open to the public, but due to past experience, seating will be limited.

The purpose of the meeting is for the Council to deliberate on the recommendations from the Arsenic Cost Working Group. The Arsenic Cost Working Group, comprised of nationally recognized technical experts, will have completed their review of the cost of compliance estimates associated with the January 22, 2001 Arsenic Rule. The Council will also provide its recommendations on the Arsenic Cost Review to the Agency. Oral statements from the public will be taken if time permits. Written statements from the public will also be accepted.

DATES: The meetings will be held on August 22 and 30, 2001 in Washington, DC

SUPPLEMENTARY INFORMATION: Following the January 22, 2001 **Federal Register** promulgation of the arsenic rule, a number of concerns were raised to EPA by States, public water systems, and other stakeholders regarding the adequacy of science and the basis for national cost estimates underlying the rule. Because of the importance of the arsenic rule and the national debate surrounding it related to science and costs, EPA's Administrator publicly announced on March 20, 2001, that the Agency would take additional steps to reassess the scientific and cost issues associated with this rule and seek further public input on each of these important issues.

The Council encourages the hearing of outside statements and will allocate, if time permits, a portion of the meeting for this purpose. Any outside parties interested in presenting an oral statement should petition the Council by telephone at (202) 260–9194, before August 20, 2001. Requests made after this date will not be accepted. Oral statements will be limited to five minutes per speaker and no more than 30 minutes total.

Any person who wishes to file a written statement can do so before or after a Council meeting. Written statements received prior to the meeting will be distributed to all members of the Council before any final discussion or vote is completed. Any statements received after the meeting will become part of the permanent meeting file and will be forwarded to the Council members for their information.

Members of the public that would like to attend the meeting, present an oral statement, or submit a written statement, should contact Ms. Janet Pawlukiewicz, Designated Federal Officer, National Drinking Water Advisory Council, U.S. EPA, Office of Ground Water and Drinking Water (4601), 1200 Pennsylvania Avenue, NW., Washington, DC 20460. The telephone number is (202) 260–9194 or E-Mail *pawlukiewicz.janet@epa.gov*

Dated: July 26, 2001.

Cynthia C. Dougherty,

Director, Office of Ground Water and Drinking Water.

[FR Doc. 01–19324 Filed 8–1–01; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

[FRL–7020–8]

Clean Water Act (CWA) 303(d): Proposed Addition of Six Waters to the State of New Jersey's 1998 Section 303(d) List

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: EPA today notices its intent to disapprove the State of New Jersey's omission of six waters on its 1998 Clean Water Act Section 303(d). EPA is proposing to add the following six waters to New Jersey's 1998 Section 303(d) list: Ackerman's Creek, Berry's Creek, Birch Swamp Creek, Capoolony Creek, Edmund's Creek, and the Singac River. EPA solicits public comment on the addition of the above six waterbodies to New Jersey's Clean Water Act Section 303(d) list.

DATES: Comments on the proposed action must be submitted to EPA on or before August 17, 2001.

ADDRESSES: Copies of the relevant supporting documents may be obtained by writing to Ms. Rosella O'Connor, U.S. Environmental Protection Agency Region 2, 290 Broadway, 24th Floor, New York, New York 10006–1866, oconnor.rosella@epamail.epa.gov, or by calling (212) 637–3823.

The administrative record containing background technical information is on file and may be inspected at the U.S. EPA, Region 2 office between the hours of 8 a.m. and 5:30 p.m., Monday through Friday, except holidays. Arrangements to examine the administrative record may be made by contacting Ms. Rosella O'Connor.

FOR FURTHER INFORMATION CONTACT: Ms. Rosella O'Connor, telephone number (212) 637–3823.

SUPPLEMENTARY INFORMATION:

I. Background

II. Proposed Action

I. Background

Section 303(d) of the Clean Water Act (CWA) and EPA's implementing regulations at 40 CFR 130.7, require states and territories to: develop lists of water-quality limited waters still requiring Total Maximum Daily Loads (TMDLs); establish a priority ranking of these waters; identify pollutants causing their impairment; and identify waters targeted for TMDL development over the next two (2) years. TMDLs include a determination of pollutant loadings compatible with achievement of applicable state water quality standards. State 303(d) lists and TMDLs are submitted to the EPA for approval or disapproval.

Under 40 CFR 130.7(b)(1), water quality-limited segments are not required to be listed on a State's Section 303(d) list where: effluent limitations required by the CWA; more stringent effluent limitations required by State or local authority; or, other pollution control requirements required by State, local or federal authority, are stringent enough to implement applicable water quality standards. Waters may be removed from the 303(d) list if any of the listed control actions result in meeting water quality standards by the next listing cycle. If water quality standards are not expected to be achieved by the next listing cycle, through implementation of other required controls, it is appropriate for waters to remain on the 303(d) list to ensure that implementation of the required controls and progress towards compliance with applicable water quality standards occur.

On September 15, 1998, the State of New Jersey (''New Jersey'') submitted its 1998 CWA Section 303(d) list to EPA for review and approval. On October 8, 1998, EPA approved New Jersey's CWA Section 303(d) list. This list included approximately 1,048 water-quality limited segments. This list was challenged in a lawsuit commenced in the Federal District Court for the District of New Jersey, entitled *American Littoral Society and New Jersey Public Interest Research Group* v. *United States Environmental Protection Agency, et al.* [Civil Action No. 96–339 (MLC)]. In a preliminary decision and order issued in this case in December 2000, the Court directed EPA to provide for the inclusion on New Jersey's 303(d) list the five following waters: Ackerman's Creek; Berry's Creek; Birch Swamp Brook; Capoolony Creek; and Edmund's Creek. These five waters should have

been included on New Jersey's list due to impairment by toxic pollutants, but were inadvertently omitted. Subsequently, during the course of the litigation, EPA determined that a sixth water, the Singac River had also been inadvertently omitted from New Jersey's 303(d) list. More specifically, while the Lower Passaic River, reach number 02030103–012–125/ at Singac, is listed in the State's 1998 303(d) list at page A 9 for fecal coliform and phosphorus, the Singac River, reach number 02030103, is not listed for whole effluent toxicity, despite the fact that New Jersey had previously determined it that was impaired due to violations of whole effluent toxicity requirements.

In preparing its 1998 CWA Section 303(d) list, New Jersey relied upon several sources of information, including the EPA approved CWA Section 304(l) lists. Under CWA Section 304(l), states were required to submit to EPA several lists, including, pursuant to Section 304(l)(A)(i)—a list of water bodies the state does not expect to achieve State water quality standards due to discharges of toxic pollutants from point or nonpoint sources (the ''mini list''). In 1993, EPA approved New Jersey's CWA Section 304(l) lists. A notice announcing EPA's final approval of New Jersey's 304(l) lists, including New Jersey's mini list, was published in the **Federal Register** on November 2, 1993 (58 FR 58548).

The six waters that EPA is proposing to add originate from New Jersey's CWA Section 304(l) mini list. With the exception of these six waters, the remaining waters listed under the CWA Section 304(l) mini list were included in New Jersey's 1998 CWA Section 303(d) list.

Five of the six waters: Ackerman's Creek, Berry's Creek, Birch Swamp Brook, Capoolony Creek, and Edmund's Creek were found to be potentially impaired due to contamination from adjacent hazardous waste sites listed under the National Priority List. The Singac River was identified by New Jersey as requiring additional water-quality based controls for whole effluent toxicity.

II. Proposed Action

EPA is proposing to disapprove New Jersey's omission of six waters from its 1998 CWA Section 303(d) list. EPA is proposing to add the six waters (shown in Table 1) to New Jersey's 1998 Section 303(d) list. Consistent with EPA's regulations, 40 CFR part 130.7(b)(4), the pollutants potentially causing impairments of the listed waters are identified in Table 1. The toxic pollutants identified for the listed waters (with the exception of the Singac River) are based on data collected at the adjacent hazardous waste sites. For the Singac River, specific toxic pollutants have yet to be identified.

TABLE 1.—LIST OF SIX WATERS PROPOSED FOR ADDITION TO NEW JERSEYS 1998 CWA SECTION 303(D) LIST

Waterbody	Reach No.	Pollutant(s)
Ackerman's Creek	02030103	Chromium, mercury, PCBs, chlorinated benzenes.
Berry's Creek	02030103034	mercury, other metals.
Birch Swamp Creek	02030104	arsenic, lead, copper, zinc, PCBs.
Capoolony Creek	02030105	DDT.
Edmund's Creek	02030105	PCBs.
Singac River	02030103	Whole Effluent Toxicity.

CWA Section 303(d)(1) and EPA's regulations at 40 CFR 130.7(b)(4) require States to prioritize waters on their Section 303(d) lists for TMDL development. EPA is proposing that a ranking of low priority be assigned to the six waters. A low priority is appropriate because of the control actions that are currently underway for the five waterbodies (Ackerman's Creek, Berry's Creek, Birch Swamp Brook, Capoolony Creek, Edmund's Creek) that have been listed due to potential contamination from adjacent hazardous waste sites. These waters should be restored upon implementation of the remediation plans for the sites impacting the waters. EPA believes that any TMDL that is developed for these waters will rely on the remediation plans, required under 40 CFR § 300.430 for the hazardous waste sites. EPA expects that New Jersey will track the progress of remediation plans for the relevant hazardous sites and the water quality of the above five waters. In the case of the Singac River, the original listing under CWA Section 304(l) was not specific and there is some uncertainty as to the specific toxic pollutants and the degree of impairment. EPA recommends that New Jersey review and evaluate existing and readily available data and information regarding the presence of toxic pollutants in the Singac River to determine the specific toxic pollutants and degree of impairment.

EPA is soliciting public comment on the proposed addition and priority ranking of Ackerman's Creek, Berry's Creek, Birch Swamp Creek, Capoolony Creek, Edmund's Creek, and the Singac River to New Jersey's 1998 CWA Section 303(d) list.

Dated: July 20, 2001.

George Pavlou,

Acting Regional Administrator.

[FR Doc. 01–19322 Filed 8–1–01; 8:45 am]

BILLING CODE 6560–50–P

FEDERAL DEPOSIT INSURANCE CORPORATION

Sunshine Act Meeting

Pursuant to the provisions of the ''Government in the Sunshine Act'' (5 U.S.C. 552b), notice is hereby given that at 3:00 p.m. on Monday, July 30, 2001, the Board of Directors of the Federal Deposit Insurance Corporation met in closed session to consider matters relating to the Corporation's resolution activities.

In calling the meeting, the Board determined, on motion of Director Ellen S. Seidman (Director, Office of Thrift Supervision), seconded by Director John D. Hawke, Jr. (Comptroller of the Currency), concurred in by Acting Chairman John M. Reich, that Corporation business required its consideration of the matters on less than seven days' notice to the public; that no earlier notice of the meeting was practicable; that the public interest did not require consideration of the matters in a meeting open to public observation; and that the matters could be considered in a closed meeting by authority of subsections (c)(6), (c)(8), (c)(9)(A)(ii), and (c)(9)(B) of the ''Government in the Sunshine Act'' (5 U.S.C. 552b(c)(6), (c)(8), (c)(9)(A)(ii), and (c)(9)(B)).

The meeting was held in the Board Room of the FDIC Building located at 550–17th Street, NW., Washington, DC.

Dated: July 31, 2001.

Federal Deposit Insurance Corporation.

Valerie J. Best,

Assistant Executive Secretary.

[FR Doc. 01–19426 Filed 7–31–01; 11:11 am]

BILLING CODE 6714–01–M

FEDERAL ELECTION COMMISSION

Sunshine Act Meeting

AGENCY: Federal Election Commission.

DATE & TIME: *Tuesday, August 7, 2001 at 10:00 a.m.*

PLACE: 999 E Street, NW., Washington, DC.

STATUS: This meeting will be closed to the public.

ITEMS TO BE DISCUSSED:

Compliance matters pursuant to 2 U.S.C. § 437g.

Audits conducted pursuant to 2 U.S.C. § 437g, § 438(b), and Title 26, U.S.C.

Matters concerning participation in civil actions or proceedings or arbitration.

Internal personnel rules and procedures or matters affecting the particular employee.

PREVIOUSLY ANNOUNCED DATE & TIME:

Thursday, August 9, 2001. Meeting Open to the Public.

This meeting has been cancelled.

PERSON TO CONTACT FOR INFORMATION:

Mr. Ron Harris, Press Officer, Telephone: (202) 694–1220.

Mary W. Dove,

Secretary of the Commission.

[FR Doc. 01–19508 Filed 7–31–01; 2:55 pm]

BILLING CODE 6715–01–M

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 27, 2001.

A. Federal Reserve Bank of Chicago (Phillip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690–1414:

1. River Valley Bancorp., Inc., Eldridge, Iowa; to acquire 80.95 percent of the voting shares of Southeast Security Bank, Mediapolis, Iowa.

B. Federal Reserve Bank of Kansas(Susan Zubradt, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198–0001:

1. FlatIrons Bank Holding Company, Loveland, Colorado; to become a bank holding company by acquiring 100 percent of the voting shares of FlatIrons Bank (In Organization), Boulder, Colorado.

Board of Governors of the Federal Reserve System, July 27, 2001.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 01–19229 Filed 8–1–01; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL TRADE COMMISSION

Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

Trans No.	Acquiring	Acquired	Entities
Transactions Granted Early Termination—6/11/2001			
20011913	TPG Partners II, L.P	Advanced Telcom Group, Inc	Advanced Telcom Group, Inc.
20011914	Solectron Corporation	Singapore Shinei Sangyo Pte Ltd	Singapore Shinei Sangyo Pte Ltd.
20011917	Network Peripherals Inc	FalconStor, Inc	FalconStor, Inc.
20011918	ReiJane Huai	Network Peripherals Inc	Network Peripherals Inc.
20011935	Robert R. Bennett	AT&T Corp	Liberty Media Corporation
20011938	Argonaut Group, Inc	Front Royal, Inc	Front Royal, Inc.
20011945	New World Coffee—Manhattan Bagel, Inc.	Einstein/Noah Bagel Corp	Einstein/Noah Bagel Corp.
20011947	Tembec Inc	Crown Vantage, Inc	Crown Paper Company
20011953	Omnicom Group Inc	Agency.COM Ltd	Agency.COM Ltd.
Transactions Granted Early Termination—06/14/2001			
20011950	ABB Ltd	Entrelec Group	Entrelec Group

Trans No.	Acquiring	Acquired	Entities
Transactions Granted Early Termination—06/15/2001			
20011971	DIC Entertainment Holdings, Inc	Golden Books Family Entertainment, Inc., debtor-in-possession.	Golden Books Home Video, Inc., LRM Acquisition Corp. Golden Books Publishing Company, Inc. Shari Lewis Enterprises, Inc., SLE Productions, Inc.
Transactions Granted Early Termination—06/18/2001			
20011898	UPMC Health System	Northwest Health System, Inc	Northwest Health System, Inc.
20011920	J.M. Huber Corporation	Noviant Oy	Noviant Oy
20011921	The News Corporation Limited	Mr. Haim Saban	MTM Enterprises, Inc.
20011922	The News Corporation Limited	The News Corporation Limited	MTM Enterprises, Inc.
20011937	El Paso Corporation	Limestone Electron Trust	Cedar Brakes II LLC
20011939	Limestone Electron Trust	El Paso Corporation	Manschief Power Company LLC.
20011942	Bruce Nelson	Service Stations Partners, LP	Avanti Holdings, Inc.
20011946	First Union Corporation	Wachovia Corporation	Wachovia Corporation
20011948	Vitesse Semiconductor Corporation	Versatile Optical Networks, Inc	Versatile Optical Networks, Inc.
20011949	CorrFlex Graphics, LLC	Chesapeake Corporation	Chesapeake Display and Packaging Company.
20011956	Berkshire Hathaway Inc	Rexam PLC	MiTek, Inc.
20011960	Yellow Pages Investments L.P	British Telecommunications plc	Yellow Book USA, Inc.
20011961	Cypress Semiconductor Corporation	Lara Networks, Inc	Lara Networks, Inc.
20011973	Conseco, Inc	vereniging AEGON	Transamerica Bank N.A. Transamerica Retail Financial Services Corporation
20011976	Alan Cohen	Boca Resorts, Inc	Florida Panthers Hockey Club, Ltd.
20011977	United Business Media plc	Douglas F. Allison	Allison-Fisher International, Inc.
20011981	Goodrich Corporation	Goodrich Corporation	Garlock Bearings LLC
20011985	UAL Corporation	MyPoints.com, Inc	MyPoints.com, Inc.
20011987	Wolseley plc	M. Francois Pinault	Westbunne Supply Inc.
Transactions Granted Early Termination—06/19/2001			
20011941	Building Materials Holding Corporation	Lawrence W. & Beverly A. Knipp	KBI Distribution, LLC Knipp Brothers Industries, LLC
20011984	The Innovation Group, plc	Halifax Capital Partners, L.P	MTW Corporation
Transactions Granted Early Termination—06/20/2001			
20011375	Excellus, Inc	Univera Healthcare Foundation	Univera Healthcare Foundation
20011885	MSC.Software Corporation	Advanced Enterprise Solutions, Inc	Advanced Enterprise Solutions, Inc.
Transactions Granted Early Termination—06/22/2001			
20011910	DoveBid, Inc	FastParts, Inc	FastParts, Inc.
20012023	The AES Corporation	Thermo Electron Corporation	Ecotek NewSub Corporation Wooldand Biomass Power Ltd.

FOR FURTHER INFORMATION CONTACT: Sandra M. Peay or Parcellena P. Fielding Contact Representatives Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, D.C. 20580, (202) 326–3100.

Donald S. Clark,

Secretary.

[FR Doc. 01–19340 Filed 8–1–01; 8:45 am]

BILLING CODE 6750–01–M

FEDERAL TRADE COMMISSION

Granting of Request for Early Termination of the Waiting Period under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

Trans No.	Acquiring	Acquired	Entities
TRANSACTIONS GRANTED EARLY TERMINATION—06/25/2001			
20011821	Apollo Investment Fund IV, L.P.	1992 Durwood, Inc. Voting Trust	AMC Entertainment, Inc.
20011975	W.C. Bradley Co.	Brunswick Corporation	Zebco Corporation.
20011996	Legg Mason, Inc.	Private Capital Management. L.P.	Private Capital Management, L.P.
20011998	Brafin S.a.p.a	Acist Medical Systems	Acist Medical Systems.
20012004	EdperPartners Limited	Enterprise Reinsurance Holdings Corporation.	Enterprise Reinsurance Holdings Corporation.
20012011	Grupo Grifols, S.A.	SeraCare, Inc.	SeraCare, Inc.
TRANSACTIONS GRANTED EARLY TERMINATION—06/26/2001			
20011958	Credence Systems Corporation	Integrated Measurement Systems, Inc.	Integrated Measurement Systems, Inc.
20011983	N.V. Bekaert S.A.	Material Sciences Corporation	Innovative Specialty Films LLC. MSC Specialty Films, Inc.
TRANSACTIONS GRANTED EARLY TERMINATION—06/27/2001			
20011933	Suez	Brambles Industries Limited	Ensco Caribe, Inc. Ensco West, Inc. Ensco, Inc. Environmental Systems Company. MSE Environmental, Inc.
20011952	Dennis M. Langley	Utilicorp United, Inc.	UtiliCorp Pipeline Systems, Inc.
20011955	Inhale Therapeutic Systems, Inc.	Shearwater Corporation	Shearwater Corporation.
20011957	NextMedia Investors LLC	PNE Media Holdings, LLC	Chesapeake Outdoor Enterprises, Inc. Crickett, Ltd. PNE Media, LLC.
20011980	Fiserv, Inc.	EPSIIA Corporation	EPSIIA Corporation.
20011988	Allianz Aktiengesellschaft	Dresdner Bank AG	Dresdner Bank AG.
20011991	Gary C. Wendt	Conseco, Inc.	Conseco, Inc.
20011994	Aventis S.A.	E.ON AG	ASTA Medica AG.
20011997	Deere & Company	Richton International Corporation	Richton International Corporation.
20012007	TMP Worldwide Inc.	Decision Point Data, Inc. d/b/a Unicru, Inc..	Decision Point Data, Inc. d/b/a Unicru, Inc.
TRANSACTIONS GRANTED EARLY TERMINATION—06/28/2001			
20011911	Technitrol, Inc.	Frederick J. & Jessica H. Kiko	Excelsus Technology.
20011915	TriQuint Semiconductor, Inc.	Sawtek Inc.	Sawtek Inc.
20011932	Rhodia	Brambles Industries Limited	Ensco Caribe, Inc. Ensco West, Inc. Ensco, Inc. Environmental Systems Company. MSE Environmental, Inc.
20012006	Affiliated Computer Services, Inc.	Systems & Computer Technology Corporation.	Omni-Tech Systems, Ltd. SGT Government Systems, Inc. SCT Property Inc.
20012008	Klaus-Michael Kuehne	USCO Contract Logistics, LLC	USCO Contract Logistics, LLC.
20012009	Klaus-Michael Kuehne	USCO Districution Services, Inc.	USCO Distribution Services, Inc.
20012018	McGraw-Hill Companies, Inc. (The)	PricewaterhouseCoopers CVC Division	PricewaterhouseCoopers CVC Division.
20012019	SCOR U.S. Corporation	Caisse Centrale des Assurances Muteuelles Agricoles.	SOREMA N.A. Holding Corporation.
20012029	Qwest Communications International Inc.	Enron Corp.	JTS Co.
TRANSACTIONS GRANTED EARLY TERMINATION—06/29/2001			
20011643	Electronic Data Systems Corporation	Sabre Holdings Corporation	Sabre Inc.
TRANSACTIONS GRANTED EARLY TERMINATION—07/02/2001			
20011776	Northrop Grumman Corporation	Gencorp Inc.	Aerojet-General Corporation.
20011974	SPX Corporation	Kendro Holdings, L.P.	Kendro Laboratory Products, L.P., Kendro Corporation.
20011999	Tyco International Ltd.	Home Products International, Inc.	Home Products International-North America, Inc.
20012013	Brian L. Roberts	The News Corporation, Limited	Outdoor Life Network, LLC.
20012030	Albemarle Corporation	Chemfirst Inc.	ChemFirst Fine Chemicals, Inc. First Chemical Corporation.
20012032	MCC Acquisition Holdings Corporation	CPI Development Corporation	Carter-Wallace, Inc. CPI Development Corporation.
20012035	Cypress Merchant Banking Partners II L.P..	MCC Acquisition Holdings Corporation	MCC Acquisition Holdings Corporation.

Trans No.	Acquiring	Acquired	Entities
20012036	Carlyle Partners III, L.P.	MCC Acquisition Holdings corporation	MCC Acquisition Holdings Corporation.
20012037	Warburg, Pincus Equity Partners, L.P.	Micro Therapeutics, Inc	Micro Therapeutics, Inc.
20012043	Cheung Kong (Holdings) Limited	priceline.com. Incorporated	priceline.com. Incorporated.
20012044	Hutchison Whampoa Limited	priceline.com Incorporated	priceline.com Incorporated.
20012054	Warburg, Pincus Equity Partners, L.P.	The Cobalt Group, Inc.	The Cobalt Group, Inc.
20012058	The St. Paul Companies	Barra, Inc.	Symphony asset Management LLC.
20012059	The St. Paul Companies, Inc.	Maestro, LLC	Symphony asset Management LLC.
20012065	Craig O. McCaw	Nextel Communications, Inc.	Nextel Communications, Inc.
TRANSACTIONS GRANTED EARLY TERMINATION—07/03/2001			
20011944	Universal Compression Holdings, Inc.	KCI, Inc.	KCI Compression Company, LP.
20012047	Verizon Communications Inc.	Carolina PCS I Limited Partnership	Carolina PCS I Limited Partnership.
20012052	Federated Department Stores, Inc.	Liberty House, Inc.	Liberty House, Inc.
20012063	The Goldman Sachs Group, Inc.	Epoch Partners, Inc.	Epoch Partners, Inc.
TRANSACTIONS GRANTED EARLY TERMINATION—07/05/2001			
20012033	Church & Dwight Co., Inc.	CPI Development Corporation	Carter-Wallace, Inc.
TRANSACTIONS GRANTED EARLY TERMINATION—07/06/2001			
20012051	AdvancePCS	Dresing-Lieman, Inc.	Dresing-Lieman, Inc.

FOR FURTHER INFORMATION CONTACT: Sandra M. Peay or Parcellena P. Fielding, Contact Representatives, Federal Trade Commission, Premerger Notification Office Bureau of Competition, room 303, Washington, DC, 20580 (202) 326–3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 01–19341 Filed 8–1–01; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Committee on Vital and Health Statistics: Meeting

Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services announces the following advisory committee meeting.

Name: National Committee on Vital and Health Statistics (NCVHS), Subcommittee on Privacy and Confidentiality.

Time and Date:

1:00 p.m.–5:30 p.m. August 21, 2001
8:30 a.m.–5:30 p.m. August 22, 2001
8:30 a.m.–12:00 p.m. August 23, 2001

Place: Hubert H. Humphrey Building, Room 705A, 200 Independence Avenue SW., Washington, DC 20201.

Status: Open.

Background: The National Committee on Vital and Health Statistics is the statutory advisory body to the Secretary of Health and Human Services in the area of health data, statistics, and health information policy. It is established by section 306(k) of the Public Health Service Act (42 U.S.C. 242k(k)), and its mandate includes advising the Secretary on the implementation of the Administrative Simplification provisions of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), Pub. L. No. 104–191).

Its Subcommittee on Privacy and Confidentiality monitors major developments in health information privacy and confidentiality on behalf of the full Committee and makes recommendations to the full Committee and assists the Department on implementation of the health information privacy provisions of HIPAA.

Purpose: This meeting of the Subcommittee on Privacy and Confidentiality will be conducted as a hearing to receive information from the public on the implementation of the regulation ''Standards for Privacy of Individually Identifiable Health Information'' (45 CFR parts 160 and 164), promulgated under the Health Insurance Portability and Accountability Act of 1996.

The regulation and further information about it can be found on the web site of the Office for Civil Rights, at *http://www.hhs.gov/ocr/hipaa/*. The regulation has been in effect since April 14, 2001. Most entities covered by the regulation must come into compliance by April 14, 2003, and many are beginning the process of implementing it.

At this hearing those who provide health care, those who pay for it (such as health plans), and those who use health information (such as the research and public health communities) and members of the public will have an opportunity to address specific issues pertaining to the implementation of the regulation.

The hearing will seek information about practical issues in implementation of the regulation, and suggestions about possible solutions for such issues. The Subcommittee particularly seeks detailed information about the following four issues: (1) The regulation's requirements for consent in order to use information for treatment, payment, and health care operations, (2) the regulation's requirements that those covered by it must make reasonable efforts to limit use and disclosure of, and requests for, protected health information to the minimum necessary to accomplish the intended purpose of the use, disclosure, or request; (3) the effects of the regulation on research (both research in which treatment is given and records-based research), and (4) the regulation's provisions for use and disclosure of health information for marketing.

The format will include one or more invited panels on each of the issues and time for questions and discussion. The Subcommittee particularly seeks focused, detailed analyses and description, with examples, of the effect the regulation is expected to have, based on early implementation efforts and preliminary assessments of impact.

In addition to the panels that will be invited to address these issues, members of the public who would like to make a brief (3 minutes or less) oral comment on one or more of the specified issues during the hearing will be placed on the agenda as time permits. To be included on the agenda, please contact Marietta Rawlinson (301) 458–4524, by e-mail at mrawlinson@cdc.gov, or postal address at NCHS, Presidential Building, Room 1100, 6525 Belcrest Road, Hyattsville, Maryland 20782 by August 7, 2001. Persons wishing to submit written testimony only (no more than 4–5 double-spaced typewritten pages) should endeavor to submit it by that date. Unfilled slots for oral testimony will also be filled on-site as time permits. Please consult Ms. Rawlinson for further information about these arrangements. Additional information about the hearing will be provided on the NCVHS website at *http://www.ncvhs.hhs.gov* shortly before the hearing date.

Contact Person For More Information: Substantive program information may be obtained from Gail Horlick, M.S.W., J.D., Lead Staff Person for the NCVHS Subcommittee on Privacy and Confidentiality, Office of Research and Demonstrations, Program Analyst, National Immunization Program, Centers for Disease Control and Prevention, 1600 Clifton Road,

NE, Mailstop E–62, Atlanta, Georgia 30333, telephone (404) 639–8345; or Marjorie S. Greenberg, Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone (301) 458–4245.

Information about the committee, including summaries of past meetings and a roster of committee members, is available on the Committee's website at *http://www.ncvhs.hhs.gov.*

Dated: July 23, 2001.

James Scanlon,

Director, Division of Data Policy, Office of the Assistant Secretary for Planning and Evaluation.

[FR Doc. 01–19238 Filed 8–1–01; 8:45 am]

BILLING CODE 4151–05–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary; Office of Intergovernmental Affairs, Office of Public Health and Science

Statements of Organization, Functions and Delegations of Authority

Part A, (Office of the Secretary), of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, Chapter AA ''Office of the Secretary'' as last amended at 60 FR 52403, dated October 6, 1995; Chapter ABC ''Office of the Deputy Under Secretary for Intergovernmental Affairs'' as last amended at 61 FR 24311–12, dated May 14, 1996; and Chapter AC ''Office of Public Health and Science'' as last amended at 65 FR 37137, dated June 13, 2000 are being amended to reflect the transfer of the Regional Health Administrators (ADA 1–X) from the Office of the Deputy Under Secretary for Intergovernmental Affairs (ABC) to the Office of Public Health and Science. The changes are as follows:

I. Under Chapter ABC, ''Office of the Deputy Under Secretary for Intergovernmental Affairs,'' make the following changes:

A. Under Paragraph AD.10 Organization, revise as follows:

AD.10 Organization. The Office of the Regional Director is under the direction and control of the Regional Director, who reports directly to the Secretary and Deputy Secretary through the Director for Intergovernmental Affairs, and consists of the Regional Director (AD 1–X).

B. Under Paragraph AD.20 Function, make the following changes:

1. Delete the last sentence under paragraph A.

2. Delete paragraph B. The Regional Health Administrator (ADA (1–X) in its entirety.

II. Under Chapter AC, ''Office of Public Health and Science,'' make the following changes:

A. Under Paragraph AC.10 Organization, insert the following paragraph, after paragraph L.

M. Office of the Regional Health Administrator (ACD 1–X).

B. Under Paragraph 20. Functions, insert the following paragraph after paragraph (12):

(13) provides oversight and directions to the Regional Health Administrators (1–X).

C. Under Paragraph 20. Functions, insert the following after Paragraph 20, subparagraph L:

M. Regional Health Administrator (ACD1–X)—Reports to the Assistant Secretary for Health. Receives professional guidance from the ASH. Participates in policy development and implementation; directs and coordinates regionally based programs of OPHS, including the offices of Emergency Preparedness, Minority Health, Women's Health and Population Affairs. Develops regional goals and objectives consistent with the needs of the region and in conformity with the national health priorities and objectives and Departmental plans and programs. Serves as the principal official in the assigned area of jurisdiction to provide oversight and coordination for Public Health Service programs. Sustains regular communication with State public health, substance abuse, and mental health agencies as well as other professional and community-based organizations to assist the Assistant Secretary for Health, and PHS Operating Divisions in the formulation, development, analysis and evaluation of PHS OPDIV field programs and cross cutting Departmental initiatives in public health. Develops plans for emergency preparedness and response and directs all Departmental health related activities necessary to ensure continuity of essential functions within the Region in case of an emergency due to enemy action or natural disaster.

Dated: July 20, 2001.

Dennis P. Williams,

Acting Assistant Secretary for Management and Budget.

[FR Doc. 01–19237 Filed 8–1–01; 8:45 am]

BILLING CODE 4150–28–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case:

Raghoottama S. Pandurangi, Ph.D., University of Missouri—Columbia (UMo): Based on the report of an investigation conducted by UMo and additional analysis conducted by ORI in its oversight review, the U.S. Public Health Service (PHS) found that Dr. Pandurangi, a former Research Assistant Professor at UMo, engaged in scientific misconduct by plagiarizing and falsifying research data taken from a journal article published by other scientists for use in supplementary materials of a research grant application submitted to the National Institutes of Health (NIH).

Specifically, PHS finds that Dr. Pandurangi plagiarized the images of data in Figures 2A and 2B and related text in supplemental material he submitted in connection with National Heart, Lung, and Blood Institute (NHLBI), NIH, grant application 1 R01 HL62517–01A2, Myocardial Viability by AII Receptor-99mTc Conjugates,'' in which he was the principal investigator. Specifically, Figures 2A and 2B and related text were plagiarized from Figures 7C and 7D of the following journal publication: Gibson, R., Beauchamp, H., Fioravanti, C., Brenner, N., and Burns, H.D. ''Receptor Binding Radiotracers for the Angiotensin II Receptor: Radioiodinated [Sar^1, Ile^8]Angiotensin II,'' Nuclear Medicine and Biology 21:593–600, 1994.

In addition, Dr. Pandurangi falsified the text in the supplement to his NIH grant application by claiming that Figures 2A and 2B represented a compound he had developed. Namely, he claimed that Figure 2A represented radioionated compound ^{123}I–2C and Figure 2B represented radioionated compound ^{123}I–2C with nonradioactive compound 2C added as a competitor. However, Figures 2A and 2B were plagiarized from the figures in the above Nuclear Medicine and Biology article, which in reality represented radiolabeled [Sar^1, Ile^8]Angiotensin II, with compound L–158–809 as a blocker/competitor.

Dr. Pandurangi has entered into a Voluntary Exclusion Agreement (Agreement) with PHS in which he has voluntarily agreed:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g.,

grants and cooperative agreements) of the United States Government as defined in 45 CFR Part 76 (Debarment Regulations) for a period of one (1) year, beginning on July 17, 2001;

(2) that for an additional period of three (3) years following the one-year period of exclusion set forth above, any institution that submits an application for PHS support for a research project on which Dr. Pandurangi's participation is proposed or which uses him in any capacity on PHS supported research, or which submits a report of PHS supported research in which Dr. Pandurangi is involved, must concurrently submit to PHS and ORI (a) a plan for supervision of his duties during the particular PHS supported project at issue, which must be designed to ensure the scientific integrity of his research contribution; and (b) a certification that the data provided by Dr. Pandurangi are based on actual experiments or are otherwise legitimately derived, and that the data, procedures, and methodology are accurately reported in the application or research project; and

(3) to exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of four (4) years, beginning on July 17, 2001.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight Office of Research Integrity 5515 Security Lane, Suite 700 Rockville, MD 20852 (301) 443–5330.

Chris B. Pascal,

Director, Office of Research Integrity.

[FR Doc. 01–19307 Filed 8–1–01; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS–1196–N]

RIN 0938–ZA18

Medicare Program: Notice of Practicing Physicians Advisory Council Rechartering and Request for Nominations

AGENCY: Centers for Medicare & Medicaid Services, HHS.

ACTION: Notice.

SUMMARY: In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C. App. 2), this notice announces that the Practicing Physicians Advisory Council (the Council) has been rechartered for a 2-year period, through June 12, 2003. This notice also invites all organizations representing physicians to submit nominees for membership on the Council. There are currently three vacancies on the Council.

EFFECTIVE DATE: Nominations will be considered if we receive them at the appropriate address, provided below, no later than 5 p.m., E.S.T., on August 13, 2001.

ADDRESSES: Mail or deliver nominations to the following address: Centers for Medicare & Medicaid Services, Center for Medicare Management, Office of Professional Relations, Attention: Paul Rudolf, MD, JD, Executive Director, Practicing Physicians Advisory Council, Room 435H, Hubert H. Humphrey Building, 200 Independence Avenue, SW, Washington, DC 20201

FOR FURTHER INFORMATION CONTACT: Paul Rudolf, MD, JD, Executive Director, Practicing Physicians Advisory Council, (202) 690–7418.

SUPPLEMENTARY INFORMATION: Section 4112 of the Omnibus Budget Reconciliation Act of 1990 (Public Law 101–508) added a new section 1868 to the Social Security Act (the Act), which established the Practicing Physicians Advisory Council (the Council). The Council advises the Secretary of the Department of Health and Human Services (the Secretary) on proposed regulations and manual issuances related to physicians' services. An advisory committee created by the Congress, such as this one, is subject to the provisions of the Federal Advisory Committee Act (5 U.S.C. App. 2).

Section 1868(a) of the Act requires that the Council consist of 15 physicians, each of whom must have submitted at least 250 claims for physicians' services under Medicare in the previous year. At least 11 Council members must be physicians as defined in section 1861(r)(1) of the Act; that is, State-licensed physicians of medicine or osteopathy. The other four Council members may include dentists, podiatrists, optometrists, and chiropractors.

The Council must include both participating and nonparticipating physicians, as well as physicians practicing in rural and underserved urban areas. In addition, section 1868(a) of the Act provides that nominations to the Secretary for Council membership must be made by medical organizations representing physicians.

This notice is an invitation to all organizations representing physicians to submit nominees for membership on the Council. Current members whose terms expired on February 28, 2001 will be considered for reappointment, if renominated, subject to the Department's administrative guidelines for advisory committee management. Candidates nominated in December 2000 are still being considered for the vacant Council seats. With the changes in Administration and the government-wide freeze on new appointments it has been necessary to extend and reopen the nomination process to identify additional candidates for seats on the Council. Therefore, the Centers for Medicare & Medicaid Services will be accepting additional nominees to the Council if they are received by the close of business August 13, 2001. The Secretary will appoint new members to the Council from among those candidates determined to have the expertise required to meet specific agency needs and in a manner to ensure appropriate balance of membership.

Each nomination must state that the nominee has expressed a willingness to serve as a Council member and must be accompanied by a short resume or description of the nominee's experience. To permit an evaluation of possible sources of conflict of interest, potential candidates will be asked to provide detailed information concerning financial holdings, consultant positions, research grants, and contracts.

Section 1868(b) of the Act provides that the Council meet once each calendar quarter, as requested by the Secretary, to discuss proposed changes in regulations and manual issuances that relate to physicians' services. Council members are expected to participate in all meetings. Section 1868(c) of the Act provides for payment of expenses and a per diem allowance for Council members at a rate equal to payment provided members of other advisory committees. In addition to making these payments, the Department of Health and Human Services provides management and support services to the Council.

Authority: (Section 1868 of the Social Security Act (42 U.S.C. 1395ee) and section 10(a) of Public Law 92–463 (5 U.S.C. App. 2 section 10(a)).

Dated: July 30, 2001.

Thomas A. Scully,

Administrator, Centers for Medicare & Medicaid Services.

[FR Doc. 01–19328 Filed 8–1–01; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Center for Mental Health Services; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of a Telephone Conference Call meeting of the Center for Mental Health Services (CMHS) National Advisory Council in August 2001. The meeting will include the review, discussion and evaluation of individual grant applications. Therefore the meeting will be closed to the public as determined by the Administrator, SAMHSA,in accordance with Title 5 U.S.C. 552b(c)(6) and 5 U.S.C. App. 2, Section 10(d). Substantive program information, a summary of the meeting and a roster of Council members may be obtained from the contact listed below.

Committee Name: Center for Mental Health Services National Advisory Council.

Meeting Date: August 7, 2001 (Closed).

Time: 11:00 a.m.–12:30 p.m.

Place(s): Parklawn Building 5600 Fishers Lane, Conference Room 17–94 Rockville, Maryland 20857.

Contact: Eileen S. Pensinger, M.Ed. 5600 Fishers Lane, Parklawn Building Room 17C–27, Rockville, Maryland 20857 Telephone: (301) 443–4823.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Dated: July 27, 2001.

Toian Vaughn,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 01–19308 Filed 8–1–01; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Center for Substance Abuse Prevention; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of a closed meeting of the Center for Substance Abuse Prevention (CSAP) National Advisory Council in August 2001.

The agenda of the meeting will include the review, discussion, and evaluation of individual grant applications. Therefore this meeting will be closed to the public as determined by the Administrator, SAMHSA, in accordance with Title 5 U.S.C. 552b(c)(6) and 5 U.S.C. App. 2, Section 10(d). If anyone needs special accommodations for persons with disabilities, please notify the contact listed below.

A roster of committee members may be obtained from Yuth Nimit, Ph.D., Executive Secretary, Rockwall II building, Suite 901, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 443–8455. Substantive program information may be obtained from the contact person listed below.

Committee Name: Center for Substance Abuse Prevention National Advisory Council.

Meeting Date: Monday, August 6, 2001.

Place: 5515 Security Lane, Rockwall II Building, Suite 1075 Rockville, Maryland 20857 Telephone: (301) 443–8455.

Closed: August 6, 2001, 2:00—3:00 p.m.

Contact: Yuth Nimit, Ph.D. 5515 Security Lane, Rockwall II Building, Suite 901 Rockville, Maryland 20852 Telephone: (301) 443–8455

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Dated: July 27, 2001.

Toian Vaughn,

Executive Secretary/Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 01–19309 Filed 8–1–01; 8:45 am]

BILLING CODE 4160–20–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4650–N–53]

Notice of Submission of Proposed Information Collection to OMB Housing Discrimination Information

AGENCY: Office of the Chief Information Officer, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: *Comments Due Date:* September 4, 2001.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval number (2529–0011) and should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT: Wayne Eddins, Reports Management Officer, Q, Department of Housing and Urban Development, 451 Seventh Street, Southwest, Washington, DC, 20410; e-mail *Wayne_Eddins@HUD.gov;* telephone (202) 708–2374. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Mr. Eddins.

SUPPLEMENTARY INFORMATION: The Department has submitted the proposal for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. Chapter 35). The Notice lists the following information: (1) The title of the information collection proposal; (2) the office of the agency to collect the information; (3) the OMB approval number, if applicable; (4) the description of the need for the information and its proposed use; (5) the agency form number, if applicable; (6) what members of the public will be affected by the proposal; (7) how frequently information submissions will be required; (8) an estimate of the total number of hours needed to prepare the information submission including number of respondents, frequency of response, and hours of response; (9) whether the proposal is new, an extension, reinstatement, or revision of an information collection requirement; and (10) the name and telephone number of an agency official familiar with the proposal and of the OMB Desk Officer for the Department.

This Notice also lists the following information:

Title of Proposal: Housing Discrimination Information.

OMB Approval Number: 2529–0011.

Form Numbers: HUD–903, (English); HUD–903A (Spanish), 903.1.

Description of the Need for the Information and its Proposed Use: This collection of information is necessary when a housing discrimination complaint is filed under the Fair Housing Act (the Act). The information is needed to contact the person(s) who files a complaint, and for making initial assessments regarding HUD's jurisdiction under the Act.

Respondents: Individuals or households, Business or other for-profit, Not-for-profit institutions, Farms, State, Local or Tribal Government.

Frequency of Submission: On Occasion.

Reporting Burden:

	Number of respondents	×	Frequency of response	×	Hours per response	=	Burden hours
Reporting Burden	10,750		1		.66		7,148

Total Estimated Burden Hours: 7,148.

Status: Extension of a currently approved collection.

Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended.

Dated: July 25, 2001.

Wayne Eddins,

Departmental Reports Management Officer, Office of the Chief Information Officer.

[FR Doc. 01–19222 Filed 8–1–01; 8:45 am]

BILLING CODE 4210–72–M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4650––N–52]

Notice of Submission of Proposed Information Collection to OMB; Periodical Estimate for Partial Payment and Related Schedules

AGENCY: Office of the Chief Information Officer, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: *Comments Due Date:* September 4, 2001.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval number (2577–0025) and should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT: Wayne Eddins, Reports Management Officer, Q, Department of Housing and Urban Development, 451 Seventh Street, Southwest, Washington, DC 20410; e-mail Wayne_Eddins@HUD.gov; telephone (202) 708–2374. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Mr. Eddins.

SUPPLEMENTARY INFORMATION: The Department has submitted the proposal for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. Chapter 35). The Notice lists the following information: (1) The title of the information collection proposal; (2) the office of the agency to collect the information; (3) the OMB approval number, if applicable; (4) the description of the need for the information and its proposed use; (5) the agency form number, if applicable; (6) what members of the public will be affected by the proposal; (7) how frequently information submissions will be required; (8) an estimate of the total number of hours needed to prepare the information submission including number of respondents, frequency of response, and hours of response; (9) whether the proposal is new, an extension, reinstatement, or revision of an information collection requirement; and (10) the name and telephone number of an agency official familiar with the proposal and of the OMB Desk Officer for the Department.

This Notice Also Lists the Following Information

Title of Proposal: Periodical Estimate for Partial Payment and Related Schedules.

OMB Approval Number: 2577–0025.

Form Numbers: HUD–51001, HUD–51002, HUD–51003, and HUD–51004.

Description of the Need for the Information and Its Proposed Use: Housing Agencies are responsible for contract administration to ensure that the work for project development is done in accordance with State laws and HUD requirements. Contract/subcontractor reports provide details, and summaries of payments, change orders, and schedule of materials stored for the project.

Respondents: Not-for-profit institutions, State or Local or Tribal Government.

Frequency of Submission: Recordkeeping.

	Number of respondents	×	Frequency of response	×	Hours per response	=	Burden hours
Reporting Burden	145		70		1.98		20,155

Total Estimated Burden Hours: 20,155.

Status: Extension of a currently approved collections.

Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended.

Dated: July 26, 2001.

Wayne Eddins,

Departmental Reports Management Officer, Office of the Chief Information Officer.

[FR Doc. 01–19227 Filed 8–1–01; 8:45 am]

BILLING CODE 4210–72–M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4650–N–54]

Notice of Submission of Proposed Information Collection to OMB HUD Urban Scholars Fellowship Program

AGENCY: Office of the Chief Information Officer, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: *Comments Due Date:* September 4, 2001.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval number (2528–0214) and should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT: Wayne Eddins, Reports Management Officer, Q, Department of Housing and

Urban Development, 451 Seventh Street, Southwest, Washington, DC 20410; e-mail Wayne_Eddins@HUD.gov; telephone (202) 708–2374. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Mr. Eddins.

SUPPLEMENTARY INFORMATION: The Department has submitted the proposal for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. chapter 35). The Notice lists the following information: (1) The title of the information collection proposal; (2) the office of the agency to collect the information; (3) the OMB approval number, if applicable; (4) the description of the need for the information and its proposed use; (5) the agency form number, if applicable; (6) what members of the public will be affected by the proposal; (7) how frequently information submissions will be required; (8) an estimate of the total number of hours needed to prepare the information submission including number of respondents, frequency of response, and hours of response; (9) whether the proposal is new, an extension, reinstatement, or revision of an information collection requirement; and (10) the name and telephone number of an agency official familiar with the proposal and of the OMB Desk Officer for the Department.

This Notice Also Lists the Following Information

Title of Proposal: HUD Urban Scholars Fellowship Program.

OMB Approval Number: 2528–0214.

Form Numbers: HUD–424.

Description of the Need for the Information and its Proposed Use: HUD provides fellowships of up to $55,000 to Ph.D's to conduct research on HUD-related topics. Fellows are selected through competitive application. Mid-term progress reports are required.

Respondents: Individuals or households.

Frequency of Submission: On Occasion.

	Number of respondents	x	Frequency of response	x	Hours per response	=	Burden hours
Reporting Burden	100		1.2		27.6		3,320

Total Estimated Burden Hours: 3,320.

Status: Extension of a currently approved collection.

Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended.

Dated: July 27, 2001.

Wayne Eddins,

Departmental Reports Management Officer, Office of the Chief Information Officer.

[FR Doc. 01–19228 Filed 8–1–01; 8:45 am]

BILLING CODE 4210–72–M

DEPARTMENT OF THE INTERIOR

Indian Arts and Crafts Board

Proposed Agency Information Collection To Identify Tribal Non-Member Indian Artisan Certification Programs; Comment Request

AGENCY: Indian Arts and Crafts Board.

ACTION: Notice.

SUMMARY: This notice announces that the Indian Arts and Crafts Board is requesting information from those federally recognized Indian tribes that have established a non-member Indian artisan certification program as described in P.L. 101–644. This request for information from the tribes will be submitted to the Office of Information and Regulatory Affairs, Office of Management and Budget, for review and approval after the public comment period as required by the Paperwork Reduction Act of 1995.

DATES: Submit comments on or before October 1, 2001.

ADDRESSES: Send your written comments to Attention: Indian Arts and Crafts Board, U.S. Department of the Interior, 1849 C Street, NW., MS 4004 MIB, Washington, DC 20240. If you wish to submit comments by facsimile, the number is (202) 208–5196, or you may send them by e-mail to ''*iacb@os.doi.gov*''. Please mention that your comments concern ''Non-member Indian Artisan Certification Programs.''

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the proposed information collection instruments should be directed to Meridith Z. Stanton, Director, Indian Arts and Crafts Board, 1849 C Street, NW., MS 4004 MIB, Washington, DC 20240. You may also call (202) 208–3773 (not a toll free call), or send your request by e-mail to ''*iacb@os.doi.gov*'', or by facsimile to (202) 208–5196.

SUPPLEMENTARY INFORMATION:

I. Abstract

The Indian Arts and Crafts Board (Board) is the agency responsible for the enforcement of the Indian Arts and Crafts Act of 1990, P.L. 101–644. The Act is a truth-in-advertising law that prohibits the offer or display for sale, or sale of any art or craft product in a manner that falsely suggests it is Indian produced, an Indian product, or the product of a particular Indian tribe. Under the law, an ''Indian'' is defined as ''any individual who is a member of an Indian tribe, or for the purposes of this section is certified as an Indian artisan by an Indian tribe.'' It is voluntary for a tribe to establish a certification program in accordance with 25 CFR Part 309.

As the agency responsible for the enforcement of the Indian Arts and Crafts Act, it is necessary for the Board to know which federally recognized tribes have established a non-member artist certification program in accordance with the Act. This information is important for the effective enforcement of the Act because it will enable the Board to quickly verify whether or not a particular federally recognized tribe has a certification program under the Act, and to make a preliminary determination as to whether an individual is making a truthful claim regarding his or her certification by a particular federally recognized tribe.

Finally, this information will enable the Board to answer general inquiries from the public regarding tribal non-member certification programs.

II. Method of Collection

In order to identify those federally recognized Indian tribes that have established a non-member Indian artisan certification program as set forth in P.L. 101–644, the Indian Arts and Crafts Board is mailing a response form and a self-addressed stamped envelope to federally recognized Indian tribes requesting that they (1) identify whether or not they have established a non-member artist certification program and, (2) if the tribe has established such a program, whether or not the tribe is willing to mail or fax to the Board a copy of the tribal statutory language establishing the certification program, and (3) whether the federally recognized tribe authorizes the Board to distribute

its tribal language upon request by other tribes in search of a model for establishing their certification program. Submission of the information and authorization is strictly voluntary on behalf of the tribe.

Information collected	Reason for collection
Name of organization, address, telephone number, and name of contact.	To identify the federally recognized Indian tribe responding and to obtain a method and name of contact.
Whether or not the tribe has established a non-member artist certification program.	To identify those federally recognized Indian tribes that have established a non-member artist certification program.
Whether or not the tribe is will to send to the Board by mail or fax its non-member artist certification program language.	To identify those federally recognized tribes that are willing to submit to the Board a copy of the tribal language establishing a non-member artist certification program.
Whether or not the tribe authorizes the Board to use its non-member artist certification program language as a model for other tribes.	To obtain the federally recognized tribe's authorization to use the tribal language establishing a non-member artist certification program as a model for other tribes.

The proposed use of the information: The information collected will be used by the Indian Arts and Crafts Board to determine which federally recognized Indian tribes have established a non-member Indian artisan certification program as contemplated by the Indian Arts and Crafts Act of 1990. This will enable the Indian Arts and Crafts Board to provide accurate responses to inquires from artisans and members of the public seeking this information.

III. Data

(1) *Title:* Non-member Indian Artisan Certification Program.

OMB Control Number: 1085–xxxx.

Type of Review: New Collection.

Affected Entities: Federally recognized Tribal Governments.

Number of respondents: 580.

Frequency of response: One time data gathering.

(2) Total annual reporting and record keeping burden.

Total reporting per respondent: 10 minutes.

Total annual reporting: 97 hours.

(3) *Description of the need for the information and proposed use of the information:* The Board is requesting the foregoing information from federally recognized Indian tribes in order to identify those federally recognized tribes that have established a program for certifying non-member Indian artisans as described in P.L. 101–644 and 25 C.F.R. part 309.

IV. Request for Comments

The Department of the Interior invites comments on:

(a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(b) The accuracy of the agency's estimate of the burden of the collection and validity of the methodology and assumptions used;

(c) Ways to enhance the quality, utility, and clarity of the information to be collected; and

(d) Ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other collection techniques or other forms of information technology. Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, disclose or provide information to or for a federal agency. This includes the time needed to review instructions; to develop, acquire, install and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information, to search data sources, to complete and review the collection of information; and to transmit or otherwise disclose the information.

All written comments will be available for public inspection in Room 4004 of the Main Interior Building, 1849 C Street, N.W., Washington, D.C. from 9:00 a.m. until 3:00 p.m., Monday through Friday, excluding legal holidays. A valid picture identification is required for entry into the Department of the Interior. The comments, names and addresses of commenters will be available for public view during regular business hours. If you wish us to withhold your personal information, you must state what personal information you want us to withhold prominently at the beginning of your comment. We will honor your request to the extent allowable by law.

An agency may not conduct or sponsor, and a person is not required to respond, to a collection of information unless it displays a currently valid Office of Management and Budget control number.

Dated: July 27, 2001.

Meridith Z. Stanton,

Director, Indian Arts and Crafts Board.

[FR Doc. 01–19305 Filed 8–1–01; 8:45 am]

BILLING CODE 4310–RK–P

DEPARTMENT OF THE INTERIOR

Indian Arts and Crafts Board

Proposed Agency Information Collection for Source Directory Publication; Comment Request

AGENCY: Indian Arts and Crafts Board, Interior

ACTION: Notice.

SUMMARY: The Indian Arts and Crafts Board announces an information collection to identify and revise listings for the *Source Directory* of American Indian and Alaska native owned and operated arts and crafts businesses. Comments on this collection are requested from the public. After the public review, we will submit the information collection to OIRA–OMB for review and approval as required by the Paperwork Reduction Act of 1995.

DATES: Submit comments on or before October 1, 2001.

ADDRESSES: Send your written comments to Attention: Indian Arts and Crafts Board, U.S. Department of the Interior, 1849 C Street, N.W., MS–4004 MIB, Washington, D.C. 20240. If you wish to submit comments by facsimile, the number is (202) 208–5196, or you may send them by e-mail to ''*iacb@os.doi.gov*''. Please mention that your comments concern the *Source Directory.*

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the *Source Directory* application or renewal forms, i.e., the information collection instruments, should be directed to Meridith Z. Stanton, Director, Indian Arts and Crafts Board, 1849 C Street, N.W., MS 4004 MIB, Washington, D.C. 20240. You may

also call (202) 208–3773 (not a toll free call), or send your request by e-mail to ''*iacb@os.doi.gov*'' or by facsimile to (202) 208–5196.

SUPPLEMENTARY INFORMATION:

I. Abstract

The *Source Directory* of American Indian and Alaska Native owned and operated arts and crafts enterprises is a program of the Indian Arts and Crafts Board that promotes American Indian and Alaska Native arts and crafts. The *Source Directory* is a forty-one page full-color illustrated publication featuring fine examples of contemporary American Indian and Alaska Native art from the major cultural areas in the United States. The *Source Directory* also comes with a listing of American Indian and Alaska native owned and operated arts and crafts businesses. This listing is included as an insert in the back cover of the *Source Directory.*

The service of being listed in this publication is provided free-of-charge to members of federally recognized tribes. Businesses listed in the *Source Directory* include American Indian and Alaska Native artists and craftspeople, cooperatives, tribal arts and crafts enterprises, businesses privately-owned-and-operated by American Indian and Alaska native artists, designers, and craftspeople, and businesses privately owned-and-operated by American Indian and Alaska Native merchants who retail and/or wholesale authentic Indian and Alaska native arts and crafts. Business listings in the *Source Directory* are arranged alphabetically by State. The *Source Directory* may be ordered from the Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250–7954, for a cost of $8.00 which includes shipping and handling. The business listings are also available on the Board's website located at ''*www.iacb.doi.gov*''.

The Director of the Board uses this information to determine whether an individual or business applying to be listed in the *Source Directory* meets the requirements for listing. The approved application will be printed in the *Source Directory.* The *Source Directory* is updated annually to include new businesses and to update existing information.

II. Method of Collection

To be listed in the *Source Directory,* interested individuals and businesses must submit: (1) A letter requesting an entry in the *Source Directory,* (2) a draft of their business information in a format like the other *Source Directory* listings, (3) a copy of the individual's or business owner's tribal enrollment card; and for businesses, proof that the business is organized under tribal, state or federal law; and (4) a certification that the business is an American Indian or Alaska Native owned and operated cooperative, tribal enterprise, or nonprofit organization or that the owner of the enterprise is an enrolled member of a federally recognized American Indian tribe or Alaska Native group.

The following information is collected in a single-page form that is distributed by the Indian Arts and Crafts Board. Although listing in the *Source Directory* is voluntary, submission of this information is required for inclusion in the *Directory.*

Information collected	Reason for collection
Name of business, mailing address, city, zip code (highway location, Indian reservation, etc.), telephone number and e-mail address.	To identify the business to be listed in the *Source Directory,* and method of contact.
Type of organization	To identify the nature of the business entity.
Hours/season of operation.	To identify those days and times when customers may contact the business.
Internet website address.	To identify whether the business advertises and/or sells inventory online.
Main categories of products.	To identify the products that the business produces.
Retail or wholesale products.	To identify whether the business is a retail or wholesale business.
Mail order and/or catalog.	To identify whether the business has a mail order and/or catalog
Price list information, if applicable.	To identify the cost of the listed products.
For a cooperative or tribal enterprise, a copy of documents showing that the organization is formally organized under tribal, state or federal law.	To determine whether the business meets the eligibility requirement for listing in the *Source Directory.*
Signed certification that the business is an American Indian or Alaska native owned and operated cooperative, tribal enterprise, or nonprofit organization.	To obtain verification that the business is an American Indian or Alaska Native owned and operated business.
Copy of the business owner's tribal enrollment card.	To determine whether the business owner is an enrolled number of a federally-recognized tribe.
Signed certification that the owner of the business is a member of a federally recognized tribe.	To obtain verification that the business owner is an enrolled member of a federally recognized tribe.

The proposed use of the information: The information collected will be used by the Indian Arts and Crafts Board:

(a) to determine whether an individual or business meets the eligibility requirements for inclusion in the *Source Directory,* i.e., whether they are either an American Indian or Alaska Native owned and operated cooperative, tribal enterprise, or nonprofit organization, or an enrolled member of a federally-recognized American Indian tribe or Alaska Native group;

(b) to identify the applicant's business information to be printed in the *Source Directory.*

III. Data

(1) *Title:* Department of the Interior, Indian Arts and Crafts Board, *Source Directory* of American Indian and Alaska Native owned and operated arts and crafts businesses.

OMB Control Number: 1085-xxxx.

Type of Review: New Collection.

Affected Entities: Business or other for-profit; Tribes.

Estimated annual number of respondents: 100.

Frequency of response: Annual.

(2) Annual reporting and record keeping burden.

Total annual reporting per respondent: 15 minutes.

Total annual reporting: 25 hours.

(3) *Description of the need and use of the information:* Submission of this information is required to receive the benefit of being listed in the Indian Arts and Crafts Board *Source Directory.* The information is collected to determine the applicant's eligibility for the service and to obtain the applicant's name and business address to be printed in the publication.

IV. Request for Comments

The Department of the Interior invites comments on:

(a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(b) The accuracy of the agency's estimate of the burden of the collection and the validity of the methodology and assumptions used;

(c) Ways to enhance the quality, utility, and clarity of the information to be collected; and

(d) Ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other collection techniques or other forms of information technology.

Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, disclose or provide information to or for a federal agency. This includes the time needed to review instructions; to develop, acquire, install and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information, to search data sources, to complete and review the collection of information; and to transmit or otherwise disclose the information.

All written comments will be available for public inspection in Room 4004 of the Main Interior Building, 1849 C Street, NW., Washington, DC from 9 a.m. until 3 p.m., Monday through Friday, excluding legal holidays. A valid picture identification is required for entry into the Department of the Interior. The comments, names and addresses of commenters will be available for public view during regular business hours. If you wish us to withhold your personal information, you must state what personal information you want us to withhold prominently at the beginning of your comment. We will honor your request to the extent allowable by law.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget control number.

Dated: July 27, 2001.

Meridith Z. Stanton,

Director, Indian Arts and Crafts Board.

[FR Doc. 01–19306 Filed 8–1–01; 8:45 am]

BILLING CODE 4310–RK–P

DEPARTMENT OF THE INTERIOR

Minerals Management Service

Preparation of an Environmental Assessment for TotalFinaElf Exploration and Production USA, Inc.'s (TotalFinaElf) and Williams Field Services—Gulf Coast Company, L.P. (Williams) Pipeline and Platform Applications (Canyon Express and Canyon Station Pipeline Applications)

AGENCY: Minerals Management Service, Interior.

ACTION: Preparation of an environmental assessment and notice of unlisted activities pursuant to 15 CFR 930.54.

Note: This FR Notice replaces the DEPARTMENT OF THE INTERIOR, Minerals Management Service FR Notice/Vol. 66, No. 119, Wednesday, June 20, 2001/Page 33109 for above subject

SUMMARY: The Minerals Management Service (MMS) is preparing an environmental assessment (EA) for a proposed deepwater project to develop and produce hydrocarbon reserves about 70 miles offshore Louisiana and about 90 miles south of Alabama in Mississippi Canyon Block 348 (Camden Hills Prospect), Mississippi Canyon Block 305 (Aconcagua Prospect), and DeSoto Canyon Blocks 133 and 177 and Mississippi Canyon Block 217 (Kings Peak Prospect) in the Central and Eastern Planning Areas. This Notice provides additional information about the proposed activities and replaces the Notice published on June 20, 2001.

FOR FURTHER INFORMATION CONTACT: Minerals Management Service, Gulf of Mexico OCS Region, 1201 Elmwood Park Boulevard, New Orleans, Louisiana 70123–2394, Mr. Alvin Jones, telephone (504) 736–1713.

SUPPLEMENTARY INFORMATION: This EA implements the tiering process outlined in 40 CFR 1502.20, which encourages agencies to tier environmental documents, eliminating repetitive discussions of the same issue. By use of tiering to the most recent final environmental impact statement (EIS) for the Gulf of Mexico Central Planning Area for Lease Sales 169, 172, 175, 178, and 182 and by referencing related environmental documents, this EA concentrates on environmental issues specific to the proposed action. This Notice also provides constructive notification of these activities pursuant to 15 CFR 930.54.

The MMS Gulf of Mexico Region received Pipeline Right-of-Way (ROW) Applications from TotalFinaElf E&P USA, Inc., that propose to construct, maintain, and operate pipelines and umbilicals and produce the hydrocarbon reserves discovered in the Camden Hills field [Mississippi Canyon (MC) Block 348], the Aconcagua field (MC Block 305), and the Kings Peak field (MC Blocks 217 and 173; DeSoto Canyon (DC) Blocks 133 and 177). The Region also received a Right-of-Use and Easement application from Williams Field Services, Gulf Coast Company, L.P., for the installation and operation of a hydrocarbon processing platform located in Main Pass (MP) Block 261, which will receive production from the Camden Hills, Aconcagua, and Kings Peak fields. The combined Applications are referred to as the Canyon Express / Station Project. TotalFinaElf is the designated operator (DO) for the Canyon Express system, which includes the Camden Hills field [leased by Marathon Oil Company (DO)]; the Aconcagua field [leased by TotalFinaElf (DO)]; and the Kings Peak field, [leased by BP; (DO)]. The proposed Canyon Station processing platform would be installed and operated by Williams Field Services and would be within 100 km of the Breton National Wildlife Refuge. Between nine and eleven wells that were proposed under previously-approved Plans and Development Operations Coordination Documents will be operated by TotalFinaElf. Williams' proposed platform would receive gas and condensate from the Canyon Express Project and export the gas through four proposed export pipelines to four existing pipelines, all within MP Block 261. The Canyon Express/Station Project, which includes all export lines, flow lines, supply lines, jumpers, and umbilicals, consists of 32 individual pipeline segments to be permitted as ROW and lease-term pipelines and one host platform to be permitted as a Right-of-Use and Easement.

The Canyon Express ROW Applications consist of 28 ROW and lease-term pipeline segments. The lengths of pipeline segments range from 60 feet to over 55 miles. The water depth ranges from 7,265 feet in MC Block 348 to 299 feet at the proposed host platform in MP Block 261. TotalFinaElf will use a support base located in Fourchon, Louisiana, to support pipelaying activities associated with the Canyon Express Project. Some segments and portions of the proposed Canyon Express pipeline originate in and/or traverse six blocks in the Eastern Planning Area.

The Canyon Station Right-of-Use and Easement processing platform application consists of a processing platform and four export pipeline applications all within the Central

Planning Area's MP Block 261. The water depth of the four export pipelines ranges from 282 to 307 feet. The average length of the four proposed export pipelines is 1.12 miles. Williams will initially use a support base in Venice, Louisiana, and switch operations to Mobile, Alabama, once production commences.

The two Canyon Express main flowlines are 12.75 inches in diameter and extend about 55 miles starting in MC Block 348 to MP Block 261. Outer Continental Shelf areas and blocks traversed by the Canyon Express/Station proposed pipelines are as follows: MC Blocks 348, 349, 305, 261, 217, 173, 85, and 41; DC Blocks 265, 221, 177, 133, 89, and 45 (within the Eastern Planning Area); Viosca Knoll (VK) Blocks 1003, 1002, 958, 914, 913, 869, 825, 824, 781, 780, 736, and 692; and MP Blocks 282, 261, and 260. The MC, VK, and MP areas and blocks are in the Central Planning Area. No additional drilling operations are considered as a part of this project.

Gas and condensate produced at the Camden Hills, Aconcagua, and Kings Peak fields will be transported to the proposed platform in MP Block 261. No single field contains sufficient reserves to economically justify development costs. The total reserves in the three fields are estimated as high as 900 billion cubic feet of gas. Greater than 99 percent of this gas is pure methane. Maximum Canyon Express hydrocarbon flow rate is 500 million cubic feet (0.5 BCF) per day with approximately 1,500 barrels of condensate per day. Canyon Express pipelines will be laid using a dynamically positioned vessel and construction time is estimated at about 90 days. Installation of the host platform, export lines, and production equipment for Canyon Station is expected to take several months.

The nearest distance of the Canyon Express easternmost flowline in DC Block 45 (in the Eastern Planning Area) is 98 miles from the Florida shoreline, 89 miles from the Alabama shoreline, 93 miles from the Mississippi shoreline, and 68 miles from the Louisiana shoreline. The nearest distance of the proposed host platform (in the Central Planning Area's MP Block 261) is 74 miles from the Florida shoreline, 60 miles from the Alabama shoreline, 63 miles from the Mississippi shoreline, and 56 miles from the Louisiana shoreline.

This EA will analyze the environmental effects and alternatives associated with the construction, maintenance, and operation of the pipelines and host platform as proposed by TotalFinaElf and Williams. Alternatives will include the proposed action with additional mitigations and no action (*i.e.,* disapproval of the plan).

For more information regarding the Canyon Express and Canyon Station applications, please visit those documents at *http://www.gomr.mms.gov/homepg/offshore/canyon/*. For more information about pipelines, impacts associated with pipelaying activities, and mitigative measures, please visit the document at *http://www.gomr.mms.gov/homepg/offshore/canyon/pipe_install.pdf.*

Public Comments: The MMS requests interested parties to submit comments regarding issues that should be addressed in the EA to Minerals Management Service, Gulf of Mexico OCS Region, Office of Leasing and Environment, Attention: Regional Supervisor (MS 5400), 1201 Elmwood Park Boulevard, New Orleans, Louisiana 70123–2394. Comments must be submitted no later than 30 days from the publication date of this Notice.

Dated: July 3, 2001.

Charles J. Schoennagel,

Deputy Regional Director, Gulf of Mexico OCS Region.

[FR Doc. 01–19223 Filed 8–1–01; 8:45 am]

BILLING CODE 4310–MR–P

DEPARTMENT OF LABOR

Office of the Assistant Secretary for Policy

Proposed Information Collection Request Submitted for Public Comment and Recommendations: The National Agricultural Workers Survey

ACTION: Notice.

SUMMARY: The Department of Labor, as part of its continuing effort to reduce paperwork and respondent burden, conducts a preclearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) (44 U.S.C. 3506(c)(2)(A)). This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed.

DATES: Submit comments on or before September 30, 2001.

ADDRESSES: Send comments to Daniel Carroll, Economist, Office of the Assistant Secretary for Policy, U.S. Department of Labor, Room S–2312, 200 Constitution Ave., NW, Washington, D.C. 20210. Commenters are encouraged to send their comments on a computer disk, or via Internet E-mail to *carroll-daniel@dol.gov,* along with an original printed copy. Mr. Carroll can be reached at (202) 693–5077 (voice), or (202) 693–5960 (facsimile).

FOR FURTHER INFORMATION CONTACT: Daniel Carroll, Economist and Program Officer for the National Agricultural Workers Survey, Office of the Assistant Secretary for Policy, U.S. Department of Labor, Room S–2312, 200 Constitution Ave., NW, Washington, D.C. 20210. Mr. Carroll can be reached via Internet E-mail at *carroll-daniel@dol.gov* or by telephone (202) 693–5077. Copies of the referenced information collection request are available for inspection and copying and will be mailed to persons who request copies by telephoning Daniel Carroll at (202) 693–5077. For more information about the National Agricultural Workers Survey (NAWS), consult the NAWS home page at: *http://www.dol.gov/dol/asp/public/programs/agworker/naws.htm.*

SUPPLEMENTARY INFORMATION:

I. Background

The Department of Labor (DOL) began surveying hired farm workers in 1988 via the National Agricultural Workers Survey (NAWS). The primary focus of the NAWS is to describe the demographic and employment characteristics of hired crop farm workers at the national level. To date, over 30,000 farm workers have been interviewed.

Prior to the NAWS and throughout the post-war period, data on farm workers was collected through the Current Population Survey (CPS). The U.S. Department of Agriculture (USDA) funded this effort and its Economic Research Service (ERS) analyzed and published the data. The responsibility for collecting data on the demographic and employment characteristics of hired farm workers was assumed by the Department of Labor in 1988.

The NAWS provides an understanding of the manpower resources available to U.S. agriculture, and both public and private service programs use the data for planning, implementing, and evaluating farm worker programs. It is the only national data source on the demographic and employment characteristics of hired farm workers.

The NAWS samples crop farm workers in three cycles each year in order to capture the seasonality of

agricultural employment. Workers are located and sampled at their work sites. During the initial contact, arrangements are made to interview the respondent at home or at another convenient location. Currently, approximately 4,000 interviews are obtained each year.

The NAWS includes a primary questionnaire and four supplements (youth, parent, injury, and health). The purpose of this notice is to solicit comments on a proposed revision to the health supplement. The questionnaires are described below.

The NAWS Questionnaire (Primary Instrument)

The primary instrument, in place since 1988, is administered to persons 14 years and older. Currently, approximately 4,000 interviews are conducted each year. It contains a family/household grid, where the interviewer records the education level and migration patterns of each member of the respondent's household, and an employment grid, where a full year of information on the work and geographic movement of the respondent is recorded. It also contains sections on income, assets and use of public services, experience working with pesticides, including special training, and work authorization status.

The employment profile includes the task and crop for agricultural jobs, type and amount of non-agricultural work, periods of unemployment and time spent abroad, and the respondent's location for every week of the year preceding the interview. For the respondent's current job, the NAWS collects information on wages and payment method (piece or hourly), health insurance, workers compensation and unemployment insurance, housing arrangements and other benefits and working conditions.

The demographic profile includes age, gender, place of birth, marital status, language ability, use of education and job training programs, and family history working in U.S. agriculture.

The Youth Labor and Education Supplement

This supplement, in place since fiscal year 2000, is administered to workers ages 14 to 18 who complete the primary NAWS questionnaire. Approximately 450 interviews are conducted each year. The labor component solicits the respondent's age when he/she first went to an agricultural field in the U.S. and when he/she first worked in U.S. agriculture, the method of payment for work, the types of implements (ladder) and equipment (machines, vehicles) used and age when used, and how earnings from agricultural employment are allocated.

The education component solicits school and attendance information for the 12-month period preceding the date of interview and, for those youth who did not attend any school in the previous 12 months, the date of last attendance, type and location of school, reasons for no longer attending, and educational aspirations in the U.S.

The Parent Labor and Education Supplement

This supplement, in place since fiscal year 2000, is administered to NAWS respondents who are parents of U.S. resident, dependent children between the ages of 6 and 18. Currently, approximately 750 parents provide information on an average of two children each, or 1,500 children per year. The labor component asks, for those children who did U.S. farm work in the 12-month period preceding the date of the interview, how many days the child worked in agriculture, if the child received a separate (individual) payment for that work, and the reason why the child worked.

The education component solicits information on school attendance and performance in the 12-month period preceding the interview, including number and type of schools attended, average grades, number of school days missed and reasons for days absent, number of times the parent met with the child's teacher to discuss the child's educational progress, and the parent's expectations for the child to graduate.

The Occupational Injury Supplement

This supplement, sponsored by the Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (CDC/NIOSH), has been in place since 1999. It is administered to all NAWS respondents who had a qualifying occupational injury in U.S. agriculture in the 12-month period preceding the date of interview. Currently, each year approximately 4,000 respondents are administered one question to determine if the respondent has a qualifying injury. Respondents who have a qualifying injury are administered the full injury module. For each qualifying injury, the respondent is asked how, when and where the injury occurred, the body part(s) injured, where medical treatment was received and how the treatment was paid for, and the number of days the respondent couldn't work or worked at a reduced activity level.

The Health Supplement

This supplement, sponsored by the Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (CDC/NIOSH), has been in place since 1999. It is administered to all NAWS respondents. Four types of health information are solicited: history of smoking and drinking, a 12-month history of problems with body systems (gastrointestinal, respiratory, musculoskeletal, and skin) a lifetime health history of disease, and access to health care.

The proposed revision to this supplement is to include four new questions that would be administered to adult women only (about 600 per year). The four questions will come from the Behavioral Risk Factor Survey and will solicit information on cervical cancer screening. Collecting cervical cancer screening data from adult farm worker women will help CDC's Division of Cancer Prevention and Control address its mission of identifying and then reaching women who have rarely or never received cervical cancer screening. CDC has identified migrant and seasonal farm worker women as having an increased risk of cervical cancer and a population in which surveillance for cervical cancer screening has been minimal.

II. Desired Focus of Comments

Currently, the Office of the Assistant Secretary for Policy (OASP) is soliciting comments concerning the proposed revision of the CDC/NIOSH sponsored health supplement and the extension of the information collection via all NAWS instruments. OASP is particularly interested in comments which:

Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

Enhance the quality, utility, and clarity of the information to be collected; and

Minimize the burden of the collection of information on those who are to respond.

Hard copies of the instruments associated with the proposed information collection request may be obtained by contacting the employee listed above in the **FOR FURTHER INFORMATION CONTACT** section of this notice.

III. Current Actions

This action requests OMB approval of the paperwork requirements for revising the health supplement to the National Agricultural Workers Survey (NAWS).

Type of Review: Revision.

Agency: Office of the Assistant Secretary for Policy.

Title: CDC/NIOSH Health Supplement to the National Agricultural Workers Survey.

OMB Number: 1225–0044.

Record keeping: Records are kept for four years.

Affected Public: Farm workers and farm employers

Total Respondents: 5,500 (4,000 farm workers will receive an interview and 1,500 employers will be briefly interviewed to ascertain the location of the potential worker respondents).

Frequency: Annually. The survey is administered in three 10–12 week cycles each year, beginning in October, February, and June.

Total Responses: The primary questionnaire will be administered to approximately 4,000 hired crop workers each year. All of these respondents will receive the general health supplement. Approximately 600 of the 4,000 respondents will be adult females. The 600 adult females will be administered four additional questions on cervical cancer screening. Approximately 450 of the 4,000 respondents will be youth between the ages of 14 and 18. The 450 youth will receive the youth supplement. Approximately 750 of the 4,000 respondents will be parents of U.S. resident, dependent children. The 750 parents will be administered the parent supplement.

Average Time Per Response: The primary questionnaire and the general health supplement together take approximately one hour. The parent and youth supplements each take approximately 20 minutes. The injury supplement, when a qualifying injury is reported, takes approximately 15 minutes. The interview with the farm employer takes about 20 minutes.

Estimated Total Burden Hours: 4,390 hours. The burden time reflects the time to administer the primary questionnaire and all supplements, including the time to conduct initial interviews with agricultural employers. No added burden time would result from the revised health supplement, as a greater number of preexisting questions will be discontinued.

Total Burden Cost (capital/startup): $0.

Total Burden Cost (operating/maintaining): $0.

Comments submitted in response to this notice will be summarized and/or included in the request for Office of Management and Budget approval of the information collection request; they will also become a matter of public record.

Dated: July 26, 2001.

Authorized Official in the Office of the Assistant Secretary for Policy.

Roland G. Droitsch,

Deputy Assistant Secretary for Policy.

[FR Doc. 01–19311 Filed 8–1–01; 8:45 am]

BILLING CODE 4510–23–P

DEPARTMENT OF LABOR

Employment and Training Administration

Labor Certification Process for the Temporary Employment of Aliens in Agriculture and Logging in the United States: 2001 Adverse Effect Wage Rates, Allowable Charges for Agricultural and Logging Workers' Meals, And Maximum Travel Subsistence Reimbursement

AGENCY: Employment and Training Administration, Labor.

ACTION: Notice of adverse effect wage rates (AEWRs), allowable charges for meals, and maximum travel subsistence reimbursement for 2001.

SUMMARY: The Employment and Training Administration (ETA) announces 2001 adverse effect wage rates (AEWRs) for employers seeking nonimmigrant alien (H–2A) workers for temporary or seasonal agricultural labor or services, the allowable charges employers seeking nonimmigrant alien workers for temporary or seasonal agricultural labor or services or logging work may levy upon their workers when they provide three meals per day, and the maximum travel subsistence reimbursement which a worker with receipts may claim in 2001.

AEWRs are the minimum wage rates which the Department of Labor has determined must be offered and paid to U.S. and alien workers by employers of nonimmigrant alien agricultural workers (H–2A visaholders). AEWRs are established to prevent the employment of these aliens from adversely affecting wages of similarly employed U.S. workers.

ETA also announces the new rates which covered agricultural and logging employers may charge their workers for three daily meals.

Under specified conditions, workers are entitled to reimbursement for travel subsistence expense. The minimum reimbursement is the charge for three daily meals as discussed above. ETA here announces the current maximum reimbursement for workers with receipts.

EFFECTIVE DATE: August 2, 2001.

FOR FURTHER INFORMATION CONTACT: Mrs. Grace A. Kilbane, Administrator, Office of Workforce Security, U.S. Department of Labor, Room S–4231, 200 Constitution Avenue, NW., Washington, DC 20210. Telephone: 202–693–3200 (this is not a toll-free number).

SUPPLEMENTARY INFORMATION: The Attorney General may not approve an employer's petition for admission of non-immigrant alien agricultural (H–2A) workers to perform agricultural labor or services of a temporary or seasonal nature in the United States unless the petitioner has applied to the Department of Labor (DOL) for an H–2A labor certification. The labor certification must show that: (1) There are not sufficient U.S. workers who are able, willing, and qualified and who will be available at the time and place needed to perform the labor or services involved in the petition; and (2) the employment of the alien in such labor or services will not adversely affect the wages and working conditions of workers in the United States similarly employed. 8 U.S.C. 1101(a)(15)(H)(ii)(a), 1184(c), and 1188.

DOL's regulations for the H–2A program require that covered employers offer and pay their U.S. and H–2A workers no less than the applicable hourly adverse effect wage rate (AEWR). 20 CFR 655.102(b)(9); see also 20 CFR 655.107. Reference should be made to the preamble to the July 5, 1989, final rule (54 FR 28037), which explains in great depth the purpose and history of AEWRs, DOL's discretion in setting AEWRs, and the AEWR computation methodology at 20 CFR 655.107(a). See also 52 FR 20496, 20502–20505 (June 1, 1987).

A. Adverse Effect Wage Rates (AEWRs) for 2001

Adverse effect wage rates (AEWRs) are the minimum wage rates which DOL has determined must be offered and paid to U.S. and alien workers by employers of nonimmigrant (H–2A) agricultural workers. DOL emphasizes, however, that such employers must pay the highest of the AEWR, the applicable prevailing hourly wage rate, or the legal federal or State minimum wage rate, as specified in the regulations. 20 CFR 655.102(b)(9). Except as otherwise provided in 20 CFR Part 655, Subpart B, the regionwide AEWR for all agricultural employment (except those occupations deemed inappropriate under the special circumstances provisions of 20 CFR 655.93) for which

temporary alien agricultural labor (H–2A) certification is being sought, is equal to the annual weighted average hourly wage rate for field and livestock workers (combined) for the region as published annually by the U.S. Department of Agriculture (USDA does not provide data on Alaska). 20 CFR 655.107(a).

The regulation at 20 CFR 655.107(a) requires the Administrator, Office of Workforce Security, to publish USDA field and livestock worker (combined) wage data as AEWRs in a **Federal Register** notice. Accordingly, the 2001 AEWRs for work performed on or after the effective date of this notice, are set forth in the table below:

TABLE.—2001 ADVERSE EFFECT WAGE RATES (AEWRS)

State	2001 AEWR
Alabama	$6.83
Arizona	6.71
Arkansas	6.69
California	7.56
Colorado	7.43
Connecticut	8.17
Delaware	7.37
Florida	7.66
Georgia	6.83
Hawaii	9.05
Idaho	7.26
Illinois	8.09
Indiana	8.09
Iowa	7.84
Kansas	7.81
Kentucky	6.60
Louisiana	6.69
Maine	8.17
Maryland	7.37
Massachusetts	8.17
Michigan	8.07
Minnesota	8.07
Mississippi	6.69
Missouri	7.84
Montana	7.26
Nebraska	7.81
Nevada	7.43
New Hampshire	8.17
New Jersey	7.37
New Mexico	6.71
New York	8.17
North Carolina	7.06
North Dakota	7.81
Ohio	8.09
Oklahoma	6.98
Oregon	8.14
Pennsylvania	7.37
Rhode Island	8.17
South Carolina	6.83
South Dakota	7.81
Tennessee	6.60
Texas	6.98
Utah	7.43
Vermont	8.17
Virginia	7.06
Washington	8.14
West Virginia	6.60
Wisconsin	8.07
Wyoming	7.26

B. Allowable Meal Charges

Among the minimum benefits and working conditions which DOL requires employers to offer their alien and U.S. workers in their applications for temporary logging and H–2A agricultural labor certification is the provision of three meals per day or free and convenient cooking and kitchen facilities. 20 CFR 655.102(b)(4) and 655.202(b)(4). Where the employer provides meals, the job offer must state the charge, if any, to the worker for meals.

DOL has published at 20 CFR 655.102(b)(4) and 655.111(a) the methodology for determining the maximum amounts covered H–2A agricultural employers may charge their U.S. and foreign workers for meals. The same methodology is applied at 20 CFR 655.202(b)(4) and 655.211(a) to covered H–2 logging employers. These rules provide for annual adjustments of the previous year's allowable charges based upon Consumer Price Index (CPI) data.

Each year the maximum charges allowed by 20 CFR 655.102(b)(4) and 655.202(b)(4) are changed by the same percentage as the twelve-month percent change in the CPI for all Urban Consumers for Food (CPI-U for Food) between December of the year just past and December of the year prior to that. Those regulations and 20 CFR 655.111(a) and 655.211(a) provide that the appropriate Regional Administrator (RA), Employment and Training Administration, may permit an employer to charge workers no more than a higher maximum amount for providing them with three meals a day, if justified and sufficiently documented. Each year, the higher maximum amounts permitted by 20 CFR 655.111(a) and 655.211(a) are changed by the same percentage as the twelve-month percent change in the CPI-U for Food between December of the year just past and December of the year prior to that. The regulations require the Administrator, Office of Workforce Security, to make the annual adjustments and to cause a notice to be published in the **Federal Register** each calendar year, announcing annual adjustments in allowable charges that may be made by covered agricultural and logging employers for providing three meals daily to their U.S. and alien workers. The 2000 rates were published in a notice on February 4, 2000 at 65 FR 5696.

DOL has determined the percentage change between December of 1999 and December of 2000 for the CPI-U for Food was 2.3 percent.

Accordingly, the maximum allowable charges under 20 CFR 655.102(b)(4), 655.202(b)(4), 655.111, and 655.211 were adjusted using this percentage change, and the new permissible charges for 2001 are as follows: (1) for 20 CFR 655.102(b)(4) and 655.202(b)(4), the charge, if any, shall be no more than $8.18 per day, unless the RA has approved a higher charge pursuant to 20 CFR 655.111 or 655.211(b); for 20 CFR 655.111 and 655.211, the RA may permit an employer to charge workers up to $10.13 per day for providing them with three meals per day, if the employer justifies the charge and submits to the RA the documentation required to support the higher charge.

C. Maximum Travel Subsistence Expense

The regulations at 20 CFR 655.102(b)(5) establish that the minimum daily subsistence expense related to travel expenses, for which a worker is entitled to reimbursement, is the employer's daily charge for three meals or, if the employer makes no charge, the amount permitted under 20 CFR 655.104(b)(4). The regulation is silent about the maximum amount to which a qualifying worker is entitled.

The Department, in Field Memorandum 42–94, established that the maximum is the meals component of the standard CONUS (continental United States) per diem rate established by the General Services Administration (GSA) and published at 41 CFR Ch. 301. The CONUS meal component is now $30.00 per day.

Workers who qualify for travel reimbursement are entitled to reimbursement up to the CONUS meal rate for related subsistence when they provide receipts. In determining the appropriate amount of subsistence reimbursement, the employer may use the GSA system under which a traveler qualifies for meal expense reimbursement per quarter of a day. Thus, a worker whose travel occurred during two quarters of a day is entitled, with receipts, to a maximum reimbursement of $15.00. If a worker has no receipts, the employer is not obligated to reimburse above the minimum stated at 20 CFR 655.102(b)(4) as specified above.

Signed at Washington, DC, this 27th day of July, 2001.

Grace A. Kilbane,

Administrator, Office of Workforce Security.

[FR Doc. 01–19298 Filed 8–1–01; 8:45 am]

BILLING CODE 4510–30–P

NATIONAL SCIENCE FOUNDATION

Sunshine Act Meeting

AGENCY HOLDING MEETING: National Science Foundation, National Science Board.

DATE AND TIME:
August 9, 2001: 12:00 Noon–12:30 p.m.—Closed Session
August 9, 2001: 1:00 p.m.–3:30 p.m.—Closed Session
August 9, 2001: 3:30 p.m.–5:00 p.m.—Open Session

PLACE: The National Science Foundation, Room 1235, 4201 Wilson Boulevard, Arlington, VA 22230, www.nsf.gov/nsb.

STATUS: Part of this meeting will be closed to the public. Part of this meeting will open to the public.

MATTERS TO BE CONSIDERED:

Thursday, August 9, 2001

Closed Session (12 Noon–12:30 p.m.)

—Closed Session Minutes, May, 2001
—NSB Member Proposals

Closed Session (1:00 p.m.–3:30 p.m.)

—Awards and Agreements
—NSF FY 03 Budget

Open Session (3:30 p.m.–5:00 p.m.)

—Open Session Minutes, May, 2001
—Closed Session Items for October, 2001
—Chairman's Report
—Director's Report
—Presentation: Urban Systemics Evaluation
—S&E Indicators 2002 Review
—Committee Reports
—Other Business

Marta Cehelsky,
Executive Officer.
[FR Doc. 01–19427 Filed 7–31–01; 11:34 am]
BILLING CODE 7555–01–M

NUCLEAR REGULATORY COMMISSION

Agency Information Collection Activities: Submission for the Office of Management and Budget (OMB) Review; Comment Request

AGENCY: U. S. Nuclear Regulatory Commission (NRC)

ACTION: Notice of the OMB review of information collection and solicitation of public comment.

SUMMARY: The NRC has recently submitted to OMB for review the following proposal for the collection of information under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. chapter 35). The NRC hereby informs potential respondents that an agency may not conduct or sponsor, and that a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

1. *Type of submission, new, revision, or extension:*
Revision.
2. *The title of the information collection:*
NRC Form 4, ''Cumulative Occupational Dose History''
NRC Form 5, ''Occupational Exposure Record for a Monitoring Period''.
3. *The form number if applicable:*
NRC Form 4: 3150–0005.
NRC Form 5: 3150–0006.
4. *How often the collection is required:*
NRC Form 4: Occasionally.
NRC Form 5: Annually.
5. *Who will be required or asked to report:*
Licensees who are required to comply with 10 CFR part 20.
6. *An estimate of the number of responses:*
NRC Form 4–23,077.
NRC Form 5–370,212.
7. *The estimated number of annual respondents:*
NRC Form 4: 286 (104 reactor sites and 182 materials licensees).
NRC Form 5: 5,400 (104 reactor and 5,296 materials licensees) are required to keep records; 286 (104 reactor sites and 182 material licensees) are required to submit reports in accordance with 10 CFR 20.2206(a).
8. *An estimate of the total number of hours needed annually to complete the requirement or request:*
NRC Form 4: 11,531 hours or an average of 0.5 hours per response.
NRC Form 5: 66.682 (55,242 hours for recordkeeping hours or an average of 0.33 hours per record and 11,440 hours for reporting hours or an average of 40 hours per licensee).
9. *An indication of whether Section 3507(d), Pub. L. 104–13 applies:*
Not applicable.
10. *Abstract:* NRC Form 4 is used to record the summary of an individual's cumulative occupational radiation dose for the current year to ensure that dose does not exceed regulatory limits.
NRC Form 5 is used to record and report the results of individual monitoring for an occupational dose from radiation during a one-year period to ensure regulatory compliance with annual dose limits.
A copy of the final supporting statement may be viewed free of charge at the NRC Public Document Room, One White Flint North, 11555 Rockville Pike, Room O–1 F23, Rockville, MD 20852. OMB clearance requests are available at the NRC worldwide web site: http://www.nrc.gov/NRC/PUBLIC/OMB/index.html. The document will be available on the NRC home page site for 60 days after the signature date of this notice.
Comments and questions should be directed to the OMB reviewer listed below by September 4, 2001. Comments received after this date will be considered if it is practical to do so, but assurance of consideration cannot be given to comments received after this date.
Bryon Allen, Office of Information and Regulatory Affairs, (3150–0005 and 3150–0006), NEOB–10202, Office of Management and Budget, Washington, DC 20503.
Comments can also be submitted by telephone at (202) 395–3087.
The NRC Clearance Officer is Brenda Jo. Shelton, 301–415–7233.

Dated at Rockville, Maryland, this 25th day of July 2001.
For the Nuclear Regulatory Commission.

Brenda Jo. Shelton,
NRC Clearance Officer, Office of the Chief Information Officer.
[FR Doc. 01–19301 Filed 8–1–01; 8:45 am]
BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

[Docket Nos. 50–352 and 50–353]

Exelon Generation Company, LLC; Limerick Generating Station, Unit Nos. 1 and 2 Environmental Assessment and Finding of No Significant Impact

The U.S. Nuclear Regulatory Commission (NRC) is considering issuance of an exemption from Title 10 of the Code of Federal Regulations (10 CFR) Part 50, Section 71(e)(4) to Facility Operating License Nos. NPF–39 and NPF–85, issued to Exelon Generation Company, LLC, (the licensee), for operation of the Limerick Generating Station (LGS), Unit Nos. 1 and 2, located in Montgomery County, Pennsylvania.

Environmental Assessment

Identification of the Proposed Action

The proposed action would exempt the licensee from some requirements of 10 CFR 50.71(e)(4) regarding submission of revisions to the Updated Final Safety Analysis Report (UFSAR). The proposed exemption would allow updates to the combined UFSAR for LGS, Unit Nos. 1 and 2, to be submitted within 6 months following completion of each LGS Unit

1 refueling outage, not to exceed 24 months from the previous submittal.

The proposed action is in accordance with the licensee's application for exemption dated May 30, 2001.

The Need for the Proposed Action

10 CFR 50.71(e)(4), requires licensees to submit updates to their UFSAR annually or within 6 months after each refueling outage provided that the interval between successive updates does not exceed 24 months. Since Units 1 and 2 share a common UFSAR, the licensee must update the same document annually or within 6 months after a refueling outage for either unit. The last change to 10 CFR 50.71(e)(4) was published in the **Federal Register** (57 FR 39358) on August 31, 1992, and became effective on October 1, 1992. The underlying purpose of the rule change was to relieve licensees of the burden of filing annual UFSAR revisions while assuring that such revisions are made at least every 24 months. However, as written, the burden reduction can only be realized by single-unit facilities, or multiple-unit facilities that maintain separate UFSARs for each unit. In the Summary and Analysis of Public Comments accompanying the 10 CFR 50.71(e)(4) rule change published in the **Federal Register** (57 FR 39355, 1992), the NRC acknowledged that the final rule did not provide burden reduction to multiple-unit facilities sharing a common UFSAR. The NRC stated: ''With respect to the concern about multiple facilities sharing a common FSAR, licensees will have maximum flexibility for scheduling updates on a case-by-case basis.'' Granting this exemption would provide burden reduction to LGS while still assuring that revisions to the UFSAR are made at least every 24 months.

Environmental Impacts of the Proposed Action

The NRC has completed its evaluation of the proposed action and concludes that it involves administrative activities unrelated to plant operation.

The proposed action will not increase the probability or consequences of accidents, no changes are being made in the types of any effluents that may be released off site, and there is no increase in occupational or public radiation exposure. Therefore, there are no significant radiological environmental impacts associated with the proposed action.

With regard to potential non-radiological impacts, the proposed action does not involve any historic sites. It does not affect non-radiological plant effluents and has no other environmental impact. Therefore, there are no significant non-radiological environmental impacts associated with the proposed action.

Accordingly, the NRC concludes that there are no significant environmental impacts associated with the proposed action.

Alternatives to the Proposed Action

As an alternative to the proposed action, the staff considered denial of the proposed action (i.e., the ''no-action'' alternative). Denial of the application would result in no change in current environmental impacts. The environmental impacts of the proposed action and the alternative action are similar.

Alternative Use of Resources

This action does not involve the use of any resources not previously considered in the Final Environmental Statement for LGS.

Agencies and Persons Consulted

In accordance with its stated policy, on June 18, 2001, the NRC staff consulted with the Pennsylvania State official, David Nye, of the Pennsylvania Department of Environmental Protection, Nuclear Safety Division, regarding the environmental impact of the proposed action. The State official had no comments.

Finding of No Significant Impact

On the basis of the environmental assessment, the NRC concludes that the proposed action will not have a significant effect on the quality of the human environment. Accordingly, the NRC has determined not to prepare an environmental impact statement for the proposed action.

For further details with respect to the proposed action, see the licensee's letter dated May 30, 2001. Documents may be examined, and/or copied for a fee, at the NRC's Public Document Room, located at One White Flint North, 11555 Rockville Pike (first floor), Rockville, Maryland. Publicly available records will be accessible electronically from the Agencywide Documents Access and Management Systems (ADAMS) Public Electronic Reading Room on the Internet at the NRC web site, http://www.nrc.gov/NRC/ADAMS/index.html. Persons who do not have access to ADAMS or who encounter problems in accessing the documents located in ADAMS may contact the NRC Public Document Room (PDR) Reference staff by telephone at 1–800–397–4209, 301–415–4737, or by e-mail to pdr@nrc.gov.

Dated at Rockville, Maryland, this 27th day of July, 2001.

For the Nuclear Regulatory Commission.

Christopher Gratton, Sr.,

Project Manager, Section 2, Project Directorate I, Division of Licensing Project Management, Office of Nuclear Reactor Regulation.

[FR Doc. 01–19302 Filed 8–1–01; 8:45 am]

BILLING CODE 7590–01–P

SECURITIES AND EXCHANGE COMMISSION

[Release No. IA–1955/803–164]

International Bank for Reconstruction and Development and International Development Association; Notice of Application

July 27, 2001.

AGENCY: Securities and Exchange Commission (the ''Commission'').

ACTION: Notice of application for exemption under the investment advisers act of 1940 (''Advisers Act'').

Applicants: International Bank for Reconstruction and Development (''IBRD'') and International Development Association (''IDA'').

Relevant Advisers Act Sections: Exemption requested under section 202(a)(11)(F) from section 202(a)(11).

SUMMARY OF APPLICATION: Applicants request an order declaring them to be persons not within the intent of section 202(a)(11), which defines the term ''investment adviser.''

Filing Dates: The application was filed on June 22, 2001.

Hearing or Notification of Hearing: An order granting the application will be issued unless the Commission orders a hearing. Interested persons may request a hearing by writing to the Commission's Secretary and serving Applicants with a copy of the request, personally or by mail. Hearing requests should be received by the Commission by 5:30 p.m. on August 31, 2001, and should be accompanied by proof of service on Applicants, in the form of an affidavit or, for lawyers, a certificate of service. Hearing requests should state the nature of the writer's interest, the reason for the request, and the issues contested. Persons may request notification of a hearing by writing to the Commission's Secretary.

ADDRESSES: Secretary: SEC, 450 Fifth Street, NW., Washington, DC 20549–0609. Applicants: International Bank for Reconstruction and Development and International Development Association, 1818 H Street, NW., Washington, DC 20433.

FOR FURTHER INFORMATION CONTACT: Marilyn D. Barker, Senior Counsel, (202) 942–0719, or Jennifer L. Swain, Assistant Director, at (202) 942–0719 (Division of Investment Management, Office of Investment Adviser Regulation).

SUPPLEMENTARY INFORMATION: The following is a summary of the application. The complete application may be obtained for a fee at the Commission's Public Reference Branch.

Applicant's Representations

1. IBRD was established by international treaty and its principal purpose is reducing poverty by promoting the economic development of member countries. IBRD has operated since 1946 under Articles of Agreement signed by the governments of its member countries, and its member countries own all of its capital stock.

2. IDA is an affiliated international organization, and membership in IDA is open only to members of IBRD. IDA was established in 1960, and its main goal is reducing poverty by promoting the economic development of its less developed member countries. IDA's members own all of its capital stock.

3. IBRD and IDA have the same staff. Applicants represent that since 1990, they have regularly offered multi-country technical assistance on reserves asset management to central banks of member countries, to other government institutions of member countries, and to other international organizations owned entirely by their sovereign nation members substantially all of which are also members of Applicants (''Sovereign Organizations''). Applicants represent this program's objectives is to assist central banks in adopting portfolio management techniques.

4. Applicants represent that they seek to expand their reserve assets technical assistance program to meet requests for more sustained services and requests for asset management. Applicants would provide the expanded services to member countries, central banks of member countries, other government institutions of member countries, and Sovereign Organizations. Applicants represent that they would manage only government or other public assets.

5. Applicants represent that they have also hosted financial assistance seminars for member countries, and that these courses have included asset and liability management, capital markets and derivatives activities, and middle and back office operations. Applicants represent that they now seek to provide detailed advice on debt management, hedging techniques for specific transactions (*e.g.,* derivatives), and capital market borrowing.

6. Applicants represent that they plan to charge a fee for the expanded services, to recover the costs associated with the expanded services, including the incremental costs of additional assets under management.

Applicants' Legal Analysis

1. Section 202(a)(11) of the Advisers Act defines ''investment adviser'' to mean ''any person who, for compensation, engages in the business of advising others * * * as to the value of securities or as to the advisability of investing in, purchasing, or selling securities, or who, for compensation and as a part of a regular business, issues or promulgates analyses or reports concerning securities * * *.''

2. Applicants propose to offer asset management and other advisory services on a regular, recurring basis and to charge recipients a fee for these services. Accordingly, Applicants would be ''in the business of'' providing investment advice for compensation and would be ''investment advisers'' for purposes of the Advisers Act.

3. Section 202(a)(11)(F) of the Adviser Act authorizes the Commission to exclude from the definition of ''investment adviser'' person that are not within the intent of section 202(a)(ii). Applicants request that the Commission issue an order under section 202(a)(11)(F) declaring them to be persons not within the intent of section 202(a)(11).

4. Applicants argue that the Advisers Act contemplates the regulation of private sector entities and was not intended to regulate an entity that is an organization of sovereign nations providing investment advice to its sovereign nation members, their central banks and other government institutions, and Sovereign Organizations. Applicants state that section 202(b) of the Advisers Act provides that the Advisers Act is not applicable to the ''United States, a State, or any political subdivision of a State, or any agency, authority, or instrumentality of any one or more of the foregoing, or any corporation which is wholly owned directly or indirectly by any one or more of the foregoing, or any officer, agent, or employee of any of the foregoing acting as such in the course of his official duty, unless such provision makes specific reference thereto.'' While Applicants acknowledge that the Advisers Act does not expressly exempt international organizations made up solely of sovereign nations, Applicants argue that the Advisers Act seems clearly intended not to apply to such organizations.

5. Applicants acknowledge that a foreign individual or corporate investor would expect the protections of the United States securities laws to apply when doing business with an investment adviser resident in the United States. Applicants assert, however, that, given the particular nature of IBRD and IDA, their unique purposes, and the nature of their constituent members, recipients of the proposed investment advice would not reasonably expect the Advisers Act to apply.

By the Commission.

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 01–19315 Filed 8–1–01; 8:45 am]

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–44597; File No. SR–CBOE–2001–37]

Self-Regulatory Organizations; Notice of Filing and Immediate Effectiveness of Proposed Rule Change and Amendment No. 1 by the Chicago Board Options Exchange, Inc. Amending its Schedule of Exchange Fees

July 26, 2001.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act''),[1] and Rule 19b–4 thereunder,[2] notice is hereby given that on June 28, 2001, the Chicago Board Options Exchange, Inc. (''Exchange'' or ''CBOE'') filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the CBOE. On July 20, 2001, the CBOE submitted Amendment No. 1 to the proposed rule change.[3] The Commission is publishing this notice to solicit comments on the proposed rule change and Amendment No. 1 from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The CBOE proposes to amend its fee schedule. The text of the proposed rule

[1] 15 U.S.C. 78s(b)(1).

[2] 17 CFR 240.19b–4.

[3] *See* letter to Nancy Sanow, Assistant Director, Division of Market Regulation (''Division''), Commission, from Christopher Hill, Attorney II, CBOE, dated July 19, 2001 (''Amendment No. 1''). In Amendment No. 1, the CBOE made technical corrections to the rule text.

change is available at the Office of the Secretary, CBOE and the Commission.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the CBOE included statements concerning the purpose of and basis for the proposed rule change, as amended, and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The CBOE has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

The purpose of this proposed rule change is to make certain fee changes and deletions, and to renew and amend the Exchange's Prospective Fee Reduction Program. The proposal is the product of the Exchange's annual budget review. The fee changes were approved by the Exchange's Board of Directors pursuant to CBOE Rule 2.22. The CBOE proposes that the changes would be effective as of July 1, 2001.

The Exchange is amending the following fees. (1) Registration fees for Registered Representatives, Registered Options Principals, and Financial/Operations Principals will be increased from $45 to $55 for initial applications. Annual and transfer fees for these registered persons will be increased from $40 to $50. The Exchange proposes to amend CBOE Rule 2.22(b) to reflect the increase in these registration fees. (2) The ILX trading floor booth terminal rental fee will be increased from $400 to $425 per month, the ILX installation fee will be increased from $150 to $175 per month, the ILX removal fee will be increased from $100 to $125 per month, and the ILX relocation fee will be increased from $200 to $225 per month. (3) The various monthly booth fees will each be raised 10%. (4) The various membership application fees will each be raised 10%, except for the Fingerprint Processing fee, which will be raised 14% (from $35 to $40), and New Member Orientation Fee, which will remain unchanged at $500. The Exchange proposes to amend its Membership Fee Circular to reflect these membership application fee changes.

The various amendments contained in this filing are structured to fairly allocate the costs of operating the Exchange.

The Exchange proposes to renew and amend its Prospective Fee Reduction Program (''Program''). The Program provides that if at the end of any quarter of the Exchange's fiscal year, the Exchange's average contract volume per day on a fiscal year-to-date basis exceeds one of certain predetermined volume thresholds, the Exchange's market-maker transaction fees will be reduced in the following fiscal quarter in accordance with a fee reduction schedule. Trading volume in the fourth quarter of fiscal year 2001 will be used to determine the discount applied in the first quarter of fiscal year 2002. The CBOE proposes that the Program begin on July 1, 2001 at the beginning of the Exchange's 2002 fiscal year, and continue through the end of the Exchange's 2002 fiscal year, terminating June 30, 2002.

The amendments to the Program are structured to fairly allocate the costs of operating the Exchange in the event that the Exchange experiences higher volume. In addition, although the proposed rule change provides that the Exchange's Program will terminate at the end of the Exchange's 2002 fiscal year, the Exchange intends to evaluate this Program prior to the beginning of the 2002 fiscal year and may renew this Program in the same or modified form for the 2003 fiscal year.[4]

2. Statutory Basis

The Exchange believes the proposed rule change, as amended, is consistent with Section 6(b) Act[5] in general, and furthers the objectives of Section 6(b)(4) of the Act[6] in particular, in that it is designed to provide for the equitable allocation of reasonable dues, fees, and other changes among CBOE members.

B. Self-Regulatory Organization's Statement on Burden on Competition

The Exchange does not believe that the proposed rule change, as amended, will impose any burden on competition not necessary or appropriate in furtherance of purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

No written comments were either solicited or received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Because the foregoing rule change establishes or changes a due, fee, or other charge imposed by the Exchange, it has become effective pursuant to Section 19(b)(3)(A)[7] of the Act and Rule 19b–4(f)(2)[8] thereunder. At any time within 60 days of the filing of the proposed rule change, as amended, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change, as amended, is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change, as amended, that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the CBOE. All submissions should refer to File No. SR–CBOE–2001–37 and should be submitted by August 23, 2001.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[9]

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 01–19281 Filed 8–1–01; 8:45 am]

BILLING CODE 8010–01–M

[4] The Commission notes and the Exchange acknowledges that it would be required to file a proposed rule change pursuant to Section 19(b) of the Act before renewing or modifying this program. Telephone conversation between Christopher Hill, Attorney II, CBOE, and Frank N. Genco, Attorney Advisor, Division, Commission on July 9, 2001.

[5] 15 U.S.C. 78f(b).

[6] 15 U.S.C. 78f(b)(4).

[7] 15 U.S.C. 78s(b)(3)(A).

[8] 17 CFR 240.19b–4(f)(2).

[9] 17 CFR 200.30–3(a)(12).

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–44593; File No. SR–NASD–2001–39]

Self-Regulatory Organizations; Notice of Filing and Immediate Effectiveness of Proposed Rule Change by the National Association of Securities Dealers, Inc. Relating to the Manning Pilot on the OTC Bulletin Board

July 26, 2001.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act'')[1] and Rule 19b–4[2] thereunder, notice is hereby given that on June 7, 2001, the National Association of Securities Dealers, Inc. (''NASD''), through its subsidiary, The Nasdaq Stock Market, Inc. (''Nasdaq''), filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I, II, and III below, which Items have been prepared by Nasdaq. Nasdaq has designated the proposed rule change as constituting a ''non-controversial'' rule change under Paragraph (f)(6) of Rule 19b–4 under the Act,[3] which renders the proposal effective upon receipt of this filing by the Commission. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

Nasdaq is herewith filing a proposal to amend NASD Rule 6541 which, for a pilot period ending February 8, 2002, prohibits member firms from trading ahead of customer limit orders in designated OTC Bulletin Board (''OTCBB'') securities. Specifically, Nasdaq proposes to amend Subsection (b) of NASD Rule 6541 for a three-month pilot period to reduce the minimum price improvement increment establishment therein from five cents to one cent, as explained in more detail below. Nasdaq believes that this change is non-controversial and, therefore, will implement the change immediately upon filing, pursuant to Rule 19b–4(f)(6) under the Act. The three-month pilot change to NASD Rule 6541(b) will operate from August 1, 2001, to November 1, 2001.

The text of this rule change is provided below. Proposed new language is in italics; proposed deletions are in brackets.

* * * * *

6541. Limit Order Protection

(a) Members shall be prohibited from ''trading ahead'' of customer limit orders that a member accepts in securities quoted on the OTCBB. Members handling customer limit orders, whether received from their own customers or from another member, are prohibited from trading at prices equal or superior to that of the customer limit order without executing the limit order. Members are under no obligation to accept limit orders from any customer.

(b) Members may not avoid such obligation specified in paragraph (a) through the provision of price improvement, unless*:* [such price improvement is for a minimum of the lesser of $.05 or one-half (½) of the current inside spread.]:

(1) for customer limit orders priced at or inside the current inside spread, the price improvement is for a minimum of the lesser of $.01 or one-half (½) of the current inside spread; or

(2) for customer limit orders priced outside the current inside spread by $.01 or less, the market maker executes the incoming order at or better than the inside bid (for held buy orders) or offer (for held sell orders).

(3) for customer limit orders priced more than $.01 outside the current inside spread, no obligation is imposed under subsection (a) above.

For purposes of this rule, the inside spread shall be defined as the difference between the best reasonably available bid and offer in the subject security.

(c)–(e) No change.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, Nasdaq included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. Nasdaq has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

On February 8, 2001, the Commission approved new NASD Rule 6541 which, on a pilot basis, applies the basic customer limit order protection principles that presently apply to Nasdaq securities to certain designated securities that are traded on the OTCBB. NASD Rule 6541(a), in general, prohibits member firms that accept customer limit orders in these securities from trading ''ahead'' of their customers for their own account at prices equal or superior to the limit orders, without executing them at the limit price. NASD Rule 6541(b) requires member firms to provide a minimum level of price improvement to incoming orders in OTCBB securities if the firm chooses to trade as principal with those incoming orders at prices superior to customer limit orders they currently hold. Specifically, NASD Rule 6541(b) states that members may not avoid their obligations under the Rule ''through the provision of price improvement, unless such price improvement is for a minimum of the lesser of $0.05 or one-half (½) of the current inside spread.'' If a firm fails to provide the minimum level of price improvement to the incoming order, the firm must execute its held customer limit orders. Generally, if a firm fails to provide the requisite amount of price improvement and also fails to execute its held customer limit orders, it is in violation of the rule.

On March 2, 2001, the Commission approved on a pilot basis a Nasdaq proposal that established a different price improvement increment for the tradining of Nasdaq issues than that established in NASD Rule 6541 with respect to the OTCBB.[4] Nasdaq's proposal established a uniform $0.01 price improvement standard for Nasdaq market makers who elect to execute proprietary transactions in decimalized securities while holding customer limit orders on the same side of the market in those securities without triggering an obligation to ''protect'' (*i.e.,* execute, up to the amount of shares traded proprietarily by the market maker) those customer orders. After that approval, Nasdaq became aware of certain anomalies that occur under its then-existing Manning rule when market makers elect to provide their customers the ability to enter orders into the firms' proprietary system in price increments smaller than a penny. Accordingly, on April 6, 2001, the Commission approved, on an expedited basis, modifications to NASD IM–2110–2.[5]

[1] 15 U.S.C. 78s(b)(1).

[2] 17 CFR 240.19b–4.

[3] 17 CFR 240.19b–4(f)(6).

[4] *See* Securities Exchange Act Release No. 44030 (March 2, 2001), 66 FR 14235 (March 9, 2001).

[5] *See* Securities Exchange Act Release No. 44165 (April 6, 2001), 66 FR 19268 (April 13, 2001) (approving proposal to establish new trading-ahead

As noted in the original filing to extend trading-ahead probhibitions to OTCBB securities on a pilot basis, the limit order protection embodied in NASD Rule 6541 is an investor protection tool based on NASD IM–2110–2 (commonly known as the ''Manning Rule''). In *Manning,* the NASD found and the Commission affirmed that a member firm that accepts a customer limit order has a fiduciary duty not to trade for its own account at prices more favorable than the customer order.[6] NASD Rule 6541 expands, to securities traded on the OTCBB, the protections that NASD IM–2110–2 currently provides only to securities traded on the Nasdaq National Market and SmallCap Market. In fact, when Nasdaq proposed to the Commission that the price improvement increment be set at five cents, it indicated that ''this increment is based upon, and consistent with, Nasdaq's guidance on Members' Manning obligations when trading Nasdaq National Market and SmallCap securities.''[7]

Nasdaq believes that the cost for stepping ahead of a customer's limit order should not be higher in the OTCB, where stock prices are significantly lower, than in Nasdaq. Accordingly, Nasdaq is amending NASD Rule 6541(b) to resemble the relevant language of NASD IM–2110–2, including the amendments approved by the Commission on April 6, 2001. Nasdaq will implement this rule change for three months from the date that NASD Rule 6541 takes effect. Nasdaq has stated that it will give effect to NASD Rule 6541 30 days following the publication of a Notice to Members that explains the operation of NASD Rule 6541, including the operation of the price improvement increment.

Under the proposal, Nasdaq would implement on the OTCBB a price improvement requirement of $0.01 or one-half the inside spread (whichever is less) for a market maker wishing to trade on a proprietary basis in front of a held customer limit order that is priced at or inside the current inside spread for an OTCBB security. For customer limit orders priced outside the inside spread, however, Nasdaq proposes to adopt a different standard. This standard would require a market maker seeking to trade in front of such a limit order, without triggering a Manning obligation, to execute its trade at a price at least equal to the inside bid (with respect to held customer limit orders to buy) or inside offer (for held orders to sell[8]). Market makers will be required to protect only customer limit orders that fall within $0.01 outside the current inside spread.

The following examples illustrate how the proposed rule would operate:

Example #1

Market is 5.00 to 5.01 with MMA's posted bid and offer at the inside

MM receives and accepts Customer #1's limit order to buy priced at 5.004 for 2000 shares

MM receives a market sell order directed to its posted bid of 5.00 for 1000 shares and immediately executes that order on a proprietary basis

Here, since MMA has executed within $0.01 of Customer #1's inside-the-spread buy limit order of 5.004, MMA would be obligated to protect that order and execute 1000 shares of Customer #1's order at a price of 5.004. if MMA wished to avoid a Manning obligation with respect to Customer #1's 5.004 buy limit order, MMA would have to execute its proprietary trade at a price at least $0.005 better than that limit order and execute at 5.009.

Example #2

Market is 10.00 to 10.01 with MMA's posted bid and offer at the inside

MM receives and accepts Customer #2's limit order to buy priced at 9.993 for 500 shares

MM receives a market sell order directed to its posted bid of 10.00 for 700 shares and immediately executes that order on a proprietary basis

Under the Manning changes proposed here, since the market maker's 700 share proprietary order was executed at a price (10.00) that is at least equal to the inside bid, it would not be obligated to execute that limit order. Similarly, if the market remained at 10.00 to 10.01 and MMA held a customer limit order to sell priced at 10.016, MMA could trade proprietarily with an incoming buy order without triggering a Manning obligation with respect to the 10.016 outside-the-spread limit order if the market maker executes its proprietary trade at a price of at least 10.01.[9]

Nasdaq believes that the proposed rule change draws an appropriate balance between providing effective limit order protection for customers who aggressively seek to participate in trading at the inside market while reducing the incidence of forced trading losses to market makers who, in meeting their firm quote and best-execution obligations to other market participants, trade near customer limit orders priced outside the spread.

Nasdaq has stated that both Nasdaq and NASD Regulation will closely monitor the protection of customer limit orders and analyze and evaluate trading activity to determine if future changes to the NASD Rule 6541 price improvement standard are warranted. One goal of this pilot program is to bring NASD Rule 6541 into closer conformity with NASD IM–2110–2, and to permit Nasdaq to analyze the extent to which the two rules should differ.

2. Statutory Basis

Nasdaq believes that the proposed rule change is consistent with the provisions of Section 15A(b)(6) of the Act[10] in that it is designed to: (1) Promote just and equitable principles of trade; (2) foster cooperation and coordination with persons engaged in regulating, clearing, settling, processing information with respect to and facilitating transactions in securities; (3) perfect the mechanism of a free and open market and a national market system; and (4) protect investors and the public interest.

B. Self-Regulatory Organization's Statement on Burden on Competition

Nasdaq does not believe that the proposed rule change will result in any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received from Members, participants, or Others

Written comments were neither solicited nor received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The proposed rule change has been filed by Nasdaq as a ''non-controversial''

increment on Nasdaq, on a pilot basis, until July 9, 2001); *see also* Securities Exchange Act Release No. 44529 (July 9, 2001), 66 FR 37082 (July 16, 2001) (extending pilot program until November 5, 2001.)

[6] *See* In re E.F. Hutton & Co., Securities Exchange Act Release No. 25887 (July 6, 1988) (''Manning'')

[7] *See* Letter from Jeffrey S. Davis, Assistant General Counsel, Nasdaq, to Nancy Sanow, Assistant Director, Division of Market Regulation, Commission, dated January 24, 2001 (Amendment No. 2 to SR–NASD–00–22).

[8] In the filing submitted by the NASD, this phrase originally appeared as ''* * * or inside offer (for held orders to *buy*)'' but has been corrected in the manner that appears above. Telephone Conservation between Jeffrey S. Davis, Assistant General Counsel, Nasdaq, and Michael Gaw, Special Counsel, Division of Market Regulation, Commission, on July 16, 2001.

[9] A third example that was provided in the draft notice has not been published at the request of Nasdaq. Telephone conversation between Jeffrey Davis, Assistant General Counsel, Nasdaq, and Michael Gaw, Special Counsel, Division of Market Regulation, Commission, on July 24, 2001.

[10] 15 U.S.C. 78o–3(b)(6).

rule change pursuant to Rule 19b-4(f)(6) under the Act.[11] Nasdaq has stated that, because the foregoing proposed rule change: (1) Does not significantly affect the protection of investors or the public interest; (2) does not impose any significant burden on competition; and (3) does not become operative until more than 30 days from the date on which it was filed, and Nasdaq provided the Commission with written notice of its intent to file the proposed rule change at least five days prior to the filing date, the proposed rule change has become immediately effective. In addition, the establishment of this pilot program will permit Nasdaq to monitor the operation of NASD Rule 6541 on the OTCBB, and to analyze the extent to which NASD Rule 6541 and NASD IM–2110–2 should differ.

At any time within 60 days of this filing, the Commission may summarily abrogate this proposal if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

Nasdaq has stated that it would implement the new trading-ahead provisions of NASD Rule 6541(b) for a three-month period from the date that NASD Rule 6541 takes effect. Nasdaq also has stated that it would give effect to NASD Rule 6541 30 days following publication of a Notice to Members that will explain the operation of NASD Rule 6541, including the operation of the new price improvement provisions. This Notice to Members was published in July 2001 and indicates that NASD Rule 6541 will become effective on August 1, 2001, and that the price improvement provisions of NASD Rule 6541(b) will be effective until November 1, 2001.[12] The overall pilot program for Manning protection of selected OTCBB securities will be effective until February 8, 2002.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the NASD. All submissions should refer to File No. SR–NASD–2001–39 and should be submitted by August 23, 2001.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[13]

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 01–19283 Filed 8–1–01; 8:45 am]

BILLING CODE 8010–01–M

[11] 17 CFR 240.19b–4(f)(6)

[12] *See* NASD Notice to Members 01–46.

[13] 17 CFR 200.30–3(a)(12).

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–44596; File No. SR–NYSE–00–61]

Self-Regulatory Organizations; Order Approving Proposed Rule Change by the New York Stock Exchange, Inc., Amending the Interpretation of NYSE Rule 412, ''Customer Account Transfer Contracts''

July 26, 2001.

On December 22, 2000, the New York Stock Exchange, Inc., (''NYSE'') filed with the Securities and Exchange Commission (''Commission'') a proposed rule change pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act'') and on February 12, 2001, amended the proposed rule change.[1] Notice of the proposal was published in the **Federal Register** on May 22, 2001.[2] Four comment letters were received.[3] For the reasons discussed below, the Commission is approving the proposed rule change.

I. Description

NYSE Rule 412, ''Customer Account Transfer Contracts,'' prescribes procedures for member organizations transferring customer accounts and requires the use of the Automated Customer Account Transfer Service (''ACATS'') that is administered by the National Securities Clearing Corporation (''NSCC''). Since ACATS's inception in 1985, several enhancements to the system and to NYSE Rule 412 have allowed for faster and more efficient transfers of customer accounts. Recent ACATS modifications facilitate the transfer of accounts containing third party and/or proprietary products.

In the current ACATS environment, a carrying firms must deliver third party mutual funds without knowing whether the receiving firm has the capability to accept, service, and support such funds. If the receiving firm cannot support a particular fund, the delivery will be made to the receiving firms and then reversed back to the carrying firm. This results in substantial processing time by both firms and an overall delay in completing the transfer.[4]

The proposed amendments to paragraphs (b)(1)/01, /04, and /06 of the Interpretation of NYSE Rule 412, in conjunction with the corresponding recent modifications to the ACATS system, require the receiving firms to review an asset validation report provided by the carrying firms and designate those third party products (i.e., mutual funds/money market funds) it is unable to support. Regarding the third party products it is unable to support, the receiving firm will have to provide the customer with a list of the specific assets and will have to request in writing further instructions from the customer with respect to the disposition of those third party products prior to or at the time it makes such a designation. The customer would, at minimum, have to be provided with the following options: (1) Liquidation; (2) retention by the carrying organization; (3) physical delivery in the customer's name to the customer; or (4) transfer to the third party that is the original source of the product. The transfer of the other assets in the account will be undertaken simultaneously with the receiving firm's designation of nontransferable assets.

The amendments also include a notification enhancement that will expedite the disposition of nontransferable proprietary products of

[1] 15 U.S.C. 78s(b)(1).

[2] Securities Exchange Act Release No. 44302 (May 14, 2001), 66 FR 28210.

[3] Letters to Jonathan G. Katz, Secretary, Commission from Richard Bommer, President, Customer Account Transfer Division, Securities Industry Association (June 6, 2001); Brian Warshaw, Director, Merrill Lynch, Pierce, Fenner & Smith (June 8, 2001); Pattie Schuchman, Associate Vice President, A.G. Edwards & Sons, Inc. (June 11, 2001); and Frederic M. Krieger, Senior Vice President, Charles Schwab & Co., Inc. (June 15, 2001).

[4] NYSE-member organizations approximate that 50% of their ACATS ''fails-to-deliver'' that are ultimately reversed are caused by the attempted transfer of mutual funds that the receiving firm is unable to support. The ACATS-generated fails result in considerable expense to carrying firms because they are required to credit the receiving firm funds equivalent to the value of the assets they are unable to deliver.

the carrying firm. The current Interpretation requires that the carrying organization provide general notification to the customer if an account to be transferred contains any nontransferable assets. The amendments require the carrying organization to provide the customer with a list of the specific nontransferable, proprietary products of the carrying firm that are in the customer's account.

Finally, the NYSE is amendment the Interpretation of Rule 412 to address situations where a carrying organization internally reassigns customer accounts to other registered representatives and establishes new account numbers. The proposed amendment places responsibility for tracking these account number changes with the carrying organization and makes clear that a transfer request rejected on the basis of such reassignment will not be considered a legitimate exception under Rule 412.

II. Comments

The Commission received four comment letters. All the commenters expressed strong support for the proposed changes to the Interpretation of Rule 412 discussed above.

III. Discussion

The Commission finds that the proposed rule change is consistent with the Act's requirements and the rules and regulations thereunder and particularly with the requirements of Section 6(b)(5) of the Act.[5] Section 6(b)(5) of the Act[6] requires that the rules of a national securities exchange be designed to remove impediments to and perfect the mechanism of a free and open market and a national market system, and protect investors and the public interest. These obligations are met when procedures governing the transfer of customer accounts are made faster and more efficient. For example, the proposed designation requirements on the part of the receiving firm should reduce the overall timeframe for transferring proprietary and/or third party products and should lower the related costs incurred by NYSE's member organizations. The change to the Interpretation should also reduce customer confusion and facilitate decisions by customers concerning the disposition of proprietary and third party products.

IV. Conclusion

On the basis of the foregoing, the Commission finds that the proposal is consistent with the requirements of the act and in particular with the requirements of Section 17A of the Act and the rules and regulations thereunder.

It is Therefore Ordered, pursuant to Section 19(b)(2) of the Act, that the proposed rule change (File No. SR–NYSE–00–61) be, and hereby is, approved.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[7]

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 01–19280 Filed 8–1–01; 8:45 am]

BILLING CODE 8010–01–M

[5] 15 U.S.C. 78f(b)(5).

[6] 15 U.S.C. 78f(b)(5).

[7] 17 CFR 200.30–3(a)(12).

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–44595; File No. SR–NYSE–2001–15]

Self-Regulatory Organizations; Order Granting Accelerated Approval to Proposed Rule Change by the New York Stock Exchange, Inc. Amending NYSE Rules 104 and 1100 Relating to Trading of ETFs

July 26, 2001.

I. Introduction

On June 15, 2001, the New York Stock Exchange, Inc. (''NYSE'' or ''Exchange'' filed with the Securities and Exchange Commission (''SEC'' or ''Commission''), pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act'')[1] and Rule 19b–4 thereunder,[2] a proposed rule change consisting of an amendment to NYSE Rule 104 to facilitate trading in Exchange Traded Funds (''ETFs''), and amendments to NYSE Rule 1100 to clarify that rules relating to Investment Company Units apply to such securities traded on the basis of unlisted trading privileges (''UTP''), and to authorize the Exchange to close trading in an ETF at 4:05 p.m. when trading in a related futures contract has closed at that time on the last trading day of the month. The proposed rule change was published for comment in the **Federal Register** on June 28, 2001.[3] The Commission received one comment on the proposal.[4] On July 26, 2001, the Exchange submitted a response to the comment letter.[5]

II. Description of the Proposed Rule Change

The Exchange plans to begin trading certain ETFs on the Exchange on a UTP basis on July 31, 2001. These ETFs are The NASDAQ 100 Trust (symbol QQQ), Standard and Poor's Depositary Receipts (symbol SPY) and the Dow Industrials DIAMONDS (symbol DIA). ETFs are securities which are defined as Investment Company Units in Section 703.16 of the Exchange's Listed Company Manual. The Exchange proposes to amend NYSE Rule 1100(a) to clarify that NYSE rules applying to Investment Company Unites also apply to securities fitting that definition that are traded on the Exchange on the basis of UTP.

NYSE Rule 104 governs specialists' dealings in Their specialty stocks. NYSE Rule 104.10 requires specialists to obtain Floor Official approval when purchasing on a direct plus tick or selling on a direct minus tick, or when purchasing on a zero plus tick more than 50% of the stock offered. These transactions are seen as destabilizing, and may be effected by the specialist only with Floor Official approval. NYSE Rule 104.10(7) was amended several years ago to permit a specialist registered in an Investment Company Unit to effect proprietary destabilizing trades without Floor Official approval to bring the security into parity with the value of the index on which the unit is based or with The net asset value of the securities comprising the unit. The purpose of that amendment was to permit a specialist registered in a ''country basket'' to act expeditiously to bring the basket into parity with the value of the securities comprising the basket.[6]

As noted above, ETFs are within the meaning of the term Investment Company Units, and thus, an ETF specialist is permitted under NYSE Rule 104.10(7) to effect proprietary destabilizing trades without Floor Official approval to bring the ETF into parity with the underlying index or the net asset value of the securities comprising the ETF. The Exchange proposes to permit specialists to effect proprietary destabilizing trades without floor official approval to bring the ETF into parity with a futures contract on the value of the index on which the Unit is

[1] 15 U.S.C. 78s(b)(1).

[2] 17 CFR 240.19b–4.

[3] *See* Securities Exchange Act Release No. 44465 (June 22, 2001), 66 FR 34503.

[4] *See* letter from Alton B. Harris, Ungaretti & Harris, to Jonathan G. Katz, Secretary, Commission, dated July 13, 2001.

[5] *See* letter from James E. Buck, Senior Vice President and Secretary, NYSE, to Nancy Sanow, Assistant Director of Market Regulation (''Division''), Commission, dated July 26, 2001.

[6] *See* Securities Exchange Act Release No. 37016 (March 22, 1996), 61 FR 14185 (March 29, 1996.)

based. Such transactions remain subject to the requirement that they be effected in a manner that is consistent with the maintenances of a fair and orderly market.

Finally, the Exchange proposes to close trading in an ETF at 4:05 p.m. (Eastern Time) on the last business day of each month, which is the same time that trading in a related futures contract closes on the last business day of the month.

III. Summary of Comments

The commenter stated that registered competitive market makers on the Exchange should be treated in a similar manner as specialists when trading ETFs on a UTP basis with respect to the ability to effect destabilizing transactions.

The Exchange responded that, as a matter of policy, it has a determined to utilize a unitary market maker system, *i.e.,* specialists, when trading ETFs on a UTP basis.

IV. Discussion

After careful review, the Commission finds that the proposed rule change is consistent with the requirements of the Act and the rules and regulations thereunder applicable to a national securities exchange [7] and, in particular, the requirements of Section 6 of the Act [8] and the rules and regulations thereunder. The Commission finds specifically that the proposed rule change is consistent with Section 6(b)(5) of the Act [9] because it is designed to promote just and equitable principles of trade, to remove impediments to and perfect the mechanism of a free and open market and a national market system and, in general, to protect investors and the public interest.

In particular, the Commission finds that the proposed amendments to NYSE Rules 104 and 1100 will enable the NYSE to accommodate the trading of ETFs on a UTP basis. The Commission believes clarifying NYSE Rule 1100(a) to expressly state that NYSE rules applying to Investment Company Units will also apply to ETFs trading on the Exchange on the basis of UTP should provide members and investors with notice as to the rules applicable to ETFs traded on the NYSE.

In addition, because ETFs are considered Investment Company Units, an ETF specialist is permitted under current NYSE Rule 104.10(7) to effect proprietary destabilizing trades without Floor Official approval to bring the ETF into parity with the underlying index or the net asset value of the securities comprising the ETF. The Exchange proposes to amend this rule to permit an ETF specialist to effect proprietary destabilizing transactions without Floor Official approval to bring the ETF into parity with a futures contract on the index on which the ETF is based. The Commission believes that it is reasonable to allow such transactions without Floor Official approval, so long as such trades are effected in a manner that is consistent with the maintenance of a fair and orderly market.[10] The Commission notes that ETFs have a pricing and trading relationship linked to the index on which the ETF is based, the net asset value of securities comprising the Unit, as well as the futures contract on the value of the index on which the Unit is based. Thus, a specialist may determine that it needs to engage in a parity transaction to bring the ETF in line with these related products. The requirement to secure floor approval could delay specialists from effectuating such transactions, during which time the values of the related index, components, or futures contract could continue to move. Therefore, the Commission believes that it is reasonable for NYSE to remove floor official approval when a specialist engages in transactions to bring an ETF in line with its related futures contract.

Furthermore, the Exchange proposal to close trading in an ETF at 4:05 p.m. on the last business day of each month is consistent with the close of trading in ETFs and futures on other markets and should facilitate the trading of these products across markets.

Finally, the Commission notes that the proposal was noticed for a 15-day comment period and the Commission received only one comment letter regarding the proposal for which the Exchange provided a response. Accordingly, the Commission finds good cause pursuant to Section 19(b)(2) of the Act [11] to approve the proposed rule change on an accelerated basis prior to the thirtieth day after the date of publication of notice of filing thereof in the **Federal Register** in order to allow the NYSE to have these amendments to its rules in place to accommodate the trading of ETFs on a UTP basis scheduled to begin on July 31, 2001.

V. Conclusion

For the foregoing reasons, the Commission finds that the proposal is consistent with the requirements of the Act and rules and regulations thereunder.

It is Therefore Ordered, pursuant to Section 19(b)(2) of the Act [12] that the proposed rule change (File No. SR–NYSE–2001–15) be, and it hereby is, approved on an accelerated basis.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[13]

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 01–19282 Filed 8–1–01; 8:45 am]

BILLING CODE 8010–01–M

[7] In approving this proposed rule change, the Commission notes that it has considered the proposed rule's impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).

[8] 15 U.S.C. 78f.

[9] 15 U.S.C. 78f(b)(5).

[10] The Commission notes, however, that direct destabilizing transactions that are leading, rather than following, the related futures contract would continue to require Floor Official approval. In addition, specialists remain subject to all other requirements of NYSE Rule 104 with respect to their affirmative and negative obligations to maintain a fair and orderly market. Telephone conversation between Don Siemer, Director, Market Surveillance, NYSE, and Kelly Riley, Special Counsel, Division, Commission, on July 26, 2001.

[11] 15 U.S.C. 78s(b)(2).

[12] 15 U.S.C. 78s(b)(2).

[13] 17 CFR 200.30–3(a)(12).

SMALL BUSINESS ADMINISTRATION

[Declaration of Disaster #3355]

State of Ohio and Contiguous Counties in Indiana and Kentucky

Butler and Hamilton Counties and the contiguous counties of Clermont, Montgomery, Preble, and Warren in the State of Ohio; Dearborn, Franklin, and Union Counties in the State of Indiana; and Boone, Campbell, and Kenton Counties in the Commonwealth of Kentucky constitute a disaster area due to damages caused by severe storms and flooding that occurred July 15 through July 18, 2001. Applications for loans for physical damage as a result of this disaster may be filed until the close of business on September 27, 2001 and for economic injury until the close of business on April 29, 2002 at the address listed below or other locally announced locations:

U.S. Small Business Administration, Disaster Area 2 Office, One Baltimore Place, Suite 300, Atlanta, GA 30308.

The interest rates are:

	Percent
For Physical Damage:	
Homeowners With Credit Available Elsewhere	6.625
Homeowners Without Credit Available Elsewhere	3.312
Businesses With Credit Available Elsewhere	8.000
Businesses and Non-Profit Organizations Without Credit Available Elsewhere	4.000

	Percent
Others (INCLUDING NON-PROFIT Organizations) With Credit Available Elsewhere ...	7.125
For Economic Injury:	
Businesses and Small Agricultural Cooperatives Without Credit Available Elsewhere ...	4.000

The numbers assigned to this disaster for physical damage are 335511 for Ohio, 335611 for Indiana, and 335711 for Kentucky. The numbers assigned to this disaster for economic injury are 9M2300 for Ohio, 9M2400 for Indiana, and 9M2500 for Kentucky.

(Catalog of Federal Domestic Assistance Program Nos. 59002 and 59008)

Dated: July 27, 2001.

John Whitmore,

Acting Administrator.

[FR Doc. 01–19361 Filed 8–1–01; 8:45 am]

BILLING CODE 8025–01–P

DEPARTMENT OF STATE

[Public Notice 3736]

Culturally Significant Objects Imported for Exhibition Determinations: ''The Short Century: Independence and Liberation Movements in Africa 1945–1994''

ACTION: Notice.

SUMMARY: Notice is hereby given of the following determinations: Pursuant to the authority vested in me by the Act of October 19, 1965 [79 Stat. 985, 22 U.S.C. 2459], the Foreign Affairs Reform and Restructuring Act of 1998 [112 Stat. 2681 *et seq.*], Delegation of Authority No. 234 of October 1, 1999 [64 FR 56014], Delegation of Authority No. 236 of October 19, 1999 [64 FR 57920], as amended by Delegation of Authority No. 236–3 of August 28, 2000 [65 FR 53795], and Delegation of Authority dated June 29, 2001, I hereby determine that the objects to be included in the exhibit, ''The Short Century: Independence and Liberation Movements in Africa 1945–1994,'' imported from abroad for the temporary exhibition without profit within the United States, are of cultural significance. These objects are imported pursuant to loan agreements with foreign lenders. I also determine that the temporary exhibition or display of the exhibit objects at the Museum of Contemporary Art, Chicago, Illinois from on or about September 8, 2001, to on or about December 30, 2001, and at the P.S.1 Contemporary Art Center, Long Island City, New York from on or about February 10, 2002, to on or about May 5, 2002, is in the national interest. Public Notice of these determinations is ordered to be published in the **Federal Register.**

FOR FURTHER INFORMATION CONTACT: For further information, including a list of exhibit objects, contact Paul W. Manning, Attorney-Adviser, Office of the Legal Adviser, 202/619–5997, and the address is United States Department of State, SA–44, Room 700, 301 4th Street, SW., Washington, DC 20547–0001.

Dated: July 26, 2001.

Brian J. Sexton,

Deputy Assistant Secretary for Professional Exchanges, United States Department of State.

[FR Doc. 01–19332 Filed 8–1–01; 8:45 am]

BILLING CODE 4710–08–P

DEPARTMENT OF STATE

[Public Notice 3734]

Bureau of Educational and Cultural Affairs Request for Grant Proposals: Administration of Partnership Programs in Higher Education

SUMMARY: The Humphrey Fellowships and Institutional Linkages Branch of the Office of Global Educational Programs in the Bureau of Educational and Cultural Affairs of the United States Department of State announces an open competition for an assistance award to cooperate with the Bureau in the administration of partnership programs in higher education in Fiscal Year 2002. These programs include the Educational Partnerships Program (formerly known as the College and University Affiliations Program), the NIS College and University Partnerships Program (NISCUPP), and the NIS Community College Partnerships Program (NISCCPP). The partnership programs in higher education award grants to accredited U.S. post-secondary institutions to administer projects that will strengthen mutual understanding and scholarly cooperation on subjects of enduring common interest to the United States, to other countries, and to the participating institutions. Contingent on the availability of funds, approximately 35 to 45 grant awards in an amount totaling between $7 million and $9 million may be issued under these programs during Fiscal Year 2002.

The integrity of these programs requires that they maintain the highest and most consistent standards of academic and professional quality in the selection of proposals and the implementation of projects. Public and private non-profit organizations meeting the provisions described in IRS regulation 26 CFR 1.501(c) may submit proposals to provide administrative and program services for the Bureau's educational partnership programs in Fiscal Year 2002 by undertaking the following activities: (1) Technical review of approximately 225 proposals that are expected to be submitted to the Bureau for these programs in Fiscal Year 2002; (2) coordinating the academic review of eligible proposals by independent panels of scholarly and professional experts in consultation with representatives of the Department of State, and providing expert recommendations about the merits of the proposals that should receive final consideration; (3) making substantive recommendations concerning the administration of the exchange projects to be funded through these programs and about the parameters and guidelines for these programs in future years; (4) dissemination of information about these programs for the FY2003 cycle; (5) conducting a proposal development workshop for approximately 25 administrators and faculty members at U.S. institutions of higher education; (6) cooperation in announcing the issuance of the FY 2002 grant awards and in promoting visibility for the projects funded under these programs; and, (7) development of an illustrated brochure for use in disseminating information about the purposes and achievements of educational partnership programs since their establishment by the Bureau in 1982.

Program Information

Overview

The Bureau's international institutional partnership programs in higher education support cooperative partnerships of U.S. colleges and universities with foreign post-secondary institutions through faculty and staff exchanges and related activities. Competitions target specified themes and geographic regions and typically focus on the humanities, the social sciences, public administration, business, law, journalism and mass communications, public health policy and administration, or educational administration. A list of previously issued educational partnership and affiliations grants can be found online at: *http://exchanges.state.gov/education/cuap/history.* Programs for which administrative cooperation is requested through this solicitation include the following programs:

(1) The Educational Partnerships Program, formerly known as the College and University Affiliations Program,

supports partnerships with institutions in selected countries in every world region except the New Independent States of the former Soviet Union (NIS). Funding is currently provided from the Bureau's exchanges appropriation or through interagency transfers, for example, under the Support for East European Democracies (SEED) Act or the U.S.-North African Economic Partnership (USNAEP). Under this program, colleges and universities conduct exchanges of professors and administrators in projects designed to ensure a broad and coherent impact.

(2) On a parallel track and with funding provided through interagency transfers under the FREEDOM Support Act, the NIS College and University Partnerships Program (NISCUPP) supports partnerships with institutions in the NIS with an emphasis on projects that will assist countries in that world region in their transitions toward market-oriented economies and democratic political practices.

(3) Also with funding under the FREEDOM Support Act, the NIS Community College Partnerships Program (NISCCPP) supports the partnerships of U.S. community colleges with institutions in selected countries of the NIS with the same emphasis as in the NIS College and University Partnerships Program.

Based on recent experience, the Bureau anticipates receiving from 100 to 120 proposals for the Educational Partnerships Program; from 60 to 85 for the NISCUPP; and from 10 to 20 for the NISCCPP. The deadline for the submission of applications in these competitions is anticipated for January 2002. All competitions for which cooperation is invited in this solicitation will be announced in the **Federal Register** as Requests for Grant Proposals.

Applicant organizations should explain how they will administer the technical review in a fast and efficient manner, and how they will organize the independent review of eligible proposals by qualified experts in terms of the review criteria specified in the Requests for Grant Proposals. In addition, the proposal should explain how the applicant organization will utilize the expertise of panelists and its own knowledge of educational exchange programs to formulate recommendations for the administration of the FY2002 exchange projects and for the guidelines and parameters for these programs in future years. The proposal should also outline a strategy designed to ensure that information about these programs is widely disseminated to potential applicants for the FY2003 application cycles. An application workshop should be designed in consultation with the Bureau to increase the competitiveness of proposals submitted for these competitions. The proposal should outline a strategy for announcing the issuance of the FY2002 grant awards for these Programs in order to give appropriate visibility to funded projects and to the partnership programs within the U.S. and foreign academic communities. Finally, the proposal should outline a plan to prepare and publish a brochure about the purposes and achievements of educational partnership projects during the twenty years since the establishment of the College and University Affiliations Program in 1982.

Approximate Program Dates: Pending the availability of FY-2002 funds, the grant should begin on or about December 1, 2001 and end approximately November 30, 2002.

Guidelines

Project Description

The Humphrey Fellowships and Institutional Linkages Branch of the Bureau's Office of Global Educational Programs will work closely with the recipient of the cooperative agreement and will maintain a regular dialogue on administrative issues and questions as they arise over the duration of the award. In consultation with the Branch, the award recipient shall undertake the following tasks:

(1) Review approximately 225 proposals for compliance with the technical eligibility factors published in the appropriate Request for Grant Proposals (RFGP) for FY 2002 competitions. Copies of previous year RFGPs for the three partnership programs listed in this solicitation document will be provided in the application package. In addition, copies of the FY 2002 RFGPs will be made available if they are published prior to the deadline for this competition. Currently open RFGPs may also be accessed online at *http://exchanges.state.gov/education/rfgps.* RFGPs generally provide guidelines about eligible countries, fields, types of institutions, funding levels, deadlines and other requirements. Proposals may be declared ineligible due to: (a) Ineligibility of a U.S. or foreign partner institutions; (b) submission by an organization other than the U.S. partner; (c) ineligibility of the foreign country or location for the competition in question; (d) ineligibility of the amount of funding requested, or other factors. Upon completion of the technical review, the recipient should provide the Bureau with a list of eligible proposals, organized by foreign country or location.

(2) Coordinate the independent review of technically eligible proposals in meetings of scholarly and professional experts who are qualified by their regional and subject expertise to evaluate the proposals in terms of the published review criteria. The recipient of the cooperative agreement shall organize the meetings to review the proposals regionally or thematically in consultation with the program office. Applicants are encouraged to discuss and to recommend, in their submissions, options for organizing the review of proposals. Following the panel meetings, the cooperating agency shall promptly provide the Bureau with a detailed appraisal report, including a summary of the panel discussion, to facilitate the Department of State's review of those proposals recommended for its consideration. The appraisal reports shall also provide an adequate basis for the Bureau's program office to provide constructive suggestions for improving the proposals under review.

(3) Provide, based on discussions with the independent reviewers and on its own knowledge of international scholarly and educational exchange programs, substantive and broad-ranging recommendations to the Bureau regarding the proposed exchange projects and for program guidelines and parameters in future years.

(4) Disseminate information to institutions that have not previously applied to receive grants through the educational partnership programs administered by the Office of Global Educational Programs. Proposals should include creative strategies for identifying and communicating effectively with appropriate institutional officials as well as potential project directors with subject and regional interests that coincide with eligible competition themes and regions.

(5) Conduct one one-day proposal development workshop for approximately 25 representatives of institutions that submitted proposals in FY2000, FY2001, or FY2002 but which were not funded. The purpose of the workshop would be to enable these institutions to improve the quality of their submissions in the future. The proposal should outline a strategy for sharing the costs of this workshop with the participating institutions and for developing an appropriate agenda that will meet their needs as well as those of the program office.

(6) In coordination with the Bureau, announce the issuance of the FY2002 grant awards in order to achieve greater

visibility for the educational partnership programs.

(7) In consultation with the Bureau, develop a brochure about the educational partnership programs, which have been administered by the Bureau since 1982. Summarize and highlight their objectives and achievements and, using information available on the program's website, report on the distribution of grants by field, country, and world region over more than twenty years of program activity.

In its submission, the applicant shall designate a coordinator to cooperate with the Bureau in overseeing the process for identifying qualified panelists, the technical reviews, the independent panel review meetings, the preparation of the detailed summaries of the academic review discussions, the provision of recommendations to the Bureau for the administration of these Programs, the dissemination of information about the FY2003 programs, the design and administration of the proposal development workshop, the announcement of the issuance of the FY2002 grant awards, and the preparation of the brochure.

Eligibility

To facilitate the observation of the panel review meetings by U.S. Department of State representatives, applicants should have the capacity to conduct the panel meetings in the Washington, D.C. metropolitan area.

Budget Guidelines

Because grants awarded to eligible organizations with less than four years of experience in conducting international exchange programs will be limited to $60,000, such organizations are not encouraged to apply in this competition.

Applicants must submit a comprehensive budget for the entire program. The total request to the Bureau, including any amount requested for a Travel Management Center (TMC) account, may not exceed $225,000. Please note that the Proposal Submission Instructions explain the use of TMC accounts and that a minimum travel budget of $20,000 is required to establish a TMC account. There must be a summary budget as well as separate sub-budgets for each program component to provide clarification.

Please refer to the Solicitation Package for complete budget guidelines and formatting instructions.

Announcement Title and Number: All correspondence with the Bureau concerning this RFGP should reference the above title and number ECA/A/S/U–02–02 (Administration of Partnerhsip Programs in Higher Education).

FOR FURTHER INFORMATION CONTACT: The Office of Global Educational Programs, ECA/A/S/U, room 349, U.S. Department of State, SA–44, 301 4th Street, S.W., Washington, D.C. 20547, telephone: 202–619–4126; fax: 202–401–1433; e-mail: jcebra@pd.state.gov to request a Solicitation Package. The Solicitation Package contains detailed award criteria, required application forms, specific budget instructions, and standard guidelines for proposal preparation. Please specify Bureau Program Officer Jonathan Cebra on all inquiries and correspondence.

Please read the complete **Federal Register** announcement before sending inquiries or submitting proposals. Once the RFGP deadline has passed, Bureau staff may not discuss this competition with applicants until the proposal review process has been completed.

To Download a Solicitation Package Via Internet

The entire Solicitation Package may be downloaded from the Bureau's website at http://exchanges.state.gov/education/RFGPs. Please read all information before downloading.

Deadline for Proposals

All proposal copies must be received at the Bureau of Educational and Cultural Affairs by 5 p.m. Washington, D.C. time on Friday, October 19, 2001.

Faxed documents will not be accepted at any time. Documents postmarked the due date but received on a later date will not be accepted. Each applicant must ensure that the proposals are received by the above deadline.

Applicants must follow all instructions in the Solicitation Package. The original and seven copies of the application should be sent to: U.S. Department of State, SA–44, Bureau of Educational and Cultural Affairs, Ref.: ECA/A/S/U–02–02, Program Management, ECA/EX/PM, Room 534, 301 4th Street, SW., Washington, DC 20547.

Diversity, Freedom and Democracy Guidelines

Pursuant to the Bureau's authorizing legislation, programs must maintain a non-political character and should be balanced and representative of the diversity of American political, social, and cultural life. ''Diversity'' should be interpreted in the broadest sense and encompass differences including, but not limited to ethnicity, race, gender, religion, geographic location, socio-economic status, and physical challenges. Applicants are strongly encouraged to adhere to the advancement of this principle both in program administration and in program content. Please refer to the review criteria under the 'Support for Diversity' section for specific suggestions on incorporating diversity into the total proposal. Public Law 104–319 provides that ''in carrying out programs of educational and cultural exchange in countries whose people do not fully enjoy freedom and democracy,'' the Bureau ''shall take appropriate steps to provide opportunities for participation in such programs to human rights and democracy leaders of such countries.'' Public Law 106–113 requires that the governments of the countries described above do not have inappropriate influence in the selection process. Proposals should reflect advancement of these goals in their program contents, to the full extent deemed feasible.

Review Process

The Bureau will acknowledge receipt of all proposals and will review them for technical eligibility. Proposals will be deemed ineligible if they do not fully adhere to the guidelines stated herein and in the Solicitation Package. All eligible proposals will be reviewed by the program office. Eligible proposals will be subject to compliance with Federal and Bureau regulations and guidelines and forwarded to Bureau grant panels for advisory review. Proposals may also be reviewed by the Office of the Legal Adviser or by other Department elements. Final funding decisions are at the discretion of the Department of State's Acting Assistant Secretary for Educational and Cultural Affairs. Final technical authority for assistance awards (grants or cooperative agreements) resides with the Bureau's Grants Officer.

Review Criteria

Technically eligible applications will be competitively reviewed according to the criteria stated below. These criteria are not rank ordered and all carry equal weight in the proposal evaluation:

1. Quality of Program Plan/Ability to Achieve Program Objectives: Agenda and plan should adhere to the program overview and guidelines described above and in the Application Package. Objectives should be reasonable, feasible, and flexible. The proposal should clearly demonstrate how the organization will meet the program's objectives and plan, including the coordination of staffing for overlapping review schedules.

2. Institution's Record/Ability/Capacity: Proposed personnel and institutional resources should be

adequate and appropriate to achieve the project's goals. The proposal should demonstrate responsible fiscal management and full compliance with all reporting requirements for past Bureau grants as determined by Bureau's Grants Division.

3. Support of Diversity: Proposals should demonstrate substantive support of the Bureau's policy on diversity. The proposal should describe the process for ensuring diversity among the review panelists. In addition to knowledge of eligible regions and subjects, panelists should also have appropriate experience with or knowledge of the types of institutions represented in the proposals to be reviewed.

4. Project Evaluation: Proposals should include a plan to evaluate the success of each program component. Draft survey questionnaires for the use of panelists and workshop participants should be provided.

5. Cost-effectiveness: The overhead and administrative components of the proposal, including salaries and honoraria, should be kept as low as possible. All other items should be necessary and appropriate. Proposals should maximize cost-sharing through other private sector support as well as institutional direct funding contributions.

Authority

Overall grant making authority for this program is contained in the Mutual Educational and Cultural Exchange Act of 1961, Public Law 87–256, as amended, also known as the Fulbright-Hays Act. The purpose of the Act is ''to enable the Government of the United States to increase mutual understanding between the people of the United States and the people of other countries * * *; to strengthen the ties which unite us with other nations by demonstrating the educational and cultural interests, developments, and achievements of the people of the United States and other nations * * * and thus to assist in the development of friendly, sympathetic and peaceful relations between the United States and the other countries of the world.'' The funding authority for portions of the program cited above is provided through the Freedom for Russia and Emerging Eurasian Democracies and Open Markets Support Act of 1992 (FREEDOM Support Act) and through the Support for East European Democracies Act.

Notice

The terms and conditions published in this RFGP are binding and may not be modified by any Bureau representative. Explanatory information provided by the Bureau that contradicts published language will not be binding. Issuance of the RFGP does not constitute an award commitment on the part of the Government. The Bureau reserves the right to reduce, revise, or increase proposal budgets in accordance with the needs of the program and the availability of funds. Awards made will be subject to periodic reporting and evaluation requirements.

Notification

Final awards cannot be made until funds have been appropriated by Congress, allocated and committed through internal Bureau procedures.

Dated: July 24, 2001.

Brian J. Sexton,

Deputy Assistant Secretary for Professional Exchanges, Bureau of Educational and Cultural Affairs, U.S. Department of State.

[FR Doc. 01–19194 Filed 8–1–01; 8:45 am]

BILLING CODE 4710–05–P

DEPARTMENT OF TRANSPORTATION

Federal Highway Administration

Environmental Impact Statement, Riverside County, California

AGENCY: Federal Highway Administration (FHWA), Department of Transportation (DOT).

ACTION: Notice of Intent.

SUMMARY: The Federal Highway Administration (FHWA), as lead agency, in cooperation with the Riverside County Transportation Commission (RCTC) and the California Department of Transportation intend to prepare an Environmental Impact Statement (EIS) in accordance with the National Environmental Policy Act of 1969 (NEPA). The EIS will study alternatives to implement transportation corridor improvements in western Riverside County, specifically improvements for the Hemet to Corona/Lake Elsinore (East to West) transportation corridor.

Pursuant to 40 CFR 1508.28, FHWA intends to tier the EIS for this project. The Tier 1 EIS to be prepared pursuant to this notice will be used to support a route location decision. A future Tier 2 EIS will be prepared to present the design features and construction level of detail for the evaluation of alternatives within the preferred route.

FOR FURTHER INFORMATION CONTACT: Mary Ann Rondinella, Environmental Specialist, Federal Highway Administration, 980 Ninth Street, Suite 400, Sacramento, CA 95814–2724. Telephone: (916) 498–5040. Fax: (916) 498–5008. Cathy Bechtel, RCTC, 3560 University Avenue, Suite 100, Riverside, CA 92501. Telephone: (909) 787–7141. Fax: (909) 787–7920.

SUPPLEMENTARY INFORMATION: The Hemet to Corona/Lake Elsinore (East to West) transportation corridor is part of the Community and Environmental Transportation Acceptability Process (CETAP) being undertaken jointly by the County of Riverside and the RCTC. CETAP is one component of the Riverside County Integrated Project (RCIP), which also includes a new Riverside County General Plan and a Multi-Species Habitat Conservation Plan (MSHCP) for western Riverside County. According to current projections by the Southern California Association of Governments (SCAG), population and employment are expected to more than double in western Riverside County within the next 20 years. Due to the fast pace of development, opportunities are being lost to preserve land for habitat conservation and regional transportation facilities. These facilities are intended to address the mobility needs for both people and goods, with the potential for incorporating the needs for highways, transit, and utilities, where appropriate.

In July, 2000, the RCTC Board of Directors and the Riverside County Board of Supervisors directed the initiation of engineering and environmental studies for two corridors: Winchester to Temecula (North to South) and Hemet to Corona/Lake Elsinore (East to West), which will move forward in parallel. A separate Notice of Intent is being issued for the Winchester to Temecula Corridor.

The objective of the proposed EIS is to provide environmental analysis of a multimodal transportation facility within the Hemet to Corona/Lake Elsinore Corridor to allow agencies to proceed with the preservation of right-of-way for a preferred alternative. One goal of the RCIP process is to preserve the rights-of-way needed for the transportation facilities while minimizing potential impacts on habitat, aquatic resources, communities, landowners, and other elements of the environment.

Additional information regarding the Riverside County Integrated Project is also available on the Internet at *www.rcip.org.*

Public scoping meetings will be held. The public will be notified through local newspapers, postings in public places, and through other public notification methods. The notices will identify the place, dates, and time of the meetings.

To ensure that the full range of issues related to the proposed improvements

are addressed and all significant issues identified, comments and suggestions are invited from all interested parties. Comments or questions concerning this proposed action and the EIS should be directed to FHWA and/or RCTC at the addresses provided above.

(Catalog of Federal Assistance Program Number 20.205, Highway Planning, and Construction. The regulations implementing Executive Order 12372 regarding intergovernmental consultation on Federal programs and activities apply to this program.)

Issued on: July 23, 2001.

Jeffrey W. Kolb,

Team Leader, Program Delivery Team-South Sacramento, California.

[FR Doc. 01–19342 Filed 8–1–01; 8:45 am]

BILLING CODE 4910–22–M

DEPARTMENT OF TRANSPORTATION

Federal Highway Administration

Environmental Impact Statement, Riverside County, California

AGENCY: Federal Highway Administration (FHWA), Department of Transportation (DOT).

ACTION: Notice of Intent.

SUMMARY: The Federal Highway Administration (FHWA), as lead agency, in cooperation with the Riverside County Transportation Commission (RCTC) and the California Department of Transportation intend to prepare an Environmental Impact Statement (EIS) in accordance with the National Environmental Policy Act of 1969 (NEPA). The EIS will study alternatives to implement transportation corridor improvements in western Riverside County, specifically improvements for the Winchester to Temecula (North to South) transportation corridor.

Pursuant to 40 CFR 1508.28, FHWA intends to tier the EIS for this project. The Tier 1 EIS to be prepared pursuant to this notice will be used to support a route location decision. A future Tier 2 EIS will be prepared to present the design features and construction level of detail for the evaluation of alternatives within the preferred route.

FOR FURTHER INFORMATION CONTACT: Mary Ann Rondinella, Environmental Specialist, Federal Highway Administration, 980 Ninth Street, Suite 400, Sacramento, CA 95814–2724. Telephone: (916) 498–5040. Fax: (916) 498–5008. Cathy Bechtel, RCTC, 3560 University Avenue, Suite 100, Riverside, CA 92501. Telephone: (909) 787–7141. Fax: (909) 787–7920.

SUPPLEMENTARY INFORMATION: The Winchester to Temecula (North to south) transportation corridor is part of the Community and Environmental Transportation Acceptability Process (CETAP) being undertaken jointly by the county of Riverside and the RCTC. CETAP is one component of the Riverside County Integrated Project (RCIP), which also includes a new Riverside County General Plan and a Multi-Species Habitat Conservation Plan (MSHCP) for western Riverside County. According to current projections by the southern California Association of Governments (SCAG), population and employment are expected to more than double in western Riverside County within the next 20 years. Due to the fast pace of development, opportunities are being lost to preserve land for habitat conservation and regional transportation facilities. These facilities are intended to address the mobility needs for both people and goods, with the potential for incorporating the needs for highways, transit, and utilities, where appropriate.

In July, 2000, the RCTC Board of Directors and the Riverside County Board of Supervisors directed the initiation of engineering and environmental studies for two corridors: Winchester to Temecula (North to south) and Hemet to Corona/Lake Elsinore (East to West), which will move forward in parallel. A separate Notice of Intent is being issued for the Hemet to Corona/Lake Elsinore (East to West) Corridor.

The objective of the proposed EIS is to provide environmental analysis of a multimodal transportation facility within the Winchester to Temecula Corridor to allow agencies to proceed with the preservation of right-of-way for a preferred alternative. One goal of the RCIP process is to preserve the rights-of-way needed for the transportation facilities while minimizing potential impacts on habitat, aquatic resources, communities, landowners, and other elements of the environment.

Additional information regarding the Riverside County integrated Project is also available on the Internet at *www.rcip.org.*

Public scoping meetings will be held. The public will be notified through local newspapers, postings in public places, and through other public notification methods. The notices will identify the place, dates, and time of the meetings.

To ensure that the full range of issues related to the proposed improvements are addressed and all significant issues identified, comments and suggestions are invited from all interested parties. Comments or questions concerning this tiered EIS should be directed to the FHWA and/or RCTC at the addresses provided above.

(Catalog of Federal Assistance Program Number 20.205, Highway Planning, and Construction. The regulations implementing Executive Order 12372 regarding intergovernmental consultation on Federal programs and activities apply to this program.)

Issued on: July 23, 2001.

Jeffrey W. Kolb,

Team Leader, Program Delivery Team-South Sacramento, California.

[FR Doc. 01–19343 Filed 8–1–01; 8:45 am]

BILLING CODE 4910–22–M

DEPARTMENT OF TRANSPORTATION

Surface Transportation Board

[STB Docket No. MC–F–20983]

Tedesco Family ESB Trust-Continuance in Control and Acquisition of Properties-Academy Bus, L.L.C., et al.

AGENCY: Surface Transportation Board.

ACTION: Notice Tentatively Approving Finance Application.

SUMMARY: Tedesco Family ESB Trust, Francis Tedesco and Mark Tedesco, settlers, of Hoboken, NJ (Tedesco Family Trust or applicant), a noncarrier, has filed an application under 49 U.S.C. 14303 to continue in control of Academy Express, L.L.C., Academy Lines, L.L.C., and No. 22 Hillside, L.L.C., upon their becoming motor carriers of passengers, and upon applicant's acquisition of the properties of certain motor carriers of passengers already directly or indirectly controlled by applicant. Persons wishing to oppose the application must follow the rules at 49 CFR 1182.5 and 1182.8. The Board has tentatively approved the transaction and, if no opposing comments are timely filed, this notice will be the final Board action.

DATES: Comments must be filed by September 17, 2001. Applicant may file a reply by October 1, 2001. If no comments are filed by September 17, 2001, the approval is effective on that date.

ADDRESSES: Send an original and 10 copies of any comments referring to STB Docket No. MC–F–20983 to: Surface Transportation Board, Office of the Secretary, Case Control Unit, 1925 K Street, N.W., Washington, DC 20423–0001. In addition, send one copy of any comments to applicant's representative: Fritz R. Kahn, 1920 N. Street, N.W. (8th floor), Washington, DC 20036–1601.

FOR FURTHER INFORMATION CONTACT: Joseph H. Dettmar, (202) 565–1600. [TDD for the hearing impaired: 1-(800)-877–8339.]

SUPPLEMENTARY INFORMATION: Applicant proposes to simplify its corporate structure, reorganize its enterprise for tax purposes, and have its operating companies be limited liability companies, organized under the laws of the State of New Jersey.

Instead of ten companies [1] which heretofore had been authorized to render operations as motor carriers of passengers, there will be three operating bus lines as follows.

Academy Express, L.L.C., will be the motor carrier of passengers principally rendering special and charter operations, pursuant to operating authority to be issued by the Federal Motor Carrier Safety Administration (FMCSA). Subject to Board authorization, it will acquire the properties of Academy Bus Tours, Inc., and Academy Express, Inc., including those of American Limousine Service, Inc., Inner Circle Qonexions, Inc. (Reentitled Academy Express, Inc.), Academy Bus Tours, Inc. (PA), and Commuter Bus, Lines, Inc., whose operating authorities thereafter will be surrendered for cancellation.

Academy Lines, L.L.C., will be the motor carrier of passengers principally rendering commuter operations, pursuant to operating authority to be issued by FMCSA. Subject to Board authorization, it will acquire properties of Academy Lines, Inc., including those of Asbury Park Transit Lines, Inc., whose operating authorities thereafter will be surrendered for cancellation.

No. 22 Hillside, L.L.C., will become a motor carrier of passengers pursuant to operating authority to be issued by FMCSA. Subject to Board authorization, it will acquire the properties of No. 22 Hillside, Inc., whose operating authority thereafter will be surrendered for cancellation.

The three operating companies, Academy Express, L.L.C., Academy Lines, L.L.C., and No. 22 Hillside, L.L.C., will be controlled by a newly formed noncarrier, Academy Bus, L.L.C., a company indirectly controlled by applicant.

Academy Bus Tours, Inc., Academy Lines, Inc., No. 22 Hillside Corp., and Academy Express, Inc., thereafter will be noncarriers. The operating authority of Consolidated Bus Service, Inc., will be surrendered for cancellation, and it too will be a noncarrier.

According to applicant, these changes, while of obvious advantage to it, will also inure to the benefit of the passengers served by its directly-controlled and indirectly-controlled motor carriers of passengers. The transaction will diminish the need for fare increases and offer passengers better organized, highly specialized, and more responsive carriers in furtherance of the public interest.

Under 49 U.S.C. 14303(b), we must approve and authorize a transaction we find consistent with the public interest, taking into consideration at least: (1) the effect of the transaction on the adequacy of transportation to the public; (2) the total fixed charges that result; and (3) the interest of affected carrier employees.

Applicant has submitted the information required by 49 CFR 1182.2, including information to demonstrate that the proposed transaction is consistent with the public interest under 49 U.S.C. 14303. Specifically, applicant has stated that the proposed transaction will have a positive effect on the adequacy of transportation to the public and will result in no increase in fixed charges and no changes in employment. See 49 CFR 1182.2(a)(7). Additional information may be obtained from applicant's representative.

On the basis of the application, we find that the proposed transaction is consistent with the public interest and should be authorized. If any opposing comments are timely filed, this finding will be deemed vacated and, unless a final decision can be made on the record as developed, a procedural schedule will be adopted to reconsider the application. See 49 CFR 1182.6(c). If no opposing comments are filed by the expiration of the comment period, this decision will take effect automatically and will be the final Board action.

Board decisions and notices are available on our website at ''WWW.STB.DOT.GOV.''

This decision will not significantly affect either the quality of the human environment or the conservation of energy resources.

It is ordered:

1. The proposed continuance in control and acquisition of properties is approved and authorized, subject to the filing of opposing comments.

2. If timely opposing comments are filed, the findings made in this decision will be deemed vacated.

3. This decision will be effective on September 17, 2001, unless timely opposing comments are filed.

4. A copy of this notice will be served on: (1) U.S. Department of Transportation, Federal Motor Carrier Safety Administration—MC–RI, 400 Virginia Avenue, S.W., Suite 600, Washington, DC 20024; (2) the U.S. Department of Justice, Antitrust Division, 10th Street & Pennsylvania Avenue, N.W., Washington, DC 20530; and (3) the U.S. Department of Transportation, Office of the General Counsel, 400 7th Street, SW., Washington, DC 20590.

Decided: July 26, 2001.

By the Board, Chairman Morgan, Vice Chairman Clyburn, and Commissioner Burkes.

Vernon A. Williams,

Secretary.

[FR Doc. 01–19336 Filed 8–1–01; 8:45 am]

BILLING CODE 4915–00–P

[1] Academy Bus Tours, Inc. (MC–165004), Academy Lines, Inc. (MC–106207), Asbury Park Transit Lines, Inc. (MC–1002); No. 22 Hillside Corp. (MC–182453), Academy Express, Inc. (MC–228481), American Limousine Service, Inc. (MC–186879), Inner Circle Qonexions, Inc. (Reentitled Academy Express, Inc.) (MC–145482), Academy Bus Tours, Inc. (PA) (MC–215354), Commuter Bus Line, Inc. (MC–162133), and Consolidated Bus Service, Inc. (MC–174942).

DEPARTMENT OF TRANSPORTATION

Surface Transportation Board

[STB Docket No. AB–565 (Sub-No. 2X); STB Docket No. AB–55 (Sub-No. 594X)]

New York Central Lines, LLC—Abandonment Exemption—in Middlesex County, MA; CSX Transportation, Inc.—Discontinuance of Service Exemption—in Middlesex County, MA

New York Central Lines, LLC (NYC) and CSX Transportation, Inc. (CSXT), have filed a notice of exemption under 49 CFR 1152 subpart F—*Exempt Abandonments and Discontinuances of Service* for NYC to abandon and CSXT to discontinue service over approximately 4.17 miles of railroad between milepost QBH–2.60 near Sherborn and milepost QBH–6.77 near Holliston, in Middlesex County, MA.[1] The line traverses United States Postal Service Zip Codes 01770 and 01746.

NYC and CSXT have certified that: (1) No local traffic has moved over the line for at least 2 years; (2) there has been no overhead traffic on the line; (3) no formal complaint filed by a user of rail service on the line (or by a state or local

[1] Pursuant to Board authorization in 1998, CSX Corporation, CSXT's parent company, and Norfolk Southern Corporation jointly acquired control of Conrail Inc., and its wholly owned subsidiary, Consolidated Rail Corporation (Conrail). As a result of that acquisition, certain assets of Conrail have been assigned to NYC, a wholly owned subsidiary of Conrail, to be exclusively operated by CSXT pursuant to an operating agreement. The line to be abandoned is included among the property being operated by CSXT pursuant to the NYC operating agreement.

government entity acting on behalf of such user) regarding cessation of service over the line either is pending with the Surface Transportation Board (Board) or with any U.S. District Court or has been decided in favor of complainant within the 2-year period; and (4) the requirements at 49 CFR 1105.7 (environmental reports), 49 CFR 1105.8 (historic reports), 49 CFR 1105.11 (transmittal letter), 49 CFR 1105.12 (newspaper publication), and 49 CFR 1152.50(d)(1) (notice to governmental agencies) have been met.

As a condition to these exemptions, any employee adversely affected by the abandonment or discontinuance shall be protected under *Oregon Short Line R. Co.—Abandonment—Goshen,* 360 I.C.C. 91 (1979). To address whether this condition adequately protects affected employees, a petition for partial revocation under 49 U.S.C. 10502(d) must be filed. Provided no formal expression of intent to file an offer of financial assistance (OFA) has been received, these exemptions will be effective on September 1, 2001, unless stayed pending reconsideration. Petitions to stay that do not involve environmental issues,[2] formal expressions of intent to file an OFA under 49 CFR 1152.27(c)(2),[3] and trail use/rail banking requests under 49 CFR 1152.29 must be filed by August 13, 2001. Petitions to reopen or requests for public use conditions under 49 CFR 1152.28 must be filed by August 22, 2001, with: Surface Transportation Board, Office of the Secretary, Case Control Unit, 1925 K Street, N.W., Washington, DC 20423.

A copy of any petition filed with the Board should be sent to applicants' representative: Natalie S. Rosenberg, Counsel, CSX Transportation, Inc., 500 Water Street J150, Jacksonville, FL 32202.

If the verified notice contains false or misleading information, the exemption is void *ab initio.*

NYC and CSXT have filed an environmental report which addresses the effects, if any, of the abandonment and discontinuance on the environment and historic resources. SEA will issue an environmental assessment (EA) by August 7, 2001. Interested persons may obtain a copy of the EA by writing to SEA (Room 500, Surface Transportation Board, Washington, DC 20423) or by calling SEA, at (202) 565–1545. Comments on environmental and historic preservation matters must be filed within 15 days after the EA becomes available to the public.

Environmental, historic preservation, public use, or trail use/rail banking conditions will be imposed, where appropriate, in a subsequent decision.

Pursuant to the provisions of 49 CFR 1152.29(e)(2), NYC shall file a notice of consummation with the Board to signify that it has exercised the authority granted and fully abandoned the line. If consummation has not been effected by NYC's filing of a notice of consummation by August 2, 2002, and there are no legal or regulatory barriers to consummation, the authority to abandon will automatically expire.

Board decisions and notices are available on our website at *www.stb.dot.gov.*

Decided: July 25, 2001.

By the Board, David M. Konschnik, Director, Office of Proceedings.

Vernon A. Williams,

Secretary.

[FR Doc. 01–19020 Filed 8–1–01; 8:45 am]

BILLING CODE 4915–00–P

[2] The Board will grant a stay if an informed decision on environmental issues (whether raised by a party or by the Board's Section of Environmental Analysis (SEA) in its independent investigation) cannot be made before the exemption's effective date. *See Exemption of Out-of-Service Rail Lines,* 5 I.C.C.2d 377 (1989). Any request for a stay should be filed as soon as possible so that the Board may take appropriate action before the exemption's effective date.

[3] Each offer of financial assistance must be accompanied by the filing fee, which currently is set at $1000. *See* 49 CFR 1002.2(f)(25).

DEPARTMENT OF THE TREASURY

Submission for OMB Review; Comment Request

July 26, 2001.

The Department of Treasury has submitted the following public information collection requirement(s) to OMB for review and clearance under the Paperwork Reduction Act of 1995, Public Law 104–13. Copies of the submission(s) may be obtained by calling the Treasury Bureau Clearance Officer listed. Comments regarding this information collection should be addressed to the OMB reviewer listed and to the Treasury Department Clearance Officer, Department of the Treasury, Room 2110, 1425 New York Avenue, NW., Washington, DC 20220.

DATES: Written comments should be received on or before September 4, 2001 to be assured of consideration.

Internal Revenue Service (IRS)

OMB Number: 1545–0121.

Form Number: IRS Form 1116.

Type of Review: Revision.

Title: Foreign Tax Credit (Individual, Estate, Trust, or Nonresident Alien Individual).

Description: Form 1116 is used by individuals (including nonresident aliens), estates or trusts who paid foreign income taxes on U.S. taxable income to compute the foreign tax credit. This information is used by the IRS to verify the foreign tax credit.

Respondents: Individuals or households.

Estimated Number of Respondents/Recordkeeper: 442,425.

Estimated Burden Hours Per Respondent/Recordkeeper:

Recordkeeping—2 hr., 43 min.

Learning about the law or the form—1 hr., 10 min.

Preparing the form—3 hr., 4 min.

Copying, assembling, and sending the form to the IRS—34 min.

Frequency of Response: Annually.

Estimated Total Reporting/Recordkeeping Burden: 2,862,104 hours.

OMB Number: 1545–0936.

Form Number: IRS Form 8453.

Type of Review: Extension.

Title: U.S. Individual Income Tax Declaration for an IRS e-file Return.

Description: This form will be used to secure taxpayers' signatures and declarations in conjunction with the Electronic Filing program. This form, together with the electronic transmission, will comprise the taxpayer's income tax return.

Respondents: Individuals or households.

Estimated Number of Respondents/Recordkeepers: 12,300,000.

Estimated Burden Hours Per Respondent/Recordkeeper: 15 minutes.

Frequency of Response: Annually.

Estimated Total Reporting/Recordkeeping Burden: 3,075,000 hours.

Clearance Officer: Garrick Shear, Internal Revenue Service, Room 5244, 1111 Constitution Avenue, NW., Washington, DC 20224.

OMB Reviewer: Alexander T. Hunt (202) 395–7860, Office of Management and Budget, Room 10202, New Executive Office Building, Washington, DC 20503.

Mary A. Able,

Departmental Reports Management Officer.

[FR Doc. 01–19244 Filed 8–1–01; 8:45 am]

BILLING CODE 4830–01–P

DEPARTMENT OF VETERANS AFFAIRS

OMB Control No. 2900–0129

Proposed Information Collection Activity: Proposed Collection; Comment Request

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: The Veterans Benefits Administration (VBA), Department of Veterans Affairs (VA), is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act (PRA) of 1995, Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of a currently approved collection, and allow 60 days for public comment in response to the notice. This notice solicits comments on information needed to process a claim for disability benefits.

DATES: Written comments and recommendations on the proposed collection of information should be received on or before October 1, 2001.

ADDRESSES: Submit written comments on the collection of information to Nancy J. Kessinger, Veterans Benefits Administration (20S52), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420 or e-mail: *irmnkess@vba.va.gov.* Please refer to ''OMB Control No. 2900–0129'' in any correspondence.

FOR FURTHER INFORMATION CONTACT: Nancy J. Kessinger at (202) 273–7079 or FAX (202) 275–5947.

SUPPLEMENTARY INFORMATION: Under the PRA of 1995 (Public Law 104–13; 44 U.S.C., 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. This request for comment is being made pursuant to Section 3506(c)(2)(A) of the PRA.

With respect to the following collection of information, VBA invites comments on: (1) whether the proposed collection of information is necessary for the proper performance of VBA's functions, including whether the information will have practical utility; (2) the accuracy of VBA's estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or the use of other forms of information technology.

Title: Supplemental Disability Report, VA Form Letter 29–30a.

OMB Control Number: 2900–0129.

Type of Review: Extension of a currently approved collection.

Abstract: VA Form Letter 29–30a is used to determine the insurer's eligibility to obtain disability insurance benefits. VA uses the data collected on the form letter when evaluating a claim for disability insurance benefits.

Affected Public: Individuals or households.

Estimated Annual Burden: 548 hours.

Estimated Average Burden Per Respondent: 5 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 6,570.

Dated: July 12, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19287 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0317]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 *et seq.*), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 273–8030, FAX (202) 273–5981 or e-mail: *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0317.''

SUPPLEMENTARY INFORMATION:

Title: Request for Identifying Information Re: Veteran's Loan Records, VA Form Letter 26–626.

OMB Control Number: 2900–0317.

Type of Review: Extension of a currently approved collection.

Abstract: The form letter is used to notify a correspondent of additional information needed to complete a claimant's application. The information is needed to determine if a veteran's loan guaranty benefit is involved. Without this form, VA would be unable to obtain the necessary information to associate the correspondence with the veteran's application or loan records.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published on April 24, 2001, at page 20722.

Affected Public: Individuals or households.

Estimated Annual Burden: 200 hours.

Estimated Average Burden Per Respondent: 5 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 2,400.

Send comments and recommendations concerning any aspect of the information collection to VA's OMB Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0317'' in any correspondence.

Dated: July 17, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19284 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0046]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 et seq.), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 273–8030, FAX (202) 273–5981 or e-mail: denise.mclamb@mail.va.gov. Please refer to ''OMB Control No. 2900–0046.''

SUPPLEMENTARY INFORMATION:

Title: Statement of Heirs for Payment of Credits Due Estate, VA Form Letter 29–596.

OMB Control Number: 2900–0046.

Type of Review: Extension of a currently approved collection.

Abstract: The form letter is used to obtain information for payment of credits due the estate of a deceased veteran. The information is used by VA to establish entitlement to refundable credits.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published on April 16, 2001, at pages 19605—19606.

Affected Public: Individuals or households.

Estimated Annual Burden: 78 hours.

Estimated Average Burden Per Respondent: 15 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 312.

Send comments and recommendations concerning any aspect of the information collection to VA's OMB Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0046'' in any correspondence.

Dated: July 17, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19285 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0066]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 *et seq.*), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 273–8030, FAX (202) 273–5981 or e-mail: *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0066.''

SUPPLEMENTARY INFORMATION:

Title: Request to Employer for Employment Information in Connection with Claim for Disability Benefits, VA Form Letter 29–459.

OMB Control Number: 2900–0066.

Type of Review: Extension of a currently approved collection.

Abstract: The form letter is used to request employment information from an employer in connection with a veteran's claim for disability benefits. VA uses the information to establish the veteran's eligibility for disability insurance benefits.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published on April 24, 2001, at pages 20720—20721.

Affected Public: Individuals or households.

Estimated Annual Burden: 862 hours.

Estimated Average Burden Per Respondent: 10 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 5,167.

Send comments and recommendations concerning any aspect of the information collection to VA's Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503, (202) 395–7316. Please refer to ''OMB Control No. 2900–0066'' in any correspondence.

Dated: July 17, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19286 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0525]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 *et seq.*), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 273–8030, FAX (202) 273–5981 or e-mail: *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0525.''

SUPPLEMENTARY INFORMATION:

Title: VA MATIC Change, VA Form 29–0165.

OMB Control Number: 2900–0525.

Type of Review: Reinstatement, without change, of a previously approved collection for which approval has expired.

Abstract: The form is used by the insured to change the bank account number and/or bank from which VA currently deducts his/her premium payments. VA uses the information to process the insured's request.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published on March 29, 2001 at page 17228.

Estimated Annual Burden: 1,250 hours.

Estimated Average Burden Per Respondent: 15 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 5,000.

Send comments and recommendations concerning any aspect of the information collection to VA's OMB Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0525'' in any correspondence.

Dated: July 10, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19288 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0020]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 *et seq.*), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 273–8030, FAX (202) 273–5981 or e-mail: *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0020.''

SUPPLEMENTARY INFORMATION:

Title: Designation of Beneficiary, Government Life Insurance, VA Form 29–336.

OMB Control Number: 2900–0020.

Type of Review: Extension of a currently approved collection.

Abstract: The form is used by the insured to designate a beneficiary and select an optional settlement to be used when the insurance matures by death. The information is required to determine claimant's eligibility to receive proceeds of the insurance.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published on April 16, 2001, at page 19607.

Affected Public: Individuals or households.

Estimated Annual Burden: 13,917 hours.

Estimated Average Burden Per Respondent: 10 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 83,500.

Send comments and recommendations concerning any aspect of the information collection to VA's OMB Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0020'' in any correspondence.

Dated: July 12, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19289 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0212]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 *et seq.*), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 273–8030, FAX (202) 273–5981 or e-mail: *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0212.''

SUPPLEMENTARY INFORMATION:

Title: Veterans Mortgage Life Insurance Statement, VA Form 29–8636.

OMB Control Number: 2900–0212.

Type of Review: Extension of a currently approved collection.

Abstract: The form is used by veterans who have received Specially Adapted Housing Grants to Veterans Mortgage Life Insurance or to provide information upon which the insurance premium can be based. VA uses the information to process a veteran's request.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published on April 16, 2001, at page 19606.

Affected Public: Individuals or households.

Estimated Annual Burden: 113 hours.

Estimated Average Burden Per Respondent: 15 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 450.

Send comments and recommendations concerning any aspect of the information collection to VA's OMB Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0212'' in any correspondence.

Dated: July 12, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19290 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0133]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995

(44 U.S.C., 3501 *et seq.*), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 273–8030 or FAX (202) 273–5981 or e-mail *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0133.''

SUPPLEMENTARY INFORMATION:

Title: Application for Amounts on Deposit for Deceased Veteran, VA Form 21–6898.

OMB Control Number: 2900–0133.

Type of Review: Extension of a currently approved collection.

Abstract: The form is used to gather the necessary information to determine the individual(s) who may be entitled to accrued benefits of deceased beneficiaries.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published on April 20, 2001 at page 20352.

Affected Public: Individuals or households.

Estimated Annual Burden: 175 hours.

Estimated Average Burden Per Respondent: 15 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 700.

Send comments and recommendations concerning any aspect of the information collection to VA's Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0133'' in any correspondence.

Dated: July 12, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19291 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0442]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 *et seq.*), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW, Washington, DC 20420, (202) 273–8030, FAX (202) 273–5981 or e-mail: *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0442.''

SUPPLEMENTARY INFORMATION:

Title: Request for Armed Forces Separation Records from Veterans, VA Form Letter 21–80e.

OMB Control Number: 2900–0442.

Type of Review: Reinstatement, without change, of a previously approved collection for which approval has expired.

Abstract: In order to establish entitlement to VA compensation or pension benefits, a veteran must have had active military service which resulted in separation under other than dishonorable conditions. VA Form Letter 21–80e is completed by the veteran to furnish information relative to his/her military service to aid VA in requesting verification of service. Compensation and pension benefits cannot be paid without verification of service.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** document with a 60-day comment period soliciting comments on this collection of information was published on April 16, 2001 at pages 19606—19607.

Affected Public: Individuals or households.

Estimated Annual Burden: 17,000 hours.

Estimated Average Burden Per Respondent: 10 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 102,000.

Send comments and recommendations concerning any aspect of the information collection to VA's OMB Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0442'' in any correspondence.

Dated: July 10, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19292 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0099]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 et seq.), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 273–8030, FAX (202) 273–5981 or e-mail: *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0099.''

SUPPLEMENTAL INFORMATION:

Title: Request for Change of Program or Place of Training, Survivors' and Dependents' Educational Assistance, (Under Provisions of Chapter 35, Title 38, U.S.C.), VA Form 22–5495.

OMB Control Number: 2900–0099.

Type of Review: Revision of a currently approved collection.

Abstract: Spouses, surviving spouses, or children of veterans who are eligible for Dependent's Educational Assistance, complete VA Form 22–5495 to change their program of education and/or place of training. VA uses the information to determine if the new program selected is suitable to their abilities, aptitudes, and interests and to verify that the new place of training is approved for benefits.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** document with a 60-day comment period soliciting comments on this collection of information was published on April 24, 2001 at page 20721.

Affected Public: Individuals or households.

Estimated Annual Burden: 3,000 hours.

Estimated Average Burden Per Respondent: 15 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 12,000.

Send comments and recommendations concerning any aspect of the information collection to VA's OMB Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0099'' in any correspondence.

Dated: July 10, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19293 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0065]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 *et seq.*), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 273–8030 or FAX (202) 273–5981 or e-mail *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0065.''

SUPPLEMENTARY INFORMATION:

Title: Request for Employment Information in Connection With Claim for Disability Benefits, VA Form 21–4192.

OMB Control Number: 2900–0065.

Type of Review: Extension of a currently approved collection.

Abstract: VA Form 21–4192 is used to request employment information of a claimant applying for disability benefits. The information is necessary to determine the date of termination of the claimant's employment.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** notice with a 60-day comment period soliciting comments on this collection of information was published on April 24, 2001 at page 20720.

Estimated Annual Burden: 15,000 hours.

Estimated Average Burden Per Respondent: 15 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 60,000.

Send comments and recommendations concerning any aspect of the information collection to VA's Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0065'' in any correspondence.

Dated: July 12, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19294 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0387]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 et seq.), this notice announces that the Veterans Benefits Administration (VBA), Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW, Washington, DC 20420, (202) 273–8030, FAX (202) 273–5981 or e-mail *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0387.''

SUPPLEMENTARY INFORMATION:

Title: Request for Verification of Deposit, VA Form 26–8497a.

OMB Control Number: 2900–0387.

Type of Review: Extension of a currently approved collection.

Abstract: VA is prohibited from guaranteeing or making any loan unless the contemplated terms of payment required in any mortgage to be given in part payment of the purchase price or the construction cost bear a proper relation to the veteran's present and anticipated income and expenses and that the veteran is a satisfactory credit risk. Lenders making guaranteed and insured loans use the form to verify the applicant's deposits in banks and other savings institutions. It is also used to process direct loans, offers on acquired properties, and release from liability/substitution of entitlement cases when needed. In these types of cases, part I of the form is completed by the lender and signed by the applicant then forwarded to the depository. The depository completes part II, verifying the applicant's deposits, providing information and payment experience on outstanding loans, and returns the form to the lender.

An agency may not conduct or sponsor, and a person is not required to

respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published on April 26, 2001, at pages 21042–21043.

Affected Public: Business or other for-profit.

Estimated Annual Burden: 16,318 hours.

Estimated Average Burden Per Respondent: 5 minutes.

Frequency of Response: On occasion.

Estimated Number of Respondents: 195,817.

Send comments and recommendations concerning any aspect of the information collection to VA's OMB Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0387'' in any correspondence.

Dated: July 12, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19295 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0455]

Agency Information Collection Activities Under OMB Review

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C., 3501 *et seq.*), this notice announces that the Veterans Benefits Administration, Department of Veterans Affairs, has submitted the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden; it includes the actual data collection instrument.

DATES: Comments must be submitted on or before September 4, 2001.

FOR FURTHER INFORMATION OR A COPY OF THE SUBMISSION CONTACT: Denise McLamb, Information Management Service (045A4), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 273–8030 or FAX (202) 273–5981 or e-mail to: *denise.mclamb@mail.va.gov.* Please refer to ''OMB Control No. 2900–0455'' in any correspondence.

SUPPLEMENTARY INFORMATION:

Title: Equal Opportunity Compliance Review Report, VA Form 20–8734 and Supplement to Equal Opportunity Compliance Review Report, VA Form 20–8734a.

OMB Control Number: 2900–0455.

Type of Review: Reinstatement, without change, of a previously approved collection for which approval has expired.

Abstract: Executive Order 12250, Leadership and Coordination of Nondiscrimination Laws, delegated authority to the Attorney General to coordinate the implementation and enforcement by Executive agencies of various equal opportunity laws that prohibit discrimination in programs and activities that receive Federal financial assistance. Government-wide guidelines issued by the Department of Justice (DOJ) in 29 CFR 42.406 instruct funding agencies to ''provide for the collection of data and information from applicants for and recipients of Federal assistance sufficient to permit effective enforcement of Title VI.'' Executive Order 12250 extended the delegation to cover Title IX of the Education Amendments of 1972, and Section 504 of the Rehabilitation Act of 1973, as amended.

VA's regulation that effectuates external civil rights requirements is contained in 38 CFR, part 18. The regulation provides that the responsible agency official or designee shall, from time to time, review the practices of recipients to determine whether they are complying with the equal opportunity provisions. VA Form 20–8734 is used to gather information from post-secondary proprietary schools below college level. The information is used to assure that VA-funded programs are in compliance with equal opportunity laws. VA Form 20–8734a is used to gather information from students and instructors at post-secondary proprietary schools below college level. The information is used to assure that participants have equal access to equal treatment in VA-funded programs.

The forms are used by Education Compliance Survey Specialists in VA field stations during regularly scheduled educational compliance survey visits, as well as during investigations of equal opportunity complaints, to identify areas which may indicate whether there is disparate treatment of members of protected groups. The information obtained on these forms is analyzed and maintained on file at the regional office. If this information were not collected, VA would be unable to carry out the civil rights enforcement responsibilities established in the DOJ's guidelines and VA's regulations.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published on April 11, 2001, at pages 18851—18852.

Affected Public: Business or other for profit.

Estimated Annual Burden and Average Burden Per Respondent: Based on past experience, VBA estimates that 76 interviews will be conducted with recipients using VA Form 20–8734 at an average of 1 hour and 45 minutes per interview (133 hours). This includes one hour for an interview with the principal facility official, plus 45 minutes for reviewing records and reports and touring the facility. It is also estimated that 76 interviews will be conducted with students using VA Form 20–8734a at an average of 30 minutes per interview (38 hours) and with instructors at an average of 30 minutes per interview (38 hours) with a total of 76 hours. Interviews are also conducted with 76 students without instructors at an average time of 30 minutes.

VBA estimates that it will take 1 hour to conduct an interview with the recipients (76 hours) and 30 minutes with the instructors (38 hours). The total number of hours for interviewing recipients and instructors is estimated at 114.

Frequency of Response: On occasion.

Estimated Number of Respondents: 228.

Send comments and recommendations concerning any aspect of the information collection to VA's OMB Desk Officer, OMB Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 (202) 395–7316. Please refer to ''OMB Control No. 2900–0455'' in any correspondence.

Dated: July 12, 2001.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 01–19296 Filed 8–1–01; 8:45 am]

BILLING CODE 8320–01–P

Corrections

Federal Register

Vol. 66, No. 149

Thursday, August 2, 2001

This section of the FEDERAL REGISTER contains editorial corrections of previously published Presidential, Rule, Proposed Rule, and Notice documents. These corrections are prepared by the Office of the Federal Register. Agency prepared corrections are issued as signed documents and appear in the appropriate document categories elsewhere in the issue.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. 01D-0294 and 01D-0295]

Draft Guidances for Industry on Providing Regulatory Submissions to Office of Food Additive Safety in Electronic Format: General Considerations and for Food Additive and Color Additive Petitions; Availability

Correction

In notice document 01–18948 beginning on page 39517 in the issue of Tuesday, July 31, 2001, make the following correction:

On page 39521, in the first column under the heading **V. Electronic Access**, in the third line, ''http://www.cfsan.fda.gov/@dms/opa-toc.html.'' should read ''http://www.dfsan.fda.gov/~dms/opa-toc.html.''

[FR Doc. C1–18948 Filed 8–1–01; 8:45 am]

BILLING CODE 1505–01–D

LIBRARY OF CONGRESS

Copyright Office

37 CFR Part 202

[Docket No. RM 2001–5]

Copyright Rules and Regulations: Copyright, Registration of Claims to Copyright, Freedom of Information, Privacy, Service of Process, Mask Works

Correction

In rule document 01–16188 beginning on page 34372 in the issue of Thursday, June 28, 2001, make the following corrections:

§202.2 [Corrected]

1. On page 34373, in the second column, in §202.2, in the first paragraph, in the third line ''ad interim'' should read ''*ad interim* ''.

§202.17 [Corrected]

2. On the same page, in the same column, in §202.17, in the first paragraph, in the third line, ''cum testamento annexo'' should read ''*cum testamento annexo*''.

3. On the same page, in the same column, in the same section, in the same paragraph, in the fifth line, ''de bonis non cum testamento annexo'' should read ''*de bonis non cum testamento annexo*''.

[FR Doc. C1–16188 Filed 8–1–01; 8:45 am]

BILLING CODE 1505–01–D

Federal Register

Thursday,
August 2, 2001

Part II

Environmental Protection Agency

40 CFR Part 63

National Emission Standards for Hazardous Air Pollutants: Reinforced Plastic Composites Production; Proposed Rule

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 63

[FRL–7005–6]

RIN 2060–AE79

National Emission Standards for Hazardous Air Pollutants: Reinforced Plastic Composites Production

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: This action proposes national emission standards for hazardous air pollutants (NESHAP) for new and existing reinforced plastic composites production facilities. The proposed standards regulate production and ancillary processes used to manufacture products with thermoset resins and gel coats. Reinforced plastic composites production facilities emit hazardous air pollutants (HAP), such as styrene, methyl methacrylate (MMA), and methylene chloride (dichloromethane). These HAP have adverse health effects including headache, fatigue, depression, irritation of skin, eyes, and mucous membranes. Methylene chloride has been classified as a probable human carcinogen. These proposed standards will implement section 112(d) of the Clean Air Act (CAA) by requiring all major sources in this category to meet HAP emission standards reflecting the application of the maximum achievable control technology (MACT). We estimate the proposed NESHAP would reduce nationwide emissions of HAP from these facilities by approximately 14,500 tons per year (tpy) (65 percent).

DATES: *Comments*. Submit comments on or before October 1, 2001.

Public Hearing. If anyone contacts the EPA requesting to speak at a public hearing by August 22, 2001, a public hearing will be held on September 4, 2001.

ADDRESSES: *Comments*. By U.S. Postal Service, send comments (in duplicate if possible) to: Air and Radiation Docket and Information Center (6102), Attention Docket Number A–94–52, U.S. EPA, 1200 Pennsylvania Avenue, NW., Washington, DC 20460. In person or by courier, deliver comments (in duplicate if possible) to: Air and Radiation Docket and Information Center (6102), Attention Docket Number A–94–52, U.S. EPA, 401 M Street, SW., Washington, DC 20460. We request a separate copy also be sent to the contact person listed below in the **FOR FURTHER INFORMATION CONTACT** section.

Public Hearing. If a public hearing is held, it will be held at EPA's Office of Administration Auditorium, Research Triangle Park, North Carolina.

Docket. Docket No. A–94–52 contains supporting information used in developing the standards. The docket is located at the U.S. EPA, 401 M Street, SW., Washington, DC 20460 in Room M–1500, Waterside Mall (ground floor), and may be inspected from 8:30 a.m. to 5:30 p.m., Monday through Friday, excluding legal holidays.

FOR FURTHER INFORMATION CONTACT: Keith Barnett, Organic Chemicals Group, Emission Standards Division (MD–13), U.S. EPA, Research Triangle Park, North Carolina 27711, (919) 541–5605, barnett.keith@epamail.epa.gov. For public hearing information, contact Maria Noell, Organic Chemicals Group, Emission Standards Division (MD–13), U.S. EPA, Research Triangle Park, North Carolina 27711, (919) 541–5607.

SUPPLEMENTARY INFORMATION:

Comments. Comments and data may be submitted by electronic mail (e-mail) to: a-and-r-docket@epa.gov. Electronic comments must be submitted either as an ASCII file to avoid the use of special characters and encryption problems or on disks in WordPerfect™ version 5.1, 6.1 or Corel 8 file format. All comments and data submitted in electronic form must note the docket number: A–94–52. No confidential business information (CBI) should be submitted by e-mail. Electronic comments may be filed online at many Federal Depository Libraries.

Commenters wishing to submit proprietary information for consideration must clearly distinguish such information from other comments and clearly label it as CBI. Send submissions containing such proprietary information directly to the following address, and not to the public docket, to ensure that proprietary information is not inadvertently placed in the docket: Attention: Keith Barnett, c/o OAQPS Document Control Officer (Room 740B), U.S. EPA, 411 W. Chapel Hill Street, Durham, NC 27701. The EPA will disclose information identified as CBI only to the extent allowed by the procedures set forth in 40 CFR part 2. If no claim of confidentiality accompanies a submission when it is received by the EPA, the information may be made available to the public without further notice to the commenter.

Public Hearing. Persons interested in presenting oral testimony or inquiring as to whether a hearing is to be held should contact Maria Noell, Organic Chemicals Group, Emission Standards Division (MD–13), U.S. EPA, Research Triangle Park, North Carolina 27711, (919) 541–5607 at least 2 days in advance of the public hearing. Persons interested in attending the public hearing must also call Maria Noell to verify the time, date, and location of the hearing. The public hearing will provide interested parties the opportunity to present data, views, or arguments concerning these proposed emission standards.

Docket. The docket is an organized and complete file of the information considered by the EPA in the development of this rulemaking. The docket is a dynamic file because material is added throughout the rulemaking process. The docketing system is intended to allow members of the public and industries involved to readily identify and locate documents so that they can effectively participate in the rulemaking process. Along with the proposed and promulgated standards and their preambles, the contents of the docket, excluding interagency review materials, will serve as the record in the case of judicial review. (See section 307(d)(7)(A) of the CAA.) The regulatory text and other materials related to this rulemaking are available for review in the docket or copies may be mailed on request from the Air Docket by calling (202) 260–7548. A reasonable fee may be charged for copying docket materials.

World Wide Web (WWW). In addition to being available in the docket, an electronic copy of the proposed NESHAP will also be available on the WWW through the Technology Transfer Network (TTN). Following signature, a copy of the proposed NESHAP will be posted on the TTN's policy and guidance page for newly proposed or promulgated rules http://www.epa.gov/ttn/oarpg. The TTN provides information and technology exchange in various areas of air pollution control. If more information regarding the TTN is needed, call the TTN HELP line at (919) 541–5384.

Regulated Entities. Categories and entities potentially regulated by this action include:

Category	NAICS code	SIC code	Examples of regulated entities
Industry	325211	2821	Reinforced plastic composites production facilities that manufacture and/or repair intermediate and/or final products using HAP containing thermoset resins and gel coats.
	326122	3084	
	325991	3087	
	326191	3088	
	.....	3089	
	327991	3281	
	327993	3296	
	332998	3431	
	33312	3531	
	33651	3531	
	335311	3612	
	335313	3613	
	335312	3621	
	33422	3663	
	336211	3711	
	336112	3711	
	336211	3713	
	33651	.....	
	33653	3714	
	336399	3714	
	33612	3716	
	336213	3728	
	336413	3743	
	336214	3792	
	.....	3999	
Federal Government	.....	.....	Federally owned facilities that manufacture and/or repair intermediate and/or final products using HAP containing thermoset resins and gel coats.

This table is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be regulated by this action. To determine whether your facility is regulated by this action, you should examine the applicability criteria in § 63.5785 of the proposed rule. If you have any questions regarding the applicability of this action to a particular entity, consult the person listed in the preceding **FOR FURTHER INFORMATION CONTACT** section.

Outline. The information presented in this preamble is organized as follows:

I. Introduction
- A. What is the source of authority for development of NESHAP?
- B. What criteria are used in the development of NESHAP?
- C. What are the potential health effects of the HAP emitted by the reinforced plastic composites production industry?
- D. How were the proposed NESHAP developed?
- E. What processes and operations are included in the Reinforced Plastic Composites Production source category?

II. Summary of Proposed NESHAP
- A. What source categories and subcategories are affected by this proposed rule?
- B. What are the primary sources of HAP emissions and what are the emissions?
- C. What is the affected source?
- D. What are the proposed emission limits, operating limits, and other standards?
- E. What is the MACT model point value and how is it used in these proposed NESHAP?
- F. When would I need to comply with these proposed NESHAP?
- G. What are the proposed options for demonstrating compliance?
- H. What are the proposed testing and initial compliance requirements?
- I. What are the proposed continuous compliance requirements?
- J. What are the proposed notification, recordkeeping and reporting requirements?

III. Rationale for Proposed NESHAP
- A. How did we determine the source category to regulate?
- B. What pollutants are regulated under these proposed NESHAP?
- C. What is the ''affected source'' and how did EPA select the operations to be regulated by these proposed NESHAP?
- D. What is a new affected source?
- E. How did we determine the MACT floor for existing sources?
- F. How did we determine the MACT floor for new sources?
- G. Did we consider options more stringent than the MACT floor?
- H. Why are some reinforced plastic composites production operations not subject to these proposed NESHAP?
- I. How did we select the proposed compliance dates for existing and new sources?
- J. How did we select the form of these proposed NESHAP?
- K. How did we select the test methods for determining compliance with the proposed NESHAP?
- L. How did we determine the proposed monitoring and recordkeeping requirements?
- M. How did we select the proposed notification and reporting requirements?
- N. What are some of the areas where we are specifically soliciting comments?

IV. Summary of Environmental, Energy, and Economic Impacts
- A. What facilities are affected by the proposed NESHAP?
- B. What are the air quality impacts?
- C. What are the water quality impacts?
- D. What are the solid and hazardous waste impacts?
- E. What are the energy impacts?
- F. What are the cost impacts?
- G. What are the economic impacts?

V. Relationship of Proposed NESHAP to Other Standards and Programs under the CAA
- A. National Emission Standards for Closed Vent Systems, Control Devices, Recovery Devices, and Routing to a Fuel Gas System or a Process (40 CFR Part 63, Subpart SS)
- B. Operating Permit Program
- C. NESHAP for Plastic Parts and Products

VI. Administrative Requirements
- A. Executive Order 12866, Regulatory Planning and Review
- B. Paperwork Reduction Act
- C. Executive Order 13132, Federalism
- D. Executive Order 13175, Consultation and Coordination with Indian Tribal Governments
- E. Unfunded Mandates Reform Act of 1995
- F. Regulatory Flexibility Act (RFA), as amended by the Small Business Regulatory Enforcement Fairness Act of 1996 (SBREFA), 5 U.S.C. 601 *et seq.*
- G. National Technology Transfer and Advancement Act
- H. Executive Order 13045, Protection of Children from Environmental Health Risks and Safety Risks

I. Introduction

A. What Is the Source of Authority for Development of NESHAP?

Section 112 of the CAA requires us to list categories and subcategories of major sources and area sources of HAP and to establish NESHAP for the listed source categories and subcategories. Reinforced Plastic Composites Production (major sources only) was included on the initial list of source categories published on July 16, 1992 (57 FR 31576). Major sources of HAP are those that have the potential to emit greater than 10 tpy of any one HAP or 25 tpy of any combination of HAP.

B. What Criteria Are Used in the Development of NESHAP?

The CAA requires NESHAP to reflect the maximum degree of reduction in emissions of HAP that is achievable. This level of control is commonly referred to as the MACT.

The MACT floor is the minimum control level allowed for NESHAP. This concept appears in section 112(d)(3) of the CAA. For new sources, the MACT floor cannot be less stringent than the emission control that is achieved in practice by the best-controlled similar source. The MACT standards for existing sources can be less stringent than standards for new sources, but they cannot be less stringent than the average emission limitation achieved by the best-performing 12 percent of existing sources in the category or subcategory (or the best-performing 5 sources for categories or subcategories with fewer than 30 sources).

In developing MACT, we also consider control options that are more stringent than the floor. We may establish standards more stringent than the floor based on the consideration of cost of achieving the emissions reductions, any nonair quality health and environmental impacts, and energy requirements.

C. What Are the Potential Health Effects of the HAP Emitted by the Reinforced Plastic Composites Production Industry?

Today's proposed NESHAP protect air quality and promote the public health by reducing emissions of some of the HAP listed in section 112(b)(1) of the CAA.

The HAP emitted by the reinforced plastic composites production industry include, but are not limited to, approximately 20,000 tpy of styrene, 550 tpy of methyl methacrylate, and 1100 tpy of methylene chloride. Exposure to these compounds has been demonstrated to cause adverse health effects, including chronic health disorders (*e.g.*, headache, fatigue, and depression) and acute health disorders (*e.g.*, irritation of skin, eyes, and mucous membranes and decreased respiratory function). Methylene chloride has been classified as a probable human carcinogen and styrene as a possible human carcinogen. In general, these findings have only been shown with concentrations higher than those typically in the ambient air.

We do not have the type of current detailed data on each of the operations covered by today's proposed NESHAP (and the people living around the operations) necessary to conduct an analysis to determine the actual population exposures to the HAP emitted from these facilities and the potential for resultant health effects. Therefore, we do not know the extent to which the adverse health effects described above occur in the populations surrounding these operations. However, to the extent the adverse effects do occur, the proposed rule will reduce emissions and subsequent exposures.

1. Styrene

Acute (short-term) exposure to styrene in humans results in mucous membrane and eye irritation and gastrointestinal effects. Chronic (long-term) exposure to styrene in humans may cause effects on the central nervous system (CNS) such as headache, fatigue, weakness, depression, and hearing loss. There is limited evidence that occupational exposure to styrene is associated with an increased frequency of spontaneous abortions and decreased frequency of births and an increased risk of leukemia and lymphoma. The EPA considers this evidence on occupational exposure to styrene to be inconclusive. The International Agency for Research on Cancer has classified styrene as a Group 2B, possible human carcinogen. The EPA has not classified styrene with respect to carcinogenicity.

2. Methyl Methacrylate

Methyl methacrylate irritates the skin, eyes, and mucous membranes in humans. An allergic response to dermal exposure may develop. Respiratory effects following acute (short-term) exposure include chest tightness, dyspnea, coughing, wheezing, and reduced lung function. Neurological symptoms including headache, lethargy, lightheadedness, and a sensation of heaviness in the arms and legs have also been reported following acute exposure to MMA. Effects to the liver, kidney, brain, spleen, and bone marrow have been reported in chronic (long-term) animal studies of MMA inhalation. Fetal abnormalities have been reported in animals exposed to MMA by injection and inhalation. In several animal studies, no carcinogenic effects were observed. The EPA has classified MMA in Group E (not likely to be carcinogenic in humans).

3. Methylene Chloride

Acute (short-term) exposure to methylene chloride by inhalation affects the nervous system, causing decreased visual, auditory, and motor functions. These effects are reversible once exposure ceases. The effects of chronic (long-term) exposure to methylene chloride suggest that the CNS is a potential target in both humans and animals. Limited animal studies have reported developmental effects. Human data are inconclusive regarding methylene chloride and cancer. Animal studies have shown increases in liver and lung cancer and benign mammary gland tumors following the inhalation of methylene chloride. The EPA has classified methylene chloride as a Group B2, probable human carcinogen.

D. How Were the Proposed NESHAP Developed?

We started the development of the proposed NESHAP by sending information collection request (ICR) surveys to facilities with applicable standard industries classification (SIC) codes. In addition to these surveys, we consulted with numerous members of the reinforced plastic composites industry, representatives of industry trade associations, and material and equipment vendors in developing the proposed NESHAP.

We held a series of approximately 35 meetings and visited approximately 25 facilities over a period of 8 years. These meetings and site visits were held to keep stakeholders informed and to gather additional data and information on issues relevant to the proposed NESHAP. The stakeholders helped in data gathering, arranged site visits, identified issues and provided information to help resolve issues in the rulemaking process.

We identified the MACT floor control level with information obtained through survey responses, site visits, telephone contacts, and operating permits. We assessed control options more stringent than the MACT floor by identifying the level(s) and method(s) of control achieved by the best controlled sources in the industry and conducting analyses designed to determine the cost, economic, energy, and environmental impacts of implementing the more stringent control options.

E. What Processes and Operations Are Included in the Reinforced Plastic Composites Production Source Category?

The Reinforced Plastic Composites Production source category involves the production of plastic products from cross-linking resins, usually in combination with reinforcing materials and inorganic fillers. The production of products that do not contain reinforcing materials is also included in this category, as well as the production of intermediate compounds which are later used to make the final plastic products. These non-reinforced products were included because they are produced using the same types of resins, have similar emission characteristics and would use similar emission controls. This source category is limited to those resins which contain styrene, either by itself or with a combination of other monomers or solvents.

There are a wide variety of operations that use styrene-containing resins to make thermoset plastics. Such production operations include manual resin application, mechanical resin application, filament winding, gel coat application, compression/injection molding, resin transfer molding, centrifugal casting, continuous lamination/continuous casting, polymer casting, pultrusion, and sheet molding compound (SMC) manufacturing. There are also ancillary operations such as cleaning, mixing/bulk molding compound (BMC) manufacturing, and storage that occur in conjunction with these production operations. Many facilities will use multiple operations in the manufacturing of their product.

This category does not include facilities which repair previously manufactured reinforced plastic composites, but do not have any co-located reinforced plastic composite manufacturing operations. The reason is that we believe that repair operations that are co-located with manufacturing operations use the same materials as the manufacturing processes. Repair operations that are not co-located may use different materials and application techniques.

II. Summary of Proposed NESHAP

This preamble section discusses the proposed NESHAP as they apply to you, the owner or operator of a new or existing reinforced plastic composites production facility.

A. What Source Categories and Subcategories Are Affected by This Proposed Rule?

Today's proposed rule applies to the Reinforced Plastic Composites Production source category. We evaluated the use of subcategories based on size (*i.e.*, tpy of HAP emitted). These subcategories played an important role in defining the new source MACT floors. However, the available data that we used to develop the MACT floor for existing sources do not show significant differences between larger-emitting versus smaller-emitting sources. Thus, we did not go through a separate analysis for each subcategory of existing sources.

B. What Are the Primary Sources of HAP Emissions and What Are the Emissions?

The primary source of HAP emissions from the Reinforced Plastic Composites Production source category is the evaporation of styrene and other organic liquid HAP contained in the resin during the application and/or curing of the resin. Since styrene participates in the curing reaction, not all of it is emitted. The HAP emissions also occur during ancillary operations such as cleaning, mixing/BMC manufacturing, and storage.

Total baseline HAP emissions from the Reinforced Plastic Composites Production source category are approximately 22,200 tpy. Emissions from spray lay-up and gel coating constitute approximately 56 percent and 19 percent of the total baseline emissions, respectively. The remaining HAP emissions are primarily from hand lay-up/bucket and tool application, compression molding/injection molding, filament winding, SMC manufacturing, and centrifugal casting.

C. What Is the Affected Source?

Under this proposed rule, the affected source would be the combination of all operations regulated under these standards at a reinforced plastic composites production facility. The following regulated operations are typically performed at reinforced plastic composites production facilities and are part of the affected source: open molding, closed molding, centrifugal casting, continuous lamination/continuous casting, polymer casting, pultrusion, SMC manufacturing, equipment cleaning, BMC/manufacturing/mixing, and storage of HAP containing materials.

D. What Are the Proposed Emission Limits, Operating Limits, and Other Standards?

We are proposing the requirements of these NESHAP in the form of emission limits (*i.e.*, point value, mass rate, or percent reduction), operating limits, and work practice standards. Work practice standards include design, equipment, work practices, and operational standards.

In developing proposed requirements for reinforced plastic composites affected sources, we have provided an alternative format where possible. For example, a facility meeting a 95 percent emission reduction requirement for open molding processes can alternatively meet a point value. We have also provided alternatives for meeting the limits for continuous lamination and continuous casting processes.

We are proposing a threshold for existing sources to distinguish between sources that would meet the floor requirements, that are generally based on pollution prevention, and those that would have to meet a more stringent above-the-floor requirement based on 95 percent control of HAP emissions. For small businesses, the threshold is 250 tpy of combined HAP emissions for open molding, centrifugal casting, continuous lamination/casting, pultrusion, and SMC manufacturing. The definition of a small business for this source category ranges from 500 to 1000 employees. More specific information on the definition of a small business may be found in the discussion of the Regulatory Flexibility Act in the Administrative Requirements section of this preamble. For businesses that are not small businesses, the threshold is combined emissions of HAP of 100 tpy from the same operations.

For all open molding operations (*i.e.*, corrosion-resistant, noncorrosion-resistant, tooling, and gel coat) and centrifugal casting (corrosion-resistant and noncorrosion-resistant) at existing sources below the threshold, and new sources with HAP emissions less than 100 tpy, you must comply with a HAP emission limit that is calculated for your facility using MACT model point value equations for each open molding and centrifugal casting operation. For open molding and centrifugal casting operations at new sources with HAP emissions equal to or greater than 100 tpy, and existing sources with HAP emissions equal to or greater than the applicable thresholds (*i.e.*, 100 tpy for large businesses and 250 tpy for small businesses), we are proposing to require owners and operators to reduce emissions by 95 percent from these operations or comply with a corresponding HAP emission limit calculated using the MACT model point value equations.

We are proposing to require owners and operators of continuous lamination/continuous casting operations at existing sources below the above-the-

floor applicability thresholds, and new sources with HAP emissions less than 100 tpy, to reduce emissions by 58 percent. Other new and existing sources must reduce emissions by 95 percent.

We are proposing to require owners and operators of pultrusion operations at existing sources below the above-the-floor thresholds, and new sources with HAP emissions less than 100 tpy, to reduce emissions by 60 percent. This reduction is based on applying a wet enclosure or using direct die injection to limit emissions. Other new and existing sources must reduce emissions by 95 percent.

We are proposing to require owners and operators at both new and existing sources using injection/compression molding operations to reduce HAP emissions through the use of a work practice, whereby only one charge per machine is uncovered, unwrapped, or exposed per mold cycle per compression/injection molding machine.

We are proposing to require owners and operators of sheet molding compound operations at existing sources below the above-the-floor thresholds, and new sources with HAP emissions less than 100 tpy, to reduce emissions by using a nylon film, or film with equal or lower permeability to styrene, to enclose their SMC operation. Other new and existing sources must reduce emissions by 95 percent.

We are proposing to require owners and operators of all new and existing reinforced plastic composites affected sources to use cleaners containing no HAP.

We are proposing to require owners and operators of resin mixing and bulk molding compound operations at existing sources below the above-the-floor applicability thresholds, and new sources with HAP emissions less than 100 tpy, to limit HAP emissions by covering mixers such that there are no visible gaps. For other new and existing sources, we are proposing to require that you reduce emissions from mixing and BMC manufacturing by 95 percent.

For existing sources that are subject to the above-the-floor control level of 95 percent HAP emission reduction, we examined an alternative, based on pollution prevention, that would be more effective than the requirements of the MACT floor for existing sources. However, we were unable to develop an acceptable alternative to include in the proposed standards that meets the statutory requirements of MACT. We are soliciting comment on a possible alternative.

We are proposing to require all owners and operators at any existing or new affected source to keep all organic HAP-containing storage vessels covered, except during the addition or removal of materials.

E. What Is the MACT Model Point Value and How Is It Used in These Proposed NESHAP?

The MACT model point value is a number calculated for each open molding operation and centrifugal casting operation and is a surrogate for emissions. The MACT model point value is a way to rank the relative performance of different resin and gel coat emissions reduction techniques. This approach allows you to create control strategies using different resin and gel coat emissions reduction techniques. The proposed standards provide equations to calculate MACT model point values based on HAP content and application method for each material that you use. These MACT model point values are then averaged and compared to limits in the proposed standards to determine if your open molding operations are in compliance.

The MACT model point values have units of pounds of HAP per ton of resin or gel coat applied. It is important to note that the MACT model point values are surrogates for emissions, and the MACT model point value equations are used only for determining compliance with the proposed Reinforced Plastic Composites Production NESHAP. The MACT model point value equations cannot be used in place of emission factor equations to demonstrate compliance with other regulations.

The MACT model point value equations only account for HAP content and application method. Other factors (including curing time, part thickness, and operator technique) also affect emissions, and these factors are not accounted for in the MACT model point value equations for reasons discussed in section III–E. Determining the HAP content of materials and the method of application is relatively simple, and these factors are the most significant in affecting emissions. More information on the development of this model is available in the docket.

F. When Would I Need To Comply With These Proposed NESHAP?

We are proposing that all existing sources comply within 3 years of publication of the promulgated NESHAP in the **Federal Register**. New affected sources that startup before the promulgated NESHAP are published in the **Federal Register** must comply no later than the effective date of the NESHAP, which will be the same as the publication date. New affected sources that startup after the promulgated NESHAP are published in the **Federal Register** must comply upon startup. Existing area sources that increase their emissions or their potential to emit such that they become a major source of HAP must be in compliance within 3 years of the date they become a major source. New area sources that become major sources of HAP must comply upon becoming a major source. All open molding and centrifugal casting operations that comply by meeting a specified point value on a 12-month rolling average will have 1 year from the compliance date to demonstrate compliance.

We are proposing to provide new and existing facilities 3 years to comply from the time their HAP emissions reach or exceed the applicability thresholds requiring the installation of add-on controls, if these HAP emissions increases occur after their initial compliance date.

G. What Are the Proposed Options for Demonstrating Compliance?

Today's proposed NESHAP provide several options for compliance. We are providing these options to afford industry the flexibility to decide which method is best suited for each particular situation.

1. Open Molding and Centrifugal Casting Operations

For open molding operations at existing and new sources, this proposal would allow you to choose to comply by meeting the individual MACT point value for each operation at your affected source, or by meeting the weighted average MACT point value for all open molding operations at your affected source. In addition, if you have any combination of manual resin application, mechanical resin application, filament winding, or centrifugal casting operations at your affected source, you could comply by meeting the MACT point value for any one of these operations and by using the same resin for all the other operations.

For open molding and centrifugal casting operations where the proposed rule would require you to meet a percent reduction, you could use an add-on control device to achieve the required reduction or you may choose to meet a MACT point value that corresponds to that particular operation's percent reduction.

2. Continuous Casting/Lamination Operations

For continuous casting/lamination operations at existing and new sources, we are proposing that you could

demonstrate that each continuous casting line and each continuous lamination line meets the appropriate standard. Alternatively, you could average all your continuous casting and continuous lamination lines together, and demonstrate that they meet the appropriate standard. An additional alternative would be to capture your emissions from your wet-out area in a permanent total enclosure that meets EPA's criteria, as specified in Method 204 in appendix M of 40 CFR part 51, and vent these wet-out emissions through a closed vent system to a control device achieving 95 percent reduction of HAP emissions. Under this proposed rule, these alternatives could be used in combination to demonstrate compliance.

3. Pultrusion Operations

For existing and new pultrusion operations, under this proposed rule you could capture and vent your emissions to a control device that achieves the required percent reduction of HAP emissions. You could also elect to use direct die injection pultrusion machines with resin drip collection systems that meet the criteria specified. We are also proposing an additional alternative only available to existing sources: the use of a wet-area enclosure with a resin drip collection system. For both new and existing sources, you could use the available options in combination to achieve compliance under this proposed rule.

4. Ancillary Operations

For ancillary operations at all sources, such as cleaning, storage, and mixing/BMC operations at existing sources, the only option we are proposing is to comply with the specified work practice standards.

H. What Are the Testing and Initial Compliance Requirements?

We are proposing to require owners and operators of all affected sources which use a control device to demonstrate compliance to conduct an initial performance test using specified EPA test methods. The owner or operator would test at the inlet and outlet of the control device, and using these results, calculate a percent reduction.

We are also proposing to require owners and operators that use permanent total enclosures to conduct a design evaluation as specified by EPA Method 204. If your enclosure does not meet the requirements for a permanent total enclosure, you would need to test the enclosure using EPA Methods 204B through E to determine the capture efficiency.

Prior to the initial performance test, owners and operators of affected sources would be required to install the parameter monitoring equipment to be used to demonstrate compliance with the operating limits. During the initial performance test, the owners and operators would use the parameter monitoring equipment to establish operating parameter limits.

I. What Are the Continuous Compliance Requirements?

If you use an add-on control device, we are proposing that you monitor and record the operating parameters established during the initial performance test, and calculate average operating parameter values averaged over the period of time specified in these proposed NESHAP to demonstrate continuous compliance with the operating limits.

If you use the MACT point value system to maintain a point value less than or equal to the appropriate point value listed in today's proposed NESHAP, we are proposing to require that you calculate the point value one time if the resins or gel coats used in the operation remain the same, or if all the resins and gel coats used individually meet the required point values. You are required to calculate the point value on a 12-month rolling average each month if the resin or gel coat varies between operations or over time, and not all resins or gel coats taken individually meet the required point value.

If you are complying with work practice standards, we are proposing that you demonstrate compliance with the work practice standards in today's proposed NESHAP by performing the necessary work practices and by keeping a record certifying that you are in compliance with the work practices.

J. What Are the Proposed Notification, Reporting, and Recordkeeping Requirements?

We are proposing that you submit Initial Notification, Notification of Performance Tests, and Notification of Compliance Status reports by the specified dates in the proposed NESHAP, which may vary depending on whether the affected source is new or existing.

You would also need to submit semiannual compliance reports. If you take action that is inconsistent with your approved startup, shutdown, and malfunction (SSM) plan, then you would need to submit SSM reports within 2 days of starting such action, and within 7 days of ending such action.

We are proposing that you keep a copy of each notification and report, along with supporting documentation for 5 years. Of this time, the first 2 years must be on-site. You would need to keep records related to SSM, records of performance tests, and records for each continuous parameter monitoring system. Under this proposed rule, if you must comply with the work practice standards, you would also need to keep records certifying that you are in compliance with the work practices for 5 years. If you are use the MACT point value system to demonstrate compliance, you would need to keep all data, assumptions, and calculations used to determine your MACT point value. For new and existing continuous lamination/casting operations, you would also need to keep the following records when complying with the percent reduction or pound per ton requirements: All data, assumptions, and calculations used to determine the percent reduction and/or pounds per ton, as applicable; a brief description of the rationale for the assignment of an equation or factor to each formula; all data, assumptions, and calculations used to derive facility-specific emission estimations and factors; identification and rationale for the worst-case scenario; and documentation that the appropriate regulatory agency has approved all emission estimation equations and factors.

III. Rationale for Proposed NESHAP

A. How Did We Determine the Source Category To Regulate?

Reinforced Plastic Composites Production was included on the initial list of source categories published on July 16, 1992 (57 FR 31576). In establishing the source category list, we stated that we would refine category descriptions during the rulemaking process, if necessary, based on additional information available. We did not find it necessary to refine the source category description for Reinforced Plastic Composites Production. However, we did define a number of different process groupings in order to develop representative MACT floors as described in the section on MACT floor development.

B. What Pollutants Are Regulated Under These Proposed NESHAP?

The proposed NESHAP regulate total HAP rather than individual HAP compounds. Standards for total HAP simplify compliance and enforcement compared with standards for individual

HAP compounds. Styrene is the HAP emitted in the largest magnitude. Other HAP emitted from reinforced plastic composites production facilities include MMA and methylene chloride.

C. What Is the ''Affected Source'' and How Did EPA Select the Operations To Be Regulated by These Proposed NESHAP?

To provide compliance flexibility, we defined the affected source as the combination of all reinforced plastic composites operations at a site. This broad source definition allows a manufacturer to determine compliance by averaging the HAP content of different products used throughout the facility, within certain defined operations, and to use different application techniques as needed to meet product quality specifications.

D. What Is a New Affected Source?

A new affected source is any reinforced plastic composites production facility that meets both of these criteria:

- It commenced construction after today's date; and
- It is at a site that does not presently contain any reinforced plastic composites production operations.

In section 112 of the CAA, the definition of new sources also includes stationary sources that commence reconstruction after the publication date of a proposed NESHAP. The Small Business Advocacy Review (SBAR) Panel recommended that we carefully review our definition of reconstruction for this industry. As defined in the General Provisions for 40 CFR part 63, ''reconstruction'' means the replacement of components of an affected, or a previously unaffected, stationary source to such an extent that: (1) the fixed capital cost of the new components exceeds 50 percent of the fixed capital cost that would be required to construct a comparable new source; and (2) it is technologically and economically feasible for the reconstructed source to meet the relevant standards (as established by the Administrator or a State) pursuant to section 112 of the CAA.

We envision that the types of changes that would typically occur at existing facilities would include replacement of spray equipment and molds. We do not believe that it would be technologically and economically feasible for an existing source making these types of changes to meet new source MACT. Thus, such changes do not meet the definition of reconstruction in the General Provisions and would not subject the sources making such changes to new source MACT.

E. How Did We Determine the MACT Floor for Existing Sources?

Several considerations underlie our MACT floor determinations. These considerations include: if/how the source category is to be subcategorized, how emissions types within the affected source are to be analyzed, and what are the best performing sources.

We identified 433 facilities that are major sources based on their potential to emit or have the potential to be major sources based on collocation with other HAP-emitting processes not part of this source category.

If technical differences in emissions characteristics, processes, control device applicability, or opportunities for pollution prevention exist within the source category, it may be appropriate to set separate floors based on these characteristics. In analyzing the available data on this source category, it was apparent that reinforced plastic composite facilities, as a whole, are extremely diverse in their emissions characteristics, control device applicability, and opportunities for pollution prevention. Therefore, we explored various ways of grouping the operations that may be present at these facilities.

For existing sources, it was apparent that almost all of the existing source floors would be based on pollution-prevention techniques such as lowering the HAP content in resins and gel coats, covering baths and containers holding resins, and using nonatomized spray applications. The extent and performance of pollution-prevention techniques are dependent on the specific operation. For this reason, the data were subdivided by specific operation, and a floor for each operation was developed.

Operations were segregated by several factors. The first was mold type (i.e., open, partially open, and closed). We also segregated operations by resin and gel coat application method; these include mechanical, manual, filament winding, and centrifugal casting. The type of mold and resin application method impacts the emission potential of a particular operation and also the effectiveness and applicability of different control techniques. We also segregated continuous operations such as pultrusion, continuous lamination, continuous casting, and the manufacture of sheet molding compound.

The final criteria used was product type. The required properties of the final product place certain constraints on the raw materials that can be used. This, in turn, influences the limits on levels of HAP in the raw materials. We identified several product criteria where the raw materials required to produce the product are dissimilar enough that a separate floor determination was required. The first is corrosion resistance. Reinforced plastic composites can generally be divided into two types—corrosion-resistant and noncorrosion-resistant products. Corrosion-resistant products require resins specifically formulated for corrosion-resistant applications. We also included high-strength applications in the corrosion-resistant grouping. These applications include products such as structural members and utility poles. These require resins with higher HAP contents than general purpose resins. The higher HAP contents for both corrosion-resistant and high-strength applications are necessary to produce a laminate with a greater concentration of styrene cross-linking. This higher level of cross-linking is necessary for either corrosion-resistance or high-strength.

We also separated gel coats from resins because these materials have significantly different functions in the final product and are formulated differently. Gel coats were further subdivided into clear, white and off-white, and other colors. Clear gel coats require significantly higher HAP content than pigmented gel coats, and are, therefore, unable to be formulated to the same HAP levels. White and off-white gel coats can be formulated to lower HAP contents on a weight-percent basis than other colors due to the fact that white pigments are heavier than other color pigments.

Class 1 fire and smoke rated products were separated from other products because their unique properties require a resin with a significantly higher HAP content than any other products. Separating Class 1 fire and smoke rated products was also one of the recommendations of the SBAR Panel.

Tooling resins and gel coats are used to make the molds that, in turn, are used to produce reinforced plastic parts. Molds must have different properties compared to the products they are used to produce. These include a high level of dimensional stability and resistance to heat compared to other reinforced plastic composites. Therefore, separate floors were developed for tooling resins and gel coats.

Once the data were subdivided by specific operation, the data were ranked by HAP emissions. Open molding and centrifugal casting operations were ranked based on a surrogate emission factor called a point value. As

previously discussed, point values are based on resin and gel coat application method and HAP content, and provide a relative measure of emissions between operations with varying resin and gel coat HAP contents and application methods.

Other factors such as gel time, part thickness, application temperature, and operator technique also affect emissions. However, there are less data available to determine the effects of these factors in a production setting. In addition, some of these factors, such as part thickness, are inherent to the process and cannot be changed without changing the final product. For this reason, other factors are not included in the MACT model point value equations. The point value system was also developed to allow a facility to average different operations together to meet the applicable proposed standards. The ability to average is intended to provide additional compliance flexibility.

The individual operations were then ranked based on the point value (for open molding and centrifugal casting), percent of emission reduction (pultrusion, continuous lamination/casting, SMC manufacturing), covering open containers or exposed resin (storage, BMC manufacturing/mixing, injection/compression molding), or the use on non-HAP cleaning solvents (equipment cleaning). The median facility of the top 12 percent (or top 5 for operations with less than 30 sources) was then selected as representing the existing source floor.

For some of these operations, the available data were insufficient to perform a ranking. These were non-white pigmented gel coats, products with a Class 1 fire and smoke rating, and high-strength products.

We identified two facilities that produce products that require a Class 1 fire and smoke rating. Both facilities use a resin with a 60 percent HAP content. We chose use of this resin as the floor. From a 60 percent HAP resin, we calculated different point values for mechanical, manual, and filament winding resin application.

The data we used to set floors for pigmented gel coats were weighted averages reported by the facilities. This data included some information on colors, but not enough facilities reported color information to perform a meaningful ranking. Because of the predominance of white and off-white gel coats, these data are not representative for other colors. However, many facilities offer other colors. The pigments used in white and off-white gel coats are much denser than the pigments used in other colors. For that reason, weight percent HAP in white and off-white gel coats tends to be lower. A floor based on white and off-white gel coat HAP contents would preclude a facility using other colors.

Based on industry comments and the recommendation of the SBAR panel, we determined that a HAP content of 37 percent is the minimum that would provide acceptable gel coat performance for gel coats with colors other than white and off-white. In the absence of any other data, we adopted a 37 percent HAP as the floor for these gel coats. The 37 percent HAP content was converted to a point value using the appropriate point value equation. (See the final report of the SBAR Panel in the docket.) We request comments and supporting data on the appropriateness of 37 percent as a minimum HAP content for acceptable performance for gel coats with colors other than white and off-white.

The data supplied by industry did not differentiate products that require higher than typical strength properties. Therefore, we could not determine a floor with the facility data base. We discussed this issue as part of the SBAR Panel with several manufacturers that produce high-strength products. We also reviewed the requirements of South Coast Air Quality Management District Rule 1162. Rule 1162 specifically addresses high-strength products and contains the same requirements for high-strength products and corrosion-resistant products. As a result, we determined using the data for corrosion-resistant resins would be the most appropriate way to determine floors for high-strength products. Therefore, we are proposing the same floors for high-strength products and corrosion-resistant products. This is consistent with a recommendation of the SBAR Panel. We solicit comments on this approach.

There are many facilities that use multiple operations to produce a product. An example of this would be a facility producing corrosion-resistant tanks using filament winding to produce the main circular portion, mechanical resin application for the tank ends, and manual resin application to join the parts together. Industry representatives pointed out that the floors we had developed from the data base would potentially require a facility to use three different resins to produce a single product. This could potentially lead to problems of resin compatibility and product failures. The SBAR Panel report included a recommendation that we allow a facility to use the same resin for all processes.

As a result, we reexamined the floors for facilities with multiple processes. We determined that, based on the data available, the appropriate approach would be to have a provision in the proposed standards to allow a facility to select one operation, determine the resin they could use to meet the floor, and then use that same resin in all other operations. We did not have the data to determine what that operation should be in all cases, so we are not specifying a particular operation in the proposed standards. We assumed that a facility would select the operation that allows them to use the highest HAP content resin.

At the recommendation of the SBAR Panel, we also reexamined the floors for tooling resins. Several of the small entity representatives that advised the panel stated that the proposed floor for tooling resins will result in inferior quality tools. We believe that the current floor for tooling resins allows sufficient flexibility in resin HAP content as long as the resin can be applied with nonatomized spray technology. We are specifically soliciting comment on the applicability of nonatomized spray technology to tooling resins. Based on any comments, we intend to further examine the floor for tooling resins.

F. How Did We Determine the MACT Floor For New Sources?

In developing the floor for new sources, we developed two subcategories—sources with emissions of 100 tpy or above and sources with emissions below 100 tpy. Our reason for examining sources with emissions below 100 tpy separately is that such facilities are likely to have more difficulty maintaining and operating add-on controls than larger-emitting sources, and we are unsure of the performance of add-on controls at these facilities. Separating the data into large and small HAP-emitting sources for developing new source MACT floors was also one of the recommendations of the SBAR Panel.

In examining the facilities with emissions of 100 tpy or more, we found two facilities that control emissions from open molding and mixing by 95 percent overall. These facilities range in size from approximately 100 tpy to 1000 tpy of HAP emissions prior to the add-on control device. This level of control was chosen as the new source MACT floor for open molding and mixing at facilities with 100 tpy or more of uncontrolled emissions.

We also considered whether to evaluate the applicability of add-on controls to each of the different

operations as was done in setting floors for existing sources. The two facilities that control emissions by 95 percent have operations including gel coat and mechanical resin application. The performance and cost of add-on controls is mainly a function of air flows and HAP concentration from the process. We have no data to suggest that the air flows and HAP concentrations present in other open molding production processes in this industry are not adequately represented by these two facilities.

The two facilities produce parts that range in size from that of bathtubs to truck caps. It is possible that larger size parts may require larger enclosures. We have not identified any facilities in the reinforced plastic composites industry where processes producing large parts, such as storage tanks and swimming pools, have applied 100 percent efficient capture systems. However, we have identified facilities using 100 percent efficient capture systems that apply coatings to large parts such as helicopters and ships. These coating operations have similar issues of large air flows (due to worker exposure concerns) and low outlet HAP emission concentrations. Based on this, we believe that it is technically feasible to apply 100 percent efficient capture systems to larger parts in the reinforced plastic composites industry.

We evaluated the applicability of the 95 percent control level as the new source floor for other operations. Centrifugal casting, continuous lamination/casting, pultrusion, and SMC manufacturing are similar in emissions characteristics to open molding. There are five facilities that have applied highly efficient add-on controls to these operations, with overall control efficiencies ranging from 90 to 95 percent. For this reason, we chose 95 percent control as the new source MACT floor for these operations at facilities with uncontrolled emissions of at least 100 tpy.

We also considered whether the new source MACT floor for the previously mentioned operations should be incorporation of the pollution-prevention measures that make up the existing source floors, combined with 95 percent control. This approach would actually result in a higher overall emissions reduction. In addition, incorporating the pollution prevention measures would reduce the potential for worker exposure in situations where processes have to be enclosed to meet the 95 percent control requirement.

However, we determined that selecting incorporation of pollution-prevention techniques in addition to the 95 percent control requirement as the new source floor was not appropriate because the facilities that incorporate 95 percent control, which we determined represent the best controlled facilities, do not also incorporate the best pollution prevention techniques. Therefore, combining the pollution-prevention requirements with the 95 percent control requirements would actually result in an overall control level that exceeds the levels at the best controlled facilities.

We are requesting comment on whether the new source floor for facilities that must meet the 95 percent control requirements should also incorporate the pollution-prevention requirements. We also request that commentors provide any available data on worker exposure that would help us quantify the benefits of incorporating pollution-prevention requirements with the 95 percent control requirements.

We are not proposing 95 percent control for closed molding, polymer casting, equipment cleaning, and resin storage, which have much lower emissions than the other types of operations. One of the facilities that sets the new source floor has a closed molding operation on site. This operation is not controlled through the use of an add-on control device. We attempted to identify other means of emissions reductions for these processes. For compression/injection molding, which is a type of closed molding, the only identified means of emission reduction was the work practice of uncovering one charge at a time. Therefore, this was chosen as the new source MACT floor for compression/injection molding. For polymer casting and resin transfer molding, we were not able to identify any means of reduction, either add-on controls or process modifications such as the use of low HAP resins. Thus, the new source MACT floor for these sources is no emissions reduction.

For equipment cleaning, the proposed new source floor is based on use of cleaners with no HAP. Of the 433 facilities that reported information on cleaning, 353 reported using no cleaning materials containing HAP. However, we are not regulating solvents used for cleaning cured resin or gel coat from application equipment because we know of no means of reducing HAP emissions. Cured resin or gel coat inside a gun is usually the result of operator error or an equipment failure. To clean cured resin and gel coat, an aggressive solvent is needed, and no low-HAP alternatives are available. The equipment is usually soaked in a covered bucket resulting in little evaporation of the solvent. The amount of solvent needed per year is determined by the size of the facility, degree of operator error, and equipment failure rates. Because operator error and equipment failure are hard to predict, we could determine no basis for an annual limit of solvent usage that would be achievable by all facilities. These proposed NESHAP, therefore, allow HAP-containing solvents only for cleaning cured resin and gel coat from the application equipment.

Over 250 facilities reported covering storage containers. We selected covering storage containers as the new source MACT floor for storage. We identified two facilities that vent the storage areas to a control device; however, we determined that the available data are insufficient to quantify additional emissions reductions that would result from controlling storage tanks and containers by 95 percent versus just covering the storage tanks and containers.

We calculated separate floors for facilities with less than 100 tpy of emissions from open molding, centrifugal casting continuous lamination/casting, pultrusion, SMC manufacturing, and BMC manufacturing/mixing. Though there are facilities with emissions below 100 tpy that have add-on controls, data were not available to substantiate their level of control. Therefore, we could not state that they achieved a level of control above that achieved by the pollution-prevention techniques, and thus, meet the definition of best controlled facilities. Also, smaller-emitting facilities tend to operate with fewer shifts than larger ones. The more frequent startups and shutdowns could tend to make it more difficult to maintain and operate add-on controls compared to larger-emitting facilities. For these reasons, the floor for new sources with less than 100 tpy of emissions is based on pollution-prevention techniques.

For these smaller-emitting facilities, we are proposing to set the new source MACT floor at the same level as the existing source MACT floor. This approach was recommended by the SBAR Panel. We believe the existing source MACT floor represents the greatest degree of emissions reduction that is achievable for small facilities under all circumstances. For new sources, the CAA requires the MACT floor to be based on the HAP emissions control achieved in practice by the best controlled similar source, as determined by the Administrator. The reinforced plastic composites industry is extraordinarily diverse. The products

produced, even in the same operation, can include skylights, bathtubs, and parts for automobiles. Given this diversity, it is difficult to identify the ''best controlled'' source. Products manufactured by this industry generally must meet certain minimal strength and durability requirements. The HAP content of the resin is a factor in meeting such requirements. Use of a resin with a given HAP content may be the most stringent level of control possible for a particular process, while it may be possible to use a lower-HAP resin in a different process without jeopardizing the strength or durability of the product.

While some facilities are using lower-HAP materials and techniques than represented by the existing source MACT floor, we do not believe that these examples are universally applicable to all new reinforced plastic composites manufacturers. We have no data to precisely define the particular combination of requirements where these lower-emitting options can be used and still maintain the minimum required strength and durability requirements of these products. Consequently, we have set the proposed floor at the most stringent level that we have determined all sources emitting less than 100 tpy can achieve.

We did not find that the quantity of HAP emissions from the source had any effect on its ability to incorporate pollution-prevention technology, or on the effectiveness of these technologies. For that reason, we did not subdivide the data for existing sources where the floors are based mainly on pollution prevention.

During the SBAR Panel discussions, many of the small entity representatives expressed concern regarding the affordability and technical feasibility of add-on controls, and commented that they may be able to achieve similar HAP reductions using pollution-prevention measures, which tend to be less expensive. For example, if a facility could reduce its emissions by 50 percent each year for 3 years using the pollution-prevention alternative, it may be able to achieve reductions similar to thermal oxidation (nearly 90 percent versus 95 percent). The panel recommended that EPA explore with industry the possibility of a more stringent pollution-prevention option as an alternative to add-on controls. The panel believed that this option should be more stringent than the pollution-prevention technology present in the current existing source MACT floors.

We discussed with industry the possibility of a pollution-prevention control option in lieu of add-on controls. We were unable to develop an option that we believe meets the statutory requirements of MACT. However, we are soliciting comment on a possible pollution-prevention alternative to the 95 percent HAP reduction requirement. The specific information we are seeking is the maximum level of control that can be achieved by pollution prevention, and the time necessary to incorporate pollution-prevention techniques. The pollution-prevention techniques of which we are aware include low HAP resins and gel coats, nonatomized resin and gel coat applications, vapor suppressed resins, vacuum bagging, accelerated resin curing, and conversion of open molding processes to closed molding. We are soliciting information on other pollution-prevention techniques of which we are not aware, and information on the maximum level of emissions reductions achievable by these techniques.

The general concept of an alternative would be a facility that elects to use this option to submit notification to the appropriate permitting authority of their intent. The facility would then have to submit a plan to meet specific emissions reductions through pollution prevention. The plan would outline the techniques they intend to use, the research and testing required, and a schedule with annual milestones for achieving the goal.

In the next step, the facility would calculate an overall emission factor for all processes at the facility that are required to meet the 95 percent emission reduction.

Once a facility has determined a base year emission factor, they would be required to incorporate the pollution-prevention techniques outlined in the plan and make annual reports of progress. If a facility was unable to meet an interim milestone, they would be required to provide an updated plan within a specified time.

We are also soliciting comment on determination of a base year and baseline emission factor, and reporting requirements.

G. Did We Consider Options More Stringent Than the MACT Floor?

For existing sources, an above-the-floor control level was evaluated which was based on the new source floor for sources with emissions of 100 tpy or more. This above-the-floor control level would require 95 percent control of HAP emissions from all open molding, centrifugal casting, continuous lamination/casting, pultrusion, SMC manufacturing, and resin mixing/BMC manufacturing.

We then looked at several options. These were selecting the floor level of control as MACT for all facilities, selecting the above-the-floor level as MACT for all facilities, or choosing an alternative where facilities at or above a certain HAP emissions quantity would meet the above-the-floor level, and the rest would meet the floor. In looking at this third alternative, we also evaluated different HAP emission thresholds.

The option of having all facilities meet the above-the-floor level of control had an incremental cost of $4,300 per additional ton of HAP emission reduction. The economic analysis for this option indicated that 126 small businesses would be impacted at a level of 3 percent of sales or more, and there were 90 projected closures of small businesses. Because of the impacts on small businesses, we believe that the benefit of controlling all existing sources to this level is not commensurate with the economic impacts. Therefore, we are not proposing this alternative as MACT.

We then looked at a combination of the MACT floor for facilities below a specified HAP emissions quantity based on actual emissions prior to any add-on controls, and the above-the-floor level of control for larger-emitting facilities. We also examined the impacts from the standpoint of small businesses and their ability to obtain the capital to purchase pollution control equipment. We believe that the capital costs of the above-the-floor option for most small businesses would be prohibitive because they do not have the same access to capital as large businesses. The available data indicate that at a threshold of 250 tpy, none of the existing small businesses in the data base would be impacted significantly by the above-the-floor control level. For this reason, we determined MACT for small businesses to be the floor for facilities that emit less than 250 tpy of HAP, and the above-the-floor control level for facilities that emit 250 tpy or more. For large businesses, we determined MACT to be the floor for facilities that emit less than 100 tpy of HAP, and the above-the-floor control level for facilities that emit 100 tpy or more of HAP. The incorporation of the 250 tpy threshold for small businesses was one of the recommendations of the SBAR Panel, and the economic impacts of the selected option are reasonable.

Industry representatives independently developed costs for add-on controls and submitted them to the Agency. Their analysis is in the docket for this proposed rulemaking. The SBAR Panel recommended that we reconsider our estimates of costs for add-on controls in light of that study. The

industry cost estimates are at least three times higher than our cost estimates. The major reason for these differences in cost are the design assumptions for the permanent total enclosures and the estimated air flows. Our cost estimates assume an inlet concentration of 100 parts per million by volume (ppmv). The industry study assumes lower concentrations that vary based on the specific facility. However, available test data for measured concentrations in the exhaust streams for reinforced plastic composites facilities range from 61 to 249 ppmv, with an average concentration of 120 and a median of 82. Based on this, we believe our 100 ppmv estimate is still reasonable, and we have decided not to revise our cost analysis at this time. We will review the industry's cost analysis in more depth following proposal, and make any appropriate changes based on our review and on comments we receive. We are soliciting comment on the cost and feasibility of add-on controls, data on design and operation of permanent total enclosures from this or similar industries, and data on typical exhaust HAP concentrations and air flows for reinforced plastic composite facilities.

We did not identify an above-the-floor option for the following operations: closed molding, polymer casting, and equipment cleaning. We were able to find no examples where any closed molding process was controlled using add-on controls. Therefore, we believe it is not technically and economically feasible to use add-on controls for closed molding processes. We do not believe it is technically feasible to use add-on controls for equipment cleaning operations. In any case, application of the floor level of control we are proposing would eliminate HAP-containing cleaners, except for cases where cured resin has to be removed from application equipment. This floor level of control would achieve close to 100 percent HAP emissions reductions.

For new sources, we examined an above-the-floor option of requiring all sources to meet the 95 percent control requirement for open molding, centrifugal casting, continuous lamination/casting, pultrusion, SMC manufacturing, and resin mixing/BMC manufacturing. We determined that, even if we could resolve the issues surrounding the performance of add-on control devices at the smaller-emitting sources, the incremental cost would be $15,000 per ton of additional HAP emissions reduction. For this reason, we chose the floor level of control as MACT for new sources.

We also considered an even more stringent above-the-floor control level for both existing and new sources. This control level would require facilities to use add-on controls to meet a 95 percent HAP emission reduction, and also require them to incorporate pollution-prevention techniques such as the use of low HAP resins and gel coats, and nonatomized resin application techniques. As previously discussed, the benefits of this approach would be that by incorporating the pollution-prevention measures in addition to the add-on control, the overall HAP emissions reduction would be increased. In addition, the potential for worker exposure in these situations would be reduced. However, we determined that this control level would result in approximately a 2 percent incremental HAP emissions reduction compared to the above-the-floor control level based on a 95 percent emissions reduction alone. The incremental cost of a control level that combines 95 percent HAP emissions reductions and pollution-prevention measures would be $36,900 per ton of additional HAP emissions reduction. Though there may be worker exposure benefits, we did not include this above-the-floor control level in this proposed rule. This possibility is still under consideration, and we are requesting comment. We also request that commentors provide any available data on worker exposure that would allow us to quantify the additional worker exposure benefits of incorporating pollution-prevention requirements with the 95 percent control requirements.

We did not identify an above-the-floor option for new sources for the following operations: Closed molding, polymer casting, and equipment cleaning for the same reasons as discussed above for existing sources.

We also examined an above-the-floor control option for existing sources based on pollution prevention. As was the case with the new source MACT floor, we are unable at this time to develop an alternative that we believe meets the statutory requirements of MACT. However, we are specifically soliciting comments on pollution-prevention techniques that could be used in lieu of the above-the-floor alternative as were discussed in the section on new source floors.

In addition to the previous discussion, we also evaluated non-air quality environmental impacts of these above-the-floors options. These impacts are discussed in section IV, Summary of Environmental, Energy, and Economic Impacts.

H. Why Are Some Reinforced Plastic Composites Production Operations Not Subject to These Proposed NESHAP?

These proposed NESHAP would not regulate mold sealing and release agents and mold stripping and cleaning solvents because we were unable to set MACT floors or determine MACT for these operations. In both cases, the information and data available to us suggest that mold maintenance practices, part shape and size, and production schedules determine emissions more than the HAP content of these materials. We do not have sufficient data to identify and prescribe work practices to reduce emissions from these operations. Therefore, these proposed NESHAP do not require emissions reductions for these materials.

For mold stripping and cleaning solvents, the amount of HAP used per unit of mold surface area applied depends on facility-specific mold maintenance practices and production requirements. These may include mold cycle time, how often the mold is used, and whether the mold is stored indoors or outdoors. The size of the part may also influence mold maintenance. We do not have sufficient data to identify those differences in production requirements or work practices that determine mold cleaning solvent usage. Therefore, we cannot identify a MACT floor or MACT.

I. How Did We Select the Proposed Compliance Dates for Existing and New Sources?

The CAA instructs EPA to establish a compliance date or dates for existing sources that will provide for compliance ''as expeditiously as practicable, but in no event later than 3 years after the effective date.'' For existing sources, we are proposing a compliance date 3 years from [DATE OF PUBLICATION OF THE FINAL RULE IN THE **Federal Register**].

Existing sources complying with the point value limits, which is a pollution-prevention approach, will need to make changes in application equipment and raw materials. We believe these sources need the full 3-year period provided by the CAA in order to evaluate the effect of these changes on their production processes, particularly because they may need to try out different resins. In addition, we believe that providing the maximum amount of allowable time will provide more sources the opportunity to change their raw materials and production techniques so that each resin and gel coat can meet the MACT specific to each process type rather than averaging the HAP content

of resins across the source, thereby reducing the amount of records and paperwork needed to demonstrate initial and continuous compliance.

We are also proposing a 3-year compliance date for existing sources that must use add-on controls. We believe the full 3 years provided by the CAA is necessary for these sources as well to allow sufficient time for them to design, purchase, install, and work out operational problems that occur in trying to start up a new control device. In addition, if an existing source's emissions exceed one of the thresholds in the proposed rule that requires an add-on control device to comply, the 3-year period would provide sufficient time to evaluate whether there are pollution-prevention approaches that would get them below the threshold. We encourage the use of pollution-prevention as a control approach, and pollution prevention could be a significant cost savings over add-on controls for these sources.

The CAA instructs EPA to establish compliance dates for new sources that will provide for compliance upon start up, or the effective date of the final rule, whichever is later. These are the dates we are proposing in this proposed rule.

New and existing sources that comply by meeting point values on a 12-month rolling average must initiate collection of these data on the compliance date. New and existing sources that comply using add-on control devices must conduct the required performance testing within the 180-day time period as specified in the General Provisions to part 63.

We are also proposing to provide sources 3 years to comply from the time their HAP emissions reach or exceed the applicability thresholds requiring the installation of add-on controls, if these HAP emissions increase after their initial compliance date. We are providing this compliance time for sources under these circumstances because, as explained previously, we believe this is the necessary amount of time to get these control devices installed and operational.

J. How Did We Select the Form of These Proposed NESHAP?

We decided to offer several forms for complying with the proposed NESHAP. The purpose of multiple forms is to provide the flexibility to comply in the most cost-effective and efficient manner. We considered the following factors in selecting the form of the proposed NESHAP:

- The form should allow for multiple compliance techniques for the various types of facilities in the industry.
- The form should simplify compliance and ensure that the cost of compliance is not excessive.
- The form should be enforceable.

The form of these proposed NESHAP is based on a combination of emission limits (point values or percent reduction), equipment standards, and work practice standards.

1. Emission Limits Based on Point Values

These proposed NESHAP for open molding operations and centrifugal casting operations are based on point values which are in units of pounds of HAP per ton of resin used. The point value development has been previously described. This form was chosen over an absolute emission limit because it accurately determines the amount of pollution-prevention control a source has incorporated in its process, but does not require a facility to perform emission testing. This form also allows for averaging across open molding processes or across centrifugal casting processes. This means that a source has the option to over-control some operations, under-control others (relative to the limit for that individual process), but still meet the overall limit for such operations combined. This allows a source to have additional flexibility in meeting the proposed standards.

The emission limits for open molding and centrifugal casting for new sources are based on a percent reduction using add-on controls. However, we have provided an alternative standard for new sources also based on point values. These point values were determined by applying the required percent reduction requirement to the existing source MACT floors. The new source floor is based on a control efficiency, and the facilities that have these controls do not have examples of every possible type of open molding or centrifugal casting process. Therefore, we were not able to use the best-controlled sources to directly determine a point value that is equivalent to the 95 percent emissions reductions requirement for all operations. For operations where we could directly determine a point value equivalent, the approach of using existing source floors and applying 95 percent control is slightly more stringent. Therefore, we believe applying this approach to all open molding and centrifugal casting operations will produce a limit that is no less stringent, while providing opportunities for facilities to incorporate pollution prevention into their process, meet a percent reduction requirement less than 95 percent, but still meet the new source floor.

2. Emission Limits Based on Percent Reduction

The form of the standards for new open molding, centrifugal casting, SMC manufacturing, and resin/mixing/BMC manufacturing, and the standards for new and existing sources for pultrusion and SMC manufacturing are based on a percent reduction. These standards were all developed from facilities using add-on controls. It is possible to design a control device to meet a specified percent reduction. But based on the data available, it was not possible to determine an uncontrolled emission factor for open molding, centrifugal casting, SMC manufacturing, and mixing/BMC manufacturing that was generally applicable. Therefore, we could not develop a standard based on an emission factor. For continuous lamination/casting, we were able to develop an absolute emission limit based on the facilities that set the floor. These absolute emission limits are presented as alternatives to the percent reduction limits. In the case of pultrusion operations, there are alternative standards based on wet-area enclosures or direct die injection. Emission testing has determined that using this equipment as specified in the proposed rule will achieve the percent reductions specified in the NESHAP.

3. Emission Limits Based on Equipment/Work Practice Standards

Section 112(h) of the CAA states that ''* * * if it is not feasible in the judgement of the Administrator to prescribe or enforce an emission standard for control of a hazardous air pollutant or pollutants, the Administrator may, in lieu thereof, promulgate a design, equipment, work practice, or operational standard, or combination thereof * * *'' Section 112(h)(2) further defines the phrase ''not feasible to prescribe or enforce an emission standard'' as any situation in which ''* * * a hazardous air pollutant or pollutants cannot be emitted through a conveyance designed and constructed to emit or capture such pollutant, * * * or the application of measurement methodology to a particular class of sources is not practicable due to technological and economic limitations.''

The emission limits for equipment cleaning and storage at new and existing sources are based on work practice and equipment standards. The reason for choosing work practice and equipment standards for storage is that storage areas may be located outside the rest of

the production area, and in some cases, may be located outside the building. We do not believe it would be practicable due to economic limitations to test storage areas, and we do not have sufficient data to calculate an emission limit for the required work practice.

The standard for existing pultrusion facilities is based on the equipment standard combined with a work practice. We have proposed the standard as a percent reduction to allow the use of add-on controls. However, we do not believe it would be technologically or economically feasible to actually test facilities that choose to use a wet-area enclosure or direct die injection.

The limits for SMC and resin mixing/BMC at existing facilities are also based on work practices or equipment standards. We have no data to determine a specific percent reduction to the work practices for these operations. Therefore, we could not set a specific emission limit.

Cleaning operations may take place outside the regular production area. It would not be technologically or economically practicable to perform emission testing for cleaning operations.

4. Selection of Averaging Time for Demonstrating Compliance

As a reinforced plastic composites manufacturer, we are proposing that you could show compliance with the proposed NESHAP on a 12-month, rolling-average basis. A 12-month rolling average is determined at the end of each month by calculating a weighted average actual point value based on that month's resin and gel coat use, and a weighted average floor value based on that month's resin and gel coat use. The floor must also be calculated because the floors for different operations are not the same, and the weighted average floor may change based on the relative amounts of resin used in different operations. You would then sum the current month's weighted averages (floor and actual) with the monthly averages for each of the previous 11 months, divide the resulting sums by 12, and compare the two results. If the actual 12-month weighted average point value is less than or equal to the floor 12-month weighted average point value, you are in compliance.

We believe a 12-month averaging time provides a balance between operating flexibility and enforceability of the proposed standards. The 12-month period is sufficiently long so that you can identify potential compliance problems and change your operations in time to maintain compliance. The rolling-average aspect provides an enforceable emission limit 12 times per year.

Many reinforced plastic composites manufacturers already track material usage monthly to comply with State regulations and permit requirements, so we believe monthly tracking is consistent with current practice. Tracking on a more frequent basis would be unnecessarily burdensome for this particular industry. Reinforced plastic composites manufacturers need a 12-month rolling-average period to respond to both short-term variations in HAP content that are inherent in all chemical products, and to account for short-term needs for higher-HAP materials due to variations in product mix.

In order to calculate a 12-month rolling average, facilities must have 12 months of data. For this reason, we are proposing to allow facilities that elect to use a 12-month rolling average to demonstrate compliance 12 months and 30 days after the compliance date. This includes the time to generate 12 months of data to determine the average plus 30 days to perform the necessary calculations and generate the compliance report. If we were to establish a demonstration date prior to this, as a practical matter, facilities would have to actually achieve compliance prior to the compliance date. For reasons previously discussed, we believe it is reasonable and appropriate to give facilities the maximum time allowed by the CAA to comply.

K. How Did We Select the Test Methods for Determining Compliance With the Proposed NESHAP?

The proposed NESHAP have several options for achieving compliance. For open molding and centrifugal casting, this includes meeting a specified point value for existing sources, or a percent reduction or point value for new sources. For most other processes, you achieve compliance by using an enclosure and add-on control device to meet a percent reduction requirement or an absolute emission limit.

In order to calculate a point value, under this proposed rule, you must determine the HAP content of the raw material. The method to determine material HAP content is the use of the Material Safety Data Sheets (MSDS) or other product specification sheets provided by the material manufacturer. We chose not to propose requiring testing of the material. The data used to develop the standards were mainly based on MSDS; therefore, we believe it is reasonable that MSDS be used to determine compliance.

Under the proposed NESHAP, if you chose to use an enclosure and add-on control device, you would have to determine the capture efficiency of the enclosure and measure the HAP from the control device. To determine the capture efficiency of the enclosure, you would use EPA Method 204 (Criteria for and Verification of Permanent or Temporary Total Enclosure). If the enclosure meets the criteria in EPA Method 204 for a permanent total enclosure, then you could assume that its capture efficiency is 100 percent. If the enclosure is not a total enclosure, then you would build a total temporary enclosure around it that meets the definition of a total temporary enclosure in EPA Method 204. You would then have to measure emissions from both the control device and the total temporary enclosure and use the combined emissions to determine compliance.

To measure HAP, you would be able to use either EPA Method 18 (Measurement of Gaseous Organic Compound Emissions by Gas Chromatography) to measure the sum of individual species of HAP, or EPA Method 25A (Determination of Total Gaseous Organic Matter Concentration Using a Flame Ionization Analyzer) for total hydrocarbons (THC) as a surrogate for total HAP. The EPA Method 25A would allow you the flexibility to use a simpler method than EPA Method 18 which does not speciate HAP in cases where measuring THC is sufficient to demonstrate compliance. You could measure THC as a surrogate for total HAP if most of the THC emitted from an enclosure were HAP, such as styrene and MMA from resin and gel coat operations. For compliance determinations, the EPA will assume that all THC measured with EPA Method 25A are HAP.

We have not included in this proposed rule a test method for determining the effectiveness of vapor suppressed resins. A draft protocol entitled ''Vapor Suppressant Effectiveness Test Protocol,'' dated April 7, 1999, has been developed by industry and is available for review in the docket for this proposed rule. The draft protocol is insufficiently detailed for inclusion in this proposed rule. We are currently requesting additional details and soliciting comment on the test protocol or an alternate test protocol.

L. How Did We Determine the Proposed Monitoring and Recordkeeping Requirements?

Which monitoring and recordkeeping requirements you would meet depend

on how you choose to comply with these proposed NESHAP. For each compliance option, the proposed monitoring and recordkeeping requirements are the minimum necessary to determine initial and ongoing compliance and are consistent with the General Provisions (40 CFR part 63, subpart A).

This section describes how to comply with emission limits based on point values, emission averaging provisions, equipment and work practice standards, and the emission limit for an add-on control device.

1. Compliance With Emission Limits Based on Point Values

For all operations subject to HAP content limits, we are proposing four tasks: monitor and record the HAP content of the material used, monitor and record the monthly consumption of the material, monitor and record which operations use the material, and record the computations to show that the weighted average point value over the past 12 months meets the proposed standards.

The SBAR Panel recommended that we look for alternatives to simplify reporting and recordkeeping. We have identified two alternatives we believe simplify the reporting and recordkeeping process. The first is that an owner and operator may use purchase records to determine monthly consumption. However, an owner and operator can track actual material flows to each process if desired. We believe this is reasonable because facilities have no financial incentive to keep significant inventories of raw material on hand, and we have no evidence that keeping large amounts of raw material on hand is a common practice. Therefore, purchases and actual consumption should track fairly closely. We are requiring that the owner and operator have a reasonable method to estimate the amounts of each resin used by a specific operation. The second alternative applies where all the materials used in an operation result in a point value that meets the emission limit, in which case, an owner and operator only need to record HAP content and the resulting point value and do not need to track monthly consumption of each individual material.

2. Compliance With Averaging Provisions

To comply with the averaging provisions for open molding operations and centrifugal casting operations, you must monitor and record HAP content as well as how use of the material is split between different operations, and you must record the computations needed to show compliance. You must use these data as well as the MACT model point value equations in the proposed NESHAP to calculate the point values in that operation for the past 12 months. Compliance is then determined relative to the allowable weighted average point value calculated for those operations for the past 12 months. Compliance would be calculated monthly, and monthly purchase records may be used to determine resin and gel coat use.

3. Compliance With Equipment and Work Practice Standards

The proposed NESHAP require resin and gel coat mixing containers to be fitted with covers that have no visible gaps. You will be required to inspect container covers each month to ensure the covers are in place and properly maintained. You must record the results of the inspections. The inspections should be sufficient to ensure that the covers are in place and properly maintained. We believe monthly inspections are a reasonable interval because the nature of failure in these pieces of equipment is likely due to wear and tear and not a sudden failure. Longer time periods between inspections, however, would allow a failure to go too long before being repaired.

The proposed NESHAP for production resin and tooling resin requires most manufacturers to use nonatomized resin application methods to comply. These methods include flowcoaters and pressure-fed resin rollers, among others. We could identify no parameters to monitor whether these methods are being used. Rather, compliance through the use of these methods would be determined during enforcement inspections. As long as flowcoaters, pressure-fed resin rollers, or other similar devices are installed and operated according to manufacturer's specifications, they will comply with the requirements to use nonatomized resin application methods.

4. Compliance for Sources Using Enclosures and Add-On Control Devices

The requirements for enclosures and add-on control devices in the proposed NESHAP are consistent with other air quality regulations that require capture and control of emissions. They are the minimum needed to demonstrate that the capture and control system is operated properly.

We are proposing that you must initially demonstrate compliance with the emission limit by demonstrating that the enclosure is a total enclosure or by also measuring the fugitive emissions that escape the enclosure. You would also need to measure the efficiency of the add-on control using EPA Method 25A for THC (as a surrogate for HAP) or EPA Method 18 for HAP. The EPA Method 18 measures individual HAP that you sum to calculate total HAP.

After the initial compliance test, we are proposing that you must monitor control device parameters to demonstrate that the control device continues to be operated as it was during the initial test. In the case of thermal oxidizers, you would need to monitor and record combustion temperature every 15 minutes both during and after the performance test. We are proposing that you must calculate the average temperature achieved during the test. After the test, you would need to maintain the average temperature at or above the temperature achieved during the performance test. Temperature monitors and recorders are standard features on thermal oxidizers. For other devices we are proposing that you must determine appropriate parameters to monitor and receive our approval to use these parameters.

M. How Did We Select the Proposed Notification and Reporting Requirements?

We believe that the proposed notices and reports are the minimum needed to determine if you are subject to the proposed NESHAP and whether you are in compliance. We are proposing that you must submit an initial notification stating that you are subject to the proposed NESHAP. After the compliance date for your facility, you would need to submit a notification of your compliance status. You would also need to submit semiannual reports of your compliance status. If you have an add-on control device and you become out of compliance, we are proposing that you must submit quarterly reports of your compliance status until we approve a request to return to semiannual reporting.

If your facility is a new source, we are proposing that you have additional preconstruction notification requirements. You would also have additional notification and reporting requirements if you use an add-on control device, including notifications and reports for the control device performance test. These proposed notification and reporting requirements are consistent with those specified in the General Provisions. We believe that these requirements are the minimum needed for us to determine compliance for sources with add-on control devices.

The SSM plan specified by the General Provisions will be required only for sources using an add-on control device and will apply only to the add-on control device. For operations not using a control device, the nature of the materials and equipment used to comply with the proposed Reinforced Plastic Composites Production NESHAP is such that malfunctions will not lead to excess emissions.

N. What Are Some of the Areas Where We Are Specifically Soliciting Comments?

The purpose of this section is to highlight particular issues of concern to the EPA or to other parties. We solicit comments on these issues, along with data to support the comments.

The proposed rule requires that certain new and existing sources control HAP emissions by 95 percent. In order to meet this requirement, facilities will likely have to capture 100 percent of their emissions from the affected processes and route these emissions to an add-on control device. We are soliciting data on the technical feasibility of permanent total enclosures (PTE); factors that affect the feasibility of PTE such as product size, operation grouping, and vent stream concentrations and air flow from the processes where capture systems are used; and interactions of these requirements with OSHA rules. For example, the feasibility of 100 percent emissions capture using PTE is based on data from two facilities. We believe that the process operations in these facilities are representative of the industry as a whole. However, we are soliciting comment on types of facilities that may not be able to apply PTE, along with data to support these comments. We solicit data on a facility's ability to maintain and operate add-on controls. We are especially interested in cost and design data from facilities in this industry that have successfully applied add-on controls. Data on control device inlet air flows and HAP concentrations combined with worker exposure monitoring data would be especially useful. We solicit data on typical operating hours in this industry, particularly in relation to the size of facilities and their operations (e.g., resin use or number of employees) since operating hours affect cost effectiveness and the number of start-ups and shutdowns.

The proposed rule sets different thresholds for existing source requirements at small versus large businesses, above which control of HAP emissions by 95 percent is required. The higher threshold for small businesses is based on concerns that it is more difficult for small businesses to raise the necessary capital to purchase add-on controls to comply with the 95 percent control level. We solicit comments on this conclusion, along with data on capital availability for large and small businesses and the impact of this threshold on large businesses. We solicit information and data on other factors to consider in evaluating control requirements more stringent than the MACT floor, including data on costs to the industry.

We believe that we have captured the full range of processes and products in our proposed operation groups. We request comments with supporting data on any processes or products that might not be adequately represented. Along these lines, we have specifically provided separate process groups for products with a Class I smoke and fire rating, and have defined high strength products as part of the corrosion resistant process group because of specific product requirements that require specialized raw materials. We solicit comments on this approach and data on any additional processes or products that have unique properties that may require separate process groupings for MACT floor development.

This proposed rule contains point value equations for open molding and centrifugal casting. We are soliciting comments on the data and assumptions used to develop MACT point value equations, and information on other methods or emission models that could be used to rank facilities for the purposes of setting MACT.

We also solicit information on the adequacy or necessity of the monitoring, recordkeeping, and reporting requirements in this proposed rule. We specifically solicit comments on the recordkeeping and reporting burden estimates set forth in the Paperwork Reduction Act discussion in this preamble and information on ways to minimize respondent burden.

IV. Summary of Environmental, Energy, and Economic Impacts

A. What Facilities Are Affected By the Proposed NESHAP?

There are approximately 433 existing facilities manufacturing reinforced plastic composites that are major sources and would be subject to the proposed NESHAP. The rate of growth for the reinforced plastic composites industry is estimated to be 84 new facilities over the next 5 years.

B. What Are the Air Quality Impacts?

The 1997 baseline HAP emissions from the reinforced plastic composites industry are approximately 22,200 tpy. The proposed NESHAP would reduce HAP from existing sources by 14,500 tpy, a reduction of 65 percent.

The proposed NESHAP would result in small increases in other air pollution emissions from combustion devices that will be installed in the next 5 years to comply with today's proposed rule. These increases result from both the combustion device directly, and estimated emissions that occur at electrical generating plants to generate the electricity necessary to operate the add-on controls and associated air handling equipment. These emissions are estimated to be 38 tpy of sulfur oxides (SO_X), 69 tpy of nitrogen oxides (NO_X), 125 tpy of carbon monoxide (CO), and 1.5 tpy of particulate matter (PM) emissions.

C. What Are the Water Quality Impacts?

We estimate that the proposed Reinforced Plastic Composites Production NESHAP will have no adverse water quality impacts. We do not expect anyone to comply by using add-on control devices or process modifications that would generate wastewater.

D. What Are the Solid and Hazardous Waste Impacts?

We estimate that the proposed NESHAP would decrease the amount of solid waste generated by the reinforced plastic composites industry by approximately 1,400 tpy. The decrease in solid waste is directly related to switching to nonatomized resin application equipment (i.e., flowcoaters and resin rollers). Switching to flowcoaters results in a decrease in overspray because of a greater transfer efficiency of resin from flowcoaters to the part being manufactured. A decrease in resin overspray consequently reduces the amount of waste from disposable floor coverings, cured resin waste, and personal protective equipment (PPE) for workers. Disposable floor coverings are replaced on a periodic basis to prevent resin buildup on the floor. We estimate that solid waste generation of floor coverings will decrease by approximately 360 tpy and that cured resin solid waste will decrease by approximately 1,040 tpy.

We project that the decreased overspray from flowcoaters will result in a decreased usage of PPE, which also consequently reduces the amount of solid waste. Workers who use flowcoaters typically wear less PPE than

when using spray guns because of the reduced presence of resin aerosols and lower styrene levels in the workplace. Because we did not have information on the many different types of PPE currently used, we did not estimate this decrease in solid waste.

Some facilities that switch from spray guns to flowcoaters may have a small increase of hazardous waste from the used flowcoater cleaning solvents. However, most facilities would not see an increase under this proposed rule, and the overall impact on the industry will be small relative to the solid waste reductions. Nearly all flowcoaters require resin and catalyst to be mixed inside the gun (internal-mix) and must be flushed when work is stopped for more than a few minutes. External-mix spray guns do not need to be flushed because resin is mixed with catalyst outside the gun. Facilities that switch from external-mix spray guns to flowcoaters will use more solvent. Solvent usage should not change at facilities switching from internal-mix spray guns to flowcoaters. The most common flushing solvents are acetone and water-based emulsifiers. Only a couple of ounces of solvent are typically needed to flush the mixing chamber and nozzle of flowcoaters and internal-mix spray guns.

We do not have adequate data to predict the potential solvent waste impact from switching to flowcoaters. The magnitude of the impact depends on the type of gun currently used (internal- or external-mix), the frequency of flushing, and the type of solvent used. However, because of the small amount of solvent used, and since most is allowed to evaporate, we believe the overall solvent waste increase will be small compared to the solid waste reductions.

E. What Are the Energy Impacts?

We determined that the overall energy demand for operations in the Reinforced Plastic Composites Production source category could increase by 159 million standard cubic feet per year of natural gas, and 10 million kilowatt hours of electricity per year as a result of the proposed rule. We determined this net increase based on the additional energy demand for control devices installed to meet the proposed standards. No information for comparison is available on the baseline energy consumption for this source category.

F. What Are the Cost Impacts?

We have estimated the capital costs for emission control equipment, including equipment such as open container covers, resin bath enclosures, capture systems, and control devices as $73.9 million for existing sources and $11.7 million for new sources. The capital costs include the costs to purchase and install the control equipment.

We have estimated that annual costs of the proposed rule are $26.0 million per year for existing sources and $3.2 million for new sources. Annual costs include fixed annual costs, such as reporting, recordkeeping and capital amortization, and variable annual costs such as natural gas. The estimated average cost of the proposed rule is $1,600 per ton of HAP emissions reduction for existing sources and $2,200 per ton of HAP emissions reduction for new sources.

As discussed elsewhere in this preamble, we will review in more depth the industry's analysis on the cost of this proposed rule following proposal. Where appropriate, we will make changes to our estimates of costs based on our review and on comments we receive, and make the results of our detailed review available in the public docket at promulgation.

G. What Are the Economic Impacts?

The Agency conducted a detailed economic impact analysis to determine the market- and industry-level impacts associated with the proposed rule. We expect the aggregate price increase for reinforced plastic composites would be only 0.3 percent, or $0.01 per pound, as a result of the proposed standards. We project that directly affected producers would reduce total production by 0.8 percent, while producers not directly affected would increase their production by 0.3 percent. Markets for reinforced plastic composites used in general construction, corrosion-resistant products, and land transportation are expected to be more heavily impacted with price increases of up to 0.5 percent and reductions in directly affected domestic production of between 1 and 1.5 percent.

In terms of industry impacts, captive producers of reinforced plastic composites are expected to fully absorb their compliance costs, while merchant producers will attempt to pass through costs to their customers. Through the market impacts described above, the proposed NESHAP create both gainers and losers within the merchant segment. Some merchant facilities are projected to experience profit increases with the proposed rule; however, the majority that continue operating are projected to lose profits. Furthermore, the economic impact analysis indicates that 29 out of 299 merchant facilities (9.7 percent) and 73 out of 471 product lines (15.5 percent) at these facilities are at risk of closure because of the proposed NESHAP. All of the facilities determined to be at risk for closure are believed to be small businesses. More information on the measures we have taken to minimize these impacts may be found in the Regulatory Flexibility Act discussion in this preamble.

Based on the market analysis, the annual social costs of the proposed rule are projected to be $25.7 million. These costs are distributed across the many consumers and producers of reinforced plastic composites. Producers, in aggregate, are expected to bear $10.6 million annually in costs, with those directly affected by the proposed NESHAP losing $19.3 million and those not subject to the proposed NESHAP gaining $8.7 million. The consumers of reinforced plastic composites are expected to incur the remaining $15.1 million in costs associated with the proposed NESHAP. For more information, consult the docket for this project.

V. Relationship of Proposed NESHAP to Other Standards and Programs Under the CAA

A. National Emission Standards for Closed Vent Systems, Control Devices, Recovery Devices, and Routing to a Fuel Gas System or a Process (40 CFR Part 63, Subpart SS)

If you use an add-on control device(s) to control emissions, you will need to comply with certain provisions in 40 CFR part 63, subpart SS, for add-on controls. The standards in subpart SS cited by the proposed NESHAP are applicable to most sources using an add-on control device. The proposed NESHAP cite these sections in subpart SS rather than repeating them in the proposed regulatory text.

B. Operating Permit Program

Under the operating permit program codified at 40 CFR parts 70 and 71, all major sources subject to standards under section 111 or 112 of the CAA must obtain an operating permit (See §§ 70.3(a)(1) and 71.3(a)(1)). Therefore, all major sources subject to these proposed NESHAP must obtain an operating permit.

Some reinforced plastic composites production facilities may be major sources based solely on their potential to emit even though their actual emissions are below the major source level. These facilities may choose to obtain a federally enforceable limit on their potential to emit so that they are no longer considered major sources subject to the proposed NESHAP.

Sources that opt to limit their potential to emit (e.g., limits on operating hours or amount of material used) are referred to by the EPA as ''synthetic area'' sources. To become a synthetic area source, you must contact your local permitting authority to obtain an operating permit with the appropriate operating limits. These operating limits will then be federally enforceable under 40 CFR 70.6(b).

C. NESHAP for Plastic Parts and Products

There are currently NESHAP under development for proposal that will regulate coating of plastic parts and products. The SBAR Panel recommended that we consider the interaction of the Plastic Parts and Product NESHAP with today's proposed NESHAP. The Plastic Parts and Products NESHAP may potentially affect facilities that produce reinforced plastic parts and then apply a coating to the finished parts. We have coordinated with this project and have determined that there should be no overlap (i.e., specific operations covered by today's proposed NESHAP should not also be covered in the Plastic Parts and Products NESHAP). We have not determined any requirements of the proposed NESHAP that would overlap, conflict, or cause a duplication of effort.

VI. Administrative Requirements

A. Executive Order 12866: Regulatory Planning and Review

Under Executive Order 12866 (58 FR 51735, October 4, 1993), we must determine whether a proposed regulatory action is ''significant'' and therefore subject to Office of Management and Budget (OMB) review and the requirements of the Executive Order. The Executive Order defines ''significant regulatory action'' as one that is likely to result in a rule that may:

(1) Have an annual effect on the economy of $100 million or more or adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities;

(2) Create a serious inconsistency or otherwise interfere with an action taken or planned by another agency;

(3) Materially alter the budgetary impact of entitlements, grants, user fees, or loan programs or the rights and obligations of recipients thereof; or

(4) Raise novel legal or policy issues arising out of legal mandates, the President's priorities, or the principles set forth in the Executive Order.

Pursuant to the terms of Executive Order 12866, OMB has notified EPA that it considers this rulemaking a ''significant regulatory action'' within the meaning of the Executive Order. The EPA submitted this action to OMB for review. Changes made in response to suggestions or recommendations from OMB are documented and included in the public record.

B. Paperwork Reduction Act

The information collection requirements in this proposed rule have been submitted for approval to the OMB under the Paperwork Reduction Act, 44 U.S.C. 3501 *et seq.* An ICR document has been prepared by EPA (ICR No.) and a copy may be obtained from Sandy Farmer by mail at the Office of Environmental Information, Collection Strategies Division (2822), U.S. EPA, 1200 Pennsylvania Avenue, NW, Washington, DC 20460, by e-mail at ''farmer.sandy@epa.gov,'' or by calling (202) 260–2740. A copy may also be downloaded from the internet at ''http://www.epa.gov/icr.''

These proposed NESHAP contain monitoring, reporting, and recordkeeping requirements. We believe that the proposed notices and reports are the minimum needed by us to determine if you are subject to the NESHAP and whether you are in compliance. We believe the proposed recordkeeping requirements are the minimum necessary to determine initial and ongoing compliance. Based on reported information, we would decide which reinforced plastic composites facilities and what records or processes should be inspected. The recordkeeping and reporting requirements are consistent with the General Provisions of 40 CFR part 63.

These proposed recordkeeping and reporting requirements are specifically authorized by section 114 of the CAA (42 U.S.C. 7414). All information submitted to us for which a claim of confidentiality is made will be safeguarded according to our policies in 40 CFR part 2.

The EPA expects these proposed NESHAP to affect a total of approximately 486 facilities over the first 3 years after promulgation of the rule. This includes 433 existing facilities, and 53 new reinforced plastic composites facilities will become subject to the proposed NESHAP during the first 3 years.

The estimated average annual burden for the first 3 years after promulgation of these proposed NESHAP for industry and the implementing agency is outlined below. You can find the details of this information collection in the ''Standard Form 83 Supporting Statement for ICR No. 1976.01,'' in Docket No. A–94–52.

Affected entity	Total hours	Labor costs	Total annual O&M costs	Total costs
Industry	15,122	$673,120	$17,265	$690,385
Implementing agency	11,293	450,972	NA	450,972

Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Control numbers for EPA's regulations are listed in 40 CFR part 9 and 48 CFR chapter 15.

Comments are requested on the Agency's need for this information, the accuracy of the provided burden estimates, and any suggested methods for minimizing respondent burden, including the use of automated collection techniques. Send comments on the ICR to the Director, Office of Environmental Information, Collection Strategies Division (2822), U.S. EPA, 1200 Pennsylvania Avenue NW, Washington, DC 20460; and to the Office of Information and Regulatory

Affairs, OMB, 725 17th Street, NW, Washington, DC 20503, marked ''Attention: Desk Officer for EPA.'' Include the ICR number in any correspondence. Since OMB is required to make a decision concerning the ICR between 30 and 60 days after August 2, 2001, a comment to OMB is best assured of having its full effect if OMB receives it by September 4, 2001. The final rule will respond to any OMB or public comments on the information collection requirements contained in this proposal.

C. Executive Order 13132, Federalism

Executive Order 13132, entitled ''Federalism'' (64 FR 43255, August 10, 1999), requires EPA to develop an accountable process to ensure ''meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications.'' ''Policies that have federalism implications'' is defined in the Executive Order to include regulations that have ''substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.''

This proposed rule does not have federalism implications. It will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132. No reinforced plastic composites production facilities subject to these proposed NESHAP are owned by State or local governments. Therefore, State and local governments will not have any direct compliance costs resulting from this proposed rule. Furthermore, these proposed NESHAP do not require these governments to take on any new responsibilities. Thus, the requirements of section 6 of the Executive Order do not apply to this proposed rule. Thus, Executive Order 13132 does not apply to this rule.

In the spirit of Executive Order 13132, and consistent with EPA policy to promote communications between EPA and State and local governments, EPA specifically solicits comment on this proposed rule from State and local officials.

D. Executive Order 13175, Consultation and Coordination With Indian Tribal Governments

Executive Order 13175, entitled ''Consultation and Coordination with Indian Tribal Governments'' (65 FR 67249, November 6, 2000), requires EPA to develop an accountable process to ensure ''meaningful and timely input by tribal officials in the development of regulatory policies that have tribal implications.'' ''Policies that have tribal implications'' is defined in the Executive Order to include regulations that have ''substantial direct effects on one or more Indian tribes, on the relationship between the Federal government and the Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes.''

This proposed rule does not have tribal implications. It will not have substantial direct effects on tribal governments, on the relationship between the Federal government and Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes, as specified in Executive Order 13175, because we are not aware of any Indian tribal governments or communities affected by the proposed rule. Thus, Executive Order 13175 does not apply to this proposed rule.

In the spirit of Executive Order 13175, and consistent with EPA policy to promote communications between EPA and tribal governments, EPA specifically solicits additional comment on this proposed rule from tribal officials.

E. Unfunded Mandates Reform Act of 1995

Title II of the Unfunded Mandates Reform Act of 1995 (UMRA), Public Law 104–4, establishes requirements for Federal agencies to assess the effects of their regulatory actions on State, local, and tribal governments and the private sector. Under section 202 of the UMRA, we must generally prepare a written statement, including a cost-benefit analysis, for proposed and final rules with ''Federal mandates'' that may result in expenditures to State, local, and tribal governments, in the aggregate, or to the private sector, of $100 million or more in any 1 year. Before promulgating a rule for which a written statement is needed, section 205 of the UMRA generally requires us to identify and consider a reasonable number of regulatory alternatives and adopt the least costly, most cost effective, or least burdensome alternative that achieves the objectives of the rule. The provisions of section 205 do not apply when they are inconsistent with applicable law. Moreover, section 205 allows us to adopt an alternative other than the least costly, most cost-effective, or least burdensome alternative if the Administrator publishes with the final rule an explanation why that alternative was not adopted. Before we establish any regulatory requirements that may significantly or uniquely affect small governments, including tribal governments, it must have developed under section 203 of the UMRA a small government agency plan. The plan must provide for notifying potentially affected small governments, enabling officials of affected small governments to have meaningful and timely input in the development of our regulatory proposals with significant Federal intergovernmental mandates, and informing, educating, and advising small governments on compliance with the regulatory requirements.

We have determined that this proposed rule does not contain a Federal mandate that may result in expenditures of $100 million or more by State, local, and tribal governments, in the aggregate, or the private sector in any 1 year. The total cost to the private sector is approximately $29.2 million per year. This proposed rule contains no mandates affecting State, local, or Tribal governments. Thus, today's proposed rule is not subject to the requirements of sections 202 and 205 of the UMRA.

We have determined that this proposed rule contains no regulatory requirements that might significantly or uniquely affect small governments because it contains no requirements that apply to such governments or impose obligations upon them.

F. Regulatory Flexibility Act (RFA), as Amended by the Small Business Regulatory Enforcement Fairness Act of 1996 (SBREFA), 5 U.S.C. 601 et seq.

The RFA generally requires an agency to prepare a regulatory flexibility analysis of any rule subject to notice and comment rulemaking requirements under the Administrative Procedure Act or any other statute unless the agency certifies that the rule will not have a significant economic impact on a substantial number of small entities. Small entities include small businesses, small organizations, and small governmental jurisdictions.

For purposes of assessing the impacts of today's proposed rule on small entities, small entity is defined as (1) a small business ranging from 500–1,000 employees; (2) a small governmental jurisdiction that is a government of a city, county, town, school district or special district with a population of less than 50,000; and (3) a small organization that is any not-for-profit enterprise which is independently owned and operated and is not dominant in its field. The table below presents the size threshold for small businesses by SIC Code.

Category	SIC codes	NAICS codes	Maximum number of employees to be considered a small business
Manufacturing	3621	335312	1000
	3711	336211, 336112.	
	3716	33612.	
	3728	336213.	
	3743	336413.	
		33651.	
	2821	325211	750
	3296	327993.	
	3431	332998.	
	3531	33312, 33651.	
	3612	335311.	
	3613	335313.	
	3663	33422.	
	3714	33653, 336399.	
	All other identified SIC Codes in this source category.	All other identified NAICS Codes in this source category.	500

In accordance with section 603 of the RFA, EPA prepared an initial regulatory flexibility analysis (IRFA) that examines the impact of the proposed rule on small entities along with regulatory alternatives that could reduce that impact. The IRFA is available for review in the docket and is summarized below.

Section 112 of the CAA requires us to list categories and subcategories of major sources and, in some cases, area sources of HAP and to establish NESHAP for the listed source categories and subcategories. Reinforced plastic composites production (major sources only) was included on the initial list of source categories published on July 16, 1992 (57 FR 31576). Major sources of HAP are those that have the potential to emit greater than 10 tpy of any one HAP or 25 tpy of any combination of HAP.

The objective of this proposed rule is to apply standards based on maximum achievable control technology to all major sources in this source category. The criteria used to establish MACT are contained in section 112 (d) of the CAA.

Based on SBA size definitions and reported sales and employment data, EPA identified 278 of the 356 companies owning reinforced plastic composites facilities as small businesses. Although small businesses represent almost 80 percent of the companies within the source category, they are expected to incur only 31 percent of the total industry compliance costs of $26.0 million. The average total annual compliance cost is projected to be $30,000 per small company as compared to the industry average of $70,000 per company. Under the proposed standards, the mean annual compliance cost, as a share of sales, for small businesses is 0.7 percent, and the median is 0.4 percent, with a range of 0.01 to 7.5 percent. The EPA estimates that 17 percent of small businesses (or 47 firms) may experience an impact greater than 1 percent of sales, but only 3 percent of small businesses (or 8 firms) may experience an impact greater than 3 percent of sales.

The Agency also performed an economic impact analysis (EIA) that accounted for firm behavior to provide an estimate of the facility and market impacts of the regulation. This industry is characterized by profit margins of 3 to 4 percent. Small businesses were found to have higher per-unit production costs under baseline conditions and incur slightly higher per-unit compliance costs. As a result of these factors, the economic analysis indicates that almost 10 percent of facilities owned by small business are at risk of closure because of this proposed rule.

Although any facility closures are cause for concern, the number of facilities at risk for closure would be the same if this proposed rule required only the MACT floor level of control for all facilities. The MACT floor is the least stringent level allowed by statute. As discussed below, this proposed rule contains a significant number of accommodations for small business. Without additional data, we do not believe we can make the proposed rule any less stringent and comply with the objectives of the CAA. In this regard, we have requested data and comment elsewhere in this preamble on issues relevant to this industry.

The EPA's efforts to minimize small-business impacts have materially improved today's proposal. Economic analysis of provisions under earlier consideration for inclusion in this proposed rule indicated greater impacts on small businesses than those proposed today. In earlier versions, almost 42 percent of the total industry compliance costs would have been incurred by small businesses (compared with 31 percent of costs incurred by small businesses in today's proposal). The average total annual compliance cost would have been roughly $50,000 per small company (compared with $30,000 in today's proposal). About 22 percent of small businesses (or 60 firms) would have experienced an impact greater than 1 percent of sales (compared with 17 percent of small businesses in today's proposal). And 7 percent of small businesses (or 19 firms) would have experienced impacts greater than 3 percent of sales (compared with 3 percent of small businesses in today's proposal). The reduction in small-business costs from earlier versions of this proposed rule is attributable to EPA's outreach and accommodation for small firms in keeping with both RFA and CAA requirements, including the conduct of a SBAR Panel, as discussed further below.

The proposed reporting and recordkeeping requirements for these small businesses include initial notifications, startup notifications and compliance reports. These requirements were discussed in more detail under the discussion of the Paperwork Reduction Act above. We estimate that 302 existing facilities owned by small businesses will be impacted by these requirements, and 53 new facilities will be impacted in the first three years. The professional

skills required to complete these reports include the ability to calculate emissions and resin use and read and follow report format guidance. All facilities impacted by this proposed rule should have personnel with the necessary skills because they would need these skills to comply with other regulatory requirements such as Toxic Release Inventory (TRI) reporting.

Provisions to minimize the reporting and recordkeeping requirements on small business have been incorporated into this proposed rule. These provisions include allowing: The facility to substantiate resin and gel coat HAP contents with Material Safety Data Sheets rather then requiring testing of each resin and gel coat; use of resin purchase records to determine resin use; and exemption of facilities that can demonstrate that all their resin and gel coats comply with the required HAP content limits from the requirement to keep records of resin use and calculate point value averages. These provisions have also been extended to all companies subject to today's proposed NESHAP.

These facilities may also be subject to the NESHAP being developed for plastic parts and products. There should be no duplication of effort as a result of this proposed rule and the Plastic Parts and Products NESHAP being developed because these NESHAP will cover different operations. Facilities subject to this proposed rule are also subject to emissions estimate reporting under the TRI requirements. In this proposed rule, we could determine no ways to combine TRI and the reporting requirements of the proposed NESHAP because the objectives and statutory authorities of these requirements are different. However, we invite comments from all interested parties on ways to combine these reports and still meet the statutory requirements of the CAA.

As indicated above, we have incorporated significant alternatives into the proposed rule to minimize the impact on small business but still meet the objectives of the CAA.

As required by section 609(b) of the RFA, EPA conducted outreach to small entities and convened a SBAR panel to review advice and recommendations from representatives of the small entities that potentially would be subject to the proposed rule requirements. The panel convened on April 6, 2000 and was comprised of representatives from OMB, the SBA Office of Advocacy, the EPA Small Business Advocacy Chair, and the Emission Standards Division of the Office of Air Quality Planning and Standards of EPA. The panel solicited advice from 17 small entity representatives (SER) from a cross-section of the different industry sectors likely to be directly regulated by this action. On April 18, 2000, the panel distributed a package of descriptive and technical materials explaining the rule-in-progress to the SER. On May 2, 2000, the panel met with the SER to hear their comments on preliminary options for regulatory flexibility and related information. The panel also received written comments from the SER in response to both the outreach materials and the discussions at the meeting.

Consistent with RFA/SBREFA requirements, the panel evaluated the assembled materials and small-entity comments on issues related to the elements of the IRFA. A copy of the panel report is included in the docket for this proposed rule.

The panel considered numerous regulatory flexibility options in response to concerns raised by the SER. The major concerns included the affordability and technical feasibility of add-on controls, the resin and gel coat HAP contents required to meet some of the MACT floors, and the regulatory treatment of speciality products.

These are the major panel recommendations and EPA's response in today's proposal:

- Recommend setting higher thresholds than EPA had initially considered for requirements to use add-on controls.

Response: In today's action, EPA proposes to allow facilities owned by small firms to emit 250 tpy (as distinct from the 100 tpy limit for facilities owned by large firms) before installing add-on controls.

- Recommend setting the new source floor for small-owned sources at the level of the existing source floor.

Response: Today's proposal includes this provision.

- Recommend establishing separate floors for speciality products.

Response: Today's proposal includes this provision.

- Explore pollution-prevention alternatives to add-on controls.

Response: The EPA did explore this possibility with industry sources. Although we could not devise a workable pollution-prevention alternative to include in today's proposal, the Agency is requesting comment on how such a mechanism might be structured within the requirements of the CAA.

- Recommend allowing individual facilities to use the same resin in all resin application processes.

Response: Today's proposal includes this provision.

- Reconsider the resin HAP content requirement for tooling resins.

Response: Today's proposal includes a revised provision.

- Recommend separate floors for white and non-white gel coats.

Response: Today's proposal includes this provision.

- Reconsider the Agency's estimates of the cost of add-on controls.

Response: Even though today's proposal eliminates the likelihood that existing small-owned facilities will be subject to add-on controls, EPA has reconsidered its cost estimates in light of those offered by the industry. As discussed elsewhere in this preamble, EPA continues to believe our estimates are realistic. Nevertheless, as mentioned in section III–M, we are soliciting comments on all data and assumptions that affect add-on control costs. Moreover, as mentioned previously, we will review in more depth the industry's analysis on the cost of this proposed rule following proposal. Where appropriate, we will make changes to our estimates of costs based on our review and on comments we receive, and make the results of our detailed review available in the public docket at promulgation.

- Recommend grouping high-strength applications with corrosion-resistant operations.

Response: Today's proposal includes this provision.

Detailed information on all these recommendations is contained in the panel report in the docket for this proposed rule.

G. National Technology Transfer and Advancement Act

Section 12(d) of the National Technology Transfer and Advancement Act (NTTAA) of 1995 (Public Law No. 104–113; 15 U.S.C. 272 note) directs EPA to use voluntary consensus standards in their regulatory and procurement activities unless to do so would be inconsistent with applicable law or otherwise impractical. Voluntary consensus standards are technical standards (e.g., materials specifications, test methods, sampling procedures, business practices) developed or adopted by one or more voluntary consensus bodies. The NTTAA directs EPA to provide Congress, through annual reports to OMB, with explanations when an agency does not use available and applicable voluntary consensus standards.

This proposed rulemaking involves technical standards. The EPA proposes in this rule to use EPA Methods 1, 1A, 2, 2A, 2C, 2D, 2F, 2G, 3, 3A, 3B, 4, 18, 25, 25A, 204, and 204B, C, D, E.

Consistent with the NTTAA, the EPA conducted searches to identify voluntary consensus standards in addition to these EPA methods. One voluntary consensus standard was identified as applicable and EPA proposes to use this standard in this proposed rule.

The one consensus standard, ASTM D6420–99, Standard Test Method for Determination of Gaseous Organic Compounds by Direct Interface Gas Chromatography-Mass Spectrometry (GC/MS), is appropriate in the cases described below for inclusion in this proposed rule in addition to the currently available EPA Method 18 codified at 40 CFR part 60, appendix A.

Similar to EPA's performance based Method 18, ASTM D6420–99 is also a performance based method for measurement of gaseous organic compounds. However, ASTM D6420–99 was written to support the specific use of highly portable and automated GC/MS. While offering advantages over the traditional Method 18, the ASTM method does allow some less stringent criteria for accepting GC/MS results than required by Method 18. Therefore, ASTM D6420–99 is a suitable alternative to Method 18 where: (1) The target compound(s) are those listed in Section 1.1 of ASTM D6420–99, and (2) the target concentration is between 150 parts per billion (volume) and 100 ppm(v).

For target compound(s) not listed in Table 1.1 of ASTM D6420–99, but potentially detected by mass spectrometry, the regulation specifies that the additional system continuing calibration check after each run, as detailed in section 10.5.3 of the ASTM method, must be followed, met, documented, and submitted with the data report even if there is no moisture condenser used or the compound is not considered water soluble.

For target compound(s) not listed in Table 1.1 of ASTM D6420–99, and not amenable to detection by mass spectrometry, ASTM D6420–99 does not apply.

As a result, EPA proposes to incorporate by reference (IBR) ASTM 6420–99 into 40 CFR 63.14 for application with proposed subpart WWWW of part 63. The EPA will also cite Method 18 as a gas chromatography (GC) option in addition to ASTM D6420–99. This will allow the continued use of other GC configurations.

In addition to the voluntary consensus standards EPA proposes to use in this proposed rule, the search for emissions monitoring procedures identified 17 other voluntary consensus standards. The EPA determined that 13 of these 17 standards identified for measuring emissions of the HAP or surrogates subject to emission standards in the proposed rule would not be practical due to lack of equivalency, detail, and/or quality assurance/quality control requirements. The remaining four of the 17 consensus standards identified are under development or under EPA review. Therefore, we do not propose to use these voluntary consensus standards in this proposed rulemaking. More information on the reasons we chose not to propose to use these standards is available in the docket for this proposed rule.

The EPA takes comments on proposed compliance demonstration requirements in this proposed rulemaking and specifically invites the public to identify potentially applicable voluntary consensus standards. Commentors should also explain why this proposed rule should adopt these voluntary consensus standards in lieu of or in addition to EPA's methods. Emission test methods and performance specifications submitted for evaluation should be accompanied with a basis for the recommendation, including method validation data and the procedure used to validate the candidate method (if method other than Method 301, 40 CFR part 63, appendix A was used).

Table 6 of proposed subpart WWWW lists the EPA test methods and performance standards. Most of the standards have been used by States and industry for more than 10 years. Nevertheless, under § 63.7(f), the proposal also allows any State or source to apply to EPA for permission to use an alternative methods in place of any of the EPA testing methods or performance standards listed in the proposed NESHAP.

H. Executive Order 13045, Protection of Children from Environmental Health Risks and Safety Risks

Executive Order 13045 (62 FR 19885, April 23, 1997) applies to any rule that: (1) Is determined to be ''economically significant'' as defined under Executive Order 12866, and (2) concerns an environmental health or safety risk that we have reason to believe may have a disproportionate effect on children. If the regulatory action meets both criteria, the Agency must evaluate the environmental health or safety effects of the planned rule on children, and explain why the planned regulation is preferable to other potentially effective and reasonably feasible alternatives considered by the Agency.

The EPA interprets Executive Order 13045 as applying only to those regulatory actions that are based on health or safety risks, such that the analysis required under section 5–501 of the Executive Order has the potential to influence the regulation. This proposal is not subject to Executive Order 13045 because it is based on technology performance and not on health or safety risks.

List of Subjects in 40 CFR Part 63

Environmental protection, Air pollution control, Hazardous air pollutants, Incorporation by reference, Reporting and recordkeeping requirements, Volatile organic compounds.

Dated: June 22, 2001.

Christine Todd Whitman,

Administrator.

For the reasons stated in the preamble, title 40, chapter I, part 63 of the Code of the Federal Regulations is proposed to be amended as follows:

PART 63—[AMENDED]

1. The authority citation for part 63 continues to read as follows:

Authority: 42 U.S.C. 7401 *et seq.*

2. Section 63.14 is proposed to be amended by adding paragraph (b)(21) to read as follows:

§ 63.14 Incorporation's by reference

* * * * *

(b) * * *

(21) ASTM D6420–99, Standard Test Method for Determination of Gaseous Organic compounds by Direct Interface Gas Chromatography-Mass spectrometry, IBR approved for § 63.5798 and § 63.5850.

* * * * *

3. Part 63 is proposed to be amended by adding subpart WWWW to read as follows:

Subpart WWWW—National Emission Standards for Hazardous Air Pollutants: Reinforced Plastic Composites Production

Sec.

What This Subpart Covers

63.5780 What is the purpose of this subpart?
63.5785 Am I subject to this subpart?
63.5790 What parts of my plant does this subpart cover?
63.5795 How do I know if my reinforced plastic composites production facility is a new affected source or an existing affected source?
63.5797 What are model point values and how are they used in this subpart?
63.5798 How do I determine my facility's HAP emissions on a tons per year (tpy) basis?

63.5800 When do I have to comply with this subpart?

Standards

63.5805 What standards must I meet to comply with this subpart?

Options for Meeting Standards

63.5810 What are my options for meeting the standards for new and existing open molding and centrifugal casting operations?
63.5820 What are my options for meeting the standards for continuous lamination/casting operations?
63.5825 What are my options for meeting the standards for new pultrusion operations?
63.5830 What are my options for meeting the standards for existing pultrusion operations?

General Compliance Requirements

63.5835 What are my general requirements for complying with this subpart?

Testing and Initial Compliance Requirements

63.5840 By what date must I conduct a performance test or other initial compliance demonstration?
63.5845 When must I conduct subsequent performance tests?
63.5850 How do I conduct performance tests, performance evaluations, and design evaluations?
63.5855 What are my monitor installation and operation requirements?
63.5860 How do I demonstrate initial compliance with the standards?

Additional Compliance Calculation Procedures for Continuous Lamination/Casting Operations

63.5865 What data must I generate to demonstrate compliance with the standards for continuous lamination/casting operations?
63.5870 How do I calculate annual uncontrolled and controlled emissions from my wet-out area(s) and from my oven(s)?
63.5875 How do I determine the capture efficiency of the enclosure on my wet-out area and the capture efficiency of my oven(s)?
63.5880 How do I determine how much neat resin plus is applied to the line and how much neat gel coat plus is applied to the line?
63.5885 How do I calculate percent reduction to demonstrate compliance?
63.5890 How do I calculate an emission factor to demonstrate compliance?

Continuous Compliance Requirements

63.5895 How do I monitor and collect data to demonstrate continuous compliance?
63.5900 How do I demonstrate continuous compliance with the standards?

Notifications, Reports, and Records

63.5905 What notifications must I submit and when?
63.5910 What reports must I submit and when?
63.5915 What records must I keep?
63.5920 In what form and how long must I keep my records?

Other Requirements and Information

63.5925 What parts of the General Provisions apply to me?
63.5930 Who implements and enforces this subpart?
63.5935 What definitions apply to this subpart?

Tables to Subpart WWWW of Part 63

Table 1 to Subpart WWWW of Part 63—Model Equations to Calculate Point Values for Specific Open Molding and Centrifugal Casting Process Streams
Table 2 to Subpart WWWW of Part 63—Compliance Dates for New and Existing Reinforced Plastic Composites Facilities
Table 3 to Subpart WWWW of Part 63—Emission Limits for Existing Small Business Sources Emitting Less Than 250 TPY of HAP, or Other Sources Emitting Less Than 100 TPY of HAP
Table 4 to Subpart WWWW of Part 63—Work Practice Standards
Table 5 to Subpart WWWW of Part 63—Alternative Emission Limits for Open Molding and Centrifugal Casting Operations Where the Standard Is Based on a Percent Reduction Requirement
Table 6 to Subpart WWWW of Part 63—Basic Requirements for Performance Tests, Performance Evaluations, and Design Evaluations for New and Existing Sources Using Add-On Control Devices
Table 7 to Subpart WWWW of Part 63—Options Allowing Use of the Same Resin Across Different Operations That Use the Same Resin Type
Table 8 to Subpart WWWW of Part 63—Initial Compliance With Emission Limits
Table 9 to Subpart WWWW of Part 63—Initial Compliance With Work Practice Standards for Existing Sources
Table 10 to Subpart WWWW of Part 63—Data Requirements for New and Existing Continuous Lamination Lines and Continuous Casting Lines Complying with a Percent Reduction Limit on a Per Line Basis
Table 11 to Subpart WWWW of Part 63—Data Requirements for New and Existing Continuous Lamination and Continuous Casting Lines Complying with a Percent Reduction Limit or a Lbs/Ton Limit on an Averaging Basis
Table 12 to Subpart WWWW of Part 63—Data Requirements for New and Existing Continuous Lamination Lines and Continuous Casting Lines Complying with a Lbs/Ton on a Per Line Basis
Table 13 to Subpart WWWW of Part 63—Applicability and Timing of Notifications
Table 14 to Subpart WWWW of Part 63—Requirements for Reports
Table 15 to Subpart WWWW of Part 63—Applicability of General Provisions (Subpart A) to Subpart WWWW of Part 63

What This Subpart Covers

§ 63.5780 What is the purpose of this subpart?

This subpart establishes national emission standards for hazardous air pollutants (NESHAP) for reinforced plastic composites production. This subpart also establishes requirements to demonstrate initial and continuous compliance with the emission standards.

§ 63.5785 Am I subject to this subpart?

You are subject to this subpart if you own or operate a reinforced plastic composites production facility that is located at a major source of hazardous air pollutants (HAP) emissions. Reinforced plastic composites production consists of operations in which reinforced and/or nonreinforced plastic composites or plastic molding compounds are manufactured. These operations use thermoset resins and/or gel coats that contain styrene and/or methyl methacrylate to produce plastic composites, which contain materials designed to enhance the chemical, physical, and/or thermal properties of the product. Reinforced plastic composites production also includes cleaning, mixing, and material storage associated with the production of plastic composites. Facilities that only repair previously manufactured reinforced plastic composites are not covered by this subpart.

§ 63.5790 What parts of my plant does this subpart cover?

(a) This subpart applies to each new or existing affected source at reinforced plastic composites production facilities.

(b) The affected source consists of all parts of your facility engaged in the following operations: Open molding, closed molding, centrifugal casting, continuous lamination, continuous casting, polymer casting, pultrusion, sheet molding compound (SMC) manufacturing, bulk molding compound (BMC) manufacturing, mixing, cleaning of equipment used in reinforced plastic composites manufacture, material storage, any other plastic composites operations.

§ 63.5795 How do I know if my reinforced plastic composites production facility is a new affected source or an existing affected source?

(a) A reinforced plastic composites production facility is a new affected

source if it meets all the criteria in paragraphs (a)(1) and (2) of this section.

(1) You commence construction of the affected source after August 2, 2001.

(2) When you commence construction, no other reinforced plastic composites production affected source exists at that site.

(b) For the purposes of this subpart, an existing affected source is any affected source that is not a new affected source.

§ 63.5797 What are model point values and how are they used in this subpart?

The model point value is a number calculated using the equations in Table 1 to this subpart. Equations are available for each open molding operation and centrifugal casting operation. The model point values have units of pounds (lbs) of HAP per ton of resin or gel coat applied. Point values are used in this subpart to determine compliance with certain emission limits in Tables 3 and 5 of this subpart. The model point values are surrogates for emissions, and the model point value equations are used only for determining compliance with this subpart. The model point value equations cannot be used in place of emission factor equations to demonstrate compliance with other regulations.

§ 63.5798 How do I determine my facility's HAP emissions on a tons per year (tpy) basis?

To determine your facility's HAP emissions, you must use the procedures in either paragraph (a) or (b) of this section and calculate the combined HAP emissions in tpy from the following operations: Open molding, centrifugal casting, continuous lamination, continuous casting, pultrusion, sheet molding compound manufacturing, mixing, and bulk molding compound manufacturing.

(a) For existing facilities, you may use the procedures in either paragraph (a)(1) or (2) of this section.

(1) *Use point value equations or emission factors.* Calculate a weighted average emission factor on a lbs/ton of resin and gel coat basis. Base the weighted average on the 12 months of operation prior to the effective date of this subpart. Multiply the weighted average emission factor by resin and gel coat use over the same period. You may calculate this emission factor based on the point value equations in Table 1 of this subpart, or you may use any emission factor approved by us such as factors from the Compilation of Air Pollutant Emission Factors, Volume I: Stationary Point and Area Sources (AP–42). This calculation must be repeated and reported annually.

(2) *Conduct performance testing.* Perform performance testing using the methods specified in this subpart to determine a facility-specific emission factor in lbs of HAP emissions per ton of resin and gel coat used. The test should be performed under conditions expected to result in the highest possible HAP emissions, or the facility must stay within 10 percent of the same mix of operations that occurred during testing. Multiply this factor by annual resin and gel coat use to determine annual emissions.

(b) For new facilities, calculate a weighted average emission factor on a lbs/ton of resin and gel coat basis. Base the weighted average on your projected operation for the 12 months subsequent to facility startup. Multiply the weighted average emission factor by projected resin use over the same period. You may calculate this emission factor based on the point value equations in Table 1 of this subpart, or you may use any emission factor approved by us, such as factors from AP–42, or emission test data from similar facilities. This calculation must be repeated and reported annually.

§ 63.5800 When do I have to comply with this subpart?

(a) You must initially comply with the standards in this subpart by the dates specified in Table 2 to this subpart. Facilities meeting an emissions standard based on a 12-month rolling average must begin collecting data on the compliance date in order to demonstrate compliance.

(b) If your facility is a new affected source and emits less than 100 tpy of HAP at the time of initial compliance with this subpart, and subsequently increases its actual HAP emissions to 100 tpy or more, then your facility must subsequently meet the standards in § 63.5805(d). You must be in compliance with these more stringent standards within 3 years of the date your facility meets or exceeds the 100 tpy threshold.

(c) If your facility is an existing affected source and emits less than 250 tpy of HAP (if you are a small business) or less than 100 tpy of HAP (if you are not a small business) at the time of initial compliance with this subpart, and subsequently increases its actual HAP emissions to 250 tpy or more (small business) or to 100 tpy or more (non-small business), then your facility must subsequently meet the standards at § 63.5805(b). You must be in compliance with these more stringent standards within 3 years of the date your facility meets or exceeds the 250 tpy or 100 tpy threshold.

Standards

§ 63.5805 What standards must I meet to comply with this subpart?

All facilities must meet the requirements of paragraphs (a) through (f) of this section that apply. There are options to meeting these standards described in §§ 63.5810 through 63.5830.

(a) If you have an existing facility that is a small business, as defined by the Small Business Administration's (SBA's) regulations at 13 CFR 121.201, and emits less than 250 tpy of HAP, or a facility that is not a small business and that emits less than 100 tpy of HAP from the combination of all open molding, centrifugal casting, continuous lamination/casting, pultrusion, SMC manufacturing, and mixing/BMC manufacturing, you must meet the annual average emission limits in Table 3 of this subpart and the work practice standards in Table 4 of this subpart that apply to you.

(b) If you have an existing facility that is a small business as defined by the SBA regulations at 13 CFR 121.201 and emits 250 tpy or more of HAP, or if you have a facility that is not a small business and emits 100 tpy or more of HAP from the combination of all open molding, centrifugal casting, continuous lamination/casting, pultrusion, SMC manufacturing, and mixing/BMC manufacturing operations, you must reduce the total HAP emissions from these operations by at least 95 percent by weight and meet any applicable work practice standards in Table 4 of this subpart that apply to you. As an alternative to meeting 95 percent by weight, you may meet the emission limits in Table 5 of this subpart. If you have a continuous lamination/casting operation, that operation may alternatively meet an emission limit of 1.47 lbs of HAP per ton of neat resin plus and neat gel coat plus applied.

(c) If you have a new facility that emits less than 100 tpy of HAP from the combination of all open molding, centrifugal casting, continuous lamination/casting, pultrusion, SMC manufacturing, and mixing/BMC manufacturing, you must meet the annual average emission limits in Table 3 of this subpart and the work practice standards in Table 4 of this subpart that apply to you.

(d) If you have a new facility that emits 100 tpy or more of HAP from the combination of all open molding, centrifugal casting, continuous lamination/casting, pultrusion, SMC manufacturing, and mixing/BMC manufacturing, you must reduce the total HAP emissions from these

operations by at least 95 percent by weight and meet any applicable work practice standards in Table 4 of this subpart that apply to you. As an alternative to meeting 95 percent by weight, you may meet the emission limits in Table 5 of this subpart. If you have a continuous lamination/casting operation, that operation may alternatively meet an emission limit of 1.47 lbs of HAP per ton of neat resin plus and neat gel coat plus applied.

(e) If you use an add-on control device to comply with this subpart, you must meet all requirements contained in 40 CFR part 63, subpart SS.

Options for Meeting Standards

§ 63.5810 What are my options for meeting the standards for new and existing open molding and centrifugal casting operations?

You must use one of the following methods in paragraphs (a) through (c) of this section to meet the standards in § 63.5805. The necessary calculations must be completed within 30 days after the end of the each month.

(a) *Meet the individual model point values for each operation.* Demonstrate that you meet the individual model point values for each open molding operation and for each centrifugal casting operation in Table 3 or 5 of this subpart that apply to you. This is done in two steps. First, determine a point value for each individual resin and gel coat, application method, and control method you use in a particular operation. Then, calculate a weighted average of those point values based on resin and gel coat use. These calculations shall be performed monthly, and within 30 days of the end of the month. You must either be at or below the applicable point value in Table 3 or 5 of this subpart each month, or at or below the applicable point value in Table 3 or 5 of this subpart, based on a 12-month rolling average. The procedures are described in paragraphs (a)(1) and (2) of this section.

(1) Calculate your actual point values for each different process stream within each operation. Process streams within operations are different from each other if any of the following three characteristics vary: The neat resin plus or neat gel coat plus HAP content, the application technique, or the control technique. You must calculate the different process stream point values by using the appropriate model point value equations in Table 1 of this subpart for open molding and for centrifugal casting. If you want to use vapor suppressants to meet the point value for open molding, you must determine the vapor suppressant effectiveness by conducting testing to demonstrate the vapor suppressant effectiveness. If you want to use an add-on control device to meet the point value, you must determine the add-on control factor by conducting capture and control efficiency testing as indicated in Table 6 of this subpart. The point value calculated from the equations in Table 1 of this subpart is multiplied by the add-on control factor to calculate the point value after control. Use Equation 1 of this section to calculate the add-on control factor used in the model point value equations.

$$\text{Add-on Control Factor} = 1 - \frac{\%\ \text{Control Efficiency}}{100} \qquad \text{(Eq. 1)}$$

Where:

% Control Efficiency = a value calculated from emission test measurements made according to the requirements of Table 6 of this subpart

(2) Calculate your actual operation point value for each calendar month for each open molding operation and for each centrifugal casting operation by calculating the weighted average of the individual process stream point values within each respective operation. To do this, sum the product of your actual process stream point values and the amount of neat resin plus and neat gel coat plus used in each process stream and divide the numerator by the total amount of neat resin plus and neat gel coat plus used in the process streams. Use Equation 2 of this section to calculate your actual individual point value for each operation.

$$\text{Actual Operation Point Value} = \frac{\sum_{i=1}^{n}\left(\text{Actual Process Stream PV}_i * \text{Material}_i\right)}{\sum_{i=1}^{n}\text{Material}_i} \qquad \text{(Eq. 2)}$$

Where:

Actual Process Stream PV_i = actual point value from process stream i, lbs/ton

$Material_i$ = neat resin plus or neat gel coat plus used during the calendar month for process stream i, tons

n = number of process streams where you calculated a point value

(b) *Point value averaging option.* Demonstrate each month that you meet the weighted average point value of the open molding operations and the weighted average point value of the centrifugal casting operations in Table 3 or 5 of this subpart that apply to you. When using this averaging option, do not apply the procedures across open molding and centrifugal casting operations.

(1) Each month calculate the weighted average point value for your facility for that month to determine which point value you must meet. To do this, you must sum the product of the individual point values in Table 3 or 5 of this subpart, and the amount of neat resin plus or neat gel coat plus used in each operation and divide the numerator by the total amount of neat resin plus and neat gel coat plus used in the operation. Use Equation 3 of this section to calculate the weighted average point value.

$$\text{Weighted Average Point Value} = \frac{\sum_{i=1}^{n}\left(PV_i * Material_i\right)}{\sum_{i=1}^{n} Material_i} \qquad \text{(Eq. 3)}$$

Where:

PV_i = point value from operation i, lbs/ton from Table 3 or 5 of this subpart

$Material_i$ = neat resin plus or neat gel coat plus used during the calendar month for operation i, tons

n = number of operations

(2) Each month calculate your actual weighted average point value. Do this by summing the product of your actual operation point values and the amount of neat resin plus and neat gel coat plus used in each operation and dividing the numerator by the total amount of neat resin plus and neat gel coat plus used in the operation groupings. You must calculate your actual individual point values for each operation as described in paragraphs (a)(1) and (2) of this section. Use Equation 4 of this section to calculate your actual weighted average point value.

$$\begin{matrix}\text{Actual}\\ \text{Weighted}\\ \text{Average}\\ \text{Point Value}\end{matrix} = \frac{\sum_{i=1}^{n}\left(\text{Actual Operation } PV_i * Material_i\right)}{\sum_{i=1}^{n} Material_i} \qquad \text{(Eq. 4)}$$

Where:

Actual Individual PV_i = Actual point value from operation i, lbs/ton

$Material_i$ = neat resin plus or neat gel coat plus used during the calendar month for operation i, tons

n = number of operations

(3) Calculate a 12-month weighted average floor point value and actual point value by summing the values calculated in paragraphs (b)(1) and (2) of this section with the values calculated in the previous 11 months and dividing the result by 12. If the actual value 12-month rolling average is less than or equal to the floor 12-month rolling average, then you are in compliance.

(c) *Select one resin point value for multiple operations.* If you have any combination of manual resin application, mechanical resin application, filament winding, or centrifugal casting, you may elect to meet the point value for any one of these operations and use that operation's same resin in all of the resin operations listed in this paragraph (c). If you select this option, for purposes of assigning point values and determining compliance, use Table 7 of this subpart which presents the possible combinations based on a facility selecting the application process that results in the highest allowable HAP content resin. The averaging provisions in paragraph (b) of this section may still be used, but you must use the point value(s) according to this paragraph (c) to calculate compliance.

§ 63.5820 What are my options for meeting the standards for continuous lamination/casting operations?

You must use one or more of the options in paragraphs (a) through (d) of this section to meet the standards in § 63.5805. Use the calculation procedures in § 63.5865.

(a) *Compliant line option.* Demonstrate that each continuous lamination line and each continuous casting line complies with the applicable standard.

(b) *Averaging option.* Demonstrate that all continuous lamination and continuous casting lines combined comply with the applicable standard.

(c) *Add-on control device option.* If your operation must meet the 58.5 weight percent emission limit in Table 3 of this subpart, you have the option of demonstrating that you achieve 95 percent control of all wet-out area emissions.

(d) *Combination option.* Use a combination of options in paragraphs (a) and (b) of this section or, for affected sources at existing facilities, a combination of options in paragraphs (a), (b), and (c) of this section (in which one or more lines meet the standards on their own, two or more lines averaged together meet the standards, and one or more lines have their wet-out areas controlled to a level of 95 percent).

§ 63.5825 What are my options for meeting the standards for new pultrusion operations?

You must use one or more of the options in paragraphs (a) through (c) of this section to meet the 95 percent emission reduction standard in § 63.5805.

(a) *Add-on control device option.* Capture the emissions and vent them to a control device or any combination of control devices that achieves a 95 percent reduction of HAP emissions. Conduct capture and destruction efficiency testing as indicated in Table 6 of this subpart to determine the percent emission reduction.

(b) *Direct die injection with resin drip collection option.* Use direct die injection pultrusion machines with resin drip collection systems that meet the following criteria in paragraphs (b)(1) through (3) of this section:

(1) All the resin that is applied to the reinforcement is delivered directly to the die.

(2) No exposed resin is present except at the face of the die.

(3) Resin drip is captured in closed piping and recycled directly to the resin injection chamber.

(c) *Combination option.* Use a combination of options in paragraphs (a) and (b) of this section in which some lines meet the standards by complying with paragraph (a) of this section, and the remaining lines meet the standards by complying with paragraph (b) of this section.

§ 63.5830 What are my options for meeting the standards for existing pultrusion operations?

You must use one or more of the options in paragraphs (a) through (d) of this section to meet the 60 weight percent emission limit in Table 3 of this subpart as required in § 63.5805.

(a) *Add-on control device option.* Capture the emissions and vent them to a control device or any combination of control devices that achieves a 60

weight percent reduction of HAP emissions. Conduct capture and destruction efficiency testing as indicated in Table 6 of this subpart to determine the percent HAP emission reduction.

(b) *Wet area enclosure with resin drip collection option.* Design, install, and operate wet area enclosures and resin drip collection systems on pultrusion machines that meet the criteria in paragraphs (b)(1) through (11) of this section.

(1) The enclosure must cover and enclose the open resin bath and the forming area in which reinforcements are pre-wet or wet-out and moving toward the die(s). The surfaces of the enclosure must be closed except for openings to allow material to enter and exit the enclosure.

(2) For pultrusion machines with a radio frequency pre-heat unit, the enclosure must extend from the beginning of the resin bath to within 12.5 inches or less of the entrance of the radio frequency pre-heat unit. If the stock that is within 12.5 inches or less of the entrance to the radio frequency pre-heat unit has any drip, it must be enclosed. The stock exiting the radio frequency pre-heat unit is not required to be in an enclosure if the stock has no drip between the exit of the radio frequency pre-heat unit to within 0.5 inches of the entrance of the die.

(3) For open bath pultrusion machines without a radio frequency pre-heat unit, the enclosure must extend from the beginning of the resin bath to within 0.5 inches or less of the die entrance.

(4) For pultrusion lines with a pre-wet area prior to direct die injection, the enclosure must extend from the point at which the resin is applied to the reinforcement to within 12.5 inches or less of the entrance of the die(s). If the stock that is within 12.5 inches or less of the entrance to the die has any drip, it must be enclosed.

(5) The enclosure can only be constructed high enough to clear the highest part of the pultrusion line that must be inside the enclosure.

(6) The total open area of the enclosure must not exceed 2 times the cross sectional area of the puller window(s) and must comply with the requirements in paragraphs (b)(6)(i) through (iii) of this section.

(i) All areas which are open need to be included in the total open area calculation with the exception of access panels, doors, and/or hatches that are part of the enclosure.

(ii) The area which is displaced by entering reinforcement or exiting product is considered open.

(iii) Areas that are covered by brush covers are considered closed.

(7) Open areas for level control devices, monitoring devices, agitation shafts, and/or fill hoses must have no more than 1.0 inch clearance.

(8) The access panels, doors, and/or hatches that are part of the enclosure must close tightly to avoid vapor leakage. Damaged access panels, doors, and/or hatches that allow vapor leakage must be replaced.

(9) The enclosure may not be removed from the pultrusion line and access panels, doors, and/or hatches that are part of the enclosure must remain closed whenever resin is in the bath except for the time period discussed in paragraph (b)(10) of this section.

(10) The maximum length of time the enclosure may be removed from the pultrusion line or the access panels, doors, and/or hatches and may be open is 30 minutes per 8 hour shift (or 45 minutes per 12 hour shift).

(11) No fans, blowers, and/or air lines may be allowed within the enclosure. The enclosure must not be ventilated.

(c) *Direct die injection with resin drip collection option.* Use direct die injection pultrusion machines with resin drip collection systems that meet all the criteria in paragraphs (c)(1) through (3) of this section.

(1) All the resin that is applied to the reinforcement is delivered directly to the die.

(2) No exposed resin is present except at the face of the die.

(3) Resin drip is captured in closed piping and recycled directly to the resin injection chamber.

(d) *Combination option.* Use a combination of options in paragraphs (a) through (c) of this section in which different pultrusion lines comply with different options described in paragraphs (a) through (c) of this section.

General Compliance Requirements

§ 63.5835 What are my general requirements for complying with this subpart?

(a) You must be in compliance at all times with the work practice standards in Table 4 of this subpart, as well as emission limits in Table 3 or 5 of this subpart, as applicable, that you are meeting without the use of add-on controls.

(b) You must be in compliance with all emission limits in this subpart that you meet using add-on controls, except during periods of startup, shutdown, and malfunction.

(c) You must always operate and maintain your affected source, including air pollution control and monitoring equipment, according to the provisions in § 63.6(e)(1)(i).

(d) You must develop and implement a written startup, shutdown, and malfunction plan according to the provisions in § 63.6(e)(3) for any emission limits you meet using an add-on control.

Testing and Initial Compliance Requirements

§ 63.5840 By what date must I conduct a performance test or other initial compliance demonstration?

You must conduct performance tests, performance evaluations, design evaluations, capture efficiency testing, and other initial compliance demonstrations by the compliance date specified in Table 2 of this subpart with two exceptions. Open molding and centrifugal casting operations that elect to meet a point value on a 12-month rolling average must initiate collection of the required data on the compliance date, and demonstrate compliance 1 year and 30 days after the compliance date. New and existing sources that are required to use add-on controls to initially meet compliance must demonstrate compliance 180 days after the compliance date.

§ 63.5845 When must I conduct subsequent performance tests?

You must also conduct a performance test every 5 years following the initial performance test for any standards you meet with an add-on control device.

§ 63.5850 How do I conduct performance tests, performance evaluations, and design evaluations?

(a) If you are using any add-on controls to meet an emission limit in this subpart, you must conduct each performance test, performance evaluation, and design evaluation in 40 CFR part 63, subpart SS, that applies to you.

(b) Each performance test must be conducted according to the requirements in § 63.7(e)(1) and under the specific conditions that 40 CFR part 63, subpart SS, specifies.

(c) Each performance evaluation must be conducted according to the requirements in § 63.8(e) and under the specific conditions that 40 CFR part 63, subpart SS, specifies.

(d) You may not conduct performance tests or performance evaluations during periods of startup, shutdown, or malfunction, as specified in § 63.7(e)(1).

(e) You must conduct three separate test runs for each performance test required in this section, as specified in § 63.7(e)(3). Each test run must last at least 1 hour.

(f) You must conduct a design evaluation of any permanent total enclosures as specified by EPA Method 204. If your enclosure does not meet the Method 204 design and operation requirements for a permanent total enclosure, you must test the enclosure to determine the capture efficiency by Methods 2B through E or an alternative method that meets the data quality objectives and lower confidence limit approaches contained in 40 CFR part 63, subpart KK. Test runs for Methods 2B through E or alternative test methods must be at least 3 hours.

§ 63.5855 What are my monitor installation and operation requirements?

You must monitor and operate all add-on control devices according to the procedures in 40 CFR part 63, subpart SS.

§ 63.5860 How do I demonstrate initial compliance with the standards?

(a) You must demonstrate initial compliance with each emission standard in paragraphs (a) through (d) of § 63.5805 that applies to you, as shown in Tables 8 and 9 of this subpart.

(b) If using an add-on control device, you must establish each site-specific operating limit in 40 CFR part 63, subpart SS, that applies to you.

Additional Compliance Calculation Procedures For Continuous Lamination/ Casting Operations

§ 63.5865 What data must I generate to demonstrate compliance with the standards for continuous lamination/casting operations?

(a) For continuous lamination/casting affected sources complying with a percent reduction requirement, you must generate the data identified in Tables 10 and 11 of this subpart for each data requirement that applies to your facility.

(b) For continuous lamination/casting affected sources complying with a lbs/ ton limit, you must generate the data identified in Tables 11 and 12 of this subpart for each data requirement that applies to your facility.

§ 63.5870 How do I calculate annual uncontrolled and controlled emissions from my wet-out area(s) and from my oven(s)?

To calculate your annual uncontrolled and controlled emissions from your wet-out areas and from your ovens, you must develop uncontrolled and controlled wet-out area and uncontrolled and controlled oven emission estimation equations or factors to apply to each formula applied on each line, determine how much of each formula for each end product is applied each year on each line, and assign uncontrolled and controlled wet-out area and uncontrolled and controlled oven emission estimation equations or factors to each formula. You must determine the overall capture efficiency using the procedures in Table 6 of this subpart.

(a) To develop uncontrolled and controlled emission estimation equations and factors, you must, at minimum, do the following as specified in paragraphs (a)(1) through (6) of this section:

(1) Identify each end product and the thickness of each end product produced on the line. Separate end products into the following end product groupings, as applicable: corrosion-resistant gel coated end products, noncorrosion-resistant gel coated end products, corrosion-resistant nongel coated end products, and noncorrosion-resistant nongel coated end products. This step creates end product/thickness combinations.

(2) Identify each formula used on the line to produce each end product/ thickness combination. Identify the amount of each such formula applied (need to specify a time frame). Rank each formula used to produce each end product/thickness combination according to usage within each end product/thickness combination.

(3) For each end product/thickness combination being produced, select the formula with the highest usage rate for testing.

(4) If not already selected, also select the worst-case formula (likely to be associated with the formula with the highest HAP content, type of HAP, application of gel coat, thin product, low line speed, higher resin table temperature) amongst all formulae. (You may use the results of the worst-case formula test for all formulae if desired to limit the amount of testing required.)

(5) For each formula selected for testing, conduct at least one test (consisting of three runs). During the test, track information on HAP content and type of HAP, end product thickness, line speed, and resin temperature on the wet-out area table.

(6) Using the test results, develop uncontrolled and controlled emission estimation equations (or factors) or series of equations (or factors) that best fit the results for estimating uncontrolled and controlled emissions, taking into account the HAP content and type of HAP, end product thickness, line speed, and resin temperature on the wet-out area table.

(b) In lieu of using the method specified in paragraph (a) of this section for developing uncontrolled and controlled emission estimation equations and factors, you may use any of the methods specified in paragraphs (b)(1) through (4) of this section, as applicable.

(1) For either uncontrolled or controlled emission estimates, you may use previously established, facility-specific emission equations or factors, provided they allow estimation of both wet-out area and oven emissions, where necessary, and have been approved by the regulatory agency. If a previously established equation or factor is specific to the wet-out area only or to the oven only, then you must develop the corresponding uncontrolled or controlled equation or factor for the other emission source.

(2) For uncontrolled (controlled) emission estimates, you may use controlled (uncontrolled) emission estimates and control device destruction efficiency to calculate your uncontrolled (controlled) emissions provided the control device destruction efficiency was calculated at the same time you collected the data to develop your facility's controlled (uncontrolled) emission estimation equations and factors.

(c) Assign to each formula an uncontrolled emission estimation equation or factor based on the end product/ thickness combination for which that formula is used.

(d)(1) To calculate your annual uncontrolled emissions from wet-out areas that do not have any capture and control from wet-out areas that are captured by an enclosure but are vented to the atmosphere and not to a control device, multiply each formula's annual usage by its appropriate emission estimation equation or factor and sum the individual results.

(2) To calculate your annual uncontrolled emissions that escape from the enclosure on the wet-out area, multiply each formula's annual usage by its appropriate uncontrolled emission estimation equation or factor, sum the individual results, and multiply the summation by 1 minus the percent capture (expressed as a fraction).

(3) To calculate your annual uncontrolled oven emissions, multiply each formula's annual usage by its appropriate uncontrolled emission estimation equation or factor and sum the individual results.

(4) To calculate your annual controlled emissions, multiply each formula's annual usage by its appropriate emission estimation equation or factor and sum the individual results to obtain total annual controlled emissions.

(e) Where a facility is calculating both uncontrolled and controlled emission

estimation equations and factors, you must test the same formulae. In addition, you must develop both sets of equations and factors from the same tests.

§ 63.5875 How do I determine the capture efficiency of the enclosure on my wet-out area and the capture efficiency of my oven(s)?

(a) The capture efficiency of a wet-out area enclosure is assumed to be 100 percent if it meets the design and operation requirements for a permanent total enclosure specified in EPA Method 204. If a permanent total enclosure does not exist, then a temporary total enclosure must be constructed and verified using Method 204, and capture efficiency testing must be determined using Methods 204B through E.

(b) The capture efficiency of an oven is to be considered 100 percent provided the oven is operated under negative pressure.

§ 63.5880 How do I determine how much neat resin plus is applied to the line and how much neat gel coat plus is applied to the line?

Use the following procedures to determine how much neat resin plus and neat gel coat plus is applied to the line each year.

(a) Track formula usage by end product/thickness combinations.

(b) Use in-house records to show usage. This may be either from automated systems or manual records.

(c) Record daily the usage of each formula/end product combination on each line. This is to be recorded at the end of each run (i.e., when a changeover in formula or product is made) and at the end of each shift.

(d) Sum the amounts from the daily records to calculate annual usage of each formula/end product combination by line.

§ 63.5885 How do I calculate the percent reduction to demonstrate compliance?

(a) *Compliant line option.* If all of your wet-out areas have permanent enclosures that meet the requirements of Method 204 for a permanent total enclosure, and all of your wet-out area emissions and oven emissions are vented to an add-on control device, use Equation 1 of this section to demonstrate compliance. In all other situations, use Equation 2 of this section to demonstrate compliance.

$$PR = \frac{(\text{Inlet}) - (\text{Outlet})}{(\text{Inlet})} \times 100 \qquad \text{(Eq. 1)}$$

Where:

PR = percent reduction

Inlet = emissions entering the control device, lbs per year

Outlet = emissions exiting the control device to the atmosphere, lbs per year

$$PR = \frac{(WAE_u + O_u) - (WAE_c + O_c)}{(WAE_u + O_u)} \times 100 \qquad \text{(Eq. 2)}$$

Where:

PR = percent reduction

WAE_u = uncontrolled wet-out area emissions, lbs per year

O_u = uncontrolled oven emissions, lbs per year

WAE_c = controlled wet-out area emissions, lbs per year

O_c = controlled oven emissions, lbs per year

(b) *Averaging Option.* Use Equation 3 of this section to calculate percent reduction.

$$PR = \frac{\left(\sum_{i=1}^{m} WAE_{ui} + \sum_{j=1}^{n} O_{uj}\right) - \left(\sum_{i=1}^{o} WAE_{ci} + \sum_{j=1}^{p} O_{cj}\right)}{\left(\sum_{i=1}^{m} WAE_{ui} + \sum_{j=1}^{n} O_{uj}\right)} \times 100 \qquad \text{(Eq. 3)}$$

Where:

PR = percent reduction

WAE_{ui} = uncontrolled emissions from wet-out area i, lbs per year

O_{uj} = uncontrolled emissions from oven j, lbs per year

WAE_{ci} = controlled emissions from wet-out area i, lbs per year

Oc_j = controlled emissions from oven j, lbs per year

i = number of wet-out areas

j = number of ovens

m = number of wet-out areas uncontrolled

n = number of ovens uncontrolled

o = number of wet-out areas controlled

p = number of ovens controlled

(3) *Add-on control device option.* Use Equation 1 of this section to calculate percent reduction.

(4) *Combination option.* Use Equations 1 through 3 of this section, as applicable, to calculate percent reduction.

§ 63.5890 How do I calculate an emission factor to demonstrate compliance?

(a) *Compliant line option.* Use Equation 1 of this section to calculate an emission factor in lbs/ton.

$$E = \frac{WAE_u + WAE_c + O_u + O_c}{(R + G)} \times 100 \qquad \text{(Eq. 1)}$$

Where:

E = emission factor in lbs/ton of resin and gel coat

WAE_u = uncontrolled wet-out area emissions, lbs per year

WAE_c = controlled wet-out area emissions, lbs per year

O_u = uncontrolled oven emissions, lbs per year

O_c = controlled oven emissions, lbs per year

R = total usage of neat resin plus, tpy

G = total usage of neat gel coat plus, tpy

(b) *Averaging option.* Use Equation 2 of this section to demonstrate compliance.

$$E = \frac{\sum_{i=1}^{m} WAE_{ui} + \sum_{i=1}^{o} WAE_{ci} + \sum_{j=1}^{n} O_{uj} + \sum_{j=1}^{p} O_{cj}}{(R+G)} \times 100 \qquad \text{(Eq. 2)}$$

Where:

E = emission factor in lbs/ton of resin and gel coat

WAE_{ui} = uncontrolled emissions from wet-out area i, lbs per year

WAE_{ci} = controlled emissions from wet-out area i, lbs per year

O_{uj} = uncontrolled emissions from oven j, lbs per year

O_{cj} = controlled emissions from oven j, lbs per year

i = number of wet-out areas

j = number of ovens

m = number of wet-out areas uncontrolled

n = number of ovens uncontrolled

o = number of wet-out areas controlled

p = number of ovens controlled

R = total usage of neat resin plus, tpy

G = total usage of neat gel coat plus, tpy

(c) *Combination option.* Use Equations 1 and 2 of this section, as applicable, to demonstrate compliance.

Continuous Compliance Requirements

§ 63.5895 How do I monitor and collect data to demonstrate continuous compliance?

(a) You must collect and keep a record of data as indicated in 40 CFR part 63, subpart SS.

(b) You must monitor and collect data as specified in paragraphs (b)(1) through (4) of this section.

(1) Except for monitoring malfunctions, associated repairs, and required quality assurance or control activities (including, as applicable, calibration checks and required zero and span adjustments), you must conduct all monitoring in continuous operation (or collect data at all required intervals) at all times that the affected source is operating.

(2) You may not use data recorded during monitoring malfunctions, associated repairs, and required quality assurance or control activities for purposes of this subpart, including data averages and calculations, or fulfilling a minimum data availability requirement, if applicable. You must use all the data collected during all other periods in assessing the operation of the control device and associated control system.

(3) At all times, you must maintain necessary parts for routine repairs of the monitoring equipment.

(4) A monitoring malfunction is any sudden, infrequent, not reasonably preventable failure of the monitoring equipment to provide valid data. Monitoring failures that are caused in part by poor maintenance or careless operation are not malfunctions.

(c) You must collect and keep records of resin and gel coat use, HAP content, and operation where the resin is used if you are meeting any emission limits based on a point value. Resin use records may be based on purchase records if you can reasonably estimate how the resin is applied. The HAP content records may be based on Material Safety Data Sheets or on resin specifications supplied by the resin supplier.

(d) If you initially demonstrate that all resins and gel coats meet the applicable point value emission limits, then resin and gel coat use records are not required. If after this initial demonstration, you change to a higher HAP resin or gel coat, or increase the resin or gel coat HAP content, or change to a higher emitting resin or gel coat application method, then you must either again demonstrate that all resins and gel coats still meet the applicable point value emission limits, or begin collecting resin use records and calculate compliance on a 12-month rolling average.

(e) You must record all times that wet area enclosures on any pultrusion machines are open, and resin is present in the resin bath.

§ 63.5900 How do I demonstrate continuous compliance with the standards?

(a) You must demonstrate continuous compliance with each standard in § 63.5805 that applies to you according to the methods specified in paragraphs (a)(1) through (3) of this section.

(1) Compliance with emission limits for sources using add-on control devices is demonstrated following the procedures in 40 CFR part 63, subpart SS. Sources using add-on controls may also use continuous emission monitors to demonstrate continuous compliance as an alternative to control parameter monitoring.

(2) Compliance with emission limits using the point value system is demonstrated by maintaining a point value less than or equal to the appropriate point value listed in Table 3 or 5 of this subpart, on a 12-month rolling average, or by including in each compliance report a certification that all resins and gel coats meet the appropriate point value limits, as discussed in § 63.5895(d).

(3) Compliance with the work practice standards in Table 4 of this subpart is demonstrated by performing the work practice required for your operation.

(b) You must report each deviation from each standard that applies to you in § 63.5805. The deviations must be reported according to the requirements in § 63.5910.

(c) With the exception provided in paragraph (d) of this section, during periods of startup, shutdown or malfunction, you must meet the emission limits and work practice standards that apply to you.

(d) During periods of startup, shutdown, or malfunction, you do not need to meet the standard(s) in § 63.5805 that require an add-on control device, but you must operate your affected source in accordance with the startup, shutdown, and malfunction plan and meet all standards that do not require the operation of the add-on control device.

(e) Consistent with §§ 63.6(e) and 63.7(e)(1), deviations that occur during a period of malfunction for those affected sources and standards specified in paragraph (d) of this section are not violations if you demonstrate to the Administrator's satisfaction that you were operating in accordance with the startup, shutdown, and malfunction plan. The Administrator will determine whether deviations that occur during a period of startup, shutdown, and malfunction are violations, according to the provisions in § 63.6(e).

Notifications, Reports, And Records

§ 63.5905 What notifications must I submit and when?

(a) You must submit all of the notifications in Table 13 of this subpart that apply to you, by the dates in Table 13 of this subpart. The notifications are described more fully in subpart A, General Provisions, referenced in Table 13.

(b) If you change any information submitted in any notification, you must submit the changes in writing to the Administrator within 15 calendar days after the change.

§ 63.5910 What reports must I submit and when?

(a) You must submit each report in Table 14 of this subpart that applies to you.

(b) Unless the Administrator has approved a different schedule for submission of reports under § 63.10(a),

you must submit each report by the date in Table 14 of this subpart and according to paragraphs (b)(1) through (5) of this section.

(1) The first compliance report must cover the period beginning on the compliance date that is specified for your affected source in § 63.5800 and ending on June 30 or December 31, whichever date is the first date following the end of the first calendar half after the compliance date that is specified for your source in § 63.5800.

(2) The first compliance report must be postmarked or delivered no later than July 31 or January 31, whichever date follows the end of the first calendar half after the compliance date that is specified for your affected source in § 63.5800.

(3) Each subsequent compliance report must cover the semiannual reporting period from January 1 through June 30 or the semiannual reporting period from July 1 through December 31.

(4) Each subsequent compliance report must be postmarked or delivered no later than July 31 or January 31, whichever date is the first date following the end of the semiannual reporting period.

(5) For each affected source that is subject to permitting requirements pursuant to 40 CFR part 70 or 71, and if the permitting authority has established dates for submitting semiannual reports pursuant to § 70.6(3)(iii)(A) or § 71.6(3)(iii)(A), you may submit the first and subsequent compliance reports according to the dates the permitting authority has established instead of according to the dates in paragraphs (b)(1) through (4) of this section.

(c) The compliance report must contain the information in paragraphs (c)(1) through (6) of this section:

(1) Company name and address.

(2) Statement by a responsible official with that official's name, title, and signature, certifying the truth, accuracy, and completeness of the content of the report.

(3) Date of the report and beginning and ending dates of the reporting period.

(4) If you had a startup, shutdown or malfunction during the reporting period and you took actions consistent with your startup, shutdown, and malfunction plan, the compliance report must include the information in § 63.10(d)(5)(i).

(5) If there are no deviations from any emission limitations (emission limit and operating limit) that applies to you, and there are no deviations from the requirements for work practice standards in Table 4 of this subpart, a statement that there were no deviations from the emission limitations or work practice standards during the reporting period.

(6) If there were no periods during which the continuous monitoring system (CMS), including a continuous emission monitoring system (CEMS), and operating parameter monitoring systems was out of control as specified in § 63.8(c)(7), a statement that there were no periods during the which the CMS was out of control during the reporting period.

(d) For each deviation from an emission limitation (i.e., emission limit, operating limit) and for each deviation from the requirements for work practice standards that occurs at an affected source where you are not using a CMS to comply with the emission limitations or work practice standards in this subpart, the compliance report must contain the information in paragraphs (c)(1) through (4) of this section and in paragraphs (d)(1) and (2) of this section. This includes periods of startup, shutdown, and malfunction.

(1) The total operating time of each affected source during the reporting period.

(2) Information on the number, duration, and cause of deviations (including unknown cause, if applicable), as applicable, and the corrective action taken.

(e) For each deviation from an emission limitation (i.e., emission limit and operating limit) occurring at an affected source where you are using a CMS to comply with the emission limitation in this subpart, you must include the information in paragraphs (c)(1) through (4) of this section and in paragraphs (e)(1) through (12) of this section. This includes periods of startup, shutdown, and malfunction.

(1) The date and time that each malfunction started and stopped.

(2) The date and time that each CMS was inoperative, except for zero (low-level) and high-level checks.

(3) The date, time and duration that each CMS was out of control, including the information in § 63.8(c)(8).

(4) The date and time that each deviation started and stopped, and whether each deviation occurred during a period of startup, shutdown, or malfunction, or during another period.

(5) A summary of the total duration of the deviation during the reporting period and the total duration as a percent of the total source operating time during that reporting period.

(6) A breakdown of the total duration of the deviations during the reporting period into those that are due to startup, shutdown, control equipment problems, process problems, other known causes, and other unknown causes.

(7) A summary of the total duration of CMS downtime during the reporting period and the total duration of CMS downtime as a percent of the total source operating time during that reporting period.

(8) An identification of each hazardous air pollutant that was monitored at the affected source.

(9) A brief description of the process units.

(10) A brief description of the CMS.

(11) The date of the latest CMS certification or audit.

(12) A description of any changes in CMS, processes, or controls since the last reporting period.

(f) Each affected source that has obtained a title V operating permit pursuant to 40 CFR part 70 or 71 must report all deviations as defined in this subpart in the semiannual monitoring report required by § 70.6(a)(3)(iii)(A) or § 71.6(a)(3)(iii)(A). If an affected source submits a compliance report pursuant to Table 14 of this subpart along with, or as part of, the semiannual monitoring report required by § 70.6(a)(3)(iii)(A) or § 71.6(a)(3)(iii)(A), and the compliance report includes all required information concerning deviations from any emission limitation (including any operating limit) or work practice requirement in this subpart, submission of the compliance report shall be deemed to satisfy any obligation to report the same deviations in the semiannual monitoring report. However, submission of a compliance report shall not otherwise affect any obligation the affected source may have to report deviations from permit requirements to the permit authority.

(g) You should submit compliance reports and startup, shutdown, malfunction reports based on the requirements in Table 14 of this subpart. You do not need to consider the requirements in § 63.999 when submitting these reports.

§ 63.5915 What records must I keep?

(a) You must keep the records listed in paragraphs (a)(1) through (3) of this section.

(1) A copy of each notification and report that you submitted to comply with this subpart, including all documentation supporting any Initial Notification or Notification of Compliance Status that you submitted, according to the requirements in § 63.10(b)(2)(xiv).

(2) The records in § 63.6(e)(3)(iii) through (v) related to startup, shutdown, and malfunction.

(3) Records of performance tests, design, and performance evaluations as required in § 63.10(b)(2)(viii).

(b) If you use an add-on control device, you must keep all records required in 40 CFR part 63, subpart SS, to show continuous compliance with this subpart.

(c) You must keep all data, assumptions, and calculations used to determine point values for operations listed in Tables 3 and 5 of this subpart.

(d) You must keep a certified statement that you are in compliance with the work practice requirements in Table 4 of this subpart, as applicable.

(e) For a new or existing continuous lamination/ casting operation, you must keep the records listed in paragraphs (e)(1) through (4) of this section, when complying with the percent reduction and/or lbs/ton requirements specified in paragraphs (a) through (d) of § 63.5805.

(1) You must keep all data, assumptions, and calculations used to determine percent reduction and/or lbs/ton as applicable;

(2) You must keep a brief description of the rationale for the assignment of an equation or factor to each formula;

(3) When using facility-specific emission estimation equations or factors, you must keep all data, assumptions, and calculations used to derive the emission estimation equations and factors and identification and rationale for the worst-case formula; and

(4) For all emission estimation equations and emission factors, you must keep documentation that the appropriate regulatory agency has approved them.

§ 63.5920 In what form and how long must I keep my records?

(a) You must maintain all applicable records in such a manner that they can be readily accessed and are suitable for inspection according to § 63.10(b)(1).

(b) As specified in § 63.10(b)(1), you must keep each record for 5 years following the date of each occurrence, measurement, maintenance, corrective action, report, or record.

(c) You must retain your records of the most recent 2 years onsite, or your records must be accessible to an inspector while onsite. Your records of the remaining 3 years may be retained offsite.

Other Requirements and Information

§ 63.5925 What parts of the General Provisions apply to me?

Table 15 of this subpart shows which parts of the General Provisions in §§ 63.1 through 63.15 apply to you.

§ 63.5930 Who implements and enforces this subpart?

(a) This subpart can be administered by us, the EPA, or a delegated authority such as your State, local, or tribal agency. If the EPA Administrator has delegated authority to your State, local, or tribal agency, then that agency has the authority to administer and enforce this subpart. You should contact your EPA Regional Office to find out if this subpart is delegated to your State, local, or tribal agency.

(b) In delegating implementation and enforcement authority of this subpart to a State, local, or tribal agency under section 40 CFR part 63, subpart E, the authorities contained in paragraph (c) of this section are not delegated.

(c) The authorities that will not be delegated to State, local, or tribal agencies are listed in paragraphs (c)(1) through (4) of this section:

(1) Approval of alternatives to the emission standards in § 63.5805 under § 63.6(g).

(2) Approval of major alternatives to test methods under § 63.7(e)(2)(ii) and (f) and as defined in § 63.90.

(3) Approval of major alternatives to monitoring under § 63.8(f) and as defined in § 63.90.

(4) Approval of major alternatives to recordkeeping and reporting under § 63.10(f) and as defined in § 63.90.

§ 63.5935 What definitions apply to this subpart?

Terms used in this subpart are defined in the Clean Air Act, in 40 CFR 63.2, the General Provisions, and in this section as follows:

Atomized mechanical application means application of resin or gel coat with spray equipment that separates the liquid into a fine mist. This fine mist may be created by forcing the liquid under high pressure through an elliptical orifice, bombarding a liquid stream with directed air jets, or a combination of these techniques.

Bulk molding compound (BMC) means a putty-like molding compound that contains resins, catalysts, fillers, and reinforcements in a form that is ready to mold. Bulk molding compound can be used in compression molding and injection molding operations to manufacture reinforced plastic composites products.

BMC manufacturing means a process that involves the preparation of BMC.

BMC manufacturing/mixing means a grouping of processes that involves BMC manufacturing and/or mixing.

Centrifugal casting means a process for fabricating cylindrical composites, such as pipes, in which composite materials are positioned inside a rotating hollow mandrel and held in place by centrifugal forces until the part is cured.

Charge means the amount of SMC or BMC that is placed into a compression or injection mold to complete one mold cycle.

Cleaning means removal of composite materials, such as cured and uncured resin from equipment, finished surfaces, floors, hands of employees, or any other surfaces.

Clear production gel coat means an unpigmented, unfilled, quick-setting resin used to improve the surface appearance and/or performance of composites. It can be used to form the surface layer of any composites other than those used for molds in tooling operations.

Closed molding means a grouping of processes for fabricating composites in a way that HAP-containing materials are not exposed to the atmosphere except during the material loading stage (e.g., compression molding, injection molding, and resin transfer molding).

Composite means a shaped and cured part produced by using composite materials.

Composite materials means a combination of the following materials: resin, gel coat, monomer, catalyst, pigment, filler, and reinforcement.

Compression molding means a closed molding process for fabricating composites in which composite materials are placed inside matched metal dies that are used to cure the materials under heat and pressure without exposure to the atmosphere. The composite materials used in this process are generally SMC or BMC.

Compression/injection molding means a grouping of processes that involves the use of compression molding and/or injection molding.

Continuous casting means a continuous process for fabricating composites in which composite materials are placed on an in-line conveyor belt to produce cast sheets that are cured in an oven.

Continuous lamination means a continuous process for fabricating composites in which composite materials are typically sandwiched between plastic films, pulled through compaction rollers, and cured in an oven. This process is generally used to produce flat or corrugated products on an in-line conveyor.

Continuous lamination/casting means a grouping of processes that involves the use of continuous lamination and/or continuous casting.

Controlled emissions means those emissions that are vented from a control device to the atmosphere.

Corrosion-resistant end-use applications means applications where the product is manufactured specifically for an application that requires a level of chemical inertness or resistance to chemical attack above that required for typical reinforced plastic composites products. These applications include, but are not limited to, chemical processing and storage; pulp and paper production; sewer and wastewater treatment; power generation; potable water transfer and storage; food and drug processing; pollution or odor control; metals production and plating; semiconductor manufacturing; petroleum production, refining, and storage; mining; textile production; nuclear materials storage; swimming pools; and cosmetic production, as well as end-use applications that require high strength resins.

Corrosion-resistant industry standard includes the following standards: ASME RTP–1 or Sect. X; ASTM D5364, D3299, D4097, D2996, D2997, D3262, D3517, D3754, D3840, D4024, D4160, D4161, D4162, D4184, D3982, or D3839; ANSI/AWWA C950; UL 1316 or UL 1746, or written customer requirements for resistance to specified chemical environments.

Corrosion-resistant product means a product made with a corrosion-resistant resin and is manufactured to a corrosion-resistant industry standard, or a food contact industry standard, or is manufactured for corrosion-resistant end-use applications involving continuous or temporary chemical exposures.

Corrosion-resistant resin means a resin that either: (1) Displays substantial retention of mechanical properties when undergoing ASTM C–581 coupon testing, where the resin is exposed for 6 months or more to one of the following materials: material with a pH ≥ 12.0 or ≤ 3.0, oxidizing or reducing agents, organic solvents, or fuels or fuel additives as defined in 40 CFR 79.2. In the coupon testing, the exposed resin needs to demonstrate a minimum of 50 percent retention of the relevant mechanical property compared to the same resin in unexposed condition. In addition, the exposed resin needs to demonstrate an increased retention of the relevant mechanical property of at least 20 percent when compared to a similarly exposed general-purpose resin. For example, if the general-purpose resin retains 45 percent of the relevant property when tested as specified above, then a corrosion-resistant resin needs to retain at least 65 percent (45 percent plus 20 percent) of its property. The general-purpose resin used in the test needs to have an average molecular weight of greater than 1,000, be formulated with a 1:2 ratio of maleic anhydride to phthalic anhydride and 100 percent diethylene glycol, and a styrene content between 43 to 48 percent; or

(2) Complies with industry standards that require specific exposure testing to corrosive media, such as UL 1316, UL 1746, or ASTM F–1216.

Doctor box means the box or trough on an SMC machine into which the liquid resin paste is delivered before it is metered onto the carrier film.

Filament winding means an open molding process for fabricating composites in which reinforcements are fed through a resin bath and wound onto a rotating mandrel. The materials on the mandrel may be rolled out or worked by using nonmechanical tools prior to curing. Resin application to the reinforcement on the mandrel by means other than the resin bath, such as spray guns, pressure-fed rollers, flow coaters, or brushes is not considered filament winding.

Filled means that fillers have been added to a resin such that the amount of inert substances is at least 10 percent by weight of the total resin plus filler mixture.

Fillers means inert substances dispersed throughout a resin, such as calcium carbonate, alumina trihydrate, hydrous aluminum silicate, mica, feldspar, wollastonite, silica, and talc. Materials that are not considered to be fillers are glass fibers or any type of reinforcement and microspheres.

Fluid impingement technology means a spray gun that produces an expanding non-misting curtain of liquid by the impingement of low-pressure uninterrupted liquid streams.

Food contact industry standard means a standard related to food contact application contained in Food and Drug Administration's regulations at 21 CFR 177.2420.

Gel coat application means a process where either clear production, pigmented production or tooling gel coat is applied.

High strength resins means polyester resins which have a casting tensile strength of 10,000 pounds per square inch or more and which are used for manufacturing products that have high strength requirements such as structural members and utility poles.

Injection molding means a closed molding process for fabricating composites in which composite materials are injected under pressure into a heated mold cavity that represents the exact shape of the product. The composite materials are cured in the heated mold cavity.

Manual resin application means an open molding process for fabricating composites in which composite materials are applied to the mold by pouring or by using hands and nonmechanical tools, such as brushes and rollers. Materials are rolled out or worked by using nonmechanical tools prior to curing. The use of pressure-fed rollers and flow coaters to apply resin is not considered manual resin application.

Material storage means an ancillary process which involves keeping HAP-containing materials, such as resins, gel coats, catalysts, monomers, and cleaners, in containers for any length of time. Containers may include bulk storage terminals, tanks, totes, vessels, and buckets.

Mechanical resin application means an open molding process for fabricating composites in which composite materials (except gel coat) are applied to the mold by using mechanical tools such as spray guns, pressure-fed rollers, and flow coaters. Materials are rolled out or worked by using nonmechanical tools prior to curing.

Mixing means the blending or agitation of any HAP-containing materials in vessels that are 5.00 gallons (18.9 liters) or larger. Mixing may involve the blending of resin, gel coat, filler, reinforcement, pigments, catalysts, monomers, and any other additives.

Model point value equations means algebraic expressions that were derived to estimate the quantity of HAP emitted based on parameters that can be regulated. Parameters that can be regulated include resin and gel coat HAP content. Model point value equations were derived for open molding and centrifugal casting processes. They are used to calculate point values that reflect the relative emission control status of a process. Model point value equations are not to be used to estimate actual emissions because not all parameters that are known to affect emissions are incorporated into the equations.

Mold means a cavity or matrix into or onto which the composite materials are placed and from which the product takes its form.

Neat gel coat plus means gel coat plus any organic HAP-containing materials that are added to the gel coat by the supplier or the facility, excluding catalysts and promoters. Neat gel coat plus does include any additions of styrene or methyl methacrylate monomer in any form, including in catalysts and promoters.

Neat resin plus means neat resin plus any organic HAP-containing materials

that are added to the resin by the supplier or the facility. Neat resin plus does not include any added filler, reinforcements, catalysts, or promoters. Neat resin does include any additions of styrene or methyl methacrylate monomer in any form, including in catalysts and promoters.

Non-atomized mechanical application means the use of application tools other than brushes to apply resin and gel coat that do not create a fine liquid mist. Examples include flow coaters, pressure fed rollers, and fluid impingement technology spray guns.

Noncorrosion-resistant resin means any resin other than a corrosion-resistant resin or a tooling resin.

Noncorrosion-resistant product means any product other than a corrosion-resistant product or a mold.

Operation means a specific process typically found at a reinforced plastic composites facility. Examples of operations are noncorrosion-resistant manual resin application, corrosion-resistant mechanical resin application, pigmented gel coat application, mixing and storage.

Operation Group means a grouping of individual operations based primarily on mold type. Examples are open molding, closed molding, and centrifugal casting.

Open molding means a process for fabricating composites in a way that HAP-containing materials are exposed to the atmosphere. Open molding includes processes such as manual resin application, mechanical resin application, filament winding, and gel coat application.

Pigmented production gel coat means a pigmented quick-setting resin used to improve surface appearance and/or performance of composites. It can be used to form the surface layer of any composites other than those used for molds in tooling operations.

Point value means a relative measure of the use of emissions reductions techniques and their effectiveness. Model point value equations were developed for each open molding and centrifugal casting process to calculate point values, which have units of lbs of HAP emissions per ton of neat resin plus or neat gel coat plus used. Point values are calculated by using the appropriate model point value equation for a given process, multiplied by any applicable control factors. Control factors are used to incorporate emissions reductions achieved from add-on control devices.

Polymer casting means a process for fabricating composites in which composite materials are ejected from a casting machine or poured into an open, partially open, or closed mold and cured. After the composite materials are poured into the mold, they are not rolled out or worked prior to curing. The composite materials may or may not include reinforcements. Products produced by the polymer casting process include cultured marble products and polymer concrete.

Pultrusion means a continuous process for manufacturing composites that have a uniform cross-sectional shape. The process consists of pulling a fiber-reinforcing material through a resin impregnation chamber or bath and through a shaping die, where the resin is subsequently cured. There are several types of pultrusion equipment, such as open bath, resin injection, and direct die injection equipment.

Resin transfer molding means a process for manufacturing composites whereby catalyzed resin is transferred or injected into a closed mold in which fiberglass reinforcement has been placed.

Sheet molding compound (SMC) means a ready-to-mold putty-like molding compound processed into sheet form. The molding compound is sandwiched between a top and a bottom film, and it contains resins, catalysts, fillers, chemical thickeners, mold release agents, reinforcements, and other ingredients. Sheet molding compound can be used in compression molding to manufacture reinforced plastic composites products.

SMC manufacturing means a process which involves the preparation of SMC.

Tooling means mold production or repair.

Tooling gel coat means a gel coat that is used to form the surface layer of molds. Tooling gel coats generally have high heat distortion temperatures, low shrinkage, high barcol hardness, and high dimensional stability.

Tooling resin means a resin that is used to produce molds. Tooling resins generally have high heat distortion temperatures, low shrinkage, high barcol hardness, and high dimensional stability.

Uncontrolled oven emissions means those emissions emitted from the oven through closed vent systems to the atmosphere and not to a control device. These emissions do not include emissions that may escape into the workplace through the opening of panels or doors on the ovens or other similar fugitive emissions in the workplace.

Uncontrolled wet-out area emissions means any or all of the following: Emissions from wet-out areas that do not have any capture and control, emissions that escape from wet-out area enclosures, and emissions from wet-out areas that are captured by an enclosure but are vented to the atmosphere and not to an add-on control device.

Unfilled means that there has been no addition of fillers to a resin or that less than 10 percent of fillers by weight of the total resin plus filler mixture has been added.

Vapor suppressant means an additive, typically a wax, that migrates to the surface of the resin during curing and forms a barrier to seal in the styrene and reduce styrene emissions.

Vapor-suppressed resin means a resin containing a vapor suppressant added for the purpose of reducing styrene emissions during curing.

Tables to Subpart WWWW of Part 63

As required in §§ 63.5797, 63.5798(a)(1) and (b), and 63.5810(a)(1), to calculate model point values for specific open molding and centrifugal casting process streams you must use the equations in the following table:

TABLE 1 TO SUBPART WWWW OF PART 63.—MODEL EQUATIONS TO CALCULATE POINT VALUES FOR SPECIFIC OPEN MOLDING AND CENTRIFUGAL CASTING PROCESS STREAMS

If your operation type is a new or existing . . .	And you use . . .	With . . .	Use this Model Point Value (PV) Equation [a b c] . . .
1. Open molding operation	a. Manual resin application	i. Nonvapor-suppressed resin	$PV = 0.028 \times (\%HAP)^{2.275}$
		ii. Vapor-suppressed resin	$PV = 0.028 \times (\%HAP)^{2.275} \times (1 - (0.5419 \times VSR\ test\ value))$
		iii. Vacuum bagging/closed-mold curing with roll out.	$PV = 0.028 \times (\%HAP)^{2.275} \times (1 - 0.2133)$
		iv. Vacuum bagging/closed-mold curing without roll-out.	$PV = 0.028 \times (\%HAP)^{2.275} \times (1 - 0.4554)$

TABLE 1 TO SUBPART WWWW OF PART 63.—MODEL EQUATIONS TO CALCULATE POINT VALUES FOR SPECIFIC OPEN MOLDING AND CENTRIFUGAL CASTING PROCESS STREAMS—Continued

If your operation type is a new or existing . . .	And you use . . .	With . . .	Use this Model Point Value (PV) Equation [a b c] . . .
	b. Mechanical resin application.	i. Nonvapor-suppressed resin and atomized application.	$PV = 0.028 \times (\%HAP)^{2.425}$
		ii. Vapor-suppressed resin and atomised application.	$PV = 0.028 \times (\%HAP)^{2.425} \times (1-(0.4559 \times VSR\ test\ value))$
		iii. Vacuum bagging/closed-mold curing with roll-out and atomized application.	$PV = 0.028 \times (\%HAP)^{2.425} \times (1-0.1535)$
		iv. Vacuum bagging/closed-mold curing without roll-out and atomized application.	$PV = 0.028 \times (\%HAP)^{2.425} \times (1-0.3261)$
		v. Nonvapor-suppressed resin and nonatomized application.	$PV = 0.028 \times (\%HAP)^{2.275}$
		vi. Vapor-suppressed resin and nonatomized application.	$PV = 0.028 \times (\%HAP)^{2.275} \times (1-(0.5419 \times VSR\ test\ value))$
		vii. Closed-mold curing with roll-out and non atomized application.	$PV = 0.028 \times (\%HAP)^{2.275} \times (1-0.2133)$
		viii. Vacuum bagging/closed-mold curing without roll-out and nonatomized application.	$PV = 0.028 \times (\%HAP)^{2.275} \times (1-0.4554)$
	c. Filament winding	i. Nonvapor-suppressed resin	$PV = 1.675 \times (\%HAP)^{1.225}$
		ii. Vapor-suppressed resin	$PV = 1.675 \times (\%HAP)^{1.225} \times (1-(0.4693 \times VSR\ test\ value))$
	d. Gel coat application	Nonvapor-suppressed gel coat	$PV = 0.890 \times (\%HAP)^{1.675}$
2. Centrifugal casting operation.	Centrifugal casting	Nonvapor-suppressed resin	$PV = 11.16 \times (\%HAP)$

[a] To obtain the model point value for an operation with an add-on control device multiply the PV above by the add-on control factor calculated using Equation 1 of § 63.5810. The model point values have limits of lbs of HAP per ton of resin or gel coat applied.
[b] Percent HAP means total weight percent of HAP in the resin or gel coat prior to the addition of fillers, catalyst, and promoters.
[c] VSR test value means the percent reduction in HAP emissions expressed as a decimal measured by the VSR test method.

As required in §§ 63.5800 and 63.5840 you must demonstrate compliance with the standards by the dates in the following table:

TABLE 2 TO SUBPART WWWW OF PART 63.—COMPLIANCE DATES FOR NEW AND EXISTING REINFORCED PLASTIC COMPOSITES FACILITIES

If your facility is . . .	And . . .	Then you must comply by this date:
1. An existing source	Is a major source on or before the publication date of the final rule.	i. [Date 3 years after the publication date of the final rule], or ii. You must accept and meet an enforceable HAP emission limit below the major source threshold prior to [date 3 years after the publication date of final rule].
2. An existing source that is an area source	Becomes a major source after the publication date of the final rule.	3 years after becoming a major source or [date 3 years after the publication date of the final rule], whichever is later.
3. A new source	Is a major source at startup	Upon startup or [publication date of the final rule], whichever is later.
4. A new source	Is an area source at startup and becomes a major source.	Immediately upon becoming a major source.

As required in §§ 63.5805 (a) and (c), 63.5810(a) through (b), 63.5820(c), 63.5830, 63.5835, and 63.5900(a)(2), you must meet the appropriate emission limits in the following table:

TABLE 3 TO SUBPART WWWW OF PART 63.—EMISSION LIMITS FOR EXISTING SMALL BUSINESS SOURCES EMITTING LESS THAN 250 TPY OF HAP, OR OTHER SOURCES EMITTING LESS THAN 100 TPY OF HAP

If your operation type is . . .	And you use . . .	Your emission limit is [a] . . .
1. Open molding—corrosion-resistant (CR) [b]	a. Mechanical resin application	190 lb/ton.
	b. Filament winding	163 lb/ton.
	c. Manual resin application	124 lb/ton.
2. Open molding—non-CR	a. Mechanical resin application-unfilled	110 lb/ton.
	b. Mechanical resin application-filled	144 lb/ton.
	c. Filament winding	178 lb/ton.
	d. Manual resin application	83 lb/ton.
3. Open molding—tooling	a. Mechanical resin application	256 lb/ton.
	b. Manual resin application	123 lb/ton.

TABLE 3 TO SUBPART WWWW OF PART 63.—EMISSION LIMITS FOR EXISTING SMALL BUSINESS SOURCES EMITTING LESS THAN 250 TPY OF HAP, OR OTHER SOURCES EMITTING LESS THAN 100 TPY OF HAP—Continued

If your operation type is . . .	And you use . . .	Your emission limit is [a] . . .
4. Open molding—products that require class 1 fire and smoke ratings.	a. Mechanical resin application	575 lb/ton.
	b. Filament winding	253 lb/ton.
	c. Manual resin application	311 lb/ton.
5. Open molding—gel coat	a. Tooling gel coating	394 lb/ton.
	b. White/off white pigmented gel coating	265 lb/ton.
	c. All other pigmented gel coating	377 lb/ton.
	d. Clear production gel coating	504 lb/ton.
6. Centrifugal casting—CR	N/A	536 lb/ton.
7. Centrifugal casting—non-CR	N/A	396 lb/ton.
8. Pultrusion	N/A	Reduce total HAP emissions by at least 60 weight percent.
9. Continuous lamination/casting	N/A	Reduce total HAP emissions by at least 58.5 weight percent or not exceed an emission limit of 15.7 lbs of HAP per ton of neat resin plus and neat gel coat plus.

[a] Emission limits for open molding and centrifugal casting expressed as lb/ton are point values calculated using the equations shown in Table 1 of this subpart. You must be at or below these values based on a 12-month rolling average.
[b] Corrosion-resistant applications also include high-strength products.

As required in § 63.5805 (a) through (d) you must meet the appropriate work practice standards in the following table:

TABLE 4 TO SUBPART WWWW OF PART 63.—WORK PRACTICE STANDARDS

For . . .	You must . . .
1. A new or existing closed molding operation using compression/injection molding.	Uncover, unwrap or expose only one charge per mold cycle per compression/injection molding machine.
2. A new or existing cleaning operation	Not use cleaning solvents that contain HAP.
3. A new or existing materials storage operation	Keep containers that store HAP materials closed or covered except during the addition or removal of materials.
4. An existing pultrusion operation using a wet-area enclosure	Keep access panels, doors, and/or hatches closed whenever resin is in the bath, except that access panels, doors, and/or hatches may be open 30 minutes per 8-hour shift, or 45 minutes per 12-hour shift.
5. An existing SMC manufacturing operation	Close or cover the doctor box on each SMC manufacturing machine.
6. An existing SMC manufacturing operation	Fold or seal edges of SMC prior to storage and/or transport.
7. An existing SMC manufacturing operation	Use a nylon film or a film with an equal or lower permeability to styrene than nylon to enclose SMC.
8. A new or existing BMC manufacturing/mixing operation [a]	Use mixer covers with no visible gaps present in the mixer covers.
9. An existing BMC manufacturing/mixing	Not actively vent mixers to the atmosphere.
10. A new or existing BMC manufacturing/mixing operation [a]	Keep the mixer covers closed during mixing except when adding materials to the mixing vessels.

[a] Containers of 5 gallons or less may be open when active mixing is taking place, or during periods when they are in process (i.e., they are actively being used to apply resin). For polymer casting mixing operations, containers of 21 gallons or less may be open while active mixing is taking place.

As specified in § 63.5805 (b) and (d), as an alternative to the 95 percent HAP emission reduction requirement, you may meet the appropriate emission limits in the following table:

TABLE 5 TO SUBPART WWWW OF PART 63.—ALTERNATIVE EMISSION LIMITS FOR OPEN MOLDING AND CENTRIFUGAL CASTING OPERATIONS WHERE THE STANDARD IS BASED ON A PERCENT REDUCTION REQUIREMENT

If your operation type is . . .	And you use . . .	Your emission limit is [a] . . .
1. 0pen molding—corrosion-resistant (CR)	a. Mechanical resin application	10 lb/ton.
	b. Filament winding	9 lb/ton.
	c. Manual resin application	7 lb/ton.
2. Open molding—non-CR	a. Mechanical resin application-unfilled	8 lb/ton.
	b. Mechanical resin application-filled	6 lb/ton.
	c. Filament winding	9 lb/ton.
	d. Manual resin application	4 lb/ton.
3. Open molding—tooling	a. Mechanical resin application	13 lb/ton.
	b. Manual resin application	7 lb/ton.
4. Open molding—products that require Class 1 Fire and Smoke Ratings.	a. Mechanical resin application	29 lb/ton.
	b. Filament winding	13 lb/ton.
	c. Manual resin application	16 lb/ton.

TABLE 5 TO SUBPART WWWW OF PART 63.—ALTERNATIVE EMISSION LIMITS FOR OPEN MOLDING AND CENTRIFUGAL CASTING OPERATIONS WHERE THE STANDARD IS BASED ON A PERCENT REDUCTION REQUIREMENT—Continued

If your operation type is . . .	And you use . . .	Your emission limit is [a] . . .
5. Open molding—gel coat	a. Tooling gel coating	20 lb/ton.
	b. White/off white pigmented gel coating	14 lb/ton.
	c. All other pigmented gel coating	19 lb/ton.
	d. Clear production gel coating	26 lb/ton.
6. Centrifugal Casting—CR	N/A	27 lb/ton.
7. Centrifugal Casting—Non-CR	N/A	20 lb/ton.

[a] The emission limits are calculated using the equations shown in Table 1 of this subpart. You must be at or below these values based on a 12-month rolling average.
[b] Corrosion-resistant applications also include high-strength products.

As required in §§ 63.5810(a)(1), 63.5825(a), 63.5830(a), and 63.5870, you must conduct performance tests, performance evaluations, and design evaluation according to the requirements in the following table:

TABLE 6 TO SUBPART WWWW OF PART 63.—BASIC REQUIREMENTS FOR PERFORMANCE TESTS, PERFORMANCE EVALUATIONS, AND DESIGN EVALUATIONS FOR NEW AND EXISTING SOURCES USING ADD-ON CONTROL DEVICES

For . . .	You must . . .	Using . . .	According to the following requirements
1. Each enclosure used to collect and route HAP emissions to an add-on control device.	a. Determine the capture efficiency of each enclosure used to capture HAP emissions to sent to an add-on control device.	i. EPA methods 204 and 204B through E in Appendix M of 40 CFR part 51, or. ii. An alternative test method that meets the data quality objectives and lower confidence limit approaches for alternative capture efficiency protocols and test methods contined in 40 CFR part 63 subpart KK, appendix A.	(1) Enclosures that meet the requirements for a permanent total enclosure are assumed to have a capture efficiency of 100%. Enclosures that do not meet permanent total enclosure requirements must determine the capture efficiency by constructing a temporary total enclosure according to the requirements of EPA Method 204 and measuring the mass flow rates of the HAP in the exhaust streams going to the atmosphere and to the control device, or, (2) Use an alternative test method that meets the requirements of 40 CFR part 51, appendix M. Follow the requirements in 1.a.i (1) and (2) of this table.
2. Each control device used to comply with an percent reduction requirement, or a point value limit.	Determine the control efficiency of each control device used to control HAP emissions.	The appropriate test methods specified in 40 CFR part 63, subpart SS.	Testing and evaluation requirements are contained in 40 CFR part 63, subpart SS.
3. Each control device used to comply with a emission factor limit for continuous lamination/continuous casting.	a. Determine the control efficiency of each control device used to control HAP emissions, or determine the mass HAP emission rate at the control device outlet.	The appropriate test methods specified in 40 CFR part 63 subpart SS.	Testing and evaluation requirements are contained in 40 CFR part 63, subpart SS.

As required in § 63.5810(c), when selecting one resin point value for multiple operations you must use the values in the following table:

TABLE 7 TO SUBPART WWWW OF PART 63.—OPTIONS ALLOWING USE OF THE SAME RESIN ACROSS DIFFERENT OPERATIONS THAT USE THE SAME RESIN TYPE

If your facility has the following resin application operation . . .	The highest resin weight percent HAP content you can use for . . .	Is . . .	The point value assignd to all uses of this resin is . . .
1. Corrosion-resistant (CR) nonatomized mechanical	a. CR mechanical	48.3	190
	b. CR filament winding	48.3	190
	c. CR manual	48.3	190
	d. CR centrifugal casting	48.3	190
2. CR centrifugal casting	a. CR filament winding	48	536
	b. CR manual	48	536
	c. CR centrifugal casting	48	536

TABLE 7 TO SUBPART WWWW OF PART 63.—OPTIONS ALLOWING USE OF THE SAME RESIN ACROSS DIFFERENT OPERATIONS THAT USE THE SAME RESIN TYPE—Continued

If your facility has the following resin application operation . . .	The highest resin weight percent HAP content you can use for . . .	Is . . .	The point value assignd to all uses of this resin is . . .
3. CR filament winding	a. CR filament winding	42	163
	b. CR manual	42	163
4. Non-CR filament winding	a. Non-CR mechanical (filled or unfilled	45	178
	b. non-CR manual	45	178
	c. non-CR centrifugal casting	45	178
5. Non-CR nonatomized filled mechanical	a. non-CR nonatomized unfilled mechanical	144	42.8
	b. non-CR manual	144	42.8
	c. non-CR centrifugal casting	144	42.8
6. Non-CR nonatomized unfilled mechanical	a. non-CR manual	110	38
	b. non-CR centrifugal casting	110	38
7. Non-CR centrifugal casting	a. non-CR manual	35.5	396
	b. non-CR atomized filled mechanical	35.5	396
8. Non-CR atomized filled mechanical	a. non-CR manual	33.9	144
9. Non-CR manual	a. Non-CR atomized unfilled mechanical	33.6	83
10. Tooling nonatomized mechanical	a. tooling manual	55.1	256
11. Tooling atomized mechanical	a. tooling manual	43	256

As required in § 63.5860(b), you must demonstrate initial compliance with emission limits as specified in the following table:

TABLE 8 TO SUBPART WWWW OF PART 63.—INITIAL COMPLIANCE WITH EMISSION LIMITS

For . . .	That must meet the following emission limit . . .	You have demonstrated initial compliance if . . .
1. Open molding and centrifugal casting operations.	a. A point value emission limit shown in Table 3 or 5 of this subpart.	i. You have met the appropriate point value for these operations as calculated using the procedures in § 63.5810 on a 12-month rolling average 1 year plus 30 days after the appropriate compliance date, or, ii. You demonstrate by using the appropriate point value model equations in Table 1 that all resins and gel coats considered individually meet the appropriate point value emission limit.
2. Open molding, centrifugal casting, continuous lamination/casting, SMC manufacturing mixing/BMC manufacturing operations.	Reduce total HAP emissions by at least 95 percent by weight.	Total HAP emissions, based on the results of the capture efficiency and destruction efficiency testing specified in Table 6 of this subpart, are reduced by at least 95 percent by weight.
3. Continuous lamination/casting operations	a. Reduce total HAP emissions by at least 58.5 weight percent or.	Total HAP emissions, based on the results of the capture efficiency and destruction efficiency testing specified in Table 6 of this subpart and the calculation procedures specified in §§ 63.5865 through 63.5890, are reduced by at least 58.5 percent by weight.
	b. Not exceed an emission limit of 15.7 lbs. of HAP per ton of neat resin plus and neat gel coat plus 95 percent by weight.	Total HAP emissions, based on the results of the capture efficiency and destruction efficiency testing specified in Table 6 of this subpart and the calculation procedures specified in §§ 63.5865 through 63.5890, do not exceed 15.7 lbs. of HAP per ton of neat resin plus and neat gel coat plus.
4. Continuous lamination/casting operations	a. Reduce total HAP emissions by at least 95 weight percent or.	Total HAP emissions, based on the results of the capture efficiency and destruction efficiency testing specified in Table 6 of this subpart and the calculation procedures specified in §§ 63.5865 through 63.5890, are reduced by at least 95 percent by weight or,

TABLE 8 TO SUBPART WWWW OF PART 63.—INITIAL COMPLIANCE WITH EMISSION LIMITS—Continued

For . . .	That must meet the following emission limit . . .	You have demonstrated initial compliance if . . .
	b. Not exceed an emission limit of 1.47 lbs. of HAP per ton of neat resin plus and neat gel coat plus 95 percent by weight.	Total HAP emissions, based on the results of the capture efficiency and destruction efficiency testing specified in Table 5 and the calculation procedures specified in §§ 63.5865–63.5890, do not exceed 1.47 lbs. of HAP per ton of neat resin plus an neat gel coat plus.
5. Pultrusion operations	a. Reduce total HAP emissions by at least 60 percent by weight.	i. Total HAP emissions, based on the results of the capture efficiency and add-on control device destruction efficiency testing specified in Table 6 of this subpart, are reduced by at least 60 percent by weight, or ii. As part of the notification of initial compliance status, the owner/operator submits a certified statement that all pultrusion lines not controlled with add-on control device are using direct die injection and/or wet-area enclosures that meet the criteria of § 63.5825.
6. Pultrusion operations	a. Reduce total HAP emissions by at least 95 percent by weight.	i. Total HAP emissions, based on the results of the capture efficiency and add-on control device destruction efficiency testing specified in Table 6 of this subpart, are reduced by at least 95 percent by weight, or, ii. As part of the notification of initial compliance status, the owner/operator submits a certified statement that all pultrusion lines not controlled by an add-on control device are using direct die injection that meet the criteria of § 63.5825.

As required in § 63.5860(b), you must demonstrate initial compliance with work practice standards as specified in the following table:

TABLE 9 TO SUBPART WWWW OF PART 63.—INITIAL COMPLIANCE WITH WORK PRACTICE STANDARDS

For . . .	That must meet the following standard . . .	You have demonstrated initial compliance if . . .
1. A new or existing closed molding operation using compression/injection molding.	Uncover, unwrap or expose only one charge per mold cycle per compression/injection molding machine.	The owner or operator submits a certified statement in the notice of compliance status that only one charge is uncovered, unwrapped or exposed per mold cycle per compression/injection molding machine.
2. An existing SMC manufacturing operation	Close or cover the doctor box on each SMC manufacturing machine.	The onwner or operator submits a certified statement in the notice of compliance status that the doctor box on each SMC manufacturing machine is closed or covered.
3. An existing SMC manufacturing operation	Fold edges of SMC prior to storage and/or transport.	The owner or operator submits a certified statement in the notice of compliance status that the edges of SMC are folded prior to storage and/or transport.
4. An existing SMC manufacturing operation	Use nylon film or a film with an equal or lower permeability to styrene than nylon to enclose SMC.	The owner or operator submits a certified statement in the notice of compliance status that a nylon film or film with an equal or lower permeability to styrene than nylon is used to enclose SMC.
5. A new or existing BMC manufacturing/mixing operation.	Use mixer covers with no visible gaps present in the mixer covers.	The owner or operator submits a certified statement in the notice of compliance status that each mixer is equipped with a cover that does not contain any visible gaps.
6. An existing BMC manufacturing/mixing operation.	Keep the mixer covers closed during mixing except when adding materials to the mixers.	The owner or operator submits a certified statement in the notice of compliance status that mixer covers are closed during mixing except when adding materials to the mixers.

TABLE 9 TO SUBPART WWWW OF PART 63.—INITIAL COMPLIANCE WITH WORK PRACTICE STANDARDS—Continued

For . . .	That must meet the following standard . . .	You have demonstrated initial compliance if . . .
7. An existing BMC manufacturing/mixing	Not actively vent mixers to the atmosphere	The owner or operator submits a certified statement in the notice of compliance status that mixers are not actively vented to the atmosphere.

As required in § 63.5865(a), in order to comply with a percent reduction limit for continuous lamination lines and continuous casting lines you must determine the data in the following table:

TABLE 10 TO SUBPART WWWW OF PART 63.—DATA REQUIREMENTS FOR NEW AND EXISTING CONTINUOUS LAMINATION LINES AND CONTINUOUS CASTING LINES COMPLYING WITH A PERCENT REDUCTION LIMIT ON A PER LINE BASIS

For each line where the wet-out area . . .	And the oven . . .	You must determine . . .
1. Has an enclosure that is not a PTE and the captured emissions are controlled by an add-on control device.	a. Is uncontrolled	i. Annual uncontrolled wet-out area emissions; ii. Annual controlled wet-out area emissions; iii. Annual uncontrolled oven emissions; iv. The capture efficiency of the wet-out area enclosure; v. The destruction efficiency of the add-on control device; and vi. The amount of neat resin plus and neat gel coat plus applied.
2. Has an enclosure that is a PTE and the captured emissions are controlled by an add-on control device.	a. Is uncontrolled	i. Annual uncontrolled wet-out area emissions; ii. Annual controlled wet-out area emissions; iii. Annual uncontrolled oven emissions; iv. That the wet-out area enclosure meets the requirements of Method 204 for a PTE; v. The destruction efficiency of the add-on control device; and vi. The amount of neat resin plus and neat gel coat plus applied.
3. Is uncontrolled	a. Is controlled by an add-on control device ...	i. Annual uncontrolled wet-out area emissions; ii. Annual uncontrolled oven emissions; iii. Annual controlled oven emissions; iv. The capture efficiency of the oven; v. The destruction efficiency of the add-on control device; and vi. The amount of neat resin plus and neat gel coat plus applied.
4. Has an enclosure that is not a PTE and the captured emissions are controlled by an add-on control device.	a. Is controlled by an add-on control device ...	i. Annual uncontrolled wet-out area emissions; ii. Annual controlled wet-out area emissions; iii. Annual uncontrolled oven emissions; iv. Annual controlled oven emissions; v. The capture efficiency of the wet-out area enclosure; vi. Inlet emissions to the add-on control device; vii. Outlet emissions from the add-on control device; and viii. The amount of neat resin plus and neat gel coat plus applied
5. Has an enclosure that is a PTE and the captured emissions are controlled by an add-on control device.	a. Is controlled by an add-on control device ...	i. That the wet-out area enclosure meets the requirements of Method 204 for a PTE; ii. The capture efficiency of the oven; and iii. The destruction efficiency of the add-on control device.

As required in § 63.5865, in order to comply with a percent reduction limit or a lbs/ton limit on an averaging basis for continuous lamination lines and continuous casting lines you must determine the data in the following table:

TABLE 11 TO SUBPART WWWW OF PART 63.—DATA REQUIREMENTS FOR NEW AND EXISTING CONTINUOUS LAMINATION AND CONTINUOUS CASTING LINES COMPLYING WITH A PERCENT REDUCTION LIMIT OR A LBS/TON LIMIT ON AN AVERAGING BASIS

For each . . .	That . . .	You must determine
1. Wet-out area	Is uncontrolled	Annual uncontrolled wet-out area emissions.

TABLE 11 TO SUBPART WWWW OF PART 63.—DATA REQUIREMENTS FOR NEW AND EXISTING CONTINUOUS LAMINATION AND CONTINUOUS CASTING LINES COMPLYING WITH A PERCENT REDUCTION LIMIT OR A LBS/TON LIMIT ON AN AVERAGING BASIS—Continued

For each . . .	That . . .	You must determine
2. Wet-out area	a. Has an enclosure that is not a PTE	i. The capture efficiency of the enclosure; and ii. Annual emissions that escape the enclosure.
3. Wet-out area	Has an enclosure that is a PTE	That the enclosure meets the requirements of Method 204 for a PTE.
4. Oven	Is uncontrolled	Annual uncontrolled oven emissions.
5. Line	a. Is controlled or uncontrolled	i. The amount of neat resin plus applied; and ii. The amount of neat gel coat plus applied.
6. Add-on control device	N/A	Total annual inlet emissions; and total annual on outlet emissions.

As required in § 63.5865(b), in order to comply with a lbs/ton emission limit for continuous lamination lines and continuous casting lines you must determine the data in the following table:

TABLE 12 TO SUBPART WWWW OF PART 63.—DATA REQUIREMENTS FOR NEW AND EXISTING CONTINUOUS LAMINATION LINES AND CONTINUOUS CASTING LINES COMPLYING WITH A LBS/TON ON A PER LINE BASIS

For each line where the wet-out area . . .	And the oven . . .	You must determine . . .
1. Is uncontrolled	a. Is uncontrolled	i. Annual uncontrolled wet-out area emissions; ii. Annual uncontrolled oven emissions; and iii. Annual neat resin plus and neat gel coat plus applied.
2. Has an enclosure that is not a PTE, and the captured emissions are controlled by an add-on control device.	a. Is uncontrolled	i. Annual uncontrolled wet-out area emissions; ii. Annual controlled wet-out area emissions; iii. Annual uncontrolled oven emissions; iv. The capture efficiency of the wet-out area controlled enclosure; v. The destruction efficiency of the add-on control device; and vi. The amount of neat resin plus and neat gel coat plus applied.
3. Has an enclosure that is a PTE, and the captured emissions are controlled by an add-on control device.	a. Is uncontrolled	i. Annual uncontrolled wet-out area emissions; ii. Annual controlled wet-out area emissions; iii. Annual uncontrolled oven emissions; iv. That the wet-out area enclosure meets the requirements of Method 204 for a PTE; v. The destruction efficiency of the add-on control device; and vi. The amount of neat resin plus and neat gel coat plus applied.
4. Is uncontrolled	a. Is controlled by an add-on control device	i. Annual uncontrolled wet-out area emissions; ii. Annual uncontrolled oven emissions; iii. Annual controlled oven emissions; iv. The capture efficiency of the oven; v. The destruction efficiency of the add-on control device; and vi. The amount of neat resin plus and neat gel coat plus applied.
5. Has an enclosure that is not a PTE and the captured emissions are controlled by an add-on control device.	a. Is controlled by an add-on control device	i. Annual uncontrolled wet-out area emissions; ii. Annual controlled wet-out area emissions; iii. Annual uncontrolled oven emissions; iv. Annual controlled oven emissions; v. The capture efficiency of the wet-out area control enclosure; vi. The capture efficiency of the oven; vii. The destruction efficiency of the add-on control device; and viii. The amount of neat resin plus and neat gel coat plus applied.
6. Has an enclosure that is a PTE, and the captured emissions are controlled by an add-on control device.	a. Is controlled by an add-on control device	i. That the wet-out area enclosure meets the requirements of Method 204 for a PTE; ii. The capture efficiency of the oven; iii. Inlet emissions to the add-on control are device; and iv. Outlet emissions from the add-on control control device.

As required in § 63.5905, you must determine the applicable notifications and submit them by the dates shown in the following table:

TABLE 13 TO SUBPART WWWW OF PART 63.—APPLICABILITY AND TIMING OF NOTIFICATIONS

If your facility . . .	You must submit . . .	By this date . . .
1. Is an existing source subject to this regulation.	An Initial Notification containing the information specified in § 63.9(b)(2).	No later than the dates specified in § 63.9(b)(2).
2. Is a new source subject to this regulation	The notifications specified in § 63.9(b)(3) to (5).	No later than the dates specified in § 63.9(b)(4) and (5).
3. Qualifies for a compliance extension as specified in § 63.9(c) of subpart A.	A request for a compliance extension as specified in § 63.9(c).	No later than the dates specified in § 63.9(i).
4. Is complying with model point value averaging provisions.	A Notification of Compliance Status as specified in § 63.9(h).	No later than 1 year plus 30 days after your facility's compliance date.
5. Is complying with HAP content limits, application equipment requirements, or emission limit other than model point value averaging.	A Notification of Compliance Status as specified in § 63.9(h).	No later than 30 calendar days after facility's compliance date.
6. Is complying by using an add = on control device.	a. A notification of intent to conduct a performance test as specified in § 63.9(e).	No later than the date specified in § 63.9(e).
	b. A notification of the date for the CMS performance evaluation as specified in § 63.9(g).	The date of submission of notification of intent to conduct a performance test.
	c. A Notification of Compliance Status as specified in § 63.9(h).	No later than 60 calendar days after the completion of the add-on control device performance test and CMS performance evaluation.

As required in § 63.5910(a) through (b) and (f) through (g), you must submit reports on the schedule shown in the following table:

TABLE 14 TO SUBPART WWWW OF PART 63.—REQUIREMENTS FOR REPORTS

You must submit a(n)	The report must contain . . .	You must submit the report . . .
1. Compliance report	a. A statement that there were no deviations during that reporting period if there were no deviations from any emission limitations (emission limit, operating limit, opacity limit, and visible emission limit) that apply to you and there were no deviations from the requirements for work practice standards in Table 4 of this subpart that apply to you. If there were no periods during which the CMS, including CEMS, and operating parameter monitoring systems, was out of control as specified in § 63.8(c)(7), the report must also contain a statement that there were no periods during which the CMS was out of control during the reporting period.	Semiannually according to the requirements in § 63.5910(b).
	b. The information in § 63.5910(d) if you have a deviation from any emission the limitation (emission limit, operating limit, or work practice standard) during the reporting period. If there were periods during which the CMS, including CEMS, and operating parameter monitoring systems, was out of control, as specified in § 63.8(c)(7), the report must contain the information in § 63.5910(e).	Semiannually according to the requirements in § 63.5910(b).
	c. The information in § 63.10(d)(5)(i). If you had a startup, shutdown or malfunction during the reporting period, and you took actions consistent with your startup, shutdown, and malfunction plan.	Semiannually according to the requirements in § 63.5910(b).
2. An immediate startup, shutdown, and malfunction report if you had a startup, shutdown, or malfunction during the reporting period that is not consistent with your startup, shutdown, and malfunction plan.	a. Actions taken for the event.	By fax or telephone within 2 working days after starting actions inconsistent with the plan.
	b. The information in § 63.10(d)(5)(ii).	By letter within 7 working days after the end of the event unless you have made alternative arrangements with the permitting authority. (§ 63.10(d)(5)(ii)).

As specified in § 63.5925, the parts of the General Provisions which apply to you are shown in the following table:

TABLE 15 TO SUBPART WWWW OF PART 63.—APPLICABILITY OF GENERAL PROVISIONS (SUBPART A) TO SUBPART WWWW OF PART 63

The general provisions reference . . .	That addresses . . .	And applies to subpart WWWW of Part 63 . . .	Subject to the following additional information . . .
§ 63.1(a)(1)	General applicability of the general provisions.	Yes	Additional terms defined in subpart WWWW of Part 63; when overlap between subparts A and WWWW of Part 63 of this part, subpart WWWW of Part 63 takes precedence.
§ 63.1(a)(2) through (4)	General applicability of the general provisions.	Yes.	
§ 63.1(a)(5)	Reserved	No.	
§ 63.1(a)(6) through (7)	General applicability of the general provisions.	Yes.	
§ 63.1(a)(8)	General applicability of the general provisions.	Yes.	
§ 63.1(a)(9)	Reserved	No.	
§ 63.1(a)(10) through (14)	General applicability of the general provisions.	Yes.	
§ 63.1(b)(1)	Initial applicability determination	Yes	Subpart WWWW of Part 63 clarifies the applicability in §§ 63.5780 and 63.5785.
§ 63.1(b)(2)	Title V operating permit requirement	Yes	All major affected sources are required to obtain a title V permit.
§ 63.1(b)(3)	Record of the applicability determination	Yes.	
§ 63.1(c)(1)	Applicability of this part after a relevant standard has been set under this part.	Yes	Subpart WWWW of Part 63 clarifies the applicability of each paragraph of subpart A to sources subject to subpart WWWW of Part 63.
§ 63.1(c)(2)	Title V operating permit requirement	Yes	All major affected sources are required to obtain a title V operating permit. Area sources are not subject to subpart WWWW of Part 63.
§ 63.1(c)(3)	Reserved	No.	
§ 63.1(c)(4)	Requirements for an existing source that obtains an extension of compliance.	Yes.	
§ 63.1(c)(5)	Notification requirements for an area source that increases HAP emissions to major source levels.	Yes.	
§ 63.1(d)	Reserved	No.	
§ 63.1(e)	Applicability of permit program before a relevant standard has been set under this part.	Yes.	
§ 63.2	Definitions	Yes	Subpart WWWW of Part 63 defines terms in § 63.5935. When overlap between subparts A and WWWW of Part 63 occurs, you must comply with the subpart WWWW of Part 63 definitions, which take precedence over the subpart A definitions.
§ 63.3	Units and abbreviations	Yes.	Other units and abbreviations used in subpart WWWW of Part 63 are defined in subpart WWWW of Part 63.
§ 63.4	Prohibited activities and circumvention	Yes	§ 63.4(a)(4) is reserved and does not apply.
§ 63.5(a)(1) through (2)	Applicability of construction and reconstruction.	Yes	Existing facilities do not become reconstructed under subpart WWWW of Part 63.
§ 63.5(b)(1)	Relevant standards for new sources upon construction.	Yes	Existing facilities do not become reconstructed under subpart WWWW of Part 63.
§ 63.5(b)(2)	Reserved	No.	
§ 63.5(b)(3)	New construction/reconstructed	Yes	Existing facilities do not become reconstructed under subpart WWWW of Part 63.
§ 63.5(b)(4)	Construction/reconstruction notification	Yes	Existing facilities do not become reconstructed under subpart WWWW of Part 63.
§ 63.5(b)(5)	Construction/reconstruction compliance	Yes	Existing facilities do not become reconstructed under subpart WWWW of Part 63.
§ 63.5(b)(6)	Equipment addition or process change	Yes	Existing facilities do not become reconstructed under subpart WWWW of Part 63.

TABLE 15 TO SUBPART WWWW OF PART 63.—APPLICABILITY OF GENERAL PROVISIONS (SUBPART A) TO SUBPART WWWW OF PART 63—Continued

The general provisions reference . . .	That addresses . . .	And applies to subpart WWWW of Part 63 . . .	Subject to the following additional information . . .
§ 63.5(c)	Reserved	No.	
§ 63.5(d)(1)	General application for approval of construction or reconstruction.	Yes	Existing facilities do not become reconstructed under subpart WWWW of Part 63.
§ 63.5(d)(2)	Application for approval of construction	Yes.	
§ 63.5(d)(3)	Application for approval of reconstruction	No.	
§ 63.5(d)(4)	Additional information	Yes.	
§ 63.5(e)(1) through (5)	Approval of construction or reconstruction.	Yes.	
§ 63.5(f)(1) through (2)	Approval of construction or reconstruction based on prior State preconstruction review.	Yes.	
§ 63.6(a)(1)	Applicability of compliance with standards and maintenance requirements.	Yes.	
§ 63.6(a)(2)	Applicability of area sources that increase emissions to become major sources.	Yes.	
§ 63.6(b)(1) through (2)	Compliance dates for new and reconstructed sources.	Yes	Subpart WWWW of Part 63 clarifies compliance dates in § 63.5800.
§ 63.6(b)(3) through (5)	Compliance dates for area sources that become major sources.	Yes	Subpart WWWW of Part 63 clarifies compliance dates in § 63.5800.
§ 63.6(b)(6)	Reserved	No.	
§ 63.6(b)(7)	Compliance dates for new sources resulting from new unaffected area sources becoming subject to standards.	Yes	Subpart WWWW of Part 63 clarifies compliance dates in § 63.5800.
§ 63.6(c)(1) through (2)	Compliance dates for existing sources	Yes	Subpart WWWW of Part 63 clarifies compliance dates in § 63.5800.
§ 63.6(c)(3) through (4)	Reserved	No.	
§ 63.6(c)(5)	Compliance dates for existing area sources that become major.	Yes	Subpart WWWW of Part 63 clarifies compliance dates in § 63.5800.
§ 63.6(d)	Reserved	No.	
§ 63.6(e)(1) through (2)	Operation & maintenance requirements	Yes.	
§ 63.6(e)(3)	Startup, shutdown, and malfunction plan and recordkeeping.	Yes	Subpart WWWW of Part 63 requires a startup, shutdown, and malfunction plan only for sources using add-on controls.
§ 63.6(f)(1)	Compliance except during periods of startup, shutdown, and malfunction.	No	Subpart WWWW of Part 63 requires compliance during periods of startup, shutdown, and malfunctions, except startup, shutdown, and malfunctions for sources using add-on controls.
§ 63.6(f)(23)	Methods for determining compliance	Yes.	
§ 63.6(g)(1) through (3)	Alternative standard	Yes.	
§ 63.6(h)	Opacity and visible emission Standards	No	Subpart WWWW of Part 63 does not contain opacity or visible emission standards.
§ 63.6(i)(1) through (14)	Compliance extensions	Yes.	
§ 63.6(i)(15)	Reserved	No.	
§ 63.6(i)(16)	Compliance extensions	Yes.	
§ 63.6(j)	Presidential compliance exemption	Yes.	
§ 63.7(a)(1)	Applicability of performance testing requirements.	Yes.	
§ 63.7(a)(2)	Performance test dates	No	Subpart WWWW of Part 63 initial compliance requirements are in § 63.5840.
§ 63.7(a)(3)	Section 114 authority	Yes.	
§ 63.7(b)(1)	Notification of performance test	Yes.	
§ 63.7(b)(2)	Notification of rescheduled performance test.	Yes.	
§ 63.7(c)	Quality assurance program, including test plan.	Yes	Except that the test plan must be submitted with the notification of the performance test.
§ 63.7(d)	Performance testing facilities	Yes.	
§ 63.7(e)(1) through (4)	Conditions for conducting performance tests.	Yes	Performance test requirements are contained in § 63.5850. Additional requirements for conducting performance tests for continuous lamination/casting are included in § 63.5865.
§ 63.7(f)	Use of alternative test method	Yes.	

TABLE 15 TO SUBPART WWWW OF PART 63.—APPLICABILITY OF GENERAL PROVISIONS (SUBPART A) TO SUBPART WWWW OF PART 63—Continued

The general provisions reference . . .	That addresses . . .	And applies to subpart WWWW of Part 63 . . .	Subject to the following additional information . . .
§ 63.7(g)	Performance test data analysis, recordkeeping, and reporting.	Yes.	
§ 63.7(h)	Waiver of performance tests	Yes.	
§ 63.8(a)(1) through (2)	Applicability of monitoring requirements	Yes.	
§ 63.8(a)(3)	Reserved	No.	
§ 63.8(a)(4)	Monitoring requirements when using flares.	Yes.	
§ 63.8(b)(1)	Conduct of monitoring exceptions	Yes.	
§ 63.8(b)(2) through (3)	Multiple effluents and multiple monitoring systems.	Yes.	
§ 63.8(c)(1)(i)	Ensure immediate repair or replacement of CMS parts to correct ''routine'' or otherwise predictable malfunctions.	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(c)(1)(ii)	Report CMS malfunctions that are not addressed by the startup, shutdown, and malfunction plan.	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(c)(1)(iii)	Compliance with CMS operation and maintenance requirements.	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(c)(2) through (3)	Monitoring system installation	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(c)(4)	CMS requirements	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(c)(5)	COMS minimum procedures	No	Subpart WWWW of Part 63 does not contain opacity standards.
§ 63.8(c)(6) through (8)	CMS calibration and periods CMS is out of control.	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(d)	CMS quality control program, including current test plan and all previous versions.	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(e)(1)	Performance evaluation of CMS	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(e)(2)	Notification of performance evaluation	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(e)(3) through (4)	CMS requirements/alternatives	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(e)(5)(i)	Reporting performance evaluation results.	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(e)(5)(ii)	Results of COMS performance evaluation.	No	Subpart WWWW of Part 63 does not contain opacity standards.
§ 63.8(f)(1) through (3)	Use of an alternative monitoring method	Yes.	
§ 63.8(f)(4)	Request to use an alternative monitoring method.	Yes.	
§ 63.8(f)(5)	Approval of request to use an alternative monitoring method.	Yes.	
§ 63.8(f)(6)	Request for alternative to relative accuracy test and associated records.	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.8(g)(1) through (5)	Data reduction	Yes.	
§ 63.9(a)(1) through (4)	Notification requirements and general information.	Yes.	
§ 63.9(b)(1)	Initial notification applicability	Yes.	
§ 63.9(b)(2)	Notification for affected source with initial startup before effective date of standard.	Yes.	
§ 63.9(b)(3)	Notification that subject to the rule for new or reconstructed affected source with initial startup after effective date and for which an application for approval of construction or reconstruction is not required.	Yes.	

TABLE 15 TO SUBPART WWWW OF PART 63.—APPLICABILITY OF GENERAL PROVISIONS (SUBPART A) TO SUBPART WWWW OF PART 63—Continued

The general provisions reference . . .	That addresses . . .	And applies to subpart WWWW of Part 63 . . .	Subject to the following additional information . . .
§ 63.9(b)(4)(i) through (iii)	Notification for a new or reconstructed major affected source with initial start-up after effective date for which an application for approval of construction or reconstruction is required.	Yes.	
§ 63.9(b)(4)(iv)	Reserved	No.	
§ 63.9(b)(4)(v)	Notification for a new or reconstructed major affected source with initial start-up after effective date for which an application for approval of construction or reconstruction is required.	Yes	Existing facilities do not become reconstructed under subpart WWWW of Part 63.
§ 63.9(b)(5)	After effective date of standard, notification of intended construction or reconstruction.	Yes.	Existing facilities do not become reconstructed under subpart WWWW of Part 63.
§ 63.9(c)	Request for compliance extension	Yes.	
§ 63.9(d)	Notification of special compliance requirements for new source.	Yes.	
§ 63.9(e)	Notification of performance test	Yes.	
§ 63.9(f)	Notification of opacity and visible emissions observations.	No	Subpart WWWW of Part 63 does not contain opacity or visible emission standards.
§ 63.9(g)(1)	Additional notification requirements for sources using CMS.	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.9(g)(2)	Notification of compliance with opacity emission standard.	No	Subpart WWWW of Part 63 does not contain opacity emission standards.
§ 63.9(g)(3)	Notification that criterion to continue use of alternative to relative accuracy testing has been exceeded.	Yes	This section applies if you elect use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.9(h)(1) through (3)	Notification of compliance status	Yes.	
§ 63.9(h)(4)	Reserved	No.	
§ 63.9(h)(5) through (6)	Notification of compliance status	Yes.	
§ 63.9(i)	Adjustment of submittal deadlines	Yes.	
§ 63.9(j)	Change in information provided	Yes.	
§ 63.10(a)(1) through (7)	Applicability of recordkeeping and reporting.	Yes.	
§ 63.10(b)(1)	Records retention	Yes.	
§ 63.10(b)(2)(i) through (v)	Records related to startup, shutdown, and malfunction.	Yes	Only applies to facilities that use an add-on control device.
§ 63.10(b)(2)(vi) through (xi)	CMS records	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.10(b)(2)(xii)	Record of waiver of recordkeeping and reporting.	Yes.	
§ 63.10(b)(2)(xiii)	Record for alternative to the relative accuracy test.	Yes.	
§ 63.10(b)(2)(xiv)	Records supporting initial notification and notification of compliance status.	Yes.	
§ 63.10(b)(3)	Records for applicability determinations	Yes.	
§ 63.10(c)(1)	CMS records	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.10(c)(2) through (4)	Reserved	No.	
§ 63.10(c)(5) through (8)	CMS records	Yes	This section applies if you elect to use a CMS to demonstrate continuous compliance with an emission limit.
§ 63.10(c)(9)	Reserved	No.	
§ 63.10(d)(1)	General reporting requirements	Yes.	
§ 63.10(d)(2)	Report of performance test results	Yes.	
§ 63.10(d)(3)	Reporting results of opacity or visible emission observations.	No	Subpart WWWW of Part 63 does not contain opacity or visible emission standards.
§ 63.10(d)(4)	Progress reports as part of extension of compliance.	Yes.	
§ 63.10(d)(5)	Startup, shutdown, and malfunction reports.	Yes	Only applies if you use an add-on control device.
§ 63.10(e)(1) through (3)	Additional reporting requirements for CMS.	Yes	This section applies if you have an add-on control device and elect to use a CEM to demonstrate continuous compliance with an emission limit.

TABLE 15 TO SUBPART WWWW OF PART 63.—APPLICABILITY OF GENERAL PROVISIONS (SUBPART A) TO SUBPART WWWW OF PART 63—Continued

The general provisions reference . . .	That addresses . . .	And applies to subpart WWWW of Part 63 . . .	Subject to the following additional information . . .
§ 63.10(e)(4)	Reporting COMS data	No	Subpart WWWW of Part 63 does not data contain opacity standards.
§ 63.10(f)	Waiver for recordkeeping or reporting	Yes.	
§ 63.11	Control device requirements	Yes	Only applies if you elect to use a flare as a control device.
§ 63.12	State authority and delegations	Yes.	
§ 63.13	Addresses of State air pollution control agencies and EPA Regional Offices.	Yes.	
§ 63.14	Incorporations by reference	Yes.	
§ 63.15	Availability of information and confidentiality.	Yes.	

[FR Doc. 01–17564 Filed 8–1–01; 8:45 am]

BILLING CODE 6560–50–P

Federal Register

Thursday,
August 2, 2001

Part III

Department of Health and Human Services

Center for Medicare & Medicaid Services

42 CFR Parts 405 et al.

Medicare Programs; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2002; Proposed Rule

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 405, 410, 411, 414, and 415

[CMS–1169–P]

RIN 0938–AK57

Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2002

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Proposed rule.

SUMMARY: This proposed rule would refine the resource-based practice expense relative value units and make several changes to Medicare Part B payment. The policy changes concern services and supplies incident to a physician's professional service; anesthesia base unit variations; recognition of CPT tracking codes; and nurse practitioners, physician assistants, and clinical nurse specialists performing screening sigmoidoscopies. We are proposing these refinements and changes to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services. We are soliciting comments on the proposed policy changes as well as comments on the payment policy for CPT modifier 62 that is used to report the work of co-surgeons.

The Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 modernizes the mammography screening benefit and authorizes payment under the physician fee schedule effective January 1, 2002; provides for biennial screening pelvic examinations for certain beneficiaries effective July 1, 2001; provides for annual glaucoma screenings for high-risk beneficiaries effective January 1, 2002; expands coverage for screening colonoscopies to all beneficiaries effective July 1, 2001; establishes coverage for medical nutrition therapy services for certain beneficiaries effective January 1, 2002; expands payment for telehealth services effective October 1, 2001; requires certain Indian Health Service providers to be paid for some services under the physician fee schedule effective July 1, 2001; and revises the payment for certain physician pathology services effective January 1, 2001. This proposed rule would conform our regulations to reflect the statutory provisions.

DATES: We will consider comments if we receive them at the appropriate address, as provided below, no later than 5 p.m. on October 1, 2001.

ADDRESSES: Mail written comments (1 original and 3 copies) to the following address:

Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–1169–P, P.O. Box 8013, Baltimore, MD 21244–8013.

To insure that mailed comments are received in time for us to consider them, please allow for possible delays in delivering them. If you prefer, you may deliver your written comments (1 original and 3 copies) to one of the following addresses: Room C5–14–03, 7500 Security Boulevard, Baltimore, MD 21244–8013.

Comments mailed to the above addresses may be delayed and received too late for us to consider them.

Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission. In commenting, please refer to file code CMS–1169–P.

For information on viewing public comments, please see the beginning of the Supplementary Information section.

FOR FURTHER INFORMATION CONTACT: Carolyn Mullen, (410) 786–4589 or Marc Hartstein, (410) 786–4539 (for issues related to resource-based practice expense relative value units).

Carlos Cano, (410) 786–0245 (for issues related to screenings for sigmoidoscopies).

Paul W. Kim, (410) 786–7410 (for issues related to incident to services).

Rick Ensor, (410) 786–5617 (for issues related to mammography screenings).

Bill Larson, (410) 786–4639 (for issues related to screening pelvic examinations, screenings for glaucoma, and coverage for screening colonoscopies).

Bob Ulikowski, (410) 786–5721 (for issues related to the payment for screening colonoscopies).

Mary Stojak, (410) 786–6939 (for issues related to medical nutrition therapy).

Joan Mitchell, (410) 786–4508 (for issues related to the payment for medical nutrition therapy).

Craig Dobyski, (410) 786–4584 (for issues related to telehealth).

Terri Harris, (410) 786–6830 (for issues related to Indian Health Service providers).

Jim Menas, (410) 786–4507 (for issues related to anesthesia and pathology services).

Diane Milstead, (410) 786–3355 (for all other issues).

SUPPLEMENTARY INFORMATION:

Inspection of Public Comments: Comments received timely will be available for public inspection as they are received, generally beginning approximately 3 weeks after publication of a document, at 7500 Security Blvd, Baltimore, Maryland 21244, Monday through Friday of each week from 8:30 a.m. to 5 p.m. Please call (410) 786–7197 to make an appointment to view the public comments.

Copies: To order copies of the **Federal Register** containing this document, send your request to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250–7954. Specify the date of the issue requested and enclose a check or money order payable to the Superintendent of Documents, or enclose your Visa or Master Card number and expiration date. Credit card orders can also be placed by calling the order desk at (202) 512–1800 or by faxing to (202) 512–2250. The cost for each copy is $9. As an alternative, you can view and photocopy the **Federal Register** document at most libraries designated as Federal Depository Libraries and at many other public and academic libraries throughout the country that receive the **Federal Register**.

This **Federal Register** document is also available from the **Federal Register** online database through *GPO Access,* a service of the U.S. Government Printing Office. The Website address is: *http://www.access.gpo.gov/nara/index.html.*

Information on the physician fee schedule can be found on our homepage. You can access this data by using the following directions:

1. Go to the CMS homepage (http://www.cms.hhs.gov).
2. Click on ''Medicare.''
3. Click on ''Professional/Technical Information.''
4. Select Medicare Payment Systems.
5. Select Physician Fee Schedule.

Or, you can go directly to the Physician Fee Schedule page by typing the following: http://www.cms.hhs.gov/medicare/pfsmain.htm.

To assist readers in referencing sections contained in this preamble, we are providing the following table of contents. Some of the issues discussed in this preamble affect the payment policies but do not require changes to the regulations in the Code of Federal Regulations. Information on the regulation's impact appears throughout the preamble and is not exclusively in section VI.

Table of Contents

I. Background

A. Legislative History
B. Published Changes to the Fee Schedule
II. Specific Proposals for Calendar Year 2002
A. Resource-Based Practice Expense Relative Value Units
B. Nurse Practitioners, Physician Assistants, and Clinical Nurse Specialists Performing Screening Sigmoidoscopies
C. Services and Supplies Incident to a Physician's Professional Services: Conditions
D. Anesthesia Services
E. Performance Measurement and Emerging Technology Codes
F. Payment Policy for CPT Modifier 62 (Co-Surgery)
III. Implementation of Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000
A. Screening Mammography
B. Screening Pelvic Examinations
C. Screening for Glaucoma
D. Screening Colonoscopy
E. Medical Nutrition Therapy
F. Telehealth Services
G. Indian Health Service
H. Pathology Services
IV. Collection of Information Requirements
V.Response to Comments
VI. Regulatory Impact Analysis
Addendum A—Explanation and Use of Addendum B
Addendum B—2002 Relative Value Units and Related Information Used in Determining Medicare Payments for 2002

In addition, because of the many organizations and terms to which we refer by acronym in this proposed rule, we are listing these acronyms and their corresponding terms in alphabetical order below:

AMA American Medical Association
BBA Balanced Budget Act of 1997
BBRA Balanced Budget Refinement Act of 1999
CF Conversion factor
CFR Code of Federal Regulations
CPT [Physicians'] Current Procedural Terminology [4th Edition, 1997, copyrighted by the American Medical Association]
CPEP Clinical Practice Expert Panel
CRNA Certified Registered Nurse Anesthetist
E/M Evaluation and management
EB Electrical bioimpedance
FMR Fair market rental
GAF Geographic adjustment factor
GPCI Geographic practice cost index
CMS Centers for Medicare & Medicaid Services
HCPCS Healthcare Common Procedure Coding System
HHA Home health agency
HHS [Department of] Health and Human Services
IDTFs Independent Diagnostic Testing Facilities
MCM Medicare Carrier Manual
MedPAC Medicare Payment Advisory Commission
MEI Medicare Economic Index
MGMA Medical Group Management Association
MSA Metropolitan Statistical Area
NAMCS National Ambulatory Medical Care Survey
PC Professional component
PEAC Practice Expense Advisory Committee
PPAC Practicing Physicians Advisory Council
PPS Prospective payment system
RUC [AMA's Specialty Society] Relative [Value] Update Committee
RVU Relative value unit
SGR Sustainable growth rate
SMS [AMA's] Socioeconomic Monitoring System
TC Technical component

I. Background

A. Legislative History

Since January 1, 1992, Medicare has paid for physicians' services under section 1848 of the Social Security Act (the Act), ''Payment for Physicians'' Services.'' This section provides for three major elements: (1) A fee schedule for the payment of physicians' services; (2) a sustainable growth rate for the rates of increase in Medicare expenditures for physicians' services; and (3) limits on the amounts that nonparticipating physicians can charge beneficiaries. The Act requires that payments under the fee schedule be based on national uniform relative value units (RVUs) based on the resources used in furnishing a service. Section 1848(c) of the Act requires that national RVUs be established for physician work, practice expense, and malpractice expense. Section 1848(c)(2)(B)(ii)(II) of the Act provides that adjustments in RVUs may not cause total physician fee schedule payments to differ by more than $20 million from what they would have been had the adjustments not been made. If adjustments to RVUs cause expenditures to change by more than $20 million, we must make adjustments to preserve budget neutrality.

B. Published Changes to the Fee Schedule

In the July 2000 proposed rule (65 FR 44177), we listed all of the final rules published through November 1999, relating to the updates to the RVUs and revisions to payment policies under the physician fee schedule.

In the November 2000 final rule with comment period (65 FR 65376), we revised the policy for resource-based practice expense relative value units (RVUs); the geographic practice cost indices; resource-based malpractice RVUs; critical care RVUs; care plan oversight, physician certification and recertification for home health services; observation care codes; ocular photodynamic therapy and other ophthalmologic treatments; electrical bioimpedance; antigen supply, and the implantation of ventricular assist devices. This rule also addressed the comments received on the May 3, 2000 interim final rule (65 FR 25664) on the supplemental survey criteria and made modifications to the criteria for data submitted in 2001. Based on public comments, we withdrew our proposals related to the global period for insertion, removal, and replacement of pacemakers and cardioverter defibrillators, and to the removal of RVUs for low intensity ultrasound. The November 2000 final rule also discussed or clarified the payment policy for incomplete medical direction, pulse oximetry services, outpatient therapy supervision, outpatient therapy caps, HCPCS ''G'' Codes, and the second 5-year refinement of work RVUs for services furnished beginning January 1, 2002. In addition, we finalized the calendar year (CY) 2000 interim physician work RVUs and issued interim RVUs for new and revised codes for CY 2001. We made these changes to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services. This final rule also announced the CY 2001 Medicare physician fee schedule conversion factor under the Medicare Supplementary Medical Insurance (Part B) program as required by section 1848(d) of the Act. The 2001 Medicare physician fee schedule conversion factor was $38.2581.

II. Specific Proposals for Calendar Year 2002

This proposed rule would affect the regulations set forth at Part 405, Federal health insurance for the aged and disabled, Part 410, Supplementary medical insurance (SMI) benefits; Part 411, Exclusions from Medicare and limitations on Medicare payment; Part 414, Payment for Part B medical and other health services; and Part 415, Services furnished by physicians in providers, supervising physicians in teaching settings, and residents in certain settings.

A. Resource-Based Practice Expense Relative Value Units

1. Resource-Based Practice Expense Legislation

Section 121 of the Social Security Act Amendments of 1994 (Public Law 103–432), enacted on October 31, 1994, required us to develop a methodology for a resource-based system for determining practice expense RVUs for each physician's service beginning in

1998. In developing the methodology, we were to consider the staff, equipment, and supplies used in providing medical and surgical services in various settings. The legislation specifically required that, in implementing the new system of practice expense RVUs, we apply the same budget-neutrality provisions that we apply to other adjustments under the physician fee schedule.

Section 4505(a) of the BBA amended section 1848(c)(2)(ii) of the Act and delayed the effective date of the resource-based practice expense RVU system until January 1, 1999. In addition, section 4505(b) of the BBA provided for a 4-year transition period from charge-based practice expense RVUs to resource-based RVUs. The practice expense RVUs for CY 1999 were the product of 75 percent of charge-based RVUs and 25 percent of the resource-based RVUs. For CY 2000, the RVUs were 50 percent charge-based RVUs and 50 percent resource-based RVUs. For CY 2001, the RVUs are 25 percent charge-based and 75 percent resource-based. After CY 2001, the RVUs will be totally resource-based.

Section 4505(e) of the BBA amended section 1848(c)(2) of the Act by providing that 1998 practice expense RVUs be adjusted for certain services in anticipation of implementation of resource-based practice expenses beginning in 1999. As a result, the statute required us to increase practice expense RVUs for office visits. For other services in which practice expense RVUs exceeded 110 percent of the work RVUs and were furnished less than 75 percent of the time in an office setting, the statute required us to reduce the 1998 practice expense RVUs to a number equal to 110 percent of the work RVUs. This reduction did not apply to services that had proposed resource-based practice expense RVUs that increased from their 1997 practice expense RVUs as reflected in the June 18, 1997 proposed rule (62 FR 33196). The services affected and the final RVUs for 1998 were published in the October 1997 final rule (62 FR 59103).

Further legislation affecting resource-based practice expense RVUs was included in the Balanced Budget Refinement Act of 1999 (BBRA) (Public Law 106–113). Section 212 of the BBRA amended section 1848(c)(2)(ii) of the Act by directing us to establish a process under which we accept and use, to the maximum extent practicable and consistent with sound data practices, data collected or developed by entities and organizations. These data would supplement the data we normally collect in determining the practice expense component of the physician fee schedule for payments in CY 2001 and CY 2002.

2. Current Methodology for Computing the Practice Expense Relative Value Unit System

Effective with services furnished on or after January 1, 1999, we established a new methodology for computing resource-based practice expense RVUs that used the two significant sources of actual practice expense data we have available—the Clinical Practice Expert Panel (CPEP) data and the American Medical Association's (AMA) Socioeconomic Monitoring System (SMS) data. The methodology was based on an assumption that current aggregate specialty practice costs are a reasonable way to establish initial estimates of relative resource costs for physicians' services across specialties. The methodology allocated these aggregate specialty practice costs to specific procedures and, thus, can be seen as a ''top-down'' approach. Discussion of the various elements of the methodology and their application follow.

a. Practice Expense Cost Pools. We used actual practice expense data by specialty, derived from the 1995 through 1998 SMS survey data, to create six cost pools—administrative labor, clinical labor, medical supplies, medical equipment, office supplies, and all other expenses. There were three steps in the creation of the cost pools. (Please note that use of the 1998 data was incorporated for CY 2001.)

- Step (1) We used the AMA's SMS survey of actual cost data to determine practice expenses per hour by cost category. The practice expenses per hour for each physician respondent's practice was calculated as the practice expenses for the practice divided by the total number of hours spent in patient care activities. The practice expenses per hour for the specialty were an average of the practice expenses per hour for the respondent physicians in that specialty. For the CY 2000 physician fee schedule, we also used data from a survey submitted by the Society of Thoracic Surgeons (STS) in calculating thoracic and cardiac surgeons' practice expense per hour. (Please see the November 1999 final rule (64 FR 59391) for additional information concerning acceptance of these data.) For CY 2001 we used these STS data, as well as survey data submitted by the American Society of Vascular Surgery and the Society of Vascular Surgery. (Please see the November 2000 final rule (65 FR 65385) for additional information on acceptance of these data.)
- Step (2) We determined the total number of physician hours (by specialty) spent treating Medicare patients. This was calculated from physician time data for each procedure code and from Medicare claims data.
- Step (3) We calculated the practice expense pools by specialty and by cost category by multiplying the specialty practice expenses per hour for each category by the total physician hours.

For services with work RVUs equal to zero (including the technical component (TC) of services with a TC and professional component (PC)), we created a separate practice expense pool using the average clinical staff time from the CPEP data (since these codes by definition do not have physician time) and the ''all physicians'' practice expense per hour.

b. Cost Allocation Methodology. For each specialty, we divided the six practice expense pools into two groups, based on whether direct or indirect costs were involved, and used a different allocation basis for each group. The first group included clinical labor, medical supplies, and medical equipment. The second group included administrative labor, office expenses, and all other expenses.

(i) Direct Costs. For direct costs (including clinical labor, medical supplies, and medical equipment), we used the CPEP data as the allocation basis. The CPEP data for clinical labor, medical supplies, and medical equipment were used to allocate the costs for each of the respective cost pools.

For the separate practice expense pool for services with work RVUs equal to zero, we used adjusted 1998 practice expense RVUs as an interim measure to allocate the direct cost pools. (Please see the November 1998 final rule (63 FR 58891) for further information related to this adjustment.) Also, for all radiology services that are assigned work RVUs, we used the adjusted 1998 practice expense RVUs for radiology services as an interim measure to allocate the direct practice expense cost pool for radiology. For all other specialties that perform radiology services, we used the CPEP data for radiology services in the allocation of that specialty's direct practice expense cost pools.

(ii) Indirect Costs. To allocate the cost pools for indirect costs, including administrative labor, office expenses, and all other expenses, we used the total direct costs, as described above, in combination with the physician fee schedule work RVUs. We converted the work RVUs to dollars using the Medicare CF (expressed in 1995 dollars

for consistency with the SMS survey years).

The SMS pool was divided by the CPEP pool for each specialty to produce a scaling factor that was applied to the CPEP direct cost inputs. This was intended to match costs counted as practice expenses in the SMS survey with items counted as practice expenses in the CPEP process. When the specialty-specific scaling factor exceeded the average scaling factor by more than 3 standard deviations, we used the average scaling factor. (Please see the November 1999 final rule (64 FR 59390) for further discussion of this issue.)

For procedures performed by more than one specialty, the final procedure code allocation was a weighted average of allocations for the specialties that perform the procedure, with the weights being the frequency with which each specialty performs the procedure on Medicare patients.

c. Other Methodological Issues. (i) Global Practice Expense Relative Value Units. For services with the PC and TC paid under the physician fee schedule, the global practice expense RVUs were set equal to the sum of the PC and TC.

(ii) Practice Expenses per Hour Adjustments and Specialty Crosswalks. Since many specialties identified in our claims data did not correspond exactly to the specialties included in the practice expense tables from the SMS survey data, it was necessary to crosswalk these specialties to the most appropriate SMS specialty category. We also made the following adjustments to the practice expense per hour data. (For the rationale for these adjustments to the practice expense per hour, see the November 1998 final rule (63 FR 58841).)

- We set the medical materials and supplies practice expenses per hour for the specialty of ''oncology'' equal to the ''all physician'' medical materials and supplies practice expenses per hour.
- We based the administrative payroll, office, and other practice expenses per hour for the specialties of ''physical therapy'' and ''occupational therapy'' on data used to develop the salary equivalency guidelines for these specialties. We set the remaining practice expense per hour categories equal to the ''all physician'' practice expenses per hour from the SMS survey data. (Note that in the November 2000 final rule (65 FR 65403), we increased the space allotment for therapy services to 750 square feet.)
- Due to uncertainty concerning the appropriate crosswalk and time data for the nonphysician specialty ''audiologist,'' we derived the resource-based practice expense RVUs for codes performed by audiologists from the practice expenses per hour of the other specialties that perform these services.
- For the specialty of ''emergency medicine,'' we used the ''all physician'' practice expense per hour to create practice expense cost pools for the categories ''clerical payroll'' and ''other expenses.''
- For the specialty of ''podiatry,'' we used the ''all physician'' practice expense per hour to create the practice expense pool.
- For the specialty of ''pathology,'' we removed the supervision and autopsy hours reimbursed through Part A of the Medicare program from the practice expense per hour calculation.
- For the specialty ''maxillofacial prosthetics,'' we used the ''all physician'' practice expense per hour to create practice expense cost pools and, as an interim measure, allocated these pools using the adjusted 1998 practice expense RVUs.
- We split the practice expenses per hour for the specialty ''radiology'' into ''radiation oncology'' and ''radiology other than radiation oncology'' and used this split practice expense per hour to create practice expense cost pools for these specialties.

(iii) Time Associated with the Work RVUs. The time data resulting from the refinement of the work RVUs have been, on average, 25 percent greater than the time data obtained by the Harvard study for the same services. We increased the Harvard study's time data to ensure consistency between these data sources.

For services with no assigned physician time, such as dialysis, physical therapy, psychology, and many radiology and other diagnostic services, we calculated estimated total physician time based on work RVUs, maximum clinical staff time for each service as shown in the CPEP data, or the judgment of our clinical staff.

We calculated the time for CPT codes (hereafter referred to as ''codes'') 00100 through 01996 using the base and time units from the anesthesia fee schedule and the Medicare allowed claims data.

3. Refinement

a. Background. Section 4505(d)(1)(C) of the BBA amended section 1848(c)(2)(C)(ii) of the Act by directing us to develop a refinement process to be used during each of the 4 years of the transition period. We did not propose a specific long-term refinement process in the June 1998 proposed rule (63 FR 30835). Rather, we set out the parameters for an acceptable refinement process for practice expense RVUs and solicited comments on our proposal. We received a variety of comments about broad methodology issues, practice expense per-hour data, and detailed code-level data. We made adjustments to our proposal based on comments we received. We also indicated that we would consider other comments for possible refinement and that the RVUs for all codes would be considered interim for 1999 and for future years during the transition period.

We outlined in the November 1998 final rule (63 FR 58832) the steps we were undertaking as part of the initial refinement process. These steps included the following:

- Establishment of a mechanism to receive independent advice for dealing with broad practice expense RVU technical and methodological issues.
- Evaluation of any additional recommendations from the General Accounting Office, the Medicare Payment Advisory Commission (MedPAC), and the Practicing Physicians Advisory Council (PPAC).
- Consultation with physician and other groups about these issues.

We also discussed a proposal submitted by the AMA's Specialty Society Relative Value Update Committee (RUC) for development of a new advisory committee, the Practice Expense Advisory Committee (PEAC), to review comments and recommendations on the code-specific CPEP data during the refinement period. In addition, we solicited comments and suggestions about our practice expense methodology from organizations that have a broad range of interests and expertise in practice expense and survey issues.

b. Current Status of Refinement Activities. In the 1999 and 2000 proposed and final rules, we provided further information on refinement activities underway, including the AMA's formation of the PEAC and the support contract that we awarded to the Lewin Group to focus on methodologic issues. In addition, in these rules we announced actions taken and decisions made in response to the hundreds of comments received on our resource-based physician practice expense initiative. Because the transition will be completed in CY 2002 and the practice expense RVUs will then be totally resource-based, it is appropriate to recap the specific achievements reached and decisions implemented during this refinement effort to date.

(i) Use of the Top-Down Approach. Most of the physician organizations commenting agreed that this methodology was preferred for computing resource-based practice expense RVUs and that it was in accordance with the requirements of the

BBA. KPMG Peat Marwick, under contract to us, reviewed the top-down methodology in which aggregate specialty costs are applied to specific procedures and concluded that it followed reasonable cost accounting principles. A 1999 GAO report concludes, ''HCFA's new approach represents a reasonable starting point for creating resource-based practice expense RVUs. It uses the best available data for this purpose and explicitly recognizes specialty differences in practice expense.'' Based on these comments and assessments, we made the decision to continue to use the top-down methodology to calculate the resource-based practice expense RVUs.

(ii) Use of the SMS Survey. The supplemental non-SMS survey data submitted by several specialties in response to the 1998 proposed rule, with the exception of the survey data from the thoracic surgeons, were not compatible with the format or methodology of the SMS. We awarded a contract to the Lewin Group to recommend criteria for the acceptance of specialty-specific practice expense data so that we could supplement the SMS data as appropriate. These recommended criteria are contained in the final report, ''An Evaluation of the Health Care Financing Administration's Resource-Based Practice Expense Methodology.'' This report is available on our web page under the same title. (Access to our web site is discussed under the **SUPPLEMENTARY INFORMATION** section above.)

The report also contains recommendations for revisions to the SMS or other surveys to efficiently meet the needs of our practice expense methodology. We augmented these recommendations and forwarded our suggestions for revisions to any future surveys to the AMA. For example, we developed supplementary survey questions that would allow us to distinguish both costs and direct patient care hours for all midlevel practitioners. We also suggested revisions that would capture the necessary information on separately billable supplies and services so that we could eliminate these costs from the specialty-specific practice expense per-hour calculations.

To obtain supplementary specialty-specific practice expense data that could be used in computing practice expense RVUs beginning January 1, 2001, we published an interim final rule on May 3, 2000 (65 FR 25664) that set forth the criteria applicable to supplemental survey data submitted to us by August 1, 2000.

We also provided a 60-day period for submission of public comments on our criteria for survey data submitted between August 2, 2000 and August 1, 2001 for use in computing the practice expense RVUs for the CY 2002 physician fee schedule.

In the November 1, 2000 final rule (65 FR 65385), we responded to comments received on the interim final rule and made modifications to the criteria for supplemental survey data that will be considered in computing practice expense RVUs for the CY 2002 physician fee schedule. These data can then be used to supplement the SMS survey data currently used to estimate each specialty's aggregate practice costs or to replace the crosswalks used for specialties not represented in the SMS.

In our November 1999 final rule, we accepted supplementary data submitted by the thoracic surgeons and, in our November 2000 rule, we accepted survey data from the vascular surgeons that replaced the previously crosswalked practice expense per hour data for that specialty. If we receive additional specialty-specific survey data before August 1, 2001 that meets the criteria outlined in the November 1, 2000 final rule, we will use this supplementary data in calculating the CY 2002 practice expense RVUs.

We accepted our contractor's recommendation to incorporate the latest SMS data into our practice-expense-per-hour calculations. For CY 2001, we incorporated the 1998 SMS data into a 4-year average and are proposing to incorporate the 1999 SMS data into a 5-year average to calculate the CY 2002 practice expense RVUs.

We also accepted the contractor's recommendation to standardize the survey practice expense data to a common year. We adjusted the data to reflect a 1995 cost year.

We received comments that urged us to use the median SMS specialty-specific data instead of the mean, as well as comments supporting our use of the mean values. We made a decision to continue to use the mean in calculating the specialty-specific practice expense per hour. We believe that, in a small sample, using the median could eliminate outlying data from the calculation that represent real costs and thus should be considered.

(iii) CPEP Data. The AMA has formed a multispecialty sub-committee of their Relative Value Update Committee (RUC), the Practice Expense Advisory Committee (PEAC), to review the CPEP clinical staff, equipment, and supply data for all physician services. This multispecialty committee, which includes representatives from all major specialty societies, would then make recommendations on suggested refinements to this data. We indicated in our November 1998 final rule (63 FR 58833) that we would work with the PEAC and RUC to refine the practice expense direct cost inputs. This refinement process was supported in comments we received from almost every major physician specialty society.

In our 1999 physician fee schedule final rule, we implemented most CPEP refinements recommended by the RUC. For the 2000 final rule, the RUC forwarded to us significant additional refinement recommendations that reflected multispecialty agreement on the typical resources for many important services, including visit codes, that account for approximately 24 percent of Medicare spending for physician services. Again we received and accepted almost all of these RUC recommendations. In addition, at its October 2000, February 2001, and April 2001 meetings, the PEAC focused on high-volume services and on standardizing inputs across wide ranges of services. We, therefore, anticipate that the pace of refinement of the CPEP inputs will continue to accelerate.

In addition to implementing most of the RUC-recommended refinements, we responded to comments on errors and anomalies in the CPEP data in both the November 1999 and November 2000 final rules. For example, we removed separately billable casting supplies and drugs from all services, we adjusted the prices of certain supplies that were clearly in error, we removed duplicated equipment from the direct inputs of the nuclear medicine codes, we added clearly essential equipment that was missing from the lithotripsy and photochemotherapy codes, we corrected anomalies in inputs within several families of codes, and we changed the crosswalks for the CPEP inputs of several codes not valued by the CPEP panels when a commenter suggested more appropriate crosswalks.

We simplified the refinement of equipment inputs by combining both the procedure-specific and overhead equipment into a single equipment category. We also deleted stand-by equipment and equipment used for multiple services at one time from the direct cost inputs because of the difficulty of allocating these costs at the code-specific level.

We are resolving issues related to averaging input costs for codes that were valued by more than one CPEP panel. While we have received comments agreeing and disagreeing with our use of mean costs, the issue is moot because we are substituting refined data for the data previously produced by multiple CPEPs.

(iv) Physician Time Data. In the November 1999 rule (64 FR 59404), we stated that, in general, requests for revisions for the procedure-specific physician times should be deferred to either the RUC process or the 5-year review process. However, we did adopt the newer data to correct the physician time for the pediatric surgery codes and made the requested revisions to correct anomalies in the times of certain psychotherapy codes.

In response to comments on the times associated with physical and occupational therapy services, we added preservice and postservice times to all of these codes.

(v) Crosswalk Issues. In response to concerns expressed by specialty societies representing emergency medicine that the SMS data did not capture the costs of uncompensated care, we crosswalked emergency medicine's administrative labor and other expenses cost pools to the practice expense per hour for ''all physicians.''

We resolved issues related to the specialty crosswalk for nursing specialties by eliminating the separate practice expense pools for midlevel practitioners.

(vi) Calculation of Practice Expense Pools—Other Issues. We addressed concerns that potential errors in our specialty utilization data will have an effect on the calculation of practice expense RVUs. In the July 2000 proposed rule (65 FR 44178), we discussed our simulations that demonstrated that the small percentage of potential errors in our very large database have no adverse effect on specialty-specific practice expense RVUs.

We have created the zero-work pool for services with no physician work to ensure that these services are not inappropriately disadvantaged by our methodology. We have also agreed with the request of all the specialty societies that commented that their services should be moved out of the zero-work pool and into the specialty-specific pool. The specialties whose services remain in the zero-work pool have indicated that they wish their services to remain there. We plan to eliminate this separate pool for services with no physician work only when we have determined what revisions to our methodology are required so that we can value these services appropriately outside of the zero-work pool.

(vii) Calculation of Indirect Cost. We requested that our contractor evaluate various options for calculating indirect costs. The final report, referenced above, contains an analysis of the impacts of six alternative allocation methodologies. In confirming the suitability of our allocation methodology, the report concludes that ''HCFA's approach is broadly consistent with most of the alternative methods. This consistency suggests that, from a broad perspective, no other allocation methodology offers a compelling reason to abandon the current HCFA approach.''

(viii) Site-of-Service. The practice expense RVUs would be expected to be higher in the non-facility setting, where the practitioner bears the costs of the necessary staff, supplies, and equipment, than in the facility setting. To prevent potential anomalies in our calculations due to the different mix of specialties performing a given service in different settings, we capped the facility practice expense RVUs at the non-facility level for each specific service.

In the November 1999 final rule (64 FR 59407), in response to a comment from the Renal Physicians Association, we agreed that the monthly capitated service codes should always be reported using the non-facility designation. The site of service designations are not meaningful for a monthly service that may be provided in different settings for the same patient during a given month.

Although we need to do additional work to complete the refinement of all practice expense RVUs, we believe that the above description of our actions to date shows that much has been accomplished. We also believe that it demonstrates that we have been responsive to comments from the medical community and have established a process that enables this community to participate fully in the refinement of both the specialty-specific practice expense per hour and the CPEP code-specific inputs.

Practice Expense Proposals for Calendar Year 2002

(1) Use of 1999 SMS Survey Data

We are currently using data from the 1995 through the 1998 SMS surveys (1994 through 1997 practice expense data) in order to calculate the specialty-specific practice expense per hour. The 1999 SMS survey data is now available. Because we want to incorporate the most recent survey data into our methodology during the transition period, we are proposing to add this 1999 data to the 4 years of data we are currently using.

We are proposing to use these 5 years of data in addition to any supplemental specialty-specific data that meet our criteria as the basis of the practice expense per hour calculations until the first 5-year review of practice expense RVUs in 2007. At that time, we anticipate that newer practice expense survey data might be available.

The proposed specialty-specific practice-expense per hour calculations are shown in Table 1. The specialty level impact of using the additional SMS data is shown in Table 5 of the regulatory impact statement. As indicated, Table 5 shows the impact of this change only relative to the current estimated fully-implemented practice expense RVUs.

TABLE 1.—SPECIALTY-SPECIFIC PRACTICE EXPENSE PER HOUR CALCULATIONS

Specialty	Clinical payroll per hour	Clerical payroll per hour	Office expense per hour	Supplies expense per hour	Equipment expense per hour	Other expense per hour	Total expense per hour
ALL PHYSICIANS	12.3	15.4	19.4	7.4	3.2	11.5	69
GENERAL/FAMILY PRACTICE	14.8	14.9	17.7	7.9	3.1	8.8	67.1
GENERAL INTERNAL MEDICINE	9.4	14.4	17.9	6.1	2.1	6.6	56.5
CARDIOVASCULAR DISEASE	15.8	15.2	20.7	6.2	5.9	17.8	81.6
GASTROENTEROLOGY	8.9	17	18	3.6	2.1	12.3	61.8
ALLERGY/IMMUNOLOGY	36.3	25.3	31.4	16	2	15.8	128.8
PULMONARY DISEASE	6.9	12.4	15.7	2.6	1.6	6.9	46.1
ONCOLOGY (with supplies adjustment)	27.4	24.1	26.5	7.4	4.6	9.3	99.3
GENERAL SURGERY	7.2	15.6	16.8	3.4	2	9.9	54.9
OTOLARYNGOLOGY	17.2	25.2	32.9	7.5	5.6	17.2	105.7
ORTHOPEDIC SURGERY	16.6	28.5	29.7	10.3	3.8	19.1	108
OPHTHALMOLOGY	25.1	25.8	34.1	10.8	8.4	21.1	125.3
UROLOGICAL SURGERY	12.4	18.5	23.2	25.5	5.3	11.3	96.2
PLASTIC SURGERY	15	20.3	32.4	18.5	5.7	25.2	117.2
NEUROLOGICAL SURGERY	8.6	25.6	28.6	1.8	1.4	16.1	82.2
CARDIAC/THORACIC SURGERY	18.1	16.8	16.8	1.8	2.2	13.1	68.8

TABLE 1.—SPECIALTY-SPECIFIC PRACTICE EXPENSE PER HOUR CALCULATIONS—Continued

Specialty	Clinical payroll per hour	Clerical payroll per hour	Office expense per hour	Supplies expense per hour	Equipment expense per hour	Other expense per hour	Total expense per hour
PEDIATRICS	12.4	12.9	18.9	10.2	1.7	8.6	64.8
OBSTETRICS/GYNECOLOGY	16.4	18.8	24.7	7.3	3.2	11.2	81.7
RADIATION ONCOLOGY	14	9.2	12.1	5.4	9.7	16.4	66.8
RADIOLOGY	9.3	10.8	14.8	4.8	7.4	20.9	68
PSYCHIATRY	1.7	5.1	10.5	0.4	0.4	7.2	25.3
ANESTHESIOLOGY	11.3	3.7	5.9	0.4	0.4	5.9	27.6
PATHOLOGY (adjusted to remove Part A Hrs)	11.2	14	11.9	6.8	2	21	66.9
DERMATOLOGY	22.5	28.4	33.4	12.6	5.4	17.2	119.4
EMERGENCY MEDICINE (adjusted for admin/other)	3.3	15.4	2	0.7	0.1	11.5	33
NEUROLOGY	8.3	23	19.5	5.2	4.4	9.3	69.7
PHYS MED/RHEUMATOLOGY	14.9	23.7	30.7	6.5	6.2	12.2	94.2
OTHER SPECIALTY	9.3	13	19.3	4.9	1.9	8.8	57.3
VASCULAR SURGERY (supplemental data)	20.2	18.1	17.7	3.2	4.5	11.4	75.1
PHYSICAL AND OCCUPATIONAL THERAPY (see	12.3	5.9	7.5	7.4	3.2	4.4	40.7

*Total expenses exclude professional liability insurance premiums and employee physician payroll.

Notes:

—Only self-employed non-federal non-resident patient care physicians who responded to all relevant expense questions are included. Self-employed physician respondents with no practice expenses for the year are excluded.

—Physicians whose typical number of hours worked in patient care activities per week is missing, less than 20, or equal to 168 are excluded. Physicians whose number of weeks worked the previous year is missing or less than 26 are excluded.

—For each respondent, total practice expense and expense components per hour are calculated as (4)/(5) below.

—Expenses adjusted for practice size = self-employed respondent expenses X # physician owners

—Hours adjusted for practice size =(respondent hours * # physician owners) + (employee physician hours (see (6) below) * # employee physicians)

—The typical number of hours worked in patient care activities for the employee physician(s) of a self-employed physician's practice is not known.

Mean hours worked in patient care activities for employee physicians of each specialty are used as an estimate of employee physician hours.

—As described earlier in this proposed rule, the practice expense per hour shown above reflect:

—the ''All Physician'' supplies expense per hour for Oncology

—use of supplemental SMS practice expense data for Cardiac and Thoracic Surgery in addition to regular SMS data collection.

—removal of hours spent in Part A activities for Pathology.

—Using the ''All Physician'' administration and other practice expense data for Emergency Medicine.

—Vascular Surgery data is based on supplemental survey not the SMS.

—Physical and occupational therapy data is based on ''All Physician'' for clinical, staff, supplies and equipment.

It is based on salary equivalency guidelines assuming 750 square feet of office space for clerical, office and other.

Supplemental Practice Expense Survey Data

To ensure the maximum opportunity for specialties to submit supplementary practice expense data, we are proposing to accept survey data that meets the criteria set forth in the November 2000 final rule for an additional 2 years. The deadlines for submission of such supplemental data to be considered in CY 2003 and CY 2004 are August 1, 2002 and August 1, 2003, respectively.

Repricing of CPEP Inputs

The cost of the original CPEP inputs for staff, supplies, and equipment were assigned by our contractor, Abt Associates, based primarily on 1994 and 1995 pricing data. In addition, for many items on the equipment and supply list, the associated costs were based on the recommendation of a CPEP panel member, rather than on actual catalog prices. Several equipment and supply items and clinical staff types also have been added subsequent to the CPEP panels. In general, the costs of these inputs have been provided by the relevant specialty society, with and without documentation of the costs.

We are proposing to revise the salary and cost estimates by using the most current pricing data available. We contracted with a consultant to help us in this endeavor and the contractor also solicited advice and information from the major medical specialty societies. We appreciate the time and effort given to this project by the staff of many of the specialty societies. We have at this time completed our proposals for the update of clinical staff salary data and discuss these proposals below. However, we have not yet completed the pricing update for all of the hundreds of supplies and pieces of equipment that are in our CPEP database. We have had difficulty in identifying some of these inputs because many of the original descriptions are too general to price (for example, ''laser'' or ''antibody'') or because the item cannot be found in any supplier's catalog. In addition, several of the pieces of equipment are now obsolete and we need input regarding the appropriate equipment to price. Therefore, we need to work closely with the specialty societies in the coming months so that we can propose accurate prices for all the supply and equipment inputs in next year's proposed rule.

Staff Types and Wages

For the original CPEP wage data, Abt Associates used three primary external data sets: The Bureau of Labor Statistics' (BLS) Occupation Compensation Survey, 1993; The University of Texas Medical Branch (UTMB) Survey of Hospital and Medical School Salaries, 1994; and the Current Population Survey, 1993. Abt's report on the CPEP cost estimation stated that, ''* * * the BLS data were considered to be the preferred data set. The BLS' reputation for publishing valid estimates that are nationally representative led to the choice of the BLS data as the main source. If more than one data set provided an exact mapping for a receptionist, then the BLS wage was chosen over any other mapping.''

We agreed with this assessment and directed our current contractor to use the most current BLS survey (1999) as the main source of wage data. The two other data sets used by Abt were not useful in this pricing update. The UTMB survey has apparently not been repeated and the Current Population Survey was used mainly for administrative staff types that are no longer treated as a direct cost.

It should also be noted that the BLS discontinued the Occupational Compensation Survey used in 1995 and now conducts the National Compensation Survey that has a different breakdown of staff types than the earlier survey. This survey also does not cover all the staff types contained in the CPEP data. Therefore, it has been necessary for us to crosswalk or extrapolate the wages for several staff types using supplementary data sources for verification whenever possible.

We used three other data sources to price wages of staff types that were not referenced in the BLS data—the American Society of Clinical

Pathologists' survey of laboratory staff salaries (found at *www.ascp.org*); the survey done by the American Academy of Health Physics and the American Board of Health Physics (found at *www.hps1.org*); and national salary data from the *Salary Expert,* an Internet site that develops national and local salary ranges and averages for thousands of job titles using mainly government sources. (A detailed explanation of the methodology used to determine the specific job salaries can be found at *www.salaryexpert.com.*)

We welcome comments and input on both our proposed wage rates and our proposed crosswalks. We are particularly seeking any additional sources of reliable national pricing for the wages of staff types not included in the BLS. Anecdotal information regarding individual pay scales will not be particularly helpful for setting national rates, though such information could help with verification of other data. For those staff types that are included in the BLS, we would require data that is equally representative and valid in order to consider revising our proposed salaries.

The table below lists the clinical staff types whose input has been priced, the source for the data, the staff type crosswalk used, the proposed annual salary in 2001 dollars (using the Medicare Economic Index to convert 1999 salaries to 2001 dollars), the proposed cost per minute (including benefits) and the current cost per minute (including benefits) for comparison purposes. The proposed cost per minute was derived by dividing the annual salary by 2080 to arrive at the hourly wage rate and then again by 60 to arrive at the per minute cost. To account for the employers' cost of providing fringe benefits, such as sick leave, we used the same benefits multiplier of 1.366 used by Abt. The last column in the table refers to the numbered notes following the table that contain proposals regarding the pricing of the staff types and additional information as needed.

TABLE 2.—PROPOSED WAGE RATES FOR CPEP CLINICAL STAFF TYPES

Description	Source	Crosswalk	Mean yrly 2001	Proposed per minute	Current per minute	Note #
Physical Therapy Aide	BLS	Physical Therapist Aides	21,077.36	0.226	0.232	
Medical Assistant	BLS	Medical Assistants	23,680.67	0.254	0.162	1
Technical Aide	BLS	Medical Assistants	23,680.67	0.254	0.225	1
Medical Technician	BLS	Medical Assistants	23,680.67	0.254	0.225	1
EKG Technician	BLS	Medical Assistants	23,680.67	0.254	0.204	1
Anesthesia Technician	BLS	Medical Assistants	23,680.67	0.254	0.225	1
Technician	BLS	Medical Assistants	23,680.67	0.254	0.225	1
Cast Technician	BLS	Medical Assistants	23,680.67	0.254	0.177	1
LPN	BLS	Licensed Practical Nurses	30,340.53	0.325	0.267	
RN	BLS	Registered Nurses	46,493.56	0.498	0.422	
RN Cardiology	BLS	Registered Nurses	46,493.56	0.498	0.574	2
RN Oncology	BLS	Registered Nurses plus adjustment	54,862.40	0.587	0.497	2
Surgery Assistant	BLS	Surgical Technologists	28,814.09	0.308	0.326	3
Certified Surgical Technician	BLS	Surgical Technologists	28,814.09	0.308	0.262	
Lab Technician	BLS	Medical and Clinical Laboratory Technicians.	29,723.68	0.318	0.288	
Histotechnician	ASCP	Histologic Technologist	33,924.51	0.363	0.306	4
Electron Microscopy Technician	ASCP	Histologic Technologist	33,924.51	0.363	0.312	5
Cytotechnologist	BLS	Medical and Clinical Laboratory Technologists.	41,098.76	0.440	0.415	
EEG Technician	Salary Expert	Electroencephalographic Technician.	29,150.74	0.312	0.283	6
Electrodiagnostic Technologist	BLS	Electroneurodiagnostic Technologists.	33,529.31	0.359	0.302	6
Registered EEG Technologist	Current Rate	Registered EEG Technologist	37,645.00	0.403	0.403	6
Vascular Technician	BLS	Cardiovascular Technologists and Technicians.	34,794.37	0.372	0.351	7
Cardiovascular Technician	BLS	Cardiovascular Technologists and Technicians.	34,794.37	0.372	0.351	
Radiation Technologist	BLS	Radiologic Technologists and Technicians.	37,125.85	0.397	0.319	8
X-Ray Technologist	BLS	Radiologic Technologists and Technicians.	37,125.85	0.397	0.319	8
Angiographic Technician	BLS	Radiologic Technologists and Technicians.	37,125.85	0.397	0.351	9
CAT Scan Technician	BLS	Radiologic Technologists and Technicians.	37,125.85	0.397	0.319	9
MRI Technician	BLS	Radiologic Technologists and Technicians.	37,125.85	0.397	0.319	9
Nuclear Medicine Technician	BLS	Nuclear Medicine Technologists	44,360.73	0.475	0.392	
Nuclear Cardiology Technician	BLS	Nuclear Medicine Technologists	44,360.73	0.475	0.392	10
Ultrasound Technician	BLS	Diagnostic Medical Sonographers	45,751.26	0.490	0.389	11
Sonographer	BLS	Diagnostic Medical Sonographers	45,751.26	0.490	0.389	11
Cardiac Sonographer	BLS	Diagnostic Medical Sonographers	45,751.26	0.490	0.389	11
Radiation Technical Therapist	BLS	Radiation Therapists	45,333.05	0.485	0.404	
Dosimetrist	BLS	Radiation Therapists	45,333.05	0.485	0.500	
Physicist	AAHP	Certified Health Physicists	84,495.54	0.905	0.968	12
COT	X–WALK	Lab Technician	29,723.68	0.318	0.256	13
COMT	X–WALK	Histotechnician	33,924.51	0.363	0.278	13
Optician	BLS	Opticians, Dispensing	26,336.25	0.282	0.278	

TABLE 2.—PROPOSED WAGE RATES FOR CPEP CLINICAL STAFF TYPES—Continued

Description	Source	Crosswalk	Mean yrly 2001	Proposed per minute	Current per minute	Note #
Certified Retinal Angiographer	Salary Expert	Ophthalmic Photographer	35,453.04	0.380	0.351	14
Orthoptist	X–WALK	COMT	33,924.51	0.363	0.315	15
Respiratory Therapist	BLS	Respiratory Therapists	38,537.28	0.413	0.421	
Speech Pathologist	BLS	Speech-Language Pathologists	49,996.00	0.535	0.419	
Audiologist	BLS	Audiologists	47,748.17	0.511	0.411	
Registered Dietician	BLS	Dieticians and Nutritionists	39,049.57	0.418	0.365	
Counselor	BLS	Mental Health Counselors	30,769.18	0.329	0.422	

(1) We are proposing to collapse the medical assistant, technical aide, medical technician, EKG technician, anesthesia technician, technician, and cast technician staff types into a new staff type called, ''medical or technical assistant'' that will be priced at the medical assistant proposed wage rate per minute. This will represent an increased per minute rate for all the bundled staff types.

(2) We are proposing to bundle the staff type ''RN-cardiology'' into the staff type ''RN.'' RN-cardiology is used as the staff type for the pre- and post-service time of only three percutaneous valvuloplasty services, codes 92986, 92987 and 92990. We were unable to find any national salary data for the oncology certified nurse (OCN). In the absence of other information, we are adjusting the proposed wage rate to be 18 percent higher than the RN; this is the same differential that currently exists between these two staff types.

(3) We are proposing to bundle the staff type ''surgery assistant'', which is assigned to only 19 surgical services, into the staff type ''certified surgical technologist (CST)'', which is assigned to 133 services. It also appears that Abt mapped the averaged costs from a first assistant and certified scrub technician to the surgery assistant staff type, which does not appear to be the most appropriate crosswalk for the office setting.

(4) We used the average hourly rate for histologic technologists from the 1998 American Society of Clinical Pathologists' survey to propose a wage for the histotechnician staff type. This survey's average hourly rate of $12.90 for laboratory technician generally corresponds to our proposed rate of $13.67 and its average hourly rate of $19.00 for cytotechnologists almost matches our proposed rate of $18.90. Therefore, we believe that the $15.60 hourly rate we are proposing for the histotechnician maintains the current relativity between these laboratory staff types.

(5) We were unable to find any national salary data for the electron microscopy technician and, in the absence of such data, are crosswalking the salary from the wage rate for the histotechnician. This does represent an increase in the per minute cost for this staff type. However, we would welcome reliable national survey data from the specialty that we could use in pricing this staff type.

(6) We were only able to find direct BLS salary data for the electroneurodiagnostic technologist staff type. This information was contained in the BLS Occupational Outlook Handbook rather than in the listing of Occupational Employment Statistics where we found all other BLS data. We are proposing to crosswalk the corresponding salary from the Handbook to the electrodiagnostic technologist staff type. Data for the EEG technician came from the *Salary Expert.* We were unable to find any national salary data for registered EEG technologist (REEGT) and are proposing to maintain the current rate, since the speciality society recently recommended this rate of pay. However, we would also welcome reliable national survey data from the specialty that we could use in pricing these three levels of neurodiagnostic staff.

(7) We are proposing to bundle the vascular technician in with the cardiovascular technology staff type. Currently both are priced at the same rate.

(8) We are proposing to merge the x-ray technician and radiation technologist staff types, which are currently priced at the same rate, into a staff type called ''Radiologic Technologist.''

(9) Because we were unable to find any national survey data regarding the salaries for CAT scan technician, MRI technician, or angiographic technician, we are proposing to crosswalk these staff types to the BLS radiologic technologist pay scale. If there is a generally applied differential for these specialized radiologic technologists, we would welcome any reliable national survey data that would allow us to separately price these staff types.

(10) We are proposing to merge the nuclear cardiology technician in with the nuclear medicine technician staff type. Currently, both are priced at the same rate.

(11) We are proposing to merge the cardiac sonographer and the ultrasound technician into the sonographer staff type. Currently, all three are priced at the same rate.

(12) We are proposing to use the average salary data for all certified health physicists from the 1999 survey done by the American Academy of Health Physics and the American Board of Health Physics.

(13) We were unable to find representative national salary data for either the certified ophthalmic technician (COT) or the certified ophthalmic medical technologist (COMT). Until we can obtain such data, we are proposing to crosswalk the COT and COMT to the lab technician and histotechnician, respectively, since we believe that the skill and responsibility of these staff types would generally correspond. Again, we would welcome reliable and representative national salary data for these staff types.

(14) Data for our proposed salary for the certified retinal angiographer came from the *Salary Expert.* The position description for the ophthalmic photographer appeared to match the duties of a retinal angiographer: ''Photographs medical phenomena of eye to document diseases, surgeries, treatment and congenital problems * * * Injects contrast medium into vein of patient and photographs fluorescent dye as it flows through retina or iris vessels to obtain angiogram of eye * * *''

(15) In the absence of any national salary data for the orthoptist, we crosswalked the salary from that of the COMT, the highest level of ophthalmic medical personnel.

We are also proposing to delete those clinical staff that can bill separately from the list of CPEP staff types. We believe that these staff types are used as physician extenders and thus their salaries should not be considered as

practice expense. Therefore, we are proposing to substitute physical therapy aide for physical therapist, registered nurse for physician assistant, nurse practitioner and psychologist, and counselor for social worker. We are also proposing to delete as redundant the ophthalmic medical personnel (OMP) staff type and are substituting the COMT/COT/RN/CST blend that was suggested by the American Academy of Ophthalmology and recommended by the AMA's Relative Value Update Committee.

The CPEP clinical staff inputs also include blends of staff types that are used for those services where more than one type of clinical staff may be used in the performance of the service. We are proposing to establish the payment rates for these blends by calculating a simple average of the wage rates of the staff types included. The table below shows the blended staff types, the proposed cost per minute and the current cost per minute.

TABLE 3.—PROPOSED WAGE RATES FOR CPEP BLENDED CLINICAL STAFF TYPES

Current description	Proposed description	Proposed per minute	Current per minute
COMT/COT/RN/CST	Same	0.372	0.307
EKG Tech/MA	Medical or Technical Assistant (MTA)	0.254	0.183
EKG Tech/Med Tech	Medical or Technical Assistant (MTA)	0.254	0.214
Lab Tech/Histotech	Same	0.341	0.297
Lab Tech/Med Tech	Lab Tech/MTA	0.286	0.257
Optician/COMT	Same	0.323	0.278
RN/LPN	Same	0.412	0.389
RN/LPN/MA	RN/LPN/MTA	0.359	0.317
RN/LPN/MA/Tech	RN/LPN/MTA	0.359	0.269
RN/Med Tech/MA	RN/LPN/MTA	0.359	0.269
RN/OCN	Same	0.543	0.497
RN/PA/Cast Tech	RN/LPN/MTA	0.359	0.402
RN/Respiratory Therapist	Same	0.456	0.421
RN/Tech	RN/LPN/MTA	0.359	0.323
RN/Ultrasound Tech	RN/Sonographer	0.494	0.405
RN//MA	RN/LPN/MTA	0.359	0.326

Note: The proposed descriptions are based on our proposals on staff types from the previous table. We have eliminated the staff types we have proposed deleting from the above blends. We are also proposing to add LPN to the blend of an RN and a medical or technical assistant because we believe that if an RN and an assistant can perform a service, it is reasonable to assume that an LPN could as well.

Revision of the Ophthalmology Visit Supply Package

In its May 2000 submission to us, the RUC recommended the use of an ophthalmology visit supply package that would contain the routine supplies typically used in each 90-day global postsurgical visit for ophthalmology services. We accepted this recommendation. However, upon further review, we noted that two of the supplies—rev eyes and post myd spectacles—were not used in many of the postsurgical office visits. Therefore, after consulting with the ophthalmology specialty society, we are proposing to remove these two items from the ophthalmology visit package. Instead, we propose to include these items as appropriate on a code-by-code basis.

Deletion of Contrast Agents From the Practice Expense Inputs

Section 430(b) of BIPA amends section 1861(t)(1) of the Act to include contrast agents in the definition of drugs and biologicals. Previously, contrast agents were defined as supplies and were included in the list of CPEP supplies for the appropriate services. Therefore, we are proposing to delete the costs of the following contrast agents from our CPEP data—hypaque, methylene blue, high density barium, polibar, telopaque tablets, barium paste contrast, effervescent sparkies (fizzies) and renographin-60 iodinated contrast.

Physician Time

RUC Time Database

The primary sources for the physician time data used in creating the specialty-specific practice expense pools are the surveys performed for the initial establishment of the work RVUs and the surveys submitted to the AMA RUC. The AMA informed us that some of the times used for the November 1998 final rule (63 FR 58823) differed from the official RUC database, and we agreed to use the RUC-verified physician time database when we received it from the AMA. Subsequently, the AMA notified us that there were gaps in its own database for certain global surgery codes and that a revised time database would be sent to us once all the times were verified. We have now received this revised database and are proposing to use it in the calculation of the specialty-specific practice expense pools. It should be noted that the RUC database reflects the proposed physician times for those codes that were surveyed as part of the 5-year review of physician work.

c. Site-of-Service: Comments on Site of Service. In the November 2, 1998 final rule (63 FR 58830) and the November 2, 1999 final rule (64 FR 59407), we indicated the circumstances under which either the facility or the non-facility RVUs are used to calculate payment for a service. Specifically, we indicated that the lower facility practice expense RVUs apply when the service is performed in an Ambulatory Service Center (ASC) and the procedure is on the ASC-approved procedures list. The higher non-facility practice expense RVUs apply to procedures performed in an ASC that are not on the ASC-approved list because there will be no separate facility payment for these services. We have recently received a number of inquiries asking about the place-of-service that should be used on the Medicare claim when a service not on the ASC-approved procedures list is provided in an ASC. In these circumstances, physicians should indicate ASC as the place-of-service on the Medicare claim. Other questions have arisen as to whether a beneficiary can be billed the ASC facility fee when Medicare does not pay a facility fee because a procedure not on the ASC list is performed in a certified ASC. In this situation, Medicare pays the higher non-facility practice expense RVUs because the ASC is effectively serving as a physician's office, and Medicare's payment for the physician's service

includes payment for all practice expenses incurred in furnishing the service. The ASC benefit does not apply since the services do not meet the provisions of section 1833(i) of the Act. The services are covered as physicians' services and paid under the physician fee schedule. Therefore, payment to the physician reflects payment for the whole service, and the beneficiary cannot be charged in excess of the limiting charge for the physician fee schedule service.

B. Nurse Practitioners, Physician Assistants, and Clinical Nurse Specialists Performing Screening Sigmoidoscopies

On January 1, 1998, we implemented regulations at § 410.37(d) (Conditions for coverage of screening flexible sigmoidoscopies) requiring that screening flexible sigmoidoscopies be performed by a doctor of medicine or osteopathy (as defined in section 1861(r)(1) of the Act). Based on our review of current medical literature, we believe that there are other practitioners whose services are covered under Medicare who have been trained and are qualified to perform these procedures safely and accurately, such as nurse practitioners, clinical nurse specialists, and physician assistants.

A growing body of literature has shown that certain non-physician health care professionals can carry out screening by flexible sigmoidoscopy as accurately and safely as physicians when properly trained. This procedure requires fewer supervised examinations to attain objective measures of technical competency than other endoscopic procedures, does not require sedation, and has a low rate of related complications. In the studies reviewed, physician and non-physician endoscopists achieved similar polyp detection rates and depth of insertion in screenings performed independently. No significant complications from sigmoidoscopy were reported in any of these studies. The level of satisfaction with the procedure was similar for all practitioners.

Therefore, we are proposing to revise § 410.37(d) to provide that, in addition to medical doctors and doctors of osteopathy, physician assistants, nurse practitioners, and clinical nurse specialists also be allowed to perform screening flexible sigmoidoscopies for beneficiaries if they meet the applicable Medicare qualification requirements in §§ 410.74, 410.75, and 410.76, and if they are authorized to perform these services under State law.

C. Services and Supplies Incident to a Physician's Professional Services: Conditions

Section 1861(s)(2)(A) of the Act authorizes coverage of services and supplies (including drugs and biologicals that cannot, as determined in accordance with regulations, be self-administered) furnished as an incident to a physician's service, of kinds which are commonly furnished in physicians' offices and are commonly either furnished without charge or included in the physician's bills. This statutory ''incident to'' benefit differs from the ''incident to'' benefit in the hospital setting as set forth in section 1861(s)(2)(B) of the Act, which authorizes coverage of hospital services (including drugs and biologicals which cannot, as determined in accordance with regulations, be self-administered) incident to a physician's service furnished to outpatients and partial hospitalization services furnished to outpatients incident to a physician's service. This proposal only addresses the ''incident to'' benefit set forth in section 1861(s)(2)(A) of the Act.

In addition, the statute provides Medicare coverage of services incident to practitioners other than physicians. For example, section 1861(s)(2)(K) of the Act authorizes Medicare to pay for services incident to a service of a nurse practitioner or a physician assistant.

Section 2050 of the Medicare Carriers Manual (the manual) clarifies the coverage of services ''incident to'' physician services as described in section 1861(s)(2)(A) of the Act. Specifically, services incident to a physician service may be furnished by an employee of the physician. Alternatively, both the physician and the individual furnishing the ''incident to'' service must be employed by a common employer. Furthermore, the individual furnishing the ''incident to'' service may be any staff member working with the physician and not just one of the non-physician practitioners listed in section 1842(b)(18)(C) of the Act. We shall refer to these staff members as auxiliary personnel, a term which includes registered nurses and medical assistants.

Currently, our manual requires that the physician be either the employer of the auxiliary personnel or be an employee of the same entity that employs the auxiliary personnel. We note that, under our manual, auxiliary personnel may be either employees, leased employees, or independent contractors. An independent contractor relationship appears to be common current practice because it affords the auxiliary personnel the flexibility to work with various physicians or practitioners on a part-time basis. We do not believe that the nature of the employment relationship is critical for purposes of payment for services incident to the services of physicians and practitioners, so long as the auxiliary personnel reports to a physician or practitioner under the required level of supervision. We see no clinical reason to exclude independent contractor physicians and practitioners from the class of practitioners who can receive Medicare payment for services incident to their own services based solely on their status as independent contractors. Accordingly, we propose to allow auxiliary personnel to provide services incident to the services of physicians or practitioners who supervise them, regardless of the employment relationship. Thus, auxiliary personnel may be employees, leased employees, or independent contractors, and may provide services incident to the services of physicians and practitioners who employ or contract with them or who are employees or independent contractors of the same entity, provided that the other requirements for payment for ''incident to'' services are met. We note, however, that the employment relationship remains relevant under our rules prohibiting reassignment of Medicare benefits. (§§ 424.73 and 424.80) We also propose to codify the following definitions:

- *Auxiliary personnel* means any individual who is acting under the supervision of a physician, regardless of whether the individual is an employee, leased employee, or independent contractor of the physician (or other practitioner) or of the same entity that employs or contracts with the physician (or other practitioner).
- *Direct supervision* means the level of supervision by the physician (or other practitioner) of auxiliary personnel as defined in § 410.32(b)(3)(ii).
- *Independent contractor* means an individual who performs part-time or full-time work for which the individual receives an IRS–1099 form.
- *Leased employment* means an employment relationship that is recognized by applicable State law and that is established by two employers by a contract such that one employer hires the services of an employee of the other employer.
- *Noninstitutional setting* means all settings other than a hospital or skilled nursing facility.
- *Practitioner* means a non-physician practitioner who is authorized by the

Act to receive payment for services incident to his or her own services.

• *Services and supplies* means any service or supply (including any drug and biological that cannot be self-administered) that is included in section 1861(s)(2)(A) of the Act and is not specifically listed in the Act as a separate benefit included in the Medicare program.

We also propose to codify the provisions in section 2050 of the manual by revising § 410.26 to clarify the requirements for ''incident to'' services. Section 410.26 would be revised as follows:

• Services and supplies must be furnished in a noninstitutional setting to noninstitutional patients.

• Services and supplies must be an integral, although incidental, part of the service of a physician (or other practitioner) in the course of diagnosis or treatment of an injury or illness.

• Services and supplies must be commonly furnished without charge or included in the bill of a physician (or other practitioner).

• Services and supplies must be of a type that are commonly furnished in the office or clinic of a physician (or other practitioner).

• Services and supplies must be furnished under the direct supervision of the physician (or other practitioner).

• Services and supplies must be furnished by the physician, practitioner with an incident to benefit, or by auxiliary personnel.

• A physician (or other practitioner) may be an employee or an independent contractor.

• Drugs and biologicals are also subject to the limitations specified in § 410.29.

D. Anesthesia Services

Section 4048(b) of the Omnibus Budget Reconciliation Act of 1987 amended section 1842(b) of the Act and required us to establish a uniform relative value guide for use in all carrier localities in determining payment for anesthesia services furnished by physicians under Medicare Part B. In accordance with the law, the uniform relative value guide was designed so that Medicare payment for anesthesia services would not exceed the amount that would have occurred under the then-existing system of payment.

We implemented the uniform relative value guide in March 1989 and selected the 1988 American Society of Anesthesiologists' (ASA) Relative Value Guide as the basis for the uniform relative value guide. (For a discussion of this issue, please see the August 7, 1990 final rule (55 FR 32078).)

To determine base unit values, we used the 1988 ASA base unit values for each anesthesia code, except for codes 00142 (lens surgery) and 00147 (iridectomy). The base unit values for each of these codes were set at 4 units instead of the ASA values of 6 and 5 units, respectively.

The ASA has requested that we ensure that the anesthesia base units under our uniform relative value guide are the same as those listed in the ASA's most current guide. Standardization of base units between Medicare and the ASA guide will simplify billing by anesthesiologists. The ASA's base unit values for the following 8 codes are different than CMS's values:

Code	CMS	ASA
0081	6	5
00902	4	5
01150	8	10
01214	10	8
01432	5	6
01440	5	8
01770	8	6
01921	7	8

We are proposing to use the ASA base unit values from the 1999 guide beginning in CY 2002 for the above codes. However, the base unit values for codes 00142 and 00147 would remain at 4 units. The values for these codes were established by us under the ''inherent reasonableness'' process in 1987.

We would make an adjustment to the anesthesia conversion factor in 2001 so that payments would not exceed payments that would have been made using the current values. We currently estimate that this adjustment will be less than 0.5 percent.

E. Performance Measurement and Emerging Technology Codes

In modernizing the CPT, the AMA has developed two new categories of codes. In addition to the traditional codes for physicians' and other practitioners' services, referred to as Category I CPT codes, which are coded by five digit numbers, the new codes describe Performance Measures and Emerging Technologies and are coded with four digits followed by a letter.

The Performance Measure codes, referred to as Category II CPT codes, are intended to facilitate data collection. These codes are designed to decrease the need for review of medical records to document when services were performed. They allow practitioners to indicate in their billing records that the visit addressed issues that need to be tracked for quality and outcome measurement. For example, there is likely to be a code to indicate that a diabetic patient received a retinal examination. The visit that contained that specific service might have been reported with an evaluation and management code or with a more general ophthalmological service code and paid for based on the code selected. Thus, the performance measurement code is used only to assist the practitioner to specify that the performance measurement service was furnished. The syntax of this code will be four digits followed by the letter ''F.'' We are proposing that no values are placed on the Performance Measure codes and no additional payment is made for the use of these codes. Practitioners will, however, be able to list them on their Medicare bills, to facilitate the tracking of these services.

The Emerging Technology codes, referred to as Category III CPT codes, are intended to track new and emerging technologies. These codes were developed to facilitate data collection on and assessment of new services and procedures. These data could be used to document the use of services and procedures in the Food and Drug Administration approval process or while the efficacy of a procedure is being demonstrated. The syntax of these codes is four digits followed by the letter ''T.'' In general, these codes represent services that are still experimental or have unverified effectiveness and would not be covered services. Although we were concerned that codes with a ''T'' designation might be needed for use by some Medicaid programs, we now believe that we would be able to process claims with the ''T'' in the fifth digit. However, we propose not to provide payment for all of the Emerging Technology Codes. Rather, we would provide payment on a case-by-case basis only in specific situations when we determine that the codes represent services that are not, in fact, experimental, but have been shown to be safe and effective. If the coverage policy is not consistent with the existing tracking codes, a Medicare-specific code may need to be developed to allow payment for the service. Thus, we propose that only specific emerging technology codes will be recognized for Medicare payment.

F. Payment Policy for CPT Modifier 62 (Co-Surgery)

The CPT modifier code 62 is used to report the work of co-surgeons. Currently, if we pay for co-surgery, we pay a total of 125 percent of the fee schedule amount to the co-surgeons who each receive half of this total payment. This policy was established at the beginning of the fee schedule and

the level of payment reflected the predominant payment rate used by Medicare carriers at that time. Unlike other components of the fee schedule, this payment policy was not based on an analysis of the relative physician work effort for surgical services involving co-surgeons.

In addition, surgical practice has changed significantly over the past 10 years. For example, there is increasing use of noninvasive, minimally invasive, percutaneous, and endoscopic approaches to performing surgical procedures that were formerly performed as open procedures. Therefore, we are reviewing our payment policies for co-surgery to consider possible ways to ensure that they reflect current clinical practices and properly reflect the relative resources and work effort required to perform these services.

Among the issues we are considering are:

(1) Whether it would be possible to establish criteria for distinguishing the roles of a co-surgeon (when both surgeons are paid at 125 percent of the surgery amount) and assistant at surgery (when the total payment is 116 percent of the surgery amount);

(2) Whether any such criteria should vary by type of procedure (that is, open surgical, minimally invasive (including interventional procedures), and endoscopic procedures);

(3) Which procedures require a co-surgeon and under what circumstances should documentation be required for payment; and

(4) How to value the work performed by a co-surgeon.

While we are not making a specific proposal at this time, we will consider any information we receive to assist us in deciding whether to make a future proposal affecting payments for co-surgery.

III. Implementation of Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000

The Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) (Public Law 106–554), enacted on December 21, 2000, provides for revisions to policies applicable to the physician fee schedule. These revisions are presented below.

A. Screening Mammography

Medicare has paid for screening mammography since January 1, 1991. Section 1834(c) of the Act governing these screenings did not include screening mammography under the physician fee schedule and required payment using a different methodology. As stated in § 405.534, Medicare payment for screening mammography currently equals the lesser of the following: the actual charge for the service; the applicable amount under the physician fee schedule in an area for a bilateral diagnostic mammogram; or $55, a figure specified in section 1834(c)(3) of the Act, updated since 1991 by the Medicare Economic Index (MEI). In 2001, the statutory payment limit for screening mammography is $69.23. In most cases, payment for screening mammography is made at the national limit with no differences among geographical areas.

Section 104 of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) amends section 1848(j)(3) of the Act to include screening mammography as a physician service for which payment is made under the physician fee schedule beginning January 1, 2002. We are proposing to amend §§ 405.534 and 405.535 to reflect the inclusion of screening mammography as a physician service which will be payable under the physician fee schedule. In addition, we are amending § 414.2 to include screening mammography under the definition for physicians' services. In accordance with part 414, payments for screening mammography will be resource-based and will have geographic adjustments that reflect cost differences among areas as do all other services under the physician fee schedule, including diagnostic mammography. The following is a discussion of our proposed RVUs for the professional and technical components (PC and TC) of a screening mammography, code 76092, under the physician fee schedule.

Professional Component

We are proposing to establish physician work RVUs=0.70. This value is equal to the proposed work RVUs from the 5-year review of physician work for code 76090, unilateral diagnostic mammogram. Due to the comparable number of views taken in both a unilateral diagnostic mammography and a screening mammography, we believe the physician work associated with the performance of screening mammography is similar to the physician work associated with unilateral diagnostic mammography.

We note that in the June 8, 2001 proposed notice on the 5-year review of work RVUs (66 FR 31028), we proposed to increase the work RVUs for unilateral diagnostic mammography from 0.58 to 0.70 RVUs, an increase of 21 percent. Additionally, we are proposing to increase the work RVUs for bilateral diagnostic mammography from 0.69 to 0.87 RVUs, an increase of 26 percent. Both of these increases would be effective for services performed on or after January 1, 2002. Our proposal to establish physician work RVUs for screening mammography equal to the physician work RVUs for unilateral diagnostic mammography, since both involve a four view film study, incorporates the increases we have proposed in the June 8, 2001 proposed notice.

We also believe that the practice expense and malpractice expense for the professional component of screening mammography is similar to the professional component of unilateral diagnostic mammography. As a result, we are proposing 0.25 practice expense RVUs and 0.03 malpractice RVUs for the PC of screening mammography. These proposed RVUs reflect changes to the practice expense RVUs for code 76090.

Technical Component

We propose valuing the technical component of screening mammography using a methodology that updates the original statutory limit for the technical component of screening mammography of $37.40, by the cumulative increase in physician fee schedule rates between 1992 and 2001. While screening mammography payments increased through application of the MEI between 1992 and 2001, resulting in a cumulative increase of 25.9 percent, physician fee schedule payments increased by 35.6 percent during this period. As a result, increasing payment for screening mammography by the statutory limit led to lower payment than if payment for the procedure had increased at the same rate as physician fee schedule services.

We propose updating the technical component of the initial screening mammography statutory limit of $37.40 by the same update factor that would have applied if screening mammography had received the same increases as physician fee schedule services. Currently, payment for the technical component of a screening mammography is equal to 68 percent of the statutory payment limit. To update the current value, we took 68 percent of the original $55 payment limit and increased it by 35.6 percent ($55 × 0.68 × 1.356 = $50.70). We divided this figure by the 2001 physician fee schedule CF of $38.2581 to determine total RVUs of 1.33. Since the TC is comprised only of practice and malpractice RVUs, we then used the

practice expense and malpractice expense percentages for the TC of unilateral diagnostic mammography (95.3 and 4.7 percent, respectively) to determine the practice expense and malpractice RVUs for the technical component of screening mammography. We multiplied the total RVUs of 1.33 by 0.953 to determine the proposed practice expense RVUs of 1.27 and by 0.047 to determine the proposed malpractice expense RVUs of 0.06.

Overall, the proposed total RVUs associated with the combined PC and TC of code 76092 are 2.31 (0.70 work RVUs, 1.52 practice expense RVUs, and 0.09 malpractice expense RVUs). These proposed RVUs would result in a payment for CY 2002 of approximately $88.50, before application of any geographic adjustments.

New Technology Mammography

The BIPA requires us to determine whether the assignment of new HCPCS codes is appropriate for both screening and diagnostic mammography using new technologies. If new codes are appropriate, the provision requires us to provide for their use beginning January 1, 2002. The provision defines new technology mammography to be an advance in technology with respect to the test or equipment that results in: (a) A significant increase or decrease in the resources used in the test or in the manufacture of the equipment; (b) a significant improvement in the performance of the test or equipment; or (c) a significant advance in medical technology that is expected to significantly improve the treatment of Medicare beneficiaries.

Before January 1, 2002, the BIPA provides for temporary payment amounts during the period April 1, 2001 to December 31, 2001 for two types of new technology mammography used in both diagnostic and screening procedures. The BIPA specifies that payment for technologies that directly take digital images would equal 150 percent of the amount that would otherwise be paid for bilateral diagnostic mammography. The BIPA also specifies that for technologies that convert standard film to a digital form which is then analyzed, payment would be equal to the statutory screening mammography limit for CY 2001, plus an additional payment of $15.00. Moreover, the BIPA specifies that the same payment amount be used for a screening or diagnostic procedure for each of the new technologies. We have implemented the temporary payment provisions via a Program Memorandum sent to Medicare carriers on February 1, 2000.

We believe that new HCPCS codes are appropriate for new technology mammography beginning with January 1, 2002 and propose codes to be used with the associated RVUs described below. We propose to establish three separate codes for directly taking a digital image (one for screening and one each for unilateral and bilateral diagnostic). Our approach would establish a single add-on code for computer-aided diagnosis with conversion of standard film images to digital images. At the present time, the FDA has approved computer-aided diagnosis only for use in conjunction with standard film screening mammography. Thus, at the present time, our proposal would only allow Gxxx4 to be billed as an add-on to 76090 if medically necessary. In the section that follows, we discuss the proposed coding and payment methodologies for new technology mammography.

Screening mammography, direct digital image (Gxxx1). We propose to use HCPCS code Gxxx1 to report screening mammography performed using direct digital images as opposed to mammography that is performed using the standard film images associated with code 76092, or conversion of a standard film image to a digital image. (**Note:** Gxxx is used as a placeholder; the actual ''G'' code designation for payment will be included in the final rule.)

We believe that the physician work and malpractice expense associated with both the PC and TC of HCPCS code Gxxx1 are analogous to the professional and technical components of CPT code 76092. (**Note:** Proposed work RVUs for code 76092, discussed above, are being increased to 0.70.) However, because the equipment involved with direct digital images is different from the equipment involved with standard film images, we believe that the practice expense RVUs are different than the practice expense RVUs for code 76092. Thus, we are proposing to value the practice expense for the PC of this service using the methodology for determining resource-based practice expense RVUs. We are proposing to value the practice expense RVUs for the TC of the service using the practice expense methodology for the ''zero work pool.'' (For more information about the practice expense methodology for PC and TC services, see the November 2, 1998 final rule (63 FR 58817).

For the PC of HCPCS code Gxxx1, we propose 0.70 work RVUs, 0.28 practice expense RVUs, and 0.03 malpractice expense RVUs. For the TC of HCPCS code Gxxx1, for which there is no physician work associated, we propose 2.50 practice expense RVUs and 0.06 malpractice RVUs. Please see Table 4 below for a summary of all component RVUs associated with this and other mammography services.

Diagnostic mammography, unilateral, direct digital image (Gxxx2). We propose to use HCPCS code Gxxx2 to report unilateral diagnostic mammography performed using direct digital images as opposed to mammography performed using the standard film images associated with code 76090, or conversion of a standard film image to a digital image.

We believe that the physician work and malpractice expense associated with both the PC and TC of HCPCS code Gxxx2 are analogous to the PC and TC of code 76090. (**Note:** Proposed work RVUs for code 76090, discussed above, are being increased to 0.70). However, because the equipment involved with direct digital images is different from the equipment involved with standard film images, we believe that the practice expense RVUs are different than those for code 76090. Thus, we are proposing to value the practice expense for the PC of this service using the methodology for determining resource-based practice expense RVUs. We are proposing to value the practice expense RVUs for the TC of the service using the practice expense methodology for the ''zero work pool.''

For the professional component of HCPCS code Gxxx2, we propose 0.70 work RVUs, 0.28 practice expense RVUs, and 0.03 malpractice expense RVUs. For the TC of HCPCS code Gxxx2, for which there is no physician work associated, we propose 1.99 practice expense RVUs and 0.05 malpractice expense RVUs. Please see Table 4 below for a summary of all component RVUs associated with this and other mammography services.

Diagnostic mammography, bilateral, direct digital image (Gxxx3). We propose to use HCPCS code Gxxx3 to report bilateral diagnostic mammography that is performed using direct digital images as opposed to mammography performed using the standard film images associated with code 76091, or conversion of a standard film image to a digital image.

We believe that the physician work and malpractice expenses associated with both the PC and TC of HCPCS code Gxxx3 are analogous to the PC and TC of code 76091. (**Note:** Proposed work RVUs for code 76091, discussed above, are being increased to 0.87). However, because the equipment involved with direct digital images is different from the equipment involved with standard

film images, we believe that the practice expense RVUs are different than those for code 76091. Thus, we are proposing to value the practice expense for the PC of this service using the methodology for determining resource-based practice expense RVUs. The practice expense RVUs for the TC of the service are being valued using the practice expense methodology for the ''zero work pool.''

For the PC of HCPCS code Gxxx3, we propose 0.87 work RVUs, 0.34 practice expense RVUs, and 0.03 malpractice expense RVUs. For the TC of HCPCS code Gxxx3, with which there is no physician work associated, we propose 2.47 practice expense RVUs and 0.06 malpractice expense RVUs. Please see Table 4 below for a summary of all component relative values associated with this and other mammography services.

Computer-aided detection, conversion of standard film images to digital images (HCPCS Code Gxxx4). We propose to use HCPCS code Gxxx4 to report conversion of standard film images to digital images when used in conjunction with computer-aided diagnosis software.

We propose establishing HCPCS code Gxxx4 as an add-on code that can be billed only in conjunction with the primary service, code 76092. At this time, we understand that the only FDA-approved use of the computer-aided diagnosis mammography software is with screening film images. If there are other FDA-approved uses of computer-aided diagnosis, we allow for use of Gxxx4 as an add-on to other mammography services. We believe that the physician work associated with CPT code 76375, *Coronal, sagittal, multiplanar, oblique, 3-dimensional and/or holographic reconstruction of computerized tomography, magnetic resonance imaging, or other tomographic modality*, is comparable, per unit of time, to the physician work of Gxxx4. We have determined that the physician time associated with HCPCS code Gxxx4 is approximately 1/3 of the physician time associated with CPT code 76375. Using this relationship, we propose 0.06 work relative value units for HCPCS code Gxxx4. Additionally, we believe the malpractice expense RVUs for HCPCS code Gxxx4 are analogous to a level two established office visit, CPT code 99212. However, we believe that the practice expense RVUs for HCPCS code Gxxx4 are markedly different from either of the two aforementioned services; therefore, we are valuing the PC of this service using the methodology for determining resource-based practice expense RVUs. The TC of the service is being valued using the practice expense methodology for the ''zero work pool.''

For the PC of code Gxxx4, we propose 0.06 work RVUs, 0.02 practice expense RVUs, and 0.01 malpractice expense RVUs. For the TC of HCPCS code Gxxx4, with which there is no physician work associated, we propose 0.41 practice expense RVUs and 0.01 malpractice expense RVUs. Table 4 below summarizes all component RVUs associated with this and other mammography services.

TABLE 4.—PROPOSED RVUS FOR MAMMOGRAPHY SERVICES

Code	Modifier	Work	Practice expense	Malpractice	Total
76090		0.70	1.28	0.08	2.06
76090	26	0.70	0.24	0.03	0.97
76090	TC	0.00	1.04	0.05	1.09
76091		0.87	1.59	0.09	2.55
76091	26	0.87	0.30	0.03	1.20
76091	TC	0.00	1.29	0.06	1.35
76092		0.70	1.52	0.09	2.31
76092	26	0.70	0.25	0.03	0.98
76092	TC	0.00	1.27	0.06	1.33
Gxxx1		0.70	2.78	0.09	3.57
Gxxx1	26	0.70	0.28	0.03	1.01
Gxxx1	TC	0.00	2.50	0.06	2.56
Gxxx2		0.70	2.27	0.08	3.05
Gxxx2	26	0.70	0.28	0.03	1.01
Gxxx2	TC	0.00	1.99	0.05	2.04
Gxxx3		0.87	2.81	0.09	3.77
Gxxx3	26	0.87	0.34	0.03	1.24
Gxxx3	TC	0.00	2.47	0.06	2.53
Gxxx4		0.06	0.43	0.02	0.51
Gxxx4	26	0.06	0.02	0.01	0.09
Gxxx4	TC	0.00	0.41	0.01	0.42

B. Screening Pelvic Examinations

Before the enactment of the BIPA, section 1861(nn)(2) of the Act authorized Medicare coverage for a screening pelvic examination (including a clinical breast examination) furnished to a woman for the purpose of early detection of cervical or vaginal cancer once every 3 years, or once every year for a woman who is at high risk for one of these conditions, or who is of childbearing age and meets certain other requirements.

Section 101 of the BIPA amends section 1861(nn)(2) of the Act (effective July 1, 2001) to provide that a woman who does not qualify for annual coverage of a screening pelvic examination under one of the statutory exceptions, qualifies for coverage of a screening pelvic examination (including a clinical breast examination) once every 2 years rather than once every 3 years.

We are conforming § 410.56 (Screening Pelvic Examinations) of the regulations to the new statutory provision that has been implemented through sections 4603, 3628.1 and 4731 of the Medicare Carrier Manual, the Medicare Intermediary Manual, and the Medicare Hospital Manual, respectively.

C. Screening for Glaucoma

Section 102 of BIPA provides for Medicare coverage under Part B for screening for glaucoma for individuals with diabetes, a family history of glaucoma, or others determined to be at ''high risk'' for glaucoma effective for services furnished on or after January 1,

2002. The statute provides for coverage of glaucoma screening, including (1) a dilated eye examination with an intraocular pressure measurement, and (2) a direct ophthalmoscopy or a slit-lamp biomicroscopic examination, subject to certain frequency and other limitations.

Currently, Medicare coverage policy allows for payment for examinations to diagnose glaucoma and related medically necessary services that are furnished to beneficiaries. Under this policy, diagnostic glaucoma tests are covered if they are medically necessary to evaluate a specific complaint or symptom that might indicate glaucoma or to monitor an existing medical condition of an individual who has had a history of elevated intraocular pressure or other signs of possible glaucoma. This coverage is based on sections 1861(s)(1) and (s)(3) of the Act. Section 1861(s)(1) of the Act provides for general Medicare coverage of physicians' services, including a physician's interpretation of the results of tests performed. Section 1861(s)(3) of the Act provides for general Medicare coverage of diagnostic x-ray, clinical laboratory, and other diagnostic tests. Before the enactment of the BIPA, screening for glaucoma was excluded from coverage based on § 411.15 (Particular services excluded from coverage), paragraphs (a) and (k).

To conform our regulations to the statutory requirements of the BIPA, we are specifying an exception to the list of examples of routine physical checkups excluded from coverage in §§ 411.15(a)(1) and 411.15(k)(9) for glaucoma screening examinations that meet the frequency limitation and the conditions for coverage that we are specifying under new § 410.23 (Screening for Glaucoma: Conditions for and Limitations on Coverage). Coverage of glaucoma screening is provided under Medicare Part B only. As provided in the statute, this new coverage allows payment for one glaucoma screening examination every year. We are proposing to add new § 410.23 (Screening for Glaucoma: Conditions for and Limitations on Coverage), to provide for coverage of the various types of glaucoma screening examinations specified in the statute. We are proposing several definitions of terms that would be included to implement the statutory provisions and to help the reader in understanding the provisions of the regulation. These include definitions of the following terms: (1) Screening for glaucoma, (2) eligible beneficiaries, and (3) direct supervision.

Section 102(b) of the BIPA defines the term ''screening for glaucoma'' to mean a dilated eye examination with an intraocular pressure measurement and a direct ophthalmoscopy or a slit-lamp biomicroscopic examination for the early detection of glaucoma. This section also provides that the screening examinations that are to be covered under Medicare are to be furnished by or under the direct supervision of an optometrist or ophthalmologist who is legally authorized to furnish these services under State law (or the State regulatory mechanism provided by State law) of the State in which the services are furnished. These are services that would otherwise be covered if furnished by a physician or as incident to a physician's professional service.

Section 102(a) of BIPA also provides that coverage of screening for glaucoma services will be available only for individuals determined to be at high risk for glaucoma, individuals with a family history of glaucoma and individuals with diabetes. Based on our review of the medical literature, and consultation with staff of the National Eye Institute and representatives of the American Academy of Ophthalmology and the American Optometric Association, we are proposing to interpret the statutory language, ''individuals determined to be at high risk for glaucoma'' to include Medicare beneficiaries who are African-Americans age 50 and over. While the National Eye Institute and others have provided us with information indicating that age and other factors may place a Medicare beneficiary at increased risk for glaucoma, we believe that the medical evidence available at this time is only sufficient to support inclusion of African-Americans age 50 and over in the statutory ''high risk'' category, in addition to individuals with diabetes and those with a family history of glaucoma who are covered separately under the new screening benefit. Studies have shown that the prevalence of glaucoma increases with age and is four to five times more likely to occur in African-Americans than in Caucasians. (Tielsch et al. JAMA 1991; Quigley. NEJM 1997) For African-Americans, the evidence indicates that the onset of the disease comes at an earlier age, and that the damage is more severe at the time of diagnosis. In view of the possibility that it may be appropriate to include other individuals in the statutory definition of those at ''high risk'' for glaucoma, however, we are requesting public comments on this issue. Specifically, we ask that anyone providing us with specific recommendations on this issue should provide documentation in support of them from the medical literature. In addition, we are proposing to use the term ''eligible beneficiaries'' to indicate who may qualify for the new screening glaucoma benefit, and we are proposing to define that term to include: (1) Individuals with diabetes mellitus, (2) individuals with a family history of glaucoma, and (3) African-Americans age 50 and over.

Section 102(b) of the BIPA also provides that the glaucoma screening examination is to be furnished by or under the direct supervision of an ophthalmologist or optometrist who is legally authorized to furnish such services under State law or regulation in which the services are furnished. We are proposing to define the term ''direct supervision'' as that term is defined in § 410.32(b)(3)(ii) for purposes of the oversight of covered diagnostic laboratory services as they are performed in the office setting. Specifically, we are proposing that the term ''direct supervision'' be defined to mean that the ophthalmologist or optometrist must be present in the office suite and immediately available to furnish assistance and direction throughout the performance of the procedure. The proposed definition states that the term ''direct supervision'' does not mean the physician must be present in the room when the procedure is performed.

Payment for Glaucoma Screening

We believe that services provided as part of glaucoma screening will often overlap other services a physician provides during a patient encounter as part of basic ophthalmological services and will result in no additional work or practice expense. Therefore, we propose bundling payment for glaucoma screening when it is provided on the same day as an evaluation and management (E/M) service, or when it is provided as part of any ophthalmology service. When glaucoma screening is the only service provided, or when it is provided as part of an otherwise noncovered service (for example, CPT 99397, preventive services visit), we propose to establish the following HCPCS codes and payments:

Gxxx5, Glaucoma Screening Furnished by a Physician for High Risk Patients

For physician work and for malpractice, we propose crosswalking this new HCPCS code to a level II E/M code, CPT 99212, which we believe represents a comparable level of work. The proposed work and malpractice RVUs are 0.45 and 0.02, respectively.

Gxxx6, Glaucoma Screening Furnished Under the Direct Supervision of a Physician for High Risk Patients

For physician work and for malpractice, we propose crosswalking this new HCPCS code to the lowest level E/M code, CPT 99211, which we believe represents a comparable level of work. The proposed work and malpractice RVUs are 0.17 and 0.01, respectively.

For non-facility settings, we propose the following practice expense inputs for both of the above HCPCS Codes:

clinical staff time-certified ophthalmic medical technologist/certified ophthalmic technician/registered nurse: five minutes;
equipment: screening lane; and
supplies: ophthalmology visit supply package.

D. Screening Colonoscopy

Before the enactment of the BIPA, sections 1861(pp)(1)(C) and 1834(d)(3)(E) of the Act authorized Medicare coverage of screening colonoscopies once every 2 years for individuals at high risk for colorectal cancer. Individuals not at high risk for colorectal cancer did not qualify for coverage of screening colonoscopies under the colorectal cancer screening benefit, but they did qualify for coverage of other colorectal cancer screening examinations specified in the statute. These other examinations that were covered for individuals not at high risk for colorectal cancer included screening fecal-occult blood tests, screening flexible sigmoidoscopies, and screening barium enema examinations at certain frequency intervals specified in the statute and the regulations at § 410.37 (Colorectal cancer screening tests).

Section 103 of the BIPA amended sections 1861(pp)(1)(C), 1834(d)(2)(E)(ii), and 1834(d)(3)(F) of the Act to add coverage of screening colonoscopies once every 10 years for individuals not at high risk for colorectal cancer. However, in the case of an individual who is not at high risk for colorectal cancer, but who has had a screening flexible sigmoidoscopy within the last 4 years, the statute provides that payment may be made for a screening colonoscopy only after at least 47 months have passed following the month in which the last screening flexible sigmoidoscopy was performed. In addition, the statute provides that in the case of an individual who is not at high risk for colorectal cancer but who does have a screening colonoscopy performed on or after July 1, 2001, payment may be made for a screening flexible sigmoidoscopy only after at least 119 months have passed following the month in which the last screening colonoscopy was performed.

In view of the statutory changes, we are conforming §§ 410.37(e) and 410.37(g) (related to limitations on coverage of screening colonoscopies and screening flexible sigmoidoscopies) to make them consistent with the new provisions of the statute that have been implemented through manual provisions of the Medicare Carriers Manual, the Medicare Intermediary Manual Part III, and the Medicare Hospital Manual in transmittal numbers 6097, 1824, and 7069, respectively, in February 2001.

Payment for Screening Colonoscopy

Payment for screening colonoscopy will be made under HCPCS code G0121: colorectal screening; colonoscopy for an individual not meeting criteria for high risk. As with current code G0105, screening colonoscopy for an individual at high risk, payment will be made at the level for a diagnostic colonoscopy, CPT code 45378, because the work is the same whether a procedure is screening or diagnostic. As the statute requires for both individuals who are or are not at high risk, if, during the course of the screening colonoscopy, a lesion or growth is detected that results in a biopsy or removal of the growth, the appropriate diagnostic procedure classified as colonoscopy with biopsy or removal should be billed and paid rather than HCPCS code G0105 or G0121.

E. Medical Nutrition Therapy

1. Legislation

Section 105 of the BIPA amended section 1861(s)(2) of the Act to authorize Medicare Part B coverage under Part B of medical nutrition therapy (MNT) for beneficiaries who have diabetes or renal disease, effective for services furnished on or after January 1, 2002. The legislation also:

- Authorizes dietitians and nutritionists who meet certain qualifications to be reimbursed directly by Medicare.
- Excludes from coverage beneficiaries who are receiving maintenance dialysis for which payment is made under section 1881 of the Act.
- Requires coordination of medical nutrition therapy benefits with the existing benefit for diabetes outpatient self-management training services.
- Defines a registered dietitian or other nutrition professional, and grandfathers dietitians or nutrition professionals who were licensed or certified in their States as of December 21, 2000, but would not otherwise meet the new requirements.
- Specifies that Medicare payment for MNT services must equal 80 percent of the lesser of the actual charge for the services or 85 percent of the amount determined under the physician fee schedule for the same services if furnished by a physician.
- Requires that we submit a report to the Congress by July 1, 2003, that contains recommendations with respect to expansion of the MNT benefit for other medical conditions.

This new benefit, while related, differs from the diabetes outpatient self-management training (DSMT) benefit, which was established by the BBA in section 1861(s)(2)(S) of the Act and described at section 1861(qq). The DSMT benefit is a comprehensive diabetes training program, of which nutrition training is only one component. Most of the available research (Diabetes Control and Complication Trial Research Group, 1993; UK Prospective Diabetes Study Group, 1995; and UK Prospective Diabetes Study Group, 1998) supports the use of a multi-disciplinary approach to diabetes, which includes nutrition training. As a result, nutrition training is considered to be an essential element of the DSMT benefit. Section 1861(qq) of the Act mandates the use of quality standards for DSMT and allows certified individuals or entities designated by the Secretary that meet such standards to receive Medicare payment for the service, provided that the physician managing the patient certified that DSMT is needed.

The approach in the BIPA with regard to MNT is different. The statute mandates specific qualifications regarding who may provide MNT services, but does not require that we establish quality standards. We are also instructed by the Congress to establish criteria for recognition of individuals in States that do not have licensure or certification requirements for registered dietitians or nutrition professionals.

We set specific duration and frequency limits for DSMT, consistent with the statutory authority granted by the BBA. In accordance with our regulations in § 410.141(c), all beneficiaries receiving the DSMT benefit may have up to 10 hours of initial training within a continuous 12-month period. For most beneficiaries, 9 of these 10 hours of training must be in a group setting. One hour of training may be on an individual basis for purposes of conducting an individual assessment and providing specialized training. Once a beneficiary has completed the 10 hours of initial

training, the benefit provides for up to 2 hours of follow-up training each subsequent year. As with the DSMT benefit the duration and frequency of the MNT benefit was not prescribed by the Congress. However, since the Congress has indicated that beneficiaries who have received DSMT within a designated time period (to be specified by the Secretary) are not eligible for MNT, the two benefits must be coordinated.

2. Proposed Policy

Consistent with section 105(a)(3) of the BIPA, we considered the protocols of the American Dietetic Association and the National Kidney Foundation regarding nutrition training for both diabetes and renal disease. Because the protocols were inconclusive with respect to the duration and frequency issues, we are proposing to determine the duration and frequency of the benefit through the National Coverage Determination (NCD) process rather than through the rulemaking process. We will solicit the opinions of all interested parties as a part of the NCD process.

We propose to set forth the provisions regarding medical nutrition therapy at Part 410, subpart G and at § 414.64. The MNT provisions of the proposed rule are as follows:

Definitions (§ 410.130). We propose to define ''renal disease'' for the purpose of this benefit as only chronic renal insufficiency and post-transplant care provided after discharge from the hospital. The exclusion of patients receiving maintenance dialysis under section 1881 of the Act is consistent with section 1861(s)(2) of the Act, as amended by section 105(a)(3) of the BIPA. We propose to limit post-transplant care to care furnished within 6 months after discharge from the hospital, if the transplant is viable and effective, because under such conditions we believe the beneficiary would no longer have renal disease and would not be eligible to receive the benefit under the statutory provision. We propose a 6-month time period based on expert opinions. We specifically request comments on this proposed time period and request that commenters submit articles from clinical journals to support their comments. We do not make separate payments for MNT while the beneficiary is an inpatient in the hospital because the statute only authorizes payment for this service under Part B. We are proposing definitions of ''diabetes'' and ''chronic renal insufficiency'' for the purpose of this benefit using definitions from the Institute of Medicine report, ''The Role of Nutrition in Maintaining Health in the Nation's Elderly,'' published in 2000.

We propose to define ''episode of care'' as a time period that may not exceed 12 months, starting with the assessment (based on a referral from a physician), and including all covered interventions. The number of episodes of care covered during the lifetime of an individual beneficiary is unlimited. We chose a 12-month period to allow for the coordination of the MNT and DSMT benefits, as authorized by section 105(a)(3) of the BIPA.

Finally, in accordance with the statute, we define MNT services as nutritional diagnostic, therapy, and counseling services provided by a registered dietitian or nutrition professional for the purpose of managing disease. This definition tracks the language of the statute.

Medical Nutrition Therapy (§ 410.132).

At proposed § 410.132(a), we set forth conditions for coverage of MNT services. Specifically, we provide that Medicare Part B pays for MNT services furnished by a registered dietitian or nutrition professional as defined in § 410.134 when the beneficiary is referred for the service by the beneficiary's treating physician. We limit the definition of physician to ''treating physician'' to ensure that the physician establishing the need for MNT is actually treating the beneficiary for the chronic disease and the therapy is coordinated with the care being provided by the treating physician. Referrals by a non-treating physician might also be interpreted as an indication that a fraudulent situation exists.

We are proposing that the services covered will consist of nutritional assessment, interventions, reassessment, and follow-up interventions. We chose not to define the specific components of the benefit in more detail because we anticipate that registered dietitians and nutritionists will use nationally recognized protocols, such as those developed by the American Dietetic Association (ADA) as they normally would in their business practice. We also chose not to specify the number of hours of MNT that will be covered. Rather, we will develop these frequency limits using the NCD process. After we complete a literature review, we will solicit input from interested parties as part of the NCD process.

At § 410.132(b), we set forth proposed coverage limitations for MNT services. In accordance with section 1861(s)(2)(V)(ii) of the Act, we would provide that MNT services are not covered for beneficiaries on dialysis for end-stage renal disease. We do not exclude all beneficiaries who are diagnosed with end-stage renal disease because a few individuals with end-stage renal disease do not receive maintenance dialysis and the statute specifically excludes beneficiaries receiving maintenance dialysis under section 1881 of the Act. The other provisions of this section would coordinate the referrals for MNT for diabetes and renal disease, and coordinate MNT services with DSMT services as follows:

- If a beneficiary has both diabetes and a renal disease as defined in this subpart, the beneficiary may receive both MNT and DSMT, but coverage in any 12-month period would be limited to the number of hours the beneficiary would receive under either the MNT benefit or the DSMT benefit for that period, whichever is greater.
- MNT would only be covered if the beneficiary had not started initial training under the diabetes self-management training benefit (as described in § 410.141) within the past 12 months, unless: (1) the need for a reassessment had been documented by the referring physician; or (2) the beneficiary had been diagnosed with both diabetes and renal disease.
- If a beneficiary diagnosed with diabetes was referred for both follow-up DSMT services and MNT, the beneficiary would only receive the total amount of hours covered under either follow-up DSMT services or MNT, whichever was greater.

If DSMT and MNT benefits overlapped, we would not allow the number of hours covered under the MNT benefit to exceed the hours Medicare would cover if the beneficiary was only receiving DSMT, except if a beneficiary receiving initial DSMT subsequently was diagnosed with renal disease or if there was a change in diagnosis or medical condition that occurred during an episode of care. We would allow additional hours of coverage for patients with renal disease and diabetes because MNT for renal disease is more complex than MNT for diabetes alone.

Eligibility for MNT services would be dependent upon diagnoses and referrals made by the treating physician. At proposed § 410.132(c), we provide that referral may only be made by the treating physician when the beneficiary has been diagnosed with diabetes or renal disease, with documentation maintained by the referring physician in the beneficiary's medical record. Referrals must be made for each episode of care. We note that the statute

specifies that a physician, as defined in section 1861(r)(1) of the Act, must refer the beneficiary in order for the therapy to be covered. We are proposing to limit referrals to those made by the treating physician as noted earlier.

At proposed § 410.132(d), we set forth requirements regarding reassessment and follow-up interventions. Specifically, we provide that reassessments and follow-up interventions would only be covered when the referring physician determines that there was a change of diagnosis or medical condition within an episode of care that made a change in diet necessary.

Provider Qualifications (§ 410.134). BIPA specifies how we must define ''registered dietitian or nutrition professional'' for the purposes of this benefit and allows for the grandfathering of nutrition professionals licensed or certified by States at the time of BIPA's enactment. Pursuant to BIPA, a registered dietitian or nutrition professional means an individual who meets the following criteria:

- Holds a bachelor's or higher degree granted by a regionally accredited ollege or university in the United States (or an equivalent foreign degree) with completion of the academic requirements of a program in nutrition or dietetics, as accredited by an appropriate national accreditation organization we have recognized for this purpose.
- Has completed at least 900 hours of supervised dietetics practice under the supervision of a registered dietitian or nutrition professional.
- Is licensed or certified as a dietitian or nutrition professional by the State in which the services are performed, or, if a State does not provide for licensure or certification, meets other criteria established by the Secretary.

We propose to exercise our statutory discretion, with respect to such alternative criteria, by providing that in States that do not provide licensure or certification requirements, we would use the designation of ''registered dietitian'' as certified by the Commission on Dietetic Registration, the credentialing agency for the American Dietetic Association; or require compliance with the statutory educational and experience requirements alone. The Commission on Dietetic Registration is currently considered to be the recognized standard in certification programs for registered dietitians. If an individual can supply documentation to us that he/she is a ''registered dietitian,'' we would not require that individual to also supply documentation that he/she meets the minimum statutory educational and experience requirements, because these latter requirements are also requirements an individual must currently meet to become a ''registered dietitian.'' Likewise, if an individual supplies documentation to us that he/she meets the minimum statutory educational and experience requirements, that individual would not need to supply documentation to us that he/she is a ''registered dietitian.''

The statute also requires that an individual who, as of December 21, 2000 (BIPA's date of enactment), is licensed or certified under the law of the State in which the services are performed as a dietitian or nutrition professional, qualifies as a ''registered dietitian or nutrition professional'' even if he or she does not meet the other education and experience requirements. There is no provision in the law to allow grandfathering of dietitian or nutrition professionals in States with no licensure or certification requirements, or of individuals who did not choose to be licensed or credentialed as of the date of enactment of section 1861(vv)(3) of the Act. Therefore, we only provide for ''grandfathering'' of individuals who do meet the specific criteria of section 1861(vv)(3) of the Act.

Payment for Medical Nutrition Therapy (§ 414.64). Section 105(c) of the BIPA requires that we pay for medical nutrition therapy services at 80 percent of the lesser of the actual charge for the services or 85 percent of the amount determined under the physician fee schedule for the same services if such services had been furnished by a physician. Section 1848 of the Act requires that payments under the physician fee schedule be established on national uniform RVUs based on the resources used in furnishing a service. We have consulted with the ADA to assess the types of resource inputs that are used to furnish a 15-minute medical nutrition therapy session by a Registered Dietitian or Professional Nutritionist.

As stated above, these services would be paid under the physician fee schedule. Malpractice RVUs for medical nutrition therapy services have been extrapolated based on analogous service procedures. The statute specifically provides that medical nutrition therapy services may only be provided by registered dietitians or nutrition professionals. We do not believe that physicians will be able to satisfy the qualification requirements and therefore will not be able to provide this service themselves. Therefore, we are not establishing physician work RVUs for this service. We interpret section 105(c)(2) of BIPA to mean that if a physician were to furnish this service, that the service was performed ''incident to'' the physicians treatment plan and provided by a registered dietitian or nutrition professional. Since we are not proposing work RVUs for medical nutrition therapy, we propose to determine practice expense RVUs using the practice expense methodology for the ''zero work pool.'' (For more information about the practice expense methodology for services that have no physician work, see the November 2, 1998 final rule (63 FR 58814)). The proposed RVUs for individuals and individuals in a group are found in Table 5 as follows:

TABLE 5.—RVUS FOR INDIVIDUALS AND INDIVIDUALS IN A GROUP

Code	Description	Work RVUs	Practice expense RVUs	Malpractice RVUs	Total
97802	Medical nutrition, individual, initial	0.00	0.47	0.01	0.48
97803	Medical nutrition, individual, subseq	0.00	0.34	0.01	0.35
97804	Medical nutrition, group	0.00	0.14	0.01	0.15

Much like diabetes education, the number of MNT beneficiaries attending a group session would vary. As defined in the CPT's Physical Medicine Rehabilitation codes, a group is considered to be two or more individuals.

We would refine the medical nutritional therapy services payment amounts in the future by including the services into the refinement process

used for other Medicare services payable under the physician fee schedule.

Medicare co-payments and deductibles would apply for medical nutritional therapy services. We are proposing to pay for this service under the physician fee schedule using the following codes:

CPT 97802—Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes.

CPT 97803—reassessments and intervention, individual, face-to-face with the patient, each 15 minutes.

CPT 97804—Group, 2 or more individuals, each 30 minutes.

Since payment for MNT will be included in our payment for facility services, separate payment will not be made for hospital inpatients or skilled nursing facility patients. Section 105(c) of BIPA amends section 1833(a)(1) to add subparagraph (T), requiring Medicare payment to equal 80 percent of the of the lesser of the actual charge for the service or 85 percent of the amount determined under the physician fee schedule. Thus, we will make payment in the hospital outpatient department, Federally Qualified Health Centers and Rural Health Clinics at the lesser of 80 percent of the actual charge or 85 percent of the physician fee schedule amount. The RVUs shown above do not reflect this 85 percent adjustment. To determine payment, the RVUs shown above will need to be multiplied by the physician fee schedule conversion factor and 0.85. We expect to provide the Medicare carriers with a payment file that includes this 85 percent adjustment. That is, we expect to determine the payment amount using the RVUs shown and apply the 85 percent adjustment to the product of the geographically adjusted RVUs and conversion factor. The Medicare carriers will not need to make any additional adjustment to the payments we provide.

F. Telehealth Services

1. Background

a. History. Before January 1, 1999, payment for services delivered via a telecommunications system was limited to services that do not require a face-to-face, ''hands-on'' encounter under the traditional delivery of medical care. Examples of these services include interpretation of an x-ray, electrocardiogram and electroencephalogram tracings, and cardiac pacemaker analysis.

The BBA provided for coverage of and payment for consultation services delivered via a telecommunications system to Medicare beneficiaries residing in rural health professional shortage areas (HPSA) as defined by section 332(a)(1)(A) of the Public Health Services Act. Additionally, a Medicare practitioner was required to be with the patient at the time of a teleconsultation.

The BBA specified that payment for a teleconsultation had to be shared between the consulting physician or practitioner and the referring physician or practitioner and could not exceed the fee schedule payment which would have been made to the consultant for the service provided. The BBA prohibited payment for any line charges or facility fees associated with the teleconsultation and clarified that the beneficiary may not be billed for these charges or fees.

These provisions became effective January 1, 1999. The November 2, 1998 final rule on ''Revisions to Payment Policies Under the Physicians Fee Schedule for Calendar Year 1999'' (63 FR 58879) implemented these provisions.

b. Legislative Summary. In section 223 of the BIPA, the Congress provided for a ''Revision of Medicare Reimbursement for Telehealth Services'' and specified a ''sunset'' date for the current statutory teleconsultation provisions. The current teleconsultation provisions contained in section 4206(a) and (b) of the BBA and implemented in §§ 410.78 and 414.65 apply only to teleconsultations provided on or after January 1, 1999 and before October 1, 2001.

Beginning October 1, 2001, the BIPA amends section 1834 of the Act to provide for a new subsection (m) ''Payment for Telehealth Services.'' This amendment provides for an expansion of Medicare payment for telehealth services. A summary of the expansion appears below.

The BIPA specifies that we pay for telehealth services that are furnished via a telecommunications system by a physician (as defined in section 1861(r) of the Act) or a practitioner (described in section 1842(b)(18)(C) of the Act). Telehealth services may be provided only to an eligible telehealth individual enrolled under Medicare, notwithstanding the fact that the individual physician or practitioner providing the telehealth service is not at the same location as the beneficiary.

The BIPA defines Medicare telehealth services as professional consultations, office or other outpatient visits, and office psychiatry services identified as of July 1, 2000, by CPT codes 99241 through 99275; 99201 through 99215, 90804 through 90809 and 90862 (and as we may subsequently modify) and any additional service we specify.

The statute requires us to establish a process that provides, on an annual basis, for the addition or deletion of services (and HCPCS codes) as appropriate, to the services specified above, for authorized payment under Medicare.

Section 1834(m)(4)(B) of the Act, as added by the BIPA, specifies that an eligible telehealth individual means an individual enrolled under Part B who receives a telehealth service furnished at an originating site. Originating sites are defined only as specified medical facilities located in specific geographic areas. Section 1834(m)(4)(C) of the Act, as added by the BIPA, limits originating sites to the following types of facilities:

- The office of a physician or practitioner.
- A critical access hospital (as defined in section 1861(mm)(1) of the Act).
- A rural health clinic (as defined in section 1861(aa)(s) of the Act).
- A Federally qualified health center (as defined in section 1861(aa)(4) of the Act).
- A hospital (as defined in section 1861(e) of the Act).

The BIPA specifies that the originating site must be located in one of the following geographic areas:

- In an area that is designated as a rural health professional shortage area under section 332(a)(1)(A) of the Public Health Service Act.
- In a county that is not included in a Metropolitan Statistical Area.
- From an entity that participates in a Federal telemedicine demonstration project that has been approved by (or receives funding from) the Secretary of Health and Human Services as of December 31, 2000.

The BIPA relaxes some of the conditions for payment imposed by the BBA. Section 1834(m)(2)(C) of the Act, as added by the BIPA, specifies that a telepresenter is not required and specifically states that nothing in section 1834(m)(2)(C) of the Act shall be construed as requiring an eligible telehealth beneficiary to be presented by a physician or practitioner at the originating site for the furnishing of a service via a telecommunications system, unless it is medically necessary (as determined by the physician or practitioner at the distant site).

Additionally, section 1834(m)(1) of the Act, as added by the BIPA, specifies that, for purposes of defining a telecommunications system, in the case of any Federal telemedicine demonstration program conducted in Alaska or Hawaii, the term ''telecommunications system'' includes store and forward technologies that

provide for the asynchronous transmission of health care information in single or multimedia formats.

Section 1834(m)(2) of the Act, as added by the BIPA, states that we pay a physician or practitioner located at a distant site that furnishes a telehealth service to an eligible telehealth beneficiary an amount equal to the amount that the physician or practitioner would have been paid under Medicare had the service been furnished without the use of a telecommunications system.

This section also provides for a facility fee payment to the originating site. It specifies that for the period beginning October 1, 2001 through December 31, 2002, the originating site facility fee is equal to $20. For each subsequent year, the facility fee for the preceding year is increased by the percentage increase in the MEI as defined in section 1842(i)(3) of the Act.

The BIPA amended section 1833(a)(1) of the Act by adding subparagraph (U), specifying that with respect to the originating site facility fees, the amount paid is 80 percent of the lesser of the actual charge or the amounts specified in new section 1834(m)(2) of the Act.

Section 1834(m)(3) of the Act requires that the provisions of sections 1848(g) and 1842(b)(18)(A) and (B) of the Act apply to physicians and practitioners. The provisions of section 1842(b)(18) of the Act apply to originating sites receiving a facility payment as the provisions apply to practitioners under section 1834(m) of the Act.

Section 1848(g) of the Act provides a limitation of charges to beneficiaries and provides sanctions if a physician, supplier, or other person knowingly and willfully bills or collects for services in violation of the limitation. It also provides for sanctions if a physician, supplier, or other person fails—(1) to timely correct excess charges by reducing the actual charge billed for the service to an amount that does not exceed the limiting charge for the service, or (2) to timely refund excess collections. In addition, it requires that physicians and suppliers submit claims for services they furnished to a beneficiary to a carrier on behalf of the beneficiary using a standard Medicare claim form. The statute imposes a penalty for failure to submit the claim. In addition, section 1848(g) of the Act prohibits imposing any charge relating to completing and submitting the claim. Section 1842(b)(18) of the Act provides that services furnished by a physician assistant, nurse practitioner, clinical nurse specialist, certified registered nurse anesthetist, anesthesiologist's assistant, certified nurse-midwife, clinical social worker, or clinical psychologist for which payment may be made on a reasonable charge or fee schedule basis may be made only on an assignment-related basis. It also limits the beneficiary's liability to any applicable deductible and coinsurance amounts. It further provides for sanctions against a practitioner who knowingly and willfully bills (or collects an amount) in violation of the limitation.

c. Implementation. Section 223 of the BIPA limits the application of the existing telehealth provision to services furnished before October 1, 2001 and mandates that the expanded benefit be effective for services furnished on or after October 1, 2001. Therefore, this benefit expansion is being implemented via program memorandum. The program memorandum is effective October 1, 2001 when the telehealth benefit supercedes the teleconsultation benefit authorized by section 4206 of the BBA and existing regulations at § 410.78 and § 414.65. Any regulatory changes resulting from this rulemaking process will be effective January 1, 2002.

d. Proposed Policies. This rule proposes to establish policies for implementing the provisions of section 1834(m) of the Act, as added by the BIPA, that change Medicare payment for telehealth services.

(i) Scope of telehealth benefit. Section 1834(m)(4)(B) of the Act, as added by the BIPA, defines an eligible telehealth individual as a Medicare beneficiary who receives a telehealth service furnished at an originating site. As discussed earlier, originating sites are limited to certain facilities within specifically identified geographic areas.

We would revise § 410.78 to specify that Medicare beneficiaries are eligible for telehealth services only if they receive services from an originating site located in either a rural HPSA as defined by section 332(a)(1)(A) of the Public Health Services Act or in a county outside of a MSA as defined by section 1886(d)(2)(D) of the Act. Additionally, we would provide for an exception if an entity participates in a Federal telemedicine demonstration project that has been approved by, or receives funding from, us as of December 31, 2000. That entity would not be required to be in a rural HPSA or non-MSA as described above.

We would also specify that, providing the geographic criteria are met, the following sites qualify as originating sites under this provision:

- The office of a physician or practitioner.
- A hospital as defined in section 1861(e) of the Act.
- A critical access hospital as defined in section 1861(mm)(1).
- A rural health clinic as defined in section 1861(aa)(2) of the Act.
- A Federally qualified health center as defined in section 1861(aa)(4) of the Act.

Covered Services. Section 1834(m)(4)(F) of the Act, as added by the BIPA, defines telehealth services as professional consultations, office and other outpatient visits, individual psychotherapy, pharmacologic management and any additional service we specify. Additionally, this provision identifies covered services by HCPCS codes identified as of July 1, 2000. We propose to revise § 410.78 to implement this coverage expansion. The services and corresponding CPT codes are listed below:

- Consultations (codes 99241 through 99275).
- Office and other outpatient visits (codes 99201 through 99215).
- Individual Psychotherapy (codes 90804 through 90809).
- Pharmacologic management (code 90862).

The BIPA provision is effective for services beginning on October 1, 2001. Payment for the statutorily specified codes, as listed above, will be implemented beginning with that date. We propose to make any additions or deletions to the services defined as telehealth effective on a January 1st basis. We plan to use the annual physician fee schedule proposed rule published in the summer and the final rule (published by November 1) each year as the vehicle to make these changes. Since the statutory provision will be implemented on October 1, 2001, and there is limited published data on telehealth in clinical settings, we will not make any recommendations on additional services until we have had time to ensure we have a process for redefining covered services in place.

We are soliciting suggestions and comments from the public regarding the guidelines that we should use to make additions or deletions of services. We also solicit suggestions and comments about specific services that may be appropriate to be covered under the Medicare telehealth benefit. Once we complete our review of these suggestions and comments, we will propose a more detailed approach as to how we would make modifications to the existing telehealth benefit.

(ii) Conditions of Payment: *Technology.* The Congress defines the term ''telecommunications system'' with respect to demonstration projects conducted in Alaska or Hawaii; however, the BIPA does not define a

telecommunications system in any other case. In a non-telehealth setting, Medicare pays for these codes only if there is a face-to-face encounter between the patient and attending physician or practitioner. We believe that the patient's presence and use of an interactive audio and video telecommunications system permitting the distant site practitioner to interact with the patient provides a reasonable substitute for a face-to-face encounter.

Limited exception to the interactive telecommunications requirement. For purposes of defining a telecommunications system, section 1834(m)(1) of the Act includes the use of store and forward technology in very limited circumstances. This provision specifies that, in the case of a Federal telemedicine demonstration program conducted in Alaska or Hawaii, Medicare payment is permitted when asynchronous, store and forward technologies, in single or multimedia formats is used to deliver the service.

Store and forward technology substitutes for an interactive, patient-present encounter in these limited circumstances. The patient is not present or available to interact with the distant site physician or practitioner in real-time.

We believe that when store and forward technologies are used to substitute for an interactive patient encounter, the technology must permit the distant site practitioner adequate medical information for recommending or confirming a diagnosis or treatment plan. A patient's medical information may typically include various combinations of the following items—video clips, still images, x-rays, magnetic resonance images, electrocardiogram and electroencephalogram tracings, tissue samples, laboratory results, and audio clips of heart or lungs.

We propose to specify at § 410.78 that, except for the statutory provision noted above, an interactive telecommunications system must be used and that the medical examination of the patient is at the control of the physician or practitioner at the distant site. We would define interactive telecommunications system as multimedia communications equipment that includes, at a minimum, audio and video equipment permitting two-way, real-time interactive communication between the patient and physician or practitioner at the distant site. We would also specify that telephones, facsimile machines, and electronic mail systems do not meet the definition of an interactive telecommunications system.

Additionally, we would provide an exception to the interactive requirements where the patient must be present for a Federal telemedicine demonstration program conducted in Alaska or Hawaii. We would specify that for Federal telemedicine demonstration programs conducted in Alaska or Hawaii, Medicare payment is permitted for telehealth when asynchronous store and forward technologies, in single or multimedia formats, are used as a substitute for an interactive telecommunications system. Additionally, we would specify that the physician or practitioner at the distant site must be affiliated with the demonstration program.

This exception would be permitted for Federal telemedicine demonstration projects conducted in Alaska or Hawaii only. Interactive telecommunications system with the real-time presence of the patient is required as a condition of payment in all other circumstances.

We would define asynchronous, store and forward technologies, as the transmission of the patient's medical information from an originating site to the physician or practitioner at the distant site. The physician or practitioner at the distant site can review the medical case without the patient being present. Asynchronous telecommunications system in single media format does not include telephone calls, images transmitted via facsimile machines, and text messages without visualization of the patient (electronic mail). Photographs must be specific to the patient's medical condition and adequate for rendering or confirming a diagnosis or treatment plan. Dermatological photographs, for example, a photograph of a skin lesion may be considered to meet the requirement of a single media format under this provision.

Additionally, we would define the originating site as the location of an eligible Medicare beneficiary at the time the service being furnished via a telecommunications system occurs. For asynchronous, store and forward telecommunications technologies, an originating site is a Federal telemedicine demonstration program conducted in Alaska or Hawaii.

Telepresenter. As mentioned earlier, the BIPA changed the telepresenter requirements. In accordance with section 1834(m)(2)(C) of the Act, a telepresenter is not required to be present. Therefore, we would not require a telepresenter as a condition of Medicare payment.

Practitioners eligible to receive payment for Medicare Telehealth Services. Section 1834(m)(1) of the Act requires that Medicare make payments for telehealth services furnished via a telecommunications system by a physician or a practitioner (described in section 1842(b)(18)(C) of the Act). Non-physician practitioners described in this section of the Act include nurse practitioners, physician assistants, clinical nurse specialists, certified nurse midwives, clinical psychologists, clinical social workers, and certified registered nurse anesthetists or anesthesiologists' assistants. Section 1834(m)(2) of the Act specifies that the payment amount to the physician or practitioner at the distant site who furnishes a telehealth service be equal to the amount that the physician or practitioner would have been paid under Medicare had the service been furnished without the use of a telecommunications system.

As discussed earlier in this document, covered telehealth services include office visits (codes 99201 through 99215), consultation (codes 99241 through 99275), individual psychotherapy (codes 90804 through 90809), and pharmacologic management (code 90862). If a physician, clinical nurse specialist, nurse practitioner, physician assistant, nurse midwife, clinical psychologist, or clinical social worker is licensed under State law to provide a service listed above, then these practitioners may bill for and receive payment for this service when delivered via a telecommunications system.

Clinical psychologists and clinical social workers cannot bill or receive payment for psychotherapy involving evaluation and management services under Medicare when the service is delivered face-to-face (that is, without the use of a telecommunications system). Therefore, clinical psychologists and clinical social workers cannot receive payment for these services under the telehealth benefit.

Certified registered nurse anesthetists and anesthesiologists' assistants are not eligible. Certified registered nurse anesthetists and anesthesiologists' assistants would not be permitted to bill for and receive payment for a telehealth service under this provision. Section 1861(bb) of the Act defines services provided by these practitioners as anesthesia services and related care only. Under the Medicare program, these practitioners do not receive payment for office visits, consultation, individual psychotherapy, or pharmacologic management when these services are furnished without the use of a telecommunications system. Section 1834(m)(2) of the Act specifies that the

payment amount made to the distant site physician or practitioner must be equal to what would have been paid for the service without the use of a telecommunications system. Therefore, certified registered nurse anesthetists and anesthesiologists' assistants would not receive payment for telehealth services.

Proposed regulatory provisions. Based on the law, we would state at § 410.78 that, as a condition of Part B payment for telehealth services, the physician or practitioner at the distant site must be licensed to provide the service under State law. When the physician or practitioner at the distant site is licensed under State law to provide a covered telehealth service (that is, professional consultations, office and other outpatient visits, individual psychotherapy, and pharmacologic management), then he or she may bill for and receive payment for this service when delivered via a telecommunications system.

We would specify that the physician or practitioner at the distant site may be any of the following (provided that the physician or practitioner is licensed to bill for the service being furnished via a telecommunications system):

- A physician as described in § 410.20.
- A physician assistant as defined in § 410.74.
- A nurse practitioner as defined in § 410.75.
- A clinical nurse specialist as described in § 410.76.
- A nurse midwife as defined in § 410.77.
- A clinical psychologist as described in § 410.71.
- A clinical social worker as defined in § 410.73.

However, we would further specify that a clinical psychologist and clinical social worker may bill for individual psychotherapy furnished via a telecommunications system, but may not seek payment for medical evaluation and management services.

Documentation. Documentation requirements as specified in our most recent documentation guidelines are applicable to services delivered via a telecommunications system. At this time, we will not require additional documentation under this provision beyond what is already required for medical services delivered without the use of a telecommunications system. Medicare documentation guidelines are available from our web site. You may access our documentation guidelines by using the following directions:

1. Go to the CMS Homepage (*http://www.cms.gov*).
2. Click on ''Medicare'' (Top left hand column).
3. Click on ''Professional/Technical Information''
4. Click on ''Documentation Guidelines for Evaluation and Management Services:''
5. You may choose the 1995 version or the 1997 version whichever best fits your needs.

(iii) Payment provisions. *Professional Services: General*—Section 1834(m)(2)(A) of the Act, specifies that the payment amount for the professional service is equal to the amount that would have been paid without the use of a telecommunications system. Medicare payment for physicians' services is generally based, under section 1848 of the Act, on the resource-based physician fee schedule. Payment to other health care practitioners listed earlier, authorized under section 1833 of the Act, is based on a percentage of the physician fee schedule payment amount. Therefore, we would pay for office or other outpatient visits, consultation, individual psychotherapy, and pharmacologic management services furnished by physicians at 80 percent of the lower of the actual charge or the fee schedule amount for physicians' services. We would also pay for services furnished by other practitioners at 80 percent of the lower of the actual charge or that practitioner's respective percentage of the physician fee schedule (for example, the fee schedule amount for clinical psychologists would be 100 percent of the physician fee schedule; for clinical social workers, the payment would be made at 75 percent of the clinical psychologist fee schedule; for certified nurse midwives, the payment would be made at 65 percent of the physicians fee schedule; and for all other eligible health care practitioners, payment would be made at 85 percent of the physician fee schedule). Assuming the beneficiary has met his or her Part B deductible, the beneficiary would be responsible for 20 percent of the appropriate payment amount.

Payment for Telepresenter. Section 1834(m)(2) of the Act, provides for a professional fee for the physician or practitioner at the distant site (equal to the applicable Part B fee schedule amount) and a $20 facility fee for the originating site. Telepresenters are not required, unless one is deemed medically necessary by the physician or practitioner at the distant site. BIPA does not address the issue of payment for the telepresenter. The Office of the Inspector General has advised us that permitting the physician or practitioner at the distant site to pay the telepresenter creates a significant risk under the anti-kickback statute and may also violate many State fee-splitting laws. Therefore, we would propose in § 414.65 that payments made to the distant site physician or practitioner for professional fees, including deductible and coinsurance (for the professional service), are not to be shared with the referring practitioner or telepresenter.

However, the telepresenter could bill and receive payment for services that are not telehealth services that a telepresenter would otherwise be allowed to provide under the Medicare statute, including services furnished on the same day as the telehealth service.

Facility Fee for the Originating Site. The BBA prohibited any payment for line charges or facility fees associated with a professional consultation via a telecommunications system. Section 1834(m)(2)(B) of the Act, as added by the BIPA, provides for a facility fee payment to the originating site, specifying that the amount of payment is 80 percent of the lesser of the actual charge or a facility fee of $20.00. The BIPA further specifies that, beginning January 1, 2003, the originating facility fee be increased annually by the Medicare Economic Index (MEI) as defined in section 1842(i)(3) of the Act. Additionally, we clarify that the Geographic Practice Cost Index (GPCI) would not apply to the facility fee for the originating site. This fee is statutorily set and is not subject to the geographic payment adjustments authorized under the physician's fee schedule. The beneficiary is responsible for any unmet deductible amount and Medicare coinsurance. We would revise § 414.65 to provide for payment of a facility fee to the originating site.

Coding. For office and other outpatient visits, consultation, individual psychotherapy, and pharmacologic management delivered via a telecommunications system, we would use modifiers in conjunction with existing CPT codes to indicate the use of a telecommunications system in delivering the service.

A new HCPCS code for the facility fee for the originating site will be used to identify this fee. Since this is a new occasion of payment under Medicare, a separate and distinct code for the facility fee is necessary for contractors to make the appropriate payment.

G. Indian Health Service

The Indian health care system provides primary health care to many American Indian and Alaska Native Medicare beneficiaries. This system consists of programs operated by a

Federal agency, the Indian Health Service (IHS), and Federally funded programs operated by Indian tribes, tribal organizations, and urban Indian organizations (as those terms are defined in section 4 of the Indian Health Care Improvement Act). These programs deliver a range of clinical and preventive health services to their beneficiaries through a network of facilities including hospitals and outpatient clinics. Programs operated in IHS-owned or leased facilities, by IHS or by tribes or tribal organizations, are considered ''Federal providers'' by Medicare. Sections 1814(c) and 1835(d) of the Act generally prohibit payment to Federal providers, subject to exceptions contained in section 1880 of the Act for these IHS facilities. Prior to enactment of the BIPA, the exception in section 1880 of the Act was applicable only to IHS hospitals including provider-based clinics (IHS hospital outpatient clinics) and skilled nursing facilities. The exception did not permit Medicare to pay for services furnished by IHS free-standing outpatient clinics or to pay any IHS facilities for services by physicians and other practitioners paid under a fee schedule.

Effective July 1, 2001, section 432 of the BIPA extends the exception in section 1880 of the Act to permit Medicare payments to hospitals and outpatient clinics (provider-based or free-standing), operated by the IHS or by a tribe or tribal organization, for services furnished by physicians and specified non-physician practitioners in or at the direction of an IHS hospital or outpatient clinic. Payments for these services are made to the IHS or tribal hospital or outpatient clinic, not to the physician or other practitioner. These payments are subject to the same situations, terms, and conditions as would apply if the services were furnished in or at the direction of a hospital or outpatient clinic that is not operated by the IHS or by a tribe or tribal organization. The payments include incentive payments for physicians furnishing covered physicians' services in rural or urban HPSAs if the usual HPSA criteria are met. (For further information see section 1833 of the Act and § 414.42 of our regulations.) Payments will not be made under these provisions to the extent that Medicare is otherwise paying for the same services under other provisions (for example, as part of a bundled payment, or if a tribal hospital outpatient clinic continues to bill as a Federally qualified health center (FQHC)).

We are adding a new § 410.46 to our regulations to reflect this new statutory provision. Due to the statutory effective date of July 1, 2001, we will implement this BIPA provision through program memorandum instructions.

H. Pathology Services

Background

The November 2, 1999 final rule (64 FR 59380) provided that, for services furnished on or after January, 1, 2001, carriers would no longer pay claims to independent laboratories under the physician fee schedule for the technical component (TC) of physician pathology services for hospital inpatients. Before this rule, independent laboratories could bill the carrier under the physician fee schedule for the TC of a physician pathology service furnished to a hospital inpatient. Under the rule, independent labs would still have been able to bill and receive payment for TC physician pathology services furnished to patients who are not hospital inpatients. (The TC of physicians' pathology services includes the TC of cytopathology and surgical pathology physicians' services as described in the Medicare Carrier Manual, section 15020 B and C.) This change was to take effect for services furnished on or after January 1, 2001. The delay between publication and effective date was intended to allow independent laboratories and hospitals sufficient time to negotiate new arrangements, if necessary.

BIPA Provision

Section 542 of the BIPA requires the Medicare carrier to continue to pay for the TC of physician pathology services when an independent laboratory furnishes these services to an inpatient or outpatient of a covered hospital. The BIPA provisions apply to TC services furnished during the 2-year period beginning January 1, 2001 and continuing through December 31, 2002. We informed the carriers and the intermediaries of this provision through program memorandum AB–01–47 which was issued in March 2001. This program memorandum requested the carriers to notify independent laboratories of this provision in their next regularly scheduled bulletin and to place this bulletin on their Internet web site.

In the absence of further legislation, the policy of the November 1999 final rule will take effect for the TC of physician pathology services furnished to hospital patients after December 31, 2002.

Definitions

For this provision, ''covered hospital'' means a hospital that had an arrangement with an independent laboratory that was in effect as of July 22, 1999, under which a laboratory furnished the TC of physician pathology services to fee-for-service Medicare beneficiaries who were hospital inpatients or outpatients and submitted claims for payment for the TC to a carrier. The TC could have been submitted separately or combined with the professional component and reported as a combined service.

The term ''fee-for-service Medicare beneficiary'' means an individual who—(1) Is entitled to benefits under Part A or enrolled under Part B of Title XVIII or both, and; (2) Is not enrolled in any of the following:

- A Medicare+Choice plan under Part C of that title.
- A plan offered by an eligible organization under section 1876 of the Act.
- A program of all-inclusive care for the elderly (PACE) under section 1894 of the Act.
- A social health maintenance organization (SHMO) demonstration project established under section 4018(b) of the Omnibus Budget Reconciliation Act of 1987.

V. Collection of Information Requirements

Under the Paperwork Reduction Act (PRA) of 1995, we are required to provide 60-day notice in the **Federal Register** and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires that we solicit comment on the following issues:

- The need for the information collection and its usefulness in carrying out the proper functions of our agency.
- The accuracy of our estimate of the information collection burden.
- The quality, utility, and clarity of the information to be collected.
- Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

We are soliciting public comment on each of these issues for the following sections of this document that contain information collection requirements:

§ 410.132—Medical Nutrition Therapy

Paragraph (c) of this section requires a referring physician or practitioner to

maintain referral documentation in the beneficiary's medical record for each referral. Paragraph (b)(3)(i) requires that the referring physician or qualified non-physician practitioner document a reassessment in the beneficiary's medical record. Paragraph (e) of this section requires the medical nutrition therapy care plan to be sent to the referring physician initially and each time the medical nutrition therapy care plan is updated. If the physician makes recommendations regarding the medical nutrition therapy care plan, the registered dietitian or nutrition professional must integrate the requirements into the medical nutrition therapy care plan.

We believe the burden associated with these provisions is exempt in accordance with 5 CFR 1320.3(b)(2) because the time, effort, and financial resources necessary to comply with these requirements would be incurred by certified providers in the normal course of business activities.

If you comment on these information collection and recordkeeping requirements, please mail copies directly to the following:

Health Care Financing Administration, Office of Information Services, Information Technology Investment Management Group, Attn.: John Burke, CMS–1169–P, Room N2–14–26, 7500 Security Boulevard, Baltimore, MD 21244–1850.

Office of Information and Regulatory Affairs, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503, Attn: Allison Eydt, CMS Desk Officer.

VI. Response to Comments

Because of the large number of items of correspondence we normally receive on **Federal Register** documents published for comment, we are not able to acknowledge or respond to them individually. We will consider all comments we receive by the date and time specified in the ''DATES'' section of this preamble, and, if we proceed with a subsequent document, we will respond to the major comments in the preamble to that document.

VII. Regulatory Impact Analysis

We have examined the impact of this rule as required by Executive Order 12866 (September 1993, Regulatory Planning and Review) and the Regulatory Flexibility Act (RFA) (Public Law 96–354). Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). A regulatory impact analysis must be prepared for proposed rules with economically significant effects (that is, a proposed rule that would have an annual effect on the economy of $100 million or more or would adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities). We estimate the changes to the practice expense RVUs (not including earlier proposed changes to the work RVUs) may result in a redistribution of payments among physician specialties of approximately $100 million. We estimate the benefit changes in this proposed rule resulting from the BIPA will likely result in additional Medicare expenditures of $210 to $360 million or more for any single FY through FY 2006. Therefore, this proposed rule is considered economically significant, and, thus, we have prepared a regulatory impact analysis.

The RFA requires agencies to analyze options for regulatory relief of small businesses. For purposes of the RFA, small entities include small businesses, nonprofit organizations and government agencies. Most hospitals, and most other providers, physicians, and health care suppliers are small entities, either by nonprofit status or by having revenues of $7.5 million or less annually for physicians and $5 million or less for other practitioners. For purposes of the RFA and based on small business administration data for 1997, we estimate that there are 162,000 physician organizations that meet the definition of a small entity. There are about 700,000 physicians and other practitioners who receive Medicare payment under the physician fee schedule. Individuals and States are not included in the definition of a small entity.

Section 1102(b) of the Social Security Act requires us to prepare a regulatory impact analysis for any proposed rule that may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 603 of the RFA. For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside a Metropolitan Statistical Area and has fewer than 100 beds.

Section 202 of the Unfunded Mandates Reform Act of 1995 also requires that agencies assess anticipated costs and benefits before issuing any rule that may result in expenditure in any one year by State, local, or tribal governments, in the aggregate, or by the private sector, of $110 million. We have determined that this proposed rule will have no consequential effect on State, local, or tribal governments. We believe the private sector cost of this rule falls below the above-stated threshold as well.

Thus, we have prepared the following analysis, which together with the rest of this preamble, meets all assessment requirements. It explains the rationale for, and purposes of, the rule, details the costs and benefits of the rule, analyzes alternatives, and presents the measures we propose to use to minimize the burden on small entities.

A. Resource-Based Practice Expense Relative Value Units and 5-Year Review Changes

Under section 1848(c)(2) of the Act, adjustments to relative value units may not cause the amount of expenditures to differ by more than $20 million from the amount expenditures would have been without such adjustments. We are proposing several changes that would result in a change of expenditures exceeding $20 million without offsetting adjustments to either the conversion factor or relative value units. In the June 8, 2001 Five-Year Review of Relative Value Units Under the Physician Fee Schedule, (66 FR 31028), we described the specialty level impact on payments of proposed changes in work RVUs. We estimated that the increase in physician work RVUs would increase expenditures by more than $20 million without an offsetting adjustment to either the relative value units or conversion factor. We proposed to meet the budget neutrality requirements in the statute by reducing the physician fee schedule conversion factor by an estimated 0.3 percent. Since the changes to the physician work RVUs included in our earlier proposed notice will affect payments in 2002, we are repeating those impacts in Table 6. In addition, we are also showing the impact of proposed changes that will affect the practice expense relative value units.

With respect to practice expense, our policy has been to meet the budget neutrality requirements in the statute by incorporating a rescaling adjustment in the practice expense methodology. That is, we determined the aggregate number of practice expense relative values that will be paid under current and proposed policy in 2002. We apply a uniform adjustment factor to all proposed practice expense relative value units to make them equal to the aggregate

number of practice expense relative values that we estimate will be paid under current policy. Table 6 shows the specialty level impact on payment of changes being proposed for 2002.

The three columns under the label ''5-Year Review of Work'' show the estimated change in payments that will result from our earlier notice on the 5-Year Review of Work Relative Value Units. The column labeled ''Work'' shows the impact on total payments that will result from increases in physician work relative value units. Since the practice expense relative value units are based, in part, on the physician work, the 5-year review will also result in a change to the practice expense relative value units. The column labeled ''Practice Expense'' shows this impact and includes the effect of the rescaling adjustment discussed above to make the practice expense relative value units budget neutral. The column labeled ''Total'' reflects the total impact on payments resulting from proposed changes in work and practice expense from the 5-year review of physician work. This column includes the effect of a 0.3 percent reduction to the physician fee schedule conversion factor to meet the budget neutrality requirements in the statute.

The column labeled ''New Time'' reflects the estimated specialty level impact on payments that will result from using new physician times in the practice expense methodology. As described earlier in section II.A., physician time is used in conjunction with information on practice expense per hour and Medicare utilization to create specialty practice expense pools that are used to allocate practice expenses to different services. The RUC earlier indicated to us that some of the times we were using in the practice expense methodology differed from the times included in the RUC database. We understand that the RUC has made substantial efforts to validate the time in its database with physician specialty societies and to supply us with times that were missing for some services. The RUC recently forwarded the results of this effort to us and is recommending that we use the new times in the practice expense methodology. In addition, several physician specialty societies obtained new and more recent survey times as a result of the five-year review of physician work. The RUC has reviewed and forwarded these times to us as well and is also recommending that we use them in the practice expense methodology. We believe the times supplied to us by the RUC are more likely to be reflective of the actual time it takes to perform a procedure. For this reason, we are proposing to use these new times in the practice expense methodology. As indicated in our June 8, 2001 proposed notice, our expectation was that the substitution of new times would reduce payments to cardiac and thoracic surgeons because the new times for many heart and chest procedures are shorter than those we have been using in the practice expense methodology. We estimate that substitution of new physician times will reduce payments to cardiac and thoracic surgeons by an estimated 5 and 4 percent, respectively. Combining this reduction with the change in work relative value units will result in a total estimated increase in payments from between 0 and 1 percent for cardiac and thoracic surgeons. We estimate change in payments to other specialties from using new time data will be one percent or less.

The column labeled ''New SMS'' refers to our proposal to recalculate the practice expense per hour data based on the 1995 through 1999 SMS. (We refer to the SMS based on its publication year. The practice expense data is actually from surveys performed the year prior to publication. For example, the 1998 SMS includes 1997 cost data.) The proposed changes in practice expense per hour from incorporating the latest SMS data are modest. Payments to pathologists are estimated to increase by 2 percent. Specialty 69—Independent Laboratory, the largest specialty included in the supplier category, bills for many of the same services as pathologists, producing our estimated 2 percent increase in Medicare payments to suppliers.

The column labeled ''Clinical Labor Repricing'' reflects our proposal to use 1999 information from the Bureau of Labor Statistics to update the wage rate information that is used to price clinical labor inputs in the practice expense methodology. We estimate that this proposal will result in less than a 1 percent change in payments to any physician specialty.

The column labeled ''Other'' refers to our proposal to make minor modifications to the specialty utilization. As discussed earlier, we are proposing to recode the specialty for several very low volume physician specialties that likely have practice expenses that are similar to other larger physician specialties. In addition, this policy reflects our proposal to drop the utilization for a number of specialties from the practice expense methodology because a very small percentage (one percent or less) of their allowed charges are from physician fee schedule services. The modifications to the utilization data that we are proposing have virtually no specialty level impact on any specialty.

TABLE 6.—IMPACT OF PROPOSED WORK AND PRACTICE EXPENSE CHANGES TOTAL ALLOWED CHARGES BY SPECIALTY

Specialty	Allowed charges $ Billions	5 year review of work practice			New time	New SMS	Clinical labor re-pricing	Other	Total
		Work	Expense	Total					
ANESTHESIOLOGY	1.5	1%	0%	1%	0%	0%	0%	0%	1%
CARDIAC SURGERY	0.3	5%	1%	6%	5%	0%	0%	0%	0%
CARDIOLOGY	4.2	0%	0%	0%	0%	0%	0%	0%	0%
CHIROPRACTOR	0.4	0%	0%	0%	0%	0%	0%	0%	0%
CLINICS	1.6	0%	0%	0%	0%	0%	0%	0%	0%
DERMATOLOGY	1.4	0%	0%	0%	0%	1%	0%	0%	1%
EMERGENCY MEDICINE	1.0	0%	0%	0%	0%	0%	0%	0%	0%
FAMILY PRACTICE	3.3	0%	0%	0%	0%	0%	0%	0%	0%
GASTROENTEROLOGY	1.2	0%	0%	0%	1%	0%	0%	0%	1%
GENERAL PRACTICE	1.0	0%	0%	0%	0%	0%	0%	0%	0%
GENERAL SURGERY	2.0	3%	1%	4%	0%	0%	0%	0%	4%
HEMATOLOGY ONCOLOGY	0.6	0%	−1%	−1%	0%	0%	0%	0%	0%
INTERNAL MEDICINE	7.1	0%	0%	0%	0%	0%	0%	0%	0%
NEPHROLOGY	1.0	0%	0%	0%	0%	0%	0%	0%	0%
NEUROLOGY	0.9	0%	0%	0%	0%	0%	0%	0%	0%
NEUROSURGERY	0.4	0%	0%	0%	0%	0%	0%	0%	0%
NONPHYSICIAN PRACTITIONER	1.2	0%	0%	0%	0%	0%	0%	0%	0%
OBSTETRICS/GYNECOLOGY	0.4	0%	0%	1%	0%	1%	0%	0%	1%
OPHTHALMOLOGY	3.9	0%	0%	0%	0%	−1%	0%	0%	−1%
OPTOMETRIST	0.5	0%	0%	0%	0%	−1%	1%	0%	0%

TABLE 6.—IMPACT OF PROPOSED WORK AND PRACTICE EXPENSE CHANGES TOTAL ALLOWED CHARGES BY SPECIALTY—Continued

Specialty	Allowed charges $ Billions	5 year review of work practice			New time	New SMS	Clinical labor re-pricing	Other	Total
		Work	Expense	Total					
ORTHOPEDIC SURGERY	2.3	0%	0%	0%	0%	0%	0%	0%	0%
OTHER PHYSICIAN	1.6	0%	0%	0%	0%	0%	0%	0%	1%
OTOLARYNGOLOGY	0.6	0%	0%	0%	1%	0%	0%	0%	0%
PATHOLOGY	0.6	0%	0%	0%	0%	2%	0%	0%	3%
PLASTIC SURGERY	0.2	0%	0%	0%	0%	0%	0%	0%	0%
PODIATRY	1.1	0%	0%	0%	1%	0%	0%	0%	1%
PSYCHIATRY	1.1	0%	0%	0%	0%	0%	0%	0%	0%
PULMONARY	1.1	0%	0%	0%	0%	0%	0%	0%	0%
RADIATION ONCOLOGY	0.7	0%	−1%	−1%	0%	0%	0%	0%	0%
RADIOLOGY	3.3	0%	−1%	0%	0%	0%	0%	0%	0%
RHEUMATOLOGY	0.3	0%	0%	0%	0%	0%	0%	0%	0%
SUPPLIERS	0.5	0%	−1%	−1%	−1%	2%	0%	1%	2%
THORACIC SURGERY	0.5	4%	1%	5%	−4%	0%	0%	0%	1%
UROLOGY	1.3	0%	0%	0%	0%	0%	0%	0%	1%
VASCULAR SURGERY	0.3	2%	0%	2%	−1%	0%	0%	0%	2%

Table 7 shows the impact on payments for selected high volume procedures of all of the changes previously discussed. This table shows the combined impact of the change in physician work and the fully implemented practice expense relative value units on total payment for the procedure. There are separate columns that show the change in the old and new facility rates and the old and new nonfacility rates. The table does not show the actual change in payments from 2001 to 2002 for the procedures because the ''old'' payments do not take into account that the practice expense relative value units in 2001 are a blend of the old charge-based relative value units and the new resource-based practice expense relative value determined under current policy. We show the amounts in this way to isolate the impact of new proposals on the change in payment without including the effect of continuing to transition resource-based practice expense relative value units that will occur regardless of whether we publish this proposed rule. For an explanation of facility and non-facility practice expense refer to § 414.22(b)(5)(i).

TABLE 7.—IMPACT OF 5 YEAR REVIEW AND PROPOSED RULE ON MEDICARE PAYMENT FOR SELECTED PROCEDURES

HCPCS	MOD	Desc	Old non-facility	New non-facility	Percent change	Old facility	New facility	Percent change
11721		Debride nail, 6 or more	$42.47	$42.47	0%	$30.61	$30.61	0%
17000		Destroy benign/premal lesion	$63.89	$65.80	3%	$34.43	$34.43	0%
27130		Total hip replacement	NA	NA	NA	$1,499.72	$1,502.40	0%
27236		Treat thigh fracture	NA	NA	NA	$1,150.80	$1,152.72	0%
27244		Treat thigh fracture	NA	NA	NA	$1,174.91	$1,177.20	0%
27447		Total knee replacement	NA	NA	NA	$1,567.43	$1,570.50	0%
33533		CABG, arterial, single	NA	NA	NA	$1,855.90	$1,900.28	2%
35301		Rechanneling of artery	NA	NA	NA	$1,170.32	$1,141.24	−2%
43239		Upper GI endoscopy, biopsy	$298.03	$318.31	7%	$157.24	$158.39	1%
45385		Lesion removal colonoscopy	$501.95	$534.47	6%	$299.56	$303.00	1%
66821		After cataract laser surgery	$229.93	$228.02	−1%	$215.01	$212.72	−1%
66984		Cataract surg w/iol, i stage	NA	NA	NA	$697.83	$691.71	−1%
67210		Treatment of retinal lesion	$627.82	$620.55	−1%	$575.40	$569.66	−1%
71010	26	Chest x-ray	$9.56	$9.56	0%	$9.56	$9.56	0%
71020	26	Chest x-ray	$11.86	$11.86	0%	$11.86	$11.86	0%
77427		Radiation tx management, x5	$176.75	$177.52	0%	$176.75	$177.52	0%
78465	26	Heart image (3d), multiple	$79.58	$78.81	−1%	$79.58	$78.81	−1%
88305	26	Tissue exam by pathologist	$42.08	$42.85	2%	$42.08	$42.85	2%
90801		Psy dx interview	$153.80	$152.65	−1%	$145.00	$144.62	0%
90806		Psytx, off, 45–50 min	$102.15	$101.38	−1%	$96.41	$96.41	0%
90807		Psytx, off, 45–50 min w/e&m	$109.80	$109.42	0%	$104.44	$104.44	0%
90862		Medication management	$53.94	$53.94	0%	$48.97	$48.97	0%
90921		ESRD related services, month	$278.90	$279.28	0%	$278.90	$279.28	0%
90935		Hemodialysis, one evaluation	NA	NA	NA	$77.66	$78.05	1%
92004		Eye exam, new patient	$131.23	$130.84	0%	$92.58	$92.20	0%
92012		Eye exam established pat	$66.19	$65.80	−1%	$37.88	$37.49	−1%
92014		Eye exam & treatment	$94.88	$94.50	0%	$62.36	$61.60	−1%
92980		Insert intracoronary stent	NA	NA	NA	$845.12	$832.88	1%
92982		Coronary artery dilation	NA	NA	NA	$625.90	$616.34	−2%
93000		Electrocardiogram, complete	$27.55	$27.16	−1%	NA	NA	NA
93010		Electrocardiogram report	$9.56	$9.18	−4%	$9.56	$9.18	−4%
93015		Cardiovascular stress test	$108.65	$107.51	−1%	NA	NA	NA
93307	26	Echo exam of heart	$51.27	$50.50	−2%	$51.27	$50.50	−2%
93510	26	Left heart catheterization	$246.00	$242.17	−2%	$246.00	$242.17	−2%
98941		Chiropractic manipulation	$37.49	$37.49	0%	$32.52	$32.52	0%
99202		Office/outpatient visit, new	$63.89	$63.89	0%	$48.21	$48.21	0%
99203		Office/outpatient visit, new	$95.65	$95.26	0%	$73.46	$73.46	0%
99204		Office/outpatient visit, new	$137.73	$136.96	−1%	$108.65	$108.65	0%
99205		Office/outpatient visit, new	$174.46	$174.46	0%	$143.85	$143.47	0%
99211		Office/outpatient visit, est	$21.04	$21.04	0%	$9.18	$9.18	0%
99212		Office/outpatient visit, est	$37.49	$37.49	0%	$24.49	$24.49	0%

TABLE 7.—IMPACT OF 5 YEAR REVIEW AND PROPOSED RULE ON MEDICARE PAYMENT FOR SELECTED PROCEDURES—Continued

HCPCS	MOD	Desc	Old non-facility	New non-facility	Percent change	Old facility	New facility	Percent change
99213		Office/outpatient visit, est	$52.41	$52.41	0%	$35.96	$35.96	0%
99214		Office/outpatient visit, est	$82.64	$82.64	0%	$58.92	$58.92	0%
99215		Office/outpatient visit, est	$120.90	$121.28	0%	$95.26	$95.26	0%
99221		Initial hospital care	NA	NA	NA	$68.86	$68.86	0%
99222		Initial hospital care	NA	NA	NA	$114.01	$114.01	0%
99223		Initial hospital care	NA	NA	NA	$159.15	$159.15	0%
99231		Subsequent hospital care	NA	NA	NA	$34.43	$34.43	0%
99232		Subsequent hospital care	NA	NA	NA	$56.24	$56.24	0%
99233		Subsequent hospital care	NA	NA	NA	$80.34	$80.34	0%
99236		Observ/hosp same date	NA	NA	NA	$225.72	$225.34	0%
99238		Hospital discharge day	NA	NA	NA	$67.72	$67.72	0%
99239		Hospital discharge day	NA	NA	NA	$92.58	$92.58	0%
99241		Office consultation	$48.97	$48.97	0%	$34.81	$34.81	0%
99242		Office consultation	$91.05	$90.67	0%	$71.54	$71.54	0%
99243		Office consultation	$120.90	$120.51	0%	$95.26	$94.88	0%
99244		Office consultation	$171.78	$171.78	0%	$140.79	$140.79	0%
99245		Office consultation	$223.04	$223.43	0%	$186.70	$186.32	0%
99251		Initial inpatient consult	NA	NA	NA	$38.26	$38.26	0%
99252		Initial inpatient consult	NA	NA	NA	$75.37	$75.37	0%
99253		Initial inpatient consult	NA	NA	NA	$102.15	$102.15	0%
99254		Initial inpatient consult	NA	NA	NA	$146.15	$146.15	0%
99255		Initial inpatient consult	NA	NA	NA	$200.47	$200.47	0%
99261		Follow-up inpatient consult	NA	NA	NA	$24.87	$24.87	0%
99262		Follow-up inpatient consult	NA	NA	NA	$47.82	$47.82	0%
99263		Follow-up inpatient consult	NA	NA	NA	$70.01	$70.01	0%
99282		Emergency dept visit	NA	NA	NA	$27.93	$27.93	0%
99283		Emergency dept visit	NA	NA	NA	$62.74	$62.74	0%
99284		Emergency dept visit	NA	NA	NA	$97.94	$98.32	0%
99285		Emergency dept visit	NA	NA	NA	$152.65	$153.03	0%
99291		Critical care, first hour	$218.45	$219.22	0%	$208.89	$209.27	0%
99292		Critical care, addl 30 min	$111.71	$112.10	0%	$104.06	$104.44	0%
99301		Nursing facility care	NA	NA	NA	$63.51	$63.51	0%
99302		Nursing facility care	NA	NA	NA	$84.93	$84.93	0%
99303		Nursing facility care	NA	NA	NA	$105.59	$105.59	0%
99311		Nursing fac care, subseq	NA	NA	NA	$31.75	$31.75	0%
99312		Nursing fac care, subseq	NA	NA	NA	$52.41	$52.41	0%
99313		Nursing fac care, subseq	NA	NA	NA	$74.60	$74.60	0%
99348		Home visit, est patient	$77.28	$76.90	0%	$70.01	$70.01	0%
99350		Home visit, est patient	$176.37	$175.60	0%	$164.13	$164.13	0%

B. Nurse Practitioners, Physician Assistants, and Clinical Nurse Specialists Performing Screening Sigmoidoscopies

As discussed in section II.B. of the preamble, this proposed regulation would expand the scope of who is allowed to perform screening flexible sigmoidoscopies for Medicare coverage and payment purposes to include nurse practitioners, physician assistants, and clinical nurse specialists, as long as those practitioners meet applicable Medicare qualification requirements, and they are authorized to perform those screening services under State law. At present, the Medicare condition of coverage for screening flexible sigmoidoscopies limits coverage of those services to those that are performed by either a doctor of medicine or osteopathy (as defined in section 1861(r)(1) of the Act) who is authorized under State law to perform the examination.

We estimate that this expansion in the scope of who is allowed to perform screening flexible sigmoidoscopies will increase beneficiary access to these screening services and will result in an increase in the number of covered exams that are performed. At the same time, we estimate that this proposed rule will result in a decrease in payments that are made for certain screening flexible sigmoidoscopies because they will be performed by nurse practitioners, physician assistants, and clinical nurse specialists who are paid at 85 percent of the amount of payment that is made to physicians for the same screening service. Taking these factors into account, we estimate that this proposal will result in negligible additional Medicare program costs. For a more detailed discussion of this provision see section II.B. of this preamble.

C. Services and Supplies Incident to a Physician's Professional Services—Conditions

We are proposing to allow auxiliary personnel to provide services incident to the services of physicians or practitioners who supervise them, regardless of the employment relationship. There are no costs or savings to the Medicare program associated with this proposal because the same physicians and practitioners would have performed these services before publication of this proposed rule. For a more detailed discussion of this provision see section II.C. of this preamble.

D. Anesthesia Services—Anesthesia Base Units

As previously discussed in section II.D. of the preamble, with the exception of codes 00142 and 00147, we propose to use the same anesthesia base unit per anesthesia code as the ASA provides in its uniform relative value guide. There are eight codes for which the base unit values would be different under our proposed rule.

Under this proposal, the estimated total number of base units would decrease. This is due primarily to the fact that code 001214 is the dominant code in terms of allowed services and the base unit for this code would decrease from 10 to 8 units.

To maintain neutrality in the anesthesia conversion factor, we would provide for a slight increase in the

anesthesia conversion factor, less than 0.5 percent. For a more detailed discussion of this provision see section II.D. of this preamble.

E. Performance Measurement and Emerging Technology Codes

As previously discussed in section II.E. of the preamble, the AMA has developed two new categories of codes: performance codes and emerging technology. Allowing the performance measurement code to be referenced on Medicare billing forms will have no budgetary impact since we are not proposing payment for these codes. We are proposing to allow for carrier pricing of the emerging technology codes.

We expect that the emerging technology codes will be used infrequently and may be used in place of ''unlisted'' procedure codes that are also carrier priced. There would be few, if any, no Medicare program costs associated with this proposal. For a more detailed discussion of this provision see section II.E. of this preamble.

F. BIPA Provisions Included in This Proposed Rule

The following provisions of the BIPA are discussed in detail in section III of this preamble. This proposed rule would conform the regulations text to the BIPA provisions. Table 8 provides the estimated costs (in millions of dollars) for the Medicare program for these provisions for the fiscal years shown:

TABLE 8.—MEDICARE COST ESTIMATES FOR BIPA 2000 PROVISIONS

[In millions]

BIPA provisions	FY 2002	FY 2003	FY 2004	FY 2005	FY 2006
Sec. 101 Biennial Pelvic Examinations	10	20	20	20	20
Sec. 102 Screening Glaucoma	30	50	50	60	60
Sec. 103 Screening Colonoscopy	40	40	30	10	10
Sec. 104 Screening Mammography	30	40	40	40	50
Sec. 105 Medical Nutrition	20	50	60	70	70
Sec. 223 Telehealth Services	20	30	40	50	60
Sec. 432 Indian Health	60	70	80	80	90

1. Screening Mammography

As discussed in section III.A. of the preamble, the BIPA eliminates the statutorily prescribed payment rate for screening mammography and specifies that it will be paid under the physician fee schedule beginning January 1, 2002. To pay for the professional component of the screening mammography, we propose to use the work and malpractice RVUs that have been established for unilateral diagnostic mammography. We are establishing the practice expense RVUs for the professional component under the resource-based methodology. To establish practice expense RVUs for the technical component, we propose using the statutory payment limit and the applicable physician fee schedule update factor used each year. Currently, we pay for screening mammography under section 1834(c) of the Act. Payment for screening mammography is not subject to the budget neutrality requirements that apply to physician fee schedule services under section 1848(c)(2)(B)(ii)(II) of the Act. Effective January 1, 2002, screening mammography will be subject to the budget neutrality requirements that apply to physician fee schedule services. We will include the current payment amounts for screening mammography in aggregate physician fee schedule payments subject to the budget neutrality requirements. As a result, the BIPA requirement to pay for screening mammography under the physician fee schedule will not result in an increase in Medicare program expenditures. However, the increase in payment for screening mammography under the physician fee schedule will be included in the budget neutrality adjustments that apply to physician fee schedule services. The BIPA also establishes a methodology for determining payment for certain types of new technology that are used in providing both diagnostic and screening mammography services. The statutory provisions are in effect from April 1, 2001 to December 31, 2001. The statute gives us the authority to determine whether separate codes and payment amounts are appropriate for screening and diagnostic mammography services that involve use of a new technology on or after January 1, 2002. We are proposing several new codes and fee schedule amounts for screening and diagnostic mammography services that involve use of a new technology. The BIPA provisions related to new technology mammography will result in the Medicare program costs shown in Table 8. The BIPA makes no changes to provisions for Medicare coverage of screening mammography.

2. Screening Pelvic Examinations

As discussed in section III.B. of the preamble, section 101 of the BIPA provides for expanded coverage for screening pelvic examinations (including a clinical breast examination) furnished on or after July 1, 2001. Specifically, the revised benefit will allow for biennial coverage of screening pelvic examination for all women who do not qualify under the law for annual coverage of such tests. We estimate that this change in the frequency of coverage for certain beneficiaries will result in an increase in Medicare payments. These payments will be made to a large number of physicians and other practitioners who provide these tests, any medically necessary follow-up tests, or treatment that may be required as a result of the increased frequency of coverage of these tests. Medicare program expenditures associated with screening pelvic examinations have been included in the budget. The impact of this provision is shown in Table 8.

3. Screening for Glaucoma

As discussed in section III.C. of the preamble, section 102 of the BIPA authorizes coverage of glaucoma screening examinations effective January 1, 2002, subject to certain frequency and other limitations. We believe services provided as part of glaucoma screening will often overlap with other services a physician provides during a patient encounter that is associated with a higher payment amount. We believe that physicians will more commonly provide glaucoma tests in conjunction with other services and will rarely provide only glaucoma screening to Medicare patients. Based on the projected utilization of these screening services and related medically necessary follow-up tests and treatment that may be required for the beneficiaries screened, we estimate that this new benefit will result in an

increase in Medicare payments. These payments will be made to ophthalmologists or optometrists who will provide these screening tests and related follow-up tests and treatment that may be required. Medicare program expenditures associated with the BIPA provision that establishes coverage for screening glaucoma are shown in Table 8.

4. Screening Colonoscopy

As discussed in section III.D. of the preamble, section 103 of the BIPA amended the Act to add coverage of screening colonoscopies once every 10 years for individuals not at high risk for colorectal cancer. We estimate that this new benefit will result in an increase in Medicare payments. These payments will be made to practitioners who will provide these screening tests and related follow-up tests and treatment that may be required. The impact of this provision is shown in Table 8.

5. Medical Nutrition Therapy

As discussed in section III.E. of the preamble, section 105 of the BIPA amended the Act to authorize Medicare coverage under Part B of medical nutrition therapy (MNT) for beneficiaries who have diabetes or renal disease, effective for services furnished on or after January 1, 2002. We propose to implement this provision at part 410, subpart G. Specifically, the proposed rule discusses the education, experience, and licensing requirements for dietitians or nutritionists furnishing the service. In addition, the proposed rule discusses the payment provisions, a referral requirement, and the manner by which the medical nutrition therapy and diabetes outpatient self-management training benefits will be coordinated to avoid duplicate payment. We also propose to establish payment amounts for these services under the physician fee schedule.

We estimate that this new benefit will result in an increase in Medicare payments. These payments will be made to dietitians and nutrition professionals who will provide these diagnostic therapy and counseling services. Costs to the Medicare program associated with this provision are shown in Table 8.

6. Telehealth

We estimate that the cost of providing office or other outpatient visits, consultation services, individual psychotherapy, and pharmacologic management in accordance with section 223 of the BIPA will be approximately $20 million in FY 2002 and approximately $60 million by FY 2006, as indicated above in Table 8.

This rule does not mandate that entities provide consultation, office or other outpatient visits, individual psychotherapy or pharmacological management services via a telecommunications system. Thus, this rule would not require entities to purchase telehealth equipment or to acquire the telecommunications infrastructure necessary to deliver these services via a telecommunications system. Therefore, this rule does not impose costs associated with starting and operating a telehealth network.

7. Indian Health Services

As discussed in section III.G. of the preamble, in addition to payment for Medicare services in hospitals and skilled nursing facilities, section 432 of the BIPA authorizes payment under the physician fee schedule to physicians and certain practitioners for services furnished in a hospital and an ambulatory care clinic, whether provider-based or free-standing, of the Indian Health Service effective for services furnished on or after July 1, 2001. We propose to add a new § 410.46 to conform our regulations to the statute. Costs to the Medicare program for this BIPA provision are shown in Table 8.

8. Pathology Services

As discussed in section III.H. of the preamble, in the November 2, 1999 physician fee schedule final rule (64 FR 59381), we stated that we would implement a policy to pay only hospitals for the TC of physician pathology services furnished to hospital inpatients. Before the effective date of this proposal, any independent laboratory could bill the carrier under the physician fee schedule for the TC of physician pathology to a hospital inpatient. The regulation provided that for services furnished on or after January 1, 2001, the carriers would no longer pay claims to an independent laboratory under the physician fee schedule for the TC of physician pathology services furnished for hospital inpatients. Similar treatment was provided under the hospital outpatient prospective payment system for the TC of physician pathology services to hospital outpatients. We delayed implementation of this provision for one year; it was to take effect for services furnished on or after January 1, 2001. The delay was intended to allow independent laboratories and hospitals sufficient time to negotiate arrangements.

Section 542 of the BIPA requires Medicare to continue to pay for the TC of physician pathology services when an independent laboratory furnishes this service to an inpatient or outpatient of a covered hospital. This provision applies to TC services furnished during the 2-year period beginning on January 1, 2001.

In the November 2, 1999 final rule, we estimated that payment under the physician fee schedule for TC billings by independent laboratories would decrease by $6 million per year if the original proposal had been implemented on January 1, 2001. As a result of the BIPA, these savings are not realized for two years.

G. Budget Neutrality

Each year since the fee schedule has been implemented, our actuaries have determined any adjustments needed to meet the budget neutrality requirement of the statute. A component of the actuarial determination of budget-neutrality involves estimating the impact of changes in the volume and intensity of physicians' services provided to Medicare beneficiaries as a result of the proposed changes. Since the November 1998 final rule (63 FR 58891), we have used a model that assumes 30 percent of anticipated payment reductions will be offset through an increase in the volume and intensity of services. We will continue to use the same assumption in this year's final rule.

H. Impact on Beneficiaries

Although changes in physicians' payments were large when the physician fee schedule was implemented in 1992, we detected no problems with beneficiary access to care. Furthermore, since beginning our transition to a resource-based practice expense system in 1999, we have not found that there are problems with beneficiary access to care. In addition, the implementation of the BIPA proposals that are contained in this rule will improve beneficiary access to health care under the Medicare program since certain preventative services, such as screening glaucoma, will now be covered for the first time and coverage of several existing services is being expanded.

I. Federalism

We have examined this proposed rule in accordance with Executive Order 13132 and have determined that this regulation would not have any negative impact on the rights, roles, or responsibilities of State, local, or tribal governments.

In accordance with the provisions of Executive Order 12866, this regulation

was reviewed by the Office of Management and Budget.

List of Subjects

42 CFR Part 405

Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medicare, Reporting and recordkeeping requirements, Rural areas, X-rays.

42 CFR Part 410

Health facilities, Health professions, Kidney diseases, Laboratories, Medicare, Rural areas, X-rays.

42 CFR Part 411

Kidney diseases, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 414

Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medicare, Reporting and recordkeeping requirements, Rural areas, X-rays.

42 CFR Part 415

Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements.

For the reasons set forth in the preamble, the Health Care Financing Administration proposes to amend 42 CFR chapter IV as follows:

PART 405—FEDERAL HEALTH INSURANCE FOR THE AGED AND DISABLED

1. The authority citation for part 405 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

2. In § 405.534, an introductory paragraph is added to read as follows:

§ 405.534 Limitation on payment for screening mammography services.

The provisions in paragraphs (a), (b), and (c) of this section apply for services provided from January 1, 1991 until December 31, 2001. Screening mammography services provided after December 31, 2001 are paid under the physician fee schedule in accordance with § 414.2 of this chapter.

* * * * *

3. In § 405.535, the section heading is revised and the introductory text is amended by adding two sentences to the beginning to read as follows:

§ 405.535 Special rule for nonparticipating physicians and suppliers furnishing screening mammography services before January 1, 2002.

The provisions in this section apply for screening mammography services provided from January 1, 1991 until December 31, 2001. Screening mammography services provided after December 31, 2001 are paid under the physician fee schedule in accordance with § 414.2 of this chapter. * * *

* * * * *

PART 410—SUPPLEMENTARY MEDICAL INSURANCE (SMI) BENEFITS

1. The authority citation for part 410 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

2. Section 410.3 is amended by revising paragraph (a)(1) to read as follows:

§ 410.3 Scope of benefits.

(a) * * *

(1) Medical and other health services such as physicians' services, outpatient services furnished by a hospital or a CAH, diagnostic tests, outpatient physical therapy and speech pathology services, rural health clinic services, Federally qualified health center services, IHS, Indian tribe, or tribal organization facility services, and outpatient renal dialysis services.

* * * * *

3. Section 410.10 is amended by adding paragraph (x) to read as follows:

§ 410.10 Medical and other health services: Included services.

* * * * *

(x) IHS, Indian tribe, or tribal organization facility services.

4. Section 410.22 is redesignated as § 410.21, § 410.23 is redesignated as § 410.22, and a new § 410.23 is added to read as follows:

§ 410.23 Screening for glaucoma: Conditions for and limitations on coverage.

(a) *Definitions:* As used in this section, the following definitions apply:

(1) *Direct supervision in the office setting* means the optometrist or the ophthalmologist must be present in the office suite and be immediately available to furnish assistance and direction throughout the performance of the procedure. It does not mean the physician must be present in the room when the procedure is performed.

(2) *Eligible beneficiary* means:

(i) Individual with diabetes mellitus;

(ii) Individual with a family history of glaucoma; or

(iii) African-Americans age 50 and over.

(3) *Screening for glaucoma* means the following procedures furnished to an individual for the early detection of glaucoma:

(i) A dilated eye examination with an intraocular pressure measurement.

(ii) A direct ophthalmoscopy examination, or a slit-lamp biomicroscopic examination.

(b) *Condition for coverage of screening for glaucoma.*

Medicare Part B pays for glaucoma screening examinations provided to eligible beneficiaries as described in paragraph (a)(2) of this section if they are furnished by or under the direct supervision in the office setting of an optometrist or ophthalmologist who is legally authorized to perform these services under State law (or the State regulatory mechanism provided by State law) of the State in which the services are furnished, as would otherwise be covered if furnished by a physician or incident to a physician's professional service.

(c) *Limitations on coverage of glaucoma screening examinations.*

(1) Payment may not be made for a glaucoma screening examination that is performed for an individual who is not an eligible beneficiary as described in paragraph (a)(2) of this section.

(2) Payment may be made for a glaucoma screening examination that is performed on an individual who is an eligible beneficiary as described in paragraph (a)(2) of this section, after at least 11 months have passed following the month in which the last glaucoma screening examination was performed.

5. In § 410.26, paragraph (b) is redesignated as paragraph (c), paragraph (a) is redesignated as paragraph (b) and revised, a new paragraph (a) is added, and newly designated paragraph (c) is amended by adding a paragraph heading:

§ 410.26 Services and supplies incident to a physician's professional service: Conditions.

(a) *Definitions.* For purposes of this section, the following definitions apply:

(1) *Auxiliary personnel* means any individual who is acting under the supervision of a physician, regardless of whether the individual is an employee, leased employee, or independent contractor of the physician (or other practitioner) or of the same entity that employs or contracts with the physician (or other practitioner).

(2) *Direct supervision* means the level of supervision by the physician (or other practitioner) of auxiliary personnel as defined in § 410.32(b)(3)(ii).

(3) *Independent contractor* means an individual who performs part-time or full-time work for which the individual receives an IRS–1099 form.

(4) *Leased employment* means an employment relationship that is

recognized by applicable State law and that is established by two employers by a contract such that one employer hires the services of an employee of the other employer.

(5) *Noninstitutional setting* means all settings other than a hospital or skilled nursing facility.

(6) *Practitioner* means a non-physician practitioner who is authorized by the Act to receive payment for services incident to his or her own services.

(7) *Services and supplies* means any service or supply (including any drug or biological that cannot be self-administered) that is included in section 1861(s)(2)(A) of the Act and is not specifically listed in the Act as a separate benefit included in the Medicare program.

(b) Medicare Part B pays for services and supplies incident to the service of a physician (or other practitioner).

(1) Services and supplies must be furnished in a noninstitutional setting to noninstitutional patients.

(2) Services and supplies must be an integral, though incidental, part of the service of a physician (or other practitioner) in the course of diagnosis or treatment of an injury or illness.

(3) Services and supplies must be commonly furnished without charge or included in the bill of a physician (or other practitioner).

(4) Services and supplies must be of a type that are commonly furnished in the office or clinic of a physician (or other practitioner).

(5) Services and supplies must be furnished under the supervision of the physician (or other practitioner).

(6) Services and supplies must be furnished by the physician, practitioner with an incident to benefit, or auxiliary personnel.

(7) A physician (or other practitioner) may be an employee or an independent contractor.

(c) *Limitation.* * * *

6. In § 410.37, paragraphs (d), (e)(2), and (g) are revised and paragraph (e)(3) is added to read as follows:

§ 410.37 Colorectal cancer screening tests: Conditions for and limitations on coverage.

* * * * *

(d) *Condition for coverage of flexible sigmoidoscopy screening.* Medicare Part B pays for a flexible sigmoidoscopy screening service if it is performed by a doctor of medicine or osteopathy (as defined in section 1861(r)(1) of the Act), or by a physician assistant, nurse practitioner, or clinical nurse specialist (as defined in section 1861(aa)(5) of the Act and §§ 410.74, 410.75, and 410.76) who is authorized under State law to perform the examination.

(e) *Limitations on coverage of screening flexible sigmoidoscopies.* * * *

(2) For an individual 50 years of age or over, except as described in paragraph (e)(3) of this section, payment may be made for screening flexible sigmoidoscopy after at least 47 months have passed following the month in which the last screening flexible sigmoidoscopy or, as provided in paragraphs (h) and (i) of this section, the last screening barium enema was performed.

(3) In the case of an individual who is not at high risk for colorectal cancer as described in paragraph (a)(3) of this section but who has had a screening colonoscopy performed, payment may be made for a screening flexible sigmoidosocopy only after at least 119 months have passed following the month in which the last screening colonoscopy was performed.

* * * * *

(g) *Limitations on coverage of screening colonoscopies.* (1) Effective for services furnished on or after January 1, 1998 through June 30, 2001, payment may not be made for a screening colonoscopy for an individual who is not at high risk for colorectal cancer as described in paragraph (a)(3) of this section.

(2) Effective for services furnished on or after July 1, 2001, except as described in paragraph (g)(4) of this section, payment may be made for a screening colonoscopy performed for an individual who is not at high risk for colorectal cancer as described in paragraph (a)(3) of this section, after at least 119 months have passed following the month in which the last screening colonoscopy was performed.

(3) Payment may be made for a screening colonoscopy performed for an individual who is at high risk for colorectal cancer as described in paragraph (a)(3) of this section, after at least 23 months have passed following the month in which the last screening colonoscopy was performed, or, as provided in paragraphs (h) and (i) of this section, the last screening barium enema was performed.

(4) In the case of an individual who is not at high risk for colorectal cancer as described in paragraph (a)(3) of this section but who has had a screening flexible sigmoidoscopy performed, payment may be made for a screening colonoscopy only after at least 47 months have passed following the month in which the last screening flexible sigmoidoscopy was performed.

* * * * *

7. Section 410.46 is added to read as follows:

§ 410.46 Physician and other practitioner services furnished in or at the direction of an IHS or Indian tribal hospital or clinic: Scope and conditions.

(a) Medicare Part B pays, in accordance with the physician fee schedule, for services furnished in or at the direction of a hospital or outpatient clinic (provider-based or free-standing) that is operated by the Indian Health Service (IHS) or by an Indian tribe or tribal organization (as those terms are defined in section 4 of the Indian Health Care Improvement Act). These services are subject to the same situations, terms, and conditions that would apply if the services were furnished in or at the direction of a hospital or clinic that is not operated by IHS or by an Indian tribe or tribal organization. Payments include health professional shortage areas incentive payments when the requirements for these incentive payments in § 414.42 of this chapter are met.

(b) Payment is not made under this section to the extent that Medicare otherwise pays for the same services under other provisions.

(c) Payment is made under these provisions for the following services:

(1) Services for which payment is made under the physician fee schedule in accordance with part 414 of this chapter.

(2) Services furnished by non-physician practitioners for which payment under Part B is made under the physician fee schedule.

(3) Services furnished by a physical therapist or occupational therapist, for which payment under Part B is made under the physician fee schedule.

(d) Payments under these provisions will be paid to the IHS or tribal hospital or clinic.

8. In § 410.56, paragraphs (b)(1), the introductory text of (b)(2), and (b)(3) are revised to read as follows:

§ 410.56 Screening pelvic examinations.

* * * * *

(b) * * *

(1) *General rule.* Except as specified in paragraphs (b)(2) and (b)(3) of this section, payment may be made for a pelvic examination performed on an asymptomatic woman only if the individual has not had a pelvic examination paid for by Medicare during the preceding 23 months following the month in which her last Medicare-covered screening pelvic examination was performed.

(2) *More frequent screening based on high-risk factors.* Subject to the limitation as specified in paragraph (b)(4) of this section, payment may be made for a screening pelvic examination performed more frequently than once every 24 months if the test is performed by a physician or other practitioner specified in paragraph (a) of this section, and there is evidence that the woman is at high risk (on the basis of her medical history or other findings) of developing cervical cancer or vaginal cancer, as determined in accordance with the following risk factors:

* * * * *

(3) *More frequent screening for women of childbearing age.* Subject to the limitation as specified in paragraph (b)(4) of this section, payment may be made for a screening pelvic examination performed more frequently than once every 24 months if the test is performed by a physician or other practitioner as specified in paragraph (a) of this section for a woman of childbearing age who has had an examination that indicated the presence of cervical or vaginal cancer or other abnormality during any of the preceding 3 years. The term ''woman of childbearing age'' means a woman who is premenopausal, and has been determined by a physician, or a qualified practitioner, as specified in paragraph (a) of this section, to be of childbearing age, based on her medical history or other findings.

* * * * *

9. Section 410.78 is revised to read as follows:

§ 410.78 Office and other outpatient visits, consultation, individual psychotherapy and pharmacologic management via an interactive telecommunications system.

(a) *Definitions.* For the purposes of this section the following definitions apply:

(1) *Asynchronous store and forward technologies* means the transmission of a patient's medical information from an originating site to the physician or practitioner at the distant site. The physician or practitioner at the distant site can review the medical case without the patient being present. An asynchronous telecommunications system in single media format does not include telephone calls, images transmitted via facsimile machines and text messages without visualization of the patient (electronic mail). Photographs visualized by a telecommunications system must be specific to the patient's medical condition and adequate for furnishing or confirming a diagnosis and or treatment plan. Dermatological photographs, for example, a photograph of a skin lesion, may be considered to meet the requirement of a single media format under this provision.

(2) *Distant site* means the site at which the physician or practitioner delivering the service is located at the time the service is provided via a telecommunications system.

(3) *Interactive telecommunications system* means multimedia communications equipment that includes, at a minimum, audio and video equipment permitting two-way, real-time interactive communication between the patient and distant site physician or practitioner. Telephones, facsimile machines, and electronic mail systems do not meet the definition of an interactive telecommunications system.

(4) *Originating site* means, for purposes of a consultation, office or other outpatient visit, individual psychotherapy, or pharmacologic management via an interactive telecommunications system, the location of an eligible Medicare beneficiary at the time the service being furnished via a telecommunications system occurs. For asynchronous store and forward telecommunications technologies, the only originating sites are Federal telemedicine demonstration programs conducted in Alaska or Hawaii.

(b) *General rule.* Medicare Part B pays for office and other outpatient visits, professional consultation, individual psychotherapy, and pharmacologic management furnished by means of an interactive telecommunications system if the following conditions are met:

(1) The physician or practitioner at the distant site must be licensed to provide the service under State law. When the physician or practitioner at the distant site is licensed under State law to provide a covered telehealth service (that is, professional consultations, office and other outpatient visits, individual psychotherapy, and pharmacologic management), he or she may bill for, and receive payment for, this service when delivered via a telecommunications system.

(2) The practitioner at the distant site is one of the following:

(i) A physician as described in § 410.20.

(ii) A physician assistant as described § 410.74.

(iii) A nurse practitioner as described in § 410.75.

(iv) A clinical nurse specialist as described in § 410.76.

(v) A nurse-midwife as described in § 410.77.

(vi) A clinical psychologist as described in § 410.71.

(vii) A clinical social worker as described in § 410.73.

(3) The services are furnished to a beneficiary at an originating site, which is one of the following:

(i) The office of a physician or practitioner.

(ii) A critical access hospital (as described in section 1861(mm)(1) of the Act).

(iii) A rural health clinic (as described in section 1861(aa)(2) of the Act).

(iv) A Federally qualified health center (as defined in section 1861(aa)(4) of the Act).

(v) A hospital (as defined in section 1861(e) of the Act).

(4) Originating sites must be located in either a rural health professional shortage area as defined under section 332(a)(1)(A) of the Public Health Service Act (42 U.S.C. 254e(a)(1)(A)) or in a county that is not included in a Metropolitan Statistical Area as defined in section 1886(d)(2)(D) of the Act. Entities participating in a Federal telemedicine demonstration project that have been approved by, or receive funding from, the Secretary as of December 31, 2000 qualify as an eligible originating site regardless of geographic location.

(5) The medical examination of the patient is under the control of the physician or practitioner at the distant site.

(c) *Telepresenter not required.* A telepresenter is not required as a condition of payment unless a telepresenter is medically necessary as determined by the physician or practitioner at the distant site.

(d) *Exception to the interactive telecommunications system requirement.* For Federal telemedicine demonstration programs conducted in Alaska or Hawaii only, Medicare payment is permitted for telehealth when asynchronous store and forward technologies, in single or multimedia formats, are used as a substitute for an interactive telecommunications system.

(e) *Limitation.* A clinical psychologist and a clinical social worker may bill and receive payment for individual psychotherapy via a telecommunications system, but may not seek payment for medical evaluation and management services.

10. A new subpart G is added to read as follows:

Subpart G—Medical Nutrition Therapy

Sec.

410.130 Definitions.
410.132 Medical nutrition therapy.
410.134 Provider qualifications.

Subpart G—Medical Nutrition Therapy

§ 410.130 Definitions.

For the purposes of this subpart, the following definitions apply:

Chronic renal insufficiency is defined as the stage of renal disease associated with a reduction in renal function not severe enough to require dialysis or transplantation (glomerular filtration rate [GFR] 13–50 ml/min/1.73m^2).

Diabetes is diabetes mellitus consisting of two types. Type 1 is an autoimmune disease that destroys the beta cells of the pancreas, leading to insulin deficiency. Type 2 is familial hyperglycemia that occurs primarily in adults but can also occur in children and adolescents. The diagnostic criterion for a diagnosis of diabetes for a fasting glucose tolerance test is greater than or equal to 126 mg/dL.

Episode of care means a time period not exceeding 12 months, starting with the assessment and including all covered interventions based on a referral from a physician as specified in § 410.132(c).

Medical nutrition therapy services means nutritional diagnostic, therapy, and counseling services provided by a registered dietitian or nutrition professional for the purpose of managing diabetes or renal disease.

Physician means a doctor of medicine or osteopathy legally authorized to practice medicine and surgery by the State in which he or she performs such function or action (including a physician within the meaning of section of 1101(a)(7) of the Act).

Renal disease means chronic renal insufficiency and the medical condition of a beneficiary who has been discharged from the hospital within the last six months after a successful renal transplant.

§ 410.132 Medical nutrition therapy.

(a) *Conditions for coverage of medical nutrition therapy services.* Medicare Part B pays for medical nutrition therapy services provided by a registered dietitian or nutrition professional as defined in § 410.134 when the beneficiary is referred for the service by the treating physician. Services covered consist of nutritional assessment, interventions, and reassessment and follow-up interventions in accordance with nationally accepted dietary or nutritional protocols.

(b) *Limitations on coverage of medical nutrition therapy services.*

(1) Medical nutrition therapy services are not covered for beneficiaries receiving maintenance dialysis for which payment is made under section 1881 of the Act.

(2) If a beneficiary has both diabetes and renal disease, the beneficiary may receive both MNT and DSMT, but coverage is limited to the number of hours the beneficiary would receive under either the MNT benefit or the DSMT benefit for the episode of care, whichever is greater.

(3) Medical nutrition therapy is only covered if the beneficiary has not started initial training under the diabetes self-management training benefit as described in § 410.141 within the 12 months previous to initial referral for MNT, unless—

(i) The need for a reassessment and additional therapy has been documented by the referring physician as a result of a change in diagnosis or medical condition; or

(ii) The beneficiary is diagnosed with both diabetes and renal disease.

(4) If a beneficiary diagnosed with diabetes has been referred for both follow-up diabetes self-management training services and medical nutrition therapy, the number of hours the beneficiary may receive is limited to the number of hours under either follow-up diabetes self-management training services or medical nutrition therapy for any 12 month period.

(c) *Referrals.* Referral may only be made by the treating physician when the beneficiary has been diagnosed with diabetes or renal disease as defined in this subpart with documentation maintained by the referring physician in the beneficiary's medical record. Referrals must be made for each episode of care and any reassessments or follow-up interventions during an episode of care.

(d) *Reassessments and follow-up interventions.* Reassessments and follow-up interventions are only covered within an episode of care when the referring physician determines there is a change of diagnosis or medical condition within such episode of care that makes a change in diet necessary.

§ 410.134 Provider qualifications.

For Medicare Part B coverage of medical nutrition therapy, only a registered dietitian or nutrition professional may provide the services. ''Registered dietitian or nutrition professional'' means an individual who on or after December 22, 2000—

(a) Holds a bachelor's or higher degree granted by a regionally accredited college or university in the United States (or an equivalent foreign degree) with completion of the academic requirements of a program in nutrition or dietetics, as accredited by an appropriate national accreditation organization recognized for this purpose;

(b) Has completed at least 900 hours of supervised dietetics practice under the supervision of a registered dietitian or nutrition professional; and

(c) Is licensed or certified as a dietitian or nutrition professional by the State in which the services are performed. In a State that does not provide for licensure or certification, the individual will be deemed to have met this requirement if he or she is recognized as a ''registered dietitian'' by the Commission on Dietetic Registration or its successor organization, or meets the requirements of paragraphs (a) and (b) of this section; or a dietitian or nutritionist licensed or certified in a State as of December 21, 2000.

PART 411—EXCLUSIONS FROM MEDICARE AND LIMITATIONS ON MEDICARE PAYMENT

1. The authority citation for part 411 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

2. In § 411.15, paragraph (a)(1) is revised, and a new paragraph (k)(10) is added to read as follows:

§ 411.15 Particular services excluded from coverage.

* * * * *

(a) * * *

(1) Examinations performed for a purpose other than treatment or diagnosis of a specific illness, symptoms, complaint, or injury, except for screening mammography, colorectal cancer screening tests, screening pelvic examinations, prostate cancer screening tests, or glaucoma screening exams that meet the criteria specified in paragraphs (k)(6) through (k)(10) of this section.

* * * * *

(k) * * *

(10) In the case of screening exams for glaucoma, for the purpose of early detection of glaucoma, subject to the conditions and limitations specified in § 410.23 of this chapter.

* * * * *

PART 414—PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES

1. The authority citation for part 414 continues to read as follows:

Authority: Secs. 1102, 1871, and 1881(b)(1) of the Social Security Act (42 U.S.C. 1302, 1395hh, and 1395rr(b)(1)).

2. In 414.2, the definition of ''Physician services'' is amended by

adding a new paragraph (8) to read as follows:

§ 414.2 Definitions.

* * * * *

Physician Services * * *

(8) Screening mammography services.

* * * * *

3. A new § 414.64 is added to read as follows:

§ 414.64 Payment for medical nutrition therapy.

(a) *Payment under the physician fee schedule.* Medicare payment for medical nutrition therapy is made under the physician fee schedule in accordance with subpart B of this part.

(b) *To whom payment may be made.* Payment may be made to a supplier (registered dietitian or nutrition professional) approved by CMS to furnish medical nutrition therapy in accordance with part 410, subpart G of this chapter.

(c) *Effective date of payment.* Medicare pays suppliers of medical nutrition therapy on or after the effective date of enrollment of the supplier at the carrier.

(d) *Limitation on payment.* Payment is made only for nutritional therapy sessions actually attended by the beneficiary and documented for payment purposes.

(e) *Other conditions for fee-for-service payment.* Payment is made only if the beneficiary:

(1) Is not an inpatient of a hospital, SNF, nursing home, or hospice.

(2) Is not receiving services in an RHC, FQHC or ESRD dialysis facility.

4. Section 414.65 is revised to read as follows:

§ 414.65 Payment for office or other outpatient visits, consultation, individual psychotherapy, and pharmacologic management via interactive telecommunications systems.

(a) *Professional service.* Medicare payment for the professional service via an interactive telecommunications system is made according to the following limitations:

(1) The Medicare payment amount for office or other outpatient visits, consultation, individual psychotherapy, and pharmacologic management via an interactive telecommunications system is equal to the current fee schedule amount applicable to services of the physician or practitioner.

(2) Only the physician or practitioner at the distant site may bill and receive payment for the professional service via an interactive telecommunications system.

(3) Payments made to the physician or practitioner at the distant site, including deductible and coinsurance, for the professional service may not be shared with the referring practitioner or telepresenter.

(b) *Originating site facility fee.* For office or other outpatient visits, consultation, individual psychotherapy, or pharmacologic management services delivered via an interactive telecommunications system furnished on or after October 1, 2001.

(1) *Payment amount.* For services furnished on or after October 1, 2001 through December 31, 2002, the payment amount to the originating site is the lesser of the actual charge or the originating site facility fee of $20. For services furnished on or after January 1 of each subsequent year, the facility fee for the originating site will be updated by the Medicare Economic Index (MEI) as defined in section 1842(i)(3) of the Act.

(2) *Who may bill for the originating site facility fee.* Only the originating site may bill for the originating site facility fee and only on an assignment-related basis. The distant site physician or practitioner may not bill for or receive payment for facility fees associated with the professional service furnished via an interactive telecommunications system.

(c) *Deductible and coinsurance apply.* The payment for the professional service and originating site facility fee is subject to the coinsurance and deductible requirements of sections 1833(a)(1) and (b) of the Act.

(d) *Sanctions.* A distant site practitioner or originating site facility may be subject to the applicable sanctions provided for in chapter IV, part 402 and chapter V, parts 1001, 1002, and 1003 of this title if he or she does any of the following:

(1) Knowingly and willfully bills or collects for services in violation of the limitation of this section.

(2) Fails to timely correct excess charges by reducing the actual charge billed for the service in an amount that does not exceed the limiting charge for the service or fails to timely refund excess collections.

(3) Fails to submit a claim on a standard form for services provided for which payment is made on a fee schedule basis; or

(4) Imposes a charge for completing and submitting the standard claims form.

PART 415—SERVICES FURNISHED BY PHYSICIANS IN PROVIDERS, SUPERVISING PHYSICIANS IN TEACHING SETTINGS, AND RESIDENTS IN CERTAIN SETTINGS

1. The authority citation for part 415 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

2. Section 415.130 is amended by:

A. Redesignating paragraphs (a), (b), and (c) as paragraphs (b), (c), and (d).

B. Adding a new paragraph (a).

C. Amending newly designated paragraph (b)(3) by removing the reference ''paragraph (b)'' and adding ''paragraph (c)'' in its place.

D. Amending newly designated paragraph (b)(4) by removing the reference ''paragraphs (b)(1), (b)(3), and (b)(4)'' and adding ''paragraphs (c)(1), (c)(3), and (c)(4)'' in their place.

E. Revising newly designated paragraph (d).

§ 415.130 Conditions for payment: Physician pathology services.

(a) *Definitions.* The following definitions are used in this section.

(1) *Covered hospital* means, with respect to an inpatient or an outpatient, a hospital that had an arrangement with an independent laboratory that was in effect as of July 22, 1999, under which a laboratory furnished the technical component of physician pathology services to fee-for-service Medicare beneficiaries who were hospital inpatients or outpatients, and submitted claims for payment for this technical component to a Medicare carrier and not to the hospital.

(2) *Fee-for-service Medicare beneficiaries* means those beneficiaries who are entitled to benefits under Part A or are enrolled under Part B of Title XVIII of the Act or both and are not enrolled in any of the following:

(i) A Medicare+Choice plan under Part C of Title XVIII of the Act.

(ii) A plan offered by an eligible organization under section 1876 of the Act;

(iii) A program of all-inclusive care for the elderly (PACE) under 1894 of the Act; or

(iv) A social health maintenance organization (SHMO) demonstration project established under section 4018(b) of the Omnibus Budget Reconciliation Act of 1987.

* * * * *

(d) *Physician pathology services furnished by an independent laboratory.* The technical component of physician pathology services furnished by an independent laboratory to a hospital inpatient or outpatient before January 1, 2001 may be paid on a fee schedule basis. After December 31, 2001 but before January 1, 2003, if an independent laboratory furnishes the technical component of a physician pathology service to a fee-for-service Medicare beneficiary who is an

inpatient or outpatient of a covered hospital, the carrier will treat the technical component as a service for which payment will be made to the laboratory under the physician fee schedule. The service will not be treated as an inpatient hospital service for which payment is made to the hospital under section 1886(d) of the Act or as an outpatient hospital service for which payment is made to the hospital under section 1833(t) of the Act. After December 31, 2002, the technical component for physician pathology services furnished by an independent laboratory to a hospital inpatient or outpatient is paid only to the hospital.

(Catalog of Federal Domestic Assistance Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: June 19, 2001.

Thomas A. Scully,

Administrator, Health Care Financing Administration.

Approved: July 12, 2001.

Tommy G. Thompson,

Secretary.

Note: These addenda will not appear in the Code of Federal Regulations.

Addendum A—Explanation and Use of Addenda B

The addenda on the following pages provide various data pertaining to the Medicare fee schedule for physicians' services furnished in 2002. Addendum B contains the RVUs for work, non-facility practice expense, facility practice expense, and malpractice expense, and other information for all services included in the physician fee schedule.

Addendum B—2002 Relative Value Units and Related Information Used in Determining Medicare Payments for 2002

This addendum contains the following information for each CPT code and alphanumeric HCPCS code, except for alphanumeric codes beginning with B (enteral and parenteral therapy), E (durable medical equipment), K (temporary codes for nonphysicians' services or items), or L (orthotics), and codes for anesthesiology.

1. *CPT/HCPCS code.* This is the CPT or alphanumeric HCPCS number for the service. Alphanumeric HCPCS codes are included at the end of this addendum.

2. *Modifier.* A modifier is shown if there is a technical component (modifier TC) and a professional component (PC) (modifier -26) for the service. If there is a PC and a TC for the service, Addendum B contains three entries for the code: One for the global values (both professional and technical); one for modifier -26 (PC); and one for modifier TC. The global service is not designated by a modifier, and physicians must bill using the code without a modifier if the physician furnishes both the PC and the TC of the service.

Modifier -53 is shown for a discontinued procedure. There will be RVUs for the code (CPT code 45378) with this modifier.

3. *Status indicator.* This indicator shows whether the CPT/HCPCS code is in the physician fee schedule and whether it is separately payable if the service is covered.

A = Active code. These codes are separately payable under the fee schedule if covered. There will be RVUs for codes with this status. The presence of an ''A'' indicator does not mean that Medicare has made a national decision regarding the coverage of the service. Carriers remain responsible for coverage decisions in the absence of a national Medicare policy.

B = Bundled code. Payment for covered services is always bundled into payment for other services not specified. If RVUs are shown, they are not used for Medicare payment. If these services are covered, payment for them is subsumed by the payment for the services to which they are incident. (An example is a telephone call from a hospital nurse regarding care of a patient.)

C = Carrier-priced code. Carriers will establish RVUs and payment amounts for these services, generally on a case-by-case basis following review of documentation, such as an operative report.

D = Deleted code. These codes are deleted effective with the beginning of the calendar year.

E = Excluded from physician fee schedule by regulation. These codes are for items or services that we chose to exclude from the physician fee schedule payment by regulation. No RVUs are shown, and no payment may be made under the physician fee schedule for these codes. Payment for them, if they are covered, continues under reasonable charge or other payment procedures.

G = Code not valid for Medicare purposes. Medicare does not recognize codes assigned this status. Medicare uses another code for reporting of, and payment for, these services.

N = Noncovered service. These codes are noncovered services. Medicare payment may not be made for these codes. If RVUs are shown, they are not used for Medicare payment.

P = Bundled or excluded code. There are no RVUs for these services. No separate payment should be made for them under the physician fee schedule.

—If the item or service is covered as incident to a physician's service and is furnished on the same day as a physician's service, payment for it is bundled into the payment for the physician's service to which it is incident (an example is an elastic bandage furnished by a physician incident to a physician's service).

—If the item or service is covered as other than incident to a physician's service, it is excluded from the physician fee schedule (for example, colostomy supplies) and is paid under the other payment provisions of the Act.

R = Restricted coverage. Special coverage instructions apply. If the service is covered and no RVUs are shown, it is carrier-priced.

T = Injections. There are RVUs for these services, but they are only paid if there are no other services payable under the physician fee schedule billed on the same date by the same provider. If any other services payable under the physician fee schedule are billed on the same date by the same provider, these services are bundled into the service(s) for which payment is made.

X = Exclusion by law. These codes represent an item or service that is not within the definition of ''physicians'' services'' for physician fee schedule payment purposes. No RVUs are shown for these codes, and no payment may be made under the physician fee schedule. (Examples are ambulance services and clinical diagnostic laboratory services.)

4. *Description of code.* This is an abbreviated version of the narrative description of the code.

5. *Physician work RVUs.* These are the RVUs for the physician work for this service in 2000. Codes that are not used for Medicare payment are identified with a ''+.''

6. *Facility practice expense RVUs.* These are the fully implemented resource-based practice expense RVUs for facility settings.

7. *Non-facility practice expense RVUs.* These are the fully implemented resource-based practice expense RVUs for non-facility settings.

8. *Malpractice expense RVUs.* These are the RVUs for the malpractice expense for the service for 2000.

9. *Facility total.* This is the sum of the work, fully implemented facility practice expense, and malpractice expense RVUs.

10. *Non-facility total.* This is the sum of the work, fully implemented non-facility practice expense, and malpractice expense RVUs.

11. *Global period.* This indicator shows the number of days in the global period for the code (0, 10, or 90 days). An explanation of the alpha codes follows:

MMM = The code describes a service furnished in uncomplicated maternity cases including antepartum care, delivery, and postpartum care. The usual global surgical concept does not apply. See the 1999 Physicians' Current Procedural Terminology for specific definitions.

XXX = The global concept does not apply.

YYY = The global period is to be set by the carrier (for example, unlisted surgery codes).

ZZZ = The code is part of another service and falls within the global period for the other service.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
10040		A	Acne surgery of skin abscess	1.18	0.52	1.63	0.05	1.75	2.86	010
10060		A	Drainage of skin abscess	1.17	0.66	1.35	0.08	1.91	2.60	010
10061		A	Drainage of skin abscess	2.40	1.15	2.07	0.17	3.72	4.64	010
10080		A	Drainage of pilonidal cyst	1.17	0.71	2.11	0.09	1.97	3.37	010
10081		A	Drainage of pilonidal cyst	2.45	1.55	2.89	0.19	4.19	5.53	010
10120		A	Remove foreign body	1.22	0.73	1.83	0.10	2.05	3.15	010
10121		A	Remove foreign body	2.69	1.77	2.83	0.25	4.71	5.77	010
10140		A	Drainage of hematoma/fluid	1.53	0.87	1.42	0.15	2.55	3.10	010
10160		A	Puncture drainage of lesion	1.20	0.77	1.56	0.11	2.08	2.87	010
10180		A	Complex drainage, wound	2.25	1.25	1.51	0.25	3.75	4.01	010
11000		A	Debride infected skin	0.60	0.24	0.58	0.05	0.89	1.23	000
11001		A	Debride infected skin add-on	0.30	0.11	0.34	0.02	0.43	0.66	ZZZ
11010		A	Debride skin, fx	4.20	2.00	2.51	0.45	6.65	7.16	010
11011		A	Debride skin/muscle, fx	4.95	2.59	3.87	0.53	8.07	9.35	000
11012		A	Debride skin/muscle/bone, fx	6.88	4.21	5.67	0.89	11.98	13.44	000
11040		A	Debride skin, partial	0.50	0.21	0.50	0.05	0.76	1.05	000
11041		A	Debride skin, full	0.82	0.34	0.67	0.08	1.24	1.57	000
11042		A	Debride skin/tissue	1.12	0.46	0.95	0.11	1.69	2.18	000
11043		A	Debride tissue/muscle	2.38	1.38	2.60	0.24	4.00	5.22	010
11044		A	Debride tissue/muscle/bone	3.06	1.80	3.11	0.34	5.20	6.51	010
11055		R	Trim skin lesion	0.27	0.12	0.38	0.02	0.41	0.67	000
11056		R	Trim skin lesion, 2 to 4	0.39	0.17	0.42	0.03	0.59	0.84	000
11057		R	Trim skin lesions, over 4	0.50	0.22	0.46	0.04	0.76	1.00	000
11100		A	Biopsy of skin lesion	0.81	0.38	1.49	0.04	1.23	2.34	000
11101		A	Biopsy, skin add-on	0.41	0.20	0.70	0.02	0.63	1.13	ZZZ
11200		A	Removal of skin tags	0.77	0.31	1.17	0.04	1.12	1.98	010
11201		A	Remove skin tags add-on	0.29	0.12	0.52	0.02	0.43	0.83	ZZZ
11300		A	Shave skin lesion	0.51	0.22	1.02	0.03	0.76	1.56	000
11301		A	Shave skin lesion	0.85	0.38	1.11	0.04	1.27	2.00	000
11302		A	Shave skin lesion	1.05	0.48	1.21	0.05	1.58	2.31	000
11303		A	Shave skin lesion	1.24	0.54	1.34	0.06	1.84	2.64	000
11305		A	Shave skin lesion	0.67	0.29	0.81	0.04	1.00	1.52	000
11306		A	Shave skin lesion	0.99	0.43	1.06	0.05	1.47	2.10	000
11307		A	Shave skin lesion	1.14	0.51	1.18	0.05	1.70	2.37	000
11308		A	Shave skin lesion	1.41	0.63	1.27	0.07	2.11	2.75	000
11310		A	Shave skin lesion	0.73	0.33	1.12	0.04	1.10	1.89	000
11311		A	Shave skin lesion	1.05	0.50	1.23	0.05	1.60	2.33	000
11312		A	Shave skin lesion	1.20	0.57	1.30	0.06	1.83	2.56	000
11313		A	Shave skin lesion	1.62	0.75	1.58	0.09	2.46	3.29	000
11400		A	Removal of skin lesion	0.91	0.73	2.42	0.06	1.70	3.39	010
11401		A	Removal of skin lesion	1.32	0.88	2.43	0.09	2.29	3.84	010
11402		A	Removal of skin lesion	1.61	0.96	2.52	0.12	2.69	4.25	010
11403		A	Removal of skin lesion	1.92	1.07	2.76	0.16	3.15	4.84	010
11404		A	Removal of skin lesion	2.20	1.17	2.92	0.18	3.55	5.30	010
11406		A	Removal of skin lesion	2.76	1.38	3.20	0.25	4.39	6.21	010
11420		A	Removal of skin lesion	1.06	0.77	2.03	0.08	1.91	3.17	010
11421		A	Removal of skin lesion	1.53	0.99	2.36	0.11	2.63	4.00	010
11422		A	Removal of skin lesion	1.76	1.06	2.51	0.14	2.96	4.41	010
11423		A	Removal of skin lesion	2.17	1.22	2.94	0.17	3.56	5.28	010
11424		A	Removal of skin lesion	2.62	1.41	3.09	0.21	4.24	5.92	010
11426		A	Removal of skin lesion	3.78	1.85	3.74	0.34	5.97	7.86	010
11440		A	Removal of skin lesion	1.15	0.92	2.54	0.08	2.15	3.77	010
11441		A	Removal of skin lesion	1.61	1.16	2.70	0.11	2.88	4.42	010
11442		A	Removal of skin lesion	1.87	1.25	2.77	0.14	3.26	4.78	010
11443		A	Removal of skin lesion	2.49	1.59	3.32	0.18	4.26	5.99	010
11444		A	Removal of skin lesion	3.42	2.00	3.74	0.25	5.67	7.41	010
11446		A	Removal of skin lesion	4.49	2.49	4.18	0.30	7.28	8.97	010
11450		A	Removal, sweat gland lesion	2.73	1.05	4.02	0.26	4.04	7.01	090
11451		A	Removal, sweat gland lesion	3.95	1.59	4.83	0.39	5.93	9.17	090
11462		A	Removal, sweat gland lesion	2.51	0.98	4.14	0.23	3.72	6.88	090
11463		A	Removal, sweat gland lesion	3.95	1.62	5.63	0.40	5.97	9.98	090
11470		A	Removal, sweat gland lesion	3.25	1.28	4.41	0.30	4.83	7.96	090
11471		A	Removal, sweat gland lesion	4.41	1.77	5.42	0.40	6.58	10.23	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
11600		A	Removal of skin lesion	1.41	0.94	2.57	0.09	2.44	4.07	010
11601		A	Removal of skin lesion	1.93	1.08	2.63	0.12	3.13	4.68	010
11602		A	Removal of skin lesion	2.09	1.32	2.69	0.13	3.54	4.91	010
11603		A	Removal of skin lesion	2.35	1.39	2.88	0.16	3.90	5.39	010
11604		A	Removal of skin lesion	2.58	1.46	3.07	0.18	4.22	5.83	010
11606		A	Removal of skin lesion	3.43	1.75	3.63	0.28	5.46	7.34	010
11620		A	Removal of skin lesion	1.34	0.89	2.53	0.09	2.32	3.96	010
11621		A	Removal of skin lesion	1.97	1.35	2.67	0.12	3.44	4.76	010
11622		A	Removal of skin lesion	2.34	1.50	2.84	0.15	3.99	5.33	010
11623		A	Removal of skin lesion	2.93	1.71	2.79	0.20	4.84	5.92	010
11624		A	Removal of skin lesion	3.43	1.93	3.16	0.25	5.61	6.84	010
11626		A	Removal of skin lesion	4.30	2.34	4.18	0.35	6.99	8.83	010
11640		A	Removal of skin lesion	1.53	1.11	2.62	0.10	2.74	4.25	010
11641		A	Removal of skin lesion	2.44	1.66	2.96	0.15	4.25	5.55	010
11642		A	Removal of skin lesion	2.93	1.88	2.89	0.18	4.99	6.00	010
11643		A	Removal of skin lesion	3.50	2.17	3.25	0.24	5.91	6.99	010
11644		A	Removal of skin lesion	4.55	2.68	3.91	0.33	7.56	8.79	010
11646		A	Removal of skin lesion	5.95	3.38	5.19	0.46	9.79	11.60	010
11719		R	Trim nail(s)	0.11	0.07	0.54	0.01	0.19	0.66	000
11720		A	Debride nail, 1–5	0.32	0.13	0.42	0.02	0.47	0.76	000
11721		A	Debride nail, 6 or more	0.54	0.22	0.53	0.04	0.80	1.11	000
11730		A	Removal of nail plate	1.13	0.46	0.74	0.09	1.68	1.96	000
11732		A	Remove nail plate, add-on	0.57	0.24	0.29	0.05	0.86	0.91	ZZZ
11740		A	Drain blood from under nail	0.37	0.14	0.68	0.03	0.54	1.08	000
11750		A	Removal of nail bed	1.86	0.79	1.55	0.16	2.81	3.57	010
11752		A	Remove nail bed/finger tip	2.67	1.75	1.99	0.33	4.75	4.99	010
11755		A	Biopsy, nail unit	1.31	0.59	1.03	0.06	1.96	2.40	000
11760		A	Repair of nail bed	1.58	1.19	1.70	0.17	2.94	3.45	010
11762		A	Reconstruction of nail bed	2.89	1.87	2.15	0.32	5.08	5.36	010
11765		A	Excision of nail fold, toe	0.69	0.45	0.97	0.05	1.19	1.71	010
11770		A	Removal of pilonidal lesion	2.61	1.26	2.97	0.24	4.11	5.82	010
11771		A	Removal of pilonidal lesion	5.74	3.92	5.34	0.56	10.22	11.64	090
11772		A	Removal of pilonidal lesion	6.98	4.36	6.12	0.68	12.02	13.78	090
11900		A	Injection into skin lesions	0.52	0.23	0.76	0.02	0.77	1.30	000
11901		A	Added skin lesions injection	0.80	0.37	0.89	0.03	1.20	1.72	000
11920		R	Correct skin color defects	1.61	0.83	2.24	0.17	2.61	4.02	000
11921		R	Correct skin color defects	1.93	1.04	2.63	0.21	3.18	4.77	000
11922		R	Correct skin color defects	0.49	0.26	0.39	0.05	0.80	0.93	ZZZ
11950		R	Therapy for contour defects	0.84	0.47	1.28	0.06	1.37	2.18	000
11951		R	Therapy for contour defects	1.19	0.54	1.71	0.10	1.83	3.00	000
11952		R	Therapy for contour defects	1.69	0.89	2.15	0.17	2.75	4.01	000
11954		R	Therapy for contour defects	1.85	0.94	2.85	0.19	2.98	4.89	000
11960		A	Insert tissue expander(s)	9.08	10.76	NA	0.88	20.72	NA	090
11970		A	Replace tissue expander	7.06	5.06	NA	0.77	12.89	NA	090
11971		A	Remove tissue expander(s)	2.13	3.86	6.15	0.21	6.20	8.49	090
11975		N	Insert contraceptive cap	+1.48	0.59	1.54	0.14	2.21	3.16	XXX
11976		R	Removal of contraceptive cap	1.78	0.77	1.58	0.17	2.72	3.53	XXX
11977		N	Removal/reinsert contra cap	+3.30	1.30	2.25	0.31	4.91	5.86	XXX
11980		A	Implant hormone pellet(s)	1.48	0.63	1.13	0.10	2.21	2.71	000
12001		A	Repair superficial wound(s)	1.70	0.83	2.31	0.13	2.66	4.14	010
12002		A	Repair superficial wound(s)	1.86	0.86	2.41	0.15	2.87	4.42	010
12004		A	Repair superficial wound(s)	2.24	0.98	2.59	0.17	3.39	5.00	010
12005		A	Repair superficial wound(s)	2.86	1.23	3.05	0.23	4.32	6.14	010
12006		A	Repair superficial wound(s)	3.67	1.92	4.15	0.31	5.90	8.13	010
12007		A	Repair superficial wound(s)	4.12	2.24	4.63	0.37	6.73	9.12	010
12011		A	Repair superficial wound(s)	1.76	0.83	2.37	0.14	2.73	4.27	010
12013		A	Repair superficial wound(s)	1.99	0.89	2.53	0.16	3.04	4.68	010
12014		A	Repair superficial wound(s)	2.46	1.06	2.83	0.18	3.70	5.47	010
12015		A	Repair superficial wound(s)	3.19	1.26	3.26	0.24	4.69	6.69	010
12016		A	Repair superficial wound(s)	3.93	1.50	3.79	0.32	5.75	8.04	010
12017		A	Repair superficial wound(s)	4.71	2.44	5.41	0.39	7.54	10.51	010
12018		A	Repair superficial wound(s)	5.53	2.69	6.31	0.46	8.68	12.30	010
12020		A	Closure of split wound	2.62	1.45	2.60	0.24	4.31	5.46	010
12021		A	Closure of split wound	1.84	1.12	2.11	0.19	3.15	4.14	010
12031		A	Layer closure of wound(s)	2.15	1.19	2.74	0.15	3.49	5.04	010
12032		A	Layer closure of wound(s)	2.47	1.27	2.80	0.15	3.89	5.42	010
12034		A	Layer closure of wound(s)	2.92	1.44	3.06	0.21	4.57	6.19	010
12035		A	Layer closure of wound(s)	3.43	1.65	3.03	0.30	5.38	6.76	010
12036		A	Layer closure of wound(s)	4.05	2.47	5.20	0.41	6.93	9.66	010
12037		A	Layer closure of wound(s)	4.67	2.82	5.61	0.49	7.98	10.77	010
12041		A	Layer closure of wound(s)	2.37	1.26	3.03	0.17	3.80	5.57	010
12042		A	Layer closure of wound(s)	2.74	1.41	3.01	0.17	4.32	5.92	010
12044		A	Layer closure of wound(s)	3.14	1.61	3.17	0.24	4.99	6.55	010
12045		A	Layer closure of wound(s)	3.64	1.84	3.58	0.34	5.82	7.56	010

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
12046		A	Layer closure of wound(s)	4.25	2.53	5.31	0.40	7.18	9.96	010
12047		A	Layer closure of wound(s)	4.65	2.90	5.94	0.41	7.96	11.00	010
12051		A	Layer closure of wound(s)	2.47	1.41	3.00	0.16	4.04	5.63	010
12052		A	Layer closure of wound(s)	2.77	1.37	2.97	0.17	4.31	5.91	010
12053		A	Layer closure of wound(s)	3.12	1.51	3.11	0.20	4.83	6.43	010
12054		A	Layer closure of wound(s)	3.46	1.63	3.43	0.25	5.34	7.14	010
12055		A	Layer closure of wound(s)	4.43	2.14	4.67	0.35	6.92	9.45	010
12056		A	Layer closure of wound(s)	5.24	2.86	6.76	0.43	8.53	12.43	010
12057		A	Layer closure of wound(s)	5.96	3.88	6.67	0.50	10.34	13.13	010
13100		A	Repair of wound or lesion	3.12	1.85	3.38	0.21	5.18	6.71	010
13101		A	Repair of wound or lesion	3.92	2.31	3.61	0.22	6.45	7.75	010
13102		A	Repair wound/lesion add-on	1.24	0.58	0.74	0.10	1.92	2.08	ZZZ
13120		A	Repair of wound or lesion	3.30	1.92	3.49	0.23	5.45	7.02	010
13121		A	Repair of wound or lesion	4.33	2.40	3.82	0.25	6.98	8.40	010
13122		A	Repair wound/lesion add-on	1.44	0.67	0.86	0.12	2.23	2.42	ZZZ
13131		A	Repair of wound or lesion	3.79	2.22	3.73	0.25	6.26	7.77	010
13132		A	Repair of wound or lesion	5.95	3.28	4.56	0.32	9.55	10.83	010
13133		A	Repair wound/lesion add-on	2.19	1.02	1.21	0.17	3.38	3.57	ZZZ
13150		A	Repair of wound or lesion	3.81	2.68	5.27	0.29	6.78	9.37	010
13151		A	Repair of wound or lesion	4.45	3.13	5.18	0.28	7.86	9.91	010
13152		A	Repair of wound or lesion	6.33	4.03	5.89	0.38	10.74	12.60	010
13153		A	Repair wound/lesion add-on	2.38	1.11	1.34	0.18	3.67	3.90	ZZZ
13160		A	Late closure of wound	10.48	6.24	NA	1.19	17.91	NA	090
14000		A	Skin tissue rearrangement	5.89	4.63	7.50	0.46	10.98	13.85	090
14001		A	Skin tissue rearrangement	8.47	5.99	8.93	0.65	15.11	18.05	090
14020		A	Skin tissue rearrangement	6.59	5.36	8.11	0.50	12.45	15.20	090
14021		A	Skin tissue rearrangement	10.06	7.16	9.38	0.69	17.91	20.13	090
14040		A	Skin tissue rearrangement	7.87	6.12	8.33	0.53	14.52	16.73	090
14041		A	Skin tissue rearrangement	11.49	7.98	10.13	0.68	20.15	22.30	090
14060		A	Skin tissue rearrangement	8.50	6.97	8.82	0.59	16.06	17.91	090
14061		A	Skin tissue rearrangement	12.29	8.92	10.97	0.75	21.96	24.01	090
14300		A	Skin tissue rearrangement	11.76	8.50	10.37	0.88	21.14	23.01	090
14350		A	Skin tissue rearrangement	9.61	6.41	NA	1.09	17.11	NA	090
15000		A	Skin graft	4.00	1.92	2.52	0.37	6.29	6.89	000
15001		A	Skin graft add-on	1.00	0.43	0.56	0.11	1.54	1.67	ZZZ
15050		A	Skin pinch graft	4.30	3.94	4.91	0.46	8.70	9.67	090
15100		A	Skin split graft	9.05	6.17	6.26	0.94	16.16	16.25	090
15101		A	Skin split graft add-on	1.72	0.75	1.21	0.18	2.65	3.11	ZZZ
15120		A	Skin split graft	9.83	6.67	8.99	0.87	17.37	19.69	090
15121		A	Skin split graft add-on	2.67	1.25	1.57	0.27	4.19	4.51	ZZZ
15200		A	Skin full graft	8.03	5.64	9.59	0.73	14.40	18.35	090
15201		A	Skin full graft add-on	1.32	0.65	1.00	0.14	2.11	2.46	ZZZ
15220		A	Skin full graft	7.87	6.23	9.66	0.68	14.78	18.21	090
15221		A	Skin full graft add-on	1.19	0.58	1.00	0.12	1.89	2.31	ZZZ
15240		A	Skin full graft	9.04	7.12	9.28	0.77	16.93	19.09	090
15241		A	Skin full graft add-on	1.86	0.96	1.53	0.17	2.99	3.56	ZZZ
15260		A	Skin full graft	10.06	7.53	9.16	0.63	18.22	19.85	090
15261		A	Skin full graft add-on	2.23	1.16	1.63	0.17	3.56	4.03	ZZZ
15342		A	Cultured skin graft, 25 cm	1.00	0.79	2.18	0.39	2.18	3.57	010
15343		A	Culture skn graft addl 25 cm	0.25	0.10	0.27	0.09	0.44	0.61	ZZZ
15350		A	Skin homograft	4.00	4.37	7.37	0.42	8.79	11.79	090
15351		A	Skin homograft add-on	1.00	0.42	0.94	0.11	1.53	2.05	ZZZ
15400		A	Skin heterograft	4.00	4.96	4.96	0.40	9.36	9.36	090
15401		A	Skin heterograft add-on	1.00	0.46	1.14	0.11	1.57	2.25	ZZZ
15570		A	Form skin pedicle flap	9.21	6.27	8.42	0.96	16.44	18.59	090
15572		A	Form skin pedicle flap	9.27	6.18	7.54	0.93	16.38	17.74	090
15574		A	Form skin pedicle flap	9.88	6.94	8.53	0.92	17.74	19.33	090
15576		A	Form skin pedicle flap	8.69	6.35	8.97	0.72	15.76	18.38	090
15600		A	Skin graft	1.91	2.34	6.62	0.19	4.44	8.72	090
15610		A	Skin graft	2.42	2.70	4.56	0.25	5.37	7.23	090
15620		A	Skin graft	2.94	3.29	6.92	0.28	6.51	10.14	090
15630		A	Skin graft	3.27	3.73	6.19	0.28	7.28	9.74	090
15650		A	Transfer skin pedicle flap	3.97	3.84	6.26	0.36	8.17	10.59	090
15732		A	Muscle-skin graft, head/neck	17.84	11.39	NA	1.50	30.73	NA	090
15734		A	Muscle-skin graft, trunk	17.79	11.31	NA	1.91	31.01	NA	090
15736		A	Muscle-skin graft, arm	16.27	10.77	NA	1.78	28.82	NA	090
15738		A	Muscle-skin graft, leg	17.92	11.27	NA	1.95	31.14	NA	090
15740		A	Island pedicle flap graft	10.25	7.12	8.87	0.62	17.99	19.74	090
15750		A	Neurovascular pedicle graft	11.41	8.05	NA	1.12	20.58	NA	090
15756		A	Free muscle flap, microvasc	35.23	18.80	NA	3.11	57.14	NA	090
15757		A	Free skin flap, microvasc	35.23	22.15	NA	3.37	60.75	NA	090
15758		A	Free fascial flap, microvasc	35.10	22.48	NA	3.52	61.10	NA	090
15760		A	Composite skin graft	8.74	6.79	9.31	0.72	16.25	18.77	090
15770		A	Derma-fat-fascia graft	7.52	6.02	NA	0.78	14.32	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
15775		R	Hair transplant punch grafts	3.96	1.58	3.04	0.43	5.97	7.43	000
15776		R	Hair transplant punch grafts	5.54	2.94	3.88	0.60	9.08	10.02	000
15780		A	Abrasion treatment of skin	7.29	6.30	6.30	0.41	14.00	14.00	090
15781		A	Abrasion treatment of skin	4.85	4.76	4.76	0.27	9.88	9.88	090
15782		A	Abrasion treatment of skin	4.32	4.10	4.10	0.21	8.63	8.63	090
15783		A	Abrasion treatment of skin	4.29	3.46	4.45	0.26	8.01	9.00	090
15786		A	Abrasion, lesion, single	2.03	1.27	1.69	0.11	3.41	3.83	010
15787		A	Abrasion, lesions, add-on	0.33	0.17	0.37	0.02	0.52	0.72	ZZZ
15788		R	Chemical peel, face, epiderm	2.09	1.05	3.00	0.11	3.25	5.20	090
15789		R	Chemical peel, face, dermal	4.92	3.67	5.59	0.27	8.86	10.78	090
15792		R	Chemical peel, nonfacial	1.86	1.81	2.77	0.10	3.77	4.73	090
15793		A	Chemical peel, nonfacial	3.74	3.34	NA	0.17	7.25	NA	090
15810		A	Salabrasion	4.74	3.85	3.85	0.42	9.01	9.01	090
15811		A	Salabrasion	5.39	4.03	4.03	0.52	9.94	9.94	090
15819		A	Plastic surgery, neck	9.38	6.82	NA	0.77	16.97	NA	090
15820		A	Revision of lower eyelid	5.15	6.55	10.91	0.30	12.00	16.36	090
15821		A	Revision of lower eyelid	5.72	6.67	11.61	0.31	12.70	17.64	090
15822		A	Revision of upper eyelid	4.45	5.86	8.92	0.22	10.53	13.59	090
15823		A	Revision of upper eyelid	7.05	6.95	10.06	0.32	14.32	17.43	090
15824		R	Removal of forehead wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15825		R	Removal of neck wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15826		R	Removal of brow wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15828		R	Removal of face wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15829		R	Removal of skin wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15831		A	Excise excessive skin tissue	12.40	8.14	NA	1.30	21.84	NA	090
15832		A	Excise excessive skin tissue	11.59	7.81	NA	1.21	20.61	NA	090
15833		A	Excise excessive skin tissue	10.64	7.55	NA	1.17	19.36	NA	090
15834		A	Excise excessive skin tissue	10.85	6.03	NA	1.18	18.06	NA	090
15835		A	Excise excessive skin tissue	11.67	5.70	NA	1.13	18.50	NA	090
15836		A	Excise excessive skin tissue	9.34	6.16	NA	0.95	16.45	NA	090
15837		A	Excise excessive skin tissue	8.43	6.10	7.85	0.78	15.31	17.06	090
15838		A	Excise excessive skin tissue	7.13	5.70	NA	0.58	13.41	NA	090
15839		A	Excise excessive skin tissue	9.38	5.95	7.60	0.88	16.21	17.86	090
15840		A	Graft for face nerve palsy	13.26	9.84	NA	1.15	24.25	NA	090
15841		A	Graft for face nerve palsy	23.26	15.24	NA	2.65	41.15	NA	090
15842		A	Flap for face nerve palsy	37.96	21.68	NA	3.99	63.63	NA	090
15845		A	Skin and muscle repair, face	12.57	8.65	NA	0.80	22.02	NA	090
15850		B	Removal of sutures	+0.78	0.31	1.37	0.04	1.13	2.19	XXX
15851		A	Removal of sutures	0.86	0.35	1.56	0.05	1.26	2.47	000
15852		A	Dressing change,not for burn	0.86	0.36	1.76	0.07	1.29	2.69	000
15860		A	Test for blood flow in graft	1.95	0.80	1.31	0.13	2.88	3.39	000
15876		R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15877		R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15878		R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15879		R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15920		A	Removal of tail bone ulcer	7.95	5.38	NA	0.83	14.16	NA	090
15922		A	Removal of tail bone ulcer	9.90	7.27	NA	1.06	18.23	NA	090
15931		A	Remove sacrum pressure sore	9.24	5.59	NA	0.95	15.78	NA	090
15933		A	Remove sacrum pressure sore	10.85	7.74	NA	1.14	19.73	NA	090
15934		A	Remove sacrum pressure sore	12.69	8.36	NA	1.35	22.40	NA	090
15935		A	Remove sacrum pressure sore	14.57	10.35	NA	1.56	26.48	NA	090
15936		A	Remove sacrum pressure sore	12.38	8.98	NA	1.32	22.68	NA	090
15937		A	Remove sacrum pressure sore	14.21	10.45	NA	1.51	26.17	NA	090
15940		A	Remove hip pressure sore	9.34	5.94	NA	0.98	16.26	NA	090
15941		A	Remove hip pressure sore	11.43	9.77	NA	1.23	22.43	NA	090
15944		A	Remove hip pressure sore	11.46	8.68	NA	1.21	21.35	NA	090
15945		A	Remove hip pressure sore	12.69	9.83	NA	1.38	23.90	NA	090
15946		A	Remove hip pressure sore	21.57	14.57	NA	2.32	38.46	NA	090
15950		A	Remove thigh pressure sore	7.54	5.17	NA	0.80	13.51	NA	090
15951		A	Remove thigh pressure sore	10.72	7.67	NA	1.14	19.53	NA	090
15952		A	Remove thigh pressure sore	11.39	7.38	NA	1.19	19.96	NA	090
15953		A	Remove thigh pressure sore	12.63	8.89	NA	1.38	22.90	NA	090
15956		A	Remove thigh pressure sore	15.52	10.60	NA	1.64	27.76	NA	090
15958		A	Remove thigh pressure sore	15.48	10.97	NA	1.66	28.11	NA	090
15999		C	Removal of pressure sore	0.00	0.00	0.00	0.00	0.00	0.00	YYY
16000		A	Initial treatment of burn(s)	0.89	0.27	1.06	0.06	1.22	2.01	000
16010		A	Treatment of burn(s)	0.87	0.38	1.17	0.07	1.32	2.11	000
16015		A	Treatment of burn(s)	2.35	0.97	1.93	0.22	3.54	4.50	000
16020		A	Treatment of burn(s)	0.80	0.26	1.17	0.06	1.12	2.03	000
16025		A	Treatment of burn(s)	1.85	0.68	1.87	0.16	2.69	3.88	000
16030		A	Treatment of burn(s)	2.08	0.93	3.03	0.18	3.19	5.29	000
16035		A	Incision of burn scab, initi	3.75	1.53	NA	0.36	5.64	NA	090
16036		A	Incise burn scab, addl incis	1.50	0.61	NA	0.18	2.29	NA	ZZZ
17000		A	Destroy benign/premal lesion	0.60	0.27	1.09	0.03	0.90	1.72	010

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
17003		A	Destroy lesions, 2–14	0.15	0.07	0.24	0.01	0.23	0.40	ZZZ
17004		A	Destroy lesions, 15 or more	2.79	1.29	2.56	0.12	4.20	5.47	010
17106		A	Destruction of skin lesions	4.59	2.68	4.68	0.28	7.55	9.55	090
17107		A	Destruction of skin lesions	9.16	4.75	6.80	0.53	14.44	16.49	090
17108		A	Destruction of skin lesions	13.20	7.27	8.63	0.89	21.36	22.72	090
17110		A	Destruct lesion, 1–14	0.65	0.26	1.07	0.04	0.95	1.76	010
17111		A	Destruct lesion, 15 or more	0.92	0.40	1.13	0.04	1.36	2.09	010
17250		A	Chemical cautery, tissue	0.50	0.21	0.71	0.04	0.75	1.25	000
17260		A	Destruction of skin lesions	0.91	0.42	1.37	0.04	1.37	2.32	010
17261		A	Destruction of skin lesions	1.17	0.55	1.48	0.05	1.77	2.70	010
17262		A	Destruction of skin lesions	1.58	0.75	1.68	0.07	2.40	3.33	010
17263		A	Destruction of skin lesions	1.79	0.82	1.79	0.08	2.69	3.66	010
17264		A	Destruction of skin lesions	1.94	0.84	1.87	0.08	2.86	3.89	010
17266		A	Destruction of skin lesions	2.34	0.94	2.08	0.11	3.39	4.53	010
17270		A	Destruction of skin lesions	1.32	0.62	1.57	0.06	2.00	2.95	010
17271		A	Destruction of skin lesions	1.49	0.72	1.64	0.06	2.27	3.19	010
17272		A	Destruction of skin lesions	1.77	0.85	1.78	0.07	2.69	3.62	010
17273		A	Destruction of skin lesions	2.05	0.98	1.93	0.09	3.12	4.07	010
17274		A	Destruction of skin lesions	2.59	1.19	2.19	0.11	3.89	4.89	010
17276		A	Destruction of skin lesions	3.20	1.71	2.50	0.15	5.06	5.85	010
17280		A	Destruction of skin lesions	1.17	0.54	1.40	0.05	1.76	2.62	010
17281		A	Destruction of skin lesions	1.72	0.83	1.76	0.07	2.62	3.55	010
17282		A	Destruction of skin lesions	2.04	0.99	1.92	0.09	3.12	4.05	010
17283		A	Destruction of skin lesions	2.64	1.24	2.23	0.11	3.99	4.98	010
17284		A	Destruction of skin lesions	3.21	1.50	2.52	0.14	4.85	5.87	010
17286		A	Destruction of skin lesions	4.44	2.48	3.15	0.22	7.14	7.81	010
17304		A	Chemosurgery of skin lesion	7.60	3.67	7.75	0.31	11.58	15.66	000
17305		A	2nd stage chemosurgery	2.85	1.38	3.60	0.12	4.35	6.57	000
17306		A	3rd stage chemosurgery	2.85	1.39	3.64	0.12	4.36	6.61	000
17307		A	Followup skin lesion therapy	2.85	1.41	3.16	0.12	4.38	6.13	000
17310		A	Extensive skin chemosurgery	0.95	0.48	1.49	0.05	1.48	2.49	000
17340		A	Cryotherapy of skin	0.76	0.27	1.36	0.04	1.07	2.16	010
17360		A	Skin peel therapy	1.43	0.70	1.48	0.06	2.19	2.97	010
17380		R	Hair removal by electrolysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
17999		C	Skin tissue procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
19000		A	Drainage of breast lesion	0.84	0.29	1.23	0.07	1.20	2.14	000
19001		A	Drain breast lesion add-on	0.42	0.15	0.83	0.03	0.60	1.28	ZZZ
19020		A	Incision of breast lesion	3.57	3.41	6.96	0.35	7.33	10.88	090
19030		A	Injection for breast x-ray	1.53	0.53	11.25	0.07	2.13	12.85	000
19100		A	Biopsy of breast	1.27	0.45	3.56	0.10	1.82	4.93	000
19101		A	Biopsy of breast, open	3.18	3.09	10.62	0.20	6.47	14.00	010
19102		A	Bx breast percut w/image	2.00	0.71	4.88	0.08	2.79	6.96	000
19103		A	Bx breast percut w/device	2.37	0.84	11.46	0.08	3.29	13.91	000
19110		A	Nipple exploration	4.30	4.40	8.43	0.44	9.14	13.17	090
19112		A	Excise breast duct fistula	3.67	3.09	7.24	0.38	7.14	11.29	090
19120		A	Removal of breast lesion	5.56	3.55	4.41	0.56	9.67	10.53	090
19125		A	Excision, breast lesion	6.06	3.70	5.02	0.61	10.37	11.69	090
19126		A	Excision, addl breast lesion	2.93	1.05	NA	0.30	4.28	NA	ZZZ
19140		A	Removal of breast tissue	5.14	3.72	9.03	0.52	9.38	14.69	090
19160		A	Removal of breast tissue	5.99	4.52	NA	0.61	11.12	NA	090
19162		A	Remove breast tissue, nodes	13.53	7.94	NA	1.38	22.85	NA	090
19180		A	Removal of breast	8.80	5.97	NA	0.88	15.65	NA	090
19182		A	Removal of breast	7.73	5.01	NA	0.79	13.53	NA	090
19200		A	Removal of breast	15.49	9.24	NA	1.51	26.24	NA	090
19220		A	Removal of breast	15.72	9.22	NA	1.56	26.50	NA	090
19240		A	Removal of breast	16.00	8.82	NA	1.62	26.44	NA	090
19260		A	Removal of chest wall lesion	15.44	9.35	NA	1.64	26.43	NA	090
19271		A	Revision of chest wall	18.90	11.61	NA	2.27	32.78	NA	090
19272		A	Extensive chest wall surgery	21.55	12.54	NA	2.54	36.63	NA	090
19290		A	Place needle wire, breast	1.27	0.44	5.08	0.06	1.77	6.41	000
19291		A	Place needle wire, breast	0.63	0.22	1.72	0.03	0.88	2.38	ZZZ
19295		A	Place breast clip, percut	0.00	NA	2.65	0.01	NA	2.66	ZZZ
19316		A	Suspension of breast	10.69	7.65	NA	1.15	19.49	NA	090
19318		A	Reduction of large breast	15.62	10.47	NA	1.69	27.78	NA	090
19324		A	Enlarge breast	5.85	4.64	NA	0.63	11.12	NA	090
19325		A	Enlarge breast with implant	8.45	6.82	NA	0.90	16.17	NA	090
19328		A	Removal of breast implant	5.68	4.63	NA	0.61	10.92	NA	090
19330		A	Removal of implant material	7.59	5.35	NA	0.81	13.75	NA	090
19340		A	Immediate breast prosthesis	6.33	3.25	NA	0.68	10.26	NA	ZZZ
19342		A	Delayed breast prosthesis	11.20	8.01	NA	1.21	20.42	NA	090
19350		A	Breast reconstruction	8.92	6.92	14.29	0.95	16.79	24.16	090
19355		A	Correct inverted nipple(s)	7.57	6.10	12.05	0.80	14.47	20.42	090
19357		A	Breast reconstruction	18.16	14.04	NA	1.96	34.16	NA	090
19361		A	Breast reconstruction	19.26	12.20	NA	2.08	33.54	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
19364		A	Breast reconstruction	41.00	22.78	NA	3.91	67.69	NA	090
19366		A	Breast reconstruction	21.28	12.20	NA	2.27	35.75	NA	090
19367		A	Breast reconstruction	25.73	15.53	NA	2.78	44.04	NA	090
19368		A	Breast reconstruction	32.42	19.28	NA	3.51	55.21	NA	090
19369		A	Breast reconstruction	29.82	18.49	NA	3.24	51.55	NA	090
19370		A	Surgery of breast capsule	8.05	6.21	NA	0.86	15.12	NA	090
19371		A	Removal of breast capsule	9.35	7.32	NA	1.01	17.68	NA	090
19380		A	Revise breast reconstruction	9.14	7.21	NA	0.98	17.33	NA	090
19396		A	Design custom breast implant	2.17	0.80	5.35	0.23	3.20	7.75	000
19499		C	Breast surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
20000		A	Incision of abscess	2.12	1.19	2.01	0.17	3.48	4.30	010
20005		A	Incision of deep abscess	3.42	2.20	2.92	0.34	5.96	6.68	010
20100		A	Explore wound, neck	10.08	4.47	5.92	0.99	15.54	16.99	010
20101		A	Explore wound, chest	3.22	1.30	3.00	0.24	4.76	6.46	010
20102		A	Explore wound, abdomen	3.94	1.67	3.34	0.35	5.96	7.63	010
20103		A	Explore wound, extremity	5.30	2.98	4.10	0.57	8.85	9.97	010
20150		A	Excise epiphyseal bar	13.69	7.83	NA	0.96	22.48	NA	090
20200		A	Muscle biopsy	1.46	0.62	1.72	0.17	2.25	3.35	000
20205		A	Deep muscle biopsy	2.35	0.98	3.72	0.23	3.56	6.30	000
20206		A	Needle biopsy, muscle	0.99	0.36	3.15	0.06	1.41	4.20	000
20220		A	Bone biopsy, trocar/needle	1.27	3.02	4.98	0.06	4.35	6.31	000
20225		A	Bone biopsy, trocar/needle	1.87	3.03	4.52	0.11	5.01	6.50	000
20240		A	Bone biopsy, excisional	3.23	4.07	NA	0.33	7.63	NA	010
20245		A	Bone biopsy, excisional	7.78	6.69	NA	0.44	14.91	NA	010
20250		A	Open bone biopsy	5.03	4.30	NA	0.50	9.83	NA	010
20251		A	Open bone biopsy	5.56	4.74	NA	0.79	11.09	NA	010
20500		A	Injection of sinus tract	1.23	4.03	5.37	0.10	5.36	6.70	010
20501		A	Inject sinus tract for x-ray	0.76	0.26	13.46	0.03	1.05	14.25	000
20520		A	Removal of foreign body	1.85	3.37	5.40	0.17	5.39	7.42	010
20525		A	Removal of foreign body	3.50	4.15	6.66	0.40	8.05	10.56	010
20550		A	Inject tendon/ligament/cyst	0.86	0.22	2.05	0.06	1.14	2.97	000
20600		A	Drain/inject, joint/bursa	0.66	0.27	1.38	0.06	0.99	2.10	000
20605		A	Drain/inject, joint/bursa	0.68	0.27	1.71	0.06	1.01	2.45	000
20610		A	Drain/inject, joint/bursa	0.79	0.56	2.11	0.08	1.43	2.98	000
20615		A	Treatment of bone cyst	2.28	2.51	4.52	0.19	4.98	6.99	010
20650		A	Insert and remove bone pin	2.23	2.90	4.38	0.28	5.41	6.89	010
20660		A	Apply,remove fixation device	2.51	1.49	NA	0.48	4.48	NA	000
20661		A	Application of head brace	4.89	6.47	NA	0.92	12.28	NA	090
20662		A	Application of pelvis brace	6.07	5.15	NA	0.81	12.03	NA	090
20663		A	Application of thigh brace	5.43	4.78	NA	0.77	10.98	NA	090
20664		A	Halo brace application	8.06	8.21	NA	1.49	17.76	NA	090
20665		A	Removal of fixation device	1.31	1.23	2.34	0.17	2.71	3.82	010
20670		A	Removal of support implant	1.74	3.37	5.51	0.23	5.34	7.48	010
20680		A	Removal of support implant	3.35	4.98	4.98	0.46	8.79	8.79	090
20690		A	Apply bone fixation device	3.52	1.89	NA	0.47	5.88	NA	090
20692		A	Apply bone fixation device	6.41	2.50	NA	0.60	9.51	NA	090
20693		A	Adjust bone fixation device	5.86	11.53	NA	0.85	18.24	NA	090
20694		A	Remove bone fixation device	4.16	5.77	8.18	0.57	10.50	12.91	090
20802		A	Replantation, arm, complete	41.15	31.17	NA	5.81	78.13	NA	090
20805		A	Replant, forearm, complete	50.00	49.91	NA	3.95	103.86	NA	090
20808		A	Replantation hand, complete	61.65	43.88	NA	6.49	112.02	NA	090
20816		A	Replantation digit, complete	30.94	43.13	NA	3.01	77.08	NA	090
20822		A	Replantation digit, complete	25.59	39.51	NA	3.07	68.17	NA	090
20824		A	Replantation thumb, complete	30.94	36.86	NA	3.48	71.28	NA	090
20827		A	Replantation thumb, complete	26.41	45.96	NA	3.21	75.58	NA	090
20838		A	Replantation foot, complete	41.41	28.52	NA	5.85	75.78	NA	090
20900		A	Removal of bone for graft	5.58	5.83	6.77	0.77	12.18	13.12	090
20902		A	Removal of bone for graft	7.55	8.29	NA	1.06	16.90	NA	090
20910		A	Remove cartilage for graft	5.34	6.69	8.21	0.50	12.53	14.05	090
20912		A	Remove cartilage for graft	6.35	7.51	NA	0.55	14.41	NA	090
20920		A	Removal of fascia for graft	5.31	5.57	NA	0.54	11.42	NA	090
20922		A	Removal of fascia for graft	6.61	6.25	8.76	0.88	13.74	16.25	090
20924		A	Removal of tendon for graft	6.48	6.73	NA	0.82	14.03	NA	090
20926		A	Removal of tissue for graft	5.53	6.23	NA	0.73	12.49	NA	090
20930		B	Spinal bone allograft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
20931		A	Spinal bone allograft	1.81	0.97	NA	0.34	3.12	NA	ZZZ
20936		B	Spinal bone autograft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
20937		A	Spinal bone autograft	2.79	1.53	NA	0.43	4.75	NA	ZZZ
20938		A	Spinal bone autograft	3.02	1.63	NA	0.52	5.17	NA	ZZZ
20950		A	Fluid pressure, muscle	1.26	2.10	NA	0.16	3.52	NA	000
20955		A	Fibula bone graft, microvasc	39.21	30.01	NA	4.35	73.57	NA	090
20956		A	Iliac bone graft, microvasc	39.27	28.48	NA	5.77	73.52	NA	090
20957		A	Mt bone graft, microvasc	40.65	24.37	NA	5.74	70.76	NA	090
20962		A	Other bone graft, microvasc	39.27	28.18	NA	5.19	72.64	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
20969		A	Bone/skin graft, microvasc	43.92	32.94	NA	4.34	81.20	NA	090
20970		A	Bone/skin graft, iliac crest	43.06	30.40	NA	4.64	78.10	NA	090
20972		A	Bone/skin graft, metatarsal	42.99	18.86	NA	6.07	67.92	NA	090
20973		A	Bone/skin graft, great toe	45.76	22.15	NA	4.65	72.56	NA	090
20974		A	Electrical bone stimulation	0.62	0.34	0.39	0.09	1.05	1.10	000
20975		A	Electrical bone stimulation	2.60	1.42	NA	0.42	4.44	NA	000
20979		A	Us bone stimulation	0.62	0.25	0.56	0.04	0.91	1.22	000
20999		C	Musculoskeletal surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21010		A	Incision of jaw joint	10.14	7.05	NA	0.54	17.73	NA	090
21015		A	Resection of facial tumor	5.29	7.20	NA	0.52	13.01	NA	090
21025		A	Excision of bone, lower jaw	10.06	6.86	7.38	0.79	17.71	18.23	090
21026		A	Excision of facial bone(s)	4.85	4.83	5.49	0.40	10.08	10.74	090
21029		A	Contour of face bone lesion	7.71	6.11	6.87	0.74	14.56	15.32	090
21030		A	Removal of face bone lesion	6.46	4.88	5.39	0.60	11.94	12.45	090
21031		A	Remove exostosis, mandible	3.24	2.11	3.34	0.28	5.63	6.86	090
21032		A	Remove exostosis, maxilla	3.24	2.15	3.30	0.27	5.66	6.81	090
21034		A	Removal of face bone lesion	16.17	10.67	12.00	1.37	28.21	29.54	090
21040		A	Removal of jaw bone lesion	2.11	1.85	2.98	0.19	4.15	5.28	090
21041		A	Removal of jaw bone lesion	6.71	4.34	5.61	0.56	11.61	12.88	090
21044		A	Removal of jaw bone lesion	11.86	7.92	NA	0.87	20.65	NA	090
21045		A	Extensive jaw surgery	16.17	10.27	NA	1.20	27.64	NA	090
21050		A	Removal of jaw joint	10.77	11.32	NA	0.84	22.93	NA	090
21060		A	Remove jaw joint cartilage	10.23	10.11	NA	1.16	21.50	NA	090
21070		A	Remove coronoid process	8.20	6.09	NA	0.67	14.96	NA	090
21076		A	Prepare face/oral prosthesis	13.42	7.29	9.70	1.36	22.07	24.48	010
21077		A	Prepare face/oral prosthesis	33.75	18.34	24.39	3.43	55.52	61.57	090
21079		A	Prepare face/oral prosthesis	22.34	12.68	17.23	1.59	36.61	41.16	090
21080		A	Prepare face/oral prosthesis	25.10	14.25	19.36	2.55	41.90	47.01	090
21081		A	Prepare face/oral prosthesis	22.88	12.99	17.65	1.87	37.74	42.40	090
21082		A	Prepare face/oral prosthesis	20.87	11.34	15.08	1.46	33.67	37.41	090
21083		A	Prepare face/oral prosthesis	19.30	10.96	14.89	1.96	32.22	36.15	090
21084		A	Prepare face/oral prosthesis	22.51	12.78	17.36	1.57	36.86	41.44	090
21085		A	Prepare face/oral prosthesis	9.00	4.89	6.50	0.65	14.54	16.15	010
21086		A	Prepare face/oral prosthesis	24.92	14.15	19.22	1.86	40.93	46.00	090
21087		A	Prepare face/oral prosthesis	24.92	13.54	18.00	2.22	40.68	45.14	090
21088		C	Prepare face/oral prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	090
21089		C	Prepare face/oral prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	090
21100		A	Maxillofacial fixation	4.22	4.06	5.89	0.18	8.46	10.29	090
21110		A	Interdental fixation	5.21	4.57	5.23	0.28	10.06	10.72	090
21116		A	Injection, jaw joint x-ray	0.81	0.30	8.08	0.05	1.16	8.94	000
21120		A	Reconstruction of chin	4.93	6.32	10.45	0.29	11.54	15.67	090
21121		A	Reconstruction of chin	7.64	5.82	8.09	0.56	14.02	16.29	090
21122		A	Reconstruction of chin	8.52	7.36	NA	0.59	16.47	NA	090
21123		A	Reconstruction of chin	11.16	8.54	NA	1.16	20.86	NA	090
21125		A	Augmentation, lower jaw bone	10.62	8.72	9.17	0.72	20.06	20.51	090
21127		A	Augmentation, lower jaw bone	11.12	6.69	9.64	0.76	18.57	21.52	090
21137		A	Reduction of forehead	9.82	6.95	NA	0.53	17.30	NA	090
21138		A	Reduction of forehead	12.19	9.93	NA	1.47	23.59	NA	090
21139		A	Reduction of forehead	14.61	9.39	NA	1.02	25.02	NA	090
21141		A	Reconstruct midface, lefort	18.10	11.14	NA	1.63	30.87	NA	090
21142		A	Reconstruct midface, lefort	18.81	11.26	NA	1.16	31.23	NA	090
21143		A	Reconstruct midface, lefort	19.58	11.74	NA	0.90	32.22	NA	090
21145		A	Reconstruct midface, lefort	19.94	11.43	NA	2.09	33.46	NA	090
21146		A	Reconstruct midface, lefort	20.71	12.11	NA	2.13	34.95	NA	090
21147		A	Reconstruct midface, lefort	21.77	13.27	NA	1.52	36.56	NA	090
21150		A	Reconstruct midface, lefort	25.24	14.91	NA	1.09	41.24	NA	090
21151		A	Reconstruct midface, lefort	28.30	18.38	NA	1.98	48.66	NA	090
21154		A	Reconstruct midface, lefort	30.52	18.49	NA	4.86	53.87	NA	090
21155		A	Reconstruct midface, lefort	34.45	18.24	NA	5.48	58.17	NA	090
21159		A	Reconstruct midface, lefort	42.38	21.37	NA	6.74	70.49	NA	090
21160		A	Reconstruct midface, lefort	46.44	24.49	NA	4.39	75.32	NA	090
21172		A	Reconstruct orbit/forehead	27.80	18.30	NA	1.91	48.01	NA	090
21175		A	Reconstruct orbit/forehead	33.17	18.70	NA	5.16	57.03	NA	090
21179		A	Reconstruct entire forehead	22.25	18.90	NA	2.48	43.63	NA	090
21180		A	Reconstruct entire forehead	25.19	19.28	NA	2.15	46.62	NA	090
21181		A	Contour cranial bone lesion	9.90	8.90	NA	0.97	19.77	NA	090
21182		A	Reconstruct cranial bone	32.19	22.36	NA	2.53	57.08	NA	090
21183		A	Reconstruct cranial bone	35.31	23.10	NA	2.75	61.16	NA	090
21184		A	Reconstruct cranial bone	38.24	21.38	NA	4.12	63.74	NA	090
21188		A	Reconstruction of midface	22.46	15.78	NA	1.85	40.09	NA	090
21193		A	Reconst lwr jaw w/o graft	17.15	11.03	NA	1.53	29.71	NA	090
21194		A	Reconst lwr jaw w/graft	19.84	12.07	NA	1.39	33.30	NA	090
21195		A	Reconst lwr jaw w/o fixation	17.24	12.94	NA	1.20	31.38	NA	090
21196		A	Reconst lwr jaw w/fixation	18.91	12.88	NA	1.62	33.41	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
21198		A	Reconstr lwr jaw segment	14.16	11.84	NA	1.05	27.05	NA	090
21199		A	Reconstr lwr jaw w/advance	16.00	10.56	NA	1.00	27.56	NA	090
21206		A	Reconstruct upper jaw bone	14.10	10.13	NA	1.01	25.24	NA	090
21208		A	Augmentation of facial bones	10.23	8.46	10.12	0.92	19.61	21.27	090
21209		A	Reduction of facial bones	6.72	5.69	8.96	0.60	13.01	16.28	090
21210		A	Face bone graft	10.23	8.02	8.95	0.88	19.13	20.06	090
21215		A	Lower jaw bone graft	10.77	6.88	8.75	1.04	18.69	20.56	090
21230		A	Rib cartilage graft	10.77	10.27	NA	0.96	22.00	NA	090
21235		A	Ear cartilage graft	6.72	8.03	11.81	0.52	15.27	19.05	090
21240		A	Reconstruction of jaw joint	14.05	11.49	NA	1.15	26.69	NA	090
21242		A	Reconstruction of jaw joint	12.95	11.53	NA	1.40	25.88	NA	090
21243		A	Reconstruction of jaw joint	20.79	14.75	NA	1.85	37.39	NA	090
21244		A	Reconstruction of lower jaw	11.86	9.03	NA	0.95	21.84	NA	090
21245		A	Reconstruction of jaw	11.86	10.15	16.56	0.88	22.89	29.30	090
21246		A	Reconstruction of jaw	12.47	10.98	12.51	1.21	24.66	26.19	090
21247		A	Reconstruct lower jaw bone	22.63	18.84	NA	2.21	43.68	NA	090
21248		A	Reconstruction of jaw	11.48	8.01	8.86	1.01	20.50	21.35	090
21249		A	Reconstruction of jaw	17.52	10.16	11.38	1.39	29.07	30.29	090
21255		A	Reconstruct lower jaw bone	16.72	10.96	NA	1.13	28.81	NA	090
21256		A	Reconstruction of orbit	16.19	13.20	NA	1.04	30.43	NA	090
21260		A	Revise eye sockets	16.52	11.65	NA	1.25	29.42	NA	090
21261		A	Revise eye sockets	31.49	19.12	NA	2.20	52.81	NA	090
21263		A	Revise eye sockets	28.42	14.84	NA	2.16	45.42	NA	090
21267		A	Revise eye sockets	18.90	14.43	NA	1.35	34.68	NA	090
21268		A	Revise eye sockets	24.48	11.93	NA	0.79	37.20	NA	090
21270		A	Augmentation, cheek bone	10.23	9.10	10.49	0.73	20.06	21.45	090
21275		A	Revision, orbitofacial bones	11.24	11.24	NA	1.03	23.51	NA	090
21280		A	Revision of eyelid	6.03	5.88	NA	0.27	12.18	NA	090
21282		A	Revision of eyelid	3.49	5.04	NA	0.21	8.74	NA	090
21295		A	Revision of jaw muscle/bone	1.53	3.55	NA	0.13	5.21	NA	090
21296		A	Revision of jaw muscle/bone	4.25	5.17	NA	0.30	9.72	NA	090
21299		C	Cranio/maxillofacial surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21300		A	Treatment of skull fracture	0.72	0.27	2.37	0.09	1.08	3.18	000
21310		A	Treatment of nose fracture	0.58	0.15	2.54	0.05	0.78	3.17	000
21315		A	Treatment of nose fracture	1.51	1.24	3.30	0.12	2.87	4.93	010
21320		A	Treatment of nose fracture	1.85	1.99	4.85	0.15	3.99	6.85	010
21325		A	Treatment of nose fracture	3.77	3.71	NA	0.31	7.79	NA	090
21330		A	Treatment of nose fracture	5.38	5.50	NA	0.48	11.36	NA	090
21335		A	Treatment of nose fracture	8.61	7.10	NA	0.64	16.35	NA	090
21336		A	Treat nasal septal fracture	5.72	5.50	NA	0.45	11.67	NA	090
21337		A	Treat nasal septal fracture	2.70	3.17	5.02	0.22	6.09	7.94	090
21338		A	Treat nasoethmoid fracture	6.46	5.94	NA	0.53	12.93	NA	090
21339		A	Treat nasoethmoid fracture	8.09	6.95	NA	0.76	15.80	NA	090
21340		A	Treatment of nose fracture	10.77	9.36	NA	0.85	20.98	NA	090
21343		A	Treatment of sinus fracture	12.95	9.99	NA	1.06	24.00	NA	090
21344		A	Treatment of sinus fracture	19.72	13.42	NA	1.72	34.86	NA	090
21345		A	Treat nose/jaw fracture	8.16	7.44	8.86	0.60	16.20	17.62	090
21346		A	Treat nose/jaw fracture	10.61	10.35	NA	0.85	21.81	NA	090
21347		A	Treat nose/jaw fracture	12.69	9.36	NA	1.14	23.19	NA	090
21348		A	Treat nose/jaw fracture	16.69	10.37	NA	1.50	28.56	NA	090
21355		A	Treat cheek bone fracture	3.77	2.41	4.84	0.29	6.47	8.90	010
21356		A	Treat cheek bone fracture	4.15	3.25	NA	0.36	7.76	NA	010
21360		A	Treat cheek bone fracture	6.46	5.77	NA	0.52	12.75	NA	090
21365		A	Treat cheek bone fracture	14.95	11.37	NA	1.30	27.62	NA	090
21366		A	Treat cheek bone fracture	17.77	12.08	NA	1.41	31.26	NA	090
21385		A	Treat eye socket fracture	9.16	7.63	NA	0.64	17.43	NA	090
21386		A	Treat eye socket fracture	9.16	8.03	NA	0.76	17.95	NA	090
21387		A	Treat eye socket fracture	9.70	8.16	NA	0.78	18.64	NA	090
21390		A	Treat eye socket fracture	10.13	8.38	NA	0.70	19.21	NA	090
21395		A	Treat eye socket fracture	12.68	10.07	NA	1.09	23.84	NA	090
21400		A	Treat eye socket fracture	1.40	1.08	2.93	0.12	2.60	4.45	090
21401		A	Treat eye socket fracture	3.26	3.25	5.59	0.34	6.85	9.19	090
21406		A	Treat eye socket fracture	7.01	6.60	NA	0.59	14.20	NA	090
21407		A	Treat eye socket fracture	8.61	7.71	NA	0.67	16.99	NA	090
21408		A	Treat eye socket fracture	12.38	9.70	NA	1.24	23.32	NA	090
21421		A	Treat mouth roof fracture	5.14	6.35	7.45	0.42	11.91	13.01	090
21422		A	Treat mouth roof fracture	8.32	7.21	NA	0.69	16.22	NA	090
21423		A	Treat mouth roof fracture	10.40	8.19	NA	0.95	19.54	NA	090
21431		A	Treat craniofacial fracture	7.05	5.25	NA	0.58	12.88	NA	090
21432		A	Treat craniofacial fracture	8.61	7.40	NA	0.55	16.56	NA	090
21433		A	Treat craniofacial fracture	25.35	17.86	NA	2.46	45.67	NA	090
21435		A	Treat craniofacial fracture	17.25	11.71	NA	1.66	30.62	NA	090
21436		A	Treat craniofacial fracture	28.04	18.98	NA	2.32	49.34	NA	090
21440		A	Treat dental ridge fracture	2.70	3.38	5.43	0.22	6.30	8.35	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
21445		A	Treat dental ridge fracture	5.38	5.37	7.07	0.55	11.30	13.00	090
21450		A	Treat lower jaw fracture	2.97	2.67	6.70	0.23	5.87	9.90	090
21451		A	Treat lower jaw fracture	4.87	5.49	6.58	0.39	10.75	11.84	090
21452		A	Treat lower jaw fracture	1.98	3.84	9.04	0.14	5.96	11.16	090
21453		A	Treat lower jaw fracture	5.54	6.28	7.56	0.49	12.31	13.59	090
21454		A	Treat lower jaw fracture	6.46	6.01	NA	0.55	13.02	NA	090
21461		A	Treat lower jaw fracture	8.09	7.83	9.74	0.73	16.65	18.56	090
21462		A	Treat lower jaw fracture	9.79	7.91	11.11	0.80	18.50	21.70	090
21465		A	Treat lower jaw fracture	11.91	7.37	NA	0.84	20.12	NA	090
21470		A	Treat lower jaw fracture	15.34	9.83	NA	1.36	26.53	NA	090
21480		A	Reset dislocated jaw	0.61	0.18	1.59	0.05	0.84	2.25	000
21485		A	Reset dislocated jaw	3.99	3.49	3.80	0.31	7.79	8.10	090
21490		A	Repair dislocated jaw	11.86	7.50	NA	1.31	20.67	NA	090
21493		A	Treat hyoid bone fracture	1.27	3.05	NA	0.10	4.42	NA	090
21494		A	Treat hyoid bone fracture	6.28	5.28	NA	0.44	12.00	NA	090
21495		A	Treat hyoid bone fracture	5.69	4.83	NA	0.41	10.93	NA	090
21497		A	Interdental wiring	3.86	3.78	4.72	0.31	7.95	8.89	090
21499		C	Head surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21501		A	Drain neck/chest lesion	3.81	3.57	4.31	0.36	7.74	8.48	090
21502		A	Drain chest lesion	7.12	7.71	NA	0.79	15.62	NA	090
21510		A	Drainage of bone lesion	5.74	6.86	NA	0.67	13.27	NA	090
21550		A	Biopsy of neck/chest	2.06	1.22	2.24	0.13	3.41	4.43	010
21555		A	Remove lesion, neck/chest	4.35	2.47	4.15	0.41	7.23	8.91	090
21556		A	Remove lesion, neck/chest	5.57	3.24	NA	0.51	9.32	NA	090
21557		A	Remove tumor, neck/chest	8.88	7.74	NA	0.85	17.47	NA	090
21600		A	Partial removal of rib	6.89	7.59	NA	0.81	15.29	NA	090
21610		A	Partial removal of rib	14.61	10.68	NA	1.85	27.14	NA	090
21615		A	Removal of rib	9.87	8.29	NA	1.20	19.36	NA	090
21616		A	Removal of rib and nerves	12.04	8.18	NA	1.31	21.53	NA	090
21620		A	Partial removal of sternum	6.79	8.03	NA	0.77	15.59	NA	090
21627		A	Sternal debridement	6.81	12.78	NA	0.82	20.41	NA	090
21630		A	Extensive sternum surgery	17.38	13.87	NA	1.95	33.20	NA	090
21632		A	Extensive sternum surgery	18.14	12.62	NA	2.16	32.92	NA	090
21700		A	Revision of neck muscle	6.19	7.11	8.71	0.31	13.61	15.21	090
21705		A	Revision of neck muscle/rib	9.60	7.18	NA	0.92	17.70	NA	090
21720		A	Revision of neck muscle	5.68	7.01	7.61	0.80	13.49	14.09	090
21725		A	Revision of neck muscle	6.99	6.89	NA	0.90	14.78	NA	090
21740		A	Reconstruction of sternum	16.50	12.24	NA	2.03	30.77	NA	090
21750		A	Repair of sternum separation	10.77	9.98	NA	1.35	22.10	NA	090
21800		A	Treatment of rib fracture	0.96	1.01	2.21	0.09	2.06	3.26	090
21805		A	Treatment of rib fracture	2.75	4.06	NA	0.29	7.10	NA	090
21810		A	Treatment of rib fracture(s)	6.86	6.27	NA	0.60	13.73	NA	090
21820		A	Treat sternum fracture	1.28	1.46	2.61	0.15	2.89	4.04	090
21825		A	Treat sternum fracture	7.41	10.09	NA	0.84	18.34	NA	090
21899		C	Neck/chest surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21920		A	Biopsy soft tissue of back	2.06	0.75	2.32	0.12	2.93	4.50	010
21925		A	Biopsy soft tissue of back	4.49	4.47	10.95	0.44	9.40	15.88	090
21930		A	Remove lesion, back or flank	5.00	2.65	4.56	0.49	8.14	10.05	090
21935		A	Remove tumor, back	17.96	13.26	NA	1.87	33.09	NA	090
22100		A	Remove part of neck vertebra	9.73	8.67	NA	1.55	19.95	NA	090
22101		A	Remove part, thorax vertebra	9.81	8.49	NA	1.51	19.81	NA	090
22102		A	Remove part, lumbar vertebra	9.81	8.70	NA	1.46	19.97	NA	090
22103		A	Remove extra spine segment	2.34	1.30	NA	0.37	4.01	NA	ZZZ
22110		A	Remove part of neck vertebra	12.74	10.53	NA	2.20	25.47	NA	090
22112		A	Remove part, thorax vertebra	12.81	10.60	NA	1.96	25.37	NA	090
22114		A	Remove part, lumbar vertebra	12.81	10.34	NA	1.98	25.13	NA	090
22116		A	Remove extra spine segment	2.32	1.19	NA	0.40	3.91	NA	ZZZ
22210		A	Revision of neck spine	23.82	16.94	NA	4.23	44.99	NA	090
22212		A	Revision of thorax spine	19.42	14.35	NA	2.78	36.55	NA	090
22214		A	Revision of lumbar spine	19.45	14.92	NA	2.78	37.15	NA	090
22216		A	Revise, extra spine segment	6.04	3.31	NA	0.98	10.33	NA	ZZZ
22220		A	Revision of neck spine	21.37	15.46	NA	3.65	40.48	NA	090
22222		A	Revision of thorax spine	21.52	13.62	NA	3.08	38.22	NA	090
22224		A	Revision of lumbar spine	21.52	15.68	NA	3.20	40.40	NA	090
22226		A	Revise, extra spine segment	6.04	3.30	NA	1.01	10.35	NA	ZZZ
22305		A	Treat spine process fracture	2.05	1.87	3.03	0.29	4.21	5.37	090
22310		A	Treat spine fracture	2.61	3.28	4.38	0.37	6.26	7.36	090
22315		A	Treat spine fracture	8.84	8.89	NA	1.37	19.10	NA	090
22318		A	Treat odontoid fx w/o graft	21.50	14.60	NA	4.26	40.36	NA	090
22319		A	Treat odontoid fx w/graft	24.00	16.89	NA	4.76	45.65	NA	090
22325		A	Treat spine fracture	18.30	14.45	NA	2.61	35.36	NA	090
22326		A	Treat neck spine fracture	19.59	15.28	NA	3.54	38.41	NA	090
22327		A	Treat thorax spine fracture	19.20	14.83	NA	2.75	36.78	NA	090
22328		A	Treat each add spine fx	4.61	2.30	NA	0.66	7.57	NA	ZZZ

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
22505		A	Manipulation of spine	1.87	3.01	4.59	0.27	5.15	6.73	010
22520		A	Percut vertebroplasty thor	8.91	3.91	NA	0.89	13.71	NA	010
22521		A	Percut vertebroplasty lumb	8.34	3.68	NA	0.84	12.86	NA	010
22522		A	Percut vertebroplasty addl	3.00	1.19	NA	0.30	4.49	NA	ZZZ
22548		A	Neck spine fusion	25.82	17.74	NA	4.98	48.54	NA	090
22554		A	Neck spine fusion	18.62	13.65	NA	3.51	35.78	NA	090
22556		A	Thorax spine fusion	23.46	16.42	NA	3.78	43.66	NA	090
22558		A	Lumbar spine fusion	22.28	14.36	NA	3.18	39.82	NA	090
22585		A	Additional spinal fusion	5.53	2.92	NA	0.98	9.43	NA	ZZZ
22590		A	Spine & skull spinal fusion	20.51	15.33	NA	3.81	39.65	NA	090
22595		A	Neck spinal fusion	19.39	14.31	NA	3.62	37.32	NA	090
22600		A	Neck spine fusion	16.14	12.58	NA	2.89	31.61	NA	090
22610		A	Thorax spine fusion	16.02	12.54	NA	2.66	31.22	NA	090
22612		A	Lumbar spine fusion	21.00	15.36	NA	3.28	39.64	NA	090
22614		A	Spine fusion, extra segment	6.44	3.53	NA	1.04	11.01	NA	ZZZ
22630		A	Lumbar spine fusion	20.84	15.57	NA	3.79	40.20	NA	090
22632		A	Spine fusion, extra segment	5.23	2.82	NA	0.90	8.95	NA	ZZZ
22800		A	Fusion of spine	18.25	13.64	NA	2.71	34.60	NA	090
22802		A	Fusion of spine	30.88	21.30	NA	4.42	56.60	NA	090
22804		A	Fusion of spine	36.27	24.04	NA	5.23	65.54	NA	090
22808		A	Fusion of spine	26.27	18.18	NA	4.36	48.81	NA	090
22810		A	Fusion of spine	30.27	19.81	NA	4.49	54.57	NA	090
22812		A	Fusion of spine	32.70	21.83	NA	4.67	59.20	NA	090
22818		A	Kyphectomy, 1–2 segments	31.83	21.14	NA	5.01	57.98	NA	090
22819		A	Kyphectomy, 3 or more	36.44	20.86	NA	5.20	62.50	NA	090
22830		A	Exploration of spinal fusion	10.85	9.57	NA	1.73	22.15	NA	090
22840		A	Insert spine fixation device	12.54	8.37	NA	2.03	22.94	NA	ZZZ
22841		B	Insert spine fixation device	0.00	0.00	0.00	0.00	0.00	0.00	XXX
22842		A	Insert spine fixation device	12.58	6.87	NA	2.04	21.49	NA	ZZZ
22843		A	Insert spine fixation device	13.46	8.86	NA	2.10	24.42	NA	ZZZ
22844		A	Insert spine fixation device	16.44	10.54	NA	2.42	29.40	NA	ZZZ
22845		A	Insert spine fixation device	11.96	7.95	NA	2.22	22.13	NA	ZZZ
22846		A	Insert spine fixation device	12.42	8.21	NA	2.26	22.89	NA	ZZZ
22847		A	Insert spine fixation device	13.80	8.97	NA	2.36	25.13	NA	ZZZ
22848		A	Insert pelv fixation device	6.00	4.75	NA	0.88	11.63	NA	ZZZ
22849		A	Reinsert spinal fixation	18.51	13.72	NA	2.87	35.10	NA	090
22850		A	Remove spine fixation device	9.52	8.41	NA	1.51	19.44	NA	090
22851		A	Apply spine prosth device	6.71	5.08	NA	1.11	12.90	NA	ZZZ
22852		A	Remove spine fixation device	9.01	8.18	NA	1.40	18.59	NA	090
22855		A	Remove spine fixation device	15.13	11.28	NA	2.74	29.15	NA	090
22899		C	Spine surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
22900		A	Remove abdominal wall lesion	5.80	4.29	NA	0.58	10.67	NA	090
22999		C	Abdomen surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
23000		A	Removal of calcium deposits	4.36	6.59	8.98	0.50	11.45	13.84	090
23020		A	Release shoulder joint	8.93	10.02	NA	1.23	20.18	NA	090
23030		A	Drain shoulder lesion	3.43	4.18	5.88	0.42	8.03	9.73	010
23031		A	Drain shoulder bursa	2.74	3.82	5.81	0.33	6.89	8.88	010
23035		A	Drain shoulder bone lesion	8.61	14.53	NA	1.19	24.33	NA	090
23040		A	Exploratory shoulder surgery	9.20	10.87	NA	1.28	21.35	NA	090
23044		A	Exploratory shoulder surgery	7.12	9.79	NA	0.97	17.88	NA	090
23065		A	Biopsy shoulder tissues	2.27	1.29	2.53	0.14	3.70	4.94	010
23066		A	Biopsy shoulder tissues	4.16	6.04	7.42	0.50	10.70	12.08	090
23075		A	Removal of shoulder lesion	2.39	3.08	5.25	0.25	5.72	7.89	010
23076		A	Removal of shoulder lesion	7.63	8.03	NA	0.87	16.53	NA	090
23077		A	Remove tumor of shoulder	16.09	14.40	NA	1.81	32.30	NA	090
23100		A	Biopsy of shoulder joint	6.03	8.01	NA	0.81	14.85	NA	090
23101		A	Shoulder joint surgery	5.58	8.10	NA	0.77	14.45	NA	090
23105		A	Remove shoulder joint lining	8.23	9.64	NA	1.13	19.00	NA	090
23106		A	Incision of collarbone joint	5.96	8.29	NA	0.82	15.07	NA	090
23107		A	Explore treat shoulder joint	8.62	9.61	NA	1.19	19.42	NA	090
23120		A	Partial removal, collar bone	7.11	8.86	NA	0.99	16.96	NA	090
23125		A	Removal of collar bone	9.39	10.24	NA	1.27	20.90	NA	090
23130		A	Remove shoulder bone, part	7.55	9.11	NA	1.06	17.72	NA	090
23140		A	Removal of bone lesion	6.89	8.21	NA	0.82	15.92	NA	090
23145		A	Removal of bone lesion	9.09	11.52	NA	1.24	21.85	NA	090
23146		A	Removal of bone lesion	7.83	9.97	NA	1.11	18.91	NA	090
23150		A	Removal of humerus lesion	8.48	9.44	NA	1.14	19.06	NA	090
23155		A	Removal of humerus lesion	10.35	10.88	NA	1.20	22.43	NA	090
23156		A	Removal of humerus lesion	8.68	9.69	NA	1.18	19.55	NA	090
23170		A	Remove collar bone lesion	6.86	10.32	NA	0.84	18.02	NA	090
23172		A	Remove shoulder blade lesion	6.90	10.73	NA	0.95	18.58	NA	090
23174		A	Remove humerus lesion	9.51	10.99	NA	1.30	21.80	NA	090
23180		A	Remove collar bone lesion	8.53	14.68	NA	1.18	24.39	NA	090
23182		A	Remove shoulder blade lesion	8.15	15.09	NA	1.08	24.32	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
23184		A	Remove humerus lesion	9.38	14.91	NA	1.24	25.53	NA	090
23190		A	Partial removal of scapula	7.24	8.12	NA	0.97	16.33	NA	090
23195		A	Removal of head of humerus	9.81	10.47	NA	1.38	21.66	NA	090
23200		A	Removal of collar bone	12.08	13.34	NA	1.48	26.90	NA	090
23210		A	Removal of shoulder blade	12.49	13.73	NA	1.61	27.83	NA	090
23220		A	Partial removal of humerus	14.56	14.41	NA	2.03	31.00	NA	090
23221		A	Partial removal of humerus	17.74	16.13	NA	2.51	36.38	NA	090
23222		A	Partial removal of humerus	23.92	19.80	NA	3.37	47.09	NA	090
23330		A	Remove shoulder foreign body	1.85	4.11	5.58	0.18	6.14	7.61	010
23331		A	Remove shoulder foreign body	7.38	8.97	NA	1.02	17.37	NA	090
23332		A	Remove shoulder foreign body	11.62	11.35	NA	1.62	24.59	NA	090
23350		A	Injection for shoulder x-ray	1.00	0.35	9.72	0.05	1.40	10.77	000
23395		A	Muscle transfer,shoulder/arm	16.85	13.51	NA	2.29	32.65	NA	090
23397		A	Muscle transfers	16.13	14.01	NA	2.24	32.38	NA	090
23400		A	Fixation of shoulder blade	13.54	12.98	NA	1.91	28.43	NA	090
23405		A	Incision of tendon & muscle	8.37	8.93	NA	1.12	18.42	NA	090
23406		A	Incise tendon(s) & muscle(s)	10.79	10.89	NA	1.48	23.16	NA	090
23410		A	Repair of tendon(s)	12.45	11.71	NA	1.72	25.88	NA	090
23412		A	Repair of tendon(s)	13.31	12.29	NA	1.86	27.46	NA	090
23415		A	Release of shoulder ligament	9.97	9.62	NA	1.39	20.98	NA	090
23420		A	Repair of shoulder	13.30	13.10	NA	1.86	28.26	NA	090
23430		A	Repair biceps tendon	9.98	10.45	NA	1.40	21.83	NA	090
23440		A	Remove/transplant tendon	10.48	10.69	NA	1.47	22.64	NA	090
23450		A	Repair shoulder capsule	13.40	12.40	NA	1.86	27.66	NA	090
23455		A	Repair shoulder capsule	14.37	12.91	NA	2.01	29.29	NA	090
23460		A	Repair shoulder capsule	15.37	13.57	NA	2.17	31.11	NA	090
23462		A	Repair shoulder capsule	15.30	13.41	NA	2.16	30.87	NA	090
23465		A	Repair shoulder capsule	15.85	12.40	NA	1.61	29.86	NA	090
23466		A	Repair shoulder capsule	14.22	12.83	NA	2.00	29.05	NA	090
23470		A	Reconstruct shoulder joint	17.15	14.42	NA	2.40	33.97	NA	090
23472		A	Reconstruct shoulder joint	21.10	16.66	NA	2.37	40.13	NA	090
23480		A	Revision of collar bone	11.18	11.16	NA	1.56	23.90	NA	090
23485		A	Revision of collar bone	13.43	12.42	NA	1.84	27.69	NA	090
23490		A	Reinforce clavicle	11.86	10.64	NA	1.11	23.61	NA	090
23491		A	Reinforce shoulder bones	14.21	12.60	NA	2.00	28.81	NA	090
23500		A	Treat clavicle fracture	2.08	2.38	3.55	0.26	4.72	5.89	090
23505		A	Treat clavicle fracture	3.69	3.78	5.48	0.50	7.97	9.67	090
23515		A	Treat clavicle fracture	7.41	7.70	NA	1.03	16.14	NA	090
23520		A	Treat clavicle dislocation	2.16	2.42	3.49	0.26	4.84	5.91	090
23525		A	Treat clavicle dislocation	3.60	3.65	5.36	0.44	7.69	9.40	090
23530		A	Treat clavicle dislocation	7.31	8.24	NA	0.85	16.40	NA	090
23532		A	Treat clavicle dislocation	8.01	8.09	NA	1.13	17.23	NA	090
23540		A	Treat clavicle dislocation	2.23	2.40	4.13	0.24	4.87	6.60	090
23545		A	Treat clavicle dislocation	3.25	3.46	4.74	0.39	7.10	8.38	090
23550		A	Treat clavicle dislocation	7.24	7.74	NA	0.94	15.92	NA	090
23552		A	Treat clavicle dislocation	8.45	8.31	NA	1.18	17.94	NA	090
23570		A	Treat shoulder blade fx	2.23	2.49	3.53	0.29	5.01	6.05	090
23575		A	Treat shoulder blade fx	4.06	4.00	5.61	0.53	8.59	10.20	090
23585		A	Treat scapula fracture	8.96	8.85	NA	1.25	19.06	NA	090
23600		A	Treat humerus fracture	2.93	3.37	5.09	0.39	6.69	8.41	090
23605		A	Treat humerus fracture	4.87	6.04	7.59	0.67	11.58	13.13	090
23615		A	Treat humerus fracture	9.35	9.54	NA	1.31	20.20	NA	090
23616		A	Treat humerus fracture	21.27	15.63	NA	2.98	39.88	NA	090
23620		A	Treat humerus fracture	2.40	3.11	4.79	0.32	5.83	7.51	090
23625		A	Treat humerus fracture	3.93	5.07	6.64	0.53	9.53	11.10	090
23630		A	Treat humerus fracture	7.35	7.69	NA	1.03	16.07	NA	090
23650		A	Treat shoulder dislocation	3.39	3.37	5.22	0.31	7.07	8.92	090
23655		A	Treat shoulder dislocation	4.57	4.06	NA	0.52	9.15	NA	090
23660		A	Treat shoulder dislocation	7.49	7.67	NA	1.01	16.17	NA	090
23665		A	Treat dislocation/fracture	4.47	5.35	6.96	0.60	10.42	12.03	090
23670		A	Treat dislocation/fracture	7.90	8.14	NA	1.10	17.14	NA	090
23675		A	Treat dislocation/fracture	6.05	6.26	7.75	0.83	13.14	14.63	090
23680		A	Treat dislocation/fracture	10.06	9.35	NA	1.39	20.80	NA	090
23700		A	Fixation of shoulder	2.52	3.22	NA	0.35	6.09	NA	010
23800		A	Fusion of shoulder joint	14.16	13.57	NA	1.97	29.70	NA	090
23802		A	Fusion of shoulder joint	16.60	15.04	NA	2.34	33.98	NA	090
23900		A	Amputation of arm & girdle	19.72	14.75	NA	2.47	36.94	NA	090
23920		A	Amputation at shoulder joint	14.61	13.93	NA	1.92	30.46	NA	090
23921		A	Amputation follow-up surgery	5.49	6.54	NA	0.78	12.81	NA	090
23929		C	Shoulder surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
23930		A	Drainage of arm lesion	2.94	3.86	5.96	0.32	7.12	9.22	010
23931		A	Drainage of arm bursa	1.79	3.38	5.50	0.21	5.38	7.50	010
23935		A	Drain arm/elbow bone lesion	6.09	11.98	NA	0.84	18.91	NA	090
24000		A	Exploratory elbow surgery	5.82	5.71	NA	0.77	12.30	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
24006		A	Release elbow joint	9.31	8.16	NA	1.27	18.74	NA	090
24065		A	Biopsy arm/elbow soft tissue	2.08	3.25	5.41	0.14	5.47	7.63	010
24066		A	Biopsy arm/elbow soft tissue	5.21	6.39	8.70	0.61	12.21	14.52	090
24075		A	Remove arm/elbow lesion	3.92	5.87	8.10	0.43	10.22	12.45	090
24076		A	Remove arm/elbow lesion	6.30	6.92	NA	0.70	13.92	NA	090
24077		A	Remove tumor of arm/elbow	11.76	13.74	NA	1.32	26.82	NA	090
24100		A	Biopsy elbow joint lining	4.93	5.51	NA	0.62	11.06	NA	090
24101		A	Explore/treat elbow joint	6.13	6.33	NA	0.84	13.30	NA	090
24102		A	Remove elbow joint lining	8.03	7.45	NA	1.09	16.57	NA	090
24105		A	Removal of elbow bursa	3.61	4.84	NA	0.49	8.94	NA	090
24110		A	Remove humerus lesion	7.39	9.03	NA	0.99	17.41	NA	090
24115		A	Remove/graft bone lesion	9.63	9.42	NA	1.15	20.20	NA	090
24116		A	Remove/graft bone lesion	11.81	11.23	NA	1.66	24.70	NA	090
24120		A	Remove elbow lesion	6.65	6.33	NA	0.87	13.85	NA	090
24125		A	Remove/graft bone lesion	7.89	6.60	NA	0.88	15.37	NA	090
24126		A	Remove/graft bone lesion	8.31	7.22	NA	0.90	16.43	NA	090
24130		A	Removal of head of radius	6.25	6.43	NA	0.87	13.55	NA	090
24134		A	Removal of arm bone lesion	9.73	15.45	NA	1.31	26.49	NA	090
24136		A	Remove radius bone lesion	7.99	6.71	NA	0.85	15.55	NA	090
24138		A	Remove elbow bone lesion	8.05	7.37	NA	1.12	16.54	NA	090
24140		A	Partial removal of arm bone	9.18	15.93	NA	1.23	26.34	NA	090
24145		A	Partial removal of radius	7.58	10.30	NA	1.01	18.89	NA	090
24147		A	Partial removal of elbow	7.54	10.34	NA	1.04	18.92	NA	090
24149		A	Radical resection of elbow	14.20	10.85	NA	1.90	26.95	NA	090
24150		A	Extensive humerus surgery	13.27	13.78	NA	1.81	28.86	NA	090
24151		A	Extensive humerus surgery	15.58	15.36	NA	2.19	33.13	NA	090
24152		A	Extensive radius surgery	10.06	8.95	NA	1.19	20.20	NA	090
24153		A	Extensive radius surgery	11.54	7.34	NA	0.64	19.52	NA	090
24155		A	Removal of elbow joint	11.73	8.81	NA	1.42	21.96	NA	090
24160		A	Remove elbow joint implant	7.83	7.33	NA	1.07	16.23	NA	090
24164		A	Remove radius head implant	6.23	6.36	NA	0.84	13.43	NA	090
24200		A	Removal of arm foreign body	1.76	3.16	5.90	0.15	5.07	7.81	010
24201		A	Removal of arm foreign body	4.56	6.75	8.45	0.56	11.87	13.57	090
24220		A	Injection for elbow x-ray	1.31	0.47	10.76	0.07	1.85	12.14	000
24301		A	Muscle/tendon transfer	10.20	8.94	NA	1.30	20.44	NA	090
24305		A	Arm tendon lengthening	7.45	7.15	NA	0.98	15.58	NA	090
24310		A	Revision of arm tendon	5.98	7.77	NA	0.74	14.49	NA	090
24320		A	Repair of arm tendon	10.56	10.12	NA	1.00	21.68	NA	090
24330		A	Revision of arm muscles	9.60	8.44	NA	1.21	19.25	NA	090
24331		A	Revision of arm muscles	10.65	8.80	NA	1.41	20.86	NA	090
24340		A	Repair of biceps tendon	7.89	7.23	NA	1.08	16.20	NA	090
24341		A	Repair arm tendon/muscle	7.90	7.30	NA	1.08	16.28	NA	090
24342		A	Repair of ruptured tendon	10.62	8.91	NA	1.48	21.01	NA	090
24350		A	Repair of tennis elbow	5.25	5.91	NA	0.72	11.88	NA	090
24351		A	Repair of tennis elbow	5.91	6.34	NA	0.82	13.07	NA	090
24352		A	Repair of tennis elbow	6.43	6.61	NA	0.90	13.94	NA	090
24354		A	Repair of tennis elbow	6.48	6.55	NA	0.88	13.91	NA	090
24356		A	Revision of tennis elbow	6.68	6.74	NA	0.90	14.32	NA	090
24360		A	Reconstruct elbow joint	12.34	9.65	NA	1.69	23.68	NA	090
24361		A	Reconstruct elbow joint	14.08	10.36	NA	1.95	26.39	NA	090
24362		A	Reconstruct elbow joint	14.99	10.93	NA	1.92	27.84	NA	090
24363		A	Replace elbow joint	18.49	13.26	NA	2.52	34.27	NA	090
24365		A	Reconstruct head of radius	8.39	7.62	NA	1.11	17.12	NA	090
24366		A	Reconstruct head of radius	9.13	8.06	NA	1.28	18.47	NA	090
24400		A	Revision of humerus	11.06	11.89	NA	1.53	24.48	NA	090
24410		A	Revision of humerus	14.82	13.84	NA	1.89	30.55	NA	090
24420		A	Revision of humerus	13.44	15.43	NA	1.82	30.69	NA	090
24430		A	Repair of humerus	12.81	12.15	NA	1.80	26.76	NA	090
24435		A	Repair humerus with graft	13.17	13.11	NA	1.84	28.12	NA	090
24470		A	Revision of elbow joint	8.74	7.17	NA	1.23	17.14	NA	090
24495		A	Decompression of forearm	8.12	9.47	NA	0.92	18.51	NA	090
24498		A	Reinforce humerus	11.92	11.60	NA	1.67	25.19	NA	090
24500		A	Treat humerus fracture	3.21	3.11	4.67	0.41	6.73	8.29	090
24505		A	Treat humerus fracture	5.17	6.31	8.09	0.72	12.20	13.98	090
24515		A	Treat humerus fracture	11.65	10.79	NA	1.63	24.07	NA	090
24516		A	Treat humerus fracture	11.65	11.17	NA	1.63	24.45	NA	090
24530		A	Treat humerus fracture	3.50	4.44	5.64	0.47	8.41	9.61	090
24535		A	Treat humerus fracture	6.87	6.38	8.13	0.96	14.21	15.96	090
24538		A	Treat humerus fracture	9.43	9.79	NA	1.25	20.47	NA	090
24545		A	Treat humerus fracture	10.46	9.60	NA	1.47	21.53	NA	090
24546		A	Treat humerus fracture	15.69	13.03	NA	2.18	30.90	NA	090
24560		A	Treat humerus fracture	2.80	2.89	4.48	0.35	6.04	7.63	090
24565		A	Treat humerus fracture	5.56	5.62	7.40	0.74	11.92	13.70	090
24566		A	Treat humerus fracture	7.79	9.23	NA	1.10	18.12	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
24575		A	Treat humerus fracture	10.66	8.03	NA	1.44	20.13	NA	090
24576		A	Treat humerus fracture	2.86	3.01	4.25	0.38	6.25	7.49	090
24577		A	Treat humerus fracture	5.79	5.75	7.51	0.81	12.35	14.11	090
24579		A	Treat humerus fracture	11.60	10.69	NA	1.62	23.91	NA	090
24582		A	Treat humerus fracture	8.55	9.72	NA	1.20	19.47	NA	090
24586		A	Treat elbow fracture	15.21	10.77	NA	2.12	28.10	NA	090
24587		A	Treat elbow fracture	15.16	10.55	NA	2.14	27.85	NA	090
24600		A	Treat elbow dislocation	4.23	4.70	6.32	0.49	9.42	11.04	090
24605		A	Treat elbow dislocation	5.42	4.75	NA	0.72	10.89	NA	090
24615		A	Treat elbow dislocation	9.42	7.58	NA	1.31	18.31	NA	090
24620		A	Treat elbow fracture	6.98	6.21	NA	0.90	14.09	NA	090
24635		A	Treat elbow fracture	13.19	15.10	NA	1.84	30.13	NA	090
24640		A	Treat elbow dislocation	1.20	1.70	3.24	0.11	3.01	4.55	010
24650		A	Treat radius fracture	2.16	2.65	4.13	0.28	5.09	6.57	090
24655		A	Treat radius fracture	4.40	4.90	6.70	0.58	9.88	11.68	090
24665		A	Treat radius fracture	8.14	8.79	NA	1.13	18.06	NA	090
24666		A	Treat radius fracture	9.49	9.53	NA	1.32	20.34	NA	090
24670		A	Treat ulnar fracture	2.54	2.85	4.10	0.33	5.72	6.97	090
24675		A	Treat ulnar fracture	4.72	5.12	6.84	0.65	10.49	12.21	090
24685		A	Treat ulnar fracture	8.80	9.15	NA	1.23	19.18	NA	090
24800		A	Fusion of elbow joint	11.20	9.43	NA	1.41	22.04	NA	090
24802		A	Fusion/graft of elbow joint	13.69	11.22	NA	1.89	26.80	NA	090
24900		A	Amputation of upper arm	9.60	10.69	NA	1.18	21.47	NA	090
24920		A	Amputation of upper arm	9.54	12.12	NA	1.22	22.88	NA	090
24925		A	Amputation follow-up surgery	7.07	8.94	NA	0.95	16.96	NA	090
24930		A	Amputation follow-up surgery	10.25	11.17	NA	1.23	22.65	NA	090
24931		A	Amputate upper arm & implant	12.72	11.41	NA	1.56	25.69	NA	090
24935		A	Revision of amputation	15.56	11.97	NA	1.58	29.11	NA	090
24940		C	Revision of upper arm	0.00	0.00	0.00	0.00	0.00	0.00	090
24999		C	Upper arm/elbow surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
25000		A	Incision of tendon sheath	3.38	6.63	NA	0.45	10.46	NA	090
25020		A	Decompression of forearm	5.92	10.41	NA	0.75	17.08	NA	090
25023		A	Decompression of forearm	12.96	16.09	NA	1.50	30.55	NA	090
25028		A	Drainage of forearm lesion	5.25	9.40	NA	0.61	15.26	NA	090
25031		A	Drainage of forearm bursa	4.14	9.13	NA	0.50	13.77	NA	090
25035		A	Treat forearm bone lesion	7.36	15.24	NA	0.98	23.58	NA	090
25040		A	Explore/treat wrist joint	7.18	8.62	NA	0.96	16.76	NA	090
25065		A	Biopsy forearm soft tissues	1.99	2.42	2.42	0.12	4.53	4.53	010
25066		A	Biopsy forearm soft tissues	4.13	7.44	NA	0.49	12.06	NA	090
25075		A	Removal of forearm lesion	3.74	6.93	NA	0.40	11.07	NA	090
25076		A	Removal of forearm lesion	4.92	11.70	NA	0.59	17.21	NA	090
25077		A	Remove tumor, forearm/wrist	9.76	15.47	NA	1.10	26.33	NA	090
25085		A	Incision of wrist capsule	5.50	9.97	NA	0.71	16.18	NA	090
25100		A	Biopsy of wrist joint	3.90	6.70	NA	0.50	11.10	NA	090
25101		A	Explore/treat wrist joint	4.69	7.29	NA	0.60	12.58	NA	090
25105		A	Remove wrist joint lining	5.85	10.15	NA	0.77	16.77	NA	090
25107		A	Remove wrist joint cartilage	6.43	10.29	NA	0.82	17.54	NA	090
25110		A	Remove wrist tendon lesion	3.92	7.83	NA	0.48	12.23	NA	090
25111		A	Remove wrist tendon lesion	3.39	6.12	NA	0.42	9.93	NA	090
25112		A	Reremove wrist tendon lesion	4.53	7.02	NA	0.54	12.09	NA	090
25115		A	Remove wrist/forearm lesion	8.82	15.64	NA	1.11	25.57	NA	090
25116		A	Remove wrist/forearm lesion	7.11	14.57	NA	0.90	22.58	NA	090
25118		A	Excise wrist tendon sheath	4.37	7.29	NA	0.55	12.21	NA	090
25119		A	Partial removal of ulna	6.04	10.04	NA	0.80	16.88	NA	090
25120		A	Removal of forearm lesion	6.10	13.32	NA	0.81	20.23	NA	090
25125		A	Remove/graft forearm lesion	7.48	14.60	NA	1.02	23.10	NA	090
25126		A	Remove/graft forearm lesion	7.55	13.98	NA	1.00	22.53	NA	090
25130		A	Removal of wrist lesion	5.26	7.58	NA	0.66	13.50	NA	090
25135		A	Remove & graft wrist lesion	6.89	8.35	NA	0.89	16.13	NA	090
25136		A	Remove & graft wrist lesion	5.97	6.45	NA	0.58	13.00	NA	090
25145		A	Remove forearm bone lesion	6.37	14.15	NA	0.82	21.34	NA	090
25150		A	Partial removal of ulna	7.09	11.10	NA	0.96	19.15	NA	090
25151		A	Partial removal of radius	7.39	13.87	NA	0.93	22.19	NA	090
25170		A	Extensive forearm surgery	11.09	16.11	NA	1.52	28.72	NA	090
25210		A	Removal of wrist bone	5.95	8.13	NA	0.73	14.81	NA	090
25215		A	Removal of wrist bones	7.89	11.22	NA	1.02	20.13	NA	090
25230		A	Partial removal of radius	5.23	7.50	NA	0.66	13.39	NA	090
25240		A	Partial removal of ulna	5.17	9.65	NA	0.69	15.51	NA	090
25246		A	Injection for wrist x-ray	1.45	0.51	10.21	0.07	2.03	11.73	000
25248		A	Remove forearm foreign body	5.14	9.18	NA	0.54	14.86	NA	090
25250		A	Removal of wrist prosthesis	6.60	8.22	NA	0.84	15.66	NA	090
25251		A	Removal of wrist prosthesis	9.57	11.59	NA	1.15	22.31	NA	090
25260		A	Repair forearm tendon/muscle	7.80	15.87	NA	0.97	24.64	NA	090
25263		A	Repair forearm tendon/muscle	7.82	15.18	NA	0.94	23.94	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
25265		A	Repair forearm tendon/muscle	9.88	15.91	NA	1.19	26.98	NA	090
25270		A	Repair forearm tendon/muscle	6.00	14.75	NA	0.76	21.51	NA	090
25272		A	Repair forearm tendon/muscle	7.04	15.38	NA	0.89	23.31	NA	090
25274		A	Repair forearm tendon/muscle	8.75	15.08	NA	1.11	24.94	NA	090
25280		A	Revise wrist/forearm tendon	7.22	14.41	NA	0.91	22.54	NA	090
25290		A	Incise wrist/forearm tendon	5.29	16.27	NA	0.66	22.22	NA	090
25295		A	Release wrist/forearm tendon	6.55	14.17	NA	0.84	21.56	NA	090
25300		A	Fusion of tendons at wrist	8.80	9.65	NA	1.07	19.52	NA	090
25301		A	Fusion of tendons at wrist	8.40	9.34	NA	1.08	18.82	NA	090
25310		A	Transplant forearm tendon	8.14	14.69	NA	1.01	23.84	NA	090
25312		A	Transplant forearm tendon	9.57	15.68	NA	1.22	26.47	NA	090
25315		A	Revise palsy hand tendon(s)	10.20	16.52	NA	1.26	27.98	NA	090
25316		A	Revise palsy hand tendon(s)	12.33	17.21	NA	1.74	31.28	NA	090
25320		A	Repair/revise wrist joint	10.77	10.80	NA	1.32	22.89	NA	090
25332		A	Revise wrist joint	11.41	11.30	NA	1.46	24.17	NA	090
25335		A	Realignment of hand	12.88	13.40	NA	1.66	27.94	NA	090
25337		A	Reconstruct ulna/radioulnar	10.17	12.46	NA	1.31	23.94	NA	090
25350		A	Revision of radius	8.78	14.90	NA	1.17	24.85	NA	090
25355		A	Revision of radius	10.17	15.98	NA	1.44	27.59	NA	090
25360		A	Revision of ulna	8.43	15.02	NA	1.17	24.62	NA	090
25365		A	Revise radius & ulna	12.40	16.38	NA	1.67	30.45	NA	090
25370		A	Revise radius or ulna	13.36	17.87	NA	1.88	33.11	NA	090
25375		A	Revise radius & ulna	13.04	17.69	NA	1.84	32.57	NA	090
25390		A	Shorten radius or ulna	10.40	15.98	NA	1.38	27.76	NA	090
25391		A	Lengthen radius or ulna	13.65	17.30	NA	1.73	32.68	NA	090
25392		A	Shorten radius & ulna	13.95	16.70	NA	1.73	32.38	NA	090
25393		A	Lengthen radius & ulna	15.87	16.87	NA	1.87	34.61	NA	090
25400		A	Repair radius or ulna	10.92	16.14	NA	1.50	28.56	NA	090
25405		A	Repair/graft radius or ulna	14.38	18.44	NA	1.95	34.77	NA	090
25415		A	Repair radius & ulna	13.35	17.54	NA	1.87	32.76	NA	090
25420		A	Repair/graft radius & ulna	16.33	19.34	NA	2.20	37.87	NA	090
25425		A	Repair/graft radius or ulna	13.21	24.49	NA	1.61	39.31	NA	090
25426		A	Repair/graft radius & ulna	15.82	19.57	NA	2.23	37.62	NA	090
25440		A	Repair/graft wrist bone	10.44	10.49	NA	1.41	22.34	NA	090
25441		A	Reconstruct wrist joint	12.90	11.56	NA	1.83	26.29	NA	090
25442		A	Reconstruct wrist joint	10.85	10.66	NA	1.24	22.75	NA	090
25443		A	Reconstruct wrist joint	10.39	14.76	NA	1.30	26.45	NA	090
25444		A	Reconstruct wrist joint	11.15	12.37	NA	1.43	24.95	NA	090
25445		A	Reconstruct wrist joint	9.69	12.45	NA	1.26	23.40	NA	090
25446		A	Wrist replacement	16.55	13.94	NA	2.20	32.69	NA	090
25447		A	Repair wrist joint(s)	10.37	10.50	NA	1.34	22.21	NA	090
25449		A	Remove wrist joint implant	14.49	14.77	NA	1.77	31.03	NA	090
25450		A	Revision of wrist joint	7.87	11.88	NA	0.88	20.63	NA	090
25455		A	Revision of wrist joint	9.49	11.30	NA	1.07	21.86	NA	090
25490		A	Reinforce radius	9.54	15.04	NA	1.19	25.77	NA	090
25491		A	Reinforce ulna	9.96	15.44	NA	1.41	26.81	NA	090
25492		A	Reinforce radius and ulna	12.33	14.22	NA	1.62	28.17	NA	090
25500		A	Treat fracture of radius	2.45	2.73	3.94	0.28	5.46	6.67	090
25505		A	Treat fracture of radius	5.21	5.33	7.08	0.69	11.23	12.98	090
25515		A	Treat fracture of radius	9.18	9.26	NA	1.22	19.66	NA	090
25520		A	Treat fracture of radius	6.26	6.01	7.39	0.85	13.12	14.50	090
25525		A	Treat fracture of radius	12.24	11.02	NA	1.68	24.94	NA	090
25526		A	Treat fracture of radius	12.98	14.20	NA	1.80	28.98	NA	090
25530		A	Treat fracture of ulna	2.09	2.64	3.82	0.27	5.00	6.18	090
25535		A	Treat fracture of ulna	5.14	5.29	7.08	0.68	11.11	12.90	090
25545		A	Treat fracture of ulna	8.90	9.22	NA	1.23	19.35	NA	090
25560		A	Treat fracture radius & ulna	2.44	2.69	3.94	0.27	5.40	6.65	090
25565		A	Treat fracture radius & ulna	5.63	5.55	7.34	0.76	11.94	13.73	090
25574		A	Treat fracture radius & ulna	7.01	8.12	NA	0.96	16.09	NA	090
25575		A	Treat fracture radius/ulna	10.45	10.09	NA	1.46	22.00	NA	090
25600		A	Treat fracture radius/ulna	2.63	2.85	4.13	0.34	5.82	7.10	090
25605		A	Treat fracture radius/ulna	5.81	5.73	7.51	0.81	12.35	14.13	090
25611		A	Treat fracture radius/ulna	7.77	9.27	NA	1.08	18.12	NA	090
5620		A	Treat fracture radius/ulna	8.55	9.03	NA	1.17	18.75	NA	090
25622		A	Treat wrist bone fracture	2.61	2.83	4.11	0.33	5.77	7.05	090
25624		A	Treat wrist bone fracture	4.53	4.98	6.72	0.61	10.12	11.86	090
25628		A	Treat wrist bone fracture	8.43	9.15	NA	1.14	18.72	NA	090
25630		A	Treat wrist bone fracture	2.88	2.93	4.26	0.37	6.18	7.51	090
25635		A	Treat wrist bone fracture	4.39	4.05	6.78	0.39	8.83	11.56	090
25645		A	Treat wrist bone fracture	7.25	9.29	NA	0.93	17.47	NA	090
25650		A	Treat wrist bone fracture	3.05	2.96	4.36	0.37	6.38	7.78	090
25660		A	Treat wrist dislocation	4.76	5.14	NA	0.59	10.49	NA	090
25670		A	Treat wrist dislocation	7.92	8.94	NA	1.07	17.93	NA	090
25675		A	Treat wrist dislocation	4.67	4.90	6.75	0.57	10.14	11.99	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
25676		A	Treat wrist dislocation	8.04	8.99	NA	1.10	18.13	NA	090
25680		A	Treat wrist fracture	5.99	6.13	NA	0.61	12.73	NA	090
25685		A	Treat wrist fracture	9.78	9.62	NA	1.25	20.65	NA	090
25690		A	Treat wrist dislocation	5.50	6.50	NA	0.78	12.78	NA	090
25695		A	Treat wrist dislocation	8.34	8.92	NA	1.07	18.33	NA	090
25800		A	Fusion of wrist joint	9.76	10.06	NA	1.30	21.12	NA	090
25805		A	Fusion/graft of wrist joint	11.28	11.01	NA	1.51	23.80	NA	090
25810		A	Fusion/graft of wrist joint	10.57	10.56	NA	1.37	22.50	NA	090
25820		A	Fusion of hand bones	7.45	8.83	NA	0.96	17.24	NA	090
25825		A	Fuse hand bones with graft	9.27	9.90	NA	1.20	20.37	NA	090
25830		A	Fusion, radioulnar jnt/ulna	10.06	15.03	NA	1.27	26.36	NA	090
25900		A	Amputation of forearm	9.01	13.44	NA	1.08	23.53	NA	090
25905		A	Amputation of forearm	9.12	15.44	NA	1.06	25.62	NA	090
25907		A	Amputation follow-up surgery	7.80	13.37	NA	1.01	22.18	NA	090
25909		A	Amputation follow-up surgery	8.96	15.46	NA	1.07	25.49	NA	090
25915		A	Amputation of forearm	17.08	20.29	NA	2.41	39.78	NA	090
25920		A	Amputate hand at wrist	8.68	9.45	NA	1.06	19.19	NA	090
25922		A	Amputate hand at wrist	7.42	8.61	NA	0.93	16.96	NA	090
25924		A	Amputation follow-up surgery	8.46	9.25	NA	1.07	18.78	NA	090
25927		A	Amputation of hand	8.80	13.77	NA	1.02	23.59	NA	090
25929		A	Amputation follow-up surgery	7.59	6.66	NA	0.89	15.14	NA	090
25931		A	Amputation follow-up surgery	7.81	13.86	NA	0.88	22.55	NA	090
25999		C	Forearm or wrist surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
26010		A	Drainage of finger abscess	1.54	3.50	4.85	0.14	5.18	6.53	010
26011		A	Drainage of finger abscess	2.19	5.80	6.86	0.25	8.24	9.30	010
26020		A	Drain hand tendon sheath	4.67	11.73	NA	0.59	16.99	NA	090
26025		A	Drainage of palm bursa	4.82	11.93	NA	0.60	17.35	NA	090
26030		A	Drainage of palm bursa(s)	5.93	12.37	NA	0.72	19.02	NA	090
26034		A	Treat hand bone lesion	6.23	13.53	NA	0.79	20.55	NA	090
26035		A	Decompress fingers/hand	9.51	15.47	NA	1.12	26.10	NA	090
26037		A	Decompress fingers/hand	7.25	11.90	NA	0.87	20.02	NA	090
26040		A	Release palm contracture	3.33	11.30	NA	0.45	15.08	NA	090
26045		A	Release palm contracture	5.56	12.48	NA	0.74	18.78	NA	090
26055		A	Incise finger tendon sheath	2.69	6.82	7.13	0.36	9.87	10.18	090
26060		A	Incision of finger tendon	2.81	6.75	NA	0.35	9.91	NA	090
26070		A	Explore/treat hand joint	3.69	10.47	NA	0.35	14.51	NA	090
26075		A	Explore/treat finger joint	3.79	11.05	NA	0.40	15.24	NA	090
26080		A	Explore/treat finger joint	4.24	11.75	NA	0.52	16.51	NA	090
26100		A	Biopsy hand joint lining	3.67	7.53	NA	0.45	11.65	NA	090
26105		A	Biopsy finger joint lining	3.71	10.82	NA	0.45	14.98	NA	090
26110		A	Biopsy finger joint lining	3.53	10.83	NA	0.44	14.80	NA	090
26115		A	Removal of hand lesion	3.86	7.37	7.37	0.48	11.71	11.71	090
26116		A	Removal of hand lesion	5.53	12.40	NA	0.69	18.62	NA	090
26117		A	Remove tumor, hand/finger	8.55	14.68	NA	1.01	24.24	NA	090
26121		A	Release palm contracture	7.54	14.45	NA	0.94	22.93	NA	090
26123		A	Release palm contracture	9.29	15.42	NA	1.17	25.88	NA	090
26125		A	Release palm contracture	4.61	2.58	NA	0.57	7.76	NA	ZZZ
26130		A	Remove wrist joint lining	5.42	15.08	NA	0.65	21.15	NA	090
26135		A	Revise finger joint, each	6.96	15.66	NA	0.87	23.49	NA	090
26140		A	Revise finger joint, each	6.17	14.55	NA	0.76	21.48	NA	090
26145		A	Tendon excision, palm/finger	6.32	14.53	NA	0.77	21.62	NA	090
26160		A	Remove tendon sheath lesion	3.15	7.07	7.42	0.39	10.61	10.96	090
26170		A	Removal of palm tendon, each	4.77	8.10	NA	0.60	13.47	NA	090
26180		A	Removal of finger tendon	5.18	7.90	NA	0.64	13.72	NA	090
26185		A	Remove finger bone	5.25	8.47	NA	0.67	14.39	NA	090
26200		A	Remove hand bone lesion	5.51	12.49	NA	0.71	18.71	NA	090
26205		A	Remove/graft bone lesion	7.70	14.21	NA	0.95	22.86	NA	090
26210		A	Removal of finger lesion	5.15	13.15	NA	0.64	18.94	NA	090
26215		A	Remove/graft finger lesion	7.10	13.64	NA	0.77	21.51	NA	090
26230		A	Partial removal of hand bone	6.33	11.95	NA	0.84	19.12	NA	090
26235		A	Partial removal, finger bone	6.19	11.60	NA	0.78	18.57	NA	090
26236		A	Partial removal, finger bone	5.32	11.50	NA	0.66	17.48	NA	090
26250		A	Extensive hand surgery	7.55	16.17	NA	0.92	24.64	NA	090
26255		A	Extensive hand surgery	12.43	17.40	NA	1.05	30.88	NA	090
26260		A	Extensive finger surgery	7.03	16.10	NA	0.83	23.96	NA	090
26261		A	Extensive finger surgery	9.09	17.27	NA	0.84	27.20	NA	090
26262		A	Partial removal of finger	5.67	13.02	NA	0.70	19.39	NA	090
26320		A	Removal of implant from hand	3.98	11.90	NA	0.49	16.37	NA	090
26350		A	Repair finger/hand tendon	5.99	18.44	NA	0.73	25.16	NA	090
26352		A	Repair/graft hand tendon	7.68	17.73	NA	0.93	26.34	NA	090
26356		A	Repair finger/hand tendon	8.07	19.76	NA	0.99	28.82	NA	090
26357		A	Repair finger/hand tendon	8.58	19.18	NA	1.02	28.78	NA	090
26358		A	Repair/graft hand tendon	9.14	18.83	NA	1.07	29.04	NA	090
26370		A	Repair finger/hand tendon	7.11	18.97	NA	0.90	26.98	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
26372		A	Repair/graft hand tendon	8.76	19.04	NA	1.06	28.86	NA	090
26373		A	Repair finger/hand tendon	8.16	21.85	NA	0.98	30.99	NA	090
26390		A	Revise hand/finger tendon	9.19	14.73	NA	1.09	25.01	NA	090
26392		A	Repair/graft hand tendon	10.26	20.11	NA	1.26	31.63	NA	090
26410		A	Repair hand tendon	4.63	14.73	NA	0.57	19.93	NA	090
26412		A	Repair/graft hand tendon	6.31	15.14	NA	0.80	22.25	NA	090
26415		A	Excision, hand/finger tendon	8.34	14.78	NA	0.77	23.89	NA	090
26416		A	Graft hand or finger tendon	9.37	15.98	NA	1.20	26.55	NA	090
26418		A	Repair finger tendon	4.25	14.47	NA	0.50	19.22	NA	090
26420		A	Repair/graft finger tendon	6.77	15.94	NA	0.83	23.54	NA	090
26426		A	Repair finger/hand tendon	6.15	15.25	NA	0.77	22.17	NA	090
26428		A	Repair/graft finger tendon	7.21	15.88	NA	0.84	23.93	NA	090
26432		A	Repair finger tendon	4.02	11.21	NA	0.48	15.71	NA	090
26433		A	Repair finger tendon	4.56	12.90	NA	0.56	18.02	NA	090
26434		A	Repair/graft finger tendon	6.09	12.26	NA	0.71	19.06	NA	090
26437		A	Realignment of tendons	5.82	12.65	NA	0.74	19.21	NA	090
26440		A	Release palm/finger tendon	5.02	16.29	NA	0.62	21.93	NA	090
26442		A	Release palm & finger tendon	8.16	18.65	NA	0.94	27.75	NA	090
26445		A	Release hand/finger tendon	4.31	16.15	NA	0.54	21.00	NA	090
26449		A	Release forearm/hand tendon	7.00	16.93	NA	0.84	24.77	NA	090
26450		A	Incision of palm tendon	3.67	7.35	NA	0.46	11.48	NA	090
26455		A	Incision of finger tendon	3.64	7.62	NA	0.47	11.73	NA	090
26460		A	Incise hand/finger tendon	3.46	7.16	NA	0.44	11.06	NA	090
26471		A	Fusion of finger tendons	5.73	12.60	NA	0.73	19.06	NA	090
26474		A	Fusion of finger tendons	5.32	12.98	NA	0.69	18.99	NA	090
26476		A	Tendon lengthening	5.18	13.01	NA	0.62	18.81	NA	090
26477		A	Tendon shortening	5.15	12.42	NA	0.60	18.17	NA	090
26478		A	Lengthening of hand tendon	5.80	12.68	NA	0.77	19.25	NA	090
26479		A	Shortening of hand tendon	5.74	12.93	NA	0.76	19.43	NA	090
26480		A	Transplant hand tendon	6.69	17.38	NA	0.84	24.91	NA	090
26483		A	Transplant/graft hand tendon	8.29	18.21	NA	1.03	27.53	NA	090
26485		A	Transplant palm tendon	7.70	17.29	NA	0.94	25.93	NA	090
26489		A	Transplant/graft palm tendon	9.55	16.81	NA	0.98	27.34	NA	090
26490		A	Revise thumb tendon	8.41	13.89	NA	1.05	23.35	NA	090
26492		A	Tendon transfer with graft	9.62	15.06	NA	1.19	25.87	NA	090
26494		A	Hand tendon/muscle transfer	8.47	14.39	NA	1.13	23.99	NA	090
26496		A	Revise thumb tendon	9.59	14.31	NA	1.17	25.07	NA	090
26497		A	Finger tendon transfer	9.57	14.56	NA	1.17	25.30	NA	090
26498		A	Finger tendon transfer	14.00	16.84	NA	1.74	32.58	NA	090
26499		A	Revision of finger	8.98	16.21	NA	0.94	26.13	NA	090
26500		A	Hand tendon reconstruction	5.96	13.54	NA	0.66	20.16	NA	090
26502		A	Hand tendon reconstruction	7.14	14.64	NA	0.87	22.65	NA	090
26504		A	Hand tendon reconstruction	7.47	10.07	NA	0.84	18.38	NA	090
26508		A	Release thumb contracture	6.01	13.31	NA	0.76	20.08	NA	090
26510		A	Thumb tendon transfer	5.43	12.63	NA	0.71	18.77	NA	090
26516		A	Fusion of knuckle joint	7.15	13.37	NA	0.90	21.42	NA	090
26517		A	Fusion of knuckle joints	8.83	13.80	NA	0.96	23.59	NA	090
26518		A	Fusion of knuckle joints	9.02	13.39	NA	1.13	23.54	NA	090
26520		A	Release knuckle contracture	5.30	16.60	NA	0.65	22.55	NA	090
26525		A	Release finger contracture	5.33	17.02	NA	0.66	23.01	NA	090
26530		A	Revise knuckle joint	6.69	17.06	NA	0.86	24.61	NA	090
26531		A	Revise knuckle with implant	7.91	17.47	NA	1.01	26.39	NA	090
26535		A	Revise finger joint	5.24	9.35	NA	0.66	15.25	NA	090
26536		A	Revise/implant finger joint	6.37	16.17	NA	0.80	23.34	NA	090
26540		A	Repair hand joint	6.43	13.61	NA	0.81	20.85	NA	090
26541		A	Repair hand joint with graft	8.62	14.98	NA	1.12	24.72	NA	090
26542		A	Repair hand joint with graft	6.78	12.89	NA	0.87	20.54	NA	090
26545		A	Reconstruct finger joint	6.92	14.40	NA	0.79	22.11	NA	090
26546		A	Repair nonunion hand	8.92	14.17	NA	1.14	24.23	NA	090
26548		A	Reconstruct finger joint	8.03	14.48	NA	0.98	23.49	NA	090
26550		A	Construct thumb replacement	21.24	20.44	NA	1.80	43.48	NA	090
26551		A	Great toe-hand transfer	46.58	28.68	NA	6.57	81.83	NA	090
26553		A	Single transfer, toe-hand	46.27	29.02	NA	1.99	77.28	NA	090
26554		A	Double transfer, toe-hand	54.95	34.09	NA	7.76	96.80	NA	090
26555		A	Positional change of finger	16.63	22.63	NA	2.13	41.39	NA	090
26556		A	Toe joint transfer	47.26	28.95	NA	6.67	82.88	NA	090
26560		A	Repair of web finger	5.38	13.36	NA	0.60	19.34	NA	090
26561		A	Repair of web finger	10.92	14.12	NA	0.69	25.73	NA	090
26562		A	Repair of web finger	15.00	10.53	NA	0.98	26.51	NA	090
26565		A	Correct metacarpal flaw	6.74	13.32	NA	0.84	20.90	NA	090
26567		A	Correct finger deformity	6.82	13.21	NA	0.84	20.87	NA	090
26568		A	Lengthen metacarpal/finger	9.08	17.70	NA	1.10	27.88	NA	090
26580		A	Repair hand deformity	18.18	16.51	NA	1.46	36.15	NA	090
26585		A	Repair finger deformity	14.05	14.32	NA	1.08	29.45	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
26587		C	Reconstruct extra finger	0.00	0.00	0.00	0.00	0.00	0.00	090
26590		A	Repair finger deformity	17.96	14.17	NA	1.32	33.45	NA	090
26591		A	Repair muscles of hand	3.25	13.02	NA	0.37	16.64	NA	090
26593		A	Release muscles of hand	5.31	11.86	NA	0.64	17.81	NA	090
26596		A	Excision constricting tissue	8.95	9.21	NA	0.87	19.03	NA	090
26597		A	Release of scar contracture	9.82	15.51	NA	1.20	26.53	NA	090
26600		A	Treat metacarpal fracture	1.96	2.58	3.76	0.25	4.79	5.97	090
26605		A	Treat metacarpal fracture	2.85	3.98	5.45	0.38	7.21	8.68	090
26607		A	Treat metacarpal fracture	5.36	7.74	NA	0.70	13.80	NA	090
26608		A	Treat metacarpal fracture	5.36	8.10	NA	0.73	14.19	NA	090
26615		A	Treat metacarpal fracture	5.33	7.86	NA	0.70	13.89	NA	090
26641		A	Treat thumb dislocation	3.94	4.53	6.22	0.42	8.89	10.58	090
26645		A	Treat thumb fracture	4.41	4.91	6.61	0.54	9.86	11.56	090
26650		A	Treat thumb fracture	5.72	8.28	NA	0.77	14.77	NA	090
26665		A	Treat thumb fracture	7.60	8.80	NA	0.97	17.37	NA	090
26670		A	Treat hand dislocation	3.69	4.38	5.78	0.36	8.43	9.83	090
26675		A	Treat hand dislocation	4.64	4.49	5.64	0.56	9.69	10.84	090
26676		A	Pin hand dislocation	5.52	8.12	NA	0.76	14.40	NA	090
26685		A	Treat hand dislocation	6.98	8.29	NA	0.95	16.22	NA	090
26686		A	Treat hand dislocation	7.94	9.26	NA	1.05	18.25	NA	090
26700		A	Treat knuckle dislocation	3.69	2.84	4.80	0.35	6.88	8.84	090
26705		A	Treat knuckle dislocation	4.19	4.12	5.79	0.50	8.81	10.48	090
26706		A	Pin knuckle dislocation	5.12	5.54	NA	0.64	11.30	NA	090
26715		A	Treat knuckle dislocation	5.74	7.97	NA	0.75	14.46	NA	090
26720		A	Treat finger fracture, each	1.66	1.58	2.83	0.20	3.44	4.69	090
26725		A	Treat finger fracture, each	3.33	3.05	4.83	0.43	6.81	8.59	090
26727		A	Treat finger fracture, each	5.23	8.38	NA	0.69	14.30	NA	090
26735		A	Treat finger fracture, each	5.98	8.36	NA	0.77	15.11	NA	090
26740		A	Treat finger fracture, each	1.94	2.43	3.54	0.24	4.61	5.72	090
26742		A	Treat finger fracture, each	3.85	4.93	6.64	0.49	9.27	10.98	090
26746		A	Treat finger fracture, each	5.81	8.51	NA	0.74	15.06	NA	090
26750		A	Treat finger fracture, each	1.70	2.24	3.37	0.19	4.13	5.26	090
26755		A	Treat finger fracture, each	3.10	2.94	4.75	0.37	6.41	8.22	090
26756		A	Pin finger fracture, each	4.39	8.31	NA	0.56	13.26	NA	090
26765		A	Treat finger fracture, each	4.17	7.47	NA	0.51	12.15	NA	090
26770		A	Treat finger dislocation	3.02	2.57	4.52	0.27	5.86	7.81	090
26775		A	Treat finger dislocation	3.71	3.79	5.62	0.43	7.93	9.76	090
26776		A	Pin finger dislocation	4.80	8.34	NA	0.63	13.77	NA	090
26785		A	Treat finger dislocation	4.21	7.36	NA	0.54	12.11	NA	090
26820		A	Thumb fusion with graft	8.26	14.74	NA	1.11	24.11	NA	090
26841		A	Fusion of thumb	7.13	13.62	NA	0.97	21.72	NA	090
26842		A	Thumb fusion with graft	8.24	14.38	NA	1.10	23.72	NA	090
26843		A	Fusion of hand joint	7.61	13.54	NA	0.99	22.14	NA	090
26844		A	Fusion/graft of hand joint	8.73	13.97	NA	1.12	23.82	NA	090
26850		A	Fusion of knuckle	6.97	13.04	NA	0.89	20.90	NA	090
26852		A	Fusion of knuckle with graft	8.46	13.95	NA	1.05	23.46	NA	090
26860		A	Fusion of finger joint	4.69	12.02	NA	0.60	17.31	NA	090
26861		A	Fusion of finger jnt, add-on	1.74	0.98	NA	0.22	2.94	NA	ZZZ
26862		A	Fusion/graft of finger joint	7.37	13.58	NA	0.92	21.87	NA	090
26863		A	Fuse/graft added joint	3.90	2.21	NA	0.51	6.62	NA	ZZZ
26910		A	Amputate metacarpal bone	7.60	13.34	NA	0.90	21.84	NA	090
26951		A	Amputation of finger/thumb	4.59	11.90	NA	0.56	17.05	NA	090
26952		A	Amputation of finger/thumb	6.31	13.26	NA	0.74	20.31	NA	090
26989		C	Hand/finger surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
26990		A	Drainage of pelvis lesion	7.48	14.75	NA	0.92	23.15	NA	090
26991		A	Drainage of pelvis bursa	6.68	9.26	10.55	0.85	16.79	18.08	090
26992		A	Drainage of bone lesion	13.02	18.66	NA	1.75	33.43	NA	090
27000		A	Incision of hip tendon	5.62	6.95	NA	0.76	13.33	NA	090
27001		A	Incision of hip tendon	6.94	7.86	NA	0.95	15.75	NA	090
27003		A	Incision of hip tendon	7.34	8.49	NA	0.93	16.76	NA	090
27005		A	Incision of hip tendon	9.66	9.91	NA	1.36	20.93	NA	090
27006		A	Incision of hip tendons	9.68	9.86	NA	1.33	20.87	NA	090
27025		A	Incision of hip/thigh fascia	11.16	9.72	NA	1.38	22.26	NA	090
27030		A	Drainage of hip joint	13.01	11.78	NA	1.81	26.60	NA	090
27033		A	Exploration of hip joint	13.39	11.95	NA	1.87	27.21	NA	090
27035		A	Denervation of hip joint	16.69	16.51	NA	1.70	34.90	NA	090
27036		A	Excision of hip joint/muscle	12.88	13.14	NA	1.80	27.82	NA	090
27040		A	Biopsy of soft tissues	2.87	3.82	5.89	0.21	6.90	8.97	010
27041		A	Biopsy of soft tissues	9.89	8.34	NA	1.01	19.24	NA	090
27047		A	Remove hip/pelvis lesion	7.45	6.95	9.43	0.79	15.19	17.67	090
27048		A	Remove hip/pelvis lesion	6.25	7.67	NA	0.73	14.65	NA	090
27049		A	Remove tumor, hip/pelvis	13.66	12.98	NA	1.60	28.24	NA	090
27050		A	Biopsy of sacroiliac joint	4.36	6.53	NA	0.53	11.42	NA	090
27052		A	Biopsy of hip joint	6.23	7.72	NA	0.85	14.80	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
27054		A	Removal of hip joint lining	8.54	10.02	NA	1.17	19.73	NA	090
27060		A	Removal of ischial bursa	5.43	7.97	NA	0.60	14.00	NA	090
27062		A	Remove femur lesion/bursa	5.37	6.79	NA	0.74	12.90	NA	090
27065		A	Removal of hip bone lesion	5.90	8.03	NA	0.76	14.69	NA	090
27066		A	Removal of hip bone lesion	10.33	11.61	NA	1.42	23.36	NA	090
27067		A	Remove/graft hip bone lesion	13.83	13.58	NA	1.95	29.36	NA	090
27070		A	Partial removal of hip bone	10.72	16.17	NA	1.36	28.25	NA	090
27071		A	Partial removal of hip bone	11.46	17.22	NA	1.51	30.19	NA	090
27075		A	Extensive hip surgery	35.00	25.69	NA	2.22	62.91	NA	090
27076		A	Extensive hip surgery	22.12	19.75	NA	2.86	44.73	NA	090
27077		A	Extensive hip surgery	40.00	27.07	NA	3.18	70.25	NA	090
27078		A	Extensive hip surgery	13.44	14.69	NA	1.67	29.80	NA	090
27079		A	Extensive hip surgery	13.75	14.34	NA	1.86	29.95	NA	090
27080		A	Removal of tail bone	6.39	7.60	NA	0.80	14.79	NA	090
27086		A	Remove hip foreign body	1.87	3.74	5.20	0.17	5.78	7.24	010
27087		A	Remove hip foreign body	8.54	8.42	NA	1.09	18.05	NA	090
27090		A	Removal of hip prosthesis	11.15	10.67	NA	1.55	23.37	NA	090
27091		A	Removal of hip prosthesis	22.14	16.83	NA	3.11	42.08	NA	090
27093		A	Injection for hip x-ray	1.30	0.51	12.12	0.09	1.90	13.51	000
27095		A	Injection for hip x-ray	1.50	0.52	10.61	0.10	2.12	12.21	000
27096		A	Inject sacroiliac joint	1.40	0.53	11.75	0.08	2.01	13.23	000
27097		A	Revision of hip tendon	8.80	9.30	NA	1.22	19.32	NA	090
27098		A	Transfer tendon to pelvis	8.83	9.47	NA	1.24	19.54	NA	090
27100		A	Transfer of abdominal muscle	11.08	11.75	NA	1.57	24.40	NA	090
27105		A	Transfer of spinal muscle	11.77	11.80	NA	1.66	25.23	NA	090
27110		A	Transfer of iliopsoas muscle	13.26	11.37	NA	1.38	26.01	NA	090
27111		A	Transfer of iliopsoas muscle	12.15	10.72	NA	1.48	24.35	NA	090
27120		A	Reconstruction of hip socket	18.01	13.97	NA	2.45	34.43	NA	090
27122		A	Reconstruction of hip socket	14.98	13.58	NA	2.08	30.64	NA	090
27125		A	Partial hip replacement	14.69	13.17	NA	2.05	29.91	NA	090
27130		A	Total hip replacement	20.12	16.33	NA	2.82	39.27	NA	090
27132		A	Total hip replacement	23.30	18.15	NA	3.26	44.71	NA	090
27134		A	Revise hip joint replacement	28.52	20.90	NA	3.97	53.39	NA	090
27137		A	Revise hip joint replacement	21.17	17.00	NA	2.97	41.14	NA	090
27138		A	Revise hip joint replacement	22.17	17.56	NA	3.11	42.84	NA	090
27140		A	Transplant femur ridge	12.24	11.37	NA	1.67	25.28	NA	090
27146		A	Incision of hip bone	17.43	15.10	NA	2.27	34.80	NA	090
27147		A	Revision of hip bone	20.58	17.18	NA	2.61	40.37	NA	090
27151		A	Incision of hip bones	22.51	18.88	NA	3.12	44.51	NA	090
27156		A	Revision of hip bones	24.63	19.71	NA	3.48	47.82	NA	090
27158		A	Revision of pelvis	19.74	17.31	NA	2.60	39.65	NA	090
27161		A	Incision of neck of femur	16.71	13.78	NA	2.32	32.81	NA	090
27165		A	Incision/fixation of femur	17.91	14.34	NA	2.51	34.76	NA	090
27170		A	Repair/graft femur head/neck	16.07	13.42	NA	2.20	31.69	NA	090
27175		A	Treat slipped epiphysis	8.46	6.96	NA	1.19	16.61	NA	090
27176		A	Treat slipped epiphysis	12.05	9.79	NA	1.68	23.52	NA	090
27177		A	Treat slipped epiphysis	15.08	11.34	NA	2.11	28.53	NA	090
27178		A	Treat slipped epiphysis	11.99	9.32	NA	1.68	22.99	NA	090
27179		A	Revise head/neck of femur	12.98	9.67	NA	1.84	24.49	NA	090
27181		A	Treat slipped epiphysis	14.68	10.55	NA	1.74	26.97	NA	090
27185		A	Revision of femur epiphysis	9.18	9.67	NA	1.29	20.14	NA	090
27187		A	Reinforce hip bones	13.54	12.78	NA	1.89	28.21	NA	090
27193		A	Treat pelvic ring fracture	5.56	5.05	6.60	0.77	11.38	12.93	090
27194		A	Treat pelvic ring fracture	9.65	7.32	8.78	1.32	18.29	19.75	090
27200		A	Treat tail bone fracture	1.84	1.71	2.87	0.22	3.77	4.93	090
27202		A	Treat tail bone fracture	7.04	18.71	NA	0.69	26.44	NA	090
27215		A	Treat pelvic fracture(s)	10.05	9.89	NA	1.37	21.31	NA	090
27216		A	Treat pelvic ring fracture	15.19	14.74	NA	2.15	32.08	NA	090
27217		A	Treat pelvic ring fracture	14.11	12.25	NA	1.95	28.31	NA	090
27218		A	Treat pelvic ring fracture	20.15	15.81	NA	2.85	38.81	NA	090
27220		A	Treat hip socket fracture	6.18	5.40	6.94	0.85	12.43	13.97	090
27222		A	Treat hip socket fracture	12.70	9.90	NA	1.77	24.37	NA	090
27226		A	Treat hip wall fracture	14.91	12.77	NA	2.07	29.75	NA	090
27227		A	Treat hip fracture(s)	23.45	16.93	NA	3.24	43.62	NA	090
27228		A	Treat hip fracture(s)	27.16	19.17	NA	3.77	50.10	NA	090
27230		A	Treat thigh fracture	5.50	5.85	7.09	0.73	12.08	13.32	090
27232		A	Treat thigh fracture	10.68	8.85	NA	1.45	20.98	NA	090
27235		A	Treat thigh fracture	12.16	10.62	NA	1.71	24.49	NA	090
27236		A	Treat thigh fracture	15.60	12.35	NA	2.18	30.13	NA	090
27238		A	Treat thigh fracture	5.52	5.92	NA	0.76	12.20	NA	090
27240		A	Treat thigh fracture	12.50	9.90	NA	1.69	24.09	NA	090
27244		A	Treat thigh fracture	15.94	12.60	NA	2.23	30.77	NA	090
27245		A	Treat thigh fracture	20.31	15.07	NA	2.85	38.23	NA	090
27246		A	Treat thigh fracture	4.71	5.51	6.73	0.66	10.88	12.10	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
27248		A	Treat thigh fracture	10.45	9.54	NA	1.45	21.44	NA	090
27250		A	Treat hip dislocation	6.95	6.09	NA	0.68	13.72	NA	090
27252		A	Treat hip dislocation	10.39	7.92	NA	1.37	19.68	NA	090
27253		A	Treat hip dislocation	12.92	10.54	NA	1.81	25.27	NA	090
27254		A	Treat hip dislocation	18.26	13.72	NA	2.52	34.50	NA	090
27256		A	Treat hip dislocation	4.12	4.17	NA	0.49	8.78	NA	010
27257		A	Treat hip dislocation	5.22	4.55	NA	0.56	10.33	NA	010
27258		A	Treat hip dislocation	15.43	13.02	NA	2.06	30.51	NA	090
27259		A	Treat hip dislocation	21.55	16.30	NA	2.99	40.84	NA	090
27265		A	Treat hip dislocation	5.05	5.64	NA	0.65	11.34	NA	090
27266		A	Treat hip dislocation	7.49	7.06	NA	1.04	15.59	NA	090
27275		A	Manipulation of hip joint	2.27	3.29	NA	0.31	5.87	NA	010
27280		A	Fusion of sacroiliac joint	13.39	13.42	NA	1.98	28.79	NA	090
27282		A	Fusion of pubic bones	11.34	12.51	NA	1.14	24.99	NA	090
27284		A	Fusion of hip joint	23.45	18.36	NA	2.36	44.17	NA	090
27286		A	Fusion of hip joint	16.79	14.57	NA	2.37	33.73	NA	090
27290		A	Amputation of leg at hip	23.28	16.85	NA	2.94	43.07	NA	090
27295		A	Amputation of leg at hip	18.65	13.93	NA	2.35	34.93	NA	090
27299		C	Pelvis/hip joint surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
27301		A	Drain thigh/knee lesion	6.49	13.35	15.31	0.80	20.64	22.60	090
27303		A	Drainage of bone lesion	8.28	13.63	NA	1.14	23.05	NA	090
27305		A	Incise thigh tendon & fascia	5.92	8.77	NA	0.77	15.46	NA	090
27306		A	Incision of thigh tendon	4.62	7.05	NA	0.62	12.29	NA	090
27307		A	Incision of thigh tendons	5.80	7.75	NA	0.78	14.33	NA	090
27310		A	Exploration of knee joint	9.27	9.49	NA	1.29	20.05	NA	090
27315		A	Partial removal, thigh nerve	6.97	4.58	NA	0.79	12.34	NA	090
27320		A	Partial removal, thigh nerve	6.30	4.28	NA	0.78	11.36	NA	090
27323		A	Biopsy, thigh soft tissues	2.28	3.34	5.64	0.17	5.79	8.09	010
27324		A	Biopsy, thigh soft tissues	4.90	6.53	NA	0.59	12.02	NA	090
27327		A	Removal of thigh lesion	4.47	6.19	8.40	0.50	11.16	13.37	090
27328		A	Removal of thigh lesion	5.57	6.79	NA	0.66	13.02	NA	090
27329		A	Remove tumor, thigh/knee	14.14	13.97	NA	1.68	29.79	NA	090
27330		A	Biopsy, knee joint lining	4.97	5.95	NA	0.66	11.58	NA	090
27331		A	Explore/treat knee joint	5.88	7.00	NA	0.81	13.69	NA	090
27332		A	Removal of knee cartilage	8.27	8.37	NA	1.15	17.79	NA	090
27333		A	Removal of knee cartilage	7.30	7.88	NA	1.03	16.21	NA	090
27334		A	Remove knee joint lining	8.70	9.16	NA	1.21	19.07	NA	090
27335		A	Remove knee joint lining	10.00	9.92	NA	1.41	21.33	NA	090
27340		A	Removal of kneecap bursa	4.18	5.59	NA	0.58	10.35	NA	090
27345		A	Removal of knee cyst	5.92	6.92	NA	0.81	13.65	NA	090
27347		A	Remove knee cyst	5.78	2.82	2.82	0.76	9.36	9.36	090
27350		A	Removal of kneecap	8.17	8.36	NA	1.15	17.68	NA	090
27355		A	Remove femur lesion	7.65	9.58	NA	1.07	18.30	NA	090
27356		A	Remove femur lesion/graft	9.48	10.60	NA	1.29	21.37	NA	090
27357		A	Remove femur lesion/graft	10.53	11.14	NA	1.48	23.15	NA	090
27358		A	Remove femur lesion/fixation	4.74	2.67	NA	0.67	8.08	NA	ZZZ
27360		A	Partial removal, leg bone(s)	10.50	16.98	NA	1.42	28.90	NA	090
27365		A	Extensive leg surgery	16.27	13.73	NA	2.26	32.26	NA	090
27370		A	Injection for knee x-ray	0.96	0.34	12.03	0.06	1.36	13.05	000
27372		A	Removal of foreign body	5.07	6.07	8.36	0.62	11.76	14.05	090
27380		A	Repair of kneecap tendon	7.16	7.87	NA	1.00	16.03	NA	090
27381		A	Repair/graft kneecap tendon	10.34	9.66	NA	1.44	21.44	NA	090
27385		A	Repair of thigh muscle	7.76	8.22	NA	1.09	17.07	NA	090
27386		A	Repair/graft of thigh muscle	10.56	10.34	NA	1.49	22.39	NA	090
27390		A	Incision of thigh tendon	5.33	7.26	NA	0.69	13.28	NA	090
27391		A	Incision of thigh tendons	7.20	8.37	NA	0.99	16.56	NA	090
27392		A	Incision of thigh tendons	9.20	10.37	NA	1.23	20.80	NA	090
27393		A	Lengthening of thigh tendon	6.39	7.77	NA	0.90	15.06	NA	090
27394		A	Lengthening of thigh tendons	8.50	10.05	NA	1.17	19.72	NA	090
27395		A	Lengthening of thigh tendons	11.73	12.75	NA	1.63	26.11	NA	090
27396		A	Transplant of thigh tendon	7.86	9.69	NA	1.11	18.66	NA	090
27397		A	Transplants of thigh tendons	11.28	11.12	NA	1.58	23.98	NA	090
27400		A	Revise thigh muscles/tendons	9.02	10.67	NA	1.18	20.87	NA	090
27403		A	Repair of knee cartilage	8.33	8.41	NA	1.16	17.90	NA	090
27405		A	Repair of knee ligament	8.65	9.10	NA	1.21	18.96	NA	090
27407		A	Repair of knee ligament	10.28	9.88	NA	1.38	21.54	NA	090
27409		A	Repair of knee ligaments	12.90	11.31	NA	1.75	25.96	NA	090
27418		A	Repair degenerated kneecap	10.85	10.40	NA	1.51	22.76	NA	090
27420		A	Revision of unstable kneecap	9.83	9.29	NA	1.38	20.50	NA	090
27422		A	Revision of unstable kneecap	9.78	9.30	NA	1.37	20.45	NA	090
27424		A	Revision/removal of kneecap	9.81	9.28	NA	1.38	20.47	NA	090
27425		A	Lateral retinacular release	5.22	6.72	NA	0.73	12.67	NA	090
27427		A	Reconstruction, knee	9.36	8.94	NA	1.29	19.59	NA	090
27428		A	Reconstruction, knee	14.00	11.95	NA	1.95	27.90	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
27429		A	Reconstruction, knee	15.52	12.95	NA	2.18	30.65	NA	090
27430		A	Revision of thigh muscles	9.67	9.29	NA	1.35	20.31	NA	090
27435		A	Incision of knee joint	9.49	9.21	NA	1.33	20.03	NA	090
27437		A	Revise kneecap	8.46	9.35	NA	1.18	18.99	NA	090
27438		A	Revise kneecap with implant	11.23	10.55	NA	1.56	23.34	NA	090
27440		A	Revision of knee joint	10.43	10.22	NA	1.42	22.07	NA	090
27441		A	Revision of knee joint	10.82	10.58	NA	1.49	22.89	NA	090
27442		A	Revision of knee joint	11.89	11.16	NA	1.68	24.73	NA	090
27443		A	Revision of knee joint	10.93	10.82	NA	1.52	23.27	NA	090
27445		A	Revision of knee joint	17.68	14.44	NA	2.49	34.61	NA	090
27446		A	Revision of knee joint	15.84	13.51	NA	2.22	31.57	NA	090
27447		A	Total knee replacement	21.48	16.57	NA	3.00	41.05	NA	090
27448		A	Incision of thigh	11.06	11.43	NA	1.51	24.00	NA	090
27450		A	Incision of thigh	13.98	13.10	NA	1.96	29.04	NA	090
27454		A	Realignment of thigh bone	17.56	15.15	NA	2.46	35.17	NA	090
27455		A	Realignment of knee	12.82	11.89	NA	1.78	26.49	NA	090
27457		A	Realignment of knee	13.45	11.16	NA	1.88	26.49	NA	090
27465		A	Shortening of thigh bone	13.87	13.49	NA	1.86	29.22	NA	090
27466		A	Lengthening of thigh bone	16.33	14.79	NA	1.92	33.04	NA	090
27468		A	Shorten/lengthen thighs	18.97	16.66	NA	2.68	38.31	NA	090
27470		A	Repair of thigh	16.07	15.10	NA	2.24	33.41	NA	090
27472		A	Repair/graft of thigh	17.72	16.03	NA	2.49	36.24	NA	090
27475		A	Surgery to stop leg growth	8.64	9.39	NA	1.13	19.16	NA	090
27477		A	Surgery to stop leg growth	9.85	9.25	NA	1.31	20.41	NA	090
27479		A	Surgery to stop leg growth	12.80	10.30	NA	1.81	24.91	NA	090
27485		A	Surgery to stop leg growth	8.84	8.75	NA	1.24	18.83	NA	090
27486		A	Revise/replace knee joint	19.27	15.41	NA	2.70	37.38	NA	090
27487		A	Revise/replace knee joint	25.27	18.75	NA	3.54	47.56	NA	090
27488		A	Removal of knee prosthesis	15.74	13.51	NA	2.21	31.46	NA	090
27495		A	Reinforce thigh	15.55	14.86	NA	2.18	32.59	NA	090
27496		A	Decompression of thigh/knee	6.11	7.28	NA	0.77	14.16	NA	090
27497		A	Decompression of thigh/knee	7.17	7.52	NA	0.84	15.53	NA	090
27498		A	Decompression of thigh/knee	7.99	8.72	NA	0.97	17.68	NA	090
27499		A	Decompression of thigh/knee	9.00	9.01	NA	1.18	19.19	NA	090
27500		A	Treatment of thigh fracture	5.92	7.03	9.03	0.80	13.75	15.75	090
27501		A	Treatment of thigh fracture	5.92	7.95	10.01	0.83	14.70	16.76	090
27502		A	Treatment of thigh fracture	10.58	10.59	NA	1.49	22.66	NA	090
27503		A	Treatment of thigh fracture	10.58	10.58	NA	1.49	22.65	NA	090
27506		A	Treatment of thigh fracture	17.45	13.54	NA	2.33	33.32	NA	090
27507		A	Treatment of thigh fracture	13.99	11.92	NA	1.95	27.86	NA	090
27508		A	Treatment of thigh fracture	5.83	5.13	6.64	0.80	11.76	13.27	090
27509		A	Treatment of thigh fracture	7.71	8.62	NA	1.08	17.41	NA	090
27510		A	Treatment of thigh fracture	9.13	7.02	NA	1.26	17.41	NA	090
27511		A	Treatment of thigh fracture	13.64	12.45	NA	1.91	28.00	NA	090
27513		A	Treatment of thigh fracture	17.92	14.85	NA	2.51	35.28	NA	090
27514		A	Treatment of thigh fracture	17.30	14.31	NA	2.41	34.02	NA	090
27516		A	Treat thigh fx growth plate	5.37	5.53	7.10	0.74	11.64	13.21	090
27517		A	Treat thigh fx growth plate	8.78	7.49	9.23	1.22	17.49	19.23	090
27519		A	Treat thigh fx growth plate	15.02	12.72	NA	2.09	29.83	NA	090
27520		A	Treat kneecap fracture	2.86	3.50	4.97	0.38	6.74	8.21	090
27524		A	Treat kneecap fracture	10.00	8.48	NA	1.40	19.88	NA	090
27530		A	Treat knee fracture	3.78	4.03	5.49	0.51	8.32	9.78	090
27532		A	Treat knee fracture	7.30	5.58	7.16	1.02	13.90	15.48	090
27535		A	Treat knee fracture	11.50	11.30	NA	1.61	24.41	NA	090
27536		A	Treat knee fracture	15.65	11.62	NA	2.19	29.46	NA	090
27538		A	Treat knee fracture(s)	4.87	5.15	6.98	0.67	10.69	12.52	090
27540		A	Treat knee fracture	13.10	10.02	NA	1.80	24.92	NA	090
27550		A	Treat knee dislocation	5.76	5.39	6.99	0.68	11.83	13.43	090
27552		A	Treat knee dislocation	7.90	7.56	NA	1.10	16.56	NA	090
27556		A	Treat knee dislocation	14.41	13.70	NA	2.01	30.12	NA	090
27557		A	Treat knee dislocation	16.77	14.90	NA	2.37	34.04	NA	090
27558		A	Treat knee dislocation	17.72	15.15	NA	2.51	35.38	NA	090
27560		A	Treat kneecap dislocation	3.82	3.73	5.48	0.40	7.95	9.70	090
27562		A	Treat kneecap dislocation	5.79	5.40	NA	0.69	11.88	NA	090
27566		A	Treat kneecap dislocation	12.23	9.85	NA	1.73	23.81	NA	090
27570		A	Fixation of knee joint	1.74	2.97	NA	0.24	4.95	NA	010
27580		A	Fusion of knee	19.37	15.82	NA	2.70	37.89	NA	090
27590		A	Amputate leg at thigh	12.03	12.40	NA	1.35	25.78	NA	090
27591		A	Amputate leg at thigh	12.68	13.36	NA	1.63	27.67	NA	090
27592		A	Amputate leg at thigh	10.02	11.90	NA	1.17	23.09	NA	090
27594		A	Amputation follow-up surgery	6.92	8.82	NA	0.82	16.56	NA	090
27596		A	Amputation follow-up surgery	10.60	12.19	NA	1.24	24.03	NA	090
27598		A	Amputate lower leg at knee	10.53	10.97	NA	1.24	22.74	NA	090
27599		C	Leg surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
27600		A	Decompression of lower leg	5.65	7.81	NA	0.68	14.14	NA	090
27601		A	Decompression of lower leg	5.64	7.17	NA	0.69	13.50	NA	090
27602		A	Decompression of lower leg	7.35	8.12	NA	0.85	16.32	NA	090
27603		A	Drain lower leg lesion	4.94	10.08	15.62	0.56	15.58	21.12	090
27604		A	Drain lower leg bursa	4.47	7.81	10.69	0.54	12.82	15.70	090
27605		A	Incision of achilles tendon	2.87	3.67	9.73	0.38	6.92	12.98	010
27606		A	Incision of achilles tendon	4.14	4.76	11.66	0.57	9.47	16.37	010
27607		A	Treat lower leg bone lesion	7.97	12.93	NA	1.08	21.98	NA	090
27610		A	Explore/treat ankle joint	8.34	9.84	NA	1.15	19.33	NA	090
27612		A	Exploration of ankle joint	7.33	7.59	NA	1.01	15.93	NA	090
27613		A	Biopsy lower leg soft tissue	2.17	3.13	5.62	0.16	5.46	7.95	010
27614		A	Biopsy lower leg soft tissue	5.66	6.91	11.43	0.62	13.19	17.71	090
27615		A	Remove tumor, lower leg	12.56	17.04	NA	1.39	30.99	NA	090
27618		A	Remove lower leg lesion	5.09	6.46	11.09	0.54	12.09	16.72	090
27619		A	Remove lower leg lesion	8.40	8.95	13.47	1.01	18.36	22.88	090
27620		A	Explore/treat ankle joint	5.98	7.31	NA	0.83	14.12	NA	090
27625		A	Remove ankle joint lining	8.30	9.15	NA	1.16	18.61	NA	090
27626		A	Remove ankle joint lining	8.91	9.83	NA	1.23	19.97	NA	090
27630		A	Removal of tendon lesion	4.80	6.58	11.43	0.60	11.98	16.83	090
27635		A	Remove lower leg bone lesion	7.78	10.35	NA	1.06	19.19	NA	090
27637		A	Remove/graft leg bone lesion	9.85	11.58	NA	1.38	22.81	NA	090
27638		A	Remove/graft leg bone lesion	10.57	12.14	NA	1.47	24.18	NA	090
27640		A	Partial removal of tibia	11.37	17.11	NA	1.54	30.02	NA	090
27641		A	Partial removal of fibula	9.24	14.98	NA	1.22	25.44	NA	090
27645		A	Extensive lower leg surgery	14.17	16.93	NA	1.98	33.08	NA	090
27646		A	Extensive lower leg surgery	12.66	15.65	NA	1.55	29.86	NA	090
27647		A	Extensive ankle/heel surgery	12.24	10.62	NA	1.64	24.50	NA	090
27648		A	Injection for ankle x-ray	0.96	0.34	9.37	0.05	1.35	10.38	000
27650		A	Repair achilles tendon	9.69	8.97	NA	1.35	20.01	NA	090
27652		A	Repair/graft achilles tendon	10.33	9.31	NA	1.45	21.09	NA	090
27654		A	Repair of achilles tendon	10.02	9.60	NA	1.41	21.03	NA	090
27656		A	Repair leg fascia defect	4.57	6.11	12.80	0.48	11.16	17.85	090
27658		A	Repair of leg tendon, each	4.98	8.27	14.26	0.68	13.93	19.92	090
27659		A	Repair of leg tendon, each	6.81	9.22	16.82	0.96	16.99	24.59	090
27664		A	Repair of leg tendon, each	4.59	8.23	12.05	0.63	13.45	17.27	090
27665		A	Repair of leg tendon, each	5.40	8.39	13.42	0.75	14.54	19.57	090
27675		A	Repair lower leg tendons	7.18	7.46	NA	1.01	15.65	NA	090
27676		A	Repair lower leg tendons	8.42	8.74	NA	1.15	18.31	NA	090
27680		A	Release of lower leg tendon	5.74	7.47	NA	0.80	14.01	NA	090
27681		A	Release of lower leg tendons	6.82	7.51	NA	0.92	15.25	NA	090
27685		A	Revision of lower leg tendon	6.50	7.69	10.30	0.91	15.10	17.71	090
27686		A	Revise lower leg tendons	7.46	9.22	16.33	1.05	17.73	24.84	090
27687		A	Revision of calf tendon	6.24	7.78	NA	0.88	14.90	NA	090
27690		A	Revise lower leg tendon	8.71	8.75	NA	1.22	18.68	NA	090
27691		A	Revise lower leg tendon	9.96	10.31	NA	1.40	21.67	NA	090
27692		A	Revise additional leg tendon	1.87	0.99	NA	0.26	3.12	NA	ZZZ
27695		A	Repair of ankle ligament	6.51	8.47	NA	0.90	15.88	NA	090
27696		A	Repair of ankle ligaments	8.27	8.96	NA	1.16	18.39	NA	090
27698		A	Repair of ankle ligament	9.36	8.70	NA	1.31	19.37	NA	090
27700		A	Revision of ankle joint	9.29	7.42	NA	1.24	17.95	NA	090
27702		A	Reconstruct ankle joint	13.67	12.31	NA	1.92	27.90	NA	090
27703		A	Reconstruction, ankle joint	15.87	13.65	NA	2.24	31.76	NA	090
27704		A	Removal of ankle implant	7.62	7.54	NA	0.61	15.77	NA	090
27705		A	Incision of tibia	10.38	10.88	NA	1.44	22.70	NA	090
27707		A	Incision of fibula	4.37	7.73	NA	0.60	12.70	NA	090
27709		A	Incision of tibia & fibula	9.95	10.81	NA	1.39	22.15	NA	090
27712		A	Realignment of lower leg	14.25	12.96	NA	2.00	29.21	NA	090
27715		A	Revision of lower leg	14.39	14.20	NA	2.00	30.59	NA	090
27720		A	Repair of tibia	11.79	12.75	NA	1.66	26.20	NA	090
27722		A	Repair/graft of tibia	11.82	12.39	NA	1.65	25.86	NA	090
27724		A	Repair/graft of tibia	18.20	16.34	NA	2.10	36.64	NA	090
27725		A	Repair of lower leg	15.59	14.94	NA	2.20	32.73	NA	090
27727		A	Repair of lower leg	14.01	12.62	NA	1.84	28.47	NA	090
27730		A	Repair of tibia epiphysis	7.41	10.05	14.78	0.75	18.21	22.94	090
27732		A	Repair of fibula epiphysis	5.32	8.24	11.97	0.63	14.19	17.92	090
27734		A	Repair lower leg epiphyses	8.48	9.20	NA	0.85	18.53	NA	090
27740		A	Repair of leg epiphyses	9.30	10.50	15.53	1.31	21.11	26.14	090
27742		A	Repair of leg epiphyses	10.30	11.08	15.92	1.55	22.93	27.77	090
27745		A	Reinforce tibia	10.07	10.86	NA	1.38	22.31	NA	090
27750		A	Treatment of tibia fracture	3.19	3.69	5.14	0.43	7.31	8.76	090
27752		A	Treatment of tibia fracture	5.84	5.76	7.54	0.82	12.42	14.20	090
27756		A	Treatment of tibia fracture	6.78	9.98	NA	0.94	17.70	NA	090
27758		A	Treatment of tibia fracture	11.67	11.15	NA	1.52	24.34	NA	090
27759		A	Treatment of tibia fracture	13.76	12.70	NA	1.93	28.39	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
27760		A	Treatment of ankle fracture	3.01	3.54	4.93	0.39	6.94	8.33	090
27762		A	Treatment of ankle fracture	5.25	5.34	7.10	0.71	11.30	13.06	090
27766		A	Treatment of ankle fracture	8.36	8.07	NA	1.17	17.60	NA	090
27780		A	Treatment of fibula fracture	2.65	3.36	4.88	0.33	6.34	7.86	090
27781		A	Treatment of fibula fracture	4.40	4.29	6.07	0.57	9.26	11.04	090
27784		A	Treatment of fibula fracture	7.11	8.00	NA	0.98	16.09	NA	090
27786		A	Treatment of ankle fracture	2.84	3.47	4.90	0.37	6.68	8.11	090
27788		A	Treatment of ankle fracture	4.45	4.34	6.06	0.61	9.40	11.12	090
27792		A	Treatment of ankle fracture	7.66	7.65	NA	1.07	16.38	NA	090
27808		A	Treatment of ankle fracture	2.83	4.08	5.79	0.38	7.29	9.00	090
27810		A	Treatment of ankle fracture	5.13	5.31	7.06	0.71	11.15	12.90	090
27814		A	Treatment of ankle fracture	10.68	10.27	NA	1.50	22.45	NA	090
27816		A	Treatment of ankle fracture	2.89	4.11	5.43	0.37	7.37	8.69	090
27818		A	Treatment of ankle fracture	5.50	5.48	7.27	0.74	11.72	13.51	090
27822		A	Treatment of ankle fracture	11.00	12.26	NA	1.29	24.55	NA	090
27823		A	Treatment of ankle fracture	13.00	13.32	NA	1.65	27.97	NA	090
27824		A	Treat lower leg fracture	2.89	4.09	5.83	0.39	7.37	9.11	090
27825		A	Treat lower leg fracture	6.19	5.94	7.66	0.85	12.98	14.70	090
27826		A	Treat lower leg fracture	8.54	10.89	NA	1.19	20.62	NA	090
27827		A	Treat lower leg fracture	14.06	14.00	NA	1.96	30.02	NA	090
27828		A	Treat lower leg fracture	16.23	15.15	NA	2.27	33.65	NA	090
27829		A	Treat lower leg joint	5.49	7.89	NA	0.77	14.15	NA	090
27830		A	Treat lower leg dislocation	3.79	4.05	4.53	0.44	8.28	8.76	090
27831		A	Treat lower leg dislocation	4.56	4.97	NA	0.61	10.14	NA	090
27832		A	Treat lower leg dislocation	6.49	7.75	NA	0.91	15.15	NA	090
27840		A	Treat ankle dislocation	4.58	5.60	NA	0.47	10.65	NA	090
27842		A	Treat ankle dislocation	6.21	4.91	NA	0.76	11.88	NA	090
27846		A	Treat ankle dislocation	9.79	9.79	NA	1.36	20.94	NA	090
27848		A	Treat ankle dislocation	11.20	10.93	NA	1.55	23.68	NA	090
27860		A	Fixation of ankle joint	2.34	3.59	NA	0.31	6.24	NA	010
27870		A	Fusion of ankle joint	13.91	12.94	NA	1.95	28.80	NA	090
27871		A	Fusion of tibiofibular joint	9.17	10.24	NA	1.29	20.70	NA	090
27880		A	Amputation of lower leg	11.85	11.64	NA	1.38	24.87	NA	090
27881		A	Amputation of lower leg	12.34	12.77	NA	1.59	26.70	NA	090
27882		A	Amputation of lower leg	8.94	13.04	NA	1.03	23.01	NA	090
27884		A	Amputation follow-up surgery	8.21	10.30	NA	0.95	19.46	NA	090
27886		A	Amputation follow-up surgery	9.32	11.00	NA	1.13	21.45	NA	090
27888		A	Amputation of foot at ankle	9.67	10.31	NA	1.26	21.24	NA	090
27889		A	Amputation of foot at ankle	9.98	10.64	NA	1.19	21.81	NA	090
27892		A	Decompression of leg	7.39	8.15	NA	0.86	16.40	NA	090
27893		A	Decompression of leg	7.35	8.37	NA	0.90	16.62	NA	090
27894		A	Decompression of leg	10.49	9.47	NA	1.25	21.21	NA	090
27899		C	Leg/ankle surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
28001		A	Drainage of bursa of foot	2.73	2.87	4.72	0.31	5.91	7.76	010
28002		A	Treatment of foot infection	4.62	4.11	6.34	0.56	9.29	11.52	010
28003		A	Treatment of foot infection	8.41	10.05	10.23	1.03	19.49	19.67	090
28005		A	Treat foot bone lesion	8.68	9.63	NA	1.14	19.45	NA	090
28008		A	Incision of foot fascia	4.45	5.83	7.00	0.56	10.84	12.01	090
28010		A	Incision of toe tendon	2.84	4.54	6.37	0.39	7.77	9.60	090
28011		A	Incision of toe tendons	4.14	6.04	8.32	0.58	10.76	13.04	090
28020		A	Exploration of foot joint	5.01	5.81	8.48	0.64	11.46	14.13	090
28022		A	Exploration of foot joint	4.67	5.62	7.68	0.62	10.91	12.97	090
28024		A	Exploration of toe joint	4.38	5.92	7.41	0.50	10.80	12.29	090
28030		A	Removal of foot nerve	6.15	3.44	NA	0.85	10.44	NA	090
28035		A	Decompression of tibia nerve	5.09	4.97	8.95	0.71	10.77	14.75	090
28043		A	Excision of foot lesion	3.54	4.63	6.68	0.45	8.62	10.67	090
28045		A	Excision of foot lesion	4.72	5.24	7.06	0.62	10.58	12.40	090
28046		A	Resection of tumor, foot	10.18	10.69	12.22	1.13	22.00	23.53	090
28050		A	Biopsy of foot joint lining	4.25	5.23	6.13	0.55	10.03	10.93	090
28052		A	Biopsy of foot joint lining	3.94	5.33	7.61	0.51	9.78	12.06	090
28054		A	Biopsy of toe joint lining	3.45	5.04	7.21	0.45	8.94	11.11	090
28060		A	Partial removal, foot fascia	5.23	5.91	7.83	0.69	11.83	13.75	090
28062		A	Removal of foot fascia	6.52	5.97	8.74	0.85	13.34	16.11	090
28070		A	Removal of foot joint lining	5.10	5.45	7.97	0.68	11.23	13.75	090
28072		A	Removal of foot joint lining	4.58	6.10	7.45	0.64	11.32	12.67	090
28080		A	Removal of foot lesion	3.58	4.88	6.86	0.50	8.96	10.94	090
28086		A	Excise foot tendon sheath	4.78	6.69	10.90	0.66	12.13	16.34	090
28088		A	Excise foot tendon sheath	3.86	5.84	8.17	0.52	10.22	12.55	090
28090		A	Removal of foot lesion	4.41	5.10	7.15	0.57	10.08	12.13	090
28092		A	Removal of toe lesions	3.64	5.38	7.61	0.46	9.48	11.71	090
28100		A	Removal of ankle/heel lesion	5.66	7.00	10.92	0.76	13.42	17.34	090
28102		A	Remove/graft foot lesion	7.73	7.99	NA	0.97	16.69	NA	090
28103		A	Remove/graft foot lesion	6.50	7.04	10.80	0.89	14.43	18.19	090
28104		A	Removal of foot lesion	5.12	6.22	8.21	0.69	12.03	14.02	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
28106		A	Remove/graft foot lesion	7.16	5.93	NA	1.01	14.10	NA	090
28107		A	Remove/graft foot lesion	5.56	6.31	8.70	0.74	12.61	15.00	090
28108		A	Removal of toe lesions	4.16	4.80	6.43	0.52	9.48	11.11	090
28110		A	Part removal of metatarsal	4.08	6.11	7.87	0.49	10.68	12.44	090
28111		A	Part removal of metatarsal	5.01	7.11	10.56	0.63	12.75	16.20	090
28112		A	Part removal of metatarsal	4.49	6.71	9.19	0.60	11.80	14.28	090
28113		A	Part removal of metatarsal	4.79	6.47	8.43	0.63	11.89	13.85	090
28114		A	Removal of metatarsal heads	9.79	10.01	14.52	1.36	21.16	25.67	090
28116		A	Revision of foot	7.75	6.47	8.21	1.03	15.25	16.99	090
28118		A	Removal of heel bone	5.96	6.43	9.35	0.79	13.18	16.10	090
28119		A	Removal of heel spur	5.39	5.47	7.52	0.74	11.60	13.65	090
28120		A	Part removal of ankle/heel	5.40	8.96	11.93	0.69	15.05	18.02	090
28122		A	Partial removal of foot bone	7.29	8.55	10.38	0.96	16.80	18.63	090
28124		A	Partial removal of toe	4.81	6.76	8.04	0.65	12.22	13.50	090
28126		A	Partial removal of toe	3.52	6.19	6.89	0.49	10.20	10.90	090
28130		A	Removal of ankle bone	8.11	7.90	NA	1.11	17.12	NA	090
28140		A	Removal of metatarsal	6.91	7.63	10.94	0.84	15.38	18.69	090
28150		A	Removal of toe	4.09	6.43	7.98	0.52	11.04	12.59	090
28153		A	Partial removal of toe	3.66	5.33	6.97	0.49	9.48	11.12	090
28160		A	Partial removal of toe	3.74	6.36	7.45	0.51	10.61	11.70	090
28171		A	Extensive foot surgery	9.60	8.77	NA	1.13	19.50	NA	090
28173		A	Extensive foot surgery	8.80	8.07	11.16	1.04	17.91	21.00	090
28175		A	Extensive foot surgery	6.05	6.25	8.19	0.75	13.05	14.99	090
28190		A	Removal of foot foreign body	1.96	3.19	5.55	0.16	5.31	7.67	010
28192		A	Removal of foot foreign body	4.64	5.11	7.06	0.52	10.27	12.22	090
28193		A	Removal of foot foreign body	5.73	5.94	7.46	0.63	12.30	13.82	090
28200		A	Repair of foot tendon	4.60	5.54	7.61	0.59	10.73	12.80	090
28202		A	Repair/graft of foot tendon	6.84	6.42	11.03	0.86	14.12	18.73	090
28208		A	Repair of foot tendon	4.37	5.63	7.34	0.59	10.59	12.30	090
28210		A	Repair/graft of foot tendon	6.35	5.84	8.55	0.77	12.96	15.67	090
28220		A	Release of foot tendon	4.53	5.56	6.68	0.63	10.72	11.84	090
28222		A	Release of foot tendons	5.62	6.54	7.17	0.77	12.93	13.56	090
28225		A	Release of foot tendon	3.66	5.11	6.57	0.50	9.27	10.73	090
28226		A	Release of foot tendons	4.53	6.61	6.61	0.62	11.76	11.76	090
28230		A	Incision of foot tendon(s)	4.24	6.20	6.88	0.59	11.03	11.71	090
28232		A	Incision of toe tendon	3.39	5.81	6.84	0.48	9.68	10.71	090
28234		A	Incision of foot tendon	3.37	5.33	6.91	0.46	9.16	10.74	090
28238		A	Revision of foot tendon	7.73	6.95	10.42	1.08	15.76	19.23	090
28240		A	Release of big toe	4.36	5.72	6.85	0.61	10.69	11.82	090
28250		A	Revision of foot fascia	5.92	6.62	8.40	0.81	13.35	15.13	090
28260		A	Release of midfoot joint	7.96	6.88	8.02	1.08	15.92	17.06	090
28261		A	Revision of foot tendon	11.73	8.86	9.82	1.66	22.25	23.21	090
28262		A	Revision of foot and ankle	15.83	14.52	17.21	2.22	32.57	35.26	090
28264		A	Release of midfoot joint	10.35	11.05	11.16	1.46	22.86	22.97	090
28270		A	Release of foot contracture	4.76	6.39	7.38	0.67	11.82	12.81	090
28272		A	Release of toe joint, each	3.80	4.79	6.35	0.52	9.11	10.67	090
28280		A	Fusion of toes	5.19	6.27	8.82	0.72	12.18	14.73	090
28285		A	Repair of hammertoe	4.59	5.87	7.57	0.64	11.10	12.80	090
28286		A	Repair of hammertoe	4.56	5.93	7.24	0.64	11.13	12.44	090
28288		A	Partial removal of foot bone	4.74	7.27	8.26	0.65	12.66	13.65	090
28289		A	Repair hallux rigidus	7.04	7.97	9.66	0.96	15.97	17.66	090
28290		A	Correction of bunion	5.66	8.02	9.17	0.79	14.47	15.62	090
28292		A	Correction of bunion	7.04	6.89	8.87	0.98	14.91	16.89	090
28293		A	Correction of bunion	9.15	7.21	9.98	1.28	17.64	20.41	090
28294		A	Correction of bunion	8.56	7.19	9.33	1.16	16.91	19.05	090
28296		A	Correction of bunion	9.18	7.83	10.01	1.28	18.29	20.47	090
28297		A	Correction of bunion	9.18	9.47	12.30	1.31	19.96	22.79	090
28298		A	Correction of bunion	7.94	7.52	8.91	1.12	16.58	17.97	090
28299		A	Correction of bunion	9.18	7.81	9.97	1.24	18.23	20.39	090
28300		A	Incision of heel bone	9.54	8.93	14.62	1.31	19.78	25.47	090
28302		A	Incision of ankle bone	9.55	8.75	18.58	1.15	19.45	29.28	090
28304		A	Incision of midfoot bones	9.16	7.19	9.35	1.00	17.35	19.51	090
28305		A	Incise/graft midfoot bones	10.50	9.21	14.83	0.55	20.26	25.88	090
28306		A	Incision of metatarsal	5.86	5.80	9.30	0.81	12.47	15.97	090
28307		A	Incision of metatarsal	6.33	7.76	15.35	0.71	14.80	22.39	090
28308		A	Incision of metatarsal	5.29	4.92	6.95	0.74	10.95	12.98	090
28309		A	Incision of metatarsals	12.78	10.50	NA	1.64	24.92	NA	090
28310		A	Revision of big toe	5.43	6.14	8.17	0.76	12.33	14.36	090
28312		A	Revision of toe	4.55	6.72	7.78	0.62	11.89	12.95	090
28313		A	Repair deformity of toe	5.01	8.16	8.16	0.68	13.85	13.85	090
28315		A	Removal of sesamoid bone	4.86	5.06	6.81	0.66	10.58	12.33	090
28320		A	Repair of foot bones	9.18	8.11	NA	1.27	18.56	NA	090
28322		A	Repair of metatarsals	8.34	8.17	11.63	1.17	17.68	21.14	090
28340		A	Resect enlarged toe tissue	6.98	5.73	8.90	0.98	13.69	16.86	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
28341		A	Resect enlarged toe	8.41	6.57	8.21	1.18	16.16	17.80	090
28344		A	Repair extra toe(s)	4.26	5.02	12.54	0.60	9.88	17.40	090
28345		A	Repair webbed toe(s)	5.92	6.43	8.86	0.84	13.19	15.62	090
28360		A	Reconstruct cleft foot	13.34	12.22	NA	1.88	27.44	NA	090
28400		A	Treatment of heel fracture	2.16	4.28	5.15	0.29	6.73	7.60	090
28405		A	Treatment of heel fracture	4.57	5.42	6.19	0.63	10.62	11.39	090
28406		A	Treatment of heel fracture	6.31	8.08	NA	0.87	15.26	NA	090
28415		A	Treat heel fracture	15.97	14.55	NA	2.24	32.76	NA	090
28420		A	Treat/graft heel fracture	16.64	14.62	NA	2.29	33.55	NA	090
28430		A	Treatment of ankle fracture	2.09	3.84	4.79	0.27	6.20	7.15	090
28435		A	Treatment of ankle fracture	3.40	4.34	5.43	0.47	8.21	9.30	090
28436		A	Treatment of ankle fracture	4.71	7.27	NA	0.66	12.64	NA	090
28445		A	Treat ankle fracture	15.62	12.97	NA	1.29	29.88	NA	090
28450		A	Treat midfoot fracture, each	1.90	3.69	4.69	0.25	5.84	6.84	090
28455		A	Treat midfoot fracture, each	3.09	4.56	5.17	0.43	8.08	8.69	090
28456		A	Treat midfoot fracture	2.68	5.64	NA	0.36	8.68	NA	090
28465		A	Treat midfoot fracture, each	7.01	7.32	NA	0.87	15.20	NA	090
28470		A	Treat metatarsal fracture	1.99	3.08	4.07	0.26	5.33	6.32	090
28475		A	Treat metatarsal fracture	2.97	4.02	4.75	0.41	7.40	8.13	090
28476		A	Treat metatarsal fracture	3.38	5.92	NA	0.46	9.76	NA	090
28485		A	Treat metatarsal fracture	5.71	7.13	NA	0.80	13.64	NA	090
28490		A	Treat big toe fracture	1.09	2.01	2.46	0.13	3.23	3.68	090
28495		A	Treat big toe fracture	1.58	2.06	2.59	0.19	3.83	4.36	090
28496		A	Treat big toe fracture	2.33	4.26	10.08	0.32	6.91	12.73	090
28505		A	Treat big toe fracture	3.81	5.99	10.51	0.50	10.30	14.82	090
28510		A	Treatment of toe fracture	1.09	1.99	2.20	0.13	3.21	3.42	090
28515		A	Treatment of toe fracture	1.46	2.01	2.43	0.17	3.64	4.06	090
28525		A	Treat toe fracture	3.32	5.79	10.05	0.44	9.55	13.81	090
28530		A	Treat sesamoid bone fracture	1.06	2.18	2.52	0.13	3.37	3.71	090
28531		A	Treat sesamoid bone fracture	2.35	3.40	11.43	0.33	6.08	14.11	090
28540		A	Treat foot dislocation	2.04	3.13	3.13	0.24	5.41	5.41	090
28545		A	Treat foot dislocation	2.45	3.56	3.56	0.33	6.34	6.34	090
28546		A	Treat foot dislocation	3.20	5.31	5.31	0.46	8.97	8.97	090
28555		A	Repair foot dislocation	6.30	7.85	13.60	0.88	15.03	20.78	090
28570		A	Treat foot dislocation	1.66	3.35	3.36	0.22	5.23	5.24	090
28575		A	Treat foot dislocation	3.31	4.90	5.89	0.45	8.66	9.65	090
28576		A	Treat foot dislocation	4.17	6.04	13.73	0.56	10.77	18.46	090
28585		A	Repair foot dislocation	7.99	7.63	8.63	1.13	16.75	17.75	090
28600		A	Treat foot dislocation	1.89	3.67	3.83	0.24	5.80	5.96	090
28605		A	Treat foot dislocation	2.71	4.42	4.42	0.35	7.48	7.48	090
28606		A	Treat foot dislocation	4.90	6.59	15.56	0.68	12.17	21.14	090
28615		A	Repair foot dislocation	7.77	8.82	NA	1.09	17.68	NA	090
28630		A	Treat toe dislocation	1.70	2.09	2.09	0.17	3.96	3.96	010
28635		A	Treat toe dislocation	1.91	2.32	2.32	0.24	4.47	4.47	010
28636		A	Treat toe dislocation	2.77	3.12	6.60	0.39	6.28	9.76	010
28645		A	Repair toe dislocation	4.22	4.01	6.01	0.58	8.81	10.81	090
28660		A	Treat toe dislocation	1.23	2.27	2.92	0.11	3.61	4.26	010
28665		A	Treat toe dislocation	1.92	2.44	2.44	0.24	4.60	4.60	010
28666		A	Treat toe dislocation	2.66	2.31	6.55	0.38	5.35	9.59	010
28675		A	Repair of toe dislocation	2.92	4.47	8.80	0.41	7.80	12.13	090
28705		A	Fusion of foot bones	18.80	14.55	NA	2.13	35.48	NA	090
28715		A	Fusion of foot bones	13.10	11.82	NA	1.84	26.76	NA	090
28725		A	Fusion of foot bones	11.61	10.68	NA	1.63	23.92	NA	090
28730		A	Fusion of foot bones	10.76	9.98	NA	1.51	22.25	NA	090
28735		A	Fusion of foot bones	10.85	10.28	NA	1.51	22.64	NA	090
28737		A	Revision of foot bones	9.64	8.18	NA	1.36	19.18	NA	090
28740		A	Fusion of foot bones	8.02	8.30	13.40	1.13	17.45	22.55	090
28750		A	Fusion of big toe joint	7.30	8.51	14.60	1.03	16.84	22.93	090
28755		A	Fusion of big toe joint	4.74	5.98	8.64	0.66	11.38	14.04	090
28760		A	Fusion of big toe joint	7.75	7.09	9.78	1.07	15.91	18.60	090
28800		A	Amputation of midfoot	8.21	8.68	NA	0.98	17.87	NA	090
28805		A	Amputation thru metatarsal	8.39	8.86	NA	0.97	18.22	NA	090
28810		A	Amputation toe & metatarsal	6.21	7.75	NA	0.70	14.66	NA	090
28820		A	Amputation of toe	4.41	6.86	11.18	0.51	11.78	16.10	090
28825		A	Partial amputation of toe	3.59	6.70	10.28	0.43	10.72	14.30	090
28899		C	Foot/toes surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
29000		A	Application of body cast	2.25	1.33	2.75	0.30	3.88	5.30	000
29010		A	Application of body cast	2.06	1.27	2.56	0.27	3.60	4.89	000
29015		A	Application of body cast	2.41	1.17	2.50	0.21	3.79	5.12	000
29020		A	Application of body cast	2.11	0.98	2.48	0.16	3.25	4.75	000
29025		A	Application of body cast	2.40	1.46	2.92	0.26	4.12	5.58	000
29035		A	Application of body cast	1.77	1.09	2.49	0.24	3.10	4.50	000
29040		A	Application of body cast	2.22	1.39	1.60	0.35	3.96	4.17	000
29044		A	Application of body cast	2.12	1.32	2.72	0.29	3.73	5.13	000

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
29046		A	Application of body cast	2.41	1.38	2.86	0.34	4.13	5.61	000
29049		A	Application of figure eight	0.89	0.51	1.54	0.12	1.52	2.55	000
29055		A	Application of shoulder cast	1.78	1.07	2.16	0.24	3.09	4.18	000
29058		A	Application of shoulder cast	1.31	0.64	1.81	0.14	2.09	3.26	000
29065		A	Application of long arm cast	0.87	0.54	1.27	0.12	1.53	2.26	000
29075		A	Application of forearm cast	0.77	0.47	1.22	0.11	1.35	2.10	000
29085		A	Apply hand/wrist cast	0.87	0.47	1.27	0.11	1.45	2.25	000
29105		A	Apply long arm splint	0.87	0.40	1.27	0.11	1.38	2.25	000
29125		A	Apply forearm splint	0.59	0.29	1.13	0.06	0.94	1.78	000
29126		A	Apply forearm splint	0.77	0.45	1.93	0.06	1.28	2.76	000
29130		A	Application of finger splint	0.50	0.27	0.92	0.05	0.82	1.47	000
29131		A	Application of finger splint	0.55	0.38	1.82	0.03	0.96	2.40	000
29200		A	Strapping of chest	0.65	0.30	1.40	0.04	0.99	2.09	000
29220		A	Strapping of low back	0.64	0.33	1.05	0.07	1.04	1.76	000
29240		A	Strapping of shoulder	0.71	0.32	1.43	0.05	1.08	2.19	000
29260		A	Strapping of elbow or wrist	0.55	0.27	1.16	0.04	0.86	1.75	000
29280		A	Strapping of hand or finger	0.51	0.27	1.30	0.04	0.82	1.85	000
29305		A	Application of hip cast	2.03	1.28	2.44	0.29	3.60	4.76	000
29325		A	Application of hip casts	2.32	1.44	2.59	0.31	4.07	5.22	000
29345		A	Application of long leg cast	1.40	0.85	1.65	0.19	2.44	3.24	000
29355		A	Application of long leg cast	1.53	0.87	1.67	0.20	2.60	3.40	000
29358		A	Apply long leg cast brace	1.43	0.93	1.86	0.19	2.55	3.48	000
29365		A	Application of long leg cast	1.18	0.72	1.50	0.17	2.07	2.85	000
29405		A	Apply short leg cast	0.86	0.52	1.18	0.12	1.50	2.16	000
29425		A	Apply short leg cast	1.01	0.56	1.13	0.14	1.71	2.28	000
29435		A	Apply short leg cast	1.18	0.79	1.79	0.17	2.14	3.14	000
29440		A	Addition of walker to cast	0.57	0.32	0.90	0.07	0.96	1.54	000
29445		A	Apply rigid leg cast	1.78	0.86	2.01	0.24	2.88	4.03	000
29450		A	Application of leg cast	2.08	1.01	1.69	0.13	3.22	3.90	000
29505		A	Application, long leg splint	0.69	0.42	1.61	0.06	1.17	2.36	000
29515		A	Application lower leg splint	0.73	0.43	1.17	0.07	1.23	1.97	000
29520		A	Strapping of hip	0.54	0.38	1.54	0.02	0.94	2.10	000
29530		A	Strapping of knee	0.57	0.28	1.22	0.04	0.89	1.83	000
29540		A	Strapping of ankle	0.51	0.26	0.51	0.04	0.81	1.06	000
29550		A	Strapping of toes	0.47	0.24	0.50	0.05	0.76	1.02	000
29580		A	Application of paste boot	0.57	0.31	0.85	0.05	0.93	1.47	000
29590		A	Application of foot splint	0.76	0.41	0.79	0.06	1.23	1.61	000
29700		A	Removal/revision of cast	0.57	0.31	0.81	0.07	0.95	1.45	000
29705		A	Removal/revision of cast	0.76	0.41	0.97	0.10	1.27	1.83	000
29710		A	Removal/revision of cast	1.34	0.85	1.78	0.17	2.36	3.29	000
29715		A	Removal/revision of cast	0.94	0.72	3.90	0.08	1.74	4.92	000
29720		A	Repair of body cast	0.68	0.50	1.45	0.10	1.28	2.23	000
29730		A	Windowing of cast	0.75	0.39	0.92	0.10	1.24	1.77	000
29740		A	Wedging of cast	1.12	0.53	1.35	0.15	1.80	2.62	000
29750		A	Wedging of clubfoot cast	1.26	0.59	1.58	0.16	2.01	3.00	000
29799		C	Casting/strapping procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
29800		A	Jaw arthroscopy/surgery	6.43	8.44	NA	0.84	15.71	NA	090
29804		A	Jaw arthroscopy/surgery	8.14	8.83	NA	0.66	17.63	NA	090
29815		A	Shoulder arthroscopy	5.89	7.31	NA	0.83	14.03	NA	090
29819		A	Shoulder arthroscopy/surgery	7.62	9.18	NA	1.07	17.87	NA	090
29820		A	Shoulder arthroscopy/surgery	7.07	8.81	NA	0.99	16.87	NA	090
29821		A	Shoulder arthroscopy/surgery	7.72	9.18	NA	1.08	17.98	NA	090
29822		A	Shoulder arthroscopy/surgery	7.43	9.06	NA	1.04	17.53	NA	090
29823		A	Shoulder arthroscopy/surgery	8.17	9.43	NA	1.15	18.75	NA	090
29825		A	Shoulder arthroscopy/surgery	7.62	9.19	NA	1.06	17.87	NA	090
29826		A	Shoulder arthroscopy/surgery	8.99	9.92	NA	1.26	20.17	NA	090
29830		A	Elbow arthroscopy	5.76	5.72	NA	0.79	12.27	NA	090
29834		A	Elbow arthroscopy/surgery	6.28	6.51	NA	0.86	13.65	NA	090
29835		A	Elbow arthroscopy/surgery	6.48	6.50	NA	0.88	13.86	NA	090
29836		A	Elbow arthroscopy/surgery	7.55	7.24	NA	1.06	15.85	NA	090
29837		A	Elbow arthroscopy/surgery	6.87	6.80	NA	0.96	14.63	NA	090
29838		A	Elbow arthroscopy/surgery	7.71	7.31	NA	1.07	16.09	NA	090
29840		A	Wrist arthroscopy	5.54	8.36	NA	0.69	14.59	NA	090
29843		A	Wrist arthroscopy/surgery	6.01	7.95	NA	0.82	14.78	NA	090
29844		A	Wrist arthroscopy/surgery	6.37	8.11	NA	0.86	15.34	NA	090
29845		A	Wrist arthroscopy/surgery	7.52	8.57	NA	0.84	16.93	NA	090
29846		A	Wrist arthroscopy/surgery	6.75	10.62	NA	0.89	18.26	NA	090
29847		A	Wrist arthroscopy/surgery	7.08	10.57	NA	0.91	18.56	NA	090
29848		A	Wrist endoscopy/surgery	5.44	7.82	NA	0.72	13.98	NA	090
29850		A	Knee arthroscopy/surgery	8.19	7.05	NA	0.74	15.98	NA	090
29851		A	Knee arthroscopy/surgery	13.10	11.36	NA	1.81	26.27	NA	090
29855		A	Tibial arthroscopy/surgery	10.62	10.01	NA	1.50	22.13	NA	090
29856		A	Tibial arthroscopy/surgery	14.14	11.98	NA	2.00	28.12	NA	090
29860		A	Hip arthroscopy, dx	8.05	7.61	NA	1.14	16.80	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
29861		A	Hip arthroscopy/surgery	9.15	8.76	NA	1.29	19.20	NA	090
29862		A	Hip arthroscopy/surgery	9.90	9.09	NA	1.39	20.38	NA	090
29863		A	Hip arthroscopy/surgery	9.90	9.71	NA	1.40	21.01	NA	090
29870		A	Knee arthroscopy, dx	5.07	5.81	NA	0.67	11.55	NA	090
29871		A	Knee arthroscopy/drainage	6.55	7.74	NA	0.88	15.17	NA	090
29874		A	Knee arthroscopy/surgery	7.05	7.42	NA	0.87	15.34	NA	090
29875		A	Knee arthroscopy/surgery	6.31	7.15	NA	0.88	14.34	NA	090
29876		A	Knee arthroscopy/surgery	7.92	8.57	NA	1.11	17.60	NA	090
29877		A	Knee arthroscopy/surgery	7.35	7.74	NA	1.03	16.12	NA	090
29879		A	Knee arthroscopy/surgery	8.04	8.13	NA	1.13	17.30	NA	090
29880		A	Knee arthroscopy/surgery	8.50	8.39	NA	1.19	18.08	NA	090
29881		A	Knee arthroscopy/surgery	7.76	7.97	NA	1.09	16.82	NA	090
29882		A	Knee arthroscopy/surgery	8.65	8.02	NA	1.09	17.76	NA	090
29883		A	Knee arthroscopy/surgery	11.05	9.82	NA	1.33	22.20	NA	090
29884		A	Knee arthroscopy/surgery	7.33	8.25	NA	1.03	16.61	NA	090
29885		A	Knee arthroscopy/surgery	9.09	9.19	NA	1.27	19.55	NA	090
29886		A	Knee arthroscopy/surgery	7.54	8.36	NA	1.06	16.96	NA	090
29887		A	Knee arthroscopy/surgery	9.04	9.19	NA	1.27	19.50	NA	090
29888		A	Knee arthroscopy/surgery	13.90	11.89	NA	1.95	27.74	NA	090
29889		A	Knee arthroscopy/surgery	16.00	12.98	NA	2.11	31.09	NA	090
29891		A	Ankle arthroscopy/surgery	8.40	8.76	NA	1.17	18.33	NA	090
29892		A	Ankle arthroscopy/surgery	9.00	8.60	NA	1.26	18.86	NA	090
29893		A	Scope, plantar fasciotomy	5.22	4.81	NA	0.74	10.77	NA	090
29894		A	Ankle arthroscopy/surgery	7.21	7.40	NA	1.01	15.62	NA	090
29895		A	Ankle arthroscopy/surgery	6.99	7.69	NA	0.97	15.65	NA	090
29897		A	Ankle arthroscopy/surgery	7.18	8.29	NA	1.01	16.48	NA	090
29898		A	Ankle arthroscopy/surgery	8.32	8.15	NA	1.14	17.61	NA	090
29909		C	Arthroscopy of joint	0.00	0.00	0.00	0.00	0.00	0.00	YYY
30000		A	Drainage of nose lesion	1.43	1.45	2.41	0.10	2.98	3.94	010
30020		A	Drainage of nose lesion	1.43	1.54	2.62	0.08	3.05	4.13	010
30100		A	Intranasal biopsy	0.94	0.53	1.28	0.06	1.53	2.28	000
30110		A	Removal of nose polyp(s)	1.63	0.90	2.66	0.12	2.65	4.41	010
30115		A	Removal of nose polyp(s)	4.35	4.37	NA	0.31	9.03	NA	090
30117		A	Removal of intranasal lesion	3.16	3.10	4.66	0.22	6.48	8.04	090
30118		A	Removal of intranasal lesion	9.69	7.48	NA	0.66	17.83	NA	090
30120		A	Revision of nose	5.27	5.93	5.93	0.41	11.61	11.61	090
30124		A	Removal of nose lesion	3.10	3.27	NA	0.20	6.57	NA	090
30125		A	Removal of nose lesion	7.16	6.29	NA	0.54	13.99	NA	090
30130		A	Removal of turbinate bones	3.38	3.81	NA	0.22	7.41	NA	090
30140		A	Removal of turbinate bones	3.43	4.40	NA	0.24	8.07	NA	090
30150		A	Partial removal of nose	9.14	8.58	NA	0.76	18.48	NA	090
30160		A	Removal of nose	9.58	8.39	NA	0.78	18.75	NA	090
30200		A	Injection treatment of nose	0.78	0.45	1.16	0.06	1.29	2.00	000
30210		A	Nasal sinus therapy	1.08	0.61	2.04	0.08	1.77	3.20	010
30220		A	Insert nasal septal button	1.54	0.87	2.36	0.11	2.52	4.01	010
30300		A	Remove nasal foreign body	1.04	0.38	2.43	0.07	1.49	3.54	010
30310		A	Remove nasal foreign body	1.96	1.84	NA	0.14	3.94	NA	010
30320		A	Remove nasal foreign body	4.52	5.40	NA	0.36	10.28	NA	090
30400		R	Reconstruction of nose	9.83	8.68	NA	0.80	19.31	NA	090
30410		R	Reconstruction of nose	12.98	10.55	NA	1.08	24.61	NA	090
30420		R	Reconstruction of nose	15.88	12.25	NA	1.24	29.37	NA	090
30430		R	Revision of nose	7.21	7.15	NA	0.62	14.98	NA	090
30435		R	Revision of nose	11.71	10.47	NA	1.10	23.28	NA	090
30450		R	Revision of nose	18.65	14.05	NA	1.53	34.23	NA	090
30460		A	Revision of nose	9.96	9.51	NA	0.85	20.32	NA	090
30462		A	Revision of nose	19.57	14.96	NA	1.92	36.45	NA	090
30465		A	Repair nasal stenosis	11.64	9.21	NA	0.82	21.67	NA	090
30520		A	Repair of nasal septum	5.70	5.71	NA	0.41	11.82	NA	090
30540		A	Repair nasal defect	7.75	6.46	NA	0.53	14.74	NA	090
30545		A	Repair nasal defect	11.38	8.20	NA	0.80	20.38	NA	090
30560		A	Release of nasal adhesions	1.26	1.46	2.25	0.09	2.81	3.60	010
30580		A	Repair upper jaw fistula	6.69	4.94	4.94	0.50	12.13	12.13	090
30600		A	Repair mouth/nose fistula	6.02	5.17	5.17	0.70	11.89	11.89	090
30620		A	Intranasal reconstruction	5.97	6.44	NA	0.45	12.86	NA	090
30630		A	Repair nasal septum defect	7.12	6.89	NA	0.51	14.52	NA	090
30801		A	Cauterization, inner nose	1.09	2.17	2.45	0.08	3.34	3.62	010
30802		A	Cauterization, inner nose	2.03	2.72	2.99	0.15	4.90	5.17	010
30901		A	Control of nosebleed	1.21	0.44	2.05	0.09	1.74	3.35	000
30903		A	Control of nosebleed	1.54	0.63	2.46	0.12	2.29	4.12	000
30905		A	Control of nosebleed	1.97	0.89	4.32	0.15	3.01	6.44	000
30906		A	Repeat control of nosebleed	2.45	1.35	4.56	0.17	3.97	7.18	000
30915		A	Ligation, nasal sinus artery	7.20	6.84	NA	0.50	14.54	NA	090
30920		A	Ligation, upper jaw artery	9.83	8.33	NA	0.69	18.85	NA	090
30930		A	Therapy, fracture of nose	1.26	2.05	NA	0.09	3.40	NA	010

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
30999		C	Nasal surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
31000		A	Irrigation, maxillary sinus	1.15	0.64	2.33	0.08	1.87	3.56	010
31002		A	Irrigation, sphenoid sinus	1.91	1.98	NA	0.14	4.03	NA	010
31020		A	Exploration, maxillary sinus	2.94	3.53	4.22	0.20	6.67	7.36	090
31030		A	Exploration, maxillary sinus	5.92	4.54	4.79	0.42	10.88	11.13	090
31032		A	Explore sinus,remove polyps	6.57	5.91	NA	0.47	12.95	NA	090
31040		A	Exploration behind upper jaw	9.42	6.80	NA	0.71	16.93	NA	090
31050		A	Exploration, sphenoid sinus	5.28	4.93	NA	0.39	10.60	NA	090
31051		A	Sphenoid sinus surgery	7.11	6.35	NA	0.55	14.01	NA	090
31070		A	Exploration of frontal sinus	4.28	4.85	NA	0.30	9.43	NA	090
31075		A	Exploration of frontal sinus	9.16	8.02	NA	0.64	17.82	NA	090
31080		A	Removal of frontal sinus	11.42	8.69	NA	0.78	20.89	NA	090
31081		A	Removal of frontal sinus	12.75	9.38	NA	1.84	23.97	NA	090
31084		A	Removal of frontal sinus	13.51	10.41	NA	0.96	24.88	NA	090
31085		A	Removal of frontal sinus	14.20	10.67	NA	1.18	26.05	NA	090
31086		A	Removal of frontal sinus	12.86	9.97	NA	0.90	23.73	NA	090
31087		A	Removal of frontal sinus	13.10	10.51	NA	1.15	24.76	NA	090
31090		A	Exploration of sinuses	9.53	8.66	NA	0.66	18.85	NA	090
31200		A	Removal of ethmoid sinus	4.97	5.52	NA	0.25	10.74	NA	090
31201		A	Removal of ethmoid sinus	8.37	7.61	NA	0.58	16.56	NA	090
31205		A	Removal of ethmoid sinus	10.24	8.20	NA	0.58	19.02	NA	090
31225		A	Removal of upper jaw	19.23	14.89	NA	1.38	35.50	NA	090
31230		A	Removal of upper jaw	21.94	16.19	NA	1.57	39.70	NA	090
31231		A	Nasal endoscopy, dx	1.10	0.59	1.91	0.08	1.77	3.09	000
31233		A	Nasal/sinus endoscopy, dx	2.18	1.19	2.55	0.16	3.53	4.89	000
31235		A	Nasal/sinus endoscopy, dx	2.64	1.49	2.82	0.18	4.31	5.64	000
31237		A	Nasal/sinus endoscopy, surg	2.98	1.65	3.10	0.21	4.84	6.29	000
31238		A	Nasal/sinus endoscopy, surg	3.26	1.86	3.59	0.23	5.35	7.08	000
31239		A	Nasal/sinus endoscopy, surg	8.70	6.37	NA	0.46	15.53	NA	010
31240		A	Nasal/sinus endoscopy, surg	2.61	1.59	NA	0.18	4.38	NA	000
31254		A	Revision of ethmoid sinus	4.65	2.75	NA	0.32	7.72	NA	000
31255		A	Removal of ethmoid sinus	6.96	4.07	NA	0.49	11.52	NA	000
31256		A	Exploration maxillary sinus	3.29	1.98	NA	0.23	5.50	NA	000
31267		A	Endoscopy, maxillary sinus	5.46	3.22	NA	0.38	9.06	NA	000
31276		A	Sinus endoscopy, surgical	8.85	5.16	NA	0.62	14.63	NA	000
31287		A	Nasal/sinus endoscopy, surg	3.92	2.34	NA	0.27	6.53	NA	000
31288		A	Nasal/sinus endoscopy, surg	4.58	2.71	NA	0.32	7.61	NA	000
31290		A	Nasal/sinus endoscopy, surg	17.24	11.70	NA	1.20	30.14	NA	010
31291		A	Nasal/sinus endoscopy, surg	18.19	11.90	NA	1.73	31.82	NA	010
31292		A	Nasal/sinus endoscopy, surg	14.76	10.04	NA	0.99	25.79	NA	010
31293		A	Nasal/sinus endoscopy, surg	16.21	10.71	NA	0.97	27.89	NA	010
31294		A	Nasal/sinus endoscopy, surg	19.06	11.48	NA	1.04	31.58	NA	010
31299		C	Sinus surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
31300		A	Removal of larynx lesion	14.29	16.71	NA	0.99	31.99	NA	090
31320		A	Diagnostic incision, larynx	5.26	13.00	NA	0.40	18.66	NA	090
31360		A	Removal of larynx	17.08	18.54	NA	1.20	36.82	NA	090
31365		A	Removal of larynx	24.16	22.21	NA	1.72	48.09	NA	090
31367		A	Partial removal of larynx	21.86	22.87	NA	1.57	46.30	NA	090
31368		A	Partial removal of larynx	27.09	27.69	NA	1.90	56.68	NA	090
31370		A	Partial removal of larynx	21.38	22.65	NA	1.51	45.54	NA	090
31375		A	Partial removal of larynx	20.21	20.63	NA	1.43	42.27	NA	090
31380		A	Partial removal of larynx	20.21	20.16	NA	1.40	41.77	NA	090
31382		A	Partial removal of larynx	20.52	22.33	NA	1.44	44.29	NA	090
31390		A	Removal of larynx & pharynx	27.53	28.12	NA	1.95	57.60	NA	090
31395		A	Reconstruct larynx & pharynx	31.09	33.15	NA	2.27	66.51	NA	090
31400		A	Revision of larynx	10.31	15.09	NA	0.72	26.12	NA	090
31420		A	Removal of epiglottis	10.22	14.89	NA	0.71	25.82	NA	090
31500		A	Insert emergency airway	2.33	0.68	NA	0.15	3.16	NA	000
31502		A	Change of windpipe airway	0.65	0.27	1.85	0.04	0.96	2.54	000
31505		A	Diagnostic laryngoscopy	0.61	0.34	1.74	0.04	0.99	2.39	000
31510		A	Laryngoscopy with biopsy	1.92	1.01	2.70	0.15	3.08	4.77	000
31511		A	Remove foreign body, larynx	2.16	0.77	2.94	0.16	3.09	5.26	000
31512		A	Removal of larynx lesion	2.07	1.14	2.89	0.16	3.37	5.12	000
31513		A	Injection into vocal cord	2.10	1.29	NA	0.15	3.54	NA	000
31515		A	Laryngoscopy for aspiration	1.80	0.85	2.40	0.12	2.77	4.32	000
31520		A	Diagnostic laryngoscopy	2.56	1.41	NA	0.17	4.14	NA	000
31525		A	Diagnostic laryngoscopy	2.63	1.50	2.82	0.18	4.31	5.63	000
31526		A	Diagnostic laryngoscopy	2.57	1.56	NA	0.18	4.31	NA	000
31527		A	Laryngoscopy for treatment	3.27	1.72	NA	0.21	5.20	NA	000
31528		A	Laryngoscopy and dilatation	2.37	1.31	NA	0.16	3.84	NA	000
31529		A	Laryngoscopy and dilatation	2.68	1.59	NA	0.18	4.45	NA	000
31530		A	Operative laryngoscopy	3.39	1.83	NA	0.24	5.46	NA	000
31531		A	Operative laryngoscopy	3.59	2.15	NA	0.25	5.99	NA	000
31535		A	Operative laryngoscopy	3.16	1.86	NA	0.22	5.24	NA	000

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
31536		A	Operative laryngoscopy	3.56	2.12	NA	0.25	5.93	NA	000
31540		A	Operative laryngoscopy	4.13	2.43	NA	0.29	6.85	NA	000
31541		A	Operative laryngoscopy	4.53	2.68	NA	0.32	7.53	NA	000
31560		A	Operative laryngoscopy	5.46	3.06	NA	0.38	8.90	NA	000
31561		A	Operative laryngoscopy	6.00	3.53	NA	0.42	9.95	NA	000
31570		A	Laryngoscopy with injection	3.87	2.28	4.21	0.24	6.39	8.32	000
31571		A	Laryngoscopy with injection	4.27	2.53	NA	0.30	7.10	NA	000
31575		A	Diagnostic laryngoscopy	1.10	0.62	2.10	0.08	1.80	3.28	000
31576		A	Laryngoscopy with biopsy	1.97	0.98	2.36	0.13	3.08	4.46	000
31577		A	Remove foreign body, larynx	2.47	1.34	2.79	0.17	3.98	5.43	000
31578		A	Removal of larynx lesion	2.84	1.59	3.00	0.20	4.63	6.04	000
31579		A	Diagnostic laryngoscopy	2.26	1.22	2.84	0.16	3.64	5.26	000
31580		A	Revision of larynx	12.38	15.82	NA	0.87	29.07	NA	090
31582		A	Revision of larynx	21.62	21.18	NA	1.52	44.32	NA	090
31584		A	Treat larynx fracture	19.64	18.51	NA	1.42	39.57	NA	090
31585		A	Treat larynx fracture	4.64	8.67	NA	0.30	13.61	NA	090
31586		A	Treat larynx fracture	8.03	12.02	NA	0.56	20.61	NA	090
31587		A	Revision of larynx	11.99	13.39	NA	0.88	26.26	NA	090
31588		A	Revision of larynx	13.11	16.53	NA	0.92	30.56	NA	090
31590		A	Reinnervate larynx	6.97	11.67	NA	0.50	19.14	NA	090
31595		A	Larynx nerve surgery	8.34	10.54	NA	0.62	19.50	NA	090
31599		C	Larynx surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
31600		A	Incision of windpipe	7.18	3.12	NA	0.34	10.64	NA	000
31601		A	Incision of windpipe	4.45	2.11	NA	0.39	6.95	NA	000
31603		A	Incision of windpipe	4.15	1.67	NA	0.35	6.17	NA	000
31605		A	Incision of windpipe	3.58	1.24	NA	0.33	5.15	NA	000
31610		A	Incision of windpipe	8.76	10.50	NA	0.69	19.95	NA	090
31611		A	Surgery/speech prosthesis	5.64	9.78	NA	0.40	15.82	NA	090
31612		A	Puncture/clear windpipe	0.91	0.43	1.49	0.06	1.40	2.46	000
31613		A	Repair windpipe opening	4.59	8.57	NA	0.37	13.53	NA	090
31614		A	Repair windpipe opening	7.12	11.72	NA	0.51	19.35	NA	090
31615		A	Visualization of windpipe	2.09	1.20	3.54	0.14	3.43	5.77	000
31622		A	Dx bronchoscope/wash	2.78	1.19	3.30	0.14	4.11	6.22	000
31623		A	Dx bronchoscope/brush	2.88	1.20	3.23	0.14	4.22	6.25	000
31624		A	Dx bronchoscope/lavage	2.88	1.20	2.90	0.13	4.21	5.91	000
31625		A	Bronchoscopy with biopsy	3.37	1.34	2.93	0.16	4.87	6.46	000
31628		A	Bronchoscopy with biopsy	3.81	1.45	3.36	0.14	5.40	7.31	000
31629		A	Bronchoscopy with biopsy	3.37	1.32	NA	0.13	4.82	NA	000
31630		A	Bronchoscopy with repair	3.82	2.03	NA	0.30	6.15	NA	000
31631		A	Bronchoscopy with dilation	4.37	2.06	NA	0.31	6.74	NA	000
31635		A	Remove foreign body, airway	3.68	1.73	NA	0.21	5.62	NA	000
31640		A	Bronchoscopy & remove lesion	4.94	2.37	NA	0.37	7.68	NA	000
31641		A	Bronchoscopy, treat blockage	5.03	2.20	NA	0.30	7.53	NA	000
31643		A	Diag bronchoscope/catheter	3.50	1.17	1.17	0.15	4.82	4.82	000
31645		A	Bronchoscopy, clear airways	3.16	1.26	NA	0.13	4.55	NA	000
31646		A	Bronchoscopy, reclear airway	2.72	1.12	NA	0.12	3.96	NA	000
31656		A	Bronchoscopy, inj for xray	2.17	0.94	NA	0.10	3.21	NA	000
31700		A	Insertion of airway catheter	1.34	0.75	2.53	0.07	2.16	3.94	000
31708		A	Instill airway contrast dye	1.41	0.63	NA	0.06	2.10	NA	000
31710		A	Insertion of airway catheter	1.30	0.74	NA	0.06	2.10	NA	000
31715		A	Injection for bronchus x-ray	1.11	0.66	NA	0.06	1.83	NA	000
31717		A	Bronchial brush biopsy	2.12	0.92	2.79	0.09	3.13	5.00	000
31720		A	Clearance of airways	1.06	0.34	1.88	0.06	1.46	3.00	000
31725		A	Clearance of airways	1.96	0.62	NA	0.10	2.68	NA	000
31730		A	Intro, windpipe wire/tube	2.85	1.13	2.43	0.15	4.13	5.43	000
31750		A	Repair of windpipe	13.02	15.46	NA	1.02	29.50	NA	090
31755		A	Repair of windpipe	15.93	18.50	NA	1.15	35.58	NA	090
31760		A	Repair of windpipe	22.35	11.89	NA	1.48	35.72	NA	090
31766		A	Reconstruction of windpipe	30.43	17.60	NA	3.16	51.19	NA	090
31770		A	Repair/graft of bronchus	22.51	14.69	NA	2.27	39.47	NA	090
31775		A	Reconstruct bronchus	23.54	14.06	NA	2.91	40.51	NA	090
31780		A	Reconstruct windpipe	17.72	12.93	NA	1.55	32.20	NA	090
31781		A	Reconstruct windpipe	23.53	13.82	NA	2.04	39.39	NA	090
31785		A	Remove windpipe lesion	17.23	12.69	NA	1.36	31.28	NA	090
31786		A	Remove windpipe lesion	23.98	14.62	NA	2.20	40.80	NA	090
31800		A	Repair of windpipe injury	7.43	6.95	NA	0.67	15.05	NA	090
31805		A	Repair of windpipe injury	13.13	10.09	NA	1.45	24.67	NA	090
31820		A	Closure of windpipe lesion	4.49	7.70	7.74	0.35	12.54	12.58	090
31825		A	Repair of windpipe defect	6.81	10.92	11.15	0.50	18.23	18.46	090
31830		A	Revise windpipe scar	4.50	7.84	7.84	0.36	12.70	12.70	090
31899		C	Airways surgical procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
32000		A	Drainage of chest	1.54	0.51	3.04	0.07	2.12	4.65	000
32002		A	Treatment of collapsed lung	2.19	0.87	NA	0.11	3.17	NA	000
32005		A	Treat lung lining chemically	2.19	0.88	NA	0.17	3.24	NA	000

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
32020		A	Insertion of chest tube	3.98	1.48	NA	0.36	5.82	NA	000
32035		A	Exploration of chest	8.67	7.78	NA	1.02	17.47	NA	090
32036		A	Exploration of chest	9.68	8.82	NA	1.20	19.70	NA	090
32095		A	Biopsy through chest wall	8.36	8.17	NA	0.99	17.52	NA	090
32100		A	Exploration/biopsy of chest	15.24	10.45	NA	1.45	27.14	NA	090
32110		A	Explore/repair chest	23.00	13.15	NA	1.63	37.78	NA	090
32120		A	Re-exploration of chest	11.54	9.57	NA	1.42	22.53	NA	090
32124		A	Explore chest free adhesions	12.72	9.38	NA	1.51	23.61	NA	090
32140		A	Removal of lung lesion(s)	13.93	10.02	NA	1.68	25.63	NA	090
32141		A	Remove/treat lung lesions	14.00	10.20	NA	1.72	25.92	NA	090
32150		A	Removal of lung lesion(s)	14.15	9.78	NA	1.60	25.53	NA	090
32151		A	Remove lung foreign body	14.21	10.46	NA	1.49	26.16	NA	090
32160		A	Open chest heart massage	9.30	6.29	NA	1.01	16.60	NA	090
32200		A	Drain, open, lung lesion	15.29	10.30	NA	1.46	27.05	NA	090
32201		A	Drain, percut, lung lesion	4.00	6.49	NA	0.18	10.67	NA	000
32215		A	Treat chest lining	11.33	9.64	NA	1.34	22.31	NA	090
32220		A	Release of lung	24.00	13.70	NA	2.39	40.09	NA	090
32225		A	Partial release of lung	13.96	10.10	NA	1.70	25.76	NA	090
32310		A	Removal of chest lining	13.44	9.86	NA	1.65	24.95	NA	090
32320		A	Free/remove chest lining	24.00	13.32	NA	2.50	39.82	NA	090
32400		A	Needle biopsy chest lining	1.76	0.58	1.94	0.07	2.41	3.77	000
32402		A	Open biopsy chest lining	7.56	8.16	NA	0.91	16.63	NA	090
32405		A	Biopsy, lung or mediastinum	1.93	0.67	2.34	0.09	2.69	4.36	000
32420		A	Puncture/clear lung	2.18	0.86	NA	0.11	3.15	NA	000
32440		A	Removal of lung	25.00	13.83	NA	2.56	41.39	NA	090
32442		A	Sleeve pneumonectomy	26.24	15.04	NA	3.12	44.40	NA	090
32445		A	Removal of lung	25.09	13.71	NA	3.11	41.91	NA	090
32480		A	Partial removal of lung	23.75	12.95	NA	2.24	38.94	NA	090
32482		A	Bilobectomy	25.00	13.65	NA	2.35	41.00	NA	090
32484		A	Segmentectomy	20.69	12.09	NA	2.54	35.32	NA	090
32486		A	Sleeve lobectomy	23.92	13.44	NA	3.00	40.36	NA	090
32488		A	Completion pneumonectomy	25.71	14.22	NA	3.18	43.11	NA	090
32491		R	Lung volume reduction	21.25	13.52	NA	2.66	37.43	NA	090
32500		A	Partial removal of lung	22.00	12.94	NA	1.77	36.71	NA	090
32501		A	Repair bronchus add-on	4.69	1.59	NA	0.56	6.84	NA	ZZZ
32520		A	Remove lung & revise chest	21.68	12.88	NA	2.71	37.27	NA	090
32522		A	Remove lung & revise chest	24.20	13.48	NA	2.84	40.52	NA	090
32525		A	Remove lung & revise chest	26.50	14.29	NA	3.25	44.04	NA	090
32540		A	Removal of lung lesion	14.64	10.51	NA	1.84	26.99	NA	090
32601		A	Thoracoscopy, diagnostic	5.46	3.67	NA	0.63	9.76	NA	000
32602		A	Thoracoscopy, diagnostic	5.96	3.85	NA	0.70	10.51	NA	000
32603		A	Thoracoscopy, diagnostic	7.81	4.29	NA	0.76	12.86	NA	000
32604		A	Thoracoscopy, diagnostic	8.78	4.83	NA	0.97	14.58	NA	000
32605		A	Thoracoscopy, diagnostic	6.93	4.36	NA	0.86	12.15	NA	000
32606		A	Thoracoscopy, diagnostic	8.40	4.65	NA	0.99	14.04	NA	000
32650		A	Thoracoscopy, surgical	10.75	8.63	NA	1.25	20.63	NA	090
32651		A	Thoracoscopy, surgical	12.91	8.87	NA	1.50	23.28	NA	090
32652		A	Thoracoscopy, surgical	18.66	11.51	NA	2.30	32.47	NA	090
32653		A	Thoracoscopy, surgical	12.87	9.30	NA	1.55	23.72	NA	090
32654		A	Thoracoscopy, surgical	12.44	7.38	NA	1.51	21.33	NA	090
32655		A	Thoracoscopy, surgical	13.10	8.99	NA	1.53	23.62	NA	090
32656		A	Thoracoscopy, surgical	12.91	9.71	NA	1.61	24.23	NA	090
32657		A	Thoracoscopy, surgical	13.65	9.51	NA	1.64	24.80	NA	090
32658		A	Thoracoscopy, surgical	11.63	9.85	NA	1.47	22.95	NA	090
32659		A	Thoracoscopy, surgical	11.59	8.96	NA	1.39	21.94	NA	090
32660		A	Thoracoscopy, surgical	17.43	10.64	NA	2.09	30.16	NA	090
32661		A	Thoracoscopy, surgical	13.25	9.75	NA	1.66	24.66	NA	090
32662		A	Thoracoscopy, surgical	16.44	10.73	NA	2.01	29.18	NA	090
32663		A	Thoracoscopy, surgical	18.47	11.44	NA	2.28	32.19	NA	090
32664		A	Thoracoscopy, surgical	14.20	9.22	NA	1.70	25.12	NA	090
32665		A	Thoracoscopy, surgical	15.54	9.49	NA	1.79	26.82	NA	090
32800		A	Repair lung hernia	13.69	9.70	NA	1.51	24.90	NA	090
32810		A	Close chest after drainage	13.05	9.65	NA	1.55	24.25	NA	090
32815		A	Close bronchial fistula	23.15	13.57	NA	2.84	39.56	NA	090
32820		A	Reconstruct injured chest	21.48	13.85	NA	2.31	37.64	NA	090
32850		X	Donor pneumonectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
32851		A	Lung transplant, single	38.63	20.37	NA	4.90	63.90	NA	090
32852		A	Lung transplant with bypass	41.80	22.29	NA	5.17	69.26	NA	090
32853		A	Lung transplant, double	47.81	23.87	NA	6.13	77.81	NA	090
32854		A	Lung transplant with bypass	50.98	24.28	NA	6.41	81.67	NA	090
32900		A	Removal of rib(s)	20.27	12.21	NA	2.42	34.90	NA	090
32905		A	Revise & repair chest wall	20.75	12.70	NA	2.54	35.99	NA	090
32906		A	Revise & repair chest wall	26.77	15.56	NA	3.30	45.63	NA	090
32940		A	Revision of lung	19.43	12.41	NA	2.47	34.31	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
32960		A	Therapeutic pneumothorax	1.84	0.60	1.58	0.12	2.56	3.54	000
32997		A	Total lung lavage	6.00	2.12	NA	0.55	8.67	NA	000
32999		C	Chest surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
33010		A	Drainage of heart sac	2.24	1.00	NA	0.13	3.37	NA	000
33011		A	Repeat drainage of heart sac	2.24	1.04	NA	0.13	3.41	NA	000
33015		A	Incision of heart sac	6.80	4.48	NA	0.64	11.92	NA	090
33020		A	Incision of heart sac	12.61	7.93	NA	1.50	22.04	NA	090
33025		A	Incision of heart sac	12.09	7.94	NA	1.50	21.53	NA	090
33030		A	Partial removal of heart sac	18.71	12.50	NA	2.40	33.61	NA	090
33031		A	Partial removal of heart sac	21.79	13.63	NA	2.78	38.20	NA	090
33050		A	Removal of heart sac lesion	14.36	10.20	NA	1.73	26.29	NA	090
33120		A	Removal of heart lesion	24.56	16.06	NA	3.06	43.68	NA	090
33130		A	Removal of heart lesion	21.39	13.11	NA	2.51	37.01	NA	090
33140		A	Heart revascularize (tmr)	20.00	10.59	NA	2.27	32.86	NA	090
33141		A	Heart tmr w/other procedure	4.84	1.69	NA	0.60	7.13	NA	ZZZ
33200		A	Insertion of heart pacemaker	12.48	9.74	NA	1.17	23.39	NA	090
33201		A	Insertion of heart pacemaker	10.18	9.67	NA	1.21	21.06	NA	090
33206		A	Insertion of heart pacemaker	6.67	5.54	NA	0.50	12.71	NA	090
33207		A	Insertion of heart pacemaker	8.04	6.05	NA	0.57	14.66	NA	090
33208		A	Insertion of heart pacemaker	8.13	6.20	NA	0.54	14.87	NA	090
33210		A	Insertion of heart electrode	3.30	1.32	NA	0.17	4.79	NA	000
33211		A	Insertion of heart electrode	3.40	1.39	NA	0.17	4.96	NA	000
33212		A	Insertion of pulse generator	5.52	4.48	NA	0.44	10.44	NA	090
33213		A	Insertion of pulse generator	6.37	4.86	NA	0.46	11.69	NA	090
33214		A	Upgrade of pacemaker system	7.75	6.00	NA	0.52	14.27	NA	090
33216		A	Revise eltrd pacing-defib	5.39	4.96	NA	0.36	10.71	NA	090
33217		A	Revise eltrd pacing-defib	5.75	5.30	NA	0.36	11.41	NA	090
33218		A	Revise eltrd pacing-defib	5.44	4.53	NA	0.40	10.37	NA	090
33220		A	Revise eltrd pacing-defib	5.52	4.59	NA	0.39	10.50	NA	090
33222		A	Revise pocket, pacemaker	4.96	3.97	NA	0.39	9.32	NA	090
33223		A	Revise pocket, pacing-defib	6.46	5.19	NA	0.44	12.09	NA	090
33233		A	Removal of pacemaker system	3.29	3.86	NA	0.22	7.37	NA	090
33234		A	Removal of pacemaker system	7.82	5.67	NA	0.56	14.05	NA	090
33235		A	Removal of pacemaker electro	9.40	6.33	NA	0.68	16.41	NA	090
33236		A	Remove electrode/thoracotomy	12.60	9.27	NA	1.49	23.36	NA	090
33237		A	Remove electrode/thoracotomy	13.71	9.90	NA	1.57	25.18	NA	090
33238		A	Remove electrode/thoracotomy	15.22	9.86	NA	1.56	26.64	NA	090
33240		A	Insert pulse generator	7.60	5.57	NA	0.53	13.70	NA	090
33241		A	Remove pulse generator	3.24	3.47	NA	0.21	6.92	NA	090
33243		A	Remove eltrd/thoracotomy	22.64	10.96	NA	2.53	36.13	NA	090
33244		A	Remove eltrd, transven	13.76	8.29	NA	1.05	23.10	NA	090
33245		A	Insert epic eltrd pace-defib	14.30	10.98	NA	1.28	26.56	NA	090
33246		A	Insert epic eltrd/generator	20.71	14.37	NA	2.22	37.30	NA	090
33249		A	Eltrd/insert pace-defib	14.23	9.00	NA	0.80	24.03	NA	090
33250		A	Ablate heart dysrhythm focus	21.85	13.79	NA	1.01	36.65	NA	090
33251		A	Ablate heart dysrhythm focus	24.88	14.75	NA	2.41	42.04	NA	090
33253		A	Reconstruct atria	31.06	17.03	NA	3.68	51.77	NA	090
33261		A	Ablate heart dysrhythm focus	24.88	14.70	NA	2.82	42.40	NA	090
33282		A	Implant pat-active ht record	4.17	4.64	NA	0.39	9.20	NA	090
33284		A	Remove pat-active ht record	2.50	4.16	NA	0.23	6.89	NA	090
33300		A	Repair of heart wound	17.92	12.15	NA	1.91	31.98	NA	090
33305		A	Repair of heart wound	21.44	13.61	NA	2.68	37.73	NA	090
33310		A	Exploratory heart surgery	18.51	12.35	NA	2.26	33.12	NA	090
33315		A	Exploratory heart surgery	22.37	13.84	NA	2.90	39.11	NA	090
33320		A	Repair major blood vessel(s)	16.79	11.30	NA	1.66	29.75	NA	090
33321		A	Repair major vessel	20.20	13.19	NA	2.70	36.09	NA	090
33322		A	Repair major blood vessel(s)	20.62	13.29	NA	2.51	36.42	NA	090
33330		A	Insert major vessel graft	21.43	13.08	NA	2.49	37.00	NA	090
33332		A	Insert major vessel graft	23.96	13.61	NA	2.45	40.02	NA	090
33335		A	Insert major vessel graft	30.01	16.34	NA	3.79	50.14	NA	090
33400		A	Repair of aortic valve	28.50	17.31	NA	3.09	48.90	NA	090
33401		A	Valvuloplasty, open	23.91	15.66	NA	2.71	42.28	NA	090
33403		A	Valvuloplasty, w/cp bypass	24.89	15.61	NA	2.48	42.98	NA	090
33404		A	Prepare heart-aorta conduit	28.54	17.27	NA	3.31	49.12	NA	090
33405		A	Replacement of aortic valve	35.00	18.13	NA	3.86	56.99	NA	090
33406		A	Replacement of aortic valve	37.50	18.83	NA	4.07	60.40	NA	090
33410		A	Replacement of aortic valve	32.46	17.28	NA	4.11	53.85	NA	090
33411		A	Replacement of aortic valve	36.25	18.61	NA	4.16	59.02	NA	090
33412		A	Replacement of aortic valve	42.00	22.33	NA	4.66	68.99	NA	090
33413		A	Replacement of aortic valve	43.50	23.30	NA	4.26	71.06	NA	090
33414		A	Repair of aortic valve	30.35	18.26	NA	3.79	52.40	NA	090
33415		A	Revision, subvalvular tissue	27.15	17.07	NA	3.25	47.47	NA	090
33416		A	Revise ventricle muscle	30.35	16.61	NA	3.85	50.81	NA	090
33417		A	Repair of aortic valve	28.53	17.74	NA	3.58	49.85	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
33420		A	Revision of mitral valve	22.70	11.82	NA	1.48	36.00	NA	090
33422		A	Revision of mitral valve	25.94	15.09	NA	3.30	44.33	NA	090
33425		A	Repair of mitral valve	27.00	14.50	NA	3.00	44.50	NA	090
33426		A	Repair of mitral valve	33.00	17.51	NA	3.87	54.38	NA	090
33427		A	Repair of mitral valve	40.00	19.71	NA	4.30	64.01	NA	090
33430		A	Replacement of mitral valve	33.50	17.65	NA	3.95	55.10	NA	090
33460		A	Revision of tricuspid valve	23.60	14.40	NA	3.02	41.02	NA	090
33463		A	Valvuloplasty, tricuspid	25.62	15.07	NA	3.17	43.86	NA	090
33464		A	Valvuloplasty, tricuspid	27.33	15.63	NA	3.47	46.43	NA	090
33465		A	Replace tricuspid valve	28.79	15.92	NA	3.61	48.32	NA	090
33468		A	Revision of tricuspid valve	30.12	20.51	NA	4.00	54.63	NA	090
33470		A	Revision of pulmonary valve	20.81	13.69	NA	2.81	37.31	NA	090
33471		A	Valvotomy, pulmonary valve	22.25	14.65	NA	3.00	39.90	NA	090
33472		A	Revision of pulmonary valve	22.25	14.77	NA	2.92	39.94	NA	090
33474		A	Revision of pulmonary valve	23.04	13.61	NA	2.84	39.49	NA	090
33475		A	Replacement, pulmonary valve	33.00	19.81	NA	2.64	55.45	NA	090
33476		A	Revision of heart chamber	25.77	14.43	NA	2.40	42.60	NA	090
33478		A	Revision of heart chamber	26.74	15.00	NA	3.56	45.30	NA	090
33496		A	Repair, prosth valve clot	27.25	17.25	NA	3.44	47.94	NA	090
33500		A	Repair heart vessel fistula	25.55	13.93	NA	2.80	42.28	NA	090
33501		A	Repair heart vessel fistula	17.78	10.63	NA	2.05	30.46	NA	090
33502		A	Coronary artery correction	21.04	16.64	NA	2.51	40.19	NA	090
33503		A	Coronary artery graft	21.78	12.32	NA	1.42	35.52	NA	090
33504		A	Coronary artery graft	24.66	17.34	NA	3.04	45.04	NA	090
33505		A	Repair artery w/tunnel	26.84	18.35	NA	1.52	46.71	NA	090
33506		A	Repair artery, translocation	35.50	19.13	NA	3.19	57.82	NA	090
33510		A	CABG, vein, single	29.00	16.12	NA	3.13	48.25	NA	090
33511		A	CABG, vein, two	30.00	16.25	NA	3.34	49.59	NA	090
33512		A	CABG, vein, three	31.80	17.01	NA	3.70	52.51	NA	090
33513		A	CABG, vein, four	32.00	17.09	NA	3.99	53.08	NA	090
33514		A	CABG, vein, five	32.75	17.36	NA	4.37	54.48	NA	090
33516		A	Cabg, vein, six or more	35.00	18.13	NA	4.62	57.75	NA	090
33517		A	CABG, artery-vein, single	2.57	0.86	NA	0.32	3.75	NA	ZZZ
33518		A	CABG, artery-vein, two	4.85	1.63	NA	0.61	7.09	NA	ZZZ
33519		A	CABG, artery-vein, three	7.12	2.39	NA	0.89	10.40	NA	ZZZ
33521		A	CABG, artery-vein, four	9.40	3.15	NA	1.18	13.73	NA	ZZZ
33522		A	CABG, artery-vein, five	11.67	3.91	NA	1.48	17.06	NA	ZZZ
33523		A	Cabg, art-vein, six or more	13.95	4.62	NA	1.78	20.35	NA	ZZZ
33530		A	Coronary artery, bypass/reop	5.86	1.95	NA	0.73	8.54	NA	ZZZ
33533		A	CABG, arterial, single	30.00	16.43	NA	3.24	49.67	NA	090
33534		A	CABG, arterial, two	32.20	16.71	NA	3.63	52.54	NA	090
33535		A	CABG, arterial, three	34.50	17.46	NA	3.97	55.93	NA	090
33536		A	Cabg, arterial, four or more	37.50	15.94	NA	3.29	56.73	NA	090
33542		A	Removal of heart lesion	28.85	17.56	NA	3.61	50.02	NA	090
33545		A	Repair of heart damage	36.78	20.21	NA	4.40	61.39	NA	090
33572		A	Open coronary endarterectomy	4.45	1.50	NA	0.55	6.50	NA	ZZZ
33600		A	Closure of valve	29.51	16.62	NA	2.30	48.43	NA	090
33602		A	Closure of valve	28.54	14.97	NA	2.90	46.41	NA	090
33606		A	Anastomosis/artery-aorta	30.74	15.77	NA	3.59	50.10	NA	090
33608		A	Repair anomaly w/conduit	31.09	18.69	NA	4.17	53.95	NA	090
33610		A	Repair by enlargement	30.61	19.41	NA	4.02	54.04	NA	090
33611		A	Repair double ventricle	34.00	18.98	NA	3.28	56.26	NA	090
33612		A	Repair double ventricle	35.00	20.65	NA	4.44	60.09	NA	090
33615		A	Repair, simple fontan	34.00	21.46	NA	3.15	58.61	NA	090
33617		A	Repair, modified fontan	37.00	21.51	NA	4.09	62.60	NA	090
33619		A	Repair single ventricle	45.00	25.91	NA	4.71	75.62	NA	090
33641		A	Repair heart septum defect	21.39	12.07	NA	2.67	36.13	NA	090
33645		A	Revision of heart veins	24.82	14.37	NA	3.27	42.46	NA	090
33647		A	Repair heart septum defects	28.73	17.60	NA	3.37	49.70	NA	090
33660		A	Repair of heart defects	30.00	17.54	NA	2.82	50.36	NA	090
33665		A	Repair of heart defects	28.60	17.59	NA	3.81	50.00	NA	090
33670		A	Repair of heart chambers	35.00	16.14	NA	2.18	53.32	NA	090
33681		A	Repair heart septum defect	30.61	18.11	NA	3.53	52.25	NA	090
33684		A	Repair heart septum defect	29.65	17.18	NA	3.77	50.60	NA	090
33688		A	Repair heart septum defect	30.62	16.22	NA	3.89	50.73	NA	090
33690		A	Reinforce pulmonary artery	19.55	14.09	NA	2.56	36.20	NA	090
33692		A	Repair of heart defects	30.75	16.68	NA	3.77	51.20	NA	090
33694		A	Repair of heart defects	34.00	18.48	NA	4.27	56.75	NA	090
33697		A	Repair of heart defects	36.00	19.78	NA	4.54	60.32	NA	090
33702		A	Repair of heart defects	26.54	15.95	NA	3.45	45.94	NA	090
33710		A	Repair of heart defects	29.71	15.86	NA	3.85	49.42	NA	090
33720		A	Repair of heart defect	26.56	16.35	NA	3.21	46.12	NA	090
33722		A	Repair of heart defect	28.41	17.16	NA	3.80	49.37	NA	090
33730		A	Repair heart-vein defect(s)	34.25	17.77	NA	2.85	54.87	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
33732		A	Repair heart-vein defect	28.16	15.96	NA	2.78	46.90	NA	090
33735		A	Revision of heart chamber	21.39	13.10	NA	1.12	35.61	NA	090
33736		A	Revision of heart chamber	23.52	15.44	NA	2.70	41.66	NA	090
33737		A	Revision of heart chamber	21.76	14.04	NA	2.93	38.73	NA	090
33750		A	Major vessel shunt	21.41	14.61	NA	1.74	37.76	NA	090
33755		A	Major vessel shunt	21.79	14.05	NA	2.93	38.77	NA	090
33762		A	Major vessel shunt	21.79	11.09	NA	1.59	34.47	NA	090
33764		A	Major vessel shunt & graft	21.79	12.21	NA	1.93	35.93	NA	090
33766		A	Major vessel shunt	22.76	15.50	NA	3.04	41.30	NA	090
33767		A	Major vessel shunt	24.50	15.24	NA	3.14	42.88	NA	090
33770		A	Repair great vessels defect	37.00	19.57	NA	4.49	61.06	NA	090
33771		A	Repair great vessels defect	34.65	17.81	NA	4.67	57.13	NA	090
33774		A	Repair great vessels defect	30.98	16.36	NA	4.18	51.52	NA	090
33775		A	Repair great vessels defect	32.20	16.84	NA	4.34	53.38	NA	090
33776		A	Repair great vessels defect	34.04	17.57	NA	4.58	56.19	NA	090
33777		A	Repair great vessels defect	33.46	17.34	NA	4.51	55.31	NA	090
33778		A	Repair great vessels defect	40.00	19.93	NA	4.83	64.76	NA	090
33779		A	Repair great vessels defect	36.21	18.50	NA	2.40	57.11	NA	090
33780		A	Repair great vessels defect	41.75	24.12	NA	5.21	71.08	NA	090
33781		A	Repair great vessels defect	36.45	18.52	NA	4.91	59.88	NA	090
33786		A	Repair arterial trunk	39.00	20.29	NA	4.69	63.98	NA	090
33788		A	Revision of pulmonary artery	26.62	15.90	NA	3.32	45.84	NA	090
33800		A	Aortic suspension	16.24	10.41	NA	1.11	27.76	NA	090
33802		A	Repair vessel defect	17.66	9.73	NA	1.56	28.95	NA	090
33803		A	Repair vessel defect	19.60	13.91	NA	2.63	36.14	NA	090
33813		A	Repair septal defect	20.65	13.64	NA	2.78	37.07	NA	090
33814		A	Repair septal defect	25.77	17.46	NA	2.52	45.75	NA	090
33820		A	Revise major vessel	16.29	11.56	NA	2.10	29.95	NA	090
33822		A	Revise major vessel	17.32	13.89	NA	2.33	33.54	NA	090
33824		A	Revise major vessel	19.52	12.77	NA	2.61	34.90	NA	090
33840		A	Remove aorta constriction	20.63	12.98	NA	2.36	35.97	NA	090
33845		A	Remove aorta constriction	22.12	14.93	NA	2.90	39.95	NA	090
33851		A	Remove aorta constriction	21.27	13.86	NA	2.86	37.99	NA	090
33852		A	Repair septal defect	23.71	15.17	NA	3.19	42.07	NA	090
33853		A	Repair septal defect	31.72	18.40	NA	4.23	54.35	NA	090
33860		A	Ascending aortic graft	38.00	19.11	NA	4.30	61.41	NA	090
33861		A	Ascending aortic graft	42.00	20.36	NA	4.24	66.60	NA	090
33863		A	Ascending aortic graft	45.00	21.45	NA	4.60	71.05	NA	090
33870		A	Transverse aortic arch graft	44.00	21.05	NA	5.09	70.14	NA	090
33875		A	Thoracic aortic graft	33.06	17.33	NA	4.08	54.47	NA	090
33877		A	Thoracoabdominal graft	42.60	22.98	NA	5.07	70.65	NA	090
33910		A	Remove lung artery emboli	24.59	14.45	NA	3.06	42.10	NA	090
33915		A	Remove lung artery emboli	21.02	12.55	NA	1.20	34.77	NA	090
33916		A	Surgery of great vessel	25.83	14.01	NA	3.04	42.88	NA	090
33917		A	Repair pulmonary artery	24.50	16.12	NA	3.17	43.79	NA	090
33918		A	Repair pulmonary atresia	26.45	14.57	NA	3.42	44.44	NA	090
33919		A	Repair pulmonary atresia	40.00	21.39	NA	3.48	64.87	NA	090
33920		A	Repair pulmonary atresia	31.95	15.83	NA	3.61	51.39	NA	090
33922		A	Transect pulmonary artery	23.52	14.54	NA	2.30	40.36	NA	090
33924		A	Remove pulmonary shunt	5.50	1.86	NA	0.74	8.10	NA	ZZZ
33930		X	Removal of donor heart/lung	0.00	0.00	0.00	0.00	0.00	0.00	XXX
33935		R	Transplantation, heart/lung	60.96	28.42	NA	8.15	97.53	NA	090
33940		X	Removal of donor heart	0.00	0.00	0.00	0.00	0.00	0.00	XXX
33945		R	Transplantation of heart	42.10	21.97	NA	5.42	69.49	NA	090
33960		A	External circulation assist	19.36	6.32	NA	2.14	27.82	NA	XXX
33961		A	External circulation assist	10.93	3.64	NA	1.47	16.04	NA	ZZZ
33968		A	Remove aortic assist device	0.64	0.25	NA	0.07	0.96	NA	000
33970		A	Aortic circulation assist	6.75	2.36	NA	0.70	9.81	NA	000
33971		A	Aortic circulation assist	9.69	7.99	NA	0.97	18.65	NA	090
33973		A	Insert balloon device	9.76	3.40	NA	1.01	14.17	NA	000
33974		A	Remove intra-aortic balloon	14.41	10.78	NA	1.48	26.67	NA	090
33975		A	Implant ventricular device	21.00	5.63	NA	1.72	28.35	NA	XXX
33976		A	Implant ventricular device	23.00	7.71	NA	2.82	33.53	NA	XXX
33977		A	Remove ventricular device	19.29	10.57	NA	2.44	32.30	NA	090
33978		A	Remove ventricular device	21.73	11.51	NA	2.66	35.90	NA	090
33999		C	Cardiac surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
34001		A	Removal of artery clot	12.91	5.88	NA	1.46	20.25	NA	090
34051		A	Removal of artery clot	15.21	7.04	NA	1.90	24.15	NA	090
34101		A	Removal of artery clot	10.00	4.82	NA	1.11	15.93	NA	090
34111		A	Removal of arm artery clot	10.00	4.84	NA	0.85	15.69	NA	090
34151		A	Removal of artery clot	25.00	10.43	NA	1.84	37.27	NA	090
34201		A	Removal of artery clot	10.03	5.12	NA	1.02	16.17	NA	090
34203		A	Removal of leg artery clot	16.50	7.61	NA	1.37	25.48	NA	090
34401		A	Removal of vein clot	25.00	10.42	NA	1.20	36.62	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
34421		A	Removal of vein clot	12.00	5.96	NA	0.95	18.91	NA	090
34451		A	Removal of vein clot	27.00	11.13	NA	1.59	39.72	NA	090
34471		A	Removal of vein clot	10.18	5.02	NA	0.90	16.10	NA	090
34490		A	Removal of vein clot	9.86	6.22	NA	0.73	16.81	NA	090
34501		A	Repair valve, femoral vein	16.00	9.41	NA	1.37	26.78	NA	090
34502		A	Reconstruct vena cava	26.95	11.22	NA	2.99	41.16	NA	090
34510		A	Transposition of vein valve	18.95	10.16	NA	1.60	30.71	NA	090
34520		A	Cross-over vein graft	17.95	9.27	NA	1.41	28.63	NA	090
34530		A	Leg vein fusion	16.64	9.12	NA	2.06	27.82	NA	090
34800		A	Endovasc abdo repair w/tube	20.75	9.65	NA	1.49	31.89	NA	090
34802		A	Endovasc abdo repr w/device	23.00	10.54	NA	1.65	35.19	NA	090
34804		A	Endovasc abdo repr w/device	23.00	10.54	NA	1.65	35.19	NA	090
34808		A	Endovasc abdo occlud device	4.13	1.63	NA	0.29	6.05	NA	ZZZ
34812		A	Xpose for endoprosth, aortic	6.75	2.67	NA	0.49	9.91	NA	000
34813		A	Xpose for endoprosth, femorl	4.80	1.90	NA	0.34	7.04	NA	ZZZ
34820		A	Xpose for endoprosth, iliac	9.75	3.85	NA	0.70	14.30	NA	000
34825		A	Endovasc extend prosth, init	12.00	6.19	NA	0.86	19.05	NA	090
34826		A	Endovasc exten prosth, addl	4.13	1.63	NA	0.29	6.05	NA	ZZZ
34830		A	Open aortic tube prosth repr	32.59	14.68	NA	2.34	49.61	NA	090
34831		A	Open aortoiliac prosth repr	35.34	15.77	NA	2.53	53.64	NA	090
34832		A	Open aortofemor prosth repr	35.34	15.77	NA	2.53	53.64	NA	090
35001		A	Repair defect of artery	19.64	8.49	NA	2.44	30.57	NA	090
35002		A	Repair artery rupture, neck	21.00	9.60	NA	1.82	32.42	NA	090
35005		A	Repair defect of artery	18.12	8.12	NA	1.35	27.59	NA	090
35011		A	Repair defect of artery	18.00	7.55	NA	1.30	26.85	NA	090
35013		A	Repair artery rupture, arm	22.00	8.94	NA	1.91	32.85	NA	090
35021		A	Repair defect of artery	19.65	8.91	NA	1.93	30.49	NA	090
35022		A	Repair artery rupture, chest	23.18	9.48	NA	1.99	34.65	NA	090
35045		A	Repair defect of arm artery	17.57	9.04	NA	1.25	27.86	NA	090
35081		A	Repair defect of artery	28.01	11.65	NA	3.20	42.86	NA	090
35082		A	Repair artery rupture, aorta	38.50	15.04	NA	4.07	57.61	NA	090
35091		A	Repair defect of artery	35.40	14.28	NA	4.09	53.77	NA	090
35092		A	Repair artery rupture, aorta	45.00	17.41	NA	4.31	66.72	NA	090
35102		A	Repair defect of artery	30.76	12.58	NA	3.44	46.78	NA	090
35103		A	Repair artery rupture, groin	40.50	15.75	NA	3.79	60.04	NA	090
35111		A	Repair defect of artery	25.00	10.36	NA	1.81	37.17	NA	090
35112		A	Repair artery rupture,spleen	30.00	11.97	NA	1.95	43.92	NA	090
35121		A	Repair defect of artery	30.00	12.29	NA	2.93	45.22	NA	090
35122		A	Repair artery rupture, belly	35.00	13.81	NA	3.54	52.35	NA	090
35131		A	Repair defect of artery	25.00	10.62	NA	2.11	37.73	NA	090
35132		A	Repair artery rupture, groin	30.00	12.05	NA	2.48	44.53	NA	090
35141		A	Repair defect of artery	20.00	8.67	NA	1.65	30.32	NA	090
35142		A	Repair artery rupture, thigh	23.30	9.81	NA	1.75	34.86	NA	090
35151		A	Repair defect of artery	22.64	9.75	NA	1.93	34.32	NA	090
35152		A	Repair artery rupture, knee	25.62	10.60	NA	1.93	38.15	NA	090
35161		A	Repair defect of artery	18.76	8.92	NA	2.21	29.89	NA	090
35162		A	Repair artery rupture	19.78	9.44	NA	2.21	31.43	NA	090
35180		A	Repair blood vessel lesion	13.62	6.05	NA	1.44	21.11	NA	090
35182		A	Repair blood vessel lesion	30.00	12.49	NA	1.88	44.37	NA	090
35184		A	Repair blood vessel lesion	18.00	7.83	NA	1.34	27.17	NA	090
35188		A	Repair blood vessel lesion	14.28	6.49	NA	1.53	22.30	NA	090
35189		A	Repair blood vessel lesion	28.00	11.66	NA	2.12	41.78	NA	090
35190		A	Repair blood vessel lesion	12.75	5.81	NA	1.33	19.89	NA	090
35201		A	Repair blood vessel lesion	16.14	7.14	NA	1.17	24.45	NA	090
35206		A	Repair blood vessel lesion	13.25	7.64	NA	1.04	21.93	NA	090
35207		A	Repair blood vessel lesion	10.15	9.54	NA	1.15	20.84	NA	090
35211		A	Repair blood vessel lesion	22.12	13.89	NA	2.83	38.84	NA	090
35216		A	Repair blood vessel lesion	18.75	11.66	NA	2.17	32.58	NA	090
35221		A	Repair blood vessel lesion	24.39	10.30	NA	1.79	36.48	NA	090
35226		A	Repair blood vessel lesion	14.50	8.72	NA	0.84	24.06	NA	090
35231		A	Repair blood vessel lesion	20.00	9.35	NA	1.32	30.67	NA	090
35236		A	Repair blood vessel lesion	17.11	9.07	NA	1.19	27.37	NA	090
35241		A	Repair blood vessel lesion	23.12	14.48	NA	2.90	40.50	NA	090
35246		A	Repair blood vessel lesion	26.45	14.54	NA	2.22	43.21	NA	090
35251		A	Repair blood vessel lesion	30.20	12.23	NA	1.87	44.30	NA	090
35256		A	Repair blood vessel lesion	18.36	9.67	NA	1.32	29.35	NA	090
35261		A	Repair blood vessel lesion	17.80	7.57	NA	1.34	26.71	NA	090
35266		A	Repair blood vessel lesion	14.91	8.23	NA	1.16	24.30	NA	090
35271		A	Repair blood vessel lesion	22.12	13.34	NA	2.77	38.23	NA	090
35276		A	Repair blood vessel lesion	24.25	13.98	NA	2.37	40.60	NA	090
35281		A	Repair blood vessel lesion	28.00	11.70	NA	1.82	41.52	NA	090
35286		A	Repair blood vessel lesion	16.16	8.76	NA	1.36	26.28	NA	090
35301		A	Rechanneling of artery	18.70	8.90	NA	2.23	29.83	NA	090
35311		A	Rechanneling of artery	27.00	11.11	NA	2.75	40.86	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
35321		A	Rechanneling of artery	16.00	6.86	NA	1.36	24.22	NA	090
35331		A	Rechanneling of artery	26.20	11.03	NA	2.71	39.94	NA	090
35341		A	Rechanneling of artery	25.11	10.64	NA	2.87	38.62	NA	090
35351		A	Rechanneling of artery	23.00	9.86	NA	2.29	35.15	NA	090
35355		A	Rechanneling of artery	18.50	8.29	NA	1.80	28.59	NA	090
35361		A	Rechanneling of artery	28.20	11.63	NA	2.66	42.49	NA	090
35363		A	Rechanneling of artery	30.20	12.17	NA	2.77	45.14	NA	090
35371		A	Rechanneling of artery	14.72	6.75	NA	1.32	22.79	NA	090
35372		A	Rechanneling of artery	18.00	7.91	NA	1.53	27.44	NA	090
35381		A	Rechanneling of artery	15.81	7.38	NA	1.80	24.99	NA	090
35390		A	Reoperation, carotid add-on	3.19	1.11	NA	0.38	4.68	NA	ZZZ
35400		A	Angioscopy	3.00	1.05	NA	0.34	4.39	NA	ZZZ
35450		A	Repair arterial blockage	10.07	3.76	NA	0.84	14.67	NA	000
35452		A	Repair arterial blockage	6.91	3.20	NA	0.76	10.87	NA	000
35454		A	Repair arterial blockage	6.04	2.85	NA	0.67	9.56	NA	000
35456		A	Repair arterial blockage	7.35	3.30	NA	0.82	11.47	NA	000
35458		A	Repair arterial blockage	9.49	4.01	NA	1.09	14.59	NA	000
35459		A	Repair arterial blockage	8.63	3.68	NA	0.96	13.27	NA	000
35460		A	Repair venous blockage	6.04	2.71	NA	0.66	9.41	NA	000
35470		A	Repair arterial blockage	8.63	4.00	NA	0.50	13.13	NA	000
35471		A	Repair arterial blockage	10.07	4.67	NA	0.50	15.24	NA	000
35472		A	Repair arterial blockage	6.91	3.39	NA	0.39	10.69	NA	000
35473		A	Repair arterial blockage	6.04	3.05	NA	0.34	9.43	NA	000
35474		A	Repair arterial blockage	7.36	3.54	NA	0.40	11.30	NA	000
35475		R	Repair arterial blockage	9.49	4.23	NA	0.47	14.19	NA	000
35476		A	Repair venous blockage	6.04	2.97	NA	0.27	9.28	NA	000
35480		A	Atherectomy, open	11.08	4.61	NA	1.13	16.82	NA	000
35481		A	Atherectomy, open	7.61	3.48	NA	0.84	11.93	NA	000
35482		A	Atherectomy, open	6.65	3.04	NA	0.75	10.44	NA	000
35483		A	Atherectomy, open	8.10	3.61	NA	0.81	12.52	NA	000
35484		A	Atherectomy, open	10.44	4.32	NA	1.13	15.89	NA	000
35485		A	Atherectomy, open	9.49	4.22	NA	1.06	14.77	NA	000
35490		A	Atherectomy, percutaneous	11.08	4.95	NA	0.55	16.58	NA	000
35491		A	Atherectomy, percutaneous	7.61	3.54	NA	0.49	11.64	NA	000
35492		A	Atherectomy, percutaneous	6.65	3.30	NA	0.43	10.38	NA	000
35493		A	Atherectomy, percutaneous	8.10	3.93	NA	0.47	12.50	NA	000
35494		A	Atherectomy, percutaneous	10.44	4.63	NA	0.48	15.55	NA	000
35495		A	Atherectomy, percutaneous	9.49	4.58	NA	0.51	14.58	NA	000
35500		A	Harvest vein for bypass	6.45	2.03	NA	0.63	9.11	NA	ZZZ
35501		A	Artery bypass graft	19.19	8.17	NA	2.33	29.69	NA	090
35506		A	Artery bypass graft	19.67	8.29	NA	2.33	30.29	NA	090
35507		A	Artery bypass graft	19.67	8.27	NA	2.27	30.21	NA	090
35508		A	Artery bypass graft	18.65	7.99	NA	2.34	28.98	NA	090
35509		A	Artery bypass graft	18.07	7.75	NA	2.12	27.94	NA	090
35511		A	Artery bypass graft	21.20	8.89	NA	1.74	31.83	NA	090
35515		A	Artery bypass graft	18.65	8.01	NA	2.26	28.92	NA	090
35516		A	Artery bypass graft	16.32	7.05	NA	1.88	25.25	NA	090
35518		A	Artery bypass graft	21.20	8.71	NA	1.78	31.69	NA	090
35521		A	Artery bypass graft	22.20	9.51	NA	1.82	33.53	NA	090
35526		A	Artery bypass graft	29.95	12.21	NA	2.18	44.34	NA	090
35531		A	Artery bypass graft	36.20	14.49	NA	2.91	53.60	NA	090
35533		A	Artery bypass graft	28.00	11.56	NA	2.35	41.91	NA	090
35536		A	Artery bypass graft	31.70	12.90	NA	2.62	47.22	NA	090
35541		A	Artery bypass graft	25.80	10.99	NA	2.74	39.53	NA	090
35546		A	Artery bypass graft	25.54	10.67	NA	2.84	39.05	NA	090
35548		A	Artery bypass graft	21.57	9.21	NA	2.45	33.23	NA	090
35549		A	Artery bypass graft	23.35	9.97	NA	2.77	36.09	NA	090
35551		A	Artery bypass graft	26.67	11.21	NA	3.19	41.07	NA	090
35556		A	Artery bypass graft	21.76	9.44	NA	2.48	33.68	NA	090
35558		A	Artery bypass graft	21.20	9.20	NA	1.58	31.98	NA	090
35560		A	Artery bypass graft	32.00	13.04	NA	2.73	47.77	NA	090
35563		A	Artery bypass graft	24.20	10.33	NA	1.68	36.21	NA	090
35565		A	Artery bypass graft	23.20	9.88	NA	1.71	34.79	NA	090
35566		A	Artery bypass graft	26.92	13.89	NA	3.02	43.83	NA	090
35571		A	Artery bypass graft	24.06	12.17	NA	2.14	38.37	NA	090
35582		A	Vein bypass graft	27.13	11.40	NA	3.11	41.64	NA	090
35583		A	Vein bypass graft	22.37	10.60	NA	2.53	35.50	NA	090
35585		A	Vein bypass graft	28.39	14.59	NA	3.21	46.19	NA	090
35587		A	Vein bypass graft	24.75	12.80	NA	2.17	39.72	NA	090
35600		A	Harvest artery for cabg	4.95	1.96	NA	0.54	7.45	NA	ZZZ
35601		A	Artery bypass graft	17.50	7.50	NA	2.08	27.08	NA	090
35606		A	Artery bypass graft	18.71	7.91	NA	2.17	28.79	NA	090
35612		A	Artery bypass graft	15.76	6.84	NA	1.72	24.32	NA	090
35616		A	Artery bypass graft	15.70	7.02	NA	1.84	24.56	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
35621		A	Artery bypass graft	20.00	8.87	NA	1.68	30.55	NA	090
35623		A	Bypass graft, not vein	24.00	10.22	NA	1.91	36.13	NA	090
35626		A	Artery bypass graft	27.75	11.13	NA	2.89	41.77	NA	090
35631		A	Artery bypass graft	34.00	13.77	NA	2.83	50.60	NA	090
35636		A	Artery bypass graft	29.50	12.31	NA	2.37	44.18	NA	090
35641		A	Artery bypass graft	24.57	10.47	NA	2.83	37.87	NA	090
35642		A	Artery bypass graft	17.98	8.52	NA	1.84	28.34	NA	090
35645		A	Artery bypass graft	17.47	7.98	NA	1.91	27.36	NA	090
35646		A	Artery bypass graft	25.81	10.89	NA	2.98	39.68	NA	090
35650		A	Artery bypass graft	19.00	7.91	NA	1.64	28.55	NA	090
35651		A	Artery bypass graft	25.04	10.68	NA	2.53	38.25	NA	090
35654		A	Artery bypass graft	25.00	10.57	NA	2.10	37.67	NA	090
35656		A	Artery bypass graft	19.53	8.44	NA	2.21	30.18	NA	090
35661		A	Artery bypass graft	19.00	8.26	NA	1.50	28.76	NA	090
35663		A	Artery bypass graft	22.00	9.64	NA	1.55	33.19	NA	090
35665		A	Artery bypass graft	21.00	9.17	NA	1.76	31.93	NA	090
35666		A	Artery bypass graft	22.19	11.95	NA	2.19	36.33	NA	090
35671		A	Artery bypass graft	19.33	10.48	NA	1.68	31.49	NA	090
35681		A	Composite bypass graft	1.60	2.34	NA	0.18	4.12	NA	ZZZ
35682		A	Composite bypass graft	7.20	2.51	NA	0.83	10.54	NA	ZZZ
35683		A	Composite bypass graft	8.50	2.96	NA	0.98	12.44	NA	ZZZ
35691		A	Arterial transposition	18.05	7.66	NA	2.06	27.77	NA	090
35693		A	Arterial transposition	15.36	6.82	NA	1.80	23.98	NA	090
35694		A	Arterial transposition	19.16	8.12	NA	2.13	29.41	NA	090
35695		A	Arterial transposition	19.16	8.01	NA	2.19	29.36	NA	090
35700		A	Reoperation, bypass graft	3.08	2.96	NA	0.36	6.40	NA	ZZZ
35701		A	Exploration, carotid artery	8.50	4.61	NA	0.64	13.75	NA	090
35721		A	Exploration, femoral artery	7.18	5.16	NA	0.59	12.93	NA	090
35741		A	Exploration popliteal artery	8.00	5.37	NA	0.60	13.97	NA	090
35761		A	Exploration of artery/vein	5.37	4.46	NA	0.60	10.43	NA	090
35800		A	Explore neck vessels	7.02	3.96	NA	0.79	11.77	NA	090
35820		A	Explore chest vessels	12.88	4.33	NA	1.61	18.82	NA	090
35840		A	Explore abdominal vessels	9.77	5.19	NA	1.06	16.02	NA	090
35860		A	Explore limb vessels	5.55	3.59	NA	0.63	9.77	NA	090
35870		A	Repair vessel graft defect	22.17	10.21	NA	2.47	34.85	NA	090
35875		A	Removal of clot in graft	10.13	6.55	NA	0.97	17.65	NA	090
35876		A	Removal of clot in graft	17.00	9.07	NA	1.88	27.95	NA	090
35879		A	Revise graft w/vein	16.00	8.23	NA	1.35	25.58	NA	090
35881		A	Revise graft w/vein	18.00	9.21	NA	1.44	28.65	NA	090
35901		A	Excision, graft, neck	8.19	5.68	NA	0.90	14.77	NA	090
35903		A	Excision, graft, extremity	9.39	8.15	NA	1.03	18.57	NA	090
35905		A	Excision, graft, thorax	31.25	15.71	NA	2.15	49.11	NA	090
35907		A	Excision, graft, abdomen	35.00	14.91	NA	2.17	52.08	NA	090
36000		A	Place needle in vein	0.18	0.05	0.64	0.01	0.24	0.83	XXX
36005		A	Injection, venography	0.95	0.33	15.92	0.04	1.32	16.91	000
36010		A	Place catheter in vein	2.43	0.87	NA	0.16	3.46	NA	XXX
36011		A	Place catheter in vein	3.14	1.13	NA	0.17	4.44	NA	XXX
36012		A	Place catheter in vein	3.52	1.26	NA	0.17	4.95	NA	XXX
36013		A	Place catheter in artery	2.52	0.77	NA	0.17	3.46	NA	XXX
36014		A	Place catheter in artery	3.02	1.09	NA	0.14	4.25	NA	XXX
36015		A	Place catheter in artery	3.52	1.26	NA	0.16	4.94	NA	XXX
36100		A	Establish access to artery	3.02	1.20	NA	0.18	4.40	NA	XXX
36120		A	Establish access to artery	2.01	0.71	NA	0.11	2.83	NA	XXX
36140		A	Establish access to artery	2.01	0.71	NA	0.12	2.84	NA	XXX
36145		A	Artery to vein shunt	2.01	0.73	NA	0.10	2.84	NA	XXX
36160		A	Establish access to aorta	2.52	0.93	NA	0.20	3.65	NA	XXX
36200		A	Place catheter in aorta	3.02	1.08	NA	0.15	4.25	NA	XXX
36215		A	Place catheter in artery	4.68	1.69	NA	0.22	6.59	NA	XXX
36216		A	Place catheter in artery	5.28	1.90	NA	0.24	7.42	NA	XXX
36217		A	Place catheter in artery	6.30	2.31	NA	0.32	8.93	NA	XXX
36218		A	Place catheter in artery	1.01	0.40	NA	0.05	1.46	NA	ZZZ
36245		A	Place catheter in artery	4.68	1.79	NA	0.23	6.70	NA	XXX
36246		A	Place catheter in artery	5.28	1.92	NA	0.26	7.46	NA	XXX
36247		A	Place catheter in artery	6.30	2.26	NA	0.32	8.88	NA	XXX
36248		A	Place catheter in artery	1.01	0.40	NA	0.06	1.47	NA	ZZZ
36260		A	Insertion of infusion pump	9.71	5.58	NA	1.00	16.29	NA	090
36261		A	Revision of infusion pump	5.45	3.47	NA	0.50	9.42	NA	090
36262		A	Removal of infusion pump	4.02	2.52	NA	0.43	6.97	NA	090
36299		C	Vessel injection procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
36400		A	Drawing blood	0.18	0.05	0.64	0.01	0.24	0.83	XXX
36405		A	Drawing blood	0.18	0.06	0.57	0.01	0.25	0.76	XXX
36406		A	Drawing blood	0.18	0.05	0.80	0.01	0.24	0.99	XXX
36410		A	Drawing blood	0.18	0.05	0.49	0.01	0.24	0.68	XXX
36415		I	Drawing blood	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
36420		A	Establish access to vein	1.01	0.31	NA	0.09	1.41	NA	XXX
36425		A	Establish access to vein	0.76	0.17	3.39	0.05	0.98	4.20	XXX
36430		A	Blood transfusion service	0.00	NA	0.99	0.05	NA	1.04	XXX
36440		A	Blood transfusion service	1.03	0.29	NA	0.08	1.40	NA	XXX
36450		A	Exchange transfusion service	2.23	0.74	NA	0.16	3.13	NA	XXX
36455		A	Exchange transfusion service	2.43	0.96	NA	0.10	3.49	NA	XXX
36460		A	Transfusion service, fetal	6.59	2.38	NA	0.56	9.53	NA	XXX
36468		R	Injection(s), spider veins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
36469		R	Injection(s), spider veins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
36470		A	Injection therapy of vein	1.09	0.39	2.64	0.10	1.58	3.83	010
36471		A	Injection therapy of veins	1.57	0.58	3.25	0.15	2.30	4.97	010
36481		A	Insertion of catheter, vein	6.99	2.85	NA	0.40	10.24	NA	000
36488		A	Insertion of catheter, vein	1.35	0.74	NA	0.09	2.18	NA	000
36489		A	Insertion of catheter, vein	2.50	1.06	3.84	0.08	3.64	6.42	000
36490		A	Insertion of catheter, vein	1.67	0.85	NA	0.17	2.69	NA	000
36491		A	Insertion of catheter, vein	1.43	0.76	NA	0.13	2.32	NA	000
36493		A	Repositioning of cvc	1.21	0.87	NA	0.06	2.14	NA	000
36500		A	Insertion of catheter, vein	3.52	1.30	NA	0.14	4.96	NA	000
36510		A	Insertion of catheter, vein	1.09	0.63	NA	0.06	1.78	NA	000
36520		A	Plasma and/or cell exchange	1.74	1.00	NA	0.06	2.80	NA	000
36521		A	Apheresis w/ adsorp/reinfuse	1.74	1.00	NA	0.06	2.80	NA	000
36522		A	Photopheresis	1.67	1.13	6.29	0.07	2.87	8.03	000
36530		R	Insertion of infusion pump	6.20	3.70	NA	0.56	10.46	NA	010
36531		R	Revision of infusion pump	4.87	3.26	NA	0.44	8.57	NA	010
36532		R	Removal of infusion pump	3.30	1.56	NA	0.34	5.20	NA	010
36533		A	Insertion of access device	5.32	3.45	4.31	0.49	9.26	10.12	010
36534		A	Revision of access device	2.80	1.50	NA	0.19	4.49	NA	010
36535		A	Removal of access device	2.27	1.85	2.84	0.21	4.33	5.32	010
36540		B	Collect blood venous device	0.00	0.00	0.00	0.00	0.00	0.00	XXX
36550		A	Declot vascular device	0.00	NA	0.37	0.31	NA	0.68	XXX
36600		A	Withdrawal of arterial blood	0.32	0.09	0.43	0.02	0.43	0.77	XXX
36620		A	Insertion catheter, artery	1.15	0.25	NA	0.06	1.46	NA	000
36625		A	Insertion catheter, artery	2.11	0.57	NA	0.16	2.84	NA	000
36640		A	Insertion catheter, artery	2.10	0.74	NA	0.18	3.02	NA	000
36660		A	Insertion catheter, artery	1.40	0.47	NA	0.08	1.95	NA	000
36680		A	Insert needle, bone cavity	1.20	0.60	NA	0.08	1.88	NA	000
36800		A	Insertion of cannula	2.43	1.62	NA	0.17	4.22	NA	000
36810		A	Insertion of cannula	3.97	2.34	NA	0.40	6.71	NA	000
36815		A	Insertion of cannula	2.62	1.73	NA	0.26	4.61	NA	000
36819		A	Av fusion by basilic vein	14.00	6.55	NA	1.53	22.08	NA	090
36821		A	Av fusion direct any site	8.93	5.04	NA	0.97	14.94	NA	090
36822		A	Insertion of cannula(s)	5.42	6.99	NA	0.63	13.04	NA	090
36823		A	Insertion of cannula(s)	21.00	10.55	NA	2.18	33.73	NA	090
36825		A	Artery-vein graft	9.84	5.61	NA	1.09	16.54	NA	090
36830		A	Artery-vein graft	12.00	6.16	NA	1.32	19.48	NA	090
36831		A	Av fistula excision, open	8.00	4.02	NA	0.79	12.81	NA	090
36832		A	Av fistula revision, open	10.50	5.62	NA	1.13	17.25	NA	090
36833		A	Av fistula revision	11.95	6.10	NA	1.29	19.34	NA	090
36834		A	Repair A-V aneurysm	9.93	3.84	NA	1.06	14.83	NA	090
36835		A	Artery to vein shunt	7.15	4.47	NA	0.80	12.42	NA	090
36860		A	External cannula declotting	2.01	1.68	2.36	0.10	3.79	4.47	000
36861		A	Cannula declotting	2.52	1.84	NA	0.14	4.50	NA	000
36870		A	Av fistula revision, open	5.16	2.49	31.10	0.40	8.05	36.66	090
37140		A	Revision of circulation	23.60	10.54	NA	1.21	35.35	NA	090
37145		A	Revision of circulation	24.61	10.87	NA	2.48	37.96	NA	090
37160		A	Revision of circulation	21.60	9.42	NA	2.16	33.18	NA	090
37180		A	Revision of circulation	24.61	10.79	NA	2.63	38.03	NA	090
37181		A	Splice spleen/kidney veins	26.68	11.10	NA	2.67	40.45	NA	090
37195		A	Thrombolytic therapy, stroke	0.00	NA	7.93	0.38	NA	8.31	XXX
37200		A	Transcatheter biopsy	4.56	1.62	NA	0.19	6.37	NA	000
37201		A	Transcatheter therapy infuse	5.00	2.62	NA	0.24	7.86	NA	000
37202		A	Transcatheter therapy infuse	5.68	3.23	NA	0.38	9.29	NA	000
37203		A	Transcatheter retrieval	5.03	2.65	NA	0.23	7.91	NA	000
37204		A	Transcatheter occlusion	18.14	6.20	NA	0.85	25.19	NA	000
37205		A	Transcatheter stent	8.28	3.92	NA	0.43	12.63	NA	000
37206		A	Transcatheter stent add-on	4.13	1.56	NA	0.22	5.91	NA	ZZZ
37207		A	Transcatheter stent	8.28	3.62	NA	0.89	12.79	NA	000
37208		A	Transcatheter stent add-on	4.13	1.47	NA	0.44	6.04	NA	ZZZ
37209		A	Exchange arterial catheter	2.27	0.83	NA	0.11	3.21	NA	000
37250		A	Iv us first vessel add-on	2.10	0.81	NA	0.17	3.08	NA	ZZZ
37251		A	Iv us each add vessel add-on	1.60	0.61	NA	0.14	2.35	NA	ZZZ
37565		A	Ligation of neck vein	10.88	5.13	NA	0.45	16.46	NA	090
37600		A	Ligation of neck artery	11.25	6.41	NA	0.40	18.06	NA	090
37605		A	Ligation of neck artery	13.11	6.61	NA	0.77	20.49	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
37606		A	Ligation of neck artery	6.28	3.72	NA	0.79	10.79	NA	090
37607		A	Ligation of a-v fistula	6.16	3.71	NA	0.67	10.54	NA	090
37609		A	Temporal artery procedure	3.00	2.53	6.59	0.21	5.74	9.80	010
37615		A	Ligation of neck artery	5.73	3.65	NA	0.57	9.95	NA	090
37616		A	Ligation of chest artery	16.49	10.83	NA	1.93	29.25	NA	090
37617		A	Ligation of abdomen artery	22.06	9.60	NA	1.69	33.35	NA	090
37618		A	Ligation of extremity artery	4.84	3.55	NA	0.54	8.93	NA	090
37620		A	Revision of major vein	10.56	5.50	NA	0.75	16.81	NA	090
37650		A	Revision of major vein	7.80	4.66	NA	0.56	13.02	NA	090
37660		A	Revision of major vein	21.00	9.33	NA	1.17	31.50	NA	090
37700		A	Revise leg vein	3.73	3.20	NA	0.40	7.33	NA	090
37720		A	Removal of leg vein	5.66	3.71	NA	0.61	9.98	NA	090
37730		A	Removal of leg veins	7.33	4.59	NA	0.77	12.69	NA	090
37735		A	Removal of leg veins/lesion	10.53	5.84	NA	1.17	17.54	NA	090
37760		A	Revision of leg veins	10.47	5.79	NA	1.11	17.37	NA	090
37780		A	Revision of leg vein	3.84	2.93	NA	0.41	7.18	NA	090
37785		A	Revision secondary varicosit	3.84	2.89	6.94	0.41	7.14	11.19	090
37788		A	Revascularization, penis	22.01	12.79	NA	1.35	36.15	NA	090
37790		A	Penile venous occlusion	8.34	7.01	NA	0.63	15.98	NA	090
37799		C	Vascular surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
38100		A	Removal of spleen, total	14.50	6.64	NA	1.30	22.44	NA	090
38101		A	Removal of spleen, partial	15.31	7.00	NA	1.38	23.69	NA	090
38102		A	Removal of spleen, total	4.80	1.72	NA	0.49	7.01	NA	ZZZ
38115		A	Repair of ruptured spleen	15.82	7.14	NA	1.40	24.36	NA	090
38120		A	Laparoscopy, splenectomy	17.00	7.48	NA	1.73	26.21	NA	090
38129		C	Laparoscope proc, spleen	0.00	0.00	0.00	0.00	0.00	0.00	YYY
38200		A	Injection for spleen x-ray	2.64	0.96	NA	0.12	3.72	NA	000
38230		R	Bone marrow collection	4.54	2.34	NA	0.25	7.13	NA	010
38231		R	Stem cell collection	1.50	0.60	NA	0.05	2.15	NA	000
38240		R	Bone marrow/stem transplant	2.24	0.85	NA	0.08	3.17	NA	XXX
38241		R	Bone marrow/stem transplant	2.24	0.84	NA	0.08	3.16	NA	XXX
38300		A	Drainage, lymph node lesion	1.99	2.63	4.62	0.15	4.77	6.76	010
38305		A	Drainage, lymph node lesion	6.00	6.37	8.67	0.36	12.73	15.03	090
38308		A	Incision of lymph channels	6.45	5.65	NA	0.51	12.61	NA	090
38380		A	Thoracic duct procedure	7.46	7.38	NA	0.68	15.52	NA	090
38381		A	Thoracic duct procedure	12.88	9.76	NA	1.58	24.22	NA	090
38382		A	Thoracic duct procedure	10.08	9.46	NA	1.08	20.62	NA	090
38500		A	Biopsy/removal, lymph nodes	3.75	2.57	2.98	0.28	6.60	7.01	010
38505		A	Needle biopsy, lymph nodes	1.14	1.16	3.06	0.09	2.39	4.29	000
38510		A	Biopsy/removal, lymph nodes	6.43	5.38	NA	0.38	12.19	NA	090
38520		A	Biopsy/removal, lymph nodes	6.67	5.56	NA	0.52	12.75	NA	090
38525		A	Biopsy/removal, lymph nodes	6.07	4.44	NA	0.48	10.99	NA	090
38530		A	Biopsy/removal, lymph nodes	7.98	5.69	NA	0.63	14.30	NA	090
38542		A	Explore deep node(s), neck	5.91	5.90	NA	0.50	12.31	NA	090
38550		A	Removal, neck/armpit lesion	6.92	4.92	NA	0.69	12.53	NA	090
38555		A	Removal, neck/armpit lesion	14.14	10.70	NA	1.46	26.30	NA	090
38562		A	Removal, pelvic lymph nodes	10.49	6.59	NA	0.97	18.05	NA	090
38564		A	Removal, abdomen lymph nodes	10.83	6.42	NA	1.06	18.31	NA	090
38570		A	Laparoscopy, lymph node biop	9.25	4.53	NA	0.89	14.67	NA	010
38571		A	Laparoscopy, lymphadenectomy	12.38	5.53	NA	0.80	18.71	NA	010
38572		A	Laparoscopy, lymphadenectomy	16.59	7.58	NA	1.32	25.49	NA	010
38589		C	Laparoscope proc, lymphatic	0.00	0.00	0.00	0.00	0.00	0.00	YYY
38700		A	Removal of lymph nodes, neck	8.24	13.31	NA	0.60	22.15	NA	090
38720		A	Removal of lymph nodes, neck	13.61	15.74	NA	1.03	30.38	NA	090
38724		A	Removal of lymph nodes, neck	14.54	16.21	NA	1.10	31.85	NA	090
38740		A	Remove armpit lymph nodes	10.02	5.87	NA	0.69	16.58	NA	090
38745		A	Remove armpit lymph nodes	13.00	8.24	NA	0.90	22.14	NA	090
38746		A	Remove thoracic lymph nodes	4.89	1.65	NA	0.55	7.09	NA	ZZZ
38747		A	Remove abdominal lymph nodes	4.89	1.75	NA	0.50	7.14	NA	ZZZ
38760		A	Remove groin lymph nodes	12.94	7.26	NA	0.88	21.08	NA	090
38765		A	Remove groin lymph nodes	19.98	11.36	NA	1.50	32.84	NA	090
38770		A	Remove pelvis lymph nodes	13.23	6.94	NA	0.94	21.11	NA	090
38780		A	Remove abdomen lymph nodes	16.59	9.49	NA	1.60	27.68	NA	090
38790		A	Inject for lymphatic x-ray	1.29	0.46	37.13	0.09	1.84	38.51	000
38792		A	Identify sentinel node	0.52	0.19	NA	0.04	0.75	NA	000
38794		A	Access thoracic lymph duct	4.45	1.67	NA	0.17	6.29	NA	090
38999		C	Blood/lymph system procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
39000		A	Exploration of chest	6.10	7.52	NA	0.73	14.35	NA	090
39010		A	Exploration of chest	11.79	9.80	NA	1.46	23.05	NA	090
39200		A	Removal chest lesion	13.62	10.17	NA	1.65	25.44	NA	090
39220		A	Removal chest lesion	17.42	11.54	NA	2.10	31.06	NA	090
39400		A	Visualization of chest	5.61	7.22	NA	0.69	13.52	NA	010
39499		C	Chest procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
39501		A	Repair diaphragm laceration	13.19	7.76	NA	1.38	22.33	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
39502		A	Repair paraesophageal hernia	16.33	8.38	NA	1.68	26.39	NA	090
39503		A	Repair of diaphragm hernia	34.85	15.15	NA	3.52	53.52	NA	090
39520		A	Repair of diaphragm hernia	16.10	9.81	NA	1.83	27.74	NA	090
39530		A	Repair of diaphragm hernia	15.41	8.61	NA	1.66	25.68	NA	090
39531		A	Repair of diaphragm hernia	16.42	9.33	NA	1.83	27.58	NA	090
39540		A	Repair of diaphragm hernia	13.32	7.83	NA	1.38	22.53	NA	090
39541		A	Repair of diaphragm hernia	14.41	8.06	NA	1.52	23.99	NA	090
39545		A	Revision of diaphragm	13.37	9.52	NA	1.55	24.44	NA	090
39560		A	Resect diaphragm, simple	12.00	7.91	NA	1.35	21.26	NA	090
39561		A	Resect diaphragm, complex	17.50	9.85	NA	1.97	29.32	NA	090
39599		C	Diaphragm surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
40490		A	Biopsy of lip	1.22	0.62	1.61	0.06	1.90	2.89	000
40500		A	Partial excision of lip	4.28	5.61	5.65	0.31	10.20	10.24	090
40510		A	Partial excision of lip	4.70	6.46	6.70	0.38	11.54	11.78	090
40520		A	Partial excision of lip	4.67	6.93	7.81	0.42	12.02	12.90	090
40525		A	Reconstruct lip with flap	7.55	8.40	NA	0.68	16.63	NA	090
40527		A	Reconstruct lip with flap	9.13	9.25	NA	0.82	19.20	NA	090
40530		A	Partial removal of lip	5.40	6.34	6.49	0.47	12.21	12.36	090
40650		A	Repair lip	3.64	4.55	5.53	0.31	8.50	9.48	090
40652		A	Repair lip	4.26	6.53	6.53	0.39	11.18	11.18	090
40654		A	Repair lip	5.31	7.67	7.86	0.48	13.46	13.65	090
40700		A	Repair cleft lip/nasal	12.79	10.51	NA	0.93	24.23	NA	090
40701		A	Repair cleft lip/nasal	15.85	10.01	NA	1.36	27.22	NA	090
40702		A	Repair cleft lip/nasal	13.04	9.40	NA	1.01	23.45	NA	090
40720		A	Repair cleft lip/nasal	13.55	12.69	NA	1.31	27.55	NA	090
40761		A	Repair cleft lip/nasal	14.72	11.77	NA	1.41	27.90	NA	090
40799		C	Lip surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
40800		A	Drainage of mouth lesion	1.17	0.46	1.93	0.09	1.72	3.19	010
40801		A	Drainage of mouth lesion	2.53	1.90	2.45	0.18	4.61	5.16	010
40804		A	Removal, foreign body, mouth	1.24	2.15	2.58	0.09	3.48	3.91	010
40805		A	Removal, foreign body, mouth	2.69	2.70	3.10	0.17	5.56	5.96	010
40806		A	Incision of lip fold	0.31	0.88	0.88	0.02	1.21	1.21	000
40808		A	Biopsy of mouth lesion	0.96	2.05	2.05	0.07	3.08	3.08	010
40810		A	Excision of mouth lesion	1.31	2.34	2.67	0.09	3.74	4.07	010
40812		A	Excise/repair mouth lesion	2.31	2.86	2.89	0.17	5.34	5.37	010
40814		A	Excise/repair mouth lesion	3.42	4.07	4.07	0.26	7.75	7.75	090
40816		A	Excision of mouth lesion	3.67	4.39	4.39	0.27	8.33	8.33	090
40818		A	Excise oral mucosa for graft	2.41	4.03	4.03	0.14	6.58	6.58	090
40819		A	Excise lip or cheek fold	2.41	3.54	3.54	0.17	6.12	6.12	090
40820		A	Treatment of mouth lesion	1.28	2.15	2.33	0.08	3.51	3.69	010
40830		A	Repair mouth laceration	1.76	2.39	2.50	0.14	4.29	4.40	010
40831		A	Repair mouth laceration	2.46	2.84	2.84	0.21	5.51	5.51	010
40840		R	Reconstruction of mouth	8.73	6.22	6.22	0.79	15.74	15.74	090
40842		R	Reconstruction of mouth	8.73	5.98	5.98	0.65	15.36	15.36	090
40843		R	Reconstruction of mouth	12.10	8.48	8.48	0.84	21.42	21.42	090
40844		R	Reconstruction of mouth	16.01	8.37	8.93	1.63	26.01	26.57	090
40845		R	Reconstruction of mouth	18.58	10.56	10.56	1.47	30.61	30.61	090
40899		C	Mouth surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
41000		A	Drainage of mouth lesion	1.30	1.53	2.36	0.09	2.92	3.75	010
41005		A	Drainage of mouth lesion	1.26	1.24	2.11	0.09	2.59	3.46	010
41006		A	Drainage of mouth lesion	3.24	3.40	3.51	0.25	6.89	7.00	090
41007		A	Drainage of mouth lesion	3.10	3.03	3.34	0.22	6.35	6.66	090
41008		A	Drainage of mouth lesion	3.37	3.18	3.59	0.24	6.79	7.20	090
41009		A	Drainage of mouth lesion	3.59	3.19	3.60	0.25	7.03	7.44	090
41010		A	Incision of tongue fold	1.06	2.97	2.97	0.06	4.09	4.09	010
41015		A	Drainage of mouth lesion	3.96	3.17	4.36	0.29	7.42	8.61	090
41016		A	Drainage of mouth lesion	4.07	3.39	4.17	0.28	7.74	8.52	090
41017		A	Drainage of mouth lesion	4.07	3.30	4.04	0.32	7.69	8.43	090
41018		A	Drainage of mouth lesion	5.10	3.88	4.55	0.35	9.33	10.00	090
41100		A	Biopsy of tongue	1.63	2.54	2.59	0.12	4.29	4.34	010
41105		A	Biopsy of tongue	1.42	2.43	2.43	0.10	3.95	3.95	010
41108		A	Biopsy of floor of mouth	1.05	2.20	2.29	0.08	3.33	3.42	010
41110		A	Excision of tongue lesion	1.51	2.47	3.04	0.11	4.09	4.66	010
41112		A	Excision of tongue lesion	2.73	3.50	3.50	0.20	6.43	6.43	090
41113		A	Excision of tongue lesion	3.19	3.48	3.48	0.23	6.90	6.90	090
41114		A	Excision of tongue lesion	8.47	6.36	NA	0.64	15.47	NA	090
41115		A	Excision of tongue fold	1.74	2.33	2.33	0.13	4.20	4.20	010
41116		A	Excision of mouth lesion	2.44	3.38	3.38	0.17	5.99	5.99	090
41120		A	Partial removal of tongue	9.77	8.68	NA	0.70	19.15	NA	090
41130		A	Partial removal of tongue	11.15	9.53	NA	0.81	21.49	NA	090
41135		A	Tongue and neck surgery	23.09	15.92	NA	1.66	40.67	NA	090
41140		A	Removal of tongue	25.50	18.11	NA	1.85	45.46	NA	090
41145		A	Tongue removal, neck surgery	30.06	21.54	NA	2.11	53.71	NA	090
41150		A	Tongue, mouth, jaw surgery	23.04	17.08	NA	1.67	41.79	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
41153		A	Tongue, mouth, neck surgery	23.77	17.84	NA	1.71	43.32	NA	090
41155		A	Tongue, jaw, & neck surgery	27.72	19.87	NA	2.02	49.61	NA	090
41250		A	Repair tongue laceration	1.91	1.63	2.82	0.15	3.69	4.88	010
41251		A	Repair tongue laceration	2.27	2.27	2.80	0.18	4.72	5.25	010
41252		A	Repair tongue laceration	2.97	2.32	3.63	0.23	5.52	6.83	010
41500		A	Fixation of tongue	3.71	4.25	NA	0.26	8.22	NA	090
41510		A	Tongue to lip surgery	3.42	4.51	NA	0.24	8.17	NA	090
41520		A	Reconstruction, tongue fold	2.73	3.17	3.17	0.19	6.09	6.09	090
41599		C	Tongue and mouth surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
41800		A	Drainage of gum lesion	1.17	1.31	1.90	0.09	2.57	3.16	010
41805		A	Removal foreign body, gum	1.24	1.93	1.93	0.09	3.26	3.26	010
41806		A	Removal foreign body,jawbone	2.69	2.38	2.58	0.22	5.29	5.49	010
41820		R	Excision, gum, each quadrant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
41821		R	Excision of gum flap	0.00	0.00	0.00	0.00	0.00	0.00	XXX
41822		R	Excision of gum lesion	2.31	0.89	2.89	0.24	3.44	5.44	010
41823		R	Excision of gum lesion	3.30	2.75	3.77	0.29	6.34	7.36	090
41825		A	Excision of gum lesion	1.31	2.25	2.36	0.10	3.66	3.77	010
41826		A	Excision of gum lesion	2.31	2.57	2.62	0.17	5.05	5.10	010
41827		A	Excision of gum lesion	3.42	3.58	3.58	0.25	7.25	7.25	090
41828		R	Excision of gum lesion	3.09	2.29	3.03	0.22	5.60	6.34	010
41830		R	Removal of gum tissue	3.35	3.14	3.18	0.23	6.72	6.76	010
41850		R	Treatment of gum lesion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
41870		R	Gum graft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
41872		R	Repair gum	2.59	2.69	2.69	0.18	5.46	5.46	090
41874		R	Repair tooth socket	3.09	2.33	2.83	0.23	5.65	6.15	090
41899		C	Dental surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
42000		A	Drainage mouth roof lesion	1.23	1.59	2.42	0.10	2.92	3.75	010
42100		A	Biopsy roof of mouth	1.31	2.36	2.36	0.10	3.77	3.77	010
42104		A	Excision lesion, mouth roof	1.64	2.44	2.44	0.12	4.20	4.20	010
42106		A	Excision lesion, mouth roof	2.10	2.63	2.63	0.16	4.89	4.89	010
42107		A	Excision lesion, mouth roof	4.44	4.05	4.05	0.32	8.81	8.81	090
42120		A	Remove palate/lesion	6.17	5.99	NA	0.44	12.60	NA	090
42140		A	Excision of uvula	1.62	3.18	3.65	0.12	4.92	5.39	090
42145		A	Repair palate, pharynx/uvula	8.05	7.31	NA	0.56	15.92	NA	090
42160		A	Treatment mouth roof lesion	1.80	2.60	3.16	0.13	4.53	5.09	010
42180		A	Repair palate	2.50	2.10	2.75	0.19	4.79	5.44	010
42182		A	Repair palate	3.83	2.99	3.95	0.27	7.09	8.05	010
42200		A	Reconstruct cleft palate	12.00	10.00	NA	0.97	22.97	NA	090
42205		A	Reconstruct cleft palate	13.29	9.62	NA	0.82	23.73	NA	090
42210		A	Reconstruct cleft palate	14.50	7.95	NA	1.24	23.69	NA	090
42215		A	Reconstruct cleft palate	8.82	7.48	NA	0.96	17.26	NA	090
42220		A	Reconstruct cleft palate	7.02	5.82	NA	0.41	13.25	NA	090
42225		A	Reconstruct cleft palate	9.54	8.92	NA	0.75	19.21	NA	090
42226		A	Lengthening of palate	10.01	9.14	NA	0.73	19.88	NA	090
42227		A	Lengthening of palate	9.52	6.67	NA	0.70	16.89	NA	090
42235		A	Repair palate	7.87	5.92	NA	0.49	14.28	NA	090
42260		A	Repair nose to lip fistula	9.80	7.33	7.33	0.85	17.98	17.98	090
42280		A	Preparation, palate mold	1.54	0.81	1.41	0.12	2.47	3.07	010
42281		A	Insertion, palate prosthesis	1.93	1.04	2.00	0.14	3.11	4.07	010
42299		C	Palate/uvula surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
42300		A	Drainage of salivary gland	1.93	1.77	2.55	0.15	3.85	4.63	010
42305		A	Drainage of salivary gland	6.07	5.16	NA	0.46	11.69	NA	090
42310		A	Drainage of salivary gland	1.56	1.67	2.25	0.11	3.34	3.92	010
42320		A	Drainage of salivary gland	2.35	2.12	2.79	0.17	4.64	5.31	010
42325		A	Create salivary cyst drain	2.75	1.21	3.32	0.17	4.13	6.24	090
42326		A	Create salivary cyst drain	3.78	2.10	3.29	0.34	6.22	7.41	090
42330		A	Removal of salivary stone	2.21	1.22	2.70	0.16	3.59	5.07	010
42335		A	Removal of salivary stone	3.31	3.56	3.56	0.23	7.10	7.10	090
42340		A	Removal of salivary stone	4.60	4.57	4.57	0.34	9.51	9.51	090
42400		A	Biopsy of salivary gland	0.78	0.40	2.37	0.06	1.24	3.21	000
42405		A	Biopsy of salivary gland	3.29	3.27	3.36	0.24	6.80	6.89	010
42408		A	Excision of salivary cyst	4.54	4.62	4.62	0.34	9.50	9.50	090
42409		A	Drainage of salivary cyst	2.81	3.44	3.44	0.20	6.45	6.45	090
42410		A	Excise parotid gland/lesion	9.34	7.76	NA	0.77	17.87	NA	090
42415		A	Excise parotid gland/lesion	16.89	12.43	NA	1.26	30.58	NA	090
42420		A	Excise parotid gland/lesion	19.59	14.02	NA	1.45	35.06	NA	090
42425		A	Excise parotid gland/lesion	13.02	10.29	NA	0.98	24.29	NA	090
42426		A	Excise parotid gland/lesion	21.26	14.84	NA	1.57	37.67	NA	090
42440		A	Excise submaxillary gland	6.97	5.87	NA	0.51	13.35	NA	090
42450		A	Excise sublingual gland	4.62	4.91	4.99	0.34	9.87	9.95	090
42500		A	Repair salivary duct	4.30	4.69	4.69	0.30	9.29	9.29	090
42505		A	Repair salivary duct	6.18	5.36	5.36	0.44	11.98	11.98	090
42507		A	Parotid duct diversion	6.11	5.84	NA	0.66	12.61	NA	090
42508		A	Parotid duct diversion	9.10	7.95	NA	0.64	17.69	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
42509		A	Parotid duct diversion	11.54	7.62	NA	1.24	20.40	NA	090
42510		A	Parotid duct diversion	8.15	7.45	NA	0.57	16.17	NA	090
42550		A	Injection for salivary x-ray	1.25	0.44	12.88	0.06	1.75	14.19	000
42600		A	Closure of salivary fistula	4.82	5.54	6.03	0.34	10.70	11.19	090
42650		A	Dilation of salivary duct	0.77	0.43	1.06	0.06	1.26	1.89	000
42660		A	Dilation of salivary duct	1.13	1.15	1.15	0.07	2.35	2.35	000
42665		A	Ligation of salivary duct	2.53	3.65	3.72	0.17	6.35	6.42	090
42699		C	Salivary surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
42700		A	Drainage of tonsil abscess	1.62	1.79	3.08	0.12	3.53	4.82	010
42720		A	Drainage of throat abscess	5.42	4.66	4.75	0.39	10.47	10.56	010
42725		A	Drainage of throat abscess	10.72	8.30	NA	0.80	19.82	NA	090
42800		A	Biopsy of throat	1.39	2.46	2.90	0.10	3.95	4.39	010
42802		A	Biopsy of throat	1.54	2.58	3.00	0.11	4.23	4.65	010
42804		A	Biopsy of upper nose/throat	1.24	2.42	2.85	0.09	3.75	4.18	010
42806		A	Biopsy of upper nose/throat	1.58	2.60	3.27	0.12	4.30	4.97	010
42808		A	Excise pharynx lesion	2.30	3.01	4.67	0.17	5.48	7.14	010
42809		A	Remove pharynx foreign body	1.81	1.66	3.33	0.13	3.60	5.27	010
42810		A	Excision of neck cyst	3.25	4.42	5.33	0.25	7.92	8.83	090
42815		A	Excision of neck cyst	7.07	6.44	NA	0.53	14.04	NA	090
42820		A	Remove tonsils and adenoids	3.91	3.87	NA	0.28	8.06	NA	090
42821		A	Remove tonsils and adenoids	4.29	4.12	NA	0.30	8.71	NA	090
42825		A	Removal of tonsils	3.42	3.55	NA	0.24	7.21	NA	090
42826		A	Removal of tonsils	3.38	3.59	NA	0.23	7.20	NA	090
42830		A	Removal of adenoids	2.57	2.25	NA	0.18	5.00	NA	090
42831		A	Removal of adenoids	2.71	2.50	NA	0.19	5.40	NA	090
42835		A	Removal of adenoids	2.30	2.44	NA	0.17	4.91	NA	090
42836		A	Removal of adenoids	3.18	3.55	NA	0.22	6.95	NA	090
42842		A	Extensive surgery of throat	8.76	7.71	NA	0.61	17.08	NA	090
42844		A	Extensive surgery of throat	14.31	11.33	NA	1.04	26.68	NA	090
42845		A	Extensive surgery of throat	24.29	17.53	NA	1.76	43.58	NA	090
42860		A	Excision of tonsil tags	2.22	2.98	NA	0.16	5.36	NA	090
42870		A	Excision of lingual tonsil	5.40	5.80	NA	0.38	11.58	NA	090
42890		A	Partial removal of pharynx	12.94	10.63	NA	0.91	24.48	NA	090
42892		A	Revision of pharyngeal walls	15.83	12.19	NA	1.14	29.16	NA	090
42894		A	Revision of pharyngeal walls	22.88	16.90	NA	1.64	41.42	NA	090
42900		A	Repair throat wound	5.25	3.75	NA	0.39	9.39	NA	010
42950		A	Reconstruction of throat	8.10	7.42	NA	0.58	16.10	NA	090
42953		A	Repair throat, esophagus	8.96	8.98	NA	0.73	18.67	NA	090
42955		A	Surgical opening of throat	7.39	6.27	NA	0.63	14.29	NA	090
42960		A	Control throat bleeding	2.33	2.08	NA	0.17	4.58	NA	010
42961		A	Control throat bleeding	5.59	5.22	NA	0.40	11.21	NA	090
42962		A	Control throat bleeding	7.14	6.27	NA	0.51	13.92	NA	090
42970		A	Control nose/throat bleeding	5.43	3.79	NA	0.37	9.59	NA	090
42971		A	Control nose/throat bleeding	6.21	5.70	NA	0.45	12.36	NA	090
42972		A	Control nose/throat bleeding	7.20	5.31	NA	0.54	13.05	NA	090
42999		C	Throat surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43020		A	Incision of esophagus	8.09	6.30	NA	0.70	15.09	NA	090
43030		A	Throat muscle surgery	7.69	6.79	NA	0.60	15.08	NA	090
43045		A	Incision of esophagus	20.12	10.99	NA	2.15	33.26	NA	090
43100		A	Excision of esophagus lesion	9.19	7.27	NA	0.79	17.25	NA	090
43101		A	Excision of esophagus lesion	16.24	8.55	NA	1.81	26.60	NA	090
43107		A	Removal of esophagus	40.00	18.57	NA	3.29	61.86	NA	090
43108		A	Removal of esophagus	34.19	15.74	NA	3.78	53.71	NA	090
43112		A	Removal of esophagus	43.50	20.06	NA	3.67	67.23	NA	090
43113		A	Removal of esophagus	35.27	16.69	NA	4.33	56.29	NA	090
43116		A	Partial removal of esophagus	31.22	20.19	NA	2.62	54.03	NA	090
43117		A	Partial removal of esophagus	40.00	18.55	NA	3.51	62.06	NA	090
43118		A	Partial removal of esophagus	33.20	15.82	NA	3.56	52.58	NA	090
43121		A	Partial removal of esophagus	29.19	14.85	NA	3.44	47.48	NA	090
43122		A	Parital removal of esophagus	40.00	18.10	NA	3.27	61.37	NA	090
43123		A	Partial removal of esophagus	33.20	16.59	NA	3.96	53.75	NA	090
43124		A	Removal of esophagus	27.32	15.10	NA	2.95	45.37	NA	090
43130		A	Removal of esophagus pouch	11.75	8.80	NA	1.06	21.61	NA	090
43135		A	Removal of esophagus pouch	16.10	9.86	NA	1.85	27.81	NA	090
43200		A	Esophagus endoscopy	1.59	1.18	6.85	0.11	2.88	8.55	000
43202		A	Esophagus endoscopy, biopsy	1.89	1.13	5.67	0.12	3.14	7.68	000
43204		A	Esophagus endoscopy & inject	3.77	1.69	NA	0.18	5.64	NA	000
43205		A	Esophagus endoscopy/ligation	3.79	1.70	NA	0.17	5.66	NA	000
43215		A	Esophagus endoscopy	2.60	1.25	NA	0.17	4.02	NA	000
43216		A	Esophagus endoscopy/lesion	2.40	1.19	NA	0.15	3.74	NA	000
43217		A	Esophagus endoscopy	2.90	1.35	NA	0.17	4.42	NA	000
43219		A	Esophagus endoscopy	2.80	1.40	NA	0.16	4.36	NA	000
43220		A	Esoph endoscopy, dilation	2.10	1.11	NA	0.12	3.33	NA	000
43226		A	Esoph endoscopy, dilation	2.34	1.18	NA	0.12	3.64	NA	000

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
43227		A	Esoph endoscopy, repair	3.60	1.62	NA	0.18	5.40	NA	000
43228		A	Esoph endoscopy, ablation	3.77	1.73	NA	0.25	5.75	NA	000
43231		A	Esoph endoscopy w/us exam	4.09	1.89	NA	0.24	6.22	NA	000
43232		A	Esoph endoscopy w/us fn bx	4.71	2.22	NA	0.28	7.21	NA	000
43234		A	Upper GI endoscopy, exam	2.01	1.04	3.89	0.13	3.18	6.03	000
43235		A	Uppr gi endoscopy, diagnosis	2.39	1.20	5.27	0.13	3.72	7.79	000
43239		A	Upper GI endoscopy, biopsy	2.69	1.31	5.49	0.14	4.14	8.32	000
43240		A	Esoph endoscope w/drain cyst	7.39	3.14	NA	0.45	10.98	NA	000
43241		A	Upper GI endoscopy with tube	2.59	1.25	NA	0.14	3.98	NA	000
43242		A	Uppr gi endoscopy w/us fn bx	5.51	2.00	2.00	0.34	7.85	7.85	000
43243		A	Upper gi endoscopy & inject	4.57	1.98	NA	0.21	6.76	NA	000
43244		A	Upper GI endoscopy/ligation	4.59	1.99	NA	0.21	6.79	NA	000
43245		A	Operative upper GI endoscopy	3.39	1.53	NA	0.18	5.10	NA	000
43246		A	Place gastrostomy tube	4.33	1.82	NA	0.24	6.39	NA	000
43247		A	Operative upper GI endoscopy	3.39	1.53	NA	0.17	5.09	NA	000
43248		A	Uppr gi endoscopy/guide wire	3.15	1.46	NA	0.15	4.76	NA	000
43249		A	Esoph endoscopy, dilation	2.90	1.36	NA	0.15	4.41	NA	000
43250		A	Upper GI endoscopy/tumor	3.20	1.46	NA	0.17	4.83	NA	000
43251		A	Operative upper GI endoscopy	3.70	1.65	NA	0.19	5.54	NA	000
43255		A	Operative upper GI endoscopy	4.40	1.80	NA	0.20	6.40	NA	000
43256		A	Uppr gi endoscopy w stent	4.35	1.58	1.58	0.26	6.19	6.19	000
43258		A	Operative upper GI endoscopy	4.55	1.97	NA	0.22	6.74	NA	000
43259		A	Endoscopic ultrasound exam	4.89	2.19	NA	0.22	7.30	NA	000
43260		A	Endo cholangiopancreatograph	5.96	2.48	NA	0.27	8.71	NA	000
43261		A	Endo cholangiopancreatograph	6.27	2.59	NA	0.29	9.15	NA	000
43262		A	Endo cholangiopancreatograph	7.39	3.01	NA	0.34	10.74	NA	000
43263		A	Endo cholangiopancreatograph	6.19	2.58	NA	0.28	9.05	NA	000
43264		A	Endo cholangiopancreatograph	8.90	3.57	NA	0.41	12.88	NA	000
43265		A	Endo cholangiopancreatograph	8.90	3.56	NA	0.42	12.88	NA	000
43267		A	Endo cholangiopancreatograph	7.39	3.01	NA	0.34	10.74	NA	000
43268		A	Endo cholangiopancreatograph	7.39	3.01	NA	0.34	10.74	NA	000
43269		A	Endo cholangiopancreatograph	6.04	2.51	NA	0.28	8.83	NA	000
43271		A	Endo cholangiopancreatograph	7.39	3.00	NA	0.34	10.73	NA	000
43272		A	Endo cholangiopancreatograph	7.39	3.01	NA	0.34	10.74	NA	000
43280		A	Laparoscopy, fundoplasty	17.25	8.37	NA	1.76	27.38	NA	090
43289		C	Laparoscope proc, esoph	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43300		A	Repair of esophagus	9.14	7.43	NA	0.85	17.42	NA	090
43305		A	Repair esophagus and fistula	17.39	12.48	NA	1.36	31.23	NA	090
43310		A	Repair of esophagus	25.39	14.68	NA	3.18	43.25	NA	090
43312		A	Repair esophagus and fistula	28.42	18.43	NA	3.38	50.23	NA	090
43320		A	Fuse esophagus & stomach	19.93	10.60	NA	1.59	32.12	NA	090
43324		A	Revise esophagus & stomach	20.57	9.71	NA	1.72	32.00	NA	090
43325		A	Revise esophagus & stomach	20.06	9.97	NA	1.65	31.68	NA	090
43326		A	Revise esophagus & stomach	19.74	10.75	NA	1.84	32.33	NA	090
43330		A	Repair of esophagus	19.77	9.69	NA	1.52	30.98	NA	090
43331		A	Repair of esophagus	20.13	11.46	NA	1.93	33.52	NA	090
43340		A	Fuse esophagus & intestine	19.61	10.60	NA	1.53	31.74	NA	090
43341		A	Fuse esophagus & intestine	20.85	13.19	NA	2.14	36.18	NA	090
43350		A	Surgical opening, esophagus	15.78	10.59	NA	1.15	27.52	NA	090
43351		A	Surgical opening, esophagus	18.35	9.93	NA	1.51	29.79	NA	090
43352		A	Surgical opening, esophagus	15.26	9.64	NA	1.28	26.18	NA	090
43360		A	Gastrointestinal repair	35.70	16.95	NA	3.00	55.65	NA	090
43361		A	Gastrointestinal repair	40.50	19.13	NA	3.52	63.15	NA	090
43400		A	Ligate esophagus veins	21.20	10.43	NA	0.99	32.62	NA	090
43401		A	Esophagus surgery for veins	22.09	10.05	NA	1.73	33.87	NA	090
43405		A	Ligate/staple esophagus	20.01	9.83	NA	1.63	31.47	NA	090
43410		A	Repair esophagus wound	13.47	8.91	NA	1.15	23.53	NA	090
43415		A	Repair esophagus wound	25.00	12.50	NA	1.92	39.42	NA	090
43420		A	Repair esophagus opening	14.35	9.56	NA	0.86	24.77	NA	090
43425		A	Repair esophagus opening	21.03	11.55	NA	2.03	34.61	NA	090
43450		A	Dilate esophagus	1.38	0.62	1.34	0.07	2.07	2.79	000
43453		A	Dilate esophagus	1.51	0.67	NA	0.08	2.26	NA	000
43456		A	Dilate esophagus	2.57	1.06	NA	0.14	3.77	NA	000
43458		A	Dilate esophagus	3.06	1.25	NA	0.17	4.48	NA	000
43460		A	Pressure treatment esophagus	3.80	1.53	NA	0.21	5.54	NA	000
43496		C	Free jejunum flap, microvasc	0.00	0.00	0.00	0.00	0.00	0.00	090
43499		C	Esophagus surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43500		A	Surgical opening of stomach	11.05	5.16	NA	0.84	17.05	NA	090
43501		A	Surgical repair of stomach	20.04	8.75	NA	1.55	30.34	NA	090
43502		A	Surgical repair of stomach	23.13	9.96	NA	1.83	34.92	NA	090
43510		A	Surgical opening of stomach	13.08	7.42	NA	0.90	21.40	NA	090
43520		A	Incision of pyloric muscle	9.99	5.92	NA	0.84	16.75	NA	090
43600		A	Biopsy of stomach	1.91	1.02	NA	0.11	3.04	NA	000
43605		A	Biopsy of stomach	11.98	5.44	NA	0.93	18.35	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
43610		A	Excision of stomach lesion	14.60	6.79	NA	1.14	22.53	NA	090
43611		A	Excision of stomach lesion	17.84	8.06	NA	1.38	27.28	NA	090
43620		A	Removal of stomach	30.04	12.99	NA	2.29	45.32	NA	090
43621		A	Removal of stomach	30.73	13.14	NA	2.36	46.23	NA	090
43622		A	Removal of stomach	32.53	13.74	NA	2.48	48.75	NA	090
43631		A	Removal of stomach, partial	22.59	9.65	NA	1.99	34.23	NA	090
43632		A	Removal of stomach, partial	22.59	9.65	NA	2.00	34.24	NA	090
43633		A	Removal of stomach, partial	23.10	9.84	NA	2.05	34.99	NA	090
43634		A	Removal of stomach, partial	25.12	10.50	NA	2.18	37.80	NA	090
43635		A	Removal of stomach, partial	2.06	0.74	NA	0.21	3.01	NA	ZZZ
43638		A	Removal of stomach, partial	29.00	12.03	NA	2.24	43.27	NA	090
43639		A	Removal of stomach, partial	29.65	12.28	NA	2.31	44.24	NA	090
43640		A	Vagotomy & pylorus repair	17.02	7.66	NA	1.51	26.19	NA	090
43641		A	Vagotomy & pylorus repair	17.27	7.79	NA	1.53	26.59	NA	090
43651		A	Laparoscopy, vagus nerve	10.15	4.72	NA	1.03	15.90	NA	090
43652		A	Laparoscopy, vagus nerve	12.15	5.37	NA	1.25	18.77	NA	090
43653		A	Laparoscopy, gastrostomy	7.73	4.27	NA	0.78	12.78	NA	090
43659		C	Laparoscope proc, stom	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43750		A	Place gastrostomy tube	4.49	2.63	NA	0.33	7.45	NA	010
43752		B	Nasal/orogastric w/stent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
43760		A	Change gastrostomy tube	1.10	0.46	1.41	0.07	1.63	2.58	000
43761		A	Reposition gastrostomy tube	2.01	0.82	NA	0.10	2.93	NA	000
43800		A	Reconstruction of pylorus	13.69	6.56	NA	1.07	21.32	NA	090
43810		A	Fusion of stomach and bowel	14.65	6.86	NA	1.10	22.61	NA	090
43820		A	Fusion of stomach and bowel	15.37	7.07	NA	1.18	23.62	NA	090
43825		A	Fusion of stomach and bowel	19.22	8.39	NA	1.50	29.11	NA	090
43830		A	Place gastrostomy tube	9.53	4.98	NA	0.69	15.20	NA	090
43831		A	Place gastrostomy tube	7.84	4.26	NA	0.81	12.91	NA	090
43832		A	Place gastrostomy tube	15.60	7.56	NA	1.13	24.29	NA	090
43840		A	Repair of stomach lesion	15.56	7.12	NA	1.20	23.88	NA	090
43842		A	Gastroplasty for obesity	18.47	11.14	NA	1.51	31.12	NA	090
43843		A	Gastroplasty for obesity	18.65	11.01	NA	1.53	31.19	NA	090
43846		A	Gastric bypass for obesity	24.05	13.28	NA	1.96	39.29	NA	090
43847		A	Gastric bypass for obesity	26.92	14.88	NA	2.14	43.94	NA	090
43848		A	Revision gastroplasty	29.39	15.95	NA	2.39	47.73	NA	090
43850		A	Revise stomach-bowel fusion	24.72	10.34	NA	1.97	37.03	NA	090
43855		A	Revise stomach-bowel fusion	26.16	11.24	NA	2.01	39.41	NA	090
43860		A	Revise stomach-bowel fusion	25.00	10.52	NA	2.03	37.55	NA	090
43865		A	Revise stomach-bowel fusion	26.52	11.05	NA	2.15	39.72	NA	090
43870		A	Repair stomach opening	9.69	5.08	NA	0.71	15.48	NA	090
43880		A	Repair stomach-bowel fistula	24.65	10.86	NA	1.94	37.45	NA	090
43999		C	Stomach surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
44005		A	Freeing of bowel adhesion	16.23	7.34	NA	1.39	24.96	NA	090
44010		A	Incision of small bowel	12.52	6.42	NA	1.05	19.99	NA	090
44015		A	Insert needle cath bowel	2.62	0.93	NA	0.25	3.80	NA	ZZZ
44020		A	Exploration of small bowel	13.99	6.50	NA	1.20	21.69	NA	090
44021		A	Decompress small bowel	14.08	6.90	NA	1.18	22.16	NA	090
44025		A	Incision of large bowel	14.28	6.61	NA	1.21	22.10	NA	090
44050		A	Reduce bowel obstruction	14.03	6.52	NA	1.15	21.70	NA	090
44055		A	Correct malrotation of bowel	22.00	9.38	NA	1.32	32.70	NA	090
44100		A	Biopsy of bowel	2.01	1.07	NA	0.12	3.20	NA	000
44110		A	Excision of bowel lesion(s)	11.81	5.78	NA	1.00	18.59	NA	090
44111		A	Excision of bowel lesion(s)	14.29	7.20	NA	1.22	22.71	NA	090
44120		A	Removal of small intestine	17.00	7.59	NA	1.46	26.05	NA	090
44121		A	Removal of small intestine	4.45	1.60	NA	0.45	6.50	NA	ZZZ
44125		A	Removal of small intestine	17.54	7.77	NA	1.49	26.80	NA	090
44130		A	Bowel to bowel fusion	14.49	6.69	NA	1.23	22.41	NA	090
44132		R	Enterectomy, cadaver donor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
44133		R	Enterectomy, live donor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
44135		R	Intestine transplnt, cadaver	0.00	0.00	0.00	0.00	0.00	0.00	XXX
44136		R	Intestine transplant, live	0.00	0.00	0.00	0.00	0.00	0.00	XXX
44139		A	Mobilization of colon	2.23	0.80	NA	0.21	3.24	NA	ZZZ
44140		A	Partial removal of colon	21.00	9.46	NA	1.83	32.29	NA	090
44141		A	Partial removal of colon	19.51	11.66	NA	1.95	33.12	NA	090
44143		A	Partial removal of colon	22.99	12.88	NA	2.02	37.89	NA	090
44144		A	Partial removal of colon	21.53	11.57	NA	1.89	34.99	NA	090
44145		A	Partial removal of colon	26.42	11.77	NA	2.22	40.41	NA	090
44146		A	Partial removal of colon	27.54	14.77	NA	2.20	44.51	NA	090
44147		A	Partial removal of colon	20.71	10.09	NA	1.74	32.54	NA	090
44150		A	Removal of colon	23.95	13.79	NA	2.05	39.79	NA	090
44151		A	Removal of colon/ileostomy	26.88	14.74	NA	1.97	43.59	NA	090
44152		A	Removal of colon/ileostomy	27.83	16.60	NA	2.36	46.79	NA	090
44153		A	Removal of colon/ileostomy	30.59	16.26	NA	2.33	49.18	NA	090
44155		A	Removal of colon/ileostomy	27.86	15.02	NA	2.26	45.14	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
44156		A	Removal of colon/ileostomy	30.79	16.48	NA	2.19	49.46	NA	090
44160		A	Removal of colon	18.62	8.56	NA	1.55	28.73	NA	090
44200		A	Laparoscopy, enterolysis	14.44	6.78	NA	1.46	22.68	NA	090
44201		A	Laparoscopy, jejunostomy	9.78	5.11	NA	0.97	15.86	NA	090
44202		A	Laparo, resect intestine	22.04	9.78	NA	2.16	33.98	NA	090
44209		C	Laparoscope proc, intestine	0.00	0.00	0.00	0.00	0.00	0.00	YYY
44300		A	Open bowel to skin	12.11	6.62	NA	0.88	19.61	NA	090
44310		A	Ileostomy/jejunostomy	15.95	10.29	NA	1.13	27.37	NA	090
44312		A	Revision of ileostomy	8.02	5.02	NA	0.54	13.58	NA	090
44314		A	Revision of ileostomy	15.05	10.19	NA	0.99	26.23	NA	090
44316		A	Devise bowel pouch	21.09	14.20	NA	1.41	36.70	NA	090
44320		A	Colostomy	17.64	11.80	NA	1.28	30.72	NA	090
44322		A	Colostomy with biopsies	11.98	9.91	NA	1.18	23.07	NA	090
44340		A	Revision of colostomy	7.72	4.71	NA	0.56	12.99	NA	090
44345		A	Revision of colostomy	15.43	8.19	NA	1.11	24.73	NA	090
44346		A	Revision of colostomy	16.99	8.74	NA	1.20	26.93	NA	090
44360		A	Small bowel endoscopy	2.59	1.36	NA	0.14	4.09	NA	000
44361		A	Small bowel endoscopy/biopsy	2.87	1.46	NA	0.15	4.48	NA	000
44363		A	Small bowel endoscopy	3.50	1.65	NA	0.19	5.34	NA	000
44364		A	Small bowel endoscopy	3.74	1.78	NA	0.21	5.73	NA	000
44365		A	Small bowel endoscopy	3.31	1.63	NA	0.18	5.12	NA	000
44366		A	Small bowel endoscopy	4.41	2.02	NA	0.22	6.65	NA	000
44369		A	Small bowel endoscopy	4.52	2.00	NA	0.23	6.75	NA	000
44370		A	Small bowel endoscopy/stent	4.33	1.59	1.59	0.26	6.18	6.18	000
44372		A	Small bowel endoscopy	4.41	2.02	NA	0.27	6.70	NA	000
44373		A	Small bowel endoscopy	3.50	1.74	NA	0.19	5.43	NA	000
44376		A	Small bowel endoscopy	5.26	2.32	NA	0.29	7.87	NA	000
44377		A	Small bowel endoscopy/biopsy	5.53	2.45	NA	0.28	8.26	NA	000
44378		A	Small bowel endoscopy	7.13	3.02	NA	0.37	10.52	NA	000
44379		A	S bowel endoscope w/stent	7.07	2.55	2.55	0.45	10.07	10.07	000
44380		A	Small bowel endoscopy	1.05	0.77	NA	0.08	1.90	NA	000
44382		A	Small bowel endoscopy	1.27	0.86	NA	0.09	2.22	NA	000
44383		A	Ileoscopy w/stent	2.41	0.87	0.87	0.15	3.43	3.43	000
44385		A	Endoscopy of bowel pouch	1.82	0.94	4.40	0.12	2.88	6.34	000
44386		A	Endoscopy, bowel pouch/biop	2.12	1.09	5.56	0.15	3.36	7.83	000
44388		A	Colon endoscopy	2.82	1.39	6.06	0.18	4.39	9.06	000
44389		A	Colonoscopy with biopsy	3.13	1.52	6.65	0.18	4.83	9.96	000
44390		A	Colonoscopy for foreign body	3.83	1.80	7.38	0.22	5.85	11.43	000
44391		A	Colonoscopy for bleeding	4.32	1.76	6.17	0.23	6.31	10.72	000
44392		A	Colonoscopy and polypectomy	3.82	1.76	6.74	0.23	5.81	10.79	000
44393		A	Colonoscopy, lesion removal	4.84	2.15	7.45	0.27	7.26	12.56	000
44394		A	Colonoscopy w/snare	4.43	1.99	7.40	0.26	6.68	12.09	000
44397		A	Colonoscopy w stent	4.23	1.90	NA	0.30	6.43	NA	000
44500		A	Intro, gastrointestinal tube	0.49	0.36	NA	0.02	0.87	NA	000
44602		A	Suture, small intestine	16.03	7.26	NA	1.07	24.36	NA	090
44603		A	Suture, small intestine	18.66	8.18	NA	1.39	28.23	NA	090
44604		A	Suture, large intestine	16.03	7.26	NA	1.42	24.71	NA	090
44605		A	Repair of bowel lesion	19.53	8.92	NA	1.54	29.99	NA	090
44615		A	Intestinal stricturoplasty	15.93	7.20	NA	1.39	24.52	NA	090
44620		A	Repair bowel opening	12.20	5.79	NA	1.05	19.04	NA	090
44625		A	Repair bowel opening	15.05	6.83	NA	1.30	23.18	NA	090
44626		A	Repair bowel opening	25.36	10.52	NA	2.19	38.07	NA	090
44640		A	Repair bowel-skin fistula	21.65	9.57	NA	1.46	32.68	NA	090
44650		A	Repair bowel fistula	22.57	9.80	NA	1.49	33.86	NA	090
44660		A	Repair bowel-bladder fistula	21.36	9.40	NA	1.14	31.90	NA	090
44661		A	Repair bowel-bladder fistula	24.81	10.56	NA	1.53	36.90	NA	090
44680		A	Surgical revision, intestine	15.40	7.38	NA	1.37	24.15	NA	090
44700		A	Suspend bowel w/prosthesis	16.11	7.43	NA	1.21	24.75	NA	090
44799		C	Intestine surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
44800		A	Excision of bowel pouch	11.23	5.51	NA	1.11	17.85	NA	090
44820		A	Excision of mesentery lesion	12.09	5.89	NA	1.03	19.01	NA	090
44850		A	Repair of mesentery	10.74	5.55	NA	0.99	17.28	NA	090
44899		C	Bowel surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
44900		A	Drain app abscess, open	10.14	5.83	NA	0.84	16.81	NA	090
44901		A	Drain app abscess, percut	3.38	5.25	NA	0.17	8.80	NA	000
44950		A	Appendectomy	10.00	5.25	NA	0.88	16.13	NA	090
44955		A	Appendectomy add-on	1.53	0.57	NA	0.16	2.26	NA	ZZZ
44960		A	Appendectomy	12.34	6.41	NA	1.09	19.84	NA	090
44970		A	Laparoscopy, appendectomy	8.70	4.16	NA	0.88	13.74	NA	090
44979		C	Laparoscope proc, app	0.00	0.00	0.00	0.00	0.00	0.00	YYY
45000		A	Drainage of pelvic abscess	4.52	3.86	NA	0.37	8.75	NA	090
45005		A	Drainage of rectal abscess	1.99	1.57	4.41	0.18	3.74	6.58	010
45020		A	Drainage of rectal abscess	4.72	3.89	NA	0.41	9.02	NA	090
45100		A	Biopsy of rectum	3.68	2.08	4.75	0.33	6.09	8.76	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
45108		A	Removal of anorectal lesion	4.76	3.06	5.90	0.46	8.28	11.12	090
45110		A	Removal of rectum	28.00	13.10	NA	2.26	43.36	NA	090
45111		A	Partial removal of rectum	16.48	8.62	NA	1.60	26.70	NA	090
45112		A	Removal of rectum	30.54	13.57	NA	2.35	46.46	NA	090
45113		A	Partial proctectomy	30.58	12.85	NA	2.13	45.56	NA	090
45114		A	Partial removal of rectum	27.32	12.41	NA	2.28	42.01	NA	090
45116		A	Partial removal of rectum	24.58	11.19	NA	2.00	37.77	NA	090
45119		A	Remove rectum w/reservoir	30.84	13.31	NA	2.13	46.28	NA	090
45120		A	Removal of rectum	24.60	11.41	NA	2.28	38.29	NA	090
45121		A	Removal of rectum and colon	27.04	12.37	NA	2.66	42.07	NA	090
45123		A	Partial proctectomy	16.71	7.62	NA	1.04	25.37	NA	090
45126		A	Pelvic exenteration	45.16	19.69	NA	3.23	68.08	NA	090
45130		A	Excision of rectal prolapse	16.44	7.66	NA	1.12	25.22	NA	090
45135		A	Excision of rectal prolapse	19.28	9.16	NA	1.52	29.96	NA	090
45150		A	Excision of rectal stricture	5.67	3.08	5.08	0.46	9.21	11.21	090
45160		A	Excision of rectal lesion	15.32	6.97	NA	1.07	23.36	NA	090
45170		A	Excision of rectal lesion	11.49	5.80	NA	0.89	18.18	NA	090
45190		A	Destruction, rectal tumor	9.74	5.19	NA	0.76	15.69	NA	090
45300		A	Proctosigmoidoscopy dx	0.38	0.23	1.28	0.05	0.66	1.71	000
45303		A	Proctosigmoidoscopy dilate	0.44	0.26	1.47	0.06	0.76	1.97	000
45305		A	Proctosigmoidoscopy & biopsy	1.01	0.45	1.55	0.09	1.55	2.65	000
45307		A	Protosigmoidoscopy fb	0.94	0.42	2.35	0.15	1.51	3.44	000
45308		A	Protosigmoidoscopy removal	0.83	0.39	1.53	0.13	1.35	2.49	000
45309		A	Proctosigmoidoscopy	2.01	0.80	2.46	0.17	2.98	4.64	000
45315		A	Protosigmoidoscopy removal	1.40	0.60	2.42	0.20	2.20	4.02	000
45317		A	Protosigmoidoscopy bleed	1.50	0.63	1.79	0.20	2.33	3.49	000
45320		A	Protosigmoidoscopy ablate	1.58	0.67	1.74	0.20	2.45	3.52	000
45321		A	Protosigmoidoscopy volvul	1.17	0.52	NA	0.17	1.86	NA	000
45327		A	Proctosigmoidoscopy w/stent	1.46	0.81	NA	0.12	2.39	NA	000
45330		A	Diagnostic sigmoidoscopy	0.88	0.45	1.88	0.05	1.38	2.81	000
45331		A	Sigmoidoscopy and biopsy	1.15	0.53	2.13	0.07	1.75	3.35	000
45332		A	Sigmoidoscopy w/fb removal	1.79	0.76	3.73	0.11	2.66	5.63	000
45333		A	Sigmoidoscopy & polypectomy	1.79	0.76	3.37	0.12	2.67	5.28	000
45334		A	Sigmoidoscopy for bleeding	2.73	1.11	NA	0.16	4.00	NA	000
45337		A	Sigmoidoscopy & decompress	2.36	0.97	NA	0.15	3.48	NA	000
45338		A	Sigmoidoscpy w/tumr remove	2.34	0.96	4.01	0.15	3.45	6.50	000
45339		A	Sigmoidoscopy	3.14	1.26	3.05	0.17	4.57	6.36	000
45341		A	Sigmoidoscopy w/ultrasound	3.46	1.68	NA	0.24	5.38	NA	000
45342		A	Sigmoidoscopy w/us guide bx	4.08	1.83	NA	0.29	6.20	NA	000
45345		A	Sigmodoscopy w/stent	2.66	1.32	NA	0.18	4.16	NA	000
45355		A	Surgical colonoscopy	3.52	1.27	NA	0.26	5.05	NA	000
45378		A	Diagnostic colonoscopy	3.68	1.74	7.30	0.20	5.62	11.18	000
45378	53	A	Diagnostic colonoscopy	0.88	0.45	1.88	0.05	1.38	2.81	000
45379		A	Colonoscopy w/fb removal	4.69	2.09	7.87	0.25	7.03	12.81	000
45380		A	Colonoscopy and biopsy	4.01	1.86	7.53	0.21	6.08	11.75	000
45382		A	Colonoscopy/control bleeding	5.69	2.28	8.80	0.27	8.24	14.76	000
45383		A	Lesion removal colonoscopy	5.87	2.52	8.59	0.32	8.71	14.78	000
45384		A	Colonoscopy	4.70	2.11	8.21	0.24	7.05	13.15	000
45385		A	Lesion removal colonoscopy	5.31	2.33	8.38	0.28	7.92	13.97	000
45387		A	Colonoscopy w/stent	5.62	2.44	NA	0.36	8.42	NA	000
45500		A	Repair of rectum	7.29	4.19	NA	0.56	12.04	NA	090
45505		A	Repair of rectum	7.58	3.73	NA	0.50	11.81	NA	090
45520		A	Treatment of rectal prolapse	0.55	0.19	0.75	0.04	0.78	1.34	000
45540		A	Correct rectal prolapse	16.27	7.98	NA	1.17	25.42	NA	090
45541		A	Correct rectal prolapse	13.40	6.83	NA	0.88	21.11	NA	090
45550		A	Repair rectum/remove sigmoid	23.00	10.25	NA	1.58	34.83	NA	090
45560		A	Repair of rectocele	10.58	5.99	NA	0.73	17.30	NA	090
45562		A	Exploration/repair of rectum	15.38	7.40	NA	1.15	23.93	NA	090
45563		A	Exploration/repair of rectum	23.47	11.08	NA	1.84	36.39	NA	090
45800		A	Repair rect/bladder fistula	17.77	8.10	NA	1.14	27.01	NA	090
45805		A	Repair fistula w/colostomy	20.78	9.94	NA	1.47	32.19	NA	090
45820		A	Repair rectourethral fistula	18.48	8.48	NA	1.17	28.13	NA	090
45825		A	Repair fistula w/colostomy	21.25	10.11	NA	0.97	32.33	NA	090
45900		A	Reduction of rectal prolapse	2.61	1.03	NA	0.17	3.81	NA	010
45905		A	Dilation of anal sphincter	2.30	0.95	3.50	0.14	3.39	5.94	010
45910		A	Dilation of rectal narrowing	2.80	1.15	4.78	0.14	4.09	7.72	010
45915		A	Remove rectal obstruction	3.14	1.11	4.59	0.17	4.42	7.90	010
45999		C	Rectum surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
46030		A	Removal of rectal marker	1.23	1.20	3.35	0.11	2.54	4.69	010
46040		A	Incision of rectal abscess	4.96	3.06	5.40	0.48	8.50	10.84	090
46045		A	Incision of rectal abscess	4.32	2.77	NA	0.40	7.49	NA	090
46050		A	Incision of anal abscess	1.19	1.30	3.53	0.11	2.60	4.83	010
46060		A	Incision of rectal abscess	5.69	3.75	NA	0.52	9.96	NA	090
46070		A	Incision of anal septum	2.71	2.48	NA	0.27	5.46	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
46080		A	Incision of anal sphincter	2.49	1.61	3.81	0.23	4.33	6.53	010
46083		A	Incise external hemorrhoid	1.40	1.47	4.60	0.12	2.99	6.12	010
46200		A	Removal of anal fissure	3.42	2.35	3.90	0.30	6.07	7.62	090
46210		A	Removal of anal crypt	2.67	2.15	5.01	0.26	5.08	7.94	090
46211		A	Removal of anal crypts	4.25	2.94	5.48	0.37	7.56	10.10	090
46220		A	Removal of anal tab	1.56	0.56	1.24	0.14	2.26	2.94	010
46221		A	Ligation of hemorrhoid(s)	2.04	0.73	3.40	0.12	2.89	5.56	010
46230		A	Removal of anal tabs	2.57	1.68	4.18	0.22	4.47	6.97	010
46250		A	Hemorrhoidectomy	3.89	2.67	5.25	0.43	6.99	9.57	090
46255		A	Hemorrhoidectomy	4.60	2.88	5.87	0.51	7.99	10.98	090
46257		A	Remove hemorrhoids & fissure	5.40	3.06	NA	0.59	9.05	NA	090
46258		A	Remove hemorrhoids & fistula	5.73	3.27	NA	0.64	9.64	NA	090
46260		A	Hemorrhoidectomy	6.37	3.94	NA	0.68	10.99	NA	090
46261		A	Remove hemorrhoids & fissure	7.08	4.05	NA	0.70	11.83	NA	090
46262		A	Remove hemorrhoids & fistula	7.50	4.31	NA	0.76	12.57	NA	090
46270		A	Removal of anal fistula	3.72	2.55	4.91	0.36	6.63	8.99	090
46275		A	Removal of anal fistula	4.56	2.78	4.70	0.40	7.74	9.66	090
46280		A	Removal of anal fistula	5.98	3.69	NA	0.50	10.17	NA	090
46285		A	Removal of anal fistula	4.09	2.60	3.91	0.34	7.03	8.34	090
46288		A	Repair anal fistula	7.13	4.16	NA	0.60	11.89	NA	090
46320		A	Removal of hemorrhoid clot	1.61	1.50	3.79	0.14	3.25	5.54	010
46500		A	Injection into hemorrhoids	1.61	0.59	2.63	0.12	2.32	4.36	010
46600		A	Diagnostic anoscopy	0.50	0.15	0.79	0.04	0.69	1.33	000
46604		A	Anoscopy and dilation	1.31	0.47	0.95	0.09	1.87	2.35	000
46606		A	Anoscopy and biopsy	0.81	0.29	0.88	0.07	1.17	1.76	000
46608		A	Anoscopy/ remove for body	1.51	0.46	1.82	0.13	2.10	3.46	000
46610		A	Anoscopy/remove lesion	1.32	0.48	1.44	0.12	1.92	2.88	000
46611		A	Anoscopy	1.81	0.65	2.00	0.15	2.61	3.96	000
46612		A	Anoscopy/ remove lesions	2.34	0.85	2.46	0.18	3.37	4.98	000
46614		A	Anoscopy/control bleeding	2.01	0.71	1.68	0.14	2.86	3.83	000
46615		A	Anoscopy	2.68	0.96	1.72	0.23	3.87	4.63	000
46700		A	Repair of anal stricture	9.13	4.68	NA	0.56	14.37	NA	090
46705		A	Repair of anal stricture	6.90	4.73	NA	0.73	12.36	NA	090
46715		A	Repair of anovaginal fistula	7.20	4.50	NA	0.76	12.46	NA	090
46716		A	Repair of anovaginal fistula	15.07	7.81	NA	1.30	24.18	NA	090
46730		A	Construction of absent anus	26.75	12.10	NA	2.03	40.88	NA	090
46735		A	Construction of absent anus	32.17	14.90	NA	2.64	49.71	NA	090
46740		A	Construction of absent anus	30.00	12.81	NA	1.99	44.80	NA	090
46742		A	Repair of imperforated anus	35.80	17.97	NA	2.63	56.40	NA	090
46744		A	Repair of cloacal anomaly	52.63	20.67	NA	2.27	75.57	NA	090
46746		A	Repair of cloacal anomaly	58.22	26.84	NA	2.51	87.57	NA	090
46748		A	Repair of cloacal anomaly	64.21	29.21	NA	2.77	96.19	NA	090
46750		A	Repair of anal sphincter	10.25	5.65	NA	0.69	16.59	NA	090
46751		A	Repair of anal sphincter	8.77	6.30	NA	0.78	15.85	NA	090
46753		A	Reconstruction of anus	8.29	4.04	NA	0.58	12.91	NA	090
46754		A	Removal of suture from anus	2.20	1.32	5.40	0.12	3.64	7.72	010
46760		A	Repair of anal sphincter	14.43	6.74	NA	0.86	22.03	NA	090
46761		A	Repair of anal sphincter	13.84	6.62	NA	0.84	21.30	NA	090
46762		A	Implant artificial sphincter	12.71	5.67	NA	0.71	19.09	NA	090
46900		A	Destruction, anal lesion(s)	1.91	0.77	3.28	0.13	2.81	5.32	010
46910		A	Destruction, anal lesion(s)	1.86	1.49	3.52	0.14	3.49	5.52	010
46916		A	Cryosurgery, anal lesion(s)	1.86	1.60	3.44	0.09	3.55	5.39	010
46917		A	Laser surgery, anal lesions	1.86	1.57	4.61	0.16	3.59	6.63	010
46922		A	Excision of anal lesion(s)	1.86	1.43	3.81	0.17	3.46	5.84	010
46924		A	Destruction, anal lesion(s)	2.76	1.70	5.01	0.20	4.66	7.97	010
46934		A	Destruction of hemorrhoids	3.51	3.49	5.92	0.26	7.26	9.69	090
46935		A	Destruction of hemorrhoids	2.43	0.87	4.07	0.17	3.47	6.67	010
46936		A	Destruction of hemorrhoids	3.69	3.34	5.73	0.30	7.33	9.72	090
46937		A	Cryotherapy of rectal lesion	2.69	2.44	4.03	0.12	5.25	6.84	010
46938		A	Cryotherapy of rectal lesion	4.66	3.48	3.99	0.40	8.54	9.05	090
46940		A	Treatment of anal fissure	2.32	0.83	3.08	0.17	3.32	5.57	010
46942		A	Treatment of anal fissure	2.04	0.71	3.21	0.14	2.89	5.39	010
46945		A	Ligation of hemorrhoids	1.84	2.13	3.83	0.17	4.14	5.84	090
46946		A	Ligation of hemorrhoids	2.58	2.44	5.05	0.22	5.24	7.85	090
46999		C	Anus surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
47000		A	Needle biopsy of liver	1.90	0.67	9.17	0.09	2.66	11.16	000
47001		A	Needle biopsy, liver add-on	1.90	0.68	NA	0.18	2.76	NA	ZZZ
47010		A	Open drainage, liver lesion	16.01	9.58	NA	0.65	26.24	NA	090
47011		A	Percut drain, liver lesion	3.70	6.24	NA	0.17	10.11	NA	000
47015		A	Inject/aspirate liver cyst	15.11	7.96	NA	0.86	23.93	NA	090
47100		A	Wedge biopsy of liver	11.67	6.37	NA	0.75	18.79	NA	090
47120		A	Partial removal of liver	35.50	16.79	NA	2.29	54.58	NA	090
47122		A	Extensive removal of liver	55.13	23.83	NA	3.60	82.56	NA	090
47125		A	Partial removal of liver	49.19	21.66	NA	3.18	74.03	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
47130		A	Partial removal of liver	53.35	23.34	NA	3.47	80.16	NA	090
47133		X	Removal of donor liver	0.00	0.00	0.00	0.00	0.00	0.00	XXX
47134		R	Partial removal, donor liver	39.15	14.22	NA	3.98	57.35	NA	XXX
47135		R	Transplantation of liver	81.52	42.54	NA	8.13	132.19	NA	090
47136		R	Transplantation of liver	68.60	46.19	NA	6.93	121.72	NA	090
47300		A	Surgery for liver lesion	15.08	7.62	NA	0.97	23.67	NA	090
47350		A	Repair liver wound	19.56	9.32	NA	1.25	30.13	NA	090
47360		A	Repair liver wound	26.92	12.57	NA	1.71	41.20	NA	090
47361		A	Repair liver wound	47.12	20.03	NA	3.11	70.26	NA	090
47362		A	Repair liver wound	18.51	10.17	NA	1.22	29.90	NA	090
47379		C	Laparoscope procedure, liver	0.00	0.00	0.00	0.00	0.00	0.00	YYY
47399		C	Liver surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
47400		A	Incision of liver duct	32.49	14.82	NA	1.82	49.13	NA	090
47420		A	Incision of bile duct	19.88	9.28	NA	1.70	30.86	NA	090
47425		A	Incision of bile duct	19.83	9.54	NA	1.60	30.97	NA	090
47460		A	Incise bile duct sphincter	18.04	8.90	NA	1.24	28.18	NA	090
47480		A	Incision of gallbladder	10.82	6.52	NA	0.85	18.19	NA	090
47490		A	Incision of gallbladder	7.23	7.60	NA	0.33	15.16	NA	090
47500		A	Injection for liver x-rays	1.96	0.68	NA	0.09	2.73	NA	000
47505		A	Injection for liver x-rays	0.76	0.26	15.72	0.03	1.05	16.51	000
47510		A	Insert catheter, bile duct	7.83	9.35	NA	0.36	17.54	NA	090
47511		A	Insert bile duct drain	10.50	10.59	NA	0.47	21.56	NA	090
47525		A	Change bile duct catheter	5.55	3.33	NA	0.24	9.12	NA	010
47530		A	Revise/reinsert bile tube	5.85	5.02	NA	0.29	11.16	NA	090
47550		A	Bile duct endoscopy add-on	3.02	1.08	NA	0.30	4.40	NA	ZZZ
47552		A	Biliary endoscopy thru skin	6.04	2.51	NA	0.42	8.97	NA	000
47553		A	Biliary endoscopy thru skin	6.35	2.70	NA	0.30	9.35	NA	000
47554		A	Biliary endoscopy thru skin	9.06	3.52	NA	0.74	13.32	NA	000
47555		A	Biliary endoscopy thru skin	7.56	3.13	NA	0.35	11.04	NA	000
47556		A	Biliary endoscopy thru skin	8.56	3.48	NA	0.38	12.42	NA	000
47560		A	Laparoscopy w/cholangio	4.89	1.90	NA	0.49	7.28	NA	000
47561		A	Laparo w/cholangio/biopsy	5.18	2.22	NA	0.49	7.89	NA	000
47562		A	Laparoscopic cholecystectomy	11.09	4.82	NA	1.13	17.04	NA	090
47563		A	Laparoscopic cholecystectomy	11.94	5.32	NA	1.21	18.47	NA	090
47564		A	Laparo cholecystectomy/explr	14.23	6.94	NA	1.44	22.61	NA	090
47570		A	Laparo cholecystoenterostomy	12.58	5.93	NA	1.28	19.79	NA	090
47579		C	Laparoscope proc, biliary	0.00	0.00	0.00	0.00	0.00	0.00	YYY
47600		A	Removal of gallbladder	13.58	6.75	NA	1.16	21.49	NA	090
47605		A	Removal of gallbladder	14.69	7.14	NA	1.25	23.08	NA	090
47610		A	Removal of gallbladder	18.82	8.75	NA	1.61	29.18	NA	090
47612		A	Removal of gallbladder	18.78	8.59	NA	1.60	28.97	NA	090
47620		A	Removal of gallbladder	20.64	9.25	NA	1.77	31.66	NA	090
47630		A	Remove bile duct stone	9.11	3.17	NA	0.46	12.74	NA	090
47700		A	Exploration of bile ducts	15.62	8.73	NA	1.40	25.75	NA	090
47701		A	Bile duct revision	27.81	13.42	NA	3.00	44.23	NA	090
47711		A	Excision of bile duct tumor	23.03	11.21	NA	1.98	36.22	NA	090
47712		A	Excision of bile duct tumor	30.24	14.20	NA	2.67	47.11	NA	090
47715		A	Excision of bile duct cyst	18.80	8.85	NA	1.59	29.24	NA	090
47716		A	Fusion of bile duct cyst	16.44	9.46	NA	1.41	27.31	NA	090
47720		A	Fuse gallbladder & bowel	15.91	8.67	NA	1.37	25.95	NA	090
47721		A	Fuse upper gi structures	19.12	9.77	NA	1.63	30.52	NA	090
47740		A	Fuse gallbladder & bowel	18.48	9.61	NA	1.59	29.68	NA	090
47741		A	Fuse gallbladder & bowel	21.34	10.50	NA	1.82	33.66	NA	090
47760		A	Fuse bile ducts and bowel	25.85	12.12	NA	2.21	40.18	NA	090
47765		A	Fuse liver ducts & bowel	24.88	12.79	NA	2.18	39.85	NA	090
47780		A	Fuse bile ducts and bowel	26.50	12.37	NA	2.27	41.14	NA	090
47785		A	Fuse bile ducts and bowel	31.18	14.72	NA	2.69	48.59	NA	090
47800		A	Reconstruction of bile ducts	23.30	11.22	NA	1.95	36.47	NA	090
47801		A	Placement, bile duct support	15.17	10.25	NA	0.69	26.11	NA	090
47802		A	Fuse liver duct & intestine	21.55	11.28	NA	1.84	34.67	NA	090
47900		A	Suture bile duct injury	19.90	10.04	NA	1.65	31.59	NA	090
47999		C	Bile tract surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
48000		A	Drainage of abdomen	28.07	12.79	NA	1.32	42.18	NA	090
48001		A	Placement of drain, pancreas	35.45	14.98	NA	1.90	52.33	NA	090
48005		A	Resect/debride pancreas	42.17	17.36	NA	2.26	61.79	NA	090
48020		A	Removal of pancreatic stone	15.70	7.61	NA	1.36	24.67	NA	090
48100		A	Biopsy of pancreas	12.23	6.89	NA	1.08	20.20	NA	090
48102		A	Needle biopsy, pancreas	4.68	2.44	8.98	0.20	7.32	13.86	010
48120		A	Removal of pancreas lesion	15.85	7.51	NA	1.35	24.71	NA	090
48140		A	Partial removal of pancreas	22.94	10.69	NA	2.12	35.75	NA	090
48145		A	Partial removal of pancreas	24.02	11.58	NA	2.25	37.85	NA	090
48146		A	Pancreatectomy	26.40	13.53	NA	2.43	42.36	NA	090
48148		A	Removal of pancreatic duct	17.34	9.25	NA	1.61	28.20	NA	090
48150		A	Partial removal of pancreas	48.00	21.99	NA	4.43	74.42	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
48152		A	Pancreatectomy	43.75	20.61	NA	4.07	68.43	NA	090
48153		A	Pancreatectomy	47.89	21.97	NA	4.40	74.26	NA	090
48154		A	Pancreatectomy	44.10	20.71	NA	4.10	68.91	NA	090
48155		A	Removal of pancreas	24.64	13.79	NA	2.30	40.73	NA	090
48160		N	Pancreas removal/transplant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
48180		A	Fuse pancreas and bowel	24.72	11.10	NA	2.24	38.06	NA	090
48400		A	Injection, intraop add-on	1.95	0.68	NA	0.10	2.73	NA	ZZZ
48500		A	Surgery of pancreas cyst	15.28	7.53	NA	1.35	24.16	NA	090
48510		A	Drain pancreatic pseudocyst	14.31	7.48	NA	1.07	22.86	NA	090
48511		A	Drain pancreatic pseudocyst	4.00	4.71	NA	0.17	8.88	NA	000
48520		A	Fuse pancreas cyst and bowel	15.59	7.29	NA	1.41	24.29	NA	090
48540		A	Fuse pancreas cyst and bowel	19.72	8.81	NA	1.82	30.35	NA	090
48545		A	Pancreatorrhaphy	18.18	8.74	NA	1.61	28.53	NA	090
48547		A	Duodenal exclusion	25.83	10.89	NA	2.30	39.02	NA	090
48550		X	Donor pancreatectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
48554		R	Transpl allograft pancreas	34.17	12.27	NA	3.30	49.74	NA	090
48556		A	Removal, allograft pancreas	15.71	8.56	NA	1.52	25.79	NA	090
48999		C	Pancreas surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
49000		A	Exploration of abdomen	11.68	6.14	NA	1.17	18.99	NA	090
49002		A	Reopening of abdomen	10.49	6.02	NA	1.06	17.57	NA	090
49010		A	Exploration behind abdomen	12.28	6.94	NA	1.22	20.44	NA	090
49020		A	Drain abdominal abscess	22.84	11.55	NA	1.31	35.70	NA	090
49021		A	Drain abdominal abscess	3.38	6.31	NA	0.16	9.85	NA	000
49040		A	Drain, open, abdom abscess	13.52	8.00	NA	0.84	22.36	NA	090
49041		A	Drain, percut, abdom abscess	4.00	6.50	NA	0.18	10.68	NA	000
49060		A	Drain, open, retrop abscess	15.86	9.58	NA	0.77	26.21	NA	090
49061		A	Drain, percut, retroper absc	3.70	6.44	NA	0.17	10.31	NA	000
49062		A	Drain to peritoneal cavity	11.36	7.15	NA	1.08	19.59	NA	090
49080		A	Puncture, peritoneal cavity	1.35	0.62	3.08	0.07	2.04	4.50	000
49081		A	Removal of abdominal fluid	1.26	0.59	2.93	0.06	1.91	4.25	000
49085		A	Remove abdomen foreign body	12.14	6.59	NA	0.88	19.61	NA	090
49180		A	Biopsy, abdominal mass	1.73	0.60	7.64	0.08	2.41	9.45	000
49200		A	Removal of abdominal lesion	10.25	6.43	NA	0.89	17.57	NA	090
49201		A	Removal of abdominal lesion	14.84	8.71	NA	1.44	24.99	NA	090
49215		A	Excise sacral spine tumor	33.50	14.97	NA	2.48	50.95	NA	090
49220		A	Multiple surgery, abdomen	14.88	7.71	NA	1.51	24.10	NA	090
49250		A	Excision of umbilicus	8.35	5.10	NA	0.84	14.29	NA	090
49255		A	Removal of omentum	11.14	6.63	NA	1.12	18.89	NA	090
49320		A	Diag laparo separate proc	5.10	3.04	NA	0.50	8.64	NA	010
49321		A	Laparoscopy; biopsy	5.40	3.08	NA	0.53	9.01	NA	010
49322		A	Laparoscopy; aspiration	5.70	3.47	NA	0.57	9.74	NA	010
49323		A	Laparo drain lymphocele	9.48	4.01	NA	0.88	14.37	NA	090
49329		C	Laparo proc, abdm/per/oment	0.00	0.00	0.00	0.00	0.00	0.00	YYY
49400		A	Air injection into abdomen	1.88	0.81	NA	0.11	2.80	NA	000
49420		A	Insert abdominal drain	2.22	0.98	NA	0.13	3.33	NA	000
49421		A	Insert abdominal drain	5.54	4.03	NA	0.55	10.12	NA	090
49422		A	Remove perm cannula/catheter	6.25	2.96	NA	0.63	9.84	NA	010
49423		A	Exchange drainage catheter	1.46	0.69	NA	0.07	2.22	NA	000
49424		A	Assess cyst, contrast inject	0.76	0.45	NA	0.03	1.24	NA	000
49425		A	Insert abdomen-venous drain	11.37	6.70	NA	1.21	19.28	NA	090
49426		A	Revise abdomen-venous shunt	9.63	6.06	NA	0.93	16.62	NA	090
49427		A	Injection, abdominal shunt	0.89	0.49	NA	0.05	1.43	NA	000
49428		A	Ligation of shunt	6.06	3.22	NA	0.31	9.59	NA	010
49429		A	Removal of shunt	7.40	3.49	NA	0.81	11.70	NA	010
49495		A	Repair inguinal hernia, init	5.89	3.49	NA	0.55	9.93	NA	090
49496		A	Repair inguinal hernia, init	8.79	6.44	NA	0.89	16.12	NA	090
49500		A	Repair inguinal hernia	5.48	3.38	NA	0.46	9.32	NA	090
49501		A	Repair inguinal hernia, init	8.88	4.48	NA	0.76	14.12	NA	090
49505		A	Repair inguinal hernia	7.60	4.07	4.53	0.65	12.32	12.78	090
49507		A	Repair inguinal hernia	9.57	6.05	NA	0.83	16.45	NA	090
49520		A	Rerepair inguinal hernia	9.63	5.41	NA	0.84	15.88	NA	090
49521		A	Repair inguinal hernia, rec	11.97	5.78	NA	1.04	18.79	NA	090
49525		A	Repair inguinal hernia	8.57	4.90	NA	0.74	14.21	NA	090
49540		A	Repair lumbar hernia	10.39	5.62	NA	0.90	16.91	NA	090
49550		A	Repair femoral hernia	8.63	4.48	NA	0.75	13.86	NA	090
49553		A	Repair femoral hernia, init	9.44	4.91	NA	0.83	15.18	NA	090
49555		A	Repair femoral hernia	9.03	5.21	NA	0.79	15.03	NA	090
49557		A	Repair femoral hernia, recur	11.15	5.51	NA	0.97	17.63	NA	090
49560		A	Repair abdominal hernia	11.57	6.03	NA	1.00	18.60	NA	090
49561		A	Repair incisional hernia	14.25	6.64	NA	1.23	22.12	NA	090
49565		A	Rerepair abdominal hernia	11.57	6.21	NA	1.00	18.78	NA	090
49566		A	Repair incisional hernia	14.40	6.69	NA	1.24	22.33	NA	090
49568		A	Hernia repair w/mesh	4.89	1.76	NA	0.50	7.15	NA	ZZZ
49570		A	Repair epigastric hernia	5.69	3.44	NA	0.50	9.63	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
49572		A	Repair epigastric hernia	6.73	3.95	NA	0.58	11.26	NA	090
49580		A	Repair umbilical hernia	4.11	2.92	NA	0.34	7.37	NA	090
49582		A	Repair umbilical hernia	6.65	4.82	NA	0.57	12.04	NA	090
49585		A	Repair umbilical hernia	6.23	4.07	NA	0.53	10.83	NA	090
49587		A	Repair umbilical hernia	7.56	4.21	NA	0.65	12.42	NA	090
49590		A	Repair abdominal hernia	8.54	4.89	NA	0.74	14.17	NA	090
49600		A	Repair umbilical lesion	10.96	6.30	NA	1.13	18.39	NA	090
49605		A	Repair umbilical lesion	22.66	10.94	NA	2.57	36.17	NA	090
49606		A	Repair umbilical lesion	18.60	9.23	NA	2.22	30.05	NA	090
49610		A	Repair umbilical lesion	10.50	6.73	NA	0.77	18.00	NA	090
49611		A	Repair umbilical lesion	8.92	6.42	NA	0.65	15.99	NA	090
49650		A	Laparo hernia repair initial	6.27	3.29	NA	0.64	10.20	NA	090
49651		A	Laparo hernia repair recur	8.24	4.34	NA	0.84	13.42	NA	090
49659		C	Laparo proc, hernia repair	0.00	0.00	0.00	0.00	0.00	0.00	YYY
49900		A	Repair of abdominal wall	12.28	6.72	NA	1.23	20.23	NA	090
49905		A	Omental flap	6.55	2.30	NA	0.61	9.46	NA	ZZZ
49906		C	Free omental flap, microvasc	0.00	0.00	0.00	0.00	0.00	0.00	090
49999		C	Abdomen surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
50010		A	Exploration of kidney	10.98	6.80	NA	0.79	18.57	NA	090
50020		A	Renal abscess, open drain	14.66	13.73	NA	0.80	29.19	NA	090
50021		A	Renal abscess, percut drain	3.38	12.63	NA	0.15	16.16	NA	000
50040		A	Drainage of kidney	14.94	11.46	NA	0.82	27.22	NA	090
50045		A	Exploration of kidney	15.46	8.23	NA	1.06	24.75	NA	090
50060		A	Removal of kidney stone	19.30	9.60	NA	1.14	30.04	NA	090
50065		A	Incision of kidney	20.79	7.79	NA	1.13	29.71	NA	090
50070		A	Incision of kidney	20.32	10.48	NA	1.20	32.00	NA	090
50075		A	Removal of kidney stone	25.34	12.28	NA	1.51	39.13	NA	090
50080		A	Removal of kidney stone	14.71	10.56	NA	0.86	26.13	NA	090
50081		A	Removal of kidney stone	21.80	12.63	NA	1.30	35.73	NA	090
50100		A	Revise kidney blood vessels	16.09	9.39	NA	1.64	27.12	NA	090
50120		A	Exploration of kidney	15.91	8.65	NA	1.04	25.60	NA	090
50125		A	Explore and drain kidney	16.52	8.73	NA	1.07	26.32	NA	090
50130		A	Removal of kidney stone	17.29	8.89	NA	1.04	27.22	NA	090
50135		A	Exploration of kidney	19.18	9.49	NA	1.18	29.85	NA	090
50200		A	Biopsy of kidney	2.63	0.93	NA	0.12	3.68	NA	000
50205		A	Biopsy of kidney	11.31	6.38	NA	0.94	18.63	NA	090
50220		A	Removal of kidney	17.15	8.98	NA	1.16	27.29	NA	090
50225		A	Removal of kidney	20.23	9.94	NA	1.26	31.43	NA	090
50230		A	Removal of kidney	22.07	10.54	NA	1.35	33.96	NA	090
50234		A	Removal of kidney & ureter	22.40	10.62	NA	1.37	34.39	NA	090
50236		A	Removal of kidney & ureter	24.86	13.67	NA	1.50	40.03	NA	090
50240		A	Partial removal of kidney	22.00	12.71	NA	1.36	36.07	NA	090
50280		A	Removal of kidney lesion	15.67	8.38	NA	0.99	25.04	NA	090
50290		A	Removal of kidney lesion	14.73	8.15	NA	1.11	23.99	NA	090
50300		X	Removal of donor kidney	0.00	0.00	0.00	0.00	0.00	0.00	XXX
50320		A	Removal of donor kidney	22.21	10.41	NA	1.78	34.40	NA	090
50340		A	Removal of kidney	12.15	8.83	NA	1.15	22.13	NA	090
50360		A	Transplantation of kidney	31.53	17.54	NA	2.97	52.04	NA	090
50365		A	Transplantation of kidney	36.81	21.31	NA	3.51	61.63	NA	090
50370		A	Remove transplanted kidney	13.72	9.67	NA	1.26	24.65	NA	090
50380		A	Reimplantation of kidney	20.76	13.56	NA	1.80	36.12	NA	090
50390		A	Drainage of kidney lesion	1.96	0.68	NA	0.09	2.73	NA	000
50392		A	Insert kidney drain	3.38	1.17	NA	0.15	4.70	NA	000
50393		A	Insert ureteral tube	4.16	1.44	NA	0.18	5.78	NA	000
50394		A	Injection for kidney x-ray	0.76	0.26	13.83	0.04	1.06	14.63	000
50395		A	Create passage to kidney	3.38	1.16	NA	0.16	4.70	NA	000
50396		A	Measure kidney pressure	2.09	0.88	NA	0.10	3.07	NA	000
50398		A	Change kidney tube	1.46	0.50	1.36	0.07	2.03	2.89	000
50400		A	Revision of kidney/ureter	19.50	9.69	NA	1.21	30.40	NA	090
50405		A	Revision of kidney/ureter	23.93	12.83	NA	1.45	38.21	NA	090
50500		A	Repair of kidney wound	19.57	11.22	NA	1.45	32.24	NA	090
50520		A	Close kidney-skin fistula	17.23	10.54	NA	1.26	29.03	NA	090
50525		A	Repair renal-abdomen fistula	22.27	12.65	NA	1.51	36.43	NA	090
50526		A	Repair renal-abdomen fistula	24.02	15.49	NA	1.62	41.13	NA	090
50540		A	Revision of horseshoe kidney	19.93	10.96	NA	1.28	32.17	NA	090
50541		A	Laparo ablate renal cyst	16.00	6.63	NA	0.99	23.62	NA	090
50544		A	Laparoscopy, pyeloplasty	22.40	8.83	NA	1.41	32.64	NA	090
50545		A	Laparo radical nephrectomy	24.00	9.44	NA	1.81	35.25	NA	090
50546		A	Laparoscopic nephrectomy	20.48	8.27	NA	1.37	30.12	NA	090
50547		A	Laparo removal donor kidney	25.50	10.71	NA	2.04	38.25	NA	090
50548		A	Laparo remove k/ureter	24.40	9.47	NA	1.49	35.36	NA	090
50549		C	Laparoscope proc, renal	0.00	0.00	0.00	0.00	0.00	0.00	YYY
50551		A	Kidney endoscopy	5.60	1.87	4.62	0.33	7.80	10.55	000
50553		A	Kidney endoscopy	5.99	2.05	16.02	0.35	8.39	22.36	000

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
50555		A	Kidney endoscopy & biopsy	6.53	2.20	18.71	0.38	9.11	25.62	000
50557		A	Kidney endoscopy & treatment	6.62	2.22	18.82	0.39	9.23	25.83	000
50559		A	Renal endoscopy/radiotracer	6.78	2.43	NA	0.27	9.48	NA	000
50561		A	Kidney endoscopy & treatment	7.59	2.56	16.87	0.44	10.59	24.90	000
50570		A	Kidney endoscopy	9.54	3.20	NA	0.56	13.30	NA	000
50572		A	Kidney endoscopy	10.35	3.47	NA	0.64	14.46	NA	000
50574		A	Kidney endoscopy & biopsy	11.02	3.69	NA	0.65	15.36	NA	000
50575		A	Kidney endoscopy	13.98	4.69	NA	0.84	19.51	NA	000
50576		A	Kidney endoscopy & treatment	10.99	3.65	NA	0.66	15.30	NA	000
50578		A	Renal endoscopy/radiotracer	11.35	3.80	NA	0.67	15.82	NA	000
50580		A	Kidney endoscopy & treatment	11.86	3.99	NA	0.70	16.55	NA	000
50590		A	Fragmenting of kidney stone	9.09	5.07	10.10	0.54	14.70	19.73	090
50600		A	Exploration of ureter	15.84	8.51	NA	0.99	25.34	NA	090
50605		A	Insert ureteral support	15.46	8.71	NA	1.13	25.30	NA	090
50610		A	Removal of ureter stone	15.92	8.96	NA	1.08	25.96	NA	090
50620		A	Removal of ureter stone	15.16	8.09	NA	0.91	24.16	NA	090
50630		A	Removal of ureter stone	14.94	8.16	NA	0.90	24.00	NA	090
50650		A	Removal of ureter	17.41	9.25	NA	1.07	27.73	NA	090
50660		A	Removal of ureter	19.55	10.03	NA	1.19	30.77	NA	090
50684		A	Injection for ureter x-ray	0.76	0.26	14.20	0.04	1.06	15.00	000
50686		A	Measure ureter pressure	1.51	0.71	4.77	0.09	2.31	6.37	000
50688		A	Change of ureter tube	1.17	1.75	NA	0.06	2.98	NA	010
50690		A	Injection for ureter x-ray	1.16	0.40	14.48	0.06	1.62	15.70	000
50700		A	Revision of ureter	15.21	8.97	NA	0.86	25.04	NA	090
50715		A	Release of ureter	18.90	12.10	NA	1.68	32.68	NA	090
50722		A	Release of ureter	16.35	9.40	NA	1.41	27.16	NA	090
50725		A	Release/revise ureter	18.49	10.26	NA	1.44	30.19	NA	090
50727		A	Revise ureter	8.18	6.23	NA	0.51	14.92	NA	090
50728		A	Revise ureter	12.02	7.80	NA	0.88	20.70	NA	090
50740		A	Fusion of ureter & kidney	18.42	9.33	NA	1.49	29.24	NA	090
50750		A	Fusion of ureter & kidney	19.51	10.28	NA	1.24	31.03	NA	090
50760		A	Fusion of ureters	18.42	9.70	NA	1.25	29.37	NA	090
50770		A	Splicing of ureters	19.51	9.93	NA	1.25	30.69	NA	090
50780		A	Reimplant ureter in bladder	18.36	9.65	NA	1.20	29.21	NA	090
50782		A	Reimplant ureter in bladder	19.54	11.18	NA	1.13	31.85	NA	090
50783		A	Reimplant ureter in bladder	20.55	10.62	NA	1.35	32.52	NA	090
50785		A	Reimplant ureter in bladder	20.52	10.37	NA	1.30	32.19	NA	090
50800		A	Implant ureter in bowel	14.52	9.38	NA	0.92	24.82	NA	090
50810		A	Fusion of ureter & bowel	20.05	12.91	NA	1.78	34.74	NA	090
50815		A	Urine shunt to bowel	19.93	11.47	NA	1.31	32.71	NA	090
50820		A	Construct bowel bladder	21.89	11.33	NA	1.38	34.60	NA	090
50825		A	Construct bowel bladder	28.18	14.68	NA	1.81	44.67	NA	090
50830		A	Revise urine flow	31.28	15.36	NA	2.20	48.84	NA	090
50840		A	Replace ureter by bowel	20.00	11.53	NA	1.26	32.79	NA	090
50845		A	Appendico-vesicostomy	20.89	9.67	NA	1.26	31.82	NA	090
50860		A	Transplant ureter to skin	15.36	8.67	NA	1.01	25.04	NA	090
50900		A	Repair of ureter	13.62	7.77	NA	0.98	22.37	NA	090
50920		A	Closure ureter/skin fistula	14.33	8.72	NA	0.84	23.89	NA	090
50930		A	Closure ureter/bowel fistula	18.72	9.73	NA	1.57	30.02	NA	090
50940		A	Release of ureter	14.51	8.17	NA	1.04	23.72	NA	090
50945		A	Laparoscopy ureterolithotomy	17.00	7.41	NA	1.15	25.56	NA	090
50947		A	Laparo new ureter/bladder	24.50	11.58	NA	1.84	37.92	NA	090
50948		A	Laparo new ureter/bladder	22.50	10.47	NA	1.70	34.67	NA	090
50949		C	Laparoscope proc, ureter	0.00	0.00	0.00	0.00	0.00	0.00	YYY
50951		A	Endoscopy of ureter	5.84	1.96	5.01	0.35	8.15	11.20	000
50953		A	Endoscopy of ureter	6.24	2.09	17.98	0.37	8.70	24.59	000
50955		A	Ureter endoscopy & biopsy	6.75	2.30	18.69	0.38	9.43	25.82	000
50957		A	Ureter endoscopy & treatment	6.79	2.28	18.28	0.40	9.47	25.47	000
50959		A	Ureter endoscopy & tracer	4.40	1.59	NA	0.18	6.17	NA	000
50961		A	Ureter endoscopy & treatment	6.05	2.04	22.48	0.35	8.44	28.88	000
50970		A	Ureter endoscopy	7.14	2.40	NA	0.43	9.97	NA	000
50972		A	Ureter endoscopy & catheter	6.89	2.37	NA	0.39	9.65	NA	000
50974		A	Ureter endoscopy & biopsy	9.17	3.01	NA	0.53	12.71	NA	000
50976		A	Ureter endoscopy & treatment	9.04	3.03	NA	0.53	12.60	NA	000
50978		A	Ureter endoscopy & tracer	5.10	1.75	NA	0.30	7.15	NA	000
50980		A	Ureter endoscopy & treatment	6.85	2.31	NA	0.41	9.57	NA	000
51000		A	Drainage of bladder	0.78	0.25	1.95	0.05	1.08	2.78	000
51005		A	Drainage of bladder	1.02	0.35	3.25	0.08	1.45	4.35	000
51010		A	Drainage of bladder	3.53	1.86	6.96	0.23	5.62	10.72	010
51020		A	Incise & treat bladder	6.71	5.42	NA	0.42	12.55	NA	090
51030		A	Incise & treat bladder	6.77	5.46	NA	0.42	12.65	NA	090
51040		A	Incise & drain bladder	4.40	4.19	NA	0.27	8.86	NA	090
51045		A	Incise bladder/drain ureter	6.77	5.73	NA	0.47	12.97	NA	090
51050		A	Removal of bladder stone	6.92	4.98	NA	0.42	12.32	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
51060		A	Removal of ureter stone	8.85	6.16	NA	0.54	15.55	NA	090
51065		A	Removal of ureter stone	8.85	5.99	NA	0.53	15.37	NA	090
51080		A	Drainage of bladder abscess	5.96	5.51	NA	0.35	11.82	NA	090
51500		A	Removal of bladder cyst	10.14	5.99	NA	0.88	17.01	NA	090
51520		A	Removal of bladder lesion	9.29	6.21	NA	0.58	16.08	NA	090
51525		A	Removal of bladder lesion	13.97	7.78	NA	0.85	22.60	NA	090
51530		A	Removal of bladder lesion	12.38	7.37	NA	0.82	20.57	NA	090
51535		A	Repair of ureter lesion	12.57	7.80	NA	0.90	21.27	NA	090
51550		A	Partial removal of bladder	15.66	8.38	NA	1.05	25.09	NA	090
51555		A	Partial removal of bladder	21.23	10.64	NA	1.37	33.24	NA	090
51565		A	Revise bladder & ureter(s)	21.62	11.17	NA	1.40	34.19	NA	090
51570		A	Removal of bladder	24.24	12.39	NA	1.59	38.22	NA	090
51575		A	Removal of bladder & nodes	30.45	14.82	NA	1.88	47.15	NA	090
51580		A	Remove bladder/revise tract	31.08	15.33	NA	1.94	48.35	NA	090
51585		A	Removal of bladder & nodes	35.23	16.59	NA	2.18	54.00	NA	090
51590		A	Remove bladder/revise tract	32.66	15.48	NA	2.01	50.15	NA	090
51595		A	Remove bladder/revise tract	37.14	16.93	NA	2.23	56.30	NA	090
51596		A	Remove bladder/create pouch	39.52	18.20	NA	2.39	60.11	NA	090
51597		A	Removal of pelvic structures	38.35	17.93	NA	2.49	58.77	NA	090
51600		A	Injection for bladder x-ray	0.88	0.30	14.75	0.04	1.22	15.67	000
51605		A	Preparation for bladder xray	0.64	0.22	15.45	0.04	0.90	16.13	000
51610		A	Injection for bladder x-ray	1.05	0.36	15.23	0.05	1.46	16.33	000
51700		A	Irrigation of bladder	0.88	0.33	3.74	0.05	1.26	4.67	000
51705		A	Change of bladder tube	1.02	1.25	2.50	0.06	2.33	3.58	010
51710		A	Change of bladder tube	1.49	1.39	4.72	0.09	2.97	6.30	010
51715		A	Endoscopic injection/implant	3.74	1.28	4.20	0.24	5.26	8.18	000
51720		A	Treatment of bladder lesion	1.96	0.66	4.03	0.12	2.74	6.11	000
51725		A	Simple cystometrogram	1.51	NA	5.50	0.13	NA	7.14	000
51725	26	A	Simple cystometrogram	1.51	0.52	0.52	0.10	2.13	2.13	000
51725	TC	A	Simple cystometrogram	0.00	NA	4.98	0.03	NA	5.01	000
51726		A	Complex cystometrogram	1.71	NA	4.33	0.15	NA	6.19	000
51726	26	A	Complex cystometrogram	1.71	0.59	0.59	0.11	2.41	2.41	000
51726	TC	A	Complex cystometrogram	0.00	NA	3.74	0.04	NA	3.78	000
51736		A	Urine flow measurement	0.61	NA	0.99	0.05	NA	1.65	000
51736	26	A	Urine flow measurement	0.61	0.21	0.21	0.04	0.86	0.86	000
51736	TC	A	Urine flow measurement	0.00	NA	0.78	0.01	NA	0.79	000
51741		A	Electro-uroflowmetry, first	1.14	NA	1.75	0.09	NA	2.98	000
51741	26	A	Electro-uroflowmetry, first	1.14	0.39	0.39	0.07	1.60	1.60	000
51741	TC	A	Electro-uroflowmetry, first	0.00	NA	1.36	0.02	NA	1.38	000
51772		A	Urethra pressure profile	1.61	NA	4.42	0.16	NA	6.19	000
51772	26	A	Urethra pressure profile	1.61	0.58	0.58	0.12	2.31	2.31	000
51772	TC	A	Urethra pressure profile	0.00	NA	3.84	0.04	NA	3.88	000
51784		A	Anal/urinary muscle study	1.53	NA	3.08	0.13	NA	4.74	000
51784	26	A	Anal/urinary muscle study	1.53	0.53	0.53	0.10	2.16	2.16	000
51784	TC	A	Anal/urinary muscle study	0.00	NA	2.55	0.03	NA	2.58	000
51785		A	Anal/urinary muscle study	1.53	NA	3.12	0.12	NA	4.77	000
51785	26	A	Anal/urinary muscle study	1.53	0.53	0.53	0.09	2.15	2.15	000
51785	TC	A	Anal/urinary muscle study	0.00	NA	2.59	0.03	NA	2.62	000
51792		A	Urinary reflex study	1.10	NA	3.18	0.20	NA	4.48	000
51792	26	A	Urinary reflex study	1.10	0.44	0.44	0.09	1.63	1.63	000
51792	TC	A	Urinary reflex study	0.00	NA	2.74	0.11	NA	2.85	000
51795		A	Urine voiding pressure study	1.53	NA	4.53	0.18	NA	6.24	000
51795	26	A	Urine voiding pressure study	1.53	0.53	0.53	0.10	2.16	2.16	000
51795	TC	A	Urine voiding pressure study	0.00	NA	4.00	0.08	NA	4.08	000
51797		A	Intraabdominal pressure test	1.60	NA	4.48	0.14	NA	6.22	000
51797	26	A	Intraabdominal pressure test	1.60	0.55	0.55	0.10	2.25	2.25	000
51797	TC	A	Intraabdominal pressure test	0.00	NA	3.93	0.04	NA	3.97	000
51800		A	Revision of bladder/urethra	17.42	9.26	NA	1.17	27.85	NA	090
51820		A	Revision of urinary tract	17.89	10.78	NA	1.45	30.12	NA	090
51840		A	Attach bladder/urethra	10.71	6.65	NA	0.87	18.23	NA	090
51841		A	Attach bladder/urethra	13.03	8.36	NA	1.04	22.43	NA	090
51845		A	Repair bladder neck	9.73	6.56	NA	0.62	16.91	NA	090
51860		A	Repair of bladder wound	12.02	7.66	NA	0.89	20.57	NA	090
51865		A	Repair of bladder wound	15.04	8.55	NA	1.01	24.60	NA	090
51880		A	Repair of bladder opening	7.66	5.56	NA	0.54	13.76	NA	090
51900		A	Repair bladder/vagina lesion	12.97	7.93	NA	0.87	21.77	NA	090
51920		A	Close bladder-uterus fistula	11.81	7.67	NA	0.86	20.34	NA	090
51925		A	Hysterectomy/bladder repair	15.58	9.17	NA	1.48	26.23	NA	090
51940		A	Correction of bladder defect	28.43	14.31	NA	1.97	44.71	NA	090
51960		A	Revision of bladder & bowel	23.01	12.58	NA	1.41	37.00	NA	090
51980		A	Construct bladder opening	11.36	7.01	NA	0.74	19.11	NA	090
51990		A	Laparo urethral suspension	12.50	6.53	NA	1.02	20.05	NA	090
51992		A	Laparo sling operation	14.01	6.54	NA	0.93	21.48	NA	090
52000		A	Cystoscopy	2.01	0.68	3.20	0.12	2.81	5.33	000

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
52005		A	Cystoscopy & ureter catheter	2.37	0.79	4.97	0.15	3.31	7.49	000
52007		A	Cystoscopy and biopsy	3.02	1.01	NA	0.18	4.21	NA	000
52010		A	Cystoscopy & duct catheter	3.02	1.02	5.34	0.18	4.22	8.54	000
52204		A	Cystoscopy	2.37	0.80	5.72	0.15	3.32	8.24	000
52214		A	Cystoscopy and treatment	3.71	1.24	6.08	0.22	5.17	10.01	000
52224		A	Cystoscopy and treatment	3.14	1.05	5.94	0.18	4.37	9.26	000
52234		A	Cystoscopy and treatment	4.63	1.55	6.86	0.27	6.45	11.76	000
52235		A	Cystoscopy and treatment	5.45	1.83	7.15	0.32	7.60	12.92	000
52240		A	Cystoscopy and treatment	9.72	3.26	8.58	0.58	13.56	18.88	000
52250		A	Cystoscopy and radiotracer	4.50	1.51	NA	0.27	6.28	NA	000
52260		A	Cystoscopy and treatment	3.92	1.32	NA	0.23	5.47	NA	000
52265		A	Cystoscopy and treatment	2.94	0.99	3.62	0.18	4.11	6.74	000
52270		A	Cystoscopy & revise urethra	3.37	1.13	6.47	0.20	4.70	10.04	000
52275		A	Cystoscopy & revise urethra	4.70	1.57	6.96	0.28	6.55	11.94	000
52276		A	Cystoscopy and treatment	5.00	1.67	7.06	0.30	6.97	12.36	000
52277		A	Cystoscopy and treatment	6.17	2.10	NA	0.38	8.65	NA	000
52281		A	Cystoscopy and treatment	2.80	0.94	3.62	0.17	3.91	6.59	000
52282		A	Cystoscopy, implant stent	6.40	2.15	7.23	0.38	8.93	14.01	000
52283		A	Cystoscopy and treatment	3.74	1.26	6.37	0.22	5.22	10.33	000
52285		A	Cystoscopy and treatment	3.61	1.21	6.58	0.22	5.04	10.41	000
52290		A	Cystoscopy and treatment	4.59	1.55	NA	0.27	6.41	NA	000
52300		A	Cystoscopy and treatment	5.31	1.78	NA	0.32	7.41	NA	000
52301		A	Cystoscopy and treatment	5.51	1.79	NA	0.39	7.69	NA	000
52305		A	Cystoscopy and treatment	5.31	1.78	NA	0.31	7.40	NA	000
52310		A	Cystoscopy and treatment	2.81	0.94	14.32	0.17	3.92	17.30	000
52315		A	Cystoscopy and treatment	5.21	1.75	15.30	0.31	7.27	20.82	000
52317		A	Remove bladder stone	6.72	2.25	24.35	0.40	9.37	31.47	000
52318		A	Remove bladder stone	9.19	3.08	NA	0.54	12.81	NA	000
52320		A	Cystoscopy and treatment	4.70	1.58	NA	0.28	6.56	NA	000
52325		A	Cystoscopy, stone removal	6.16	2.06	NA	0.37	8.59	NA	000
52327		A	Cystoscopy, inject material	5.19	1.77	NA	0.32	7.28	NA	000
52330		A	Cystoscopy and treatment	5.04	1.69	19.35	0.30	7.03	24.69	000
52332		A	Cystoscopy and treatment	2.83	0.95	29.05	0.17	3.95	32.05	000
52334		A	Create passage to kidney	4.83	1.62	NA	0.28	6.73	NA	000
52341		A	Cysto w/ureter stricture tx	6.00	2.37	NA	0.34	8.71	NA	000
52342		A	Cysto w/up stricture tx	6.50	2.57	NA	0.36	9.43	NA	000
52343		A	Cysto w/renal stricture tx	7.20	2.85	NA	0.40	10.45	NA	000
52344		A	Cysto/uretero, stone remove	7.70	3.04	NA	0.42	11.16	NA	000
52345		A	Cysto/uretero w/up stricture	8.20	3.24	NA	0.46	11.90	NA	000
52346		A	Cystouretero w/renal strict	9.23	3.65	NA	0.51	13.39	NA	000
52351		A	Cystouretro & or pyeloscope	5.86	1.97	NA	0.32	8.15	NA	000
52352		A	Cystouretro w/stone remove	6.88	2.31	NA	0.38	9.57	NA	000
52353		A	Cystouretero w/lithotripsy	7.97	2.67	NA	0.44	11.08	NA	000
52354		A	Cystouretero w/biopsy	7.34	2.46	NA	0.41	10.21	NA	000
52355		A	Cystouretero w/excise tumor	8.82	2.96	NA	0.50	12.28	NA	000
52400		A	Cystouretero w/congen repr	9.68	5.45	NA	0.53	15.66	NA	090
52450		A	Incision of prostate	7.64	6.17	NA	0.46	14.27	NA	090
52500		A	Revision of bladder neck	8.47	6.44	NA	0.50	15.41	NA	090
52510		A	Dilation prostatic urethra	6.72	5.50	NA	0.40	12.62	NA	090
52601		A	Prostatectomy (TURP)	12.37	7.76	NA	0.74	20.87	NA	090
52606		A	Control postop bleeding	8.13	5.93	NA	0.49	14.55	NA	090
52612		A	Prostatectomy, first stage	7.98	6.29	NA	0.48	14.75	NA	090
52614		A	Prostatectomy, second stage	6.84	5.89	NA	0.41	13.14	NA	090
52620		A	Remove residual prostate	6.61	5.83	NA	0.39	12.83	NA	090
52630		A	Remove prostate regrowth	7.26	6.05	NA	0.43	13.74	NA	090
52640		A	Relieve bladder contracture	6.62	5.40	NA	0.39	12.41	NA	090
52647		A	Laser surgery of prostate	10.36	5.33	57.84	0.61	16.30	68.81	090
52648		A	Laser surgery of prostate	11.21	7.39	NA	0.66	19.26	NA	090
52700		A	Drainage of prostate abscess	6.80	5.98	NA	0.41	13.19	NA	090
53000		A	Incision of urethra	2.28	2.46	7.27	0.13	4.87	9.68	010
53010		A	Incision of urethra	3.64	3.97	NA	0.20	7.81	NA	090
53020		A	Incision of urethra	1.77	0.66	3.91	0.11	2.54	5.79	000
53025		A	Incision of urethra	1.13	0.44	4.44	0.07	1.64	5.64	000
53040		A	Drainage of urethra abscess	6.40	7.92	12.82	0.41	14.73	19.63	090
53060		A	Drainage of urethra abscess	2.63	3.03	6.22	0.23	5.89	9.08	010
53080		A	Drainage of urinary leakage	6.29	7.84	NA	0.42	14.55	NA	090
53085		A	Drainage of urinary leakage	10.27	9.30	NA	0.67	20.24	NA	090
53200		A	Biopsy of urethra	2.59	0.96	5.28	0.17	3.72	8.04	000
53210		A	Removal of urethra	12.57	7.75	NA	0.81	21.13	NA	090
53215		A	Removal of urethra	15.58	8.41	NA	0.93	24.92	NA	090
53220		A	Treatment of urethra lesion	7.00	5.35	NA	0.44	12.79	NA	090
53230		A	Removal of urethra lesion	9.58	6.09	NA	0.60	16.27	NA	090
53235		A	Removal of urethra lesion	10.14	6.33	NA	0.60	17.07	NA	090
53240		A	Surgery for urethra pouch	6.45	4.92	NA	0.42	11.79	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
53250		A	Removal of urethra gland	5.89	4.21	NA	0.35	10.45	NA	090
53260		A	Treatment of urethra lesion	2.98	2.33	5.88	0.23	5.54	9.09	010
53265		A	Treatment of urethra lesion	3.12	2.28	6.20	0.20	5.60	9.52	010
53270		A	Removal of urethra gland	3.09	2.41	5.55	0.21	5.71	8.85	010
53275		A	Repair of urethra defect	4.53	3.22	NA	0.28	8.03	NA	010
53400		A	Revise urethra, stage 1	12.77	7.82	NA	0.85	21.44	NA	090
53405		A	Revise urethra, stage 2	14.48	8.12	NA	0.91	23.51	NA	090
53410		A	Reconstruction of urethra	16.44	8.72	NA	0.99	26.15	NA	090
53415		A	Reconstruction of urethra	19.41	9.63	NA	1.16	30.20	NA	090
53420		A	Reconstruct urethra, stage 1	14.08	8.41	NA	0.90	23.39	NA	090
53425		A	Reconstruct urethra, stage 2	15.98	8.93	NA	0.97	25.88	NA	090
53430		A	Reconstruction of urethra	16.34	8.88	NA	1.01	26.23	NA	090
53440		A	Correct bladder function	12.34	7.66	NA	0.73	20.73	NA	090
53442		A	Remove perineal prosthesis	8.27	5.81	NA	0.55	14.63	NA	090
53443		A	Reconstruction of urethra	19.89	9.44	NA	1.25	30.58	NA	090
53445		A	Correct urine flow control	14.06	8.26	NA	0.84	23.16	NA	090
53447		A	Remove artificial sphincter	13.17	7.55	NA	0.79	21.51	NA	090
53449		A	Correct artificial sphincter	9.70	6.38	NA	0.57	16.65	NA	090
53450		A	Revision of urethra	6.14	4.84	NA	0.37	11.35	NA	090
53460		A	Revision of urethra	7.12	5.21	NA	0.43	12.76	NA	090
53502		A	Repair of urethra injury	7.63	5.42	NA	0.50	13.55	NA	090
53505		A	Repair of urethra injury	7.63	5.35	NA	0.46	13.44	NA	090
53510		A	Repair of urethra injury	10.11	6.41	NA	0.60	17.12	NA	090
53515		A	Repair of urethra injury	13.31	7.29	NA	0.83	21.43	NA	090
53520		A	Repair of urethra defect	8.68	5.82	NA	0.53	15.03	NA	090
53600		A	Dilate urethra stricture	1.21	0.50	3.94	0.07	1.78	5.22	000
53601		A	Dilate urethra stricture	0.98	0.43	3.87	0.06	1.47	4.91	000
53605		A	Dilate urethra stricture	1.28	0.43	NA	0.08	1.79	NA	000
53620		A	Dilate urethra stricture	1.62	0.54	5.85	0.10	2.26	7.57	000
53621		A	Dilate urethra stricture	1.35	0.45	5.87	0.08	1.88	7.30	000
53660		A	Dilation of urethra	0.71	0.34	3.72	0.04	1.09	4.47	000
53661		A	Dilation of urethra	0.72	0.24	3.77	0.04	1.00	4.53	000
53665		A	Dilation of urethra	0.76	0.26	NA	0.05	1.07	NA	000
53670		A	Insert urinary catheter	0.50	0.21	3.48	0.03	0.74	4.01	000
53675		A	Insert urinary catheter	1.47	0.48	4.70	0.09	2.04	6.26	000
53850		A	Prostatic microwave thermotx	9.45	4.98	82.83	0.56	14.99	92.84	090
53852		A	Prostatic rf thermotx	9.88	5.23	71.16	0.58	15.69	81.62	090
53899		C	Urology surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
54000		A	Slitting of prepuce	1.54	1.39	5.42	0.10	3.03	7.06	010
54001		A	Slitting of prepuce	2.19	2.01	6.02	0.14	4.34	8.35	010
54015		A	Drain penis lesion	5.32	3.07	6.85	0.33	8.72	12.50	010
54050		A	Destruction, penis lesion(s)	1.24	0.50	2.64	0.07	1.81	3.95	010
54055		A	Destruction, penis lesion(s)	1.22	1.40	6.48	0.07	2.69	7.77	010
54056		A	Cryosurgery, penis lesion(s)	1.24	0.53	2.92	0.06	1.83	4.22	010
54057		A	Laser surg, penis lesion(s)	1.24	1.30	2.92	0.08	2.62	4.24	010
54060		A	Excision of penis lesion(s)	1.93	1.56	5.37	0.12	3.61	7.42	010
54065		A	Destruction, penis lesion(s)	2.42	2.08	5.28	0.13	4.63	7.83	010
54100		A	Biopsy of penis	1.90	0.74	3.57	0.10	2.74	5.57	000
54105		A	Biopsy of penis	3.50	2.09	6.24	0.21	5.80	9.95	010
54110		A	Treatment of penis lesion	10.13	7.76	NA	0.60	18.49	NA	090
54111		A	Treat penis lesion, graft	13.57	8.81	NA	0.79	23.17	NA	090
54112		A	Treat penis lesion, graft	15.86	9.64	NA	0.94	26.44	NA	090
54115		A	Treatment of penis lesion	6.15	6.49	10.30	0.39	13.03	16.84	090
54120		A	Partial removal of penis	9.97	7.69	NA	0.60	18.26	NA	090
54125		A	Removal of penis	13.53	8.86	NA	0.81	23.20	NA	090
54130		A	Remove penis & nodes	20.14	11.35	NA	1.19	32.68	NA	090
54135		A	Remove penis & nodes	26.36	13.47	NA	1.58	41.41	NA	090
54150		A	Circumcision	1.81	1.91	7.90	0.17	3.89	9.88	010
54152		A	Circumcision	2.31	1.71	NA	0.16	4.18	NA	010
54160		A	Circumcision	2.48	1.71	5.89	0.16	4.35	8.53	010
54161		A	Circumcision	3.27	1.99	NA	0.20	5.46	NA	010
54200		A	Treatment of penis lesion	1.06	0.37	2.62	0.06	1.49	3.74	010
54205		A	Treatment of penis lesion	7.93	7.15	NA	0.47	15.55	NA	090
54220		A	Treatment of penis lesion	2.42	1.00	1.94	0.15	3.57	4.51	000
54230		A	Prepare penis study	1.34	0.45	NA	0.08	1.87	NA	000
54231		A	Dynamic cavernosometry	2.04	0.80	2.19	0.14	2.98	4.37	000
54235		A	Penile injection	1.19	0.40	1.11	0.07	1.66	2.37	000
54240		A	Penis study	1.31	NA	1.19	0.13	NA	2.63	000
54240	26	A	Penis study	1.31	0.45	0.45	0.08	1.84	1.84	000
54240	TC	A	Penis study	0.00	NA	0.74	0.05	NA	0.79	000
54250		A	Penis study	2.22	NA	3.37	0.16	NA	5.75	000
54250	26	A	Penis study	2.22	0.74	0.74	0.14	3.10	3.10	000
54250	TC	A	Penis study	0.00	NA	2.63	0.02	NA	2.65	000
54300		A	Revision of penis	10.41	8.42	NA	0.64	19.47	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
54304		A	Revision of penis	12.49	9.50	NA	0.74	22.73	NA	090
54308		A	Reconstruction of urethra	11.83	9.16	NA	0.70	21.69	NA	090
54312		A	Reconstruction of urethra	13.57	10.23	NA	0.81	24.61	NA	090
54316		A	Reconstruction of urethra	16.82	11.67	NA	1.00	29.49	NA	090
54318		A	Reconstruction of urethra	11.25	9.18	NA	1.15	21.58	NA	090
54322		A	Reconstruction of urethra	13.01	8.75	NA	0.77	22.53	NA	090
54324		A	Reconstruction of urethra	16.31	11.64	NA	1.03	28.98	NA	090
54326		A	Reconstruction of urethra	15.72	10.09	NA	0.93	26.74	NA	090
54328		A	Revise penis/urethra	15.65	10.43	NA	0.92	27.00	NA	090
54332		A	Revise penis/urethra	17.08	11.76	NA	1.01	29.85	NA	090
54336		A	Revise penis/urethra	20.04	16.59	NA	1.90	38.53	NA	090
54340		A	Secondary urethral surgery	8.91	7.79	NA	0.72	17.42	NA	090
54344		A	Secondary urethral surgery	15.94	11.73	NA	1.10	28.77	NA	090
54348		A	Secondary urethral surgery	17.15	12.66	NA	1.02	30.83	NA	090
54352		A	Reconstruct urethra/penis	24.74	15.36	NA	1.62	41.72	NA	090
54360		A	Penis plastic surgery	11.93	8.27	NA	0.72	20.92	NA	090
54380		A	Repair penis	13.18	9.18	NA	1.16	23.52	NA	090
54385		A	Repair penis	15.39	11.82	NA	0.71	27.92	NA	090
54390		A	Repair penis and bladder	21.61	13.41	NA	1.28	36.30	NA	090
54400		A	Insert semi-rigid prosthesis	8.99	6.12	NA	0.53	15.64	NA	090
54401		A	Insert self-contd prosthesis	10.28	6.93	NA	0.61	17.82	NA	090
54402		A	Remove penis prosthesis	9.21	6.23	NA	0.55	15.99	NA	090
54405		A	Insert multi-comp prosthesis	13.43	8.03	NA	0.80	22.26	NA	090
54407		A	Remove multi-comp prosthesis	13.34	7.62	NA	0.80	21.76	NA	090
54409		A	Revise penis prosthesis	12.20	7.37	NA	0.73	20.30	NA	090
54420		A	Revision of penis	11.42	8.18	NA	0.72	20.32	NA	090
54430		A	Revision of penis	10.15	7.71	NA	0.60	18.46	NA	090
54435		A	Revision of penis	6.12	5.81	NA	0.36	12.29	NA	090
54440		C	Repair of penis	0.00	0.00	0.00	0.00	0.00	0.00	090
54450		A	Preputial stretching	1.12	0.47	1.01	0.07	1.66	2.20	000
54500		A	Biopsy of testis	1.31	0.45	6.11	0.08	1.84	7.50	000
54505		A	Biopsy of testis	3.46	2.57	NA	0.21	6.24	NA	010
54510		A	Removal of testis lesion	5.45	3.43	NA	0.35	9.23	NA	090
54512		A	Excise lesion testis	8.58	4.92	NA	0.51	14.01	NA	090
54520		A	Removal of testis	5.23	3.55	NA	0.33	9.11	NA	090
54522		A	Orchiectomy, partial	9.50	5.88	NA	0.57	15.95	NA	090
54530		A	Removal of testis	8.58	5.18	NA	0.53	14.29	NA	090
54535		A	Extensive testis surgery	12.16	7.07	NA	0.83	20.06	NA	090
54550		A	Exploration for testis	7.78	4.70	NA	0.49	12.97	NA	090
54560		A	Exploration for testis	11.13	6.79	NA	0.79	18.71	NA	090
54600		A	Reduce testis torsion	7.01	4.21	NA	0.45	11.67	NA	090
54620		A	Suspension of testis	4.90	3.05	NA	0.31	8.26	NA	010
54640		A	Suspension of testis	6.90	4.21	NA	0.49	11.60	NA	090
54650		A	Orchiopexy (Fowler-Stephens)	11.45	7.11	NA	0.81	19.37	NA	090
54660		A	Revision of testis	5.11	3.26	NA	0.35	8.72	NA	090
54670		A	Repair testis injury	6.41	4.16	NA	0.41	10.98	NA	090
54680		A	Relocation of testis(es)	12.65	7.47	NA	0.94	21.06	NA	090
54690		A	Laparoscopy, orchiectomy	10.96	6.42	NA	0.99	18.37	NA	090
54692		A	Laparoscopy, orchiopexy	12.88	5.68	NA	0.87	19.43	NA	090
54699		C	Laparoscope proc, testis	0.00	0.00	0.00	0.00	0.00	0.00	YYY
54700		A	Drainage of scrotum	3.43	3.32	8.16	0.23	6.98	11.82	010
54800		A	Biopsy of epididymis	2.33	0.81	6.31	0.14	3.28	8.78	000
54820		A	Exploration of epididymis	5.14	3.55	NA	0.33	9.02	NA	090
54830		A	Remove epididymis lesion	5.38	3.64	NA	0.34	9.36	NA	090
54840		A	Remove epididymis lesion	5.20	3.57	NA	0.31	9.08	NA	090
54860		A	Removal of epididymis	6.32	4.14	NA	0.38	10.84	NA	090
54861		A	Removal of epididymis	8.90	5.01	NA	0.52	14.43	NA	090
54900		A	Fusion of spermatic ducts	13.20	7.06	NA	1.34	21.60	NA	090
54901		A	Fusion of spermatic ducts	17.94	9.80	NA	1.83	29.57	NA	090
55000		A	Drainage of hydrocele	1.43	0.49	2.10	0.10	2.02	3.63	000
55040		A	Removal of hydrocele	5.36	3.40	NA	0.35	9.11	NA	090
55041		A	Removal of hydroceles	7.74	4.43	NA	0.50	12.67	NA	090
55060		A	Repair of hydrocele	5.52	3.44	NA	0.37	9.33	NA	090
55100		A	Drainage of scrotum abscess	2.13	3.56	9.32	0.15	5.84	11.60	010
55110		A	Explore scrotum	5.70	3.55	NA	0.36	9.61	NA	090
55120		A	Removal of scrotum lesion	5.09	3.32	NA	0.33	8.74	NA	090
55150		A	Removal of scrotum	7.22	4.52	NA	0.47	12.21	NA	090
55175		A	Revision of scrotum	5.24	3.66	NA	0.33	9.23	NA	090
55180		A	Revision of scrotum	10.72	6.39	NA	0.72	17.83	NA	090
55200		A	Incision of sperm duct	4.24	3.06	NA	0.25	7.55	NA	090
55250		A	Removal of sperm duct(s)	3.29	3.00	9.03	0.21	6.50	12.53	090
55300		A	Prepare, sperm duct x-ray	3.51	1.45	NA	0.20	5.16	NA	000
55400		A	Repair of sperm duct	8.49	5.17	NA	0.50	14.16	NA	090
55450		A	Ligation of sperm duct	4.12	2.42	7.52	0.24	6.78	11.88	010

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
55500		A	Removal of hydrocele	5.59	3.61	NA	0.43	9.63	NA	090
55520		A	Removal of sperm cord lesion	6.03	3.72	NA	0.56	10.31	NA	090
55530		A	Revise spermatic cord veins	5.66	3.74	NA	0.36	9.76	NA	090
55535		A	Revise spermatic cord veins	6.56	4.05	NA	0.42	11.03	NA	090
55540		A	Revise hernia & sperm veins	7.67	4.30	NA	0.74	12.71	NA	090
55550		A	Laparo ligate spermatic vein	6.57	3.34	NA	0.47	10.38	NA	090
55559		C	Laparo proc, spermatic cord	0.00	0.00	0.00	0.00	0.00	0.00	YYY
55600		A	Incise sperm duct pouch	6.38	4.18	NA	0.38	10.94	NA	090
55605		A	Incise sperm duct pouch	7.96	5.13	NA	0.54	13.63	NA	090
55650		A	Remove sperm duct pouch	11.80	6.17	NA	0.72	18.69	NA	090
55680		A	Remove sperm pouch lesion	5.19	3.84	NA	0.31	9.34	NA	090
55700		A	Biopsy of prostate	1.57	0.53	3.75	0.10	2.20	5.42	000
55705		A	Biopsy of prostate	4.57	3.71	NA	0.26	8.54	NA	010
55720		A	Drainage of prostate abscess	7.64	5.92	NA	0.44	14.00	NA	090
55725		A	Drainage of prostate abscess	8.68	6.48	NA	0.51	15.67	NA	090
55801		A	Removal of prostate	17.80	9.33	NA	1.08	28.21	NA	090
55810		A	Extensive prostate surgery	22.58	11.34	NA	1.35	35.27	NA	090
55812		A	Extensive prostate surgery	27.51	13.82	NA	1.69	43.02	NA	090
55815		A	Extensive prostate surgery	30.46	14.38	NA	1.84	46.68	NA	090
55821		A	Removal of prostate	14.25	7.83	NA	0.85	22.93	NA	090
55831		A	Removal of prostate	15.62	8.32	NA	0.94	24.88	NA	090
55840		A	Extensive prostate surgery	22.69	11.76	NA	1.37	35.82	NA	090
55842		A	Extensive prostate surgery	24.38	12.37	NA	1.48	38.23	NA	090
55845		A	Extensive prostate surgery	28.55	13.70	NA	1.71	43.96	NA	090
55859		A	Percut/needle insert, pros	12.52	7.41	NA	0.74	20.67	NA	090
55860		A	Surgical exposure, prostate	14.45	8.41	NA	0.82	23.68	NA	090
55862		A	Extensive prostate surgery	18.39	9.45	NA	1.14	28.98	NA	090
55865		A	Extensive prostate surgery	22.87	11.07	NA	1.37	35.31	NA	090
55870		A	Electroejaculation	2.58	1.15	1.84	0.14	3.87	4.56	000
55873		A	Cryoablate prostate	17.80	9.99	NA	1.01	28.80	NA	090
55899		C	Genital surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
55970		N	Sex transformation, M to F	0.00	0.00	0.00	0.00	0.00	0.00	XXX
55980		N	Sex transformation, F to M	0.00	0.00	0.00	0.00	0.00	0.00	XXX
56405		A	I & D of vulva/perineum	1.44	1.26	2.35	0.14	2.84	3.93	010
56420		A	Drainage of gland abscess	1.39	1.19	2.33	0.13	2.71	3.85	010
56440		A	Surgery for vulva lesion	2.84	2.32	3.58	0.28	5.44	6.70	010
56441		A	Lysis of labial lesion(s)	1.97	2.02	2.56	0.17	4.16	4.70	010
56501		A	Destruction, vulva lesion(s)	1.53	1.35	2.31	0.15	3.03	3.99	010
56515		A	Destruction, vulva lesion(s)	2.76	2.35	3.11	0.18	5.29	6.05	010
56605		A	Biopsy of vulva/perineum	1.10	0.50	1.79	0.11	1.71	3.00	000
56606		A	Biopsy of vulva/perineum	0.55	0.23	1.56	0.06	0.84	2.17	ZZZ
56620		A	Partial removal of vulva	7.47	5.00	NA	0.76	13.23	NA	090
56625		A	Complete removal of vulva	8.40	5.92	NA	0.84	15.16	NA	090
56630		A	Extensive vulva surgery	12.36	7.84	NA	1.23	21.43	NA	090
56631		A	Extensive vulva surgery	16.20	10.53	NA	1.63	28.36	NA	090
56632		A	Extensive vulva surgery	20.29	12.33	NA	2.03	34.65	NA	090
56633		A	Extensive vulva surgery	16.47	9.51	NA	1.66	27.64	NA	090
56634		A	Extensive vulva surgery	17.88	11.26	NA	1.78	30.92	NA	090
56637		A	Extensive vulva surgery	21.97	13.02	NA	2.18	37.17	NA	090
56640		A	Extensive vulva surgery	22.17	12.70	NA	2.26	37.13	NA	090
56700		A	Partial removal of hymen	2.52	2.06	2.90	0.24	4.82	5.66	010
56720		A	Incision of hymen	0.68	0.70	1.67	0.07	1.45	2.42	000
56740		A	Remove vagina gland lesion	4.57	3.00	3.91	0.37	7.94	8.85	010
56800		A	Repair of vagina	3.89	2.73	NA	0.37	6.99	NA	010
56805		A	Repair clitoris	18.86	9.64	NA	1.82	30.32	NA	090
56810		A	Repair of perineum	4.13	2.83	NA	0.41	7.37	NA	010
57000		A	Exploration of vagina	2.97	2.35	NA	0.28	5.60	NA	010
57010		A	Drainage of pelvic abscess	6.03	3.86	NA	0.57	10.46	NA	090
57020		A	Drainage of pelvic fluid	1.50	0.65	1.61	0.15	2.30	3.26	000
57022		A	I &d vaginal hematoma, ob	2.56	1.58	NA	0.14	4.28	NA	010
57023		A	I &d vag hematoma, trauma	2.56	1.58	NA	0.14	4.28	NA	010
57061		A	Destruction vagina lesion(s)	1.25	1.24	2.25	0.13	2.62	3.63	010
57065		A	Destruction vagina lesion(s)	2.61	2.32	2.97	0.26	5.19	5.84	010
57100		A	Biopsy of vagina	1.20	0.52	1.56	0.10	1.82	2.86	000
57105		A	Biopsy of vagina	1.69	2.23	2.25	0.17	4.09	4.11	010
57106		A	Remove vagina wall, partial	6.36	2.55	2.55	0.58	9.49	9.49	090
57107		A	Remove vagina tissue, part	23.00	10.63	NA	2.17	35.80	NA	090
57109		A	Vaginectomy partial w/nodes	27.00	12.01	NA	1.97	40.98	NA	090
57110		A	Remove vagina wall, complete	14.29	7.53	NA	1.43	23.25	NA	090
57111		A	Remove vagina tissue, compl	27.00	12.71	NA	2.71	42.42	NA	090
57112		A	Vaginectomy w/nodes, compl	29.00	12.95	NA	2.19	44.14	NA	090
57120		A	Closure of vagina	7.41	4.75	NA	0.75	12.91	NA	090
57130		A	Remove vagina lesion	2.43	2.15	NA	0.23	4.81	NA	010
57135		A	Remove vagina lesion	2.67	2.25	2.95	0.26	5.18	5.88	010

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
57150		A	Treat vagina infection	0.55	0.22	1.00	0.06	0.83	1.61	000
57160		A	Insert pessary/other device	0.89	0.37	1.38	0.09	1.35	2.36	000
57170		A	Fitting of diaphragm/cap	0.91	0.35	1.42	0.09	1.35	2.42	000
57180		A	Treat vaginal bleeding	1.58	1.47	2.28	0.16	3.21	4.02	010
57200		A	Repair of vagina	3.94	3.03	NA	0.38	7.35	NA	090
57210		A	Repair vagina/perineum	5.17	3.54	NA	0.50	9.21	NA	090
57220		A	Revision of urethra	4.31	3.43	NA	0.42	8.16	NA	090
57230		A	Repair of urethral lesion	5.64	4.34	NA	0.50	10.48	NA	090
57240		A	Repair bladder & vagina	6.07	4.46	NA	0.53	11.06	NA	090
57250		A	Repair rectum & vagina	5.53	3.89	NA	0.54	9.96	NA	090
57260		A	Repair of vagina	8.27	5.06	NA	0.83	14.16	NA	090
57265		A	Extensive repair of vagina	11.34	7.10	NA	1.14	19.58	NA	090
57268		A	Repair of bowel bulge	6.76	4.40	NA	0.66	11.82	NA	090
57270		A	Repair of bowel pouch	12.11	6.45	NA	1.17	19.73	NA	090
57280		A	Suspension of vagina	15.04	7.62	NA	1.44	24.10	NA	090
57282		A	Repair of vaginal prolapse	8.86	5.31	NA	0.86	15.03	NA	090
57284		A	Repair paravaginal defect	12.70	7.28	NA	1.17	21.15	NA	090
57287		A	Revise/remove sling repair	10.71	7.13	NA	0.64	18.48	NA	090
57288		A	Repair bladder defect	13.02	6.95	NA	0.86	20.83	NA	090
57289		A	Repair bladder & vagina	11.58	6.89	NA	0.95	19.42	NA	090
57291		A	Construction of vagina	7.95	6.21	NA	0.78	14.94	NA	090
57292		A	Construct vagina with graft	13.09	7.45	NA	1.29	21.83	NA	090
57300		A	Repair rectum-vagina fistula	7.61	4.72	NA	0.70	13.03	NA	090
57305		A	Repair rectum-vagina fistula	13.77	6.94	NA	1.33	22.04	NA	090
57307		A	Fistula repair & colostomy	15.93	7.63	NA	1.59	25.15	NA	090
57308		A	Fistula repair, transperine	9.94	5.85	NA	0.91	16.70	NA	090
57310		A	Repair urethrovaginal lesion	6.78	4.69	NA	0.45	11.92	NA	090
57311		A	Repair urethrovaginal lesion	7.98	5.30	NA	0.51	13.79	NA	090
57320		A	Repair bladder-vagina lesion	8.01	5.38	NA	0.60	13.99	NA	090
57330		A	Repair bladder-vagina lesion	12.35	6.72	NA	0.86	19.93	NA	090
57335		A	Repair vagina	18.73	9.43	NA	1.66	29.82	NA	090
57400		A	Dilation of vagina	2.27	1.33	NA	0.22	3.82	NA	000
57410		A	Pelvic examination	1.75	1.09	2.64	0.14	2.98	4.53	000
57415		A	Remove vaginal foreign body	2.17	2.06	3.48	0.19	4.42	5.84	010
57452		A	Examination of vagina	0.99	0.46	1.60	0.10	1.55	2.69	000
57454		A	Vagina examination & biopsy	1.27	0.62	1.79	0.13	2.02	3.19	000
57460		A	Cervix excision	2.83	1.20	2.13	0.28	4.31	5.24	000
57500		A	Biopsy of cervix	0.97	0.50	2.12	0.10	1.57	3.19	000
57505		A	Endocervical curettage	1.14	1.27	1.95	0.12	2.53	3.21	010
57510		A	Cauterization of cervix	1.90	1.58	3.18	0.18	3.66	5.26	010
57511		A	Cryocautery of cervix	1.90	0.78	2.43	0.18	2.86	4.51	010
57513		A	Laser surgery of cervix	1.90	1.57	2.60	0.19	3.66	4.69	010
57520		A	Conization of cervix	4.04	2.87	4.28	0.41	7.32	8.73	090
57522		A	Conization of cervix	3.36	2.58	3.81	0.34	6.28	7.51	090
57530		A	Removal of cervix	4.79	3.65	NA	0.48	8.92	NA	090
57531		A	Removal of cervix, radical	28.00	13.63	NA	2.46	44.09	NA	090
57540		A	Removal of residual cervix	12.22	6.32	NA	1.21	19.75	NA	090
57545		A	Remove cervix/repair pelvis	13.03	6.90	NA	1.30	21.23	NA	090
57550		A	Removal of residual cervix	5.53	3.91	NA	0.55	9.99	NA	090
57555		A	Remove cervix/repair vagina	8.95	5.73	NA	0.89	15.57	NA	090
57556		A	Remove cervix, repair bowel	8.37	5.05	NA	0.80	14.22	NA	090
57700		A	Revision of cervix	3.55	2.53	NA	0.33	6.41	NA	090
57720		A	Revision of cervix	4.13	3.34	NA	0.41	7.88	NA	090
57800		A	Dilation of cervical canal	0.77	0.36	1.18	0.08	1.21	2.03	000
57820		A	D & c of residual cervix	1.67	2.24	2.53	0.17	4.08	4.37	010
58100		A	Biopsy of uterus lining	0.71	0.29	2.06	0.07	1.07	2.84	000
58120		A	Dilation and curettage	3.27	2.46	3.86	0.33	6.06	7.46	010
58140		A	Removal of uterus lesion	14.60	7.26	NA	1.46	23.32	NA	090
58145		A	Removal of uterus lesion	8.04	4.99	NA	0.80	13.83	NA	090
58150		A	Total hysterectomy	15.24	7.77	NA	1.53	24.54	NA	090
58152		A	Total hysterectomy	20.60	10.05	NA	1.52	32.17	NA	090
58180		A	Partial hysterectomy	15.29	7.72	NA	1.54	24.55	NA	090
58200		A	Extensive hysterectomy	21.59	11.52	NA	2.15	35.26	NA	090
58210		A	Extensive hysterectomy	28.85	14.52	NA	2.91	46.28	NA	090
58240		A	Removal of pelvis contents	38.39	19.57	NA	3.76	61.72	NA	090
58260		A	Vaginal hysterectomy	12.98	6.54	NA	1.23	20.75	NA	090
58262		A	Vaginal hysterectomy	14.77	7.32	NA	1.42	23.51	NA	090
58263		A	Vaginal hysterectomy	16.06	7.85	NA	1.55	25.46	NA	090
58267		A	Hysterectomy & vagina repair	17.04	8.25	NA	1.51	26.80	NA	090
58270		A	Hysterectomy & vagina repair	14.26	7.09	NA	1.37	22.72	NA	090
58275		A	Hysterectomy/revise vagina	15.76	7.64	NA	1.51	24.91	NA	090
58280		A	Hysterectomy/revise vagina	17.01	8.11	NA	1.54	26.66	NA	090
58285		A	Extensive hysterectomy	22.26	11.76	NA	1.88	35.90	NA	090
58300		N	Insert intrauterine device	+1.01	0.40	1.37	0.10	1.51	2.48	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
58301		A	Remove intrauterine device	1.27	0.52	1.57	0.13	1.92	2.97	000
58321		A	Artificial insemination	0.92	0.36	0.92	0.10	1.38	1.94	000
58322		A	Artificial insemination	1.10	0.44	1.04	0.11	1.65	2.25	000
58323		A	Sperm washing	0.23	0.10	0.53	0.02	0.35	0.78	000
58340		A	Catheter for hysterography	0.88	0.34	11.96	0.08	1.30	12.92	000
58345		A	Reopen fallopian tube	4.66	1.87	NA	0.36	6.89	NA	010
58350		A	Reopen fallopian tube	1.01	1.11	2.06	0.10	2.22	3.17	010
58353		A	Endometr ablate, thermal	3.56	2.26	NA	0.19	6.01	NA	010
58400		A	Suspension of uterus	6.36	4.09	NA	0.62	11.07	NA	090
58410		A	Suspension of uterus	12.73	6.75	NA	1.09	20.57	NA	090
58520		A	Repair of ruptured uterus	11.92	6.04	NA	1.17	19.13	NA	090
58540		A	Revision of uterus	14.64	7.29	NA	1.28	23.21	NA	090
58550		A	Laparo-asst vag hysterectomy	14.19	7.04	NA	1.44	22.67	NA	010
58551		A	Laparoscopy, remove myoma	14.21	6.95	NA	1.45	22.61	NA	010
58555		A	Hysteroscopy, dx, sep proc	3.33	1.52	2.90	0.34	5.19	6.57	000
58558		A	Hysteroscopy, biopsy	4.75	2.14	3.50	0.49	7.38	8.74	000
58559		A	Hysteroscopy, lysis	6.17	2.54	2.54	0.62	9.33	9.33	000
58560		A	Hysteroscopy, resect septum	7.00	3.02	3.02	0.71	10.73	10.73	000
58561		A	Hysteroscopy, remove myoma	10.00	4.27	4.27	1.02	15.29	15.29	000
58562		A	Hysteroscopy, remove fb	5.21	2.30	NA	0.52	8.03	NA	000
58563		A	Hysteroscopy, ablation	6.17	2.62	2.62	0.62	9.41	9.41	000
58578		C	Laparo proc, uterus	0.00	0.00	0.00	0.00	0.00	0.00	YYY
58579		C	Hysteroscope procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
58600		A	Division of fallopian tube	5.60	3.43	NA	0.39	9.42	NA	090
58605		A	Division of fallopian tube	5.00	3.19	NA	0.33	8.52	NA	090
58611		A	Ligate oviduct(s) add-on	1.45	0.61	NA	0.07	2.13	NA	ZZZ
58615		A	Occlude fallopian tube(s)	3.90	2.62	NA	0.40	6.92	NA	010
58660		A	Laparoscopy, lysis	11.29	5.48	NA	1.14	17.91	NA	090
58661		A	Laparoscopy, remove adnexa	11.05	5.42	NA	1.12	17.59	NA	010
58662		A	Laparoscopy, excise lesions	11.79	5.68	NA	1.18	18.65	NA	090
58670		A	Laparoscopy, tubal cautery	5.60	3.65	NA	0.55	9.80	NA	090
58671		A	Laparoscopy, tubal block	5.60	3.72	NA	0.56	9.88	NA	090
58672		A	Laparoscopy, fimbrioplasty	12.88	6.09	NA	1.22	20.19	NA	090
58673		A	Laparoscopy, salpingostomy	13.74	7.12	NA	1.40	22.26	NA	090
58679		C	Laparo proc, oviduct-ovary	0.00	0.00	0.00	0.00	0.00	0.00	YYY
58700		A	Removal of fallopian tube	12.05	6.05	NA	0.64	18.74	NA	090
58720		A	Removal of ovary/tube(s)	11.36	5.92	NA	1.14	18.42	NA	090
58740		A	Revise fallopian tube(s)	14.00	7.22	NA	0.59	21.81	NA	090
58750		A	Repair oviduct	14.84	7.52	NA	1.52	23.88	NA	090
58752		A	Revise ovarian tube(s)	14.84	7.91	NA	1.51	24.26	NA	090
58760		A	Remove tubal obstruction	13.13	6.58	NA	1.34	21.05	NA	090
58770		A	Create new tubal opening	13.97	7.24	NA	1.42	22.63	NA	090
58800		A	Drainage of ovarian cyst(s)	4.14	4.40	4.55	0.36	8.90	9.05	090
58805		A	Drainage of ovarian cyst(s)	5.88	3.53	NA	0.56	9.97	NA	090
58820		A	Drain ovary abscess, open	4.22	3.30	NA	0.29	7.81	NA	090
58822		A	Drain ovary abscess, percut	10.13	5.16	NA	0.92	16.21	NA	090
58823		A	Drain pelvic abscess, percut	3.38	3.18	NA	0.18	6.74	NA	000
58825		A	Transposition, ovary(s)	10.98	5.96	NA	0.62	17.56	NA	090
58900		A	Biopsy of ovary(s)	5.99	3.62	NA	0.56	10.17	NA	090
58920		A	Partial removal of ovary(s)	11.36	5.62	NA	0.68	17.66	NA	090
58925		A	Removal of ovarian cyst(s)	11.36	5.70	NA	1.14	18.20	NA	090
58940		A	Removal of ovary(s)	7.29	4.06	NA	0.73	12.08	NA	090
58943		A	Removal of ovary(s)	18.43	9.79	NA	1.86	30.08	NA	090
58950		A	Resect ovarian malignancy	16.93	9.26	NA	1.55	27.74	NA	090
58951		A	Resect ovarian malignancy	22.38	11.66	NA	2.20	36.24	NA	090
58952		A	Resect ovarian malignancy	25.01	12.80	NA	2.50	40.31	NA	090
58960		A	Exploration of abdomen	14.65	8.39	NA	1.47	24.51	NA	090
58970		A	Retrieval of oocyte	3.53	1.81	8.66	0.36	5.70	12.55	000
58974		C	Transfer of embryo	0.00	0.00	0.00	0.00	0.00	0.00	000
58976		A	Transfer of embryo	3.83	1.51	2.25	0.39	5.73	6.47	000
58999		C	Genital surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
59000		A	Amniocentesis	1.30	0.64	1.95	0.23	2.17	3.48	000
59012		A	Fetal cord puncture,prenatal	3.45	1.70	NA	0.62	5.77	NA	000
59015		A	Chorion biopsy	2.20	0.95	1.39	0.40	3.55	3.99	000
59020		A	Fetal contract stress test	0.66	NA	0.79	0.20	NA	1.65	000
59020	26	A	Fetal contract stress test	0.66	0.28	0.28	0.12	1.06	1.06	000
59020	TC	A	Fetal contract stress test	0.00	NA	0.51	0.08	NA	0.59	000
59025		A	Fetal non-stress test	0.53	NA	0.45	0.12	NA	1.10	000
59025	26	A	Fetal non-stress test	0.53	0.22	0.22	0.10	0.85	0.85	000
59025	TC	A	Fetal non-stress test	0.00	NA	0.23	0.02	NA	0.25	000
59030		A	Fetal scalp blood sample	1.99	0.97	NA	0.36	3.32	NA	000
59050		A	Fetal monitor w/report	0.89	0.36	NA	0.16	1.41	NA	XXX
59051		A	Fetal monitor/interpret only	0.74	0.29	NA	0.14	1.17	NA	XXX
59100		A	Remove uterus lesion	12.35	6.34	NA	2.21	20.90	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
59120		A	Treat ectopic pregnancy	11.49	6.28	NA	2.06	19.83	NA	090
59121		A	Treat ectopic pregnancy	11.67	6.31	NA	2.09	20.07	NA	090
59130		A	Treat ectopic pregnancy	14.22	7.04	NA	2.54	23.80	NA	090
59135		A	Treat ectopic pregnancy	13.88	6.90	NA	2.49	23.27	NA	090
59136		A	Treat ectopic pregnancy	13.18	6.99	NA	2.36	22.53	NA	090
59140		A	Treat ectopic pregnancy	5.46	3.28	NA	0.98	9.72	NA	090
59150		A	Treat ectopic pregnancy	11.67	6.57	NA	1.23	19.47	NA	090
59151		A	Treat ectopic pregnancy	11.49	6.03	NA	1.41	18.93	NA	090
59160		A	D & c after delivery	2.71	2.26	3.60	0.49	5.46	6.80	010
59200		A	Insert cervical dilator	0.79	0.33	1.35	0.15	1.27	2.29	000
59300		A	Episiotomy or vaginal repair	2.41	1.01	2.10	0.43	3.85	4.94	000
59320		A	Revision of cervix	2.48	1.46	NA	0.45	4.39	NA	000
59325		A	Revision of cervix	4.07	2.11	NA	0.73	6.91	NA	000
59350		A	Repair of uterus	4.95	2.03	NA	0.88	7.86	NA	000
59400		A	Obstetrical care	23.06	15.19	NA	4.14	42.39	NA	MMM
59409		A	Obstetrical care	13.50	5.58	NA	2.42	21.50	NA	MMM
59410		A	Obstetrical care	14.78	6.67	NA	2.65	24.10	NA	MMM
59412		A	Antepartum manipulation	1.71	0.73	1.34	0.31	2.75	3.36	MMM
59414		A	Deliver placenta	1.61	1.31	NA	0.29	3.21	NA	MMM
59425		A	Antepartum care only	4.81	5.18	5.23	0.86	10.85	10.90	MMM
59426		A	Antepartum care only	8.28	8.95	8.95	1.49	18.72	18.72	MMM
59430		A	Care after delivery	2.13	1.26	1.27	0.38	3.77	3.78	MMM
59510		A	Cesarean delivery	26.22	17.34	NA	4.70	48.26	NA	MMM
59514		A	Cesarean delivery only	15.97	6.53	NA	2.86	25.36	NA	MMM
59515		A	Cesarean delivery	17.37	8.42	NA	3.12	28.91	NA	MMM
59525		A	Remove uterus after cesarean	8.54	3.51	NA	1.53	13.58	NA	ZZZ
59610		A	Vbac delivery	24.62	15.74	NA	4.41	44.77	NA	MMM
59612		A	Vbac delivery only	15.06	6.38	NA	2.70	24.14	NA	MMM
59614		A	Vbac care after delivery	16.34	7.64	NA	2.93	26.91	NA	MMM
59618		A	Attempted vbac delivery	27.78	18.17	NA	4.98	50.93	NA	MMM
59620		A	Attempted vbac delivery only	17.53	6.91	NA	3.15	27.59	NA	MMM
59622		A	Attempted vbac after care	18.93	8.88	NA	3.39	31.20	NA	MMM
59812		A	Treatment of miscarriage	4.01	2.50	3.68	0.58	7.09	8.27	090
59820		A	Care of miscarriage	4.01	2.75	3.70	0.72	7.48	8.43	090
59821		A	Treatment of miscarriage	4.47	2.96	3.86	0.80	8.23	9.13	090
59830		A	Treat uterus infection	6.11	3.88	NA	1.10	11.09	NA	090
59840		R	Abortion	3.01	2.27	3.96	0.54	5.82	7.51	010
59841		R	Abortion	5.24	3.63	5.70	0.94	9.81	11.88	010
59850		R	Abortion	5.91	2.85	NA	1.06	9.82	NA	090
59851		R	Abortion	5.93	3.20	NA	1.06	10.19	NA	090
59852		R	Abortion	8.24	4.45	NA	1.48	14.17	NA	090
59855		R	Abortion	6.12	3.35	NA	1.10	10.57	NA	090
59856		R	Abortion	7.48	3.68	NA	1.34	12.50	NA	090
59857		R	Abortion	9.29	4.40	NA	1.66	15.35	NA	090
59866		R	Abortion (mpr)	4.00	1.58	NA	0.72	6.30	NA	000
59870		A	Evacuate mole of uterus	6.01	3.90	NA	0.77	10.68	NA	090
59871		A	Remove cerclage suture	2.13	0.92	1.99	0.38	3.43	4.50	000
59898		C	Laparo proc, ob care/deliver	0.00	0.00	0.00	0.00	0.00	0.00	YYY
59899		C	Maternity care procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
60000		A	Drain thyroid/tongue cyst	1.76	2.26	2.38	0.14	4.16	4.28	010
60001		A	Aspirate/inject thyriod cyst	0.97	0.36	1.58	0.06	1.39	2.61	000
60100		A	Biopsy of thyroid	1.56	0.56	2.63	0.05	2.17	4.24	000
60200		A	Remove thyroid lesion	9.55	6.63	NA	0.84	17.02	NA	090
60210		A	Partial thyroid excision	10.88	6.54	NA	1.01	18.43	NA	090
60212		A	Parital thyroid excision	16.03	8.59	NA	1.51	26.13	NA	090
60220		A	Partial removal of thyroid	11.90	7.05	NA	0.97	19.92	NA	090
60225		A	Partial removal of thyroid	14.19	7.96	NA	1.31	23.46	NA	090
60240		A	Removal of thyroid	16.06	9.11	NA	1.50	26.67	NA	090
60252		A	Removal of thyroid	20.57	11.58	NA	1.63	33.78	NA	090
60254		A	Extensive thyroid surgery	26.99	15.89	NA	1.96	44.84	NA	090
60260		A	Repeat thyroid surgery	17.47	10.39	NA	1.39	29.25	NA	090
60270		A	Removal of thyroid	20.27	11.95	NA	1.78	34.00	NA	090
60271		A	Removal of thyroid	16.83	9.80	NA	1.35	27.98	NA	090
60280		A	Remove thyroid duct lesion	5.87	5.19	NA	0.45	11.51	NA	090
60281		A	Remove thyroid duct lesion	8.53	6.43	NA	0.67	15.63	NA	090
60500		A	Explore parathyroid glands	16.23	7.84	NA	1.61	25.68	NA	090
60502		A	Re-explore parathyroids	20.35	9.63	NA	2.00	31.98	NA	090
60505		A	Explore parathyroid glands	21.49	11.03	NA	2.14	34.66	NA	090
60512		A	Autotransplant parathyroid	4.45	1.70	NA	0.44	6.59	NA	ZZZ
60520		A	Removal of thymus gland	16.81	9.87	NA	1.84	28.52	NA	090
60521		A	Removal of thymus gland	18.87	11.73	NA	2.34	32.94	NA	090
60522		A	Removal of thymus gland	23.09	13.10	NA	2.83	39.02	NA	090
60540		A	Explore adrenal gland	17.03	7.85	NA	1.42	26.30	NA	090
60545		A	Explore adrenal gland	19.88	9.55	NA	1.75	31.18	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
60600		A	Remove carotid body lesion	17.93	13.45	NA	1.87	33.25	NA	090
60605		A	Remove carotid body lesion	20.24	18.32	NA	2.28	40.84	NA	090
60650		A	Laparoscopy adrenalectomy	20.00	8.26	NA	1.98	30.24	NA	090
60659		C	Laparo proc, endocrine	0.00	0.00	0.00	0.00	0.00	0.00	YYY
60699		C	Endocrine surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
61000		A	Remove cranial cavity fluid	1.58	1.56	1.72	0.13	3.27	3.43	000
61001		A	Remove cranial cavity fluid	1.49	1.37	1.86	0.15	3.01	3.50	000
61020		A	Remove brain cavity fluid	1.51	1.46	2.26	0.26	3.23	4.03	000
61026		A	Injection into brain canal	1.69	1.68	2.19	0.21	3.58	4.09	000
61050		A	Remove brain canal fluid	1.51	1.59	NA	0.13	3.23	NA	000
61055		A	Injection into brain canal	2.10	1.76	NA	0.13	3.99	NA	000
61070		A	Brain canal shunt procedure	0.89	1.17	6.75	0.09	2.15	7.73	000
61105		A	Twist drill hole	5.14	3.63	NA	1.05	9.82	NA	090
61107		A	Drill skull for implantation	5.00	3.13	NA	1.02	9.15	NA	000
61108		A	Drill skull for drainage	10.19	6.95	NA	2.04	19.18	NA	090
61120		A	Burr hole for puncture	8.76	5.81	NA	1.81	16.38	NA	090
61140		A	Pierce skull for biopsy	15.90	9.91	NA	3.15	28.96	NA	090
61150		A	Pierce skull for drainage	17.57	10.63	NA	3.52	31.72	NA	090
61151		A	Pierce skull for drainage	12.42	8.26	NA	2.45	23.13	NA	090
61154		A	Pierce skull & remove clot	14.99	9.48	NA	3.05	27.52	NA	090
61156		A	Pierce skull for drainage	16.32	10.33	NA	3.42	30.07	NA	090
61210		A	Pierce skull, implant device	5.84	3.52	NA	1.16	10.52	NA	000
61215		A	Insert brain-fluid device	4.89	4.17	NA	0.99	10.05	NA	090
61250		A	Pierce skull & explore	10.42	6.70	NA	2.02	19.14	NA	090
61253		A	Pierce skull & explore	12.36	7.36	NA	2.26	21.98	NA	090
61304		A	Open skull for exploration	21.96	12.68	NA	4.33	38.97	NA	090
61305		A	Open skull for exploration	26.61	15.06	NA	5.25	46.92	NA	090
61312		A	Open skull for drainage	24.57	14.43	NA	4.99	43.99	NA	090
61313		A	Open skull for drainage	24.93	14.66	NA	5.07	44.66	NA	090
61314		A	Open skull for drainage	24.23	12.45	NA	4.00	40.68	NA	090
61315		A	Open skull for drainage	27.68	16.13	NA	5.62	49.43	NA	090
61320		A	Open skull for drainage	25.62	15.03	NA	5.20	45.85	NA	090
61321		A	Open skull for drainage	28.50	16.15	NA	5.35	50.00	NA	090
61330		A	Decompress eye socket	23.32	17.12	NA	2.58	43.02	NA	090
61332		A	Explore/biopsy eye socket	27.28	19.52	NA	4.15	50.95	NA	090
61333		A	Explore orbit/remove lesion	27.95	16.03	NA	2.24	46.22	NA	090
61334		A	Explore orbit/remove object	18.27	11.86	NA	3.02	33.15	NA	090
61340		A	Relieve cranial pressure	18.66	11.56	NA	3.66	33.88	NA	090
61343		A	Incise skull (press relief)	29.77	17.82	NA	6.04	53.63	NA	090
61345		A	Relieve cranial pressure	27.20	16.42	NA	5.23	48.85	NA	090
61440		A	Incise skull for surgery	26.63	16.16	NA	5.57	48.36	NA	090
61450		A	Incise skull for surgery	25.95	14.71	NA	5.11	45.77	NA	090
61458		A	Incise skull for brain wound	27.29	15.81	NA	5.28	48.38	NA	090
61460		A	Incise skull for surgery	28.39	16.82	NA	5.13	50.34	NA	090
61470		A	Incise skull for surgery	26.06	14.19	NA	4.65	44.90	NA	090
61480		A	Incise skull for surgery	26.49	14.00	NA	5.54	46.03	NA	090
61490		A	Incise skull for surgery	25.66	15.05	NA	5.37	46.08	NA	090
61500		A	Removal of skull lesion	17.92	10.99	NA	3.26	32.17	NA	090
61501		A	Remove infected skull bone	14.84	9.17	NA	2.63	26.64	NA	090
61510		A	Removal of brain lesion	28.45	16.46	NA	5.77	50.68	NA	090
61512		A	Remove brain lining lesion	35.09	20.04	NA	7.14	62.27	NA	090
61514		A	Removal of brain abscess	25.26	14.64	NA	5.12	45.02	NA	090
61516		A	Removal of brain lesion	24.61	14.81	NA	4.94	44.36	NA	090
61518		A	Removal of brain lesion	37.32	22.11	NA	7.53	66.96	NA	090
61519		A	Remove brain lining lesion	41.39	24.02	NA	8.15	73.56	NA	090
61520		A	Removal of brain lesion	54.84	31.79	NA	10.10	96.73	NA	090
61521		A	Removal of brain lesion	44.48	26.00	NA	8.85	79.33	NA	090
61522		A	Removal of brain abscess	29.45	17.12	NA	5.30	51.87	NA	090
61524		A	Removal of brain lesion	27.86	16.60	NA	5.01	49.47	NA	090
61526		A	Removal of brain lesion	52.17	30.36	NA	6.72	89.25	NA	090
61530		A	Removal of brain lesion	43.86	27.22	NA	6.17	77.25	NA	090
61531		A	Implant brain electrodes	14.63	9.23	NA	2.84	26.70	NA	090
61533		A	Implant brain electrodes	19.71	12.05	NA	3.80	35.56	NA	090
61534		A	Removal of brain lesion	20.97	12.99	NA	4.15	38.11	NA	090
61535		A	Remove brain electrodes	11.63	7.73	NA	2.29	21.65	NA	090
61536		A	Removal of brain lesion	35.52	20.53	NA	6.68	62.73	NA	090
61538		A	Removal of brain tissue	26.81	16.08	NA	5.38	48.27	NA	090
61539		A	Removal of brain tissue	32.08	19.01	NA	6.62	57.71	NA	090
61541		A	Incision of brain tissue	28.85	16.37	NA	5.50	50.72	NA	090
61542		A	Removal of brain tissue	31.02	18.89	NA	6.49	56.40	NA	090
61543		A	Removal of brain tissue	29.22	17.92	NA	6.11	53.25	NA	090
61544		A	Remove & treat brain lesion	25.50	12.06	NA	4.91	42.47	NA	090
61545		A	Excision of brain tumor	43.80	24.74	NA	8.88	77.42	NA	090
61546		A	Removal of pituitary gland	31.30	18.26	NA	6.06	55.62	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
61548		A	Removal of pituitary gland	21.53	13.57	NA	3.63	38.73	NA	090
61550		A	Release of skull seams	14.65	7.59	NA	1.14	23.38	NA	090
61552		A	Release of skull seams	19.56	10.42	NA	0.88	30.86	NA	090
61556		A	Incise skull/sutures	22.26	12.47	NA	3.57	38.30	NA	090
61557		A	Incise skull/sutures	22.38	12.86	NA	4.68	39.92	NA	090
61558		A	Excision of skull/sutures	25.58	13.34	NA	2.61	41.53	NA	090
61559		A	Excision of skull/sutures	32.79	19.09	NA	6.86	58.74	NA	090
61563		A	Excision of skull tumor	26.83	16.05	NA	4.46	47.34	NA	090
61564		A	Excision of skull tumor	33.83	19.37	NA	7.08	60.28	NA	090
61570		A	Remove foreign body, brain	24.60	13.42	NA	4.60	42.62	NA	090
61571		A	Incise skull for brain wound	26.39	15.08	NA	5.23	46.70	NA	090
61575		A	Skull base/brainstem surgery	34.36	21.06	NA	5.02	60.44	NA	090
61576		A	Skull base/brainstem surgery	52.43	29.82	NA	4.68	86.93	NA	090
61580		A	Craniofacial approach, skull	30.35	19.50	NA	2.75	52.60	NA	090
61581		A	Craniofacial approach, skull	34.60	21.70	NA	3.37	59.67	NA	090
61582		A	Craniofacial approach, skull	31.66	19.38	NA	6.30	57.34	NA	090
61583		A	Craniofacial approach, skull	36.21	22.33	NA	6.94	65.48	NA	090
61584		A	Orbitocranial approach/skull	34.65	20.92	NA	6.53	62.10	NA	090
61585		A	Orbitocranial approach/skull	38.61	22.75	NA	6.19	67.55	NA	090
61586		A	Resect nasopharynx, skull	25.10	16.18	NA	3.52	44.80	NA	090
61590		A	Infratemporal approach/skull	41.78	25.75	NA	4.28	71.81	NA	090
61591		A	Infratemporal approach/skull	43.68	26.81	NA	5.26	75.75	NA	090
61592		A	Orbitocranial approach/skull	39.64	23.45	NA	7.55	70.64	NA	090
61595		A	Transtemporal approach/skull	29.57	19.37	NA	3.05	51.99	NA	090
61596		A	Transcochlear approach/skull	35.63	22.22	NA	4.25	62.10	NA	090
61597		A	Transcondylar approach/skull	37.96	21.94	NA	6.65	66.55	NA	090
61598		A	Transpetrosal approach/skull	33.41	20.82	NA	4.60	58.83	NA	090
61600		A	Resect/excise cranial lesion	25.85	16.64	NA	3.12	45.61	NA	090
61601		A	Resect/excise cranial lesion	27.89	17.15	NA	5.29	50.33	NA	090
61605		A	Resect/excise cranial lesion	29.33	18.58	NA	2.51	50.42	NA	090
61606		A	Resect/excise cranial lesion	38.83	23.30	NA	6.81	68.94	NA	090
61607		A	Resect/excise cranial lesion	36.27	21.90	NA	5.69	63.86	NA	090
61608		A	Resect/excise cranial lesion	42.10	24.57	NA	8.31	74.98	NA	090
61609		A	Transect artery, sinus	9.89	4.61	NA	2.07	16.57	NA	ZZZ
61610		A	Transect artery, sinus	29.67	12.80	NA	3.52	45.99	NA	ZZZ
61611		A	Transect artery, sinus	7.42	2.93	NA	1.55	11.90	NA	ZZZ
61612		A	Transect artery, sinus	27.88	14.33	NA	3.55	45.76	NA	ZZZ
61613		A	Remove aneurysm, sinus	40.86	24.08	NA	8.32	73.26	NA	090
61615		A	Resect/excise lesion, skull	32.07	20.45	NA	4.64	57.16	NA	090
61616		A	Resect/excise lesion, skull	43.33	27.05	NA	7.02	77.40	NA	090
61618		A	Repair dura	16.99	11.22	NA	2.92	31.13	NA	090
61619		A	Repair dura	20.71	13.26	NA	3.42	37.39	NA	090
61624		A	Occlusion/embolization cath	20.15	7.28	NA	1.15	28.58	NA	000
61626		A	Occlusion/embolization cath	16.62	5.88	NA	0.84	23.34	NA	000
61680		A	Intracranial vessel surgery	30.71	18.55	NA	6.04	55.30	NA	090
61682		A	Intracranial vessel surgery	61.57	34.03	NA	12.69	108.29	NA	090
61684		A	Intracranial vessel surgery	39.81	22.06	NA	7.87	69.74	NA	090
61686		A	Intracranial vessel surgery	64.49	36.32	NA	13.20	114.01	NA	090
61690		A	Intracranial vessel surgery	29.31	17.73	NA	5.51	52.55	NA	090
61692		A	Intracranial vessel surgery	51.87	29.41	NA	10.17	91.45	NA	090
61697		A	Brain aneurysm repr, complx	50.52	28.07	NA	9.57	88.16	NA	090
61698		A	Brain aneurysm repr, complx	48.41	27.18	NA	9.28	84.87	NA	090
61700		A	Brain aneurysm repr , simple	50.52	28.07	NA	10.18	88.77	NA	090
61702		A	Inner skull vessel surgery	48.41	27.18	NA	9.75	85.34	NA	090
61703		A	Clamp neck artery	17.47	11.04	NA	3.62	32.13	NA	090
61705		A	Revise circulation to head	36.20	20.39	NA	6.67	63.26	NA	090
61708		A	Revise circulation to head	35.30	16.07	NA	2.18	53.55	NA	090
61710		A	Revise circulation to head	29.67	14.41	NA	2.42	46.50	NA	090
61711		A	Fusion of skull arteries	36.33	20.11	NA	7.39	63.83	NA	090
61720		A	Incise skull/brain surgery	16.77	10.75	NA	3.51	31.03	NA	090
61735		A	Incise skull/brain surgery	20.43	12.67	NA	4.16	37.26	NA	090
61750		A	Incise skull/brain biopsy	18.20	11.09	NA	3.71	33.00	NA	090
61751		A	Brain biopsy w/ ct/mr guide	17.62	10.82	NA	3.57	32.01	NA	090
61760		A	Implant brain electrodes	22.27	13.25	NA	4.59	40.11	NA	090
61770		A	Incise skull for treatment	21.44	12.86	NA	4.09	38.39	NA	090
61790		A	Treat trigeminal nerve	10.86	6.17	NA	1.82	18.85	NA	090
61791		A	Treat trigeminal tract	14.61	9.33	NA	3.03	26.97	NA	090
61793		A	Focus radiation beam	17.24	10.92	NA	3.51	31.67	NA	090
61795		A	Brain surgery using computer	4.04	2.12	NA	0.81	6.97	NA	ZZZ
61850		A	Implant neuroelectrodes	12.39	8.00	NA	2.23	22.62	NA	090
61860		A	Implant neuroelectrodes	20.87	12.80	NA	4.04	37.71	NA	090
61862		A	Implant neurostimul, subcort	19.34	12.05	NA	3.97	35.36	NA	090
61870		A	Implant neuroelectrodes	14.94	11.37	NA	1.70	28.01	NA	090
61875		A	Implant neuroelectrodes	15.06	9.86	NA	2.42	27.34	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
61880		A	Revise/remove neuroelectrode	6.29	5.20	NA	1.31	12.80	NA	090
61885		A	Implant neurostim one array	5.85	4.26	NA	1.22	11.33	NA	090
61886		A	Implant neurostim arrays	8.00	6.07	NA	1.64	15.71	NA	090
61888		A	Revise/remove neuroreceiver	5.07	3.86	NA	1.04	9.97	NA	010
62000		A	Treat skull fracture	12.53	5.48	NA	0.87	18.88	NA	090
62005		A	Treat skull fracture	16.17	9.04	NA	2.33	27.54	NA	090
62010		A	Treatment of head injury	19.81	11.71	NA	4.05	35.57	NA	090
62100		A	Repair brain fluid leakage	22.03	13.99	NA	4.07	40.09	NA	090
62115		A	Reduction of skull defect	21.66	10.54	NA	4.53	36.73	NA	090
62116		A	Reduction of skull defect	23.59	13.81	NA	4.85	42.25	NA	090
62117		A	Reduction of skull defect	26.60	15.24	NA	5.56	47.40	NA	090
62120		A	Repair skull cavity lesion	23.35	14.11	NA	3.07	40.53	NA	090
62121		A	Incise skull repair	21.58	13.89	NA	2.47	37.94	NA	090
62140		A	Repair of skull defect	13.51	8.60	NA	2.60	24.71	NA	090
62141		A	Repair of skull defect	14.91	9.74	NA	2.85	27.50	NA	090
62142		A	Remove skull plate/flap	10.79	7.22	NA	2.10	20.11	NA	090
62143		A	Replace skull plate/flap	13.05	8.70	NA	2.55	24.30	NA	090
62145		A	Repair of skull & brain	18.82	11.37	NA	3.81	34.00	NA	090
62146		A	Repair of skull with graft	16.12	10.46	NA	2.94	29.52	NA	090
62147		A	Repair of skull with graft	19.34	12.26	NA	3.64	35.24	NA	090
62180		A	Establish brain cavity shunt	21.06	12.91	NA	4.32	38.29	NA	090
62190		A	Establish brain cavity shunt	11.07	7.68	NA	2.18	20.93	NA	090
62192		A	Establish brain cavity shunt	12.25	8.21	NA	2.46	22.92	NA	090
62194		A	Replace/irrigate catheter	5.03	2.11	NA	0.50	7.64	NA	010
62200		A	Establish brain cavity shunt	18.32	11.46	NA	3.70	33.48	NA	090
62201		A	Establish brain cavity shunt	14.86	9.19	NA	2.52	26.57	NA	090
62220		A	Establish brain cavity shunt	13.00	8.63	NA	2.53	24.16	NA	090
62223		A	Establish brain cavity shunt	12.87	8.45	NA	2.58	23.90	NA	090
62225		A	Replace/irrigate catheter	5.41	4.05	NA	1.09	10.55	NA	090
62230		A	Replace/revise brain shunt	10.54	6.61	NA	2.10	19.25	NA	090
62252		A	Csf shunt reprogram	0.74	NA	1.38	0.04	NA	2.16	XXX
62252	26	A	Csf shunt reprogram	0.74	0.29	0.29	0.02	1.05	1.05	XXX
62252	TC	A	Csf shunt reprogram	0.00	NA	1.09	0.02	NA	1.11	XXX
62256		A	Remove brain cavity shunt	6.60	5.30	NA	1.34	13.24	NA	090
62258		A	Replace brain cavity shunt	14.54	8.70	NA	2.91	26.15	NA	090
62263		A	Lysis epidural adhesions	6.14	2.27	5.65	0.42	8.83	12.21	010
62268		A	Drain spinal cord cyst	4.74	2.74	NA	0.29	7.77	NA	000
62269		A	Needle biopsy, spinal cord	5.02	2.35	NA	0.29	7.66	NA	000
62270		A	Spinal fluid tap, diagnostic	1.13	0.48	3.78	0.06	1.67	4.97	000
62272		A	Drain spinal fluid	1.35	0.62	3.26	0.13	2.10	4.74	000
62273		A	Treat epidural spine lesion	2.15	1.27	1.31	0.14	3.56	3.60	000
62280		A	Treat spinal cord lesion	2.63	0.70	3.38	0.17	3.50	6.18	010
62281		A	Treat spinal cord lesion	2.66	0.61	3.81	0.16	3.43	6.63	010
62282		A	Treat spinal canal lesion	2.33	0.61	5.23	0.14	3.08	7.70	010
62284		A	Injection for myelogram	1.54	0.71	4.39	0.10	2.35	6.03	000
62287		A	Percutaneous diskectomy	8.08	4.74	NA	0.66	13.48	NA	090
62290		A	Inject for spine disk x-ray	3.00	1.27	5.68	0.20	4.47	8.88	000
62291		A	Inject for spine disk x-ray	2.91	1.16	5.74	0.17	4.24	8.82	000
62292		A	Injection into disk lesion	7.86	4.76	NA	0.65	13.27	NA	090
62294		A	Injection into spinal artery	11.83	6.17	NA	0.85	18.85	NA	090
62310		A	Inject spine c/t	1.94	0.42	3.61	0.11	2.47	5.66	000
62311		A	Inject spine l/s (cd)	1.57	0.36	3.87	0.09	2.02	5.53	000
62318		A	Inject spine w/cath, c/t	2.08	0.46	3.70	0.12	2.66	5.90	000
62319		A	Inject spine w/cath l/s (cd)	1.90	0.39	3.18	0.11	2.40	5.19	000
62350		A	Implant spinal canal cath	6.87	3.70	NA	0.64	11.21	NA	090
62351		A	Implant spinal canal cath	10.00	6.77	NA	1.79	18.56	NA	090
62355		A	Remove spinal canal catheter	5.45	2.80	NA	0.47	8.72	NA	090
62360		A	Insert spine infusion device	2.62	2.22	NA	0.21	5.05	NA	090
62361		A	Implant spine infusion pump	5.42	3.54	NA	0.50	9.46	NA	090
62362		A	Implant spine infusion pump	7.04	4.08	NA	0.86	11.98	NA	090
62365		A	Remove spine infusion device	5.42	3.06	NA	0.58	9.06	NA	090
62367		C	Analyze spine infusion pump	0.00	0.00	0.00	0.00	0.00	0.00	XXX
62367	26	A	Analyze spine infusion pump	0.48	0.14	0.14	0.03	0.65	0.65	XXX
62367	TC	C	Analyze spine infusion pump	0.00	0.00	0.00	0.00	0.00	0.00	XXX
62368		C	Analyze spine infusion pump	0.00	0.00	0.00	0.00	0.00	0.00	XXX
62368	26	A	Analyze spine infusion pump	0.75	0.20	0.20	0.05	1.00	1.00	XXX
62368	TC	C	Analyze spine infusion pump	0.00	0.00	0.00	0.00	0.00	0.00	XXX
63001		A	Removal of spinal lamina	15.82	11.55	NA	3.03	30.40	NA	090
63003		A	Removal of spinal lamina	15.95	11.68	NA	2.98	30.61	NA	090
63005		A	Removal of spinal lamina	14.92	11.16	NA	2.62	28.70	NA	090
63011		A	Removal of spinal lamina	14.52	9.38	NA	1.43	25.33	NA	090
63012		A	Removal of spinal lamina	15.40	10.10	NA	2.71	28.21	NA	090
63015		A	Removal of spinal lamina	19.35	13.43	NA	3.84	36.62	NA	090
63016		A	Removal of spinal lamina	19.20	13.38	NA	3.62	36.20	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
63017		A	Removal of spinal lamina	15.94	11.68	NA	2.91	30.53	NA	090
63020		A	Neck spine disk surgery	14.81	11.10	NA	2.89	28.80	NA	090
63030		A	Low back disk surgery	12.00	9.64	NA	2.21	23.85	NA	090
63035		A	Spinal disk surgery add-on	3.15	1.66	NA	0.57	5.38	NA	ZZZ
63040		A	Laminotomy, single cervical	18.81	13.04	NA	3.36	35.21	NA	090
63042		A	Laminotomy, single lumbar	17.47	12.65	NA	3.11	33.23	NA	090
63043		C	Laminotomy, addl cervical	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
63044		C	Laminotomy, addl lumbar	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
63045		A	Removal of spinal lamina	16.50	11.99	NA	3.19	31.68	NA	090
63046		A	Removal of spinal lamina	15.80	11.64	NA	2.89	30.33	NA	090
63047		A	Removal of spinal lamina	14.61	11.09	NA	2.61	28.31	NA	090
63048		A	Remove spinal lamina add-on	3.26	1.75	NA	0.58	5.59	NA	ZZZ
63055		A	Decompress spinal cord	21.99	14.82	NA	4.09	40.90	NA	090
63056		A	Decompress spinal cord	20.36	14.12	NA	3.34	37.82	NA	090
63057		A	Decompress spine cord add-on	5.26	2.69	NA	0.81	8.76	NA	ZZZ
63064		A	Decompress spinal cord	24.61	16.74	NA	4.72	46.07	NA	090
63066		A	Decompress spine cord add-on	3.26	1.76	NA	0.63	5.65	NA	ZZZ
63075		A	Neck spine disk surgery	19.41	13.57	NA	3.73	36.71	NA	090
63076		A	Neck spine disk surgery	4.05	2.16	NA	0.78	6.99	NA	ZZZ
63077		A	Spine disk surgery, thorax	21.44	14.91	NA	3.44	39.79	NA	090
63078		A	Spine disk surgery, thorax	3.28	1.70	NA	0.50	5.48	NA	ZZZ
63081		A	Removal of vertebral body	23.73	16.42	NA	4.46	44.61	NA	090
63082		A	Remove vertebral body add-on	4.37	2.34	NA	0.82	7.53	NA	ZZZ
63085		A	Removal of vertebral body	26.92	17.85	NA	4.70	49.47	NA	090
63086		A	Remove vertebral body add-on	3.19	1.66	NA	0.55	5.40	NA	ZZZ
63087		A	Removal of vertebral body	35.57	21.93	NA	5.87	63.37	NA	090
63088		A	Remove vertebral body add-on	4.33	2.28	NA	0.77	7.38	NA	ZZZ
63090		A	Removal of vertebral body	28.16	17.88	NA	4.27	50.31	NA	090
63091		A	Remove vertebral body add-on	3.03	1.52	NA	0.45	5.00	NA	ZZZ
63170		A	Incise spinal cord tract(s)	19.83	13.68	NA	3.89	37.40	NA	090
63172		A	Drainage of spinal cyst	17.66	13.11	NA	3.46	34.23	NA	090
63173		A	Drainage of spinal cyst	21.99	14.91	NA	4.14	41.04	NA	090
63180		A	Revise spinal cord ligaments	18.27	12.45	NA	3.83	34.55	NA	090
63182		A	Revise spinal cord ligaments	20.50	12.80	NA	3.48	36.78	NA	090
63185		A	Incise spinal column/nerves	15.04	9.84	NA	2.08	26.96	NA	090
63190		A	Incise spinal column/nerves	17.45	12.01	NA	2.88	32.34	NA	090
63191		A	Incise spinal column/nerves	17.54	12.40	NA	3.50	33.44	NA	090
63194		A	Incise spinal column & cord	19.19	13.15	NA	4.01	36.35	NA	090
63195		A	Incise spinal column & cord	18.84	12.11	NA	3.44	34.39	NA	090
63196		A	Incise spinal column & cord	22.30	12.35	NA	4.66	39.31	NA	090
63197		A	Incise spinal column & cord	21.11	13.76	NA	4.42	39.29	NA	090
63198		A	Incise spinal column & cord	25.38	13.57	NA	5.31	44.26	NA	090
63199		A	Incise spinal column & cord	26.89	14.17	NA	5.62	46.68	NA	090
63200		A	Release of spinal cord	19.18	13.16	NA	3.61	35.95	NA	090
63250		A	Revise spinal cord vessels	40.76	20.99	NA	7.65	69.40	NA	090
63251		A	Revise spinal cord vessels	41.20	23.28	NA	7.98	72.46	NA	090
63252		A	Revise spinal cord vessels	41.19	22.61	NA	7.75	71.55	NA	090
63265		A	Excise intraspinal lesion	21.56	13.21	NA	4.29	39.06	NA	090
63266		A	Excise intraspinal lesion	22.30	13.55	NA	4.47	40.32	NA	090
63267		A	Excise intraspinal lesion	17.95	11.36	NA	3.50	32.81	NA	090
63268		A	Excise intraspinal lesion	18.52	10.91	NA	3.18	32.61	NA	090
63270		A	Excise intraspinal lesion	26.80	16.01	NA	5.41	48.22	NA	090
63271		A	Excise intraspinal lesion	26.92	16.14	NA	5.56	48.62	NA	090
63272		A	Excise intraspinal lesion	25.32	15.26	NA	5.07	45.65	NA	090
63273		A	Excise intraspinal lesion	24.29	14.68	NA	5.08	44.05	NA	090
63275		A	Biopsy/excise spinal tumor	23.68	14.18	NA	4.68	42.54	NA	090
63276		A	Biopsy/excise spinal tumor	23.45	14.11	NA	4.63	42.19	NA	090
63277		A	Biopsy/excise spinal tumor	20.83	12.87	NA	4.03	37.73	NA	090
63278		A	Biopsy/excise spinal tumor	20.56	12.49	NA	4.02	37.07	NA	090
63280		A	Biopsy/excise spinal tumor	28.35	16.74	NA	5.80	50.89	NA	090
63281		A	Biopsy/excise spinal tumor	28.05	16.50	NA	5.67	50.22	NA	090
63282		A	Biopsy/excise spinal tumor	26.39	15.69	NA	5.33	47.41	NA	090
63283		A	Biopsy/excise spinal tumor	25.00	14.89	NA	5.12	45.01	NA	090
63285		A	Biopsy/excise spinal tumor	36.00	20.43	NA	7.31	63.74	NA	090
63286		A	Biopsy/excise spinal tumor	35.63	20.55	NA	7.07	63.25	NA	090
63287		A	Biopsy/excise spinal tumor	36.70	20.93	NA	7.48	65.11	NA	090
63290		A	Biopsy/excise spinal tumor	37.38	21.51	NA	7.65	66.54	NA	090
63300		A	Removal of vertebral body	24.43	14.89	NA	4.78	44.10	NA	090
63301		A	Removal of vertebral body	27.60	15.85	NA	5.03	48.48	NA	090
63302		A	Removal of vertebral body	27.81	15.89	NA	5.25	48.95	NA	090
63303		A	Removal of vertebral body	30.50	17.46	NA	5.21	53.17	NA	090
63304		A	Removal of vertebral body	30.33	16.32	NA	4.72	51.37	NA	090
63305		A	Removal of vertebral body	32.03	18.86	NA	5.39	56.28	NA	090
63306		A	Removal of vertebral body	32.22	17.06	NA	2.39	51.67	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
63307		A	Removal of vertebral body	31.63	18.18	NA	4.23	54.04	NA	090
63308		A	Remove vertebral body add-on	5.25	2.77	NA	1.01	9.03	NA	ZZZ
63600		A	Remove spinal cord lesion	14.02	5.95	NA	1.22	21.19	NA	090
63610		A	Stimulation of spinal cord	8.73	5.07	NA	0.43	14.23	NA	000
63615		A	Remove lesion of spinal cord	16.28	10.42	NA	2.85	29.55	NA	090
63650		A	Implant neuroelectrodes	6.74	3.03	NA	0.48	10.25	NA	090
63655		A	Implant neuroelectrodes	10.29	7.11	NA	1.85	19.25	NA	090
63660		A	Revise/remove neuroelectrode	6.16	3.66	NA	0.65	10.47	NA	090
63685		A	Implant neuroreceiver	7.04	4.40	NA	0.96	12.40	NA	090
63688		A	Revise/remove neuroreceiver	5.39	3.68	NA	0.70	9.77	NA	090
63700		A	Repair of spinal herniation	16.53	10.39	NA	2.69	29.61	NA	090
63702		A	Repair of spinal herniation	18.48	10.70	NA	1.36	30.54	NA	090
63704		A	Repair of spinal herniation	21.18	12.18	NA	3.84	37.20	NA	090
63706		A	Repair of spinal herniation	24.11	14.00	NA	4.73	42.84	NA	090
63707		A	Repair spinal fluid leakage	11.26	7.85	NA	1.96	21.07	NA	090
63709		A	Repair spinal fluid leakage	14.32	9.62	NA	2.49	26.43	NA	090
63710		A	Graft repair of spine defect	14.07	9.36	NA	2.61	26.04	NA	090
63740		A	Install spinal shunt	11.36	7.56	NA	2.15	21.07	NA	090
63741		A	Install spinal shunt	8.25	4.72	NA	1.05	14.02	NA	090
63744		A	Revision of spinal shunt	8.10	5.49	NA	1.51	15.10	NA	090
63746		A	Removal of spinal shunt	6.43	4.53	NA	1.15	12.11	NA	090
64400		A	Injection for nerve block	1.11	0.27	2.55	0.06	1.44	3.72	000
64402		A	Injection for nerve block	1.25	0.44	4.03	0.07	1.76	5.35	000
64405		A	Injection for nerve block	1.32	0.31	2.53	0.08	1.71	3.93	000
64408		A	Injection for nerve block	1.41	0.70	2.77	0.09	2.20	4.27	000
64410		A	Injection for nerve block	1.43	0.30	2.45	0.08	1.81	3.96	000
64412		A	Injection for nerve block	1.18	0.27	2.56	0.08	1.53	3.82	000
64413		A	Injection for nerve block	1.40	0.36	2.79	0.09	1.85	4.28	000
64415		A	Injection for nerve block	1.48	0.31	2.62	0.08	1.87	4.18	000
64417		A	Injection for nerve block	1.44	0.33	2.57	0.09	1.86	4.10	000
64418		A	Injection for nerve block	1.32	0.29	2.34	0.07	1.68	3.73	000
64420		A	Injection for nerve block	1.18	0.27	2.33	0.07	1.52	3.58	000
64421		A	Injection for nerve block	1.68	0.38	2.74	0.10	2.16	4.52	000
64425		A	Injection for nerve block	1.75	0.40	2.30	0.11	2.26	4.16	000
64430		A	Injection for nerve block	1.46	0.43	2.60	0.11	2.00	4.17	000
64435		A	Injection for nerve block	1.45	0.57	2.88	0.15	2.17	4.48	000
64445		A	Injection for nerve block	1.48	0.34	3.25	0.08	1.90	4.81	000
64450		A	Injection for nerve block	1.27	0.33	1.60	0.08	1.68	2.95	000
64470		A	Inj paravertebral c/t	1.85	0.50	3.84	0.12	2.47	5.81	000
64472		A	Inj paravertebral c/t add-on	1.29	0.35	3.50	0.09	1.73	4.88	ZZZ
64475		A	Inj paravertebral l/s	1.41	0.38	3.67	0.09	1.88	5.17	000
64476		A	Inj paravertebral l/s add-on	0.98	0.26	4.03	0.06	1.30	5.07	ZZZ
64479		A	Inj foramen epidural c/t	2.20	0.62	3.97	0.14	2.96	6.31	000
64480		A	Inj foramen epidural add-on	1.54	0.42	4.11	0.09	2.05	5.74	ZZZ
64483		A	Inj foramen epidural l/s	1.90	0.53	3.85	0.12	2.55	5.87	000
64484		A	Inj foramen epidural add-on	1.33	0.36	4.02	0.08	1.77	5.43	ZZZ
64505		A	Injection for nerve block	1.36	0.35	2.23	0.08	1.79	3.67	000
64508		A	Injection for nerve block	1.12	0.37	2.82	0.06	1.55	4.00	000
64510		A	Injection for nerve block	1.22	0.26	2.54	0.07	1.55	3.83	000
64520		A	Injection for nerve block	1.35	0.29	3.48	0.08	1.72	4.91	000
64530		A	Injection for nerve block	1.58	0.36	3.14	0.09	2.03	4.81	000
64550		A	Apply neurostimulator	0.18	0.05	0.51	0.01	0.24	0.70	000
64553		A	Implant neuroelectrodes	2.31	1.29	4.86	0.17	3.77	7.34	010
64555		A	Implant neuroelectrodes	2.27	0.71	2.41	0.11	3.09	4.79	010
64560		A	Implant neuroelectrodes	2.36	0.87	2.44	0.17	3.40	4.97	010
64565		A	Implant neuroelectrodes	1.76	0.62	3.16	0.08	2.46	5.00	010
64573		A	Implant neuroelectrodes	7.50	5.42	NA	1.48	14.40	NA	090
64575		A	Implant neuroelectrodes	4.35	3.19	NA	0.37	7.91	NA	090
64577		A	Implant neuroelectrodes	4.62	3.58	NA	0.50	8.70	NA	090
64580		A	Implant neuroelectrodes	4.12	4.22	NA	0.21	8.55	NA	090
64585		A	Revise/remove neuroelectrode	2.06	2.17	2.75	0.29	4.52	5.10	010
64590		A	Implant neuroreceiver	2.40	2.36	NA	0.40	5.16	NA	010
64595		A	Revise/remove neuroreceiver	1.73	2.07	NA	0.22	4.02	NA	010
64600		A	Injection treatment of nerve	3.45	2.07	3.11	0.28	5.80	6.84	010
64605		A	Injection treatment of nerve	5.61	2.80	4.14	0.53	8.94	10.28	010
64610		A	Injection treatment of nerve	7.16	3.79	NA	1.12	12.07	NA	010
64612		A	Destroy nerve, face muscle	1.96	1.60	2.84	0.09	3.65	4.89	010
64613		A	Destroy nerve, spine muscle	1.96	1.46	1.77	0.10	3.52	3.83	010
64614		A	Destroy nerve, extrem musc	2.20	0.80	3.56	0.16	3.16	5.92	010
64620		A	Injection treatment of nerve	2.84	0.68	2.94	0.17	3.69	5.95	010
64622		A	Destr paravertebrl nerve l/s	3.00	0.73	4.38	0.17	3.90	7.55	010
64623		A	Destr paravertebral n add-on	0.99	0.24	3.46	0.06	1.29	4.51	ZZZ
64626		A	Destr paravertebrl nerve c/t	3.28	0.88	3.84	0.22	4.38	7.34	010
64627		A	Destr paravertebral n add-on	1.16	0.31	3.19	0.08	1.55	4.43	ZZZ

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
64630		A	Injection treatment of nerve	3.00	0.79	3.61	0.16	3.95	6.77	010
64640		A	Injection treatment of nerve	2.76	1.01	5.49	0.11	3.88	8.36	010
64680		A	Injection treatment of nerve	2.62	0.65	2.82	0.15	3.42	5.59	010
64702		A	Revise finger/toe nerve	4.23	3.78	NA	0.51	8.52	NA	090
64704		A	Revise hand/foot nerve	4.57	3.14	NA	0.59	8.30	NA	090
64708		A	Revise arm/leg nerve	6.12	4.90	NA	0.82	11.84	NA	090
64712		A	Revision of sciatic nerve	7.75	5.01	NA	0.54	13.30	NA	090
64713		A	Revision of arm nerve(s)	11.00	5.85	NA	1.01	17.86	NA	090
64714		A	Revise low back nerve(s)	10.33	3.99	NA	0.64	14.96	NA	090
64716		A	Revision of cranial nerve	6.31	5.01	NA	0.59	11.91	NA	090
64718		A	Revise ulnar nerve at elbow	5.99	5.00	NA	0.87	11.86	NA	090
64719		A	Revise ulnar nerve at wrist	4.85	4.51	NA	0.63	9.99	NA	090
64721		A	Carpal tunnel surgery	4.29	5.65	5.97	0.59	10.53	10.85	090
64722		A	Relieve pressure on nerve(s)	4.70	3.02	NA	0.32	8.04	NA	090
64726		A	Release foot/toe nerve	4.18	3.03	NA	0.57	7.78	NA	090
64727		A	Internal nerve revision	3.10	1.62	NA	0.40	5.12	NA	ZZZ
64732		A	Incision of brow nerve	4.41	3.46	NA	0.77	8.64	NA	090
64734		A	Incision of cheek nerve	4.92	3.53	NA	0.83	9.28	NA	090
64736		A	Incision of chin nerve	4.60	2.98	NA	0.71	8.29	NA	090
64738		A	Incision of jaw nerve	5.73	3.64	NA	0.84	10.21	NA	090
64740		A	Incision of tongue nerve	5.59	4.08	NA	0.43	10.10	NA	090
64742		A	Incision of facial nerve	6.22	4.84	NA	0.69	11.75	NA	090
64744		A	Incise nerve, back of head	5.24	3.92	NA	0.98	10.14	NA	090
64746		A	Incise diaphragm nerve	5.93	4.64	NA	0.75	11.32	NA	090
64752		A	Incision of vagus nerve	7.06	4.71	NA	0.83	12.60	NA	090
64755		A	Incision of stomach nerves	13.52	6.22	NA	1.16	20.90	NA	090
64760		A	Incision of vagus nerve	6.96	4.02	NA	0.51	11.49	NA	090
64761		A	Incision of pelvis nerve	6.41	3.31	NA	0.26	9.98	NA	090
64763		A	Incise hip/thigh nerve	6.93	6.37	NA	0.77	14.07	NA	090
64766		A	Incise hip/thigh nerve	8.67	6.18	NA	0.99	15.84	NA	090
64771		A	Sever cranial nerve	7.35	5.56	NA	1.32	14.23	NA	090
64772		A	Incision of spinal nerve	7.21	4.96	NA	1.20	13.37	NA	090
64774		A	Remove skin nerve lesion	5.17	3.66	NA	0.60	9.43	NA	090
64776		A	Remove digit nerve lesion	5.12	3.81	NA	0.63	9.56	NA	090
64778		A	Digit nerve surgery add-on	3.11	1.52	NA	0.38	5.01	NA	ZZZ
64782		A	Remove limb nerve lesion	6.23	3.65	NA	0.79	10.67	NA	090
64783		A	Limb nerve surgery add-on	3.72	2.02	NA	0.48	6.22	NA	ZZZ
64784		A	Remove nerve lesion	9.82	6.39	NA	1.17	17.38	NA	090
64786		A	Remove sciatic nerve lesion	15.46	10.25	NA	2.22	27.93	NA	090
64787		A	Implant nerve end	4.30	2.21	NA	0.56	7.07	NA	ZZZ
64788		A	Remove skin nerve lesion	4.61	3.31	NA	0.54	8.46	NA	090
64790		A	Removal of nerve lesion	11.31	7.17	NA	1.68	20.16	NA	090
64792		A	Removal of nerve lesion	14.92	9.04	NA	1.88	25.84	NA	090
64795		A	Biopsy of nerve	3.01	1.85	NA	0.40	5.26	NA	000
64802		A	Remove sympathetic nerves	9.15	5.53	NA	0.87	15.55	NA	090
64804		A	Remove sympathetic nerves	14.64	7.82	NA	1.79	24.25	NA	090
64809		A	Remove sympathetic nerves	13.67	5.32	NA	0.96	19.95	NA	090
64818		A	Remove sympathetic nerves	10.30	5.79	NA	1.08	17.17	NA	090
64820		A	Remove sympathetic nerves	10.37	7.88	NA	1.17	19.42	NA	090
64831		A	Repair of digit nerve	9.44	7.17	NA	1.14	17.75	NA	090
64832		A	Repair nerve add-on	5.66	3.12	NA	0.68	9.46	NA	ZZZ
64834		A	Repair of hand or foot nerve	10.19	7.18	NA	1.23	18.60	NA	090
64835		A	Repair of hand or foot nerve	10.94	7.82	NA	1.36	20.12	NA	090
64836		A	Repair of hand or foot nerve	10.94	7.67	NA	1.32	19.93	NA	090
64837		A	Repair nerve add-on	6.26	3.40	NA	0.80	10.46	NA	ZZZ
64840		A	Repair of leg nerve	13.02	9.23	NA	0.86	23.11	NA	090
64856		A	Repair/transpose nerve	13.80	9.39	NA	1.71	24.90	NA	090
64857		A	Repair arm/leg nerve	14.49	9.76	NA	1.76	26.01	NA	090
64858		A	Repair sciatic nerve	16.49	10.31	NA	2.78	29.58	NA	090
64859		A	Nerve surgery	4.26	2.30	NA	0.50	7.06	NA	ZZZ
64861		A	Repair of arm nerves	19.24	12.91	NA	2.45	34.60	NA	090
64862		A	Repair of low back nerves	19.44	9.63	NA	2.47	31.54	NA	090
64864		A	Repair of facial nerve	12.55	8.72	NA	1.13	22.40	NA	090
64865		A	Repair of facial nerve	15.24	10.03	NA	1.37	26.64	NA	090
64866		A	Fusion of facial/other nerve	15.74	9.73	NA	1.06	26.53	NA	090
64868		A	Fusion of facial/other nerve	14.04	9.38	NA	1.40	24.82	NA	090
64870		A	Fusion of facial/other nerve	15.99	7.98	NA	1.08	25.05	NA	090
64872		A	Subsequent repair of nerve	1.99	1.11	NA	0.24	3.34	NA	ZZZ
64874		A	Repair & revise nerve add-on	2.98	1.58	NA	0.34	4.90	NA	ZZZ
64876		A	Repair nerve/shorten bone	3.38	1.34	NA	0.39	5.11	NA	ZZZ
64885		A	Nerve graft, head or neck	17.53	11.25	NA	1.51	30.29	NA	090
64886		A	Nerve graft, head or neck	20.75	13.10	NA	1.73	35.58	NA	090
64890		A	Nerve graft, hand or foot	15.15	10.14	NA	1.74	27.03	NA	090
64891		A	Nerve graft, hand or foot	16.14	7.59	NA	1.38	25.11	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
64892		A	Nerve graft, arm or leg	14.65	8.73	NA	1.65	25.03	NA	090
64893		A	Nerve graft, arm or leg	15.60	10.34	NA	1.77	27.71	NA	090
64895		A	Nerve graft, hand or foot	19.25	11.12	NA	2.04	32.41	NA	090
64896		A	Nerve graft, hand or foot	20.49	9.36	NA	1.85	31.70	NA	090
64897		A	Nerve graft, arm or leg	18.24	10.73	NA	2.64	31.61	NA	090
64898		A	Nerve graft, arm or leg	19.50	12.30	NA	2.71	34.51	NA	090
64901		A	Nerve graft add-on	10.22	5.29	NA	0.99	16.50	NA	ZZZ
64902		A	Nerve graft add-on	11.83	6.03	NA	1.10	18.96	NA	ZZZ
64905		A	Nerve pedicle transfer	14.02	8.63	NA	1.52	24.17	NA	090
64907		A	Nerve pedicle transfer	18.83	11.68	NA	1.79	32.30	NA	090
64999		C	Nervous system surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
65091		A	Revise eye	6.46	9.45	NA	0.26	16.17	NA	090
65093		A	Revise eye with implant	6.87	9.65	NA	0.28	16.80	NA	090
65101		A	Removal of eye	7.03	9.48	NA	0.28	16.79	NA	090
65103		A	Remove eye/insert implant	7.57	9.82	NA	0.30	17.69	NA	090
65105		A	Remove eye/attach implant	8.49	10.37	NA	0.34	19.20	NA	090
65110		A	Removal of eye	13.95	14.03	NA	0.68	28.66	NA	090
65112		A	Remove eye/revise socket	16.38	17.35	NA	0.96	34.69	NA	090
65114		A	Remove eye/revise socket	17.53	16.37	NA	0.94	34.84	NA	090
65125		A	Revise ocular implant	3.12	1.47	4.85	0.15	4.74	8.12	090
65130		A	Insert ocular implant	7.15	9.56	NA	0.28	16.99	NA	090
65135		A	Insert ocular implant	7.33	9.30	NA	0.29	16.92	NA	090
65140		A	Attach ocular implant	8.02	9.73	NA	0.31	18.06	NA	090
65150		A	Revise ocular implant	6.26	9.01	NA	0.25	15.52	NA	090
65155		A	Reinsert ocular implant	8.66	11.15	NA	0.40	20.21	NA	090
65175		A	Removal of ocular implant	6.28	9.03	NA	0.26	15.57	NA	090
65205		A	Remove foreign body from eye	0.71	0.20	5.14	0.03	0.94	5.88	000
65210		A	Remove foreign body from eye	0.84	0.31	5.30	0.03	1.18	6.17	000
65220		A	Remove foreign body from eye	0.71	0.19	6.66	0.05	0.95	7.42	000
65222		A	Remove foreign body from eye	0.93	0.28	5.24	0.04	1.25	6.21	000
65235		A	Remove foreign body from eye	7.57	6.67	NA	0.30	14.54	NA	090
65260		A	Remove foreign body from eye	10.96	11.53	NA	0.43	22.92	NA	090
65265		A	Remove foreign body from eye	12.59	13.08	NA	0.50	26.17	NA	090
65270		A	Repair of eye wound	1.90	1.98	3.59	0.08	3.96	5.57	010
65272		A	Repair of eye wound	3.82	3.81	4.88	0.16	7.79	8.86	090
65273		A	Repair of eye wound	4.36	4.26	NA	0.17	8.79	NA	090
65275		A	Repair of eye wound	5.34	4.60	5.03	0.27	10.21	10.64	090
65280		A	Repair of eye wound	7.66	7.12	NA	0.30	15.08	NA	090
65285		A	Repair of eye wound	12.90	12.78	NA	0.51	26.19	NA	090
65286		A	Repair of eye wound	5.51	6.63	7.74	0.21	12.35	13.46	090
65290		A	Repair of eye socket wound	5.41	6.69	NA	0.26	12.36	NA	090
65400		A	Removal of eye lesion	6.06	6.38	7.70	0.24	12.68	14.00	090
65410		A	Biopsy of cornea	1.47	0.65	1.61	0.06	2.18	3.14	000
65420		A	Removal of eye lesion	4.17	5.95	6.92	0.17	10.29	11.26	090
65426		A	Removal of eye lesion	5.25	5.99	7.12	0.20	11.44	12.57	090
65430		A	Corneal smear	1.47	0.69	5.79	0.06	2.22	7.32	000
65435		A	Curette/treat cornea	0.92	0.41	1.27	0.04	1.37	2.23	000
65436		A	Curette/treat cornea	4.19	4.24	5.10	0.17	8.60	9.46	090
65450		A	Treatment of corneal lesion	3.27	5.55	6.68	0.13	8.95	10.08	090
65600		A	Revision of cornea	3.40	1.45	4.65	0.14	4.99	8.19	090
65710		A	Corneal transplant	12.35	12.27	NA	0.49	25.11	NA	090
65730		A	Corneal transplant	14.25	11.75	NA	0.56	26.56	NA	090
65750		A	Corneal transplant	15.00	13.52	NA	0.59	29.11	NA	090
65755		A	Corneal transplant	14.89	13.44	NA	0.58	28.91	NA	090
65760		N	Revision of cornea	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65765		N	Revision of cornea	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65767		N	Corneal tissue transplant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65770		A	Revise cornea with implant	17.56	14.45	NA	0.69	32.70	NA	090
65771		N	Radial keratotomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65772		A	Correction of astigmatism	4.29	5.26	6.16	0.17	9.72	10.62	090
65775		A	Correction of astigmatism	5.79	7.87	NA	0.22	13.88	NA	090
65800		A	Drainage of eye	1.91	1.36	2.13	0.08	3.35	4.12	000
65805		A	Drainage of eye	1.91	1.37	2.13	0.08	3.36	4.12	000
65810		A	Drainage of eye	4.87	7.32	NA	0.19	12.38	NA	090
65815		A	Drainage of eye	5.05	6.86	7.93	0.20	12.11	13.18	090
65820		A	Relieve inner eye pressure	8.13	9.12	NA	0.32	17.57	NA	090
65850		A	Incision of eye	10.52	9.40	NA	0.41	20.33	NA	090
65855		A	Laser surgery of eye	3.85	3.56	4.83	0.17	7.58	8.85	090
65860		A	Incise inner eye adhesions	3.55	2.93	3.71	0.14	6.62	7.40	090
65865		A	Incise inner eye adhesions	5.60	6.14	NA	0.22	11.96	NA	090
65870		A	Incise inner eye adhesions	6.27	6.47	NA	0.24	12.98	NA	090
65875		A	Incise inner eye adhesions	6.54	6.59	NA	0.25	13.38	NA	090
65880		A	Incise inner eye adhesions	7.09	6.82	NA	0.28	14.19	NA	090
65900		A	Remove eye lesion	10.93	11.71	NA	0.46	23.10	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
65920		A	Remove implant from eye	8.40	7.47	NA	0.33	16.20	NA	090
65930		A	Remove blood clot from eye	7.44	7.92	NA	0.29	15.65	NA	090
66020		A	Injection treatment of eye	1.59	1.45	2.20	0.07	3.11	3.86	010
66030		A	Injection treatment of eye	1.25	1.29	2.05	0.05	2.59	3.35	010
66130		A	Remove eye lesion	7.69	5.91	6.73	0.31	13.91	14.73	090
66150		A	Glaucoma surgery	8.30	10.08	NA	0.33	18.71	NA	090
66155		A	Glaucoma surgery	8.29	10.06	NA	0.32	18.67	NA	090
66160		A	Glaucoma surgery	10.17	10.94	NA	0.41	21.52	NA	090
66165		A	Glaucoma surgery	8.01	9.97	NA	0.31	18.29	NA	090
66170		A	Glaucoma surgery	12.16	11.90	NA	0.48	24.54	NA	090
66172		A	Incision of eye	15.04	14.75	NA	0.59	30.38	NA	090
66180		A	Implant eye shunt	14.55	11.76	NA	0.57	26.88	NA	090
66185		A	Revise eye shunt	8.14	8.25	NA	0.32	16.71	NA	090
66220		A	Repair eye lesion	7.77	9.97	NA	0.32	18.06	NA	090
66225		A	Repair/graft eye lesion	11.05	9.28	NA	0.44	20.77	NA	090
66250		A	Follow-up surgery of eye	5.98	6.35	7.71	0.23	12.56	13.92	090
66500		A	Incision of iris	3.71	4.00	NA	0.15	7.86	NA	090
66505		A	Incision of iris	4.08	4.20	NA	0.17	8.45	NA	090
66600		A	Remove iris and lesion	8.68	9.14	NA	0.34	18.16	NA	090
66605		A	Removal of iris	12.79	12.23	NA	0.61	25.63	NA	090
66625		A	Removal of iris	5.13	6.88	7.80	0.20	12.21	13.13	090
66630		A	Removal of iris	6.16	7.91	NA	0.24	14.31	NA	090
66635		A	Removal of iris	6.25	6.45	NA	0.24	12.94	NA	090
66680		A	Repair iris & ciliary body	5.44	6.06	NA	0.21	11.71	NA	090
66682		A	Repair iris & ciliary body	6.21	7.95	NA	0.24	14.40	NA	090
66700		A	Destruction, ciliary body	4.78	6.25	7.59	0.19	11.22	12.56	090
66710		A	Destruction, ciliary body	4.78	6.28	7.47	0.18	11.24	12.43	090
66720		A	Destruction, ciliary body	4.78	6.24	7.37	0.19	11.21	12.34	090
66740		A	Destruction, ciliary body	4.78	5.75	NA	0.18	10.71	NA	090
66761		A	Revision of iris	4.07	4.03	5.13	0.16	8.26	9.36	090
66762		A	Revision of iris	4.58	4.19	5.26	0.18	8.95	10.02	090
66770		A	Removal of inner eye lesion	5.18	4.45	5.56	0.20	9.83	10.94	090
66820		A	Incision, secondary cataract	3.89	6.91	NA	0.16	10.96	NA	090
66821		A	After cataract laser surgery	2.35	3.11	3.51	0.10	5.56	5.96	090
66825		A	Reposition intraocular lens	8.23	8.88	NA	0.32	17.43	NA	090
66830		A	Removal of lens lesion	8.20	6.65	NA	0.32	15.17	NA	090
66840		A	Removal of lens material	7.91	6.59	NA	0.31	14.81	NA	090
66850		A	Removal of lens material	9.11	7.13	NA	0.36	16.60	NA	090
66852		A	Removal of lens material	9.97	7.59	NA	0.39	17.95	NA	090
66920		A	Extraction of lens	8.86	7.06	NA	0.35	16.27	NA	090
66930		A	Extraction of lens	10.18	8.53	NA	0.41	19.12	NA	090
66940		A	Extraction of lens	8.93	7.93	NA	0.35	17.21	NA	090
66982		A	Cataract surgery, complex	13.50	8.88	NA	0.55	22.93	NA	090
66983		A	Cataract surg w/iol, 1 stage	8.99	5.74	NA	0.37	15.10	NA	090
66984		A	Cataract surg w/iol, i stage	10.23	7.44	NA	0.41	18.08	NA	090
66985		A	Insert lens prosthesis	8.39	6.61	NA	0.33	15.33	NA	090
66986		A	Exchange lens prosthesis	12.28	8.65	NA	0.49	21.42	NA	090
66999		C	Eye surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67005		A	Partial removal of eye fluid	5.70	2.70	NA	0.22	8.62	NA	090
67010		A	Partial removal of eye fluid	6.87	3.28	NA	0.27	10.42	NA	090
67015		A	Release of eye fluid	6.92	7.62	NA	0.27	14.81	NA	090
67025		A	Replace eye fluid	6.84	7.10	14.50	0.27	14.21	21.61	090
67027		A	Implant eye drug system	10.85	8.45	16.16	0.46	19.76	27.47	090
67028		A	Injection eye drug	2.52	1.20	8.03	0.11	3.83	10.66	000
67030		A	Incise inner eye strands	4.84	6.21	NA	0.19	11.24	NA	090
67031		A	Laser surgery, eye strands	3.67	3.00	3.80	0.15	6.82	7.62	090
67036		A	Removal of inner eye fluid	11.89	8.81	NA	0.47	21.17	NA	090
67038		A	Strip retinal membrane	21.24	15.12	NA	0.84	37.20	NA	090
67039		A	Laser treatment of retina	14.52	11.91	NA	0.57	27.00	NA	090
67040		A	Laser treatment of retina	17.23	13.22	NA	0.68	31.13	NA	090
67101		A	Repair detached retina	7.53	8.49	10.38	0.29	16.31	18.20	090
67105		A	Repair detached retina	7.41	5.48	7.24	0.29	13.18	14.94	090
67107		A	Repair detached retina	14.84	12.77	NA	0.58	28.19	NA	090
67108		A	Repair detached retina	20.82	17.00	NA	0.82	38.64	NA	090
67110		A	Repair detached retina	8.81	9.89	17.89	0.35	19.05	27.05	090
67112		A	Rerepair detached retina	16.86	15.09	NA	0.66	32.61	NA	090
67115		A	Release encircling material	4.99	6.30	NA	0.19	11.48	NA	090
67120		A	Remove eye implant material	5.98	6.69	13.93	0.23	12.90	20.14	090
67121		A	Remove eye implant material	10.67	11.36	NA	0.42	22.45	NA	090
67141		A	Treatment of retina	5.20	6.47	7.44	0.20	11.87	12.84	090
67145		A	Treatment of retina	5.37	4.10	5.09	0.21	9.68	10.67	090
67208		A	Treatment of retinal lesion	6.70	6.61	7.81	0.26	13.57	14.77	090
67210		A	Treatment of retinal lesion	8.82	5.72	7.05	0.35	14.89	16.22	090
67218		A	Treatment of retinal lesion	18.53	15.13	NA	0.53	34.19	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
67220		A	Treatment of choroid lesion	13.13	9.81	10.88	0.51	23.45	24.52	090
67221		A	Ocular photodynamic ther	4.01	1.92	4.19	0.50	6.43	8.70	000
67227		A	Treatment of retinal lesion	6.58	6.72	8.39	0.26	13.56	15.23	090
67228		A	Treatment of retinal lesion	12.74	7.25	9.63	0.50	20.49	22.87	090
67250		A	Reinforce eye wall	8.66	10.21	NA	0.36	19.23	NA	090
67255		A	Reinforce/graft eye wall	8.90	10.14	NA	0.35	19.39	NA	090
67299		C	Eye surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67311		A	Revise eye muscle	6.65	6.09	NA	0.27	13.01	NA	090
67312		A	Revise two eye muscles	8.54	7.06	NA	0.35	15.95	NA	090
67314		A	Revise eye muscle	7.52	6.57	NA	0.30	14.39	NA	090
67316		A	Revise two eye muscles	9.66	7.55	NA	0.40	17.61	NA	090
67318		A	Revise eye muscle(s)	7.85	6.96	NA	0.31	15.12	NA	090
67320		A	Revise eye muscle(s) add-on	4.33	6.56	NA	0.17	11.06	NA	ZZZ
67331		A	Eye surgery follow-up add-on	4.06	5.01	NA	0.17	9.24	NA	ZZZ
67332		A	Rerevise eye muscles add-on	4.49	5.66	NA	0.18	10.33	NA	ZZZ
67334		A	Revise eye muscle w/suture	3.98	5.15	NA	0.16	9.29	NA	ZZZ
67335		A	Eye suture during surgery	2.49	1.18	NA	0.10	3.77	NA	ZZZ
67340		A	Revise eye muscle add-on	4.93	6.82	NA	0.19	11.94	NA	ZZZ
67343		A	Release eye tissue	7.35	6.94	NA	0.30	14.59	NA	090
67345		A	Destroy nerve of eye muscle	2.96	1.38	4.19	0.13	4.47	7.28	010
67350		A	Biopsy eye muscle	2.87	2.37	NA	0.13	5.37	NA	000
67399		C	Eye muscle surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67400		A	Explore/biopsy eye socket	9.76	11.78	NA	0.43	21.97	NA	090
67405		A	Explore/drain eye socket	7.93	10.62	NA	0.36	18.91	NA	090
67412		A	Explore/treat eye socket	9.50	12.91	NA	0.41	22.82	NA	090
67413		A	Explore/treat eye socket	10.00	11.35	NA	0.43	21.78	NA	090
67414		A	Explr/decompress eye socket	11.13	13.53	NA	0.48	25.14	NA	090
67415		A	Aspiration, orbital contents	1.76	0.83	NA	0.09	2.68	NA	000
67420		A	Explore/treat eye socket	20.06	17.23	NA	0.84	38.13	NA	090
67430		A	Explore/treat eye socket	13.39	19.03	NA	0.97	33.39	NA	090
67440		A	Explore/drain eye socket	13.09	14.28	NA	0.58	27.95	NA	090
67445		A	Explr/decompress eye socket	14.42	15.52	NA	0.63	30.57	NA	090
67450		A	Explore/biopsy eye socket	13.51	14.00	NA	0.56	28.07	NA	090
67500		A	Inject/treat eye socket	0.79	0.20	1.93	0.04	1.03	2.76	000
67505		A	Inject/treat eye socket	0.82	0.21	0.90	0.04	1.07	1.76	000
67515		A	Inject/treat eye socket	0.61	0.29	0.79	0.02	0.92	1.42	000
67550		A	Insert eye socket implant	10.19	11.87	NA	0.50	22.56	NA	090
67560		A	Revise eye socket implant	10.60	11.46	NA	0.47	22.53	NA	090
67570		A	Decompress optic nerve	13.58	14.77	NA	0.69	29.04	NA	090
67599		C	Orbit surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67700		A	Drainage of eyelid abscess	1.35	0.60	5.34	0.06	2.01	6.75	010
67710		A	Incision of eyelid	1.02	0.49	5.48	0.04	1.55	6.54	010
67715		A	Incision of eyelid fold	1.22	0.59	NA	0.05	1.86	NA	010
67800		A	Remove eyelid lesion	1.38	0.66	2.18	0.06	2.10	3.62	010
67801		A	Remove eyelid lesions	1.88	0.90	5.68	0.08	2.86	7.64	010
67805		A	Remove eyelid lesions	2.22	1.06	5.88	0.09	3.37	8.19	010
67808		A	Remove eyelid lesion(s)	3.80	3.79	NA	0.17	7.76	NA	090
67810		A	Biopsy of eyelid	1.48	0.71	4.45	0.06	2.25	5.99	000
67820		A	Revise eyelashes	0.89	0.38	1.56	0.04	1.31	2.49	000
67825		A	Revise eyelashes	1.38	1.66	6.95	0.06	3.10	8.39	010
67830		A	Revise eyelashes	1.70	1.87	8.18	0.07	3.64	9.95	010
67835		A	Revise eyelashes	5.56	4.53	NA	0.22	10.31	NA	090
67840		A	Remove eyelid lesion	2.04	0.97	5.75	0.08	3.09	7.87	010
67850		A	Treat eyelid lesion	1.69	1.76	7.12	0.07	3.52	8.88	010
67875		A	Closure of eyelid by suture	1.35	1.84	8.34	0.06	3.25	9.75	000
67880		A	Revision of eyelid	3.80	2.90	9.21	0.16	6.86	13.17	090
67882		A	Revision of eyelid	5.07	4.36	11.96	0.21	9.64	17.24	090
67900		A	Repair brow defect	6.14	6.16	10.03	0.30	12.60	16.47	090
67901		A	Repair eyelid defect	6.97	6.35	NA	0.32	13.64	NA	090
67902		A	Repair eyelid defect	7.03	6.44	NA	0.34	13.81	NA	090
67903		A	Repair eyelid defect	6.37	7.12	11.86	0.39	13.88	18.62	090
67904		A	Repair eyelid defect	6.26	7.21	12.42	0.26	13.73	18.94	090
67906		A	Repair eyelid defect	6.79	6.29	7.52	0.42	13.50	14.73	090
67908		A	Repair eyelid defect	5.13	5.67	8.20	0.20	11.00	13.53	090
67909		A	Revise eyelid defect	5.40	6.37	9.33	0.25	12.02	14.98	090
67911		A	Revise eyelid defect	5.27	6.15	NA	0.23	11.65	NA	090
67914		A	Repair eyelid defect	3.68	3.31	9.72	0.16	7.15	13.56	090
67915		A	Repair eyelid defect	3.18	1.54	8.46	0.13	4.85	11.77	090
67916		A	Repair eyelid defect	5.31	5.00	12.94	0.22	10.53	18.47	090
67917		A	Repair eyelid defect	6.02	6.18	9.20	0.25	12.45	15.47	090
67921		A	Repair eyelid defect	3.40	3.05	9.35	0.14	6.59	12.89	090
67922		A	Repair eyelid defect	3.06	2.89	8.41	0.13	6.08	11.60	090
67923		A	Repair eyelid defect	5.88	5.14	12.91	0.24	11.26	19.03	090
67924		A	Repair eyelid defect	5.79	5.55	8.55	0.23	11.57	14.57	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
67930		A	Repair eyelid wound	3.61	2.88	9.23	0.17	6.66	13.01	010
67935		A	Repair eyelid wound	6.22	5.19	13.75	0.29	11.70	20.26	090
67938		A	Remove eyelid foreign body	1.33	0.53	6.62	0.06	1.92	8.01	010
67950		A	Revision of eyelid	5.82	6.94	8.40	0.30	13.06	14.52	090
67961		A	Revision of eyelid	5.69	5.86	8.54	0.26	11.81	14.49	090
67966		A	Revision of eyelid	6.57	6.05	8.43	0.33	12.95	15.33	090
67971		A	Reconstruction of eyelid	9.79	7.56	NA	0.42	17.77	NA	090
67973		A	Reconstruction of eyelid	12.87	9.70	NA	0.59	23.16	NA	090
67974		A	Reconstruction of eyelid	12.84	9.61	NA	0.54	22.99	NA	090
67975		A	Reconstruction of eyelid	9.13	7.20	NA	0.38	16.71	NA	090
67999		C	Revision of eyelid	0.00	0.00	0.00	0.00	0.00	0.00	YYY
68020		A	Incise/drain eyelid lining	1.37	0.65	5.28	0.06	2.08	6.71	010
68040		A	Treatment of eyelid lesions	0.85	0.41	5.13	0.03	1.29	6.01	000
68100		A	Biopsy of eyelid lining	1.35	0.64	5.64	0.06	2.05	7.05	000
68110		A	Remove eyelid lining lesion	1.77	1.35	6.35	0.07	3.19	8.19	010
68115		A	Remove eyelid lining lesion	2.36	1.12	5.90	0.10	3.58	8.36	010
68130		A	Remove eyelid lining lesion	4.93	2.35	NA	0.19	7.47	NA	090
68135		A	Remove eyelid lining lesion	1.84	0.87	5.65	0.07	2.78	7.56	010
68200		A	Treat eyelid by injection	0.49	0.23	5.25	0.02	0.74	5.76	000
68320		A	Revise/graft eyelid lining	5.37	5.05	5.14	0.21	10.63	10.72	090
68325		A	Revise/graft eyelid lining	7.36	6.07	NA	0.30	13.73	NA	090
68326		A	Revise/graft eyelid lining	7.15	5.96	NA	0.30	13.41	NA	090
68328		A	Revise/graft eyelid lining	8.18	6.81	NA	0.40	15.39	NA	090
68330		A	Revise eyelid lining	4.83	5.00	6.69	0.19	10.02	11.71	090
68335		A	Revise/graft eyelid lining	7.19	5.16	NA	0.29	12.64	NA	090
68340		A	Separate eyelid adhesions	4.17	3.89	11.78	0.17	8.23	16.12	090
68360		A	Revise eyelid lining	4.37	4.78	5.92	0.17	9.32	10.46	090
68362		A	Revise eyelid lining	7.34	7.43	NA	0.29	15.06	NA	090
68399		C	Eyelid lining surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
68400		A	Incise/drain tear gland	1.69	1.88	8.24	0.07	3.64	10.00	010
68420		A	Incise/drain tear sac	2.30	2.17	8.38	0.10	4.57	10.78	010
68440		A	Incise tear duct opening	0.94	0.45	5.27	0.04	1.43	6.25	010
68500		A	Removal of tear gland	11.02	10.17	NA	0.60	21.79	NA	090
68505		A	Partial removal, tear gland	10.94	10.38	NA	0.57	21.89	NA	090
68510		A	Biopsy of tear gland	4.61	2.16	9.87	0.19	6.96	14.67	000
68520		A	Removal of tear sac	7.51	6.72	NA	0.33	14.56	NA	090
68525		A	Biopsy of tear sac	4.43	2.11	NA	0.18	6.72	NA	000
68530		A	Clearance of tear duct	3.66	2.76	11.01	0.16	6.58	14.83	010
68540		A	Remove tear gland lesion	10.60	8.32	NA	0.46	19.38	NA	090
68550		A	Remove tear gland lesion	13.26	10.39	NA	0.66	24.31	NA	090
68700		A	Repair tear ducts	6.60	6.10	NA	0.27	12.97	NA	090
68705		A	Revise tear duct opening	2.06	0.98	5.90	0.08	3.12	8.04	010
68720		A	Create tear sac drain	8.96	7.26	NA	0.38	16.60	NA	090
68745		A	Create tear duct drain	8.63	7.26	NA	0.38	16.27	NA	090
68750		A	Create tear duct drain	8.66	7.68	NA	0.37	16.71	NA	090
68760		A	Close tear duct opening	1.73	0.82	5.54	0.07	2.62	7.34	010
68761		A	Close tear duct opening	1.36	0.63	6.39	0.06	2.05	7.81	010
68770		A	Close tear system fistula	7.02	5.56	13.49	0.28	12.86	20.79	090
68801		A	Dilate tear duct opening	0.94	0.44	6.44	0.04	1.42	7.42	010
68810		A	Probe nasolacrimal duct	1.90	1.89	8.09	0.08	3.87	10.07	010
68811		A	Probe nasolacrimal duct	2.35	2.14	NA	0.10	4.59	NA	010
68815		A	Probe nasolacrimal duct	3.20	2.61	9.93	0.14	5.95	13.27	010
68840		A	Explore/irrigate tear ducts	1.25	0.59	7.01	0.05	1.89	8.31	010
68850		A	Injection for tear sac x-ray	0.80	0.31	12.26	0.03	1.14	13.09	000
68899		C	Tear duct system surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69000		A	Drain external ear lesion	1.45	0.58	2.03	0.10	2.13	3.58	010
69005		A	Drain external ear lesion	2.11	2.06	2.46	0.16	4.33	4.73	010
69020		A	Drain outer ear canal lesion	1.48	0.75	2.13	0.11	2.34	3.72	010
69090		N	Pierce earlobes	0.00	0.00	0.00	0.00	0.00	0.00	XXX
69100		A	Biopsy of external ear	0.81	0.41	1.44	0.04	1.26	2.29	000
69105		A	Biopsy of external ear canal	0.85	0.96	1.45	0.06	1.87	2.36	000
69110		A	Remove external ear, partial	3.44	2.79	3.43	0.24	6.47	7.11	090
69120		A	Removal of external ear	4.05	4.42	NA	0.31	8.78	NA	090
69140		A	Remove ear canal lesion(s)	7.97	7.89	NA	0.56	16.42	NA	090
69145		A	Remove ear canal lesion(s)	2.62	2.44	3.26	0.18	5.24	6.06	090
69150		A	Extensive ear canal surgery	13.43	11.19	NA	1.07	25.69	NA	090
69155		A	Extensive ear/neck surgery	20.80	15.24	NA	1.51	37.55	NA	090
69200		A	Clear outer ear canal	0.77	0.72	1.38	0.05	1.54	2.20	000
69205		A	Clear outer ear canal	1.20	1.50	NA	0.09	2.79	NA	010
69210		A	Remove impacted ear wax	0.61	0.25	1.27	0.04	0.90	1.92	000
69220		A	Clean out mastoid cavity	0.83	0.43	1.44	0.06	1.32	2.33	000
69222		A	Clean out mastoid cavity	1.40	1.63	2.12	0.10	3.13	3.62	010
69300		R	Revise external ear	6.36	4.35	NA	0.43	11.14	NA	YYY
69310		A	Rebuild outer ear canal	10.79	9.48	NA	0.77	21.04	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
69320		A	Rebuild outer ear canal	16.96	13.66	NA	1.17	31.79	NA	090
69399		C	Outer ear surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69400		A	Inflate middle ear canal	0.83	0.46	1.44	0.06	1.35	2.33	000
69401		A	Inflate middle ear canal	0.63	0.37	1.34	0.04	1.04	2.01	000
69405		A	Catheterize middle ear canal	2.63	1.48	2.97	0.18	4.29	5.78	010
69410		A	Inset middle ear (baffle)	0.33	0.16	1.38	0.02	0.51	1.73	000
69420		A	Incision of eardrum	1.33	0.72	2.22	0.10	2.15	3.65	010
69421		A	Incision of eardrum	1.73	1.83	2.46	0.13	3.69	4.32	010
69424		A	Remove ventilating tube	0.85	0.89	1.59	0.06	1.80	2.50	000
69433		A	Create eardrum opening	1.52	0.86	2.20	0.11	2.49	3.83	010
69436		A	Create eardrum opening	1.96	1.97	NA	0.14	4.07	NA	010
69440		A	Exploration of middle ear	7.57	7.11	NA	0.53	15.21	NA	090
69450		A	Eardrum revision	5.57	5.90	NA	0.39	11.86	NA	090
69501		A	Mastoidectomy	9.07	7.91	NA	0.65	17.63	NA	090
69502		A	Mastoidectomy	12.38	10.47	NA	0.86	23.71	NA	090
69505		A	Remove mastoid structures	12.99	10.66	NA	0.92	24.57	NA	090
69511		A	Extensive mastoid surgery	13.52	11.04	NA	0.96	25.52	NA	090
69530		A	Extensive mastoid surgery	19.19	14.65	NA	1.32	35.16	NA	090
69535		A	Remove part of temporal bone	36.14	24.24	NA	2.59	62.97	NA	090
69540		A	Remove ear lesion	1.20	1.52	2.13	0.09	2.81	3.42	010
69550		A	Remove ear lesion	10.99	9.68	NA	0.80	21.47	NA	090
69552		A	Remove ear lesion	19.46	14.31	NA	1.36	35.13	NA	090
69554		A	Remove ear lesion	33.16	21.82	NA	2.32	57.30	NA	090
69601		A	Mastoid surgery revision	13.24	11.61	NA	0.92	25.77	NA	090
69602		A	Mastoid surgery revision	13.58	11.19	NA	0.94	25.71	NA	090
69603		A	Mastoid surgery revision	14.02	11.48	NA	1.00	26.50	NA	090
69604		A	Mastoid surgery revision	14.02	11.26	NA	0.98	26.26	NA	090
69605		A	Mastoid surgery revision	18.49	13.94	NA	1.29	33.72	NA	090
69610		A	Repair of eardrum	4.43	3.37	4.09	0.31	8.11	8.83	010
69620		A	Repair of eardrum	5.89	2.95	6.61	0.40	9.24	12.90	090
69631		A	Repair eardrum structures	9.86	9.04	NA	0.69	19.59	NA	090
69632		A	Rebuild eardrum structures	12.75	11.27	NA	0.89	24.91	NA	090
69633		A	Rebuild eardrum structures	12.10	10.91	NA	0.84	23.85	NA	090
69635		A	Repair eardrum structures	13.33	9.46	NA	0.87	23.66	NA	090
69636		A	Rebuild eardrum structures	15.22	12.80	NA	1.07	29.09	NA	090
69637		A	Rebuild eardrum structures	15.11	12.73	NA	1.06	28.90	NA	090
69641		A	Revise middle ear & mastoid	12.71	10.63	NA	0.89	24.23	NA	090
69642		A	Revise middle ear & mastoid	16.84	13.65	NA	1.18	31.67	NA	090
69643		A	Revise middle ear & mastoid	15.32	12.78	NA	1.08	29.18	NA	090
69644		A	Revise middle ear & mastoid	16.97	13.73	NA	1.19	31.89	NA	090
69645		A	Revise middle ear & mastoid	16.38	13.36	NA	1.16	30.90	NA	090
69646		A	Revise middle ear & mastoid	17.99	14.33	NA	1.26	33.58	NA	090
69650		A	Release middle ear bone	9.66	8.30	NA	0.68	18.64	NA	090
69660		A	Revise middle ear bone	11.90	9.53	NA	0.84	22.27	NA	090
69661		A	Revise middle ear bone	15.74	12.32	NA	1.10	29.16	NA	090
69662		A	Revise middle ear bone	15.44	12.17	NA	1.08	28.69	NA	090
69666		A	Repair middle ear structures	9.75	8.34	NA	0.68	18.77	NA	090
69667		A	Repair middle ear structures	9.76	8.29	NA	0.72	18.77	NA	090
69670		A	Remove mastoid air cells	11.51	9.91	NA	0.78	22.20	NA	090
69676		A	Remove middle ear nerve	9.52	8.62	NA	0.69	18.83	NA	090
69700		A	Close mastoid fistula	8.23	5.24	NA	0.55	14.02	NA	090
69710		N	Implant/replace hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
69711		A	Remove/repair hearing aid	10.44	9.18	NA	0.62	20.24	NA	090
69714		A	Implant temple bone w/stimul	14.00	8.65	NA	0.97	23.62	NA	090
69715		A	Temple bne implnt w/stimulat	18.25	10.42	NA	1.25	29.92	NA	090
69717		A	Temple bone implant revision	14.98	8.31	NA	1.04	24.33	NA	090
69718		A	Revise temple bone implant	18.50	10.51	NA	1.27	30.28	NA	090
69720		A	Release facial nerve	14.38	12.04	NA	1.03	27.45	NA	090
69725		A	Release facial nerve	25.38	18.21	NA	1.78	45.37	NA	090
69740		A	Repair facial nerve	15.96	11.55	NA	1.13	28.64	NA	090
69745		A	Repair facial nerve	16.69	11.91	NA	1.00	29.60	NA	090
69799		C	Middle ear surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69801		A	Incise inner ear	8.56	7.68	NA	0.60	16.84	NA	090
69802		A	Incise inner ear	13.10	10.97	NA	0.91	24.98	NA	090
69805		A	Explore inner ear	13.82	10.74	NA	0.97	25.53	NA	090
69806		A	Explore inner ear	12.35	10.50	NA	0.86	23.71	NA	090
69820		A	Establish inner ear window	10.34	9.02	NA	0.66	20.02	NA	090
69840		A	Revise inner ear window	10.26	9.90	NA	0.64	20.80	NA	090
69905		A	Remove inner ear	11.10	9.34	NA	0.77	21.21	NA	090
69910		A	Remove inner ear & mastoid	13.63	10.98	NA	0.94	25.55	NA	090
69915		A	Incise inner ear nerve	21.23	15.31	NA	1.54	38.08	NA	090
69930		A	Implant cochlear device	16.81	12.66	NA	1.19	30.66	NA	090
69949		C	Inner ear surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69950		A	Incise inner ear nerve	25.64	16.14	NA	2.90	44.68	NA	090

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
69955		A	Release facial nerve	27.04	18.47	NA	1.89	47.40	NA	090
69960		A	Release inner ear canal	27.04	17.99	NA	2.43	47.46	NA	090
69970		A	Remove inner ear lesion	30.04	19.13	NA	2.34	51.51	NA	090
69979		C	Temporal bone surgery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69990		R	Microsurgery add-on	3.47	1.88	NA	0.56	5.91	NA	ZZZ
70010		A	Contrast x-ray of brain	1.19	NA	4.69	0.24	NA	6.12	XXX
70010	26	A	Contrast x-ray of brain	1.19	0.42	0.42	0.06	1.67	1.67	XXX
70010	TC	A	Contrast x-ray of brain	0.00	NA	4.27	0.18	NA	4.45	XXX
70015		A	Contrast x-ray of brain	1.19	NA	1.76	0.12	NA	3.07	XXX
70015	26	A	Contrast x-ray of brain	1.19	0.43	0.43	0.05	1.67	1.67	XXX
70015	TC	A	Contrast x-ray of brain	0.00	NA	1.33	0.07	NA	1.40	XXX
70030		A	X-ray eye for foreign body	0.17	NA	0.47	0.03	NA	0.67	XXX
70030	26	A	X-ray eye for foreign body	0.17	0.06	0.06	0.01	0.24	0.24	XXX
70030	TC	A	X-ray eye for foreign body	0.00	NA	0.41	0.02	NA	0.43	XXX
70100		A	X-ray exam of jaw	0.18	NA	0.57	0.03	NA	0.78	XXX
70100	26	A	X-ray exam of jaw	0.18	0.06	0.06	0.01	0.25	0.25	XXX
70100	TC	A	X-ray exam of jaw	0.00	NA	0.51	0.02	NA	0.53	XXX
70110		A	X-ray exam of jaw	0.25	NA	0.70	0.04	NA	0.99	XXX
70110	26	A	X-ray exam of jaw	0.25	0.09	0.09	0.01	0.35	0.35	XXX
70110	TC	A	X-ray exam of jaw	0.00	NA	0.61	0.03	NA	0.64	XXX
70120		A	X-ray exam of mastoids	0.18	NA	0.67	0.04	NA	0.89	XXX
70120	26	A	X-ray exam of mastoids	0.18	0.06	0.06	0.01	0.25	0.25	XXX
70120	TC	A	X-ray exam of mastoids	0.00	NA	0.61	0.03	NA	0.64	XXX
70130		A	X-ray exam of mastoids	0.34	NA	0.89	0.05	NA	1.28	XXX
70130	26	A	X-ray exam of mastoids	0.34	0.12	0.12	0.01	0.47	0.47	XXX
70130	TC	A	X-ray exam of mastoids	0.00	NA	0.77	0.04	NA	0.81	XXX
70134		A	X-ray exam of middle ear	0.34	NA	0.84	0.05	NA	1.23	XXX
70134	26	A	X-ray exam of middle ear	0.34	0.12	0.12	0.01	0.47	0.47	XXX
70134	TC	A	X-ray exam of middle ear	0.00	NA	0.72	0.04	NA	0.76	XXX
70140		A	X-ray exam of facial bones	0.19	NA	0.68	0.04	NA	0.91	XXX
70140	26	A	X-ray exam of facial bones	0.19	0.07	0.07	0.01	0.27	0.27	XXX
70140	TC	A	X-ray exam of facial bones	0.00	NA	0.61	0.03	NA	0.64	XXX
70150		A	X-ray exam of facial bones	0.26	NA	0.86	0.05	NA	1.17	XXX
70150	26	A	X-ray exam of facial bones	0.26	0.09	0.09	0.01	0.36	0.36	XXX
70150	TC	A	X-ray exam of facial bones	0.00	NA	0.77	0.04	NA	0.81	XXX
70160		A	X-ray exam of nasal bones	0.17	NA	0.57	0.03	NA	0.77	XXX
70160	26	A	X-ray exam of nasal bones	0.17	0.06	0.06	0.01	0.24	0.24	XXX
70160	TC	A	X-ray exam of nasal bones	0.00	NA	0.51	0.02	NA	0.53	XXX
70170		A	X-ray exam of tear duct	0.30	NA	1.04	0.06	NA	1.40	XXX
70170	26	A	X-ray exam of tear duct	0.30	0.11	0.11	0.01	0.42	0.42	XXX
70170	TC	A	X-ray exam of tear duct	0.00	NA	0.93	0.05	NA	0.98	XXX
70190		A	X-ray exam of eye sockets	0.21	NA	0.68	0.04	NA	0.93	XXX
70190	26	A	X-ray exam of eye sockets	0.21	0.07	0.07	0.01	0.29	0.29	XXX
70190	TC	A	X-ray exam of eye sockets	0.00	NA	0.61	0.03	NA	0.64	XXX
70200		A	X-ray exam of eye sockets	0.28	NA	0.87	0.05	NA	1.20	XXX
70200	26	A	X-ray exam of eye sockets	0.28	0.10	0.10	0.01	0.39	0.39	XXX
70200	TC	A	X-ray exam of eye sockets	0.00	NA	0.77	0.04	NA	0.81	XXX
70210		A	X-ray exam of sinuses	0.17	NA	0.67	0.04	NA	0.88	XXX
70210	26	A	X-ray exam of sinuses	0.17	0.06	0.06	0.01	0.24	0.24	XXX
70210	TC	A	X-ray exam of sinuses	0.00	NA	0.61	0.03	NA	0.64	XXX
70220		A	X-ray exam of sinuses	0.25	NA	0.86	0.05	NA	1.16	XXX
70220	26	A	X-ray exam of sinuses	0.25	0.09	0.09	0.01	0.35	0.35	XXX
70220	TC	A	X-ray exam of sinuses	0.00	NA	0.77	0.04	NA	0.81	XXX
70240		A	X-ray exam, pituitary saddle	0.19	NA	0.48	0.03	NA	0.70	XXX
70240	26	A	X-ray exam, pituitary saddle	0.19	0.07	0.07	0.01	0.27	0.27	XXX
70240	TC	A	X-ray exam, pituitary saddle	0.00	NA	0.41	0.02	NA	0.43	XXX
70250		A	X-ray exam of skull	0.24	NA	0.69	0.04	NA	0.97	XXX
70250	26	A	X-ray exam of skull	0.24	0.08	0.08	0.01	0.33	0.33	XXX
70250	TC	A	X-ray exam of skull	0.00	NA	0.61	0.03	NA	0.64	XXX
70260		A	X-ray exam of skull	0.34	NA	1.00	0.06	NA	1.40	XXX
70260	26	A	X-ray exam of skull	0.34	0.12	0.12	0.01	0.47	0.47	XXX
70260	TC	A	X-ray exam of skull	0.00	NA	0.88	0.05	NA	0.93	XXX
70300		A	X-ray exam of teeth	0.10	NA	0.30	0.03	NA	0.43	XXX
70300	26	A	X-ray exam of teeth	0.10	0.04	0.04	0.01	0.15	0.15	XXX
70300	TC	A	X-ray exam of teeth	0.00	NA	0.26	0.02	NA	0.28	XXX
70310		A	X-ray exam of teeth	0.16	NA	0.47	0.03	NA	0.66	XXX
70310	26	A	X-ray exam of teeth	0.16	0.06	0.06	0.01	0.23	0.23	XXX
70310	TC	A	X-ray exam of teeth	0.00	NA	0.41	0.02	NA	0.43	XXX
70320		A	Full mouth x-ray of teeth	0.22	NA	0.85	0.05	NA	1.12	XXX
70320	26	A	Full mouth x-ray of teeth	0.22	0.08	0.08	0.01	0.31	0.31	XXX
70320	TC	A	Full mouth x-ray of teeth	0.00	NA	0.77	0.04	NA	0.81	XXX
70328		A	X-ray exam of jaw joint	0.18	NA	0.55	0.03	NA	0.76	XXX
70328	26	A	X-ray exam of jaw joint	0.18	0.06	0.06	0.01	0.25	0.25	XXX
70328	TC	A	X-ray exam of jaw joint	0.00	NA	0.49	0.02	NA	0.51	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
70330		A	X-ray exam of jaw joints	0.24	NA	0.91	0.05	NA	1.20	XXX
70330	26	A	X-ray exam of jaw joints	0.24	0.08	0.08	0.01	0.33	0.33	XXX
70330	TC	A	X-ray exam of jaw joints	0.00	NA	0.83	0.04	NA	0.87	XXX
70332		A	X-ray exam of jaw joint	0.54	NA	2.26	0.12	NA	2.92	XXX
70332	26	A	X-ray exam of jaw joint	0.54	0.19	0.19	0.02	0.75	0.75	XXX
70332	TC	A	X-ray exam of jaw joint	0.00	NA	2.07	0.10	NA	2.17	XXX
70336		A	Magnetic image, jaw joint	1.48	NA	11.55	0.56	NA	13.59	XXX
70336	26	A	Magnetic image, jaw joint	1.48	0.52	0.52	0.07	2.07	2.07	XXX
70336	TC	A	Magnetic image, jaw joint	0.00	NA	11.03	0.49	NA	11.52	XXX
70350		A	X-ray head for orthodontia	0.17	NA	0.43	0.03	NA	0.63	XXX
70350	26	A	X-ray head for orthodontia	0.17	0.06	0.06	0.01	0.24	0.24	XXX
70350	TC	A	X-ray head for orthodontia	0.00	NA	0.37	0.02	NA	0.39	XXX
70355		A	Panoramic x-ray of jaws	0.20	NA	0.63	0.04	NA	0.87	XXX
70355	26	A	Panoramic x-ray of jaws	0.20	0.07	0.07	0.01	0.28	0.28	XXX
70355	TC	A	Panoramic x-ray of jaws	0.00	NA	0.56	0.03	NA	0.59	XXX
70360		A	X-ray exam of neck	0.17	NA	0.47	0.03	NA	0.67	XXX
70360	26	A	X-ray exam of neck	0.17	0.06	0.06	0.01	0.24	0.24	XXX
70360	TC	A	X-ray exam of neck	0.00	NA	0.41	0.02	NA	0.43	XXX
70370		A	Throat x-ray & fluoroscopy	0.32	NA	1.40	0.07	NA	1.79	XXX
70370	26	A	Throat x-ray & fluoroscopy	0.32	0.11	0.11	0.01	0.44	0.44	XXX
70370	TC	A	Throat x-ray & fluoroscopy	0.00	NA	1.29	0.06	NA	1.35	XXX
70371		A	Speech evaluation, complex	0.84	NA	2.36	0.14	NA	3.34	XXX
70371	26	A	Speech evaluation, complex	0.84	0.29	0.29	0.04	1.17	1.17	XXX
70371	TC	A	Speech evaluation, complex	0.00	NA	2.07	0.10	NA	2.17	XXX
70373		A	Contrast x-ray of larynx	0.44	NA	1.90	0.11	NA	2.45	XXX
70373	26	A	Contrast x-ray of larynx	0.44	0.15	0.15	0.02	0.61	0.61	XXX
70373	TC	A	Contrast x-ray of larynx	0.00	NA	1.75	0.09	NA	1.84	XXX
70380		A	X-ray exam of salivary gland	0.17	NA	0.72	0.04	NA	0.93	XXX
70380	26	A	X-ray exam of salivary gland	0.17	0.06	0.06	0.01	0.24	0.24	XXX
70380	TC	A	X-ray exam of salivary gland	0.00	NA	0.66	0.03	NA	0.69	XXX
70390		A	X-ray exam of salivary duct	0.38	NA	1.88	0.11	NA	2.37	XXX
70390	26	A	X-ray exam of salivary duct	0.38	0.13	0.13	0.02	0.53	0.53	XXX
70390	TC	A	X-ray exam of salivary duct	0.00	NA	1.75	0.09	NA	1.84	XXX
70450		A	Ct head/brain w/o dye	0.85	NA	4.95	0.25	NA	6.05	XXX
70450	26	A	Ct head/brain w/o dye	0.85	0.30	0.30	0.04	1.19	1.19	XXX
70450	TC	A	Ct head/brain w/o dye	0.00	NA	4.65	0.21	NA	4.86	XXX
70460		A	Ct head/brain w/dye	1.13	NA	5.97	0.30	NA	7.40	XXX
70460	26	A	Ct head/brain w/dye	1.13	0.40	0.40	0.05	1.58	1.58	XXX
70460	TC	A	Ct head/brain w/dye	0.00	NA	5.57	0.25	NA	5.82	XXX
70470		A	Ct head/brain w/o&w dye	1.27	NA	7.40	0.37	NA	9.04	XXX
70470	26	A	Ct head/brain w/o&w dye	1.27	0.44	0.44	0.06	1.77	1.77	XXX
70470	TC	A	Ct head/brain w/o&w dye	0.00	NA	6.96	0.31	NA	7.27	XXX
70480		A	Ct orbit/ear/fossa w/o dye	1.28	NA	5.10	0.27	NA	6.65	XXX
70480	26	A	Ct orbit/ear/fossa w/o dye	1.28	0.45	0.45	0.06	1.79	1.79	XXX
70480	TC	A	Ct orbit/ear/fossa w/o dye	0.00	NA	4.65	0.21	NA	4.86	XXX
70481		A	Ct orbit/ear/fossa w/dye	1.38	NA	6.05	0.31	NA	7.74	XXX
70481	26	A	Ct orbit/ear/fossa w/dye	1.38	0.48	0.48	0.06	1.92	1.92	XXX
70481	TC	A	Ct orbit/ear/fossa w/dye	0.00	NA	5.57	0.25	NA	5.82	XXX
70482		A	Ct orbit/ear/fossa w/o&w dye	1.45	NA	7.47	0.37	NA	9.29	XXX
70482	26	A	Ct orbit/ear/fossa w/o&w dye	1.45	0.51	0.51	0.06	2.02	2.02	XXX
70482	TC	A	Ct orbit/ear/fossa w/o&w dye	0.00	NA	6.96	0.31	NA	7.27	XXX
70486		A	Ct maxillofacial w/o dye	1.14	NA	5.05	0.26	NA	6.45	XXX
70486	26	A	Ct maxillofacial w/o dye	1.14	0.40	0.40	0.05	1.59	1.59	XXX
70486	TC	A	Ct maxillofacial w/o dye	0.00	NA	4.65	0.21	NA	4.86	XXX
70487		A	Ct maxillofacial w/dye	1.30	NA	6.02	0.31	NA	7.63	XXX
70487	26	A	Ct maxillofacial w/dye	1.30	0.45	0.45	0.06	1.81	1.81	XXX
70487	TC	A	Ct maxillofacial w/dye	0.00	NA	5.57	0.25	NA	5.82	XXX
70488		A	Ct maxillofacial w/o&w dye	1.42	NA	7.45	0.37	NA	9.24	XXX
70488	26	A	Ct maxillofacial w/o&w dye	1.42	0.49	0.49	0.06	1.97	1.97	XXX
70488	TC	A	Ct maxillofacial w/o&w dye	0.00	NA	6.96	0.31	NA	7.27	XXX
70490		A	Ct soft tissue neck w/o dye	1.28	NA	5.10	0.27	NA	6.65	XXX
70490	26	A	Ct soft tissue neck w/o dye	1.28	0.45	0.45	0.06	1.79	1.79	XXX
70490	TC	A	Ct soft tissue neck w/o dye	0.00	NA	4.65	0.21	NA	4.86	XXX
70491		A	Ct soft tissue neck w/dye	1.38	NA	6.05	0.31	NA	7.74	XXX
70491	26	A	Ct soft tissue neck w/dye	1.38	0.48	0.48	0.06	1.92	1.92	XXX
70491	TC	A	Ct soft tissue neck w/dye	0.00	NA	5.57	0.25	NA	5.82	XXX
70492		A	Ct sft tsue nck w/o & w/dye	1.45	NA	7.47	0.37	NA	9.29	XXX
70492	26	A	Ct sft tsue nck w/o & w/dye	1.45	0.51	0.51	0.06	2.02	2.02	XXX
70492	TC	A	Ct sft tsue nck w/o & w/dye	0.00	NA	6.96	0.31	NA	7.27	XXX
70496		A	Ct angiography, head	1.75	NA	7.65	0.54	NA	9.94	XXX
70496	26	A	Ct angiography, head	1.75	0.69	0.69	0.06	2.50	2.50	XXX
70496	TC	A	Ct angiography, head	0.00	NA	6.96	0.48	NA	7.44	XXX
70498		A	Ct angiography, neck	1.75	NA	7.65	0.54	NA	9.94	XXX
70498	26	A	Ct angiography, neck	1.75	0.69	0.69	0.06	2.50	2.50	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
70498	TC	A	Ct angiography, neck	0.00	NA	6.96	0.48	NA	7.44	XXX
70540		A	Mri orbit/face/neck w/o dye	1.10	NA	11.41	0.36	NA	12.87	XXX
70540	26	A	Mri orbit/face/neck w/o dye	1.10	0.38	0.38	0.04	1.52	1.52	XXX
70540	TC	A	Mri orbit/face/neck w/o dye	0.00	NA	11.03	0.32	NA	11.35	XXX
70542		A	Mri orbit/face/neck w/dye	1.33	NA	13.69	0.43	NA	15.45	XXX
70542	26	A	Mri orbit/face/neck w/dye	1.33	0.46	0.46	0.04	1.83	1.83	XXX
70542	TC	A	Mri orbit/face/neck w/dye	0.00	NA	13.23	0.39	NA	13.62	XXX
70543		A	Mri orbt/fac/nck w/o&w dye	1.76	NA	25.13	0.78	NA	27.67	XXX
70543	26	A	Mri orbt/fac/nck w/o&w dye	1.76	0.62	0.62	0.08	2.46	2.46	XXX
70543	TC	A	Mri orbt/fac/nck w/o&w dye	0.00	NA	24.51	0.70	NA	25.21	XXX
70544		A	Mr angiography head w/o dye	1.20	NA	11.45	0.56	NA	13.21	XXX
70544	26	A	Mr angiography head w/o dye	1.20	0.42	0.42	0.07	1.69	1.69	XXX
70544	TC	A	Mr angiography head w/o dye	0.00	NA	11.03	0.49	NA	11.52	XXX
70545		A	Mr angiography head w/dye	1.20	NA	11.45	0.56	NA	13.21	XXX
70545	26	A	Mr angiography head w/dye	1.20	0.42	0.42	0.07	1.69	1.69	XXX
70545	TC	A	Mr angiography head w/dye	0.00	NA	11.03	0.49	NA	11.52	XXX
70546		A	Mr angiograph head w/o&w dye	1.80	NA	22.70	0.56	NA	25.06	XXX
70546	26	A	Mr angiograph head w/o&w dye	1.80	0.63	0.63	0.07	2.50	2.50	XXX
70546	TC	A	Mr angiograph head w/o&w dye	0.00	NA	22.07	0.49	NA	22.56	XXX
70547		A	Mr angiography neck w/o dye	1.20	NA	11.45	0.56	NA	13.21	XXX
70547	26	A	Mr angiography neck w/o dye	1.20	0.42	0.42	0.07	1.69	1.69	XXX
70547	TC	A	Mr angiography neck w/o dye	0.00	NA	11.03	0.49	NA	11.52	XXX
70548		A	Mr angiography neck w/dye	1.20	NA	11.45	0.56	NA	13.21	XXX
70548	26	A	Mr angiography neck w/dye	1.20	0.42	0.42	0.07	1.69	1.69	XXX
70548	TC	A	Mr angiography neck w/dye	0.00	NA	11.03	0.49	NA	11.52	XXX
70549		A	Mr angiograph neck w/o&w dye	1.80	NA	22.70	0.56	NA	25.06	XXX
70549	26	A	Mr angiograph neck w/o&w dye	1.80	0.63	0.63	0.07	2.50	2.50	XXX
70549	TC	A	Mr angiograph neck w/o&w dye	0.00	NA	22.07	0.49	NA	22.56	XXX
70551		A	Mri brain w/o dye	1.48	NA	11.55	0.56	NA	13.59	XXX
70551	26	A	Mri brain w/o dye	1.48	0.52	0.52	0.07	2.07	2.07	XXX
70551	TC	A	Mri brain w/o dye	0.00	NA	11.03	0.49	NA	11.52	XXX
70552		A	Mri brain w/dye	1.78	NA	13.86	0.66	NA	16.30	XXX
70552	26	A	Mri brain w/dye	1.78	0.63	0.63	0.08	2.49	2.49	XXX
70552	TC	A	Mri brain w/dye	0.00	NA	13.23	0.58	NA	13.81	XXX
70553		A	Mri brain w/o&w dye	2.36	NA	25.34	1.19	NA	28.89	XXX
70553	26	A	Mri brain w/o&w dye	2.36	0.83	0.83	0.10	3.29	3.29	XXX
70553	TC	A	Mri brain w/o&w dye	0.00	NA	24.51	1.09	NA	25.60	XXX
71010		A	Chest x-ray	0.18	NA	0.53	0.03	NA	0.74	XXX
71010	26	A	Chest x-ray	0.18	0.06	0.06	0.01	0.25	0.25	XXX
71010	TC	A	Chest x-ray	0.00	NA	0.47	0.02	NA	0.49	XXX
71015		A	Chest x-ray	0.21	NA	0.58	0.03	NA	0.82	XXX
71015	26	A	Chest x-ray	0.21	0.07	0.07	0.01	0.29	0.29	XXX
71015	TC	A	Chest x-ray	0.00	NA	0.51	0.02	NA	0.53	XXX
71020		A	Chest x-ray	0.22	NA	0.69	0.04	NA	0.95	XXX
71020	26	A	Chest x-ray	0.22	0.08	0.08	0.01	0.31	0.31	XXX
71020	TC	A	Chest x-ray	0.00	NA	0.61	0.03	NA	0.64	XXX
71021		A	Chest x-ray	0.27	NA	0.81	0.05	NA	1.13	XXX
71021	26	A	Chest x-ray	0.27	0.09	0.09	0.01	0.37	0.37	XXX
71021	TC	A	Chest x-ray	0.00	NA	0.72	0.04	NA	0.76	XXX
71022		A	Chest x-ray	0.31	NA	0.83	0.06	NA	1.20	XXX
71022	26	A	Chest x-ray	0.31	0.11	0.11	0.02	0.44	0.44	XXX
71022	TC	A	Chest x-ray	0.00	NA	0.72	0.04	NA	0.76	XXX
71023		A	Chest x-ray and fluoroscopy	0.38	NA	0.91	0.06	NA	1.35	XXX
71023	26	A	Chest x-ray and fluoroscopy	0.38	0.14	0.14	0.02	0.54	0.54	XXX
71023	TC	A	Chest x-ray and fluoroscopy	0.00	NA	0.77	0.04	NA	0.81	XXX
71030		A	Chest x-ray	0.31	NA	0.88	0.05	NA	1.24	XXX
71030	26	A	Chest x-ray	0.31	0.11	0.11	0.01	0.43	0.43	XXX
71030	TC	A	Chest x-ray	0.00	NA	0.77	0.04	NA	0.81	XXX
71034		A	Chest x-ray and fluoroscopy	0.46	NA	1.59	0.09	NA	2.14	XXX
71034	26	A	Chest x-ray and fluoroscopy	0.46	0.17	0.17	0.02	0.65	0.65	XXX
71034	TC	A	Chest x-ray and fluoroscopy	0.00	NA	1.42	0.07	NA	1.49	XXX
71035		A	Chest x-ray	0.18	NA	0.57	0.03	NA	0.78	XXX
71035	26	A	Chest x-ray	0.18	0.06	0.06	0.01	0.25	0.25	XXX
71035	TC	A	Chest x-ray	0.00	NA	0.51	0.02	NA	0.53	XXX
71040		A	Contrast x-ray of bronchi	0.58	NA	1.64	0.10	NA	2.32	XXX
71040	26	A	Contrast x-ray of bronchi	0.58	0.20	0.20	0.03	0.81	0.81	XXX
71040	TC	A	Contrast x-ray of bronchi	0.00	NA	1.44	0.07	NA	1.51	XXX
71060		A	Contrast x-ray of bronchi	0.74	NA	2.43	0.14	NA	3.31	XXX
71060	26	A	Contrast x-ray of bronchi	0.74	0.26	0.26	0.03	1.03	1.03	XXX
71060	TC	A	Contrast x-ray of bronchi	0.00	NA	2.17	0.11	NA	2.28	XXX
71090		A	X-ray & pacemaker insertion	0.54	NA	1.88	0.11	NA	2.53	XXX
71090	26	A	X-ray & pacemaker insertion	0.54	0.22	0.22	0.02	0.78	0.78	XXX
71090	TC	A	X-ray & pacemaker insertion	0.00	NA	1.66	0.09	NA	1.75	XXX
71100		A	X-ray exam of ribs	0.22	NA	0.64	0.04	NA	0.90	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
71100	26	A	X-ray exam of ribs	0.22	0.08	0.08	0.01	0.31	0.31	XXX
71100	TC	A	X-ray exam of ribs	0.00	NA	0.56	0.03	NA	0.59	XXX
71101		A	X-ray exam of ribs/chest	0.27	NA	0.75	0.04	NA	1.06	XXX
71101	26	A	X-ray exam of ribs/chest	0.27	0.09	0.09	0.01	0.37	0.37	XXX
71101	TC	A	X-ray exam of ribs/chest	0.00	NA	0.66	0.03	NA	0.69	XXX
71110		A	X-ray exam of ribs	0.27	NA	0.86	0.05	NA	1.18	XXX
71110	26	A	X-ray exam of ribs	0.27	0.09	0.09	0.01	0.37	0.37	XXX
71110	TC	A	X-ray exam of ribs	0.00	NA	0.77	0.04	NA	0.81	XXX
71111		A	X-ray exam of ribs/ chest	0.32	NA	0.99	0.06	NA	1.37	XXX
71111	26	A	X-ray exam of ribs/ chest	0.32	0.11	0.11	0.01	0.44	0.44	XXX
71111	TC	A	X-ray exam of ribs/ chest	0.00	NA	0.88	0.05	NA	0.93	XXX
71120		A	X-ray exam of breastbone	0.20	NA	0.71	0.04	NA	0.95	XXX
71120	26	A	X-ray exam of breastbone	0.20	0.07	0.07	0.01	0.28	0.28	XXX
71120	TC	A	X-ray exam of breastbone	0.00	NA	0.64	0.03	NA	0.67	XXX
71130		A	X-ray exam of breastbone	0.22	NA	0.78	0.04	NA	1.04	XXX
71130	26	A	X-ray exam of breastbone	0.22	0.08	0.08	0.01	0.31	0.31	XXX
71130	TC	A	X-ray exam of breastbone	0.00	NA	0.70	0.03	NA	0.73	XXX
71250		A	Ct thorax w/o dye	1.16	NA	6.22	0.31	NA	7.69	XXX
71250	26	A	Ct thorax w/o dye	1.16	0.40	0.40	0.05	1.61	1.61	XXX
71250	TC	A	Ct thorax w/o dye	0.00	NA	5.82	0.26	NA	6.08	XXX
71260		A	Ct thorax w/dye	1.24	NA	7.39	0.36	NA	8.99	XXX
71260	26	A	Ct thorax w/dye	1.24	0.43	0.43	0.05	1.72	1.72	XXX
71260	TC	A	Ct thorax w/dye	0.00	NA	6.96	0.31	NA	7.27	XXX
71270		A	Ct thorax w/o&w dye	1.38	NA	9.19	0.44	NA	11.01	XXX
71270	26	A	Ct thorax w/o&w dye	1.38	0.48	0.48	0.06	1.92	1.92	XXX
71270	TC	A	Ct thorax w/o&w dye	0.00	NA	8.71	0.38	NA	9.09	XXX
71275		A	Ct angiography, chest	1.20	NA	9.18	0.37	NA	10.75	XXX
71275	26	A	Ct angiography, chest	1.20	0.47	0.47	0.05	1.72	1.72	XXX
71275	TC	A	Ct angiography, chest	0.00	NA	8.71	0.32	NA	9.03	XXX
71550		A	Mri chest w/o dye	1.22	NA	11.46	0.41	NA	13.09	XXX
71550	26	A	Mri chest w/o dye	1.22	0.43	0.43	0.04	1.69	1.69	XXX
71550	TC	A	Mri chest w/o dye	0.00	NA	11.03	0.37	NA	11.40	XXX
71551		A	Mri chest w/dye	1.44	NA	13.73	0.48	NA	15.65	XXX
71551	26	A	Mri chest w/dye	1.44	0.50	0.50	0.05	1.99	1.99	XXX
71551	TC	A	Mri chest w/dye	0.00	NA	13.23	0.43	NA	13.66	XXX
71552		A	Mri chest w/o&w dye	1.89	NA	25.17	0.63	NA	27.69	XXX
71552	26	A	Mri chest w/o&w dye	1.89	0.66	0.66	0.07	2.62	2.62	XXX
71552	TC	A	Mri chest w/o&w dye	0.00	NA	24.51	0.56	NA	25.07	XXX
71555		R	Mri angio chest w or w/o dye	1.81	NA	11.66	0.57	NA	14.04	XXX
71555	26	R	Mri angio chest w or w/o dye	1.81	0.63	0.63	0.08	2.52	2.52	XXX
71555	TC	R	Mri angio chest w or w/o dye	0.00	NA	11.03	0.49	NA	11.52	XXX
72010		A	X-ray exam of spine	0.45	NA	1.17	0.08	NA	1.70	XXX
72010	26	A	X-ray exam of spine	0.45	0.16	0.16	0.03	0.64	0.64	XXX
72010	TC	A	X-ray exam of spine	0.00	NA	1.01	0.05	NA	1.06	XXX
72020		A	X-ray exam of spine	0.15	NA	0.46	0.03	NA	0.64	XXX
72020	26	A	X-ray exam of spine	0.15	0.05	0.05	0.01	0.21	0.21	XXX
72020	TC	A	X-ray exam of spine	0.00	NA	0.41	0.02	NA	0.43	XXX
72040		A	X-ray exam of neck spine	0.22	NA	0.67	0.04	NA	0.93	XXX
72040	26	A	X-ray exam of neck spine	0.22	0.08	0.08	0.01	0.31	0.31	XXX
72040	TC	A	X-ray exam of neck spine	0.00	NA	0.59	0.03	NA	0.62	XXX
72050		A	X-ray exam of neck spine	0.31	NA	0.99	0.07	NA	1.37	XXX
72050	26	A	X-ray exam of neck spine	0.31	0.11	0.11	0.02	0.44	0.44	XXX
72050	TC	A	X-ray exam of neck spine	0.00	NA	0.88	0.05	NA	0.93	XXX
72052		A	X-ray exam of neck spine	0.36	NA	1.24	0.07	NA	1.67	XXX
72052	26	A	X-ray exam of neck spine	0.36	0.13	0.13	0.02	0.51	0.51	XXX
72052	TC	A	X-ray exam of neck spine	0.00	NA	1.11	0.05	NA	1.16	XXX
72069		A	X-ray exam of trunk spine	0.22	NA	0.57	0.04	NA	0.83	XXX
72069	26	A	X-ray exam of trunk spine	0.22	0.08	0.08	0.02	0.32	0.32	XXX
72069	TC	A	X-ray exam of trunk spine	0.00	NA	0.49	0.02	NA	0.51	XXX
72070		A	X-ray exam of thoracic spine	0.22	NA	0.72	0.04	NA	0.98	XXX
72070	26	A	X-ray exam of thoracic spine	0.22	0.08	0.08	0.01	0.31	0.31	XXX
72070	TC	A	X-ray exam of thoracic spine	0.00	NA	0.64	0.03	NA	0.67	XXX
72072		A	X-ray exam of thoracic spine	0.22	NA	0.80	0.05	NA	1.07	XXX
72072	26	A	X-ray exam of thoracic spine	0.22	0.08	0.08	0.01	0.31	0.31	XXX
72072	TC	A	X-ray exam of thoracic spine	0.00	NA	0.72	0.04	NA	0.76	XXX
72074		A	X-ray exam of thoracic spine	0.22	NA	0.97	0.06	NA	1.25	XXX
72074	26	A	X-ray exam of thoracic spine	0.22	0.08	0.08	0.01	0.31	0.31	XXX
72074	TC	A	X-ray exam of thoracic spine	0.00	NA	0.89	0.05	NA	0.94	XXX
72080		A	X-ray exam of trunk spine	0.22	NA	0.74	0.05	NA	1.01	XXX
72080	26	A	X-ray exam of trunk spine	0.22	0.08	0.08	0.02	0.32	0.32	XXX
72080	TC	A	X-ray exam of trunk spine	0.00	NA	0.66	0.03	NA	0.69	XXX
72090		A	X-ray exam of trunk spine	0.28	NA	0.76	0.05	NA	1.09	XXX
72090	26	A	X-ray exam of trunk spine	0.28	0.10	0.10	0.02	0.40	0.40	XXX
72090	TC	A	X-ray exam of trunk spine	0.00	NA	0.66	0.03	NA	0.69	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
72100		A	X-ray exam of lower spine	0.22	NA	0.74	0.05	NA	1.01	XXX
72100	26	A	X-ray exam of lower spine	0.22	0.08	0.08	0.02	0.32	0.32	XXX
72100	TC	A	X-ray exam of lower spine	0.00	NA	0.66	0.03	NA	0.69	XXX
72110		A	X-ray exam of lower spine	0.31	NA	1.00	0.07	NA	1.38	XXX
72110	26	A	X-ray exam of lower spine	0.31	0.11	0.11	0.02	0.44	0.44	XXX
72110	TC	A	X-ray exam of lower spine	0.00	NA	0.89	0.05	NA	0.94	XXX
72114		A	X-ray exam of lower spine	0.36	NA	1.30	0.08	NA	1.74	XXX
72114	26	A	X-ray exam of lower spine	0.36	0.13	0.13	0.03	0.52	0.52	XXX
72114	TC	A	X-ray exam of lower spine	0.00	NA	1.17	0.05	NA	1.22	XXX
72120		A	X-ray exam of lower spine	0.22	NA	0.96	0.07	NA	1.25	XXX
72120	26	A	X-ray exam of lower spine	0.22	0.08	0.08	0.02	0.32	0.32	XXX
72120	TC	A	X-ray exam of lower spine	0.00	NA	0.88	0.05	NA	0.93	XXX
72125		A	Ct neck spine w/o dye	1.16	NA	6.22	0.31	NA	7.69	XXX
72125	26	A	Ct neck spine w/o dye	1.16	0.40	0.40	0.05	1.61	1.61	XXX
72125	TC	A	Ct neck spine w/o dye	0.00	NA	5.82	0.26	NA	6.08	XXX
72126		A	Ct neck spine w/dye	1.22	NA	7.38	0.36	NA	8.96	XXX
72126	26	A	Ct neck spine w/dye	1.22	0.42	0.42	0.05	1.69	1.69	XXX
72126	TC	A	Ct neck spine w/dye	0.00	NA	6.96	0.31	NA	7.27	XXX
72127		A	Ct neck spine w/o&w dye	1.27	NA	9.16	0.44	NA	10.87	XXX
72127	26	A	Ct neck spine w/o&w dye	1.27	0.45	0.45	0.06	1.78	1.78	XXX
72127	TC	A	Ct neck spine w/o&w dye	0.00	NA	8.71	0.38	NA	9.09	XXX
72128		A	Ct chest spine w/o dye	1.16	NA	6.22	0.31	NA	7.69	XXX
72128	26	A	Ct chest spine w/o dye	1.16	0.40	0.40	0.05	1.61	1.61	XXX
72128	TC	A	Ct chest spine w/o dye	0.00	NA	5.82	0.26	NA	6.08	XXX
72129		A	Ct chest spine w/dye	1.22	NA	7.38	0.36	NA	8.96	XXX
72129	26	A	Ct chest spine w/dye	1.22	0.42	0.42	0.05	1.69	1.69	XXX
72129	TC	A	Ct chest spine w/dye	0.00	NA	6.96	0.31	NA	7.27	XXX
72130		A	Ct chest spine w/o&w dye	1.27	NA	9.15	0.44	NA	10.86	XXX
72130	26	A	Ct chest spine w/o&w dye	1.27	0.44	0.44	0.06	1.77	1.77	XXX
72130	TC	A	Ct chest spine w/o&w dye	0.00	NA	8.71	0.38	NA	9.09	XXX
72131		A	Ct lumbar spine w/o dye	1.16	NA	6.22	0.31	NA	7.69	XXX
72131	26	A	Ct lumbar spine w/o dye	1.16	0.40	0.40	0.05	1.61	1.61	XXX
72131	TC	A	Ct lumbar spine w/o dye	0.00	NA	5.82	0.26	NA	6.08	XXX
72132		A	Ct lumbar spine w/dye	1.22	NA	7.38	0.37	NA	8.97	XXX
72132	26	A	Ct lumbar spine w/dye	1.22	0.42	0.42	0.06	1.70	1.70	XXX
72132	TC	A	Ct lumbar spine w/dye	0.00	NA	6.96	0.31	NA	7.27	XXX
72133		A	Ct lumbar spine w/o&w dye	1.27	NA	9.16	0.44	NA	10.87	XXX
72133	26	A	Ct lumbar spine w/o&w dye	1.27	0.45	0.45	0.06	1.78	1.78	XXX
72133	TC	A	Ct lumbar spine w/o&w dye	0.00	NA	8.71	0.38	NA	9.09	XXX
72141		A	Mri neck spine w/o dye	1.60	NA	11.59	0.56	NA	13.75	XXX
72141	26	A	Mri neck spine w/o dye	1.60	0.56	0.56	0.07	2.23	2.23	XXX
72141	TC	A	Mri neck spine w/o dye	0.00	NA	11.03	0.49	NA	11.52	XXX
72142		A	Mri neck spine w/dye	1.92	NA	13.92	0.67	NA	16.51	XXX
72142	26	A	Mri neck spine w/dye	1.92	0.69	0.69	0.09	2.70	2.70	XXX
72142	TC	A	Mri neck spine w/dye	0.00	NA	13.23	0.58	NA	13.81	XXX
72146		A	Mri chest spine w/o dye	1.60	NA	12.81	0.60	NA	15.01	XXX
72146	26	A	Mri chest spine w/o dye	1.60	0.56	0.56	0.07	2.23	2.23	XXX
72146	TC	A	Mri chest spine w/o dye	0.00	NA	12.25	0.53	NA	12.78	XXX
72147		A	Mri chest spine w/dye	1.92	NA	13.91	0.67	NA	16.50	XXX
72147	26	A	Mri chest spine w/dye	1.92	0.68	0.68	0.09	2.69	2.69	XXX
72147	TC	A	Mri chest spine w/dye	0.00	NA	13.23	0.58	NA	13.81	XXX
72148		A	Mri lumbar spine w/o dye	1.48	NA	12.77	0.60	NA	14.85	XXX
72148	26	A	Mri lumbar spine w/o dye	1.48	0.52	0.52	0.07	2.07	2.07	XXX
72148	TC	A	Mri lumbar spine w/o dye	0.00	NA	12.25	0.53	NA	12.78	XXX
72149		A	Mri lumbar spine w/dye	1.78	NA	13.87	0.67	NA	16.32	XXX
72149	26	A	Mri lumbar spine w/dye	1.78	0.64	0.64	0.09	2.51	2.51	XXX
72149	TC	A	Mri lumbar spine w/dye	0.00	NA	13.23	0.58	NA	13.81	XXX
72156		A	Mri neck spine w/o&w dye	2.57	NA	25.41	1.20	NA	29.18	XXX
72156	26	A	Mri neck spine w/o&w dye	2.57	0.90	0.90	0.11	3.58	3.58	XXX
72156	TC	A	Mri neck spine w/o&w dye	0.00	NA	24.51	1.09	NA	25.60	XXX
72157		A	Mri chest spine w/o&w dye	2.57	NA	25.41	1.20	NA	29.18	XXX
72157	26	A	Mri chest spine w/o&w dye	2.57	0.90	0.90	0.11	3.58	3.58	XXX
72157	TC	A	Mri chest spine w/o&w dye	0.00	NA	24.51	1.09	NA	25.60	XXX
72158		A	Mri lumbar spine w/o&w dye	2.36	NA	25.34	1.20	NA	28.90	XXX
72158	26	A	Mri lumbar spine w/o&w dye	2.36	0.83	0.83	0.11	3.30	3.30	XXX
72158	TC	A	Mri lumbar spine w/o&w dye	0.00	NA	24.51	1.09	NA	25.60	XXX
72159		N	Mr angio spine w/o&w dye	+1.80	NA	12.96	0.61	NA	15.37	XXX
72159	26	N	Mr angio spine w/o&w dye	+1.80	0.71	0.71	0.08	2.59	2.59	XXX
72159	TC	N	Mr angio spine w/o&w dye	+0.00	NA	12.25	0.53	NA	12.78	XXX
72170		A	X-ray exam of pelvis	0.17	NA	0.57	0.03	NA	0.77	XXX
72170	26	A	X-ray exam of pelvis	0.17	0.06	0.06	0.01	0.24	0.24	XXX
72170	TC	A	X-ray exam of pelvis	0.00	NA	0.51	0.02	NA	0.53	XXX
72190		A	X-ray exam of pelvis	0.21	NA	0.73	0.04	NA	0.98	XXX
72190	26	A	X-ray exam of pelvis	0.21	0.07	0.07	0.01	0.29	0.29	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
72190	TC	A	X-ray exam of pelvis	0.00	NA	0.66	0.03	NA	0.69	XXX
72191		A	Ct angiograph pelv w/o&w dye	1.20	NA	8.83	0.37	NA	10.40	XXX
72191	26	A	Ct angiograph pelv w/o&w dye	1.20	0.47	0.47	0.05	1.72	1.72	XXX
72191	TC	A	Ct angiograph pelv w/o&w dye	0.00	NA	8.36	0.32	NA	8.68	XXX
72192		A	Ct pelvis w/o dye	1.09	NA	6.20	0.31	NA	7.60	XXX
72192	26	A	Ct pelvis w/o dye	1.09	0.38	0.38	0.05	1.52	1.52	XXX
72192	TC	A	Ct pelvis w/o dye	0.00	NA	5.82	0.26	NA	6.08	XXX
72193		A	Ct pelvis w/dye	1.16	NA	7.14	0.35	NA	8.65	XXX
72193	26	A	Ct pelvis w/dye	1.16	0.40	0.40	0.05	1.61	1.61	XXX
72193	TC	A	Ct pelvis w/dye	0.00	NA	6.74	0.30	NA	7.04	XXX
72194		A	Ct pelvis w/o&w dye	1.22	NA	8.78	0.41	NA	10.41	XXX
72194	26	A	Ct pelvis w/o&w dye	1.22	0.42	0.42	0.05	1.69	1.69	XXX
72194	TC	A	Ct pelvis w/o&w dye	0.00	NA	8.36	0.36	NA	8.72	XXX
72195		A	Mri pelvis w/o dye	1.22	NA	11.46	0.41	NA	13.09	XXX
72195	26	A	Mri pelvis w/o dye	1.22	0.43	0.43	0.04	1.69	1.69	XXX
72195	TC	A	Mri pelvis w/o dye	0.00	NA	11.03	0.37	NA	11.40	XXX
72196		A	Mri pelvis w/dye	1.44	NA	13.73	0.48	NA	15.65	XXX
72196	26	A	Mri pelvis w/dye	1.44	0.50	0.50	0.05	1.99	1.99	XXX
72196	TC	A	Mri pelvis w/dye	0.00	NA	13.23	0.43	NA	13.66	XXX
72197		A	Mri pelvis w/o & w dye	1.89	NA	25.17	0.85	NA	27.91	XXX
72197	26	A	Mri pelvis w/o & w dye	1.89	0.66	0.66	0.09	2.64	2.64	XXX
72197	TC	A	Mri pelvis w/o & w dye	0.00	NA	24.51	0.76	NA	25.27	XXX
72198		N	Mr angio pelvis w/o&w dye	+1.80	NA	11.74	0.57	NA	14.11	XXX
72198	26	N	Mr angio pelvis w/o&w dye	+1.80	0.71	0.71	0.08	2.59	2.59	XXX
72198	TC	N	Mr angio pelvis w/o&w dye	+0.00	NA	11.03	0.49	NA	11.52	XXX
72200		A	X-ray exam sacroiliac joints	0.17	NA	0.57	0.03	NA	0.77	XXX
72200	26	A	X-ray exam sacroiliac joints	0.17	0.06	0.06	0.01	0.24	0.24	XXX
72200	TC	A	X-ray exam sacroiliac joints	0.00	NA	0.51	0.02	NA	0.53	XXX
72202		A	X-ray exam sacroiliac joints	0.19	NA	0.68	0.04	NA	0.91	XXX
72202	26	A	X-ray exam sacroiliac joints	0.19	0.07	0.07	0.01	0.27	0.27	XXX
72202	TC	A	X-ray exam sacroiliac joints	0.00	NA	0.61	0.03	NA	0.64	XXX
72220		A	X-ray exam of tailbone	0.17	NA	0.62	0.04	NA	0.83	XXX
72220	26	A	X-ray exam of tailbone	0.17	0.06	0.06	0.01	0.24	0.24	XXX
72220	TC	A	X-ray exam of tailbone	0.00	NA	0.56	0.03	NA	0.59	XXX
72240		A	Contrast x-ray of neck spine	0.91	NA	4.97	0.25	NA	6.13	XXX
72240	26	A	Contrast x-ray of neck spine	0.91	0.30	0.30	0.04	1.25	1.25	XXX
72240	TC	A	Contrast x-ray of neck spine	0.00	NA	4.67	0.21	NA	4.88	XXX
72255		A	Contrast x-ray, thorax spine	0.91	NA	4.56	0.22	NA	5.69	XXX
72255	26	A	Contrast x-ray, thorax spine	0.91	0.29	0.29	0.04	1.24	1.24	XXX
72255	TC	A	Contrast x-ray, thorax spine	0.00	NA	4.27	0.18	NA	4.45	XXX
72265		A	Contrast x-ray, lower spine	0.83	NA	4.28	0.22	NA	5.33	XXX
72265	26	A	Contrast x-ray, lower spine	0.83	0.27	0.27	0.04	1.14	1.14	XXX
72265	TC	A	Contrast x-ray, lower spine	0.00	NA	4.01	0.18	NA	4.19	XXX
72270		A	Contrast x-ray of spine	1.33	NA	6.44	0.34	NA	8.11	XXX
72270	26	A	Contrast x-ray of spine	1.33	0.43	0.43	0.07	1.83	1.83	XXX
72270	TC	A	Contrast x-ray of spine	0.00	NA	6.01	0.27	NA	6.28	XXX
72275		A	Epidurography	0.76	NA	2.32	0.21	NA	3.29	XXX
72275	26	A	Epidurography	0.76	0.25	0.25	0.03	1.04	1.04	XXX
72275	TC	A	Epidurography	0.00	NA	2.07	0.18	NA	2.25	XXX
72285		A	X-ray c/t spine disk	1.16	NA	8.64	0.42	NA	10.22	XXX
72285	26	A	X-ray c/t spine disk	1.16	0.39	0.39	0.06	1.61	1.61	XXX
72285	TC	A	X-ray c/t spine disk	0.00	NA	8.25	0.36	NA	8.61	XXX
72295		A	X-ray of lower spine disk	0.83	NA	8.02	0.37	NA	9.22	XXX
72295	26	A	X-ray of lower spine disk	0.83	0.28	0.28	0.04	1.15	1.15	XXX
72295	TC	A	X-ray of lower spine disk	0.00	NA	7.74	0.33	NA	8.07	XXX
73000		A	X-ray exam of collar bone	0.16	NA	0.57	0.03	NA	0.76	XXX
73000	26	A	X-ray exam of collar bone	0.16	0.06	0.06	0.01	0.23	0.23	XXX
73000	TC	A	X-ray exam of collar bone	0.00	NA	0.51	0.02	NA	0.53	XXX
73010		A	X-ray exam of shoulder blade	0.17	NA	0.57	0.03	NA	0.77	XXX
73010	26	A	X-ray exam of shoulder blade	0.17	0.06	0.06	0.01	0.24	0.24	XXX
73010	TC	A	X-ray exam of shoulder blade	0.00	NA	0.51	0.02	NA	0.53	XXX
73020		A	X-ray exam of shoulder	0.15	NA	0.52	0.03	NA	0.70	XXX
73020	26	A	X-ray exam of shoulder	0.15	0.05	0.05	0.01	0.21	0.21	XXX
73020	TC	A	X-ray exam of shoulder	0.00	NA	0.47	0.02	NA	0.49	XXX
73030		A	X-ray exam of shoulder	0.18	NA	0.62	0.04	NA	0.84	XXX
73030	26	A	X-ray exam of shoulder	0.18	0.06	0.06	0.01	0.25	0.25	XXX
73030	TC	A	X-ray exam of shoulder	0.00	NA	0.56	0.03	NA	0.59	XXX
73040		A	Contrast x-ray of shoulder	0.54	NA	2.26	0.13	NA	2.93	XXX
73040	26	A	Contrast x-ray of shoulder	0.54	0.19	0.19	0.03	0.76	0.76	XXX
73040	TC	A	Contrast x-ray of shoulder	0.00	NA	2.07	0.10	NA	2.17	XXX
73050		A	X-ray exam of shoulders	0.20	NA	0.73	0.05	NA	0.98	XXX
73050	26	A	X-ray exam of shoulders	0.20	0.07	0.07	0.02	0.29	0.29	XXX
73050	TC	A	X-ray exam of shoulders	0.00	NA	0.66	0.03	NA	0.69	XXX
73060		A	X-ray exam of humerus	0.17	NA	0.62	0.04	NA	0.83	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
73060	26	A	X-ray exam of humerus	0.17	0.06	0.06	0.01	0.24	0.24	XXX
73060	TC	A	X-ray exam of humerus	0.00	NA	0.56	0.03	NA	0.59	XXX
73070		A	X-ray exam of elbow	0.15	NA	0.56	0.03	NA	0.74	XXX
73070	26	A	X-ray exam of elbow	0.15	0.05	0.05	0.01	0.21	0.21	XXX
73070	TC	A	X-ray exam of elbow	0.00	NA	0.51	0.02	NA	0.53	XXX
73080		A	X-ray exam of elbow	0.17	NA	0.62	0.04	NA	0.83	XXX
73080	26	A	X-ray exam of elbow	0.17	0.06	0.06	0.01	0.24	0.24	XXX
73080	TC	A	X-ray exam of elbow	0.00	NA	0.56	0.03	NA	0.59	XXX
73085		A	Contrast x-ray of elbow	0.54	NA	2.27	0.13	NA	2.94	XXX
73085	26	A	Contrast x-ray of elbow	0.54	0.20	0.20	0.03	0.77	0.77	XXX
73085	TC	A	Contrast x-ray of elbow	0.00	NA	2.07	0.10	NA	2.17	XXX
73090		A	X-ray exam of forearm	0.16	NA	0.57	0.03	NA	0.76	XXX
73090	26	A	X-ray exam of forearm	0.16	0.06	0.06	0.01	0.23	0.23	XXX
73090	TC	A	X-ray exam of forearm	0.00	NA	0.51	0.02	NA	0.53	XXX
73092		A	X-ray exam of arm, infant	0.16	NA	0.55	0.03	NA	0.74	XXX
73092	26	A	X-ray exam of arm, infant	0.16	0.06	0.06	0.01	0.23	0.23	XXX
73092	TC	A	X-ray exam of arm, infant	0.00	NA	0.49	0.02	NA	0.51	XXX
73100		A	X-ray exam of wrist	0.16	NA	0.55	0.04	NA	0.75	XXX
73100	26	A	X-ray exam of wrist	0.16	0.06	0.06	0.02	0.24	0.24	XXX
73100	TC	A	X-ray exam of wrist	0.00	NA	0.49	0.02	NA	0.51	XXX
73110		A	X-ray exam of wrist	0.17	NA	0.58	0.03	NA	0.78	XXX
73110	26	A	X-ray exam of wrist	0.17	0.06	0.06	0.01	0.24	0.24	XXX
73110	TC	A	X-ray exam of wrist	0.00	NA	0.52	0.02	NA	0.54	XXX
73115		A	Contrast x-ray of wrist	0.54	NA	1.74	0.11	NA	2.39	XXX
73115	26	A	Contrast x-ray of wrist	0.54	0.19	0.19	0.03	0.76	0.76	XXX
73115	TC	A	Contrast x-ray of wrist	0.00	NA	1.55	0.08	NA	1.63	XXX
73120		A	X-ray exam of hand	0.16	NA	0.55	0.03	NA	0.74	XXX
73120	26	A	X-ray exam of hand	0.16	0.06	0.06	0.01	0.23	0.23	XXX
73120	TC	A	X-ray exam of hand	0.00	NA	0.49	0.02	NA	0.51	XXX
73130		A	X-ray exam of hand	0.17	NA	0.58	0.03	NA	0.78	XXX
73130	26	A	X-ray exam of hand	0.17	0.06	0.06	0.01	0.24	0.24	XXX
73130	TC	A	X-ray exam of hand	0.00	NA	0.52	0.02	NA	0.54	XXX
73140		A	X-ray exam of finger(s)	0.13	NA	0.46	0.03	NA	0.62	XXX
73140	26	A	X-ray exam of finger(s)	0.13	0.05	0.05	0.01	0.19	0.19	XXX
73140	TC	A	X-ray exam of finger(s)	0.00	NA	0.41	0.02	NA	0.43	XXX
73200		A	Ct upper extremity w/o dye	1.09	NA	5.26	0.26	NA	6.61	XXX
73200	26	A	Ct upper extremity w/o dye	1.09	0.38	0.38	0.05	1.52	1.52	XXX
73200	TC	A	Ct upper extremity w/o dye	0.00	NA	4.88	0.21	NA	5.09	XXX
73201		A	Ct upper extremity w/dye	1.16	NA	6.23	0.31	NA	7.70	XXX
73201	26	A	Ct upper extremity w/dye	1.16	0.41	0.41	0.05	1.62	1.62	XXX
73201	TC	A	Ct upper extremity w/dye	0.00	NA	5.82	0.26	NA	6.08	XXX
73202		A	Ct uppr extremity w/o&w dye	1.22	NA	7.74	0.38	NA	9.34	XXX
73202	26	A	Ct uppr extremity w/o&w dye	1.22	0.43	0.43	0.06	1.71	1.71	XXX
73202	TC	A	Ct uppr extremity w/o&w dye	0.00	NA	7.31	0.32	NA	7.63	XXX
73206		A	Ct angio upr extrm w/o&w dye	1.20	NA	7.78	0.37	NA	9.35	XXX
73206	26	A	Ct angio upr extrm w/o&w dye	1.20	0.47	0.47	0.05	1.72	1.72	XXX
73206	TC	A	Ct angio upr extrm w/o&w dye	0.00	NA	7.31	0.32	NA	7.63	XXX
73218		A	Mri upper extremity w/o dye	1.10	NA	11.42	0.36	NA	12.88	XXX
73218	26	A	Mri upper extremity w/o dye	1.10	0.39	0.39	0.04	1.53	1.53	XXX
73218	TC	A	Mri upper extremity w/o dye	0.00	NA	11.03	0.32	NA	11.35	XXX
73219		A	Mri upper extremity w/dye	1.33	NA	13.70	0.43	NA	15.46	XXX
73219	26	A	Mri upper extremity w/dye	1.33	0.47	0.47	0.04	1.84	1.84	XXX
73219	TC	A	Mri upper extremity w/dye	0.00	NA	13.23	0.39	NA	13.62	XXX
73220		A	Mri uppr extremity w/o&w dye	1.76	NA	25.13	0.78	NA	27.67	XXX
73220	26	A	Mri uppr extremity w/o&w dye	1.76	0.62	0.62	0.08	2.46	2.46	XXX
73220	TC	A	Mri uppr extremity w/o&w dye	0.00	NA	24.51	0.70	NA	25.21	XXX
73221		A	Mri joint upr extrem w/o dye	1.10	NA	11.42	0.36	NA	12.88	XXX
73221	26	A	Mri joint upr extrem w/o dye	1.10	0.39	0.39	0.04	1.53	1.53	XXX
73221	TC	A	Mri joint upr extrem w/o dye	0.00	NA	11.03	0.32	NA	11.35	XXX
73222		A	Mri joint upr extrem w/ dye	1.33	NA	13.70	0.43	NA	15.46	XXX
73222	26	A	Mri joint upr extrem w/ dye	1.33	0.47	0.47	0.04	1.84	1.84	XXX
73222	TC	A	Mri joint upr extrem w/ dye	0.00	NA	13.23	0.39	NA	13.62	XXX
73223		A	Mri joint upr extr w/o&w dye	1.76	NA	25.13	0.78	NA	27.67	XXX
73223	26	A	Mri joint upr extr w/o&w dye	1.76	0.62	0.62	0.08	2.46	2.46	XXX
73223	TC	A	Mri joint upr extr w/o&w dye	0.00	NA	24.51	0.70	NA	25.21	XXX
73225		N	Mr angio upr extr w/o&w dye	+1.73	NA	11.71	0.57	NA	14.01	XXX
73225	26	N	Mr angio upr extr w/o&w dye	+1.73	0.68	0.68	0.08	2.49	2.49	XXX
73225	TC	N	Mr angio upr extr w/o&w dye	+0.00	NA	11.03	0.49	NA	11.52	XXX
73500		A	X-ray exam of hip	0.17	NA	0.53	0.03	NA	0.73	XXX
73500	26	A	X-ray exam of hip	0.17	0.06	0.06	0.01	0.24	0.24	XXX
73500	TC	A	X-ray exam of hip	0.00	NA	0.47	0.02	NA	0.49	XXX
73510		A	X-ray exam of hip	0.21	NA	0.63	0.05	NA	0.89	XXX
73510	26	A	X-ray exam of hip	0.21	0.07	0.07	0.02	0.30	0.30	XXX
73510	TC	A	X-ray exam of hip	0.00	NA	0.56	0.03	NA	0.59	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
73520		A	X-ray exam of hips	0.26	NA	0.75	0.05	NA	1.06	XXX
73520	26	A	X-ray exam of hips	0.26	0.09	0.09	0.02	0.37	0.37	XXX
73520	TC	A	X-ray exam of hips	0.00	NA	0.66	0.03	NA	0.69	XXX
73525		A	Contrast x-ray of hip	0.54	NA	2.26	0.13	NA	2.93	XXX
73525	26	A	Contrast x-ray of hip	0.54	0.19	0.19	0.03	0.76	0.76	XXX
73525	TC	A	Contrast x-ray of hip	0.00	NA	2.07	0.10	NA	2.17	XXX
73530		A	X-ray exam of hip	0.29	NA	0.61	0.03	NA	0.93	XXX
73530	26	A	X-ray exam of hip	0.29	0.10	0.10	0.01	0.40	0.40	XXX
73530	TC	A	X-ray exam of hip	0.00	NA	0.51	0.02	NA	0.53	XXX
73540		A	X-ray exam of pelvis & hips	0.20	NA	0.63	0.05	NA	0.88	XXX
73540	26	A	X-ray exam of pelvis & hips	0.20	0.07	0.07	0.02	0.29	0.29	XXX
73540	TC	A	X-ray exam of pelvis & hips	0.00	NA	0.56	0.03	NA	0.59	XXX
73542		A	X-ray exam, sacroiliac joint	0.59	NA	2.28	0.13	NA	3.00	XXX
73542	26	A	X-ray exam, sacroiliac joint	0.59	0.21	0.21	0.03	0.83	0.83	XXX
73542	TC	A	X-ray exam, sacroiliac joint	0.00	NA	2.07	0.10	NA	2.17	XXX
73550		A	X-ray exam of thigh	0.17	NA	0.62	0.04	NA	0.83	XXX
73550	26	A	X-ray exam of thigh	0.17	0.06	0.06	0.01	0.24	0.24	XXX
73550	TC	A	X-ray exam of thigh	0.00	NA	0.56	0.03	NA	0.59	XXX
73560		A	X-ray exam of knee, 1 or 2	0.17	NA	0.57	0.04	NA	0.78	XXX
73560	26	A	X-ray exam of knee, 1 or 2	0.17	0.06	0.06	0.02	0.25	0.25	XXX
73560	TC	A	X-ray exam of knee, 1 or 2	0.00	NA	0.51	0.02	NA	0.53	XXX
73562		A	X-ray exam of knee, 3	0.18	NA	0.62	0.05	NA	0.85	XXX
73562	26	A	X-ray exam of knee, 3	0.18	0.06	0.06	0.02	0.26	0.26	XXX
73562	TC	A	X-ray exam of knee, 3	0.00	NA	0.56	0.03	NA	0.59	XXX
73564		A	X-ray exam, knee, 4 or more	0.22	NA	0.69	0.05	NA	0.96	XXX
73564	26	A	X-ray exam, knee, 4 or more	0.22	0.08	0.08	0.02	0.32	0.32	XXX
73564	TC	A	X-ray exam, knee, 4 or more	0.00	NA	0.61	0.03	NA	0.64	XXX
73565		A	X-ray exam of knees	0.17	NA	0.56	0.04	NA	0.77	XXX
73565	26	A	X-ray exam of knees	0.17	0.07	0.07	0.02	0.26	0.26	XXX
73565	TC	A	X-ray exam of knees	0.00	NA	0.49	0.02	NA	0.51	XXX
73580		A	Contrast x-ray of knee joint	0.54	NA	2.77	0.15	NA	3.46	XXX
73580	26	A	Contrast x-ray of knee joint	0.54	0.19	0.19	0.03	0.76	0.76	XXX
73580	TC	A	Contrast x-ray of knee joint	0.00	NA	2.58	0.12	NA	2.70	XXX
73590		A	X-ray exam of lower leg	0.17	NA	0.57	0.03	NA	0.77	XXX
73590	26	A	X-ray exam of lower leg	0.17	0.06	0.06	0.01	0.24	0.24	XXX
73590	TC	A	X-ray exam of lower leg	0.00	NA	0.51	0.02	NA	0.53	XXX
73592		A	X-ray exam of leg, infant	0.16	NA	0.55	0.03	NA	0.74	XXX
73592	26	A	X-ray exam of leg, infant	0.16	0.06	0.06	0.01	0.23	0.23	XXX
73592	TC	A	X-ray exam of leg, infant	0.00	NA	0.49	0.02	NA	0.51	XXX
73600		A	X-ray exam of ankle	0.16	NA	0.55	0.03	NA	0.74	XXX
73600	26	A	X-ray exam of ankle	0.16	0.06	0.06	0.01	0.23	0.23	XXX
73600	TC	A	X-ray exam of ankle	0.00	NA	0.49	0.02	NA	0.51	XXX
73610		A	X-ray exam of ankle	0.17	NA	0.58	0.03	NA	0.78	XXX
73610	26	A	X-ray exam of ankle	0.17	0.06	0.06	0.01	0.24	0.24	XXX
73610	TC	A	X-ray exam of ankle	0.00	NA	0.52	0.02	NA	0.54	XXX
73615		A	Contrast x-ray of ankle	0.54	NA	2.27	0.13	NA	2.94	XXX
73615	26	A	Contrast x-ray of ankle	0.54	0.20	0.20	0.03	0.77	0.77	XXX
73615	TC	A	Contrast x-ray of ankle	0.00	NA	2.07	0.10	NA	2.17	XXX
73620		A	X-ray exam of foot	0.16	NA	0.55	0.03	NA	0.74	XXX
73620	26	A	X-ray exam of foot	0.16	0.06	0.06	0.01	0.23	0.23	XXX
73620	TC	A	X-ray exam of foot	0.00	NA	0.49	0.02	NA	0.51	XXX
73630		A	X-ray exam of foot	0.17	NA	0.58	0.03	NA	0.78	XXX
73630	26	A	X-ray exam of foot	0.17	0.06	0.06	0.01	0.24	0.24	XXX
73630	TC	A	X-ray exam of foot	0.00	NA	0.52	0.02	NA	0.54	XXX
73650		A	X-ray exam of heel	0.16	NA	0.53	0.03	NA	0.72	XXX
73650	26	A	X-ray exam of heel	0.16	0.06	0.06	0.01	0.23	0.23	XXX
73650	TC	A	X-ray exam of heel	0.00	NA	0.47	0.02	NA	0.49	XXX
73660		A	X-ray exam of toe(s)	0.13	NA	0.46	0.03	NA	0.62	XXX
73660	26	A	X-ray exam of toe(s)	0.13	0.05	0.05	0.01	0.19	0.19	XXX
73660	TC	A	X-ray exam of toe(s)	0.00	NA	0.41	0.02	NA	0.43	XXX
73700		A	Ct lower extremity w/o dye	1.09	NA	5.26	0.26	NA	6.61	XXX
73700	26	A	Ct lower extremity w/o dye	1.09	0.38	0.38	0.05	1.52	1.52	XXX
73700	TC	A	Ct lower extremity w/o dye	0.00	NA	4.88	0.21	NA	5.09	XXX
73701		A	Ct lower extremity w/dye	1.16	NA	6.22	0.31	NA	7.69	XXX
73701	26	A	Ct lower extremity w/dye	1.16	0.40	0.40	0.05	1.61	1.61	XXX
73701	TC	A	Ct lower extremity w/dye	0.00	NA	5.82	0.26	NA	6.08	XXX
73702		A	Ct lwr extremity w/o&w dye	1.22	NA	7.74	0.37	NA	9.33	XXX
73702	26	A	Ct lwr extremity w/o&w dye	1.22	0.43	0.43	0.05	1.70	1.70	XXX
73702	TC	A	Ct lwr extremity w/o&w dye	0.00	NA	7.31	0.32	NA	7.63	XXX
73706		A	Ct angio lwr extr w/o&w dye	1.20	NA	7.78	0.37	NA	9.35	XXX
73706	26	A	Ct angio lwr extr w/o&w dye	1.20	0.47	0.47	0.05	1.72	1.72	XXX
73706	TC	A	Ct angio lwr extr w/o&w dye	0.00	NA	7.31	0.32	NA	7.63	XXX
73718		A	Mri lower extremity w/o dye	1.10	NA	11.41	0.36	NA	12.87	XXX
73718	26	A	Mri lower extremity w/o dye	1.10	0.38	0.38	0.04	1.52	1.52	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
73718	TC	A	Mri lower extremity w/o dye	0.00	NA	11.03	0.32	NA	11.35	XXX
73719		A	Mri lower extremity w/dye	1.33	NA	13.69	0.43	NA	15.45	XXX
73719	26	A	Mri lower extremity w/dye	1.33	0.46	0.46	0.04	1.83	1.83	XXX
73719	TC	A	Mri lower extremity w/dye	0.00	NA	13.23	0.39	NA	13.62	XXX
73720		A	Mri lwr extremity w/o&w dye	1.76	NA	25.12	0.78	NA	27.66	XXX
73720	26	A	Mri lwr extremity w/o&w dye	1.76	0.61	0.61	0.08	2.45	2.45	XXX
73720	TC	A	Mri lwr extremity w/o&w dye	0.00	NA	24.51	0.70	NA	25.21	XXX
73721		A	Mri joint of lwr extre w/o d	1.10	NA	11.42	0.36	NA	12.88	XXX
73721	26	A	Mri joint of lwr extre w/o d	1.10	0.39	0.39	0.04	1.53	1.53	XXX
73721	TC	A	Mri joint of lwr extre w/o d	0.00	NA	11.03	0.32	NA	11.35	XXX
73722		A	Mri joint of lwr extr w/dye	1.33	NA	13.70	0.43	NA	15.46	XXX
73722	26	A	Mri joint of lwr extr w/dye	1.33	0.47	0.47	0.04	1.84	1.84	XXX
73722	TC	A	Mri joint of lwr extr w/dye	0.00	NA	13.23	0.39	NA	13.62	XXX
73723		A	Mri joint lwr extr w/o&w dye	1.76	NA	25.13	0.78	NA	27.67	XXX
73723	26	A	Mri joint lwr extr w/o&w dye	1.76	0.62	0.62	0.08	2.46	2.46	XXX
73723	TC	A	Mri joint lwr extr w/o&w dye	0.00	NA	24.51	0.70	NA	25.21	XXX
73725		R	Mr ang lwr ext w or w/o dye	1.82	NA	11.67	0.57	NA	14.06	XXX
73725	26	R	Mr ang lwr ext w or w/o dye	1.82	0.64	0.64	0.08	2.54	2.54	XXX
73725	TC	R	Mr ang lwr ext w or w/o dye	0.00	NA	11.03	0.49	NA	11.52	XXX
74000		A	X-ray exam of abdomen	0.18	NA	0.57	0.03	NA	0.78	XXX
74000	26	A	X-ray exam of abdomen	0.18	0.06	0.06	0.01	0.25	0.25	XXX
74000	TC	A	X-ray exam of abdomen	0.00	NA	0.51	0.02	NA	0.53	XXX
74010		A	X-ray exam of abdomen	0.23	NA	0.64	0.04	NA	0.91	XXX
74010	26	A	X-ray exam of abdomen	0.23	0.08	0.08	0.01	0.32	0.32	XXX
74010	TC	A	X-ray exam of abdomen	0.00	NA	0.56	0.03	NA	0.59	XXX
74020		A	X-ray exam of abdomen	0.27	NA	0.70	0.04	NA	1.01	XXX
74020	26	A	X-ray exam of abdomen	0.27	0.09	0.09	0.01	0.37	0.37	XXX
74020	TC	A	X-ray exam of abdomen	0.00	NA	0.61	0.03	NA	0.64	XXX
74022		A	X-ray exam series, abdomen	0.32	NA	0.83	0.05	NA	1.20	XXX
74022	26	A	X-ray exam series, abdomen	0.32	0.11	0.11	0.01	0.44	0.44	XXX
74022	TC	A	X-ray exam series, abdomen	0.00	NA	0.72	0.04	NA	0.76	XXX
74150		A	Ct abdomen w/o dye	1.19	NA	5.98	0.30	NA	7.47	XXX
74150	26	A	Ct abdomen w/o dye	1.19	0.41	0.41	0.05	1.65	1.65	XXX
74150	TC	A	Ct abdomen w/o dye	0.00	NA	5.57	0.25	NA	5.82	XXX
74160		A	Ct abdomen w/dye	1.27	NA	7.18	0.36	NA	8.81	XXX
74160	26	A	Ct abdomen w/dye	1.27	0.44	0.44	0.06	1.77	1.77	XXX
74160	TC	A	Ct abdomen w/dye	0.00	NA	6.74	0.30	NA	7.04	XXX
74170		A	Ct abdomen w/o&w dye	1.40	NA	8.85	0.42	NA	10.67	XXX
74170	26	A	Ct abdomen w/o&w dye	1.40	0.49	0.49	0.06	1.95	1.95	XXX
74170	TC	A	Ct abdomen w/o&w dye	0.00	NA	8.36	0.36	NA	8.72	XXX
74175		A	Ct angio abdom w/o&w dye	1.20	NA	8.83	0.37	NA	10.40	XXX
74175	26	A	Ct angio abdom w/o&w dye	1.20	0.47	0.47	0.05	1.72	1.72	XXX
74175	TC	A	Ct angio abdom w/o&w dye	0.00	NA	8.36	0.32	NA	8.68	XXX
74181		A	Mri abdomen w/o dye	1.22	NA	11.46	0.41	NA	13.09	XXX
74181	26	A	Mri abdomen w/o dye	1.22	0.43	0.43	0.04	1.69	1.69	XXX
74181	TC	A	Mri abdomen w/o dye	0.00	NA	11.03	0.37	NA	11.40	XXX
74182		A	Mri abdomen w/dye	1.44	NA	13.73	0.48	NA	15.65	XXX
74182	26	A	Mri abdomen w/dye	1.44	0.50	0.50	0.05	1.99	1.99	XXX
74182	TC	A	Mri abdomen w/dye	0.00	NA	13.23	0.43	NA	13.66	XXX
74183		A	Mri abdomen w/o&w dye	1.89	NA	25.17	0.85	NA	27.91	XXX
74183	26	A	Mri abdomen w/o&w dye	1.89	0.66	0.66	0.09	2.64	2.64	XXX
74183	TC	A	Mri abdomen w/o&w dye	0.00	NA	24.51	0.76	NA	25.27	XXX
74185		R	Mri angio, abdom w or w/o dy	1.80	NA	11.66	0.57	NA	14.03	XXX
74185	26	R	Mri angio, abdom w or w/o dy	1.80	0.63	0.63	0.08	2.51	2.51	XXX
74185	TC	R	Mri angio, abdom w or w/o dy	0.00	NA	11.03	0.49	NA	11.52	XXX
74190		A	X-ray exam of peritoneum	0.48	NA	1.46	0.08	NA	2.02	XXX
74190	26	A	X-ray exam of peritoneum	0.48	0.17	0.17	0.02	0.67	0.67	XXX
74190	TC	A	X-ray exam of peritoneum	0.00	NA	1.29	0.06	NA	1.35	XXX
74210		A	Contrst x-ray exam of throat	0.36	NA	1.30	0.07	NA	1.73	XXX
74210	26	A	Contrst x-ray exam of throat	0.36	0.13	0.13	0.02	0.51	0.51	XXX
74210	TC	A	Contrst x-ray exam of throat	0.00	NA	1.17	0.05	NA	1.22	XXX
74220		A	Contrast x-ray, esophagus	0.46	NA	1.33	0.07	NA	1.86	XXX
74220	26	A	Contrast x-ray, esophagus	0.46	0.16	0.16	0.02	0.64	0.64	XXX
74220	TC	A	Contrast x-ray, esophagus	0.00	NA	1.17	0.05	NA	1.22	XXX
74230		A	Cinema x-ray, throat/esoph	0.53	NA	1.48	0.08	NA	2.09	XXX
74230	26	A	Cinema x-ray, throat/esoph	0.53	0.19	0.19	0.02	0.74	0.74	XXX
74230	TC	A	Cinema x-ray, throat/esoph	0.00	NA	1.29	0.06	NA	1.35	XXX
74235		A	Remove esophagus obstruction	1.19	NA	3.00	0.17	NA	4.36	XXX
74235	26	A	Remove esophagus obstruction	1.19	0.42	0.42	0.05	1.66	1.66	XXX
74235	TC	A	Remove esophagus obstruction	0.00	NA	2.58	0.12	NA	2.70	XXX
74240		A	X-ray exam, upper gi tract	0.69	NA	1.68	0.10	NA	2.47	XXX
74240	26	A	X-ray exam, upper gi tract	0.69	0.24	0.24	0.03	0.96	0.96	XXX
74240	TC	A	X-ray exam, upper gi tract	0.00	NA	1.44	0.07	NA	1.51	XXX
74241		A	X-ray exam, upper gi tract	0.69	NA	1.71	0.10	NA	2.50	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
74241	26	A	X-ray exam, upper gi tract	0.69	0.24	0.24	0.03	0.96	0.96	XXX
74241	TC	A	X-ray exam, upper gi tract	0.00	NA	1.47	0.07	NA	1.54	XXX
74245		A	X-ray exam, upper gi tract	0.91	NA	2.66	0.15	NA	3.72	XXX
74245	26	A	X-ray exam, upper gi tract	0.91	0.32	0.32	0.04	1.27	1.27	XXX
74245	TC	A	X-ray exam, upper gi tract	0.00	NA	2.34	0.11	NA	2.45	XXX
74246		A	Contrst x-ray uppr gi tract	0.69	NA	1.86	0.11	NA	2.66	XXX
74246	26	A	Contrst x-ray uppr gi tract	0.69	0.24	0.24	0.03	0.96	0.96	XXX
74246	TC	A	Contrst x-ray uppr gi tract	0.00	NA	1.62	0.08	NA	1.70	XXX
74247		A	Contrst x-ray uppr gi tract	0.69	NA	1.90	0.12	NA	2.71	XXX
74247	26	A	Contrst x-ray uppr gi tract	0.69	0.24	0.24	0.03	0.96	0.96	XXX
74247	TC	A	Contrst x-ray uppr gi tract	0.00	NA	1.66	0.09	NA	1.75	XXX
74249		A	Contrst x-ray uppr gi tract	0.91	NA	2.85	0.16	NA	3.92	XXX
74249	26	A	Contrst x-ray uppr gi tract	0.91	0.32	0.32	0.04	1.27	1.27	XXX
74249	TC	A	Contrst x-ray uppr gi tract	0.00	NA	2.53	0.12	NA	2.65	XXX
74250		A	X-ray exam of small bowel	0.47	NA	1.45	0.08	NA	2.00	XXX
74250	26	A	X-ray exam of small bowel	0.47	0.16	0.16	0.02	0.65	0.65	XXX
74250	TC	A	X-ray exam of small bowel	0.00	NA	1.29	0.06	NA	1.35	XXX
74251		A	X-ray exam of small bowel	0.69	NA	1.53	0.09	NA	2.31	XXX
74251	26	A	X-ray exam of small bowel	0.69	0.24	0.24	0.03	0.96	0.96	XXX
74251	TC	A	X-ray exam of small bowel	0.00	NA	1.29	0.06	NA	1.35	XXX
74260		A	X-ray exam of small bowel	0.50	NA	1.64	0.09	NA	2.23	XXX
74260	26	A	X-ray exam of small bowel	0.50	0.17	0.17	0.02	0.69	0.69	XXX
74260	TC	A	X-ray exam of small bowel	0.00	NA	1.47	0.07	NA	1.54	XXX
74270		A	Contrast x-ray exam of colon	0.69	NA	1.92	0.12	NA	2.73	XXX
74270	26	A	Contrast x-ray exam of colon	0.69	0.24	0.24	0.03	0.96	0.96	XXX
74270	TC	A	Contrast x-ray exam of colon	0.00	NA	1.68	0.09	NA	1.77	XXX
74280		A	Contrast x-ray exam of colon	0.99	NA	2.55	0.15	NA	3.69	XXX
74280	26	A	Contrast x-ray exam of colon	0.99	0.35	0.35	0.04	1.38	1.38	XXX
74280	TC	A	Contrast x-ray exam of colon	0.00	NA	2.20	0.11	NA	2.31	XXX
74283		A	Contrast x-ray exam of colon	2.02	NA	3.22	0.21	NA	5.45	XXX
74283	26	A	Contrast x-ray exam of colon	2.02	0.70	0.70	0.09	2.81	2.81	XXX
74283	TC	A	Contrast x-ray exam of colon	0.00	NA	2.52	0.12	NA	2.64	XXX
74290		A	Contrast x-ray, gallbladder	0.32	NA	0.83	0.05	NA	1.20	XXX
74290	26	A	Contrast x-ray, gallbladder	0.32	0.11	0.11	0.01	0.44	0.44	XXX
74290	TC	A	Contrast x-ray, gallbladder	0.00	NA	0.72	0.04	NA	0.76	XXX
74291		A	Contrast x-rays, gallbladder	0.20	NA	0.48	0.03	NA	0.71	XXX
74291	26	A	Contrast x-rays, gallbladder	0.20	0.07	0.07	0.01	0.28	0.28	XXX
74291	TC	A	Contrast x-rays, gallbladder	0.00	NA	0.41	0.02	NA	0.43	XXX
74300		C	X-ray bile ducts/pancreas	0.00	NA	0.00	0.00	NA	0.00	XXX
74300	26	A	X-ray bile ducts/pancreas	0.36	0.13	0.13	0.02	0.51	0.51	XXX
74300	TC	C	X-ray bile ducts/pancreas	0.00	NA	0.00	0.00	NA	0.00	XXX
74301		C	X-rays at surgery add-on	0.00	NA	0.00	0.00	NA	0.00	ZZZ
74301	26	A	X-rays at surgery add-on	0.21	0.07	0.07	0.01	0.29	0.29	ZZZ
74301	TC	C	X-rays at surgery add-on	0.00	NA	0.00	0.00	NA	0.00	ZZZ
74305		A	X-ray bile ducts/pancreas	0.42	NA	0.92	0.06	NA	1.40	XXX
74305	26	A	X-ray bile ducts/pancreas	0.42	0.15	0.15	0.02	0.59	0.59	XXX
74305	TC	A	X-ray bile ducts/pancreas	0.00	NA	0.77	0.04	NA	0.81	XXX
74320		A	Contrast x-ray of bile ducts	0.54	NA	3.29	0.16	NA	3.99	XXX
74320	26	A	Contrast x-ray of bile ducts	0.54	0.19	0.19	0.02	0.75	0.75	XXX
74320	TC	A	Contrast x-ray of bile ducts	0.00	NA	3.10	0.14	NA	3.24	XXX
74327		A	X-ray bile stone removal	0.70	NA	1.97	0.12	NA	2.79	XXX
74327	26	A	X-ray bile stone removal	0.70	0.24	0.24	0.03	0.97	0.97	XXX
74327	TC	A	X-ray bile stone removal	0.00	NA	1.73	0.09	NA	1.82	XXX
74328		A	Xray bile duct endoscopy	0.70	NA	3.34	0.17	NA	4.21	XXX
74328	26	A	Xray bile duct endoscopy	0.70	0.24	0.24	0.03	0.97	0.97	XXX
74328	TC	A	Xray bile duct endoscopy	0.00	NA	3.10	0.14	NA	3.24	XXX
74329		A	X-ray for pancreas endoscopy	0.70	NA	3.34	0.17	NA	4.21	XXX
74329	26	A	X-ray for pancreas endoscopy	0.70	0.24	0.24	0.03	0.97	0.97	XXX
74329	TC	A	X-ray for pancreas endoscopy	0.00	NA	3.10	0.14	NA	3.24	XXX
74330		A	X-ray bile/panc endoscopy	0.90	NA	3.41	0.18	NA	4.49	XXX
74330	26	A	X-ray bile/panc endoscopy	0.90	0.31	0.31	0.04	1.25	1.25	XXX
74330	TC	A	X-ray bile/panc endoscopy	0.00	NA	3.10	0.14	NA	3.24	XXX
74340		A	X-ray guide for GI tube	0.54	NA	2.77	0.14	NA	3.45	XXX
74340	26	A	X-ray guide for GI tube	0.54	0.19	0.19	0.02	0.75	0.75	XXX
74340	TC	A	X-ray guide for GI tube	0.00	NA	2.58	0.12	NA	2.70	XXX
74350		A	X-ray guide, stomach tube	0.76	NA	3.36	0.17	NA	4.29	XXX
74350	26	A	X-ray guide, stomach tube	0.76	0.26	0.26	0.03	1.05	1.05	XXX
74350	TC	A	X-ray guide, stomach tube	0.00	NA	3.10	0.14	NA	3.24	XXX
74355		A	X-ray guide, intestinal tube	0.76	NA	2.84	0.15	NA	3.75	XXX
74355	26	A	X-ray guide, intestinal tube	0.76	0.26	0.26	0.03	1.05	1.05	XXX
74355	TC	A	X-ray guide, intestinal tube	0.00	NA	2.58	0.12	NA	2.70	XXX
74360		A	X-ray guide, GI dilation	0.54	NA	3.29	0.16	NA	3.99	XXX
74360	26	A	X-ray guide, GI dilation	0.54	0.19	0.19	0.02	0.75	0.75	XXX
74360	TC	A	X-ray guide, GI dilation	0.00	NA	3.10	0.14	NA	3.24	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
74363		A	X-ray, bile duct dilation	0.88	NA	6.31	0.31	NA	7.50	XXX
74363	26	A	X-ray, bile duct dilation	0.88	0.30	0.30	0.04	1.22	1.22	XXX
74363	TC	A	X-ray, bile duct dilation	0.00	NA	6.01	0.27	NA	6.28	XXX
74400		A	Contrst x-ray, urinary tract	0.49	NA	1.83	0.11	NA	2.43	XXX
74400	26	A	Contrst x-ray, urinary tract	0.49	0.17	0.17	0.02	0.68	0.68	XXX
74400	TC	A	Contrst x-ray, urinary tract	0.00	NA	1.66	0.09	NA	1.75	XXX
74410		A	Contrst x-ray, urinary tract	0.49	NA	2.09	0.11	NA	2.69	XXX
74410	26	A	Contrst x-ray, urinary tract	0.49	0.17	0.17	0.02	0.68	0.68	XXX
74410	TC	A	Contrst x-ray, urinary tract	0.00	NA	1.92	0.09	NA	2.01	XXX
74415		A	Contrst x-ray, urinary tract	0.49	NA	2.26	0.12	NA	2.87	XXX
74415	26	A	Contrst x-ray, urinary tract	0.49	0.17	0.17	0.02	0.68	0.68	XXX
74415	TC	A	Contrst x-ray, urinary tract	0.00	NA	2.09	0.10	NA	2.19	XXX
74420		A	Contrst x-ray, urinary tract	0.36	NA	2.70	0.14	NA	3.20	XXX
74420	26	A	Contrst x-ray, urinary tract	0.36	0.12	0.12	0.02	0.50	0.50	XXX
74420	TC	A	Contrst x-ray, urinary tract	0.00	NA	2.58	0.12	NA	2.70	XXX
74425		A	Contrst x-ray, urinary tract	0.36	NA	1.41	0.08	NA	1.85	XXX
74425	26	A	Contrst x-ray, urinary tract	0.36	0.12	0.12	0.02	0.50	0.50	XXX
74425	TC	A	Contrst x-ray, urinary tract	0.00	NA	1.29	0.06	NA	1.35	XXX
74430		A	Contrast x-ray, bladder	0.32	NA	1.15	0.07	NA	1.54	XXX
74430	26	A	Contrast x-ray, bladder	0.32	0.11	0.11	0.02	0.45	0.45	XXX
74430	TC	A	Contrast x-ray, bladder	0.00	NA	1.04	0.05	NA	1.09	XXX
74440		A	X-ray, male genital tract	0.38	NA	1.24	0.07	NA	1.69	XXX
74440	26	A	X-ray, male genital tract	0.38	0.13	0.13	0.02	0.53	0.53	XXX
74440	TC	A	X-ray, male genital tract	0.00	NA	1.11	0.05	NA	1.16	XXX
74445		A	X-ray exam of penis	1.14	NA	1.51	0.10	NA	2.75	XXX
74445	26	A	X-ray exam of penis	1.14	0.40	0.40	0.05	1.59	1.59	XXX
74445	TC	A	X-ray exam of penis	0.00	NA	1.11	0.05	NA	1.16	XXX
74450		A	X-ray, urethra/bladder	0.33	NA	1.55	0.09	NA	1.97	XXX
74450	26	A	X-ray, urethra/bladder	0.33	0.11	0.11	0.02	0.46	0.46	XXX
74450	TC	A	X-ray, urethra/bladder	0.00	NA	1.44	0.07	NA	1.51	XXX
74455		A	X-ray, urethra/bladder	0.33	NA	1.66	0.10	NA	2.09	XXX
74455	26	A	X-ray, urethra/bladder	0.33	0.11	0.11	0.02	0.46	0.46	XXX
74455	TC	A	X-ray, urethra/bladder	0.00	NA	1.55	0.08	NA	1.63	XXX
74470		A	X-ray exam of kidney lesion	0.54	NA	1.42	0.08	NA	2.04	XXX
74470	26	A	X-ray exam of kidney lesion	0.54	0.19	0.19	0.02	0.75	0.75	XXX
74470	TC	A	X-ray exam of kidney lesion	0.00	NA	1.23	0.06	NA	1.29	XXX
74475		A	X-ray control, cath insert	0.54	NA	4.20	0.20	NA	4.94	XXX
74475	26	A	X-ray control, cath insert	0.54	0.19	0.19	0.02	0.75	0.75	XXX
74475	TC	A	X-ray control, cath insert	0.00	NA	4.01	0.18	NA	4.19	XXX
74480		A	X-ray control, cath insert	0.54	NA	4.20	0.20	NA	4.94	XXX
74480	26	A	X-ray control, cath insert	0.54	0.19	0.19	0.02	0.75	0.75	XXX
74480	TC	A	X-ray control, cath insert	0.00	NA	4.01	0.18	NA	4.19	XXX
74485		A	X-ray guide, GU dilation	0.54	NA	3.29	0.17	NA	4.00	XXX
74485	26	A	X-ray guide, GU dilation	0.54	0.19	0.19	0.03	0.76	0.76	XXX
74485	TC	A	X-ray guide, GU dilation	0.00	NA	3.10	0.14	NA	3.24	XXX
74710		A	X-ray measurement of pelvis	0.34	NA	1.16	0.07	NA	1.57	XXX
74710	26	A	X-ray measurement of pelvis	0.34	0.12	0.12	0.02	0.48	0.48	XXX
74710	TC	A	X-ray measurement of pelvis	0.00	NA	1.04	0.05	NA	1.09	XXX
74740		A	X-ray, female genital tract	0.38	NA	1.42	0.08	NA	1.88	XXX
74740	26	A	X-ray, female genital tract	0.38	0.13	0.13	0.02	0.53	0.53	XXX
74740	TC	A	X-ray, female genital tract	0.00	NA	1.29	0.06	NA	1.35	XXX
74742		A	X-ray, fallopian tube	0.61	NA	3.32	0.16	NA	4.09	XXX
74742	26	A	X-ray, fallopian tube	0.61	0.22	0.22	0.02	0.85	0.85	XXX
74742	TC	A	X-ray, fallopian tube	0.00	NA	3.10	0.14	NA	3.24	XXX
74775		A	X-ray exam of perineum	0.62	NA	1.66	0.10	NA	2.38	XXX
74775	26	A	X-ray exam of perineum	0.62	0.22	0.22	0.03	0.87	0.87	XXX
74775	TC	A	X-ray exam of perineum	0.00	NA	1.44	0.07	NA	1.51	XXX
75552		A	Heart mri for morph w/o dye	1.60	NA	11.59	0.56	NA	13.75	XXX
75552	26	A	Heart mri for morph w/o dye	1.60	0.56	0.56	0.07	2.23	2.23	XXX
75552	TC	A	Heart mri for morph w/o dye	0.00	NA	11.03	0.49	NA	11.52	XXX
75553		A	Heart mri for morph w/dye	2.00	NA	11.73	0.58	NA	14.31	XXX
75553	26	A	Heart mri for morph w/dye	2.00	0.70	0.70	0.09	2.79	2.79	XXX
75553	TC	A	Heart mri for morph w/dye	0.00	NA	11.03	0.49	NA	11.52	XXX
75554		A	Cardiac MRI/function	1.83	NA	11.72	0.56	NA	14.11	XXX
75554	26	A	Cardiac MRI/function	1.83	0.69	0.69	0.07	2.59	2.59	XXX
75554	TC	A	Cardiac MRI/function	0.00	NA	11.03	0.49	NA	11.52	XXX
75555		A	Cardiac MRI/limited study	1.74	NA	11.70	0.56	NA	14.00	XXX
75555	26	A	Cardiac MRI/limited study	1.74	0.67	0.67	0.07	2.48	2.48	XXX
75555	TC	A	Cardiac MRI/limited study	0.00	NA	11.03	0.49	NA	11.52	XXX
75556		N	Cardiac MRI/flow mapping	0.00	NA	0.00	0.00	NA	0.00	XXX
75600		A	Contrast x-ray exam of aorta	0.49	NA	12.61	0.56	NA	13.66	XXX
75600	26	A	Contrast x-ray exam of aorta	0.49	0.20	0.20	0.02	0.71	0.71	XXX
75600	TC	A	Contrast x-ray exam of aorta	0.00	NA	12.41	0.54	NA	12.95	XXX
75605		A	Contrast x-ray exam of aorta	1.14	NA	12.83	0.59	NA	14.56	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
75605	26	A	Contrast x-ray exam of aorta	1.14	0.42	0.42	0.05	1.61	1.61	XXX
75605	TC	A	Contrast x-ray exam of aorta	0.00	NA	12.41	0.54	NA	12.95	XXX
75625		A	Contrast x-ray exam of aorta	1.14	NA	12.81	0.59	NA	14.54	XXX
75625	26	A	Contrast x-ray exam of aorta	1.14	0.40	0.40	0.05	1.59	1.59	XXX
75625	TC	A	Contrast x-ray exam of aorta	0.00	NA	12.41	0.54	NA	12.95	XXX
75630		A	X-ray aorta, leg arteries	1.79	NA	13.58	0.65	NA	16.02	XXX
75630	26	A	X-ray aorta, leg arteries	1.79	0.65	0.65	0.08	2.52	2.52	XXX
75630	TC	A	X-ray aorta, leg arteries	0.00	NA	12.93	0.57	NA	13.50	XXX
75635		A	Ct angio abdominal arteries	1.89	NA	9.11	0.37	NA	11.37	XXX
75635	26	A	Ct angio abdominal arteries	1.89	0.75	0.75	0.05	2.69	2.69	XXX
75635	TC	A	Ct angio abdominal arteries	0.00	NA	8.36	0.32	NA	8.68	XXX
75650		A	Artery x-rays, head & neck	1.49	NA	12.93	0.61	NA	15.03	XXX
75650	26	A	Artery x-rays, head & neck	1.49	0.52	0.52	0.07	2.08	2.08	XXX
75650	TC	A	Artery x-rays, head & neck	0.00	NA	12.41	0.54	NA	12.95	XXX
75658		A	Artery x-rays, arm	1.31	NA	12.92	0.60	NA	14.83	XXX
75658	26	A	Artery x-rays, arm	1.31	0.51	0.51	0.06	1.88	1.88	XXX
75658	TC	A	Artery x-rays, arm	0.00	NA	12.41	0.54	NA	12.95	XXX
75660		A	Artery x-rays, head & neck	1.31	NA	12.88	0.60	NA	14.79	XXX
75660	26	A	Artery x-rays, head & neck	1.31	0.47	0.47	0.06	1.84	1.84	XXX
75660	TC	A	Artery x-rays, head & neck	0.00	NA	12.41	0.54	NA	12.95	XXX
75662		A	Artery x-rays, head & neck	1.66	NA	13.04	0.62	NA	15.32	XXX
75662	26	A	Artery x-rays, head & neck	1.66	0.63	0.63	0.08	2.37	2.37	XXX
75662	TC	A	Artery x-rays, head & neck	0.00	NA	12.41	0.54	NA	12.95	XXX
75665		A	Artery x-rays, head & neck	1.31	NA	12.87	0.61	NA	14.79	XXX
75665	26	A	Artery x-rays, head & neck	1.31	0.46	0.46	0.07	1.84	1.84	XXX
75665	TC	A	Artery x-rays, head & neck	0.00	NA	12.41	0.54	NA	12.95	XXX
75671		A	Artery x-rays, head & neck	1.66	NA	12.99	0.62	NA	15.27	XXX
75671	26	A	Artery x-rays, head & neck	1.66	0.58	0.58	0.08	2.32	2.32	XXX
75671	TC	A	Artery x-rays, head & neck	0.00	NA	12.41	0.54	NA	12.95	XXX
75676		A	Artery x-rays, neck	1.31	NA	12.88	0.61	NA	14.80	XXX
75676	26	A	Artery x-rays, neck	1.31	0.47	0.47	0.07	1.85	1.85	XXX
75676	TC	A	Artery x-rays, neck	0.00	NA	12.41	0.54	NA	12.95	XXX
75680		A	Artery x-rays, neck	1.66	NA	12.99	0.62	NA	15.27	XXX
75680	26	A	Artery x-rays, neck	1.66	0.58	0.58	0.08	2.32	2.32	XXX
75680	TC	A	Artery x-rays, neck	0.00	NA	12.41	0.54	NA	12.95	XXX
75685		A	Artery x-rays, spine	1.31	NA	12.87	0.60	NA	14.78	XXX
75685	26	A	Artery x-rays, spine	1.31	0.46	0.46	0.06	1.83	1.83	XXX
75685	TC	A	Artery x-rays, spine	0.00	NA	12.41	0.54	NA	12.95	XXX
75705		A	Artery x-rays, spine	2.18	NA	13.18	0.65	NA	16.01	XXX
75705	26	A	Artery x-rays, spine	2.18	0.77	0.77	0.11	3.06	3.06	XXX
75705	TC	A	Artery x-rays, spine	0.00	NA	12.41	0.54	NA	12.95	XXX
75710		A	Artery x-rays, arm/leg	1.14	NA	12.82	0.60	NA	14.56	XXX
75710	26	A	Artery x-rays, arm/leg	1.14	0.41	0.41	0.06	1.61	1.61	XXX
75710	TC	A	Artery x-rays, arm/leg	0.00	NA	12.41	0.54	NA	12.95	XXX
75716		A	Artery x-rays, arms/legs	1.31	NA	12.87	0.60	NA	14.78	XXX
75716	26	A	Artery x-rays, arms/legs	1.31	0.46	0.46	0.06	1.83	1.83	XXX
75716	TC	A	Artery x-rays, arms/legs	0.00	NA	12.41	0.54	NA	12.95	XXX
75722		A	Artery x-rays, kidney	1.14	NA	12.83	0.59	NA	14.56	XXX
75722	26	A	Artery x-rays, kidney	1.14	0.42	0.42	0.05	1.61	1.61	XXX
75722	TC	A	Artery x-rays, kidney	0.00	NA	12.41	0.54	NA	12.95	XXX
75724		A	Artery x-rays, kidneys	1.49	NA	13.00	0.59	NA	15.08	XXX
75724	26	A	Artery x-rays, kidneys	1.49	0.59	0.59	0.05	2.13	2.13	XXX
75724	TC	A	Artery x-rays, kidneys	0.00	NA	12.41	0.54	NA	12.95	XXX
75726		A	Artery x-rays, abdomen	1.14	NA	12.81	0.59	NA	14.54	XXX
75726	26	A	Artery x-rays, abdomen	1.14	0.40	0.40	0.05	1.59	1.59	XXX
75726	TC	A	Artery x-rays, abdomen	0.00	NA	12.41	0.54	NA	12.95	XXX
75731		A	Artery x-rays, adrenal gland	1.14	NA	12.81	0.59	NA	14.54	XXX
75731	26	A	Artery x-rays, adrenal gland	1.14	0.40	0.40	0.05	1.59	1.59	XXX
75731	TC	A	Artery x-rays, adrenal gland	0.00	NA	12.41	0.54	NA	12.95	XXX
75733		A	Artery x-rays, adrenals	1.31	NA	12.88	0.60	NA	14.79	XXX
75733	26	A	Artery x-rays, adrenals	1.31	0.47	0.47	0.06	1.84	1.84	XXX
75733	TC	A	Artery x-rays, adrenals	0.00	NA	12.41	0.54	NA	12.95	XXX
75736		A	Artery x-rays, pelvis	1.14	NA	12.81	0.59	NA	14.54	XXX
75736	26	A	Artery x-rays, pelvis	1.14	0.40	0.40	0.05	1.59	1.59	XXX
75736	TC	A	Artery x-rays, pelvis	0.00	NA	12.41	0.54	NA	12.95	XXX
75741		A	Artery x-rays, lung	1.31	NA	12.87	0.60	NA	14.78	XXX
75741	26	A	Artery x-rays, lung	1.31	0.46	0.46	0.06	1.83	1.83	XXX
75741	TC	A	Artery x-rays, lung	0.00	NA	12.41	0.54	NA	12.95	XXX
75743		A	Artery x-rays, lungs	1.66	NA	12.99	0.61	NA	15.26	XXX
75743	26	A	Artery x-rays, lungs	1.66	0.58	0.58	0.07	2.31	2.31	XXX
75743	TC	A	Artery x-rays, lungs	0.00	NA	12.41	0.54	NA	12.95	XXX
75746		A	Artery x-rays, lung	1.14	NA	12.81	0.59	NA	14.54	XXX
75746	26	A	Artery x-rays, lung	1.14	0.40	0.40	0.05	1.59	1.59	XXX
75746	TC	A	Artery x-rays, lung	0.00	NA	12.41	0.54	NA	12.95	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
75756		A	Artery x-rays, chest	1.14	NA	12.88	0.58	NA	14.60	XXX
75756	26	A	Artery x-rays, chest	1.14	0.47	0.47	0.04	1.65	1.65	XXX
75756	TC	A	Artery x-rays, chest	0.00	NA	12.41	0.54	NA	12.95	XXX
75774		A	Artery x-ray, each vessel	0.36	NA	12.54	0.56	NA	13.46	ZZZ
75774	26	A	Artery x-ray, each vessel	0.36	0.13	0.13	0.02	0.51	0.51	ZZZ
75774	TC	A	Artery x-ray, each vessel	0.00	NA	12.41	0.54	NA	12.95	ZZZ
75790		A	Visualize A–V shunt	1.84	NA	1.97	0.16	NA	3.97	XXX
75790	26	A	Visualize A–V shunt	1.84	0.64	0.64	0.09	2.57	2.57	XXX
75790	TC	A	Visualize A–V shunt	0.00	NA	1.33	0.07	NA	1.40	XXX
75801		A	Lymph vessel x-ray, arm/leg	0.81	NA	5.61	0.29	NA	6.71	XXX
75801	26	A	Lymph vessel x-ray, arm/leg	0.81	0.28	0.28	0.05	1.14	1.14	XXX
75801	TC	A	Lymph vessel x-ray, arm/leg	0.00	NA	5.33	0.24	NA	5.57	XXX
75803		A	Lymph vessel x-ray,arms/legs	1.17	NA	5.74	0.29	NA	7.20	XXX
75803	26	A	Lymph vessel x-ray,arms/legs	1.17	0.41	0.41	0.05	1.63	1.63	XXX
75803	TC	A	Lymph vessel x-ray,arms/legs	0.00	NA	5.33	0.24	NA	5.57	XXX
75805		A	Lymph vessel x-ray, trunk	0.81	NA	6.30	0.31	NA	7.42	XXX
75805	26	A	Lymph vessel x-ray, trunk	0.81	0.29	0.29	0.04	1.14	1.14	XXX
75805	TC	A	Lymph vessel x-ray, trunk	0.00	NA	6.01	0.27	NA	6.28	XXX
75807		A	Lymph vessel x-ray, trunk	1.17	NA	6.42	0.32	NA	7.91	XXX
75807	26	A	Lymph vessel x-ray, trunk	1.17	0.41	0.41	0.05	1.63	1.63	XXX
75807	TC	A	Lymph vessel x-ray, trunk	0.00	NA	6.01	0.27	NA	6.28	XXX
75809		A	Nonvascular shunt, x-ray	0.47	NA	0.94	0.06	NA	1.47	XXX
75809	26	A	Nonvascular shunt, x-ray	0.47	0.17	0.17	0.02	0.66	0.66	XXX
75809	TC	A	Nonvascular shunt, x-ray	0.00	NA	0.77	0.04	NA	0.81	XXX
75810		A	Vein x-ray, spleen/liver	1.14	NA	12.81	0.60	NA	14.55	XXX
75810	26	A	Vein x-ray, spleen/liver	1.14	0.40	0.40	0.06	1.60	1.60	XXX
75810	TC	A	Vein x-ray, spleen/liver	0.00	NA	12.41	0.54	NA	12.95	XXX
75820		A	Vein x-ray, arm/leg	0.70	NA	1.17	0.08	NA	1.95	XXX
75820	26	A	Vein x-ray, arm/leg	0.70	0.24	0.24	0.03	0.97	0.97	XXX
75820	TC	A	Vein x-ray, arm/leg	0.00	NA	0.93	0.05	NA	0.98	XXX
75822		A	Vein x-ray, arms/legs	1.06	NA	1.83	0.12	NA	3.01	XXX
75822	26	A	Vein x-ray, arms/legs	1.06	0.37	0.37	0.05	1.48	1.48	XXX
75822	TC	A	Vein x-ray, arms/legs	0.00	NA	1.46	0.07	NA	1.53	XXX
75825		A	Vein x-ray, trunk	1.14	NA	12.81	0.60	NA	14.55	XXX
75825	26	A	Vein x-ray, trunk	1.14	0.40	0.40	0.06	1.60	1.60	XXX
75825	TC	A	Vein x-ray, trunk	0.00	NA	12.41	0.54	NA	12.95	XXX
75827		A	Vein x-ray, chest	1.14	NA	12.80	0.59	NA	14.53	XXX
75827	26	A	Vein x-ray, chest	1.14	0.39	0.39	0.05	1.58	1.58	XXX
75827	TC	A	Vein x-ray, chest	0.00	NA	12.41	0.54	NA	12.95	XXX
75831		A	Vein x-ray, kidney	1.14	NA	12.81	0.59	NA	14.54	XXX
75831	26	A	Vein x-ray, kidney	1.14	0.40	0.40	0.05	1.59	1.59	XXX
75831	TC	A	Vein x-ray, kidney	0.00	NA	12.41	0.54	NA	12.95	XXX
75833		A	Vein x-ray, kidneys	1.49	NA	12.93	0.61	NA	15.03	XXX
75833	26	A	Vein x-ray, kidneys	1.49	0.52	0.52	0.07	2.08	2.08	XXX
75833	TC	A	Vein x-ray, kidneys	0.00	NA	12.41	0.54	NA	12.95	XXX
75840		A	Vein x-ray, adrenal gland	1.14	NA	12.81	0.61	NA	14.56	XXX
75840	26	A	Vein x-ray, adrenal gland	1.14	0.40	0.40	0.07	1.61	1.61	XXX
75840	TC	A	Vein x-ray, adrenal gland	0.00	NA	12.41	0.54	NA	12.95	XXX
75842		A	Vein x-ray, adrenal glands	1.49	NA	12.92	0.61	NA	15.02	XXX
75842	26	A	Vein x-ray, adrenal glands	1.49	0.51	0.51	0.07	2.07	2.07	XXX
75842	TC	A	Vein x-ray, adrenal glands	0.00	NA	12.41	0.54	NA	12.95	XXX
75860		A	Vein x-ray, neck	1.14	NA	12.82	0.60	NA	14.56	XXX
75860	26	A	Vein x-ray, neck	1.14	0.41	0.41	0.06	1.61	1.61	XXX
75860	TC	A	Vein x-ray, neck	0.00	NA	12.41	0.54	NA	12.95	XXX
75870		A	Vein x-ray, skull	1.14	NA	12.83	0.60	NA	14.57	XXX
75870	26	A	Vein x-ray, skull	1.14	0.42	0.42	0.06	1.62	1.62	XXX
75870	TC	A	Vein x-ray, skull	0.00	NA	12.41	0.54	NA	12.95	XXX
75872		A	Vein x-ray, skull	1.14	NA	12.81	0.59	NA	14.54	XXX
75872	26	A	Vein x-ray, skull	1.14	0.40	0.40	0.05	1.59	1.59	XXX
75872	TC	A	Vein x-ray, skull	0.00	NA	12.41	0.54	NA	12.95	XXX
75880		A	Vein x-ray, eye socket	0.70	NA	1.18	0.08	NA	1.96	XXX
75880	26	A	Vein x-ray, eye socket	0.70	0.25	0.25	0.03	0.98	0.98	XXX
75880	TC	A	Vein x-ray, eye socket	0.00	NA	0.93	0.05	NA	0.98	XXX
75885		A	Vein x-ray, liver	1.44	NA	12.91	0.60	NA	14.95	XXX
75885	26	A	Vein x-ray, liver	1.44	0.50	0.50	0.06	2.00	2.00	XXX
75885	TC	A	Vein x-ray, liver	0.00	NA	12.41	0.54	NA	12.95	XXX
75887		A	Vein x-ray, liver	1.44	NA	12.91	0.60	NA	14.95	XXX
75887	26	A	Vein x-ray, liver	1.44	0.50	0.50	0.06	2.00	2.00	XXX
75887	TC	A	Vein x-ray, liver	0.00	NA	12.41	0.54	NA	12.95	XXX
75889		A	Vein x-ray, liver	1.14	NA	12.80	0.59	NA	14.53	XXX
75889	26	A	Vein x-ray, liver	1.14	0.39	0.39	0.05	1.58	1.58	XXX
75889	TC	A	Vein x-ray, liver	0.00	NA	12.41	0.54	NA	12.95	XXX
75891		A	Vein x-ray, liver	1.14	NA	12.80	0.59	NA	14.53	XXX
75891	26	A	Vein x-ray, liver	1.14	0.39	0.39	0.05	1.58	1.58	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
75891	TC	A	Vein x-ray, liver	0.00	NA	12.41	0.54	NA	12.95	XXX
75893		A	Venous sampling by catheter	0.54	NA	12.60	0.56	NA	13.70	XXX
75893	26	A	Venous sampling by catheter	0.54	0.19	0.19	0.02	0.75	0.75	XXX
75893	TC	A	Venous sampling by catheter	0.00	NA	12.41	0.54	NA	12.95	XXX
75894		A	X-rays, transcath therapy	1.31	NA	24.22	1.12	NA	26.65	XXX
75894	26	A	X-rays, transcath therapy	1.31	0.46	0.46	0.07	1.84	1.84	XXX
75894	TC	A	X-rays, transcath therapy	0.00	NA	23.76	1.05	NA	24.81	XXX
75896		A	X-rays, transcath therapy	1.31	NA	21.14	0.97	NA	23.42	XXX
75896	26	A	X-rays, transcath therapy	1.31	0.47	0.47	0.06	1.84	1.84	XXX
75896	TC	A	X-rays, transcath therapy	0.00	NA	20.67	0.91	NA	21.58	XXX
75898		A	Follow-up angiogram	1.65	NA	1.62	0.12	NA	3.39	XXX
75898	26	A	Follow-up angiogram	1.65	0.58	0.58	0.07	2.30	2.30	XXX
75898	TC	A	Follow-up angiogram	0.00	NA	1.04	0.05	NA	1.09	XXX
75900		A	Arterial catheter exchange	0.49	NA	20.82	0.94	NA	22.25	XXX
75900	26	A	Arterial catheter exchange	0.49	0.17	0.17	0.02	0.68	0.68	XXX
75900	TC	A	Arterial catheter exchange	0.00	NA	20.65	0.92	NA	21.57	XXX
75940		A	X-ray placement, vein filter	0.54	NA	12.60	0.57	NA	13.71	XXX
75940	26	A	X-ray placement, vein filter	0.54	0.19	0.19	0.03	0.76	0.76	XXX
75940	TC	A	X-ray placement, vein filter	0.00	NA	12.41	0.54	NA	12.95	XXX
75945		A	Intravascular us	0.40	NA	4.64	0.23	NA	5.27	XXX
75945	26	A	Intravascular us	0.40	0.15	0.15	0.03	0.58	0.58	XXX
75945	TC	A	Intravascular us	0.00	NA	4.49	0.20	NA	4.69	XXX
75946		A	Intravascular us add-on	0.40	NA	2.40	0.14	NA	2.94	ZZZ
75946	26	A	Intravascular us add-on	0.40	0.14	0.14	0.03	0.57	0.57	ZZZ
75946	TC	A	Intravascular us add-on	0.00	NA	2.26	0.11	NA	2.37	ZZZ
75952		A	Endovasc repair abdom aorta	4.00	1.58	1.58	0.68	6.26	6.26	XXX
75953		A	Abdom aneurysm endovas rpr	1.36	0.54	0.54	0.68	2.58	2.58	XXX
75960		A	Transcatheter intro, stent	0.82	NA	14.97	0.68	NA	16.47	XXX
75960	26	A	Transcatheter intro, stent	0.82	0.30	0.30	0.04	1.16	1.16	XXX
75960	TC	A	Transcatheter intro, stent	0.00	NA	14.67	0.64	NA	15.31	XXX
75961		A	Retrieval, broken catheter	4.25	NA	11.83	0.64	NA	16.72	XXX
75961	26	A	Retrieval, broken catheter	4.25	1.49	1.49	0.18	5.92	5.92	XXX
75961	TC	A	Retrieval, broken catheter	0.00	NA	10.34	0.46	NA	10.80	XXX
75962		A	Repair arterial blockage	0.54	NA	15.69	0.72	NA	16.95	XXX
75962	26	A	Repair arterial blockage	0.54	0.19	0.19	0.03	0.76	0.76	XXX
75962	TC	A	Repair arterial blockage	0.00	NA	15.50	0.69	NA	16.19	XXX
75964		A	Repair artery blockage, each	0.36	NA	8.39	0.38	NA	9.13	ZZZ
75964	26	A	Repair artery blockage, each	0.36	0.13	0.13	0.02	0.51	0.51	ZZZ
75964	TC	A	Repair artery blockage, each	0.00	NA	8.26	0.36	NA	8.62	ZZZ
75966		A	Repair arterial blockage	1.31	NA	15.99	0.75	NA	18.05	XXX
75966	26	A	Repair arterial blockage	1.31	0.49	0.49	0.06	1.86	1.86	XXX
75966	TC	A	Repair arterial blockage	0.00	NA	15.50	0.69	NA	16.19	XXX
75968		A	Repair artery blockage, each	0.36	NA	8.40	0.37	NA	9.13	ZZZ
75968	26	A	Repair artery blockage, each	0.36	0.14	0.14	0.01	0.51	0.51	ZZZ
75968	TC	A	Repair artery blockage, each	0.00	NA	8.26	0.36	NA	8.62	ZZZ
75970		A	Vascular biopsy	0.83	NA	11.67	0.54	NA	13.04	XXX
75970	26	A	Vascular biopsy	0.83	0.30	0.30	0.04	1.17	1.17	XXX
75970	TC	A	Vascular biopsy	0.00	NA	11.37	0.50	NA	11.87	XXX
75978		A	Repair venous blockage	0.54	NA	15.69	0.71	NA	16.94	XXX
75978	26	A	Repair venous blockage	0.54	0.19	0.19	0.02	0.75	0.75	XXX
75978	TC	A	Repair venous blockage	0.00	NA	15.50	0.69	NA	16.19	XXX
75980		A	Contrast xray exam bile duct	1.44	NA	5.83	0.30	NA	7.57	XXX
75980	26	A	Contrast xray exam bile duct	1.44	0.50	0.50	0.06	2.00	2.00	XXX
75980	TC	A	Contrast xray exam bile duct	0.00	NA	5.33	0.24	NA	5.57	XXX
75982		A	Contrast xray exam bile duct	1.44	NA	6.51	0.33	NA	8.28	XXX
75982	26	A	Contrast xray exam bile duct	1.44	0.50	0.50	0.06	2.00	2.00	XXX
75982	TC	A	Contrast xray exam bile duct	0.00	NA	6.01	0.27	NA	6.28	XXX
75984		A	Xray control catheter change	0.72	NA	2.17	0.12	NA	3.01	XXX
75984	26	A	Xray control catheter change	0.72	0.25	0.25	0.03	1.00	1.00	XXX
75984	TC	A	Xray control catheter change	0.00	NA	1.92	0.09	NA	2.01	XXX
75989		A	Abscess drainage under x-ray	1.19	NA	3.51	0.19	NA	4.89	XXX
75989	26	A	Abscess drainage under x-ray	1.19	0.41	0.41	0.05	1.65	1.65	XXX
75989	TC	A	Abscess drainage under x-ray	0.00	NA	3.10	0.14	NA	3.24	XXX
75992		A	Atherectomy, x-ray exam	0.54	NA	15.70	0.71	NA	16.95	XXX
75992	26	A	Atherectomy, x-ray exam	0.54	0.20	0.20	0.02	0.76	0.76	XXX
75992	TC	A	Atherectomy, x-ray exam	0.00	NA	15.50	0.69	NA	16.19	XXX
75993		A	Atherectomy, x-ray exam	0.36	NA	8.40	0.37	NA	9.13	ZZZ
75993	26	A	Atherectomy, x-ray exam	0.36	0.14	0.14	0.01	0.51	0.51	ZZZ
75993	TC	A	Atherectomy, x-ray exam	0.00	NA	8.26	0.36	NA	8.62	ZZZ
75994		A	Atherectomy, x-ray exam	1.31	NA	15.99	0.75	NA	18.05	XXX
75994	26	A	Atherectomy, x-ray exam	1.31	0.49	0.49	0.06	1.86	1.86	XXX
75994	TC	A	Atherectomy, x-ray exam	0.00	NA	15.50	0.69	NA	16.19	XXX
75995		A	Atherectomy, x-ray exam	1.31	NA	15.95	0.75	NA	18.01	XXX
75995	26	A	Atherectomy, x-ray exam	1.31	0.45	0.45	0.06	1.82	1.82	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
75995	TC	A	Atherectomy, x-ray exam	0.00	NA	15.50	0.69	NA	16.19	XXX
75996		A	Atherectomy, x-ray exam	0.36	NA	8.39	0.37	NA	9.12	ZZZ
75996	26	A	Atherectomy, x-ray exam	0.36	0.13	0.13	0.01	0.50	0.50	ZZZ
75996	TC	A	Atherectomy, x-ray exam	0.00	NA	8.26	0.36	NA	8.62	ZZZ
76000		A	Fluoroscope examination	0.17	NA	1.34	0.01	NA	1.52	XXX
76001		A	Fluoroscope exam, extensive	0.67	NA	2.81	0.15	NA	3.63	XXX
76001	26	A	Fluoroscope exam, extensive	0.67	0.23	0.23	0.03	0.93	0.93	XXX
76001	TC	A	Fluoroscope exam, extensive	0.00	NA	2.58	0.12	NA	2.70	XXX
76003		A	Needle localization by x-ray	0.54	NA	1.47	0.09	NA	2.10	XXX
76003	26	A	Needle localization by x-ray	0.54	0.18	0.18	0.03	0.75	0.75	XXX
76003	TC	A	Needle localization by x-ray	0.00	NA	1.29	0.06	NA	1.35	XXX
76005		A	Fluoroguide for spine inject	0.60	NA	1.48	0.09	NA	2.17	XXX
76005	26	A	Fluoroguide for spine inject	0.60	0.19	0.19	0.03	0.82	0.82	XXX
76005	TC	A	Fluoroguide for spine inject	0.00	NA	1.29	0.06	NA	1.35	XXX
76006		A	X-ray stress view	0.41	0.19	0.19	0.04	0.64	0.64	XXX
76010		A	X-ray, nose to rectum	0.18	NA	0.57	0.03	NA	0.78	XXX
76010	26	A	X-ray, nose to rectum	0.18	0.06	0.06	0.01	0.25	0.25	XXX
76010	TC	A	X-ray, nose to rectum	0.00	NA	0.51	0.02	NA	0.53	XXX
76012		A	Percut vertebroplasty fluor	1.31	0.49	0.49	0.23	2.03	2.03	XXX
76013		A	Percut vertebroplasty, ct	1.38	0.51	0.51	0.48	2.37	2.37	XXX
76020		A	X-rays for bone age	0.19	NA	0.58	0.03	NA	0.80	XXX
76020	26	A	X-rays for bone age	0.19	0.07	0.07	0.01	0.27	0.27	XXX
76020	TC	A	X-rays for bone age	0.00	NA	0.51	0.02	NA	0.53	XXX
76040		A	X-rays, bone evaluation	0.27	NA	0.87	0.07	NA	1.21	XXX
76040	26	A	X-rays, bone evaluation	0.27	0.10	0.10	0.03	0.40	0.40	XXX
76040	TC	A	X-rays, bone evaluation	0.00	NA	0.77	0.04	NA	0.81	XXX
76061		A	X-rays, bone survey	0.45	NA	1.14	0.07	NA	1.66	XXX
76061	26	A	X-rays, bone survey	0.45	0.16	0.16	0.02	0.63	0.63	XXX
76061	TC	A	X-rays, bone survey	0.00	NA	0.98	0.05	NA	1.03	XXX
76062		A	X-rays, bone survey	0.54	NA	1.61	0.09	NA	2.24	XXX
76062	26	A	X-rays, bone survey	0.54	0.19	0.19	0.02	0.75	0.75	XXX
76062	TC	A	X-rays, bone survey	0.00	NA	1.42	0.07	NA	1.49	XXX
76065		A	X-rays, bone evaluation	0.70	NA	0.96	0.05	NA	1.71	XXX
76065	26	A	X-rays, bone evaluation	0.70	0.24	0.24	0.01	0.95	0.95	XXX
76065	TC	A	X-rays, bone evaluation	0.00	NA	0.72	0.04	NA	0.76	XXX
76066		A	Joint(s) survey, single film	0.31	NA	1.20	0.07	NA	1.58	XXX
76066	26	A	Joint(s) survey, single film	0.31	0.11	0.11	0.02	0.44	0.44	XXX
76066	TC	A	Joint(s) survey, single film	0.00	NA	1.09	0.05	NA	1.14	XXX
76070		I	CT scan, bone density study	0.25	NA	3.00	0.14	NA	3.39	XXX
76070	26	I	CT scan, bone density study	0.25	0.10	0.10	0.01	0.36	0.36	XXX
76070	TC	I	CT scan, bone density study	0.00	NA	2.90	0.13	NA	3.03	XXX
76075		A	Dual energy x-ray study	0.30	NA	3.16	0.15	NA	3.61	XXX
76075	26	A	Dual energy x-ray study	0.30	0.11	0.11	0.01	0.42	0.42	XXX
76075	TC	A	Dual energy x-ray study	0.00	NA	3.05	0.14	NA	3.19	XXX
76076		A	Dual energy x-ray study	0.22	NA	0.82	0.05	NA	1.09	XXX
76076	26	A	Dual energy x-ray study	0.22	0.08	0.08	0.01	0.31	0.31	XXX
76076	TC	A	Dual energy x-ray study	0.00	NA	0.74	0.04	NA	0.78	XXX
76078		A	Photodensitometry	0.20	NA	0.82	0.05	NA	1.07	XXX
76078	26	A	Photodensitometry	0.20	0.08	0.08	0.01	0.29	0.29	XXX
76078	TC	A	Photodensitometry	0.00	NA	0.74	0.04	NA	0.78	XXX
76080		A	X-ray exam of fistula	0.54	NA	1.23	0.07	NA	1.84	XXX
76080	26	A	X-ray exam of fistula	0.54	0.19	0.19	0.02	0.75	0.75	XXX
76080	TC	A	X-ray exam of fistula	0.00	NA	1.04	0.05	NA	1.09	XXX
76086		A	X-ray of mammary duct	0.36	NA	2.71	0.14	NA	3.21	XXX
76086	26	A	X-ray of mammary duct	0.36	0.13	0.13	0.02	0.51	0.51	XXX
76086	TC	A	X-ray of mammary duct	0.00	NA	2.58	0.12	NA	2.70	XXX
76088		A	X-ray of mammary ducts	0.45	NA	3.77	0.18	NA	4.40	XXX
76088	26	A	X-ray of mammary ducts	0.45	0.16	0.16	0.02	0.63	0.63	XXX
76088	TC	A	X-ray of mammary ducts	0.00	NA	3.61	0.16	NA	3.77	XXX
76090		A	Mammogram, one breast	0.70	NA	1.28	0.08	NA	2.06	XXX
76090	26	A	Mammogram, one breast	0.70	0.24	0.24	0.03	0.97	0.97	XXX
76090	TC	A	Mammogram, one breast	0.00	NA	1.04	0.05	NA	1.09	XXX
76091		A	Mammogram, both breasts	0.87	NA	1.59	0.09	NA	2.55	XXX
76091	26	A	Mammogram, both breasts	0.87	0.30	0.30	0.03	1.20	1.20	XXX
76091	TC	A	Mammogram, both breasts	0.00	NA	1.29	0.06	NA	1.35	XXX
76092		A	Mammogram, screening	0.70	NA	1.52	0.09	NA	2.31	XXX
76092	26	A	Mammogram, screening	0.70	0.25	0.25	0.03	0.98	0.98	XXX
76092	TC	A	Mammogram, screening	0.00	NA	1.27	0.06	NA	1.33	XXX
76093		A	Magnetic image, breast	1.63	NA	17.93	0.83	NA	20.39	XXX
76093	26	A	Magnetic image, breast	1.63	0.57	0.57	0.07	2.27	2.27	XXX
76093	TC	A	Magnetic image, breast	0.00	NA	17.36	0.76	NA	18.12	XXX
76094		A	Magnetic image, both breasts	1.63	NA	24.12	1.10	NA	26.85	XXX
76094	26	A	Magnetic image, both breasts	1.63	0.57	0.57	0.07	2.27	2.27	XXX
76094	TC	A	Magnetic image, both breasts	0.00	NA	23.55	1.03	NA	24.58	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
76095		A	Stereotactic breast biopsy	1.59	NA	7.62	0.40	NA	9.61	XXX
76095	26	A	Stereotactic breast biopsy	1.59	0.56	0.56	0.09	2.24	2.24	XXX
76095	TC	A	Stereotactic breast biopsy	0.00	NA	7.06	0.31	NA	7.37	XXX
76096		A	X-ray of needle wire, breast	0.56	NA	1.49	0.09	NA	2.14	XXX
76096	26	A	X-ray of needle wire, breast	0.56	0.20	0.20	0.03	0.79	0.79	XXX
76096	TC	A	X-ray of needle wire, breast	0.00	NA	1.29	0.06	NA	1.35	XXX
76098		A	X-ray exam, breast specimen	0.16	NA	0.47	0.03	NA	0.66	XXX
76098	26	A	X-ray exam, breast specimen	0.16	0.06	0.06	0.01	0.23	0.23	XXX
76098	TC	A	X-ray exam, breast specimen	0.00	NA	0.41	0.02	NA	0.43	XXX
76100		A	X-ray exam of body section	0.58	NA	1.43	0.09	NA	2.10	XXX
76100	26	A	X-ray exam of body section	0.58	0.20	0.20	0.03	0.81	0.81	XXX
76100	TC	A	X-ray exam of body section	0.00	NA	1.23	0.06	NA	1.29	XXX
76101		A	Complex body section x-ray	0.58	NA	1.60	0.10	NA	2.28	XXX
76101	26	A	Complex body section x-ray	0.58	0.20	0.20	0.03	0.81	0.81	XXX
76101	TC	A	Complex body section x-ray	0.00	NA	1.40	0.07	NA	1.47	XXX
76102		A	Complex body section x-rays	0.58	NA	1.90	0.12	NA	2.60	XXX
76102	26	A	Complex body section x-rays	0.58	0.20	0.20	0.03	0.81	0.81	XXX
76102	TC	A	Complex body section x-rays	0.00	NA	1.70	0.09	NA	1.79	XXX
76120		A	Cinematic x-rays	0.38	NA	1.17	0.07	NA	1.62	XXX
76120	26	A	Cinematic x-rays	0.38	0.13	0.13	0.02	0.53	0.53	XXX
76120	TC	A	Cinematic x-rays	0.00	NA	1.04	0.05	NA	1.09	XXX
76125		A	Cinematic x-rays add-on	0.27	NA	0.87	0.05	NA	1.19	ZZZ
76125	26	A	Cinematic x-rays add-on	0.27	0.10	0.10	0.01	0.38	0.38	ZZZ
76125	TC	A	Cinematic x-rays add-on	0.00	NA	0.77	0.04	NA	0.81	ZZZ
76140		I	X-ray consultation	0.00	NA	0.00	0.00	NA	0.00	XXX
76150		A	X-ray exam, dry process	0.00	NA	0.41	0.02	NA	0.43	XXX
76350		C	Special x-ray contrast study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76355		A	CAT scan for localization	1.21	NA	8.56	0.41	NA	10.18	XXX
76355	26	A	CAT scan for localization	1.21	0.43	0.43	0.06	1.70	1.70	XXX
76355	TC	A	CAT scan for localization	0.00	NA	8.13	0.35	NA	8.48	XXX
76360		A	CAT scan for needle biopsy	1.16	NA	8.53	0.40	NA	10.09	XXX
76360	26	A	CAT scan for needle biopsy	1.16	0.40	0.40	0.05	1.61	1.61	XXX
76360	TC	A	CAT scan for needle biopsy	0.00	NA	8.13	0.35	NA	8.48	XXX
76370		A	CAT scan for therapy guide	0.85	NA	3.20	0.17	NA	4.22	XXX
76370	26	A	CAT scan for therapy guide	0.85	0.30	0.30	0.04	1.19	1.19	XXX
76370	TC	A	CAT scan for therapy guide	0.00	NA	2.90	0.13	NA	3.03	XXX
76375		A	3d/holograph reconstr add-on	0.16	NA	3.54	0.16	NA	3.86	XXX
76375	26	A	3d/holograph reconstr add-on	0.16	0.06	0.06	0.01	0.23	0.23	XXX
76375	TC	A	3d/holograph reconstr add-on	0.00	NA	3.48	0.15	NA	3.63	XXX
76380		A	CAT scan follow-up study	0.98	NA	3.79	0.19	NA	4.96	XXX
76380	26	A	CAT scan follow-up study	0.98	0.34	0.34	0.04	1.36	1.36	XXX
76380	TC	A	CAT scan follow-up study	0.00	NA	3.45	0.15	NA	3.60	XXX
76390		A	Mr spectroscopy	1.40	NA	11.52	0.55	NA	13.47	XXX
76390	26	A	Mr spectroscopy	1.40	0.49	0.49	0.06	1.95	1.95	XXX
76390	TC	A	Mr spectroscopy	0.00	NA	11.03	0.49	NA	11.52	XXX
76393		A	Mr guidance for needle place	1.50	NA	11.55	0.52	NA	13.57	XXX
76393	26	A	Mr guidance for needle place	1.50	0.52	0.52	0.06	2.08	2.08	XXX
76393	TC	A	Mr guidance for needle place	0.00	NA	11.03	0.46	NA	11.49	XXX
76400		A	Magnetic image, bone marrow	1.60	NA	11.59	0.56	NA	13.75	XXX
76400	26	A	Magnetic image, bone marrow	1.60	0.56	0.56	0.07	2.23	2.23	XXX
76400	TC	A	Magnetic image, bone marrow	0.00	NA	11.03	0.49	NA	11.52	XXX
76499		C	Radiographic procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
76499	26	C	Radiographic procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76499	TC	C	Radiographic procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
76506		A	Echo exam of head	0.63	NA	1.66	0.10	NA	2.39	XXX
76506	26	A	Echo exam of head	0.63	0.26	0.26	0.03	0.92	0.92	XXX
76506	TC	A	Echo exam of head	0.00	NA	1.40	0.07	NA	1.47	XXX
76511		A	Echo exam of eye	0.94	NA	1.75	0.08	NA	2.77	XXX
76511	26	A	Echo exam of eye	0.94	0.42	0.42	0.02	1.38	1.38	XXX
76511	TC	A	Echo exam of eye	0.00	NA	1.33	0.06	NA	1.39	XXX
76512		A	Echo exam of eye	0.66	NA	1.85	0.09	NA	2.60	XXX
76512	26	A	Echo exam of eye	0.66	0.31	0.31	0.01	0.98	0.98	XXX
76512	TC	A	Echo exam of eye	0.00	NA	1.54	0.08	NA	1.62	XXX
76513		A	Echo exam of eye, water bath	0.66	NA	2.25	0.09	NA	3.00	XXX
76513	26	A	Echo exam of eye, water bath	0.66	0.31	0.31	0.01	0.98	0.98	XXX
76513	TC	A	Echo exam of eye, water bath	0.00	NA	1.94	0.08	NA	2.02	XXX
76516		A	Echo exam of eye	0.54	NA	1.35	0.07	NA	1.96	XXX
76516	26	A	Echo exam of eye	0.54	0.26	0.26	0.01	0.81	0.81	XXX
76516	TC	A	Echo exam of eye	0.00	NA	1.09	0.06	NA	1.15	XXX
76519		A	Echo exam of eye	0.54	NA	1.49	0.07	NA	2.10	XXX
76519	26	A	Echo exam of eye	0.54	0.26	0.26	0.01	0.81	0.81	XXX
76519	TC	A	Echo exam of eye	0.00	NA	1.23	0.06	NA	1.29	XXX
76529		A	Echo exam of eye	0.57	NA	2.03	0.08	NA	2.68	XXX
76529	26	A	Echo exam of eye	0.57	0.26	0.26	0.01	0.84	0.84	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
76529	TC	A	Echo exam of eye	0.00	NA	1.77	0.07	NA	1.84	XXX
76536		A	Echo exam of head and neck	0.56	NA	1.60	0.09	NA	2.25	XXX
76536	26	A	Echo exam of head and neck	0.56	0.20	0.20	0.02	0.78	0.78	XXX
76536	TC	A	Echo exam of head and neck	0.00	NA	1.40	0.07	NA	1.47	XXX
76604		A	Echo exam of chest	0.55	NA	1.48	0.08	NA	2.11	XXX
76604	26	A	Echo exam of chest	0.55	0.19	0.19	0.02	0.76	0.76	XXX
76604	TC	A	Echo exam of chest	0.00	NA	1.29	0.06	NA	1.35	XXX
76645		A	Echo exam of breast(s)	0.54	NA	1.23	0.08	NA	1.85	XXX
76645	26	A	Echo exam of breast(s)	0.54	0.19	0.19	0.03	0.76	0.76	XXX
76645	TC	A	Echo exam of breast(s)	0.00	NA	1.04	0.05	NA	1.09	XXX
76700		A	Echo exam of abdomen	0.81	NA	2.22	0.13	NA	3.16	XXX
76700	26	A	Echo exam of abdomen	0.81	0.28	0.28	0.04	1.13	1.13	XXX
76700	TC	A	Echo exam of abdomen	0.00	NA	1.94	0.09	NA	2.03	XXX
76705		A	Echo exam of abdomen	0.59	NA	1.61	0.10	NA	2.30	XXX
76705	26	A	Echo exam of abdomen	0.59	0.21	0.21	0.03	0.83	0.83	XXX
76705	TC	A	Echo exam of abdomen	0.00	NA	1.40	0.07	NA	1.47	XXX
76770		A	Echo exam abdomen back wall	0.74	NA	2.20	0.12	NA	3.06	XXX
76770	26	A	Echo exam abdomen back wall	0.74	0.26	0.26	0.03	1.03	1.03	XXX
76770	TC	A	Echo exam abdomen back wall	0.00	NA	1.94	0.09	NA	2.03	XXX
76775		A	Echo exam abdomen back wall	0.58	NA	1.60	0.10	NA	2.28	XXX
76775	26	A	Echo exam abdomen back wall	0.58	0.20	0.20	0.03	0.81	0.81	XXX
76775	TC	A	Echo exam abdomen back wall	0.00	NA	1.40	0.07	NA	1.47	XXX
76778		A	Echo exam kidney transplant	0.74	NA	2.20	0.12	NA	3.06	XXX
76778	26	A	Echo exam kidney transplant	0.74	0.26	0.26	0.03	1.03	1.03	XXX
76778	TC	A	Echo exam kidney transplant	0.00	NA	1.94	0.09	NA	2.03	XXX
76800		A	Echo exam spinal canal	1.13	NA	1.73	0.11	NA	2.97	XXX
76800	26	A	Echo exam spinal canal	1.13	0.33	0.33	0.04	1.50	1.50	XXX
76800	TC	A	Echo exam spinal canal	0.00	NA	1.40	0.07	NA	1.47	XXX
76805		A	Echo exam of pregnant uterus	0.99	NA	2.43	0.14	NA	3.56	XXX
76805	26	A	Echo exam of pregnant uterus	0.99	0.36	0.36	0.04	1.39	1.39	XXX
76805	TC	A	Echo exam of pregnant uterus	0.00	NA	2.07	0.10	NA	2.17	XXX
76810		A	Echo exam of pregnant uterus	1.97	NA	4.87	0.25	NA	7.09	XXX
76810	26	A	Echo exam of pregnant uterus	1.97	0.74	0.74	0.07	2.78	2.78	XXX
76810	TC	A	Echo exam of pregnant uterus	0.00	NA	4.13	0.18	NA	4.31	XXX
76815		A	Echo exam of pregnant uterus	0.65	NA	1.65	0.09	NA	2.39	XXX
76815	26	A	Echo exam of pregnant uterus	0.65	0.25	0.25	0.02	0.92	0.92	XXX
76815	TC	A	Echo exam of pregnant uterus	0.00	NA	1.40	0.07	NA	1.47	XXX
76816		A	Echo exam follow-up/repeat	0.57	NA	1.32	0.07	NA	1.96	XXX
76816	26	A	Echo exam follow-up/repeat	0.57	0.23	0.23	0.02	0.82	0.82	XXX
76816	TC	A	Echo exam follow-up/repeat	0.00	NA	1.09	0.05	NA	1.14	XXX
76818		A	Fetl biophys profil w/stress	0.86	NA	1.93	0.12	NA	2.91	XXX
76818	26	A	Fetl biophys profil w/stress	0.86	0.34	0.34	0.04	1.24	1.24	XXX
76818	TC	A	Fetl biophys profil w/stress	0.00	NA	1.59	0.08	NA	1.67	XXX
76819		A	Fetl biophys profil w/o strs	0.63	NA	1.84	0.11	NA	2.58	XXX
76819	26	A	Fetl biophys profil w/o strs	0.63	0.25	0.25	0.03	0.91	0.91	XXX
76819	TC	A	Fetl biophys profil w/o strs	0.00	NA	1.59	0.08	NA	1.67	XXX
76825		A	Echo exam of fetal heart	1.67	NA	2.57	0.15	NA	4.39	XXX
76825	26	A	Echo exam of fetal heart	1.67	0.63	0.63	0.06	2.36	2.36	XXX
76825	TC	A	Echo exam of fetal heart	0.00	NA	1.94	0.09	NA	2.03	XXX
76826		A	Echo exam of fetal heart	0.83	NA	1.00	0.07	NA	1.90	XXX
76826	26	A	Echo exam of fetal heart	0.83	0.30	0.30	0.03	1.16	1.16	XXX
76826	TC	A	Echo exam of fetal heart	0.00	NA	0.70	0.04	NA	0.74	XXX
76827		A	Echo exam of fetal heart	0.58	NA	1.91	0.12	NA	2.61	XXX
76827	26	A	Echo exam of fetal heart	0.58	0.22	0.22	0.02	0.82	0.82	XXX
76827	TC	A	Echo exam of fetal heart	0.00	NA	1.69	0.10	NA	1.79	XXX
76828		A	Echo exam of fetal heart	0.56	NA	1.32	0.09	NA	1.97	XXX
76828	26	A	Echo exam of fetal heart	0.56	0.23	0.23	0.02	0.81	0.81	XXX
76828	TC	A	Echo exam of fetal heart	0.00	NA	1.09	0.07	NA	1.16	XXX
76830		A	Echo exam, transvaginal	0.69	NA	1.73	0.11	NA	2.53	XXX
76830	26	A	Echo exam, transvaginal	0.69	0.24	0.24	0.03	0.96	0.96	XXX
76830	TC	A	Echo exam, transvaginal	0.00	NA	1.49	0.08	NA	1.57	XXX
76831		A	Echo exam, uterus	0.72	NA	1.76	0.10	NA	2.58	XXX
76831	26	A	Echo exam, uterus	0.72	0.27	0.27	0.02	1.01	1.01	XXX
76831	TC	A	Echo exam, uterus	0.00	NA	1.49	0.08	NA	1.57	XXX
76856		A	Echo exam of pelvis	0.69	NA	1.73	0.11	NA	2.53	XXX
76856	26	A	Echo exam of pelvis	0.69	0.24	0.24	0.03	0.96	0.96	XXX
76856	TC	A	Echo exam of pelvis	0.00	NA	1.49	0.08	NA	1.57	XXX
76857		A	Echo exam of pelvis	0.38	NA	1.17	0.07	NA	1.62	XXX
76857	26	A	Echo exam of pelvis	0.38	0.13	0.13	0.02	0.53	0.53	XXX
76857	TC	A	Echo exam of pelvis	0.00	NA	1.04	0.05	NA	1.09	XXX
76870		A	Echo exam of scrotum	0.64	NA	1.71	0.11	NA	2.46	XXX
76870	26	A	Echo exam of scrotum	0.64	0.22	0.22	0.03	0.89	0.89	XXX
76870	TC	A	Echo exam of scrotum	0.00	NA	1.49	0.08	NA	1.57	XXX
76872		A	Echo exam, transrectal	0.69	NA	1.73	0.12	NA	2.54	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
76872	26	A	Echo exam, transrectal	0.69	0.24	0.24	0.04	0.97	0.97	XXX
76872	TC	A	Echo exam, transrectal	0.00	NA	1.49	0.08	NA	1.57	XXX
76873		A	Echograp trans r, pros study	1.55	NA	2.60	0.21	NA	4.36	XXX
76873	26	A	Echograp trans r, pros study	1.55	0.53	0.53	0.08	2.16	2.16	XXX
76873	TC	A	Echograp trans r, pros study	0.00	NA	2.07	0.13	NA	2.20	XXX
76880		A	Echo exam of extremity	0.59	NA	1.61	0.10	NA	2.30	XXX
76880	26	A	Echo exam of extremity	0.59	0.21	0.21	0.03	0.83	0.83	XXX
76880	TC	A	Echo exam of extremity	0.00	NA	1.40	0.07	NA	1.47	XXX
76885		A	Echo exam, infant hips	0.74	NA	1.75	0.11	NA	2.60	XXX
76885	26	A	Echo exam, infant hips	0.74	0.26	0.26	0.03	1.03	1.03	XXX
76885	TC	A	Echo exam, infant hips	0.00	NA	1.49	0.08	NA	1.57	XXX
76886		A	Echo exam, infant hips	0.62	NA	1.61	0.10	NA	2.33	XXX
76886	26	A	Echo exam, infant hips	0.62	0.21	0.21	0.03	0.86	0.86	XXX
76886	TC	A	Echo exam, infant hips	0.00	NA	1.40	0.07	NA	1.47	XXX
76930		A	Echo guide, cardiocentesis	0.67	NA	1.76	0.10	NA	2.53	XXX
76930	26	A	Echo guide, cardiocentesis	0.67	0.27	0.27	0.02	0.96	0.96	XXX
76930	TC	A	Echo guide, cardiocentesis	0.00	NA	1.49	0.08	NA	1.57	XXX
76932		A	Echo guide for heart biopsy	0.67	NA	1.76	0.10	NA	2.53	XXX
76932	26	A	Echo guide for heart biopsy	0.67	0.27	0.27	0.02	0.96	0.96	XXX
76932	TC	A	Echo guide for heart biopsy	0.00	NA	1.49	0.08	NA	1.57	XXX
76936		A	Echo guide for artery repair	1.99	NA	6.90	0.39	NA	9.28	XXX
76936	26	A	Echo guide for artery repair	1.99	0.70	0.70	0.11	2.80	2.80	XXX
76936	TC	A	Echo guide for artery repair	0.00	NA	6.20	0.28	NA	6.48	XXX
76941		A	Echo guide for transfusion	1.34	NA	2.00	0.13	NA	3.47	XXX
76941	26	A	Echo guide for transfusion	1.34	0.50	0.50	0.06	1.90	1.90	XXX
76941	TC	A	Echo guide for transfusion	0.00	NA	1.50	0.07	NA	1.57	XXX
76942		A	Echo guide for biopsy	0.67	NA	1.72	0.12	NA	2.51	XXX
76942	26	A	Echo guide for biopsy	0.67	0.23	0.23	0.04	0.94	0.94	XXX
76942	TC	A	Echo guide for biopsy	0.00	NA	1.49	0.08	NA	1.57	XXX
76945		A	Echo guide, villus sampling	0.67	NA	1.74	0.10	NA	2.51	XXX
76945	26	A	Echo guide, villus sampling	0.67	0.24	0.24	0.03	0.94	0.94	XXX
76945	TC	A	Echo guide, villus sampling	0.00	NA	1.50	0.07	NA	1.57	XXX
76946		A	Echo guide for amniocentesis	0.38	NA	1.64	0.09	NA	2.11	XXX
76946	26	A	Echo guide for amniocentesis	0.38	0.15	0.15	0.01	0.54	0.54	XXX
76946	TC	A	Echo guide for amniocentesis	0.00	NA	1.49	0.08	NA	1.57	XXX
76948		A	Echo guide, ova aspiration	0.38	NA	1.63	0.10	NA	2.11	XXX
76948	26	A	Echo guide, ova aspiration	0.38	0.14	0.14	0.02	0.54	0.54	XXX
76948	TC	A	Echo guide, ova aspiration	0.00	NA	1.49	0.08	NA	1.57	XXX
76950		A	Echo guidance radiotherapy	0.58	NA	1.49	0.09	NA	2.16	XXX
76950	26	A	Echo guidance radiotherapy	0.58	0.20	0.20	0.03	0.81	0.81	XXX
76950	TC	A	Echo guidance radiotherapy	0.00	NA	1.29	0.06	NA	1.35	XXX
76965		A	Echo guidance radiotherapy	1.34	NA	5.94	0.31	NA	7.59	XXX
76965	26	A	Echo guidance radiotherapy	1.34	0.46	0.46	0.07	1.87	1.87	XXX
76965	TC	A	Echo guidance radiotherapy	0.00	NA	5.48	0.24	NA	5.72	XXX
76970		A	Ultrasound exam follow-up	0.40	NA	1.18	0.07	NA	1.65	XXX
76970	26	A	Ultrasound exam follow-up	0.40	0.14	0.14	0.02	0.56	0.56	XXX
76970	TC	A	Ultrasound exam follow-up	0.00	NA	1.04	0.05	NA	1.09	XXX
76975		A	GI endoscopic ultrasound	0.81	NA	1.78	0.11	NA	2.70	XXX
76975	26	A	GI endoscopic ultrasound	0.81	0.29	0.29	0.03	1.13	1.13	XXX
76975	TC	A	GI endoscopic ultrasound	0.00	NA	1.49	0.08	NA	1.57	XXX
76977		A	Us bone density measure	0.05	NA	1.42	0.05	NA	1.52	XXX
76977	26	A	Us bone density measure	0.05	0.02	0.02	0.01	0.08	0.08	XXX
76977	TC	A	Us bone density measure	0.00	NA	1.40	0.04	NA	1.44	XXX
76986		A	Ultrasound guide intraoper	1.20	NA	3.00	0.19	NA	4.39	XXX
76986	26	A	Ultrasound guide intraoper	1.20	0.42	0.42	0.07	1.69	1.69	XXX
76986	TC	A	Ultrasound guide intraoper	0.00	NA	2.58	0.12	NA	2.70	XXX
76999		C	Echo examination procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
76999	26	C	Echo examination procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76999	TC	C	Echo examination procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
77261		A	Radiation therapy planning	1.39	0.56	0.56	0.06	2.01	2.01	XXX
77262		A	Radiation therapy planning	2.11	0.83	0.83	0.09	3.03	3.03	XXX
77263		A	Radiation therapy planning	3.14	1.24	1.24	0.13	4.51	4.51	XXX
77280		A	Set radiation therapy field	0.70	NA	3.67	0.18	NA	4.55	XXX
77280	26	A	Set radiation therapy field	0.70	0.25	0.25	0.03	0.98	0.98	XXX
77280	TC	A	Set radiation therapy field	0.00	NA	3.42	0.15	NA	3.57	XXX
77285		A	Set radiation therapy field	1.05	NA	5.86	0.29	NA	7.20	XXX
77285	26	A	Set radiation therapy field	1.05	0.38	0.38	0.04	1.47	1.47	XXX
77285	TC	A	Set radiation therapy field	0.00	NA	5.48	0.25	NA	5.73	XXX
77290		A	Set radiation therapy field	1.56	NA	6.97	0.35	NA	8.88	XXX
77290	26	A	Set radiation therapy field	1.56	0.56	0.56	0.06	2.18	2.18	XXX
77290	TC	A	Set radiation therapy field	0.00	NA	6.41	0.29	NA	6.70	XXX
77295		A	Set radiation therapy field	4.57	NA	29.15	1.41	NA	35.13	XXX
77295	26	A	Set radiation therapy field	4.57	1.64	1.64	0.18	6.39	6.39	XXX
77295	TC	A	Set radiation therapy field	0.00	NA	27.51	1.23	NA	28.74	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
77299		C	Radiation therapy planning	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77299	26	C	Radiation therapy planning	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77299	TC	C	Radiation therapy planning	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77300		A	Radiation therapy dose plan	0.62	NA	1.54	0.09	NA	2.25	XXX
77300	26	A	Radiation therapy dose plan	0.62	0.22	0.22	0.03	0.87	0.87	XXX
77300	TC	A	Radiation therapy dose plan	0.00	NA	1.32	0.06	NA	1.38	XXX
77305		A	Radiation therapy dose plan	0.70	NA	2.08	0.12	NA	2.90	XXX
77305	26	A	Radiation therapy dose plan	0.70	0.25	0.25	0.03	0.98	0.98	XXX
77305	TC	A	Radiation therapy dose plan	0.00	NA	1.83	0.09	NA	1.92	XXX
77310		A	Radiation therapy dose plan	1.05	NA	2.67	0.15	NA	3.87	XXX
77310	26	A	Radiation therapy dose plan	1.05	0.38	0.38	0.04	1.47	1.47	XXX
77310	TC	A	Radiation therapy dose plan	0.00	NA	2.29	0.11	NA	2.40	XXX
77315		A	Radiation therapy dose plan	1.56	NA	3.18	0.18	NA	4.92	XXX
77315	26	A	Radiation therapy dose plan	1.56	0.56	0.56	0.06	2.18	2.18	XXX
77315	TC	A	Radiation therapy dose plan	0.00	NA	2.62	0.12	NA	2.74	XXX
77321		A	Radiation therapy port plan	0.95	NA	4.32	0.21	NA	5.48	XXX
77321	26	A	Radiation therapy port plan	0.95	0.34	0.34	0.04	1.33	1.33	XXX
77321	TC	A	Radiation therapy port plan	0.00	NA	3.98	0.17	NA	4.15	XXX
77326		A	Radiation therapy dose plan	0.93	NA	2.65	0.15	NA	3.73	XXX
77326	26	A	Radiation therapy dose plan	0.93	0.33	0.33	0.04	1.30	1.30	XXX
77326	TC	A	Radiation therapy dose plan	0.00	NA	2.32	0.11	NA	2.43	XXX
77327		A	Radiation therapy dose plan	1.39	NA	3.92	0.21	NA	5.52	XXX
77327	26	A	Radiation therapy dose plan	1.39	0.50	0.50	0.06	1.95	1.95	XXX
77327	TC	A	Radiation therapy dose plan	0.00	NA	3.42	0.15	NA	3.57	XXX
77328		A	Radiation therapy dose plan	2.09	NA	5.63	0.30	NA	8.02	XXX
77328	26	A	Radiation therapy dose plan	2.09	0.75	0.75	0.09	2.93	2.93	XXX
77328	TC	A	Radiation therapy dose plan	0.00	NA	4.88	0.21	NA	5.09	XXX
77331		A	Special radiation dosimetry	0.87	NA	0.81	0.06	NA	1.74	XXX
77331	26	A	Special radiation dosimetry	0.87	0.31	0.31	0.04	1.22	1.22	XXX
77331	TC	A	Special radiation dosimetry	0.00	NA	0.50	0.02	NA	0.52	XXX
77332		A	Radiation treatment aid(s)	0.54	NA	1.51	0.08	NA	2.13	XXX
77332	26	A	Radiation treatment aid(s)	0.54	0.19	0.19	0.02	0.75	0.75	XXX
77332	TC	A	Radiation treatment aid(s)	0.00	NA	1.32	0.06	NA	1.38	XXX
77333		A	Radiation treatment aid(s)	0.84	NA	2.17	0.13	NA	3.14	XXX
77333	26	A	Radiation treatment aid(s)	0.84	0.30	0.30	0.04	1.18	1.18	XXX
77333	TC	A	Radiation treatment aid(s)	0.00	NA	1.87	0.09	NA	1.96	XXX
77334		A	Radiation treatment aid(s)	1.24	NA	3.64	0.19	NA	5.07	XXX
77334	26	A	Radiation treatment aid(s)	1.24	0.44	0.44	0.05	1.73	1.73	XXX
77334	TC	A	Radiation treatment aid(s)	0.00	NA	3.20	0.14	NA	3.34	XXX
77336		A	Radiation physics consult	0.00	NA	2.93	0.13	NA	3.06	XXX
77370		A	Radiation physics consult	0.00	NA	3.44	0.15	NA	3.59	XXX
77399		C	External radiation dosimetry	0.00	NA	0.00	0.00	NA	0.00	XXX
77399	26	C	External radiation dosimetry	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77399	TC	C	External radiation dosimetry	0.00	NA	0.00	0.00	NA	0.00	XXX
77401		A	Radiation treatment delivery	0.00	NA	1.74	0.09	NA	1.83	XXX
77402		A	Radiation treatment delivery	0.00	NA	1.74	0.09	NA	1.83	XXX
77403		A	Radiation treatment delivery	0.00	NA	1.74	0.09	NA	1.83	XXX
77404		A	Radiation treatment delivery	0.00	NA	1.74	0.09	NA	1.83	XXX
77406		A	Radiation treatment delivery	0.00	NA	1.74	0.09	NA	1.83	XXX
77407		A	Radiation treatment delivery	0.00	NA	2.06	0.10	NA	2.16	XXX
77408		A	Radiation treatment delivery	0.00	NA	2.06	0.10	NA	2.16	XXX
77409		A	Radiation treatment delivery	0.00	NA	2.06	0.10	NA	2.16	XXX
77411		A	Radiation treatment delivery	0.00	NA	2.06	0.10	NA	2.16	XXX
77412		A	Radiation treatment delivery	0.00	NA	2.29	0.11	NA	2.40	XXX
77413		A	Radiation treatment delivery	0.00	NA	2.29	0.11	NA	2.40	XXX
77414		A	Radiation treatment delivery	0.00	NA	2.29	0.11	NA	2.40	XXX
77416		A	Radiation treatment delivery	0.00	NA	2.29	0.11	NA	2.40	XXX
77417		A	Radiology port film(s)	0.00	NA	0.58	0.03	NA	0.61	XXX
77427		A	Radiation tx management, x5	3.31	1.19	1.19	0.14	4.64	4.64	XXX
77431		A	Radiation therapy management	1.81	0.75	0.75	0.07	2.63	2.63	XXX
77432		A	Stereotactic radiation trmt	7.93	3.26	3.26	0.33	11.52	11.52	XXX
77470		A	Special radiation treatment	2.09	NA	11.73	0.58	NA	14.40	XXX
77470	26	A	Special radiation treatment	2.09	0.75	0.75	0.09	2.93	2.93	XXX
77470	TC	A	Special radiation treatment	0.00	NA	10.98	0.49	NA	11.47	XXX
77499		C	Radiation therapy management	0.00	NA	0.00	0.00	NA	0.00	XXX
77499	26	C	Radiation therapy management	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77499	TC	C	Radiation therapy management	0.00	NA	0.00	0.00	NA	0.00	XXX
77520		C	Proton trmt, simple w/o comp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77522		C	Proton trmt, simple w/comp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77523		C	Proton trmt, intermediate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77525		C	Proton treatment, complex	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77600		R	Hyperthermia treatment	1.56	NA	3.55	0.21	NA	5.32	XXX
77600	26	R	Hyperthermia treatment	1.56	0.55	0.55	0.08	2.19	2.19	XXX
77600	TC	R	Hyperthermia treatment	0.00	NA	3.00	0.13	NA	3.13	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
77605		R	Hyperthermia treatment	2.09	NA	4.75	0.31	NA	7.15	XXX
77605	26	R	Hyperthermia treatment	2.09	0.75	0.75	0.13	2.97	2.97	XXX
77605	TC	R	Hyperthermia treatment	0.00	NA	4.00	0.18	NA	4.18	XXX
77610		R	Hyperthermia treatment	1.56	NA	3.55	0.20	NA	5.31	XXX
77610	26	R	Hyperthermia treatment	1.56	0.55	0.55	0.07	2.18	2.18	XXX
77610	TC	R	Hyperthermia treatment	0.00	NA	3.00	0.13	NA	3.13	XXX
77615		R	Hyperthermia treatment	2.09	NA	4.75	0.27	NA	7.11	XXX
77615	26	R	Hyperthermia treatment	2.09	0.75	0.75	0.09	2.93	2.93	XXX
77615	TC	R	Hyperthermia treatment	0.00	NA	4.00	0.18	NA	4.18	XXX
77620		R	Hyperthermia treatment	1.56	NA	3.57	0.19	NA	5.32	XXX
77620	26	R	Hyperthermia treatment	1.56	0.57	0.57	0.06	2.19	2.19	XXX
77620	TC	R	Hyperthermia treatment	0.00	NA	3.00	0.13	NA	3.13	XXX
77750		A	Infuse radioactive materials	4.91	NA	3.08	0.23	NA	8.22	090
77750	26	A	Infuse radioactive materials	4.91	1.77	1.77	0.17	6.85	6.85	090
77750	TC	A	Infuse radioactive materials	0.00	NA	1.31	0.06	NA	1.37	090
77761		A	Apply intrcav radiat simple	3.81	NA	3.75	0.28	NA	7.84	090
77761	26	A	Apply intrcav radiat simple	3.81	1.28	1.28	0.16	5.25	5.25	090
77761	TC	A	Apply intrcav radiat simple	0.00	NA	2.47	0.12	NA	2.59	090
77762		A	Apply intrcav radiat interm	5.72	NA	5.65	0.38	NA	11.75	090
77762	26	A	Apply intrcav radiat interm	5.72	2.10	2.10	0.22	8.04	8.04	090
77762	TC	A	Apply intrcav radiat interm	0.00	NA	3.55	0.16	NA	3.71	090
77763		A	Apply intrcav radiat compl	8.57	NA	7.52	0.53	NA	16.62	090
77763	26	A	Apply intrcav radiat compl	8.57	3.10	3.10	0.34	12.01	12.01	090
77763	TC	A	Apply intrcav radiat compl	0.00	NA	4.42	0.19	NA	4.61	090
77776		A	Apply interstit radiat simpl	4.66	NA	3.28	0.35	NA	8.29	090
77776	26	A	Apply interstit radiat simpl	4.66	1.14	1.14	0.24	6.04	6.04	090
77776	TC	A	Apply interstit radiat simpl	0.00	NA	2.14	0.11	NA	2.25	090
77777		A	Apply interstit radiat inter	7.48	NA	6.85	0.50	NA	14.83	090
77777	26	A	Apply interstit radiat inter	7.48	2.68	2.68	0.32	10.48	10.48	090
77777	TC	A	Apply interstit radiat inter	0.00	NA	4.17	0.18	NA	4.35	090
77778		A	Apply iterstit radiat compl	11.19	NA	9.03	0.69	NA	20.91	090
77778	26	A	Apply iterstit radiat compl	11.19	3.97	3.97	0.47	15.63	15.63	090
77778	TC	A	Apply iterstit radiat compl	0.00	NA	5.06	0.22	NA	5.28	090
77781		A	High intensity brachytherapy	1.66	NA	20.59	0.95	NA	23.20	090
77781	26	A	High intensity brachytherapy	1.66	0.60	0.60	0.07	2.33	2.33	090
77781	TC	A	High intensity brachytherapy	0.00	NA	19.99	0.88	NA	20.87	090
77782		A	High intensity brachytherapy	2.49	NA	20.89	0.98	NA	24.36	090
77782	26	A	High intensity brachytherapy	2.49	0.90	0.90	0.10	3.49	3.49	090
77782	TC	A	High intensity brachytherapy	0.00	NA	19.99	0.88	NA	20.87	090
77783		A	High intensity brachytherapy	3.73	NA	21.32	1.03	NA	26.08	090
77783	26	A	High intensity brachytherapy	3.73	1.33	1.33	0.15	5.21	5.21	090
77783	TC	A	High intensity brachytherapy	0.00	NA	19.99	0.88	NA	20.87	090
77784		A	High intensity brachytherapy	5.61	NA	22.00	1.10	NA	28.71	090
77784	26	A	High intensity brachytherapy	5.61	2.01	2.01	0.22	7.84	7.84	090
77784	TC	A	High intensity brachytherapy	0.00	NA	19.99	0.88	NA	20.87	090
77789		A	Apply surface radiation	1.12	NA	0.86	0.05	NA	2.03	090
77789	26	A	Apply surface radiation	1.12	0.41	0.41	0.03	1.56	1.56	090
77789	TC	A	Apply surface radiation	0.00	NA	0.45	0.02	NA	0.47	090
77790		A	Radiation handling	1.05	NA	0.88	0.06	NA	1.99	XXX
77790	26	A	Radiation handling	1.05	0.38	0.38	0.04	1.47	1.47	XXX
77790	TC	A	Radiation handling	0.00	NA	0.50	0.02	NA	0.52	XXX
77799		C	Radium/radioisotope therapy	0.00	NA	0.00	0.00	NA	0.00	XXX
77799	26	C	Radium/radioisotope therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77799	TC	C	Radium/radioisotope therapy	0.00	NA	0.00	0.00	NA	0.00	XXX
78000		A	Thyroid, single uptake	0.19	NA	1.02	0.06	NA	1.27	XXX
78000	26	A	Thyroid, single uptake	0.19	0.07	0.07	0.01	0.27	0.27	XXX
78000	TC	A	Thyroid, single uptake	0.00	NA	0.95	0.05	NA	1.00	XXX
78001		A	Thyroid, multiple uptakes	0.26	NA	1.38	0.07	NA	1.71	XXX
78001	26	A	Thyroid, multiple uptakes	0.26	0.09	0.09	0.01	0.36	0.36	XXX
78001	TC	A	Thyroid, multiple uptakes	0.00	NA	1.29	0.06	NA	1.35	XXX
78003		A	Thyroid suppress/stimul	0.33	NA	1.07	0.06	NA	1.46	XXX
78003	26	A	Thyroid suppress/stimul	0.33	0.12	0.12	0.01	0.46	0.46	XXX
78003	TC	A	Thyroid suppress/stimul	0.00	NA	0.95	0.05	NA	1.00	XXX
78006		A	Thyroid imaging with uptake	0.49	NA	2.51	0.13	NA	3.13	XXX
78006	26	A	Thyroid imaging with uptake	0.49	0.17	0.17	0.02	0.68	0.68	XXX
78006	TC	A	Thyroid imaging with uptake	0.00	NA	2.34	0.11	NA	2.45	XXX
78007		A	Thyroid image, mult uptakes	0.50	NA	2.71	0.14	NA	3.35	XXX
78007	26	A	Thyroid image, mult uptakes	0.50	0.18	0.18	0.02	0.70	0.70	XXX
78007	TC	A	Thyroid image, mult uptakes	0.00	NA	2.53	0.12	NA	2.65	XXX
78010		A	Thyroid imaging	0.39	NA	1.93	0.11	NA	2.43	XXX
78010	26	A	Thyroid imaging	0.39	0.14	0.14	0.02	0.55	0.55	XXX
78010	TC	A	Thyroid imaging	0.00	NA	1.79	0.09	NA	1.88	XXX
78011		A	Thyroid imaging with flow	0.45	NA	2.53	0.13	NA	3.11	XXX
78011	26	A	Thyroid imaging with flow	0.45	0.16	0.16	0.02	0.63	0.63	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
78011	TC	A	Thyroid imaging with flow	0.00	NA	2.37	0.11	NA	2.48	XXX
78015		A	Thyroid met imaging	0.67	NA	2.77	0.15	NA	3.59	XXX
78015	26	A	Thyroid met imaging	0.67	0.24	0.24	0.03	0.94	0.94	XXX
78015	TC	A	Thyroid met imaging	0.00	NA	2.53	0.12	NA	2.65	XXX
78016		A	Thyroid met imaging/studies	0.82	NA	3.73	0.18	NA	4.73	XXX
78016	26	A	Thyroid met imaging/studies	0.82	0.30	0.30	0.03	1.15	1.15	XXX
78016	TC	A	Thyroid met imaging/studies	0.00	NA	3.43	0.15	NA	3.58	XXX
78018		A	Thyroid met imaging, body	0.86	NA	5.66	0.27	NA	6.79	XXX
78018	26	A	Thyroid met imaging, body	0.86	0.32	0.32	0.03	1.21	1.21	XXX
78018	TC	A	Thyroid met imaging, body	0.00	NA	5.34	0.24	NA	5.58	XXX
78020		A	Thyroid met uptake	0.60	NA	1.52	0.14	NA	2.26	ZZZ
78020	26	A	Thyroid met uptake	0.60	0.23	0.23	0.02	0.85	0.85	ZZZ
78020	TC	A	Thyroid met uptake	0.00	NA	1.29	0.12	NA	1.41	ZZZ
78070		A	Parathyroid nuclear imaging	0.82	NA	2.09	0.12	NA	3.03	XXX
78070	26	A	Parathyroid nuclear imaging	0.82	0.30	0.30	0.03	1.15	1.15	XXX
78070	TC	A	Parathyroid nuclear imaging	0.00	NA	1.79	0.09	NA	1.88	XXX
78075		A	Adrenal nuclear imaging	0.74	NA	5.62	0.27	NA	6.63	XXX
78075	26	A	Adrenal nuclear imaging	0.74	0.28	0.28	0.03	1.05	1.05	XXX
78075	TC	A	Adrenal nuclear imaging	0.00	NA	5.34	0.24	NA	5.58	XXX
78099		C	Endocrine nuclear procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
78099	26	C	Endocrine nuclear procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78099	TC	C	Endocrine nuclear procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
78102		A	Bone marrow imaging, ltd	0.55	NA	2.22	0.12	NA	2.89	XXX
78102	26	A	Bone marrow imaging, ltd	0.55	0.21	0.21	0.02	0.78	0.78	XXX
78102	TC	A	Bone marrow imaging, ltd	0.00	NA	2.01	0.10	NA	2.11	XXX
78103		A	Bone marrow imaging, mult	0.75	NA	3.40	0.17	NA	4.32	XXX
78103	26	A	Bone marrow imaging, mult	0.75	0.28	0.28	0.03	1.06	1.06	XXX
78103	TC	A	Bone marrow imaging, mult	0.00	NA	3.12	0.14	NA	3.26	XXX
78104		A	Bone marrow imaging, body	0.80	NA	4.30	0.21	NA	5.31	XXX
78104	26	A	Bone marrow imaging, body	0.80	0.29	0.29	0.03	1.12	1.12	XXX
78104	TC	A	Bone marrow imaging, body	0.00	NA	4.01	0.18	NA	4.19	XXX
78110		A	Plasma volume, single	0.19	NA	1.00	0.06	NA	1.25	XXX
78110	26	A	Plasma volume, single	0.19	0.07	0.07	0.01	0.27	0.27	XXX
78110	TC	A	Plasma volume, single	0.00	NA	0.93	0.05	NA	0.98	XXX
78111		A	Plasma volume, multiple	0.22	NA	2.61	0.13	NA	2.96	XXX
78111	26	A	Plasma volume, multiple	0.22	0.08	0.08	0.01	0.31	0.31	XXX
78111	TC	A	Plasma volume, multiple	0.00	NA	2.53	0.12	NA	2.65	XXX
78120		A	Red cell mass, single	0.23	NA	1.79	0.10	NA	2.12	XXX
78120	26	A	Red cell mass, single	0.23	0.09	0.09	0.01	0.33	0.33	XXX
78120	TC	A	Red cell mass, single	0.00	NA	1.70	0.09	NA	1.79	XXX
78121		A	Red cell mass, multiple	0.32	NA	2.99	0.13	NA	3.44	XXX
78121	26	A	Red cell mass, multiple	0.32	0.12	0.12	0.01	0.45	0.45	XXX
78121	TC	A	Red cell mass, multiple	0.00	NA	2.87	0.12	NA	2.99	XXX
78122		A	Blood volume	0.45	NA	4.70	0.22	NA	5.37	XXX
78122	26	A	Blood volume	0.45	0.17	0.17	0.02	0.64	0.64	XXX
78122	TC	A	Blood volume	0.00	NA	4.53	0.20	NA	4.73	XXX
78130		A	Red cell survival study	0.61	NA	3.04	0.15	NA	3.80	XXX
78130	26	A	Red cell survival study	0.61	0.23	0.23	0.03	0.87	0.87	XXX
78130	TC	A	Red cell survival study	0.00	NA	2.81	0.12	NA	2.93	XXX
78135		A	Red cell survival kinetics	0.64	NA	5.03	0.24	NA	5.91	XXX
78135	26	A	Red cell survival kinetics	0.64	0.23	0.23	0.03	0.90	0.90	XXX
78135	TC	A	Red cell survival kinetics	0.00	NA	4.80	0.21	NA	5.01	XXX
78140		A	Red cell sequestration	0.61	NA	4.09	0.20	NA	4.90	XXX
78140	26	A	Red cell sequestration	0.61	0.21	0.21	0.03	0.85	0.85	XXX
78140	TC	A	Red cell sequestration	0.00	NA	3.88	0.17	NA	4.05	XXX
78160		A	Plasma iron turnover	0.33	NA	3.75	0.19	NA	4.27	XXX
78160	26	A	Plasma iron turnover	0.33	0.14	0.14	0.03	0.50	0.50	XXX
78160	TC	A	Plasma iron turnover	0.00	NA	3.61	0.16	NA	3.77	XXX
78162		A	Iron absorption exam	0.45	NA	3.33	0.15	NA	3.93	XXX
78162	26	A	Iron absorption exam	0.45	0.18	0.18	0.01	0.64	0.64	XXX
78162	TC	A	Iron absorption exam	0.00	NA	3.15	0.14	NA	3.29	XXX
78170		A	Red cell iron utilization	0.41	NA	5.37	0.27	NA	6.05	XXX
78170	26	A	Red cell iron utilization	0.41	0.14	0.14	0.04	0.59	0.59	XXX
78170	TC	A	Red cell iron utilization	0.00	NA	5.23	0.23	NA	5.46	XXX
78172		C	Total body iron estimation	0.00	NA	0.00	0.00	NA	0.00	XXX
78172	26	A	Total body iron estimation	0.53	0.19	0.19	0.02	0.74	0.74	XXX
78172	TC	C	Total body iron estimation	0.00	NA	0.00	0.00	NA	0.00	XXX
78185		A	Spleen imaging	0.40	NA	2.46	0.13	NA	2.99	XXX
78185	26	A	Spleen imaging	0.40	0.14	0.14	0.02	0.56	0.56	XXX
78185	TC	A	Spleen imaging	0.00	NA	2.32	0.11	NA	2.43	XXX
78190		A	Platelet survival, kinetics	1.09	NA	6.02	0.31	NA	7.42	XXX
78190	26	A	Platelet survival, kinetics	1.09	0.39	0.39	0.06	1.54	1.54	XXX
78190	TC	A	Platelet survival, kinetics	0.00	NA	5.63	0.25	NA	5.88	XXX
78191		A	Platelet survival	0.61	NA	7.45	0.34	NA	8.40	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
78191	26	A	Platelet survival	0.61	0.22	0.22	0.03	0.86	0.86	XXX
78191	TC	A	Platelet survival	0.00	NA	7.23	0.31	NA	7.54	XXX
78195		A	Lymph system imaging	1.20	NA	4.45	0.23	NA	5.88	XXX
78195	26	A	Lymph system imaging	1.20	0.44	0.44	0.05	1.69	1.69	XXX
78195	TC	A	Lymph system imaging	0.00	NA	4.01	0.18	NA	4.19	XXX
78199		C	Blood/lymph nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78199	26	C	Blood/lymph nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78199	TC	C	Blood/lymph nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78201		A	Liver imaging	0.44	NA	2.48	0.13	NA	3.05	XXX
78201	26	A	Liver imaging	0.44	0.16	0.16	0.02	0.62	0.62	XXX
78201	TC	A	Liver imaging	0.00	NA	2.32	0.11	NA	2.43	XXX
78202		A	Liver imaging with flow	0.51	NA	3.03	0.14	NA	3.68	XXX
78202	26	A	Liver imaging with flow	0.51	0.19	0.19	0.02	0.72	0.72	XXX
78202	TC	A	Liver imaging with flow	0.00	NA	2.84	0.12	NA	2.96	XXX
78205		A	Liver imaging (3D)	0.71	NA	6.08	0.29	NA	7.08	XXX
78205	26	A	Liver imaging (3D)	0.71	0.26	0.26	0.03	1.00	1.00	XXX
78205	TC	A	Liver imaging (3D)	0.00	NA	5.82	0.26	NA	6.08	XXX
78206		A	Liver image (3d) w/flow	0.96	NA	6.17	0.13	NA	7.26	XXX
78206	26	A	Liver image (3d) w/flow	0.96	0.35	0.35	0.04	1.35	1.35	XXX
78206	TC	A	Liver image (3d) w/flow	0.00	NA	5.82	0.09	NA	5.91	XXX
78215		A	Liver and spleen imaging	0.49	NA	3.06	0.14	NA	3.69	XXX
78215	26	A	Liver and spleen imaging	0.49	0.17	0.17	0.02	0.68	0.68	XXX
78215	TC	A	Liver and spleen imaging	0.00	NA	2.89	0.12	NA	3.01	XXX
78216		A	Liver & spleen image/flow	0.57	NA	3.63	0.17	NA	4.37	XXX
78216	26	A	Liver & spleen image/flow	0.57	0.20	0.20	0.02	0.79	0.79	XXX
78216	TC	A	Liver & spleen image/flow	0.00	NA	3.43	0.15	NA	3.58	XXX
78220		A	Liver function study	0.49	NA	3.84	0.18	NA	4.51	XXX
78220	26	A	Liver function study	0.49	0.17	0.17	0.02	0.68	0.68	XXX
78220	TC	A	Liver function study	0.00	NA	3.67	0.16	NA	3.83	XXX
78223		A	Hepatobiliary imaging	0.84	NA	3.91	0.20	NA	4.95	XXX
78223	26	A	Hepatobiliary imaging	0.84	0.30	0.30	0.04	1.18	1.18	XXX
78223	TC	A	Hepatobiliary imaging	0.00	NA	3.61	0.16	NA	3.77	XXX
78230		A	Salivary gland imaging	0.45	NA	2.30	0.13	NA	2.88	XXX
78230	26	A	Salivary gland imaging	0.45	0.16	0.16	0.02	0.63	0.63	XXX
78230	TC	A	Salivary gland imaging	0.00	NA	2.14	0.11	NA	2.25	XXX
78231		A	Serial salivary imaging	0.52	NA	3.32	0.16	NA	4.00	XXX
78231	26	A	Serial salivary imaging	0.52	0.20	0.20	0.02	0.74	0.74	XXX
78231	TC	A	Serial salivary imaging	0.00	NA	3.12	0.14	NA	3.26	XXX
78232		A	Salivary gland function exam	0.47	NA	3.66	0.16	NA	4.29	XXX
78232	26	A	Salivary gland function exam	0.47	0.18	0.18	0.01	0.66	0.66	XXX
78232	TC	A	Salivary gland function exam	0.00	NA	3.48	0.15	NA	3.63	XXX
78258		A	Esophageal motility study	0.74	NA	3.10	0.15	NA	3.99	XXX
78258	26	A	Esophageal motility study	0.74	0.26	0.26	0.03	1.03	1.03	XXX
78258	TC	A	Esophageal motility study	0.00	NA	2.84	0.12	NA	2.96	XXX
78261		A	Gastric mucosa imaging	0.69	NA	4.30	0.21	NA	5.20	XXX
78261	26	A	Gastric mucosa imaging	0.69	0.26	0.26	0.03	0.98	0.98	XXX
78261	TC	A	Gastric mucosa imaging	0.00	NA	4.04	0.18	NA	4.22	XXX
78262		A	Gastroesophageal reflux exam	0.68	NA	4.44	0.21	NA	5.33	XXX
78262	26	A	Gastroesophageal reflux exam	0.68	0.25	0.25	0.03	0.96	0.96	XXX
78262	TC	A	Gastroesophageal reflux exam	0.00	NA	4.19	0.18	NA	4.37	XXX
78264		A	Gastric emptying study	0.78	NA	4.35	0.21	NA	5.34	XXX
78264	26	A	Gastric emptying study	0.78	0.28	0.28	0.03	1.09	1.09	XXX
78264	TC	A	Gastric emptying study	0.00	NA	4.07	0.18	NA	4.25	XXX
78267		X	Breath tst attain/anal c–14	0.00	NA	0.00	0.00	NA	0.00	XXX
78268		X	Breath test analysis, c–14	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78270		A	Vit B–12 absorption exam	0.20	NA	1.59	0.09	NA	1.88	XXX
78270	26	A	Vit B–12 absorption exam	0.20	0.07	0.07	0.01	0.28	0.28	XXX
78270	TC	A	Vit B–12 absorption exam	0.00	NA	1.52	0.08	NA	1.60	XXX
78271		A	Vit B–12 absorp exam, IF	0.20	NA	1.69	0.09	NA	1.98	XXX
78271	26	A	Vit B–12 absorp exam, IF	0.20	0.07	0.07	0.01	0.28	0.28	XXX
78271	TC	A	Vit B–12 absorp exam, IF	0.00	NA	1.62	0.08	NA	1.70	XXX
78272		A	Vit B–12 absorp, combined	0.27	NA	2.39	0.12	NA	2.78	XXX
78272	26	A	Vit B–12 absorp, combined	0.27	0.10	0.10	0.01	0.38	0.38	XXX
78272	TC	A	Vit B–12 absorp, combined	0.00	NA	2.29	0.11	NA	2.40	XXX
78278		A	Acute GI blood loss imaging	0.99	NA	5.15	0.25	NA	6.39	XXX
78278	26	A	Acute GI blood loss imaging	0.99	0.35	0.35	0.04	1.38	1.38	XXX
78278	TC	A	Acute GI blood loss imaging	0.00	NA	4.80	0.21	NA	5.01	XXX
78282		C	GI protein loss exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78282	26	A	GI protein loss exam	0.38	0.14	0.14	0.02	0.54	0.54	XXX
78282	TC	C	GI protein loss exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78290		A	Meckel's divert exam	0.68	NA	3.24	0.16	NA	4.08	XXX
78290	26	A	Meckel's divert exam	0.68	0.24	0.24	0.03	0.95	0.95	XXX
78290	TC	A	Meckel's divert exam	0.00	NA	3.00	0.13	NA	3.13	XXX
78291		A	Leveen/shunt patency exam	0.88	NA	3.34	0.17	NA	4.39	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
78291	26	A	Leveen/shunt patency exam	0.88	0.32	0.32	0.04	1.24	1.24	XXX
78291	TC	A	Leveen/shunt patency exam	0.00	NA	3.02	0.13	NA	3.15	XXX
78299		C	GI nuclear procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
78299	26	C	GI nuclear procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78299	TC	C	GI nuclear procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
78300		A	Bone imaging, limited area	0.62	NA	2.67	0.15	NA	3.44	XXX
78300	26	A	Bone imaging, limited area	0.62	0.22	0.22	0.03	0.87	0.87	XXX
78300	TC	A	Bone imaging, limited area	0.00	NA	2.45	0.12	NA	2.57	XXX
78305		A	Bone imaging, multiple areas	0.83	NA	3.90	0.19	NA	4.92	XXX
78305	26	A	Bone imaging, multiple areas	0.83	0.29	0.29	0.03	1.15	1.15	XXX
78305	TC	A	Bone imaging, multiple areas	0.00	NA	3.61	0.16	NA	3.77	XXX
78306		A	Bone imaging, whole body	0.86	NA	4.52	0.22	NA	5.60	XXX
78306	26	A	Bone imaging, whole body	0.86	0.31	0.31	0.04	1.21	1.21	XXX
78306	TC	A	Bone imaging, whole body	0.00	NA	4.21	0.18	NA	4.39	XXX
78315		A	Bone imaging, 3 phase	1.02	NA	5.07	0.25	NA	6.34	XXX
78315	26	A	Bone imaging, 3 phase	1.02	0.37	0.37	0.04	1.43	1.43	XXX
78315	TC	A	Bone imaging, 3 phase	0.00	NA	4.70	0.21	NA	4.91	XXX
78320		A	Bone imaging (3D)	1.04	NA	6.20	0.30	NA	7.54	XXX
78320	26	A	Bone imaging (3D)	1.04	0.38	0.38	0.04	1.46	1.46	XXX
78320	TC	A	Bone imaging (3D)	0.00	NA	5.82	0.26	NA	6.08	XXX
78350		A	Bone mineral, single photon	0.22	NA	0.82	0.05	NA	1.09	XXX
78350	26	A	Bone mineral, single photon	0.22	0.08	0.08	0.01	0.31	0.31	XXX
78350	TC	A	Bone mineral, single photon	0.00	NA	0.74	0.04	NA	0.78	XXX
78351		N	Bone mineral, dual photon	+0.30	0.12	1.60	0.01	0.43	1.91	XXX
78399		C	Musculoskeletal nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78399	26	C	Musculoskeletal nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78399	TC	C	Musculoskeletal nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78414		C	Non-imaging heart function	0.00	NA	0.00	0.00	NA	0.00	XXX
78414	26	A	Non-imaging heart function	0.45	0.16	0.16	0.02	0.63	0.63	XXX
78414	TC	C	Non-imaging heart function	0.00	NA	0.00	0.00	NA	0.00	XXX
78428		A	Cardiac shunt imaging	0.78	NA	2.53	0.14	NA	3.45	XXX
78428	26	A	Cardiac shunt imaging	0.78	0.31	0.31	0.03	1.12	1.12	XXX
78428	TC	A	Cardiac shunt imaging	0.00	NA	2.22	0.11	NA	2.33	XXX
78445		A	Vascular flow imaging	0.49	NA	2.01	0.11	NA	2.61	XXX
78445	26	A	Vascular flow imaging	0.49	0.18	0.18	0.02	0.69	0.69	XXX
78445	TC	A	Vascular flow imaging	0.00	NA	1.83	0.09	NA	1.92	XXX
78455		A	Venous thrombosis study	0.73	NA	4.18	0.20	NA	5.11	XXX
78455	26	A	Venous thrombosis study	0.73	0.26	0.26	0.03	1.02	1.02	XXX
78455	TC	A	Venous thrombosis study	0.00	NA	3.92	0.17	NA	4.09	XXX
78456		A	Acute venous thrombus image	1.00	NA	4.29	0.28	NA	5.57	XXX
78456	26	A	Acute venous thrombus image	1.00	0.37	0.37	0.04	1.41	1.41	XXX
78456	TC	A	Acute venous thrombus image	0.00	NA	3.92	0.24	NA	4.16	XXX
78457		A	Venous thrombosis imaging	0.77	NA	2.90	0.15	NA	3.82	XXX
78457	26	A	Venous thrombosis imaging	0.77	0.28	0.28	0.03	1.08	1.08	XXX
78457	TC	A	Venous thrombosis imaging	0.00	NA	2.62	0.12	NA	2.74	XXX
78458		A	Ven thrombosis images, bilat	0.90	NA	4.30	0.20	NA	5.40	XXX
78458	26	A	Ven thrombosis images, bilat	0.90	0.34	0.34	0.03	1.27	1.27	XXX
78458	TC	A	Ven thrombosis images, bilat	0.00	NA	3.96	0.17	NA	4.13	XXX
78459		I	Heart muscle imaging (PET)	0.00	0.74	0.74	0.00	0.74	0.74	XXX
78459	26	I	Heart muscle imaging (PET)	1.88	0.74	0.74	0.08	2.70	2.70	XXX
78459	TC	I	Heart muscle imaging (PET)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78460		A	Heart muscle blood, single	0.86	NA	2.63	0.14	NA	3.63	XXX
78460	26	A	Heart muscle blood, single	0.86	0.31	0.31	0.03	1.20	1.20	XXX
78460	TC	A	Heart muscle blood, single	0.00	NA	2.32	0.11	NA	2.43	XXX
78461		A	Heart muscle blood, multiple	1.23	NA	5.11	0.26	NA	6.60	XXX
78461	26	A	Heart muscle blood, multiple	1.23	0.46	0.46	0.05	1.74	1.74	XXX
78461	TC	A	Heart muscle blood, multiple	0.00	NA	4.65	0.21	NA	4.86	XXX
78464		A	Heart image (3d), single	1.09	NA	7.36	0.35	NA	8.80	XXX
78464	26	A	Heart image (3d), single	1.09	0.40	0.40	0.04	1.53	1.53	XXX
78464	TC	A	Heart image (3d), single	0.00	NA	6.96	0.31	NA	7.27	XXX
78465		A	Heart image (3d), multiple	1.46	NA	12.17	0.56	NA	14.19	XXX
78465	26	A	Heart image (3d), multiple	1.46	0.55	0.55	0.05	2.06	2.06	XXX
78465	TC	A	Heart image (3d), multiple	0.00	NA	11.62	0.51	NA	12.13	XXX
78466		A	Heart infarct image	0.69	NA	2.84	0.15	NA	3.68	XXX
78466	26	A	Heart infarct image	0.69	0.26	0.26	0.03	0.98	0.98	XXX
78466	TC	A	Heart infarct image	0.00	NA	2.58	0.12	NA	2.70	XXX
78468		A	Heart infarct image (ef)	0.80	NA	3.90	0.19	NA	4.89	XXX
78468	26	A	Heart infarct image (ef)	0.80	0.29	0.29	0.03	1.12	1.12	XXX
78468	TC	A	Heart infarct image (ef)	0.00	NA	3.61	0.16	NA	3.77	XXX
78469		A	Heart infarct image (3D)	0.92	NA	5.47	0.26	NA	6.65	XXX
78469	26	A	Heart infarct image (3D)	0.92	0.33	0.33	0.03	1.28	1.28	XXX
78469	TC	A	Heart infarct image (3D)	0.00	NA	5.14	0.23	NA	5.37	XXX
78472		A	Gated heart, planar, single	0.98	NA	5.79	0.29	NA	7.06	XXX
78472	26	A	Gated heart, planar, single	0.98	0.36	0.36	0.04	1.38	1.38	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
78472	TC	A	Gated heart, planar, single	0.00	NA	5.43	0.25	NA	5.68	XXX
78473		A	Gated heart, multiple	1.47	NA	8.67	0.40	NA	10.54	XXX
78473	26	A	Gated heart, multiple	1.47	0.54	0.54	0.05	2.06	2.06	XXX
78473	TC	A	Gated heart, multiple	0.00	NA	8.13	0.35	NA	8.48	XXX
78478		A	Heart wall motion add-on	0.62	NA	1.77	0.10	NA	2.49	ZZZ
78478	26	A	Heart wall motion add-on	0.62	0.24	0.24	0.02	0.88	0.88	ZZZ
78478	TC	A	Heart wall motion add-on	0.00	NA	1.53	0.08	NA	1.61	ZZZ
78480		A	Heart function add-on	0.62	NA	1.77	0.10	NA	2.49	ZZZ
78480	26	A	Heart function add-on	0.62	0.24	0.24	0.02	0.88	0.88	ZZZ
78480	TC	A	Heart function add-on	0.00	NA	1.53	0.08	NA	1.61	ZZZ
78481		A	Heart first pass, single	0.98	NA	5.52	0.26	NA	6.76	XXX
78481	26	A	Heart first pass, single	0.98	0.38	0.38	0.03	1.39	1.39	XXX
78481	TC	A	Heart first pass, single	0.00	NA	5.14	0.23	NA	5.37	XXX
78483		A	Heart first pass, multiple	1.47	NA	8.32	0.39	NA	10.18	XXX
78483	26	A	Heart first pass, multiple	1.47	0.57	0.57	0.05	2.09	2.09	XXX
78483	TC	A	Heart first pass, multiple	0.00	NA	7.75	0.34	NA	8.09	XXX
78491		I	Heart image (pet), single	0.00	NA	0.59	0.00	NA	0.59	XXX
78491	26	I	Heart image (pet), single	1.50	0.59	0.59	0.05	2.14	2.14	XXX
78491	TC	I	Heart image (pet), single	0.00	NA	0.00	0.00	NA	0.00	XXX
78492		I	Heart image (pet), multiple	+0.00	NA	0.74	0.00	NA	0.74	XXX
78492	26	I	Heart image (pet), multiple	+1.87	0.74	0.74	0.06	2.67	2.67	XXX
78492	TC	I	Heart image (pet), multiple	0.00	NA	0.00	0.00	NA	0.00	XXX
78494		A	Heart image, spect	1.19	NA	7.40	0.29	NA	8.88	XXX
78494	26	A	Heart image, spect	1.19	0.44	0.44	0.04	1.67	1.67	XXX
78494	TC	A	Heart image, spect	0.00	NA	6.96	0.25	NA	7.21	XXX
78496		A	Heart first pass add-on	0.50	NA	7.15	0.27	NA	7.92	ZZZ
78496	26	A	Heart first pass add-on	0.50	0.19	0.19	0.02	0.71	0.71	ZZZ
78496	TC	A	Heart first pass add-on	0.00	NA	6.96	0.25	NA	7.21	ZZZ
78499		C	Cardiovascular nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78499	26	C	Cardiovascular nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78499	TC	C	Cardiovascular nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78580		A	Lung perfusion imaging	0.74	NA	3.65	0.18	NA	4.57	XXX
78580	26	A	Lung perfusion imaging	0.74	0.27	0.27	0.03	1.04	1.04	XXX
78580	TC	A	Lung perfusion imaging	0.00	NA	3.38	0.15	NA	3.53	XXX
78584		A	Lung V/Q image single breath	0.99	NA	3.50	0.18	NA	4.67	XXX
78584	26	A	Lung V/Q image single breath	0.99	0.35	0.35	0.04	1.38	1.38	XXX
78584	TC	A	Lung V/Q image single breath	0.00	NA	3.15	0.14	NA	3.29	XXX
78585		A	Lung V/Q imaging	1.09	NA	5.94	0.30	NA	7.33	XXX
78585	26	A	Lung V/Q imaging	1.09	0.39	0.39	0.05	1.53	1.53	XXX
78585	TC	A	Lung V/Q imaging	0.00	NA	5.55	0.25	NA	5.80	XXX
78586		A	Aerosol lung image, single	0.40	NA	2.69	0.14	NA	3.23	XXX
78586	26	A	Aerosol lung image, single	0.40	0.14	0.14	0.02	0.56	0.56	XXX
78586	TC	A	Aerosol lung image, single	0.00	NA	2.55	0.12	NA	2.67	XXX
78587		A	Aerosol lung image, multiple	0.49	NA	2.94	0.14	NA	3.57	XXX
78587	26	A	Aerosol lung image, multiple	0.49	0.18	0.18	0.02	0.69	0.69	XXX
78587	TC	A	Aerosol lung image, multiple	0.00	NA	2.76	0.12	NA	2.88	XXX
78588		A	Perfusion lung image	1.09	NA	3.54	0.20	NA	4.83	XXX
78588	26	A	Perfusion lung image	1.09	0.39	0.39	0.05	1.53	1.53	XXX
78588	TC	A	Perfusion lung image	0.00	NA	3.15	0.15	NA	3.30	XXX
78591		A	Vent image, 1 breath, 1 proj	0.40	NA	2.95	0.14	NA	3.49	XXX
78591	26	A	Vent image, 1 breath, 1 proj	0.40	0.14	0.14	0.02	0.56	0.56	XXX
78591	TC	A	Vent image, 1 breath, 1 proj	0.00	NA	2.81	0.12	NA	2.93	XXX
78593		A	Vent image, 1 proj, gas	0.49	NA	3.57	0.17	NA	4.23	XXX
78593	26	A	Vent image, 1 proj, gas	0.49	0.17	0.17	0.02	0.68	0.68	XXX
78593	TC	A	Vent image, 1 proj, gas	0.00	NA	3.40	0.15	NA	3.55	XXX
78594		A	Vent image, mult proj, gas	0.53	NA	5.09	0.23	NA	5.85	XXX
78594	26	A	Vent image, mult proj, gas	0.53	0.19	0.19	0.02	0.74	0.74	XXX
78594	TC	A	Vent image, mult proj, gas	0.00	NA	4.90	0.21	NA	5.11	XXX
78596		A	Lung differential function	1.27	NA	7.41	0.36	NA	9.04	XXX
78596	26	A	Lung differential function	1.27	0.45	0.45	0.05	1.77	1.77	XXX
78596	TC	A	Lung differential function	0.00	NA	6.96	0.31	NA	7.27	XXX
78599		C	Respiratory nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78599	26	C	Respiratory nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78599	TC	C	Respiratory nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78600		A	Brain imaging, ltd static	0.44	NA	3.05	0.14	NA	3.63	XXX
78600	26	A	Brain imaging, ltd static	0.44	0.16	0.16	0.02	0.62	0.62	XXX
78600	TC	A	Brain imaging, ltd static	0.00	NA	2.89	0.12	NA	3.01	XXX
78601		A	Brain imaging, ltd w/ flow	0.51	NA	3.53	0.17	NA	4.21	XXX
78601	26	A	Brain imaging, ltd w/ flow	0.51	0.18	0.18	0.02	0.71	0.71	XXX
78601	TC	A	Brain imaging, ltd w/ flow	0.00	NA	3.35	0.15	NA	3.50	XXX
78605		A	Brain imaging, complete	0.53	NA	3.55	0.17	NA	4.25	XXX
78605	26	A	Brain imaging, complete	0.53	0.20	0.20	0.02	0.75	0.75	XXX
78605	TC	A	Brain imaging, complete	0.00	NA	3.35	0.15	NA	3.50	XXX
78606		A	Brain imaging, compl w/flow	0.64	NA	4.04	0.20	NA	4.88	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
78606	26	A	Brain imaging, compl w/flow	0.64	0.23	0.23	0.03	0.90	0.90	XXX
78606	TC	A	Brain imaging, compl w/flow	0.00	NA	3.81	0.17	NA	3.98	XXX
78607		A	Brain imaging (3D)	1.23	NA	6.92	0.34	NA	8.49	XXX
78607	26	A	Brain imaging (3D)	1.23	0.46	0.46	0.05	1.74	1.74	XXX
78607	TC	A	Brain imaging (3D)	0.00	NA	6.46	0.29	NA	6.75	XXX
78608		N	Brain imaging (PET)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78609		N	Brain imaging (PET)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78610		A	Brain flow imaging only	0.30	NA	1.66	0.09	NA	2.05	XXX
78610	26	A	Brain flow imaging only	0.30	0.11	0.11	0.01	0.42	0.42	XXX
78610	TC	A	Brain flow imaging only	0.00	NA	1.55	0.08	NA	1.63	XXX
78615		A	Cerebral blood flow imaging	0.42	NA	3.95	0.19	NA	4.56	XXX
78615	26	A	Cerebral blood flow imaging	0.42	0.16	0.16	0.02	0.60	0.60	XXX
78615	TC	A	Cerebral blood flow imaging	0.00	NA	3.79	0.17	NA	3.96	XXX
78630		A	Cerebrospinal fluid scan	0.68	NA	5.20	0.25	NA	6.13	XXX
78630	26	A	Cerebrospinal fluid scan	0.68	0.24	0.24	0.03	0.95	0.95	XXX
78630	TC	A	Cerebrospinal fluid scan	0.00	NA	4.96	0.22	NA	5.18	XXX
78635		A	CSF ventriculography	0.61	NA	2.74	0.14	NA	3.49	XXX
78635	26	A	CSF ventriculography	0.61	0.24	0.24	0.02	0.87	0.87	XXX
78635	TC	A	CSF ventriculography	0.00	NA	2.50	0.12	NA	2.62	XXX
78645		A	CSF shunt evaluation	0.57	NA	3.59	0.17	NA	4.33	XXX
78645	26	A	CSF shunt evaluation	0.57	0.21	0.21	0.02	0.80	0.80	XXX
78645	TC	A	CSF shunt evaluation	0.00	NA	3.38	0.15	NA	3.53	XXX
78647		A	Cerebrospinal fluid scan	0.90	NA	6.16	0.29	NA	7.35	XXX
78647	26	A	Cerebrospinal fluid scan	0.90	0.34	0.34	0.03	1.27	1.27	XXX
78647	TC	A	Cerebrospinal fluid scan	0.00	NA	5.82	0.26	NA	6.08	XXX
78650		A	CSF leakage imaging	0.61	NA	4.79	0.22	NA	5.62	XXX
78650	26	A	CSF leakage imaging	0.61	0.22	0.22	0.02	0.85	0.85	XXX
78650	TC	A	CSF leakage imaging	0.00	NA	4.57	0.20	NA	4.77	XXX
78660		A	Nuclear exam of tear flow	0.53	NA	2.28	0.12	NA	2.93	XXX
78660	26	A	Nuclear exam of tear flow	0.53	0.19	0.19	0.02	0.74	0.74	XXX
78660	TC	A	Nuclear exam of tear flow	0.00	NA	2.09	0.10	NA	2.19	XXX
78699		C	Nervous system nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78699	26	C	Nervous system nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78699	TC	C	Nervous system nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78700		A	Kidney imaging, static	0.45	NA	3.16	0.15	NA	3.76	XXX
78700	26	A	Kidney imaging, static	0.45	0.16	0.16	0.02	0.63	0.63	XXX
78700	TC	A	Kidney imaging, static	0.00	NA	3.00	0.13	NA	3.13	XXX
78701		A	Kidney imaging with flow	0.49	NA	3.67	0.17	NA	4.33	XXX
78701	26	A	Kidney imaging with flow	0.49	0.17	0.17	0.02	0.68	0.68	XXX
78701	TC	A	Kidney imaging with flow	0.00	NA	3.50	0.15	NA	3.65	XXX
78704		A	Imaging renogram	0.74	NA	4.15	0.20	NA	5.09	XXX
78704	26	A	Imaging renogram	0.74	0.26	0.26	0.03	1.03	1.03	XXX
78704	TC	A	Imaging renogram	0.00	NA	3.89	0.17	NA	4.06	XXX
78707		A	Kidney flow/function image	0.96	NA	4.75	0.23	NA	5.94	XXX
78707	26	A	Kidney flow/function image	0.96	0.35	0.35	0.04	1.35	1.35	XXX
78707	TC	A	Kidney flow/function image	0.00	NA	4.40	0.19	NA	4.59	XXX
78708		A	Kidney flow/function image	1.21	NA	4.84	0.24	NA	6.29	XXX
78708	26	A	Kidney flow/function image	1.21	0.44	0.44	0.05	1.70	1.70	XXX
78708	TC	A	Kidney flow/function image	0.00	NA	4.40	0.19	NA	4.59	XXX
78709		A	Kidney flow/function image	1.41	NA	4.90	0.25	NA	6.56	XXX
78709	26	A	Kidney flow/function image	1.41	0.50	0.50	0.06	1.97	1.97	XXX
78709	TC	A	Kidney flow/function image	0.00	NA	4.40	0.19	NA	4.59	XXX
78710		A	Kidney imaging (3D)	0.66	NA	6.05	0.29	NA	7.00	XXX
78710	26	A	Kidney imaging (3D)	0.66	0.23	0.23	0.03	0.92	0.92	XXX
78710	TC	A	Kidney imaging (3D)	0.00	NA	5.82	0.26	NA	6.08	XXX
78715		A	Renal vascular flow exam	0.30	NA	1.66	0.09	NA	2.05	XXX
78715	26	A	Renal vascular flow exam	0.30	0.11	0.11	0.01	0.42	0.42	XXX
78715	TC	A	Renal vascular flow exam	0.00	NA	1.55	0.08	NA	1.63	XXX
78725		A	Kidney function study	0.38	NA	1.89	0.10	NA	2.37	XXX
78725	26	A	Kidney function study	0.38	0.14	0.14	0.01	0.53	0.53	XXX
78725	TC	A	Kidney function study	0.00	NA	1.75	0.09	NA	1.84	XXX
78730		A	Urinary bladder retention	0.36	NA	1.57	0.09	NA	2.02	XXX
78730	26	A	Urinary bladder retention	0.36	0.13	0.13	0.02	0.51	0.51	XXX
78730	TC	A	Urinary bladder retention	0.00	NA	1.44	0.07	NA	1.51	XXX
78740		A	Ureteral reflux study	0.57	NA	2.29	0.12	NA	2.98	XXX
78740	26	A	Ureteral reflux study	0.57	0.20	0.20	0.02	0.79	0.79	XXX
78740	TC	A	Ureteral reflux study	0.00	NA	2.09	0.10	NA	2.19	XXX
78760		A	Testicular imaging	0.66	NA	2.87	0.15	NA	3.68	XXX
78760	26	A	Testicular imaging	0.66	0.23	0.23	0.03	0.92	0.92	XXX
78760	TC	A	Testicular imaging	0.00	NA	2.64	0.12	NA	2.76	XXX
78761		A	Testicular imaging/flow	0.71	NA	3.40	0.17	NA	4.28	XXX
78761	26	A	Testicular imaging/flow	0.71	0.25	0.25	0.03	0.99	0.99	XXX
78761	TC	A	Testicular imaging/flow	0.00	NA	3.15	0.14	NA	3.29	XXX
78799		C	Genitourinary nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
78799	26	C	Genitourinary nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78799	TC	C	Genitourinary nuclear exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78800		A	Tumor imaging, limited area	0.66	NA	3.58	0.18	NA	4.42	XXX
78800	26	A	Tumor imaging, limited area	0.66	0.23	0.23	0.03	0.92	0.92	XXX
78800	TC	A	Tumor imaging, limited area	0.00	NA	3.35	0.15	NA	3.50	XXX
78801		A	Tumor imaging, mult areas	0.79	NA	4.44	0.21	NA	5.44	XXX
78801	26	A	Tumor imaging, mult areas	0.79	0.28	0.28	0.03	1.10	1.10	XXX
78801	TC	A	Tumor imaging, mult areas	0.00	NA	4.16	0.18	NA	4.34	XXX
78802		A	Tumor imaging, whole body	0.86	NA	5.76	0.28	NA	6.90	XXX
78802	26	A	Tumor imaging, whole body	0.86	0.31	0.31	0.03	1.20	1.20	XXX
78802	TC	A	Tumor imaging, whole body	0.00	NA	5.45	0.25	NA	5.70	XXX
78803		A	Tumor imaging (3D)	1.09	NA	6.87	0.33	NA	8.29	XXX
78803	26	A	Tumor imaging (3D)	1.09	0.41	0.41	0.04	1.54	1.54	XXX
78803	TC	A	Tumor imaging (3D)	0.00	NA	6.46	0.29	NA	6.75	XXX
78805		A	Abscess imaging, ltd area	0.73	NA	3.62	0.18	NA	4.53	XXX
78805	26	A	Abscess imaging, ltd area	0.73	0.27	0.27	0.03	1.03	1.03	XXX
78805	TC	A	Abscess imaging, ltd area	0.00	NA	3.35	0.15	NA	3.50	XXX
78806		A	Abscess imaging, whole body	0.86	NA	6.64	0.32	NA	7.82	XXX
78806	26	A	Abscess imaging, whole body	0.86	0.31	0.31	0.03	1.20	1.20	XXX
78806	TC	A	Abscess imaging, whole body	0.00	NA	6.33	0.29	NA	6.62	XXX
78807		A	Nuclear localization/abscess	1.09	NA	6.87	0.33	NA	8.29	XXX
78807	26	A	Nuclear localization/abscess	1.09	0.41	0.41	0.04	1.54	1.54	XXX
78807	TC	A	Nuclear localization/abscess	0.00	NA	6.46	0.29	NA	6.75	XXX
78810		N	Tumor imaging (PET)	+0.00	NA	0.76	0.00	NA	0.76	XXX
78810	26	N	Tumor imaging (PET)	+1.93	0.76	0.76	0.09	2.78	2.78	XXX
78810	TC	N	Tumor imaging (PET)	0.00	NA	0.00	0.00	NA	0.00	XXX
78890		B	Nuclear medicine data proc	+0.05	NA	1.31	0.06	NA	1.42	XXX
78890	26	B	Nuclear medicine data proc	+0.05	0.02	0.02	0.01	0.08	0.08	XXX
78890	TC	B	Nuclear medicine data proc	+0.00	NA	1.29	0.05	NA	1.34	XXX
78891		B	Nuclear med data proc	+0.10	NA	2.62	0.12	NA	2.84	XXX
78891	26	B	Nuclear med data proc	+0.10	0.04	0.04	0.01	0.15	0.15	XXX
78891	TC	B	Nuclear med data proc	+0.00	NA	2.58	0.11	NA	2.69	XXX
78990		I	Provide diag radionuclide(s)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78999		C	Nuclear diagnostic exam	0.00	NA	0.00	0.00	NA	0.00	XXX
78999	26	C	Nuclear diagnostic exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78999	TC	C	Nuclear diagnostic exam	0.00	NA	0.00	0.00	NA	0.00	XXX
79000		A	Init hyperthyroid therapy	1.80	NA	3.22	0.19	NA	5.21	XXX
79000	26	A	Init hyperthyroid therapy	1.80	0.64	0.64	0.07	2.51	2.51	XXX
79000	TC	A	Init hyperthyroid therapy	0.00	NA	2.58	0.12	NA	2.70	XXX
79001		A	Repeat hyperthyroid therapy	1.05	NA	1.67	0.10	NA	2.82	XXX
79001	26	A	Repeat hyperthyroid therapy	1.05	0.38	0.38	0.04	1.47	1.47	XXX
79001	TC	A	Repeat hyperthyroid therapy	0.00	NA	1.29	0.06	NA	1.35	XXX
79020		A	Thyroid ablation	1.81	NA	3.22	0.19	NA	5.22	XXX
79020	26	A	Thyroid ablation	1.81	0.64	0.64	0.07	2.52	2.52	XXX
79020	TC	A	Thyroid ablation	0.00	NA	2.58	0.12	NA	2.70	XXX
79030		A	Thyroid ablation, carcinoma	2.10	NA	3.34	0.20	NA	5.64	XXX
79030	26	A	Thyroid ablation, carcinoma	2.10	0.76	0.76	0.08	2.94	2.94	XXX
79030	TC	A	Thyroid ablation, carcinoma	0.00	NA	2.58	0.12	NA	2.70	XXX
79035		A	Thyroid metastatic therapy	2.52	NA	3.52	0.21	NA	6.25	XXX
79035	26	A	Thyroid metastatic therapy	2.52	0.94	0.94	0.09	3.55	3.55	XXX
79035	TC	A	Thyroid metastatic therapy	0.00	NA	2.58	0.12	NA	2.70	XXX
79100		A	Hematopoetic nuclear therapy	1.32	NA	3.07	0.17	NA	4.56	XXX
79100	26	A	Hematopoetic nuclear therapy	1.32	0.49	0.49	0.05	1.86	1.86	XXX
79100	TC	A	Hematopoetic nuclear therapy	0.00	NA	2.58	0.12	NA	2.70	XXX
79200		A	Intracavitary nuclear trmt	1.99	NA	3.32	0.19	NA	5.50	XXX
79200	26	A	Intracavitary nuclear trmt	1.99	0.74	0.74	0.07	2.80	2.80	XXX
79200	TC	A	Intracavitary nuclear trmt	0.00	NA	2.58	0.12	NA	2.70	XXX
79300		C	Interstitial nuclear therapy	0.00	NA	0.00	0.00	NA	0.00	XXX
79300	26	A	Interstitial nuclear therapy	1.60	0.57	0.57	0.07	2.24	2.24	XXX
79300	TC	C	Interstitial nuclear therapy	0.00	NA	0.00	0.00	NA	0.00	XXX
79400		A	Nonhemato nuclear therapy	1.96	NA	3.30	0.20	NA	5.46	XXX
79400	26	A	Nonhemato nuclear therapy	1.96	0.72	0.72	0.08	2.76	2.76	XXX
79400	TC	A	Nonhemato nuclear therapy	0.00	NA	2.58	0.12	NA	2.70	XXX
79420		C	Intravascular nuclear ther	0.00	NA	0.00	0.00	NA	0.00	XXX
79420	26	A	Intravascular nuclear ther	1.51	0.53	0.53	0.06	2.10	2.10	XXX
79420	TC	C	Intravascular nuclear ther	0.00	NA	0.00	0.00	NA	0.00	XXX
79440		A	Nuclear joint therapy	1.99	NA	3.38	0.20	NA	5.57	XXX
79440	26	A	Nuclear joint therapy	1.99	0.80	0.80	0.08	2.87	2.87	XXX
79440	TC	A	Nuclear joint therapy	0.00	NA	2.58	0.12	NA	2.70	XXX
79900		C	Provide ther radiopharm(s)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
79999		C	Nuclear medicine therapy	0.00	NA	0.00	0.00	NA	0.00	XXX
79999	26	C	Nuclear medicine therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
79999	TC	C	Nuclear medicine therapy	0.00	NA	0.00	0.00	NA	0.00	XXX
80048		X	Basic metabolic panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
80050		N	General health panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80051		X	Electrolyte panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80053		X	Comprehen metabolic panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80055		I	Obstetric panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80061		X	Lipid panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80069		X	Renal function panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80072		X	Arthritis panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80074		X	Acute hepatitis panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80076		X	Hepatic function panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80090		X	Torch antibody panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80100		X	Drug screen, qualitate/multi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80101		X	Drug screen, single	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80102		X	Drug confirmation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80103		X	Drug analysis, tissue prep	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80150		X	Assay of amikacin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80152		X	Assay of amitriptyline	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80154		X	Assay of benzodiazepines	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80156		X	Assay, carbamazepine, total	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80157		X	Assay, carbamazepine, free	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80158		X	Assay of cyclosporine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80160		X	Assay of desipramine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80162		X	Assay of digoxin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80164		X	Assay, dipropylacetic acid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80166		X	Assay of doxepin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80168		X	Assay of ethosuximide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80170		X	Assay of gentamicin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80172		X	Assay of gold	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80173		X	Assay of haloperidol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80174		X	Assay of imipramine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80176		X	Assay of lidocaine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80178		X	Assay of lithium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80182		X	Assay of nortriptyline	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80184		X	Assay of phenobarbital	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80185		X	Assay of phenytoin, total	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80186		X	Assay of phenytoin, free	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80188		X	Assay of primidone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80190		X	Assay of procainamide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80192		X	Assay of procainamide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80194		X	Assay of quinidine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80196		X	Assay of salicylate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80197		X	Assay of tacrolimus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80198		X	Assay of theophylline	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80200		X	Assay of tobramycin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80201		X	Assay of topiramate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80202		X	Assay of vancomycin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80299		X	Quantitative assay, drug	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80400		X	Acth stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80402		X	Acth stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80406		X	Acth stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80408		X	Aldosterone suppression eval	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80410		X	Calcitonin stimul panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80412		X	CRH stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80414		X	Testosterone response	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80415		X	Estradiol response panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80416		X	Renin stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80417		X	Renin stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80418		X	Pituitary evaluation panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80420		X	Dexamethasone panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80422		X	Glucagon tolerance panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80424		X	Glucagon tolerance panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80426		X	Gonadotropin hormone panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80428		X	Growth hormone panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80430		X	Growth hormone panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80432		X	Insulin suppression panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80434		X	Insulin tolerance panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80435		X	Insulin tolerance panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80436		X	Metyrapone panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80438		X	TRH stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80439		X	TRH stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80440		X	TRH stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80500		A	Lab pathology consultation	0.37	0.17	0.19	0.01	0.55	0.57	XXX
80502		A	Lab pathology consultation	1.33	0.61	0.64	0.05	1.99	2.02	XXX
81000		X	Urinalysis, nonauto w/scope	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81001		X	Urinalysis, auto w/scope	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
81002		X	Urinalysis nonauto w/o scope	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81003		X	Urinalysis, auto, w/o scope	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81005		X	Urinalysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81007		X	Urine screen for bacteria	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81015		X	Microscopic exam of urine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81020		X	Urinalysis, glass test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81025		X	Urine pregnancy test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81050		X	Urinalysis, volume measure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81099		X	Urinalysis test procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82000		X	Assay of blood acetaldehyde	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82003		X	Assay of acetaminophen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82009		X	Test for acetone/ketones	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82010		X	Acetone assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82013		X	Acetylcholinesterase assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82016		X	Acylcarnitines, qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82017		X	Acylcarnitines, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82024		X	Assay of acth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82030		X	Assay of adp & amp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82040		X	Assay of serum albumin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82042		X	Assay of urine albumin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82043		X	Microalbumin, quantitative	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82044		X	Microalbumin, semiquant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82055		X	Assay of ethanol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82075		X	Assay of breath ethanol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82085		X	Assay of aldolase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82088		X	Assay of aldosterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82101		X	Assay of urine alkaloids	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82103		X	Alpha-1-antitrypsin, total	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82104		X	Alpha-1-antitrypsin, pheno	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82105		X	Alpha-fetoprotein, serum	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82106		X	Alpha-fetoprotein, amniotic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82108		X	Assay of aluminum	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82120		X	Amines, vaginal fluid qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82127		X	Amino acid, single qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82128		X	Amino acids, mult qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82131		X	Amino acids, single quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82135		X	Assay, aminolevulinic acid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82136		X	Amino acids, quant, 2–5	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82139		X	Amino acids, quan, 6 or more	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82140		X	Assay of ammonia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82143		X	Amniotic fluid scan	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82145		X	Assay of amphetamines	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82150		X	Assay of amylase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82154		X	Androstanediol glucuronide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82157		X	Assay of androstenedione	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82160		X	Assay of androsterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82163		X	Assay of angiotensin II	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82164		X	Angiotensin I enzyme test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82172		X	Assay of apolipoprotein	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82175		X	Assay of arsenic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82180		X	Assay of ascorbic acid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82190		X	Atomic absorption	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82205		X	Assay of barbiturates	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82232		X	Assay of beta–2 protein	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82239		X	Bile acids, total	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82240		X	Bile acids, cholylglycine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82247		X	Bilirubin, total	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82248		X	Bilirubin, direct	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82252		X	Fecal bilirubin test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82261		X	Assay of biotinidase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82270		X	Test for blood, feces	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82273		X	Test for blood, other source	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82286		X	Assay of bradykinin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82300		X	Assay of cadmium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82306		X	Assay of vitamin D	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82307		X	Assay of vitamin D	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82308		X	Assay of calcitonin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82310		X	Assay of calcium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82330		X	Assay of calcium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82331		X	Calcium infusion test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82340		X	Assay of calcium in urine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82355		X	Calculus (stone) analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82360		X	Calculus (stone) assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82365		X	Calculus (stone) assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
82370		X	X-ray assay, calculus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82373		X	Assay, c–d transfer measure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82374		X	Assay, blood carbon dioxide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82375		X	Assay, blood carbon monoxide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82376		X	Test for carbon monoxide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82378		X	Carcinoembryonic antigen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82379		X	Assay of carnitine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82380		X	Assay of carotene	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82382		X	Assay, urine catecholamines	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82383		X	Assay, blood catecholamines	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82384		X	Assay, three catecholamines	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82387		X	Assay of cathepsin-d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82390		X	Assay of ceruloplasmin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82397		X	Chemiluminescent assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82415		X	Assay of chloramphenicol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82435		X	Assay of blood chloride	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82436		X	Assay of urine chloride	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82438		X	Assay, other fluid chlorides	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82441		X	Test for chlorohydrocarbons	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82465		X	Assay, bld/serum cholesterol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82480		X	Assay, serum cholinesterase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82482		X	Assay, rbc cholinesterase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82485		X	Assay, chondroitin sulfate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82486		X	Gas/liquid chromatography	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82487		X	Paper chromatography	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82488		X	Paper chromatography	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82489		X	Thin layer chromatography	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82491		X	Chromotography, quant, sing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82492		X	Chromotography, quant, mult	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82495		X	Assay of chromium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82507		X	Assay of citrate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82520		X	Assay of cocaine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82523		X	Collagen crosslinks	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82525		X	Assay of copper	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82528		X	Assay of corticosterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82530		X	Cortisol, free	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82533		X	Total cortisol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82540		X	Assay of creatine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82541		X	Column chromotography, qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82542		X	Column chromotography, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82543		X	Column chromotograph/isotope	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82544		X	Column chromotograph/isotope	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82550		X	Assay of ck (cpk)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82552		X	Assay of cpk in blood	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82553		X	Creatine, MB fraction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82554		X	Creatine, isoforms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82565		X	Assay of creatinine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82570		X	Assay of urine creatinine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82575		X	Creatinine clearance test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82585		X	Assay of cryofibrinogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82595		X	Assay of cryoglobulin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82600		X	Assay of cyanide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82607		X	Vitamin B–12	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82608		X	B–12 binding capacity	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82615		X	Test for urine cystines	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82626		X	Dehydroepiandrosterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82627		X	Dehydroepiandrosterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82633		X	Desoxycorticosterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82634		X	Deoxycortisol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82638		X	Assay of dibucaine number	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82646		X	Assay of dihydrocodeinone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82649		X	Assay of dihydromorphinone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82651		X	Assay of dihydrotestosterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82652		X	Assay of dihydroxyvitamin d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82654		X	Assay of dimethadione	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82657		X	Enzyme cell activity	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82658		X	Enzyme cell activity, ra	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82664		X	Electrophoretic test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82666		X	Assay of epiandrosterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82668		X	Assay of erythropoietin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82670		X	Assay of estradiol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82671		X	Assay of estrogens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82672		X	Assay of estrogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82677		X	Assay of estriol	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
82679		X	Assay of estrone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82690		X	Assay of ethchlorvynol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82693		X	Assay of ethylene glycol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82696		X	Assay of etiocholanolone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82705		X	Fats/lipids, feces, qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82710		X	Fats/lipids, feces, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82715		X	Assay of fecal fat	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82725		X	Assay of blood fatty acids	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82726		X	Long chain fatty acids	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82728		X	Assay of ferritin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82731		X	Assay of fetal fibronectin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82735		X	Assay of fluoride	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82742		X	Assay of flurazepam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82746		X	Blood folic acid serum	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82747		X	Assay of folic acid, rbc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82757		X	Assay of semen fructose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82759		X	Assay of rbc galactokinase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82760		X	Assay of galactose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82775		X	Assay galactose transferase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82776		X	Galactose transferase test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82784		X	Assay of gammaglobulin igm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82785		X	Assay of gammaglobulin ige	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82787		X	Igg 1, 2, 3 or 4, each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82800		X	Blood pH	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82803		X	Blood gases: pH, pO2 & pCO2	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82805		X	Blood gases W/02 saturation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82810		X	Blood gases, O2 sat only	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82820		X	Hemoglobin-oxygen affinity	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82926		X	Assay of gastric acid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82928		X	Assay of gastric acid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82938		X	Gastrin test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82941		X	Assay of gastrin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82943		X	Assay of glucagon	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82945		X	Glucose other fluid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82946		X	Glucagon tolerance test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82947		X	Assay, glucose, blood quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82948		X	Reagent strip/blood glucose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82950		X	Glucose test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82951		X	Glucose tolerance test (GTT)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82952		X	GTT-added samples	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82953		X	Glucose-tolbutamide test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82955		X	Assay of g6pd enzyme	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82960		X	Test for G6PD enzyme	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82962		X	Glucose blood test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82963		X	Assay of glucosidase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82965		X	Assay of gdh enzyme	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82975		X	Assay of glutamine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82977		X	Assay of GGT	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82978		X	Assay of glutathione	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82979		X	Assay, rbc glutathione	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82980		X	Assay of glutethimide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82985		X	Glycated protein	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83001		X	Gonadotropin (FSH)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83002		X	Gonadotropin (LH)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83003		X	Assay, growth hormone (hgh)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83008		X	Assay of guanosine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83010		X	Assay of haptoglobin, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83012		X	Assay of haptoglobins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83013		X	H pylori analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83014		X	H pylori drug admin/collect	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83015		X	Heavy metal screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83018		X	Quantitative screen, metals	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83020		X	Hemoglobin electrophoresis	+0.00	0.16	0.16	0.00	0.16	0.16	XXX
83020	26	A	Hemoglobin electrophoresis	0.37	0.16	0.16	0.01	0.54	0.54	XXX
83021		X	Hemoglobin chromotography	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83026		X	Hemoglobin, copper sulfate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83030		X	Fetal hemoglobin, chemical	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83033		X	Fetal hemoglobin assay, qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83036		X	Glycated hemoglobin test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83045		X	Blood methemoglobin test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83050		X	Blood methemoglobin assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83051		X	Assay of plasma hemoglobin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83055		X	Blood sulfhemoglobin test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83060		X	Blood sulfhemoglobin assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
83065		X	Assay of hemoglobin heat	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83068		X	Hemoglobin stability screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83069		X	Assay of urine hemoglobin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83070		X	Assay of hemosiderin, qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83071		X	Assay of hemosiderin, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83080		X	Assay of b hexosaminidase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83088		X	Assay of histamine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83090		X	Assay of homocystine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83150		X	Assay of for hva	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83491		X	Assay of corticosteroids	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83497		X	Assay of 5-hiaa	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83498		X	Assay of progesterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83499		X	Assay of progesterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83500		X	Assay, free hydroxyproline	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83505		X	Assay, total hydroxyproline	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83516		X	Immunoassay, nonantibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83518		X	Immunoassay, dipstick	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83519		X	Immunoassay, nonantibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83520		X	Immunoassay, RIA	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83525		X	Assay of insulin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83527		X	Assay of insulin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83528		X	Assay of intrinsic factor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83540		X	Assay of iron	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83550		X	Iron binding test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83570		X	Assay of idh enzyme	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83582		X	Assay of ketogenic steroids	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83586		X	Assay 17- ketosteroids	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83593		X	Fractionation, ketosteroids	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83605		X	Assay of lactic acid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83615		X	Lactate (LD) (LDH) enzyme	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83625		X	Assay of ldh enzymes	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83632		X	Placental lactogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83633		X	Test urine for lactose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83634		X	Assay of urine for lactose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83655		X	Assay of lead	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83661		X	L/s ratio, fetal lung	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83662		X	Foam stability, fetal lung	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83663		X	Fluoro polarize, fetal lung	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83664		X	Lamellar bdy, fetal lung	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83670		X	Assay of lap enzyme	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83690		X	Assay of lipase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83715		X	Assay of blood lipoproteins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83716		X	Assay of blood lipoproteins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83718		X	Assay of lipoprotein	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83719		X	Assay of blood lipoprotein	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83721		X	Assay of blood lipoprotein	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83727		X	Assay of lrh hormone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83735		X	Assay of magnesium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83775		X	Assay of md enzyme	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83785		X	Assay of manganese	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83788		X	Mass spectrometry qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83789		X	Mass spectrometry quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83805		X	Assay of meprobamate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83825		X	Assay of mercury	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83835		X	Assay of metanephrines	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83840		X	Assay of methadone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83857		X	Assay of methemalbumin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83858		X	Assay of methsuximide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83864		X	Mucopolysaccharides	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83866		X	Mucopolysaccharides screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83872		X	Assay synovial fluid mucin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83873		X	Assay of csf protein	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83874		X	Assay of myoglobin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83883		X	Assay, nephelometry not spec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83885		X	Assay of nickel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83887		X	Assay of nicotine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83890		X	Molecule isolate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83891		X	Molecule isolate nucleic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83892		X	Molecular diagnostics	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83893		X	Molecule dot/slot/blot	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83894		X	Molecule gel electrophor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83896		X	Molecular diagnostics	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83897		X	Molecule nucleic transfer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83898		X	Molecule nucleic ampli	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
83901		X	Molecule nucleic ampli	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83902		X	Molecular diagnostics	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83903		X	Molecule mutation scan	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83904		X	Molecule mutation identify	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83905		X	Molecule mutation identify	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83906		X	Molecule mutation identify	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83912		X	Genetic examination	+0.00	0.16	0.16	0.00	0.16	0.16	XXX
83912	26	A	Genetic examination	0.37	0.16	0.16	0.01	0.54	0.54	XXX
83915		X	Assay of nucleotidase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83916		X	Oligoclonal bands	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83918		X	Organic acids, total, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83919		X	Organic acids, qual, each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83921		X	Organic acid, single, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83925		X	Assay of opiates	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83930		X	Assay of blood osmolality	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83935		X	Assay of urine osmolality	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83937		X	Assay of osteocalcin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83945		X	Assay of oxalate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83970		X	Assay of parathormone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83986		X	Assay of body fluid acidity	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83992		X	Assay for phencyclidine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84022		X	Assay of phenothiazine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84030		X	Assay of blood pku	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84035		X	Assay of phenylketones	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84060		X	Assay acid phosphatase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84061		X	Phosphatase, forensic exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84066		X	Assay prostate phosphatase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84075		X	Assay alkaline phosphatase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84078		X	Assay alkaline phosphatase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84080		X	Assay alkaline phosphatases	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84081		X	Amniotic fluid enzyme test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84085		X	Assay of rbc pg6d enzyme	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84087		X	Assay phosphohexose enzymes	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84100		X	Assay of phosphorus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84105		X	Assay of urine phosphorus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84106		X	Test for porphobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84110		X	Assay of porphobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84119		X	Test urine for porphyrins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84120		X	Assay of urine porphyrins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84126		X	Assay of feces porphyrins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84127		X	Assay of feces porphyrins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84132		X	Assay of serum potassium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84133		X	Assay of urine potassium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84134		X	Assay of prealbumin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84135		X	Assay of pregnanediol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84138		X	Assay of pregnanetriol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84140		X	Assay of pregnenolone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84143		X	Assay of 17-hydroxypregneno	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84144		X	Assay of progesterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84146		X	Assay of prolactin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84150		X	Assay of prostaglandin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84152		X	Assay of psa, complexed	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84153		X	Assay of psa, total	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84154		X	Assay of psa, free	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84155		X	Assay of protein	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84160		X	Assay of serum protein	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84165		X	Assay of serum proteins	+0.00	0.17	0.17	0.00	0.17	0.17	XXX
84165	26	A	Assay of serum proteins	0.37	0.17	0.17	0.01	0.55	0.55	XXX
84181		X	Western blot test	+0.00	0.15	0.15	0.00	0.15	0.15	XXX
84181	26	A	Western blot test	0.37	0.15	0.15	0.01	0.53	0.53	XXX
84182		X	Protein, western blot test	+0.00	0.17	0.17	0.00	0.17	0.17	XXX
84182	26	A	Protein, western blot test	0.37	0.17	0.17	0.01	0.55	0.55	XXX
84202		X	Assay RBC protoporphyrin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84203		X	Test RBC protoporphyrin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84206		X	Assay of proinsulin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84207		X	Assay of vitamin b-6	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84210		X	Assay of pyruvate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84220		X	Assay of pyruvate kinase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84228		X	Assay of quinine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84233		X	Assay of estrogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84234		X	Assay of progesterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84235		X	Assay of endocrine hormone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84238		X	Assay, nonendocrine receptor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84244		X	Assay of renin	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
84252		X	Assay of vitamin b–2	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84255		X	Assay of selenium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84260		X	Assay of serotonin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84270		X	Assay of sex hormone globul	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84275		X	Assay of sialic acid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84285		X	Assay of silica	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84295		X	Assay of serum sodium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84300		X	Assay of urine sodium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84305		X	Assay of somatomedin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84307		X	Assay of somatostatin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84311		X	Spectrophotometry	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84315		X	Body fluid specific gravity	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84375		X	Chromatogram assay, sugars	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84376		X	Sugars, single, qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84377		X	Sugars, multiple, qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84378		X	Sugars single quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84379		X	Sugars multiple quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84392		X	Assay of urine sulfate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84402		X	Assay of testosterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84403		X	Assay of total testosterone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84425		X	Assay of vitamin b–1	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84430		X	Assay of thiocyanate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84432		X	Assay of thyroglobulin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84436		X	Assay of total thyroxine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84437		X	Assay of neonatal thyroxine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84439		X	Assay of free thyroxine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84442		X	Assay of thyroid activity	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84443		X	Assay thyroid stim hormone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84445		X	Assay of tsi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84446		X	Assay of vitamin e	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84449		X	Assay of transcortin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84450		X	Transferase (AST) (SGOT)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84460		X	Alanine amino (ALT) (SGPT)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84466		X	Assay of transferrin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84478		X	Assay of triglycerides	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84479		X	Assay of thyroid (t3 or t4)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84480		X	Assay, triiodothyronine (t3)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84481		X	Free assay (FT–3)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84482		X	T3 reverse	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84484		X	Assay of troponin, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84485		X	Assay duodenal fluid trypsin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84488		X	Test feces for trypsin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84490		X	Assay of feces for trypsin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84510		X	Assay of tyrosine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84512		X	Assay of troponin, qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84520		X	Assay of urea nitrogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84525		X	Urea nitrogen semi-quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84540		X	Assay of urine/urea-n	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84545		X	Urea-N clearance test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84550		X	Assay of blood/uric acid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84560		X	Assay of urine/uric acid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84577		X	Assay of feces/urobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84578		X	Test urine urobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84580		X	Assay of urine urobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84583		X	Assay of urine urobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84585		X	Assay of urine vma	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84586		X	Assay of vip	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84588		X	Assay of vasopressin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84590		X	Assay of vitamin a	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84591		X	Assay of nos vitamin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84597		X	Assay of vitamin k	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84600		X	Assay of volatiles	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84620		X	Xylose tolerance test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84630		X	Assay of zinc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84681		X	Assay of c-peptide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84702		X	Chorionic gonadotropin test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84703		X	Chorionic gonadotropin assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84830		X	Ovulation tests	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84999		X	Clinical chemistry test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85002		X	Bleeding time test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85007		X	Differential WBC count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85008		X	Nondifferential WBC count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85009		X	Differential WBC count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85013		X	Hematocrit	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
85014		X	Hematocrit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85018		X	Hemoglobin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85021		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85022		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85023		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85024		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85025		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85027		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85031		X	Manual hemogram, cbc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85041		X	Red blood cell (RBC) count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85044		X	Reticulocyte count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85045		X	Reticulocyte count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85046		X	Reticyte/hgb concentrate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85048		X	White blood cell (WBC) count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85060		A	Blood smear interpretation	0.45	0.20	0.20	0.02	0.67	0.67	XXX
85095		A	Bone marrow aspiration	1.08	0.44	4.57	0.03	1.55	5.68	XXX
85097		A	Bone marrow interpretation	0.94	0.42	1.81	0.03	1.39	2.78	XXX
85102		A	Bone marrow biopsy	1.37	0.55	4.70	0.04	1.96	6.11	XXX
85130		X	Chromogenic substrate assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85170		X	Blood clot retraction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85175		X	Blood clot lysis time	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85210		X	Blood clot factor II test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85220		X	Blood clot factor V test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85230		X	Blood clot factor VII test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85240		X	Blood clot factor VIII test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85244		X	Blood clot factor VIII test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85245		X	Blood clot factor VIII test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85246		X	Blood clot factor VIII test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85247		X	Blood clot factor VIII test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85250		X	Blood clot factor IX test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85260		X	Blood clot factor X test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85270		X	Blood clot factor XI test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85280		X	Blood clot factor XII test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85290		X	Blood clot factor XIII test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85291		X	Blood clot factor XIII test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85292		X	Blood clot factor assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85293		X	Blood clot factor assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85300		X	Antithrombin III test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85301		X	Antithrombin III test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85302		X	Blood clot inhibitor antigen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85303		X	Blood clot inhibitor test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85305		X	Blood clot inhibitor assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85306		X	Blood clot inhibitor test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85307		X	Assay activated protein c	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85335		X	Factor inhibitor test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85337		X	Thrombomodulin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85345		X	Coagulation time	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85347		X	Coagulation time	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85348		X	Coagulation time	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85360		X	Euglobulin lysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85362		X	Fibrin degradation products	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85366		X	Fibrinogen test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85370		X	Fibrinogen test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85378		X	Fibrin degradation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85379		X	Fibrin degradation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85384		X	Fibrinogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85385		X	Fibrinogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85390		X	Fibrinolysins screen	+0.00	0.13	0.13	0.00	0.13	0.13	XXX
85390	26	A	Fibrinolysins screen	0.37	0.13	0.13	0.01	0.51	0.51	XXX
85400		X	Fibrinolytic plasmin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85410		X	Fibrinolytic antiplasmin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85415		X	Fibrinolytic plasminogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85420		X	Fibrinolytic plasminogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85421		X	Fibrinolytic plasminogen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85441		X	Heinz bodies, direct	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85445		X	Heinz bodies, induced	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85460		X	Hemoglobin, fetal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85461		X	Hemoglobin, fetal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85475		X	Hemolysin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85520		X	Heparin assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85525		X	Heparin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85530		X	Heparin-protamine tolerance	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85535		X	Iron stain, blood cells	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85536		X	Iron stain peripheral blood	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
85540		X	Wbc alkaline phosphatase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85547		X	RBC mechanical fragility	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85549		X	Muramidase	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85555		X	RBC osmotic fragility	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85557		X	RBC osmotic fragility	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85576		X	Blood platelet aggregation	+0.00	0.16	0.16	0.00	0.16	0.16	XXX
85576	26	A	Blood platelet aggregation	0.37	0.16	0.16	0.01	0.54	0.54	XXX
85585		X	Blood platelet estimation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85590		X	Platelet count, manual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85595		X	Platelet count, automated	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85597		X	Platelet neutralization	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85610		X	Prothrombin time	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85611		X	Prothrombin test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85612		X	Viper venom prothrombin time	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85613		X	Russell viper venom, diluted	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85635		X	Reptilase test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85651		X	Rbc sed rate, nonautomated	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85652		X	Rbc sed rate, automated	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85660		X	RBC sickle cell test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85670		X	Thrombin time, plasma	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85675		X	Thrombin time, titer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85705		X	Thromboplastin inhibition	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85730		X	Thromboplastin time, partial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85732		X	Thromboplastin time, partial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85810		X	Blood viscosity examination	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85999		X	Hematology procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86000		X	Agglutinins, febrile	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86001		X	Allergen specific igg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86003		X	Allergen specific IgE	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86005		X	Allergen specific IgE	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86021		X	WBC antibody identification	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86022		X	Platelet antibodies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86023		X	Immunoglobulin assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86038		X	Antinuclear antibodies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86039		X	Antinuclear antibodies (ANA)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86060		X	Antistreptolysin o, titer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86063		X	Antistreptolysin o, screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86077		A	Physician blood bank service	0.94	0.42	0.49	0.03	1.39	1.46	XXX
86078		A	Physician blood bank service	0.94	0.43	0.52	0.03	1.40	1.49	XXX
86079		A	Physician blood bank service	0.94	0.43	0.52	0.03	1.40	1.49	XXX
86140		X	C-reactive protein	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86146		X	Glycoprotein antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86147		X	Cardiolipin antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86148		X	Phospholipid antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86155		X	Chemotaxis assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86156		X	Cold agglutinin, screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86157		X	Cold agglutinin, titer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86160		X	Complement, antigen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86161		X	Complement/function activity	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86162		X	Complement, total (CH50)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86171		X	Complement fixation, each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86185		X	Counterimmunoelectrophoresis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86215		X	Deoxyribonuclease, antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86225		X	DNA antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86226		X	DNA antibody, single strand	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86235		X	Nuclear antigen antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86243		X	Fc receptor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86255		X	Fluorescent antibody, screen	+0.00	0.17	0.17	0.00	0.17	0.17	XXX
86255	26	A	Fluorescent antibody, screen	0.37	0.17	0.17	0.01	0.55	0.55	XXX
86256		X	Fluorescent antibody, titer	+0.00	0.17	0.17	0.00	0.17	0.17	XXX
86256	26	A	Fluorescent antibody, titer	0.37	0.17	0.17	0.01	0.55	0.55	XXX
86277		X	Growth hormone antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86280		X	Hemagglutination inhibition	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86294		X	Immunoassay, tumor qual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86300		X	Immunoassay, tumor ca 15–3	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86301		X	Immunoassay, tumor, ca 19–9	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86304		X	Immunoassay, tumor ca 125	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86308		X	Heterophile antibodies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86309		X	Heterophile antibodies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86310		X	Heterophile antibodies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86316		X	Immunoassay, tumor other	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86317		X	Immunoassay,infectious agent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86318		X	Immunoassay,infectious agent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86320		X	Serum immunoelectrophoresis	+0.00	0.16	0.17	0.00	0.16	0.17	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
86320	26	A	Serum immunoelectrophoresis	0.37	0.16	0.17	0.01	0.54	0.55	XXX
86325		X	Other immunoelectrophoresis	+0.00	0.16	0.16	0.00	0.16	0.16	XXX
86325	26	A	Other immunoelectrophoresis	0.37	0.16	0.16	0.01	0.54	0.54	XXX
86327		X	Immunoelectrophoresis assay	+0.00	0.19	0.19	0.00	0.19	0.19	XXX
86327	26	A	Immunoelectrophoresis assay	0.42	0.19	0.19	0.01	0.62	0.62	XXX
86329		X	Immunodiffusion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86331		X	Immunodiffusion ouchterlony	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86332		X	Immune complex assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86334		X	Immunofixation procedure	+0.00	0.17	0.17	0.00	0.17	0.17	XXX
86334	26	A	Immunofixation procedure	0.37	0.17	0.17	0.01	0.55	0.55	XXX
86337		X	Insulin antibodies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86340		X	Intrinsic factor antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86341		X	Islet cell antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86343		X	Leukocyte histamine release	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86344		X	Leukocyte phagocytosis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86353		X	Lymphocyte transformation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86359		X	T cells, total count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86360		X	T cell, absolute count/ratio	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86361		X	T cell, absolute count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86376		X	Microsomal antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86378		X	Migration inhibitory factor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86382		X	Neutralization test, viral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86384		X	Nitroblue tetrazolium dye	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86403		X	Particle agglutination test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86406		X	Particle agglutination test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86430		X	Rheumatoid factor test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86431		X	Rheumatoid factor, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86485		C	Skin test, candida	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86490		A	Coccidioidomycosis skin test	0.00	NA	0.29	0.02	NA	0.31	XXX
86510		A	Histoplasmosis skin test	0.00	NA	0.31	0.02	NA	0.33	XXX
86580		A	TB intradermal test	0.00	NA	0.25	0.02	NA	0.27	XXX
86585		A	TB tine test	0.00	NA	0.20	0.01	NA	0.21	XXX
86586		C	Skin test, unlisted	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86590		X	Streptokinase, antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86592		X	Blood serology, qualitative	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86593		X	Blood serology, quantitative	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86602		X	Antinomyces antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86603		X	Adenovirus antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86606		X	Aspergillus antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86609		X	Bacterium antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86611		X	Bartonella antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86612		X	Blastomyces antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86615		X	Bordetella antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86617		X	Lyme disease antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86618		X	Lyme disease antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86619		X	Borrelia antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86622		X	Brucella antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86625		X	Campylobacter antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86628		X	Candida antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86631		X	Chlamydia antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86632		X	Chlamydia igm antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86635		X	Coccidioides antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86638		X	Q fever antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86641		X	Cryptococcus antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86644		X	CMV antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86645		X	CMV antibody, IgM	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86648		X	Diphtheria antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86651		X	Encephalitis antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86652		X	Encephalitis antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86653		X	Encephalitis antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86654		X	Encephalitis antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86658		X	Enterovirus antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86663		X	Epstein-barr antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86664		X	Epstein-barr antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86665		X	Epstein-barr antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86666		X	Ehrlichia antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86668		X	Francisella tularensis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86671		X	Fungus antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86674		X	Giardia lamblia antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86677		X	Helicobacter pylori	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86682		X	Helminth antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86683		X	Hemoglobin, fecal antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86684		X	Hemophilus influenza	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86687		X	Htlv-i antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
86688		X	Htlv-ii antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86689		X	HTLV/HIV confirmatory test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86692		X	Hepatitis, delta agent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86694		X	Herpes simplex test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86695		X	Herpes simplex test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86696		X	Herpes simplex type 2	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86698		X	Histoplasma	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86701		X	HIV–1	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86702		X	HIV–2	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86703		X	HIV–1/HIV–2, single assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86704		X	Hep b core antibody, total	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86705		X	Hep b core antibody, igm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86706		X	Hep b surface antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86707		X	Hep be antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86708		X	Hep a antibody, total	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86709		X	Hep a antibody, igm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86710		X	Influenza virus antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86713		X	Legionella antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86717		X	Leishmania antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86720		X	Leptospira antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86723		X	Listeria monocytogenes ab	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86727		X	Lymph choriomeningitis ab	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86729		X	Lympho venereum antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86732		X	Mucormycosis antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86735		X	Mumps antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86738		X	Mycoplasma antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86741		X	Neisseria meningitidis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86744		X	Nocardia antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86747		X	Parvovirus antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86750		X	Malaria antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86753		X	Protozoa antibody nos	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86756		X	Respiratory virus antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86757		X	Rickettsia antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86759		X	Rotavirus antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86762		X	Rubella antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86765		X	Rubeola antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86768		X	Salmonella antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86771		X	Shigella antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86774		X	Tetanus antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86777		X	Toxoplasma antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86778		X	Toxoplasma antibody, igm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86781		X	Treponema pallidum, confirm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86784		X	Trichinella antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86787		X	Varicella-zoster antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86790		X	Virus antibody nos	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86793		X	Yersinia antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86800		X	Thyroglobulin antibody	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86803		X	Hepatitis c ab test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86804		X	Hep c ab test, confirm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86805		X	Lymphocytotoxicity assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86806		X	Lymphocytotoxicity assay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86807		X	Cytotoxic antibody screening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86808		X	Cytotoxic antibody screening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86812		X	HLA typing, A, B, or C	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86813		X	HLA typing, A, B, or C	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86816		X	HLA typing, DR/DQ	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86817		X	HLA typing, DR/DQ	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86821		X	Lymphocyte culture, mixed	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86822		X	Lymphocyte culture, primed	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86849		X	Immunology procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86850		X	RBC antibody screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86860		X	RBC antibody elution	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86870		X	RBC antibody identification	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86880		X	Coombs test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86885		X	Coombs test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86886		X	Coombs test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86890		X	Autologous blood process	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86891		X	Autologous blood, op salvage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86900		X	Blood typing, ABO	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86901		X	Blood typing, Rh (D)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86903		X	Blood typing, antigen screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86904		X	Blood typing, patient serum	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86905		X	Blood typing, RBC antigens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86906		X	Blood typing, Rh phenotype	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
86910		N	Blood typing, paternity test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86911		N	Blood typing, antigen system	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86915		X	Bone marrow/stem cell prep	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86920		X	Compatibility test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86921		X	Compatibility test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86922		X	Compatibility test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86927		X	Plasma, fresh frozen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86930		X	Frozen blood prep	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86931		X	Frozen blood thaw	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86932		X	Frozen blood freeze/thaw	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86940		X	Hemolysins/agglutinins, auto	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86941		X	Hemolysins/agglutinins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86945		X	Blood product/irradiation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86950		X	Leukacyte transfusion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86965		X	Pooling blood platelets	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86970		X	RBC pretreatment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86971		X	RBC pretreatment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86972		X	RBC pretreatment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86975		X	RBC pretreatment, serum	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86976		X	RBC pretreatment, serum	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86977		X	RBC pretreatment, serum	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86978		X	RBC pretreatment, serum	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86985		X	Split blood or products	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86999		X	Transfusion procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87001		X	Small animal inoculation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87003		X	Small animal inoculation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87015		X	Specimen concentration	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87040		X	Blood culture for bacteria	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87045		X	Stool culture, bacteria	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87046		X	Stool cultr, bacteria, each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87070		X	Culture, bacteria, other	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87071		X	Culture bacteri aerobic othr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87073		X	Culture bacteria anaerobic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87075		X	Culture bacteria anaerobic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87076		X	Culture anaerobe ident, each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87077		X	Culture aerobic identify	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87081		X	Culture screen only	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87084		X	Culture of specimen by kit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87086		X	Urine culture/colony count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87088		X	Urine bacteria culture	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87101		X	Skin fungi culture	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87102		X	Fungus isolation culture	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87103		X	Blood fungus culture	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87106		X	Fungi identification, yeast	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87107		X	Fungi identification, mold	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87109		X	Mycoplasma	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87110		X	Chlamydia culture	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87116		X	Mycobacteria culture	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87118		X	Mycobacteric identification	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87140		X	Cultur type immunofluoresc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87143		X	Culture typing, glc/hplc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87147		X	Culture type, immunologic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87149		X	Culture type, nucleic acid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87152		X	Culture type pulse field gel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87158		X	Culture typing, added method	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87164		X	Dark field examination	+0.00	0.17	0.18	0.00	0.17	0.18	XXX
87164	26	A	Dark field examination	0.37	0.17	0.18	0.01	0.55	0.56	XXX
87166		X	Dark field examination	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87168		X	Macroscopic exam arthropod	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87169		X	Macacroscopic exam parasite	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87172		X	Pinworm exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87176		X	Tissue homogenization, cultr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87177		X	Ova and parasites smears	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87181		X	Microbe susceptible, diffuse	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87184		X	Microbe susceptible, disk	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87185		X	Microbe susceptible, enzyme	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87186		X	Microbe susceptible, mic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87187		X	Microbe susceptible, mlc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87188		X	Microbe suscept, macrobroth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87190		X	Microbe suscept, mycobacteri	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87197		X	Bactericidal level, serum	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87205		X	Smear, gram stain	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87206		X	Smear, fluorescent/acid stai	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87207		X	Smear, special stain	+0.00	0.17	0.17	0.00	0.17	0.17	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
87207	26	A	Smear, special stain	0.37	0.17	0.17	0.01	0.55	0.55	XXX
87210		X	Smear, wet mount, saline/ink	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87220		X	Tissue exam for fungi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87230		X	Assay, toxin or antitoxin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87250		X	Virus inoculate, eggs/animal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87252		X	Virus inoculation, tissue	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87253		X	Virus inoculate tissue, addl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87254		X	Virus inoculation, shell via	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87260		X	Adenovirus ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87265		X	Pertussis ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87270		X	Chlamydia trachomatis ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87272		X	Cryptosporidum/gardia ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87273		X	Herpes simplex 2, ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87274		X	Herpes simplex 1, ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87275		X	Influenza b, ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87276		X	Influenza a, ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87277		X	Legionella micdadei, ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87278		X	Legion pneumophilia ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87279		X	Parainfluenza, ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87280		X	Respiratory syncytial ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87281		X	Pneumocystis carinii, ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87283		X	Rubeola, ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87285		X	Treponema pallidum, ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87290		X	Varicella zoster, ag, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87299		X	Antibody detection, nos, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87300		X	Ag detection, polyval, if	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87301		X	Adenovirus ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87320		X	Chylmd trach ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87324		X	Clostridium ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87327		X	Cryptococcus neoform ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87328		X	Cryptospor ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87332		X	Cytomegalovirus ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87335		X	E coli 0157 ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87336		X	Entamoeb hist dispr, ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87337		X	Entamoeb hist group, ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87338		X	Hpylori, stool, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87339		X	Hpylori ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87340		X	Hepatitis b surface ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87341		X	Hepatitis b surface, ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87350		X	Hepatitis be ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87380		X	Hepatitis delta ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87385		X	Histoplasma capsul ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87390		X	Hiv–1 ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87391		X	Hiv–2 ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87400		X	Influenza a/b, ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87420		X	Resp syncytial ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87425		X	Rotavirus ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87427		X	Shiga-like toxin ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87430		X	Strep a ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87449		X	Ag detect nos, eia, mult	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87450		X	Ag detect nos, eia, single	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87451		X	Ag detect polyval, eia, mult	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87470		X	Bartonella, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87471		X	Bartonella, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87472		X	Bartonella, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87475		X	Lyme dis, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87476		X	Lyme dis, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87477		X	Lyme dis, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87480		X	Candida, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87481		X	Candida, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87482		X	Candida, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87485		X	Chylmd pneum, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87486		X	Chylmd pneum, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87487		X	Chylmd pneum, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87490		X	Chylmd trach, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87491		X	Chylmd trach, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87492		X	Chylmd trach, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87495		X	Cytomeg, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87496		X	Cytomeg, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87497		X	Cytomeg, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87510		X	Gardner vag, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87511		X	Gardner vag, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87512		X	Gardner vag, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87515		X	Hepatitis b, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
87516		X	Hepatitis b , dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87517		X	Hepatitis b , dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87520		X	Hepatitis c , rna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87521		X	Hepatitis c , rna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87522		X	Hepatitis c, rna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87525		X	Hepatitis g , dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87526		X	Hepatitis g, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87527		X	Hepatitis g, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87528		X	Hsv, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87529		X	Hsv, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87530		X	Hsv, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87531		X	Hhv–6, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87532		X	Hhv–6, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87533		X	Hhv–6, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87534		X	Hiv–1, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87535		X	Hiv–1, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87536		X	Hiv–1, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87537		X	Hiv–2, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87538		X	Hiv–2, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87539		X	Hiv–2, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87540		X	Legion pneumo, dna, dir prob	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87541		X	Legion pneumo, dna, amp prob	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87542		X	Legion pneumo, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87550		X	Mycobacteria, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87551		X	Mycobacteria, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87552		X	Mycobacteria, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87555		X	M.tuberculo, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87556		X	M.tuberculo, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87557		X	M.tuberculo, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87560		X	M.avium-intra, dna, dir prob	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87561		X	M.avium-intra, dna, amp prob	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87562		X	M.avium-intra, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87580		X	M.pneumon, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87581		X	M.pneumon, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87582		X	M.pneumon, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87590		X	N.gonorrhoeae, dna, dir prob	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87591		X	N.gonorrhoeae, dna, amp prob	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87592		X	N.gonorrhoeae, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87620		X	Hpv, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87621		X	Hpv, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87622		X	Hpv, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87650		X	Strep a, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87651		X	Strep a, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87652		X	Strep a, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87797		X	Detect agent nos, dna, dir	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87798		X	Detect agent nos, dna, amp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87799		X	Detect agent nos, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87800		X	Detect agnt mult, dna, direc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87801		X	Detect agnt mult, dna, ampli	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87810		X	Chylmd trach assay w/optic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87850		X	N. gonorrhoeae assay w/optic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87880		X	Strep a assay w/optic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87899		X	Agent nos assay w/optic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87901		X	Genotype, dna, hiv reverse t	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87903		X	Phenotype, dna hiv w/culture	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87904		X	Phenotype, dna hiv w/clt add	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87999		X	Microbiology procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88000		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88005		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88007		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88012		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88014		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88016		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88020		N	Autopsy (necropsy), complete	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88025		N	Autopsy (necropsy), complete	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88027		N	Autopsy (necropsy), complete	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88028		N	Autopsy (necropsy), complete	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88029		N	Autopsy (necropsy), complete	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88036		N	Limited autopsy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88037		N	Limited autopsy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88040		N	Forensic autopsy (necropsy)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88045		N	Coroner's autopsy (necropsy)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88099		N	Necropsy (autopsy) procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88104		A	Cytopathology, fluids	0.56	NA	0.81	0.04	NA	1.41	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
88104	26	A	Cytopathology, fluids	0.56	0.26	0.26	0.02	0.84	0.84	XXX
88104	TC	A	Cytopathology, fluids	0.00	NA	0.55	0.02	NA	0.57	XXX
88106		A	Cytopathology, fluids	0.56	NA	0.55	0.04	NA	1.15	XXX
88106	26	A	Cytopathology, fluids	0.56	0.26	0.26	0.02	0.84	0.84	XXX
88106	TC	A	Cytopathology, fluids	0.00	NA	0.29	0.02	NA	0.31	XXX
88107		A	Cytopathology, fluids	0.76	NA	0.89	0.05	NA	1.70	XXX
88107	26	A	Cytopathology, fluids	0.76	0.35	0.35	0.03	1.14	1.14	XXX
88107	TC	A	Cytopathology, fluids	0.00	NA	0.54	0.02	NA	0.56	XXX
88108		A	Cytopath, concentrate tech	0.56	NA	0.72	0.04	NA	1.32	XXX
88108	26	A	Cytopath, concentrate tech	0.56	0.26	0.26	0.02	0.84	0.84	XXX
88108	TC	A	Cytopath, concentrate tech	0.00	NA	0.46	0.02	NA	0.48	XXX
88125		A	Forensic cytopathology	0.26	NA	0.33	0.02	NA	0.61	XXX
88125	26	A	Forensic cytopathology	0.26	0.12	0.12	0.01	0.39	0.39	XXX
88125	TC	A	Forensic cytopathology	0.00	NA	0.21	0.01	NA	0.22	XXX
88130		X	Sex chromatin identification	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88140		X	Sex chromatin identification	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88141		A	Cytopath, c/v, interpret	0.42	0.19	0.19	0.01	0.62	0.62	XXX
88142		X	Cytopath, c/v, thin layer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88143		X	Cytopath c/v thin layer redo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88144		X	Cytopath, c/v thin lyr redo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88145		X	Cytopath, c/v thin lyr sel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88147		X	Cytopath, c/v, automated	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88148		X	Cytopath, c/v, auto rescreen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88150		X	Cytopath, c/v, manual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88152		X	Cytopath, c/v, auto redo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88153		X	Cytopath, c/v, redo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88154		X	Cytopath, c/v, select	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88155		X	Cytopath, c/v, index add-on	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88160		A	Cytopath smear, other source	0.50	NA	0.98	0.04	NA	1.52	XXX
88160	26	A	Cytopath smear, other source	0.50	0.23	0.23	0.02	0.75	0.75	XXX
88160	TC	A	Cytopath smear, other source	0.00	NA	0.75	0.02	NA	0.77	XXX
88161		A	Cytopath smear, other source	0.50	NA	0.99	0.04	NA	1.53	XXX
88161	26	A	Cytopath smear, other source	0.50	0.23	0.23	0.02	0.75	0.75	XXX
88161	TC	A	Cytopath smear, other source	0.00	NA	0.76	0.02	NA	0.78	XXX
88162		A	Cytopath smear, other source	0.76	NA	0.84	0.05	NA	1.65	XXX
88162	26	A	Cytopath smear, other source	0.76	0.35	0.35	0.03	1.14	1.14	XXX
88162	TC	A	Cytopath smear, other source	0.00	NA	0.49	0.02	NA	0.51	XXX
88164		X	Cytopath tbs, c/v, manual	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88165		X	Cytopath tbs, c/v, redo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88166		X	Cytopath tbs, c/v, auto redo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88167		X	Cytopath tbs, c/v, select	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88170		A	Fine needle aspiration	1.27	NA	0.89	0.10	NA	2.26	XXX
88170	26	A	Fine needle aspiration	1.27	0.55	0.55	0.07	1.89	1.89	XXX
88170	TC	A	Fine needle aspiration	0.00	NA	0.34	0.03	NA	0.37	XXX
88171		A	Fine needle aspiration	1.27	NA	0.73	0.08	NA	2.08	XXX
88171	26	A	Fine needle aspiration	1.27	0.50	0.50	0.05	1.82	1.82	XXX
88171	TC	A	Fine needle aspiration	0.00	NA	0.23	0.03	NA	0.26	XXX
88172		A	Cytopathology eval of fna	0.60	NA	1.12	0.04	NA	1.76	XXX
88172	26	A	Cytopathology eval of fna	0.60	0.27	0.27	0.02	0.89	0.89	XXX
88172	TC	A	Cytopathology eval of fna	0.00	NA	0.85	0.02	NA	0.87	XXX
88173		A	Cytopath eval, fna, report	1.39	NA	1.35	0.07	NA	2.81	XXX
88173	26	A	Cytopath eval, fna, report	1.39	0.63	0.63	0.05	2.07	2.07	XXX
88173	TC	A	Cytopath eval, fna, report	0.00	NA	0.72	0.02	NA	0.74	XXX
88180		A	Cell marker study	0.36	NA	0.67	0.03	NA	1.06	XXX
88180	26	A	Cell marker study	0.36	0.16	0.16	0.01	0.53	0.53	XXX
88180	TC	A	Cell marker study	0.00	NA	0.51	0.02	NA	0.53	XXX
88182		A	Cell marker study	0.77	NA	1.74	0.06	NA	2.57	XXX
88182	26	A	Cell marker study	0.77	0.35	0.35	0.03	1.15	1.15	XXX
88182	TC	A	Cell marker study	0.00	NA	1.39	0.03	NA	1.42	XXX
88199		C	Cytopathology procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
88199	26	C	Cytopathology procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88199	TC	C	Cytopathology procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
88230		X	Tissue culture, lymphocyte	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88233		X	Tissue culture, skin/biopsy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88235		X	Tissue culture, placenta	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88237		X	Tissue culture, bone marrow	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88239		X	Tissue culture, tumor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88240		X	Cell cryopreserve/storage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88241		X	Frozen cell preparation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88245		X	Chromosome analysis, 20–25	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88248		X	Chromosome analysis, 50–100	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88249		X	Chromosome analysis, 100	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88261		X	Chromosome analysis, 5	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88262		X	Chromosome analysis, 15–20	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
88263		X	Chromosome analysis, 45	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88264		X	Chromosome analysis, 20–25	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88267		X	Chromosome analys, placenta	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88269		X	Chromosome analys, amniotic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88271		X	Cytogenetics, dna probe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88272		X	Cytogenetics, 3–5	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88273		X	Cytogenetics, 10–30	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88274		X	Cytogenetics, 25–99	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88275		X	Cytogenetics, 100–300	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88280		X	Chromosome karyotype study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88283		X	Chromosome banding study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88285		X	Chromosome count, additional	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88289		X	Chromosome study, additional	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88291		A	Cyto/molecular report	0.52	0.23	0.23	0.02	0.77	0.77	XXX
88299		C	Cytogenetic study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88300		A	Surgical path, gross	0.08	NA	0.44	0.02	NA	0.54	XXX
88300	26	A	Surgical path, gross	0.08	0.04	0.04	0.01	0.13	0.13	XXX
88300	TC	A	Surgical path, gross	0.00	NA	0.40	0.01	NA	0.41	XXX
88302		A	Tissue exam by pathologist	0.13	NA	1.12	0.03	NA	1.28	XXX
88302	26	A	Tissue exam by pathologist	0.13	0.06	0.06	0.01	0.20	0.20	XXX
88302	TC	A	Tissue exam by pathologist	0.00	NA	1.06	0.02	NA	1.08	XXX
88304		A	Tissue exam by pathologist	0.22	NA	0.93	0.03	NA	1.18	XXX
88304	26	A	Tissue exam by pathologist	0.22	0.10	0.10	0.01	0.33	0.33	XXX
88304	TC	A	Tissue exam by pathologist	0.00	NA	0.83	0.02	NA	0.85	XXX
88305		A	Tissue exam by pathologist	0.75	NA	1.77	0.05	NA	2.57	XXX
88305	26	A	Tissue exam by pathologist	0.75	0.35	0.35	0.02	1.12	1.12	XXX
88305	TC	A	Tissue exam by pathologist	0.00	NA	1.42	0.03	NA	1.45	XXX
88307		A	Tissue exam by pathologist	1.59	NA	2.56	0.11	NA	4.26	XXX
88307	26	A	Tissue exam by pathologist	1.59	0.73	0.73	0.06	2.38	2.38	XXX
88307	TC	A	Tissue exam by pathologist	0.00	NA	1.83	0.05	NA	1.88	XXX
88309		A	Tissue exam by pathologist	2.28	NA	3.57	0.13	NA	5.98	XXX
88309	26	A	Tissue exam by pathologist	2.28	1.04	1.04	0.08	3.40	3.40	XXX
88309	TC	A	Tissue exam by pathologist	0.00	NA	2.53	0.05	NA	2.58	XXX
88311		A	Decalcify tissue	0.24	NA	0.19	0.02	NA	0.45	XXX
88311	26	A	Decalcify tissue	0.24	0.11	0.11	0.01	0.36	0.36	XXX
88311	TC	A	Decalcify tissue	0.00	NA	0.08	0.01	NA	0.09	XXX
88312		A	Special stains	0.54	NA	1.69	0.03	NA	2.26	XXX
88312	26	A	Special stains	0.54	0.25	0.25	0.02	0.81	0.81	XXX
88312	TC	A	Special stains	0.00	NA	1.44	0.01	NA	1.45	XXX
88313		A	Special stains	0.24	NA	1.16	0.02	NA	1.42	XXX
88313	26	A	Special stains	0.24	0.11	0.11	0.01	0.36	0.36	XXX
88313	TC	A	Special stains	0.00	NA	1.05	0.01	NA	1.06	XXX
88314		A	Histochemical stain	0.45	NA	1.05	0.04	NA	1.54	XXX
88314	26	A	Histochemical stain	0.45	0.20	0.20	0.02	0.67	0.67	XXX
88314	TC	A	Histochemical stain	0.00	NA	0.85	0.02	NA	0.87	XXX
88318		A	Chemical histochemistry	0.42	NA	1.78	0.02	NA	2.22	XXX
88318	26	A	Chemical histochemistry	0.42	0.19	0.19	0.01	0.62	0.62	XXX
88318	TC	A	Chemical histochemistry	0.00	NA	1.59	0.01	NA	1.60	XXX
88319		A	Enzyme histochemistry	0.53	NA	1.75	0.04	NA	2.32	XXX
88319	26	A	Enzyme histochemistry	0.53	0.24	0.24	0.02	0.79	0.79	XXX
88319	TC	A	Enzyme histochemistry	0.00	NA	1.51	0.02	NA	1.53	XXX
88321		A	Microslide consultation	1.30	0.59	0.62	0.04	1.93	1.96	XXX
88323		A	Microslide consultation	1.35	NA	2.28	0.07	NA	3.70	XXX
88323	26	A	Microslide consultation	1.35	0.62	0.62	0.05	2.02	2.02	XXX
88323	TC	A	Microslide consultation	0.00	NA	1.66	0.02	NA	1.68	XXX
88325		A	Comprehensive review of data	2.22	0.96	0.96	0.08	3.26	3.26	XXX
88329		A	Path consult introp	0.67	0.31	0.41	0.02	1.00	1.10	XXX
88331		A	Path consult intraop, 1 bloc	1.19	NA	0.84	0.07	NA	2.10	XXX
88331	26	A	Path consult intraop, 1 bloc	1.19	0.54	0.54	0.04	1.77	1.77	XXX
88331	TC	A	Path consult intraop, 1 bloc	0.00	NA	0.30	0.03	NA	0.33	XXX
88332		A	Path consult intraop, addl	0.59	NA	0.46	0.04	NA	1.09	XXX
88332	26	A	Path consult intraop, addl	0.59	0.27	0.27	0.02	0.88	0.88	XXX
88332	TC	A	Path consult intraop, addl	0.00	NA	0.19	0.02	NA	0.21	XXX
88342		A	Immunocytochemistry	0.85	NA	1.37	0.05	NA	2.27	XXX
88342	26	A	Immunocytochemistry	0.85	0.39	0.39	0.03	1.27	1.27	XXX
88342	TC	A	Immunocytochemistry	0.00	NA	0.98	0.02	NA	1.00	XXX
88346		A	Immunofluorescent study	0.86	NA	1.38	0.05	NA	2.29	XXX
88346	26	A	Immunofluorescent study	0.86	0.39	0.39	0.03	1.28	1.28	XXX
88346	TC	A	Immunofluorescent study	0.00	NA	0.99	0.02	NA	1.01	XXX
88347		A	Immunofluorescent study	0.86	NA	1.92	0.05	NA	2.83	XXX
88347	26	A	Immunofluorescent study	0.86	0.38	0.38	0.03	1.27	1.27	XXX
88347	TC	A	Immunofluorescent study	0.00	NA	1.54	0.02	NA	1.56	XXX
88348		A	Electron microscopy	1.51	NA	6.42	0.11	NA	8.04	XXX
88348	26	A	Electron microscopy	1.51	0.68	0.68	0.05	2.24	2.24	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
88348	TC	A	Electron microscopy	0.00	NA	5.74	0.06	NA	5.80	XXX
88349		A	Scanning electron microscopy	0.76	NA	7.92	0.08	NA	8.76	XXX
88349	26	A	Scanning electron microscopy	0.76	0.35	0.35	0.03	1.14	1.14	XXX
88349	TC	A	Scanning electron microscopy	0.00	NA	7.57	0.05	NA	7.62	XXX
88355		A	Analysis, skeletal muscle	1.85	NA	3.96	0.12	NA	5.93	XXX
88355	26	A	Analysis, skeletal muscle	1.85	0.85	0.85	0.07	2.77	2.77	XXX
88355	TC	A	Analysis, skeletal muscle	0.00	NA	3.11	0.05	NA	3.16	XXX
88356		A	Analysis, nerve	3.02	NA	4.47	0.16	NA	7.65	XXX
88356	26	A	Analysis, nerve	3.02	1.36	1.36	0.10	4.48	4.48	XXX
88356	TC	A	Analysis, nerve	0.00	NA	3.11	0.06	NA	3.17	XXX
88358		A	Analysis, tumor	2.82	NA	1.71	0.16	NA	4.69	XXX
88358	26	A	Analysis, tumor	2.82	1.28	1.28	0.10	4.20	4.20	XXX
88358	TC	A	Analysis, tumor	0.00	NA	0.43	0.06	NA	0.49	XXX
88362		A	Nerve teasing preparations	2.17	NA	1.39	0.12	NA	3.68	XXX
88362	26	A	Nerve teasing preparations	2.17	0.97	0.97	0.07	3.21	3.21	XXX
88362	TC	A	Nerve teasing preparations	0.00	NA	0.42	0.05	NA	0.47	XXX
88365		A	Tissue hybridization	0.93	NA	1.43	0.05	NA	2.41	XXX
88365	26	A	Tissue hybridization	0.93	0.41	0.41	0.03	1.37	1.37	XXX
88365	TC	A	Tissue hybridization	0.00	NA	1.02	0.02	NA	1.04	XXX
88371		X	Protein, western blot tissue	+0.00	0.14	0.14	0.00	0.14	0.14	XXX
88371	26	A	Protein, western blot tissue	0.37	0.14	0.14	0.01	0.52	0.52	XXX
88372		X	Protein analysis w/probe	+0.00	0.15	0.15	0.00	0.15	0.15	XXX
88372	26	A	Protein analysis w/probe	0.37	0.15	0.15	0.01	0.53	0.53	XXX
88399		C	Surgical pathology procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
88399	26	C	Surgical pathology procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88399	TC	C	Surgical pathology procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
88400		X	Bilirubin total transcut	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89050		X	Body fluid cell count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89051		X	Body fluid cell count	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89060		X	Exam,synovial fluid crystals	+0.00	0.17	0.17	0.00	0.17	0.17	XXX
89060	26	A	Exam,synovial fluid crystals	0.37	0.17	0.17	0.01	0.55	0.55	XXX
89100		A	Sample intestinal contents	0.60	0.23	2.07	0.02	0.85	2.69	XXX
89105		A	Sample intestinal contents	0.50	0.18	2.25	0.02	0.70	2.77	XXX
89125		X	Specimen fat stain	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89130		A	Sample stomach contents	0.45	0.13	1.92	0.02	0.60	2.39	XXX
89132		A	Sample stomach contents	0.19	0.08	1.82	0.01	0.28	2.02	XXX
89135		A	Sample stomach contents	0.79	0.28	2.11	0.03	1.10	2.93	XXX
89136		A	Sample stomach contents	0.21	0.08	1.39	0.01	0.30	1.61	XXX
89140		A	Sample stomach contents	0.94	0.27	2.24	0.03	1.24	3.21	XXX
89141		A	Sample stomach contents	0.85	0.35	2.76	0.03	1.23	3.64	XXX
89160		X	Exam feces for meat fibers	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89190		X	Nasal smear for eosinophils	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89250		X	Fertilization of oocyte	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89251		X	Culture oocyte w/embryos	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89252		X	Assist oocyte fertilization	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89253		X	Embryo hatching	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89254		X	Oocyte identification	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89255		X	Prepare embryo for transfer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89256		X	Prepare cryopreserved embryo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89257		X	Sperm identification	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89258		X	Cryopreservation, embryo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89259		X	Cryopreservation, sperm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89260		X	Sperm isolation, simple	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89261		X	Sperm isolation, complex	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89264		X	Identify sperm tissue	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89300		X	Semen analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89310		X	Semen analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89320		X	Semen analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89321		X	Semen analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89325		X	Sperm antibody test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89329		X	Sperm evaluation test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89330		X	Evaluation, cervical mucus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89350		A	Sputum specimen collection	0.00	NA	0.40	0.02	NA	0.42	XXX
89355		X	Exam feces for starch	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89360		A	Collect sweat for test	0.00	NA	0.45	0.02	NA	0.47	XXX
89365		X	Water load test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89399		C	Pathology lab procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
89399	26	C	Pathology lab procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89399	TC	C	Pathology lab procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
90281		I	Human ig, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90283		I	Human ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90287		I	Botulinum antitoxin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90288		I	Botulism ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90291		I	Cmv ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
90296		E	Diphtheria antitoxin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90371		E	Hep b ig, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90375		E	Rabies ig, im/sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90376		E	Rabies ig, heat treated	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90378		X	Rsv ig, im, 50mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90379		E	Rsv ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90384		I	Rh ig, full-dose, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90385		E	Rh ig, minidose, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90386		I	Rh ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90389		E	Tetanus ig, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90393		E	Vaccina ig, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90396		E	Varicella-zoster ig, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90399		I	Immune globulin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90471		N	Immunization admin	0.00	NA	0.00	0.00	NA	0.00	XXX
90472		N	Immunization admin, each add	0.00	NA	0.00	0.00	NA	0.00	XXX
90476		E	Adenovirus vaccine, type 4	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90477		E	Adenovirus vaccine, type 7	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90581		E	Anthrax vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90585		E	Bcg vaccine, percut	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90586		E	Bcg vaccine, intravesical	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90632		E	Hep a vaccine, adult im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90633		E	Hep a vacc, ped/adol, 2 dose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90634		E	Hep a vacc, ped/adol, 3 dose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90636		E	Hep a/hep b vacc, adult im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90645		E	Hib vaccine, hboc, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90646		E	Hib vaccine, prp-d, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90647		E	Hib vaccine, prp-omp, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90648		E	Hib vaccine, prp-t, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90657		X	Flu vaccine, 6–35 mo, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90658		X	Flu vaccine, 3 yrs, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90659		X	Flu vaccine, whole, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90660		X	Flu vaccine, nasal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90665		E	Lyme disease vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90669		N	Pneumococcal vacc, ped<5	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90675		E	Rabies vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90676		E	Rabies vaccine, id	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90680		E	Rotovirus vaccine, oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90690		E	Typhoid vaccine, oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90691		E	Typhoid vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90692		E	Typhoid vaccine, h-p, sc/id	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90693		E	Typhoid vaccine, akd, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90700		E	Dtap vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90701		E	Dtp vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90702		E	Dt vaccine < 7, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90703		E	Tetanus vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90704		E	Mumps vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90705		E	Measles vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90706		E	Rubella vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90707		E	Mmr vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90708		E	Measles-rubella vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90709		E	Rubella & mumps vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90710		E	Mmrv vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90712		E	Oral poliovirus vaccine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90713		E	Poliovirus, ipv, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90716		E	Chicken pox vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90717		E	Yellow fever vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90718		E	Td vaccine > 7, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90719		E	Diphtheria vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90720		E	Dtp/hib vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90721		E	Dtap/hib vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90723		X	Dtap-hep b-ipv vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90725		E	Cholera vaccine, injectable	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90727		E	Plague vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90732		X	Pneumococcal vacc, adult/ill	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90733		E	Meningococcal vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90735		E	Encephalitis vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90740		X	Hepb vacc, ill pat 3 dose im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90743		X	Hep b vacc, adol, 2 dose, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90744		X	Hepb vacc ped/adol 3 dose im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90746		X	Hep b vaccine, adult, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90747		X	Hepb vacc, ill pat 4 dose im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90748		E	Hep b/hib vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90749		E	Vaccine toxoid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90780		A	IV infusion therapy, 1 hour	0.00	NA	1.09	0.06	NA	1.15	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
90781		A	IV infusion, additional hour	0.00	NA	0.55	0.03	NA	0.58	ZZZ
90782		T	Injection, sc/im	0.00	NA	0.10	0.01	NA	0.11	XXX
90783		T	Injection, ia	0.00	NA	0.40	0.02	NA	0.42	XXX
90784		T	Injection, iv	0.00	NA	0.47	0.03	NA	0.50	XXX
90788		T	Injection of antibiotic	0.00	NA	0.11	0.01	NA	0.12	XXX
90799		C	Ther/prophylactic/dx inject	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90801		A	Psy dx interview	2.80	0.92	1.13	0.06	3.78	3.99	XXX
90802		A	Intac psy dx interview	3.01	0.98	1.16	0.07	4.06	4.24	XXX
90804		A	Psytx, office, 20–30 min	1.21	0.39	0.53	0.03	1.63	1.77	XXX
90805		A	Psytx, off, 20–30 min w/e&m	1.37	0.44	0.59	0.03	1.84	1.99	XXX
90806		A	Psytx, off, 45–50 min	1.86	0.62	0.75	0.04	2.52	2.65	XXX
90807		A	Psytx, off, 45–50 min w/e&m	2.02	0.66	0.79	0.05	2.73	2.86	XXX
90808		A	Psytx, office, 75–80 min	2.79	0.92	1.07	0.07	3.78	3.93	XXX
90809		A	Psytx, off, 75–80, w/e&m	2.95	0.95	1.11	0.07	3.97	4.13	XXX
90810		A	Intac psytx, off, 20–30 min	1.32	0.43	0.55	0.03	1.78	1.90	XXX
90811		A	Intac psytx, 20–30, w/e&m	1.48	0.48	0.64	0.03	1.99	2.15	XXX
90812		A	Intac psytx, off, 45–50 min	1.97	0.65	0.81	0.05	2.67	2.83	XXX
90813		A	Intac psytx, 45–50 min w/e&m	2.13	0.70	0.87	0.05	2.88	3.05	XXX
90814		A	Intac psytx, off, 75–80 min	2.90	0.95	1.17	0.07	3.92	4.14	XXX
90815		A	Intac psytx, 75–80 w/e&m	3.06	0.98	1.19	0.07	4.11	4.32	XXX
90816		A	Psytx, hosp, 20–30 min	1.25	0.42	0.57	0.03	1.70	1.85	XXX
90817		A	Psytx, hosp, 20–30 min w/e&m	1.41	0.45	0.62	0.03	1.89	2.06	XXX
90818		A	Psytx, hosp, 45–50 min	1.89	0.64	0.79	0.04	2.57	2.72	XXX
90819		A	Psytx, hosp, 45–50 min w/e&m	2.05	0.65	0.82	0.05	2.75	2.92	XXX
90821		A	Psytx, hosp, 75–80 min	2.83	0.95	1.11	0.06	3.84	4.00	XXX
90822		A	Psytx, hosp, 75–80 min w/e&m	2.99	0.96	1.12	0.07	4.02	4.18	XXX
90823		A	Intac psytx, hosp, 20–30 min	1.36	0.45	0.66	0.03	1.84	2.05	XXX
90824		A	Intac psytx, hsp 20–30 w/e&m	1.52	0.49	0.71	0.03	2.04	2.26	XXX
90826		A	Intac psytx, hosp, 45–50 min	2.01	0.68	0.89	0.04	2.73	2.94	XXX
90827		A	Intac psytx, hsp 45–50 w/e&m	2.16	0.69	0.92	0.05	2.90	3.13	XXX
90828		A	Intac psytx, hosp, 75–80 min	2.94	1.00	1.21	0.07	4.01	4.22	XXX
90829		A	Intac psytx, hsp 75–80 w/e&m	3.10	1.00	1.24	0.07	4.17	4.41	XXX
90845		A	Psychoanalysis	1.79	0.58	0.69	0.04	2.41	2.52	XXX
90846		R	Family psytx w/o patient	1.83	0.61	0.73	0.04	2.48	2.60	XXX
90847		R	Family psytx w/patient	2.21	0.74	0.86	0.05	3.00	3.12	XXX
90849		R	Multiple family group psytx	0.59	0.20	0.37	0.01	0.80	0.97	XXX
90853		A	Group psychotherapy	0.59	0.20	0.35	0.01	0.80	0.95	XXX
90857		A	Intac group psytx	0.63	0.21	0.36	0.02	0.86	1.01	XXX
90862		A	Medication management	0.95	0.31	0.44	0.02	1.28	1.41	XXX
90865		A	Narcosynthesis	2.84	0.93	1.65	0.07	3.84	4.56	XXX
90870		A	Electroconvulsive therapy	1.88	0.74	0.74	0.04	2.66	2.66	000
90871		A	Electroconvulsive therapy	2.72	1.02	NA	0.06	3.80	NA	000
90875		N	Psychophysiological therapy	+1.20	0.47	0.89	0.03	1.70	2.12	XXX
90876		N	Psychophysiological therapy	+1.90	0.75	1.17	0.04	2.69	3.11	XXX
90880		A	Hypnotherapy	2.19	0.70	0.88	0.05	2.94	3.12	XXX
90882		N	Environmental manipulation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90885		B	Psy evaluation of records	+0.97	0.38	0.38	0.02	1.37	1.37	XXX
90887		B	Consultation with family	+1.48	0.59	0.82	0.03	2.10	2.33	XXX
90889		B	Preparation of report	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90899		C	Psychiatric service/therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90901		A	Biofeedback train, any meth	0.41	0.18	0.76	0.02	0.61	1.19	000
90911		A	Biofeedback peri/uro/rectal	0.89	0.37	0.89	0.04	1.30	1.82	000
90918		A	ESRD related services, month	11.18	5.35	5.35	0.30	16.83	16.83	XXX
90919		A	ESRD related services, month	8.54	4.40	4.40	0.24	13.18	13.18	XXX
90920		A	ESRD related services, month	7.27	3.81	3.81	0.19	11.27	11.27	XXX
90921		A	ESRD related services, month	4.47	2.71	2.71	0.12	7.30	7.30	XXX
90922		A	ESRD related services, day	0.37	0.16	0.16	0.01	0.54	0.54	XXX
90923		A	Esrd related services, day	0.28	0.14	0.14	0.01	0.43	0.43	XXX
90924		A	Esrd related services, day	0.24	0.13	0.13	0.01	0.38	0.38	XXX
90925		A	Esrd related services, day	0.15	0.09	0.09	0.01	0.25	0.25	XXX
90935		A	Hemodialysis, one evaluation	1.22	0.79	NA	0.03	2.04	NA	000
90937		A	Hemodialysis, repeated eval	2.11	1.11	NA	0.06	3.28	NA	000
90940		X	Hemodialysis access study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90945		A	Dialysis, one evaluation	1.28	0.81	NA	0.04	2.13	NA	000
90947		A	Dialysis, repeated eval	2.16	1.13	NA	0.06	3.35	NA	000
90989		X	Dialysis training, complete	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90993		X	Dialysis training, incompl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90997		A	Hemoperfusion	1.84	1.00	NA	0.05	2.89	NA	000
90999		C	Dialysis procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
91000		A	Esophageal intubation	0.73	NA	0.34	0.04	NA	1.11	000
91000	26	A	Esophageal intubation	0.73	0.26	0.26	0.03	1.02	1.02	000
91000	TC	A	Esophageal intubation	0.00	NA	0.08	0.01	NA	0.09	000
91010		A	Esophagus motility study	1.25	NA	1.27	0.10	NA	2.62	000
91010	26	A	Esophagus motility study	1.25	0.46	0.46	0.05	1.76	1.76	000

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
91010	TC	A	Esophagus motility study	0.00	NA	0.81	0.05	NA	0.86	000
91011		A	Esophagus motility study	1.50	NA	1.57	0.10	NA	3.17	000
91011	26	A	Esophagus motility study	1.50	0.56	0.56	0.05	2.11	2.11	000
91011	TC	A	Esophagus motility study	0.00	NA	1.01	0.05	NA	1.06	000
91012		A	Esophagus motility study	1.46	NA	1.67	0.12	NA	3.25	000
91012	26	A	Esophagus motility study	1.46	0.54	0.54	0.06	2.06	2.06	000
91012	TC	A	Esophagus motility study	0.00	NA	1.13	0.06	NA	1.19	000
91020		A	Gastric motility	1.44	NA	1.26	0.11	NA	2.81	000
91020	26	A	Gastric motility	1.44	0.51	0.51	0.06	2.01	2.01	000
91020	TC	A	Gastric motility	0.00	NA	0.75	0.05	NA	0.80	000
91030		A	Acid perfusion of esophagus	0.91	NA	0.56	0.05	NA	1.52	000
91030	26	A	Acid perfusion of esophagus	0.91	0.34	0.34	0.03	1.28	1.28	000
91030	TC	A	Acid perfusion of esophagus	0.00	NA	0.22	0.02	NA	0.24	000
91032		A	Esophagus, acid reflux test	1.21	NA	1.17	0.10	NA	2.48	000
91032	26	A	Esophagus, acid reflux test	1.21	0.44	0.44	0.05	1.70	1.70	000
91032	TC	A	Esophagus, acid reflux test	0.00	NA	0.73	0.05	NA	0.78	000
91033		A	Prolonged acid reflux test	1.30	NA	1.80	0.14	NA	3.24	000
91033	26	A	Prolonged acid reflux test	1.30	0.48	0.48	0.05	1.83	1.83	000
91033	TC	A	Prolonged acid reflux test	0.00	NA	1.32	0.09	NA	1.41	000
91052		A	Gastric analysis test	0.79	NA	0.62	0.05	NA	1.46	000
91052	26	A	Gastric analysis test	0.79	0.29	0.29	0.03	1.11	1.11	000
91052	TC	A	Gastric analysis test	0.00	NA	0.33	0.02	NA	0.35	000
91055		A	Gastric intubation for smear	0.94	NA	0.58	0.06	NA	1.58	000
91055	26	A	Gastric intubation for smear	0.94	0.28	0.28	0.04	1.26	1.26	000
91055	TC	A	Gastric intubation for smear	0.00	NA	0.30	0.02	NA	0.32	000
91060		A	Gastric saline load test	0.45	NA	0.36	0.04	NA	0.85	000
91060	26	A	Gastric saline load test	0.45	0.14	0.14	0.02	0.61	0.61	000
91060	TC	A	Gastric saline load test	0.00	NA	0.22	0.02	NA	0.24	000
91065		A	Breath hydrogen test	0.20	NA	0.42	0.03	NA	0.65	000
91065	26	A	Breath hydrogen test	0.20	0.07	0.07	0.01	0.28	0.28	000
91065	TC	A	Breath hydrogen test	0.00	NA	0.35	0.02	NA	0.37	000
91100		A	Pass intestine bleeding tube	1.08	0.46	NA	0.06	1.60	NA	000
91105		A	Gastric intubation treatment	0.37	0.20	NA	0.02	0.59	NA	000
91122		A	Anal pressure record	1.77	NA	1.34	0.17	NA	3.28	000
91122	26	A	Anal pressure record	1.77	0.64	0.64	0.10	2.51	2.51	000
91122	TC	A	Anal pressure record	0.00	NA	0.70	0.07	NA	0.77	000
91132		C	Electrogastrography	0.00	NA	0.00	0.00	NA	0.00	XXX
91132	26	C	Electrogastrography	0.00	0.00	0.00	0.00	0.00	0.00	XXX
91132	TC	C	Electrogastrography	0.00	NA	0.00	0.00	NA	0.00	XXX
91133		C	Electrogastrography w/test	0.00	NA	0.00	0.00	NA	0.00	XXX
91133	26	C	Electrogastrography w/test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
91133	TC	C	Electrogastrography w/test	0.00	NA	0.00	0.00	NA	0.00	XXX
91299		C	Gastroenterology procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
91299	26	C	Gastroenterology procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
91299	TC	C	Gastroenterology procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
92002		A	Eye exam, new patient	0.88	0.36	1.12	0.02	1.26	2.02	XXX
92004		A	Eye exam, new patient	1.67	0.71	1.72	0.03	2.41	3.42	XXX
92012		A	Eye exam established pat	0.67	0.30	1.04	0.01	0.98	1.72	XXX
92014		A	Eye exam & treatment	1.10	0.49	1.35	0.02	1.61	2.47	XXX
92015		N	Refraction	+0.38	0.15	1.43	0.01	0.54	1.82	XXX
92018		A	New eye exam & treatment	2.50	1.15	NA	0.03	3.68	NA	XXX
92019		A	Eye exam & treatment	1.31	0.60	NA	0.03	1.94	NA	XXX
92020		A	Special eye evaluation	0.37	0.17	0.70	0.01	0.55	1.08	XXX
92060		A	Special eye evaluation	0.69	NA	1.54	0.02	NA	2.25	XXX
92060	26	A	Special eye evaluation	0.69	0.30	0.30	0.01	1.00	1.00	XXX
92060	TC	A	Special eye evaluation	0.00	NA	1.24	0.01	NA	1.25	XXX
92065		A	Orthoptic/pleoptic training	0.37	NA	0.83	0.02	NA	1.22	XXX
92065	26	A	Orthoptic/pleoptic training	0.37	0.16	0.16	0.01	0.54	0.54	XXX
92065	TC	A	Orthoptic/pleoptic training	0.00	NA	0.67	0.01	NA	0.68	XXX
92070		A	Fitting of contact lens	0.70	0.33	0.98	0.01	1.04	1.69	XXX
92081		A	Visual field examination(s)	0.36	NA	1.43	0.02	NA	1.81	XXX
92081	26	A	Visual field examination(s)	0.36	0.16	0.16	0.01	0.53	0.53	XXX
92081	TC	A	Visual field examination(s)	0.00	NA	1.27	0.01	NA	1.28	XXX
92082		A	Visual field examination(s)	0.44	NA	1.28	0.02	NA	1.74	XXX
92082	26	A	Visual field examination(s)	0.44	0.20	0.20	0.01	0.65	0.65	XXX
92082	TC	A	Visual field examination(s)	0.00	NA	1.08	0.01	NA	1.09	XXX
92083		A	Visual field examination(s)	0.50	NA	1.24	0.02	NA	1.76	XXX
92083	26	A	Visual field examination(s)	0.50	0.23	0.23	0.01	0.74	0.74	XXX
92083	TC	A	Visual field examination(s)	0.00	NA	1.01	0.01	NA	1.02	XXX
92100		A	Serial tonometry exam(s)	0.92	0.40	0.78	0.02	1.34	1.72	XXX
92120		A	Tonography & eye evaluation	0.81	0.32	0.76	0.02	1.15	1.59	XXX
92130		A	Water provocation tonography	0.81	0.39	0.86	0.02	1.22	1.69	XXX
92135		A	Opthalmic dx imaging	0.35	NA	1.20	0.02	NA	1.57	XXX
92135	26	A	Opthalmic dx imaging	0.35	0.16	0.16	0.01	0.52	0.52	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
92135	TC	A	Opthalmic dx imaging	0.00	NA	1.04	0.01	NA	1.05	XXX
92140		A	Glaucoma provocative tests	0.50	0.22	0.95	0.01	0.73	1.46	XXX
92225		A	Special eye exam, initial	0.38	0.16	1.66	0.01	0.55	2.05	XXX
92226		A	Special eye exam, subsequent	0.33	0.15	1.74	0.01	0.49	2.08	XXX
92230		A	Eye exam with photos	0.60	0.18	1.28	0.02	0.80	1.90	XXX
92235		A	Eye exam with photos	0.81	NA	2.11	0.07	NA	2.99	XXX
92235	26	A	Eye exam with photos	0.81	0.38	0.38	0.02	1.21	1.21	XXX
92235	TC	A	Eye exam with photos	0.00	NA	1.73	0.05	NA	1.78	XXX
92240		A	Icg angiography	1.10	NA	2.55	0.07	NA	3.72	XXX
92240	26	A	Icg angiography	1.10	0.51	0.51	0.02	1.63	1.63	XXX
92240	TC	A	Icg angiography	0.00	NA	2.04	0.05	NA	2.09	XXX
92250		A	Eye exam with photos	0.44	NA	1.69	0.02	NA	2.15	XXX
92250	26	A	Eye exam with photos	0.44	0.20	0.20	0.01	0.65	0.65	XXX
92250	TC	A	Eye exam with photos	0.00	NA	1.49	0.01	NA	1.50	XXX
92260		A	Ophthalmoscopy/dynamometry	0.20	0.09	0.22	0.01	0.30	0.43	XXX
92265		A	Eye muscle evaluation	0.81	NA	1.35	0.04	NA	2.20	XXX
92265	26	A	Eye muscle evaluation	0.81	0.33	0.33	0.02	1.16	1.16	XXX
92265	TC	A	Eye muscle evaluation	0.00	NA	1.02	0.02	NA	1.04	XXX
92270		A	Electro-oculography	0.81	NA	1.17	0.05	NA	2.03	XXX
92270	26	A	Electro-oculography	0.81	0.36	0.36	0.03	1.20	1.20	XXX
92270	TC	A	Electro-oculography	0.00	NA	0.81	0.02	NA	0.83	XXX
92275		A	Electroretinography	1.01	NA	1.19	0.04	NA	2.24	XXX
92275	26	A	Electroretinography	1.01	0.45	0.45	0.02	1.48	1.48	XXX
92275	TC	A	Electroretinography	0.00	NA	0.74	0.02	NA	0.76	XXX
92283		A	Color vision examination	0.17	NA	0.67	0.02	NA	0.86	XXX
92283	26	A	Color vision examination	0.17	0.07	0.07	0.01	0.25	0.25	XXX
92283	TC	A	Color vision examination	0.00	NA	0.60	0.01	NA	0.61	XXX
92284		A	Dark adaptation eye exam	0.24	NA	2.15	0.02	NA	2.41	XXX
92284	26	A	Dark adaptation eye exam	0.24	0.08	0.08	0.01	0.33	0.33	XXX
92284	TC	A	Dark adaptation eye exam	0.00	NA	2.07	0.01	NA	2.08	XXX
92285		A	Eye photography	0.20	NA	1.82	0.02	NA	2.04	XXX
92285	26	A	Eye photography	0.20	0.09	0.09	0.01	0.30	0.30	XXX
92285	TC	A	Eye photography	0.00	NA	1.73	0.01	NA	1.74	XXX
92286		A	Internal eye photography	0.66	NA	1.98	0.03	NA	2.67	XXX
92286	26	A	Internal eye photography	0.66	0.31	0.31	0.01	0.98	0.98	XXX
92286	TC	A	Internal eye photography	0.00	NA	1.67	0.02	NA	1.69	XXX
92287		A	Internal eye photography	0.81	0.30	1.89	0.02	1.13	2.72	XXX
92310		N	Contact lens fitting	+1.17	0.46	1.08	0.00	1.63	2.25	XXX
92311		A	Contact lens fitting	1.08	0.40	1.02	0.03	1.51	2.13	XXX
92312		A	Contact lens fitting	1.26	0.46	1.01	0.03	1.75	2.30	XXX
92313		A	Contact lens fitting	0.92	0.31	1.02	0.02	1.25	1.96	XXX
92314		N	Prescription of contact lens	+0.69	0.27	0.89	0.00	0.96	1.58	XXX
92315		A	Prescription of contact lens	0.45	0.18	0.74	0.01	0.64	1.20	XXX
92316		A	Prescription of contact lens	0.68	0.27	0.82	0.01	0.96	1.51	XXX
92317		A	Prescription of contact lens	0.45	0.15	0.88	0.01	0.61	1.34	XXX
92325		A	Modification of contact lens	0.00	NA	0.39	0.01	NA	0.40	XXX
92326		A	Replacement of contact lens	0.00	NA	1.61	0.05	NA	1.66	XXX
92330		A	Fitting of artificial eye	1.08	0.43	0.98	0.04	1.55	2.10	XXX
92335		A	Fitting of artificial eye	0.45	0.18	0.80	0.01	0.64	1.26	XXX
92340		N	Fitting of spectacles	+0.37	0.15	0.66	0.00	0.52	1.03	XXX
92341		N	Fitting of spectacles	+0.47	0.19	0.70	0.00	0.66	1.17	XXX
92342		N	Fitting of spectacles	+0.53	0.21	0.73	0.00	0.74	1.26	XXX
92352		B	Special spectacles fitting	+0.37	0.15	0.66	0.01	0.53	1.04	XXX
92353		B	Special spectacles fitting	+0.50	0.20	0.71	0.02	0.72	1.23	XXX
92354		B	Special spectacles fitting	+0.00	NA	8.72	0.08	NA	8.80	XXX
92355		B	Special spectacles fitting	+0.00	NA	4.27	0.01	NA	4.28	XXX
92358		B	Eye prosthesis service	+0.00	NA	0.95	0.04	NA	0.99	XXX
92370		N	Repair & adjust spectacles	+0.32	0.13	0.52	0.00	0.45	0.84	XXX
92371		B	Repair & adjust spectacles	+0.00	NA	0.61	0.02	NA	0.63	XXX
92390		N	Supply of spectacles	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92391		N	Supply of contact lenses	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92392		I	Supply of low vision aids	+0.00	NA	3.98	0.02	NA	4.00	XXX
92393		I	Supply of artificial eye	+0.00	NA	12.36	0.47	NA	12.83	XXX
92395		I	Supply of spectacles	+0.00	NA	1.35	0.08	NA	1.43	XXX
92396		I	Supply of contact lenses	+0.00	NA	2.27	0.06	NA	2.33	XXX
92499		C	Eye service or procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
92499	26	C	Eye service or procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92499	TC	C	Eye service or procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
92502		A	Ear and throat examination	1.51	1.32	NA	0.06	2.89	NA	000
92504		A	Ear microscopy examination	0.18	0.09	1.02	0.01	0.28	1.21	XXX
92506		A	Speech/hearing evaluation	0.86	0.46	1.60	0.04	1.36	2.50	XXX
92507		A	Speech/hearing therapy	0.52	0.28	1.47	0.02	0.82	2.01	XXX
92508		A	Speech/hearing therapy	0.26	0.15	1.03	0.01	0.42	1.30	XXX
92510		A	Rehab for ear implant	1.50	0.86	2.02	0.06	2.42	3.58	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
92511		A	Nasopharyngoscopy	0.84	0.43	1.28	0.03	1.30	2.15	000
92512		A	Nasal function studies	0.55	0.19	1.08	0.02	0.76	1.65	XXX
92516		A	Facial nerve function test	0.43	0.24	0.89	0.02	0.69	1.34	XXX
92520		A	Laryngeal function studies	0.76	0.37	0.57	0.03	1.16	1.36	XXX
92525		G	Oral function evaluation	1.50	0.59	1.66	0.07	2.16	3.23	XXX
92526		A	Oral function therapy	0.55	0.26	1.72	0.02	0.83	2.29	XXX
92531		B	Spontaneous nystagmus study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92532		B	Positional nystagmus study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92533		B	Caloric vestibular test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92534		B	Optokinetic nystagmus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92541		A	Spontaneous nystagmus test	0.40	NA	0.43	0.04	NA	0.87	XXX
92541	26	A	Spontaneous nystagmus test	0.40	0.20	0.20	0.02	0.62	0.62	XXX
92541	TC	A	Spontaneous nystagmus test	0.00	NA	0.23	0.02	NA	0.25	XXX
92542		A	Positional nystagmus test	0.33	NA	0.43	0.03	NA	0.79	XXX
92542	26	A	Positional nystagmus test	0.33	0.17	0.17	0.01	0.51	0.51	XXX
92542	TC	A	Positional nystagmus test	0.00	NA	0.26	0.02	NA	0.28	XXX
92543		A	Caloric vestibular test	0.10	NA	0.15	0.02	NA	0.27	XXX
92543	26	A	Caloric vestibular test	0.10	0.05	0.05	0.01	0.16	0.16	XXX
92543	TC	A	Caloric vestibular test	0.00	NA	0.10	0.01	NA	0.11	XXX
92544		A	Optokinetic nystagmus test	0.26	NA	0.34	0.03	NA	0.63	XXX
92544	26	A	Optokinetic nystagmus test	0.26	0.13	0.13	0.01	0.40	0.40	XXX
92544	TC	A	Optokinetic nystagmus test	0.00	NA	0.21	0.02	NA	0.23	XXX
92545		A	Oscillating tracking test	0.23	NA	0.32	0.03	NA	0.58	XXX
92545	26	A	Oscillating tracking test	0.23	0.11	0.11	0.01	0.35	0.35	XXX
92545	TC	A	Oscillating tracking test	0.00	NA	0.21	0.02	NA	0.23	XXX
92546		A	Sinusoidal rotational test	0.29	NA	0.38	0.03	NA	0.70	XXX
92546	26	A	Sinusoidal rotational test	0.29	0.14	0.14	0.01	0.44	0.44	XXX
92546	TC	A	Sinusoidal rotational test	0.00	NA	0.24	0.02	NA	0.26	XXX
92547		A	Supplemental electrical test	0.00	NA	0.55	0.05	NA	0.60	ZZZ
92548		A	Posturography	0.50	NA	1.72	0.13	NA	2.35	XXX
92548	26	A	Posturography	0.50	0.27	0.27	0.02	0.79	0.79	XXX
92548	TC	A	Posturography	0.00	NA	1.45	0.11	NA	1.56	XXX
92551		N	Pure tone hearing test, air	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92552		A	Pure tone audiometry, air	0.00	NA	0.44	0.03	NA	0.47	XXX
92553		A	Audiometry, air & bone	0.00	NA	0.65	0.05	NA	0.70	XXX
92555		A	Speech threshold audiometry	0.00	NA	0.37	0.03	NA	0.40	XXX
92556		A	Speech audiometry, complete	0.00	NA	0.56	0.05	NA	0.61	XXX
92557		A	Comprehensive hearing test	0.00	NA	1.17	0.10	NA	1.27	XXX
92559		N	Group audiometric testing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92560		N	Bekesy audiometry, screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92561		A	Bekesy audiometry, diagnosis	0.00	NA	0.70	0.05	NA	0.75	XXX
92562		A	Loudness balance test	0.00	NA	0.40	0.03	NA	0.43	XXX
92563		A	Tone decay hearing test	0.00	NA	0.37	0.03	NA	0.40	XXX
92564		A	Sisi hearing test	0.00	NA	0.47	0.04	NA	0.51	XXX
92565		A	Stenger test, pure tone	0.00	NA	0.39	0.03	NA	0.42	XXX
92567		A	Tympanometry	0.00	NA	0.51	0.05	NA	0.56	XXX
92568		A	Acoustic reflex testing	0.00	NA	0.37	0.03	NA	0.40	XXX
92569		A	Acoustic reflex decay test	0.00	NA	0.40	0.03	NA	0.43	XXX
92571		A	Filtered speech hearing test	0.00	NA	0.38	0.03	NA	0.41	XXX
92572		A	Staggered spondaic word test	0.00	NA	0.09	0.01	NA	0.10	XXX
92573		A	Lombard test	0.00	NA	0.34	0.03	NA	0.37	XXX
92575		A	Sensorineural acuity test	0.00	NA	0.30	0.02	NA	0.32	XXX
92576		A	Synthetic sentence test	0.00	NA	0.44	0.04	NA	0.48	XXX
92577		A	Stenger test, speech	0.00	NA	0.70	0.06	NA	0.76	XXX
92579		A	Visual audiometry (vra)	0.00	NA	0.71	0.05	NA	0.76	XXX
92582		A	Conditioning play audiometry	0.00	NA	0.71	0.05	NA	0.76	XXX
92583		A	Select picture audiometry	0.00	NA	0.88	0.07	NA	0.95	XXX
92584		A	Electrocochleography	0.00	NA	2.44	0.17	NA	2.61	XXX
92585		A	Auditor evoke potent, compre	0.50	NA	2.05	0.14	NA	2.69	XXX
92585	26	A	Auditor evoke potent, compre	0.50	0.23	0.23	0.02	0.75	0.75	XXX
92585	TC	A	Auditor evoke potent, compre	0.00	NA	1.82	0.12	NA	1.94	XXX
92586		A	Auditor evoke potent, limit	0.00	NA	1.82	0.12	NA	1.94	XXX
92587		A	Evoked auditory test	0.13	NA	1.36	0.10	NA	1.59	XXX
92587	26	A	Evoked auditory test	0.13	0.07	0.07	0.01	0.21	0.21	XXX
92587	TC	A	Evoked auditory test	0.00	NA	1.29	0.09	NA	1.38	XXX
92588		A	Evoked auditory test	0.36	NA	1.62	0.12	NA	2.10	XXX
92588	26	A	Evoked auditory test	0.36	0.17	0.17	0.01	0.54	0.54	XXX
92588	TC	A	Evoked auditory test	0.00	NA	1.45	0.11	NA	1.56	XXX
92589		A	Auditory function test(s)	0.00	NA	0.52	0.05	NA	0.57	XXX
92590		N	Hearing aid exam, one ear	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92591		N	Hearing aid exam, both ears	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92592		N	Hearing aid check, one ear	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92593		N	Hearing aid check, both ears	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92594		N	Electro hearng aid test, one	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
92595		N	Electro hearng aid tst, both	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92596		A	Ear protector evaluation	0.00	NA	0.58	0.05	NA	0.63	XXX
92597		G	Oral speech device eval	1.35	0.53	1.60	0.05	1.93	3.00	XXX
92598		G	Modify oral speech device	0.99	0.39	0.80	0.04	1.42	1.83	XXX
92599		C	ENT procedure/service	0.00	NA	0.00	0.00	NA	0.00	XXX
92599	26	C	ENT procedure/service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92599	TC	C	ENT procedure/service	0.00	NA	0.00	0.00	NA	0.00	XXX
92950		A	Heart/lung resuscitation cpr	3.80	1.16	1.37	0.21	5.17	5.38	000
92953		A	Temporary external pacing	0.23	0.23	NA	0.01	0.47	NA	000
92960		A	Cardioversion electric, ext	2.25	0.88	2.22	0.08	3.21	4.55	000
92961		A	Cardioversion, electric, int	4.60	1.85	NA	0.17	6.62	NA	000
92970		A	Cardioassist, internal	3.52	1.03	NA	0.17	4.72	NA	000
92971		A	Cardioassist, external	1.77	0.88	NA	0.06	2.71	NA	000
92975		A	Dissolve clot, heart vessel	7.25	3.00	NA	0.22	10.47	NA	000
92977		A	Dissolve clot, heart vessel	0.00	NA	7.93	0.38	NA	8.31	XXX
92978		A	Intravasc us, heart add-on	1.80	NA	5.23	0.26	NA	7.29	ZZZ
92978	26	A	Intravasc us, heart add-on	1.80	0.74	0.74	0.06	2.60	2.60	ZZZ
92978	TC	A	Intravasc us, heart add-on	0.00	NA	4.49	0.20	NA	4.69	ZZZ
92979		A	Intravasc us, heart add-on	1.44	NA	2.85	0.15	NA	4.44	ZZZ
92979	26	A	Intravasc us, heart add-on	1.44	0.59	0.59	0.04	2.07	2.07	ZZZ
92979	TC	A	Intravasc us, heart add-on	0.00	NA	2.26	0.11	NA	2.37	ZZZ
92980		A	Insert intracoronary stent	14.84	6.15	NA	0.78	21.77	NA	000
92981		A	Insert intracoronary stent	4.17	1.72	NA	0.21	6.10	NA	ZZZ
92982		A	Coronary artery dilation	10.98	4.56	NA	0.57	16.11	NA	000
92984		A	Coronary artery dilation	2.97	1.22	NA	0.16	4.35	NA	ZZZ
92986		A	Revision of aortic valve	21.80	10.37	NA	1.14	33.31	NA	090
92987		A	Revision of mitral valve	22.70	10.75	NA	1.18	34.63	NA	090
92990		A	Revision of pulmonary valve	17.34	8.54	NA	0.90	26.78	NA	090
92992		C	Revision of heart chamber	0.00	0.00	0.00	0.00	0.00	0.00	090
92993		C	Revision of heart chamber	0.00	0.00	0.00	0.00	0.00	0.00	090
92995		A	Coronary atherectomy	12.09	5.01	NA	0.63	17.73	NA	000
92996		A	Coronary atherectomy add-on	3.26	1.38	NA	0.17	4.81	NA	ZZZ
92997		A	Pul art balloon repr, percut	12.00	4.84	NA	0.63	17.47	NA	000
92998		A	Pul art balloon repr, percut	6.00	2.38	NA	0.31	8.69	NA	ZZZ
93000		A	Electrocardiogram, complete	0.17	NA	0.51	0.03	NA	0.71	XXX
93005		A	Electrocardiogram, tracing	0.00	NA	0.45	0.02	NA	0.47	XXX
93010		A	Electrocardiogram report	0.17	0.06	0.06	0.01	0.24	0.24	XXX
93012		A	Transmission of ecg	0.00	NA	2.32	0.15	NA	2.47	XXX
93014		A	Report on transmitted ecg	0.52	0.19	0.19	0.02	0.73	0.73	XXX
93015		A	Cardiovascular stress test	0.75	NA	1.95	0.11	NA	2.81	XXX
93016		A	Cardiovascular stress test	0.45	0.18	0.18	0.01	0.64	0.64	XXX
93017		A	Cardiovascular stress test	0.00	NA	1.66	0.09	NA	1.75	XXX
93018		A	Cardiovascular stress test	0.30	0.12	0.12	0.01	0.43	0.43	XXX
93024		A	Cardiac drug stress test	1.17	NA	1.57	0.11	NA	2.85	XXX
93024	26	A	Cardiac drug stress test	1.17	0.47	0.47	0.04	1.68	1.68	XXX
93024	TC	A	Cardiac drug stress test	0.00	NA	1.10	0.07	NA	1.17	XXX
93040		A	Rhythm ECG with report	0.16	NA	0.19	0.02	NA	0.37	XXX
93041		A	Rhythm ECG, tracing	0.00	NA	0.14	0.01	NA	0.15	XXX
93042		A	Rhythm ECG, report	0.16	0.05	0.05	0.01	0.22	0.22	XXX
93224		A	ECG monitor/report, 24 hrs	0.52	NA	3.57	0.21	NA	4.30	XXX
93225		A	ECG monitor/record, 24 hrs	0.00	NA	1.22	0.07	NA	1.29	XXX
93226		A	ECG monitor/report, 24 hrs	0.00	NA	2.15	0.12	NA	2.27	XXX
93227		A	ECG monitor/review, 24 hrs	0.52	0.20	0.20	0.02	0.74	0.74	XXX
93230		A	ECG monitor/report, 24 hrs	0.52	NA	3.84	0.22	NA	4.58	XXX
93231		A	Ecg monitor/record, 24 hrs	0.00	NA	1.49	0.09	NA	1.58	XXX
93232		A	ECG monitor/report, 24 hrs	0.00	NA	2.14	0.11	NA	2.25	XXX
93233		A	ECG monitor/review, 24 hrs	0.52	0.20	0.20	0.02	0.74	0.74	XXX
93235		A	ECG monitor/report, 24 hrs	0.45	NA	2.75	0.13	NA	3.33	XXX
93236		A	ECG monitor/report, 24 hrs	0.00	NA	2.58	0.12	NA	2.70	XXX
93237		A	ECG monitor/review, 24 hrs	0.45	0.17	0.17	0.01	0.63	0.63	XXX
93268		A	ECG record/review	0.52	NA	3.74	0.24	NA	4.50	XXX
93270		A	ECG recording	0.00	NA	1.22	0.07	NA	1.29	XXX
93271		A	Ecg/monitoring and analysis	0.00	NA	2.32	0.15	NA	2.47	XXX
93272		A	Ecg/review, interpret only	0.52	0.20	0.20	0.02	0.74	0.74	XXX
93278		A	ECG/signal-averaged	0.25	NA	1.23	0.10	NA	1.58	XXX
93278	26	A	ECG/signal-averaged	0.25	0.10	0.10	0.01	0.36	0.36	XXX
93278	TC	A	ECG/signal-averaged	0.00	NA	1.13	0.09	NA	1.22	XXX
93303		A	Echo transthoracic	1.30	NA	4.28	0.23	NA	5.81	XXX
93303	26	A	Echo transthoracic	1.30	0.48	0.48	0.04	1.82	1.82	XXX
93303	TC	A	Echo transthoracic	0.00	NA	3.80	0.19	NA	3.99	XXX
93304		A	Echo transthoracic	0.75	NA	2.21	0.13	NA	3.09	XXX
93304	26	A	Echo transthoracic	0.75	0.30	0.30	0.02	1.07	1.07	XXX
93304	TC	A	Echo transthoracic	0.00	NA	1.91	0.11	NA	2.02	XXX
93307		A	Echo exam of heart	0.92	NA	4.17	0.22	NA	5.31	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
93307	26	A	Echo exam of heart	0.92	0.37	0.37	0.03	1.32	1.32	XXX
93307	TC	A	Echo exam of heart	0.00	NA	3.80	0.19	NA	3.99	XXX
93308		A	Echo exam of heart	0.53	NA	2.12	0.13	NA	2.78	XXX
93308	26	A	Echo exam of heart	0.53	0.21	0.21	0.02	0.76	0.76	XXX
93308	TC	A	Echo exam of heart	0.00	NA	1.91	0.11	NA	2.02	XXX
93312		A	Echo transesophageal	2.20	NA	4.57	0.32	NA	7.09	XXX
93312	26	A	Echo transesophageal	2.20	0.85	0.85	0.08	3.13	3.13	XXX
93312	TC	A	Echo transesophageal	0.00	NA	3.72	0.24	NA	3.96	XXX
93313		A	Echo transesophageal	0.95	0.21	4.70	0.05	1.21	5.70	XXX
93314		A	Echo transesophageal	1.25	NA	4.21	0.28	NA	5.74	XXX
93314	26	A	Echo transesophageal	1.25	0.49	0.49	0.04	1.78	1.78	XXX
93314	TC	A	Echo transesophageal	0.00	NA	3.72	0.24	NA	3.96	XXX
93315		A	Echo transesophageal	2.78	NA	4.78	0.34	NA	7.90	XXX
93315	26	A	Echo transesophageal	2.78	1.06	1.06	0.10	3.94	3.94	XXX
93315	TC	A	Echo transesophageal	0.00	NA	3.72	0.24	NA	3.96	XXX
93316		A	Echo transesophageal	0.95	0.23	3.35	0.05	1.23	4.35	XXX
93317		A	Echo transesophageal	1.83	NA	4.45	0.30	NA	6.58	XXX
93317	26	A	Echo transesophageal	1.83	0.73	0.73	0.06	2.62	2.62	XXX
93317	TC	A	Echo transesophageal	0.00	NA	3.72	0.24	NA	3.96	XXX
93318		C	Echo transesophageal intraop	0.00	NA	0.00	0.00	NA	0.00	XXX
93318	26	C	Echo transesophageal intraop	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93318	TC	C	Echo transesophageal intraop	0.00	NA	0.00	0.00	NA	0.00	XXX
93320		A	Doppler echo exam, heart	0.38	NA	1.84	0.11	NA	2.33	ZZZ
93320	26	A	Doppler echo exam, heart	0.38	0.15	0.15	0.01	0.54	0.54	ZZZ
93320	TC	A	Doppler echo exam, heart	0.00	NA	1.69	0.10	NA	1.79	ZZZ
93321		A	Doppler echo exam, heart	0.15	NA	1.15	0.08	NA	1.38	ZZZ
93321	26	A	Doppler echo exam, heart	0.15	0.06	0.06	0.01	0.22	0.22	ZZZ
93321	TC	A	Doppler echo exam, heart	0.00	NA	1.09	0.07	NA	1.16	ZZZ
93325		A	Doppler color flow add-on	0.07	NA	2.89	0.18	NA	3.14	ZZZ
93325	26	A	Doppler color flow add-on	0.07	0.03	0.03	0.01	0.11	0.11	ZZZ
93325	TC	A	Doppler color flow add-on	0.00	NA	2.86	0.17	NA	3.03	ZZZ
93350		A	Echo transthoracic	1.48	NA	2.33	0.13	NA	3.94	XXX
93350	26	A	Echo transthoracic	1.48	0.60	0.60	0.02	2.10	2.10	XXX
93350	TC	A	Echo transthoracic	0.00	NA	1.73	0.11	NA	1.84	XXX
93501		A	Right heart catheterization	3.02	NA	17.20	1.03	NA	21.25	000
93501	26	A	Right heart catheterization	3.02	1.21	1.21	0.16	4.39	4.39	000
93501	TC	A	Right heart catheterization	0.00	NA	15.99	0.87	NA	16.86	000
93503		A	Insert/place heart catheter	2.91	0.74	NA	0.16	3.81	NA	000
93505		A	Biopsy of heart lining	4.38	NA	3.64	0.36	NA	8.38	000
93505	26	A	Biopsy of heart lining	4.38	1.77	1.77	0.23	6.38	6.38	000
93505	TC	A	Biopsy of heart lining	0.00	NA	1.87	0.13	NA	2.00	000
93508		A	Cath placement, angiography	4.10	NA	13.61	0.75	NA	18.46	000
93508	26	A	Cath placement, angiography	4.10	1.68	1.68	0.21	5.99	5.99	000
93508	TC	A	Cath placement, angiography	0.00	NA	11.93	0.54	NA	12.47	000
93510		A	Left heart catheterization	4.33	NA	36.72	2.13	NA	43.18	000
93510	26	A	Left heart catheterization	4.33	1.78	1.78	0.22	6.33	6.33	000
93510	TC	A	Left heart catheterization	0.00	NA	34.94	1.91	NA	36.85	000
93511		A	Left heart catheterization	5.03	NA	36.08	2.11	NA	43.22	000
93511	26	A	Left heart catheterization	5.03	2.07	2.07	0.26	7.36	7.36	000
93511	TC	A	Left heart catheterization	0.00	NA	34.01	1.85	NA	35.86	000
93514		A	Left heart catheterization	7.05	NA	36.71	2.22	NA	45.98	000
93514	26	A	Left heart catheterization	7.05	2.70	2.70	0.37	10.12	10.12	000
93514	TC	A	Left heart catheterization	0.00	NA	34.01	1.85	NA	35.86	000
93524		A	Left heart catheterization	6.95	NA	47.26	2.79	NA	57.00	000
93524	26	A	Left heart catheterization	6.95	2.81	2.81	0.36	10.12	10.12	000
93524	TC	A	Left heart catheterization	0.00	NA	44.45	2.43	NA	46.88	000
93526		A	Rt & Lt heart catheters	5.99	NA	48.13	2.81	NA	56.93	000
93526	26	A	Rt & Lt heart catheters	5.99	2.46	2.46	0.31	8.76	8.76	000
93526	TC	A	Rt & Lt heart catheters	0.00	NA	45.67	2.50	NA	48.17	000
93527		A	Rt & Lt heart catheters	7.28	NA	47.43	2.81	NA	57.52	000
93527	26	A	Rt & Lt heart catheters	7.28	2.98	2.98	0.38	10.64	10.64	000
93527	TC	A	Rt & Lt heart catheters	0.00	NA	44.45	2.43	NA	46.88	000
93528		A	Rt & Lt heart catheters	9.00	NA	48.19	2.90	NA	60.09	000
93528	26	A	Rt & Lt heart catheters	9.00	3.74	3.74	0.47	13.21	13.21	000
93528	TC	A	Rt & Lt heart catheters	0.00	NA	44.45	2.43	NA	46.88	000
93529		A	Rt, Lt heart catheterization	4.80	NA	46.41	2.68	NA	53.89	000
93529	26	A	Rt, Lt heart catheterization	4.80	1.96	1.96	0.25	7.01	7.01	000
93529	TC	A	Rt, Lt heart catheterization	0.00	NA	44.45	2.43	NA	46.88	000
93530		A	Rt heart cath, congenital	4.23	NA	17.53	1.11	NA	22.87	000
93530	26	A	Rt heart cath, congenital	4.23	1.54	1.54	0.24	6.01	6.01	000
93530	TC	A	Rt heart cath, congenital	0.00	NA	15.99	0.87	NA	16.86	000
93531		A	R & l heart cath, congenital	8.35	NA	48.92	2.96	NA	60.23	000
93531	26	A	R & l heart cath, congenital	8.35	3.25	3.25	0.46	12.06	12.06	000
93531	TC	A	R & l heart cath, congenital	0.00	NA	45.67	2.50	NA	48.17	000

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
93532		A	R & I heart cath, congenital	10.00	NA	48.33	2.95	NA	61.28	000
93532	26	A	R & I heart cath, congenital	10.00	3.88	3.88	0.52	14.40	14.40	000
93532	TC	A	R & I heart cath, congenital	0.00	NA	44.45	2.43	NA	46.88	000
93533		A	R & I heart cath, congenital	6.70	NA	46.91	2.86	NA	56.47	000
93533	26	A	R & I heart cath, congenital	6.70	2.46	2.46	0.43	9.59	9.59	000
93533	TC	A	R & I heart cath, congenital	0.00	NA	44.45	2.43	NA	46.88	000
93536		A	Insert circulation assi	4.85	1.97	NA	0.27	7.09	NA	000
93539		A	Injection, cardiac cath	0.40	0.16	0.85	0.01	0.57	1.26	000
93540		A	Injection, cardiac cath	0.43	0.18	0.86	0.01	0.62	1.30	000
93541		A	Injection for lung angiogram	0.29	0.12	NA	0.01	0.42	NA	000
93542		A	Injection for heart x-rays	0.29	0.12	NA	0.01	0.42	NA	000
93543		A	Injection for heart x-rays	0.29	0.12	0.55	0.01	0.42	0.85	000
93544		A	Injection for aortography	0.25	0.10	0.53	0.01	0.36	0.79	000
93545		A	Inject for coronary x-rays	0.40	0.16	0.85	0.01	0.57	1.26	000
93555		A	Imaging, cardiac cath	0.81	NA	6.26	0.31	NA	7.38	XXX
93555	26	A	Imaging, cardiac cath	0.81	0.33	0.33	0.03	1.17	1.17	XXX
93555	TC	A	Imaging, cardiac cath	0.00	NA	5.93	0.28	NA	6.21	XXX
93556		A	Imaging, cardiac cath	0.83	NA	9.70	0.45	NA	10.98	XXX
93556	26	A	Imaging, cardiac cath	0.83	0.34	0.34	0.03	1.20	1.20	XXX
93556	TC	A	Imaging, cardiac cath	0.00	NA	9.36	0.42	NA	9.78	XXX
93561		A	Cardiac output measurement	0.50	NA	0.67	0.07	NA	1.24	000
93561	26	A	Cardiac output measurement	0.50	0.16	0.16	0.02	0.68	0.68	000
93561	TC	A	Cardiac output measurement	0.00	NA	0.51	0.05	NA	0.56	000
93562		A	Cardiac output measurement	0.16	NA	0.34	0.04	NA	0.54	000
93562	26	A	Cardiac output measurement	0.16	0.05	0.05	0.01	0.22	0.22	000
93562	TC	A	Cardiac output measurement	0.00	NA	0.29	0.03	NA	0.32	000
93571		A	Heart flow reserve measure	1.80	NA	5.19	0.31	NA	7.30	ZZZ
93571	26	A	Heart flow reserve measure	1.80	0.70	0.70	0.11	2.61	2.61	ZZZ
93571	TC	A	Heart flow reserve measure	0.00	NA	4.49	0.20	NA	4.69	ZZZ
93572		A	Heart flow reserve measure	1.44	NA	2.76	0.28	NA	4.48	ZZZ
93572	26	A	Heart flow reserve measure	1.44	0.50	0.50	0.17	2.11	2.11	ZZZ
93572	TC	A	Heart flow reserve measure	0.00	NA	2.26	0.11	NA	2.37	ZZZ
93600		A	Bundle of His recording	2.12	NA	2.79	0.22	NA	5.13	000
93600	26	A	Bundle of His recording	2.12	0.87	0.87	0.11	3.10	3.10	000
93600	TC	A	Bundle of His recording	0.00	NA	1.92	0.11	NA	2.03	000
93602		A	Intra-atrial recording	2.12	NA	1.95	0.18	NA	4.25	000
93602	26	A	Intra-atrial recording	2.12	0.86	0.86	0.12	3.10	3.10	000
93602	TC	A	Intra-atrial recording	0.00	NA	1.09	0.06	NA	1.15	000
93603		A	Right ventricular recording	2.12	NA	2.51	0.20	NA	4.83	000
93603	26	A	Right ventricular recording	2.12	0.85	0.85	0.11	3.08	3.08	000
93603	TC	A	Right ventricular recording	0.00	NA	1.66	0.09	NA	1.75	000
93607		A	Left ventricular recording	3.26	NA	2.83	0.26	NA	6.35	000
93607	26	A	Left ventricular recording	3.26	1.36	1.36	0.17	4.79	4.79	000
93607	TC	A	Left ventricular recording	0.00	NA	1.47	0.09	NA	1.56	000
93609		A	Mapping of tachycardia	10.07	NA	6.79	0.66	NA	17.52	000
93609	26	A	Mapping of tachycardia	10.07	4.11	4.11	0.52	14.70	14.70	000
93609	TC	A	Mapping of tachycardia	0.00	NA	2.68	0.14	NA	2.82	000
93610		A	Intra-atrial pacing	3.02	NA	2.54	0.25	NA	5.81	000
93610	26	A	Intra-atrial pacing	3.02	1.21	1.21	0.17	4.40	4.40	000
93610	TC	A	Intra-atrial pacing	0.00	NA	1.33	0.08	NA	1.41	000
93612		A	Intraventricular pacing	3.02	NA	2.80	0.26	NA	6.08	000
93612	26	A	Intraventricular pacing	3.02	1.21	1.21	0.17	4.40	4.40	000
93612	TC	A	Intraventricular pacing	0.00	NA	1.59	0.09	NA	1.68	000
93615		A	Esophageal recording	0.99	NA	0.70	0.05	NA	1.74	000
93615	26	A	Esophageal recording	0.99	0.39	0.39	0.03	1.41	1.41	000
93615	TC	A	Esophageal recording	0.00	NA	0.31	0.02	NA	0.33	000
93616		A	Esophageal recording	1.49	NA	0.79	0.08	NA	2.36	000
93616	26	A	Esophageal recording	1.49	0.48	0.48	0.06	2.03	2.03	000
93616	TC	A	Esophageal recording	0.00	NA	0.31	0.02	NA	0.33	000
93618		A	Heart rhythm pacing	4.26	NA	5.65	0.42	NA	10.33	000
93618	26	A	Heart rhythm pacing	4.26	1.75	1.75	0.22	6.23	6.23	000
93618	TC	A	Heart rhythm pacing	0.00	NA	3.90	0.20	NA	4.10	000
93619		A	Electrophysiology evaluation	7.32	NA	10.57	0.77	NA	18.66	000
93619	26	A	Electrophysiology evaluation	7.32	2.98	2.98	0.38	10.68	10.68	000
93619	TC	A	Electrophysiology evaluation	0.00	NA	7.59	0.39	NA	7.98	000
93620		A	Electrophysiology evaluation	11.59	NA	13.58	1.04	NA	26.21	000
93620	26	A	Electrophysiology evaluation	11.59	4.75	4.75	0.60	16.94	16.94	000
93620	TC	A	Electrophysiology evaluation	0.00	NA	8.83	0.44	NA	9.27	000
93621		C	Electrophysiology evaluation	0.00	NA	0.00	0.00	NA	0.00	000
93621	26	A	Electrophysiology evaluation	12.66	5.19	5.19	0.66	18.51	18.51	000
93621	TC	C	Electrophysiology evaluation	0.00	NA	0.00	0.00	NA	0.00	000
93622		C	Electrophysiology evaluation	0.00	NA	0.00	0.00	NA	0.00	000
93622	26	A	Electrophysiology evaluation	12.74	5.22	5.22	0.67	18.63	18.63	000
93622	TC	C	Electrophysiology evaluation	0.00	NA	0.00	0.00	NA	0.00	000

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
93623		C	Stimulation, pacing heart	0.00	NA	0.00	0.00	NA	0.00	ZZZ
93623	26	A	Stimulation, pacing heart	2.85	1.16	1.16	0.15	4.16	4.16	ZZZ
93623	TC	C	Stimulation, pacing heart	0.00	NA	0.00	0.00	NA	0.00	ZZZ
93624		A	Electrophysiologic study	4.81	NA	3.91	0.36	NA	9.08	000
93624	26	A	Electrophysiologic study	4.81	1.96	1.96	0.25	7.02	7.02	000
93624	TC	A	Electrophysiologic study	0.00	NA	1.95	0.11	NA	2.06	000
93631		A	Heart pacing, mapping	7.60	NA	8.89	1.17	NA	17.66	000
93631	26	A	Heart pacing, mapping	7.60	2.83	2.83	0.66	11.09	11.09	000
93631	TC	A	Heart pacing, mapping	0.00	NA	6.06	0.51	NA	6.57	000
93640		A	Evaluation heart device	3.52	NA	8.46	0.53	NA	12.51	000
93640	26	A	Evaluation heart device	3.52	1.40	1.40	0.18	5.10	5.10	000
93640	TC	A	Evaluation heart device	0.00	NA	7.06	0.35	NA	7.41	000
93641		A	Electrophysiology evaluation	5.93	NA	9.49	0.66	NA	16.08	000
93641	26	A	Electrophysiology evaluation	5.93	2.43	2.43	0.31	8.67	8.67	000
93641	TC	A	Electrophysiology evaluation	0.00	NA	7.06	0.35	NA	7.41	000
93642		A	Electrophysiology evaluation	4.89	NA	9.00	0.51	NA	14.40	000
93642	26	A	Electrophysiology evaluation	4.89	1.94	1.94	0.16	6.99	6.99	000
93642	TC	A	Electrophysiology evaluation	0.00	NA	7.06	0.35	NA	7.41	000
93650		A	Ablate heart dysrhythm focus	10.51	4.36	NA	0.55	15.42	NA	000
93651		A	Ablate heart dysrhythm focus	16.25	6.70	NA	0.85	23.80	NA	000
93652		A	Ablate heart dysrhythm focus	17.68	7.27	NA	0.92	25.87	NA	000
93660		A	Tilt table evaluation	1.89	NA	2.44	0.08	NA	4.41	000
93660	26	A	Tilt table evaluation	1.89	0.78	0.78	0.06	2.73	2.73	000
93660	TC	A	Tilt table evaluation	0.00	NA	1.66	0.02	NA	1.68	000
93662		A	Intracardiac ecg (ice)	2.80	1.16	NA	0.41	4.37	NA	ZZZ
93668		N	Peripheral vascular rehab	0.00	NA	0.00	0.00	NA	0.00	XXX
93720		A	Total body plethysmography	0.17	NA	0.75	0.06	NA	0.98	XXX
93721		A	Plethysmography tracing	0.00	NA	0.70	0.05	NA	0.75	XXX
93722		A	Plethysmography report	0.17	0.06	0.06	0.01	0.24	0.24	XXX
93724		A	Analyze pacemaker system	4.89	NA	5.90	0.38	NA	11.17	000
93724	26	A	Analyze pacemaker system	4.89	2.00	2.00	0.18	7.07	7.07	000
93724	TC	A	Analyze pacemaker system	0.00	NA	3.90	0.20	NA	4.10	000
93727		A	Analyze ilr system	0.52	0.19	0.19	0.05	0.76	0.76	XXX
93731		A	Analyze pacemaker system	0.45	NA	0.67	0.05	NA	1.17	XXX
93731	26	A	Analyze pacemaker system	0.45	0.18	0.18	0.02	0.65	0.65	XXX
93731	TC	A	Analyze pacemaker system	0.00	NA	0.49	0.03	NA	0.52	XXX
93732		A	Analyze pacemaker system	0.92	NA	0.87	0.06	NA	1.85	XXX
93732	26	A	Analyze pacemaker system	0.92	0.37	0.37	0.03	1.32	1.32	XXX
93732	TC	A	Analyze pacemaker system	0.00	NA	0.50	0.03	NA	0.53	XXX
93733		A	Telephone analy, pacemaker	0.17	NA	0.78	0.06	NA	1.01	XXX
93733	26	A	Telephone analy, pacemaker	0.17	0.07	0.07	0.01	0.25	0.25	XXX
93733	TC	A	Telephone analy, pacemaker	0.00	NA	0.71	0.05	NA	0.76	XXX
93734		A	Analyze pacemaker system	0.38	NA	0.49	0.03	NA	0.90	XXX
93734	26	A	Analyze pacemaker system	0.38	0.15	0.15	0.01	0.54	0.54	XXX
93734	TC	A	Analyze pacemaker system	0.00	NA	0.34	0.02	NA	0.36	XXX
93735		A	Analyze pacemaker system	0.74	NA	0.74	0.06	NA	1.54	XXX
93735	26	A	Analyze pacemaker system	0.74	0.30	0.30	0.03	1.07	1.07	XXX
93735	TC	A	Analyze pacemaker system	0.00	NA	0.44	0.03	NA	0.47	XXX
93736		A	Telephone analy, pacemaker	0.15	NA	0.68	0.06	NA	0.89	XXX
93736	26	A	Telephone analy, pacemaker	0.15	0.06	0.06	0.01	0.22	0.22	XXX
93736	TC	A	Telephone analy, pacemaker	0.00	NA	0.62	0.05	NA	0.67	XXX
93737		A	Analyze cardio/defibrillator	0.45	NA	0.67	0.04	NA	1.16	XXX
93737	26	A	Analyze cardio/defibrillator	0.45	0.18	0.18	0.01	0.64	0.64	XXX
93737	TC	A	Analyze cardio/defibrillator	0.00	NA	0.49	0.03	NA	0.52	XXX
93738		A	Analyze cardio/defibrillator	0.92	NA	0.88	0.06	NA	1.86	XXX
93738	26	A	Analyze cardio/defibrillator	0.92	0.38	0.38	0.03	1.33	1.33	XXX
93738	TC	A	Analyze cardio/defibrillator	0.00	NA	0.50	0.03	NA	0.53	XXX
93740		B	Temperature gradient studies	+0.16	NA	0.21	0.02	NA	0.39	XXX
93740	26	B	Temperature gradient studies	+0.16	0.06	0.06	0.01	0.23	0.23	XXX
93740	TC	B	Temperature gradient studies	+0.00	NA	0.15	0.01	NA	0.16	XXX
93741		A	Analyze ht pace device sngl	0.80	NA	0.98	0.05	NA	1.83	XXX
93741	26	A	Analyze ht pace device sngl	0.80	0.32	0.32	0.02	1.14	1.14	XXX
93741	TC	A	Analyze ht pace device sngl	0.00	NA	0.66	0.03	NA	0.69	XXX
93742		A	Analyze ht pace device sngl	0.91	NA	1.02	0.05	NA	1.98	XXX
93742	26	A	Analyze ht pace device sngl	0.91	0.36	0.36	0.02	1.29	1.29	XXX
93742	TC	A	Analyze ht pace device sngl	0.00	NA	0.66	0.03	NA	0.69	XXX
93743		A	Analyze ht pace device dual	1.03	NA	1.13	0.06	NA	2.22	XXX
93743	26	A	Analyze ht pace device dual	1.03	0.41	0.41	0.03	1.47	1.47	XXX
93743	TC	A	Analyze ht pace device dual	0.00	NA	0.72	0.03	NA	0.75	XXX
93744		A	Analyze ht pace device dual	1.18	NA	1.13	0.06	NA	2.37	XXX
93744	26	A	Analyze ht pace device dual	1.18	0.47	0.47	0.03	1.68	1.68	XXX
93744	TC	A	Analyze ht pace device dual	0.00	NA	0.66	0.03	NA	0.69	XXX
93760		N	Cephalic thermogram	0.00	NA	0.00	0.00	NA	0.00	XXX
93762		N	Peripheral thermogram	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
93770		B	Measure venous pressure	+0.16	NA	0.09	0.02	NA	0.27	XXX
93770	26	B	Measure venous pressure	+0.16	0.06	0.06	0.01	0.23	0.23	XXX
93770	TC	B	Measure venous pressure	+0.00	NA	0.03	0.01	NA	0.04	XXX
93784		N	Ambulatory BP monitoring	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93786		N	Ambulatory BP recording	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93788		N	Ambulatory BP analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93790		N	Review/report BP recording	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93797		A	Cardiac rehab	0.18	0.07	0.37	0.01	0.26	0.56	000
93798		A	Cardiac rehab/monitor	0.28	0.11	0.45	0.01	0.40	0.74	000
93799		C	Cardiovascular procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
93799	26	C	Cardiovascular procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93799	TC	C	Cardiovascular procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
93875		A	Extracranial study	0.22	NA	1.17	0.10	NA	1.49	XXX
93875	26	A	Extracranial study	0.22	0.08	0.08	0.01	0.31	0.31	XXX
93875	TC	A	Extracranial study	0.00	NA	1.09	0.09	NA	1.18	XXX
93880		A	Extracranial study	0.60	NA	3.89	0.33	NA	4.82	XXX
93880	26	A	Extracranial study	0.60	0.22	0.22	0.04	0.86	0.86	XXX
93880	TC	A	Extracranial study	0.00	NA	3.67	0.29	NA	3.96	XXX
93882		A	Extracranial study	0.40	NA	2.59	0.22	NA	3.21	XXX
93882	26	A	Extracranial study	0.40	0.15	0.15	0.04	0.59	0.59	XXX
93882	TC	A	Extracranial study	0.00	NA	2.44	0.18	NA	2.62	XXX
93886		A	Intracranial study	0.94	NA	4.54	0.37	NA	5.85	XXX
93886	26	A	Intracranial study	0.94	0.39	0.39	0.05	1.38	1.38	XXX
93886	TC	A	Intracranial study	0.00	NA	4.15	0.32	NA	4.47	XXX
93888		A	Intracranial study	0.62	NA	3.01	0.26	NA	3.89	XXX
93888	26	A	Intracranial study	0.62	0.24	0.24	0.04	0.90	0.90	XXX
93888	TC	A	Intracranial study	0.00	NA	2.77	0.22	NA	2.99	XXX
93922		A	Extremity study	0.25	NA	1.22	0.13	NA	1.60	XXX
93922	26	A	Extremity study	0.25	0.09	0.09	0.02	0.36	0.36	XXX
93922	TC	A	Extremity study	0.00	NA	1.13	0.11	NA	1.24	XXX
93923		A	Extremity study	0.45	NA	2.31	0.22	NA	2.98	XXX
93923	26	A	Extremity study	0.45	0.16	0.16	0.04	0.65	0.65	XXX
93923	TC	A	Extremity study	0.00	NA	2.15	0.18	NA	2.33	XXX
93924		A	Extremity study	0.50	NA	2.51	0.26	NA	3.27	XXX
93924	26	A	Extremity study	0.50	0.18	0.18	0.05	0.73	0.73	XXX
93924	TC	A	Extremity study	0.00	NA	2.33	0.21	NA	2.54	XXX
93925		A	Lower extremity study	0.58	NA	3.89	0.33	NA	4.80	XXX
93925	26	A	Lower extremity study	0.58	0.21	0.21	0.04	0.83	0.83	XXX
93925	TC	A	Lower extremity study	0.00	NA	3.68	0.29	NA	3.97	XXX
93926		A	Lower extremity study	0.39	NA	2.60	0.22	NA	3.21	XXX
93926	26	A	Lower extremity study	0.39	0.14	0.14	0.03	0.56	0.56	XXX
93926	TC	A	Lower extremity study	0.00	NA	2.46	0.19	NA	2.65	XXX
93930		A	Upper extremity study	0.46	NA	4.08	0.34	NA	4.88	XXX
93930	26	A	Upper extremity study	0.46	0.17	0.17	0.03	0.66	0.66	XXX
93930	TC	A	Upper extremity study	0.00	NA	3.91	0.31	NA	4.22	XXX
93931		A	Upper extremity study	0.31	NA	2.71	0.22	NA	3.24	XXX
93931	26	A	Upper extremity study	0.31	0.11	0.11	0.02	0.44	0.44	XXX
93931	TC	A	Upper extremity study	0.00	NA	2.60	0.20	NA	2.80	XXX
93965		A	Extremity study	0.35	NA	1.21	0.12	NA	1.68	XXX
93965	26	A	Extremity study	0.35	0.13	0.13	0.02	0.50	0.50	XXX
93965	TC	A	Extremity study	0.00	NA	1.08	0.10	NA	1.18	XXX
93970		A	Extremity study	0.68	NA	4.31	0.38	NA	5.37	XXX
93970	26	A	Extremity study	0.68	0.24	0.24	0.05	0.97	0.97	XXX
93970	TC	A	Extremity study	0.00	NA	4.07	0.33	NA	4.40	XXX
93971		A	Extremity study	0.45	NA	2.86	0.25	NA	3.56	XXX
93971	26	A	Extremity study	0.45	0.16	0.16	0.03	0.64	0.64	XXX
93971	TC	A	Extremity study	0.00	NA	2.70	0.22	NA	2.92	XXX
93975		A	Vascular study	1.80	NA	5.26	0.47	NA	7.53	XXX
93975	26	A	Vascular study	1.80	0.63	0.63	0.11	2.54	2.54	XXX
93975	TC	A	Vascular study	0.00	NA	4.63	0.36	NA	4.99	XXX
93976		A	Vascular study	1.21	NA	3.50	0.31	NA	5.02	XXX
93976	26	A	Vascular study	1.21	0.42	0.42	0.06	1.69	1.69	XXX
93976	TC	A	Vascular study	0.00	NA	3.08	0.25	NA	3.33	XXX
93978		A	Vascular study	0.65	NA	4.02	0.36	NA	5.03	XXX
93978	26	A	Vascular study	0.65	0.23	0.23	0.05	0.93	0.93	XXX
93978	TC	A	Vascular study	0.00	NA	3.79	0.31	NA	4.10	XXX
93979		A	Vascular study	0.44	NA	2.68	0.24	NA	3.36	XXX
93979	26	A	Vascular study	0.44	0.16	0.16	0.04	0.64	0.64	XXX
93979	TC	A	Vascular study	0.00	NA	2.52	0.20	NA	2.72	XXX
93980		A	Penile vascular study	1.25	NA	3.88	0.35	NA	5.48	XXX
93980	26	A	Penile vascular study	1.25	0.44	0.44	0.07	1.76	1.76	XXX
93980	TC	A	Penile vascular study	0.00	NA	3.44	0.28	NA	3.72	XXX
93981		A	Penile vascular study	0.44	NA	3.32	0.28	NA	4.04	XXX
93981	26	A	Penile vascular study	0.44	0.15	0.15	0.02	0.61	0.61	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
93981	TC	A	Penile vascular study	0.00	NA	3.17	0.26	NA	3.43	XXX
93990		A	Doppler flow testing	0.25	NA	2.56	0.21	NA	3.02	XXX
93990	26	A	Doppler flow testing	0.25	0.10	0.10	0.02	0.37	0.37	XXX
93990	TC	A	Doppler flow testing	0.00	NA	2.46	0.19	NA	2.65	XXX
94010		A	Breathing capacity test	0.17	NA	0.81	0.03	NA	1.01	XXX
94010	26	A	Breathing capacity test	0.17	0.05	0.05	0.01	0.23	0.23	XXX
94010	TC	A	Breathing capacity test	0.00	NA	0.76	0.02	NA	0.78	XXX
94014		A	Patient recorded spirometry	0.52	NA	0.50	0.03	NA	1.05	XXX
94015		A	Patient recorded spirometry	0.00	NA	0.33	0.01	NA	0.34	XXX
94016		A	Review patient spirometry	0.52	0.17	0.17	0.02	0.71	0.71	XXX
94060		A	Evaluation of wheezing	0.31	NA	1.22	0.06	NA	1.59	XXX
94060	26	A	Evaluation of wheezing	0.31	0.10	0.10	0.01	0.42	0.42	XXX
94060	TC	A	Evaluation of wheezing	0.00	NA	1.12	0.05	NA	1.17	XXX
94070		A	Evaluation of wheezing	0.60	NA	3.83	0.10	NA	4.53	XXX
94070	26	A	Evaluation of wheezing	0.60	0.19	0.19	0.02	0.81	0.81	XXX
94070	TC	A	Evaluation of wheezing	0.00	NA	3.64	0.08	NA	3.72	XXX
94150		B	Vital capacity test	+0.07	NA	0.61	0.02	NA	0.70	XXX
94150	26	B	Vital capacity test	+0.07	0.03	0.03	0.01	0.11	0.11	XXX
94150	TC	B	Vital capacity test	+0.00	NA	0.58	0.01	NA	0.59	XXX
94200		A	Lung function test (MBC/MVV)	0.11	NA	0.32	0.03	NA	0.46	XXX
94200	26	A	Lung function test (MBC/MVV)	0.11	0.04	0.04	0.01	0.16	0.16	XXX
94200	TC	A	Lung function test (MBC/MVV)	0.00	NA	0.28	0.02	NA	0.30	XXX
94240		A	Residual lung capacity	0.26	NA	1.42	0.05	NA	1.73	XXX
94240	26	A	Residual lung capacity	0.26	0.08	0.08	0.01	0.35	0.35	XXX
94240	TC	A	Residual lung capacity	0.00	NA	1.34	0.04	NA	1.38	XXX
94250		A	Expired gas collection	0.11	NA	0.66	0.02	NA	0.79	XXX
94250	26	A	Expired gas collection	0.11	0.04	0.04	0.01	0.16	0.16	XXX
94250	TC	A	Expired gas collection	0.00	NA	0.62	0.01	NA	0.63	XXX
94260		A	Thoracic gas volume	0.13	NA	0.40	0.04	NA	0.57	XXX
94260	26	A	Thoracic gas volume	0.13	0.04	0.04	0.01	0.18	0.18	XXX
94260	TC	A	Thoracic gas volume	0.00	NA	0.36	0.03	NA	0.39	XXX
94350		A	Lung nitrogen washout curve	0.26	NA	1.21	0.04	NA	1.51	XXX
94350	26	A	Lung nitrogen washout curve	0.26	0.08	0.08	0.01	0.35	0.35	XXX
94350	TC	A	Lung nitrogen washout curve	0.00	NA	1.13	0.03	NA	1.16	XXX
94360		A	Measure airflow resistance	0.26	NA	0.65	0.06	NA	0.97	XXX
94360	26	A	Measure airflow resistance	0.26	0.08	0.08	0.01	0.35	0.35	XXX
94360	TC	A	Measure airflow resistance	0.00	NA	0.57	0.05	NA	0.62	XXX
94370		A	Breath airway closing volume	0.26	NA	2.53	0.03	NA	2.82	XXX
94370	26	A	Breath airway closing volume	0.26	0.08	0.08	0.01	0.35	0.35	XXX
94370	TC	A	Breath airway closing volume	0.00	NA	2.45	0.02	NA	2.47	XXX
94375		A	Respiratory flow volume loop	0.31	NA	0.48	0.03	NA	0.82	XXX
94375	26	A	Respiratory flow volume loop	0.31	0.10	0.10	0.01	0.42	0.42	XXX
94375	TC	A	Respiratory flow volume loop	0.00	NA	0.38	0.02	NA	0.40	XXX
94400		A	CO2 breathing response curve	0.40	NA	0.84	0.06	NA	1.30	XXX
94400	26	A	CO2 breathing response curve	0.40	0.13	0.13	0.01	0.54	0.54	XXX
94400	TC	A	CO2 breathing response curve	0.00	NA	0.71	0.05	NA	0.76	XXX
94450		A	Hypoxia response curve	0.40	NA	0.82	0.04	NA	1.26	XXX
94450	26	A	Hypoxia response curve	0.40	0.11	0.11	0.02	0.53	0.53	XXX
94450	TC	A	Hypoxia response curve	0.00	NA	0.71	0.02	NA	0.73	XXX
94620		A	Pulmonary stress test/simple	0.64	NA	2.36	0.10	NA	3.10	XXX
94620	26	A	Pulmonary stress test/simple	0.64	0.21	0.21	0.02	0.87	0.87	XXX
94620	TC	A	Pulmonary stress test/simple	0.00	NA	2.15	0.08	NA	2.23	XXX
94621		A	Pulm stress test/complex	1.42	NA	2.11	0.13	NA	3.66	XXX
94621	26	A	Pulm stress test/complex	1.42	0.46	0.46	0.05	1.93	1.93	XXX
94621	TC	A	Pulm stress test/complex	0.00	NA	1.65	0.08	NA	1.73	XXX
94640		A	Airway inhalation treatment	0.00	NA	0.69	0.02	NA	0.71	XXX
94642		C	Aerosol inhalation treatment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
94650		A	Pressure breathing (IPPB)	0.00	NA	0.65	0.02	NA	0.67	XXX
94651		A	Pressure breathing (IPPB)	0.00	NA	0.60	0.02	NA	0.62	XXX
94652		A	Pressure breathing (IPPB)	0.00	NA	0.75	0.06	NA	0.81	XXX
94656		A	Initial ventilator mgmt	1.22	0.33	NA	0.06	1.61	NA	XXX
94657		A	Continued ventilator mgmt	0.83	0.26	NA	0.03	1.12	NA	XXX
94660		A	Pos airway pressure, CPAP	0.76	0.24	0.68	0.03	1.03	1.47	XXX
94662		A	Neg press ventilation, cnp	0.76	0.25	NA	0.02	1.03	NA	XXX
94664		A	Aerosol or vapor inhalations	0.00	NA	0.52	0.03	NA	0.55	XXX
94665		A	Aerosol or vapor inhalations	0.00	NA	0.53	0.04	NA	0.57	XXX
94667		A	Chest wall manipulation	0.00	NA	0.83	0.04	NA	0.87	XXX
94668		A	Chest wall manipulation	0.00	NA	0.71	0.02	NA	0.73	XXX
94680		A	Exhaled air analysis, o2	0.26	NA	0.84	0.06	NA	1.16	XXX
94680	26	A	Exhaled air analysis, o2	0.26	0.09	0.09	0.01	0.36	0.36	XXX
94680	TC	A	Exhaled air analysis, o2	0.00	NA	0.75	0.05	NA	0.80	XXX
94681		A	Exhaled air analysis, o2/co2	0.20	NA	1.70	0.11	NA	2.01	XXX
94681	26	A	Exhaled air analysis, o2/co2	0.20	0.07	0.07	0.01	0.28	0.28	XXX
94681	TC	A	Exhaled air analysis, o2/co2	0.00	NA	1.63	0.10	NA	1.73	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
94690		A	Exhaled air analysis	0.07	NA	0.55	0.04	NA	0.66	XXX
94690	26	A	Exhaled air analysis	0.07	0.02	0.02	0.01	0.10	0.10	XXX
94690	TC	A	Exhaled air analysis	0.00	NA	0.53	0.03	NA	0.56	XXX
94720		A	Monoxide diffusing capacity	0.26	NA	1.44	0.06	NA	1.76	XXX
94720	26	A	Monoxide diffusing capacity	0.26	0.08	0.08	0.01	0.35	0.35	XXX
94720	TC	A	Monoxide diffusing capacity	0.00	NA	1.36	0.05	NA	1.41	XXX
94725		A	Membrane diffusion capacity	0.26	NA	0.81	0.11	NA	1.18	XXX
94725	26	A	Membrane diffusion capacity	0.26	0.08	0.08	0.01	0.35	0.35	XXX
94725	TC	A	Membrane diffusion capacity	0.00	NA	0.73	0.10	NA	0.83	XXX
94750		A	Pulmonary compliance study	0.23	NA	3.64	0.04	NA	3.91	XXX
94750	26	A	Pulmonary compliance study	0.23	0.07	0.07	0.01	0.31	0.31	XXX
94750	TC	A	Pulmonary compliance study	0.00	NA	3.57	0.03	NA	3.60	XXX
94760		T	Measure blood oxygen level	0.00	NA	0.09	0.02	NA	0.11	XXX
94761		T	Measure blood oxygen level	0.00	NA	0.18	0.05	NA	0.23	XXX
94762		A	Measure blood oxygen level	0.00	NA	0.11	0.08	NA	0.19	XXX
94770		A	Exhaled carbon dioxide test	0.15	NA	0.76	0.07	NA	0.98	XXX
94770	26	A	Exhaled carbon dioxide test	0.15	0.04	0.04	0.01	0.20	0.20	XXX
94770	TC	A	Exhaled carbon dioxide test	0.00	NA	0.72	0.06	NA	0.78	XXX
94772		C	Breath recording, infant	0.00	NA	0.00	0.00	NA	0.00	XXX
94772	26	C	Breath recording, infant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
94772	TC	C	Breath recording, infant	0.00	NA	0.00	0.00	NA	0.00	XXX
94799		C	Pulmonary service/procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
94799	26	C	Pulmonary service/procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
94799	TC	C	Pulmonary service/procedure	0.00	NA	0.00	0.00	NA	0.00	XXX
95004		A	Allergy skin tests	0.00	NA	0.10	0.01	NA	0.11	XXX
95010		A	Sensitivity skin tests	0.15	0.07	0.44	0.01	0.23	0.60	XXX
95015		A	Sensitivity skin tests	0.15	0.06	0.48	0.01	0.22	0.64	XXX
95024		A	Allergy skin tests	0.00	NA	0.14	0.01	NA	0.15	XXX
95027		A	Skin end point titration	0.00	NA	0.14	0.01	NA	0.15	XXX
95028		A	Allergy skin tests	0.00	NA	0.23	0.01	NA	0.24	XXX
95044		A	Allergy patch tests	0.00	NA	0.20	0.01	NA	0.21	XXX
95052		A	Photo patch test	0.00	NA	0.25	0.01	NA	0.26	XXX
95056		A	Photosensitivity tests	0.00	NA	0.17	0.01	NA	0.18	XXX
95060		A	Eye allergy tests	0.00	NA	0.34	0.02	NA	0.36	XXX
95065		A	Nose allergy test	0.00	NA	0.20	0.01	NA	0.21	XXX
95070		A	Bronchial allergy tests	0.00	NA	2.25	0.02	NA	2.27	XXX
95071		A	Bronchial allergy tests	0.00	NA	2.88	0.02	NA	2.90	XXX
95075		A	Ingestion challenge test	0.95	0.42	0.88	0.03	1.40	1.86	XXX
95078		A	Provocative testing	0.00	NA	0.25	0.02	NA	0.27	XXX
95115		A	Immunotherapy, one injection	0.00	NA	0.38	0.02	NA	0.40	000
95117		A	Immunotherapy injections	0.00	NA	0.50	0.02	NA	0.52	000
95120		I	Immunotherapy, one injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95125		I	Immunotherapy, many antigens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95130		I	Immunotherapy, insect venom	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95131		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95132		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95133		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95134		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95144		A	Antigen therapy services	0.06	0.03	0.25	0.01	0.10	0.32	000
95145		A	Antigen therapy services	0.06	0.02	0.50	0.01	0.09	0.57	000
95146		A	Antigen therapy services	0.06	0.02	0.58	0.01	0.09	0.65	000
95147		A	Antigen therapy services	0.06	0.02	0.84	0.01	0.09	0.91	000
95148		A	Antigen therapy services	0.06	0.03	0.81	0.01	0.10	0.88	000
95149		A	Antigen therapy services	0.06	0.02	1.00	0.01	0.09	1.07	000
95165		A	Antigen therapy services	0.06	0.02	0.20	0.01	0.09	0.27	000
95170		A	Antigen therapy services	0.06	0.02	0.26	0.01	0.09	0.33	000
95180		A	Rapid desensitization	2.01	0.84	1.66	0.04	2.89	3.71	000
95199		C	Allergy immunology services	0.00	0.00	0.00	0.00	0.00	0.00	000
95805		A	Multiple sleep latency test	1.88	NA	7.82	0.34	NA	10.04	XXX
95805	26	A	Multiple sleep latency test	1.88	0.69	0.69	0.06	2.63	2.63	XXX
95805	TC	A	Multiple sleep latency test	0.00	NA	7.13	0.28	NA	7.41	XXX
95806		A	Sleep study, unattended	1.66	NA	1.74	0.32	NA	3.72	XXX
95806	26	A	Sleep study, unattended	1.66	0.56	0.56	0.06	2.28	2.28	XXX
95806	TC	A	Sleep study, unattended	0.00	NA	1.18	0.26	NA	1.44	XXX
95807		A	Sleep study, attended	1.66	NA	10.85	0.40	NA	12.91	XXX
95807	26	A	Sleep study, attended	1.66	0.55	0.55	0.05	2.26	2.26	XXX
95807	TC	A	Sleep study, attended	0.00	NA	10.30	0.35	NA	10.65	XXX
95808		A	Polysomnography, 1–3	2.65	NA	19.34	0.44	NA	22.43	XXX
95808	26	A	Polysomnography, 1–3	2.65	0.97	0.97	0.09	3.71	3.71	XXX
95808	TC	A	Polysomnography, 1–3	0.00	NA	18.37	0.35	NA	18.72	XXX
95810		A	Polysomnography, 4 or more	3.53	NA	16.46	0.47	NA	20.46	XXX
95810	26	A	Polysomnography, 4 or more	3.53	1.25	1.25	0.12	4.90	4.90	XXX
95810	TC	A	Polysomnography, 4 or more	0.00	NA	15.21	0.35	NA	15.56	XXX
95811		A	Polysomnography w/cpap	3.80	NA	14.73	0.49	NA	19.02	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
95811	26	A	Polysomnography w/cpap	3.80	1.33	1.33	0.13	5.26	5.26	XXX
95811	TC	A	Polysomnography w/cpap	0.00	NA	13.40	0.36	NA	13.76	XXX
95812		A	Electroencephalogram (EEG)	1.08	NA	3.68	0.13	NA	4.89	XXX
95812	26	A	Electroencephalogram (EEG)	1.08	0.47	0.47	0.04	1.59	1.59	XXX
95812	TC	A	Electroencephalogram (EEG)	0.00	NA	3.21	0.09	NA	3.30	XXX
95813		A	Electroencephalogram (EEG)	1.73	NA	4.96	0.15	NA	6.84	XXX
95813	26	A	Electroencephalogram (EEG)	1.73	0.73	0.73	0.06	2.52	2.52	XXX
95813	TC	A	Electroencephalogram (EEG)	0.00	NA	4.23	0.09	NA	4.32	XXX
95816		A	Electroencephalogram (EEG)	1.08	NA	3.33	0.12	NA	4.53	XXX
95816	26	A	Electroencephalogram (EEG)	1.08	0.48	0.48	0.04	1.60	1.60	XXX
95816	TC	A	Electroencephalogram (EEG)	0.00	NA	2.85	0.08	NA	2.93	XXX
95819		A	Electroencephalogram (EEG)	1.08	NA	3.93	0.12	NA	5.13	XXX
95819	26	A	Electroencephalogram (EEG)	1.08	0.48	0.48	0.04	1.60	1.60	XXX
95819	TC	A	Electroencephalogram (EEG)	0.00	NA	3.45	0.08	NA	3.53	XXX
95822		A	Sleep electroencephalogram	1.08	NA	2.43	0.15	NA	3.66	XXX
95822	26	A	Sleep electroencephalogram	1.08	0.48	0.48	0.04	1.60	1.60	XXX
95822	TC	A	Sleep electroencephalogram	0.00	NA	1.95	0.11	NA	2.06	XXX
95824		A	Electroencephalography	0.74	0.29	0.70	0.05	1.08	1.49	XXX
95827		A	Night electroencephalogram	1.08	NA	2.69	0.15	NA	3.92	XXX
95827	26	A	Night electroencephalogram	1.08	0.43	0.43	0.03	1.54	1.54	XXX
95827	TC	A	Night electroencephalogram	0.00	NA	2.26	0.12	NA	2.38	XXX
95829		A	Surgery electrocorticogram	6.21	NA	28.49	0.33	NA	35.03	XXX
95829	26	A	Surgery electrocorticogram	6.21	2.04	2.04	0.31	8.56	8.56	XXX
95829	TC	A	Surgery electrocorticogram	0.00	NA	26.45	0.02	NA	26.47	XXX
95830		A	Insert electrodes for EEG	1.70	0.77	3.40	0.07	2.54	5.17	XXX
95831		A	Limb muscle testing, manual	0.28	0.13	0.49	0.01	0.42	0.78	XXX
95832		A	Hand muscle testing, manual	0.29	0.11	0.43	0.01	0.41	0.73	XXX
95833		A	Body muscle testing, manual	0.47	0.24	0.56	0.01	0.72	1.04	XXX
95834		A	Body muscle testing, manual	0.60	0.29	0.57	0.02	0.91	1.19	XXX
95851		A	Range of motion measurements	0.16	0.08	0.55	0.01	0.25	0.72	XXX
95852		A	Range of motion measurements	0.11	0.05	0.45	0.01	0.17	0.57	XXX
95857		A	Tensilon test	0.53	0.24	0.63	0.02	0.79	1.18	XXX
95858		A	Tensilon test & myogram	1.56	NA	1.10	0.07	NA	2.73	XXX
95858	26	A	Tensilon test & myogram	1.56	0.71	0.71	0.04	2.31	2.31	XXX
95858	TC	A	Tensilon test & myogram	0.00	NA	0.39	0.03	NA	0.42	XXX
95860		A	Muscle test, one limb	0.96	NA	1.22	0.05	NA	2.23	XXX
95860	26	A	Muscle test, one limb	0.96	0.44	0.44	0.03	1.43	1.43	XXX
95860	TC	A	Muscle test, one limb	0.00	NA	0.78	0.02	NA	0.80	XXX
95861		A	Muscle test, two limbs	1.54	NA	1.43	0.10	NA	3.07	XXX
95861	26	A	Muscle test, two limbs	1.54	0.71	0.71	0.05	2.30	2.30	XXX
95861	TC	A	Muscle test, two limbs	0.00	NA	0.72	0.05	NA	0.77	XXX
95863		A	Muscle test, 3 limbs	1.87	NA	1.77	0.11	NA	3.75	XXX
95863	26	A	Muscle test, 3 limbs	1.87	0.85	0.85	0.06	2.78	2.78	XXX
95863	TC	A	Muscle test, 3 limbs	0.00	NA	0.92	0.05	NA	0.97	XXX
95864		A	Muscle test, 4 limbs	1.99	NA	2.67	0.16	NA	4.82	XXX
95864	26	A	Muscle test, 4 limbs	1.99	0.92	0.92	0.06	2.97	2.97	XXX
95864	TC	A	Muscle test, 4 limbs	0.00	NA	1.75	0.10	NA	1.85	XXX
95867		A	Muscle test, head or neck	0.79	NA	0.94	0.06	NA	1.79	XXX
95867	26	A	Muscle test, head or neck	0.79	0.37	0.37	0.03	1.19	1.19	XXX
95867	TC	A	Muscle test, head or neck	0.00	NA	0.57	0.03	NA	0.60	XXX
95868		A	Muscle test, head or neck	1.18	NA	1.23	0.08	NA	2.49	XXX
95868	26	A	Muscle test, head or neck	1.18	0.54	0.54	0.04	1.76	1.76	XXX
95868	TC	A	Muscle test, head or neck	0.00	NA	0.69	0.04	NA	0.73	XXX
95869		A	Muscle test, thor paraspinal	0.37	NA	0.38	0.03	NA	0.78	XXX
95869	26	A	Muscle test, thor paraspinal	0.37	0.17	0.17	0.01	0.55	0.55	XXX
95869	TC	A	Muscle test, thor paraspinal	0.00	NA	0.21	0.02	NA	0.23	XXX
95870		A	Muscle test, nonparaspinal	0.37	NA	0.37	0.03	NA	0.77	XXX
95870	26	A	Muscle test, nonparaspinal	0.37	0.16	0.16	0.01	0.54	0.54	XXX
95870	TC	A	Muscle test, nonparaspinal	0.00	NA	0.21	0.02	NA	0.23	XXX
95872		A	Muscle test, one fiber	1.50	NA	1.26	0.08	NA	2.84	XXX
95872	26	A	Muscle test, one fiber	1.50	0.67	0.67	0.04	2.21	2.21	XXX
95872	TC	A	Muscle test, one fiber	0.00	NA	0.59	0.04	NA	0.63	XXX
95875		A	Limb exercise test	1.34	NA	1.30	0.09	NA	2.73	XXX
95875	26	A	Limb exercise test	1.34	0.56	0.56	0.04	1.94	1.94	XXX
95875	TC	A	Limb exercise test	0.00	NA	0.74	0.05	NA	0.79	XXX
95900		A	Motor nerve conduction test	0.42	NA	0.75	0.03	NA	1.20	XXX
95900	26	A	Motor nerve conduction test	0.42	0.19	0.19	0.01	0.62	0.62	XXX
95900	TC	A	Motor nerve conduction test	0.00	NA	0.56	0.02	NA	0.58	XXX
95903		A	Motor nerve conduction test	0.60	NA	0.52	0.04	NA	1.16	XXX
95903	26	A	Motor nerve conduction test	0.60	0.27	0.27	0.02	0.89	0.89	XXX
95903	TC	A	Motor nerve conduction test	0.00	NA	0.25	0.02	NA	0.27	XXX
95904		A	Sense/mixed n conduction tst	0.34	NA	0.68	0.03	NA	1.05	XXX
95904	26	A	Sense/mixed n conduction tst	0.34	0.16	0.16	0.01	0.51	0.51	XXX
95904	TC	A	Sense/mixed n conduction tst	0.00	NA	0.52	0.02	NA	0.54	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
95920		A	Intraop nerve test add-on	2.11	NA	2.27	0.20	NA	4.58	ZZZ
95920	26	A	Intraop nerve test add-on	2.11	0.98	0.98	0.14	3.23	3.23	ZZZ
95920	TC	A	Intraop nerve test add-on	0.00	NA	1.29	0.06	NA	1.35	ZZZ
95921		A	Autonomic nerv function test	0.90	NA	0.71	0.05	NA	1.66	XXX
95921	26	A	Autonomic nerv function test	0.90	0.34	0.34	0.03	1.27	1.27	XXX
95921	TC	A	Autonomic nerv function test	0.00	NA	0.37	0.02	NA	0.39	XXX
95922		A	Autonomic nerv function test	0.96	NA	0.79	0.05	NA	1.80	XXX
95922	26	A	Autonomic nerv function test	0.96	0.42	0.42	0.03	1.41	1.41	XXX
95922	TC	A	Autonomic nerv function test	0.00	NA	0.37	0.02	NA	0.39	XXX
95923		A	Autonomic nerv function test	0.90	NA	2.91	0.05	NA	3.86	XXX
95923	26	A	Autonomic nerv function test	0.90	0.40	0.40	0.03	1.33	1.33	XXX
95923	TC	A	Autonomic nerv function test	0.00	NA	2.51	0.02	NA	2.53	XXX
95925		A	Somatosensory testing	0.54	NA	1.12	0.07	NA	1.73	XXX
95925	26	A	Somatosensory testing	0.54	0.23	0.23	0.02	0.79	0.79	XXX
95925	TC	A	Somatosensory testing	0.00	NA	0.89	0.05	NA	0.94	XXX
95926		A	Somatosensory testing	0.54	NA	1.14	0.07	NA	1.75	XXX
95926	26	A	Somatosensory testing	0.54	0.25	0.25	0.02	0.81	0.81	XXX
95926	TC	A	Somatosensory testing	0.00	NA	0.89	0.05	NA	0.94	XXX
95927		A	Somatosensory testing	0.54	NA	1.16	0.08	NA	1.78	XXX
95927	26	A	Somatosensory testing	0.54	0.27	0.27	0.03	0.84	0.84	XXX
95927	TC	A	Somatosensory testing	0.00	NA	0.89	0.05	NA	0.94	XXX
95930		A	Visual evoked potential test	0.35	NA	0.67	0.02	NA	1.04	XXX
95930	26	A	Visual evoked potential test	0.35	0.15	0.15	0.01	0.51	0.51	XXX
95930	TC	A	Visual evoked potential test	0.00	NA	0.52	0.01	NA	0.53	XXX
95933		A	Blink reflex test	0.59	NA	1.02	0.07	NA	1.68	XXX
95933	26	A	Blink reflex test	0.59	0.25	0.25	0.02	0.86	0.86	XXX
95933	TC	A	Blink reflex test	0.00	NA	0.77	0.05	NA	0.82	XXX
95934		A	H-reflex test	0.51	NA	0.44	0.04	NA	0.99	XXX
95934	26	A	H-reflex test	0.51	0.23	0.23	0.02	0.76	0.76	XXX
95934	TC	A	H-reflex test	0.00	NA	0.21	0.02	NA	0.23	XXX
95936		A	H-reflex test	0.55	NA	0.46	0.04	NA	1.05	XXX
95936	26	A	H-reflex test	0.55	0.25	0.25	0.02	0.82	0.82	XXX
95936	TC	A	H-reflex test	0.00	NA	0.21	0.02	NA	0.23	XXX
95937		A	Neuromuscular junction test	0.65	NA	0.61	0.04	NA	1.30	XXX
95937	26	A	Neuromuscular junction test	0.65	0.28	0.28	0.02	0.95	0.95	XXX
95937	TC	A	Neuromuscular junction test	0.00	NA	0.33	0.02	NA	0.35	XXX
95950		A	Ambulatory eeg monitoring	1.51	NA	4.05	0.44	NA	6.00	XXX
95950	26	A	Ambulatory eeg monitoring	1.51	0.68	0.68	0.08	2.27	2.27	XXX
95950	TC	A	Ambulatory eeg monitoring	0.00	NA	3.37	0.36	NA	3.73	XXX
95951		A	EEG monitoring/videorecord	6.00	NA	22.95	0.58	NA	29.53	XXX
95951	26	A	EEG monitoring/videorecord	6.00	2.67	2.67	0.20	8.87	8.87	XXX
95951	TC	A	EEG monitoring/videorecord	0.00	NA	20.28	0.38	NA	20.66	XXX
95953		A	EEG monitoring/computer	3.08	NA	7.60	0.46	NA	11.14	XXX
95953	26	A	EEG monitoring/computer	3.08	1.36	1.36	0.10	4.54	4.54	XXX
95953	TC	A	EEG monitoring/computer	0.00	NA	6.24	0.36	NA	6.60	XXX
95954		A	EEG monitoring/giving drugs	2.45	NA	4.34	0.15	NA	6.94	XXX
95954	26	A	EEG monitoring/giving drugs	2.45	1.08	1.08	0.10	3.63	3.63	XXX
95954	TC	A	EEG monitoring/giving drugs	0.00	NA	3.26	0.05	NA	3.31	XXX
95955		A	EEG during surgery	1.01	NA	2.28	0.19	NA	3.48	XXX
95955	26	A	EEG during surgery	1.01	0.35	0.35	0.05	1.41	1.41	XXX
95955	TC	A	EEG during surgery	0.00	NA	1.93	0.14	NA	2.07	XXX
95956		A	Eeg monitoring, cable/radio	3.08	NA	31.21	0.47	NA	34.76	XXX
95956	26	A	Eeg monitoring, cable/radio	3.08	1.38	1.38	0.11	4.57	4.57	XXX
95956	TC	A	Eeg monitoring, cable/radio	0.00	NA	29.83	0.36	NA	30.19	XXX
95957		A	EEG digital analysis	1.98	NA	2.57	0.17	NA	4.72	XXX
95957	26	A	EEG digital analysis	1.98	0.89	0.89	0.07	2.94	2.94	XXX
95957	TC	A	EEG digital analysis	0.00	NA	1.68	0.10	NA	1.78	XXX
95958		A	EEG monitoring/function test	4.25	NA	3.53	0.29	NA	8.07	XXX
95958	26	A	EEG monitoring/function test	4.25	1.82	1.82	0.18	6.25	6.25	XXX
95958	TC	A	EEG monitoring/function test	0.00	NA	1.71	0.11	NA	1.82	XXX
95961		A	Electrode stimulation, brain	2.97	NA	2.65	0.24	NA	5.86	XXX
95961	26	A	Electrode stimulation, brain	2.97	1.36	1.36	0.18	4.51	4.51	XXX
95961	TC	A	Electrode stimulation, brain	0.00	NA	1.29	0.06	NA	1.35	XXX
95962		A	Electrode stim, brain add-on	3.21	NA	2.73	0.23	NA	6.17	ZZZ
95962	26	A	Electrode stim, brain add-on	3.21	1.44	1.44	0.17	4.82	4.82	ZZZ
95962	TC	A	Electrode stim, brain add-on	0.00	NA	1.29	0.06	NA	1.35	ZZZ
95970		A	Analyze neurostim, no prog	0.45	0.14	0.17	0.03	0.62	0.65	XXX
95971		A	Analyze neurostim, simple	0.78	0.23	0.29	0.06	1.07	1.13	XXX
95972		A	Analyze neurostim, complex	1.50	0.56	0.64	0.17	2.23	2.31	XXX
95973		A	Analyze neurostim, complex	0.92	0.37	0.41	0.07	1.36	1.40	ZZZ
95974		A	Cranial neurostim, complex	3.00	1.35	1.35	0.15	4.50	4.50	XXX
95975		A	Cranial neurostim, complex	1.70	0.75	0.76	0.07	2.52	2.53	ZZZ
95999		C	Neurological procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
96100		A	Psychological testing	0.00	NA	1.73	0.15	NA	1.88	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
96105		A	Assessment of aphasia	0.00	NA	1.73	0.15	NA	1.88	XXX
96110		C	Developmental test, lim	0.00	0.00	0.00	0.00	0.00	0.00	XXX
96111		A	Developmental test, extend	0.00	NA	1.73	0.15	NA	1.88	XXX
96115		A	Neurobehavior status exam	0.00	NA	1.73	0.15	NA	1.88	XXX
96117		A	Neuropsych test battery	0.00	NA	1.73	0.15	NA	1.88	XXX
96400		A	Chemotherapy, sc/im	0.00	NA	0.13	0.01	NA	0.14	XXX
96405		A	Intralesional chemo admin	0.52	0.24	1.78	0.02	0.78	2.32	000
96406		A	Intralesional chemo admin	0.80	0.32	2.44	0.02	1.14	3.26	000
96408		A	Chemotherapy, push technique	0.00	NA	0.95	0.05	NA	1.00	XXX
96410		A	Chemotherapy,infusion method	0.00	NA	1.52	0.07	NA	1.59	XXX
96412		A	Chemo, infuse method add-on	0.00	NA	1.13	0.06	NA	1.19	ZZZ
96414		A	Chemo, infuse method add-on	0.00	NA	1.31	0.07	NA	1.38	XXX
96420		A	Chemotherapy, push technique	0.00	NA	1.23	0.07	NA	1.30	XXX
96422		A	Chemotherapy,infusion method	0.00	NA	1.21	0.07	NA	1.28	XXX
96423		A	Chemo, infuse method add-on	0.00	NA	0.48	0.02	NA	0.50	ZZZ
96425		A	Chemotherapy,infusion method	0.00	NA	1.41	0.07	NA	1.48	XXX
96440		A	Chemotherapy, intracavitary	2.37	1.07	8.00	0.12	3.56	10.49	000
96445		A	Chemotherapy, intracavitary	2.20	1.05	8.36	0.07	3.32	10.63	000
96450		A	Chemotherapy, into CNS	1.89	0.90	6.74	0.06	2.85	8.69	000
96520		A	Pump refilling, maintenance	0.00	NA	0.88	0.05	NA	0.93	XXX
96530		A	Pump refilling, maintenance	0.00	NA	1.05	0.05	NA	1.10	XXX
96542		A	Chemotherapy injection	1.42	0.57	4.01	0.05	2.04	5.48	XXX
96545		B	Provide chemotherapy agent	+0.00	0.00	0.00	0.00	0.00	0.00	XXX
96549		C	Chemotherapy, unspecified	0.00	0.00	0.00	0.00	0.00	0.00	XXX
96570		A	Photodynamic tx, 30 min	1.10	0.43	0.43	0.04	1.57	1.57	ZZZ
96571		A	Photodynamic tx, addl 15 min	0.55	0.22	0.22	0.02	0.79	0.79	ZZZ
96900		A	Ultraviolet light therapy	0.00	NA	0.39	0.02	NA	0.41	XXX
96902		B	Trichogram	+0.41	0.16	0.24	0.01	0.58	0.66	XXX
96910		A	Photochemotherapy with UV–B	0.00	NA	0.57	0.03	NA	0.60	XXX
96912		A	Photochemotherapy with UV–A	0.00	NA	0.65	0.04	NA	0.69	XXX
96913		A	Photochemotherapy, UV–A or B	0.00	NA	1.33	0.08	NA	1.41	XXX
96999		C	Dermatological procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97001		A	Pt evaluation	1.20	0.47	0.56	0.10	1.77	1.86	XXX
97002		A	Pt re-evaluation	0.60	0.26	0.35	0.04	0.90	0.99	XXX
97003		A	Ot evaluation	1.20	0.32	0.66	0.05	1.57	1.91	XXX
97004		A	Ot re-evaluation	0.60	0.13	0.42	0.02	0.75	1.04	XXX
97010		B	Hot or cold packs therapy	+0.06	NA	0.24	0.01	NA	0.31	XXX
97012		A	Mechanical traction therapy	0.25	NA	0.27	0.01	NA	0.53	XXX
97014		A	Electric stimulation therapy	0.18	NA	0.25	0.01	NA	0.44	XXX
97016		A	Vasopneumatic device therapy	0.18	NA	0.25	0.01	NA	0.44	XXX
97018		A	Paraffin bath therapy	0.06	NA	0.22	0.01	NA	0.29	XXX
97020		A	Microwave therapy	0.06	NA	0.23	0.01	NA	0.30	XXX
97022		A	Whirlpool therapy	0.17	NA	0.44	0.01	NA	0.62	XXX
97024		A	Diathermy treatment	0.06	NA	0.24	0.01	NA	0.31	XXX
97026		A	Infrared therapy	0.06	NA	0.22	0.01	NA	0.29	XXX
97028		A	Ultraviolet therapy	0.08	NA	0.23	0.01	NA	0.32	XXX
97032		A	Electrical stimulation	0.25	NA	0.29	0.01	NA	0.55	XXX
97033		A	Electric current therapy	0.26	NA	0.31	0.02	NA	0.59	XXX
97034		A	Contrast bath therapy	0.21	NA	0.28	0.01	NA	0.50	XXX
97035		A	Ultrasound therapy	0.21	NA	0.17	0.01	NA	0.39	XXX
97036		A	Hydrotherapy	0.28	NA	0.37	0.01	NA	0.66	XXX
97039		A	Physical therapy treatment	0.20	NA	0.28	0.01	NA	0.49	XXX
97110		A	Therapeutic exercises	0.45	NA	0.19	0.03	NA	0.67	XXX
97112		A	Neuromuscular reeducation	0.45	NA	0.30	0.02	NA	0.77	XXX
97113		A	Aquatic therapy/exercises	0.44	NA	0.32	0.03	NA	0.79	XXX
97116		A	Gait training therapy	0.40	NA	0.30	0.02	NA	0.72	XXX
97124		A	Massage therapy	0.35	NA	0.29	0.01	NA	0.65	XXX
97139		A	Physical medicine procedure	0.21	NA	0.26	0.01	NA	0.48	XXX
97140		A	Manual therapy	0.43	NA	0.32	0.02	NA	0.77	XXX
97150		A	Group therapeutic procedures	0.27	NA	0.27	0.02	NA	0.56	XXX
97504		A	Orthotic training	0.45	NA	0.30	0.03	NA	0.78	XXX
97520		A	Prosthetic training	0.45	NA	0.31	0.02	NA	0.78	XXX
97530		A	Therapeutic activities	0.44	NA	0.18	0.02	NA	0.64	XXX
97532		A	Cognitive skills development	0.44	NA	0.24	0.01	NA	0.69	XXX
97533		A	Sensory integration	0.44	NA	0.30	0.01	NA	0.75	XXX
97535		A	Self care mngment training	0.45	NA	0.30	0.02	NA	0.77	XXX
97537		A	Community/work reintegration	0.45	NA	0.30	0.01	NA	0.76	XXX
97542		A	Wheelchair mngmnt training	0.45	NA	0.30	0.01	NA	0.76	XXX
97545		R	Work hardening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97546		R	Work hardening add-on	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
97601		A	Wound care selective	0.50	NA	0.50	0.04	NA	1.04	XXX
97602		B	Wound care non-selective	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97703		A	Prosthetic checkout	0.25	NA	0.15	0.02	NA	0.42	XXX
97750		A	Physical performance test	0.45	NA	0.25	0.02	NA	0.72	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
97780		N	Acupuncture w/o stimul	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97781		N	Acupuncture w/stimul	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97799		C	Physical medicine procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97802		N	Medical nutrition, indiv, in	+0.00	NA	0.47	0.01	NA	0.48	XXX
97803		N	Med nutrition, indiv, subseq	+0.00	NA	0.34	0.01	NA	0.35	XXX
97804		N	Medical nutrition, group	+0.00	NA	0.14	0.01	NA	0.15	XXX
98925		A	Osteopathic manipulation	0.45	0.15	0.37	0.01	0.61	0.83	000
98926		A	Osteopathic manipulation	0.65	0.26	0.43	0.02	0.93	1.10	000
98927		A	Osteopathic manipulation	0.87	0.31	0.51	0.03	1.21	1.41	000
98928		A	Osteopathic manipulation	1.03	0.36	0.59	0.03	1.42	1.65	000
98929		A	Osteopathic manipulation	1.19	0.38	0.65	0.04	1.61	1.88	000
98940		A	Chiropractic manipulation	0.45	0.13	0.25	0.01	0.59	0.71	000
98941		A	Chiropractic manipulation	0.65	0.18	0.31	0.02	0.85	0.98	000
98942		A	Chiropractic manipulation	0.87	0.24	0.37	0.03	1.14	1.27	000
98943		N	Chiropractic manipulation	+0.40	0.16	0.34	0.01	0.57	0.75	XXX
99000		B	Specimen handling	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99001		B	Specimen handling	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99002		B	Device handling	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99024		B	Postop follow-up visit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99025		B	Initial surgical evaluation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99050		B	Medical services after hrs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99052		B	Medical services at night	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99054		B	Medical servcs, unusual hrs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99056		B	Non-office medical services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99058		B	Office emergency care	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99070		B	Special supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99071		B	Patient education materials	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99075		N	Medical testimony	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99078		B	Group health education	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99080		B	Special reports or forms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99082		C	Unusual physician travel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99090		B	Computer data analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99100		B	Special anesthesia service	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99116		B	Anesthesia with hypothermia	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99135		B	Special anesthesia procedure	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99140		B	Emergency anesthesia	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99141		B	Sedation, iv/im or inhalant	+0.80	0.39	2.04	0.04	1.23	2.88	XXX
99142		B	Sedation, oral/rectal/nasal	+0.60	0.31	1.19	0.03	0.94	1.82	XXX
99170		A	Anogenital exam, child	1.75	0.69	1.85	0.07	2.51	3.67	000
99172		N	Ocular function screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99173		N	Visual acuity screen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99175		A	Induction of vomiting	0.00	NA	1.37	0.08	NA	1.45	XXX
99183		A	Hyperbaric oxygen therapy	2.34	0.76	NA	0.12	3.22	NA	XXX
99185		A	Regional hypothermia	0.00	NA	0.63	0.03	NA	0.66	XXX
99186		A	Total body hypothermia	0.00	NA	1.75	0.37	NA	2.12	XXX
99190		X	Special pump services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99191		X	Special pump services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99192		X	Special pump services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99195		A	Phlebotomy	0.00	NA	0.44	0.02	NA	0.46	XXX
99199		C	Special service/proc/report	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99201		A	Office/outpatient visit, new	0.45	0.16	0.45	0.02	0.63	0.92	XXX
99202		A	Office/outpatient visit, new	0.88	0.33	0.74	0.05	1.26	1.67	XXX
99203		A	Office/outpatient visit, new	1.34	0.50	1.07	0.08	1.92	2.49	XXX
99204		A	Office/outpatient visit, new	2.00	0.74	1.48	0.10	2.84	3.58	XXX
99205		A	Office/outpatient visit, new	2.67	0.96	1.77	0.12	3.75	4.56	XXX
99211		A	Office/outpatient visit, est	0.17	0.06	0.37	0.01	0.24	0.55	XXX
99212		A	Office/outpatient visit, est	0.45	0.17	0.51	0.02	0.64	0.98	XXX
99213		A	Office/outpatient visit, est	0.67	0.24	0.67	0.03	0.94	1.37	XXX
99214		A	Office/outpatient visit, est	1.10	0.40	1.02	0.04	1.54	2.16	XXX
99215		A	Office/outpatient visit, est	1.77	0.65	1.33	0.07	2.49	3.17	XXX
99217		A	Observation care discharge	1.28	0.45	NA	0.05	1.78	NA	XXX
99218		A	Observation care	1.28	0.45	NA	0.05	1.78	NA	XXX
99219		A	Observation care	2.14	0.74	NA	0.08	2.96	NA	XXX
99220		A	Observation care	2.99	1.05	NA	0.11	4.15	NA	XXX
99221		A	Initial hospital care	1.28	0.47	NA	0.05	1.80	NA	XXX
99222		A	Initial hospital care	2.14	0.76	NA	0.08	2.98	NA	XXX
99223		A	Initial hospital care	2.99	1.07	NA	0.10	4.16	NA	XXX
99231		A	Subsequent hospital care	0.64	0.24	NA	0.02	0.90	NA	XXX
99232		A	Subsequent hospital care	1.06	0.38	NA	0.03	1.47	NA	XXX
99233		A	Subsequent hospital care	1.51	0.54	NA	0.05	2.10	NA	XXX
99234		A	Observ/hosp same date	2.56	0.92	NA	0.11	3.59	NA	XXX
99235		A	Observ/hosp same date	3.42	1.19	NA	0.13	4.74	NA	XXX
99236		A	Observ/hosp same date	4.27	1.45	NA	0.17	5.89	NA	XXX
99238		A	Hospital discharge day	1.28	0.45	NA	0.04	1.77	NA	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
99239		A	Hospital discharge day	1.75	0.62	NA	0.05	2.42	NA	XXX
99241		A	Office consultation	0.64	0.23	0.60	0.04	0.91	1.28	XXX
99242		A	Office consultation	1.29	0.49	0.99	0.09	1.87	2.37	XXX
99243		A	Office consultation	1.72	0.66	1.33	0.10	2.48	3.15	XXX
99244		A	Office consultation	2.58	0.97	1.78	0.13	3.68	4.49	XXX
99245		A	Office consultation	3.43	1.28	2.25	0.16	4.87	5.84	XXX
99251		A	Initial inpatient consult	0.66	0.30	NA	0.04	1.00	NA	XXX
99252		A	Initial inpatient consult	1.32	0.57	NA	0.08	1.97	NA	XXX
99253		A	Initial inpatient consult	1.82	0.76	NA	0.09	2.67	NA	XXX
99254		A	Initial inpatient consult	2.64	1.07	NA	0.11	3.82	NA	XXX
99255		A	Initial inpatient consult	3.65	1.44	NA	0.15	5.24	NA	XXX
99261		A	Follow-up inpatient consult	0.42	0.21	NA	0.02	0.65	NA	XXX
99262		A	Follow-up inpatient consult	0.85	0.37	NA	0.03	1.25	NA	XXX
99263		A	Follow-up inpatient consult	1.27	0.52	NA	0.04	1.83	NA	XXX
99271		A	Confirmatory consultation	0.45	0.21	0.64	0.03	0.69	1.12	XXX
99272		A	Confirmatory consultation	0.84	0.36	0.88	0.06	1.26	1.78	XXX
99273		A	Confirmatory consultation	1.19	0.50	1.07	0.07	1.76	2.33	XXX
99274		A	Confirmatory consultation	1.73	0.71	1.38	0.09	2.53	3.20	XXX
99275		A	Confirmatory consultation	2.31	0.90	1.63	0.10	3.31	4.04	XXX
99281		A	Emergency dept visit	0.33	0.09	NA	0.02	0.44	NA	XXX
99282		A	Emergency dept visit	0.55	0.15	NA	0.03	0.73	NA	XXX
99283		A	Emergency dept visit	1.24	0.32	NA	0.08	1.64	NA	XXX
99284		A	Emergency dept visit	1.95	0.50	NA	0.12	2.57	NA	XXX
99285		A	Emergency dept visit	3.06	0.75	NA	0.19	4.00	NA	XXX
99288		B	Direct advanced life support	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99291		A	Critical care, first hour	4.00	1.33	1.59	0.14	5.47	5.73	XXX
99292		A	Critical care, addl 30 min	2.00	0.66	0.86	0.07	2.73	2.93	ZZZ
99295		A	Neonatal critical care	16.00	4.91	NA	0.70	21.61	NA	XXX
99296		A	Neonatal critical care	8.00	2.63	NA	0.23	10.86	NA	XXX
99297		A	Neonatal critical care	4.00	1.34	NA	0.12	5.46	NA	XXX
99298		A	Neonatal critical care	2.75	0.96	NA	0.10	3.81	NA	XXX
99301		A	Nursing facility care	1.20	0.42	NA	0.04	1.66	NA	XXX
99302		A	Nursing facility care	1.61	0.56	NA	0.05	2.22	NA	XXX
99303		A	Nursing facility care	2.01	0.69	NA	0.06	2.76	NA	XXX
99311		A	Nursing fac care, subseq	0.60	0.21	NA	0.02	0.83	NA	XXX
99312		A	Nursing fac care, subseq	1.00	0.34	NA	0.03	1.37	NA	XXX
99313		A	Nursing fac care, subseq	1.42	0.49	NA	0.04	1.95	NA	XXX
99315		A	Nursing fac discharge day	1.13	0.39	NA	0.04	1.56	NA	XXX
99316		A	Nursing fac discharge day	1.50	0.53	NA	0.05	2.08	NA	XXX
99321		A	Rest home visit, new patient	0.71	0.35	0.43	0.02	1.08	1.16	XXX
99322		A	Rest home visit, new patient	1.01	0.45	0.68	0.03	1.49	1.72	XXX
99323		A	Rest home visit, new patient	1.28	0.56	0.92	0.04	1.88	2.24	XXX
99331		A	Rest home visit, est pat	0.60	0.31	0.46	0.02	0.93	1.08	XXX
99332		A	Rest home visit, est pat	0.80	0.38	0.58	0.03	1.21	1.41	XXX
99333		A	Rest home visit, est pat	1.00	0.45	0.71	0.03	1.48	1.74	XXX
99341		A	Home visit, new patient	1.01	0.48	0.54	0.05	1.54	1.60	XXX
99342		A	Home visit, new patient	1.52	0.69	0.84	0.05	2.26	2.41	XXX
99343		A	Home visit, new patient	2.27	1.28	1.28	0.07	3.62	3.62	XXX
99344		A	Home visit, new patient	3.03	1.31	1.59	0.10	4.44	4.72	XXX
99345		A	Home visit, new patient	3.79	1.36	1.83	0.12	5.27	5.74	XXX
99347		A	Home visit, est patient	0.76	0.36	0.47	0.03	1.15	1.26	XXX
99348		A	Home visit, est patient	1.26	0.53	0.71	0.04	1.83	2.01	XXX
99349		A	Home visit, est patient	2.02	0.81	1.07	0.06	2.89	3.15	XXX
99350		A	Home visit, est patient	3.03	1.16	1.46	0.10	4.29	4.59	XXX
99354		A	Prolonged service, office	1.77	0.63	1.46	0.06	2.46	3.29	ZZZ
99355		A	Prolonged service, office	1.77	0.63	1.25	0.06	2.46	3.08	ZZZ
99356		A	Prolonged service, inpatient	1.71	0.60	NA	0.06	2.37	NA	ZZZ
99357		A	Prolonged service, inpatient	1.71	0.62	NA	0.06	2.39	NA	ZZZ
99358		B	Prolonged serv, w/o contact	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99359		B	Prolonged serv, w/o contact	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99360		X	Physician standby services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99361		B	Physician/team conference	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99362		B	Physician/team conference	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99371		B	Physician phone consultation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99372		B	Physician phone consultation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99373		B	Physician phone consultation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99374		B	Home health care supervision	+1.10	0.43	1.43	0.04	1.57	2.57	XXX
99375		G	Home health care supervision	1.73	1.68	1.68	0.06	3.47	3.47	XXX
99377		B	Hospice care supervision	+1.10	0.43	1.43	0.04	1.57	2.57	XXX
99378		G	Hospice care supervision	1.73	1.68	1.68	0.06	3.47	3.47	XXX
99379		B	Nursing fac care supervision	+1.10	0.43	1.43	0.03	1.56	2.56	XXX
99380		B	Nursing fac care supervision	+1.73	0.68	1.68	0.05	2.46	3.46	XXX
99381		N	Prev visit, new, infant	+1.19	0.47	1.46	0.04	1.70	2.69	XXX
99382		N	Prev visit, new, age 1–4	+1.36	0.54	1.50	0.04	1.94	2.90	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
99383		N	Prev visit, new, age 5–11	+1.36	0.54	1.44	0.04	1.94	2.84	XXX
99384		N	Prev visit, new, age 12–17	+1.53	0.60	1.52	0.05	2.18	3.10	XXX
99385		N	Prev visit, new, age 18–39	+1.53	0.60	1.52	0.05	2.18	3.10	XXX
99386		N	Prev visit, new, age 40–64	+1.88	0.74	1.70	0.06	2.68	3.64	XXX
99387		N	Prev visit, new, 65 & over	+2.06	0.81	1.83	0.06	2.93	3.95	XXX
99391		N	Prev visit, est, infant	+1.02	0.40	1.00	0.03	1.45	2.05	XXX
99392		N	Prev visit, est, age 1–4	+1.19	0.47	1.07	0.04	1.70	2.30	XXX
99393		N	Prev visit, est, age 5–11	+1.19	0.47	1.04	0.04	1.70	2.27	XXX
99394		N	Prev visit, est, age 12–17	+1.36	0.54	1.12	0.04	1.94	2.52	XXX
99395		N	Prev visit, est, age 18–39	+1.36	0.54	1.15	0.04	1.94	2.55	XXX
99396		N	Prev visit, est, age 40–64	+1.53	0.60	1.24	0.05	2.18	2.82	XXX
99397		N	Prev visit, est, 65 & over	+1.71	0.68	1.34	0.05	2.44	3.10	XXX
99401		N	Preventive counseling, indiv	+0.48	0.19	0.60	0.01	0.68	1.09	XXX
99402		N	Preventive counseling, indiv	+0.98	0.39	0.85	0.02	1.39	1.85	XXX
99403		N	Preventive counseling, indiv	+1.46	0.58	1.08	0.03	2.07	2.57	XXX
99404		N	Preventive counseling, indiv	+1.95	0.77	1.32	0.04	2.76	3.31	XXX
99411		N	Preventive counseling, group	+0.15	0.06	0.18	0.01	0.22	0.34	XXX
99412		N	Preventive counseling, group	+0.25	0.10	0.24	0.01	0.36	0.50	XXX
99420		N	Health risk assessment test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99429		N	Unlisted preventive service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99431		A	Initial care, normal newborn	1.17	0.36	NA	0.04	1.57	NA	XXX
99432		A	Newborn care, not in hosp	1.26	0.34	1.10	0.06	1.66	2.42	XXX
99433		A	Normal newborn care/hospital	0.62	0.20	NA	0.02	0.84	NA	XXX
99435		A	Newborn discharge day hosp	1.50	0.56	NA	0.05	2.11	NA	XXX
99436		A	Attendance, birth	1.50	0.47	0.59	0.05	2.02	2.14	XXX
99440		A	Newborn resuscitation	2.93	0.88	NA	0.11	3.92	NA	XXX
99450		N	Life/disability evaluation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99455		R	Disability examination	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99456		R	Disability examination	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99499		C	Unlisted e&m service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0021		I	Outside state ambulance serv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0030		I	Air ambulance service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0040		I	Helicopter ambulance service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0050		I	Water amb service emergency	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0080		I	Noninterest escort in non er	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0090		I	Interest escort in non er	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0100		I	Nonemergency transport taxi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0110		I	Nonemergency transport bus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0120		I	Noner transport mini-bus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0130		I	Noner transport wheelch van	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0140		I	Nonemergency transport air	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0160		I	Noner transport case worker	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0170		I	Noner transport parking fees	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0180		I	Noner transport lodgng recip	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0190		I	Noner transport meals recip	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0200		I	Noner transport lodgng escrt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0210		I	Noner transport meals escort	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0300		I	Ambulance basic non-emer all	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0302		I	Ambulance basic emergeny all	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0304		I	Amb adv non-er no serv all	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0306		I	Amb adv non-er spec serv all	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0308		I	Amb adv er no spec serv all	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0310		I	Amb adv er spec serv all	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0320		I	Amb basic non-er + supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0322		I	Amb basic emerg + supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0324		I	Adv non-er serv sep mileage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0326		I	Adv non-er no serv sep mile	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0328		I	Adv er no serv sep mileage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0330		I	Adv er spec serv sep mile	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0340		I	Amb basic non-er + mileage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0342		I	Ambul basic emer + mileage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0344		I	Amb adv non-er no serv +mile	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0346		I	Amb adv non-er serv + mile	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0348		I	Adv emer no spec serv + mile	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0350		I	Adv emer spec serv + mileage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0360		I	Basic non-er sep mile & supp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0362		I	Basic emer sep mile & supply	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0364		I	Adv non-er no serv sep mi&su	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0366		I	Adv non-er serv sep mil&supp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0368		I	Adv er no serv sep mile&supp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0370		I	Adv er spec serv sep mi&supp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0380		X	Basic life support mileage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0382		X	Basic support routine suppls	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0384		X	Bls defibrillation supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
A0390		X	Advanced life support mileag	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0392		X	Als defibrillation supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0394		X	Als IV drug therapy supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0396		X	Als esophageal intub suppls	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0398		X	Als routine disposble suppls	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0420		X	Ambulance waiting 1/2 hr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0422		X	Ambulance 02 life sustaining	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0424		X	Extra ambulance attendant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0425		X	Ground mileage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0426		X	Als 1	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0427		X	ALS1-emergency	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0428		X	bls	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0429		X	BLS-emergency	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0430		X	Fixed wing air transport	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0431		X	Rotary wing air transport	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0432		X	PI volunteer ambulance co	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0433		X	als 2	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0434		X	Specialty care transport	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0435		X	Fixed wing air mileage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0436		X	Rotary wing air mileage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0888		N	Noncovered ambulance mileage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0999		X	Unlisted ambulance service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4206		I	1 CC sterile syringe&needle	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4207		I	2 CC sterile syringe&needle	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4208		I	3 CC sterile syringe&needle	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4209		I	5+ CC sterile syringe&needle	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4210		N	Nonneedle injection device	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4211		P	Supp for self-adm injections	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4212		P	Non coring needle or stylet	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4213		I	20+ CC syringe only	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4214		P	30 CC sterile water/saline	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4215		I	Sterile needle	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4220		P	Infusion pump refill kit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4221		X	Maint drug infus cath per wk	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4222		X	Drug infusion pump supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4230		X	Infus insulin pump non needl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4231		X	Infusion insulin pump needle	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4232		X	Syringe w/needle insulin 3cc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4244		I	Alcohol or peroxide per pint	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4245		I	Alcohol wipes per box	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4246		I	Betadine/phisohex solution	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4247		I	Betadine/iodine swabs/wipes	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4250		N	Urine reagent strips/tablets	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4253		P	Blood glucose/reagent strips	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4254		X	Battery for glucose monitor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4255		X	Glucose monitor platforms	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4256		P	Calibrator solution/chips	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4258		P	Lancet device each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4259		P	Lancets per box	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4260		N	Levonorgestrel implant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4261		N	Cervical cap contraceptive	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4262		B	Temporary tear duct plug	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4263		B	Permanent tear duct plug	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4265		P	Paraffin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4270		B	Disposable endoscope sheath	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4280		X	Brst prsths adhsv attchmnt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4290		X	Sacral nerve stim test lead	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4300		B	Cath impl vasc access portal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4301		P	Implantable access syst perc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4305		P	Drug delivery system >=50 ML	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4306		P	Drug delivery system <=5 ML	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4310		P	Insert tray w/o bag/cath	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4311		P	Catheter w/o bag 2-way latex	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4312		P	Cath w/o bag 2-way silicone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4313		P	Catheter w/bag 3-way	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4314		P	Cath w/drainage 2-way latex	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4315		P	Cath w/drainage 2-way silcne	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4316		P	Cath w/drainage 3-way	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4319		X	Sterile H2O irrigation solut	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4320		P	Irrigation tray	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4321		X	Cath therapeutic irrig agent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4322		P	Irrigation syringe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4323		P	Saline irrigation solution	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4324		X	Male ext cath w/adh coating	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
A4325		X	Male ext cath w/adh strip	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4326		P	Male external catheter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4327		P	Fem urinary collect dev cup	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4328		P	Fem urinary collect pouch	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4329		P	External catheter start set	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4330		P	Stool collection pouch	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4331		X	Extension drainage tubing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4332		X	Lubricant for cath insertion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4333		X	Urinary cath anchor device	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4334		X	Urinary cath leg strap	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4335		P	Incontinence supply	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4338		P	Indwelling catheter latex	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4340		P	Indwelling catheter special	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4344		P	Cath indw foley 2 way silicn	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4346		P	Cath indw foley 3 way	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4347		P	Male external catheter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4348		X	Male ext cath extended wear	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4351		P	Straight tip urine catheter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4352		P	Coude tip urinary catheter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4353		X	Intermittent urinary cath	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4354		P	Cath insertion tray w/bag	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4355		P	Bladder irrigation tubing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4356		P	Ext ureth clmp or compr dvc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4357		P	Bedside drainage bag	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4358		P	Urinary leg bag	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4359		P	Urinary suspensory w/o leg b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4361		P	Ostomy face plate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4362		P	Solid skin barrier	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4364		P	Liq adhes for facial prosth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4365		X	Adhesive remover wipes	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4367		P	Ostomy belt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4368		X	Ostomy filter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4369		X	Skin barrier liquid per oz	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4370		X	Skin barrier paste per oz	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4371		X	Skin barrier powder per oz	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4372		X	Skin barrier solid 4x4 equiv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4373		X	Skin barrier with flange	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4374		X	Skin barrier extended wear	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4375		X	Drainable plastic pch w fcpl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4376		X	Drainable rubber pch w fcplt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4377		X	Drainable plstic pch w/o fp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4378		X	Drainable rubber pch w/o fp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4379		X	Urinary plastic pouch w fcpl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4380		X	Urinary rubber pouch w fcplt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4381		X	Urinary plastic pouch w/o fp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4382		X	Urinary hvy plstc pch w/o fp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4383		X	Urinary rubber pouch w/o fp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4384		X	Ostomy faceplt/silicone ring	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4385		X	Ost skn barrier sld ext wear	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4386		X	Ost skn barrier w flng ex wr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4387		X	Ost clsd pouch w att st barr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4388		X	Drainable pch w ex wear barr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4389		X	Drainable pch w st wear barr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4390		X	Drainable pch ex wear convex	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4391		X	Urinary pouch w ex wear barr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4392		X	Urinary pouch w st wear barr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4393		X	Urine pch w ex wear bar conv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4394		X	Ostomy pouch liq deodorant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4395		X	Ostomy pouch solid deodorant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4396		X	Peristomal hernia supprt blt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4397		P	Irrigation supply sleeve	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4398		P	Ostomy irrigation bag	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4399		P	Ostomy irrig cone/cath w brs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4400		P	Ostomy irrigation set	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4402		P	Lubricant per ounce	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4404		P	Ostomy ring each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4421		P	Ostomy supply misc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4454		P	Tape all types all sizes	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4455		P	Adhesive remover per ounce	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4460		P	Elastic compression bandage	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4462		X	Abdmnl drssng holder/binder	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4464		N	Joint support device/garment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4465		P	Non-elastic extremity binder	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4470		P	Gravlee jet washer	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
A4480		P	Vabra aspirator	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4481		X	Tracheostoma filter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4483		X	Moisture exchanger	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4490		N	Above knee surgical stocking	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4495		N	Thigh length surg stocking	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4500		N	Below knee surgical stocking	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4510		N	Full length surg stocking	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4550		B	Surgical trays	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4554		N	Disposable underpads	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4556		P	Electrodes, pair	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4557		P	Lead wires, pair	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4558		P	Conductive paste or gel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4561		X	Pessary rubber, any type	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4562		X	Pessary, non rubber,any type	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4565		X	Slings	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4570		I	Splint	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4572		X	Rib belt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4575		N	Hyperbaric o2 chamber disps	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4580		I	Cast supplies (plaster)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4590		I	Special casting material	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4595		X	TENS suppl 2 lead per month	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4608		X	Transtracheal oxygen cath	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4611		X	Heavy duty battery	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4612		X	Battery cables	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4613		X	Battery charger	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4614		X	Hand-held PEFR meter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4615		X	Cannula nasal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4616		X	Tubing (oxygen) per foot	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4617		X	Mouth piece	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4618		X	Breathing circuits	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4619		X	Face tent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4620		X	Variable concentration mask	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4621		X	Tracheotomy mask or collar	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4622		X	Tracheostomy or larngectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4623		X	Tracheostomy inner cannula	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4624		X	Tracheal suction tube	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4625		X	Trach care kit for new trach	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4626		X	Tracheostomy cleaning brush	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4627		N	Spacer bag/reservoir	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4628		X	Oropharyngeal suction cath	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4629		X	Tracheostomy care kit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4630		X	Repl bat t.e.n.s. own by pt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4631		X	Wheelchair battery	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4635		X	Underarm crutch pad	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4636		X	Handgrip for cane etc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4637		X	Repl tip cane/crutch/walker	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4640		X	Alternating pressure pad	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4641		E	Diagnostic imaging agent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4642		E	Satumomab pendetide per dose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4643		E	High dose contrast MRI	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4644		E	Contrast 100–199 MGs iodine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4645		E	Contrast 200–299 MGs iodine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4646		E	Contrast 300–399 MGs iodine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4647		B	Supp- paramagnetic contr mat	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4649		P	Surgical supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4650		X	Supp esrd centrifuge	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4655		X	Esrd syringe/needle	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4660		X	Esrd blood pressure device	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4663		X	Esrd blood pressure cuff	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4670		N	Auto blood pressure monitor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4680		X	Activated carbon filters	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4690		X	Dialyzers	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4700		X	Standard dialysate solution	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4705		X	Bicarb dialysate solution	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4712		X	Sterile water	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4714		X	Treated water for dialysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4730		X	Fistula cannulation set dial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4735		X	Local/topical anesthetics	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4740		X	Esrd shunt accessory	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4750		X	Arterial or venous tubing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4755		X	Arterial and venous tubing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4760		X	Standard testing solution	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4765		X	Dialysate concentrate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4770		X	Blood testing supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
A4771		X	Blood clotting time tube	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4772		X	Dextrostick/glucose strips	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4773		X	Hemostix	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4774		X	Ammonia test paper	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4780		X	Esrd sterilizing agent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4790		X	Esrd cleansing agents	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4800		X	Heparin/antidote dialysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4820		X	Supplies hemodialysis kit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4850		X	Rubber tipped hemostats	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4860		X	Disposable catheter caps	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4870		X	Plumbing/electrical work	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4880		X	Water storage tanks	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4890		R	Contracts/repair/maintenance	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4900		X	Capd supply kit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4901		X	Ccpd supply kit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4905		X	Ipd supply kit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4910		X	Esrd nonmedical supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4912		X	Gomco drain bottle	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4913		X	Esrd supply	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4914		X	Preparation kit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4918		X	Venous pressure clamp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4919		X	Supp dialysis dialyzer holde	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4920		X	Harvard pressure clamp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4921		X	Measuring cylinder	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4927		X	Gloves	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5051		P	Pouch clsd w barr attached	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5052		P	Clsd ostomy pouch w/o barr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5053		P	Clsd ostomy pouch faceplate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5054		P	Clsd ostomy pouch w/flange	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5055		P	Stoma cap	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5061		P	Pouch drainable w barrier at	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5062		P	Drnble ostomy pouch w/o barr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5063		P	Drain ostomy pouch w/flange	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5064		I	Drain ostomy pouch w/fceplte	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5071		P	Urinary pouch w/barrier	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5072		P	Urinary pouch w/o barrier	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5073		P	Urinary pouch on barr w/flng	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5074		I	Urinary pouch w/faceplate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5075		I	Urinary pouch on faceplate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5081		P	Continent stoma plug	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5082		P	Continent stoma catheter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5093		P	Ostomy accessory convex inse	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5102		P	Bedside drain btl w/wo tube	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5105		P	Urinary suspensory	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5112		P	Urinary leg bag	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5113		P	Latex leg strap	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5114		P	Foam/fabric leg strap	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5119		P	Skin barrier wipes box pr 50	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5121		P	Solid skin barrier 6x6	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5122		P	Solid skin barrier 8x8	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5123		P	Skin barrier with flange	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5126		P	Disk/foam pad +or- adhesive	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5131		P	Appliance cleaner	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5200		X	Percutaneous catheter anchor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5500		X	Diab shoe for density insert	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5501		X	Diabetic custom molded shoe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5502		X	Diabetic shoe density insert	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5503		X	Diabetic shoe w/roller/rockr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5504		X	Diabetic shoe with wedge	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5505		X	Diab shoe w/metatarsal bar	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5506		X	Diabetic shoe w/off set heel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5507		X	Modification diabetic shoe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5508		X	Diabetic deluxe shoe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6020		P	Collagen wound dressing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6021		X	Collagen dressing <=16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6022		X	Collagen drsg>6<=48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6023		X	Collagen dressing >48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6024		X	Collagen dsg wound filler	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6025		I	Silicone gel sheet, each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6154		P	Wound pouch each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6196		P	Alginate dressing <=16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6197		P	Alginate drsg >16 <=48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6198		P	alginate dressing > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6199		P	Alginate drsg wound filler	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
A6200		X	Compos drsg <=16 no border	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6201		X	Compos drsg >16<=48 no bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6202		X	Compos drsg >48 no border	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6203		P	Composite drsg <= 16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6204		P	Composite drsg >16<=48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6205		P	Composite drsg > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6206		P	Contact layer <= 16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6207		P	Contact layer >16<= 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6208		P	Contact layer > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6209		P	Foam drsg <=16 sq in w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6210		P	Foam drg >16<=48 sq in w/o b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6211		P	Foam drg > 48 sq in w/o brdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6212		P	Foam drg <=16 sq in w/border	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6213		P	Foam drg >16<=48 sq in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6214		P	Foam drg > 48 sq in w/border	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6215		P	Foam dressing wound filler	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6216		P	Non-sterile gauze<=16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6217		P	Non-sterile gauze>16<=48 sq	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6218		P	Non-sterile gauze > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6219		P	Gauze <= 16 sq in w/border	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6220		P	Gauze >16 <=48 sq in w/bordr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6221		P	Gauze > 48 sq in w/border	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6222		P	Gauze <=16 in no w/sal w/o b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6223		P	Gauze >16<=48 no w/sal w/o b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6224		P	Gauze > 48 in no w/sal w/o b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6228		P	Gauze <= 16 sq in water/sal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6229		P	Gauze >16<=48 sq in watr/sal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6230		P	Gauze > 48 sq in water/salne	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6231		X	Hydrogel dsg<=16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6232		X	Hydrogel dsg>16<=48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6233		X	Hydrogel dressing >48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6234		P	Hydrocolld drg <=16 w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6235		P	Hydrocolld drg >16<=48 w/o b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6236		P	Hydrocolld drg > 48 in w/o b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6237		P	Hydrocolld drg <=16 in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6238		P	Hydrocolld drg >16<=48 w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6239		P	Hydrocolld drg > 48 in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6240		P	Hydrocolld drg filler paste	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6241		P	Hydrocolloid drg filler dry	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6242		P	Hydrogel drg <=16 in w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6243		P	Hydrogel drg >16<=48 w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6244		P	Hydrogel drg >48 in w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6245		P	Hydrogel drg <= 16 in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6246		P	Hydrogel drg >16<=48 in w/b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6247		P	Hydrogel drg > 48 sq in w/b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6248		P	Hydrogel drsg gel filler	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6250		P	Skin seal protect moisturizr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6251		P	Absorpt drg <=16 sq in w/o b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6252		P	Absorpt drg >16 <=48 w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6253		P	Absorpt drg > 48 sq in w/o b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6254		P	Absorpt drg <=16 sq in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6255		P	Absorpt drg >16<=48 in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6256		P	Absorpt drg > 48 sq in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6257		P	Transparent film <= 16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6258		P	Transparent film >16<=48 in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6259		P	Transparent film > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6260		P	Wound cleanser any type/size	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6261		P	Wound filler gel/paste /oz	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6262		P	Wound filler dry form / gram	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6263		P	Non-sterile elastic gauze/yd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6264		P	Non-sterile no elastic gauze	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6265		P	Tape per 18 sq inches	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6266		P	Impreg gauze no h20/sal/yard	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6402		P	Sterile gauze <= 16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6403		P	Sterile gauze>16 <= 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6404		P	Sterile gauze > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6405		P	Sterile elastic gauze /yd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6406		P	Sterile non-elastic gauze/yd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7000		X	Disposable canister for pump	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7001		X	Nondisposable pump canister	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7002		X	Tubing used w suction pump	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7003		X	Nebulizer administration set	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7004		X	Disposable nebulizer sml vol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7005		X	Nondisposable nebulizer set	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
A7006		X	Filtered nebulizer admin set	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7007		X	Lg vol nebulizer disposable	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7008		X	Disposable nebulizer prefill	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7009		X	Nebulizer reservoir bottle	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7010		X	Disposable corrugated tubing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7011		X	Nondispos corrugated tubing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7012		X	Nebulizer water collec devic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7013		X	Disposable compressor filter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7014		X	Compressor nondispos filter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7015		X	Aerosol mask used w nebulize	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7016		X	Nebulizer dome & mouthpiece	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7017		X	Nebulizer not used w oxygen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7018		X	Water distilled w/nebulizer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7019		X	Saline solution dispenser	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7020		X	Sterile H2O or NSS w lgv neb	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7501		X	Tracheostoma valve w diaphra	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7502		X	Replacement diaphragm/fplate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7503		X	HMES filter holder or cap	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7504		X	Tracheostoma HMES filter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7505		X	HMES or trach valve housing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7506		X	HMES/trachvalve adhesivedisk	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7507		X	Integrated filter & holder	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7508		X	Housing & Integrated Adhesiv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7509		X	Heat & moisture exchange sys	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9150		E	Misc/exper non-prescript dru	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9160		N	Podiatrist non-covered servi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9170		N	Chiropractor non-covered ser	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9190		N	Misc/expe personal comfort i	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9270		N	Non-covered item or service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9300		N	Exercise equipment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9500		E	Technetium TC 99m sestamibi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9502		X	Technetium TC99M tetrofosmin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9503		E	Technetium TC 99m medronate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9504		X	Technetium tc 99m apcitide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9505		E	Thallous chloride TL 201/mci	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9507		X	Indium/111 capromab pendetid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9508		X	Iobenguane sulfate I–131	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9510		X	Technetium TC99m Disofenin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9600		X	Strontium-89 chloride	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9605		X	Samarium sm153 lexidronamm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9700		X	Echocardiography Contrast	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9900		X	Supply/accessory/service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9901		X	Delivery/set up/dispensing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0120		N	Periodic oral evaluation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0140		N	Limit oral eval problm focus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0150		R	Comprehensve oral evaluation	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0160		N	Extensv oral eval prob focus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0170		N	Re-eval,est pt,problem focus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0210		I	Intraor complete film series	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0220		I	Intraoral periapical first f	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0230		I	Intraoral periapical ea add	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0240		R	Intraoral occlusal film	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0250		R	Extraoral first film	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0260		R	Extraoral ea additional film	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0270		R	Dental bitewing single film	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0272		R	Dental bitewings two films	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0274		R	Dental bitewings four films	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0277		R	Vert bitewings-sev to eight	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0290		I	Dental film skull/facial bon	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0310		I	Dental saliography	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0320		I	Dental tmj arthrogram incl i	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0321		I	Dental other tmj films	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0322		I	Dental tomographic survey	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0330		I	Dental panoramic film	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0340		I	Dental cephalometric film	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0350		I	Oral/facial images	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0415		N	Bacteriologic study	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0425		N	Caries susceptibility test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0460		R	Pulp vitality test	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0470		N	Diagnostic casts	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0472		R	Gross exam, prep & report	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0473		R	Micro exam, prep & report	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0474		R	Micro w exam of surg margins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0480		R	Cytopath smear prep & report	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
D0501		R	Histopathologic examinations	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0502		R	Other oral pathology procedu	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0999		R	Unspecified diagnostic proce	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D1110		N	Dental prophylaxis adult	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1120		N	Dental prophylaxis child	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1201		N	Topical fluor w prophy child	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1203		N	Topical fluor w/o prophy chi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1204		N	Topical fluor w/o prophy adu	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1205		N	Topical fluoride w/ prophy a	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1310		N	Nutri counsel-control caries	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1320		N	Tobacco counseling	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1330		N	Oral hygiene instruction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1351		N	Dental sealant per tooth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1510		R	Space maintainer fxd unilat	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D1515		R	Fixed bilat space maintainer	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D1520		R	Remove unilat space maintain	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D1525		R	Remove bilat space maintain	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D1550		R	Recement space maintainer	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D2110		N	Amalgam one surface primary	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2120		N	Amalgam two surfaces primary	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2130		N	Amalgam three surfaces prima	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2131		N	Amalgam four/more surf prima	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2140		N	Amalgam one surface permanen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2150		N	Amalgam two surfaces permane	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2160		N	Amalgam three surfaces perma	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2161		N	Amalgam 4 or > surfaces perm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2330		N	Resin one surface-anterior	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2331		N	Resin two surfaces-anterior	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2332		N	Resin three surfaces-anterio	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2335		N	Resin 4/> surf or w incis an	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2336		N	Composite resin crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2337		N	Compo resin crown ant-perm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2380		N	Resin one surf poster primar	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2381		N	Resin two surf poster primar	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2382		N	Resin three/more surf post p	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2385		N	Resin one surf poster perman	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2386		N	Resin two surf poster perman	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2387		N	Resin three/more surf post p	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2388		N	Resin four/more, post perm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2410		N	Dental gold foil one surface	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2420		N	Dental gold foil two surface	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2430		N	Dental gold foil three surfa	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2510		N	Dental inlay metalic 1 surf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2520		N	Dental inlay metallic 2 surf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2530		N	Dental inlay metl 3/more sur	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2542		N	Dental onlay metallic 2 surf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2543		N	Dental onlay metallic 3 surf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2544		N	Dental onlay metl 4/more sur	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2610		N	Inlay porcelain/ceramic 1 su	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2620		N	Inlay porcelain/ceramic 2 su	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2630		N	Dental onlay porc 3/more sur	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2642		N	Dental onlay porcelin 2 surf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2643		N	Dental onlay porcelin 3 surf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2644		N	Dental onlay porc 4/more sur	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2650		N	Inlay composite/resin one su	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2651		N	Inlay composite/resin two su	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2652		N	Dental inlay resin 3/mre sur	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2662		N	Dental onlay resin 2 surface	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2663		N	Dental onlay resin 3 surface	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2664		N	Dental onlay resin 4/mre sur	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2710		N	Crown resin laboratory	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2720		N	Crown resin w/ high noble me	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2721		N	Crown resin w/ base metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2722		N	Crown resin w/ noble metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2740		N	Crown porcelain/ceramic subs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2750		N	Crown porcelain w/ h noble m	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2751		N	Crown porcelain fused base m	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2752		N	Crown porcelain w/ noble met	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2780		N	Crown 3/4 cast hi noble met	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2781		N	Crown 3/4 cast base metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2782		N	Crown 3/4 cast noble metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2783		N	Crown 3/4 porcelain/ceramic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2790		N	Crown full cast high noble m	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2791		N	Crown full cast base metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
D2792		N	Crown full cast noble metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2799		N	Provisional crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2910		N	Dental recement inlay	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2920		N	Dental recement crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2930		N	Prefab stnlss steel crwn pri	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2931		N	Prefab stnlss steel crown pe	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2932		N	Prefabricated resin crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2933		N	Prefab stainless steel crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2940		N	Dental sedative filling	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2950		N	Core build-up incl any pins	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2951		N	Tooth pin retention	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2952		N	Post and core cast + crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2953		N	Each addtnl cast post	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2954		N	Prefab post/core + crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2955		N	Post removal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2957		N	Each addtnl prefab post	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2960		N	Laminate labial veneer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2961		N	Lab labial veneer resin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2962		N	Lab labial veneer porcelain	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2970		R	Temporary- fractured tooth	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D2980		N	Crown repair	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2999		R	Dental unspec restorative pr	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D3110		N	Pulp cap direct	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3120		N	Pulp cap indirect	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3220		N	Therapeutic pulpotomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3221		N	Gross pulpal debridement	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3230		N	Pulpal therapy anterior prim	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3240		N	Pulpal therapy posterior pri	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3310		N	Anterior	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3320		N	Root canal therapy 2 canals	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3330		N	Root canal therapy 3 canals	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3331		N	Non-surg tx root canal obs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3332		N	Incomplete endodontic tx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3333		N	Internal root repair	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3346		N	Retreat root canal anterior	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3347		N	Retreat root canal bicuspid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3348		N	Retreat root canal molar	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3351		N	Apexification/recalc initial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3352		N	Apexification/recalc interim	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3353		N	Apexification/recalc final	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3410		N	Apicoect/perirad surg anter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3421		N	Root surgery bicuspid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3425		N	Root surgery molar	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3426		N	Root surgery ea add root	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3430		N	Retrograde filling	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3450		N	Root amputation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3460		R	Endodontic endosseous implan	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D3470		N	Intentional replantation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3910		N	Isolation- tooth w rubb dam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3920		N	Tooth splitting	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3950		N	Canal prep/fitting of dowel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3999		R	Endodontic procedure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4210		I	Gingivectomy/plasty per quad	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4211		I	Gingivectomy/plasty per toot	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4220		N	Gingival curettage per quadr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4240		N	Gingival flap proc w/ planin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4245		N	Apically positioned flap	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4249		N	Crown lengthen hard tissue	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4260		R	Osseous surgery per quadrant	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4263		R	Bone replce graft first site	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4264		R	Bone replce graft each add	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4266		N	Guided tiss regen resorble	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4267		N	Guided tiss regen nonresorb	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4268		R	Surgical revision procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4270		R	Pedicle soft tissue graft pr	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4271		R	Free soft tissue graft proc	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4273		R	Subepithelial tissue graft	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4274		N	Distal/proximal wedge proc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4320		N	Provision splnt intracoronal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4321		N	Provisional splint extracoro	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4341		N	Periodontal scaling & root	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4355		R	Full mouth debridement	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4381		R	Localized chemo delivery	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4910		N	Periodontal maint procedures	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
D4920		N	Unscheduled dressing change	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4999		N	Unspecified periodontal proc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5110		N	Dentures complete maxillary	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5120		N	Dentures complete mandible	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5130		N	Dentures immediat maxillary	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5140		N	Dentures immediat mandible	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5211		N	Dentures maxill part resin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5212		N	Dentures mand part resin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5213		N	Dentures maxill part metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5214		N	Dentures mandibl part metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5281		N	Removable partial denture	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5410		N	Dentures adjust cmplt maxil	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5411		N	Dentures adjust cmplt mand	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5421		N	Dentures adjust part maxill	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5422		N	Dentures adjust part mandbl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5510		N	Dentur repr broken compl bas	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5520		N	Replace denture teeth complt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5610		N	Dentures repair resin base	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5620		N	Rep part denture cast frame	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5630		N	Rep partial denture clasp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5640		N	Replace part denture teeth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5650		N	Add tooth to partial denture	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5660		N	Add clasp to partial denture	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5710		N	Dentures rebase cmplt maxil	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5711		N	Dentures rebase cmplt mand	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5720		N	Dentures rebase part maxill	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5721		N	Dentures rebase part mandbl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5730		N	Denture reln cmplt maxil ch	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5731		N	Denture reln cmplt mand chr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5740		N	Denture reln part maxil chr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5741		N	Denture reln part mand chr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5750		N	Denture reln cmplt max lab	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5751		N	Denture reln cmplt mand lab	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5760		N	Denture reln part maxil lab	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5761		N	Denture reln part mand lab	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5810		N	Denture interm cmplt maxill	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5811		N	Denture interm cmplt mandbl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5820		N	Denture interm part maxill	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5821		N	Denture interm part mandbl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5850		N	Denture tiss conditn maxill	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5851		N	Denture tiss condtin mandbl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5860		N	Overdenture complete	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5861		N	Overdenture partial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5862		N	Precision attachment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5867		N	Replacement of precision att	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5875		N	Prosthesis modification	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5899		N	Removable prosthodontic proc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5911		R	Facial moulage sectional	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5912		R	Facial moulage complete	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5913		I	Nasal prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5914		I	Auricular prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5915		I	Orbital prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5916		I	Ocular prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5919		I	Facial prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5922		I	Nasal septal prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5923		I	Ocular prosthesis interim	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5924		I	Cranial prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5925		I	Facial augmentation implant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5926		I	Replacement nasal prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5927		I	Auricular replacement	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5928		I	Orbital replacement	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5929		I	Facial replacement	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5931		I	Surgical obturator	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5932		I	Postsurgical obturator	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5933		I	Refitting of obturator	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5934		I	Mandibular flange prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5935		I	Mandibular denture prosth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5936		I	Temp obturator prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5937		I	Trismus appliance	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5951		R	Feeding aid	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5952		I	Pediatric speech aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5953		I	Adult speech aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5954		I	Superimposed prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5955		I	Palatal lift prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
D5958		I	Intraoral con def inter plt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5959		I	Intraoral con def mod palat	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5960		I	Modify speech aid prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5982		I	Surgical stent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5983		R	Radiation applicator	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5984		R	Radiation shield	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5985		R	Radiation cone locator	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5986		N	Fluoride applicator	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5987		R	Commissure splint	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5988		I	Surgical splint	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5999		I	Maxillofacial prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6010		I	Odontics endosteal implant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6020		I	Odontics abutment placement	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6040		I	Odontics eposteal implant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6050		I	Odontics transosteal implnt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6055		I	Implant connecting bar	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6056		N	Prefabricated abutment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6057		N	Custom abutment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6058		N	Abutment supported crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6059		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6060		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6061		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6062		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6063		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6064		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6065		N	Implant supported crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6066		N	Implant supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6067		N	Implant supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6068		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6069		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6070		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6071		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6072		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6073		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6074		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6075		N	Implant supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6076		N	Implant supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6077		N	Implant supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6078		N	Implnt/abut suprtd fixd dent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6079		N	Implnt/abut suprtd fixd dent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6080		I	Implant maintenance	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6090		I	Repair implant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6095		I	Odontics repr abutment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6100		I	Removal of implant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6199		I	Implant procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6210		N	Prosthodont high noble metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6211		N	Bridge base metal cast	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6212		N	Bridge noble metal cast	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6240		N	Bridge porcelain high noble	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6241		N	Bridge porcelain base metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6242		N	Bridge porcelain nobel metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6245		N	Bridge porcelain/ceramic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6250		N	Bridge resin w/high noble	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6251		N	Bridge resin base metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6252		N	Bridge resin w/noble metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6519		N	Inlay/onlay porce/ceramic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6520		N	Dental retainer two surfaces	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6530		N	Retainer metallic 3+ surface	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6543		N	Dental retainr onlay 3 surf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6544		N	Dental retainr onlay 4/more	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6545		N	Dental retainr cast metl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6548		N	Porcelain/ceramic retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6720		N	Retain crown resin w hi nble	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6721		N	Crown resin w/base metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6722		N	Crown resin w/noble metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6740		N	Crown porcelain/ceramic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6750		N	Crown porcelain high noble	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6751		N	Crown porcelain base metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6752		N	Crown porcelain noble metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6780		N	Crown 3/4 high noble metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6781		N	Crown 3/4 cast based metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6782		N	Crown 3/4 cast noble metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6783		N	Crown 3/4 porcelain/ceramic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6790		N	Crown full high noble metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
D6791		N	Crown full base metal cast	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6792		N	Crown full noble metal cast	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6920		R	Dental connector bar	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D6930		N	Dental recement bridge	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6940		N	Stress breaker	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6950		N	Precision attachment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6970		N	Post & core plus retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6971		N	Cast post bridge retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6972		N	Prefab post & core plus reta	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6973		N	Core build up for retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6975		N	Coping metal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6976		N	Each addtnl cast post	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6977		N	Each addtl prefab post	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6980		N	Bridge repair	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6999		N	Fixed prosthodontic proc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7110		R	Oral surgery single tooth	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7120		R	Each add tooth extraction	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7130		R	Tooth root removal	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7210		R	Rem imp tooth w mucoper flp	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7220		R	Impact tooth remov soft tiss	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7230		R	Impact tooth remov part bony	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7240		R	Impact tooth remov comp bony	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7241		R	Impact tooth rem bony w/comp	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7250		R	Tooth root removal	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7260		R	Oral antral fistula closure	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7270		N	Tooth reimplantation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7272		N	Tooth transplantation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7280		N	Exposure impact tooth orthod	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7281		N	Exposure tooth aid eruption	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7285		I	Biopsy of oral tissue hard	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7286		I	Biopsy of oral tissue soft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7290		N	Repositioning of teeth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7291		R	Transseptal fiberotomy	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7310		I	Alveoplasty w/ extraction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7320		I	Alveoplasty w/o extraction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7340		I	Vestibuloplasty ridge extens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7350		I	Vestibuloplasty exten graft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7410		I	Rad exc lesion up to 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7420		I	Lesion > 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7430		I	Exc benign tumor to 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7431		I	Benign tumor exc > 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7440		I	Malig tumor exc to 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7441		I	Malig tumor > 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7450		I	Rem odontogen cyst to 1.25cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7451		I	Rem odontogen cyst > 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7460		I	Rem nonodonto cyst to 1.25cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7461		I	Rem nonodonto cyst > 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7465		I	Lesion destruction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7471		I	Rem exostosis any site	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7480		I	Partial ostectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7490		I	Mandible resection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7510		I	I&d absc intraoral soft tiss	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7520		I	I&d abscess extraoral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7530		I	Removal fb skin/areolar tiss	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7540		I	Removal of fb reaction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7550		I	Removal of sloughed off bone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7560		I	Maxillary sinusotomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7610		I	Maxilla open reduct simple	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7620		I	Clsd reduct simpl maxilla fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7630		I	Open red simpl mandible fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7640		I	Clsd red simpl mandible fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7650		I	Open red simp malar/zygom fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7660		I	Clsd red simp malar/zygom fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7670		I	Closd rductn splint alveolus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7680		I	Reduct simple facial bone fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7710		I	Maxilla open reduct compound	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7720		I	Clsd reduct compd maxilla fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7730		I	Open reduct compd mandble fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7740		I	Clsd reduct compd mandble fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7750		I	Open red comp malar/zygma fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7760		I	Clsd red comp malar/zygma fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7770		I	Open reduc compd alveolus fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7780		I	Reduct compnd facial bone fx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7810		I	Tmj open reduct-dislocation	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
D7820		I	Closed tmp manipulation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7830		I	Tmj manipulation under anest	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7840		I	Removal of tmj condyle	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7850		I	Tmj meniscectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7852		I	Tmj repair of joint disc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7854		I	Tmj excisn of joint membrane	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7856		I	Tmj cutting of a muscle	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7858		I	Tmj reconstruction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7860		I	Tmj cutting into joint	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7865		I	Tmj reshaping components	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7870		I	Tmj aspiration joint fluid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7871		N	Lysis + lavage w catheters	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7872		I	Tmj diagnostic arthroscopy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7873		I	Tmj arthroscopy lysis adhesn	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7874		I	Tmj arthroscopy disc reposit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7875		I	Tmj arthroscopy synovectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7876		I	Tmj arthroscopy discectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7877		I	Tmj arthroscopy debridement	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7880		I	Occlusal orthotic appliance	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7899		I	Tmj unspecified therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7910		I	Dent sutur recent wnd to 5cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7911		I	Dental suture wound to 5 cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7912		I	Suture complicate wnd > 5 cm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7920		I	Dental skin graft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7940		R	Reshaping bone orthognathic	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7941		I	Bone cutting ramus closed	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7943		I	Cutting ramus open w/graft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7944		I	Bone cutting segmented	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7945		I	Bone cutting body mandible	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7946		I	Reconstruction maxilla total	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7947		I	Reconstruct maxilla segment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7948		I	Reconstruct midface no graft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7949		I	Reconstruct midface w/graft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7950		I	Mandible graft	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7955		I	Repair maxillofacial defects	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7960		I	Frenulectomy/frenulotomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7970		I	Excision hyperplastic tissue	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7971		I	Excision pericoronal gingiva	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7980		I	Sialolithotomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7981		I	Excision of salivary gland	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7982		I	Sialodochoplasty	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7983		I	Closure of salivary fistula	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7990		I	Emergency tracheotomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7991		I	Dental coronoidectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7995		I	Synthetic graft facial bones	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7996		I	Implant mandible for augment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7997		N	Appliance removal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7999		I	Oral surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8010		N	Limited dental tx primary	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8020		N	Limited dental tx transition	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8030		N	Limited dental tx adolescent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8040		N	Limited dental tx adult	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8050		N	Intercep dental tx primary	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8060		N	Intercep dental tx transitn	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8070		N	Compre dental tx transition	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8080		N	Compre dental tx adolescent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8090		N	Compre dental tx adult	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8210		N	Orthodontic rem appliance tx	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8220		N	Fixed appliance therapy habt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8660		N	Preorthodontic tx visit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8670		N	Periodic orthodontc tx visit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8680		N	Orthodontic retention	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8690		N	Orthodontic treatment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8691		N	Repair ortho appliance	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8692		N	Replacement retainer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8999		N	Orthodontic procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9110		R	Tx dental pain minor proc	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9210		I	Dent anesthesia w/o surgery	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9211		I	Regional block anesthesia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9212		I	Trigeminal block anesthesia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9215		I	Local anesthesia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9220		I	General anesthesia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9221		I	General anesthesia ea ad 15m	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9230		R	Analgesia	0.00	0.00	0.00	0.00	0.00	0.00	YYY

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
D9241		I	Intravenous sedation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9242		I	IV sedation ea ad 30 m	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9248		R	Sedation (non-iv)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9310		I	Dental consultation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9410		I	Dental house call	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9420		I	Hospital call	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9430		I	Office visit during hours	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9440		I	Office visit after hours	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9610		I	Dent therapeutic drug inject	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9630		R	Other drugs/medicaments	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9910		N	Dent appl desensitizing med	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9911		N	Appl desensitizing resin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9920		N	Behavior management	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9930		R	Treatment of complications	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9940		R	Dental occlusal guard	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9941		N	Fabrication athletic guard	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9950		R	Occlusion analysis	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9951		R	Limited occlusal adjustment	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9952		R	Complete occlusal adjustment	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9970		N	Enamel microabrasion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9971		N	Odontoplasty 1–2 teeth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9972		N	Extrnl bleaching per arch	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9973		N	Extrnl bleaching per tooth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9974		N	Intrnl bleaching per tooth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9999		I	Adjunctive procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0001		X	Drawing blood for specimen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0002		A	Temporary urinary catheter	0.50	0.17	3.10	0.03	0.70	3.63	000
G0004		A	ECG transm phys review & int	0.52	NA	7.35	0.45	NA	8.32	XXX
G0005		A	ECG 24 hour recording	0.00	NA	1.22	0.07	NA	1.29	XXX
G0006		A	ECG transmission & analysis	0.00	NA	5.92	0.36	NA	6.28	XXX
G0007		A	ECG phy review & interpret	0.52	0.21	0.21	0.02	0.75	0.75	XXX
G0008		X	Admin influenza virus vac	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0009		X	Admin pneumococcal vaccine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0010		X	Admin hepatitis b vaccine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0015		A	Post symptom ECG tracing	0.00	NA	5.92	0.36	NA	6.28	XXX
G0016		A	Post symptom ECG md review	0.52	0.23	0.23	0.02	0.77	0.77	XXX
G0025		B	Collagen skin test kit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0026		X	Fecal leukocyte examination	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0027		X	Semen analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0030		C	PET imaging prev PET single	0.00	NA	0.00	0.00	NA	0.00	XXX
G0030	26	A	PET imaging prev PET single	1.50	0.52	0.52	0.04	2.06	2.06	XXX
G0030	TC	C	PET imaging prev PET single	0.00	NA	0.00	0.00	NA	0.00	XXX
G0031		C	PET imaging prev PET multple	0.00	NA	0.00	0.00	NA	0.00	XXX
G0031	26	A	PET imaging prev PET multple	1.87	0.70	0.70	0.06	2.63	2.63	XXX
G0031	TC	C	PET imaging prev PET multple	0.00	NA	0.00	0.00	NA	0.00	XXX
G0032		C	PET follow SPECT 78464 singl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0032	26	A	PET follow SPECT 78464 singl	1.50	0.52	0.52	0.05	2.07	2.07	XXX
G0032	TC	C	PET follow SPECT 78464 singl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0033		C	PET follow SPECT 78464 mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0033	26	A	PET follow SPECT 78464 mult	1.87	0.70	0.70	0.06	2.63	2.63	XXX
G0033	TC	C	PET follow SPECT 78464 mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0034		C	PET follow SPECT 76865 singl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0034	26	A	PET follow SPECT 76865 singl	1.50	0.52	0.52	0.05	2.07	2.07	XXX
G0034	TC	C	PET follow SPECT 76865 singl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0035		C	PET follow SPECT 78465 mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0035	26	A	PET follow SPECT 78465 mult	1.87	0.70	0.70	0.06	2.63	2.63	XXX
G0035	TC	C	PET follow SPECT 78465 mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0036		C	PET follow cornry angio sing	0.00	NA	0.00	0.00	NA	0.00	XXX
G0036	26	A	PET follow cornry angio sing	1.50	0.52	0.52	0.04	2.06	2.06	XXX
G0036	TC	C	PET follow cornry angio sing	0.00	NA	0.00	0.00	NA	0.00	XXX
G0037		C	PET follow cornry angio mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0037	26	A	PET follow cornry angio mult	1.87	0.70	0.70	0.06	2.63	2.63	XXX
G0037	TC	C	PET follow cornry angio mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0038		C	PET follow myocard perf sing	0.00	NA	0.00	0.00	NA	0.00	XXX
G0038	26	A	PET follow myocard perf sing	1.50	0.52	0.52	0.04	2.06	2.06	XXX
G0038	TC	C	PET follow myocard perf sing	0.00	NA	0.00	0.00	NA	0.00	XXX
G0039		C	PET follow myocard perf mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0039	26	A	PET follow myocard perf mult	1.87	0.70	0.70	0.07	2.64	2.64	XXX
G0039	TC	C	PET follow myocard perf mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0040		C	PET follow stress echo singl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0040	26	A	PET follow stress echo singl	1.50	0.52	0.52	0.04	2.06	2.06	XXX
G0040	TC	C	PET follow stress echo singl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0041		C	PET follow stress echo mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0041	26	A	PET follow stress echo mult	1.87	0.70	0.70	0.05	2.62	2.62	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
G0041	TC	C	PET follow stress echo mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0042		C	PET follow ventriculogm sing	0.00	NA	0.00	0.00	NA	0.00	XXX
G0042	26	A	PET follow ventriculogm sing	1.50	0.52	0.52	0.04	2.06	2.06	XXX
G0042	TC	C	PET follow ventriculogm sing	0.00	NA	0.00	0.00	NA	0.00	XXX
G0043		C	PET follow ventriculogm mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0043	26	A	PET follow ventriculogm mult	1.87	0.70	0.70	0.06	2.63	2.63	XXX
G0043	TC	C	PET follow ventriculogm mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0044		C	PET following rest ECG singl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0044	26	A	PET following rest ECG singl	1.50	0.52	0.52	0.04	2.06	2.06	XXX
G0044	TC	C	PET following rest ECG singl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0045		C	PET following rest ECG mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0045	26	A	PET following rest ECG mult	1.87	0.70	0.70	0.06	2.63	2.63	XXX
G0045	TC	C	PET following rest ECG mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0046		C	PET follow stress ECG singl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0046	26	A	PET follow stress ECG singl	1.50	0.52	0.52	0.04	2.06	2.06	XXX
G0046	TC	C	PET follow stress ECG singl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0047		C	PET follow stress ECG mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0047	26	A	PET follow stress ECG mult	1.87	0.70	0.70	0.06	2.63	2.63	XXX
G0047	TC	C	PET follow stress ECG mult	0.00	NA	0.00	0.00	NA	0.00	XXX
G0050		A	Residual urine by ultrasound	0.00	NA	0.84	0.04	NA	0.88	XXX
G0101		A	CA screen;pelvic/breast exam	0.45	0.18	0.69	0.01	0.64	1.15	XXX
G0102		A	Prostate ca screening; dre	0.17	0.06	0.37	0.01	0.24	0.55	XXX
G0103		X	Psa, total screening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0104		A	CA screen;flexi sigmoidscope	0.88	0.45	1.88	0.05	1.38	2.81	000
G0105		A	Colorectal scrn; hi risk ind	3.68	1.74	7.30	0.20	5.62	11.18	000
G0106		A	Colon CA screen;barium enema	0.99	NA	2.55	0.15	NA	3.69	XXX
G0106	26	A	Colon CA screen;barium enema	0.99	0.35	0.35	0.04	1.38	1.38	XXX
G0106	TC	A	Colon CA screen;barium enema	0.00	NA	2.20	0.11	NA	2.31	XXX
G0107		X	CA screen; fecal blood test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0108		A	Diab manage trn per indiv	0.00	NA	1.64	0.01	NA	1.65	XXX
G0109		A	Diab manage trn ind/group	0.00	NA	0.96	0.01	NA	0.97	XXX
G0110		R	Nett pulm-rehab educ; ind	0.90	0.36	0.75	0.03	1.29	1.68	XXX
G0111		R	Nett pulm-rehab educ; group	0.27	0.11	0.29	0.01	0.39	0.57	XXX
G0112		R	Nett;nutrition guid, initial	1.72	0.68	1.48	0.05	2.45	3.25	XXX
G0113		R	Nett;nutrition guid,subseqnt	1.29	0.51	1.15	0.04	1.84	2.48	XXX
G0114		R	Nett; psychosocial consult	1.20	0.47	0.49	0.03	1.70	1.72	XXX
G0115		R	Nett; psychological testing	1.20	0.38	0.71	0.04	1.62	1.95	XXX
G0116		R	Nett; psychosocial counsel	1.11	0.44	1.24	0.04	1.59	2.39	XXX
G0120		A	Colon ca scrn; barium enema	0.99	NA	2.55	0.15	NA	3.69	XXX
G0120	26	A	Colon ca scrn; barium enema	0.99	0.35	0.35	0.04	1.38	1.38	XXX
G0120	TC	A	Colon ca scrn; barium enema	0.00	NA	2.20	0.11	NA	2.31	XXX
G0121		A	Colon ca scrn not hi rsk ind	3.68	1.74	7.30	0.20	5.62	11.18	000
G0122		N	Colon ca scrn; barium enema	+0.99	NA	2.59	0.15	NA	3.73	XXX
G0122	26	N	Colon ca scrn; barium enema	+0.99	0.39	0.39	0.04	1.42	1.42	XXX
G0122	TC	N	Colon ca scrn; barium enema	+0.00	NA	2.20	0.11	NA	2.31	XXX
G0123		X	Screen cerv/vag thin layer	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0124		A	Screen c/v thin layer by MD	0.42	0.19	0.19	0.01	0.62	0.62	XXX
G0125		A	Lung image (PET)	1.50	0.52	56.08	2.00	4.02	59.58	XXX
G0125	26	A	Lung image (PET)	1.50	0.52	0.52	0.05	2.07	2.07	XXX
G0125	TC	A	Lung image (PET)	0.00	NA	55.56	1.95	NA	57.51	XXX
G0126		A	Lung image (PET) staging	1.87	0.70	56.26	2.01	4.58	60.14	XXX
G0126	26	A	Lung image (PET) staging	1.87	0.70	0.70	0.06	2.63	2.63	XXX
G0126	TC	A	Lung image (PET) staging	0.00	NA	55.56	1.95	NA	57.51	XXX
G0127		R	Trim nail(s)	0.11	0.05	0.52	0.01	0.17	0.64	000
G0128		R	CORF skilled nursing service	0.08	0.03	0.03	0.01	0.12	0.12	XXX
G0130		A	Single energy x-ray study	0.22	NA	0.90	0.05	NA	1.17	XXX
G0130	26	A	Single energy x-ray study	0.22	0.11	0.11	0.01	0.34	0.34	XXX
G0130	TC	A	Single energy x-ray study	0.00	NA	0.79	0.04	NA	0.83	XXX
G0131		A	CT scan, bone density study	0.25	NA	3.18	0.14	NA	3.57	XXX
G0131	26	A	CT scan, bone density study	0.25	0.13	0.13	0.01	0.39	0.39	XXX
G0131	TC	A	CT scan, bone density study	0.00	NA	3.05	0.13	NA	3.18	XXX
G0132		A	CT scan, bone density study	0.22	NA	0.90	0.05	NA	1.17	XXX
G0132	26	A	CT scan, bone density study	0.22	0.11	0.11	0.01	0.34	0.34	XXX
G0132	TC	A	CT scan, bone density study	0.00	NA	0.79	0.04	NA	0.83	XXX
G0141		A	Scr c/v cyto,autosys and md	0.42	0.19	0.19	0.01	0.62	0.62	XXX
G0143		X	Scr c/v cyto,thinlayer,rescr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0144		X	Scr c/v cyto,thinlayer,rescr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0145		X	Scr c/v cyto,thinlayer,rescr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0147		X	Scr c/v cyto, automated sys	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0148		X	Scr c/v cyto, autosys, rescr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0163		A	Pet for rec of colorectal ca	1.50	0.56	56.12	2.00	4.06	59.62	XXX
G0163	26	A	Pet for rec of colorectal ca	1.50	0.56	0.56	0.05	2.11	2.11	XXX
G0163	TC	A	Pet for rec of colorectal ca	0.00	NA	55.56	1.95	NA	57.51	XXX
G0164		A	Pet for lymphoma staging	1.87	0.69	56.25	2.01	4.57	60.13	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
G0164	26	A	Pet for lymphoma staging	1.87	0.69	0.69	0.06	2.62	2.62	XXX
G0164	TC	A	Pet for lymphoma staging	0.00	NA	55.56	1.95	NA	57.51	XXX
G0165		A	Pet,rec of melanoma/met ca	1.50	0.59	56.15	2.00	4.09	59.65	XXX
G0165	26	A	Pet,rec of melanoma/met ca	1.50	0.59	0.59	0.05	2.14	2.14	XXX
G0165	TC	A	Pet,rec of melanoma/met ca	0.00	NA	55.56	1.95	NA	57.51	XXX
G0166		A	Extrnl counterpulse, per tx	0.07	0.03	3.75	0.01	0.11	3.83	XXX
G0167		C	Hyperbaric oz tx;no md reqrd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0168		A	Wound closure by adhesive	0.45	0.25	1.80	0.01	0.71	2.26	000
G0173		X	Stereo radoisurgery,complete	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0174		X	Intensitymodulatedradiation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0175		X	OPPS Service,sched team conf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0176		X	OPPS/PHP;activity therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0177		X	OPPS/PHP; train & educ serv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0178		X	Intensitymodulatedradiation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0179		A	MD recertification HHA patie	0.45	NA	1.11	0.06	NA	1.62	XXX
G0180		A	MD certification HHA patient	0.67	NA	1.19	0.06	NA	1.92	XXX
G0181		A	Home health care supervision	1.73	NA	1.45	0.06	NA	3.24	XXX
G0182		A	Hospice care supervision	1.73	NA	1.78	0.06	NA	3.57	XXX
G0183		X	Ocular photodynamic therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0184		A	Ocular photodynamic tx, 2nd	0.47	0.23	0.23	0.50	1.20	1.20	ZZZ
G0185		C	Transpuppillary thermotx	0.00	0.00	0.00	0.00	0.00	0.00	YYY
G0186		C	Dstry eye lesn,fdr vssl tech	0.00	0.00	0.00	0.00	0.00	0.00	YYY
G0187		C	Dstry mclr drusen,photocoag	0.00	0.00	0.00	0.00	0.00	0.00	YYY
G0188		C	Xray lwr extrmty-full lngth	0.00	NA	0.00	0.00	NA	0.00	XXX
G0188	26	C	Xray lwr extrmty-full lngth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0188	TC	C	Xray lwr extrmty-full lngth	0.00	NA	0.00	0.00	NA	0.00	XXX
G0190		X	Immunization administration	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0191		X	Immunization admin,each add	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0192		N	Immunization oral/intranasal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0193		C	Endoscopicstudyswallowfunctn	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0194		C	Sensorytestingendoscopicstud	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0195		A	Clinicalevalswallowingfunct	1.50	0.77	2.06	0.07	2.34	3.63	XXX
G0196		A	Evalofswallowingwithradioopa	1.50	0.77	2.06	0.07	2.34	3.63	XXX
G0197		A	Evalofptforprescipspeechdevi	1.35	0.78	1.99	0.04	2.17	3.38	XXX
G0198		A	Patientadapation&trainforspe	0.99	0.58	1.08	0.03	1.60	2.10	XXX
G0199		A	Reevaluationofpatientusespec	1.01	0.59	1.80	0.03	1.63	2.84	XXX
G0200		A	Evalofpatientprescipofvoicep	1.35	0.78	1.99	0.04	2.17	3.38	XXX
G0201		A	Modifortraininginusevoicepro	0.99	0.58	1.08	0.03	1.60	2.10	XXX
G0202		G	Screen Mammogram, digital	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0203		G	Scr Mamm, film to digital	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0204		G	Diag Mamm, digital, bilat	0.69	NA	1.56	0.09	NA	2.34	XXX
G0204	26	G	Diag Mamm, digital, bilat	0.69	0.27	0.27	0.03	0.99	0.99	XXX
G0204	TC	G	Diag Mamm, digital, bilat	0.00	NA	1.29	0.06	NA	1.35	XXX
G0205		G	Diag Mamm, film/digit/bil	0.69	NA	1.56	0.09	NA	2.34	XXX
G0205	26	G	Diag Mamm, film/digit/bil	0.69	0.27	0.27	0.03	0.99	0.99	XXX
G0205	TC	G	Diag Mamm, film/digit/bil	0.00	NA	1.29	0.06	NA	1.35	XXX
G0206		G	Diag Mamm, digital, uni	0.58	NA	1.27	0.08	NA	1.93	XXX
G0206	26	G	Diag Mamm, digital, uni	0.58	0.23	0.23	0.03	0.84	0.84	XXX
G0206	TC	G	Diag Mamm, digital, uni	0.00	NA	1.04	0.05	NA	1.09	XXX
G0207		G	Diag Mamm, film/digit/uni	0.58	NA	1.27	0.08	NA	1.93	XXX
G0207	26	G	Diag Mamm, film/digit/uni	0.58	0.23	0.23	0.03	0.84	0.84	XXX
G0207	TC	G	Diag Mamm, film/digit/uni	0.00	NA	1.04	0.05	NA	1.09	XXX
G0210		C	PET img wholebody dxlung ca	0.00	NA	0.00	0.00	NA	0.00	XXX
G0210	26	A	PET img wholebody dxlung ca	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0210	TC	C	PET img wholebody dxlung ca	0.00	NA	0.00	0.00	NA	0.00	XXX
G0211		C	PET img wholebody init lung	0.00	NA	0.00	0.00	NA	0.00	XXX
G0211	26	A	PET img wholebody init lung	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0211	TC	C	PET img wholebody init lung	0.00	NA	0.00	0.00	NA	0.00	XXX
G0212		C	PET img wholebod restag lung	0.00	NA	0.00	0.00	NA	0.00	XXX
G0212	26	A	PET img wholebod restag lung	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0212	TC	C	PET img wholebod restag lung	0.00	NA	0.00	0.00	NA	0.00	XXX
G0213		C	PET img wholebody dx colorec	0.00	NA	0.00	0.00	NA	0.00	XXX
G0213	26	A	PET img wholebody dx colorec	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0213	TC	C	PET img wholebody dx colorec	0.00	NA	0.00	0.00	NA	0.00	XXX
G0214		C	PET img wholebody init color	0.00	NA	0.00	0.00	NA	0.00	XXX
G0214	26	A	PET img wholebody init color	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0214	TC	C	PET img wholebody init color	0.00	NA	0.00	0.00	NA	0.00	XXX
G0215		C	PET img wholebod restag colr	0.00	NA	0.00	0.00	NA	0.00	XXX
G0215	26	A	PET img wholebod restag colr	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0215	TC	C	PET img wholebod restag colr	0.00	NA	0.00	0.00	NA	0.00	XXX
G0216		C	PET img wholebod dx melanoma	0.00	NA	0.00	0.00	NA	0.00	XXX
G0216	26	A	PET img wholebod dx melanoma	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0216	TC	C	PET img wholebod dx melanoma	0.00	NA	0.00	0.00	NA	0.00	XXX
G0217		C	PET img wholbod init melano	0.00	NA	0.00	0.00	NA	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
G0217	26	A	PET img wholbod init melano	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0217	TC	C	PET img wholbod init melano	0.00	NA	0.00	0.00	NA	0.00	XXX
G0218		C	PET img wholebod restag mela	0.00	NA	0.00	0.00	NA	0.00	XXX
G0218	26	A	PET img wholebod restag mela	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0218	TC	C	PET img wholebod restag mela	0.00	NA	0.00	0.00	NA	0.00	XXX
G0219		C	PET img wholbod melano non-c	0.00	NA	0.00	0.00	NA	0.00	XXX
G0219	26	A	PET img wholbod melano non-c	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0219	TC	C	PET img wholbod melano non-c	0.00	NA	0.00	0.00	NA	0.00	XXX
G0220		C	PET img wholebod dx lymphoma	0.00	NA	0.00	0.00	NA	0.00	XXX
G0220	26	A	PET img wholebod dx lymphoma	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0220	TC	C	PET img wholebod dx lymphoma	0.00	NA	0.00	0.00	NA	0.00	XXX
G0221		C	PET img wholbod init lympho	0.00	NA	0.00	0.00	NA	0.00	XXX
G0221	26	A	PET img wholbod init lympho	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0221	TC	C	PET img wholbod init lympho	0.00	NA	0.00	0.00	NA	0.00	XXX
G0222		C	PET img wholbod resta lymph	0.00	NA	0.00	0.00	NA	0.00	XXX
G0222	26	A	PET img wholbod resta lymph	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0222	TC	C	PET img wholbod resta lymph	0.00	NA	0.00	0.00	NA	0.00	XXX
G0223		C	PET imag wholbod reg dx head	0.00	NA	0.00	0.00	NA	0.00	XXX
G0223	26	A	PET imag wholbod reg dx head	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0223	TC	C	PET imag wholbod reg dx head	0.00	NA	0.00	0.00	NA	0.00	XXX
G0224		C	PET imag wholbod req ini hea	0.00	NA	0.00	0.00	NA	0.00	XXX
G0224	26	A	PET imag wholbod req ini hea	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0224	TC	C	PET imag wholbod reg ini hea	0.00	NA	0.00	0.00	NA	0.00	XXX
G0225		C	PET whol restag headneck onl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0225	26	A	PET whol restag headneck onl	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0225	TC	C	PET whol restag headneck onl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0226		C	PET img wholbod dx esophagl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0226	26	A	PET img wholbod dx esophagl	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0226	TC	C	PET img wholbod dx esophagl	0.00	NA	0.00	0.00	NA	0.00	XXX
G0227		C	PET img wholbod ini esophage	0.00	NA	0.00	0.00	NA	0.00	XXX
G0227	26	A	PET img wholbod ini esophage	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0227	TC	C	PET img wholbod ini esophage	0.00	NA	0.00	0.00	NA	0.00	XXX
G0228		C	PET img wholbod restg esopha	0.00	NA	0.00	0.00	NA	0.00	XXX
G0228	26	A	PET img wholbod restg esopha	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0228	TC	C	PET img wholbod restg esopha	0.00	NA	0.00	0.00	NA	0.00	XXX
G0229		C	PET img metabolic brain pres	0.00	NA	0.00	0.00	NA	0.00	XXX
G0229	26	A	PET img metabolic brain pres	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0229	TC	C	PET img metabolic brain pres	0.00	NA	0.00	0.00	NA	0.00	XXX
G0230		C	PET mycard viability post s	0.00	NA	0.00	0.00	NA	0.00	XXX
G0230	26	A	PET mycard viability post s	1.50	0.60	0.60	0.04	2.14	2.14	XXX
G0230	TC	C	PET mycard viability post s	0.00	NA	0.00	0.00	NA	0.00	XXX
G9001		X	MCCD, initial rate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9002		X	MCCD,maintenance rate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9003		X	MCCD, risk adj hi, initial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9004		X	MCCD, risk adj lo, initial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9005		X	MCCD, risk adj, maintenance	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9006		X	MCCD, Home monitoring	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9007		X	MCCD, sch team conf	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9008		X	Mccd,phys coor-care ovrsght	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G9016		N	Demo-smoking cessation coun	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Gxxx1		A	Mammogram, screen, dir dig	0.70	NA	2.78	0.09	NA	3.57	XXX
Gxxx1	26	A	Mammogram, screen, dir dig	0.70	0.28	0.28	0.03	1.01	1.01	XXX
Gxxx1	TC	A	Mammogram, screen, dir dig	0.00	NA	2.50	0.06	NA	2.56	XXX
Gxxx2		A	Diag mammo, unilat, dir dig	0.70	NA	2.27	0.08	NA	3.05	XXX
Gxxx2	26	A	Diag mammo, unilat, dir dig	0.70	0.28	0.28	0.03	1.01	1.01	XXX
Gxxx2	TC	A	Diag mammo, unilat, dir dig	0.00	NA	1.99	0.05	NA	2.04	XXX
Gxxx3		A	Diag mammo, bilat, dir dig	0.87	NA	2.81	0.09	NA	3.77	XXX
Gxxx3	26	A	Diag mammo, bilat, dir dig	0.87	0.34	0.34	0.03	1.24	1.24	XXX
Gxxx3	TC	A	Diag mammo, bilat, dir dig	0.00	NA	2.47	0.06	NA	2.53	XXX
Gxxx4		A	Computer aided detection	0.06	NA	0.43	0.02	NA	0.51	XXX
Gxxx4	26	A	Computer aided detection	0.06	0.02	0.02	0.01	0.09	0.09	XXX
Gxxx4	TC	A	Computer aided detection	0.00	NA	0.41	0.01	NA	0.42	XXX
Gxxx5		A	Glaucoma screen, md perform	0.45	0.22	0.39	0.02	0.69	0.86	XXX
Gxxx6		A	Glaucoma screen, md supv.	0.17	0.08	0.25	0.01	0.26	0.43	XXX
H0001		I	Alcohol and/or drug assess	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0002		I	Alcohol and/or drug screenin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0003		I	Alcohol and/or drug screenin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0004		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0005		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0006		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0007		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0008		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0009		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0010		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
H0011		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0012		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0013		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0014		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0015		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0016		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0017		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0018		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0019		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0020		I	Alcohol and/or drug services	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0021		I	Alcohol and/or drug training	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0022		I	Alcohol and/or drug interven	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0023		I	Alcohol and/or drug outreach	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0024		I	Alcohol and/or drug preventi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0025		I	Alcohol and/or drug preventi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0026		I	Alcohol and/or drug preventi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0027		I	Alcohol and/or drug preventi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0028		I	Alcohol and/or drug preventi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0029		I	Alcohol and/or drug preventi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
H0030		I	Alcohol and/or drug hotline	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0120		E	Tetracyclin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0130		E	Abciximab injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0150		E	Injection adenosine 6 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0151		E	Adenosine injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0170		E	Adrenalin epinephrin inject	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0190		E	Inj biperiden lactate/5 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0200		E	Alatrofloxacin mesylate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0205		E	Alglucerase injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0207		E	Amifostine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0210		E	Methyldopate hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0256		E	Alpha 1 proteinase inhibitor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0270		E	Alprostadil for injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0275		E	Alprostadil urethral suppos	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0280		E	Aminophyllin 250 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0282		E	Amiodarone HCl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0285		E	Amphotericin B	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0286		E	Amphotericin B lipid complex	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0290		E	Ampicillin 500 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0295		E	Ampicillin sodium per 1.5 gm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0300		E	Amobarbital 125 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0330		E	Succinycholine chloride inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0340		E	Nandrolon phenpropionate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0350		E	Injection anistreplase 30 u	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0360		E	Hydralazine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0380		E	Inj metaraminol bitartrate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0390		E	Chloroquine injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0395		E	Arbutamine HCl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0400		E	Inj trimethaphan camsylate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0456		E	Azithromycin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0460		E	Atropine sulfate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0470		E	Dimecaprol injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0475		E	Baclofen 10 MG injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0476		E	Baclofen intrathecal trial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0500		E	Dicyclomine injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0510		E	Benzquinamide injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0515		E	Inj benztropine mesylate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0520		E	Bethanechol chloride inject	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0530		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0540		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0550		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0560		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0570		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0580		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0585		E	Botulinum toxin a per unit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0590		E	Ethylnorepinephrine hcl inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0600		E	Edetate calcium disodium inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0610		E	Calcium gluconate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0620		E	Calcium glycer & lact/10 ML	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0630		E	Calcitonin salmon injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0635		E	Calcitriol injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0640		E	Leucovorin calcium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0670		E	Inj mepivacaine HCL/10 ml	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0690		E	Cefazolin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0694		E	Cefoxitin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
J0695		E	Cefonocid sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0696		E	Ceftriaxone sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0697		E	Sterile cefuroxime injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0698		E	Cefotaxime sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0702		E	Betamethasone acet&sod phosp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0704		E	Betamethasone sod phosp/4 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0710		E	Cephapirin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0713		E	Inj ceftazidime per 500 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0715		E	Ceftizoxime sodium / 500 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0720		E	Chloramphenicol sodium injec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0725		E	Chorionic gonadotropin/1000u	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0730		E	Chlorpheniramin maleate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0735		E	Clonidine hydrochloride	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0740		E	Cidofovir injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0743		E	Cilastatin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0745		E	Inj codeine phosphate /30 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0760		E	Colchicine injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0770		E	Colistimethate sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0780		E	Prochlorperazine injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0800		E	Corticotropin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0810		E	Cortisone injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0835		E	Inj cosyntropin per 0.25 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0850		E	Cytomegalovirus imm IV /vial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0895		E	Deferoxamine mesylate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0900		E	Testosterone enanthate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0945		E	Brompheniramine maleate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0970		E	Estradiol valerate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1000		E	Depo-estradiol cypionate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1020		E	Methylprednisolone 20 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1030		E	Methylprednisolone 40 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1040		E	Methylprednisolone 80 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1050		E	Medroxyprogesterone inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1055		N	Medrxyprogester acetate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1060		E	Testosterone cypionate 1 ML	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1070		E	Testosterone cypionat 100 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1080		E	Testosterone cypionat 200 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1090		E	Testosterone cypionate 50 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1095		E	Inj dexamethasone acetate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1100		E	Dexamethasone sodium phos	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1110		E	Inj dihydroergotamine mesylt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1120		E	Acetazolamid sodium injectio	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1160		E	Digoxin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1165		E	Phenytoin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1170		E	Hydromorphone injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1180		E	Dyphylline injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1190		E	Dexrazoxane HCl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1200		E	Diphenhydramine hcl injectio	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1205		E	Chlorothiazide sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1212		E	Dimethyl sulfoxide 50% 50 ML	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1230		E	Methadone injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1240		E	Dimenhydrinate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1245		E	Dipyridamole injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1250		E	Inj dobutamine HCL/250 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1260		E	Dolasetron mesylate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1320		E	Amitriptyline injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1325		E	Epoprostenol injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1327		E	Eptifibatide injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1330		E	Ergonovine maleate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1362		E	Erythromycin glucep / 250 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1364		E	Erythro lactobionate /500 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1380		E	Estradiol valerate 10 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1390		E	Estradiol valerate 20 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1410		E	Inj estrogen conjugate 25 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1435		E	Injection estrone per 1 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1436		E	Etidronate disodium inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1438		E	Etanercept injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1440		E	Filgrastim 300 mcg injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1441		E	Filgrastim 480 mcg injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1450		E	Fluconazole	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1452		E	Intraocular Fomivirsen na	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1455		E	Foscarnet sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1460		E	Gamma globulin 1 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1470		E	Gamma globulin 2 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1480		E	Gamma globulin 3 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
J1490		E	Gamma globulin 4 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1500		E	Gamma globulin 5 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1510		E	Gamma globulin 6 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1520		E	Gamma globulin 7 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1530		E	Gamma globulin 8 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1540		E	Gamma globulin 9 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1550		E	Gamma globulin 10 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1560		E	Gamma globulin > 10 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1561		E	Immune globulin 500 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1563		E	IV immune globulin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1565		E	RSV-ivig	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1570		E	Ganciclovir sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1580		E	Garamycin gentamicin inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1600		E	Gold sodium thiomaleate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1610		E	Glucagon hydrochloride/1 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1620		E	Gonadorelin hydroch/ 100 mcg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1626		E	Granisetron HCl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1630		E	Haloperidol injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1631		E	Haloperidol decanoate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1642		E	Inj heparin sodium per 10 u	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1644		E	Inj heparin sodium per 1000u	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1645		E	Dalteparin sodium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1650		E	Inj enoxaparin sodium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1670		E	Tetanus immune globulin inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1690		E	Prednisolone tebutate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1700		E	Hydrocortisone acetate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1710		E	Hydrocortisone sodium ph inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1720		E	Hydrocortisone sodium succ i	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1730		E	Diazoxide injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1739		E	Hydroxyprogesterone cap 125	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1741		E	Hydroxyprogesterone cap 250	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1742		E	Ibutilide fumarate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1745		E	Infliximab injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1750		E	Iron dextran	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1785		E	Injection imiglucerase /unit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1790		E	Droperidol injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1800		E	Propranolol injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1810		E	Droperidol/fentanyl inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1820		E	Insulin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1825		E	Interferon beta-1a	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1830		E	Interferon beta-1b / .25 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1840		E	Kanamycin sulfate 500 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1850		E	Kanamycin sulfate 75 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1885		E	Ketorolac tromethamine inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1890		E	Cephalothin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1910		E	Kutapressin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1930		E	Propiomazine injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1940		E	Furosemide injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1950		E	Leuprolide acetate /3.75 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1955		E	Inj levocarnitine per 1 gm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1956		E	Levofloxacin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1960		E	Levorphanol tartrate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1970		E	Methotrimeprazine injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1980		E	Hyoscyamine sulfate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1990		E	Chlordiazepoxide injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2000		E	Lidocaine injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2010		E	Lincomycin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2060		E	Lorazepam injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2150		E	Mannitol injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2175		E	Meperidine hydrochl /100 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2180		E	Meperidine/promethazine inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2210		E	Methylergonovin maleate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2240		E	Metocurine iodide injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2250		E	Inj midazolam hydrochloride	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2260		E	Inj milrinone lactate / 5 ML	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2270		E	Morphine sulfate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2271		E	Morphine so4 injection 100mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2275		E	Morphine sulfate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2300		E	Inj nalbuphine hydrochloride	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2310		E	Inj naloxone hydrochloride	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2320		E	Nandrolone decanoate 50 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2321		E	Nandrolone decanoate 100 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2322		E	Nandrolone decanoate 200 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2330		E	Thiothixene injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
J2350		E	Niacinamide/niacin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2352		E	Octreotide acetate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2355		E	Oprelvekin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2360		E	Orphenadrine injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2370		E	Phenylephrine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2400		E	Chloroprocaine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2405		E	Ondansetron hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2410		E	Oxymorphone hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2430		E	Pamidronate disodium /30 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2440		E	Papaverin hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2460		E	Oxytetracycline injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2480		E	Hydrochlorides of opium inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2500		E	Paricalcitol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2510		E	Penicillin g procaine inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2512		E	Inj pentagastrin per 2 ML	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2515		E	Pentobarbital sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2540		E	Penicillin g potassium inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2543		E	Piperacillin/tazobactam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2545		E	Pentamidine isethionte/300mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2550		E	Promethazine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2560		E	Phenobarbital sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2590		E	Oxytocin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2597		E	Inj desmopressin acetate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2640		E	Prednisolone sodium ph inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2650		E	Prednisolone acetate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2670		E	Totazoline hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2675		E	Inj progesterone per 50 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2680		E	Fluphenazine decanoate 25 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2690		E	Procainamide hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2700		E	Oxacillin sodium injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2710		E	Neostigmine methylslfte inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2720		E	Inj protamine sulfate/10 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2725		E	Inj protirelin per 250 mcg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2730		E	Pralidoxime chloride inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2760		E	Phentolaine mesylate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2765		E	Metoclopramide hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2770		E	Quinupristin/dalfopristin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2780		E	Ranitidine hydrochloride inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2790		E	Rho d immune globulin inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2792		E	Rho(D) immune globulin h, sd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2795		E	Ropivacaine HCl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2800		E	Methocarbamol injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2810		E	Inj theophylline per 40 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2820		E	Sargramostim injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2860		E	Secobarbital sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2910		E	Aurothioglucose injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2912		E	Sodium chloride injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2915		E	NA Ferric Gluconate Complex	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2920		E	Methylprednisolone injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2930		E	Methylprednisolone injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2950		E	Promazine hcl injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2970		E	Methicillin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2993		E	Reteplase injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2995		E	Inj streptokinase /250000 IU	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2997		E	Alteplase recombinant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3000		E	Streptomycin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3010		E	Fentanyl citrate injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3030		E	Sumatriptan succinate / 6 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3070		E	Pentazocine hcl injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3080		E	Chlorprothixene injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3105		E	Terbutaline sulfate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3120		E	Testosterone enanthate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3130		E	Testosterone enanthate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3140		E	Testosterone suspension inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3150		E	Testosteron propionate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3230		E	Chlorpromazine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3240		E	Thyrotropin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3245		E	Tirofiban hydrochloride	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3250		E	Trimethobenzamide hcl inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3260		E	Tobramycin sulfate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3265		E	Injection torsemide 10 mg/ml	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3270		E	Imipramine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3280		E	Thiethylperazine maleate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3301		E	Triamcinolone acetonide inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
J3302		E	Triamcinolone diacetate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3303		E	Triamcinolone hexacetonl inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3305		E	Inj trimetrexate glucoronate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3310		E	Perphenazine injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3320		E	Spectinomycn di-hcl inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3350		E	Urea injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3360		E	Diazepam injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3364		E	Urokinase 5000 IU injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3365		E	Urokinase 250,000 IU inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3370		R	Vancomycin hcl injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3390		E	Methoxamine injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3400		E	Triflupromazine hcl inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3410		E	Hydroxyzine hcl injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3420		E	Vitamin b12 injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3430		E	Vitamin k phytonadione inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3450		E	Mephentermine sulfate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3470		E	Hyaluronidase injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3475		E	Inj magnesium sulfate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3480		E	Inj potassium chloride	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3485		E	Zidovudine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3490		E	Drugs unclassified injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3520		N	Edetate disodium per 150 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3530		E	Nasal vaccine inhalation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3535		N	Metered dose inhaler drug	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3570		N	Laetrile amygdalin vit B17	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7030		E	Normal saline solution infus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7040		E	Normal saline solution infus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7042		E	5% dextrose/normal saline	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7050		E	Normal saline solution infus	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7051		E	Sterile saline/water	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7060		E	5% dextrose/water	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7070		E	D5w infusion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7100		E	Dextran 40 infusion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7110		E	Dextran 75 infusion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7120		E	Ringers lactate infusion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7130		E	Hypertonic saline solution	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7190		X	Factor viii	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7191		X	Factor VIII (porcine)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7192		X	Factor viii recombinant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7194		X	Factor ix complex	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7197		X	Antithrombin iii injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7198		E	Anti-inhibitor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7199		E	Hemophilia clot factor noc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7300		N	Intraut copper contraceptive	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7310		E	Ganciclovir long act implant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7315		E	Sodium hyaluronate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7320		E	Hylan G–F 20 injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7330		E	Cultured chondrocytes implnt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7500		X	Azathioprine oral 50mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7501		X	Azathioprine parenteral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7502		E	Cyclosporine oral 100 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7504		X	Lymphocyte immune globulin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7505		X	Monoclonal antibodies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7506		X	Prednisone oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7507		E	Tacrolimus oral per 1 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7508		E	Tacrolimus oral per 5 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7509		X	Methylprednisolone oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7510		X	Prednisolone oral per 5 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7513		E	Daclizumab, parenteral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7515		E	Cyclosporine oral 25 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7516		E	Cyclosporin parenteral 250mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7517		E	Mycophenolate mofetil oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7520		E	Sirolimus, oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7525		E	Tacrolimus injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7599		X	Immunosuppressive drug noc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7608		E	Acetylcysteine inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7618		E	Albuterol inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7619		E	Albuterol inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7628		E	Bitolterol mes inhal sol con	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7629		E	Bitolterol mes inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7631		E	Cromolyn sodium inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7635		E	Atropine inhal sol con	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7636		E	Atropine inhal sol unit dose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7637		E	Dexamethasone inhal sol con	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
J7638		E	Dexamethasone inhal sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7639		E	Dornase alpha inhal sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7642		E	Glycopyrrolate inhal sol con	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7643		E	Glycopyrrolate inhal sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7644		E	Ipratropium brom inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7648		E	Isoetharine hcl inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7649		E	Isoetharine hcl inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7658		E	Isoproterenolhcl inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7659		E	Isoproterenol hcl inh sol ud	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7668		E	Metaproterenol inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7669		E	Metaproterenol inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7680		E	Terbutaline so4 inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7681		E	Terbutaline so4 inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7682		E	Tobramycin inhalation sol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7683		E	Triamcinolone inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7684		E	Triamcinolone inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7699		E	Inhalation solution for DME	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7799		E	Non-inhalation drug for DME	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8499		N	Oral prescrip drug non chemo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8510		E	Oral busulfan	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8520		E	Capecitabine, oral, 150 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8521		E	Capecitabine, oral, 500 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8530		E	Cyclophosphamide oral 25 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8560		E	Etoposide oral 50 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8600		E	Melphalan oral 2 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8610		E	Methotrexate oral 2.5 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8700		E	Temozolmide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8999		E	Oral prescription drug chemo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9000		E	Doxorubic hcl 10 MG vl chemo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9001		E	Doxorubicin hcl liposome inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9015		E	Aldesleukin/single use vial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9020		E	Asparaginase injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9031		E	Bcg live intravesical vac	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9040		E	Bleomycin sulfate injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9045		E	Carboplatin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9050		E	Carmus bischl nitro inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9060		E	Cisplatin 10 MG injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9062		E	Cisplatin 50 MG injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9065		E	Inj cladribine per 1 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9070		E	Cyclophosphamide 100 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9080		E	Cyclophosphamide 200 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9090		E	Cyclophosphamide 500 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9091		E	Cyclophosphamide 1.0 grm inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9092		E	Cyclophosphamide 2.0 grm inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9093		E	Cyclophosphamide lyophilized	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9094		E	Cyclophosphamide lyophilized	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9095		E	Cyclophosphamide lyophilized	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9096		E	Cyclophosphamide lyophilized	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9097		E	Cyclophosphamide lyophilized	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9100		E	Cytarabine hcl 100 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9110		E	Cytarabine hcl 500 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9120		E	Dactinomycin actinomycin d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9130		E	Dacarbazine 10 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9140		E	Dacarbazine 200 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9150		E	Daunorubicin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9151		E	Daunorubicin citrate liposom	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9160		E	Denileukin diftitox, 300 mcg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9165		E	Diethylstilbestrol injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9170		E	Docetaxel	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9180		E	Epirubicin HCl injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9181		E	Etoposide 10 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9182		E	Etoposide 100 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9185		E	Fludarabine phosphate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9190		E	Fluorouracil injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9200		E	Floxuridine injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9201		E	Gemcitabine HCl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9202		E	Goserelin acetate implant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9206		E	Irinotecan injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9208		E	Ifosfomide injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9209		E	Mesna injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9211		E	Idarubicin hcl injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9212		E	Interferon alfacon-1	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9213		E	Interferon alfa-2a inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9214		E	Interferon alfa-2b inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
J9215		E	Interferon alfa-n3 inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9216		E	Interferon gamma 1–b inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9217		E	Leuprolide acetate suspnsion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9218		E	Leuprolide acetate injeciton	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9219		E	Leuprolide acetate implant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9230		E	Mechlorethamine hcl inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9245		E	Inj melphalan hydrochl 50 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9250		E	Methotrexate sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9260		E	Methotrexate sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9265		E	Paclitaxel injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9266		E	Pegaspargase/singl dose vial	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9268		E	Pentostatin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9270		E	Plicamycin (mithramycin) inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9280		E	Mitomycin 5 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9290		E	Mitomycin 20 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9291		E	Mitomycin 40 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9293		E	Mitoxantrone hydrochl / 5 MG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9310		E	Rituximab cancer treatment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9320		E	Streptozocin injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9340		E	Thiotepa injection	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9350		E	Topotecan	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9355		E	Trastuzumab	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9357		E	Valrubicin, 200 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9360		E	Vinblastine sulfate inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9370		E	Vincristine sulfate 1 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9375		E	Vincristine sulfate 2 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9380		E	Vincristine sulfate 5 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9390		E	Vinorelbine tartrate/10 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9600		E	Porfimer sodium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9999		E	Chemotherapy drug	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0064		A	Visit for drug monitoring	0.37	0.12	0.26	0.01	0.50	0.64	XXX
M0075		N	Cellular therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0076		N	Prolotherapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0100		N	Intragastric hypothermia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0300		N	IV chelationtherapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0301		N	Fabric wrapping of aneurysm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0302		A	Assessment of cardiac output	0.17	NA	0.85	0.02	NA	1.04	XXX
M0302	26	A	Assessment of cardiac output	0.17	0.07	0.07	0.01	0.25	0.25	XXX
M0302	TC	A	Assessment of cardiac output	0.00	NA	0.78	0.01	NA	0.79	XXX
P2028		X	Cephalin floculation test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P2029		X	Congo red blood test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P2031		N	Hair analysis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P2033		X	Blood thymol turbidity	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P2038		X	Blood mucoprotein	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P3000		X	Screen pap by tech w md supv	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P3001		A	Screening pap smear by phys	0.42	0.19	0.19	0.01	0.62	0.62	XXX
P7001		I	Culture bacterial urine	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9010		E	Whole blood for transfusion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9011		E	Blood split unit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9012		E	Cryoprecipitate each unit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9016		E	RBC leukocytes reduced	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9017		E	One donor fresh frozn plasma	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9019		E	Platelets, each unit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9020		E	Plaelet rich plasma unit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9021		E	Red blood cells unit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9022		E	Washed red blood cells unit	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9023		X	Frozen plasma, pooled, sd	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9031		X	Platelets leukocytes reduced	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9032		X	Platelets, irradiated	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9033		X	Platelets leukoreduced irrad	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9034		X	Platelets, pheresis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9035		X	Platelet pheres leukoreduced	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9036		X	Platelet pheresis irradiated	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9037		X	Plate pheres leukoredu irrad	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9038		X	RBC irradiated	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9039		X	RBC deglycerolized	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9040		X	RBC leukoreduced irradiated	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9041		X	Albumin(human), 5%	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9042		X	Albumin (human), 25%	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9043		X	Plasma protein fraction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9044		X	Cryoprecipitatereducedplasma	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9603		X	One-way allow prorated miles	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9604		X	One-way allow prorated trip	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9612		X	Catheterize for urine spec	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
P9615		X	Urine specimen collect mult	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0035		A	Cardiokymography	0.17	NA	0.45	0.03	NA	0.65	XXX
Q0035	26	A	Cardiokymography	0.17	0.07	0.07	0.01	0.25	0.25	XXX
Q0035	TC	A	Cardiokymography	0.00	NA	0.38	0.02	NA	0.40	XXX
Q0091		A	Obtaining screen pap smear	0.37	0.15	0.72	0.01	0.53	1.10	XXX
Q0092		A	Set up port xray equipment	0.00	NA	0.31	0.01	NA	0.32	XXX
Q0111		X	Wet mounts/ w preparations	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0112		X	Potassium hydroxide preps	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0113		X	Pinworm examinations	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0114		X	Fern test	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0115		X	Post-coital mucous exam	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0136		X	Non esrd epoetin alpha inj	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0144		N	Azithromycin dihydrate, oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0160		X	Factor IX non-recombinant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0161		X	Factor IX recombinant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0163		X	Diphenhydramine HCl 50mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0164		X	Prochlorperazine maleate 5mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0165		X	Prochlorperazine maleate10mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0166		X	Granisetron HCl 1 mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0167		X	Dronabinol 2.5mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0168		X	Dronabinol 5mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0169		X	Promethazine HCl 12.5mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0170		X	Promethazine HCl 25 mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0171		X	Chlorpromazine HCl 10mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0172		X	Chlorpromazine HCl 25mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0173		X	Trimethobenzamide HCl 250mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0174		X	Thiethylperazine maleate10mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0175		X	Perphenazine 4mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0176		X	Perphenazine 8mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0177		X	Hydroxyzine pamoate 25mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0178		X	Hydroxyzine pamoate 50mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0179		X	Ondansetron HCl 8mg oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0180		X	Dolasetron mesylate oral	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0181		X	Unspecified oral anti-emetic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0183		X	Nonmetabolic active tissue	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0184		X	Metabolically active tissue	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0185		X	Metabolic active D/E tissue	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0186		I	Paramedic intercept, rural	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0187		E	Factor viia recombinant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q1001		X	Ntiol category 1	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q1002		X	Ntiol category 2	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q1003		X	Ntiol category 3	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q1004		X	Ntiol category 4	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q1005		X	Ntiol category 5	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2001		N	Oral cabergoline 0.5 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2002		E	Elliotts b solution per ml	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2003		E	Aprotinin, 10,000 kiu	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2004		E	Bladder calculi irrig sol	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2005		E	Corticorelin ovine triflutat	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2006		E	Digoxin immune fab (ovine)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2007		E	Ethanolamine oleate 100 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2008		E	Fomepizole, 1.5 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2009		E	Fosphenytoin, 50 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2010		E	Glatiramer acetate, per dose	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2011		E	Hemin, per 1 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2012		E	Pegademase bovine, 25 iu	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2013		E	Pentastarch 10% solution	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2014		E	Sermorelin acetate, 0.5 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2015		E	Somatrem, 5 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2016		E	Somatropin, 1 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2017		E	Teniposide, 50 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2018		E	Urofollitropin, 75 iu	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2019		E	Basiliximab	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2020		E	Histrelin acetate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2021		E	Lepirudin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q2022		E	VonWillebrandFactrCmplxperIU	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3001		E	Brachytherapy Radioelements	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3002		E	Gallium ga 67	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3003		E	Technetium tc99m bicisate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3004		E	Xenon xe 133	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3005		E	Technetium tc99m mertiatide	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3006		E	Technetium tc99m glucepatate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3007		E	Sodium phosphate p32	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3008		E	Indium 111-in pentetreotide	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
Q3009		E	Technetium tc99m oxidronate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3010		E	Technetium tc99mlabeledrbcs	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3011		E	Chromic phosphate p32	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3012		E	Cyanocobalamin cobalt co57	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q3013		E	Injection, verteporfin, 15mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4001		X	Cast sup body cast, plas	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4002		X	Cast sup body cast, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4003		X	Cast sup shoulder cast, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4004		X	Cast sup shoulder cast, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4005		X	Cast sup long arm, ad, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4006		X	Cast sup long arm, ad, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4007		X	Cast sup long arm ped, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4008		X	Cast sup, long arm ped, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4009		X	Cast sup sh arm, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4010		X	Cast sup sh arm, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4011		X	Cast sup sh arm ped, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4012		X	Cast sup sh arm ped, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4013		X	Cast sup gauntlet, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4014		X	Cast sup gauntlet, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4015		X	Cast sup gauntlet ped,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4016		X	Cast sup gauntlet ped, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4017		X	Cast sup l arm splint, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4018		X	Cast sup l arm splint, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4019		X	Cast sup l arm splint ped, p	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4020		X	Cast sup l arm splint ped, f	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4021		X	Cast sup sh arm splint, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4022		X	Cast sup sh arm splint, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4023		X	Cast sup sh arm splint ped,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4024		X	Cast sup sh arm splint ped,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4025		X	Cast sup, hip spica, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4026		X	Cast sup hip spica, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4027		X	Cast sup hip spica, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4028		X	Cast sup, hip spica, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4029		X	Cast sup long leg, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4030		X	Cast sup, long leg, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4031		X	Cast sup, long leg ped, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4032		X	Cast sup, long leg ped, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4033		X	Cast sup, leg cylinder, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4034		X	Cast sup, leg cylinder, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4035		X	Cast sup, leg cylinder ped,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4036		X	Cast sup, leg cylinder ped,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4037		X	Cast sup, sh leg, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4038		X	Cast sup, sh leg, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4039		X	Cast sup, sh leg ped, pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4040		X	Cast sup, sh leg ped, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4041		X	Cast sup, l leg splint , pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4042		X	Cast sup, l leg splint , fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4043		X	Cast sup, l leg splintped, p	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4044		X	Cast sup, l leg splint ped,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4045		X	Cast sup, sh leg splint , pl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4046		X	Cast sup, sh leg splint, fib	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4047		X	Cast sup, sh leg splint ped,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4048		X	Cast sup, sh leg splint ped,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4049		X	Finger splint, static	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4050		X	Cast sup, unlisted casts	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q4051		X	Splint sup, misc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9920		E	Epoetin with hct <= 20	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9921		E	Epoetin with hct = 21	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9922		E	Epoetin with hct = 22	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9923		E	Epoetin with hct = 23	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9924		E	Epoetin with hct = 24	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9925		E	Epoetin with hct = 25	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9926		E	Epoetin with hct = 26	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9927		E	Epoetin with hct = 27	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9928		E	Epoetin with hct = 28	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9929		E	Epoetin with hct = 29	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9930		E	Epoetin with hct = 30	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9931		E	Epoetin with hct = 31	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9932		E	Epoetin with hct = 32	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9933		E	Epoetin with hct = 33	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9934		E	Epoetin with hct = 34	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9935		E	Epoetin with hct = 35	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9936		E	Epoetin with hct = 36	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9937		E	Epoetin with hct = 37	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
Q9938		E	Epoetin with hct = 38	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9939		E	Epoetin with hct = 39	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9940		E	Epoetin with hct >= 40	0.00	0.00	0.00	0.00	0.00	0.00	XXX
R0070		C	Transport portable x-ray	0.00	0.00	0.00	0.00	0.00	0.00	XXX
R0075		C	Transport port x-ray multipl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
R0076		B	Transport portable EKG	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0009		I	Injection, butorphanol tartr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0012		I	Butorphanol tartrate, nasal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0014		I	Tacrine hydrochloride, 10 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0016		I	Injection, amikacin sulfate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0017		I	Injection, aminocaproic acid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0020		I	Injection, bupivicaine hydro	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0021		I	Injection, cefoperazone sod	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0023		I	Injection, cimetidine hydroc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0024		I	Injection, ciprofloxacin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0028		I	Injection, famotidine, 20 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0029		I	Injection, fluconazole	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0030		I	Injection, metronidazole	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0032		I	Injection, nafcillin sodium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0034		I	Injection, ofloxacin, 400 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0039		I	Injection, sulfamethoxazole	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0040		I	Injection, ticarcillin disod	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0071		I	Injection, acyclovir sodium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0072		I	Injection, amikacin sulfate	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0073		I	Injection, aztreonam, 500 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0074		I	Injection, cefotetan disodiu	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0077		I	Injection, clindamycin phosp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0078		I	Injection, fosphenytoin sodi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0080		I	Injection, pentamidine iseth	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0081		I	Injection, piperacillin sodi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0085		I	injection, gatifloxacin	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0086		I	Injection, verteporfin, 15mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0090		I	Sildenafil citrate, 25 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0096		I	Injection, itraconazole, 200	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0156		I	Exemestane, 25 mg	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0157		I	Becaplermin gel 1%, 0.5 gm	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0220		I	Medical conference by physic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0221		I	Medical conference, 60 min	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0601		I	Screening proctoscopy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0605		I	Digital rectal examination,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0610		I	Annual gynecological examina	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0612		I	Annual gynecological examina	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0620		I	Routine ophthalmological exa	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0621		I	Routine ophthalmological exa	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0630		I	Removal of sutures	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0800		I	Laser in situ keratomileusis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0810		I	Photorefractive keratectomy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0820		I	Computerized corneal topogra	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0830		I	Ultrasound pachymetry	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S1015		I	IV tubing extension set	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S1016		I	Non-pvc intravenous administ	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2052		I	Transplantation of small int	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2053		I	Transplantation of small int	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2054		I	Transplantation of multivisc	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2055		I	Harvesting of donor multivis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2060		I	Lobar lung transplantation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2061		I	Donor lobectomy (lung)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2102		I	Islet cell tissue transplant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2103		I	Adrenal tissue transplant	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2120		I	Low density lipoprotein(LDL)	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2140		I	Cord blood harvesting	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2142		I	Cord blood-derived stem-cell	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2180		I	Donor leukocyte infusion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2202		I	Echosclerotherapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2205		I	Minimally invasive direct co	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2206		I	Minimally invasive direct co	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2207		I	Minimally invasive direct co	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2208		I	Minimally invasive direct co	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2209		I	Minimally invasive direct co	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2210		I	Cryosurgical ablation (in si	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2220		I	Thrombectomy, coronary	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2300		I	Arthroscopy, shoulder, surgi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2340		I	Chemodenervation of abductor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2350		I	Diskectomy, anterior, with d	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
S2351		I	Diskectomy, anterior, with d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2370		I	Intradiscal electrothermal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2371		I	Each additional interspace	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3620		X	Newborn metabolic screening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3645		I	HIV–1 antibody testing of or	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3650		I	Saliva test, hormone level;	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3652		I	Saliva test, hormone level;	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3700		I	Bladder tumor-associated	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3708		I	Gastrointestinal fat absorpt	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3902		I	Ballistocardiogram	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3904		I	Masters two step	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3906		I	Transfusion, direct, blood	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5000		I	Prescription drug, generic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5001		I	Prescription drug,brand name	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5002		I	Fat emulsion 10% in 250 ml	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5003		I	Fat emulsion 20% in 250 ml	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5010		I	5% dextrose and 45% saline	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5011		I	5% dextrose in lactated ring	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5012		I	5% dextrose with potassium	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5013		I	5% dextrose/45%saline,1000ml	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5014		I	5% dextrose/45%saline,1500ml	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5016		I	Antibiotic admin supplies w/	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5017		I	Antibiotic adminsupplies w/o	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5018		I	Pain therapy admin supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5019		I	Chemotherapy admin supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5020		I	Chemotherapy admin supplies	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5021		I	Hydration therapy admin supp	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5022		I	Growth hormone therapy	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5025		I	Infusion pump rental,perdiem	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S5503		I	Maintenance of implanted vas	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8001		I	Radiofrequency stimulation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8035		I	Magnetic source imaging	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8040		I	Topographic brain mapping	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8049		I	Intraoperative radiation the	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8080		I	Scintimammography	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8085		I	Fluorine-18 fluorodeoxygluco	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8092		I	Electron beam computed tomog	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8095		I	Wig (for medically-induced h	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8096		I	Portable peak flow meter	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8105		I	Oximeter for measuring blood	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8110		I	Peak expiratory flow rate (p	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8200		I	Chest compression vest	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8205		I	Chest compression system gen	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8210		I	Mucus trap	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8260		I	Oral orthotic for treatment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8400		I	Incontinence pants, each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8402		I	Diapers, each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8405		I	Incontinence liners, each	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8950		I	Complex lymphedema therapy,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8999		I	Resuscitation bag	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9001		I	Home uterine monitor with or	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9007		I	Ultrafiltration monitor	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9015		I	Automated EEG monitoring	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9022		I	Digital subtraction angiogra	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9023		I	Xenon regional cerebral bloo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9024		I	Paranasal sinus ultrasound	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9025		I	Omnicardiogram/cardiointegra	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9035		I	Medical equipment or supplie	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9055		I	Procuren or other growth fac	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9056		I	Coma stimulation per diem	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9061		I	Medical supplies and equipme	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9075		I	Smoking cessation treatment	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9085		I	Meniscal allograft transplan	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9088		I	Services provided in urgent	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9090		I	Vertebral axial decompressio	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9122		I	Home health aide or certifie	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9123		I	Nursing care, in the home; b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9124		I	Nursing care, in the home; b	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9125		I	Respite care, in the home, p	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9126		I	Hospice care, in the home, p	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9127		I	Social work visit, in the ho	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9128		I	Speech therapy, in the home,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9129		I	Occupational therapy, in the	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9140		I	Diabetic Management Program,	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
S9141		I	Diabetic Management Program,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9200		I	Nursing services and all nec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9210		I	Nursing services and all nec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9220		I	Nursing services and all nec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9225		I	Nursing services and all nec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9230		I	Nursing services and all nec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9300		I	Nursing services and all nec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9308		I	Nursing services and all nec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9310		I	Nursing services and all nec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9395		I	Nursing services and all nec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9420		I	Nursing services and all nec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9423		I	Nursing services, patient as	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9425		I	Nursing services and all nec	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9435		I	Medical foods for inborn err	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9455		I	Diabetic Management Program,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9460		I	Diabetic Management Program,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9465		I	Diabetic Management Program,	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9470		I	Nutritional counseling, diet	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9472		I	Cardiac rehabilitation progr	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9473		I	Pulmonary rehabilitation pro	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9474		I	Enterostomal therapy by a re	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9475		I	Ambulatory setting substance	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9480		I	Intensive outpatient psychia	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9485		I	Crisis intervention mental h	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9524		I	Nursing services related to	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9526		I	Skilled nursing visits for	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9527		I	Insertion of a peripherally	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9528		I	Insertion of midline central	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9533		I	Pain management, intravenous	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9535		I	Administration of hematopoie	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9539		I	Administration of antibiotic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9543		I	Administration of medication	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9545		I	Administration of immune glo	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9550		I	Home IV therapy, hydration	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9555		I	Additional home infusion	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9990		I	Services provided as part of	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9991		I	Services provided as part of	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9992		I	Transportation costs to and	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9994		I	Lodging costs (e.g. hotel ch	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9996		I	Meals for clinical trial par	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9999		I	Sales tax	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2020		X	Vision svcs frames purchases	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2025		N	Eyeglasses delux frames	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2100		X	Lens spher single plano 4.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2101		X	Single visn sphere 4.12–7.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2102		X	Singl visn sphere 7.12–20.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2103		X	Spherocylindr 4.00d/12–2.00d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2104		X	Spherocylindr 4.00d/2.12–4d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2105		X	Spherocylinder 4.00d/4.25–6d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2106		X	Spherocylinder 4.00d/>6.00d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2107		X	Spherocylinder 4.25d/12–2d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2108		X	Spherocylinder 4.25d/2.12–4d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2109		X	Spherocylinder 4.25d/4.25–6d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2110		X	Spherocylinder 4.25d/over 6d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2111		X	Spherocylindr 7.25d/.25–2.25	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2112		X	Spherocylindr 7.25d/2.25–4d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2113		X	Spherocylindr 7.25d/4.25–6d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2114		X	Spherocylinder over 12.00d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2115		X	Lens lenticular bifocal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2116		X	Nonaspheric lens bifocal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2117		X	Aspheric lens bifocal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2118		X	Lens aniseikonic single	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2199		X	Lens single vision not oth c	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2200		X	Lens spher bifoc plano 4.00d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2201		X	Lens sphere bifocal 4.12–7.0	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2202		X	Lens sphere bifocal 7.12–20.	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2203		X	Lens sphcyl bifocal 4.00d/.1	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2204		X	Lens sphcy bifocal 4.00d/2.1	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2205		X	Lens sphcy bifocal 4.00d/4.2	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2206		X	Lens sphcy bifocal 4.00d/ove	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2207		X	Lens sphcy bifocal 4.25–7d/.	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2208		X	Lens sphcy bifocal 4.25–7/2.	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2209		X	Lens sphcy bifocal 4.25–7/4.	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2210		X	Lens sphcy bifocal 4.25–7/ov	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
V2211		X	Lens sphcy bifo 7.25–12/.25–	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2212		X	Lens sphcyl bifo 7.25–12/2.2	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2213		X	Lens sphcyl bifo 7.25–12/4.2	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2214		X	Lens sphcyl bifocal over 12.	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2215		X	Lens lenticular bifocal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2216		X	Lens lenticular nonaspheric	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2217		X	Lens lenticular aspheric bif	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2218		X	Lens aniseikonic bifocal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2219		X	Lens bifocal seg width over	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2220		X	Lens bifocal add over 3.25d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2299		X	Lens bifocal speciality	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2300		X	Lens sphere trifocal 4.00d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2301		X	Lens sphere trifocal 4.12–7.	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2302		X	Lens sphere trifocal 7.12–20	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2303		X	Lens sphcy trifocal 4.0/.12-	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2304		X	Lens sphcy trifocal 4.0/2.25	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2305		X	Lens sphcy trifocal 4.0/4.25	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2306		X	Lens sphcyl trifocal 4.00/>6	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2307		X	Lens sphcy trifocal 4.25–7/.	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2308		X	Lens sphc trifocal 4.25–7/2.	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2309		X	Lens sphc trifocal 4.25–7/4.	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2310		X	Lens sphc trifocal 4.25–7/>6	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2311		X	Lens sphc trifo 7.25–12/.25-	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2312		X	Lens sphc trifo 7.25–12/2.25	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2313		X	Lens sphc trifo 7.25–12/4.25	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2314		X	Lens sphcyl trifocal over 12	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2315		X	Lens lenticular trifocal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2316		X	Lens lenticular nonaspheric	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2317		X	Lens lenticular aspheric tri	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2318		X	Lens aniseikonic trifocal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2319		X	Lens trifocal seg width > 28	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2320		X	Lens trifocal add over 3.25d	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2399		X	Lens trifocal speciality	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2410		X	Lens variab asphericity sing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2430		X	Lens variable asphericity bi	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2499		X	Variable asphericity lens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2500		X	Contact lens pmma spherical	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2501		X	Cntct lens pmma-toric/prism	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2502		X	Contact lens pmma bifocal	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2503		X	Cntct lens pmma color vision	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2510		X	Cntct gas permeable sphericl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2511		X	Cntct toric prism ballast	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2512		X	Cntct lens gas permbl bifocl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2513		X	Contact lens extended wear	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2520		P	Contact lens hydrophilic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2521		X	Cntct lens hydrophilic toric	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2522		X	Cntct lens hydrophil bifocl	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2523		X	Cntct lens hydrophil extend	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2530		X	Contact lens gas impermeable	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2531		X	Contact lens gas permeable	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2599		X	Contact lens/es other type	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2600		X	Hand held low vision aids	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2610		X	Single lens spectacle mount	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2615		X	Telescop/othr compound lens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2623		X	Plastic eye prosth custom	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2624		X	Polishing artifical eye	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2625		X	Enlargemnt of eye prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2626		X	Reduction of eye prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2627		X	Scleral cover shell	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2628		X	Fabrication & fitting	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2629		X	Prosthetic eye other type	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2630		X	Anter chamber intraocul lens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2631		X	Iris support intraoclr lens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2632		X	Post chmbr intraocular lens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2700		X	Balance lens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2710		X	Glass/plastic slab off prism	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2715		X	Prism lens/es	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2718		X	Fresnell prism press-on lens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2730		X	Special base curve	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2740		X	Rose tint plastic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2741		X	Non-rose tint plastic	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2742		X	Rose tint glass	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2743		X	Non-rose tint glass	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2744		X	Tint photochromatic lens/es	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] + Indicates RVUs are not used for Medicare payments.
[4] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	MOD	Status	Description	Physician Work RVUs [3]	Facility PE RVUs	Non-Facility PE RVUs	Mal-Practice RVUs	Facility Total	Non-Facility Total	Global
V2750		X	Anti-reflective coating	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2755		X	UV lens/es	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2760		X	Scratch resistant coating	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2770		X	Occluder lens/es	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2780		X	Oversize lens/es	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2781		X	Progressive lens per lens	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2785		X	Corneal tissue processing	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2790		X	Amniotic membrane	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2799		X	Miscellaneous vision service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5008		N	Hearing screening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5010		N	Assessment for hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5011		N	Hearing aid fitting/checking	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5014		N	Hearing aid repair/modifying	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5020		N	Conformity evaluation	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5030		N	Body-worn hearing aid air	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5040		N	Body-worn hearing aid bone	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5050		N	Hearing aid monaural in ear	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5060		N	Behind ear hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5070		N	Glasses air conduction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5080		N	Glasses bone conduction	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5090		N	Hearing aid dispensing fee	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5100		N	Body-worn bilat hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5110		N	Hearing aid dispensing fee	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5120		N	Body-worn binaur hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5130		N	In ear binaural hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5140		N	Behind ear binaur hearing ai	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5150		N	Glasses binaural hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5160		N	Dispensing fee binaural	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5170		N	Within ear cros hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5180		N	Behind ear cros hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5190		N	Glasses cros hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5200		N	Cros hearing aid dispens fee	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5210		N	In ear bicros hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5220		N	Behind ear bicros hearing ai	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5230		N	Glasses bicros hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5240		N	Dispensing fee bicros	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5299		R	Hearing service	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5336		N	Repair communication device	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5362		R	Speech screening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5363		R	Language screening	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5364		R	Dysphagia screening	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved(D0110–D9999).
[3] + Indicates RVUs are not use for Medicate payments.
[4] PE RVUs = Practice Expense Relative Value Units.

[FR Doc. 01–18951 Filed 8–1–01; 8:45 am]

BILLING CODE 4120–01–P

Federal Register

Thursday,
August 2, 2001

Part IV

Department of Education

Dropout Prevention Program; Notice

DEPARTMENT OF EDUCATION

[CFDA No. 84.215W]

Dropout Prevention Demonstration Program

ACTION: Notice Extending Deadline for Submission of Electronic Applications.

SUMMARY: On May 22, 2001, the Assistant Secretary for Elementary and Secondary Education published in the **Federal Register** a Notice Inviting Applications for New Awards for Fiscal Year (FY) 2001 under the Dropout Prevention Demonstration Program. (66 FR 28319–28339). The application closing date was July 23, 2001. Applicants were permitted to submit their applications electronically, by hand delivery, or by mail. Instructions for each type of submission were detailed in the application notice.

On July 23, 2001, a power outage affected the Department of Education's computer system and some applicants that had intended to submit electronic applications were unable to do so by the established deadline. The Department is therefore extending the deadline for submission of electronic applications under the program. The deadline for submission of applications by hand delivery or by mail is not being extended.

FOR FURTHER INFORMATION CONTACT: Christine Jackson, Dropout Prevention Demonstration Program, Academic Improvement and Demonstration Programs, Office of Elementary and Secondary Education, U.S. Department of Education, 400 Maryland Avenue, S.W., Room 2W104, FOB–6, Washington, DC 20202–6254. Telephone: (202) 260–2516. e-mail: christine.jackson@ed.gov. Individuals who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1–888–877–8339.

Individuals with disabilities may obtain this notice in an alternative format (e.g., Braille, large print, audiotape, or computer diskette) on request to the contact person listed in the preceding paragraph. Please note, however, that the Department is not able to reproduce in an alternative format the standard forms included in the notice.

Deadline for Submission of Electronic Applications: August 6, 2001.

SUPPLEMENTARY INFORMATION: Applicants that wish to submit an electronic application under the Dropout Prevention Demonstration Program must do so by the date established in this notice and comply with the requirements in the Notice Inviting Applications. As that notice states, applicants that submit electronic applications must, among other things, do so by 4:30 p.m. (EST) on the deadline date and fax a signed copy of ED 424 (Application for Federal Assistance) to the Department's Application Control Center within three working days of submitting their applications.

Some applicants that initially attempted to submit their applications electronically but were precluded from doing so due to the power outage instead submitted their applications by mail by the deadline in the Notice Inviting Applications. If any of these applicants did not include a signed copy of ED 424 with their submission, they may fax a signed copy of this form to the Department's Application Control Center within three days of the revised deadline for submission of electronic applications.

Electronic Access to This Document

You may view this document, as well as all other Department of Education documents published in the **Federal Register**, in text or Adobe Portable Document Format (PDF) on the Internet at the following site: www.ed.gov/legislation/FedRegister.

To use PDF you must have the Adobe Acrobat Reader, which is available free at this site. If you have questions about using PDF, call the U.S. Government Printing Office (GPO) at (202) 512–1530 or, (toll free, at 1–888–293–6498), or in the Washington, D.C. area at (202) 512–1530.

Note: The official version of this document is the document published in the **Federal Register**. Free Internet access to the official edition of the **Federal Register** and the Code of Federal Regulations is available on GPO Access at: http://www.access.gpo.gov/nara/index.html

Dated: July 30, 2001.

Susan B. Neuman,

Assistant Secretary for Elementary and Secondary Education.

[FR Doc. 01–19312 Filed 8–1–01; 8:45 am]

BILLING CODE 4000–01–P

Federal Register

Thursday,
August 2, 2001

Part V

The President

Executive Order 13221—Energy Efficient Standby Power Devices

Federal Register
Vol. 66, No. 149
Thursday, August 2, 2001

Presidential Documents

Title 3—

The President

Executive Order 13221 of July 31, 2001

Energy Efficient Standby Power Devices

By the authority vested in me as President by the Constitution and the laws of the United States of America, including the National Energy Conservation Policy Act (Public Law 95–619, 92 Stat. 3206, 42 U.S.C. 8252 *et seq.*), as amended by the Energy Policy Act of 1992 (EPACT) (Public Law 102–486, 106 Stat. 2776), and section 301 of title 3, United States Code, and in order to further encourage energy conservation by the Federal Government, it is hereby ordered as follows:

Section 1. *Energy Efficient Standby Power Devices.* Each agency, when it purchases commercially available, off-the-shelf products that use external standby power devices, or that contain an internal standby power function, shall purchase products that use no more than one watt in their standby power consuming mode. If such products are not available, agencies shall purchase products with the lowest standby power wattage while in their standby power consuming mode. Agencies shall adhere to these requirements, when life-cycle cost-effective and practicable and where the relevant product's utility and performance are not compromised as a result. By December 31, 2001, and on an annual basis thereafter, the Department of Energy, in consultation with the Department of Defense and the General Services Administration, shall compile a preliminary list of products to be subject to these requirements. The Department of Energy shall finalize the list and may remove products deemed inappropriate for listing.

Sec. 2. *Independent Agencies.* Independent agencies are encouraged to comply with the provisions of this order.

Sec. 3. *Definition.* ''Agency'' means an executive agency as defined in 5 U.S.C. 105. For the purpose of this order, military departments, as defined in 5 U.S.C. 102, are covered by the Department of Defense.



THE WHITE HOUSE,
July 31, 2001.

[FR Doc. 01–19562
Filed 8–1–01; 11:04 am]
Billing code 3195–01–P

Reader Aids

Federal Register

Vol. 66, No. 149

Thursday, August 2, 2001

CUSTOMER SERVICE AND INFORMATION

Federal Register/Code of Federal Regulations

General Information, indexes and other finding aids	**202–523–5227**
Laws	**523–5227**
Presidential Documents	
Executive orders and proclamations	**523–5227**
The United States Government Manual	**523–5227**
Other Services	
Electronic and on-line services (voice)	**523–4534**
Privacy Act Compilation	**523–3187**
Public Laws Update Service (numbers, dates, etc.)	**523–6641**
TTY for the deaf-and-hard-of-hearing	**523–5229**

ELECTRONIC RESEARCH

World Wide Web

Full text of the daily Federal Register, CFR and other publications:

http://www.access.gpo.gov/nara

Federal Register information and research tools, including Public Inspection List, indexes, and links to GPO Access:

http://www.nara.gov/fedreg

E-mail

PENS (Public Law Electronic Notification Service) is an E-mail service for notification of recently enacted Public Laws. To subscribe, send E-mail to

listserv@listserv.gsa.gov

with the text message:

subscribe PUBLAWS-L your name

Use listserv@www.gsa.gov only to subscribe or unsubscribe to PENS. We cannot respond to specific inquiries.

Reference questions. Send questions and comments about the Federal Register system to:

info@fedreg.nara.gov

The Federal Register staff cannot interpret specific documents or regulations.

FEDERAL REGISTER PAGES AND DATE, AUGUST

39615–40106 1
40107–40572 2

CFR PARTS AFFECTED DURING AUGUST

At the end of each month, the Office of the Federal Register publishes separately a List of CFR Sections Affected (LSA), which lists parts and sections affected by documents published since the revision date of each title.

3 CFR

Administrative Orders:
Presidential Determinations:
No. 2001-22 of July 26, 2001 40107
Notices:
Notice of July 31, 2001 40105
Executive Orders:
13221 (See Notice of July 31, 2001) 40571

7 CFR

916.....39615
917.....39615
959.....39621
989.....39623
Proposed Rules:
246.....40152
916.....39690
948.....40153, 40155
966.....40158

9 CFR

130.....39628

14 CFR

39.....39632, 40109
95.....39633
Proposed Rules:
39.....40161, 40162

16 CFR

305.....40110
1700.....40111
Proposed Rules:
1500.....39692

26 CFR

31.....39638

32 CFR

Proposed Rules:
199.....39699

33 CFR

117 .....40116, 40117, 40118
165.....40120

36 CFR

Proposed Rules:
1228.....40166

37 CFR

202.....40322

40 CFR

9.....40121
52.....40137
63.....40121
180 .....39640, 39648, 39651, 39659, 39666, 39675, 40140, 40141
Proposed Rules:
52.....40168
63.....40166, 40324
153.....40170
180 .....39705, 39709, 40170

42 CFR

405.....39828
410.....39828
412.....39828
413.....39828
482.....39828
485.....39828
486.....39828
Proposed Rules:
405.....40372
410.....40372
411.....40372
414.....40372
415.....40372

44 CFR

Proposed Rules:
204.....39715

47 CFR

73.....39682, 39683
Proposed Rules:
73 .....39726, 39727, 40174

49 CFR

232.....39683
Proposed Rules:
171.....40174
173.....40174
174.....40174
175.....40174
176.....40174
177.....40174
178.....40174
571.....40174

50 CFR

635.....40151
Proposed Rules:
223.....40176
622.....40187
660.....40188

REMINDERS

The items in this list were editorially compiled as an aid to Federal Register users. Inclusion or exclusion from this list has no legal significance.

RULES GOING INTO EFFECT AUGUST 2, 2001

AGRICULTURE DEPARTMENT

Agricultural Marketing Service

Nectarines and peaches grown in—
California; published 8-1-01

Raisins produced from grapes grown in—
California; published 8-1-01

ENVIRONMENTAL PROTECTION AGENCY

Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:
Isoxadifen-ethyl; published 8-2-01
Tepraloxydim; published 8-2-01

TRANSPORTATION DEPARTMENT

Coast Guard

Drawbridge operations:
Florida; published 7-11-01

COMMENTS DUE NEXT WEEK

AGRICULTURE DEPARTMENT

Agricultural Marketing Service

Oranges, grapefruit, tangerines, and tangelos grown in—
Florida; comments due by 8-10-01; published 7-31-01

COMMERCE DEPARTMENT

National Oceanic and Atmospheric Administration

Fishery conservation and management:
Alaska; fisheries of Exclusive Economic Zone—
American Fisheries Act; emergency revisions; comments due by 8-9-01; published 7-10-01

ENVIRONMENTAL PROTECTION AGENCY

Air pollution control; new motor vehicles and engines:
Light-duty vehicles and trucks and heavy-duty vehicles and engines; on-board diagnostic systems and emission-related repairs; comments due by 8-7-01; published 6-8-01

Air programs; State authority delegations:
Ohio; comments due by 8-10-01; published 7-11-01

Air quality implementation plans; approval and promulgation; various States:
California; comments due by 8-6-01; published 7-6-01
Illinois; comments due by 8-10-01; published 7-11-01
Texas; comments due by 8-9-01; published 7-10-01

Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:
Bacillus thuringiensis Cry1F protein, etc.; comments due by 8-6-01; published 6-6-01

Superfund program:
National oil and hazardous substances contingency plan—
National priorities list update; comments due by 8-6-01; published 7-5-01
National priorities list update; comments due by 8-6-01; published 7-5-01

Water pollution control:
National Pollutant Discharge Elimination System—
Cooling water intake structures for new facilities; comments due by 8-6-01; published 7-6-01

FEDERAL COMMUNICATIONS COMMISSION

Digital television stations; table of assignments:
Kansas; comments due by 8-9-01; published 6-28-01
South Carolina; comments due by 8-9-01; published 6-28-01

HEALTH AND HUMAN SERVICES DEPARTMENT

Food and Drug Administration

Medical devices:
Hematology and pathology; reclassification of automated differential cell counters; comments due by 8-7-01; published 5-9-01

HOUSING AND URBAN DEVELOPMENT DEPARTMENT

Public and Indian housing:
Housing Choice Voucher Program; exception payment standard to offset utility costs increase; comments due by 8-6-01; published 6-6-01

INTERIOR DEPARTMENT

Fish and Wildlife Service

Endangered and threatened species:
Critical habitat designations—
O'ahu 'elepaio; comments due by 8-6-01; published 6-6-01
Duskytail darter, etc. (four fishes reintroduced into Tellico River, Monroe County, TN); comments due by 8-7-01; published 6-8-01
Robbins' cinquefoil; comments due by 8-7-01; published 6-8-01

JUSTICE DEPARTMENT

Immigration and Naturalization Service

Nonimmigrant classes:
H-1C nonimmigrant classification; petitioning requirements; comments due by 8-10-01; published 6-11-01

LABOR DEPARTMENT

Mine Safety and Health Administration

Metal and nonmetal mine safety and health:
Underground mines—
Diesel particulate matter exposure of miners; hearing; comments due by 8-6-01; published 7-5-01

NATIONAL ARCHIVES AND RECORDS ADMINISTRATION

Privacy Act; implementation; comments due by 8-6-01; published 6-5-01

POSTAL SERVICE

Domestic Mail Manual:
Mail delivery to commercial mail receiving agency; comments due by 8-10-01; published 7-11-01

TRANSPORTATION DEPARTMENT

Federal Aviation Administration

Airworthiness directives:
Airbus; comments due by 8-10-01; published 7-11-01
Boeing; comments due by 8-10-01; published 6-11-01
CFE Co.; comments due by 8-6-01; published 6-6-01
Eurocopter France; comments due by 8-10-01; published 6-11-01
Class E airspace; comments due by 8-10-01; published 6-18-01

TRANSPORTATION DEPARTMENT

National Highway Traffic Safety Administration

Motor vehicle safety standards:
Advanced air bags performance monitoring and future air bag rulemaking data development; comments due by 8-9-01; published 6-25-01

TREASURY DEPARTMENT

Thrift Supervision Office

Gramm-Leach-Bliley Act; implementation:
Community Reinvestment Act (CRA)-related agreements; disclosure and reporting; comments due by 8-10-01; published 6-11-01

VETERANS AFFAIRS DEPARTMENT

Acquisition regulations:
Health-care resources; simplified acquisition procedures; comments due by 8-6-01; published 6-7-01

National Practitioner Data Bank; participation policy; comments due by 8-6-01; published 6-5-01

LIST OF PUBLIC LAWS

This is a continuing list of public bills from the current session of Congress which have become Federal laws. It may be used in conjunction with "P L U S" (Public Laws Update Service) on 202–523–6641. This list is also available online at http://www.nara.gov/fedreg.

The text of laws is not published in the **Federal Register** but may be ordered in "slip law" (individual pamphlet) form from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 (phone, 202–512–1808). The text will also be made available on the Internet from GPO Access at http://www.access.gpo.gov/nara/index.html. Some laws may not yet be available.

S. 360/P.L. 107–21

To honor Paul D. Coverdell. (July 26, 2001; 115 Stat. 194)

S. 1190/P.L. 107–22

To amend the Internal Revenue Code of 1986 to

rename the education individual retirement accounts as the Coverdell education savings accounts. (July 26, 2001; 115 Stat. 196)

Last List July 26, 2001

Public Laws Electronic Notification Service (PENS)

PENS is a free electronic mail notification service of newly enacted public laws. To subscribe, go to http://hydra.gsa.gov/archives/publaws-l.html or send E-mail to **listserv@listserv.gsa.gov** with the following text message:

SUBSCRIBE PUBLAWS-L Your Name.

Note: This service is strictly for E-mail notification of new laws. The text of laws is not available through this service. **PENS** cannot respond to specific inquiries sent to this address.